<SEC-DOCUMENT>0000879169-22-000010.txt : 20221101
<SEC-HEADER>0000879169-22-000010.hdr.sgml : 20221101
<ACCEPTANCE-DATETIME>20221101160615
ACCESSION NUMBER:		0000879169-22-000010
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		88
CONFORMED PERIOD OF REPORT:	20220930
FILED AS OF DATE:		20221101
DATE AS OF CHANGE:		20221101

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			INCYTE CORP
		CENTRAL INDEX KEY:			0000879169
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
		IRS NUMBER:				943136539
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-12400
		FILM NUMBER:		221350232

	BUSINESS ADDRESS:	
		STREET 1:		1801 AUGUSTINE CUT-OFF
		CITY:			WILMINGTON
		STATE:			DE
		ZIP:			19803
		BUSINESS PHONE:		3024986700

	MAIL ADDRESS:	
		STREET 1:		1801 AUGUSTINE CUT-OFF
		CITY:			WILMINGTON
		STATE:			DE
		ZIP:			19803

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INCYTE CORP
		DATE OF NAME CHANGE:	20030318

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INCYTE GENOMICS INC
		DATE OF NAME CHANGE:	20000710

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INCYTE PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19930902
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>incy-20220930.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:4b736358-c29a-4c12-bfe7-729e80c7c631,g:94be2257-4ebc-4637-90cb-08232abb2695,d:e2ffba3ee5384c86becdb38ff117ca9a--><html xmlns:incy="http://www.incyte.com/20220930" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:srt="http://fasb.org/srt/2022" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns="http://www.w3.org/1999/xhtml" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:utr="http://www.xbrl.org/2009/utr" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>incy-20220930</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930" name="dei:CurrentFiscalYearEndDate" format="ixt:date-month-day" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80L2ZyYWc6YjNhNmM2NWViMzQ1NDVlYmFjOTFjZmZkNjEyZWU4YjkvdGFibGU6YmRiYmIwZTJhMTZmNDkxYThjZmFiNTIyZTRmZDI2MzYvdGFibGVyYW5nZTpiZGJiYjBlMmExNmY0OTFhOGNmYWI1MjJlNGZkMjYzNl8yLTEtMS0xLTgx_a1764b9d-0bea-4645-85f6-8e1017cbae2e">12-31</ix:nonNumeric><ix:nonNumeric contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80L2ZyYWc6YjNhNmM2NWViMzQ1NDVlYmFjOTFjZmZkNjEyZWU4YjkvdGFibGU6YmRiYmIwZTJhMTZmNDkxYThjZmFiNTIyZTRmZDI2MzYvdGFibGVyYW5nZTpiZGJiYjBlMmExNmY0OTFhOGNmYWI1MjJlNGZkMjYzNl8zLTEtMS0xLTgx_af173c83-1e16-4173-b957-f73d90cd6c54">2022</ix:nonNumeric><ix:nonNumeric contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80L2ZyYWc6YjNhNmM2NWViMzQ1NDVlYmFjOTFjZmZkNjEyZWU4YjkvdGFibGU6YmRiYmIwZTJhMTZmNDkxYThjZmFiNTIyZTRmZDI2MzYvdGFibGVyYW5nZTpiZGJiYjBlMmExNmY0OTFhOGNmYWI1MjJlNGZkMjYzNl80LTEtMS0xLTgx_1a04a37c-c185-4d40-9216-feaba478b025">Q3</ix:nonNumeric><ix:nonNumeric contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80L2ZyYWc6YjNhNmM2NWViMzQ1NDVlYmFjOTFjZmZkNjEyZWU4YjkvdGFibGU6YmRiYmIwZTJhMTZmNDkxYThjZmFiNTIyZTRmZDI2MzYvdGFibGVyYW5nZTpiZGJiYjBlMmExNmY0OTFhOGNmYWI1MjJlNGZkMjYzNl81LTEtMS0xLTgx_11e370eb-5419-459f-95e8-33a6d24987a7">0000879169</ix:nonNumeric><ix:nonNumeric contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80L2ZyYWc6YjNhNmM2NWViMzQ1NDVlYmFjOTFjZmZkNjEyZWU4YjkvdGFibGU6YmRiYmIwZTJhMTZmNDkxYThjZmFiNTIyZTRmZDI2MzYvdGFibGVyYW5nZTpiZGJiYjBlMmExNmY0OTFhOGNmYWI1MjJlNGZkMjYzNl82LTEtMS0xLTgx_02424abc-5d61-47b4-9077-86d1af0864b9">false</ix:nonNumeric><ix:nonNumeric contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80L2ZyYWc6YjNhNmM2NWViMzQ1NDVlYmFjOTFjZmZkNjEyZWU4YjkvdGFibGU6YmRiYmIwZTJhMTZmNDkxYThjZmFiNTIyZTRmZDI2MzYvdGFibGVyYW5nZTpiZGJiYjBlMmExNmY0OTFhOGNmYWI1MjJlNGZkMjYzNl83LTEtMS0xLTgx_9f5877ca-3d81-432d-9ff4-aec4a1e085c5">Large Accelerated Filer</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="i238b3f464fe541268bf3b5f8a01e1935_D20220601-20220630" decimals="2" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81NS9mcmFnOjc3NmEwNGVlMTUyYTQxMmNhNTZjZjlmMmUyNzMzNDQwL3RhYmxlOjlhYzA3MmFlZjAyZDRjNDM4Y2U4ZTMxZWFlMjBmMDc3L3RhYmxlcmFuZ2U6OWFjMDcyYWVmMDJkNGM0MzhjZThlMzFlYWUyMGYwNzdfMS0xLTEtMS04MQ_c9bcf3f0-f514-40a1-ab69-e226fd638de5">0.05</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="ia8061bfa0edf44a5ad71ed8064f8ead3_D20220601-20220630" decimals="2" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81NS9mcmFnOjc3NmEwNGVlMTUyYTQxMmNhNTZjZjlmMmUyNzMzNDQwL3RhYmxlOjlhYzA3MmFlZjAyZDRjNDM4Y2U4ZTMxZWFlMjBmMDc3L3RhYmxlcmFuZ2U6OWFjMDcyYWVmMDJkNGM0MzhjZThlMzFlYWUyMGYwNzdfMi0xLTEtMS0xMjA0NA_a57515f4-be2f-4f4d-ad60-204304668774">0.01</ix:nonFraction><ix:nonNumeric contextRef="id2d0ce091668413589b1cf8781e2c76f_D20220101-20220930" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RleHRyZWdpb246ZmFlNDc5YmVlYzk3NGU3Njk4MDJlOTE5MjQ4MDEwYzRfMjcyMw_f68315b0-93a7-445d-8854-3803f7e59595">P3Y</ix:nonNumeric><ix:nonNumeric contextRef="id673d80f31e74643a241d2f62db94ca9_D20220701-20220930" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCostCreditExcludingServiceCostStatementOfIncomeOrComprehensiveIncomeExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV83My9mcmFnOjlkZDZlNTZmNWEzYzQwY2VhZDY2OWZjZDZjZmEzNDhiL3RleHRyZWdpb246OWRkNmU1NmY1YTNjNDBjZWFkNjY5ZmNkNmNmYTM0OGJfNjA0NzMxMzk1NDEzMQ_cd32c16f-4695-4a46-9bef-320c5c331b0a">http://fasb.org/us-gaap/2022#OtherNonoperatingIncomeExpense</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="incy-20220930.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2ee7afc3141240148065dcabb8761324_I20221025"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-10-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i3b4376f8fc614de98c9cf647198c504e_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="iab26fe441f0d4ab984456365a7f7cff0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i85b99c1e194944f7bd3b5fb62f5a2182_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i48a86cbfb7934ea9845c79f994c08295_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie260e1a53b734cf0a4f57af01f2e311d_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c3d6351306b42baba694287efd653dc_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i37c7d1d637bf4ae98b18884511c75dd9_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5c507c58a3df413e914b6c8ae5dbf2a2_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia628ec6831414d4f8e0d2c927a011f4a_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3231b94f87f649139a15ad91d06d9fd2_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib5a93dd07a4f42b6ba18bf2e816dc557_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:MilestoneRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4924faaf57ec4df5aafa757da5bce176_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:MilestoneRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2028c66e6d814be2937c324c9b244728_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:MilestoneRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic7c03930e4e24e0880a00b550c2d0c20_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:MilestoneRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id673d80f31e74643a241d2f62db94ca9_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i313b15d35b7045babd1ba61f84a077dd_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0faaba5fcd6b485781cadacae8b2fd8e_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib3978ca7e91d4a55b0da8a410f53aea4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1a13b312028f458ba711e0bcf4618c10_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic7a3e053f47b40869b9b63c44edaac78_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4cba8f9e546d4c0498d87ceb40e69a8f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6cea24b8bb274decac908bfad3a9c638_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia3d452137b9d47e98488b6d8f51dd20b_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i05bc3079ebc64f4a9ddcc9c745ce3823_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibabc38cb3fd14f2698896bf6570c921e_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i967717e321b54b36a61c6fc27425f9af_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie914017719d349ea93b5d5a6cd062896_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5bc89bf0de084e20a0006dad354ec6b3_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1c77ebb088a04a3bb81e477173b73514_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i38aa3d9ea1274ad1a0d50c3c12756c65_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if098df40ebae4afbb01da4049e945b36_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i92fea5bb4d2c40d19ea9af7ae6522acf_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idff6b81e3d0245e797ebe0c300a68bfb_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i623f636b1e544597bf91776873f38e5d_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i83c026db6e174249812a82f711cb1f78_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i083ff8458e9c4ae38eb154dc7ce1f9a0_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6f8d696d0d544a858bc29abec7dae8d2_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if646a3c30a6b46ec8912b9038eb7f0bf_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5b880c3983264395b93d1f6014da990c_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if6f74963df2d4ed483d364c3eeabd8a1_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i60075c2eb5c5499f8837e239ab042889_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1e7566ac86984c7d9bc3167d0dd68193_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i85c3cbfbb1824bc5a5e1c025e4781453_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib6839b85b6084c339df68bc47f7cff76_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibe1f6fcb358742d8947f8680dc7a2216_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i05520eab8e964199ad292516b1f688c5_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie5b42e033862404b9b0eb46dcfa04cde_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i16eb58b1ed464d849f5daa9d5c452c5d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5940926f68ee4011bffeecd1cae3a5bd_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idab40e34150649eb84f41cf937413ae9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i965f89ff7c6b4ce6bcc30af15c2742bb_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id7612db9fbac4f99a07f20a1f367748a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if318fa6e60cf4269ad7b22fe4b7d3bed_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i149762c26678449aa330b2367cbe6d4c_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i63235de3b5c048f09f04c5309d82d142_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f5bbbcd7a4e4865bf1cd728365c237b_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i510fae960406426aabb022789d463532_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b5fdbb0199e42af841de05d57267053_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5b58a259e2444d51ab47b223d8db0cb8_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i964e4f2c4c4e458a807f09f6f17794df_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i06b27465ac7d4ce4b1fe3f0cc3e247fb_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4b4b9892bc824ec58691624921a1e192_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idc6cb7baa8c74e84b9abc3c83e5894f1_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if9e03c43713740629fa4f89aa642de4f_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7e103bce07364afa8641cfcaf9141951_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i27392d6e02284d51a27f567bf09e7d8a_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i117119ef63584701b5c25a7fdb4442e6_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5519d29d74934b9387e13dee64f56289_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if29697c5381c4b6dbdca657efd2afcb9_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib314ad130b2f42d0844a18715eb4169a_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie9e0017429a94b21b8bba302af4c6a96_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i80edfdae16f74674aa25a4584796d920_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4a971b6abebd4be9a0d2b6015046b257_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i37e49a4f06ec4d2da555cee905623504_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3999e65b4d434855be24ad71cc111f8d_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifa71095b17734a079f0fd7349c7cc6a8_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a9436032c6c4652b5da596c702a1d2b_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8d3e00d0fdce4dd6a33f933968e210ae_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibf6b811e903342bb834df47cf71eeef4_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4d97c6f523444f9aa40a206f5b9705c6_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>incy:segment</xbrli:measure></xbrli:unit><xbrli:context id="i2be3671bbcdc48d9a2d0dd78d0bf79a1_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:JAKAFIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5cd55b8f35884c0687d725055f17e72c_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:JAKAFIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i710215f6e6e248c4a2a3ff81e0391758_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:JAKAFIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id03654679dfd4153b83d389aa2a13454_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:JAKAFIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib254aa03c50f46e7b589f20d3926968e_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:ICLUSIGMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c101f258c8f40a7aac78b3cbb764428_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:ICLUSIGMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3326e3ff6d134bd48eeeeede0550ad3c_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:ICLUSIGMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifa8bc47eb24948d78509e0f3fc38353b_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:ICLUSIGMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9d0a3322355e44a99c106fd274d30424_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:PemazyreMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5a43e9d7d97347f9b3479daaca253e61_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:PemazyreMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1522e02430214c97807e76b9d4f39eac_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:PemazyreMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i56581712c0e948f182f555824226c56a_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:PemazyreMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i97181295a2fc4bc38ac82fa3dbaf41dc_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:MINJUVIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id1964ea37b1844a981da5845b1efc66f_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:MINJUVIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3e487722166b436b9b1a0d17da42afcb_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:MINJUVIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie79dcd193dd74e2692c4841bc97d7582_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:MINJUVIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5b0a477af03843e4a3226411276628ad_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:OpzeluraMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibde9c5a1859245f58beebcd0ab2f8837_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:OpzeluraMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2d64d29a0d744eada29116a65f7ee606_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:OpzeluraMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i76074454312246a08eeeb082fdac82d4_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:OpzeluraMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id7988d7d482845398e5665259694affc_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:JakaviRoyaltyRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2f384ac250ef439885835d9b5c193ad9_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:JakaviRoyaltyRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i45b0b732fe1e49f8a7de40384f586a9b_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:JakaviRoyaltyRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie3424cac904843c0b18c3c76707b6e36_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:JakaviRoyaltyRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0672ace4d6734ee8aaf270d6c484063d_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:OlumiantRoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9a5b8b62e0a34310b286dc3fd7b2e45f_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:OlumiantRoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iae8216b0f9fa43a69bc74413e49ef99b_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:OlumiantRoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4bf0f6ad20014e71a14b23e5dd30857a_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:OlumiantRoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic85f6d136e8245968800b43ce0542fe8_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:TabrectaRoyaltyRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i63601b24528b4ff788ffb07ad33130f8_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:TabrectaRoyaltyRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6088baa6c1d2446691681da562d452f9_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:TabrectaRoyaltyRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibb19c48e81f541858b2a7dd6f03bfa27_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:TabrectaRoyaltyRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i897a57efbfea4fbeaa81a87e5862e1a7_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:MilestoneAndContractRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i46bcaf0cac964264acfc8967fb4fed3e_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:MilestoneAndContractRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2dece6fa44fc4ba59c58b479ca510a5f_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:MilestoneAndContractRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iae3f552bb26a4c00a17d299e8d3f716b_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:MilestoneAndContractRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia7f2a4b8ea5a46449d5a5c254bc02074_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">incy:CorporateAndGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia665e98c13fa47db9c644a1bccf8d1eb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">incy:CorporateAndGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i10d9e02673514259891fcd1d9b719b8c_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">incy:CorporateAndGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibfc4e1b1be0040ea91db0d41c92a5dfe_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">incy:CorporateAndGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i449d405309c143ba85c051e549663c3a_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i06079cbfdc734317994c136835d0952f_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie3ce7b9a2a1a476b998fe7aa7ef489e2_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i281946f958c146b0926f5dd53313b031_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia17493513b37495cac5bb47509ffe782_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2f88761cfe5c4e21a116380b0db0c026_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4b1ac47dfe8c49068229b687c55c61c7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i09bab9220bbf47b692107d83bc042e87_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia7f1808eadf04e878f5967c1674de235_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7c9b57b7436547ed808aaf19bca65fb0_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i46f205a751e14f70bdffe84975b9278e_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i65e0cbcc9a1c4a45843cde84fd23371f_D20160601-20160601"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:LiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">incy:AriadPharmaceuticalsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-06-01</xbrli:startDate><xbrli:endDate>2016-06-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide8e43b5e4774c2b80fc1d692ccd6c5f_I20160601"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:LiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">incy:AriadPharmaceuticalsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-06-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i4769291f7a5e4844bdea08699b901a87_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:LiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">incy:AriadPharmaceuticalsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9dff9f829b91403384e43e22034102b6_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:LiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">incy:AriadPharmaceuticalsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i651332485f95471bbc1f9997619b54c7_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">incy:AriadPharmaceuticalsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">incy:AccruedAndOtherCurrentLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8495b4244f744fd78c9b5dadcfa77dc2_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">incy:AriadPharmaceuticalsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">incy:AccruedAndOtherCurrentLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i683a8a412ece4de6b78e4947fd25373a_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">incy:CollaborationPartnersaBCAndDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1ed3ff5544594900b92ac9213a97bb21_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">incy:CollaborationPartnersaBCAndDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3dc5046f317541c88021a56d36951298_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">incy:CustomerAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib26d36095867409f925663486648772f_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">incy:CustomerAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i162968d5dc8e4fd680e4dc463271dc4b_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">incy:CustomerAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iefe171c3e83a4f289b8aae022d0e081b_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">incy:CustomerAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifb602509071647998b5e683e940d1fcf_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">incy:CustomerBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia8a7e40409944fc78088cd4baed567ac_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">incy:CustomerBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia8ee030161c64a7e9c95b4e2fb66c573_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">incy:CustomerBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8d5936e96208421793937f792f73038d_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">incy:CustomerBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4b1f09000aa74166ade05d1c0dcfedd2_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">incy:CustomerCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1df4e17ddac14778b89ab7f884e13730_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">incy:CustomerCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iab7d5e90e123422ea957f7b149d1df86_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">incy:CustomerCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0cc4497fd77b42f18587cdf09d459c05_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">incy:CustomerCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1fae7539f0da469083ea910f00e0898b_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">incy:CustomerDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia675debc1ef84ae2b8ec00b9932e707b_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">incy:CustomerDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaebef62b75f545d4bddd48699efd1ed1_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">incy:CustomerDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie150bdc7743d4425a27721647c883684_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">incy:CustomerDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i35e2fb28114f48528d3537b9bb4d377b_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">incy:CustomerEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7fb6ed6fc01c49089fc6fbcbb460178a_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">incy:CustomerEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0324e502e8e841449b5689a5c7c6f0ff_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">incy:CustomerEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i589bb0c60aaa4a43b9a3cb4f9adb92ce_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">incy:CustomerEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idb10cbad0c1345b9be3e38c62201ded7_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">incy:AggregateConcentrationCustomersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia6ac11b8a7e34e69a3ca81e7967cd4db_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">incy:AggregateConcentrationCustomersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7ea3b32b349549ab8ef8819fd6f23c57_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1be6071c11dc4f5baede897a7c3899d8_D20091101-20091130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:DevelopmentMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:NovartisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2009-11-01</xbrli:startDate><xbrli:endDate>2009-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i820b7b86437a49c2992e40c5dc8911be_D20091101-20091130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:RegulatoryMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:NovartisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2009-11-01</xbrli:startDate><xbrli:endDate>2009-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic2d99eb0d2fc48a4a62cef1d76a3b8fa_D20091101-20091130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:CommercializationMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:NovartisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2009-11-01</xbrli:startDate><xbrli:endDate>2009-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i05006b85a9704e02902b03623fc8c5f7_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:DevelopmentAndRegulatoryMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:NovartisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia6687beeb4034e3bbce66e159508b36e_D20091101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:DevelopmentMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:NovartisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2009-11-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieaa23329fa064e728b6bab53e01e305b_D20091101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:RegulatoryMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:NovartisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2009-11-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i50b34d5e81624a7b80626a7696d9e0d1_D20091101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:CommercializationMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:NovartisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2009-11-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7de6dcd9947241819b8f342b010b13b8_D20220401-20220430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:RegulatoryMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:TabrectaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:NovartisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3447a97d263a4e71b726a6da1a319017_D20220501-20220531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:RegulatoryMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:JakaviMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:NovartisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-01</xbrli:startDate><xbrli:endDate>2022-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if75967c7131848209fa546f5389ff144_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:JakaviMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:NovartisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i949fa939c8164aa79569420d1f965a48_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:JakaviMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:NovartisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2abac4d4d9084b0cbd214384a0bdd136_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:JAKAFIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:NovartisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifa4602ca397f4df8b24c50991489996f_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:JAKAFIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:NovartisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i829cf684375a4486846e54a47708b378_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:JAKAFIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:NovartisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i02be7adafa9342b0a09344a3239b2392_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:JAKAFIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:NovartisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6881c415becd47fa9f89334bb95c5996_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:NovartisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifbfff633ca0a4e9ea1abbaec86cf758b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:NovartisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic15fa27e6524408cb2ade84bf1015e8a_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:MilestoneAndContractRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:NovartisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5aa252a5e50f412c987b6f82e79e1f2d_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:MilestoneAndContractRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:NovartisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iab260328ac9041409b390a6d753ed302_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:JAKAFIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:NovartisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i51a40b9a674c444c9eabfee9d2524c4a_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:JAKAFIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:NovartisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia6dcb750836e4de6b839dbd19f02184f_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:JAKAFIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:NovartisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ife40116eb76549f19cb03e7d7d84733b_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:JAKAFIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:NovartisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iff64b50b378d484492f7f8d0962ecace_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:TABRECTAPRODUCTANDSERVICESMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:NovartisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2d83cfa285a94cdf9e3c412825e16ed7_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:TABRECTAPRODUCTANDSERVICESMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:NovartisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i51a445bbbf1c4bb2b3b6e0b802471593_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:TABRECTAPRODUCTANDSERVICESMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:NovartisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i30a2ee091dab4a71840f5db6371badf9_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:TABRECTAPRODUCTANDSERVICESMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:NovartisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idadd52c621494f53a41ccc71303f0944_D20091201-20091231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:DevelopmentMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:EliLillyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2009-12-01</xbrli:startDate><xbrli:endDate>2009-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5da7cd5ffebe4fc2b3889b38d5a3dd8f_D20091201-20091231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:EliLillyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:RegulatoryMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2009-12-01</xbrli:startDate><xbrli:endDate>2009-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1a1df5969f734568b13fa48eb0fff053_D20091201-20091231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:EliLillyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:CommercializationMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2009-12-01</xbrli:startDate><xbrli:endDate>2009-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i03d9a6dbc0bb43aaa8228030c1e90e5c_D20091201-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:DevelopmentMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:EliLillyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2009-12-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4562ffe6c4de4f0c8852be62011ecaa1_D20091201-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:EliLillyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:RegulatoryMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2009-12-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib271257c3c244c8491614777e365abbd_D20091201-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:EliLillyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:CommercializationMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2009-12-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaa7f2cb6de4b491abfc72a3a790e6c24_D20220601-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:EliLillyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:RegulatoryMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:OlumiantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if3576f8af5d9438f8a88daefbfe6e46c_D20220601-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:EliLillyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:RegulatoryMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:OlumiantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id7fe066d0c744249bf7ad5af413886e0_D20220601-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:EliLillyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:RegulatoryMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:OlumiantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if134f6ece59c4973a0b3eb0c742df2b4_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:EliLillyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:OlumiantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9c21ab11171944d088ad94775faa82d3_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:EliLillyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:OlumiantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i773d88ed6ec246e38116cf7dcfe2b613_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:OlumiantRoyaltyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:EliLillyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i67b271a11f4749eca413dadc55b898ff_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:OlumiantRoyaltyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:EliLillyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i95f4766b35c44fb7bd203becd9f77ad2_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:OlumiantRoyaltyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:EliLillyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i332c91272a044c69bed32a22f727d46f_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:OlumiantRoyaltyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:EliLillyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6a0eb481719843cb8e92803e3eabf444_I20160630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:EliLillyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:RegulatoryMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:GvhdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic8ef5df1d4014903a83c4bd9313a8063_D20190501-20190531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:EliLillyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:RegulatoryMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:GvhdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-05-01</xbrli:startDate><xbrli:endDate>2019-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i27b0ba8514fd434a9cc2954162a2955e_D20220301-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:EliLillyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:RegulatoryMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:GvhdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie98f2f82461347b486999bb44539bcea_D20170201-20170228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:AgenusMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:ProductGroupOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-02-01</xbrli:startDate><xbrli:endDate>2017-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i77e092a0d9e54838988930228ca59678_D20170201-20170228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:AgenusMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:ProductGroupOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-02-01</xbrli:startDate><xbrli:endDate>2017-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i322b83e81195460e8c7931fafc090d9a_D20170201-20170228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:ProductGroupTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:AgenusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-02-01</xbrli:startDate><xbrli:endDate>2017-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5094eb7ec3484534bab11f2216427143_D20170201-20170228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:AgenusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-02-01</xbrli:startDate><xbrli:endDate>2017-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c8cef81f270473fadccddb9df52f115_D20150101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:DevelopmentRegulatoryAndCommercializationMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:AgenusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id92745e544bc4129ab3571e6e1882924_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:DevelopmentRegulatoryAndCommercializationMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:AgenusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6c3197a1985e4c74a433c4e949b9a513_D20170101-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:AgenusMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:StockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5eaa2a7f03b24bb684bd8c6d31d0037c_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:AgenusMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:StockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iac9dda7781924f1c941a441ab2e2b22e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:AgenusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i181b872577d8409197ea188e8c75e75e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:AgenusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i75f5d515a0904070a5f78ec1c95a20f5_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:AgenusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib46ef2e3f9964aa1ae70251f66606bb7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:AgenusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0fde4e1ee3904f46bc27b6433525d662_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:AgenusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6737e877e1fd425cadb82670cc929c9d_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:AgenusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i595a69e029b4481b8df26f1ffe67629c_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:AgenusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9682bdfe1eb449eca0f0c2c52870768b_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:AgenusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9334ed3cba224fde929ed123a17c88d3_D20161201-20161231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:MerusNVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-12-01</xbrli:startDate><xbrli:endDate>2016-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="item"><xbrli:measure>incy:item</xbrli:measure></xbrli:unit><xbrli:context id="i9011187ffb7d41f38db3ce85ad7e7768_D20220101-20220131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:MerusNVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3734c8248498448d986bbd533587971e_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:DevelopmentAndRegulatoryMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:MerusNVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id2a299f69c6442bebb13283c32eb5495_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:CommercializationMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:MerusNVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i68cb2d0ea17a41489814062745e1a6d8_D20161201-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:MerusNVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-12-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ida045afcbce447a1922f7d64f607e199_D20161201-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:MerusNVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-12-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic6746d80cb784b16bb25e182d074023d_D20161201-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:MerusNVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-12-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3fda94064174414ba40e5f53bd348807_D20161201-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:MerusNVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-12-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7ab2a3895a964a1292f9330cada8a771_D20161201-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:MerusNVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-12-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8440f47d04e64df1b565b9e18146f65e_D20161201-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:MerusNVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-12-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idad439e73b814d62ac3f923adfd04e2a_D20161201-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:MerusNVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-12-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1a445305a100467ca73640bc7fefa6b1_D20160101-20161231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:StockPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:MerusNVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-01-01</xbrli:startDate><xbrli:endDate>2016-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i68df7b52e15747f7ae8531c9b598597e_I20161231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:StockPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:MerusNVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i372a75620ad046e48dae561ae27ead65_D20210101-20210131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:MerusNVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4725ae58984b44c88c59c206c45fa1d2_I20210131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:MerusNVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idc8b97af450a4ea5ad6a270978aca78f_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:MerusNVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9eec6fea7a9943da8efef567ce22965f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:MerusNVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i223beeaf3ff34be8ac561d2f33d4ee03_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:MerusNVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c2d69aa47e742379d1cce352dedd9ae_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:MerusNVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3700fa75a23a4f7eb6dcb20a8debd956_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:MerusNVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2665334fe7184425872feb9740fab18e_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:MerusNVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4764998569344819b699915846b00247_D20170101-20170131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:CalitheraBiosciencesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7d98c2063e874805b3cd156154e95b6a_D20170101-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:StockPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:CalitheraBiosciencesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i040b9736a2b34584b9200ad4e2e9a3fa_I20170131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:StockPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:CalitheraBiosciencesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3851ace877124ec6913ece53ee3910da_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:StockPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:CalitheraBiosciencesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i976bcd6e91034b90afc59a80f582f14d_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:CalitheraBiosciencesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i14a2cf26acb6415995411f908d84bb40_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:CalitheraBiosciencesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i73a305e484884469b7b72fee3888f57d_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:CalitheraBiosciencesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibf490fff4c3b444c824506cac379e2c3_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:CalitheraBiosciencesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia0e5eed879114b4fb4f2900138c56b8c_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:CalitheraBiosciencesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibb93f3e466f7462fb5aade7477f8d7d9_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:CalitheraBiosciencesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ied65757537b34a7aa71eb6babf067549_D20220701-20220731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:DevelopmentMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:MacrogenicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibd823a98e80f479cb6963127d5b61c4f_D20171001-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:DevelopmentMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:MacrogenicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-10-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieca316d43e864d6c9e1338c719db09da_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:DevelopmentAndRegulatoryMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:MacrogenicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id5aed6962c28461aa5a91abb86e50e12_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:CommercializationMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:MacrogenicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic18f95fb157047e8b27cafc65fd5af9c_D20171001-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:MacrogenicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-10-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie6e53682249b48c2b89c302c106844f5_D20171001-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:MacrogenicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-10-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icf19c78006d9495182f71ef7c21fe380_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:MacrogenicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3985fee19ddf43a38f40f8f7a256fbdf_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:MacrogenicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icb1732c8fda74656b87657355bf486ce_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:MacrogenicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i73db6105ad88412f9de49662c370a570_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:MacrogenicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieaa2a400ed804a53b1afde32908c0c07_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:MacrogenicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2dbf58f06d2f47308c3bad5301982ece_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:MacrogenicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i70fb3b0153d340f5aab70006b97df6d0_D20180101-20180131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:SyrosPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i152e5989713548879ee454b4d94dc97d_I20180131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:SyrosPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icafda92b12fb4c439f26f3cbf5162d94_I20180131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:DevelopmentAndRegulatoryMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:SyrosPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9b71fd409f444f9ab70ba536a99e012b_I20180131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:SyrosPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:CommercializationMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4802cd742cea475fa7d4e4c77f6ed61f_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:SyrosPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:StockPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">incy:PreSeptember2022StockSplitSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8cf0a385b080416f8c84cece61770144_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:SyrosPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:StockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i56216a9c32c046e293518645fa59581e_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:SyrosPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:AmendedStockPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">incy:PreSeptember2022StockSplitSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i84229a0cf41042c4af314a95d0c76e40_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:SyrosPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:AmendedStockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icc792aa24edf4db4b607a35782e9f099_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:SyrosPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:StockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia7d2cecabe5d473b9e10bcd188d283ba_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:SyrosPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8210542f8d5e44b9852bd20e5f5e3854_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:SyrosPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic8f331242d08460fbf44354246d36f87_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:SyrosPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7c697b731e83449fa55119d8b2fbba64_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:SyrosPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6adb3d95448a44468d8489293e1ea749_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:SyrosPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i09a141eea49e49258b3beebd24497e7e_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:SyrosPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic09f0ce12baa4ba48de314895f364fc0_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:DevelopmentAndRegulatoryMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:InnoventBiologicsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idf1c0108786a4620836caeb03784ce6c_D20220301-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:RegulatoryMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:PemazyreMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:InnoventBiologicsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie995745d247a45d38430829bee3187e8_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:CommercializationMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:InnoventBiologicsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i96f4281beb534126a1eef106e0789ece_D20190701-20190731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:DevelopmentAndRegulatoryMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:CollaborationAndLicenseAgreementWithZaiLabLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iebdcdab801a74c27a6126ac544405996_D20190701-20190731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:CommercializationMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:CollaborationAndLicenseAgreementWithZaiLabLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i900f0ac816ab4775ab2106619f594870_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:MorphosysAgMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">incy:IncyteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i591cacee8aca4012a248fa2c96cea301_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">incy:MorphosysAgMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:MorphosysAgMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6aecf3dce21d42e7851bf481a425bc46_I20200131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:DevelopmentAndRegulatoryMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:MorphosysAgMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8d1b83baba194bed8477bb9ea0de3df7_I20200131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:CommercializationMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:MorphosysAgMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifecd0798049d402f9683bec43016bf55_D20200101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:DevelopmentAndRegulatoryMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:MorphosysAgMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7acbcf60ab2042008f713a4d43e83de9_I20200131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:AmericanDepositarySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2ed4e89797ba4aaf9b7ebc41ec200ef4_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:MorphosysAgMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia375a7c89bc74d8bbfbae792527a8710_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:MorphosysAgMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i743d644eae334843b9ede7cb71b9c67d_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:MorphosysAgMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9415bb6d6cbd4c08a203ce650cc97142_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:MorphosysAgMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5c84e3647ab24388b648b9a8ab264afa_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:MorphosysAgMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idaa0f5c512544ed5bb9ed44eff567a1b_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:MorphosysAgMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie043e97a1aa74373b87fb3609b47dd3c_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:MorphosysAgMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie686f463b19c46aea6f673458c296cfa_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:MorphosysAgMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i49acad92f3dd479a8b0f38d89cfdd456_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:TafasitamabProductAndServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:MorphosysAgMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibf40aaa491714d97a2353162af92483b_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:TafasitamabProductAndServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:MorphosysAgMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i52bb96abc5854205a71aecc9f552d0a1_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:TafasitamabProductAndServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:MorphosysAgMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i052ba28ba496497ba9474f71db32c295_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:TafasitamabProductAndServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:MorphosysAgMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8d57ef7a2a5e4baea3532431671ef13c_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:MorphosysAgMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i339dc7a864644d6fa19c079e6c5c35f2_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:MorphosysAgMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib8a2da8278cb46e5a34861f79068cd18_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:MorphosysAgMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaffe85fc70e4417eb1de69b0992095b4_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:MorphosysAgMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i058a1a9cef2b4e36bcbc453963f518d2_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:MorphosysAgMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8ea67dc6fe88438cbc0a45ad09002fec_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:MorphosysAgMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i68d610f80f7e4dd1b7076852e33351b9_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:NimbleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:FutureContingentDiscoveryMilestoneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if241609d783147a2a65ee7d8f3cfab8e_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:DevelopmentAndRegulatoryMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:NimbleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0c67636b0e5c40e3bccf2287aa2dd24e_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:CommercializationMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:NimbleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i54911354715749fdbd74f62ce9dd1ad8_D20210901-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:TafasitamabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:InnocarePharmaLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7e81499535aa4d19aae8e5cfa7cac860_D20220930-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:InnocarePharmaLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:TafasitamabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-09-30</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic4b6bf4c21e94e4e8eac1ce2ff2aca3c_D20210901-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:SyndaxPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">incy:IncyteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2fc0a1b5bbc34643b361651b2d12a002_D20210901-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">incy:SyndaxPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:SyndaxPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ice2384877b1e441482f1b13c9a8dae52_D20211201-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:SyndaxPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i381ad8904ad94b698038402e2dbae630_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:DevelopmentAndRegulatoryMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:SyndaxPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9c8cc765b77d4e319490794de2d57720_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:SyndaxPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:CommercializationMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic75be732674a48cc932a3908c0f0125f_D20210901-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:StockPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:InvestmentInSyndaxPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iab65428e773d4e1f81be1d9a26ea6741_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:StockPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:InvestmentInSyndaxPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8fa5c0ac0f304b3f986fce0cfbaa390d_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:StockPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:InvestmentInSyndaxPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5ae4ff1b717c42c4b158977281cf10aa_I20211209"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:StockPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:InvestmentInSyndaxPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib136551050f34038b1062509c10fd644_D20211209-20211209"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:StockPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:InvestmentInSyndaxPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-09</xbrli:startDate><xbrli:endDate>2021-12-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8a234f090f5e47568ec964b185b6ea18_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:InvestmentInSyndaxPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8f65aa20c7b04a3aa4af35f8d8783e0d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:InvestmentInSyndaxPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0eb6eb6c67a046c99cb82fbf4c1e3ab3_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:InvestmentInSyndaxPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i91c3988b9dd7488dbbd895a2cfde280d_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:InvestmentInSyndaxPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i238b3f464fe541268bf3b5f8a01e1935_D20220601-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:StockPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:CalitheraBiosciencesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia8061bfa0edf44a5ad71ed8064f8ead3_D20220601-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:SyrosPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:StockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6a62ea7776234ba0824931335a0d4825_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i132cda3dcfdc4ce6853fafa85f1782e7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie059b8e396a34f60beab49836d33d129_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2df7a55feb96443a96a33b7ff9a2e1a5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8ffd71f442ea4f50bb5fe72e558fe509_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0b31e55bf720475390b524cce573a3d0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i706ab952dd37469eaeedc74245929deb_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i15460e5c3abd492e81486c9dd98ed0f9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if7d77528a6e8420e9064a4b8b5c0de47_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">incy:BuildingAndLeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie3fdcc8f5ffb478da66863c12a1b6a68_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">incy:BuildingAndLeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia4b01aa79b8543cb89e4d2fe5b5782db_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">incy:OperatingLeaseRightOfUseAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id090587fece240a682b2eb53308bef79_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">incy:OperatingLeaseRightOfUseAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i51126f0e89df4b60bd2aacb656a90f1a_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5fa10fd48d3a49168a51c3085f8e84c2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1b500a53ba8b41b09f796fe4eaf76bef_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RealEstatePropertiesAxis">incy:OfficeBuildingWilmingtonDelawareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:context id="i2370b8e265a34d1aa69e4cb0d71b393f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">incy:BuildingAndLeaseholdImprovementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RealEstatePropertiesAxis">incy:OfficeBuildingWilmingtonDelawareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3e022afff69a4662b44f01a7c0e13f2b_I20180228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RealEstatePropertiesAxis">incy:OfficeBuildingMorgesSwitzerlandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i98615f967e4d480b8209d68fbee3cb04_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RealEstatePropertiesAxis">incy:OfficeBuildingMorgesSwitzerlandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5b1c37d431a944d2bedb8074e5a6d652_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RealEstatePropertiesAxis">incy:OfficeBuildingMorgesSwitzerlandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia946998af0fa49ddb26d6ca660cd4f96_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RealEstatePropertiesAxis">incy:OfficeBuildingMorgesSwitzerlandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5f74da13198248b88b7490d0362d5443_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RealEstatePropertiesAxis">incy:OfficeBuildingMorgesSwitzerlandMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">incy:BuildingAndLeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ied0dbe564f15462a80f773631b1b4a84_D20180701-20180731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RealEstatePropertiesAxis">incy:LandLocatedWithinYParcSwitzerlandsLargestTechnologyParkInYverdonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if65cebf5f28640cc97c1750992f7d09c_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RealEstatePropertiesAxis">incy:LandLocatedWithinYParcSwitzerlandsLargestTechnologyParkInYverdonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i70b041b0d1e8409a9b019c7f878e45a2_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i49a1f92f5e85446da96c93ad448dbab8_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia4fb38d378634c26b981ddc5c86f5524_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i383fc0ace0f847c4a6eb8bb43c13caff_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5835316ce7724afea3bdb29dcb3a2253_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib017a2d350ba431d9ba79b402e1cfb7f_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i89ed3c93c92745279b334fa5c4526831_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7f29ae45641b4afcab178d487b406c8b_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icce988e289034a3fb382746bd6fb055e_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idcbe2a87e3f1451b8c00c0d575bc9286_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i743fbd319cfc457b9da040d45ac71e11_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i29928027a77447828aad4cf785a73286_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id3db81cbe7d44bf4b59daffdc638772b_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i18064623ae8c40b0b87d8d75806827d8_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i88f8a540b3d94b20983f8902eae30ae2_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id7acb0824a524ce2b1a6d6eeb3f5b6b8_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia05518f1a01d4291b4add6208b75e939_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie12951e0177049569a4eaac01ed75693_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icaf56e010147488ebeb835f2e5b31900_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c730d6b5a3349088cf01b0df9f09e86_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ica61680f037f4dedb0e7d3fa6de64097_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i63709951184741bbb03325606fc77885_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i48621c6db4cc4ac9ad02fc57e325cfda_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i04c8ff8acdef44f4b58b1deff299fcc5_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6a259c2680304a099d7306f0be37ed62_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie5ac7148ca1b4e0cac828a4f764cc338_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id2d0ce091668413589b1cf8781e2c76f_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id70f31d4f5454cf2a35efe177f68fc3a_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibf315c942d3a4e75bf4c724b522cbd2a_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i815d3de20f4a4db7baa12ac1511dc801_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib0879ceff7714c68a441c12f87a02bb6_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6afeedfad1cd4882a7d671b04f209a35_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if444048235584a2399361851f892f5df_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0efcc1efa4d94a789080eb3693e147ff_D20211001-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4265039234524ff8ba29f3a4b5d9b5b7_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6fd8c5827aa44407ac99325c6ecd1dcd_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i09060caa1e0a470da42482940ed7fad9_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i45da57132f0b4b1baefd68fba20589ad_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1c305a826fd9438ab670f7c9b7fa8ab4_D20221001-20221031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:VillarisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if0d0cff0ce394041bc79b1987d42f3cd_D20221001-20221031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:VillarisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:DevelopmentAndRegulatoryMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2aa7c5f2196a496abe03ba33b71612a9_D20221001-20221031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:VillarisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:CommercializationMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-10-31</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="ie2ffba3ee5384c86becdb38ff117ca9a_1"></div><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie2ffba3ee5384c86becdb38ff117ca9a_7">Table of Contents</a></span></div></div><div style="margin-top:1pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:17pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:17pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:17pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xL2ZyYWc6OWIxMjlmNjc1ZjBjNGM1MThlNDlmZmRhZDg2NmVkYWMvdGV4dHJlZ2lvbjo5YjEyOWY2NzVmMGM0YzUxOGU0OWZmZGFkODY2ZWRhY18xOTYz_62487f5a-5231-4508-9339-3c1c307f2150">10-Q</ix:nonNumeric></span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Mark One)</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.264%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930" name="dei:DocumentQuarterlyReport" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xL2ZyYWc6OWIxMjlmNjc1ZjBjNGM1MThlNDlmZmRhZDg2NmVkYWMvdGFibGU6OTJkMDQ5MGEyOWUwNDZmMGI2MzAyZDhiNTQxNjg1MWUvdGFibGVyYW5nZTo5MmQwNDkwYTI5ZTA0NmYwYjYzMDJkOGI1NDE2ODUxZV8wLTAtMS0xLTgx_b2787965-606a-4c89-a866-1e69e80397fc">x</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:114%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xL2ZyYWc6OWIxMjlmNjc1ZjBjNGM1MThlNDlmZmRhZDg2NmVkYWMvdGV4dHJlZ2lvbjo5YjEyOWY2NzVmMGM0YzUxOGU0OWZmZGFkODY2ZWRhY18xMzU_d7d0000e-01ad-4780-998d-7fbbf003aa1e">September&#160;30, 2022</ix:nonNumeric></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">or</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.264%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xL2ZyYWc6OWIxMjlmNjc1ZjBjNGM1MThlNDlmZmRhZDg2NmVkYWMvdGFibGU6NGRlYjlkOWFlYjQyNDlhNjg0MmUzZGMzMjUwOWUzNjIvdGFibGVyYW5nZTo0ZGViOWQ5YWViNDI0OWE2ODQyZTNkYzMyNTA5ZTM2Ml8wLTAtMS0xLTgx_752289dc-98d7-46cb-b8da-922ec0800e9a">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:114%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the transition period from&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;to&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Commission File Number: <ix:nonNumeric contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xL2ZyYWc6OWIxMjlmNjc1ZjBjNGM1MThlNDlmZmRhZDg2NmVkYWMvdGV4dHJlZ2lvbjo5YjEyOWY2NzVmMGM0YzUxOGU0OWZmZGFkODY2ZWRhY18xOTY4_18913267-c7cf-4c20-8750-24720466da38">001-12400</ix:nonNumeric></span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:17pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xL2ZyYWc6OWIxMjlmNjc1ZjBjNGM1MThlNDlmZmRhZDg2NmVkYWMvdGV4dHJlZ2lvbjo5YjEyOWY2NzVmMGM0YzUxOGU0OWZmZGFkODY2ZWRhY18zODQ4MjkwNjk5MjI5_881ffbfa-903d-4d5e-a312-ad55d4af3be3">INCYTE CORPORATION</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xL2ZyYWc6OWIxMjlmNjc1ZjBjNGM1MThlNDlmZmRhZDg2NmVkYWMvdGFibGU6ZTVkZjVkNzZmOWVjNDgzOTlkYTliZjllYTk4ODlmOWMvdGFibGVyYW5nZTplNWRmNWQ3NmY5ZWM0ODM5OWRhOWJmOWVhOTg4OWY5Y18wLTAtMS0xLTgx_0cbcbe81-7e1c-4f2f-b7d0-abdda476c3b1">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xL2ZyYWc6OWIxMjlmNjc1ZjBjNGM1MThlNDlmZmRhZDg2NmVkYWMvdGFibGU6ZTVkZjVkNzZmOWVjNDgzOTlkYTliZjllYTk4ODlmOWMvdGFibGVyYW5nZTplNWRmNWQ3NmY5ZWM0ODM5OWRhOWJmOWVhOTg4OWY5Y18wLTEtMS0xLTgx_f621b9d5-cb55-4eed-8a3a-4ef45396cc47">94-3136539</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(IRS Employer<br/>Identification No.)</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xL2ZyYWc6OWIxMjlmNjc1ZjBjNGM1MThlNDlmZmRhZDg2NmVkYWMvdGFibGU6ZTVkZjVkNzZmOWVjNDgzOTlkYTliZjllYTk4ODlmOWMvdGFibGVyYW5nZTplNWRmNWQ3NmY5ZWM0ODM5OWRhOWJmOWVhOTg4OWY5Y18zLTAtMS0xLTgxL3RleHRyZWdpb246ZDM3MjAyNGI0MjVmNDE4NTkyYTRiZTJkZjU5MzA1MWZfNA_ed71983a-fef4-4a4b-8a5a-6c3bc2588dc1">1801 Augustine Cut-Off</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xL2ZyYWc6OWIxMjlmNjc1ZjBjNGM1MThlNDlmZmRhZDg2NmVkYWMvdGFibGU6ZTVkZjVkNzZmOWVjNDgzOTlkYTliZjllYTk4ODlmOWMvdGFibGVyYW5nZTplNWRmNWQ3NmY5ZWM0ODM5OWRhOWJmOWVhOTg4OWY5Y18zLTAtMS0xLTgxL3RleHRyZWdpb246ZDM3MjAyNGI0MjVmNDE4NTkyYTRiZTJkZjU5MzA1MWZfNw_976cedd0-4143-4c06-b92c-b4dea3c0199e">Wilmington</ix:nonNumeric>, <ix:nonNumeric contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xL2ZyYWc6OWIxMjlmNjc1ZjBjNGM1MThlNDlmZmRhZDg2NmVkYWMvdGFibGU6ZTVkZjVkNzZmOWVjNDgzOTlkYTliZjllYTk4ODlmOWMvdGFibGVyYW5nZTplNWRmNWQ3NmY5ZWM0ODM5OWRhOWJmOWVhOTg4OWY5Y18zLTAtMS0xLTgxL3RleHRyZWdpb246ZDM3MjAyNGI0MjVmNDE4NTkyYTRiZTJkZjU5MzA1MWZfMTA_52504e5c-a02e-4a11-92e6-f87ebab1921e">DE</ix:nonNumeric>  19803</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xL2ZyYWc6OWIxMjlmNjc1ZjBjNGM1MThlNDlmZmRhZDg2NmVkYWMvdGFibGU6ZTVkZjVkNzZmOWVjNDgzOTlkYTliZjllYTk4ODlmOWMvdGFibGVyYW5nZTplNWRmNWQ3NmY5ZWM0ODM5OWRhOWJmOWVhOTg4OWY5Y18zLTEtMS0xLTgx_5248b4c7-b1de-43ca-8f49-e4f9bb7b99f5">19803</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(Zip Code)</span></td></tr></table></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xL2ZyYWc6OWIxMjlmNjc1ZjBjNGM1MThlNDlmZmRhZDg2NmVkYWMvdGV4dHJlZ2lvbjo5YjEyOWY2NzVmMGM0YzUxOGU0OWZmZGFkODY2ZWRhY18xOTY5_035905af-c2d1-4042-bea6-cd6faba50a92">302</ix:nonNumeric>) <ix:nonNumeric contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xL2ZyYWc6OWIxMjlmNjc1ZjBjNGM1MThlNDlmZmRhZDg2NmVkYWMvdGV4dHJlZ2lvbjo5YjEyOWY2NzVmMGM0YzUxOGU0OWZmZGFkODY2ZWRhY18xOTY0_bb6754e9-f7e8-47d7-9cda-5985c77fa3e3">498-6700</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.627%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.629%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 4.6pt;text-align:center;text-indent:-7.2pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Trading Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Name of exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 6pt;text-align:center;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xL2ZyYWc6OWIxMjlmNjc1ZjBjNGM1MThlNDlmZmRhZDg2NmVkYWMvdGFibGU6NTFiNzNlZjczYzJiNDkyODlkZjFkNmMzYTA1YjU2YTMvdGFibGVyYW5nZTo1MWI3M2VmNzNjMmI0OTI4OWRmMWQ2YzNhMDViNTZhM18xLTAtMS0xLTgx_d052c83c-accd-47ce-84f8-7bf4b07130dd">Common Stock, $.001 par value per share</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xL2ZyYWc6OWIxMjlmNjc1ZjBjNGM1MThlNDlmZmRhZDg2NmVkYWMvdGFibGU6NTFiNzNlZjczYzJiNDkyODlkZjFkNmMzYTA1YjU2YTMvdGFibGVyYW5nZTo1MWI3M2VmNzNjMmI0OTI4OWRmMWQ2YzNhMDViNTZhM18xLTItMS0xLTgx_e95cfda4-937f-47eb-90aa-549b04a6d66c">INCY</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xL2ZyYWc6OWIxMjlmNjc1ZjBjNGM1MThlNDlmZmRhZDg2NmVkYWMvdGFibGU6NTFiNzNlZjczYzJiNDkyODlkZjFkNmMzYTA1YjU2YTMvdGFibGVyYW5nZTo1MWI3M2VmNzNjMmI0OTI4OWRmMWQ2YzNhMDViNTZhM18xLTQtMS0xLTgx_15a4f62d-d527-45dd-b11e-ed59c2c47714">The Nasdaq Stock Market LLC</ix:nonNumeric></span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> <ix:nonNumeric contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xL2ZyYWc6OWIxMjlmNjc1ZjBjNGM1MThlNDlmZmRhZDg2NmVkYWMvdGV4dHJlZ2lvbjo5YjEyOWY2NzVmMGM0YzUxOGU0OWZmZGFkODY2ZWRhY18xOTcw_52a415b6-5d1f-431b-8058-78795ca3e759">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">o</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> No </span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> <ix:nonNumeric contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xL2ZyYWc6OWIxMjlmNjc1ZjBjNGM1MThlNDlmZmRhZDg2NmVkYWMvdGV4dHJlZ2lvbjo5YjEyOWY2NzVmMGM0YzUxOGU0OWZmZGFkODY2ZWRhY18xOTY1_d295b60c-d749-4c0b-ae06-fefb6152d568">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">o</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> No</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div style="margin-top:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.909%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Large accelerated filer </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:115%">x</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Accelerated filer </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:115%">o</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Non-accelerated filer </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:115%">o</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><ix:nonNumeric contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930" name="dei:EntitySmallBusiness" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xL2ZyYWc6OWIxMjlmNjc1ZjBjNGM1MThlNDlmZmRhZDg2NmVkYWMvdGFibGU6YzQ2Y2Y2OTIzOTExNDc5ZGI3NWUzNGIwZDhlMGNkNTUvdGFibGVyYW5nZTpjNDZjZjY5MjM5MTE0NzlkYjc1ZTM0YjBkOGUwY2Q1NV8yLTEtMS0xLTgx_09d6fa81-c286-4082-bbc0-4090ee2a1c96"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Smaller reporting company </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:115%">o</span></ix:nonNumeric></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><ix:nonNumeric contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xL2ZyYWc6OWIxMjlmNjc1ZjBjNGM1MThlNDlmZmRhZDg2NmVkYWMvdGFibGU6YzQ2Y2Y2OTIzOTExNDc5ZGI3NWUzNGIwZDhlMGNkNTUvdGFibGVyYW5nZTpjNDZjZjY5MjM5MTE0NzlkYjc1ZTM0YjBkOGUwY2Q1NV80LTEtMS0xLTgx_56f25325-571e-479f-9499-6353e32a920e"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Emerging growth company </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:115%">o</span></ix:nonNumeric></div></td></tr></table></div><div style="margin-top:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930" name="dei:EntityShellCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xL2ZyYWc6OWIxMjlmNjc1ZjBjNGM1MThlNDlmZmRhZDg2NmVkYWMvdGV4dHJlZ2lvbjo5YjEyOWY2NzVmMGM0YzUxOGU0OWZmZGFkODY2ZWRhY18xOTY2_1028a76d-0ca9-43ca-8286-cc910831682c">o</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Yes </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> No</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The number of outstanding shares of the registrant&#8217;s Common Stock, $.001 par value, was <ix:nonFraction unitRef="shares" contextRef="i2ee7afc3141240148065dcabb8761324_I20221025" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xL2ZyYWc6OWIxMjlmNjc1ZjBjNGM1MThlNDlmZmRhZDg2NmVkYWMvdGV4dHJlZ2lvbjo5YjEyOWY2NzVmMGM0YzUxOGU0OWZmZGFkODY2ZWRhY18yNzQ4Nzc5MDcxNDgy_2de0614a-ea2d-4e31-9db5-9e80ba6efd9f">222,475,468</ix:nonFraction> as of October&#160;25, 2022.</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="ie2ffba3ee5384c86becdb38ff117ca9a_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie2ffba3ee5384c86becdb38ff117ca9a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INCYTE CORPORATION</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEX</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:9.051%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:80.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.931%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ie2ffba3ee5384c86becdb38ff117ca9a_10">PART I: FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie2ffba3ee5384c86becdb38ff117ca9a_10">3</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ie2ffba3ee5384c86becdb38ff117ca9a_13">Item 1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie2ffba3ee5384c86becdb38ff117ca9a_13">Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie2ffba3ee5384c86becdb38ff117ca9a_13">3</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie2ffba3ee5384c86becdb38ff117ca9a_16">Condensed Consolidated Balance Sheets</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie2ffba3ee5384c86becdb38ff117ca9a_16">3</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie2ffba3ee5384c86becdb38ff117ca9a_19">Condensed Consolidated Statements of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie2ffba3ee5384c86becdb38ff117ca9a_19">4</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie2ffba3ee5384c86becdb38ff117ca9a_22">Condensed Consolidated Statements of Comprehensive Income (Loss)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie2ffba3ee5384c86becdb38ff117ca9a_22">5</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie2ffba3ee5384c86becdb38ff117ca9a_25">Condensed Consolidated Statements of Stockholders&#8217; Equity</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie2ffba3ee5384c86becdb38ff117ca9a_25">6</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie2ffba3ee5384c86becdb38ff117ca9a_28">Condensed Consolidated Statements of Cash Flows</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie2ffba3ee5384c86becdb38ff117ca9a_28">8</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie2ffba3ee5384c86becdb38ff117ca9a_31">Notes to Condensed Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie2ffba3ee5384c86becdb38ff117ca9a_31">9</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ie2ffba3ee5384c86becdb38ff117ca9a_82">Item 2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie2ffba3ee5384c86becdb38ff117ca9a_82">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie2ffba3ee5384c86becdb38ff117ca9a_82">28</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie2ffba3ee5384c86becdb38ff117ca9a_85">Forward-Looking Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie2ffba3ee5384c86becdb38ff117ca9a_85">28</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie2ffba3ee5384c86becdb38ff117ca9a_88">Summary Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie2ffba3ee5384c86becdb38ff117ca9a_88">32</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ie2ffba3ee5384c86becdb38ff117ca9a_121">Item 3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie2ffba3ee5384c86becdb38ff117ca9a_121">Quantitative and Qualitative Disclosures about Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie2ffba3ee5384c86becdb38ff117ca9a_121">56</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ie2ffba3ee5384c86becdb38ff117ca9a_124">Item 4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie2ffba3ee5384c86becdb38ff117ca9a_124">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie2ffba3ee5384c86becdb38ff117ca9a_124">57</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ie2ffba3ee5384c86becdb38ff117ca9a_127">PART II: OTHER INFORMATION</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ie2ffba3ee5384c86becdb38ff117ca9a_130">Item 1A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie2ffba3ee5384c86becdb38ff117ca9a_130">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie2ffba3ee5384c86becdb38ff117ca9a_130">57</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ie2ffba3ee5384c86becdb38ff117ca9a_133">Item 6.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie2ffba3ee5384c86becdb38ff117ca9a_133">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie2ffba3ee5384c86becdb38ff117ca9a_133">86</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie2ffba3ee5384c86becdb38ff117ca9a_136">Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie2ffba3ee5384c86becdb38ff117ca9a_136">87</a></span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2</span></div></div></div><div id="ie2ffba3ee5384c86becdb38ff117ca9a_10"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie2ffba3ee5384c86becdb38ff117ca9a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I: FINANCIAL INFORMATION</span></div><div id="ie2ffba3ee5384c86becdb38ff117ca9a_13"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. Financial Statements</span></div><div id="ie2ffba3ee5384c86becdb38ff117ca9a_16"></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INCYTE CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED BALANCE SHEETS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except number of shares and par value)</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021*</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:13.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b4376f8fc614de98c9cf647198c504e_I20220930" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xNi9mcmFnOjU2YmVmNWVkZGUxMDRjZDJiNzQxZGJmMjY2YmMwZmRmL3RhYmxlOjYzNjVkN2Y4YTZlYzQ4MzNiN2U3OTk3OWNlYjI2YWJlL3RhYmxlcmFuZ2U6NjM2NWQ3ZjhhNmVjNDgzM2I3ZTc5OTc5Y2ViMjZhYmVfNC0xLTEtMS04MQ_4b208c68-76e1-4814-9a97-967679c256d8">2,690,622</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab26fe441f0d4ab984456365a7f7cff0_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xNi9mcmFnOjU2YmVmNWVkZGUxMDRjZDJiNzQxZGJmMjY2YmMwZmRmL3RhYmxlOjYzNjVkN2Y4YTZlYzQ4MzNiN2U3OTk3OWNlYjI2YWJlL3RhYmxlcmFuZ2U6NjM2NWQ3ZjhhNmVjNDgzM2I3ZTc5OTc5Y2ViMjZhYmVfNC0zLTEtMS04MQ_b2051533-5f4a-4494-8edf-eee6c6a2b3f2">2,057,440</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Marketable securities&#8212;available-for-sale (amortized cost $<ix:nonFraction unitRef="usd" contextRef="i3b4376f8fc614de98c9cf647198c504e_I20220930" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xNi9mcmFnOjU2YmVmNWVkZGUxMDRjZDJiNzQxZGJmMjY2YmMwZmRmL3RhYmxlOjYzNjVkN2Y4YTZlYzQ4MzNiN2U3OTk3OWNlYjI2YWJlL3RhYmxlcmFuZ2U6NjM2NWQ3ZjhhNmVjNDgzM2I3ZTc5OTc5Y2ViMjZhYmVfNS0wLTEtMS04MS90ZXh0cmVnaW9uOmY5NGRjMTI1YmE1YTQ2MmI5ZTBiNjM3MzgxZDRlMWE3XzYx_81cc8fd3-d933-432b-96dd-92582bab67b4">292,941</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="iab26fe441f0d4ab984456365a7f7cff0_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xNi9mcmFnOjU2YmVmNWVkZGUxMDRjZDJiNzQxZGJmMjY2YmMwZmRmL3RhYmxlOjYzNjVkN2Y4YTZlYzQ4MzNiN2U3OTk3OWNlYjI2YWJlL3RhYmxlcmFuZ2U6NjM2NWQ3ZjhhNmVjNDgzM2I3ZTc5OTc5Y2ViMjZhYmVfNS0wLTEtMS04MS90ZXh0cmVnaW9uOmY5NGRjMTI1YmE1YTQ2MmI5ZTBiNjM3MzgxZDRlMWE3XzY4_1e2982cb-922c-4e5e-8b2b-498a3ee8a165">291,871</ix:nonFraction> as of September&#160;30, 2022 and December&#160;31, 2021, respectively; allowance for credit losses $<ix:nonFraction unitRef="usd" contextRef="i3b4376f8fc614de98c9cf647198c504e_I20220930" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xNi9mcmFnOjU2YmVmNWVkZGUxMDRjZDJiNzQxZGJmMjY2YmMwZmRmL3RhYmxlOjYzNjVkN2Y4YTZlYzQ4MzNiN2U3OTk3OWNlYjI2YWJlL3RhYmxlcmFuZ2U6NjM2NWQ3ZjhhNmVjNDgzM2I3ZTc5OTc5Y2ViMjZhYmVfNS0wLTEtMS04MS90ZXh0cmVnaW9uOmY5NGRjMTI1YmE1YTQ2MmI5ZTBiNjM3MzgxZDRlMWE3XzEzMA_7a02fcea-8a8b-4a52-8ba1-ebe24016361e"><ix:nonFraction unitRef="usd" contextRef="iab26fe441f0d4ab984456365a7f7cff0_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xNi9mcmFnOjU2YmVmNWVkZGUxMDRjZDJiNzQxZGJmMjY2YmMwZmRmL3RhYmxlOjYzNjVkN2Y4YTZlYzQ4MzNiN2U3OTk3OWNlYjI2YWJlL3RhYmxlcmFuZ2U6NjM2NWQ3ZjhhNmVjNDgzM2I3ZTc5OTc5Y2ViMjZhYmVfNS0wLTEtMS04MS90ZXh0cmVnaW9uOmY5NGRjMTI1YmE1YTQ2MmI5ZTBiNjM3MzgxZDRlMWE3XzEzMA_c1dbe7de-546e-4c52-a7e6-3e5d7d2922b1">0</ix:nonFraction></ix:nonFraction> as of September&#160;30, 2022 and December&#160;31, 2021)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b4376f8fc614de98c9cf647198c504e_I20220930" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xNi9mcmFnOjU2YmVmNWVkZGUxMDRjZDJiNzQxZGJmMjY2YmMwZmRmL3RhYmxlOjYzNjVkN2Y4YTZlYzQ4MzNiN2U3OTk3OWNlYjI2YWJlL3RhYmxlcmFuZ2U6NjM2NWQ3ZjhhNmVjNDgzM2I3ZTc5OTc5Y2ViMjZhYmVfNS0xLTEtMS04MQ_39d42964-9fbb-4452-9fc7-1cd346a9eef3">286,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab26fe441f0d4ab984456365a7f7cff0_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xNi9mcmFnOjU2YmVmNWVkZGUxMDRjZDJiNzQxZGJmMjY2YmMwZmRmL3RhYmxlOjYzNjVkN2Y4YTZlYzQ4MzNiN2U3OTk3OWNlYjI2YWJlL3RhYmxlcmFuZ2U6NjM2NWQ3ZjhhNmVjNDgzM2I3ZTc5OTc5Y2ViMjZhYmVfNS0zLTEtMS04MQ_8447b428-b46a-4928-ac17-4760c2443388">290,752</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:13.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b4376f8fc614de98c9cf647198c504e_I20220930" decimals="-3" name="us-gaap:AccountsReceivableNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xNi9mcmFnOjU2YmVmNWVkZGUxMDRjZDJiNzQxZGJmMjY2YmMwZmRmL3RhYmxlOjYzNjVkN2Y4YTZlYzQ4MzNiN2U3OTk3OWNlYjI2YWJlL3RhYmxlcmFuZ2U6NjM2NWQ3ZjhhNmVjNDgzM2I3ZTc5OTc5Y2ViMjZhYmVfNi0xLTEtMS04MQ_63760925-3c05-4de4-93c0-c19f4c4ff21c">618,188</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab26fe441f0d4ab984456365a7f7cff0_I20211231" decimals="-3" name="us-gaap:AccountsReceivableNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xNi9mcmFnOjU2YmVmNWVkZGUxMDRjZDJiNzQxZGJmMjY2YmMwZmRmL3RhYmxlOjYzNjVkN2Y4YTZlYzQ4MzNiN2U3OTk3OWNlYjI2YWJlL3RhYmxlcmFuZ2U6NjM2NWQ3ZjhhNmVjNDgzM2I3ZTc5OTc5Y2ViMjZhYmVfNi0zLTEtMS04MQ_93372401-3097-4fb4-aba5-1515d244972a">616,300</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:13.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b4376f8fc614de98c9cf647198c504e_I20220930" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xNi9mcmFnOjU2YmVmNWVkZGUxMDRjZDJiNzQxZGJmMjY2YmMwZmRmL3RhYmxlOjYzNjVkN2Y4YTZlYzQ4MzNiN2U3OTk3OWNlYjI2YWJlL3RhYmxlcmFuZ2U6NjM2NWQ3ZjhhNmVjNDgzM2I3ZTc5OTc5Y2ViMjZhYmVfNy0xLTEtMS04MQ_d9ef4e56-e087-4a74-8959-36aac25be7ab">45,869</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab26fe441f0d4ab984456365a7f7cff0_I20211231" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xNi9mcmFnOjU2YmVmNWVkZGUxMDRjZDJiNzQxZGJmMjY2YmMwZmRmL3RhYmxlOjYzNjVkN2Y4YTZlYzQ4MzNiN2U3OTk3OWNlYjI2YWJlL3RhYmxlcmFuZ2U6NjM2NWQ3ZjhhNmVjNDgzM2I3ZTc5OTc5Y2ViMjZhYmVfNy0zLTEtMS04MQ_aff617bc-e83b-4e79-ba13-d5ae914094ce">27,904</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:13.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b4376f8fc614de98c9cf647198c504e_I20220930" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xNi9mcmFnOjU2YmVmNWVkZGUxMDRjZDJiNzQxZGJmMjY2YmMwZmRmL3RhYmxlOjYzNjVkN2Y4YTZlYzQ4MzNiN2U3OTk3OWNlYjI2YWJlL3RhYmxlcmFuZ2U6NjM2NWQ3ZjhhNmVjNDgzM2I3ZTc5OTc5Y2ViMjZhYmVfOC0xLTEtMS04MQ_91d25526-14b7-4e41-b099-a1acaf36e23e">179,932</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab26fe441f0d4ab984456365a7f7cff0_I20211231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xNi9mcmFnOjU2YmVmNWVkZGUxMDRjZDJiNzQxZGJmMjY2YmMwZmRmL3RhYmxlOjYzNjVkN2Y4YTZlYzQ4MzNiN2U3OTk3OWNlYjI2YWJlL3RhYmxlcmFuZ2U6NjM2NWQ3ZjhhNmVjNDgzM2I3ZTc5OTc5Y2ViMjZhYmVfOC0zLTEtMS04MQ_aed9435f-2377-4b84-9119-be8127f671c6">126,278</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b4376f8fc614de98c9cf647198c504e_I20220930" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xNi9mcmFnOjU2YmVmNWVkZGUxMDRjZDJiNzQxZGJmMjY2YmMwZmRmL3RhYmxlOjYzNjVkN2Y4YTZlYzQ4MzNiN2U3OTk3OWNlYjI2YWJlL3RhYmxlcmFuZ2U6NjM2NWQ3ZjhhNmVjNDgzM2I3ZTc5OTc5Y2ViMjZhYmVfOS0xLTEtMS04MQ_f7e86627-cd0d-4920-bd4e-0168bcda78fd">3,821,111</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab26fe441f0d4ab984456365a7f7cff0_I20211231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xNi9mcmFnOjU2YmVmNWVkZGUxMDRjZDJiNzQxZGJmMjY2YmMwZmRmL3RhYmxlOjYzNjVkN2Y4YTZlYzQ4MzNiN2U3OTk3OWNlYjI2YWJlL3RhYmxlcmFuZ2U6NjM2NWQ3ZjhhNmVjNDgzM2I3ZTc5OTc5Y2ViMjZhYmVfOS0zLTEtMS04MQ_81b9eb28-02b2-4c34-bee1-9bb788316700">3,118,674</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted cash and investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b4376f8fc614de98c9cf647198c504e_I20220930" decimals="-3" name="us-gaap:RestrictedCashAndInvestmentsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xNi9mcmFnOjU2YmVmNWVkZGUxMDRjZDJiNzQxZGJmMjY2YmMwZmRmL3RhYmxlOjYzNjVkN2Y4YTZlYzQ4MzNiN2U3OTk3OWNlYjI2YWJlL3RhYmxlcmFuZ2U6NjM2NWQ3ZjhhNmVjNDgzM2I3ZTc5OTc5Y2ViMjZhYmVfMTEtMS0xLTEtODE_69dae89f-7602-43d1-b0f1-c52d6dae8a7b">1,601</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab26fe441f0d4ab984456365a7f7cff0_I20211231" decimals="-3" name="us-gaap:RestrictedCashAndInvestmentsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xNi9mcmFnOjU2YmVmNWVkZGUxMDRjZDJiNzQxZGJmMjY2YmMwZmRmL3RhYmxlOjYzNjVkN2Y4YTZlYzQ4MzNiN2U3OTk3OWNlYjI2YWJlL3RhYmxlcmFuZ2U6NjM2NWQ3ZjhhNmVjNDgzM2I3ZTc5OTc5Y2ViMjZhYmVfMTEtMy0xLTEtODE_1eb8b233-ac57-49b7-b80b-6dc5ff7e8b64">1,720</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long term investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b4376f8fc614de98c9cf647198c504e_I20220930" decimals="-3" name="us-gaap:LongTermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xNi9mcmFnOjU2YmVmNWVkZGUxMDRjZDJiNzQxZGJmMjY2YmMwZmRmL3RhYmxlOjYzNjVkN2Y4YTZlYzQ4MzNiN2U3OTk3OWNlYjI2YWJlL3RhYmxlcmFuZ2U6NjM2NWQ3ZjhhNmVjNDgzM2I3ZTc5OTc5Y2ViMjZhYmVfMTItMS0xLTEtODE_5c3e4289-22c2-459c-9b2e-e27d5105a9cf">149,124</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab26fe441f0d4ab984456365a7f7cff0_I20211231" decimals="-3" name="us-gaap:LongTermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xNi9mcmFnOjU2YmVmNWVkZGUxMDRjZDJiNzQxZGJmMjY2YmMwZmRmL3RhYmxlOjYzNjVkN2Y4YTZlYzQ4MzNiN2U3OTk3OWNlYjI2YWJlL3RhYmxlcmFuZ2U6NjM2NWQ3ZjhhNmVjNDgzM2I3ZTc5OTc5Y2ViMjZhYmVfMTItMy0xLTEtODE_b323390b-adc3-44f6-9ca5-da0d1e781f1f">221,266</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b4376f8fc614de98c9cf647198c504e_I20220930" decimals="-3" name="us-gaap:InventoryNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xNi9mcmFnOjU2YmVmNWVkZGUxMDRjZDJiNzQxZGJmMjY2YmMwZmRmL3RhYmxlOjYzNjVkN2Y4YTZlYzQ4MzNiN2U3OTk3OWNlYjI2YWJlL3RhYmxlcmFuZ2U6NjM2NWQ3ZjhhNmVjNDgzM2I3ZTc5OTc5Y2ViMjZhYmVfMTMtMS0xLTEtODE_897afb13-d5e8-4832-a80a-ba4997cbc1bc">55,264</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab26fe441f0d4ab984456365a7f7cff0_I20211231" decimals="-3" name="us-gaap:InventoryNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xNi9mcmFnOjU2YmVmNWVkZGUxMDRjZDJiNzQxZGJmMjY2YmMwZmRmL3RhYmxlOjYzNjVkN2Y4YTZlYzQ4MzNiN2U3OTk3OWNlYjI2YWJlL3RhYmxlcmFuZ2U6NjM2NWQ3ZjhhNmVjNDgzM2I3ZTc5OTc5Y2ViMjZhYmVfMTMtMy0xLTEtODE_9a27dc54-09b2-4aeb-bc2e-2812da731fba">29,034</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b4376f8fc614de98c9cf647198c504e_I20220930" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xNi9mcmFnOjU2YmVmNWVkZGUxMDRjZDJiNzQxZGJmMjY2YmMwZmRmL3RhYmxlOjYzNjVkN2Y4YTZlYzQ4MzNiN2U3OTk3OWNlYjI2YWJlL3RhYmxlcmFuZ2U6NjM2NWQ3ZjhhNmVjNDgzM2I3ZTc5OTc5Y2ViMjZhYmVfMTQtMS0xLTEtODE_9d48347a-7223-4785-8167-ee5c64a99716">715,733</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab26fe441f0d4ab984456365a7f7cff0_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xNi9mcmFnOjU2YmVmNWVkZGUxMDRjZDJiNzQxZGJmMjY2YmMwZmRmL3RhYmxlOjYzNjVkN2Y4YTZlYzQ4MzNiN2U3OTk3OWNlYjI2YWJlL3RhYmxlcmFuZ2U6NjM2NWQ3ZjhhNmVjNDgzM2I3ZTc5OTc5Y2ViMjZhYmVfMTQtMy0xLTEtODE_71b0801d-b954-45fc-84eb-ff277b2205fd">723,920</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finance lease right-of-use assets, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b4376f8fc614de98c9cf647198c504e_I20220930" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xNi9mcmFnOjU2YmVmNWVkZGUxMDRjZDJiNzQxZGJmMjY2YmMwZmRmL3RhYmxlOjYzNjVkN2Y4YTZlYzQ4MzNiN2U3OTk3OWNlYjI2YWJlL3RhYmxlcmFuZ2U6NjM2NWQ3ZjhhNmVjNDgzM2I3ZTc5OTc5Y2ViMjZhYmVfMTUtMS0xLTEtODE_f3d012ab-e32d-445b-8a45-e7986b47b222">26,679</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab26fe441f0d4ab984456365a7f7cff0_I20211231" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xNi9mcmFnOjU2YmVmNWVkZGUxMDRjZDJiNzQxZGJmMjY2YmMwZmRmL3RhYmxlOjYzNjVkN2Y4YTZlYzQ4MzNiN2U3OTk3OWNlYjI2YWJlL3RhYmxlcmFuZ2U6NjM2NWQ3ZjhhNmVjNDgzM2I3ZTc5OTc5Y2ViMjZhYmVfMTUtMy0xLTEtODE_9cbf1282-7290-4660-a18c-74da206f8b29">27,548</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other intangible assets, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b4376f8fc614de98c9cf647198c504e_I20220930" decimals="-3" name="us-gaap:OtherIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xNi9mcmFnOjU2YmVmNWVkZGUxMDRjZDJiNzQxZGJmMjY2YmMwZmRmL3RhYmxlOjYzNjVkN2Y4YTZlYzQ4MzNiN2U3OTk3OWNlYjI2YWJlL3RhYmxlcmFuZ2U6NjM2NWQ3ZjhhNmVjNDgzM2I3ZTc5OTc5Y2ViMjZhYmVfMTYtMS0xLTEtODE_9e3385ba-7bff-4db8-b8f5-67f1fd5caf73">134,603</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab26fe441f0d4ab984456365a7f7cff0_I20211231" decimals="-3" name="us-gaap:OtherIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xNi9mcmFnOjU2YmVmNWVkZGUxMDRjZDJiNzQxZGJmMjY2YmMwZmRmL3RhYmxlOjYzNjVkN2Y4YTZlYzQ4MzNiN2U3OTk3OWNlYjI2YWJlL3RhYmxlcmFuZ2U6NjM2NWQ3ZjhhNmVjNDgzM2I3ZTc5OTc5Y2ViMjZhYmVfMTYtMy0xLTEtODE_3c8bc890-fde8-4564-ac76-59c3ee25fb1a">150,755</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b4376f8fc614de98c9cf647198c504e_I20220930" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xNi9mcmFnOjU2YmVmNWVkZGUxMDRjZDJiNzQxZGJmMjY2YmMwZmRmL3RhYmxlOjYzNjVkN2Y4YTZlYzQ4MzNiN2U3OTk3OWNlYjI2YWJlL3RhYmxlcmFuZ2U6NjM2NWQ3ZjhhNmVjNDgzM2I3ZTc5OTc5Y2ViMjZhYmVfMTctMS0xLTEtODE_899b57e8-7f5e-43f2-9531-2f08affa5e52">155,593</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab26fe441f0d4ab984456365a7f7cff0_I20211231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xNi9mcmFnOjU2YmVmNWVkZGUxMDRjZDJiNzQxZGJmMjY2YmMwZmRmL3RhYmxlOjYzNjVkN2Y4YTZlYzQ4MzNiN2U3OTk3OWNlYjI2YWJlL3RhYmxlcmFuZ2U6NjM2NWQ3ZjhhNmVjNDgzM2I3ZTc5OTc5Y2ViMjZhYmVfMTctMy0xLTEtODE_ab21b2d1-a513-460b-aa0e-011f8c5fb90f">155,593</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred income tax asset</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b4376f8fc614de98c9cf647198c504e_I20220930" decimals="-3" name="us-gaap:DeferredIncomeTaxAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xNi9mcmFnOjU2YmVmNWVkZGUxMDRjZDJiNzQxZGJmMjY2YmMwZmRmL3RhYmxlOjYzNjVkN2Y4YTZlYzQ4MzNiN2U3OTk3OWNlYjI2YWJlL3RhYmxlcmFuZ2U6NjM2NWQ3ZjhhNmVjNDgzM2I3ZTc5OTc5Y2ViMjZhYmVfMTgtMS0xLTEtODE_07b3e962-1300-4cb1-8cb7-aa1e724dd524">426,840</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab26fe441f0d4ab984456365a7f7cff0_I20211231" decimals="-3" name="us-gaap:DeferredIncomeTaxAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xNi9mcmFnOjU2YmVmNWVkZGUxMDRjZDJiNzQxZGJmMjY2YmMwZmRmL3RhYmxlOjYzNjVkN2Y4YTZlYzQ4MzNiN2U3OTk3OWNlYjI2YWJlL3RhYmxlcmFuZ2U6NjM2NWQ3ZjhhNmVjNDgzM2I3ZTc5OTc5Y2ViMjZhYmVfMTgtMy0xLTEtODE_4fe141c1-36fa-4b5a-ba12-9101a45137d3">467,538</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b4376f8fc614de98c9cf647198c504e_I20220930" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xNi9mcmFnOjU2YmVmNWVkZGUxMDRjZDJiNzQxZGJmMjY2YmMwZmRmL3RhYmxlOjYzNjVkN2Y4YTZlYzQ4MzNiN2U3OTk3OWNlYjI2YWJlL3RhYmxlcmFuZ2U6NjM2NWQ3ZjhhNmVjNDgzM2I3ZTc5OTc5Y2ViMjZhYmVfMTktMS0xLTEtODE_001c5dd9-42d5-4650-baa7-2fe0e9aa80f2">23,666</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab26fe441f0d4ab984456365a7f7cff0_I20211231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xNi9mcmFnOjU2YmVmNWVkZGUxMDRjZDJiNzQxZGJmMjY2YmMwZmRmL3RhYmxlOjYzNjVkN2Y4YTZlYzQ4MzNiN2U3OTk3OWNlYjI2YWJlL3RhYmxlcmFuZ2U6NjM2NWQ3ZjhhNmVjNDgzM2I3ZTc5OTc5Y2ViMjZhYmVfMTktMy0xLTEtODE_fdb90fb3-94e4-4c9a-bb58-460ccb3832eb">37,304</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b4376f8fc614de98c9cf647198c504e_I20220930" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xNi9mcmFnOjU2YmVmNWVkZGUxMDRjZDJiNzQxZGJmMjY2YmMwZmRmL3RhYmxlOjYzNjVkN2Y4YTZlYzQ4MzNiN2U3OTk3OWNlYjI2YWJlL3RhYmxlcmFuZ2U6NjM2NWQ3ZjhhNmVjNDgzM2I3ZTc5OTc5Y2ViMjZhYmVfMjAtMS0xLTEtODE_a8c0027d-86df-4f50-bb68-ed96157685b9">5,510,214</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab26fe441f0d4ab984456365a7f7cff0_I20211231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xNi9mcmFnOjU2YmVmNWVkZGUxMDRjZDJiNzQxZGJmMjY2YmMwZmRmL3RhYmxlOjYzNjVkN2Y4YTZlYzQ4MzNiN2U3OTk3OWNlYjI2YWJlL3RhYmxlcmFuZ2U6NjM2NWQ3ZjhhNmVjNDgzM2I3ZTc5OTc5Y2ViMjZhYmVfMjAtMy0xLTEtODE_f9778eb7-1f32-44c8-85fd-d0130e80875c">4,933,352</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b4376f8fc614de98c9cf647198c504e_I20220930" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xNi9mcmFnOjU2YmVmNWVkZGUxMDRjZDJiNzQxZGJmMjY2YmMwZmRmL3RhYmxlOjYzNjVkN2Y4YTZlYzQ4MzNiN2U3OTk3OWNlYjI2YWJlL3RhYmxlcmFuZ2U6NjM2NWQ3ZjhhNmVjNDgzM2I3ZTc5OTc5Y2ViMjZhYmVfMjQtMS0xLTEtODE_a04615b3-92f2-43fc-811d-4256e5a24a02">163,175</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab26fe441f0d4ab984456365a7f7cff0_I20211231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xNi9mcmFnOjU2YmVmNWVkZGUxMDRjZDJiNzQxZGJmMjY2YmMwZmRmL3RhYmxlOjYzNjVkN2Y4YTZlYzQ4MzNiN2U3OTk3OWNlYjI2YWJlL3RhYmxlcmFuZ2U6NjM2NWQ3ZjhhNmVjNDgzM2I3ZTc5OTc5Y2ViMjZhYmVfMjQtMy0xLTEtODE_40835c2b-2701-4902-ab73-88396e64c3c6">172,110</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b4376f8fc614de98c9cf647198c504e_I20220930" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xNi9mcmFnOjU2YmVmNWVkZGUxMDRjZDJiNzQxZGJmMjY2YmMwZmRmL3RhYmxlOjYzNjVkN2Y4YTZlYzQ4MzNiN2U3OTk3OWNlYjI2YWJlL3RhYmxlcmFuZ2U6NjM2NWQ3ZjhhNmVjNDgzM2I3ZTc5OTc5Y2ViMjZhYmVfMjUtMS0xLTEtODE_36e5b2bd-82f1-417c-869f-d5ce8960c323">106,309</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab26fe441f0d4ab984456365a7f7cff0_I20211231" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xNi9mcmFnOjU2YmVmNWVkZGUxMDRjZDJiNzQxZGJmMjY2YmMwZmRmL3RhYmxlOjYzNjVkN2Y4YTZlYzQ4MzNiN2U3OTk3OWNlYjI2YWJlL3RhYmxlcmFuZ2U6NjM2NWQ3ZjhhNmVjNDgzM2I3ZTc5OTc5Y2ViMjZhYmVfMjUtMy0xLTEtODE_8c276706-81be-4435-b85a-22f276bffe25">108,962</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b4376f8fc614de98c9cf647198c504e_I20220930" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xNi9mcmFnOjU2YmVmNWVkZGUxMDRjZDJiNzQxZGJmMjY2YmMwZmRmL3RhYmxlOjYzNjVkN2Y4YTZlYzQ4MzNiN2U3OTk3OWNlYjI2YWJlL3RhYmxlcmFuZ2U6NjM2NWQ3ZjhhNmVjNDgzM2I3ZTc5OTc5Y2ViMjZhYmVfMjYtMS0xLTEtODE_3c826445-0008-496d-95e6-46de75f46100">699,814</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab26fe441f0d4ab984456365a7f7cff0_I20211231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xNi9mcmFnOjU2YmVmNWVkZGUxMDRjZDJiNzQxZGJmMjY2YmMwZmRmL3RhYmxlOjYzNjVkN2Y4YTZlYzQ4MzNiN2U3OTk3OWNlYjI2YWJlL3RhYmxlcmFuZ2U6NjM2NWQ3ZjhhNmVjNDgzM2I3ZTc5OTc5Y2ViMjZhYmVfMjYtMy0xLTEtODE_4485d81c-8885-4ab6-a73b-2c1cd340972e">533,595</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finance lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b4376f8fc614de98c9cf647198c504e_I20220930" decimals="-3" name="us-gaap:FinanceLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xNi9mcmFnOjU2YmVmNWVkZGUxMDRjZDJiNzQxZGJmMjY2YmMwZmRmL3RhYmxlOjYzNjVkN2Y4YTZlYzQ4MzNiN2U3OTk3OWNlYjI2YWJlL3RhYmxlcmFuZ2U6NjM2NWQ3ZjhhNmVjNDgzM2I3ZTc5OTc5Y2ViMjZhYmVfMjctMS0xLTEtODE_14eb8213-0b1c-46df-9024-b95e8ba1b293">3,112</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab26fe441f0d4ab984456365a7f7cff0_I20211231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xNi9mcmFnOjU2YmVmNWVkZGUxMDRjZDJiNzQxZGJmMjY2YmMwZmRmL3RhYmxlOjYzNjVkN2Y4YTZlYzQ4MzNiN2U3OTk3OWNlYjI2YWJlL3RhYmxlcmFuZ2U6NjM2NWQ3ZjhhNmVjNDgzM2I3ZTc5OTc5Y2ViMjZhYmVfMjctMy0xLTEtODE_0ddb063b-99fb-4074-bb5e-161346260c11">2,635</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisition-related contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b4376f8fc614de98c9cf647198c504e_I20220930" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xNi9mcmFnOjU2YmVmNWVkZGUxMDRjZDJiNzQxZGJmMjY2YmMwZmRmL3RhYmxlOjYzNjVkN2Y4YTZlYzQ4MzNiN2U3OTk3OWNlYjI2YWJlL3RhYmxlcmFuZ2U6NjM2NWQ3ZjhhNmVjNDgzM2I3ZTc5OTc5Y2ViMjZhYmVfMjgtMS0xLTEtODE_259523bf-94d7-4203-aeeb-4b12950fb539">34,186</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab26fe441f0d4ab984456365a7f7cff0_I20211231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xNi9mcmFnOjU2YmVmNWVkZGUxMDRjZDJiNzQxZGJmMjY2YmMwZmRmL3RhYmxlOjYzNjVkN2Y4YTZlYzQ4MzNiN2U3OTk3OWNlYjI2YWJlL3RhYmxlcmFuZ2U6NjM2NWQ3ZjhhNmVjNDgzM2I3ZTc5OTc5Y2ViMjZhYmVfMjgtMy0xLTEtODE_3f686dc6-921a-48c9-b3b6-b5bb80ea7705">37,006</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b4376f8fc614de98c9cf647198c504e_I20220930" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xNi9mcmFnOjU2YmVmNWVkZGUxMDRjZDJiNzQxZGJmMjY2YmMwZmRmL3RhYmxlOjYzNjVkN2Y4YTZlYzQ4MzNiN2U3OTk3OWNlYjI2YWJlL3RhYmxlcmFuZ2U6NjM2NWQ3ZjhhNmVjNDgzM2I3ZTc5OTc5Y2ViMjZhYmVfMjktMS0xLTEtODE_811c69b4-b379-4806-b467-b3bde0f1d848">1,006,596</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab26fe441f0d4ab984456365a7f7cff0_I20211231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xNi9mcmFnOjU2YmVmNWVkZGUxMDRjZDJiNzQxZGJmMjY2YmMwZmRmL3RhYmxlOjYzNjVkN2Y4YTZlYzQ4MzNiN2U3OTk3OWNlYjI2YWJlL3RhYmxlcmFuZ2U6NjM2NWQ3ZjhhNmVjNDgzM2I3ZTc5OTc5Y2ViMjZhYmVfMjktMy0xLTEtODE_7551f906-fdc2-4d6a-ae54-df910ab40792">854,308</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisition-related contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b4376f8fc614de98c9cf647198c504e_I20220930" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xNi9mcmFnOjU2YmVmNWVkZGUxMDRjZDJiNzQxZGJmMjY2YmMwZmRmL3RhYmxlOjYzNjVkN2Y4YTZlYzQ4MzNiN2U3OTk3OWNlYjI2YWJlL3RhYmxlcmFuZ2U6NjM2NWQ3ZjhhNmVjNDgzM2I3ZTc5OTc5Y2ViMjZhYmVfMzEtMS0xLTEtODE_00293365-c451-43a6-b69c-bbbdd79126a9">171,814</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab26fe441f0d4ab984456365a7f7cff0_I20211231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xNi9mcmFnOjU2YmVmNWVkZGUxMDRjZDJiNzQxZGJmMjY2YmMwZmRmL3RhYmxlOjYzNjVkN2Y4YTZlYzQ4MzNiN2U3OTk3OWNlYjI2YWJlL3RhYmxlcmFuZ2U6NjM2NWQ3ZjhhNmVjNDgzM2I3ZTc5OTc5Y2ViMjZhYmVfMzEtMy0xLTEtODE_78afe528-fbdd-41a9-8671-bea1133b8408">206,994</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finance lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b4376f8fc614de98c9cf647198c504e_I20220930" decimals="-3" name="us-gaap:FinanceLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xNi9mcmFnOjU2YmVmNWVkZGUxMDRjZDJiNzQxZGJmMjY2YmMwZmRmL3RhYmxlOjYzNjVkN2Y4YTZlYzQ4MzNiN2U3OTk3OWNlYjI2YWJlL3RhYmxlcmFuZ2U6NjM2NWQ3ZjhhNmVjNDgzM2I3ZTc5OTc5Y2ViMjZhYmVfMzItMS0xLTEtODE_e02fb9cc-d267-4ed1-8fdc-8e311e94c97b">30,476</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab26fe441f0d4ab984456365a7f7cff0_I20211231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xNi9mcmFnOjU2YmVmNWVkZGUxMDRjZDJiNzQxZGJmMjY2YmMwZmRmL3RhYmxlOjYzNjVkN2Y4YTZlYzQ4MzNiN2U3OTk3OWNlYjI2YWJlL3RhYmxlcmFuZ2U6NjM2NWQ3ZjhhNmVjNDgzM2I3ZTc5OTc5Y2ViMjZhYmVfMzItMy0xLTEtODE_7fb409bb-4543-4991-80ed-9c1ee575422e">31,632</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b4376f8fc614de98c9cf647198c504e_I20220930" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xNi9mcmFnOjU2YmVmNWVkZGUxMDRjZDJiNzQxZGJmMjY2YmMwZmRmL3RhYmxlOjYzNjVkN2Y4YTZlYzQ4MzNiN2U3OTk3OWNlYjI2YWJlL3RhYmxlcmFuZ2U6NjM2NWQ3ZjhhNmVjNDgzM2I3ZTc5OTc5Y2ViMjZhYmVfMzMtMS0xLTEtODE_82c5e17e-73b6-4912-9cec-976d56bb9c94">74,677</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab26fe441f0d4ab984456365a7f7cff0_I20211231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xNi9mcmFnOjU2YmVmNWVkZGUxMDRjZDJiNzQxZGJmMjY2YmMwZmRmL3RhYmxlOjYzNjVkN2Y4YTZlYzQ4MzNiN2U3OTk3OWNlYjI2YWJlL3RhYmxlcmFuZ2U6NjM2NWQ3ZjhhNmVjNDgzM2I3ZTc5OTc5Y2ViMjZhYmVfMzMtMy0xLTEtODE_fb0a3293-be85-464c-b55d-e576a9479bf6">70,414</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b4376f8fc614de98c9cf647198c504e_I20220930" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xNi9mcmFnOjU2YmVmNWVkZGUxMDRjZDJiNzQxZGJmMjY2YmMwZmRmL3RhYmxlOjYzNjVkN2Y4YTZlYzQ4MzNiN2U3OTk3OWNlYjI2YWJlL3RhYmxlcmFuZ2U6NjM2NWQ3ZjhhNmVjNDgzM2I3ZTc5OTc5Y2ViMjZhYmVfMzQtMS0xLTEtODE_3968a780-6aea-48e1-aafb-bda80dd87884">1,283,563</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab26fe441f0d4ab984456365a7f7cff0_I20211231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xNi9mcmFnOjU2YmVmNWVkZGUxMDRjZDJiNzQxZGJmMjY2YmMwZmRmL3RhYmxlOjYzNjVkN2Y4YTZlYzQ4MzNiN2U3OTk3OWNlYjI2YWJlL3RhYmxlcmFuZ2U6NjM2NWQ3ZjhhNmVjNDgzM2I3ZTc5OTc5Y2ViMjZhYmVfMzQtMy0xLTEtODE_91727336-f662-48d2-993e-b2b8b0696a27">1,163,348</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commitments and contingencies (Note 14)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i3b4376f8fc614de98c9cf647198c504e_I20220930" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xNi9mcmFnOjU2YmVmNWVkZGUxMDRjZDJiNzQxZGJmMjY2YmMwZmRmL3RhYmxlOjYzNjVkN2Y4YTZlYzQ4MzNiN2U3OTk3OWNlYjI2YWJlL3RhYmxlcmFuZ2U6NjM2NWQ3ZjhhNmVjNDgzM2I3ZTc5OTc5Y2ViMjZhYmVfMzYtMS0xLTEtODE_aafa9975-26ff-4ffa-bad8-47cb08f36d24"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="iab26fe441f0d4ab984456365a7f7cff0_I20211231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xNi9mcmFnOjU2YmVmNWVkZGUxMDRjZDJiNzQxZGJmMjY2YmMwZmRmL3RhYmxlOjYzNjVkN2Y4YTZlYzQ4MzNiN2U3OTk3OWNlYjI2YWJlL3RhYmxlcmFuZ2U6NjM2NWQ3ZjhhNmVjNDgzM2I3ZTc5OTc5Y2ViMjZhYmVfMzYtMy0xLTEtODE_ea1762bc-f12a-4cf9-a3c2-70767c18b248"></ix:nonFraction></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stockholders&#8217; equity:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="iab26fe441f0d4ab984456365a7f7cff0_I20211231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xNi9mcmFnOjU2YmVmNWVkZGUxMDRjZDJiNzQxZGJmMjY2YmMwZmRmL3RhYmxlOjYzNjVkN2Y4YTZlYzQ4MzNiN2U3OTk3OWNlYjI2YWJlL3RhYmxlcmFuZ2U6NjM2NWQ3ZjhhNmVjNDgzM2I3ZTc5OTc5Y2ViMjZhYmVfMzktMC0xLTEtODEvdGV4dHJlZ2lvbjo1MTMwNDVkZGU3NjQ0MTVhOGZlNjU0NDk3OWI1MjY3Zl8yMQ_083aa109-7ca1-486b-8006-897cd8e734ce"><ix:nonFraction unitRef="usdPerShare" contextRef="i3b4376f8fc614de98c9cf647198c504e_I20220930" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xNi9mcmFnOjU2YmVmNWVkZGUxMDRjZDJiNzQxZGJmMjY2YmMwZmRmL3RhYmxlOjYzNjVkN2Y4YTZlYzQ4MzNiN2U3OTk3OWNlYjI2YWJlL3RhYmxlcmFuZ2U6NjM2NWQ3ZjhhNmVjNDgzM2I3ZTc5OTc5Y2ViMjZhYmVfMzktMC0xLTEtODEvdGV4dHJlZ2lvbjo1MTMwNDVkZGU3NjQ0MTVhOGZlNjU0NDk3OWI1MjY3Zl8yMQ_f492395a-56e8-4c1d-a889-f855edbd70d9">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="iab26fe441f0d4ab984456365a7f7cff0_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xNi9mcmFnOjU2YmVmNWVkZGUxMDRjZDJiNzQxZGJmMjY2YmMwZmRmL3RhYmxlOjYzNjVkN2Y4YTZlYzQ4MzNiN2U3OTk3OWNlYjI2YWJlL3RhYmxlcmFuZ2U6NjM2NWQ3ZjhhNmVjNDgzM2I3ZTc5OTc5Y2ViMjZhYmVfMzktMC0xLTEtODEvdGV4dHJlZ2lvbjo1MTMwNDVkZGU3NjQ0MTVhOGZlNjU0NDk3OWI1MjY3Zl8zNQ_9f544bf8-881d-4d71-b910-67001829bcaa"><ix:nonFraction unitRef="shares" contextRef="i3b4376f8fc614de98c9cf647198c504e_I20220930" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xNi9mcmFnOjU2YmVmNWVkZGUxMDRjZDJiNzQxZGJmMjY2YmMwZmRmL3RhYmxlOjYzNjVkN2Y4YTZlYzQ4MzNiN2U3OTk3OWNlYjI2YWJlL3RhYmxlcmFuZ2U6NjM2NWQ3ZjhhNmVjNDgzM2I3ZTc5OTc5Y2ViMjZhYmVfMzktMC0xLTEtODEvdGV4dHJlZ2lvbjo1MTMwNDVkZGU3NjQ0MTVhOGZlNjU0NDk3OWI1MjY3Zl8zNQ_fa7b3925-05af-4963-a376-e5103a0adf9f">5,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="iab26fe441f0d4ab984456365a7f7cff0_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xNi9mcmFnOjU2YmVmNWVkZGUxMDRjZDJiNzQxZGJmMjY2YmMwZmRmL3RhYmxlOjYzNjVkN2Y4YTZlYzQ4MzNiN2U3OTk3OWNlYjI2YWJlL3RhYmxlcmFuZ2U6NjM2NWQ3ZjhhNmVjNDgzM2I3ZTc5OTc5Y2ViMjZhYmVfMzktMC0xLTEtODEvdGV4dHJlZ2lvbjo1MTMwNDVkZGU3NjQ0MTVhOGZlNjU0NDk3OWI1MjY3Zl81Nw_3517604c-a00b-4a87-b389-fe83e63d8693"><ix:nonFraction unitRef="shares" contextRef="iab26fe441f0d4ab984456365a7f7cff0_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xNi9mcmFnOjU2YmVmNWVkZGUxMDRjZDJiNzQxZGJmMjY2YmMwZmRmL3RhYmxlOjYzNjVkN2Y4YTZlYzQ4MzNiN2U3OTk3OWNlYjI2YWJlL3RhYmxlcmFuZ2U6NjM2NWQ3ZjhhNmVjNDgzM2I3ZTc5OTc5Y2ViMjZhYmVfMzktMC0xLTEtODEvdGV4dHJlZ2lvbjo1MTMwNDVkZGU3NjQ0MTVhOGZlNjU0NDk3OWI1MjY3Zl81Nw_593251b2-6d1d-4c05-84ac-3d6cceafcf88"><ix:nonFraction unitRef="shares" contextRef="i3b4376f8fc614de98c9cf647198c504e_I20220930" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xNi9mcmFnOjU2YmVmNWVkZGUxMDRjZDJiNzQxZGJmMjY2YmMwZmRmL3RhYmxlOjYzNjVkN2Y4YTZlYzQ4MzNiN2U3OTk3OWNlYjI2YWJlL3RhYmxlcmFuZ2U6NjM2NWQ3ZjhhNmVjNDgzM2I3ZTc5OTc5Y2ViMjZhYmVfMzktMC0xLTEtODEvdGV4dHJlZ2lvbjo1MTMwNDVkZGU3NjQ0MTVhOGZlNjU0NDk3OWI1MjY3Zl81Nw_9df062b2-622d-41fd-8c11-dc09d12d5bd7"><ix:nonFraction unitRef="shares" contextRef="i3b4376f8fc614de98c9cf647198c504e_I20220930" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xNi9mcmFnOjU2YmVmNWVkZGUxMDRjZDJiNzQxZGJmMjY2YmMwZmRmL3RhYmxlOjYzNjVkN2Y4YTZlYzQ4MzNiN2U3OTk3OWNlYjI2YWJlL3RhYmxlcmFuZ2U6NjM2NWQ3ZjhhNmVjNDgzM2I3ZTc5OTc5Y2ViMjZhYmVfMzktMC0xLTEtODEvdGV4dHJlZ2lvbjo1MTMwNDVkZGU3NjQ0MTVhOGZlNjU0NDk3OWI1MjY3Zl81Nw_ccec3e3c-7798-4518-b9b0-a8f77f39df2a">none</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> issued or outstanding</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b4376f8fc614de98c9cf647198c504e_I20220930" decimals="0" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xNi9mcmFnOjU2YmVmNWVkZGUxMDRjZDJiNzQxZGJmMjY2YmMwZmRmL3RhYmxlOjYzNjVkN2Y4YTZlYzQ4MzNiN2U3OTk3OWNlYjI2YWJlL3RhYmxlcmFuZ2U6NjM2NWQ3ZjhhNmVjNDgzM2I3ZTc5OTc5Y2ViMjZhYmVfMzktMS0xLTEtODE_c6d336d8-9fad-4790-8205-df44b2a70731">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab26fe441f0d4ab984456365a7f7cff0_I20211231" decimals="0" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xNi9mcmFnOjU2YmVmNWVkZGUxMDRjZDJiNzQxZGJmMjY2YmMwZmRmL3RhYmxlOjYzNjVkN2Y4YTZlYzQ4MzNiN2U3OTk3OWNlYjI2YWJlL3RhYmxlcmFuZ2U6NjM2NWQ3ZjhhNmVjNDgzM2I3ZTc5OTc5Y2ViMjZhYmVfMzktMy0xLTEtODE_e96915b5-acdb-463a-be5c-735c8a614d7c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="iab26fe441f0d4ab984456365a7f7cff0_I20211231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xNi9mcmFnOjU2YmVmNWVkZGUxMDRjZDJiNzQxZGJmMjY2YmMwZmRmL3RhYmxlOjYzNjVkN2Y4YTZlYzQ4MzNiN2U3OTk3OWNlYjI2YWJlL3RhYmxlcmFuZ2U6NjM2NWQ3ZjhhNmVjNDgzM2I3ZTc5OTc5Y2ViMjZhYmVfNDAtMC0xLTEtODEvdGV4dHJlZ2lvbjozODFlN2RmNWIyOTc0OWU1YjdmMmI3YTBhODFkYjk3NV8xOA_0f1ca0e8-8a11-46ea-87d6-5ccd2192f78b"><ix:nonFraction unitRef="usdPerShare" contextRef="i3b4376f8fc614de98c9cf647198c504e_I20220930" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xNi9mcmFnOjU2YmVmNWVkZGUxMDRjZDJiNzQxZGJmMjY2YmMwZmRmL3RhYmxlOjYzNjVkN2Y4YTZlYzQ4MzNiN2U3OTk3OWNlYjI2YWJlL3RhYmxlcmFuZ2U6NjM2NWQ3ZjhhNmVjNDgzM2I3ZTc5OTc5Y2ViMjZhYmVfNDAtMC0xLTEtODEvdGV4dHJlZ2lvbjozODFlN2RmNWIyOTc0OWU1YjdmMmI3YTBhODFkYjk3NV8xOA_a0e0cbcc-7dd8-4cc9-bb95-76d7bc4aa1a4">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="iab26fe441f0d4ab984456365a7f7cff0_I20211231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xNi9mcmFnOjU2YmVmNWVkZGUxMDRjZDJiNzQxZGJmMjY2YmMwZmRmL3RhYmxlOjYzNjVkN2Y4YTZlYzQ4MzNiN2U3OTk3OWNlYjI2YWJlL3RhYmxlcmFuZ2U6NjM2NWQ3ZjhhNmVjNDgzM2I3ZTc5OTc5Y2ViMjZhYmVfNDAtMC0xLTEtODEvdGV4dHJlZ2lvbjozODFlN2RmNWIyOTc0OWU1YjdmMmI3YTBhODFkYjk3NV8zMg_972252c4-6463-4867-9a91-288a25c24eea"><ix:nonFraction unitRef="shares" contextRef="i3b4376f8fc614de98c9cf647198c504e_I20220930" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xNi9mcmFnOjU2YmVmNWVkZGUxMDRjZDJiNzQxZGJmMjY2YmMwZmRmL3RhYmxlOjYzNjVkN2Y4YTZlYzQ4MzNiN2U3OTk3OWNlYjI2YWJlL3RhYmxlcmFuZ2U6NjM2NWQ3ZjhhNmVjNDgzM2I3ZTc5OTc5Y2ViMjZhYmVfNDAtMC0xLTEtODEvdGV4dHJlZ2lvbjozODFlN2RmNWIyOTc0OWU1YjdmMmI3YTBhODFkYjk3NV8zMg_a3e53381-4c32-419a-adc9-a2888349b361">400,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="i3b4376f8fc614de98c9cf647198c504e_I20220930" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xNi9mcmFnOjU2YmVmNWVkZGUxMDRjZDJiNzQxZGJmMjY2YmMwZmRmL3RhYmxlOjYzNjVkN2Y4YTZlYzQ4MzNiN2U3OTk3OWNlYjI2YWJlL3RhYmxlcmFuZ2U6NjM2NWQ3ZjhhNmVjNDgzM2I3ZTc5OTc5Y2ViMjZhYmVfNDAtMC0xLTEtODEvdGV4dHJlZ2lvbjozODFlN2RmNWIyOTc0OWU1YjdmMmI3YTBhODFkYjk3NV81NA_66715ffa-87cc-41e8-acc8-19ca1b34c5df"><ix:nonFraction unitRef="shares" contextRef="i3b4376f8fc614de98c9cf647198c504e_I20220930" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xNi9mcmFnOjU2YmVmNWVkZGUxMDRjZDJiNzQxZGJmMjY2YmMwZmRmL3RhYmxlOjYzNjVkN2Y4YTZlYzQ4MzNiN2U3OTk3OWNlYjI2YWJlL3RhYmxlcmFuZ2U6NjM2NWQ3ZjhhNmVjNDgzM2I3ZTc5OTc5Y2ViMjZhYmVfNDAtMC0xLTEtODEvdGV4dHJlZ2lvbjozODFlN2RmNWIyOTc0OWU1YjdmMmI3YTBhODFkYjk3NV81NA_a6b9bb2d-6816-4732-b10e-d28b3bde411e">222,454,839</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="iab26fe441f0d4ab984456365a7f7cff0_I20211231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xNi9mcmFnOjU2YmVmNWVkZGUxMDRjZDJiNzQxZGJmMjY2YmMwZmRmL3RhYmxlOjYzNjVkN2Y4YTZlYzQ4MzNiN2U3OTk3OWNlYjI2YWJlL3RhYmxlcmFuZ2U6NjM2NWQ3ZjhhNmVjNDgzM2I3ZTc5OTc5Y2ViMjZhYmVfNDAtMC0xLTEtODEvdGV4dHJlZ2lvbjozODFlN2RmNWIyOTc0OWU1YjdmMmI3YTBhODFkYjk3NV82MQ_71330cf8-a38b-44b6-8aca-9fe438013b82"><ix:nonFraction unitRef="shares" contextRef="iab26fe441f0d4ab984456365a7f7cff0_I20211231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xNi9mcmFnOjU2YmVmNWVkZGUxMDRjZDJiNzQxZGJmMjY2YmMwZmRmL3RhYmxlOjYzNjVkN2Y4YTZlYzQ4MzNiN2U3OTk3OWNlYjI2YWJlL3RhYmxlcmFuZ2U6NjM2NWQ3ZjhhNmVjNDgzM2I3ZTc5OTc5Y2ViMjZhYmVfNDAtMC0xLTEtODEvdGV4dHJlZ2lvbjozODFlN2RmNWIyOTc0OWU1YjdmMmI3YTBhODFkYjk3NV82MQ_ad431d2b-434d-4c95-836a-2e3a7a8c98d0">221,084,433</ix:nonFraction></ix:nonFraction> shares issued and outstanding as of September&#160;30, 2022 and December&#160;31, 2021, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b4376f8fc614de98c9cf647198c504e_I20220930" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xNi9mcmFnOjU2YmVmNWVkZGUxMDRjZDJiNzQxZGJmMjY2YmMwZmRmL3RhYmxlOjYzNjVkN2Y4YTZlYzQ4MzNiN2U3OTk3OWNlYjI2YWJlL3RhYmxlcmFuZ2U6NjM2NWQ3ZjhhNmVjNDgzM2I3ZTc5OTc5Y2ViMjZhYmVfNDAtMS0xLTEtODE_30ec0cfc-f517-4cd6-bedb-2674a870b7ab">222</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab26fe441f0d4ab984456365a7f7cff0_I20211231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xNi9mcmFnOjU2YmVmNWVkZGUxMDRjZDJiNzQxZGJmMjY2YmMwZmRmL3RhYmxlOjYzNjVkN2Y4YTZlYzQ4MzNiN2U3OTk3OWNlYjI2YWJlL3RhYmxlcmFuZ2U6NjM2NWQ3ZjhhNmVjNDgzM2I3ZTc5OTc5Y2ViMjZhYmVfNDAtMy0xLTEtODE_c35ae666-c63b-40cd-a2ad-4b928c3ec9cd">221</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b4376f8fc614de98c9cf647198c504e_I20220930" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xNi9mcmFnOjU2YmVmNWVkZGUxMDRjZDJiNzQxZGJmMjY2YmMwZmRmL3RhYmxlOjYzNjVkN2Y4YTZlYzQ4MzNiN2U3OTk3OWNlYjI2YWJlL3RhYmxlcmFuZ2U6NjM2NWQ3ZjhhNmVjNDgzM2I3ZTc5OTc5Y2ViMjZhYmVfNDEtMS0xLTEtODE_7141562e-1ed2-4a9b-a83d-b64369801083">4,721,166</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab26fe441f0d4ab984456365a7f7cff0_I20211231" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xNi9mcmFnOjU2YmVmNWVkZGUxMDRjZDJiNzQxZGJmMjY2YmMwZmRmL3RhYmxlOjYzNjVkN2Y4YTZlYzQ4MzNiN2U3OTk3OWNlYjI2YWJlL3RhYmxlcmFuZ2U6NjM2NWQ3ZjhhNmVjNDgzM2I3ZTc5OTc5Y2ViMjZhYmVfNDEtMy0xLTEtODE_edae5fe7-96ea-4772-91e4-77b1ba2743d7">4,567,111</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b4376f8fc614de98c9cf647198c504e_I20220930" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xNi9mcmFnOjU2YmVmNWVkZGUxMDRjZDJiNzQxZGJmMjY2YmMwZmRmL3RhYmxlOjYzNjVkN2Y4YTZlYzQ4MzNiN2U3OTk3OWNlYjI2YWJlL3RhYmxlcmFuZ2U6NjM2NWQ3ZjhhNmVjNDgzM2I3ZTc5OTc5Y2ViMjZhYmVfNDItMS0xLTEtODE_9cd265e3-5457-4699-9535-cc4e1bfdde85">29,062</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iab26fe441f0d4ab984456365a7f7cff0_I20211231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xNi9mcmFnOjU2YmVmNWVkZGUxMDRjZDJiNzQxZGJmMjY2YmMwZmRmL3RhYmxlOjYzNjVkN2Y4YTZlYzQ4MzNiN2U3OTk3OWNlYjI2YWJlL3RhYmxlcmFuZ2U6NjM2NWQ3ZjhhNmVjNDgzM2I3ZTc5OTc5Y2ViMjZhYmVfNDItMy0xLTEtODE_a036be63-ea7c-445e-8e5a-484496928793">19,454</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b4376f8fc614de98c9cf647198c504e_I20220930" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xNi9mcmFnOjU2YmVmNWVkZGUxMDRjZDJiNzQxZGJmMjY2YmMwZmRmL3RhYmxlOjYzNjVkN2Y4YTZlYzQ4MzNiN2U3OTk3OWNlYjI2YWJlL3RhYmxlcmFuZ2U6NjM2NWQ3ZjhhNmVjNDgzM2I3ZTc5OTc5Y2ViMjZhYmVfNDMtMS0xLTEtODE_dc9ff207-4bb6-43b7-8038-b03b3e703f0a">465,675</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iab26fe441f0d4ab984456365a7f7cff0_I20211231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xNi9mcmFnOjU2YmVmNWVkZGUxMDRjZDJiNzQxZGJmMjY2YmMwZmRmL3RhYmxlOjYzNjVkN2Y4YTZlYzQ4MzNiN2U3OTk3OWNlYjI2YWJlL3RhYmxlcmFuZ2U6NjM2NWQ3ZjhhNmVjNDgzM2I3ZTc5OTc5Y2ViMjZhYmVfNDMtMy0xLTEtODE_cde9d902-f46f-4239-a6ec-8df5b9cdb2ea">777,874</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b4376f8fc614de98c9cf647198c504e_I20220930" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xNi9mcmFnOjU2YmVmNWVkZGUxMDRjZDJiNzQxZGJmMjY2YmMwZmRmL3RhYmxlOjYzNjVkN2Y4YTZlYzQ4MzNiN2U3OTk3OWNlYjI2YWJlL3RhYmxlcmFuZ2U6NjM2NWQ3ZjhhNmVjNDgzM2I3ZTc5OTc5Y2ViMjZhYmVfNDQtMS0xLTEtODE_9fd51ab8-b4d2-40de-90f6-ac91a2415cde">4,226,651</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab26fe441f0d4ab984456365a7f7cff0_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xNi9mcmFnOjU2YmVmNWVkZGUxMDRjZDJiNzQxZGJmMjY2YmMwZmRmL3RhYmxlOjYzNjVkN2Y4YTZlYzQ4MzNiN2U3OTk3OWNlYjI2YWJlL3RhYmxlcmFuZ2U6NjM2NWQ3ZjhhNmVjNDgzM2I3ZTc5OTc5Y2ViMjZhYmVfNDQtMy0xLTEtODE_848dadc2-d7aa-49de-848e-f874e2d81e5c">3,770,004</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b4376f8fc614de98c9cf647198c504e_I20220930" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xNi9mcmFnOjU2YmVmNWVkZGUxMDRjZDJiNzQxZGJmMjY2YmMwZmRmL3RhYmxlOjYzNjVkN2Y4YTZlYzQ4MzNiN2U3OTk3OWNlYjI2YWJlL3RhYmxlcmFuZ2U6NjM2NWQ3ZjhhNmVjNDgzM2I3ZTc5OTc5Y2ViMjZhYmVfNDUtMS0xLTEtODE_63b80b6e-40ca-4096-bc85-6fdbca24e113">5,510,214</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab26fe441f0d4ab984456365a7f7cff0_I20211231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xNi9mcmFnOjU2YmVmNWVkZGUxMDRjZDJiNzQxZGJmMjY2YmMwZmRmL3RhYmxlOjYzNjVkN2Y4YTZlYzQ4MzNiN2U3OTk3OWNlYjI2YWJlL3RhYmxlcmFuZ2U6NjM2NWQ3ZjhhNmVjNDgzM2I3ZTc5OTc5Y2ViMjZhYmVfNDUtMy0xLTEtODE_6140512e-693e-4534-b6cb-bb6a4c65a5b5">4,933,352</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">The condensed consolidated balance sheet at December&#160;31, 2021 has been derived from the audited consolidated financial statements at that date. </span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3</span></div></div></div><div id="ie2ffba3ee5384c86becdb38ff117ca9a_19"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie2ffba3ee5384c86becdb38ff117ca9a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INCYTE CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, in thousands, except per share amounts)</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenues, net</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85b99c1e194944f7bd3b5fb62f5a2182_D20220701-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xOS9mcmFnOjg3NTU4NGVlZmQ2NzRjZGE4NDc4ZmZhOWY2MTg0NTk1L3RhYmxlOmVjMzUzMDdlY2E4YTQ4NzliNGU3NWU5ZWYyMDUzM2U5L3RhYmxlcmFuZ2U6ZWMzNTMwN2VjYThhNDg3OWI0ZTc1ZTllZjIwNTMzZTlfMy0xLTEtMS04MQ_b44e3c6c-d5d3-41ed-8a72-1b383ab36b13">713,010</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48a86cbfb7934ea9845c79f994c08295_D20210701-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xOS9mcmFnOjg3NTU4NGVlZmQ2NzRjZGE4NDc4ZmZhOWY2MTg0NTk1L3RhYmxlOmVjMzUzMDdlY2E4YTQ4NzliNGU3NWU5ZWYyMDUzM2U5L3RhYmxlcmFuZ2U6ZWMzNTMwN2VjYThhNDg3OWI0ZTc1ZTllZjIwNTMzZTlfMy0zLTEtMS04MQ_dbf31868-355e-4546-b2e3-0b7923087494">594,013</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie260e1a53b734cf0a4f57af01f2e311d_D20220101-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xOS9mcmFnOjg3NTU4NGVlZmQ2NzRjZGE4NDc4ZmZhOWY2MTg0NTk1L3RhYmxlOmVjMzUzMDdlY2E4YTQ4NzliNGU3NWU5ZWYyMDUzM2U5L3RhYmxlcmFuZ2U6ZWMzNTMwN2VjYThhNDg3OWI0ZTc1ZTllZjIwNTMzZTlfMy01LTEtMS04MQ_574b4a1d-44dc-43ab-a4a3-67e2f0d34169">1,982,682</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c3d6351306b42baba694287efd653dc_D20210101-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xOS9mcmFnOjg3NTU4NGVlZmQ2NzRjZGE4NDc4ZmZhOWY2MTg0NTk1L3RhYmxlOmVjMzUzMDdlY2E4YTQ4NzliNGU3NWU5ZWYyMDUzM2U5L3RhYmxlcmFuZ2U6ZWMzNTMwN2VjYThhNDg3OWI0ZTc1ZTllZjIwNTMzZTlfMy03LTEtMS04MQ_3e5c2066-d007-4847-bfe5-3042c034aedd">1,673,974</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product royalty revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37c7d1d637bf4ae98b18884511c75dd9_D20220701-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xOS9mcmFnOjg3NTU4NGVlZmQ2NzRjZGE4NDc4ZmZhOWY2MTg0NTk1L3RhYmxlOmVjMzUzMDdlY2E4YTQ4NzliNGU3NWU5ZWYyMDUzM2U5L3RhYmxlcmFuZ2U6ZWMzNTMwN2VjYThhNDg3OWI0ZTc1ZTllZjIwNTMzZTlfNC0xLTEtMS04MQ_2e21e30c-dc2d-4d26-a454-c25ffa53e591">110,293</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c507c58a3df413e914b6c8ae5dbf2a2_D20210701-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xOS9mcmFnOjg3NTU4NGVlZmQ2NzRjZGE4NDc4ZmZhOWY2MTg0NTk1L3RhYmxlOmVjMzUzMDdlY2E4YTQ4NzliNGU3NWU5ZWYyMDUzM2U5L3RhYmxlcmFuZ2U6ZWMzNTMwN2VjYThhNDg3OWI0ZTc1ZTllZjIwNTMzZTlfNC0zLTEtMS04MQ_e99f1259-88c7-4864-a0d5-4cd42e8a98bb">183,974</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia628ec6831414d4f8e0d2c927a011f4a_D20220101-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xOS9mcmFnOjg3NTU4NGVlZmQ2NzRjZGE4NDc4ZmZhOWY2MTg0NTk1L3RhYmxlOmVjMzUzMDdlY2E4YTQ4NzliNGU3NWU5ZWYyMDUzM2U5L3RhYmxlcmFuZ2U6ZWMzNTMwN2VjYThhNDg3OWI0ZTc1ZTllZjIwNTMzZTlfNC01LTEtMS04MQ_f416a5ba-d837-4ad2-b916-3de1d2e68674">350,253</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3231b94f87f649139a15ad91d06d9fd2_D20210101-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xOS9mcmFnOjg3NTU4NGVlZmQ2NzRjZGE4NDc4ZmZhOWY2MTg0NTk1L3RhYmxlOmVjMzUzMDdlY2E4YTQ4NzliNGU3NWU5ZWYyMDUzM2U5L3RhYmxlcmFuZ2U6ZWMzNTMwN2VjYThhNDg3OWI0ZTc1ZTllZjIwNTMzZTlfNC03LTEtMS04MQ_46dfbc77-47eb-4a71-b491-090e72c88799">404,440</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Milestone and contract revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5a93dd07a4f42b6ba18bf2e816dc557_D20220701-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xOS9mcmFnOjg3NTU4NGVlZmQ2NzRjZGE4NDc4ZmZhOWY2MTg0NTk1L3RhYmxlOmVjMzUzMDdlY2E4YTQ4NzliNGU3NWU5ZWYyMDUzM2U5L3RhYmxlcmFuZ2U6ZWMzNTMwN2VjYThhNDg3OWI0ZTc1ZTllZjIwNTMzZTlfNS0xLTEtMS04MQ_ac195132-841b-4bf4-b8b9-b684a8e0008a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4924faaf57ec4df5aafa757da5bce176_D20210701-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xOS9mcmFnOjg3NTU4NGVlZmQ2NzRjZGE4NDc4ZmZhOWY2MTg0NTk1L3RhYmxlOmVjMzUzMDdlY2E4YTQ4NzliNGU3NWU5ZWYyMDUzM2U5L3RhYmxlcmFuZ2U6ZWMzNTMwN2VjYThhNDg3OWI0ZTc1ZTllZjIwNTMzZTlfNS0zLTEtMS04MQ_acad1dc4-810b-44e9-aa96-81e7307ca3d9">35,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2028c66e6d814be2937c324c9b244728_D20220101-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xOS9mcmFnOjg3NTU4NGVlZmQ2NzRjZGE4NDc4ZmZhOWY2MTg0NTk1L3RhYmxlOmVjMzUzMDdlY2E4YTQ4NzliNGU3NWU5ZWYyMDUzM2U5L3RhYmxlcmFuZ2U6ZWMzNTMwN2VjYThhNDg3OWI0ZTc1ZTllZjIwNTMzZTlfNS01LTEtMS04MQ_1e8399ac-f48f-4bc2-9af8-60ba2bb60e77">135,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7c03930e4e24e0880a00b550c2d0c20_D20210101-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xOS9mcmFnOjg3NTU4NGVlZmQ2NzRjZGE4NDc4ZmZhOWY2MTg0NTk1L3RhYmxlOmVjMzUzMDdlY2E4YTQ4NzliNGU3NWU5ZWYyMDUzM2U5L3RhYmxlcmFuZ2U6ZWMzNTMwN2VjYThhNDg3OWI0ZTc1ZTllZjIwNTMzZTlfNS03LTEtMS04MQ_0e217856-c059-41ef-b7dd-b2a5759c7f02">45,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id673d80f31e74643a241d2f62db94ca9_D20220701-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xOS9mcmFnOjg3NTU4NGVlZmQ2NzRjZGE4NDc4ZmZhOWY2MTg0NTk1L3RhYmxlOmVjMzUzMDdlY2E4YTQ4NzliNGU3NWU5ZWYyMDUzM2U5L3RhYmxlcmFuZ2U6ZWMzNTMwN2VjYThhNDg3OWI0ZTc1ZTllZjIwNTMzZTlfNy0xLTEtMS04MQ_a0fb349e-a925-460e-9ca9-544f0f8ace06">823,303</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i313b15d35b7045babd1ba61f84a077dd_D20210701-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xOS9mcmFnOjg3NTU4NGVlZmQ2NzRjZGE4NDc4ZmZhOWY2MTg0NTk1L3RhYmxlOmVjMzUzMDdlY2E4YTQ4NzliNGU3NWU5ZWYyMDUzM2U5L3RhYmxlcmFuZ2U6ZWMzNTMwN2VjYThhNDg3OWI0ZTc1ZTllZjIwNTMzZTlfNy0zLTEtMS04MQ_48cfa18b-70e1-44fd-9f05-9f7bd2144714">812,987</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xOS9mcmFnOjg3NTU4NGVlZmQ2NzRjZGE4NDc4ZmZhOWY2MTg0NTk1L3RhYmxlOmVjMzUzMDdlY2E4YTQ4NzliNGU3NWU5ZWYyMDUzM2U5L3RhYmxlcmFuZ2U6ZWMzNTMwN2VjYThhNDg3OWI0ZTc1ZTllZjIwNTMzZTlfNy01LTEtMS04MQ_c7ae416b-83a8-40d8-8661-bc2c3db1f37f">2,467,935</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0faaba5fcd6b485781cadacae8b2fd8e_D20210101-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xOS9mcmFnOjg3NTU4NGVlZmQ2NzRjZGE4NDc4ZmZhOWY2MTg0NTk1L3RhYmxlOmVjMzUzMDdlY2E4YTQ4NzliNGU3NWU5ZWYyMDUzM2U5L3RhYmxlcmFuZ2U6ZWMzNTMwN2VjYThhNDg3OWI0ZTc1ZTllZjIwNTMzZTlfNy03LTEtMS04MQ_082a664b-e6ac-4a80-af83-5ff309f55ada">2,123,414</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs and expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of product revenues (including definite-lived intangible amortization)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id673d80f31e74643a241d2f62db94ca9_D20220701-20220930" decimals="-3" name="us-gaap:CostOfRevenue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xOS9mcmFnOjg3NTU4NGVlZmQ2NzRjZGE4NDc4ZmZhOWY2MTg0NTk1L3RhYmxlOmVjMzUzMDdlY2E4YTQ4NzliNGU3NWU5ZWYyMDUzM2U5L3RhYmxlcmFuZ2U6ZWMzNTMwN2VjYThhNDg3OWI0ZTc1ZTllZjIwNTMzZTlfMTAtMS0xLTEtODE_a5f6893e-ef7a-4692-b972-ddaeadcd8b8d">54,584</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i313b15d35b7045babd1ba61f84a077dd_D20210701-20210930" decimals="-3" name="us-gaap:CostOfRevenue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xOS9mcmFnOjg3NTU4NGVlZmQ2NzRjZGE4NDc4ZmZhOWY2MTg0NTk1L3RhYmxlOmVjMzUzMDdlY2E4YTQ4NzliNGU3NWU5ZWYyMDUzM2U5L3RhYmxlcmFuZ2U6ZWMzNTMwN2VjYThhNDg3OWI0ZTc1ZTllZjIwNTMzZTlfMTAtMy0xLTEtODE_f9bb010c-4f42-4771-8575-14e5eed10446">39,869</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930" decimals="-3" name="us-gaap:CostOfRevenue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xOS9mcmFnOjg3NTU4NGVlZmQ2NzRjZGE4NDc4ZmZhOWY2MTg0NTk1L3RhYmxlOmVjMzUzMDdlY2E4YTQ4NzliNGU3NWU5ZWYyMDUzM2U5L3RhYmxlcmFuZ2U6ZWMzNTMwN2VjYThhNDg3OWI0ZTc1ZTllZjIwNTMzZTlfMTAtNS0xLTEtODE_ef76493d-9794-4c51-b79f-fd8ff795af2c">147,834</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0faaba5fcd6b485781cadacae8b2fd8e_D20210101-20210930" decimals="-3" name="us-gaap:CostOfRevenue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xOS9mcmFnOjg3NTU4NGVlZmQ2NzRjZGE4NDc4ZmZhOWY2MTg0NTk1L3RhYmxlOmVjMzUzMDdlY2E4YTQ4NzliNGU3NWU5ZWYyMDUzM2U5L3RhYmxlcmFuZ2U6ZWMzNTMwN2VjYThhNDg3OWI0ZTc1ZTllZjIwNTMzZTlfMTAtNy0xLTEtODE_a3e29e36-eadc-4fdc-93ef-97b1630942b6">107,117</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id673d80f31e74643a241d2f62db94ca9_D20220701-20220930" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xOS9mcmFnOjg3NTU4NGVlZmQ2NzRjZGE4NDc4ZmZhOWY2MTg0NTk1L3RhYmxlOmVjMzUzMDdlY2E4YTQ4NzliNGU3NWU5ZWYyMDUzM2U5L3RhYmxlcmFuZ2U6ZWMzNTMwN2VjYThhNDg3OWI0ZTc1ZTllZjIwNTMzZTlfMTEtMS0xLTEtODE_76a529c9-b8bf-4af1-bbc0-32b730b5f676">384,007</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i313b15d35b7045babd1ba61f84a077dd_D20210701-20210930" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xOS9mcmFnOjg3NTU4NGVlZmQ2NzRjZGE4NDc4ZmZhOWY2MTg0NTk1L3RhYmxlOmVjMzUzMDdlY2E4YTQ4NzliNGU3NWU5ZWYyMDUzM2U5L3RhYmxlcmFuZ2U6ZWMzNTMwN2VjYThhNDg3OWI0ZTc1ZTllZjIwNTMzZTlfMTEtMy0xLTEtODE_f5fd1cbd-5d36-4ecc-a65e-48e3fa3ac662">334,945</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xOS9mcmFnOjg3NTU4NGVlZmQ2NzRjZGE4NDc4ZmZhOWY2MTg0NTk1L3RhYmxlOmVjMzUzMDdlY2E4YTQ4NzliNGU3NWU5ZWYyMDUzM2U5L3RhYmxlcmFuZ2U6ZWMzNTMwN2VjYThhNDg3OWI0ZTc1ZTllZjIwNTMzZTlfMTEtNS0xLTEtODE_f25e3b4d-f986-4982-bc15-ffe45f8925af">1,084,576</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0faaba5fcd6b485781cadacae8b2fd8e_D20210101-20210930" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xOS9mcmFnOjg3NTU4NGVlZmQ2NzRjZGE4NDc4ZmZhOWY2MTg0NTk1L3RhYmxlOmVjMzUzMDdlY2E4YTQ4NzliNGU3NWU5ZWYyMDUzM2U5L3RhYmxlcmFuZ2U6ZWMzNTMwN2VjYThhNDg3OWI0ZTc1ZTllZjIwNTMzZTlfMTEtNy0xLTEtODE_9ac7722e-75e7-442a-b8c1-4693ad440ced">985,352</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id673d80f31e74643a241d2f62db94ca9_D20220701-20220930" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xOS9mcmFnOjg3NTU4NGVlZmQ2NzRjZGE4NDc4ZmZhOWY2MTg0NTk1L3RhYmxlOmVjMzUzMDdlY2E4YTQ4NzliNGU3NWU5ZWYyMDUzM2U5L3RhYmxlcmFuZ2U6ZWMzNTMwN2VjYThhNDg3OWI0ZTc1ZTllZjIwNTMzZTlfMTItMS0xLTEtODE_44bf4a81-fa27-42e5-9f7c-ccc9fe1ab7da">266,460</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i313b15d35b7045babd1ba61f84a077dd_D20210701-20210930" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xOS9mcmFnOjg3NTU4NGVlZmQ2NzRjZGE4NDc4ZmZhOWY2MTg0NTk1L3RhYmxlOmVjMzUzMDdlY2E4YTQ4NzliNGU3NWU5ZWYyMDUzM2U5L3RhYmxlcmFuZ2U6ZWMzNTMwN2VjYThhNDg3OWI0ZTc1ZTllZjIwNTMzZTlfMTItMy0xLTEtODE_1f920e93-3194-4f15-9d5d-9ddb6ad189cb">190,704</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xOS9mcmFnOjg3NTU4NGVlZmQ2NzRjZGE4NDc4ZmZhOWY2MTg0NTk1L3RhYmxlOmVjMzUzMDdlY2E4YTQ4NzliNGU3NWU5ZWYyMDUzM2U5L3RhYmxlcmFuZ2U6ZWMzNTMwN2VjYThhNDg3OWI0ZTc1ZTllZjIwNTMzZTlfMTItNS0xLTEtODE_224f169f-c28a-4288-9fa2-9c3f95c76a6c">729,321</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0faaba5fcd6b485781cadacae8b2fd8e_D20210101-20210930" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xOS9mcmFnOjg3NTU4NGVlZmQ2NzRjZGE4NDc4ZmZhOWY2MTg0NTk1L3RhYmxlOmVjMzUzMDdlY2E4YTQ4NzliNGU3NWU5ZWYyMDUzM2U5L3RhYmxlcmFuZ2U6ZWMzNTMwN2VjYThhNDg3OWI0ZTc1ZTllZjIwNTMzZTlfMTItNy0xLTEtODE_ac909ccd-3726-40a0-9126-2a4122a56f0d">513,358</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Gain) loss on change in fair value of acquisition-related contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id673d80f31e74643a241d2f62db94ca9_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xOS9mcmFnOjg3NTU4NGVlZmQ2NzRjZGE4NDc4ZmZhOWY2MTg0NTk1L3RhYmxlOmVjMzUzMDdlY2E4YTQ4NzliNGU3NWU5ZWYyMDUzM2U5L3RhYmxlcmFuZ2U6ZWMzNTMwN2VjYThhNDg3OWI0ZTc1ZTllZjIwNTMzZTlfMTMtMS0xLTEtODE_af286acb-0fec-47ac-a63d-5fd4c7f3c42d">21,893</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i313b15d35b7045babd1ba61f84a077dd_D20210701-20210930" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xOS9mcmFnOjg3NTU4NGVlZmQ2NzRjZGE4NDc4ZmZhOWY2MTg0NTk1L3RhYmxlOmVjMzUzMDdlY2E4YTQ4NzliNGU3NWU5ZWYyMDUzM2U5L3RhYmxlcmFuZ2U6ZWMzNTMwN2VjYThhNDg3OWI0ZTc1ZTllZjIwNTMzZTlfMTMtMy0xLTEtODE_86052b7f-d534-414c-adc3-4117323fb22e">2,910</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xOS9mcmFnOjg3NTU4NGVlZmQ2NzRjZGE4NDc4ZmZhOWY2MTg0NTk1L3RhYmxlOmVjMzUzMDdlY2E4YTQ4NzliNGU3NWU5ZWYyMDUzM2U5L3RhYmxlcmFuZ2U6ZWMzNTMwN2VjYThhNDg3OWI0ZTc1ZTllZjIwNTMzZTlfMTMtNS0xLTEtODE_21f7a01a-d2b7-473e-8d37-766b1e1aaf2d">12,198</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0faaba5fcd6b485781cadacae8b2fd8e_D20210101-20210930" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xOS9mcmFnOjg3NTU4NGVlZmQ2NzRjZGE4NDc4ZmZhOWY2MTg0NTk1L3RhYmxlOmVjMzUzMDdlY2E4YTQ4NzliNGU3NWU5ZWYyMDUzM2U5L3RhYmxlcmFuZ2U6ZWMzNTMwN2VjYThhNDg3OWI0ZTc1ZTllZjIwNTMzZTlfMTMtNy0xLTEtODE_3360d55b-6220-4a8f-b31b-607969c9adcf">13,068</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration loss sharing</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id673d80f31e74643a241d2f62db94ca9_D20220701-20220930" decimals="-3" name="incy:CollaborationLossSharingExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xOS9mcmFnOjg3NTU4NGVlZmQ2NzRjZGE4NDc4ZmZhOWY2MTg0NTk1L3RhYmxlOmVjMzUzMDdlY2E4YTQ4NzliNGU3NWU5ZWYyMDUzM2U5L3RhYmxlcmFuZ2U6ZWMzNTMwN2VjYThhNDg3OWI0ZTc1ZTllZjIwNTMzZTlfMTQtMS0xLTEtODE_da7d8a77-79c9-4c58-90b3-4db5a5d7b529">1,769</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i313b15d35b7045babd1ba61f84a077dd_D20210701-20210930" decimals="-3" name="incy:CollaborationLossSharingExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xOS9mcmFnOjg3NTU4NGVlZmQ2NzRjZGE4NDc4ZmZhOWY2MTg0NTk1L3RhYmxlOmVjMzUzMDdlY2E4YTQ4NzliNGU3NWU5ZWYyMDUzM2U5L3RhYmxlcmFuZ2U6ZWMzNTMwN2VjYThhNDg3OWI0ZTc1ZTllZjIwNTMzZTlfMTQtMy0xLTEtODE_afeb2081-ae06-4e17-b02e-fe5c92367b41">9,149</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930" decimals="-3" name="incy:CollaborationLossSharingExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xOS9mcmFnOjg3NTU4NGVlZmQ2NzRjZGE4NDc4ZmZhOWY2MTg0NTk1L3RhYmxlOmVjMzUzMDdlY2E4YTQ4NzliNGU3NWU5ZWYyMDUzM2U5L3RhYmxlcmFuZ2U6ZWMzNTMwN2VjYThhNDg3OWI0ZTc1ZTllZjIwNTMzZTlfMTQtNS0xLTEtODE_ac4526d9-2a73-4e8a-80d8-2153d4678a08">9,055</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0faaba5fcd6b485781cadacae8b2fd8e_D20210101-20210930" decimals="-3" name="incy:CollaborationLossSharingExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xOS9mcmFnOjg3NTU4NGVlZmQ2NzRjZGE4NDc4ZmZhOWY2MTg0NTk1L3RhYmxlOmVjMzUzMDdlY2E4YTQ4NzliNGU3NWU5ZWYyMDUzM2U5L3RhYmxlcmFuZ2U6ZWMzNTMwN2VjYThhNDg3OWI0ZTc1ZTllZjIwNTMzZTlfMTQtNy0xLTEtODE_5aec1f6f-4f43-473b-b1f8-3f61c93c3533">29,476</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total costs and expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id673d80f31e74643a241d2f62db94ca9_D20220701-20220930" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xOS9mcmFnOjg3NTU4NGVlZmQ2NzRjZGE4NDc4ZmZhOWY2MTg0NTk1L3RhYmxlOmVjMzUzMDdlY2E4YTQ4NzliNGU3NWU5ZWYyMDUzM2U5L3RhYmxlcmFuZ2U6ZWMzNTMwN2VjYThhNDg3OWI0ZTc1ZTllZjIwNTMzZTlfMTYtMS0xLTEtODE_42cfc4f3-a3eb-4126-b4b5-c050d20c5d41">684,927</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i313b15d35b7045babd1ba61f84a077dd_D20210701-20210930" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xOS9mcmFnOjg3NTU4NGVlZmQ2NzRjZGE4NDc4ZmZhOWY2MTg0NTk1L3RhYmxlOmVjMzUzMDdlY2E4YTQ4NzliNGU3NWU5ZWYyMDUzM2U5L3RhYmxlcmFuZ2U6ZWMzNTMwN2VjYThhNDg3OWI0ZTc1ZTllZjIwNTMzZTlfMTYtMy0xLTEtODE_12839f40-0081-4064-ad6d-5ee1c13d8391">577,577</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xOS9mcmFnOjg3NTU4NGVlZmQ2NzRjZGE4NDc4ZmZhOWY2MTg0NTk1L3RhYmxlOmVjMzUzMDdlY2E4YTQ4NzliNGU3NWU5ZWYyMDUzM2U5L3RhYmxlcmFuZ2U6ZWMzNTMwN2VjYThhNDg3OWI0ZTc1ZTllZjIwNTMzZTlfMTYtNS0xLTEtODE_658af91e-148d-464d-8a03-d7c73b457689">1,958,588</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0faaba5fcd6b485781cadacae8b2fd8e_D20210101-20210930" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xOS9mcmFnOjg3NTU4NGVlZmQ2NzRjZGE4NDc4ZmZhOWY2MTg0NTk1L3RhYmxlOmVjMzUzMDdlY2E4YTQ4NzliNGU3NWU5ZWYyMDUzM2U5L3RhYmxlcmFuZ2U6ZWMzNTMwN2VjYThhNDg3OWI0ZTc1ZTllZjIwNTMzZTlfMTYtNy0xLTEtODE_7023b39a-93d6-488b-978a-7c6a4cd65861">1,648,371</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id673d80f31e74643a241d2f62db94ca9_D20220701-20220930" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xOS9mcmFnOjg3NTU4NGVlZmQ2NzRjZGE4NDc4ZmZhOWY2MTg0NTk1L3RhYmxlOmVjMzUzMDdlY2E4YTQ4NzliNGU3NWU5ZWYyMDUzM2U5L3RhYmxlcmFuZ2U6ZWMzNTMwN2VjYThhNDg3OWI0ZTc1ZTllZjIwNTMzZTlfMTgtMS0xLTEtODE_aee15b86-d987-4d00-8d6f-70f68c118245">138,376</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i313b15d35b7045babd1ba61f84a077dd_D20210701-20210930" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xOS9mcmFnOjg3NTU4NGVlZmQ2NzRjZGE4NDc4ZmZhOWY2MTg0NTk1L3RhYmxlOmVjMzUzMDdlY2E4YTQ4NzliNGU3NWU5ZWYyMDUzM2U5L3RhYmxlcmFuZ2U6ZWMzNTMwN2VjYThhNDg3OWI0ZTc1ZTllZjIwNTMzZTlfMTgtMy0xLTEtODE_997fd35a-b632-491b-af64-6247f1ecb5e1">235,410</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xOS9mcmFnOjg3NTU4NGVlZmQ2NzRjZGE4NDc4ZmZhOWY2MTg0NTk1L3RhYmxlOmVjMzUzMDdlY2E4YTQ4NzliNGU3NWU5ZWYyMDUzM2U5L3RhYmxlcmFuZ2U6ZWMzNTMwN2VjYThhNDg3OWI0ZTc1ZTllZjIwNTMzZTlfMTgtNS0xLTEtODE_8b9184a1-fb12-49ba-af4d-6621c5ed78d2">509,347</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0faaba5fcd6b485781cadacae8b2fd8e_D20210101-20210930" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xOS9mcmFnOjg3NTU4NGVlZmQ2NzRjZGE4NDc4ZmZhOWY2MTg0NTk1L3RhYmxlOmVjMzUzMDdlY2E4YTQ4NzliNGU3NWU5ZWYyMDUzM2U5L3RhYmxlcmFuZ2U6ZWMzNTMwN2VjYThhNDg3OWI0ZTc1ZTllZjIwNTMzZTlfMTgtNy0xLTEtODE_7c772438-aef1-4e1f-b1e4-e75e90a7ded5">475,043</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id673d80f31e74643a241d2f62db94ca9_D20220701-20220930" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xOS9mcmFnOjg3NTU4NGVlZmQ2NzRjZGE4NDc4ZmZhOWY2MTg0NTk1L3RhYmxlOmVjMzUzMDdlY2E4YTQ4NzliNGU3NWU5ZWYyMDUzM2U5L3RhYmxlcmFuZ2U6ZWMzNTMwN2VjYThhNDg3OWI0ZTc1ZTllZjIwNTMzZTlfMTktMS0xLTEtODE_c51e2526-84e8-4617-b227-7dde783a47fc">11,513</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i313b15d35b7045babd1ba61f84a077dd_D20210701-20210930" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xOS9mcmFnOjg3NTU4NGVlZmQ2NzRjZGE4NDc4ZmZhOWY2MTg0NTk1L3RhYmxlOmVjMzUzMDdlY2E4YTQ4NzliNGU3NWU5ZWYyMDUzM2U5L3RhYmxlcmFuZ2U6ZWMzNTMwN2VjYThhNDg3OWI0ZTc1ZTllZjIwNTMzZTlfMTktMy0xLTEtODE_ff896deb-5cb0-40af-8c4f-538f0a92a3f5">1,948</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xOS9mcmFnOjg3NTU4NGVlZmQ2NzRjZGE4NDc4ZmZhOWY2MTg0NTk1L3RhYmxlOmVjMzUzMDdlY2E4YTQ4NzliNGU3NWU5ZWYyMDUzM2U5L3RhYmxlcmFuZ2U6ZWMzNTMwN2VjYThhNDg3OWI0ZTc1ZTllZjIwNTMzZTlfMTktNS0xLTEtODE_836d076c-a053-4d22-b8d3-fb82995e0ab4">13,295</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0faaba5fcd6b485781cadacae8b2fd8e_D20210101-20210930" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xOS9mcmFnOjg3NTU4NGVlZmQ2NzRjZGE4NDc4ZmZhOWY2MTg0NTk1L3RhYmxlOmVjMzUzMDdlY2E4YTQ4NzliNGU3NWU5ZWYyMDUzM2U5L3RhYmxlcmFuZ2U6ZWMzNTMwN2VjYThhNDg3OWI0ZTc1ZTllZjIwNTMzZTlfMTktNy0xLTEtODE_2bab9001-74ab-482b-a0ce-6152ff0913f1">4,931</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id673d80f31e74643a241d2f62db94ca9_D20220701-20220930" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xOS9mcmFnOjg3NTU4NGVlZmQ2NzRjZGE4NDc4ZmZhOWY2MTg0NTk1L3RhYmxlOmVjMzUzMDdlY2E4YTQ4NzliNGU3NWU5ZWYyMDUzM2U5L3RhYmxlcmFuZ2U6ZWMzNTMwN2VjYThhNDg3OWI0ZTc1ZTllZjIwNTMzZTlfMjAtMS0xLTEtODE_d3ace7d2-9d15-4de2-850c-d65bc06beeb0">641</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i313b15d35b7045babd1ba61f84a077dd_D20210701-20210930" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xOS9mcmFnOjg3NTU4NGVlZmQ2NzRjZGE4NDc4ZmZhOWY2MTg0NTk1L3RhYmxlOmVjMzUzMDdlY2E4YTQ4NzliNGU3NWU5ZWYyMDUzM2U5L3RhYmxlcmFuZ2U6ZWMzNTMwN2VjYThhNDg3OWI0ZTc1ZTllZjIwNTMzZTlfMjAtMy0xLTEtODE_abe4a0a9-0824-425e-9102-132ef6eeb146">439</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xOS9mcmFnOjg3NTU4NGVlZmQ2NzRjZGE4NDc4ZmZhOWY2MTg0NTk1L3RhYmxlOmVjMzUzMDdlY2E4YTQ4NzliNGU3NWU5ZWYyMDUzM2U5L3RhYmxlcmFuZ2U6ZWMzNTMwN2VjYThhNDg3OWI0ZTc1ZTllZjIwNTMzZTlfMjAtNS0xLTEtODE_2fd267c3-14e0-41a8-87e0-53e8d92e1eb6">1,999</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0faaba5fcd6b485781cadacae8b2fd8e_D20210101-20210930" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xOS9mcmFnOjg3NTU4NGVlZmQ2NzRjZGE4NDc4ZmZhOWY2MTg0NTk1L3RhYmxlOmVjMzUzMDdlY2E4YTQ4NzliNGU3NWU5ZWYyMDUzM2U5L3RhYmxlcmFuZ2U6ZWMzNTMwN2VjYThhNDg3OWI0ZTc1ZTllZjIwNTMzZTlfMjAtNy0xLTEtODE_3ea5be20-68fe-43cf-a2f1-824190792707">1,156</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized loss on long term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id673d80f31e74643a241d2f62db94ca9_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xOS9mcmFnOjg3NTU4NGVlZmQ2NzRjZGE4NDc4ZmZhOWY2MTg0NTk1L3RhYmxlOmVjMzUzMDdlY2E4YTQ4NzliNGU3NWU5ZWYyMDUzM2U5L3RhYmxlcmFuZ2U6ZWMzNTMwN2VjYThhNDg3OWI0ZTc1ZTllZjIwNTMzZTlfMjEtMS0xLTEtODE_84132301-19b1-45f9-a24a-8c862a19fb5c">660</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i313b15d35b7045babd1ba61f84a077dd_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xOS9mcmFnOjg3NTU4NGVlZmQ2NzRjZGE4NDc4ZmZhOWY2MTg0NTk1L3RhYmxlOmVjMzUzMDdlY2E4YTQ4NzliNGU3NWU5ZWYyMDUzM2U5L3RhYmxlcmFuZ2U6ZWMzNTMwN2VjYThhNDg3OWI0ZTc1ZTllZjIwNTMzZTlfMjEtMy0xLTEtODE_eaf96e18-61e3-40c6-a47c-88c5aae3b174">27,450</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xOS9mcmFnOjg3NTU4NGVlZmQ2NzRjZGE4NDc4ZmZhOWY2MTg0NTk1L3RhYmxlOmVjMzUzMDdlY2E4YTQ4NzliNGU3NWU5ZWYyMDUzM2U5L3RhYmxlcmFuZ2U6ZWMzNTMwN2VjYThhNDg3OWI0ZTc1ZTllZjIwNTMzZTlfMjEtNS0xLTEtODE_82f47a0f-d87d-4bfd-b48a-1071765747fe">72,142</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0faaba5fcd6b485781cadacae8b2fd8e_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xOS9mcmFnOjg3NTU4NGVlZmQ2NzRjZGE4NDc4ZmZhOWY2MTg0NTk1L3RhYmxlOmVjMzUzMDdlY2E4YTQ4NzliNGU3NWU5ZWYyMDUzM2U5L3RhYmxlcmFuZ2U6ZWMzNTMwN2VjYThhNDg3OWI0ZTc1ZTllZjIwNTMzZTlfMjEtNy0xLTEtODE_980ec916-5edf-4e19-9952-df656610f430">28,394</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income before provision for income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id673d80f31e74643a241d2f62db94ca9_D20220701-20220930" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xOS9mcmFnOjg3NTU4NGVlZmQ2NzRjZGE4NDc4ZmZhOWY2MTg0NTk1L3RhYmxlOmVjMzUzMDdlY2E4YTQ4NzliNGU3NWU5ZWYyMDUzM2U5L3RhYmxlcmFuZ2U6ZWMzNTMwN2VjYThhNDg3OWI0ZTc1ZTllZjIwNTMzZTlfMjMtMS0xLTEtODE_3cd9bae4-b218-45d4-82eb-da3521572c39">148,588</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i313b15d35b7045babd1ba61f84a077dd_D20210701-20210930" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xOS9mcmFnOjg3NTU4NGVlZmQ2NzRjZGE4NDc4ZmZhOWY2MTg0NTk1L3RhYmxlOmVjMzUzMDdlY2E4YTQ4NzliNGU3NWU5ZWYyMDUzM2U5L3RhYmxlcmFuZ2U6ZWMzNTMwN2VjYThhNDg3OWI0ZTc1ZTllZjIwNTMzZTlfMjMtMy0xLTEtODE_bfd07b8f-1569-4918-92f5-addb37e0492b">209,469</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xOS9mcmFnOjg3NTU4NGVlZmQ2NzRjZGE4NDc4ZmZhOWY2MTg0NTk1L3RhYmxlOmVjMzUzMDdlY2E4YTQ4NzliNGU3NWU5ZWYyMDUzM2U5L3RhYmxlcmFuZ2U6ZWMzNTMwN2VjYThhNDg3OWI0ZTc1ZTllZjIwNTMzZTlfMjMtNS0xLTEtODE_add4e3dd-c59c-424b-838c-dbe3395ee2fb">448,501</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0faaba5fcd6b485781cadacae8b2fd8e_D20210101-20210930" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xOS9mcmFnOjg3NTU4NGVlZmQ2NzRjZGE4NDc4ZmZhOWY2MTg0NTk1L3RhYmxlOmVjMzUzMDdlY2E4YTQ4NzliNGU3NWU5ZWYyMDUzM2U5L3RhYmxlcmFuZ2U6ZWMzNTMwN2VjYThhNDg3OWI0ZTc1ZTllZjIwNTMzZTlfMjMtNy0xLTEtODE_2c7ebc4f-9316-4488-8bd9-7ba7dd344929">450,424</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id673d80f31e74643a241d2f62db94ca9_D20220701-20220930" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xOS9mcmFnOjg3NTU4NGVlZmQ2NzRjZGE4NDc4ZmZhOWY2MTg0NTk1L3RhYmxlOmVjMzUzMDdlY2E4YTQ4NzliNGU3NWU5ZWYyMDUzM2U5L3RhYmxlcmFuZ2U6ZWMzNTMwN2VjYThhNDg3OWI0ZTc1ZTllZjIwNTMzZTlfMjUtMS0xLTEtODE_e5b62851-ab7b-49fe-8dc4-a647abf05ee3">35,813</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i313b15d35b7045babd1ba61f84a077dd_D20210701-20210930" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xOS9mcmFnOjg3NTU4NGVlZmQ2NzRjZGE4NDc4ZmZhOWY2MTg0NTk1L3RhYmxlOmVjMzUzMDdlY2E4YTQ4NzliNGU3NWU5ZWYyMDUzM2U5L3RhYmxlcmFuZ2U6ZWMzNTMwN2VjYThhNDg3OWI0ZTc1ZTllZjIwNTMzZTlfMjUtMy0xLTEtODE_f0b93b48-29cf-48b7-bd41-0e3212a0e4ac">27,730</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xOS9mcmFnOjg3NTU4NGVlZmQ2NzRjZGE4NDc4ZmZhOWY2MTg0NTk1L3RhYmxlOmVjMzUzMDdlY2E4YTQ4NzliNGU3NWU5ZWYyMDUzM2U5L3RhYmxlcmFuZ2U6ZWMzNTMwN2VjYThhNDg3OWI0ZTc1ZTllZjIwNTMzZTlfMjUtNS0xLTEtODE_28efb929-bfe4-4f32-aa00-c5e487d735a3">136,302</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0faaba5fcd6b485781cadacae8b2fd8e_D20210101-20210930" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xOS9mcmFnOjg3NTU4NGVlZmQ2NzRjZGE4NDc4ZmZhOWY2MTg0NTk1L3RhYmxlOmVjMzUzMDdlY2E4YTQ4NzliNGU3NWU5ZWYyMDUzM2U5L3RhYmxlcmFuZ2U6ZWMzNTMwN2VjYThhNDg3OWI0ZTc1ZTllZjIwNTMzZTlfMjUtNy0xLTEtODE_8e01b7f0-9de9-42a4-ae08-b0aed13a2c93">65,694</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id673d80f31e74643a241d2f62db94ca9_D20220701-20220930" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xOS9mcmFnOjg3NTU4NGVlZmQ2NzRjZGE4NDc4ZmZhOWY2MTg0NTk1L3RhYmxlOmVjMzUzMDdlY2E4YTQ4NzliNGU3NWU5ZWYyMDUzM2U5L3RhYmxlcmFuZ2U6ZWMzNTMwN2VjYThhNDg3OWI0ZTc1ZTllZjIwNTMzZTlfMjctMS0xLTEtODE_e652bbb9-e0bf-47bf-b888-50da54ade24d">112,775</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i313b15d35b7045babd1ba61f84a077dd_D20210701-20210930" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xOS9mcmFnOjg3NTU4NGVlZmQ2NzRjZGE4NDc4ZmZhOWY2MTg0NTk1L3RhYmxlOmVjMzUzMDdlY2E4YTQ4NzliNGU3NWU5ZWYyMDUzM2U5L3RhYmxlcmFuZ2U6ZWMzNTMwN2VjYThhNDg3OWI0ZTc1ZTllZjIwNTMzZTlfMjctMy0xLTEtODE_190510b3-a511-41a5-90ac-ee096366eeb5">181,739</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xOS9mcmFnOjg3NTU4NGVlZmQ2NzRjZGE4NDc4ZmZhOWY2MTg0NTk1L3RhYmxlOmVjMzUzMDdlY2E4YTQ4NzliNGU3NWU5ZWYyMDUzM2U5L3RhYmxlcmFuZ2U6ZWMzNTMwN2VjYThhNDg3OWI0ZTc1ZTllZjIwNTMzZTlfMjctNS0xLTEtODE_96bc8eaf-24ef-462a-8305-be967a0179db">312,199</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0faaba5fcd6b485781cadacae8b2fd8e_D20210101-20210930" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xOS9mcmFnOjg3NTU4NGVlZmQ2NzRjZGE4NDc4ZmZhOWY2MTg0NTk1L3RhYmxlOmVjMzUzMDdlY2E4YTQ4NzliNGU3NWU5ZWYyMDUzM2U5L3RhYmxlcmFuZ2U6ZWMzNTMwN2VjYThhNDg3OWI0ZTc1ZTllZjIwNTMzZTlfMjctNy0xLTEtODE_221b2787-b6a2-471c-8e29-4666edfd0aef">384,730</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id673d80f31e74643a241d2f62db94ca9_D20220701-20220930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xOS9mcmFnOjg3NTU4NGVlZmQ2NzRjZGE4NDc4ZmZhOWY2MTg0NTk1L3RhYmxlOmVjMzUzMDdlY2E4YTQ4NzliNGU3NWU5ZWYyMDUzM2U5L3RhYmxlcmFuZ2U6ZWMzNTMwN2VjYThhNDg3OWI0ZTc1ZTllZjIwNTMzZTlfMzAtMS0xLTEtODE_42de4210-48f4-4594-accf-240735594cd9">0.51</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i313b15d35b7045babd1ba61f84a077dd_D20210701-20210930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xOS9mcmFnOjg3NTU4NGVlZmQ2NzRjZGE4NDc4ZmZhOWY2MTg0NTk1L3RhYmxlOmVjMzUzMDdlY2E4YTQ4NzliNGU3NWU5ZWYyMDUzM2U5L3RhYmxlcmFuZ2U6ZWMzNTMwN2VjYThhNDg3OWI0ZTc1ZTllZjIwNTMzZTlfMzAtMy0xLTEtODE_87ffe2b2-4174-48d5-9df0-5bf7d0580d3e">0.82</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xOS9mcmFnOjg3NTU4NGVlZmQ2NzRjZGE4NDc4ZmZhOWY2MTg0NTk1L3RhYmxlOmVjMzUzMDdlY2E4YTQ4NzliNGU3NWU5ZWYyMDUzM2U5L3RhYmxlcmFuZ2U6ZWMzNTMwN2VjYThhNDg3OWI0ZTc1ZTllZjIwNTMzZTlfMzAtNS0xLTEtODE_12ad026d-dfb3-4f66-beee-48c7609aa8f1">1.41</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0faaba5fcd6b485781cadacae8b2fd8e_D20210101-20210930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xOS9mcmFnOjg3NTU4NGVlZmQ2NzRjZGE4NDc4ZmZhOWY2MTg0NTk1L3RhYmxlOmVjMzUzMDdlY2E4YTQ4NzliNGU3NWU5ZWYyMDUzM2U5L3RhYmxlcmFuZ2U6ZWMzNTMwN2VjYThhNDg3OWI0ZTc1ZTllZjIwNTMzZTlfMzAtNy0xLTEtODE_2ede3052-a366-46c0-9c61-9895b07f85ae">1.75</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id673d80f31e74643a241d2f62db94ca9_D20220701-20220930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xOS9mcmFnOjg3NTU4NGVlZmQ2NzRjZGE4NDc4ZmZhOWY2MTg0NTk1L3RhYmxlOmVjMzUzMDdlY2E4YTQ4NzliNGU3NWU5ZWYyMDUzM2U5L3RhYmxlcmFuZ2U6ZWMzNTMwN2VjYThhNDg3OWI0ZTc1ZTllZjIwNTMzZTlfMzEtMS0xLTEtODE_60ba120a-b721-4fe7-bee1-921eb9fc152e">0.50</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i313b15d35b7045babd1ba61f84a077dd_D20210701-20210930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xOS9mcmFnOjg3NTU4NGVlZmQ2NzRjZGE4NDc4ZmZhOWY2MTg0NTk1L3RhYmxlOmVjMzUzMDdlY2E4YTQ4NzliNGU3NWU5ZWYyMDUzM2U5L3RhYmxlcmFuZ2U6ZWMzNTMwN2VjYThhNDg3OWI0ZTc1ZTllZjIwNTMzZTlfMzEtMy0xLTEtODE_c593e5aa-c706-426b-aa30-0590e6bffbe8">0.82</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xOS9mcmFnOjg3NTU4NGVlZmQ2NzRjZGE4NDc4ZmZhOWY2MTg0NTk1L3RhYmxlOmVjMzUzMDdlY2E4YTQ4NzliNGU3NWU5ZWYyMDUzM2U5L3RhYmxlcmFuZ2U6ZWMzNTMwN2VjYThhNDg3OWI0ZTc1ZTllZjIwNTMzZTlfMzEtNS0xLTEtODE_dc5d9960-7459-45ba-ae17-da3466c637d1">1.40</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0faaba5fcd6b485781cadacae8b2fd8e_D20210101-20210930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xOS9mcmFnOjg3NTU4NGVlZmQ2NzRjZGE4NDc4ZmZhOWY2MTg0NTk1L3RhYmxlOmVjMzUzMDdlY2E4YTQ4NzliNGU3NWU5ZWYyMDUzM2U5L3RhYmxlcmFuZ2U6ZWMzNTMwN2VjYThhNDg3OWI0ZTc1ZTllZjIwNTMzZTlfMzEtNy0xLTEtODE_88908711-c9ad-4151-a174-656491efd3e0">1.73</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares used in computing net income per share:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id673d80f31e74643a241d2f62db94ca9_D20220701-20220930" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xOS9mcmFnOjg3NTU4NGVlZmQ2NzRjZGE4NDc4ZmZhOWY2MTg0NTk1L3RhYmxlOmVjMzUzMDdlY2E4YTQ4NzliNGU3NWU5ZWYyMDUzM2U5L3RhYmxlcmFuZ2U6ZWMzNTMwN2VjYThhNDg3OWI0ZTc1ZTllZjIwNTMzZTlfMzQtMS0xLTEtODE_0035af62-0609-443c-975f-0e83402db160">222,415</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i313b15d35b7045babd1ba61f84a077dd_D20210701-20210930" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xOS9mcmFnOjg3NTU4NGVlZmQ2NzRjZGE4NDc4ZmZhOWY2MTg0NTk1L3RhYmxlOmVjMzUzMDdlY2E4YTQ4NzliNGU3NWU5ZWYyMDUzM2U5L3RhYmxlcmFuZ2U6ZWMzNTMwN2VjYThhNDg3OWI0ZTc1ZTllZjIwNTMzZTlfMzQtMy0xLTEtODE_44d7501c-b877-46ee-a3bf-ac12185b20f4">220,845</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xOS9mcmFnOjg3NTU4NGVlZmQ2NzRjZGE4NDc4ZmZhOWY2MTg0NTk1L3RhYmxlOmVjMzUzMDdlY2E4YTQ4NzliNGU3NWU5ZWYyMDUzM2U5L3RhYmxlcmFuZ2U6ZWMzNTMwN2VjYThhNDg3OWI0ZTc1ZTllZjIwNTMzZTlfMzQtNS0xLTEtODE_8f87b66e-fbc6-4df7-a464-3dada21e87de">221,801</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0faaba5fcd6b485781cadacae8b2fd8e_D20210101-20210930" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xOS9mcmFnOjg3NTU4NGVlZmQ2NzRjZGE4NDc4ZmZhOWY2MTg0NTk1L3RhYmxlOmVjMzUzMDdlY2E4YTQ4NzliNGU3NWU5ZWYyMDUzM2U5L3RhYmxlcmFuZ2U6ZWMzNTMwN2VjYThhNDg3OWI0ZTc1ZTllZjIwNTMzZTlfMzQtNy0xLTEtODE_0f31e097-29a5-4748-8cea-7cc6ce1cce0e">220,243</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id673d80f31e74643a241d2f62db94ca9_D20220701-20220930" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xOS9mcmFnOjg3NTU4NGVlZmQ2NzRjZGE4NDc4ZmZhOWY2MTg0NTk1L3RhYmxlOmVjMzUzMDdlY2E4YTQ4NzliNGU3NWU5ZWYyMDUzM2U5L3RhYmxlcmFuZ2U6ZWMzNTMwN2VjYThhNDg3OWI0ZTc1ZTllZjIwNTMzZTlfMzUtMS0xLTEtODE_eb3a6437-dff3-4130-8460-51f42747ee15">224,175</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i313b15d35b7045babd1ba61f84a077dd_D20210701-20210930" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xOS9mcmFnOjg3NTU4NGVlZmQ2NzRjZGE4NDc4ZmZhOWY2MTg0NTk1L3RhYmxlOmVjMzUzMDdlY2E4YTQ4NzliNGU3NWU5ZWYyMDUzM2U5L3RhYmxlcmFuZ2U6ZWMzNTMwN2VjYThhNDg3OWI0ZTc1ZTllZjIwNTMzZTlfMzUtMy0xLTEtODE_2263b553-6b68-4577-a3c6-0b8dc27b3346">222,248</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xOS9mcmFnOjg3NTU4NGVlZmQ2NzRjZGE4NDc4ZmZhOWY2MTg0NTk1L3RhYmxlOmVjMzUzMDdlY2E4YTQ4NzliNGU3NWU5ZWYyMDUzM2U5L3RhYmxlcmFuZ2U6ZWMzNTMwN2VjYThhNDg3OWI0ZTc1ZTllZjIwNTMzZTlfMzUtNS0xLTEtODE_b5a8edf7-f8f6-4eb7-a418-a29a7badfb4a">223,626</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0faaba5fcd6b485781cadacae8b2fd8e_D20210101-20210930" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xOS9mcmFnOjg3NTU4NGVlZmQ2NzRjZGE4NDc4ZmZhOWY2MTg0NTk1L3RhYmxlOmVjMzUzMDdlY2E4YTQ4NzliNGU3NWU5ZWYyMDUzM2U5L3RhYmxlcmFuZ2U6ZWMzNTMwN2VjYThhNDg3OWI0ZTc1ZTllZjIwNTMzZTlfMzUtNy0xLTEtODE_75f62574-fa07-4d3e-bc4e-0ba3a6302196">222,113</ix:nonFraction></span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4</span></div></div></div><div id="ie2ffba3ee5384c86becdb38ff117ca9a_22"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie2ffba3ee5384c86becdb38ff117ca9a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INCYTE CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, in thousands)</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id673d80f31e74643a241d2f62db94ca9_D20220701-20220930" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yMi9mcmFnOmRjN2EwYjIzNGZmOTRlMDI5MDdiMjVlMTQ2ZWRiZjM2L3RhYmxlOjBhMTlhOWZiOTdlYjQ0Yjg5N2UzYmYxZmY3NDY3NWViL3RhYmxlcmFuZ2U6MGExOWE5ZmI5N2ViNDRiODk3ZTNiZjFmZjc0Njc1ZWJfMi0xLTEtMS04MQ_dbb944d3-e8c8-4a62-8f9c-70a7d862556e">112,775</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i313b15d35b7045babd1ba61f84a077dd_D20210701-20210930" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yMi9mcmFnOmRjN2EwYjIzNGZmOTRlMDI5MDdiMjVlMTQ2ZWRiZjM2L3RhYmxlOjBhMTlhOWZiOTdlYjQ0Yjg5N2UzYmYxZmY3NDY3NWViL3RhYmxlcmFuZ2U6MGExOWE5ZmI5N2ViNDRiODk3ZTNiZjFmZjc0Njc1ZWJfMi0zLTEtMS04MQ_7a0217f5-2ff7-4667-852f-f4b79504e28e">181,739</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yMi9mcmFnOmRjN2EwYjIzNGZmOTRlMDI5MDdiMjVlMTQ2ZWRiZjM2L3RhYmxlOjBhMTlhOWZiOTdlYjQ0Yjg5N2UzYmYxZmY3NDY3NWViL3RhYmxlcmFuZ2U6MGExOWE5ZmI5N2ViNDRiODk3ZTNiZjFmZjc0Njc1ZWJfMi01LTEtMS04MQ_645f944f-926c-4fd8-812b-4e60ab7b4e92">312,199</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0faaba5fcd6b485781cadacae8b2fd8e_D20210101-20210930" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yMi9mcmFnOmRjN2EwYjIzNGZmOTRlMDI5MDdiMjVlMTQ2ZWRiZjM2L3RhYmxlOjBhMTlhOWZiOTdlYjQ0Yjg5N2UzYmYxZmY3NDY3NWViL3RhYmxlcmFuZ2U6MGExOWE5ZmI5N2ViNDRiODk3ZTNiZjFmZjc0Njc1ZWJfMi03LTEtMS04MQ_edf8fe72-f049-4182-8bf3-70574e74b64b">384,730</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id673d80f31e74643a241d2f62db94ca9_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yMi9mcmFnOmRjN2EwYjIzNGZmOTRlMDI5MDdiMjVlMTQ2ZWRiZjM2L3RhYmxlOjBhMTlhOWZiOTdlYjQ0Yjg5N2UzYmYxZmY3NDY3NWViL3RhYmxlcmFuZ2U6MGExOWE5ZmI5N2ViNDRiODk3ZTNiZjFmZjc0Njc1ZWJfNS0xLTEtMS04MQ_4248e7a6-8e46-4531-a327-cf24e433900b">2,513</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i313b15d35b7045babd1ba61f84a077dd_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yMi9mcmFnOmRjN2EwYjIzNGZmOTRlMDI5MDdiMjVlMTQ2ZWRiZjM2L3RhYmxlOjBhMTlhOWZiOTdlYjQ0Yjg5N2UzYmYxZmY3NDY3NWViL3RhYmxlcmFuZ2U6MGExOWE5ZmI5N2ViNDRiODk3ZTNiZjFmZjc0Njc1ZWJfNS0zLTEtMS04MQ_7577e695-ab6a-442e-9f4d-bcb77d02c149">629</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yMi9mcmFnOmRjN2EwYjIzNGZmOTRlMDI5MDdiMjVlMTQ2ZWRiZjM2L3RhYmxlOjBhMTlhOWZiOTdlYjQ0Yjg5N2UzYmYxZmY3NDY3NWViL3RhYmxlcmFuZ2U6MGExOWE5ZmI5N2ViNDRiODk3ZTNiZjFmZjc0Njc1ZWJfNS01LTEtMS04MQ_82e89630-6f74-4484-9b50-80c00e821600">5,132</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0faaba5fcd6b485781cadacae8b2fd8e_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yMi9mcmFnOmRjN2EwYjIzNGZmOTRlMDI5MDdiMjVlMTQ2ZWRiZjM2L3RhYmxlOjBhMTlhOWZiOTdlYjQ0Yjg5N2UzYmYxZmY3NDY3NWViL3RhYmxlcmFuZ2U6MGExOWE5ZmI5N2ViNDRiODk3ZTNiZjFmZjc0Njc1ZWJfNS03LTEtMS04MQ_13650ad5-1557-43f4-a644-38c1279b8103">4,061</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized loss on marketable securities, net of tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id673d80f31e74643a241d2f62db94ca9_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yMi9mcmFnOmRjN2EwYjIzNGZmOTRlMDI5MDdiMjVlMTQ2ZWRiZjM2L3RhYmxlOjBhMTlhOWZiOTdlYjQ0Yjg5N2UzYmYxZmY3NDY3NWViL3RhYmxlcmFuZ2U6MGExOWE5ZmI5N2ViNDRiODk3ZTNiZjFmZjc0Njc1ZWJfNi0xLTEtMS04MQ_2759dedd-8f24-4b80-b066-cb8d4d2008df">1,135</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i313b15d35b7045babd1ba61f84a077dd_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yMi9mcmFnOmRjN2EwYjIzNGZmOTRlMDI5MDdiMjVlMTQ2ZWRiZjM2L3RhYmxlOjBhMTlhOWZiOTdlYjQ0Yjg5N2UzYmYxZmY3NDY3NWViL3RhYmxlcmFuZ2U6MGExOWE5ZmI5N2ViNDRiODk3ZTNiZjFmZjc0Njc1ZWJfNi0zLTEtMS04MQ_6610f72c-2ecc-44fe-8b80-745f9bb3bbc7">86</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yMi9mcmFnOmRjN2EwYjIzNGZmOTRlMDI5MDdiMjVlMTQ2ZWRiZjM2L3RhYmxlOjBhMTlhOWZiOTdlYjQ0Yjg5N2UzYmYxZmY3NDY3NWViL3RhYmxlcmFuZ2U6MGExOWE5ZmI5N2ViNDRiODk3ZTNiZjFmZjc0Njc1ZWJfNi01LTEtMS04MQ_ec3cb3e3-7a9c-4bd4-823b-6d2a52bea0c6">5,322</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0faaba5fcd6b485781cadacae8b2fd8e_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yMi9mcmFnOmRjN2EwYjIzNGZmOTRlMDI5MDdiMjVlMTQ2ZWRiZjM2L3RhYmxlOjBhMTlhOWZiOTdlYjQ0Yjg5N2UzYmYxZmY3NDY3NWViL3RhYmxlcmFuZ2U6MGExOWE5ZmI5N2ViNDRiODk3ZTNiZjFmZjc0Njc1ZWJfNi03LTEtMS04MQ_89bd94f7-e7a0-4a0c-ac3b-80dc39d3ff34">251</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Defined benefit pension gain, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id673d80f31e74643a241d2f62db94ca9_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yMi9mcmFnOmRjN2EwYjIzNGZmOTRlMDI5MDdiMjVlMTQ2ZWRiZjM2L3RhYmxlOjBhMTlhOWZiOTdlYjQ0Yjg5N2UzYmYxZmY3NDY3NWViL3RhYmxlcmFuZ2U6MGExOWE5ZmI5N2ViNDRiODk3ZTNiZjFmZjc0Njc1ZWJfNy0xLTEtMS04MQ_d6a54f3c-9850-4e8f-b2eb-0281cb78e803">282</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i313b15d35b7045babd1ba61f84a077dd_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yMi9mcmFnOmRjN2EwYjIzNGZmOTRlMDI5MDdiMjVlMTQ2ZWRiZjM2L3RhYmxlOjBhMTlhOWZiOTdlYjQ0Yjg5N2UzYmYxZmY3NDY3NWViL3RhYmxlcmFuZ2U6MGExOWE5ZmI5N2ViNDRiODk3ZTNiZjFmZjc0Njc1ZWJfNy0zLTEtMS04MQ_92be5c74-cef0-4d74-8cff-9f3526f6c6ea">342</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yMi9mcmFnOmRjN2EwYjIzNGZmOTRlMDI5MDdiMjVlMTQ2ZWRiZjM2L3RhYmxlOjBhMTlhOWZiOTdlYjQ0Yjg5N2UzYmYxZmY3NDY3NWViL3RhYmxlcmFuZ2U6MGExOWE5ZmI5N2ViNDRiODk3ZTNiZjFmZjc0Njc1ZWJfNy01LTEtMS04MQ_c79ff252-1330-434d-b393-8faa8b6bb27a">846</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0faaba5fcd6b485781cadacae8b2fd8e_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yMi9mcmFnOmRjN2EwYjIzNGZmOTRlMDI5MDdiMjVlMTQ2ZWRiZjM2L3RhYmxlOjBhMTlhOWZiOTdlYjQ0Yjg5N2UzYmYxZmY3NDY3NWViL3RhYmxlcmFuZ2U6MGExOWE5ZmI5N2ViNDRiODk3ZTNiZjFmZjc0Njc1ZWJfNy03LTEtMS04MQ_ad4a08ca-629e-43e2-a260-a1cd45dac369">1,026</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id673d80f31e74643a241d2f62db94ca9_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yMi9mcmFnOmRjN2EwYjIzNGZmOTRlMDI5MDdiMjVlMTQ2ZWRiZjM2L3RhYmxlOjBhMTlhOWZiOTdlYjQ0Yjg5N2UzYmYxZmY3NDY3NWViL3RhYmxlcmFuZ2U6MGExOWE5ZmI5N2ViNDRiODk3ZTNiZjFmZjc0Njc1ZWJfOC0xLTEtMS04MQ_b670fd5a-6a19-4fa1-9a99-a6f2b172bd50">3,366</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i313b15d35b7045babd1ba61f84a077dd_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yMi9mcmFnOmRjN2EwYjIzNGZmOTRlMDI5MDdiMjVlMTQ2ZWRiZjM2L3RhYmxlOjBhMTlhOWZiOTdlYjQ0Yjg5N2UzYmYxZmY3NDY3NWViL3RhYmxlcmFuZ2U6MGExOWE5ZmI5N2ViNDRiODk3ZTNiZjFmZjc0Njc1ZWJfOC0zLTEtMS04MQ_6f3a8e47-e4cd-4ae8-9e8f-5b2276ed7b0c">373</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yMi9mcmFnOmRjN2EwYjIzNGZmOTRlMDI5MDdiMjVlMTQ2ZWRiZjM2L3RhYmxlOjBhMTlhOWZiOTdlYjQ0Yjg5N2UzYmYxZmY3NDY3NWViL3RhYmxlcmFuZ2U6MGExOWE5ZmI5N2ViNDRiODk3ZTNiZjFmZjc0Njc1ZWJfOC01LTEtMS04MQ_5c4a6337-1941-4779-922f-37df93fa3658">9,608</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0faaba5fcd6b485781cadacae8b2fd8e_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yMi9mcmFnOmRjN2EwYjIzNGZmOTRlMDI5MDdiMjVlMTQ2ZWRiZjM2L3RhYmxlOjBhMTlhOWZiOTdlYjQ0Yjg5N2UzYmYxZmY3NDY3NWViL3RhYmxlcmFuZ2U6MGExOWE5ZmI5N2ViNDRiODk3ZTNiZjFmZjc0Njc1ZWJfOC03LTEtMS04MQ_dd638787-d8eb-409a-8860-a226043ab8e0">3,286</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive income</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id673d80f31e74643a241d2f62db94ca9_D20220701-20220930" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yMi9mcmFnOmRjN2EwYjIzNGZmOTRlMDI5MDdiMjVlMTQ2ZWRiZjM2L3RhYmxlOjBhMTlhOWZiOTdlYjQ0Yjg5N2UzYmYxZmY3NDY3NWViL3RhYmxlcmFuZ2U6MGExOWE5ZmI5N2ViNDRiODk3ZTNiZjFmZjc0Njc1ZWJfMTAtMS0xLTEtODE_5e656765-e1d7-46b1-b57a-fc1a753dc5c2">109,409</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i313b15d35b7045babd1ba61f84a077dd_D20210701-20210930" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yMi9mcmFnOmRjN2EwYjIzNGZmOTRlMDI5MDdiMjVlMTQ2ZWRiZjM2L3RhYmxlOjBhMTlhOWZiOTdlYjQ0Yjg5N2UzYmYxZmY3NDY3NWViL3RhYmxlcmFuZ2U6MGExOWE5ZmI5N2ViNDRiODk3ZTNiZjFmZjc0Njc1ZWJfMTAtMy0xLTEtODE_ed2643a5-fb2b-4a26-89b8-9ee7524a3775">181,366</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yMi9mcmFnOmRjN2EwYjIzNGZmOTRlMDI5MDdiMjVlMTQ2ZWRiZjM2L3RhYmxlOjBhMTlhOWZiOTdlYjQ0Yjg5N2UzYmYxZmY3NDY3NWViL3RhYmxlcmFuZ2U6MGExOWE5ZmI5N2ViNDRiODk3ZTNiZjFmZjc0Njc1ZWJfMTAtNS0xLTEtODE_9183eed5-f283-4fb6-8763-8ebc2fd13b35">302,591</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0faaba5fcd6b485781cadacae8b2fd8e_D20210101-20210930" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yMi9mcmFnOmRjN2EwYjIzNGZmOTRlMDI5MDdiMjVlMTQ2ZWRiZjM2L3RhYmxlOjBhMTlhOWZiOTdlYjQ0Yjg5N2UzYmYxZmY3NDY3NWViL3RhYmxlcmFuZ2U6MGExOWE5ZmI5N2ViNDRiODk3ZTNiZjFmZjc0Njc1ZWJfMTAtNy0xLTEtODE_58b8f89e-8ccb-412b-93ef-d373b4c89ba5">381,444</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5</span></div></div></div><div id="ie2ffba3ee5384c86becdb38ff117ca9a_25"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie2ffba3ee5384c86becdb38ff117ca9a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INCYTE CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, in thousands, except number of shares)</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.869%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.023%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Common<br/>Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Additional<br/>Paid-in Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Accumulated Other<br/>Comprehensive Loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Accumulated<br/>Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total<br/>Stockholders&#8217;<br/>Equity</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balances at January 1, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3978ca7e91d4a55b0da8a410f53aea4_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjQ2MmI1OGU4NTY5NTRlMGJhZGRiNjYwNjMwMzVhZjFjL3RhYmxlcmFuZ2U6NDYyYjU4ZTg1Njk1NGUwYmFkZGI2NjA2MzAzNWFmMWNfMS0xLTEtMS04MQ_b1e46adb-90eb-4b64-af79-618122d9e2b1">221</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a13b312028f458ba711e0bcf4618c10_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjQ2MmI1OGU4NTY5NTRlMGJhZGRiNjYwNjMwMzVhZjFjL3RhYmxlcmFuZ2U6NDYyYjU4ZTg1Njk1NGUwYmFkZGI2NjA2MzAzNWFmMWNfMS0zLTEtMS04MQ_c068c041-f021-4750-a91f-2f3f25346b69">4,567,111</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic7a3e053f47b40869b9b63c44edaac78_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjQ2MmI1OGU4NTY5NTRlMGJhZGRiNjYwNjMwMzVhZjFjL3RhYmxlcmFuZ2U6NDYyYjU4ZTg1Njk1NGUwYmFkZGI2NjA2MzAzNWFmMWNfMS01LTEtMS04MQ_97b97847-9915-4222-84d6-32f83766b8f3">19,454</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4cba8f9e546d4c0498d87ceb40e69a8f_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjQ2MmI1OGU4NTY5NTRlMGJhZGRiNjYwNjMwMzVhZjFjL3RhYmxlcmFuZ2U6NDYyYjU4ZTg1Njk1NGUwYmFkZGI2NjA2MzAzNWFmMWNfMS03LTEtMS04MQ_a4982fef-5a60-4dc4-b179-0c65cb42fac7">777,874</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab26fe441f0d4ab984456365a7f7cff0_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjQ2MmI1OGU4NTY5NTRlMGJhZGRiNjYwNjMwMzVhZjFjL3RhYmxlcmFuZ2U6NDYyYjU4ZTg1Njk1NGUwYmFkZGI2NjA2MzAzNWFmMWNfMS05LTEtMS04MQ_5e4eea8e-234e-48dd-8be1-cf7b2088e511">3,770,004</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Issuance of <ix:nonFraction unitRef="shares" contextRef="i6cea24b8bb274decac908bfad3a9c638_D20220101-20220331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjQ2MmI1OGU4NTY5NTRlMGJhZGRiNjYwNjMwMzVhZjFjL3RhYmxlcmFuZ2U6NDYyYjU4ZTg1Njk1NGUwYmFkZGI2NjA2MzAzNWFmMWNfMi0wLTEtMS04MS90ZXh0cmVnaW9uOjIwNjAxNjFiNjA3ZTQ4MGE5NTM0MTE3ZDVlNTUxYTgyXzE2_434be87c-26e9-45c5-83a1-01c9fab1b9a8">323,582</ix:nonFraction> shares of Common Stock upon exercise of stock options and settlement of employee restricted stock units, net of shares withheld for taxes </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3d452137b9d47e98488b6d8f51dd20b_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjQ2MmI1OGU4NTY5NTRlMGJhZGRiNjYwNjMwMzVhZjFjL3RhYmxlcmFuZ2U6NDYyYjU4ZTg1Njk1NGUwYmFkZGI2NjA2MzAzNWFmMWNfMi0zLTEtMS04MQ_50b35277-6fac-469a-86b0-3461712d7fc2">14,237</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cea24b8bb274decac908bfad3a9c638_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjQ2MmI1OGU4NTY5NTRlMGJhZGRiNjYwNjMwMzVhZjFjL3RhYmxlcmFuZ2U6NDYyYjU4ZTg1Njk1NGUwYmFkZGI2NjA2MzAzNWFmMWNfMi05LTEtMS04MQ_c6c69ec2-ef19-4438-82b5-76342c8bdf21">14,237</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Issuance of <ix:nonFraction unitRef="shares" contextRef="i6cea24b8bb274decac908bfad3a9c638_D20220101-20220331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjQ2MmI1OGU4NTY5NTRlMGJhZGRiNjYwNjMwMzVhZjFjL3RhYmxlcmFuZ2U6NDYyYjU4ZTg1Njk1NGUwYmFkZGI2NjA2MzAzNWFmMWNfMy0wLTEtMS04MS90ZXh0cmVnaW9uOjcxMDlkYWZkM2RkYTQxOGFhNGVlZTEzOTVjMzg5MTIxXzE2_eb9c1fd5-5f15-4c02-8dd9-42992d605dfb">1,535</ix:nonFraction> shares of Common Stock for services rendered</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3d452137b9d47e98488b6d8f51dd20b_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjQ2MmI1OGU4NTY5NTRlMGJhZGRiNjYwNjMwMzVhZjFjL3RhYmxlcmFuZ2U6NDYyYjU4ZTg1Njk1NGUwYmFkZGI2NjA2MzAzNWFmMWNfMy0zLTEtMS04MQ_632f525e-5064-411c-b8e0-7956843f2b41">112</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cea24b8bb274decac908bfad3a9c638_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjQ2MmI1OGU4NTY5NTRlMGJhZGRiNjYwNjMwMzVhZjFjL3RhYmxlcmFuZ2U6NDYyYjU4ZTg1Njk1NGUwYmFkZGI2NjA2MzAzNWFmMWNfMy05LTEtMS04MQ_eec39ccc-ade4-47f8-bf63-0a18bba3d1d3">112</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3d452137b9d47e98488b6d8f51dd20b_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjQ2MmI1OGU4NTY5NTRlMGJhZGRiNjYwNjMwMzVhZjFjL3RhYmxlcmFuZ2U6NDYyYjU4ZTg1Njk1NGUwYmFkZGI2NjA2MzAzNWFmMWNfNC0zLTEtMS04MQ_f88a8cbf-ef46-4bbd-a1d2-ca8cb57a1b44">44,320</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cea24b8bb274decac908bfad3a9c638_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjQ2MmI1OGU4NTY5NTRlMGJhZGRiNjYwNjMwMzVhZjFjL3RhYmxlcmFuZ2U6NDYyYjU4ZTg1Njk1NGUwYmFkZGI2NjA2MzAzNWFmMWNfNC05LTEtMS04MQ_100bfe9a-07ba-45a1-af29-8f3bf6185f9f">44,320</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i05bc3079ebc64f4a9ddcc9c745ce3823_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjQ2MmI1OGU4NTY5NTRlMGJhZGRiNjYwNjMwMzVhZjFjL3RhYmxlcmFuZ2U6NDYyYjU4ZTg1Njk1NGUwYmFkZGI2NjA2MzAzNWFmMWNfNS01LTEtMS04MQ_124a206f-ff26-4497-8941-35d3cf3c896e">3,593</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cea24b8bb274decac908bfad3a9c638_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjQ2MmI1OGU4NTY5NTRlMGJhZGRiNjYwNjMwMzVhZjFjL3RhYmxlcmFuZ2U6NDYyYjU4ZTg1Njk1NGUwYmFkZGI2NjA2MzAzNWFmMWNfNS05LTEtMS04MQ_bcad2773-80b5-4d81-b3b4-29c92057cc87">3,593</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibabc38cb3fd14f2698896bf6570c921e_D20220101-20220331" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjQ2MmI1OGU4NTY5NTRlMGJhZGRiNjYwNjMwMzVhZjFjL3RhYmxlcmFuZ2U6NDYyYjU4ZTg1Njk1NGUwYmFkZGI2NjA2MzAzNWFmMWNfNi03LTEtMS04MQ_687d8f36-2920-43e7-92a9-886223fc8010">37,992</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cea24b8bb274decac908bfad3a9c638_D20220101-20220331" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjQ2MmI1OGU4NTY5NTRlMGJhZGRiNjYwNjMwMzVhZjFjL3RhYmxlcmFuZ2U6NDYyYjU4ZTg1Njk1NGUwYmFkZGI2NjA2MzAzNWFmMWNfNi05LTEtMS04MQ_1d45b454-286f-455d-8c71-ef578a987479">37,992</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at March 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i967717e321b54b36a61c6fc27425f9af_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjQ2MmI1OGU4NTY5NTRlMGJhZGRiNjYwNjMwMzVhZjFjL3RhYmxlcmFuZ2U6NDYyYjU4ZTg1Njk1NGUwYmFkZGI2NjA2MzAzNWFmMWNfNy0xLTEtMS04MQ_a940731c-cafc-456a-992a-eee37f53278c">221</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie914017719d349ea93b5d5a6cd062896_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjQ2MmI1OGU4NTY5NTRlMGJhZGRiNjYwNjMwMzVhZjFjL3RhYmxlcmFuZ2U6NDYyYjU4ZTg1Njk1NGUwYmFkZGI2NjA2MzAzNWFmMWNfNy0zLTEtMS04MQ_9504dc10-7dae-4ca5-9d93-9eef8ee21692">4,625,780</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5bc89bf0de084e20a0006dad354ec6b3_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjQ2MmI1OGU4NTY5NTRlMGJhZGRiNjYwNjMwMzVhZjFjL3RhYmxlcmFuZ2U6NDYyYjU4ZTg1Njk1NGUwYmFkZGI2NjA2MzAzNWFmMWNfNy01LTEtMS04MQ_5ff5435b-87c8-410c-90d9-a1cd1eef82a2">23,047</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1c77ebb088a04a3bb81e477173b73514_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjQ2MmI1OGU4NTY5NTRlMGJhZGRiNjYwNjMwMzVhZjFjL3RhYmxlcmFuZ2U6NDYyYjU4ZTg1Njk1NGUwYmFkZGI2NjA2MzAzNWFmMWNfNy03LTEtMS04MQ_95c2272c-9fc7-41a9-88a5-4e060ea0400a">739,882</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38aa3d9ea1274ad1a0d50c3c12756c65_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjQ2MmI1OGU4NTY5NTRlMGJhZGRiNjYwNjMwMzVhZjFjL3RhYmxlcmFuZ2U6NDYyYjU4ZTg1Njk1NGUwYmFkZGI2NjA2MzAzNWFmMWNfNy05LTEtMS04MQ_3f4d69ca-6395-4c10-81d9-6d93c2dabee4">3,863,072</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Issuance of <ix:nonFraction unitRef="shares" contextRef="if098df40ebae4afbb01da4049e945b36_D20220401-20220630" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjQ2MmI1OGU4NTY5NTRlMGJhZGRiNjYwNjMwMzVhZjFjL3RhYmxlcmFuZ2U6NDYyYjU4ZTg1Njk1NGUwYmFkZGI2NjA2MzAzNWFmMWNfOC0wLTEtMS04MS90ZXh0cmVnaW9uOmY5ZWRhMTRiYTZkNzQ3Mjg4MjhhMDRjNDBkZGRjMzNiXzE2_c2ef68b4-3fb7-4675-a640-612ec73dd8a5">274,693</ix:nonFraction> shares of Common Stock upon exercise of stock options and settlement of employee restricted stock units and performance shares, net of shares withheld for taxes and <ix:nonFraction unitRef="shares" contextRef="if098df40ebae4afbb01da4049e945b36_D20220401-20220630" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjQ2MmI1OGU4NTY5NTRlMGJhZGRiNjYwNjMwMzVhZjFjL3RhYmxlcmFuZ2U6NDYyYjU4ZTg1Njk1NGUwYmFkZGI2NjA2MzAzNWFmMWNfOC0wLTEtMS04MS90ZXh0cmVnaW9uOmY5ZWRhMTRiYTZkNzQ3Mjg4MjhhMDRjNDBkZGRjMzNiXzE4NA_bcfc0efe-cab3-4da0-a38f-5fdffc336274">189,684</ix:nonFraction> shares of Common Stock under the ESPP</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92fea5bb4d2c40d19ea9af7ae6522acf_D20220401-20220630" decimals="-3" name="incy:StockIssuedDuringPeriodValueStockOptionsAndRestrictedStockUnitsExercisedAndEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjQ2MmI1OGU4NTY5NTRlMGJhZGRiNjYwNjMwMzVhZjFjL3RhYmxlcmFuZ2U6NDYyYjU4ZTg1Njk1NGUwYmFkZGI2NjA2MzAzNWFmMWNfOC0xLTEtMS04MQ_f645c40c-d6dc-43b1-98ae-a1126da925e3">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idff6b81e3d0245e797ebe0c300a68bfb_D20220401-20220630" decimals="-3" name="incy:StockIssuedDuringPeriodValueStockOptionsAndRestrictedStockUnitsExercisedAndEmployeeStockPurchasePlan" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjQ2MmI1OGU4NTY5NTRlMGJhZGRiNjYwNjMwMzVhZjFjL3RhYmxlcmFuZ2U6NDYyYjU4ZTg1Njk1NGUwYmFkZGI2NjA2MzAzNWFmMWNfOC0zLTEtMS04MQ_cdd3e05a-dad1-4d7a-b9bf-713853cad451">16,600</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if098df40ebae4afbb01da4049e945b36_D20220401-20220630" decimals="-3" name="incy:StockIssuedDuringPeriodValueStockOptionsAndRestrictedStockUnitsExercisedAndEmployeeStockPurchasePlan" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjQ2MmI1OGU4NTY5NTRlMGJhZGRiNjYwNjMwMzVhZjFjL3RhYmxlcmFuZ2U6NDYyYjU4ZTg1Njk1NGUwYmFkZGI2NjA2MzAzNWFmMWNfOC05LTEtMS04MQ_34363ad5-f57c-4cef-8284-622c3105a88f">16,601</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Issuance of <ix:nonFraction unitRef="shares" contextRef="if098df40ebae4afbb01da4049e945b36_D20220401-20220630" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjQ2MmI1OGU4NTY5NTRlMGJhZGRiNjYwNjMwMzVhZjFjL3RhYmxlcmFuZ2U6NDYyYjU4ZTg1Njk1NGUwYmFkZGI2NjA2MzAzNWFmMWNfOS0wLTEtMS04MS90ZXh0cmVnaW9uOjczYjAyZWI2YWYzNTQ0ZjRiMWQxNjQxNzQ2NThhYzI3XzE2_57965b27-deff-4fbd-b575-4cede4277821">1,469</ix:nonFraction> shares of Common Stock for services rendered</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idff6b81e3d0245e797ebe0c300a68bfb_D20220401-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjQ2MmI1OGU4NTY5NTRlMGJhZGRiNjYwNjMwMzVhZjFjL3RhYmxlcmFuZ2U6NDYyYjU4ZTg1Njk1NGUwYmFkZGI2NjA2MzAzNWFmMWNfOS0zLTEtMS04MQ_f6108c3c-1d59-44bf-b790-802cd0d471c6">109</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if098df40ebae4afbb01da4049e945b36_D20220401-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjQ2MmI1OGU4NTY5NTRlMGJhZGRiNjYwNjMwMzVhZjFjL3RhYmxlcmFuZ2U6NDYyYjU4ZTg1Njk1NGUwYmFkZGI2NjA2MzAzNWFmMWNfOS05LTEtMS04MQ_b11a2ab1-6c12-497c-9d18-c57bf1270c6d">109</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idff6b81e3d0245e797ebe0c300a68bfb_D20220401-20220630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjQ2MmI1OGU4NTY5NTRlMGJhZGRiNjYwNjMwMzVhZjFjL3RhYmxlcmFuZ2U6NDYyYjU4ZTg1Njk1NGUwYmFkZGI2NjA2MzAzNWFmMWNfMTAtMy0xLTEtODE_b779a348-6e63-40ca-9c04-9c078544b809">46,496</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if098df40ebae4afbb01da4049e945b36_D20220401-20220630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjQ2MmI1OGU4NTY5NTRlMGJhZGRiNjYwNjMwMzVhZjFjL3RhYmxlcmFuZ2U6NDYyYjU4ZTg1Njk1NGUwYmFkZGI2NjA2MzAzNWFmMWNfMTAtOS0xLTEtODE_b8c403bb-22b6-4238-aa19-a5599547c6ae">46,496</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i623f636b1e544597bf91776873f38e5d_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjQ2MmI1OGU4NTY5NTRlMGJhZGRiNjYwNjMwMzVhZjFjL3RhYmxlcmFuZ2U6NDYyYjU4ZTg1Njk1NGUwYmFkZGI2NjA2MzAzNWFmMWNfMTEtNS0xLTEtODE_7a521de9-7fa0-49ad-bd0a-b13c1a92280e">2,649</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if098df40ebae4afbb01da4049e945b36_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjQ2MmI1OGU4NTY5NTRlMGJhZGRiNjYwNjMwMzVhZjFjL3RhYmxlcmFuZ2U6NDYyYjU4ZTg1Njk1NGUwYmFkZGI2NjA2MzAzNWFmMWNfMTEtOS0xLTEtODE_318b5e21-26d4-4c26-a90b-2bb3e9e64a06">2,649</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83c026db6e174249812a82f711cb1f78_D20220401-20220630" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjQ2MmI1OGU4NTY5NTRlMGJhZGRiNjYwNjMwMzVhZjFjL3RhYmxlcmFuZ2U6NDYyYjU4ZTg1Njk1NGUwYmFkZGI2NjA2MzAzNWFmMWNfMTItNy0xLTEtODE_042e3fc6-e220-4a39-868e-044908785ab4">161,432</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if098df40ebae4afbb01da4049e945b36_D20220401-20220630" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjQ2MmI1OGU4NTY5NTRlMGJhZGRiNjYwNjMwMzVhZjFjL3RhYmxlcmFuZ2U6NDYyYjU4ZTg1Njk1NGUwYmFkZGI2NjA2MzAzNWFmMWNfMTItOS0xLTEtODE_aa33507e-87b8-42aa-b8c9-410a8d719eec">161,432</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balances at June 30, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i083ff8458e9c4ae38eb154dc7ce1f9a0_I20220630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjQ2MmI1OGU4NTY5NTRlMGJhZGRiNjYwNjMwMzVhZjFjL3RhYmxlcmFuZ2U6NDYyYjU4ZTg1Njk1NGUwYmFkZGI2NjA2MzAzNWFmMWNfMTMtMS0xLTEtODE_5d56415f-64e6-4fa9-bab9-246bc39c83ce">222</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f8d696d0d544a858bc29abec7dae8d2_I20220630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjQ2MmI1OGU4NTY5NTRlMGJhZGRiNjYwNjMwMzVhZjFjL3RhYmxlcmFuZ2U6NDYyYjU4ZTg1Njk1NGUwYmFkZGI2NjA2MzAzNWFmMWNfMTMtMy0xLTEtODE_ec820b68-b322-4700-ab8a-ecfb3381ca39">4,688,985</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if646a3c30a6b46ec8912b9038eb7f0bf_I20220630" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjQ2MmI1OGU4NTY5NTRlMGJhZGRiNjYwNjMwMzVhZjFjL3RhYmxlcmFuZ2U6NDYyYjU4ZTg1Njk1NGUwYmFkZGI2NjA2MzAzNWFmMWNfMTMtNS0xLTEtODE_78a26eb4-1673-441e-b905-c187046a979e">25,696</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5b880c3983264395b93d1f6014da990c_I20220630" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjQ2MmI1OGU4NTY5NTRlMGJhZGRiNjYwNjMwMzVhZjFjL3RhYmxlcmFuZ2U6NDYyYjU4ZTg1Njk1NGUwYmFkZGI2NjA2MzAzNWFmMWNfMTMtNy0xLTEtODE_b4517365-0591-4301-979e-d633273457b7">578,450</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6f74963df2d4ed483d364c3eeabd8a1_I20220630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjQ2MmI1OGU4NTY5NTRlMGJhZGRiNjYwNjMwMzVhZjFjL3RhYmxlcmFuZ2U6NDYyYjU4ZTg1Njk1NGUwYmFkZGI2NjA2MzAzNWFmMWNfMTMtOS0xLTEtODE_47848a29-1a6e-464f-aad9-259bedf227f1">4,085,061</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of <ix:nonFraction unitRef="shares" contextRef="id673d80f31e74643a241d2f62db94ca9_D20220701-20220930" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjQ2MmI1OGU4NTY5NTRlMGJhZGRiNjYwNjMwMzVhZjFjL3RhYmxlcmFuZ2U6NDYyYjU4ZTg1Njk1NGUwYmFkZGI2NjA2MzAzNWFmMWNfMTQtMC0xLTEtMTU2NS90ZXh0cmVnaW9uOjQzMTY1OGZhYTVkYzRlNjA5NjI5ZjYyMzgxYjExZGVlXzI3NDg3NzkwNjk2MDA_0b7dba12-aa75-429e-9025-36cae3cef90d">578,106</ix:nonFraction> shares of Common Stock upon exercise of stock options and settlement of employee restricted stock units, net of shares withheld for taxes</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i60075c2eb5c5499f8837e239ab042889_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjQ2MmI1OGU4NTY5NTRlMGJhZGRiNjYwNjMwMzVhZjFjL3RhYmxlcmFuZ2U6NDYyYjU4ZTg1Njk1NGUwYmFkZGI2NjA2MzAzNWFmMWNfMTQtMy0xLTEtMTU2NQ_d36f6897-733b-4852-a72d-f8e35c10919f">13,572</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id673d80f31e74643a241d2f62db94ca9_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjQ2MmI1OGU4NTY5NTRlMGJhZGRiNjYwNjMwMzVhZjFjL3RhYmxlcmFuZ2U6NDYyYjU4ZTg1Njk1NGUwYmFkZGI2NjA2MzAzNWFmMWNfMTQtOS0xLTEtMTU2NQ_7cfaa583-960a-48d3-9308-a005c9806f8e">13,572</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of <ix:nonFraction unitRef="shares" contextRef="id673d80f31e74643a241d2f62db94ca9_D20220701-20220930" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjQ2MmI1OGU4NTY5NTRlMGJhZGRiNjYwNjMwMzVhZjFjL3RhYmxlcmFuZ2U6NDYyYjU4ZTg1Njk1NGUwYmFkZGI2NjA2MzAzNWFmMWNfMTUtMC0xLTEtMTU2NS90ZXh0cmVnaW9uOjhhNGQzMDg4Y2VmMjQ4ZDNhNGE3ZWY5YzM2NTNmYjA2XzI3NDg3NzkwNjk1MDc_4ba976e8-09b9-4ea1-a1e2-fca3426faeeb">1,337</ix:nonFraction> shares of Common Stock for services rendered</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60075c2eb5c5499f8837e239ab042889_D20220701-20220930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjQ2MmI1OGU4NTY5NTRlMGJhZGRiNjYwNjMwMzVhZjFjL3RhYmxlcmFuZ2U6NDYyYjU4ZTg1Njk1NGUwYmFkZGI2NjA2MzAzNWFmMWNfMTUtMy0xLTEtMTU2NQ_c44b327e-9c60-4285-a72b-c728b5244fa5">94</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id673d80f31e74643a241d2f62db94ca9_D20220701-20220930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjQ2MmI1OGU4NTY5NTRlMGJhZGRiNjYwNjMwMzVhZjFjL3RhYmxlcmFuZ2U6NDYyYjU4ZTg1Njk1NGUwYmFkZGI2NjA2MzAzNWFmMWNfMTUtOS0xLTEtMTU2NQ_6164799d-d01c-466e-befc-6e624b0d6924">94</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60075c2eb5c5499f8837e239ab042889_D20220701-20220930" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjQ2MmI1OGU4NTY5NTRlMGJhZGRiNjYwNjMwMzVhZjFjL3RhYmxlcmFuZ2U6NDYyYjU4ZTg1Njk1NGUwYmFkZGI2NjA2MzAzNWFmMWNfMTYtMy0xLTEtMTU2NQ_d82115fa-f029-480a-b083-c808ec056298">45,659</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id673d80f31e74643a241d2f62db94ca9_D20220701-20220930" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjQ2MmI1OGU4NTY5NTRlMGJhZGRiNjYwNjMwMzVhZjFjL3RhYmxlcmFuZ2U6NDYyYjU4ZTg1Njk1NGUwYmFkZGI2NjA2MzAzNWFmMWNfMTYtOS0xLTEtMTU2NQ_b33f7c12-e9a8-4a8e-b5a5-206e0c08ed0d">45,659</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1e7566ac86984c7d9bc3167d0dd68193_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjQ2MmI1OGU4NTY5NTRlMGJhZGRiNjYwNjMwMzVhZjFjL3RhYmxlcmFuZ2U6NDYyYjU4ZTg1Njk1NGUwYmFkZGI2NjA2MzAzNWFmMWNfMTctNS0xLTEtMTU2NQ_8424d83b-fdfb-432c-b1d5-40644d6ad1a5">3,366</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id673d80f31e74643a241d2f62db94ca9_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjQ2MmI1OGU4NTY5NTRlMGJhZGRiNjYwNjMwMzVhZjFjL3RhYmxlcmFuZ2U6NDYyYjU4ZTg1Njk1NGUwYmFkZGI2NjA2MzAzNWFmMWNfMTctOS0xLTEtMTU2NQ_223af8a7-cc89-4ecf-aba3-25d29f817366">3,366</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85c3cbfbb1824bc5a5e1c025e4781453_D20220701-20220930" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjQ2MmI1OGU4NTY5NTRlMGJhZGRiNjYwNjMwMzVhZjFjL3RhYmxlcmFuZ2U6NDYyYjU4ZTg1Njk1NGUwYmFkZGI2NjA2MzAzNWFmMWNfMTgtNy0xLTEtMTU2NQ_f2fa0c35-799b-4c3e-bcd7-e404a47c42aa">112,775</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id673d80f31e74643a241d2f62db94ca9_D20220701-20220930" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjQ2MmI1OGU4NTY5NTRlMGJhZGRiNjYwNjMwMzVhZjFjL3RhYmxlcmFuZ2U6NDYyYjU4ZTg1Njk1NGUwYmFkZGI2NjA2MzAzNWFmMWNfMTgtOS0xLTEtMTU2NQ_dd27a6e4-b72e-4635-a3ee-c9c848ec35c2">112,775</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balances at September 30, 2022</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6839b85b6084c339df68bc47f7cff76_I20220930" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjQ2MmI1OGU4NTY5NTRlMGJhZGRiNjYwNjMwMzVhZjFjL3RhYmxlcmFuZ2U6NDYyYjU4ZTg1Njk1NGUwYmFkZGI2NjA2MzAzNWFmMWNfMTktMS0xLTEtMTU2NQ_7abdfe59-8d9f-4fcd-a250-517db1f87cbd">222</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe1f6fcb358742d8947f8680dc7a2216_I20220930" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjQ2MmI1OGU4NTY5NTRlMGJhZGRiNjYwNjMwMzVhZjFjL3RhYmxlcmFuZ2U6NDYyYjU4ZTg1Njk1NGUwYmFkZGI2NjA2MzAzNWFmMWNfMTktMy0xLTEtMTU2NQ_b5f03867-cf5c-46c3-a064-12a23a31d535">4,721,166</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i05520eab8e964199ad292516b1f688c5_I20220930" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjQ2MmI1OGU4NTY5NTRlMGJhZGRiNjYwNjMwMzVhZjFjL3RhYmxlcmFuZ2U6NDYyYjU4ZTg1Njk1NGUwYmFkZGI2NjA2MzAzNWFmMWNfMTktNS0xLTEtMTU2NQ_80080732-dfb2-4de4-b4b2-9e6840e27e1a">29,062</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie5b42e033862404b9b0eb46dcfa04cde_I20220930" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjQ2MmI1OGU4NTY5NTRlMGJhZGRiNjYwNjMwMzVhZjFjL3RhYmxlcmFuZ2U6NDYyYjU4ZTg1Njk1NGUwYmFkZGI2NjA2MzAzNWFmMWNfMTktNy0xLTEtMTU2NQ_ce3a5a11-7227-4da9-854b-c0f7ccfa1b9c">465,675</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b4376f8fc614de98c9cf647198c504e_I20220930" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjQ2MmI1OGU4NTY5NTRlMGJhZGRiNjYwNjMwMzVhZjFjL3RhYmxlcmFuZ2U6NDYyYjU4ZTg1Njk1NGUwYmFkZGI2NjA2MzAzNWFmMWNfMTktOS0xLTEtMTU2NQ_d7dfc0d9-48e2-41e5-80c9-fb9ee464030f">4,226,651</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie2ffba3ee5384c86becdb38ff117ca9a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INCYTE CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY (CONTINUED)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, in thousands, except number of shares)</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.869%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.023%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common<br/>Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional<br/>Paid-in Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Other<br/>Comprehensive Loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Stockholders&#8217;<br/>Equity</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balances at January 1, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16eb58b1ed464d849f5daa9d5c452c5d_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjE0ZjIxMDkzZTZkMzQ0YWQ4NzgxOTkyNDQ2ZTJmZmFjL3RhYmxlcmFuZ2U6MTRmMjEwOTNlNmQzNDRhZDg3ODE5OTI0NDZlMmZmYWNfMS0xLTEtMS04MQ_24bb061e-b855-4367-b1b1-fe44f27308e4">219</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5940926f68ee4011bffeecd1cae3a5bd_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjE0ZjIxMDkzZTZkMzQ0YWQ4NzgxOTkyNDQ2ZTJmZmFjL3RhYmxlcmFuZ2U6MTRmMjEwOTNlNmQzNDRhZDg3ODE5OTI0NDZlMmZmYWNfMS0zLTEtMS04MQ_63386b72-1646-441f-b5c3-e7a95ee1fc58">4,352,864</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idab40e34150649eb84f41cf937413ae9_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjE0ZjIxMDkzZTZkMzQ0YWQ4NzgxOTkyNDQ2ZTJmZmFjL3RhYmxlcmFuZ2U6MTRmMjEwOTNlNmQzNDRhZDg3ODE5OTI0NDZlMmZmYWNfMS01LTEtMS04MQ_e08ddb5c-5d89-425c-aa33-4920ad395b0b">15,360</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i965f89ff7c6b4ce6bcc30af15c2742bb_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjE0ZjIxMDkzZTZkMzQ0YWQ4NzgxOTkyNDQ2ZTJmZmFjL3RhYmxlcmFuZ2U6MTRmMjEwOTNlNmQzNDRhZDg3ODE5OTI0NDZlMmZmYWNfMS03LTEtMS04MQ_0de131e8-c960-4d43-9115-95be99698d26">1,726,455</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7612db9fbac4f99a07f20a1f367748a_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjE0ZjIxMDkzZTZkMzQ0YWQ4NzgxOTkyNDQ2ZTJmZmFjL3RhYmxlcmFuZ2U6MTRmMjEwOTNlNmQzNDRhZDg3ODE5OTI0NDZlMmZmYWNfMS05LTEtMS04MQ_500af3fd-5032-4ee6-8a7b-33bb55f3247d">2,611,268</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of <ix:nonFraction unitRef="shares" contextRef="if318fa6e60cf4269ad7b22fe4b7d3bed_D20210101-20210331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjE0ZjIxMDkzZTZkMzQ0YWQ4NzgxOTkyNDQ2ZTJmZmFjL3RhYmxlcmFuZ2U6MTRmMjEwOTNlNmQzNDRhZDg3ODE5OTI0NDZlMmZmYWNfMi0wLTEtMS04MS90ZXh0cmVnaW9uOjY0Y2VmNGNmYjNiNzQwYjFiZDA2YzhiYTU5OWI4MmIzXzE2_d6477a7c-780a-44bb-afd5-9419f20da998">389,512</ix:nonFraction> shares of Common Stock upon exercise of stock options and settlement of employee restricted stock units, net of shares withheld for taxes </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i149762c26678449aa330b2367cbe6d4c_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjE0ZjIxMDkzZTZkMzQ0YWQ4NzgxOTkyNDQ2ZTJmZmFjL3RhYmxlcmFuZ2U6MTRmMjEwOTNlNmQzNDRhZDg3ODE5OTI0NDZlMmZmYWNfMi0xLTEtMS04MQ_0ba64307-e525-4eb3-8f29-93a0b891181d">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63235de3b5c048f09f04c5309d82d142_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjE0ZjIxMDkzZTZkMzQ0YWQ4NzgxOTkyNDQ2ZTJmZmFjL3RhYmxlcmFuZ2U6MTRmMjEwOTNlNmQzNDRhZDg3ODE5OTI0NDZlMmZmYWNfMi0zLTEtMS04MQ_dc6deafa-7855-403a-9a27-36d8417dbdf4">20,027</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if318fa6e60cf4269ad7b22fe4b7d3bed_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjE0ZjIxMDkzZTZkMzQ0YWQ4NzgxOTkyNDQ2ZTJmZmFjL3RhYmxlcmFuZ2U6MTRmMjEwOTNlNmQzNDRhZDg3ODE5OTI0NDZlMmZmYWNfMi05LTEtMS04MQ_49d1886a-2df0-4a46-83ea-32cf76ffff32">20,028</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of <ix:nonFraction unitRef="shares" contextRef="if318fa6e60cf4269ad7b22fe4b7d3bed_D20210101-20210331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjE0ZjIxMDkzZTZkMzQ0YWQ4NzgxOTkyNDQ2ZTJmZmFjL3RhYmxlcmFuZ2U6MTRmMjEwOTNlNmQzNDRhZDg3ODE5OTI0NDZlMmZmYWNfMy0wLTEtMS04MS90ZXh0cmVnaW9uOjIxNjE2NWRhY2NkYTQ0MmU4MjJlMTY0NDU4ZDYyOWVjXzE2_7ffba7cf-5bc2-4aa1-bcb5-3e92cef230ee">1,357</ix:nonFraction> shares of Common Stock for services rendered</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63235de3b5c048f09f04c5309d82d142_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjE0ZjIxMDkzZTZkMzQ0YWQ4NzgxOTkyNDQ2ZTJmZmFjL3RhYmxlcmFuZ2U6MTRmMjEwOTNlNmQzNDRhZDg3ODE5OTI0NDZlMmZmYWNfMy0zLTEtMS04MQ_6812333f-f2a1-4ecb-b141-65313b5d468f">108</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if318fa6e60cf4269ad7b22fe4b7d3bed_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjE0ZjIxMDkzZTZkMzQ0YWQ4NzgxOTkyNDQ2ZTJmZmFjL3RhYmxlcmFuZ2U6MTRmMjEwOTNlNmQzNDRhZDg3ODE5OTI0NDZlMmZmYWNfMy05LTEtMS04MQ_a219c25f-a029-40f0-8f98-dafb522e474f">108</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63235de3b5c048f09f04c5309d82d142_D20210101-20210331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjE0ZjIxMDkzZTZkMzQ0YWQ4NzgxOTkyNDQ2ZTJmZmFjL3RhYmxlcmFuZ2U6MTRmMjEwOTNlNmQzNDRhZDg3ODE5OTI0NDZlMmZmYWNfNC0zLTEtMS04MQ_d5d04e43-6928-4ee0-a3b5-882811ac45ff">47,903</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if318fa6e60cf4269ad7b22fe4b7d3bed_D20210101-20210331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjE0ZjIxMDkzZTZkMzQ0YWQ4NzgxOTkyNDQ2ZTJmZmFjL3RhYmxlcmFuZ2U6MTRmMjEwOTNlNmQzNDRhZDg3ODE5OTI0NDZlMmZmYWNfNC05LTEtMS04MQ_839b246a-29b0-4276-8541-008dc224e6f5">47,903</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9f5bbbcd7a4e4865bf1cd728365c237b_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjE0ZjIxMDkzZTZkMzQ0YWQ4NzgxOTkyNDQ2ZTJmZmFjL3RhYmxlcmFuZ2U6MTRmMjEwOTNlNmQzNDRhZDg3ODE5OTI0NDZlMmZmYWNfNS01LTEtMS04MQ_dde41b24-fe7a-4dd1-a075-bf65e64efd34">4,998</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if318fa6e60cf4269ad7b22fe4b7d3bed_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjE0ZjIxMDkzZTZkMzQ0YWQ4NzgxOTkyNDQ2ZTJmZmFjL3RhYmxlcmFuZ2U6MTRmMjEwOTNlNmQzNDRhZDg3ODE5OTI0NDZlMmZmYWNfNS05LTEtMS04MQ_14a60bd2-705d-4c50-9060-470947120f55">4,998</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i510fae960406426aabb022789d463532_D20210101-20210331" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjE0ZjIxMDkzZTZkMzQ0YWQ4NzgxOTkyNDQ2ZTJmZmFjL3RhYmxlcmFuZ2U6MTRmMjEwOTNlNmQzNDRhZDg3ODE5OTI0NDZlMmZmYWNfNi03LTEtMS04MQ_64268cce-2ec5-461e-bc38-d7c9621a2476">53,535</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if318fa6e60cf4269ad7b22fe4b7d3bed_D20210101-20210331" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjE0ZjIxMDkzZTZkMzQ0YWQ4NzgxOTkyNDQ2ZTJmZmFjL3RhYmxlcmFuZ2U6MTRmMjEwOTNlNmQzNDRhZDg3ODE5OTI0NDZlMmZmYWNfNi05LTEtMS04MQ_225bb818-5afa-448d-b13a-d6e8f0c8c4a9">53,535</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balances at March 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b5fdbb0199e42af841de05d57267053_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjE0ZjIxMDkzZTZkMzQ0YWQ4NzgxOTkyNDQ2ZTJmZmFjL3RhYmxlcmFuZ2U6MTRmMjEwOTNlNmQzNDRhZDg3ODE5OTI0NDZlMmZmYWNfNy0xLTEtMS04MQ_acadc6ec-c34a-43ea-b89a-44bcd8d1ad4d">220</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b58a259e2444d51ab47b223d8db0cb8_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjE0ZjIxMDkzZTZkMzQ0YWQ4NzgxOTkyNDQ2ZTJmZmFjL3RhYmxlcmFuZ2U6MTRmMjEwOTNlNmQzNDRhZDg3ODE5OTI0NDZlMmZmYWNfNy0zLTEtMS04MQ_6eccb55b-0cbd-43c3-8d4b-bd0e002a561c">4,420,902</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i964e4f2c4c4e458a807f09f6f17794df_I20210331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjE0ZjIxMDkzZTZkMzQ0YWQ4NzgxOTkyNDQ2ZTJmZmFjL3RhYmxlcmFuZ2U6MTRmMjEwOTNlNmQzNDRhZDg3ODE5OTI0NDZlMmZmYWNfNy01LTEtMS04MQ_5a0df0b1-2912-4761-bed6-90cfc12ce5da">20,358</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i06b27465ac7d4ce4b1fe3f0cc3e247fb_I20210331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjE0ZjIxMDkzZTZkMzQ0YWQ4NzgxOTkyNDQ2ZTJmZmFjL3RhYmxlcmFuZ2U6MTRmMjEwOTNlNmQzNDRhZDg3ODE5OTI0NDZlMmZmYWNfNy03LTEtMS04MQ_fd8d703a-b092-432b-9f3a-53685196c0c7">1,672,920</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b4b9892bc824ec58691624921a1e192_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjE0ZjIxMDkzZTZkMzQ0YWQ4NzgxOTkyNDQ2ZTJmZmFjL3RhYmxlcmFuZ2U6MTRmMjEwOTNlNmQzNDRhZDg3ODE5OTI0NDZlMmZmYWNfNy05LTEtMS04MQ_8722cbf4-bdc9-4b6c-b0bb-44a1a070077a">2,727,844</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of <ix:nonFraction unitRef="shares" contextRef="idc6cb7baa8c74e84b9abc3c83e5894f1_D20210401-20210630" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjE0ZjIxMDkzZTZkMzQ0YWQ4NzgxOTkyNDQ2ZTJmZmFjL3RhYmxlcmFuZ2U6MTRmMjEwOTNlNmQzNDRhZDg3ODE5OTI0NDZlMmZmYWNfOC0wLTEtMS04MS90ZXh0cmVnaW9uOjE5ZmI1NDM5OTJkYjRiN2VhNzM3YjhjMzRmM2QzYTdhXzE2_8614985d-c2a2-4c34-860a-67a698cbe871">390,001</ix:nonFraction> shares of Common Stock upon exercise of stock options and settlement of employee restricted stock units and performance shares, net of shares withheld for taxes and <ix:nonFraction unitRef="shares" contextRef="idc6cb7baa8c74e84b9abc3c83e5894f1_D20210401-20210630" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjE0ZjIxMDkzZTZkMzQ0YWQ4NzgxOTkyNDQ2ZTJmZmFjL3RhYmxlcmFuZ2U6MTRmMjEwOTNlNmQzNDRhZDg3ODE5OTI0NDZlMmZmYWNfOC0wLTEtMS04MS90ZXh0cmVnaW9uOjE5ZmI1NDM5OTJkYjRiN2VhNzM3YjhjMzRmM2QzYTdhXzE4NA_83a73ebc-a84f-423a-a6cb-5040a3451b9f">153,082</ix:nonFraction> shares of Common Stock under the ESPP</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9e03c43713740629fa4f89aa642de4f_D20210401-20210630" decimals="-3" name="incy:StockIssuedDuringPeriodValueStockOptionsAndRestrictedStockUnitsExercisedAndEmployeeStockPurchasePlan" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjE0ZjIxMDkzZTZkMzQ0YWQ4NzgxOTkyNDQ2ZTJmZmFjL3RhYmxlcmFuZ2U6MTRmMjEwOTNlNmQzNDRhZDg3ODE5OTI0NDZlMmZmYWNfOC0zLTEtMS04MQ_5dcff6f8-a42c-412c-86d3-175db64284ed">11,016</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc6cb7baa8c74e84b9abc3c83e5894f1_D20210401-20210630" decimals="-3" name="incy:StockIssuedDuringPeriodValueStockOptionsAndRestrictedStockUnitsExercisedAndEmployeeStockPurchasePlan" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjE0ZjIxMDkzZTZkMzQ0YWQ4NzgxOTkyNDQ2ZTJmZmFjL3RhYmxlcmFuZ2U6MTRmMjEwOTNlNmQzNDRhZDg3ODE5OTI0NDZlMmZmYWNfOC05LTEtMS04MQ_2b28225b-9887-485b-a4dd-1939f820fe60">11,016</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of <ix:nonFraction unitRef="shares" contextRef="idc6cb7baa8c74e84b9abc3c83e5894f1_D20210401-20210630" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjE0ZjIxMDkzZTZkMzQ0YWQ4NzgxOTkyNDQ2ZTJmZmFjL3RhYmxlcmFuZ2U6MTRmMjEwOTNlNmQzNDRhZDg3ODE5OTI0NDZlMmZmYWNfOS0wLTEtMS04MS90ZXh0cmVnaW9uOmZiYmNkNTM0MjNjMTRmYWI5ZTc1MDg5NmVlNjU1MDNlXzE2_4871331e-355e-492f-8ef9-ed2445afdff1">1,288</ix:nonFraction> shares of Common Stock for services rendered</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9e03c43713740629fa4f89aa642de4f_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjE0ZjIxMDkzZTZkMzQ0YWQ4NzgxOTkyNDQ2ZTJmZmFjL3RhYmxlcmFuZ2U6MTRmMjEwOTNlNmQzNDRhZDg3ODE5OTI0NDZlMmZmYWNfOS0zLTEtMS04MQ_0c5b2142-4ed3-4dd8-9f06-f3d831e3be35">109</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc6cb7baa8c74e84b9abc3c83e5894f1_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjE0ZjIxMDkzZTZkMzQ0YWQ4NzgxOTkyNDQ2ZTJmZmFjL3RhYmxlcmFuZ2U6MTRmMjEwOTNlNmQzNDRhZDg3ODE5OTI0NDZlMmZmYWNfOS05LTEtMS04MQ_246b8763-9ec8-42ba-8f3a-42606aaad2df">109</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9e03c43713740629fa4f89aa642de4f_D20210401-20210630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjE0ZjIxMDkzZTZkMzQ0YWQ4NzgxOTkyNDQ2ZTJmZmFjL3RhYmxlcmFuZ2U6MTRmMjEwOTNlNmQzNDRhZDg3ODE5OTI0NDZlMmZmYWNfMTAtMy0xLTEtODE_b994f64e-922d-44ed-bde6-10cd4896fd1d">45,351</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc6cb7baa8c74e84b9abc3c83e5894f1_D20210401-20210630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjE0ZjIxMDkzZTZkMzQ0YWQ4NzgxOTkyNDQ2ZTJmZmFjL3RhYmxlcmFuZ2U6MTRmMjEwOTNlNmQzNDRhZDg3ODE5OTI0NDZlMmZmYWNfMTAtOS0xLTEtODE_2b1c7784-c0d4-4051-b164-df66cee4448c">45,351</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e103bce07364afa8641cfcaf9141951_D20210401-20210630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjE0ZjIxMDkzZTZkMzQ0YWQ4NzgxOTkyNDQ2ZTJmZmFjL3RhYmxlcmFuZ2U6MTRmMjEwOTNlNmQzNDRhZDg3ODE5OTI0NDZlMmZmYWNfMTEtNS0xLTEtODE_8f47a4e9-7a6e-4777-9b69-f551e6c7187c">2,085</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc6cb7baa8c74e84b9abc3c83e5894f1_D20210401-20210630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjE0ZjIxMDkzZTZkMzQ0YWQ4NzgxOTkyNDQ2ZTJmZmFjL3RhYmxlcmFuZ2U6MTRmMjEwOTNlNmQzNDRhZDg3ODE5OTI0NDZlMmZmYWNfMTEtOS0xLTEtODE_20f9ba98-faef-43d7-b5c2-638a896a39a7">2,085</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27392d6e02284d51a27f567bf09e7d8a_D20210401-20210630" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjE0ZjIxMDkzZTZkMzQ0YWQ4NzgxOTkyNDQ2ZTJmZmFjL3RhYmxlcmFuZ2U6MTRmMjEwOTNlNmQzNDRhZDg3ODE5OTI0NDZlMmZmYWNfMTItNy0xLTEtODE_65c92090-45bf-4eb3-9602-db9618bf31b5">149,456</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc6cb7baa8c74e84b9abc3c83e5894f1_D20210401-20210630" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjE0ZjIxMDkzZTZkMzQ0YWQ4NzgxOTkyNDQ2ZTJmZmFjL3RhYmxlcmFuZ2U6MTRmMjEwOTNlNmQzNDRhZDg3ODE5OTI0NDZlMmZmYWNfMTItOS0xLTEtODE_9e98d73f-df55-4f40-ba9b-d96796a9566d">149,456</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balances at June 30, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i117119ef63584701b5c25a7fdb4442e6_I20210630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjE0ZjIxMDkzZTZkMzQ0YWQ4NzgxOTkyNDQ2ZTJmZmFjL3RhYmxlcmFuZ2U6MTRmMjEwOTNlNmQzNDRhZDg3ODE5OTI0NDZlMmZmYWNfMTMtMS0xLTEtODE_4fd2b1a8-0f89-4d76-9d99-33364aa0bdb2">220</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5519d29d74934b9387e13dee64f56289_I20210630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjE0ZjIxMDkzZTZkMzQ0YWQ4NzgxOTkyNDQ2ZTJmZmFjL3RhYmxlcmFuZ2U6MTRmMjEwOTNlNmQzNDRhZDg3ODE5OTI0NDZlMmZmYWNfMTMtMy0xLTEtODE_83b23ec0-8da0-463a-8d3a-60cf38c57e92">4,477,378</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if29697c5381c4b6dbdca657efd2afcb9_I20210630" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjE0ZjIxMDkzZTZkMzQ0YWQ4NzgxOTkyNDQ2ZTJmZmFjL3RhYmxlcmFuZ2U6MTRmMjEwOTNlNmQzNDRhZDg3ODE5OTI0NDZlMmZmYWNfMTMtNS0xLTEtODE_18cbbd6e-9532-495b-b56b-b5518c115bb8">18,273</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib314ad130b2f42d0844a18715eb4169a_I20210630" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjE0ZjIxMDkzZTZkMzQ0YWQ4NzgxOTkyNDQ2ZTJmZmFjL3RhYmxlcmFuZ2U6MTRmMjEwOTNlNmQzNDRhZDg3ODE5OTI0NDZlMmZmYWNfMTMtNy0xLTEtODE_ded48787-0a3a-4672-ad3d-f68c7e19d2f1">1,523,464</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9e0017429a94b21b8bba302af4c6a96_I20210630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjE0ZjIxMDkzZTZkMzQ0YWQ4NzgxOTkyNDQ2ZTJmZmFjL3RhYmxlcmFuZ2U6MTRmMjEwOTNlNmQzNDRhZDg3ODE5OTI0NDZlMmZmYWNfMTMtOS0xLTEtODE_8c23906a-090b-4296-8aa6-1a12a38dc273">2,935,861</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of <ix:nonFraction unitRef="shares" contextRef="i313b15d35b7045babd1ba61f84a077dd_D20210701-20210930" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjE0ZjIxMDkzZTZkMzQ0YWQ4NzgxOTkyNDQ2ZTJmZmFjL3RhYmxlcmFuZ2U6MTRmMjEwOTNlNmQzNDRhZDg3ODE5OTI0NDZlMmZmYWNfMTQtMC0xLTEtMjA4MC90ZXh0cmVnaW9uOjc3MTliODczY2JjYzRlNWVhZjI1OGUxYmZlMDE0Njc4XzI3NDg3NzkwNjk2MDg_03ffd5c6-dbe3-4a0a-8f9c-f758ecf34e64">459,084</ix:nonFraction> shares of Common Stock upon exercise of stock options and settlement of employee restricted stock units, net of shares withheld for taxes</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80edfdae16f74674aa25a4584796d920_D20210701-20210930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjE0ZjIxMDkzZTZkMzQ0YWQ4NzgxOTkyNDQ2ZTJmZmFjL3RhYmxlcmFuZ2U6MTRmMjEwOTNlNmQzNDRhZDg3ODE5OTI0NDZlMmZmYWNfMTQtMS0xLTEtMjA4MA_60f9bc2b-a90b-4179-a966-39f37e54e333">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4a971b6abebd4be9a0d2b6015046b257_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjE0ZjIxMDkzZTZkMzQ0YWQ4NzgxOTkyNDQ2ZTJmZmFjL3RhYmxlcmFuZ2U6MTRmMjEwOTNlNmQzNDRhZDg3ODE5OTI0NDZlMmZmYWNfMTQtMy0xLTEtMjA4MA_29e5b5b6-34a3-4f2b-a058-eac0d29528c0">11,993</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i313b15d35b7045babd1ba61f84a077dd_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjE0ZjIxMDkzZTZkMzQ0YWQ4NzgxOTkyNDQ2ZTJmZmFjL3RhYmxlcmFuZ2U6MTRmMjEwOTNlNmQzNDRhZDg3ODE5OTI0NDZlMmZmYWNfMTQtOS0xLTEtMjA4MA_6454dc96-cd5f-4122-9130-7403c9c6afec">11,992</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of <ix:nonFraction unitRef="shares" contextRef="i313b15d35b7045babd1ba61f84a077dd_D20210701-20210930" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjE0ZjIxMDkzZTZkMzQ0YWQ4NzgxOTkyNDQ2ZTJmZmFjL3RhYmxlcmFuZ2U6MTRmMjEwOTNlNmQzNDRhZDg3ODE5OTI0NDZlMmZmYWNfMTUtMC0xLTEtMjA4MC90ZXh0cmVnaW9uOmY3MGVhMjRhZmQzYjQyMGRiYzIwZTZiMTJkNjM2N2JhXzI3NDg3NzkwNjk1MTE_6a09b09e-4bc1-4c55-8eab-417d5073f26c">1,466</ix:nonFraction> shares of Common Stock for services rendered</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a971b6abebd4be9a0d2b6015046b257_D20210701-20210930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjE0ZjIxMDkzZTZkMzQ0YWQ4NzgxOTkyNDQ2ZTJmZmFjL3RhYmxlcmFuZ2U6MTRmMjEwOTNlNmQzNDRhZDg3ODE5OTI0NDZlMmZmYWNfMTUtMy0xLTEtMjA4MA_ddec1b2d-dcc6-474f-aa8e-7d17c4e95a77">108</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i313b15d35b7045babd1ba61f84a077dd_D20210701-20210930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjE0ZjIxMDkzZTZkMzQ0YWQ4NzgxOTkyNDQ2ZTJmZmFjL3RhYmxlcmFuZ2U6MTRmMjEwOTNlNmQzNDRhZDg3ODE5OTI0NDZlMmZmYWNfMTUtOS0xLTEtMjA4MA_fffb3049-6ea9-4c53-ac4e-b323d1fd7ec4">108</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a971b6abebd4be9a0d2b6015046b257_D20210701-20210930" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjE0ZjIxMDkzZTZkMzQ0YWQ4NzgxOTkyNDQ2ZTJmZmFjL3RhYmxlcmFuZ2U6MTRmMjEwOTNlNmQzNDRhZDg3ODE5OTI0NDZlMmZmYWNfMTYtMy0xLTEtMjA4MA_3dfd3ffd-65ba-48fe-b3d9-a0d50910981e">43,314</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i313b15d35b7045babd1ba61f84a077dd_D20210701-20210930" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjE0ZjIxMDkzZTZkMzQ0YWQ4NzgxOTkyNDQ2ZTJmZmFjL3RhYmxlcmFuZ2U6MTRmMjEwOTNlNmQzNDRhZDg3ODE5OTI0NDZlMmZmYWNfMTYtOS0xLTEtMjA4MA_f14e645b-f5f9-421b-bdc4-041515f735ff">43,314</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i37e49a4f06ec4d2da555cee905623504_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjE0ZjIxMDkzZTZkMzQ0YWQ4NzgxOTkyNDQ2ZTJmZmFjL3RhYmxlcmFuZ2U6MTRmMjEwOTNlNmQzNDRhZDg3ODE5OTI0NDZlMmZmYWNfMTctNS0xLTEtMjA4MA_781558b7-7a09-4489-be58-da9d8db6a0d5">373</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i313b15d35b7045babd1ba61f84a077dd_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjE0ZjIxMDkzZTZkMzQ0YWQ4NzgxOTkyNDQ2ZTJmZmFjL3RhYmxlcmFuZ2U6MTRmMjEwOTNlNmQzNDRhZDg3ODE5OTI0NDZlMmZmYWNfMTctOS0xLTEtMjA4MA_56de6f6e-0e16-4282-8232-e10febf34524">373</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3999e65b4d434855be24ad71cc111f8d_D20210701-20210930" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjE0ZjIxMDkzZTZkMzQ0YWQ4NzgxOTkyNDQ2ZTJmZmFjL3RhYmxlcmFuZ2U6MTRmMjEwOTNlNmQzNDRhZDg3ODE5OTI0NDZlMmZmYWNfMTgtNy0xLTEtMjA4MA_0a22dc91-7acf-4482-a431-ee7bcd56b50f">181,739</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i313b15d35b7045babd1ba61f84a077dd_D20210701-20210930" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjE0ZjIxMDkzZTZkMzQ0YWQ4NzgxOTkyNDQ2ZTJmZmFjL3RhYmxlcmFuZ2U6MTRmMjEwOTNlNmQzNDRhZDg3ODE5OTI0NDZlMmZmYWNfMTgtOS0xLTEtMjA4MA_8db3a578-38e8-4548-946d-006ab1dafa65">181,739</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balances at September 30, 2021</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa71095b17734a079f0fd7349c7cc6a8_I20210930" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjE0ZjIxMDkzZTZkMzQ0YWQ4NzgxOTkyNDQ2ZTJmZmFjL3RhYmxlcmFuZ2U6MTRmMjEwOTNlNmQzNDRhZDg3ODE5OTI0NDZlMmZmYWNfMTktMS0xLTEtMjA4MA_14c10488-185a-4f4e-8404-d4d4ae441d21">221</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a9436032c6c4652b5da596c702a1d2b_I20210930" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjE0ZjIxMDkzZTZkMzQ0YWQ4NzgxOTkyNDQ2ZTJmZmFjL3RhYmxlcmFuZ2U6MTRmMjEwOTNlNmQzNDRhZDg3ODE5OTI0NDZlMmZmYWNfMTktMy0xLTEtMjA4MA_cca5bead-ed4b-48ca-8371-b65fe212a64d">4,508,807</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8d3e00d0fdce4dd6a33f933968e210ae_I20210930" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjE0ZjIxMDkzZTZkMzQ0YWQ4NzgxOTkyNDQ2ZTJmZmFjL3RhYmxlcmFuZ2U6MTRmMjEwOTNlNmQzNDRhZDg3ODE5OTI0NDZlMmZmYWNfMTktNS0xLTEtMjA4MA_7f527710-78f1-4e74-8faf-d02d076edb70">18,646</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibf6b811e903342bb834df47cf71eeef4_I20210930" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjE0ZjIxMDkzZTZkMzQ0YWQ4NzgxOTkyNDQ2ZTJmZmFjL3RhYmxlcmFuZ2U6MTRmMjEwOTNlNmQzNDRhZDg3ODE5OTI0NDZlMmZmYWNfMTktNy0xLTEtMjA4MA_b44b01c6-1a07-44e6-bfb8-ca3723c63f10">1,341,725</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d97c6f523444f9aa40a206f5b9705c6_I20210930" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjE0ZjIxMDkzZTZkMzQ0YWQ4NzgxOTkyNDQ2ZTJmZmFjL3RhYmxlcmFuZ2U6MTRmMjEwOTNlNmQzNDRhZDg3ODE5OTI0NDZlMmZmYWNfMTktOS0xLTEtMjA4MA_bcf5759e-bbff-48be-8583-a856a0e24112">3,148,657</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">7</span></div></div></div><div id="ie2ffba3ee5384c86becdb38ff117ca9a_28"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie2ffba3ee5384c86becdb38ff117ca9a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INCYTE CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, in thousands)</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yOC9mcmFnOjQwYjQ0ZDhlZDA5YzQwNTI4NmY5MzVmMTk0NTBkMDdjL3RhYmxlOjRjY2I2Mjk0MmFjZDQ4MTQ5YzhmOGFjN2FkOWQ3OTQ4L3RhYmxlcmFuZ2U6NGNjYjYyOTQyYWNkNDgxNDljOGY4YWM3YWQ5ZDc5NDhfMy0xLTEtMS04MQ_6eda57e2-719f-4a3b-8713-3430a8d7a404">312,199</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0faaba5fcd6b485781cadacae8b2fd8e_D20210101-20210930" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yOC9mcmFnOjQwYjQ0ZDhlZDA5YzQwNTI4NmY5MzVmMTk0NTBkMDdjL3RhYmxlOjRjY2I2Mjk0MmFjZDQ4MTQ5YzhmOGFjN2FkOWQ3OTQ4L3RhYmxlcmFuZ2U6NGNjYjYyOTQyYWNkNDgxNDljOGY4YWM3YWQ5ZDc5NDhfMy0zLTEtMS04MQ_7bbaaf24-9382-48e0-9941-3877ea502f2f">384,730</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net income to net cash provided by operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yOC9mcmFnOjQwYjQ0ZDhlZDA5YzQwNTI4NmY5MzVmMTk0NTBkMDdjL3RhYmxlOjRjY2I2Mjk0MmFjZDQ4MTQ5YzhmOGFjN2FkOWQ3OTQ4L3RhYmxlcmFuZ2U6NGNjYjYyOTQyYWNkNDgxNDljOGY4YWM3YWQ5ZDc5NDhfNS0xLTEtMS04MQ_bb569ad8-71bc-4add-a2a1-a57c833b3cd7">49,637</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0faaba5fcd6b485781cadacae8b2fd8e_D20210101-20210930" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yOC9mcmFnOjQwYjQ0ZDhlZDA5YzQwNTI4NmY5MzVmMTk0NTBkMDdjL3RhYmxlOjRjY2I2Mjk0MmFjZDQ4MTQ5YzhmOGFjN2FkOWQ3OTQ4L3RhYmxlcmFuZ2U6NGNjYjYyOTQyYWNkNDgxNDljOGY4YWM3YWQ5ZDc5NDhfNS0zLTEtMS04MQ_eb11d18c-6ff5-4555-856a-4fee63ada8cb">42,986</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yOC9mcmFnOjQwYjQ0ZDhlZDA5YzQwNTI4NmY5MzVmMTk0NTBkMDdjL3RhYmxlOjRjY2I2Mjk0MmFjZDQ4MTQ5YzhmOGFjN2FkOWQ3OTQ4L3RhYmxlcmFuZ2U6NGNjYjYyOTQyYWNkNDgxNDljOGY4YWM3YWQ5ZDc5NDhfNi0xLTEtMS04MQ_4b2cb9e5-1319-4c76-926c-d65e378d4ff0">135,741</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0faaba5fcd6b485781cadacae8b2fd8e_D20210101-20210930" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yOC9mcmFnOjQwYjQ0ZDhlZDA5YzQwNTI4NmY5MzVmMTk0NTBkMDdjL3RhYmxlOjRjY2I2Mjk0MmFjZDQ4MTQ5YzhmOGFjN2FkOWQ3OTQ4L3RhYmxlcmFuZ2U6NGNjYjYyOTQyYWNkNDgxNDljOGY4YWM3YWQ5ZDc5NDhfNi0zLTEtMS04MQ_ca366b72-fd75-4cef-a6bd-89aa8e09b7b0">134,784</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yOC9mcmFnOjQwYjQ0ZDhlZDA5YzQwNTI4NmY5MzVmMTk0NTBkMDdjL3RhYmxlOjRjY2I2Mjk0MmFjZDQ4MTQ5YzhmOGFjN2FkOWQ3OTQ4L3RhYmxlcmFuZ2U6NGNjYjYyOTQyYWNkNDgxNDljOGY4YWM3YWQ5ZDc5NDhfNy0xLTEtMS04MQ_69e694b4-def7-4940-af30-fcedeea67062">40,432</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0faaba5fcd6b485781cadacae8b2fd8e_D20210101-20210930" decimals="-3" name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yOC9mcmFnOjQwYjQ0ZDhlZDA5YzQwNTI4NmY5MzVmMTk0NTBkMDdjL3RhYmxlOjRjY2I2Mjk0MmFjZDQ4MTQ5YzhmOGFjN2FkOWQ3OTQ4L3RhYmxlcmFuZ2U6NGNjYjYyOTQyYWNkNDgxNDljOGY4YWM3YWQ5ZDc5NDhfNy0zLTEtMS04MQ_8996a968-1c06-45ac-8166-2c36ca1c4e18">178</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:OtherNoncashIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yOC9mcmFnOjQwYjQ0ZDhlZDA5YzQwNTI4NmY5MzVmMTk0NTBkMDdjL3RhYmxlOjRjY2I2Mjk0MmFjZDQ4MTQ5YzhmOGFjN2FkOWQ3OTQ4L3RhYmxlcmFuZ2U6NGNjYjYyOTQyYWNkNDgxNDljOGY4YWM3YWQ5ZDc5NDhfOC0xLTEtMS04MQ_221473ec-b5d5-477f-bb93-34c8653e72cc">15,097</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0faaba5fcd6b485781cadacae8b2fd8e_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:OtherNoncashIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yOC9mcmFnOjQwYjQ0ZDhlZDA5YzQwNTI4NmY5MzVmMTk0NTBkMDdjL3RhYmxlOjRjY2I2Mjk0MmFjZDQ4MTQ5YzhmOGFjN2FkOWQ3OTQ4L3RhYmxlcmFuZ2U6NGNjYjYyOTQyYWNkNDgxNDljOGY4YWM3YWQ5ZDc5NDhfOC0zLTEtMS04MQ_56a2dcd3-2e7c-45b6-9401-b2c651cbe32d">5,268</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized loss on long term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yOC9mcmFnOjQwYjQ0ZDhlZDA5YzQwNTI4NmY5MzVmMTk0NTBkMDdjL3RhYmxlOjRjY2I2Mjk0MmFjZDQ4MTQ5YzhmOGFjN2FkOWQ3OTQ4L3RhYmxlcmFuZ2U6NGNjYjYyOTQyYWNkNDgxNDljOGY4YWM3YWQ5ZDc5NDhfOS0xLTEtMS04MQ_5a9ffd5a-eb16-4010-ab66-8c254ec723f4">72,142</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0faaba5fcd6b485781cadacae8b2fd8e_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yOC9mcmFnOjQwYjQ0ZDhlZDA5YzQwNTI4NmY5MzVmMTk0NTBkMDdjL3RhYmxlOjRjY2I2Mjk0MmFjZDQ4MTQ5YzhmOGFjN2FkOWQ3OTQ4L3RhYmxlcmFuZ2U6NGNjYjYyOTQyYWNkNDgxNDljOGY4YWM3YWQ5ZDc5NDhfOS0zLTEtMS04MQ_0f35d43c-341f-47ce-a7ff-651bdca0496a">28,394</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Gain) loss on change in fair value of acquisition-related contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yOC9mcmFnOjQwYjQ0ZDhlZDA5YzQwNTI4NmY5MzVmMTk0NTBkMDdjL3RhYmxlOjRjY2I2Mjk0MmFjZDQ4MTQ5YzhmOGFjN2FkOWQ3OTQ4L3RhYmxlcmFuZ2U6NGNjYjYyOTQyYWNkNDgxNDljOGY4YWM3YWQ5ZDc5NDhfMTAtMS0xLTEtODE_18b4da32-9f5f-4b3b-919b-b35e5e73978e">12,198</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0faaba5fcd6b485781cadacae8b2fd8e_D20210101-20210930" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yOC9mcmFnOjQwYjQ0ZDhlZDA5YzQwNTI4NmY5MzVmMTk0NTBkMDdjL3RhYmxlOjRjY2I2Mjk0MmFjZDQ4MTQ5YzhmOGFjN2FkOWQ3OTQ4L3RhYmxlcmFuZ2U6NGNjYjYyOTQyYWNkNDgxNDljOGY4YWM3YWQ5ZDc5NDhfMTAtMy0xLTEtODE_5e1fd1fa-fc73-49e9-92e8-9bc349cf32db">13,068</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yOC9mcmFnOjQwYjQ0ZDhlZDA5YzQwNTI4NmY5MzVmMTk0NTBkMDdjL3RhYmxlOjRjY2I2Mjk0MmFjZDQ4MTQ5YzhmOGFjN2FkOWQ3OTQ4L3RhYmxlcmFuZ2U6NGNjYjYyOTQyYWNkNDgxNDljOGY4YWM3YWQ5ZDc5NDhfMTItMS0xLTEtODE_9718ca01-9879-4b00-a513-d4f3d1e3d361">1,888</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0faaba5fcd6b485781cadacae8b2fd8e_D20210101-20210930" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yOC9mcmFnOjQwYjQ0ZDhlZDA5YzQwNTI4NmY5MzVmMTk0NTBkMDdjL3RhYmxlOjRjY2I2Mjk0MmFjZDQ4MTQ5YzhmOGFjN2FkOWQ3OTQ4L3RhYmxlcmFuZ2U6NGNjYjYyOTQyYWNkNDgxNDljOGY4YWM3YWQ5ZDc5NDhfMTItMy0xLTEtODE_9f53daee-7116-4376-aee8-98f50f3f04d4">34,695</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yOC9mcmFnOjQwYjQ0ZDhlZDA5YzQwNTI4NmY5MzVmMTk0NTBkMDdjL3RhYmxlOjRjY2I2Mjk0MmFjZDQ4MTQ5YzhmOGFjN2FkOWQ3OTQ4L3RhYmxlcmFuZ2U6NGNjYjYyOTQyYWNkNDgxNDljOGY4YWM3YWQ5ZDc5NDhfMTMtMS0xLTEtODE_3c985e0e-5786-4d87-9ea2-3dfcb4d78a52">40,016</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0faaba5fcd6b485781cadacae8b2fd8e_D20210101-20210930" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yOC9mcmFnOjQwYjQ0ZDhlZDA5YzQwNTI4NmY5MzVmMTk0NTBkMDdjL3RhYmxlOjRjY2I2Mjk0MmFjZDQ4MTQ5YzhmOGFjN2FkOWQ3OTQ4L3RhYmxlcmFuZ2U6NGNjYjYyOTQyYWNkNDgxNDljOGY4YWM3YWQ5ZDc5NDhfMTMtMy0xLTEtODE_1b948bd0-0a1b-4cd3-9b00-ca50ed0dc832">24,784</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yOC9mcmFnOjQwYjQ0ZDhlZDA5YzQwNTI4NmY5MzVmMTk0NTBkMDdjL3RhYmxlOjRjY2I2Mjk0MmFjZDQ4MTQ5YzhmOGFjN2FkOWQ3OTQ4L3RhYmxlcmFuZ2U6NGNjYjYyOTQyYWNkNDgxNDljOGY4YWM3YWQ5ZDc5NDhfMTQtMS0xLTEtODE_ca7634f2-1997-4fb5-bdc3-e139b6d5a151">48,316</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0faaba5fcd6b485781cadacae8b2fd8e_D20210101-20210930" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yOC9mcmFnOjQwYjQ0ZDhlZDA5YzQwNTI4NmY5MzVmMTk0NTBkMDdjL3RhYmxlOjRjY2I2Mjk0MmFjZDQ4MTQ5YzhmOGFjN2FkOWQ3OTQ4L3RhYmxlcmFuZ2U6NGNjYjYyOTQyYWNkNDgxNDljOGY4YWM3YWQ5ZDc5NDhfMTQtMy0xLTEtODE_a294c115-4037-4ce7-8154-0fdb96c22768">16,215</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yOC9mcmFnOjQwYjQ0ZDhlZDA5YzQwNTI4NmY5MzVmMTk0NTBkMDdjL3RhYmxlOjRjY2I2Mjk0MmFjZDQ4MTQ5YzhmOGFjN2FkOWQ3OTQ4L3RhYmxlcmFuZ2U6NGNjYjYyOTQyYWNkNDgxNDljOGY4YWM3YWQ5ZDc5NDhfMTUtMS0xLTEtODE_68181775-f2fd-4d46-a617-b9743432c59b">8,935</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0faaba5fcd6b485781cadacae8b2fd8e_D20210101-20210930" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yOC9mcmFnOjQwYjQ0ZDhlZDA5YzQwNTI4NmY5MzVmMTk0NTBkMDdjL3RhYmxlOjRjY2I2Mjk0MmFjZDQ4MTQ5YzhmOGFjN2FkOWQ3OTQ4L3RhYmxlcmFuZ2U6NGNjYjYyOTQyYWNkNDgxNDljOGY4YWM3YWQ5ZDc5NDhfMTUtMy0xLTEtODE_ee655b12-ae53-4959-8b92-b918eb5bfee6">15,742</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued and other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yOC9mcmFnOjQwYjQ0ZDhlZDA5YzQwNTI4NmY5MzVmMTk0NTBkMDdjL3RhYmxlOjRjY2I2Mjk0MmFjZDQ4MTQ5YzhmOGFjN2FkOWQ3OTQ4L3RhYmxlcmFuZ2U6NGNjYjYyOTQyYWNkNDgxNDljOGY4YWM3YWQ5ZDc5NDhfMTYtMS0xLTEtODE_058d0446-e813-4d7d-838f-545997e87170">172,384</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0faaba5fcd6b485781cadacae8b2fd8e_D20210101-20210930" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yOC9mcmFnOjQwYjQ0ZDhlZDA5YzQwNTI4NmY5MzVmMTk0NTBkMDdjL3RhYmxlOjRjY2I2Mjk0MmFjZDQ4MTQ5YzhmOGFjN2FkOWQ3OTQ4L3RhYmxlcmFuZ2U6NGNjYjYyOTQyYWNkNDgxNDljOGY4YWM3YWQ5ZDc5NDhfMTYtMy0xLTEtODE_24da13e1-2d65-4630-9ecd-0223e8f52bdf">85,037</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 32.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930" decimals="-3" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yOC9mcmFnOjQwYjQ0ZDhlZDA5YzQwNTI4NmY5MzVmMTk0NTBkMDdjL3RhYmxlOjRjY2I2Mjk0MmFjZDQ4MTQ5YzhmOGFjN2FkOWQ3OTQ4L3RhYmxlcmFuZ2U6NGNjYjYyOTQyYWNkNDgxNDljOGY4YWM3YWQ5ZDc5NDhfMTctMS0xLTEtODE_4dd34bcc-73ab-4969-ac26-784f9d50c278">686,279</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0faaba5fcd6b485781cadacae8b2fd8e_D20210101-20210930" decimals="-3" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yOC9mcmFnOjQwYjQ0ZDhlZDA5YzQwNTI4NmY5MzVmMTk0NTBkMDdjL3RhYmxlOjRjY2I2Mjk0MmFjZDQ4MTQ5YzhmOGFjN2FkOWQ3OTQ4L3RhYmxlcmFuZ2U6NGNjYjYyOTQyYWNkNDgxNDljOGY4YWM3YWQ5ZDc5NDhfMTctMy0xLTEtODE_5aec1dd2-f4ed-4c63-8f83-b0cd335ac162">634,137</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase of long term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930" decimals="-3" name="us-gaap:PaymentsToAcquireLongtermInvestments" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yOC9mcmFnOjQwYjQ0ZDhlZDA5YzQwNTI4NmY5MzVmMTk0NTBkMDdjL3RhYmxlOjRjY2I2Mjk0MmFjZDQ4MTQ5YzhmOGFjN2FkOWQ3OTQ4L3RhYmxlcmFuZ2U6NGNjYjYyOTQyYWNkNDgxNDljOGY4YWM3YWQ5ZDc5NDhfMTktMS0xLTEtODE_94cb082b-dd2f-4697-858d-0a6a616f0cc3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0faaba5fcd6b485781cadacae8b2fd8e_D20210101-20210930" decimals="-3" name="us-gaap:PaymentsToAcquireLongtermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yOC9mcmFnOjQwYjQ0ZDhlZDA5YzQwNTI4NmY5MzVmMTk0NTBkMDdjL3RhYmxlOjRjY2I2Mjk0MmFjZDQ4MTQ5YzhmOGFjN2FkOWQ3OTQ4L3RhYmxlcmFuZ2U6NGNjYjYyOTQyYWNkNDgxNDljOGY4YWM3YWQ5ZDc5NDhfMTktMy0xLTEtODE_5f0e9da8-22f5-47b5-ab12-54189580bdd5">8,662</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sale of long term investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930" decimals="-3" name="us-gaap:ProceedsFromSaleOfLongtermInvestments" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yOC9mcmFnOjQwYjQ0ZDhlZDA5YzQwNTI4NmY5MzVmMTk0NTBkMDdjL3RhYmxlOjRjY2I2Mjk0MmFjZDQ4MTQ5YzhmOGFjN2FkOWQ3OTQ4L3RhYmxlcmFuZ2U6NGNjYjYyOTQyYWNkNDgxNDljOGY4YWM3YWQ5ZDc5NDhfMjAtMS0xLTEtODE_665b6f1e-f7c1-4d04-9658-a7e0ccb7bcdc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0faaba5fcd6b485781cadacae8b2fd8e_D20210101-20210930" decimals="-3" name="us-gaap:ProceedsFromSaleOfLongtermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yOC9mcmFnOjQwYjQ0ZDhlZDA5YzQwNTI4NmY5MzVmMTk0NTBkMDdjL3RhYmxlOjRjY2I2Mjk0MmFjZDQ4MTQ5YzhmOGFjN2FkOWQ3OTQ4L3RhYmxlcmFuZ2U6NGNjYjYyOTQyYWNkNDgxNDljOGY4YWM3YWQ5ZDc5NDhfMjAtMy0xLTEtODE_f9bf3ddb-c2cb-4530-899c-aac457d52cad">10,473</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital expenditures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930" decimals="-3" name="us-gaap:PaymentsToAcquireProductiveAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yOC9mcmFnOjQwYjQ0ZDhlZDA5YzQwNTI4NmY5MzVmMTk0NTBkMDdjL3RhYmxlOjRjY2I2Mjk0MmFjZDQ4MTQ5YzhmOGFjN2FkOWQ3OTQ4L3RhYmxlcmFuZ2U6NGNjYjYyOTQyYWNkNDgxNDljOGY4YWM3YWQ5ZDc5NDhfMjEtMS0xLTEtODE_d360ee89-f104-4c67-a5cb-43087613f84f">56,560</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0faaba5fcd6b485781cadacae8b2fd8e_D20210101-20210930" decimals="-3" name="us-gaap:PaymentsToAcquireProductiveAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yOC9mcmFnOjQwYjQ0ZDhlZDA5YzQwNTI4NmY5MzVmMTk0NTBkMDdjL3RhYmxlOjRjY2I2Mjk0MmFjZDQ4MTQ5YzhmOGFjN2FkOWQ3OTQ4L3RhYmxlcmFuZ2U6NGNjYjYyOTQyYWNkNDgxNDljOGY4YWM3YWQ5ZDc5NDhfMjEtMy0xLTEtODE_97915135-fff2-4752-aff0-495e1ccaf688">146,543</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930" decimals="-3" name="us-gaap:PaymentsToAcquireMarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yOC9mcmFnOjQwYjQ0ZDhlZDA5YzQwNTI4NmY5MzVmMTk0NTBkMDdjL3RhYmxlOjRjY2I2Mjk0MmFjZDQ4MTQ5YzhmOGFjN2FkOWQ3OTQ4L3RhYmxlcmFuZ2U6NGNjYjYyOTQyYWNkNDgxNDljOGY4YWM3YWQ5ZDc5NDhfMjItMS0xLTEtODE_2ed764c1-25ed-49cc-b73a-436936a926e8">59,058</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0faaba5fcd6b485781cadacae8b2fd8e_D20210101-20210930" decimals="-3" name="us-gaap:PaymentsToAcquireMarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yOC9mcmFnOjQwYjQ0ZDhlZDA5YzQwNTI4NmY5MzVmMTk0NTBkMDdjL3RhYmxlOjRjY2I2Mjk0MmFjZDQ4MTQ5YzhmOGFjN2FkOWQ3OTQ4L3RhYmxlcmFuZ2U6NGNjYjYyOTQyYWNkNDgxNDljOGY4YWM3YWQ5ZDc5NDhfMjItMy0xLTEtODE_9927b73d-550e-4a15-986e-067c1275bc81">228,170</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sale and maturities of marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yOC9mcmFnOjQwYjQ0ZDhlZDA5YzQwNTI4NmY5MzVmMTk0NTBkMDdjL3RhYmxlOjRjY2I2Mjk0MmFjZDQ4MTQ5YzhmOGFjN2FkOWQ3OTQ4L3RhYmxlcmFuZ2U6NGNjYjYyOTQyYWNkNDgxNDljOGY4YWM3YWQ5ZDc5NDhfMjMtMS0xLTEtODE_b30d854f-64a0-4736-9bab-1de21ffc4f4f">57,988</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0faaba5fcd6b485781cadacae8b2fd8e_D20210101-20210930" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yOC9mcmFnOjQwYjQ0ZDhlZDA5YzQwNTI4NmY5MzVmMTk0NTBkMDdjL3RhYmxlOjRjY2I2Mjk0MmFjZDQ4MTQ5YzhmOGFjN2FkOWQ3OTQ4L3RhYmxlcmFuZ2U6NGNjYjYyOTQyYWNkNDgxNDljOGY4YWM3YWQ5ZDc5NDhfMjMtMy0xLTEtODE_a4e38d6e-46d9-40a2-aa94-fca47999d3fc">231,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 32.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yOC9mcmFnOjQwYjQ0ZDhlZDA5YzQwNTI4NmY5MzVmMTk0NTBkMDdjL3RhYmxlOjRjY2I2Mjk0MmFjZDQ4MTQ5YzhmOGFjN2FkOWQ3OTQ4L3RhYmxlcmFuZ2U6NGNjYjYyOTQyYWNkNDgxNDljOGY4YWM3YWQ5ZDc5NDhfMjQtMS0xLTEtODE_40852c93-ae22-4b00-9735-0d93bc2b6168">57,630</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0faaba5fcd6b485781cadacae8b2fd8e_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yOC9mcmFnOjQwYjQ0ZDhlZDA5YzQwNTI4NmY5MzVmMTk0NTBkMDdjL3RhYmxlOjRjY2I2Mjk0MmFjZDQ4MTQ5YzhmOGFjN2FkOWQ3OTQ4L3RhYmxlcmFuZ2U6NGNjYjYyOTQyYWNkNDgxNDljOGY4YWM3YWQ5ZDc5NDhfMjQtMy0xLTEtODE_6133f1d1-5696-42f6-a234-79b5f29626ba">141,652</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from issuance of common stock under stock plans</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930" decimals="-3" name="us-gaap:ProceedsFromStockPlans" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yOC9mcmFnOjQwYjQ0ZDhlZDA5YzQwNTI4NmY5MzVmMTk0NTBkMDdjL3RhYmxlOjRjY2I2Mjk0MmFjZDQ4MTQ5YzhmOGFjN2FkOWQ3OTQ4L3RhYmxlcmFuZ2U6NGNjYjYyOTQyYWNkNDgxNDljOGY4YWM3YWQ5ZDc5NDhfMjYtMS0xLTEtODE_b85c8606-038b-45bf-8ccf-ae05232e0cb3">42,989</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0faaba5fcd6b485781cadacae8b2fd8e_D20210101-20210930" decimals="-3" name="us-gaap:ProceedsFromStockPlans" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yOC9mcmFnOjQwYjQ0ZDhlZDA5YzQwNTI4NmY5MzVmMTk0NTBkMDdjL3RhYmxlOjRjY2I2Mjk0MmFjZDQ4MTQ5YzhmOGFjN2FkOWQ3OTQ4L3RhYmxlcmFuZ2U6NGNjYjYyOTQyYWNkNDgxNDljOGY4YWM3YWQ5ZDc5NDhfMjYtMy0xLTEtODE_10484fdb-a478-4e30-84b2-0989dab0aac5">48,432</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax withholdings related to restricted and performance share vesting</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yOC9mcmFnOjQwYjQ0ZDhlZDA5YzQwNTI4NmY5MzVmMTk0NTBkMDdjL3RhYmxlOjRjY2I2Mjk0MmFjZDQ4MTQ5YzhmOGFjN2FkOWQ3OTQ4L3RhYmxlcmFuZ2U6NGNjYjYyOTQyYWNkNDgxNDljOGY4YWM3YWQ5ZDc5NDhfMjctMS0xLTEtODE_6f9ef5cd-40c3-4572-b6f4-00ab120492ed">25,724</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0faaba5fcd6b485781cadacae8b2fd8e_D20210101-20210930" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yOC9mcmFnOjQwYjQ0ZDhlZDA5YzQwNTI4NmY5MzVmMTk0NTBkMDdjL3RhYmxlOjRjY2I2Mjk0MmFjZDQ4MTQ5YzhmOGFjN2FkOWQ3OTQ4L3RhYmxlcmFuZ2U6NGNjYjYyOTQyYWNkNDgxNDljOGY4YWM3YWQ5ZDc5NDhfMjctMy0xLTEtODE_64b6cca8-e61c-4181-bff7-3a77aa6745d0">29,380</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payment of finance lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yOC9mcmFnOjQwYjQ0ZDhlZDA5YzQwNTI4NmY5MzVmMTk0NTBkMDdjL3RhYmxlOjRjY2I2Mjk0MmFjZDQ4MTQ5YzhmOGFjN2FkOWQ3OTQ4L3RhYmxlcmFuZ2U6NGNjYjYyOTQyYWNkNDgxNDljOGY4YWM3YWQ5ZDc5NDhfMjgtMS0xLTEtODE_749094aa-7859-4948-bbcb-d899aa3bd694">2,106</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0faaba5fcd6b485781cadacae8b2fd8e_D20210101-20210930" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yOC9mcmFnOjQwYjQ0ZDhlZDA5YzQwNTI4NmY5MzVmMTk0NTBkMDdjL3RhYmxlOjRjY2I2Mjk0MmFjZDQ4MTQ5YzhmOGFjN2FkOWQ3OTQ4L3RhYmxlcmFuZ2U6NGNjYjYyOTQyYWNkNDgxNDljOGY4YWM3YWQ5ZDc5NDhfMjgtMy0xLTEtODE_08adbced-cff9-4010-8669-5dcfaa537a4a">1,788</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payment of contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930" decimals="-3" name="incy:PaymentOfContingentConsideration" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yOC9mcmFnOjQwYjQ0ZDhlZDA5YzQwNTI4NmY5MzVmMTk0NTBkMDdjL3RhYmxlOjRjY2I2Mjk0MmFjZDQ4MTQ5YzhmOGFjN2FkOWQ3OTQ4L3RhYmxlcmFuZ2U6NGNjYjYyOTQyYWNkNDgxNDljOGY4YWM3YWQ5ZDc5NDhfMjktMS0xLTEtODE_b4b5a784-0dde-4eaa-b241-020852ca35e2">13,473</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0faaba5fcd6b485781cadacae8b2fd8e_D20210101-20210930" decimals="-3" name="incy:PaymentOfContingentConsideration" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yOC9mcmFnOjQwYjQ0ZDhlZDA5YzQwNTI4NmY5MzVmMTk0NTBkMDdjL3RhYmxlOjRjY2I2Mjk0MmFjZDQ4MTQ5YzhmOGFjN2FkOWQ3OTQ4L3RhYmxlcmFuZ2U6NGNjYjYyOTQyYWNkNDgxNDljOGY4YWM3YWQ5ZDc5NDhfMjktMy0xLTEtODE_3e4e971e-ecb4-4d0b-a96b-02851e58eec5">20,093</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 32.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by (used in) financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yOC9mcmFnOjQwYjQ0ZDhlZDA5YzQwNTI4NmY5MzVmMTk0NTBkMDdjL3RhYmxlOjRjY2I2Mjk0MmFjZDQ4MTQ5YzhmOGFjN2FkOWQ3OTQ4L3RhYmxlcmFuZ2U6NGNjYjYyOTQyYWNkNDgxNDljOGY4YWM3YWQ5ZDc5NDhfMzAtMS0xLTEtODE_fb9a5e7a-a957-4bb6-b6bf-e4453eb72aea">1,686</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0faaba5fcd6b485781cadacae8b2fd8e_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yOC9mcmFnOjQwYjQ0ZDhlZDA5YzQwNTI4NmY5MzVmMTk0NTBkMDdjL3RhYmxlOjRjY2I2Mjk0MmFjZDQ4MTQ5YzhmOGFjN2FkOWQ3OTQ4L3RhYmxlcmFuZ2U6NGNjYjYyOTQyYWNkNDgxNDljOGY4YWM3YWQ5ZDc5NDhfMzAtMy0xLTEtODE_2f0b1756-6431-449d-8546-8a54b18b75ce">2,829</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of exchange rates on cash, cash equivalents, restricted cash and investments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930" decimals="-3" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yOC9mcmFnOjQwYjQ0ZDhlZDA5YzQwNTI4NmY5MzVmMTk0NTBkMDdjL3RhYmxlOjRjY2I2Mjk0MmFjZDQ4MTQ5YzhmOGFjN2FkOWQ3OTQ4L3RhYmxlcmFuZ2U6NGNjYjYyOTQyYWNkNDgxNDljOGY4YWM3YWQ5ZDc5NDhfMzEtMS0xLTEtODE_fc5c6751-b545-4dab-a9c7-fb3a2202c19a">2,728</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0faaba5fcd6b485781cadacae8b2fd8e_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yOC9mcmFnOjQwYjQ0ZDhlZDA5YzQwNTI4NmY5MzVmMTk0NTBkMDdjL3RhYmxlOjRjY2I2Mjk0MmFjZDQ4MTQ5YzhmOGFjN2FkOWQ3OTQ4L3RhYmxlcmFuZ2U6NGNjYjYyOTQyYWNkNDgxNDljOGY4YWM3YWQ5ZDc5NDhfMzEtMy0xLTEtODE_a3e68b15-b31d-4d9f-adeb-66ae20fc25e9">3,718</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net increase in cash, cash equivalents, restricted cash and investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yOC9mcmFnOjQwYjQ0ZDhlZDA5YzQwNTI4NmY5MzVmMTk0NTBkMDdjL3RhYmxlOjRjY2I2Mjk0MmFjZDQ4MTQ5YzhmOGFjN2FkOWQ3OTQ4L3RhYmxlcmFuZ2U6NGNjYjYyOTQyYWNkNDgxNDljOGY4YWM3YWQ5ZDc5NDhfMzItMS0xLTEtODE_218fe7eb-6d07-4873-9e69-f54758636355">633,063</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0faaba5fcd6b485781cadacae8b2fd8e_D20210101-20210930" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yOC9mcmFnOjQwYjQ0ZDhlZDA5YzQwNTI4NmY5MzVmMTk0NTBkMDdjL3RhYmxlOjRjY2I2Mjk0MmFjZDQ4MTQ5YzhmOGFjN2FkOWQ3OTQ4L3RhYmxlcmFuZ2U6NGNjYjYyOTQyYWNkNDgxNDljOGY4YWM3YWQ5ZDc5NDhfMzItMy0xLTEtODE_9b71705b-875d-4a04-bda8-fc47ed684bf8">485,938</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents, restricted cash and investments at beginning of period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab26fe441f0d4ab984456365a7f7cff0_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yOC9mcmFnOjQwYjQ0ZDhlZDA5YzQwNTI4NmY5MzVmMTk0NTBkMDdjL3RhYmxlOjRjY2I2Mjk0MmFjZDQ4MTQ5YzhmOGFjN2FkOWQ3OTQ4L3RhYmxlcmFuZ2U6NGNjYjYyOTQyYWNkNDgxNDljOGY4YWM3YWQ5ZDc5NDhfMzMtMS0xLTEtODE_6f0b0a0f-c084-4834-aa91-fc55ae9d454b">2,059,160</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7612db9fbac4f99a07f20a1f367748a_I20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yOC9mcmFnOjQwYjQ0ZDhlZDA5YzQwNTI4NmY5MzVmMTk0NTBkMDdjL3RhYmxlOjRjY2I2Mjk0MmFjZDQ4MTQ5YzhmOGFjN2FkOWQ3OTQ4L3RhYmxlcmFuZ2U6NGNjYjYyOTQyYWNkNDgxNDljOGY4YWM3YWQ5ZDc5NDhfMzMtMy0xLTEtODE_59a85898-c466-4fc4-a994-57cd001a9350">1,514,765</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents, restricted cash and investments at end of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b4376f8fc614de98c9cf647198c504e_I20220930" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yOC9mcmFnOjQwYjQ0ZDhlZDA5YzQwNTI4NmY5MzVmMTk0NTBkMDdjL3RhYmxlOjRjY2I2Mjk0MmFjZDQ4MTQ5YzhmOGFjN2FkOWQ3OTQ4L3RhYmxlcmFuZ2U6NGNjYjYyOTQyYWNkNDgxNDljOGY4YWM3YWQ5ZDc5NDhfMzQtMS0xLTEtODE_ca9bcb24-3c4b-433c-b375-3433af020803">2,692,223</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d97c6f523444f9aa40a206f5b9705c6_I20210930" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yOC9mcmFnOjQwYjQ0ZDhlZDA5YzQwNTI4NmY5MzVmMTk0NTBkMDdjL3RhYmxlOjRjY2I2Mjk0MmFjZDQ4MTQ5YzhmOGFjN2FkOWQ3OTQ4L3RhYmxlcmFuZ2U6NGNjYjYyOTQyYWNkNDgxNDljOGY4YWM3YWQ5ZDc5NDhfMzQtMy0xLTEtODE_d9097bbd-d61f-4d3a-bb18-575c7d3dbcc4">2,000,703</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental Schedule of Cash Flow Information</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes paid</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yOC9mcmFnOjQwYjQ0ZDhlZDA5YzQwNTI4NmY5MzVmMTk0NTBkMDdjL3RhYmxlOjRjY2I2Mjk0MmFjZDQ4MTQ5YzhmOGFjN2FkOWQ3OTQ4L3RhYmxlcmFuZ2U6NGNjYjYyOTQyYWNkNDgxNDljOGY4YWM3YWQ5ZDc5NDhfMzYtMS0xLTEtODE_bef47a15-50d2-4f30-955c-ee62ad44175a">116,537</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0faaba5fcd6b485781cadacae8b2fd8e_D20210101-20210930" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yOC9mcmFnOjQwYjQ0ZDhlZDA5YzQwNTI4NmY5MzVmMTk0NTBkMDdjL3RhYmxlOjRjY2I2Mjk0MmFjZDQ4MTQ5YzhmOGFjN2FkOWQ3OTQ4L3RhYmxlcmFuZ2U6NGNjYjYyOTQyYWNkNDgxNDljOGY4YWM3YWQ5ZDc5NDhfMzYtMy0xLTEtODE_b4b8b9ec-6bda-4596-ab36-87ee956c5169">45,872</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unpaid purchases of property and equipment</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yOC9mcmFnOjQwYjQ0ZDhlZDA5YzQwNTI4NmY5MzVmMTk0NTBkMDdjL3RhYmxlOjRjY2I2Mjk0MmFjZDQ4MTQ5YzhmOGFjN2FkOWQ3OTQ4L3RhYmxlcmFuZ2U6NGNjYjYyOTQyYWNkNDgxNDljOGY4YWM3YWQ5ZDc5NDhfMzctMS0xLTEtODE_83f345fd-974d-4265-917d-d768e37e2b6e">8,836</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0faaba5fcd6b485781cadacae8b2fd8e_D20210101-20210930" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yOC9mcmFnOjQwYjQ0ZDhlZDA5YzQwNTI4NmY5MzVmMTk0NTBkMDdjL3RhYmxlOjRjY2I2Mjk0MmFjZDQ4MTQ5YzhmOGFjN2FkOWQ3OTQ4L3RhYmxlcmFuZ2U6NGNjYjYyOTQyYWNkNDgxNDljOGY4YWM3YWQ5ZDc5NDhfMzctMy0xLTEtODE_cee0b293-ceb0-4953-ae83-8f4438739191">23,892</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leased assets obtained in exchange for new operating lease liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yOC9mcmFnOjQwYjQ0ZDhlZDA5YzQwNTI4NmY5MzVmMTk0NTBkMDdjL3RhYmxlOjRjY2I2Mjk0MmFjZDQ4MTQ5YzhmOGFjN2FkOWQ3OTQ4L3RhYmxlcmFuZ2U6NGNjYjYyOTQyYWNkNDgxNDljOGY4YWM3YWQ5ZDc5NDhfMzgtMS0xLTEtODE_ea351bef-7b2b-4f7e-8962-8cc63230105b">3,650</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0faaba5fcd6b485781cadacae8b2fd8e_D20210101-20210930" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yOC9mcmFnOjQwYjQ0ZDhlZDA5YzQwNTI4NmY5MzVmMTk0NTBkMDdjL3RhYmxlOjRjY2I2Mjk0MmFjZDQ4MTQ5YzhmOGFjN2FkOWQ3OTQ4L3RhYmxlcmFuZ2U6NGNjYjYyOTQyYWNkNDgxNDljOGY4YWM3YWQ5ZDc5NDhfMzgtMy0xLTEtODE_7a082a19-31b5-4d40-bf39-1d29d7673c74">9,068</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leased assets obtained in exchange for new finance lease liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yOC9mcmFnOjQwYjQ0ZDhlZDA5YzQwNTI4NmY5MzVmMTk0NTBkMDdjL3RhYmxlOjRjY2I2Mjk0MmFjZDQ4MTQ5YzhmOGFjN2FkOWQ3OTQ4L3RhYmxlcmFuZ2U6NGNjYjYyOTQyYWNkNDgxNDljOGY4YWM3YWQ5ZDc5NDhfMzktMS0xLTEtODE_c2e046fd-e753-4546-8a12-2c4253a7006d">1,448</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0faaba5fcd6b485781cadacae8b2fd8e_D20210101-20210930" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yOC9mcmFnOjQwYjQ0ZDhlZDA5YzQwNTI4NmY5MzVmMTk0NTBkMDdjL3RhYmxlOjRjY2I2Mjk0MmFjZDQ4MTQ5YzhmOGFjN2FkOWQ3OTQ4L3RhYmxlcmFuZ2U6NGNjYjYyOTQyYWNkNDgxNDljOGY4YWM3YWQ5ZDc5NDhfMzktMy0xLTEtODE_95911ec1-04f9-43b9-a735-4a894158a1e7">455</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">8</span></div></div></div><div id="ie2ffba3ee5384c86becdb38ff117ca9a_31"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie2ffba3ee5384c86becdb38ff117ca9a_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INCYTE CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">September&#160;30, 2022</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Unaudited)</span></div><div id="ie2ffba3ee5384c86becdb38ff117ca9a_34"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 1. Organization and Business</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><ix:nonNumeric contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8zNC9mcmFnOjI5NTZiNTc1OTVlOTQzYmFhMTIxNmY2ZTRkODcyN2I3L3RleHRyZWdpb246Mjk1NmI1NzU5NWU5NDNiYWExMjE2ZjZlNGQ4NzI3YjdfNTg1_6683abc3-2202-47b1-aaa1-36c7348c94cf" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Incyte Corporation (including its subsidiaries, &#8220;Incyte,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; or &#8220;our&#8221;) is a biopharmaceutical company focused on developing and commercializing proprietary therapeutics. Our portfolio includes compounds in various stages, ranging from preclinical to late stage development, and commercialized products JAKAFI&#174; (ruxolitinib), ICLUSIG&#174; (ponatinib), PEMAZYRE&#174; (pemigatinib), OPZELURA&#8482; (ruxolitinib cream),</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MINJUVI&#174; (tafasitamab) and MONJUVI&#174; (tafasitamab-cxix), which is co-commercialized. Our operations are treated as <ix:nonFraction unitRef="segment" contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8zNC9mcmFnOjI5NTZiNTc1OTVlOTQzYmFhMTIxNmY2ZTRkODcyN2I3L3RleHRyZWdpb246Mjk1NmI1NzU5NWU5NDNiYWExMjE2ZjZlNGQ4NzI3YjdfNTY1_7a40737b-841d-41c5-acaa-a34d84c938d0">one</ix:nonFraction> operating segment.</span></ix:nonNumeric></div><div id="ie2ffba3ee5384c86becdb38ff117ca9a_37"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 2. Summary of Significant Accounting Policies</span></div><ix:nonNumeric contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8zNy9mcmFnOjA1Zjc0OGVlZDVjMzQwNDk4OGIzODA3OTYzMzFkZmQ5L3RleHRyZWdpb246MDVmNzQ4ZWVkNWMzNDA0OTg4YjM4MDc5NjMzMWRmZDlfMjU2OQ_b55798b5-c121-4918-807e-d74e794fb9ff" continuedAt="ie91aeaed1a9f4c0986abceb58e5d6ad7" escape="true"><ix:nonNumeric contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8zNy9mcmFnOjA1Zjc0OGVlZDVjMzQwNDk4OGIzODA3OTYzMzFkZmQ5L3RleHRyZWdpb246MDVmNzQ4ZWVkNWMzNDA0OTg4YjM4MDc5NjMzMWRmZDlfMjU3MA_f8588a00-f0de-43bd-970b-a8c950deaaf9" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of presentation</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. The condensed consolidated balance sheet as of September&#160;30, 2022, the condensed consolidated statements of operations, comprehensive income (loss), and stockholders&#8217; equity for the three and nine months ended September&#160;30, 2022 and 2021, and the condensed consolidated statements of cash flows for the nine months ended September&#160;30, 2022 and 2021, are unaudited, but include all adjustments, consisting only of normal recurring adjustments, which we consider necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented. The condensed consolidated balance sheet at December&#160;31, 2021 has been derived from our audited consolidated financial statements.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we believe that the disclosures in these financial statements are adequate to make the information presented not misleading, certain information and footnote information normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States (&#8220;U.S. GAAP&#8221;) have been condensed or omitted pursuant to the rules and regulations of the Securities and Exchange Commission.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Results for any interim period are not necessarily indicative of results for any future interim period or for the entire year. The accompanying financial statements should be read in conjunction with the financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December&#160;31, 2021.</span></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><ix:nonNumeric contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8zNy9mcmFnOjA1Zjc0OGVlZDVjMzQwNDk4OGIzODA3OTYzMzFkZmQ5L3RleHRyZWdpb246MDVmNzQ4ZWVkNWMzNDA0OTg4YjM4MDc5NjMzMWRmZDlfMjU3MQ_b3dc0b72-bce1-4549-b1e3-f1b2efd0b5c8" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Principles of Consolidation.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The condensed consolidated financial statements include the accounts of Incyte Corporation and our wholly owned subsidiaries. All inter-company accounts, transactions, and profits have been eliminated in consolidation.</span></ix:nonNumeric></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><ix:nonNumeric contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8zNy9mcmFnOjA1Zjc0OGVlZDVjMzQwNDk4OGIzODA3OTYzMzFkZmQ5L3RleHRyZWdpb246MDVmNzQ4ZWVkNWMzNDA0OTg4YjM4MDc5NjMzMWRmZDlfMjU3Mg_e018aab4-9043-4060-8cc5-f56057f17f8a" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of Estimates.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.</span></ix:nonNumeric></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8zNy9mcmFnOjA1Zjc0OGVlZDVjMzQwNDk4OGIzODA3OTYzMzFkZmQ5L3RleHRyZWdpb246MDVmNzQ4ZWVkNWMzNDA0OTg4YjM4MDc5NjMzMWRmZDlfMjU3Mw_bb1ff614-bffb-4070-8fd8-eef86ae3c5b6" continuedAt="i484a170a129b463094e715939d1c258c" escape="true">Recent Accounting Pronouncements</ix:nonNumeric></span></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ie91aeaed1a9f4c0986abceb58e5d6ad7"><ix:continuation id="i484a170a129b463094e715939d1c258c">There were no new accounting pronouncements issued nor adopted since our filing of the Annual Report on Form 10-K for the year ended December&#160;31, 2021, which could have a significant effect on our condensed consolidated financial statements.</ix:continuation></ix:continuation> </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">9</span></div></div></div><div id="ie2ffba3ee5384c86becdb38ff117ca9a_40"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie2ffba3ee5384c86becdb38ff117ca9a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 3. Revenues</span></div><ix:nonNumeric contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80MC9mcmFnOmQwZTdiYzBhNTk1MjRkYzQ4MzU1MDkwYTlkNzVjNmIzL3RleHRyZWdpb246ZDBlN2JjMGE1OTUyNGRjNDgzNTUwOTBhOWQ3NWM2YjNfMjky_278a8d41-ecaa-4f21-9aaf-a06038536056" continuedAt="i14e25d6372284e03af60e256a496cbac" escape="true"><ix:nonNumeric contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80MC9mcmFnOmQwZTdiYzBhNTk1MjRkYzQ4MzU1MDkwYTlkNzVjNmIzL3RleHRyZWdpb246ZDBlN2JjMGE1OTUyNGRjNDgzNTUwOTBhOWQ3NWM2YjNfMjkz_ca3ec8a9-ecab-407d-ae0a-a9967943bb54" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues are recognized under guidance within ASC 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The following table presents our disaggregated revenue for the periods presented (in thousands):  </span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">JAKAFI revenues, net</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2be3671bbcdc48d9a2d0dd78d0bf79a1_D20220701-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80MC9mcmFnOmQwZTdiYzBhNTk1MjRkYzQ4MzU1MDkwYTlkNzVjNmIzL3RhYmxlOjY1MTM0MjU3ZGY4ZDRhYmM4MGZkY2RmNzRiYTFjZmM4L3RhYmxlcmFuZ2U6NjUxMzQyNTdkZjhkNGFiYzgwZmRjZGY3NGJhMWNmYzhfMi0xLTEtMS04MQ_c0785d73-870a-4da1-b4ed-23f0e6885082">619,595</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cd55b8f35884c0687d725055f17e72c_D20210701-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80MC9mcmFnOmQwZTdiYzBhNTk1MjRkYzQ4MzU1MDkwYTlkNzVjNmIzL3RhYmxlOjY1MTM0MjU3ZGY4ZDRhYmM4MGZkY2RmNzRiYTFjZmM4L3RhYmxlcmFuZ2U6NjUxMzQyNTdkZjhkNGFiYzgwZmRjZGY3NGJhMWNmYzhfMi0zLTEtMS04MQ_115d02d1-0d64-4360-a80a-1d5a6d88ee1b">547,373</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i710215f6e6e248c4a2a3ff81e0391758_D20220101-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80MC9mcmFnOmQwZTdiYzBhNTk1MjRkYzQ4MzU1MDkwYTlkNzVjNmIzL3RhYmxlOjY1MTM0MjU3ZGY4ZDRhYmM4MGZkY2RmNzRiYTFjZmM4L3RhYmxlcmFuZ2U6NjUxMzQyNTdkZjhkNGFiYzgwZmRjZGY3NGJhMWNmYzhfMi01LTEtMS04MQ_ad6e8142-7577-41b5-ae59-6fd02ead229f">1,761,732</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id03654679dfd4153b83d389aa2a13454_D20210101-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80MC9mcmFnOmQwZTdiYzBhNTk1MjRkYzQ4MzU1MDkwYTlkNzVjNmIzL3RhYmxlOjY1MTM0MjU3ZGY4ZDRhYmM4MGZkY2RmNzRiYTFjZmM4L3RhYmxlcmFuZ2U6NjUxMzQyNTdkZjhkNGFiYzgwZmRjZGY3NGJhMWNmYzhfMi03LTEtMS04MQ_d69bbeef-5d39-4d2e-b8f6-8f4d54394e22">1,542,138</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ICLUSIG revenues, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib254aa03c50f46e7b589f20d3926968e_D20220701-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80MC9mcmFnOmQwZTdiYzBhNTk1MjRkYzQ4MzU1MDkwYTlkNzVjNmIzL3RhYmxlOjY1MTM0MjU3ZGY4ZDRhYmM4MGZkY2RmNzRiYTFjZmM4L3RhYmxlcmFuZ2U6NjUxMzQyNTdkZjhkNGFiYzgwZmRjZGY3NGJhMWNmYzhfMy0xLTEtMS04MQ_ada731f4-abeb-4a63-b0a6-d581d26ef123">25,929</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c101f258c8f40a7aac78b3cbb764428_D20210701-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80MC9mcmFnOmQwZTdiYzBhNTk1MjRkYzQ4MzU1MDkwYTlkNzVjNmIzL3RhYmxlOjY1MTM0MjU3ZGY4ZDRhYmM4MGZkY2RmNzRiYTFjZmM4L3RhYmxlcmFuZ2U6NjUxMzQyNTdkZjhkNGFiYzgwZmRjZGY3NGJhMWNmYzhfMy0zLTEtMS04MQ_a8b91d12-a38e-4f7f-af27-f6ee875089e1">28,522</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3326e3ff6d134bd48eeeeede0550ad3c_D20220101-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80MC9mcmFnOmQwZTdiYzBhNTk1MjRkYzQ4MzU1MDkwYTlkNzVjNmIzL3RhYmxlOjY1MTM0MjU3ZGY4ZDRhYmM4MGZkY2RmNzRiYTFjZmM4L3RhYmxlcmFuZ2U6NjUxMzQyNTdkZjhkNGFiYzgwZmRjZGY3NGJhMWNmYzhfMy01LTEtMS04MQ_fff2c755-848a-43bc-a78e-bfdceb318948">78,222</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa8bc47eb24948d78509e0f3fc38353b_D20210101-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80MC9mcmFnOmQwZTdiYzBhNTk1MjRkYzQ4MzU1MDkwYTlkNzVjNmIzL3RhYmxlOjY1MTM0MjU3ZGY4ZDRhYmM4MGZkY2RmNzRiYTFjZmM4L3RhYmxlcmFuZ2U6NjUxMzQyNTdkZjhkNGFiYzgwZmRjZGY3NGJhMWNmYzhfMy03LTEtMS04MQ_10be6d93-b1e0-4934-aa53-3f39095c0375">82,356</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PEMAZYRE revenues, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d0a3322355e44a99c106fd274d30424_D20220701-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80MC9mcmFnOmQwZTdiYzBhNTk1MjRkYzQ4MzU1MDkwYTlkNzVjNmIzL3RhYmxlOjY1MTM0MjU3ZGY4ZDRhYmM4MGZkY2RmNzRiYTFjZmM4L3RhYmxlcmFuZ2U6NjUxMzQyNTdkZjhkNGFiYzgwZmRjZGY3NGJhMWNmYzhfNC0xLTEtMS04MQ_ae3348f3-b6be-4645-95e7-72c3700495bb">23,414</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a43e9d7d97347f9b3479daaca253e61_D20210701-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80MC9mcmFnOmQwZTdiYzBhNTk1MjRkYzQ4MzU1MDkwYTlkNzVjNmIzL3RhYmxlOjY1MTM0MjU3ZGY4ZDRhYmM4MGZkY2RmNzRiYTFjZmM4L3RhYmxlcmFuZ2U6NjUxMzQyNTdkZjhkNGFiYzgwZmRjZGY3NGJhMWNmYzhfNC0zLTEtMS04MQ_232eb6f3-f59c-4d65-93ee-f460b25a6f5e">17,562</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1522e02430214c97807e76b9d4f39eac_D20220101-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80MC9mcmFnOmQwZTdiYzBhNTk1MjRkYzQ4MzU1MDkwYTlkNzVjNmIzL3RhYmxlOjY1MTM0MjU3ZGY4ZDRhYmM4MGZkY2RmNzRiYTFjZmM4L3RhYmxlcmFuZ2U6NjUxMzQyNTdkZjhkNGFiYzgwZmRjZGY3NGJhMWNmYzhfNC01LTEtMS04MQ_f752114a-29bb-4e72-aed7-8f8edb7a7862">60,429</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56581712c0e948f182f555824226c56a_D20210101-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80MC9mcmFnOmQwZTdiYzBhNTk1MjRkYzQ4MzU1MDkwYTlkNzVjNmIzL3RhYmxlOjY1MTM0MjU3ZGY4ZDRhYmM4MGZkY2RmNzRiYTFjZmM4L3RhYmxlcmFuZ2U6NjUxMzQyNTdkZjhkNGFiYzgwZmRjZGY3NGJhMWNmYzhfNC03LTEtMS04MQ_7905e3c8-d2ff-4ea7-9a73-b1e5db51fe3d">48,924</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MINJUVI revenues, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97181295a2fc4bc38ac82fa3dbaf41dc_D20220701-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80MC9mcmFnOmQwZTdiYzBhNTk1MjRkYzQ4MzU1MDkwYTlkNzVjNmIzL3RhYmxlOjY1MTM0MjU3ZGY4ZDRhYmM4MGZkY2RmNzRiYTFjZmM4L3RhYmxlcmFuZ2U6NjUxMzQyNTdkZjhkNGFiYzgwZmRjZGY3NGJhMWNmYzhfNS0xLTEtMS04MQ_e8516bab-80bf-4f8f-973b-c142a77d1754">5,932</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1964ea37b1844a981da5845b1efc66f_D20210701-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80MC9mcmFnOmQwZTdiYzBhNTk1MjRkYzQ4MzU1MDkwYTlkNzVjNmIzL3RhYmxlOjY1MTM0MjU3ZGY4ZDRhYmM4MGZkY2RmNzRiYTFjZmM4L3RhYmxlcmFuZ2U6NjUxMzQyNTdkZjhkNGFiYzgwZmRjZGY3NGJhMWNmYzhfNS0zLTEtMS04MQ_efca5931-3d0a-4f7b-8298-d44823540264">556</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e487722166b436b9b1a0d17da42afcb_D20220101-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80MC9mcmFnOmQwZTdiYzBhNTk1MjRkYzQ4MzU1MDkwYTlkNzVjNmIzL3RhYmxlOjY1MTM0MjU3ZGY4ZDRhYmM4MGZkY2RmNzRiYTFjZmM4L3RhYmxlcmFuZ2U6NjUxMzQyNTdkZjhkNGFiYzgwZmRjZGY3NGJhMWNmYzhfNS01LTEtMS04MQ_ab7f961e-9594-4b14-868d-54b6ab94683f">14,845</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie79dcd193dd74e2692c4841bc97d7582_D20210101-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80MC9mcmFnOmQwZTdiYzBhNTk1MjRkYzQ4MzU1MDkwYTlkNzVjNmIzL3RhYmxlOjY1MTM0MjU3ZGY4ZDRhYmM4MGZkY2RmNzRiYTFjZmM4L3RhYmxlcmFuZ2U6NjUxMzQyNTdkZjhkNGFiYzgwZmRjZGY3NGJhMWNmYzhfNS03LTEtMS04MQ_9b4f0305-aaf6-4a5a-8a68-f89d5b135968">556</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OPZELURA revenues, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b0a477af03843e4a3226411276628ad_D20220701-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80MC9mcmFnOmQwZTdiYzBhNTk1MjRkYzQ4MzU1MDkwYTlkNzVjNmIzL3RhYmxlOjY1MTM0MjU3ZGY4ZDRhYmM4MGZkY2RmNzRiYTFjZmM4L3RhYmxlcmFuZ2U6NjUxMzQyNTdkZjhkNGFiYzgwZmRjZGY3NGJhMWNmYzhfNi0xLTEtMS04MQ_28722702-1275-48f1-ae65-cf1007459651">38,140</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibde9c5a1859245f58beebcd0ab2f8837_D20210701-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80MC9mcmFnOmQwZTdiYzBhNTk1MjRkYzQ4MzU1MDkwYTlkNzVjNmIzL3RhYmxlOjY1MTM0MjU3ZGY4ZDRhYmM4MGZkY2RmNzRiYTFjZmM4L3RhYmxlcmFuZ2U6NjUxMzQyNTdkZjhkNGFiYzgwZmRjZGY3NGJhMWNmYzhfNi0zLTEtMS04MQ_bea67331-00da-48e8-9151-505968bf96d9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d64d29a0d744eada29116a65f7ee606_D20220101-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80MC9mcmFnOmQwZTdiYzBhNTk1MjRkYzQ4MzU1MDkwYTlkNzVjNmIzL3RhYmxlOjY1MTM0MjU3ZGY4ZDRhYmM4MGZkY2RmNzRiYTFjZmM4L3RhYmxlcmFuZ2U6NjUxMzQyNTdkZjhkNGFiYzgwZmRjZGY3NGJhMWNmYzhfNi01LTEtMS04MQ_7b039a9e-8330-4954-9958-54289ad6fd15">67,454</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76074454312246a08eeeb082fdac82d4_D20210101-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80MC9mcmFnOmQwZTdiYzBhNTk1MjRkYzQ4MzU1MDkwYTlkNzVjNmIzL3RhYmxlOjY1MTM0MjU3ZGY4ZDRhYmM4MGZkY2RmNzRiYTFjZmM4L3RhYmxlcmFuZ2U6NjUxMzQyNTdkZjhkNGFiYzgwZmRjZGY3NGJhMWNmYzhfNi03LTEtMS04MQ_d701b3c8-3609-45a2-aea8-c7ee6c901dd5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total product revenues, net</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85b99c1e194944f7bd3b5fb62f5a2182_D20220701-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80MC9mcmFnOmQwZTdiYzBhNTk1MjRkYzQ4MzU1MDkwYTlkNzVjNmIzL3RhYmxlOjY1MTM0MjU3ZGY4ZDRhYmM4MGZkY2RmNzRiYTFjZmM4L3RhYmxlcmFuZ2U6NjUxMzQyNTdkZjhkNGFiYzgwZmRjZGY3NGJhMWNmYzhfNy0xLTEtMS04MQ_67f5f101-d48f-4fb6-816d-a03d2f78e2cf">713,010</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48a86cbfb7934ea9845c79f994c08295_D20210701-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80MC9mcmFnOmQwZTdiYzBhNTk1MjRkYzQ4MzU1MDkwYTlkNzVjNmIzL3RhYmxlOjY1MTM0MjU3ZGY4ZDRhYmM4MGZkY2RmNzRiYTFjZmM4L3RhYmxlcmFuZ2U6NjUxMzQyNTdkZjhkNGFiYzgwZmRjZGY3NGJhMWNmYzhfNy0zLTEtMS04MQ_f7af14e2-a486-4f57-bd12-76676804cda1">594,013</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie260e1a53b734cf0a4f57af01f2e311d_D20220101-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80MC9mcmFnOmQwZTdiYzBhNTk1MjRkYzQ4MzU1MDkwYTlkNzVjNmIzL3RhYmxlOjY1MTM0MjU3ZGY4ZDRhYmM4MGZkY2RmNzRiYTFjZmM4L3RhYmxlcmFuZ2U6NjUxMzQyNTdkZjhkNGFiYzgwZmRjZGY3NGJhMWNmYzhfNy01LTEtMS04MQ_62feda78-90e1-4db2-9884-14d46974256c">1,982,682</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c3d6351306b42baba694287efd653dc_D20210101-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80MC9mcmFnOmQwZTdiYzBhNTk1MjRkYzQ4MzU1MDkwYTlkNzVjNmIzL3RhYmxlOjY1MTM0MjU3ZGY4ZDRhYmM4MGZkY2RmNzRiYTFjZmM4L3RhYmxlcmFuZ2U6NjUxMzQyNTdkZjhkNGFiYzgwZmRjZGY3NGJhMWNmYzhfNy03LTEtMS04MQ_5df67022-5324-4a62-bacf-10ef06a2543e">1,673,974</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">JAKAVI product royalty revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7988d7d482845398e5665259694affc_D20220701-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80MC9mcmFnOmQwZTdiYzBhNTk1MjRkYzQ4MzU1MDkwYTlkNzVjNmIzL3RhYmxlOjY1MTM0MjU3ZGY4ZDRhYmM4MGZkY2RmNzRiYTFjZmM4L3RhYmxlcmFuZ2U6NjUxMzQyNTdkZjhkNGFiYzgwZmRjZGY3NGJhMWNmYzhfOC0xLTEtMS04MQ_d0ca02a5-cacb-49f3-bc5f-11cbd7f9dd0d">85,808</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f384ac250ef439885835d9b5c193ad9_D20210701-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80MC9mcmFnOmQwZTdiYzBhNTk1MjRkYzQ4MzU1MDkwYTlkNzVjNmIzL3RhYmxlOjY1MTM0MjU3ZGY4ZDRhYmM4MGZkY2RmNzRiYTFjZmM4L3RhYmxlcmFuZ2U6NjUxMzQyNTdkZjhkNGFiYzgwZmRjZGY3NGJhMWNmYzhfOC0zLTEtMS04MQ_6a2bf343-021a-41a7-afed-faa1cfa075c9">94,655</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45b0b732fe1e49f8a7de40384f586a9b_D20220101-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80MC9mcmFnOmQwZTdiYzBhNTk1MjRkYzQ4MzU1MDkwYTlkNzVjNmIzL3RhYmxlOjY1MTM0MjU3ZGY4ZDRhYmM4MGZkY2RmNzRiYTFjZmM4L3RhYmxlcmFuZ2U6NjUxMzQyNTdkZjhkNGFiYzgwZmRjZGY3NGJhMWNmYzhfOC01LTEtMS04MQ_828570d4-c813-4220-81d4-1a38237fdffc">240,386</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3424cac904843c0b18c3c76707b6e36_D20210101-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80MC9mcmFnOmQwZTdiYzBhNTk1MjRkYzQ4MzU1MDkwYTlkNzVjNmIzL3RhYmxlOjY1MTM0MjU3ZGY4ZDRhYmM4MGZkY2RmNzRiYTFjZmM4L3RhYmxlcmFuZ2U6NjUxMzQyNTdkZjhkNGFiYzgwZmRjZGY3NGJhMWNmYzhfOC03LTEtMS04MQ_612ac2fa-25b1-4516-ab5a-59844db06be3">242,295</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OLUMIANT product royalty revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0672ace4d6734ee8aaf270d6c484063d_D20220701-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80MC9mcmFnOmQwZTdiYzBhNTk1MjRkYzQ4MzU1MDkwYTlkNzVjNmIzL3RhYmxlOjY1MTM0MjU3ZGY4ZDRhYmM4MGZkY2RmNzRiYTFjZmM4L3RhYmxlcmFuZ2U6NjUxMzQyNTdkZjhkNGFiYzgwZmRjZGY3NGJhMWNmYzhfOS0xLTEtMS04MQ_3f050481-17c0-4c10-bb2e-e2ad9a8f50e9">20,371</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a5b8b62e0a34310b286dc3fd7b2e45f_D20210701-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80MC9mcmFnOmQwZTdiYzBhNTk1MjRkYzQ4MzU1MDkwYTlkNzVjNmIzL3RhYmxlOjY1MTM0MjU3ZGY4ZDRhYmM4MGZkY2RmNzRiYTFjZmM4L3RhYmxlcmFuZ2U6NjUxMzQyNTdkZjhkNGFiYzgwZmRjZGY3NGJhMWNmYzhfOS0zLTEtMS04MQ_33bdf58b-9101-43e5-a0b0-05b542774d06">86,572</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae8216b0f9fa43a69bc74413e49ef99b_D20220101-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80MC9mcmFnOmQwZTdiYzBhNTk1MjRkYzQ4MzU1MDkwYTlkNzVjNmIzL3RhYmxlOjY1MTM0MjU3ZGY4ZDRhYmM4MGZkY2RmNzRiYTFjZmM4L3RhYmxlcmFuZ2U6NjUxMzQyNTdkZjhkNGFiYzgwZmRjZGY3NGJhMWNmYzhfOS01LTEtMS04MQ_4b6d5704-2bab-4e91-aaf1-73cfe8149ffb">98,689</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bf0f6ad20014e71a14b23e5dd30857a_D20210101-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80MC9mcmFnOmQwZTdiYzBhNTk1MjRkYzQ4MzU1MDkwYTlkNzVjNmIzL3RhYmxlOjY1MTM0MjU3ZGY4ZDRhYmM4MGZkY2RmNzRiYTFjZmM4L3RhYmxlcmFuZ2U6NjUxMzQyNTdkZjhkNGFiYzgwZmRjZGY3NGJhMWNmYzhfOS03LTEtMS04MQ_553d13aa-a14a-40b8-9ea3-a29098731bf9">154,875</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TABRECTA product royalty revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic85f6d136e8245968800b43ce0542fe8_D20220701-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80MC9mcmFnOmQwZTdiYzBhNTk1MjRkYzQ4MzU1MDkwYTlkNzVjNmIzL3RhYmxlOjY1MTM0MjU3ZGY4ZDRhYmM4MGZkY2RmNzRiYTFjZmM4L3RhYmxlcmFuZ2U6NjUxMzQyNTdkZjhkNGFiYzgwZmRjZGY3NGJhMWNmYzhfMTAtMS0xLTEtODE_0caa7c9e-6ec4-4c57-b7c5-af0cbcb46131">4,114</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63601b24528b4ff788ffb07ad33130f8_D20210701-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80MC9mcmFnOmQwZTdiYzBhNTk1MjRkYzQ4MzU1MDkwYTlkNzVjNmIzL3RhYmxlOjY1MTM0MjU3ZGY4ZDRhYmM4MGZkY2RmNzRiYTFjZmM4L3RhYmxlcmFuZ2U6NjUxMzQyNTdkZjhkNGFiYzgwZmRjZGY3NGJhMWNmYzhfMTAtMy0xLTEtODE_3f570741-289f-4190-8a39-b398d393995f">2,747</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6088baa6c1d2446691681da562d452f9_D20220101-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80MC9mcmFnOmQwZTdiYzBhNTk1MjRkYzQ4MzU1MDkwYTlkNzVjNmIzL3RhYmxlOjY1MTM0MjU3ZGY4ZDRhYmM4MGZkY2RmNzRiYTFjZmM4L3RhYmxlcmFuZ2U6NjUxMzQyNTdkZjhkNGFiYzgwZmRjZGY3NGJhMWNmYzhfMTAtNS0xLTEtODE_f29f0613-c032-47fa-b77e-4fdc7c934783">11,178</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb19c48e81f541858b2a7dd6f03bfa27_D20210101-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80MC9mcmFnOmQwZTdiYzBhNTk1MjRkYzQ4MzU1MDkwYTlkNzVjNmIzL3RhYmxlOjY1MTM0MjU3ZGY4ZDRhYmM4MGZkY2RmNzRiYTFjZmM4L3RhYmxlcmFuZ2U6NjUxMzQyNTdkZjhkNGFiYzgwZmRjZGY3NGJhMWNmYzhfMTAtNy0xLTEtODE_0966a079-414a-4db7-add1-2f73dd8aa087">7,270</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total product royalty revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37c7d1d637bf4ae98b18884511c75dd9_D20220701-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80MC9mcmFnOmQwZTdiYzBhNTk1MjRkYzQ4MzU1MDkwYTlkNzVjNmIzL3RhYmxlOjY1MTM0MjU3ZGY4ZDRhYmM4MGZkY2RmNzRiYTFjZmM4L3RhYmxlcmFuZ2U6NjUxMzQyNTdkZjhkNGFiYzgwZmRjZGY3NGJhMWNmYzhfMTEtMS0xLTEtODE_bc615c69-81ec-45f8-9cc0-03315cc0357d">110,293</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c507c58a3df413e914b6c8ae5dbf2a2_D20210701-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80MC9mcmFnOmQwZTdiYzBhNTk1MjRkYzQ4MzU1MDkwYTlkNzVjNmIzL3RhYmxlOjY1MTM0MjU3ZGY4ZDRhYmM4MGZkY2RmNzRiYTFjZmM4L3RhYmxlcmFuZ2U6NjUxMzQyNTdkZjhkNGFiYzgwZmRjZGY3NGJhMWNmYzhfMTEtMy0xLTEtODE_4918a1a6-8613-4d07-bcd9-e08df5f239c4">183,974</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia628ec6831414d4f8e0d2c927a011f4a_D20220101-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80MC9mcmFnOmQwZTdiYzBhNTk1MjRkYzQ4MzU1MDkwYTlkNzVjNmIzL3RhYmxlOjY1MTM0MjU3ZGY4ZDRhYmM4MGZkY2RmNzRiYTFjZmM4L3RhYmxlcmFuZ2U6NjUxMzQyNTdkZjhkNGFiYzgwZmRjZGY3NGJhMWNmYzhfMTEtNS0xLTEtODE_e1976381-2e3a-470d-b628-7c807ed5c988">350,253</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3231b94f87f649139a15ad91d06d9fd2_D20210101-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80MC9mcmFnOmQwZTdiYzBhNTk1MjRkYzQ4MzU1MDkwYTlkNzVjNmIzL3RhYmxlOjY1MTM0MjU3ZGY4ZDRhYmM4MGZkY2RmNzRiYTFjZmM4L3RhYmxlcmFuZ2U6NjUxMzQyNTdkZjhkNGFiYzgwZmRjZGY3NGJhMWNmYzhfMTEtNy0xLTEtODE_07e794d9-a0ff-4e38-888d-cc8c09a64c9f">404,440</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Milestone and contract revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i897a57efbfea4fbeaa81a87e5862e1a7_D20220701-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80MC9mcmFnOmQwZTdiYzBhNTk1MjRkYzQ4MzU1MDkwYTlkNzVjNmIzL3RhYmxlOjY1MTM0MjU3ZGY4ZDRhYmM4MGZkY2RmNzRiYTFjZmM4L3RhYmxlcmFuZ2U6NjUxMzQyNTdkZjhkNGFiYzgwZmRjZGY3NGJhMWNmYzhfMTItMS0xLTEtODE_e0f9643e-a737-47bc-afa2-b1cc8f52fb90">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46bcaf0cac964264acfc8967fb4fed3e_D20210701-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80MC9mcmFnOmQwZTdiYzBhNTk1MjRkYzQ4MzU1MDkwYTlkNzVjNmIzL3RhYmxlOjY1MTM0MjU3ZGY4ZDRhYmM4MGZkY2RmNzRiYTFjZmM4L3RhYmxlcmFuZ2U6NjUxMzQyNTdkZjhkNGFiYzgwZmRjZGY3NGJhMWNmYzhfMTItMy0xLTEtODE_824482b2-8d4c-4abf-a9f1-63721809e716">35,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2dece6fa44fc4ba59c58b479ca510a5f_D20220101-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80MC9mcmFnOmQwZTdiYzBhNTk1MjRkYzQ4MzU1MDkwYTlkNzVjNmIzL3RhYmxlOjY1MTM0MjU3ZGY4ZDRhYmM4MGZkY2RmNzRiYTFjZmM4L3RhYmxlcmFuZ2U6NjUxMzQyNTdkZjhkNGFiYzgwZmRjZGY3NGJhMWNmYzhfMTItNS0xLTEtODE_37463e04-8d38-40f2-bb8d-d237bb5d9638">135,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae3f552bb26a4c00a17d299e8d3f716b_D20210101-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80MC9mcmFnOmQwZTdiYzBhNTk1MjRkYzQ4MzU1MDkwYTlkNzVjNmIzL3RhYmxlOjY1MTM0MjU3ZGY4ZDRhYmM4MGZkY2RmNzRiYTFjZmM4L3RhYmxlcmFuZ2U6NjUxMzQyNTdkZjhkNGFiYzgwZmRjZGY3NGJhMWNmYzhfMTItNy0xLTEtODE_e214f7f2-6d03-4330-ba68-347b554f0b58">45,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id673d80f31e74643a241d2f62db94ca9_D20220701-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80MC9mcmFnOmQwZTdiYzBhNTk1MjRkYzQ4MzU1MDkwYTlkNzVjNmIzL3RhYmxlOjY1MTM0MjU3ZGY4ZDRhYmM4MGZkY2RmNzRiYTFjZmM4L3RhYmxlcmFuZ2U6NjUxMzQyNTdkZjhkNGFiYzgwZmRjZGY3NGJhMWNmYzhfMTMtMS0xLTEtODE_0ef8afa1-01fe-471a-976f-ed0821ca4053">823,303</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i313b15d35b7045babd1ba61f84a077dd_D20210701-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80MC9mcmFnOmQwZTdiYzBhNTk1MjRkYzQ4MzU1MDkwYTlkNzVjNmIzL3RhYmxlOjY1MTM0MjU3ZGY4ZDRhYmM4MGZkY2RmNzRiYTFjZmM4L3RhYmxlcmFuZ2U6NjUxMzQyNTdkZjhkNGFiYzgwZmRjZGY3NGJhMWNmYzhfMTMtMy0xLTEtODE_b57145b8-b47a-4548-8840-1115e62b568f">812,987</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80MC9mcmFnOmQwZTdiYzBhNTk1MjRkYzQ4MzU1MDkwYTlkNzVjNmIzL3RhYmxlOjY1MTM0MjU3ZGY4ZDRhYmM4MGZkY2RmNzRiYTFjZmM4L3RhYmxlcmFuZ2U6NjUxMzQyNTdkZjhkNGFiYzgwZmRjZGY3NGJhMWNmYzhfMTMtNS0xLTEtODE_2d078e77-eda9-4927-8495-64e571acee2c">2,467,935</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0faaba5fcd6b485781cadacae8b2fd8e_D20210101-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80MC9mcmFnOmQwZTdiYzBhNTk1MjRkYzQ4MzU1MDkwYTlkNzVjNmIzL3RhYmxlOjY1MTM0MjU3ZGY4ZDRhYmM4MGZkY2RmNzRiYTFjZmM4L3RhYmxlcmFuZ2U6NjUxMzQyNTdkZjhkNGFiYzgwZmRjZGY3NGJhMWNmYzhfMTMtNy0xLTEtODE_037a3c9d-3043-49e2-9bb3-4d454eaee55b">2,123,414</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:nonNumeric><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><ix:continuation id="i14e25d6372284e03af60e256a496cbac"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For further information on our revenue-generating contracts,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">refer to Note 7.</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">  </span></div><div id="ie2ffba3ee5384c86becdb38ff117ca9a_43"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 4. Fair Value of Financial Instruments</span></div><ix:nonNumeric contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80My9mcmFnOmU5ZDJjOTllOGFlODQ4MDdiZDgxMTY0ZThhOWVkYWU3L3RleHRyZWdpb246ZTlkMmM5OWU4YWU4NDgwN2JkODExNjRlOGE5ZWRhZTdfNDAzOA_b2c9608a-42e9-449f-ad0b-11d973cccc1c" continuedAt="i78e29315229b495ba1cab43111ef4ee3" escape="true"><ix:nonNumeric contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80My9mcmFnOmU5ZDJjOTllOGFlODQ4MDdiZDgxMTY0ZThhOWVkYWU3L3RleHRyZWdpb246ZTlkMmM5OWU4YWU4NDgwN2JkODExNjRlOGE5ZWRhZTdfNDAzOQ_4ee8e918-50a7-4e77-a4e9-09857604ecc2" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of our marketable security portfolio for the periods presented (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities (government)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7f2a4b8ea5a46449d5a5c254bc02074_I20220930" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80My9mcmFnOmU5ZDJjOTllOGFlODQ4MDdiZDgxMTY0ZThhOWVkYWU3L3RhYmxlOjY1NmQzZjMzM2YxZDQzZGM5YzMzYzY5ZDU5NWJlYzE2L3RhYmxlcmFuZ2U6NjU2ZDNmMzMzZjFkNDNkYzljMzNjNjlkNTk1YmVjMTZfMi0xLTEtMS04MQ_1dc2fff6-af85-4e92-9b71-31e0c0982ddb">292,941</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia7f2a4b8ea5a46449d5a5c254bc02074_I20220930" decimals="-3" sign="-" name="us-gaap:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80My9mcmFnOmU5ZDJjOTllOGFlODQ4MDdiZDgxMTY0ZThhOWVkYWU3L3RhYmxlOjY1NmQzZjMzM2YxZDQzZGM5YzMzYzY5ZDU5NWJlYzE2L3RhYmxlcmFuZ2U6NjU2ZDNmMzMzZjFkNDNkYzljMzNjNjlkNTk1YmVjMTZfMi0zLTEtMS04MQ_26ece443-e4b3-47e6-a8c1-25780b999021">6,441</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7f2a4b8ea5a46449d5a5c254bc02074_I20220930" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80My9mcmFnOmU5ZDJjOTllOGFlODQ4MDdiZDgxMTY0ZThhOWVkYWU3L3RhYmxlOjY1NmQzZjMzM2YxZDQzZGM5YzMzYzY5ZDU5NWJlYzE2L3RhYmxlcmFuZ2U6NjU2ZDNmMzMzZjFkNDNkYzljMzNjNjlkNTk1YmVjMTZfMi01LTEtMS04MQ_04ac5140-8240-4613-8f5a-e1dc963369f5">286,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities (government)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia665e98c13fa47db9c644a1bccf8d1eb_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80My9mcmFnOmU5ZDJjOTllOGFlODQ4MDdiZDgxMTY0ZThhOWVkYWU3L3RhYmxlOjY1NmQzZjMzM2YxZDQzZGM5YzMzYzY5ZDU5NWJlYzE2L3RhYmxlcmFuZ2U6NjU2ZDNmMzMzZjFkNDNkYzljMzNjNjlkNTk1YmVjMTZfNS0xLTEtMS04MQ_9ee85ee2-66e0-496d-a4f2-d11e767a395a">291,871</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia665e98c13fa47db9c644a1bccf8d1eb_I20211231" decimals="-3" sign="-" name="us-gaap:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80My9mcmFnOmU5ZDJjOTllOGFlODQ4MDdiZDgxMTY0ZThhOWVkYWU3L3RhYmxlOjY1NmQzZjMzM2YxZDQzZGM5YzMzYzY5ZDU5NWJlYzE2L3RhYmxlcmFuZ2U6NjU2ZDNmMzMzZjFkNDNkYzljMzNjNjlkNTk1YmVjMTZfNS0zLTEtMS04MQ_a1bd7c94-0b72-4848-9363-a199d225d94a">1,119</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia665e98c13fa47db9c644a1bccf8d1eb_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80My9mcmFnOmU5ZDJjOTllOGFlODQ4MDdiZDgxMTY0ZThhOWVkYWU3L3RhYmxlOjY1NmQzZjMzM2YxZDQzZGM5YzMzYzY5ZDU5NWJlYzE2L3RhYmxlcmFuZ2U6NjU2ZDNmMzMzZjFkNDNkYzljMzNjNjlkNTk1YmVjMTZfNS01LTEtMS04MQ_572a3cb8-5d8e-4a7c-a211-cdde67126351">290,752</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our available-for-sale debt securities generally have contractual maturity dates of between <ix:nonNumeric contextRef="i10d9e02673514259891fcd1d9b719b8c_D20220101-20220930" name="us-gaap:DebtInstrumentTerm" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80My9mcmFnOmU5ZDJjOTllOGFlODQ4MDdiZDgxMTY0ZThhOWVkYWU3L3RleHRyZWdpb246ZTlkMmM5OWU4YWU4NDgwN2JkODExNjRlOGE5ZWRhZTdfMjQ5_e5312223-e3aa-4109-907d-cff2d34e65a8">12</ix:nonNumeric> to <ix:nonNumeric contextRef="ibfc4e1b1be0040ea91db0d41c92a5dfe_D20220101-20220930" name="us-gaap:DebtInstrumentTerm" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80My9mcmFnOmU5ZDJjOTllOGFlODQ4MDdiZDgxMTY0ZThhOWVkYWU3L3RleHRyZWdpb246ZTlkMmM5OWU4YWU4NDgwN2JkODExNjRlOGE5ZWRhZTdfMjU2_e6319dd8-f104-4d12-9c76-0987b9c852d1">18</ix:nonNumeric> months. Debt security assets were assessed for risk of expected credit losses. As of September&#160;30, 2022 and December&#160;31, 2021, the available-for-sale debt securities were held in U.S.-government backed securities and in Treasury bonds and were assessed on an individual security basis to have a de minimis risk of credit loss.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FASB accounting guidance defines fair value as the price that would be received to sell an asset or paid to transfer a liability (&#8220;the exit price&#8221;) in an orderly transaction between market participants at the measurement date. The standard outlines a valuation framework and creates a fair value hierarchy in order to increase the consistency and comparability of fair value measurements and the related disclosures. In determining fair value we use quoted prices and observable inputs. Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of us. The fair value hierarchy is broken down into three levels based on the source of inputs as follows:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1&#8212;Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities.</span></div></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie2ffba3ee5384c86becdb38ff117ca9a_7">Table of Contents</a></span></div></div><ix:continuation id="i78e29315229b495ba1cab43111ef4ee3" continuedAt="i8b02e21f3bc64184af40485888f544fc"><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2&#8212;Valuations based on observable inputs and quoted prices in active markets for similar assets and liabilities.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3&#8212;Valuations based on inputs that are unobservable and models that are significant to the overall fair value measurement.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recurring Fair Value Measurements</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our marketable securities consist of investments in U.S. government debt securities that are classified as available-for-sale. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September&#160;30, 2022 and December&#160;31, 2021, our Level 2 U.S. government debt securities were valued using readily available pricing sources which utilize market observable inputs, including the current interest rate and other characteristics for similar types of investments. Our long term investments classified as Level 1 were valued using their respective closing stock prices on The Nasdaq Stock Market. We did not experience any transfers of financial instruments between the fair value hierarchy levels during the nine months ended September&#160;30, 2022.</span></div><ix:nonNumeric contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80My9mcmFnOmU5ZDJjOTllOGFlODQ4MDdiZDgxMTY0ZThhOWVkYWU3L3RleHRyZWdpb246ZTlkMmM5OWU4YWU4NDgwN2JkODExNjRlOGE5ZWRhZTdfNDA0MA_1d1cdd63-a77f-4948-9740-1b477657d22d" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following fair value hierarchy table presents information about each major category of our financial assets measured at fair value on a recurring basis (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurement at Reporting Date Using:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Quoted Prices in<br/>Active Markets for<br/>Identical Assets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Significant Other<br/>Observable<br/>Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance as of <br/>September 30, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i449d405309c143ba85c051e549663c3a_I20220930" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80My9mcmFnOmU5ZDJjOTllOGFlODQ4MDdiZDgxMTY0ZThhOWVkYWU3L3RhYmxlOjEwZGVkYjM0NjIyMDRjZGZiNzAyOWU0YmMxZTdkNzQ1L3RhYmxlcmFuZ2U6MTBkZWRiMzQ2MjIwNGNkZmI3MDI5ZTRiYzFlN2Q3NDVfMi0xLTEtMS04MQ_25b0ec5e-4ded-441e-8358-28af440c50cb">2,690,622</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06079cbfdc734317994c136835d0952f_I20220930" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80My9mcmFnOmU5ZDJjOTllOGFlODQ4MDdiZDgxMTY0ZThhOWVkYWU3L3RhYmxlOjEwZGVkYjM0NjIyMDRjZGZiNzAyOWU0YmMxZTdkNzQ1L3RhYmxlcmFuZ2U6MTBkZWRiMzQ2MjIwNGNkZmI3MDI5ZTRiYzFlN2Q3NDVfMi0zLTEtMS04MQ_6cf6028e-3a45-4264-88ea-512326b28692">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3ce7b9a2a1a476b998fe7aa7ef489e2_I20220930" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80My9mcmFnOmU5ZDJjOTllOGFlODQ4MDdiZDgxMTY0ZThhOWVkYWU3L3RhYmxlOjEwZGVkYjM0NjIyMDRjZGZiNzAyOWU0YmMxZTdkNzQ1L3RhYmxlcmFuZ2U6MTBkZWRiMzQ2MjIwNGNkZmI3MDI5ZTRiYzFlN2Q3NDVfMi01LTEtMS04MQ_b9d7958b-14b6-44e2-8bd9-6414129a0244">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i281946f958c146b0926f5dd53313b031_I20220930" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80My9mcmFnOmU5ZDJjOTllOGFlODQ4MDdiZDgxMTY0ZThhOWVkYWU3L3RhYmxlOjEwZGVkYjM0NjIyMDRjZGZiNzAyOWU0YmMxZTdkNzQ1L3RhYmxlcmFuZ2U6MTBkZWRiMzQ2MjIwNGNkZmI3MDI5ZTRiYzFlN2Q3NDVfMi03LTEtMS04MQ_ee2cfcf0-e422-4d64-aea0-93b2c8d8ec45">2,690,622</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities (government)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i449d405309c143ba85c051e549663c3a_I20220930" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80My9mcmFnOmU5ZDJjOTllOGFlODQ4MDdiZDgxMTY0ZThhOWVkYWU3L3RhYmxlOjEwZGVkYjM0NjIyMDRjZGZiNzAyOWU0YmMxZTdkNzQ1L3RhYmxlcmFuZ2U6MTBkZWRiMzQ2MjIwNGNkZmI3MDI5ZTRiYzFlN2Q3NDVfMy0xLTEtMS04MQ_9a99c6f4-4a24-4934-8946-f66d95333f08">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06079cbfdc734317994c136835d0952f_I20220930" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80My9mcmFnOmU5ZDJjOTllOGFlODQ4MDdiZDgxMTY0ZThhOWVkYWU3L3RhYmxlOjEwZGVkYjM0NjIyMDRjZGZiNzAyOWU0YmMxZTdkNzQ1L3RhYmxlcmFuZ2U6MTBkZWRiMzQ2MjIwNGNkZmI3MDI5ZTRiYzFlN2Q3NDVfMy0zLTEtMS04MQ_849edfe4-e2b9-4ee5-9258-8b722be65003">286,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3ce7b9a2a1a476b998fe7aa7ef489e2_I20220930" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80My9mcmFnOmU5ZDJjOTllOGFlODQ4MDdiZDgxMTY0ZThhOWVkYWU3L3RhYmxlOjEwZGVkYjM0NjIyMDRjZGZiNzAyOWU0YmMxZTdkNzQ1L3RhYmxlcmFuZ2U6MTBkZWRiMzQ2MjIwNGNkZmI3MDI5ZTRiYzFlN2Q3NDVfMy01LTEtMS04MQ_c5dfae1c-f1be-4cfd-a69b-0803e988c77a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i281946f958c146b0926f5dd53313b031_I20220930" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80My9mcmFnOmU5ZDJjOTllOGFlODQ4MDdiZDgxMTY0ZThhOWVkYWU3L3RhYmxlOjEwZGVkYjM0NjIyMDRjZGZiNzAyOWU0YmMxZTdkNzQ1L3RhYmxlcmFuZ2U6MTBkZWRiMzQ2MjIwNGNkZmI3MDI5ZTRiYzFlN2Q3NDVfMy03LTEtMS04MQ_aa8b846f-88e7-4f63-9521-2224331976ca">286,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long term investments (Note 7)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i449d405309c143ba85c051e549663c3a_I20220930" decimals="-3" name="us-gaap:LongTermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80My9mcmFnOmU5ZDJjOTllOGFlODQ4MDdiZDgxMTY0ZThhOWVkYWU3L3RhYmxlOjEwZGVkYjM0NjIyMDRjZGZiNzAyOWU0YmMxZTdkNzQ1L3RhYmxlcmFuZ2U6MTBkZWRiMzQ2MjIwNGNkZmI3MDI5ZTRiYzFlN2Q3NDVfNC0xLTEtMS04MQ_e54f8cd1-dbbb-489c-8ee5-3f6530669ba1">149,124</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06079cbfdc734317994c136835d0952f_I20220930" decimals="-3" name="us-gaap:LongTermInvestments" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80My9mcmFnOmU5ZDJjOTllOGFlODQ4MDdiZDgxMTY0ZThhOWVkYWU3L3RhYmxlOjEwZGVkYjM0NjIyMDRjZGZiNzAyOWU0YmMxZTdkNzQ1L3RhYmxlcmFuZ2U6MTBkZWRiMzQ2MjIwNGNkZmI3MDI5ZTRiYzFlN2Q3NDVfNC0zLTEtMS04MQ_908727e5-1129-45bf-8304-09e6b54f4c82">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3ce7b9a2a1a476b998fe7aa7ef489e2_I20220930" decimals="-3" name="us-gaap:LongTermInvestments" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80My9mcmFnOmU5ZDJjOTllOGFlODQ4MDdiZDgxMTY0ZThhOWVkYWU3L3RhYmxlOjEwZGVkYjM0NjIyMDRjZGZiNzAyOWU0YmMxZTdkNzQ1L3RhYmxlcmFuZ2U6MTBkZWRiMzQ2MjIwNGNkZmI3MDI5ZTRiYzFlN2Q3NDVfNC01LTEtMS04MQ_512018c2-1626-4b62-828b-f2c1b381b3fe">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i281946f958c146b0926f5dd53313b031_I20220930" decimals="-3" name="us-gaap:LongTermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80My9mcmFnOmU5ZDJjOTllOGFlODQ4MDdiZDgxMTY0ZThhOWVkYWU3L3RhYmxlOjEwZGVkYjM0NjIyMDRjZGZiNzAyOWU0YmMxZTdkNzQ1L3RhYmxlcmFuZ2U6MTBkZWRiMzQ2MjIwNGNkZmI3MDI5ZTRiYzFlN2Q3NDVfNC03LTEtMS04MQ_21e6d3a4-fcbf-4e43-8147-5d6c14263337">149,124</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i449d405309c143ba85c051e549663c3a_I20220930" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80My9mcmFnOmU5ZDJjOTllOGFlODQ4MDdiZDgxMTY0ZThhOWVkYWU3L3RhYmxlOjEwZGVkYjM0NjIyMDRjZGZiNzAyOWU0YmMxZTdkNzQ1L3RhYmxlcmFuZ2U6MTBkZWRiMzQ2MjIwNGNkZmI3MDI5ZTRiYzFlN2Q3NDVfNS0xLTEtMS04MQ_f3c666c1-b707-4f62-9fbc-d2320155afa3">2,839,746</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06079cbfdc734317994c136835d0952f_I20220930" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80My9mcmFnOmU5ZDJjOTllOGFlODQ4MDdiZDgxMTY0ZThhOWVkYWU3L3RhYmxlOjEwZGVkYjM0NjIyMDRjZGZiNzAyOWU0YmMxZTdkNzQ1L3RhYmxlcmFuZ2U6MTBkZWRiMzQ2MjIwNGNkZmI3MDI5ZTRiYzFlN2Q3NDVfNS0zLTEtMS04MQ_40996344-8ae0-413c-aaa4-7b2c1065b85d">286,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3ce7b9a2a1a476b998fe7aa7ef489e2_I20220930" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80My9mcmFnOmU5ZDJjOTllOGFlODQ4MDdiZDgxMTY0ZThhOWVkYWU3L3RhYmxlOjEwZGVkYjM0NjIyMDRjZGZiNzAyOWU0YmMxZTdkNzQ1L3RhYmxlcmFuZ2U6MTBkZWRiMzQ2MjIwNGNkZmI3MDI5ZTRiYzFlN2Q3NDVfNS01LTEtMS04MQ_dcd2578d-9ff8-4654-a070-00a3bf65132d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i281946f958c146b0926f5dd53313b031_I20220930" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80My9mcmFnOmU5ZDJjOTllOGFlODQ4MDdiZDgxMTY0ZThhOWVkYWU3L3RhYmxlOjEwZGVkYjM0NjIyMDRjZGZiNzAyOWU0YmMxZTdkNzQ1L3RhYmxlcmFuZ2U6MTBkZWRiMzQ2MjIwNGNkZmI3MDI5ZTRiYzFlN2Q3NDVfNS03LTEtMS04MQ_80560ba6-7a76-4725-a80a-df5c613b48b7">3,126,246</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurement at Reporting Date Using:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Quoted Prices in<br/>Active Markets for<br/>Identical Assets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Significant Other<br/>Observable<br/>Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Balance as of<br/>December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia17493513b37495cac5bb47509ffe782_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80My9mcmFnOmU5ZDJjOTllOGFlODQ4MDdiZDgxMTY0ZThhOWVkYWU3L3RhYmxlOjYyM2IyMmI2MmQzYTRjYTc5OWFmZGQyNDQ0NWYyMDhjL3RhYmxlcmFuZ2U6NjIzYjIyYjYyZDNhNGNhNzk5YWZkZDI0NDQ1ZjIwOGNfMi0xLTEtMS04MQ_08155833-39fd-4f7d-88e6-ad61151c6b0a">2,057,440</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f88761cfe5c4e21a116380b0db0c026_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80My9mcmFnOmU5ZDJjOTllOGFlODQ4MDdiZDgxMTY0ZThhOWVkYWU3L3RhYmxlOjYyM2IyMmI2MmQzYTRjYTc5OWFmZGQyNDQ0NWYyMDhjL3RhYmxlcmFuZ2U6NjIzYjIyYjYyZDNhNGNhNzk5YWZkZDI0NDQ1ZjIwOGNfMi0zLTEtMS04MQ_0b745b67-2522-41fe-84c9-9d763e074786">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b1ac47dfe8c49068229b687c55c61c7_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80My9mcmFnOmU5ZDJjOTllOGFlODQ4MDdiZDgxMTY0ZThhOWVkYWU3L3RhYmxlOjYyM2IyMmI2MmQzYTRjYTc5OWFmZGQyNDQ0NWYyMDhjL3RhYmxlcmFuZ2U6NjIzYjIyYjYyZDNhNGNhNzk5YWZkZDI0NDQ1ZjIwOGNfMi01LTEtMS04MQ_2320fa4d-4fbd-4e13-825e-55b0531b1c30">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09bab9220bbf47b692107d83bc042e87_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80My9mcmFnOmU5ZDJjOTllOGFlODQ4MDdiZDgxMTY0ZThhOWVkYWU3L3RhYmxlOjYyM2IyMmI2MmQzYTRjYTc5OWFmZGQyNDQ0NWYyMDhjL3RhYmxlcmFuZ2U6NjIzYjIyYjYyZDNhNGNhNzk5YWZkZDI0NDQ1ZjIwOGNfMi03LTEtMS04MQ_916381f4-d651-4533-b626-2b7de4908be3">2,057,440</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities (government)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia17493513b37495cac5bb47509ffe782_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80My9mcmFnOmU5ZDJjOTllOGFlODQ4MDdiZDgxMTY0ZThhOWVkYWU3L3RhYmxlOjYyM2IyMmI2MmQzYTRjYTc5OWFmZGQyNDQ0NWYyMDhjL3RhYmxlcmFuZ2U6NjIzYjIyYjYyZDNhNGNhNzk5YWZkZDI0NDQ1ZjIwOGNfMy0xLTEtMS04MQ_debc402d-2273-4b60-a26b-c4b565d33190">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f88761cfe5c4e21a116380b0db0c026_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80My9mcmFnOmU5ZDJjOTllOGFlODQ4MDdiZDgxMTY0ZThhOWVkYWU3L3RhYmxlOjYyM2IyMmI2MmQzYTRjYTc5OWFmZGQyNDQ0NWYyMDhjL3RhYmxlcmFuZ2U6NjIzYjIyYjYyZDNhNGNhNzk5YWZkZDI0NDQ1ZjIwOGNfMy0zLTEtMS04MQ_197ba2aa-18eb-4d46-b746-588d2f79d0d3">290,752</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b1ac47dfe8c49068229b687c55c61c7_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80My9mcmFnOmU5ZDJjOTllOGFlODQ4MDdiZDgxMTY0ZThhOWVkYWU3L3RhYmxlOjYyM2IyMmI2MmQzYTRjYTc5OWFmZGQyNDQ0NWYyMDhjL3RhYmxlcmFuZ2U6NjIzYjIyYjYyZDNhNGNhNzk5YWZkZDI0NDQ1ZjIwOGNfMy01LTEtMS04MQ_51a76c85-5101-443c-b97e-2bb1d8621bef">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09bab9220bbf47b692107d83bc042e87_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80My9mcmFnOmU5ZDJjOTllOGFlODQ4MDdiZDgxMTY0ZThhOWVkYWU3L3RhYmxlOjYyM2IyMmI2MmQzYTRjYTc5OWFmZGQyNDQ0NWYyMDhjL3RhYmxlcmFuZ2U6NjIzYjIyYjYyZDNhNGNhNzk5YWZkZDI0NDQ1ZjIwOGNfMy03LTEtMS04MQ_82aea52c-e87f-4a7b-a107-0250287d59d2">290,752</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long term investments (Note 7)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia17493513b37495cac5bb47509ffe782_I20211231" decimals="-3" name="us-gaap:LongTermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80My9mcmFnOmU5ZDJjOTllOGFlODQ4MDdiZDgxMTY0ZThhOWVkYWU3L3RhYmxlOjYyM2IyMmI2MmQzYTRjYTc5OWFmZGQyNDQ0NWYyMDhjL3RhYmxlcmFuZ2U6NjIzYjIyYjYyZDNhNGNhNzk5YWZkZDI0NDQ1ZjIwOGNfNC0xLTEtMS04MQ_6bb88631-e5f1-428e-93aa-168106df4c44">221,266</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f88761cfe5c4e21a116380b0db0c026_I20211231" decimals="-3" name="us-gaap:LongTermInvestments" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80My9mcmFnOmU5ZDJjOTllOGFlODQ4MDdiZDgxMTY0ZThhOWVkYWU3L3RhYmxlOjYyM2IyMmI2MmQzYTRjYTc5OWFmZGQyNDQ0NWYyMDhjL3RhYmxlcmFuZ2U6NjIzYjIyYjYyZDNhNGNhNzk5YWZkZDI0NDQ1ZjIwOGNfNC0zLTEtMS04MQ_d40a28aa-409c-42c4-9072-96a87120e81b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b1ac47dfe8c49068229b687c55c61c7_I20211231" decimals="-3" name="us-gaap:LongTermInvestments" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80My9mcmFnOmU5ZDJjOTllOGFlODQ4MDdiZDgxMTY0ZThhOWVkYWU3L3RhYmxlOjYyM2IyMmI2MmQzYTRjYTc5OWFmZGQyNDQ0NWYyMDhjL3RhYmxlcmFuZ2U6NjIzYjIyYjYyZDNhNGNhNzk5YWZkZDI0NDQ1ZjIwOGNfNC01LTEtMS04MQ_39fc07f7-8a5b-4172-bae9-056611e3e15f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09bab9220bbf47b692107d83bc042e87_I20211231" decimals="-3" name="us-gaap:LongTermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80My9mcmFnOmU5ZDJjOTllOGFlODQ4MDdiZDgxMTY0ZThhOWVkYWU3L3RhYmxlOjYyM2IyMmI2MmQzYTRjYTc5OWFmZGQyNDQ0NWYyMDhjL3RhYmxlcmFuZ2U6NjIzYjIyYjYyZDNhNGNhNzk5YWZkZDI0NDQ1ZjIwOGNfNC03LTEtMS04MQ_d6badb4f-4c30-40b4-a67b-933a60e1915f">221,266</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia17493513b37495cac5bb47509ffe782_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80My9mcmFnOmU5ZDJjOTllOGFlODQ4MDdiZDgxMTY0ZThhOWVkYWU3L3RhYmxlOjYyM2IyMmI2MmQzYTRjYTc5OWFmZGQyNDQ0NWYyMDhjL3RhYmxlcmFuZ2U6NjIzYjIyYjYyZDNhNGNhNzk5YWZkZDI0NDQ1ZjIwOGNfNS0xLTEtMS04MQ_7bddcf18-0b21-471c-ac86-a4446072507e">2,278,706</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f88761cfe5c4e21a116380b0db0c026_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80My9mcmFnOmU5ZDJjOTllOGFlODQ4MDdiZDgxMTY0ZThhOWVkYWU3L3RhYmxlOjYyM2IyMmI2MmQzYTRjYTc5OWFmZGQyNDQ0NWYyMDhjL3RhYmxlcmFuZ2U6NjIzYjIyYjYyZDNhNGNhNzk5YWZkZDI0NDQ1ZjIwOGNfNS0zLTEtMS04MQ_ba628b0b-58ed-4da7-870b-58ddeaf61d63">290,752</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b1ac47dfe8c49068229b687c55c61c7_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80My9mcmFnOmU5ZDJjOTllOGFlODQ4MDdiZDgxMTY0ZThhOWVkYWU3L3RhYmxlOjYyM2IyMmI2MmQzYTRjYTc5OWFmZGQyNDQ0NWYyMDhjL3RhYmxlcmFuZ2U6NjIzYjIyYjYyZDNhNGNhNzk5YWZkZDI0NDQ1ZjIwOGNfNS01LTEtMS04MQ_d75f811e-331a-46c5-ada2-0237ba185c7c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09bab9220bbf47b692107d83bc042e87_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80My9mcmFnOmU5ZDJjOTllOGFlODQ4MDdiZDgxMTY0ZThhOWVkYWU3L3RhYmxlOjYyM2IyMmI2MmQzYTRjYTc5OWFmZGQyNDQ0NWYyMDhjL3RhYmxlcmFuZ2U6NjIzYjIyYjYyZDNhNGNhNzk5YWZkZDI0NDQ1ZjIwOGNfNS03LTEtMS04MQ_f044234a-2f25-4aa2-93f4-41e97dd0bed5">2,569,458</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80My9mcmFnOmU5ZDJjOTllOGFlODQ4MDdiZDgxMTY0ZThhOWVkYWU3L3RleHRyZWdpb246ZTlkMmM5OWU4YWU4NDgwN2JkODExNjRlOGE5ZWRhZTdfNDA0MQ_d38a3e21-410a-4676-ac46-b46aa8f5ba9c" continuedAt="i951d752a615f4ddea9b392c8b89197be" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following fair value hierarchy table presents information about each major category of our financial liabilities measured at fair value on a recurring basis as (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurement at Reporting Date Using:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Quoted Prices in<br/>Active Markets for<br/>Identical Liabilities<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Significant Other<br/>Observable<br/>Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance as of<br/>September 30, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition-related contingent consideration</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i449d405309c143ba85c051e549663c3a_I20220930" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80My9mcmFnOmU5ZDJjOTllOGFlODQ4MDdiZDgxMTY0ZThhOWVkYWU3L3RhYmxlOjgwNGUwODJiMTFlYjQyZDdiM2E2YWY3MWNhMDRjODBjL3RhYmxlcmFuZ2U6ODA0ZTA4MmIxMWViNDJkN2IzYTZhZjcxY2EwNGM4MGNfMi0xLTEtMS04MQ_91f11a4e-a6be-444a-acab-cf54e28f4c4e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06079cbfdc734317994c136835d0952f_I20220930" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80My9mcmFnOmU5ZDJjOTllOGFlODQ4MDdiZDgxMTY0ZThhOWVkYWU3L3RhYmxlOjgwNGUwODJiMTFlYjQyZDdiM2E2YWY3MWNhMDRjODBjL3RhYmxlcmFuZ2U6ODA0ZTA4MmIxMWViNDJkN2IzYTZhZjcxY2EwNGM4MGNfMi0zLTEtMS04MQ_fa0360ca-60d0-4842-97e1-a5a728c0fe7a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3ce7b9a2a1a476b998fe7aa7ef489e2_I20220930" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80My9mcmFnOmU5ZDJjOTllOGFlODQ4MDdiZDgxMTY0ZThhOWVkYWU3L3RhYmxlOjgwNGUwODJiMTFlYjQyZDdiM2E2YWY3MWNhMDRjODBjL3RhYmxlcmFuZ2U6ODA0ZTA4MmIxMWViNDJkN2IzYTZhZjcxY2EwNGM4MGNfMi01LTEtMS04MQ_eaa8915d-0a14-4dfe-a9ca-3562e512ac3b">206,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i281946f958c146b0926f5dd53313b031_I20220930" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80My9mcmFnOmU5ZDJjOTllOGFlODQ4MDdiZDgxMTY0ZThhOWVkYWU3L3RhYmxlOjgwNGUwODJiMTFlYjQyZDdiM2E2YWY3MWNhMDRjODBjL3RhYmxlcmFuZ2U6ODA0ZTA4MmIxMWViNDJkN2IzYTZhZjcxY2EwNGM4MGNfMi03LTEtMS04MQ_9c15157a-ab49-4762-a669-f9572b798c1f">206,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i449d405309c143ba85c051e549663c3a_I20220930" decimals="-3" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80My9mcmFnOmU5ZDJjOTllOGFlODQ4MDdiZDgxMTY0ZThhOWVkYWU3L3RhYmxlOjgwNGUwODJiMTFlYjQyZDdiM2E2YWY3MWNhMDRjODBjL3RhYmxlcmFuZ2U6ODA0ZTA4MmIxMWViNDJkN2IzYTZhZjcxY2EwNGM4MGNfMy0xLTEtMS04MQ_748fb4b0-03dd-4c9b-9d60-64e3ea200786">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06079cbfdc734317994c136835d0952f_I20220930" decimals="-3" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80My9mcmFnOmU5ZDJjOTllOGFlODQ4MDdiZDgxMTY0ZThhOWVkYWU3L3RhYmxlOjgwNGUwODJiMTFlYjQyZDdiM2E2YWY3MWNhMDRjODBjL3RhYmxlcmFuZ2U6ODA0ZTA4MmIxMWViNDJkN2IzYTZhZjcxY2EwNGM4MGNfMy0zLTEtMS04MQ_21bb04c1-ed0b-492a-b861-50b8faf8ea37">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3ce7b9a2a1a476b998fe7aa7ef489e2_I20220930" decimals="-3" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80My9mcmFnOmU5ZDJjOTllOGFlODQ4MDdiZDgxMTY0ZThhOWVkYWU3L3RhYmxlOjgwNGUwODJiMTFlYjQyZDdiM2E2YWY3MWNhMDRjODBjL3RhYmxlcmFuZ2U6ODA0ZTA4MmIxMWViNDJkN2IzYTZhZjcxY2EwNGM4MGNfMy01LTEtMS04MQ_9f3bb8d8-357a-473d-a310-697c94bbff70">206,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i281946f958c146b0926f5dd53313b031_I20220930" decimals="-3" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80My9mcmFnOmU5ZDJjOTllOGFlODQ4MDdiZDgxMTY0ZThhOWVkYWU3L3RhYmxlOjgwNGUwODJiMTFlYjQyZDdiM2E2YWY3MWNhMDRjODBjL3RhYmxlcmFuZ2U6ODA0ZTA4MmIxMWViNDJkN2IzYTZhZjcxY2EwNGM4MGNfMy03LTEtMS04MQ_d03edb7b-fe9f-4e3a-b695-d61fe2dd8c0b">206,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie2ffba3ee5384c86becdb38ff117ca9a_7">Table of Contents</a></span></div></div><ix:continuation id="i8b02e21f3bc64184af40485888f544fc"><div style="margin-top:12pt"><ix:continuation id="i951d752a615f4ddea9b392c8b89197be"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurement at Reporting Date Using:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices in<br/>Active Markets for<br/>Identical Liabilities<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Other<br/>Observable<br/>Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance as of<br/>December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition-related contingent consideration</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia17493513b37495cac5bb47509ffe782_I20211231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80My9mcmFnOmU5ZDJjOTllOGFlODQ4MDdiZDgxMTY0ZThhOWVkYWU3L3RhYmxlOjFhMWE3NzQzZWE1YjRkNjk4NjJjZDBiNjQwMTc2ZTQzL3RhYmxlcmFuZ2U6MWExYTc3NDNlYTViNGQ2OTg2MmNkMGI2NDAxNzZlNDNfMi0xLTEtMS04MQ_836b2cf9-ff71-40a5-9b26-6a0747202ac4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f88761cfe5c4e21a116380b0db0c026_I20211231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80My9mcmFnOmU5ZDJjOTllOGFlODQ4MDdiZDgxMTY0ZThhOWVkYWU3L3RhYmxlOjFhMWE3NzQzZWE1YjRkNjk4NjJjZDBiNjQwMTc2ZTQzL3RhYmxlcmFuZ2U6MWExYTc3NDNlYTViNGQ2OTg2MmNkMGI2NDAxNzZlNDNfMi0zLTEtMS04MQ_9fcbf294-3aa7-480a-9201-861a9b40ac41">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b1ac47dfe8c49068229b687c55c61c7_I20211231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80My9mcmFnOmU5ZDJjOTllOGFlODQ4MDdiZDgxMTY0ZThhOWVkYWU3L3RhYmxlOjFhMWE3NzQzZWE1YjRkNjk4NjJjZDBiNjQwMTc2ZTQzL3RhYmxlcmFuZ2U6MWExYTc3NDNlYTViNGQ2OTg2MmNkMGI2NDAxNzZlNDNfMi01LTEtMS04MQ_621e4c0d-0bc5-4ae8-8658-6a5c78e473ce">244,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09bab9220bbf47b692107d83bc042e87_I20211231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80My9mcmFnOmU5ZDJjOTllOGFlODQ4MDdiZDgxMTY0ZThhOWVkYWU3L3RhYmxlOjFhMWE3NzQzZWE1YjRkNjk4NjJjZDBiNjQwMTc2ZTQzL3RhYmxlcmFuZ2U6MWExYTc3NDNlYTViNGQ2OTg2MmNkMGI2NDAxNzZlNDNfMi03LTEtMS04MQ_657b9689-7ec6-4145-8709-b877f9904376">244,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia17493513b37495cac5bb47509ffe782_I20211231" decimals="-3" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80My9mcmFnOmU5ZDJjOTllOGFlODQ4MDdiZDgxMTY0ZThhOWVkYWU3L3RhYmxlOjFhMWE3NzQzZWE1YjRkNjk4NjJjZDBiNjQwMTc2ZTQzL3RhYmxlcmFuZ2U6MWExYTc3NDNlYTViNGQ2OTg2MmNkMGI2NDAxNzZlNDNfMy0xLTEtMS04MQ_4ee17f61-63ef-414a-a50a-66f902af0bfc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f88761cfe5c4e21a116380b0db0c026_I20211231" decimals="-3" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80My9mcmFnOmU5ZDJjOTllOGFlODQ4MDdiZDgxMTY0ZThhOWVkYWU3L3RhYmxlOjFhMWE3NzQzZWE1YjRkNjk4NjJjZDBiNjQwMTc2ZTQzL3RhYmxlcmFuZ2U6MWExYTc3NDNlYTViNGQ2OTg2MmNkMGI2NDAxNzZlNDNfMy0zLTEtMS04MQ_1b21931c-305d-49eb-8187-e8fd72fb69fc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b1ac47dfe8c49068229b687c55c61c7_I20211231" decimals="-3" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80My9mcmFnOmU5ZDJjOTllOGFlODQ4MDdiZDgxMTY0ZThhOWVkYWU3L3RhYmxlOjFhMWE3NzQzZWE1YjRkNjk4NjJjZDBiNjQwMTc2ZTQzL3RhYmxlcmFuZ2U6MWExYTc3NDNlYTViNGQ2OTg2MmNkMGI2NDAxNzZlNDNfMy01LTEtMS04MQ_21dde53f-aefd-47f3-8363-647ee3782b04">244,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09bab9220bbf47b692107d83bc042e87_I20211231" decimals="-3" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80My9mcmFnOmU5ZDJjOTllOGFlODQ4MDdiZDgxMTY0ZThhOWVkYWU3L3RhYmxlOjFhMWE3NzQzZWE1YjRkNjk4NjJjZDBiNjQwMTc2ZTQzL3RhYmxlcmFuZ2U6MWExYTc3NDNlYTViNGQ2OTg2MmNkMGI2NDAxNzZlNDNfMy03LTEtMS04MQ_1d58347a-6f11-4fb9-8c64-4b0ecdb160bd">244,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><ix:nonNumeric contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80My9mcmFnOmU5ZDJjOTllOGFlODQ4MDdiZDgxMTY0ZThhOWVkYWU3L3RleHRyZWdpb246ZTlkMmM5OWU4YWU4NDgwN2JkODExNjRlOGE5ZWRhZTdfNDA0Mg_d89a0064-bf65-4cff-970c-292c870c0392" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a rollforward of our Level 3 liabilities (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January 1, </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7f1808eadf04e878f5967c1674de235_I20211231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80My9mcmFnOmU5ZDJjOTllOGFlODQ4MDdiZDgxMTY0ZThhOWVkYWU3L3RhYmxlOmMxODFjZGJkMDdlNjQ5MmRiODQ5ZTEwNTYyYWY0NTljL3RhYmxlcmFuZ2U6YzE4MWNkYmQwN2U2NDkyZGI4NDllMTA1NjJhZjQ1OWNfMS0xLTEtMS04MQ_84808e2d-1c54-41d9-b88d-a24645c06031">244,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration earned during the period but not yet paid</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7c9b57b7436547ed808aaf19bca65fb0_D20220101-20220930" decimals="-3" name="incy:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityConsiderationEarned" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80My9mcmFnOmU5ZDJjOTllOGFlODQ4MDdiZDgxMTY0ZThhOWVkYWU3L3RhYmxlOmMxODFjZGJkMDdlNjQ5MmRiODQ5ZTEwNTYyYWY0NTljL3RhYmxlcmFuZ2U6YzE4MWNkYmQwN2U2NDkyZGI4NDllMTA1NjJhZjQ1OWNfMi0xLTEtMS04MQ_86c88e8d-f573-48c3-917a-bd5a1f6a4840">25,802</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7c9b57b7436547ed808aaf19bca65fb0_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80My9mcmFnOmU5ZDJjOTllOGFlODQ4MDdiZDgxMTY0ZThhOWVkYWU3L3RhYmxlOmMxODFjZGJkMDdlNjQ5MmRiODQ5ZTEwNTYyYWY0NTljL3RhYmxlcmFuZ2U6YzE4MWNkYmQwN2U2NDkyZGI4NDllMTA1NjJhZjQ1OWNfMy0xLTEtMS04MQ_a847138f-32d2-4374-add0-5cf70d55ad21">12,198</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30,</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46f205a751e14f70bdffe84975b9278e_I20220930" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80My9mcmFnOmU5ZDJjOTllOGFlODQ4MDdiZDgxMTY0ZThhOWVkYWU3L3RhYmxlOmMxODFjZGJkMDdlNjQ5MmRiODQ5ZTEwNTYyYWY0NTljL3RhYmxlcmFuZ2U6YzE4MWNkYmQwN2U2NDkyZGI4NDllMTA1NjJhZjQ1OWNfNC0xLTEtMS04MQ_de20677c-b785-47d5-a6ee-a4f5c0c68678">206,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the contingent consideration was determined on the date of acquisition, June&#160;1, 2016, using an income approach based on projected future net revenues of ICLUSIG in the European Union and other countries for the approved third line treatment over <ix:nonNumeric contextRef="i65e0cbcc9a1c4a45843cde84fd23371f_D20160601-20160601" name="incy:FairValueInputsCashFlowsEstimatedPeriod" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80My9mcmFnOmU5ZDJjOTllOGFlODQ4MDdiZDgxMTY0ZThhOWVkYWU3L3RleHRyZWdpb246ZTlkMmM5OWU4YWU4NDgwN2JkODExNjRlOGE5ZWRhZTdfMzAzNQ_c1b06d7b-bb14-4af6-a041-fd310318ebf2">18</ix:nonNumeric> years, and discounted to present value at a rate of <ix:nonFraction unitRef="number" contextRef="ide8e43b5e4774c2b80fc1d692ccd6c5f_I20160601" decimals="2" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80My9mcmFnOmU5ZDJjOTllOGFlODQ4MDdiZDgxMTY0ZThhOWVkYWU3L3RleHRyZWdpb246ZTlkMmM5OWU4YWU4NDgwN2JkODExNjRlOGE5ZWRhZTdfMzA4NA_811e20b1-56a7-443d-9ce7-41725b388ebb">10</ix:nonFraction>%. The fair value of the contingent consideration is remeasured each reporting period, with changes in fair value recorded in the condensed consolidated statements of operations. The valuation inputs utilized to estimate the fair value of the contingent consideration as of September&#160;30, 2022 and December&#160;31, 2021 included a discount rate of <ix:nonFraction unitRef="number" contextRef="i4769291f7a5e4844bdea08699b901a87_I20211231" decimals="2" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80My9mcmFnOmU5ZDJjOTllOGFlODQ4MDdiZDgxMTY0ZThhOWVkYWU3L3RleHRyZWdpb246ZTlkMmM5OWU4YWU4NDgwN2JkODExNjRlOGE5ZWRhZTdfMzM5OA_8d43167e-eea9-4c1f-8b73-8367cda1e942"><ix:nonFraction unitRef="number" contextRef="i9dff9f829b91403384e43e22034102b6_I20220930" decimals="2" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80My9mcmFnOmU5ZDJjOTllOGFlODQ4MDdiZDgxMTY0ZThhOWVkYWU3L3RleHRyZWdpb246ZTlkMmM5OWU4YWU4NDgwN2JkODExNjRlOGE5ZWRhZTdfMzM5OA_e9c3e9c5-e6da-404b-a5fa-568359f19f2e">10</ix:nonFraction></ix:nonFraction>% and updated projections of future net revenues of ICLUSIG in the European Union and other countries for the approved third line treatment. The gain on change in fair value of the contingent consideration during the three and nine months ended September&#160;30, 2022 was due primarily to the changes in foreign currency exchange rates included within the updated projections of future net revenues of ICLUSIG.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generally make payments to Takeda Pharmaceutical Company Limited quarterly based on the royalties or any additional milestone payments earned in the previous quarter. At September&#160;30, 2022 and December&#160;31, 2021, contingent consideration earned but not yet paid was $<ix:nonFraction unitRef="usd" contextRef="i651332485f95471bbc1f9997619b54c7_D20220101-20220930" decimals="-5" name="incy:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityConsiderationEarned" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80My9mcmFnOmU5ZDJjOTllOGFlODQ4MDdiZDgxMTY0ZThhOWVkYWU3L3RleHRyZWdpb246ZTlkMmM5OWU4YWU4NDgwN2JkODExNjRlOGE5ZWRhZTdfMzk1Ng_aca704c0-0d60-49ea-b122-e4ea91fb9654">25.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i8495b4244f744fd78c9b5dadcfa77dc2_D20210101-20211231" decimals="-5" name="incy:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityConsiderationEarned" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80My9mcmFnOmU5ZDJjOTllOGFlODQ4MDdiZDgxMTY0ZThhOWVkYWU3L3RleHRyZWdpb246ZTlkMmM5OWU4YWU4NDgwN2JkODExNjRlOGE5ZWRhZTdfMzk2Mw_8bd19288-3dd4-425d-847c-6ae1b1f2a0e0">19.6</ix:nonFraction> million, respectively, and was included in accrued and other current liabilities.</span></div></ix:continuation><div id="ie2ffba3ee5384c86becdb38ff117ca9a_46"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 5. Concentration of Credit Risk and Current Expected Credit Losses</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><ix:nonNumeric contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930" name="us-gaap:ConcentrationRiskDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80Ni9mcmFnOjA1ZTZhN2Q0ODZjZjRhMDBiZDMzMzEyMDk5Y2NmNTI4L3RleHRyZWdpb246MDVlNmE3ZDQ4NmNmNGEwMGJkMzMzMTIwOTljY2Y1MjhfMjAzNg_a400fce3-ddd4-46b4-a62f-708bf299e3e9" continuedAt="i42e1fb65ea884bcd8abe0d03f8004cd0" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2009, we entered into a collaboration and license agreement with Novartis Pharmaceutical International Ltd. (&#8220;Novartis&#8221;). In December 2009, we entered into a license, development and commercialization agreement with Eli Lilly and Company (&#8220;Lilly&#8221;). In December 2018, we entered into a research collaboration and licensing agreement with Innovent Biologics, Inc. (&#8220;Innovent&#8221;). In July 2019, we entered into a collaboration and license agreement with Zai Lab (Shanghai) Co., Ltd., a subsidiary of Zai Lab Limited (collectively, &#8220;Zai Lab&#8221;). The above collaboration partners comprised, in aggregate, <ix:nonFraction unitRef="number" contextRef="i683a8a412ece4de6b78e4947fd25373a_D20220101-20220930" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80Ni9mcmFnOjA1ZTZhN2Q0ODZjZjRhMDBiZDMzMzEyMDk5Y2NmNTI4L3RleHRyZWdpb246MDVlNmE3ZDQ4NmNmNGEwMGJkMzMzMTIwOTljY2Y1MjhfNjg2_ab3f8eef-5679-4433-b3ed-eeed22b0d064">19</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i1ed3ff5544594900b92ac9213a97bb21_D20210101-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80Ni9mcmFnOjA1ZTZhN2Q0ODZjZjRhMDBiZDMzMzEyMDk5Y2NmNTI4L3RleHRyZWdpb246MDVlNmE3ZDQ4NmNmNGEwMGJkMzMzMTIwOTljY2Y1MjhfNjk0_b568484f-1a68-4db7-b5cc-84d847f0c884">36</ix:nonFraction>% of the accounts receivable balance as of September&#160;30, 2022 and December&#160;31, 2021, respectively. For further information relating to these collaboration and license agreements,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">refer to Note 7.</span></ix:nonNumeric></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie2ffba3ee5384c86becdb38ff117ca9a_7">Table of Contents</a></span></div></div><ix:continuation id="i42e1fb65ea884bcd8abe0d03f8004cd0"><ix:nonNumeric contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930" name="incy:SchedulesOfConcentrationOfRiskByRiskFactorRelatedToCollaborativePartnersTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80Ni9mcmFnOjA1ZTZhN2Q0ODZjZjRhMDBiZDMzMzEyMDk5Y2NmNTI4L3RleHRyZWdpb246MDVlNmE3ZDQ4NmNmNGEwMGJkMzMzMTIwOTljY2Y1MjhfMjAzNw_304b7207-db09-46c0-83ef-67e9e4b26033" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2011, we began commercialization and distribution of JAKAFI, in April 2020, we began commercialization and distribution of PEMAZYRE, and in October 2021, we began commercialization and distribution of OPZELURA. Our product revenues are concentrated in a number of these customers. The concentration of credit risk related to our JAKAFI, PEMAZYRE and OPZELURA product revenues is as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Percentage of Total Net<br/>Product Revenues for the<br/>Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Percentage of Total Net<br/>Product Revenues for the<br/>Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer A</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3dc5046f317541c88021a56d36951298_D20220701-20220930" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80Ni9mcmFnOjA1ZTZhN2Q0ODZjZjRhMDBiZDMzMzEyMDk5Y2NmNTI4L3RhYmxlOjMzMjQ5OGRmOTQxMTQxMjhiODkwNDNjMzkwMmM5ZThhL3RhYmxlcmFuZ2U6MzMyNDk4ZGY5NDExNDEyOGI4OTA0M2MzOTAyYzllOGFfMy0xLTEtMS04MQ_744e7657-980d-4177-9990-8e4e77e4568f">19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib26d36095867409f925663486648772f_D20210701-20210930" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80Ni9mcmFnOjA1ZTZhN2Q0ODZjZjRhMDBiZDMzMzEyMDk5Y2NmNTI4L3RhYmxlOjMzMjQ5OGRmOTQxMTQxMjhiODkwNDNjMzkwMmM5ZThhL3RhYmxlcmFuZ2U6MzMyNDk4ZGY5NDExNDEyOGI4OTA0M2MzOTAyYzllOGFfMy0zLTEtMS04MQ_2a3b88d7-a0a2-4954-b336-15951c1980a1">19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i162968d5dc8e4fd680e4dc463271dc4b_D20220101-20220930" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80Ni9mcmFnOjA1ZTZhN2Q0ODZjZjRhMDBiZDMzMzEyMDk5Y2NmNTI4L3RhYmxlOjMzMjQ5OGRmOTQxMTQxMjhiODkwNDNjMzkwMmM5ZThhL3RhYmxlcmFuZ2U6MzMyNDk4ZGY5NDExNDEyOGI4OTA0M2MzOTAyYzllOGFfMy01LTEtMS04MQ_38fb9bc3-210e-4c84-9788-7bb29293b7b9">19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iefe171c3e83a4f289b8aae022d0e081b_D20210101-20210930" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80Ni9mcmFnOjA1ZTZhN2Q0ODZjZjRhMDBiZDMzMzEyMDk5Y2NmNTI4L3RhYmxlOjMzMjQ5OGRmOTQxMTQxMjhiODkwNDNjMzkwMmM5ZThhL3RhYmxlcmFuZ2U6MzMyNDk4ZGY5NDExNDEyOGI4OTA0M2MzOTAyYzllOGFfMy03LTEtMS04MQ_433fd3ca-59cf-4f97-a23b-17c5c40ee63e">19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer B</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ifb602509071647998b5e683e940d1fcf_D20220701-20220930" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80Ni9mcmFnOjA1ZTZhN2Q0ODZjZjRhMDBiZDMzMzEyMDk5Y2NmNTI4L3RhYmxlOjMzMjQ5OGRmOTQxMTQxMjhiODkwNDNjMzkwMmM5ZThhL3RhYmxlcmFuZ2U6MzMyNDk4ZGY5NDExNDEyOGI4OTA0M2MzOTAyYzllOGFfNC0xLTEtMS04MQ_c6427519-87f9-4d9d-b15f-98c3ab36b566">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia8a7e40409944fc78088cd4baed567ac_D20210701-20210930" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80Ni9mcmFnOjA1ZTZhN2Q0ODZjZjRhMDBiZDMzMzEyMDk5Y2NmNTI4L3RhYmxlOjMzMjQ5OGRmOTQxMTQxMjhiODkwNDNjMzkwMmM5ZThhL3RhYmxlcmFuZ2U6MzMyNDk4ZGY5NDExNDEyOGI4OTA0M2MzOTAyYzllOGFfNC0zLTEtMS04MQ_292b6fb9-0f0a-4aa7-8a85-f4c14aa87396">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia8ee030161c64a7e9c95b4e2fb66c573_D20220101-20220930" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80Ni9mcmFnOjA1ZTZhN2Q0ODZjZjRhMDBiZDMzMzEyMDk5Y2NmNTI4L3RhYmxlOjMzMjQ5OGRmOTQxMTQxMjhiODkwNDNjMzkwMmM5ZThhL3RhYmxlcmFuZ2U6MzMyNDk4ZGY5NDExNDEyOGI4OTA0M2MzOTAyYzllOGFfNC01LTEtMS04MQ_ea0c4661-dc0e-42db-b3cd-9931976994ea">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8d5936e96208421793937f792f73038d_D20210101-20210930" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80Ni9mcmFnOjA1ZTZhN2Q0ODZjZjRhMDBiZDMzMzEyMDk5Y2NmNTI4L3RhYmxlOjMzMjQ5OGRmOTQxMTQxMjhiODkwNDNjMzkwMmM5ZThhL3RhYmxlcmFuZ2U6MzMyNDk4ZGY5NDExNDEyOGI4OTA0M2MzOTAyYzllOGFfNC03LTEtMS04MQ_4c06f2c0-0670-4af4-afc9-83eaddac834a">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer C</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4b1f09000aa74166ade05d1c0dcfedd2_D20220701-20220930" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80Ni9mcmFnOjA1ZTZhN2Q0ODZjZjRhMDBiZDMzMzEyMDk5Y2NmNTI4L3RhYmxlOjMzMjQ5OGRmOTQxMTQxMjhiODkwNDNjMzkwMmM5ZThhL3RhYmxlcmFuZ2U6MzMyNDk4ZGY5NDExNDEyOGI4OTA0M2MzOTAyYzllOGFfNS0xLTEtMS04MQ_f5dd05ba-53b3-48da-a700-822029565f42">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1df4e17ddac14778b89ab7f884e13730_D20210701-20210930" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80Ni9mcmFnOjA1ZTZhN2Q0ODZjZjRhMDBiZDMzMzEyMDk5Y2NmNTI4L3RhYmxlOjMzMjQ5OGRmOTQxMTQxMjhiODkwNDNjMzkwMmM5ZThhL3RhYmxlcmFuZ2U6MzMyNDk4ZGY5NDExNDEyOGI4OTA0M2MzOTAyYzllOGFfNS0zLTEtMS04MQ_f917bdd1-a6b6-4402-86b0-24f0b752f084">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iab7d5e90e123422ea957f7b149d1df86_D20220101-20220930" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80Ni9mcmFnOjA1ZTZhN2Q0ODZjZjRhMDBiZDMzMzEyMDk5Y2NmNTI4L3RhYmxlOjMzMjQ5OGRmOTQxMTQxMjhiODkwNDNjMzkwMmM5ZThhL3RhYmxlcmFuZ2U6MzMyNDk4ZGY5NDExNDEyOGI4OTA0M2MzOTAyYzllOGFfNS01LTEtMS04MQ_6788b9eb-6ef3-4acd-8ffd-4f7bb09cbe20">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0cc4497fd77b42f18587cdf09d459c05_D20210101-20210930" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80Ni9mcmFnOjA1ZTZhN2Q0ODZjZjRhMDBiZDMzMzEyMDk5Y2NmNTI4L3RhYmxlOjMzMjQ5OGRmOTQxMTQxMjhiODkwNDNjMzkwMmM5ZThhL3RhYmxlcmFuZ2U6MzMyNDk4ZGY5NDExNDEyOGI4OTA0M2MzOTAyYzllOGFfNS03LTEtMS04MQ_b552c8c8-9e8a-4aba-84c5-b21e3c9692ba">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer D</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1fae7539f0da469083ea910f00e0898b_D20220701-20220930" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80Ni9mcmFnOjA1ZTZhN2Q0ODZjZjRhMDBiZDMzMzEyMDk5Y2NmNTI4L3RhYmxlOjMzMjQ5OGRmOTQxMTQxMjhiODkwNDNjMzkwMmM5ZThhL3RhYmxlcmFuZ2U6MzMyNDk4ZGY5NDExNDEyOGI4OTA0M2MzOTAyYzllOGFfNi0xLTEtMS04MQ_7ae78a42-ab12-44e0-8dc4-fb5390ae8d53">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia675debc1ef84ae2b8ec00b9932e707b_D20210701-20210930" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80Ni9mcmFnOjA1ZTZhN2Q0ODZjZjRhMDBiZDMzMzEyMDk5Y2NmNTI4L3RhYmxlOjMzMjQ5OGRmOTQxMTQxMjhiODkwNDNjMzkwMmM5ZThhL3RhYmxlcmFuZ2U6MzMyNDk4ZGY5NDExNDEyOGI4OTA0M2MzOTAyYzllOGFfNi0zLTEtMS04MQ_a66ce566-3cf9-4c4b-83eb-33b1d9e59d21">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iaebef62b75f545d4bddd48699efd1ed1_D20220101-20220930" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80Ni9mcmFnOjA1ZTZhN2Q0ODZjZjRhMDBiZDMzMzEyMDk5Y2NmNTI4L3RhYmxlOjMzMjQ5OGRmOTQxMTQxMjhiODkwNDNjMzkwMmM5ZThhL3RhYmxlcmFuZ2U6MzMyNDk4ZGY5NDExNDEyOGI4OTA0M2MzOTAyYzllOGFfNi01LTEtMS04MQ_139b690a-ed40-4a97-b826-a2d59b681552">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie150bdc7743d4425a27721647c883684_D20210101-20210930" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80Ni9mcmFnOjA1ZTZhN2Q0ODZjZjRhMDBiZDMzMzEyMDk5Y2NmNTI4L3RhYmxlOjMzMjQ5OGRmOTQxMTQxMjhiODkwNDNjMzkwMmM5ZThhL3RhYmxlcmFuZ2U6MzMyNDk4ZGY5NDExNDEyOGI4OTA0M2MzOTAyYzllOGFfNi03LTEtMS04MQ_e8fc0e09-f184-44f6-a737-7bf866bd1827">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer E</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i35e2fb28114f48528d3537b9bb4d377b_D20220701-20220930" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80Ni9mcmFnOjA1ZTZhN2Q0ODZjZjRhMDBiZDMzMzEyMDk5Y2NmNTI4L3RhYmxlOjMzMjQ5OGRmOTQxMTQxMjhiODkwNDNjMzkwMmM5ZThhL3RhYmxlcmFuZ2U6MzMyNDk4ZGY5NDExNDEyOGI4OTA0M2MzOTAyYzllOGFfNy0xLTEtMS04MQ_8b1f2bb9-9a82-412d-87c3-4601341036d7">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7fb6ed6fc01c49089fc6fbcbb460178a_D20210701-20210930" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80Ni9mcmFnOjA1ZTZhN2Q0ODZjZjRhMDBiZDMzMzEyMDk5Y2NmNTI4L3RhYmxlOjMzMjQ5OGRmOTQxMTQxMjhiODkwNDNjMzkwMmM5ZThhL3RhYmxlcmFuZ2U6MzMyNDk4ZGY5NDExNDEyOGI4OTA0M2MzOTAyYzllOGFfNy0zLTEtMS04MQ_da6fee56-35d5-433e-8137-087206b2a132">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0324e502e8e841449b5689a5c7c6f0ff_D20220101-20220930" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80Ni9mcmFnOjA1ZTZhN2Q0ODZjZjRhMDBiZDMzMzEyMDk5Y2NmNTI4L3RhYmxlOjMzMjQ5OGRmOTQxMTQxMjhiODkwNDNjMzkwMmM5ZThhL3RhYmxlcmFuZ2U6MzMyNDk4ZGY5NDExNDEyOGI4OTA0M2MzOTAyYzllOGFfNy01LTEtMS04MQ_f0cc92d5-36fa-4cf9-849a-1d8843bd83d6">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i589bb0c60aaa4a43b9a3cb4f9adb92ce_D20210101-20210930" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80Ni9mcmFnOjA1ZTZhN2Q0ODZjZjRhMDBiZDMzMzEyMDk5Y2NmNTI4L3RhYmxlOjMzMjQ5OGRmOTQxMTQxMjhiODkwNDNjMzkwMmM5ZThhL3RhYmxlcmFuZ2U6MzMyNDk4ZGY5NDExNDEyOGI4OTA0M2MzOTAyYzllOGFfNy03LTEtMS04MQ_721d37b8-88d5-45f3-9a21-5decaccdb217">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to risks associated with extending credit to customers related to the sale of products. Customers A, B, C, D and E comprised, in aggregate, <ix:nonFraction unitRef="number" contextRef="idb10cbad0c1345b9be3e38c62201ded7_D20220101-20220930" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80Ni9mcmFnOjA1ZTZhN2Q0ODZjZjRhMDBiZDMzMzEyMDk5Y2NmNTI4L3RleHRyZWdpb246MDVlNmE3ZDQ4NmNmNGEwMGJkMzMzMTIwOTljY2Y1MjhfMjc0ODc3OTA3MTU3Mg_a8f83248-17a0-48d4-9b03-6745d530440f">36</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="ia6ac11b8a7e34e69a3ca81e7967cd4db_D20210101-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80Ni9mcmFnOjA1ZTZhN2Q0ODZjZjRhMDBiZDMzMzEyMDk5Y2NmNTI4L3RleHRyZWdpb246MDVlNmE3ZDQ4NmNmNGEwMGJkMzMzMTIwOTljY2Y1MjhfMTQ0NQ_549a57a9-d4c5-43ee-8822-eb588b3e723d">31</ix:nonFraction>% of the accounts receivable balance as of September&#160;30, 2022 and December&#160;31, 2021, respectively. The concentration of credit risk relating to our other product revenues or accounts receivable is not significant.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assessed our collaborative and customer receivable assets as of September&#160;30, 2022 according to our accounting policy for applying reserves for expected credit losses, noting minimal history of uncollectible receivables and the continued perceived creditworthiness of our third party sales relationships, upon which the expected credit losses were considered de minimis. As of September&#160;30, 2022 and December&#160;31, 2021, we had <ix:nonFraction unitRef="usd" contextRef="i3b4376f8fc614de98c9cf647198c504e_I20220930" decimals="-5" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80Ni9mcmFnOjA1ZTZhN2Q0ODZjZjRhMDBiZDMzMzEyMDk5Y2NmNTI4L3RleHRyZWdpb246MDVlNmE3ZDQ4NmNmNGEwMGJkMzMzMTIwOTljY2Y1MjhfMjAwMg_ad520e3d-f0d0-4a17-bc98-e3eeff7bc945"><ix:nonFraction unitRef="usd" contextRef="iab26fe441f0d4ab984456365a7f7cff0_I20211231" decimals="-5" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80Ni9mcmFnOjA1ZTZhN2Q0ODZjZjRhMDBiZDMzMzEyMDk5Y2NmNTI4L3RleHRyZWdpb246MDVlNmE3ZDQ4NmNmNGEwMGJkMzMzMTIwOTljY2Y1MjhfMjAwMg_da0774b3-7857-4ca1-91ac-d1ccb80af192">no</ix:nonFraction></ix:nonFraction> allowance for doubtful accounts.</span></div></ix:continuation><div id="ie2ffba3ee5384c86becdb38ff117ca9a_49"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 6. Inventory</span></div><ix:nonNumeric contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930" name="us-gaap:InventoryDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80OS9mcmFnOjRlZjZkOWQ4ZTExMjQ1NjFiMWFmZGYwNDk0OWQ4OWYxL3RleHRyZWdpb246NGVmNmQ5ZDhlMTEyNDU2MWIxYWZkZjA0OTQ5ZDg5ZjFfMTU2OA_bf33dabc-e105-4e3e-8b64-46fdac16fb0c" continuedAt="i76832e7efa7841cf9a282218879f2fa7" escape="true"><ix:nonNumeric contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930" name="incy:ScheduleOfInventoryTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80OS9mcmFnOjRlZjZkOWQ4ZTExMjQ1NjFiMWFmZGYwNDk0OWQ4OWYxL3RleHRyZWdpb246NGVmNmQ5ZDhlMTEyNDU2MWIxYWZkZjA0OTQ5ZDg5ZjFfMTU2OQ_02f1df61-6d38-491e-bfcb-7b328fe39b44" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our inventory balance consists of the following (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b4376f8fc614de98c9cf647198c504e_I20220930" decimals="-3" name="us-gaap:InventoryRawMaterialsNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80OS9mcmFnOjRlZjZkOWQ4ZTExMjQ1NjFiMWFmZGYwNDk0OWQ4OWYxL3RhYmxlOmEzMzJhN2ZlMjZhZjQwYjNiZmU0MDg2MjA4NDBjYmRiL3RhYmxlcmFuZ2U6YTMzMmE3ZmUyNmFmNDBiM2JmZTQwODYyMDg0MGNiZGJfMS0xLTEtMS04MQ_dcdebcbb-8548-4365-b354-d4c446000232">32,289</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab26fe441f0d4ab984456365a7f7cff0_I20211231" decimals="-3" name="us-gaap:InventoryRawMaterialsNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80OS9mcmFnOjRlZjZkOWQ4ZTExMjQ1NjFiMWFmZGYwNDk0OWQ4OWYxL3RhYmxlOmEzMzJhN2ZlMjZhZjQwYjNiZmU0MDg2MjA4NDBjYmRiL3RhYmxlcmFuZ2U6YTMzMmE3ZmUyNmFmNDBiM2JmZTQwODYyMDg0MGNiZGJfMS0zLTEtMS04MQ_7e12962a-d5cc-4076-ab17-08daf7829218">1,275</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b4376f8fc614de98c9cf647198c504e_I20220930" decimals="-3" name="us-gaap:InventoryWorkInProcessNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80OS9mcmFnOjRlZjZkOWQ4ZTExMjQ1NjFiMWFmZGYwNDk0OWQ4OWYxL3RhYmxlOmEzMzJhN2ZlMjZhZjQwYjNiZmU0MDg2MjA4NDBjYmRiL3RhYmxlcmFuZ2U6YTMzMmE3ZmUyNmFmNDBiM2JmZTQwODYyMDg0MGNiZGJfMi0xLTEtMS04MQ_8b51c554-984b-4fc6-8fd6-947a66b22771">35,465</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab26fe441f0d4ab984456365a7f7cff0_I20211231" decimals="-3" name="us-gaap:InventoryWorkInProcessNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80OS9mcmFnOjRlZjZkOWQ4ZTExMjQ1NjFiMWFmZGYwNDk0OWQ4OWYxL3RhYmxlOmEzMzJhN2ZlMjZhZjQwYjNiZmU0MDg2MjA4NDBjYmRiL3RhYmxlcmFuZ2U6YTMzMmE3ZmUyNmFmNDBiM2JmZTQwODYyMDg0MGNiZGJfMi0zLTEtMS04MQ_89cf84b6-b9e6-497e-ae66-27ca6022f9c9">39,895</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b4376f8fc614de98c9cf647198c504e_I20220930" decimals="-3" name="us-gaap:InventoryFinishedGoodsNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80OS9mcmFnOjRlZjZkOWQ4ZTExMjQ1NjFiMWFmZGYwNDk0OWQ4OWYxL3RhYmxlOmEzMzJhN2ZlMjZhZjQwYjNiZmU0MDg2MjA4NDBjYmRiL3RhYmxlcmFuZ2U6YTMzMmE3ZmUyNmFmNDBiM2JmZTQwODYyMDg0MGNiZGJfMy0xLTEtMS04MQ_6da1d5d6-36b4-46fd-96d8-abf9be137b7f">33,379</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab26fe441f0d4ab984456365a7f7cff0_I20211231" decimals="-3" name="us-gaap:InventoryFinishedGoodsNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80OS9mcmFnOjRlZjZkOWQ4ZTExMjQ1NjFiMWFmZGYwNDk0OWQ4OWYxL3RhYmxlOmEzMzJhN2ZlMjZhZjQwYjNiZmU0MDg2MjA4NDBjYmRiL3RhYmxlcmFuZ2U6YTMzMmE3ZmUyNmFmNDBiM2JmZTQwODYyMDg0MGNiZGJfMy0zLTEtMS04MQ_b4a2f260-96bd-426d-b6ee-368d5900fdb7">15,768</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventory</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b4376f8fc614de98c9cf647198c504e_I20220930" decimals="-3" name="incy:InventoryNetCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80OS9mcmFnOjRlZjZkOWQ4ZTExMjQ1NjFiMWFmZGYwNDk0OWQ4OWYxL3RhYmxlOmEzMzJhN2ZlMjZhZjQwYjNiZmU0MDg2MjA4NDBjYmRiL3RhYmxlcmFuZ2U6YTMzMmE3ZmUyNmFmNDBiM2JmZTQwODYyMDg0MGNiZGJfNC0xLTEtMS04MQ_706c2491-5909-41a5-809c-d8ba2dd74c03">101,133</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab26fe441f0d4ab984456365a7f7cff0_I20211231" decimals="-3" name="incy:InventoryNetCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80OS9mcmFnOjRlZjZkOWQ4ZTExMjQ1NjFiMWFmZGYwNDk0OWQ4OWYxL3RhYmxlOmEzMzJhN2ZlMjZhZjQwYjNiZmU0MDg2MjA4NDBjYmRiL3RhYmxlcmFuZ2U6YTMzMmE3ZmUyNmFmNDBiM2JmZTQwODYyMDg0MGNiZGJfNC0zLTEtMS04MQ_4556f752-9c40-45ac-8315-ca88352ce8cc">56,938</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories, stated at the lower of cost and net realizable value, consist of raw materials, work in process and finished goods. At September&#160;30, 2022, $<ix:nonFraction unitRef="usd" contextRef="i3b4376f8fc614de98c9cf647198c504e_I20220930" decimals="-5" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80OS9mcmFnOjRlZjZkOWQ4ZTExMjQ1NjFiMWFmZGYwNDk0OWQ4OWYxL3RleHRyZWdpb246NGVmNmQ5ZDhlMTEyNDU2MWIxYWZkZjA0OTQ5ZDg5ZjFfMjI1_ebbecdb4-26c9-4d83-b94d-769efb8410c7">45.9</ix:nonFraction> million of inventory was classified as current on the condensed consolidated balance sheet as we expect this inventory to be consumed for commercial use within the next twelve months. At September&#160;30, 2022, $<ix:nonFraction unitRef="usd" contextRef="i3b4376f8fc614de98c9cf647198c504e_I20220930" decimals="-5" name="us-gaap:InventoryNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80OS9mcmFnOjRlZjZkOWQ4ZTExMjQ1NjFiMWFmZGYwNDk0OWQ4OWYxL3RleHRyZWdpb246NGVmNmQ5ZDhlMTEyNDU2MWIxYWZkZjA0OTQ5ZDg5ZjFfNDEx_66d16c9d-3ae8-400a-8ae6-983e418c0c47">55.3</ix:nonFraction> million of inventory was classified as non-current on the condensed consolidated balance sheet as we did not expect this inventory to be consumed for commercial use within the next twelve months. We obtain some inventory components from a limited number of suppliers due to technology, availability, price, quality or other considerations. The loss of a supplier, the deterioration of our relationship with a supplier, or any unilateral violation of the contractual terms under which we are supplied components by a supplier could adversely affect our total revenues and gross margins.</span></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i76832e7efa7841cf9a282218879f2fa7">We capitalize inventory after U.S. Food and Drug Administration (FDA) approval as the related costs are expected to be recoverable through the commercialization of the product. Costs incurred prior to FDA approval are recorded as research and development expense in our statements of operations. At September&#160;30, 2022, inventory with approximately $<ix:nonFraction unitRef="usd" contextRef="i3b4376f8fc614de98c9cf647198c504e_I20220930" decimals="-5" name="incy:InventoryRecordedAsResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80OS9mcmFnOjRlZjZkOWQ4ZTExMjQ1NjFiMWFmZGYwNDk0OWQ4OWYxL3RleHRyZWdpb246NGVmNmQ5ZDhlMTEyNDU2MWIxYWZkZjA0OTQ5ZDg5ZjFfMTMyNA_40ce8814-d52e-4dcc-8334-d2fa13699701">56.8</ix:nonFraction> million of product costs incurred prior to FDA approval had not yet been sold. We expect to sell the pre-commercialization inventory over the next <ix:nonNumeric contextRef="i7ea3b32b349549ab8ef8819fd6f23c57_D20220101-20220930" name="incy:PeriodOfDeviationFromAverageCostOfGoodsSold" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80OS9mcmFnOjRlZjZkOWQ4ZTExMjQ1NjFiMWFmZGYwNDk0OWQ4OWYxL3RleHRyZWdpb246NGVmNmQ5ZDhlMTEyNDU2MWIxYWZkZjA0OTQ5ZDg5ZjFfMTQ2Ng_20a2c3ff-9391-484b-ae3d-724276f34d41">28</ix:nonNumeric> months and, as a result, cost of product revenues will reflect a lower average per unit cost of materials.</ix:continuation> </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">13</span></div></div></div><div id="ie2ffba3ee5384c86becdb38ff117ca9a_52"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie2ffba3ee5384c86becdb38ff117ca9a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 7. License Agreements</span></div><ix:nonNumeric contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930" name="incy:LicenseAgreementsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMzg0ODI5MDgxODYzMg_fc868bab-f4b9-4ab1-bd06-38bca590a86a" continuedAt="icdae8bb3b8364921a1ea14c8b7d9ef86" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Novartis</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2009, we entered into a Collaboration and License Agreement with Novartis. Under the terms of the agreement, Novartis received exclusive development and commercialization rights outside of the United States to our JAK inhibitor ruxolitinib and certain back-up compounds for hematologic and oncology indications, including all hematological malignancies, solid tumors and myeloproliferative diseases. We retained exclusive development and commercialization rights to JAKAFI (ruxolitinib) in the United States and in certain other indications. Novartis also received worldwide exclusive development and commercialization rights to our MET inhibitor compound capmatinib and certain back-up compounds in all indications.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under this agreement, we were initially eligible to receive up to $<ix:nonFraction unitRef="usd" contextRef="i1be6071c11dc4f5baede897a7c3899d8_D20091101-20091130" decimals="-5" name="incy:LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfODI1_f44bb478-267e-46d5-b796-aef0c956d174">174.0</ix:nonFraction> million for the achievement of development milestones, up to $<ix:nonFraction unitRef="usd" contextRef="i820b7b86437a49c2992e40c5dc8911be_D20091101-20091130" decimals="-5" name="incy:LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfODgy_a7ace47e-c7f2-4efc-9363-5d1f7f4f509b">495.0</ix:nonFraction> million for the achievement of regulatory milestones and up to $<ix:nonFraction unitRef="usd" contextRef="ic2d99eb0d2fc48a4a62cef1d76a3b8fa_D20091101-20091130" decimals="-5" name="incy:LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfOTQw_413d1127-5909-45a9-97a9-d25e82fd8f82">500.0</ix:nonFraction> million for the achievement of sales milestones. In addition, under an amendment to this agreement, we were initially eligible to receive up to $<ix:nonFraction unitRef="usd" contextRef="i05006b85a9704e02902b03623fc8c5f7_D20220101-20220930" decimals="-5" name="incy:LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMTAzMA_25f486ca-0a6c-4e25-8067-b2d180345676">75.0</ix:nonFraction> million of additional potential development and regulatory milestones relating to graft-versus-host-disease (&#8220;GVHD&#8221;). We have recognized and received, in the aggregate, $<ix:nonFraction unitRef="usd" contextRef="ia6687beeb4034e3bbce66e159508b36e_D20091101-20220930" decimals="-5" name="incy:LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMTE5NA_8035000c-89ee-4eb5-9ac3-ae670b8b1769">157.0</ix:nonFraction> million for the achievement of development milestones, $<ix:nonFraction unitRef="usd" contextRef="ieaa23329fa064e728b6bab53e01e305b_D20091101-20220930" decimals="-5" name="incy:LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMTI0NA_ca55c87c-b5f1-48d1-a4c1-6509a5a1fadd">340.0</ix:nonFraction> million for the achievement of regulatory milestones, and $<ix:nonFraction unitRef="usd" contextRef="i50b34d5e81624a7b80626a7696d9e0d1_D20091101-20220930" decimals="-5" name="incy:LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMTI5Nw_c16a3517-fd15-46bc-9f6a-6876ad1cee18">200.0</ix:nonFraction> million for the achievement of sales milestones through September&#160;30, 2022. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2022, we recognized a $<ix:nonFraction unitRef="usd" contextRef="i7de6dcd9947241819b8f342b010b13b8_D20220401-20220430" decimals="-5" name="incy:LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMTM3Nw_8faa5a5e-84c1-4a12-898e-cde61bd21802">15.0</ix:nonFraction> million regulatory milestone for the positive opinion issued by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) that recommends granting marketing authorization for capmatinib (TABRECTA) as a monotherapy for the treatment of adults with advanced non-small cell lung cancer. Additionally, in May 2022, we recognized a $<ix:nonFraction unitRef="usd" contextRef="i3447a97d263a4e71b726a6da1a319017_D20220501-20220531" decimals="-5" name="incy:LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMTczMg_1ad1b1f5-abcc-4181-9a80-508647ae13c9">45.0</ix:nonFraction> million regulatory milestone as a result of the European Commission&#8217;s approval of JAKAVI (ruxolitinib) as the first post-steroid treatment for acute and chronic GVHD.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also are eligible to receive tiered, double-digit royalties ranging from the upper-teens to the mid-twenties on future JAKAVI net sales outside of the United States, and tiered, worldwide royalties on TABRECTA net sales that range from <ix:nonFraction unitRef="number" contextRef="if75967c7131848209fa546f5389ff144_D20220101-20220930" decimals="2" name="incy:PercentageOfRoyaltyRatePayments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMjEzMw_9fdce69e-f34b-4a3c-9285-2e65315c6223">12</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i949fa939c8164aa79569420d1f965a48_D20220101-20220930" decimals="2" name="incy:PercentageOfRoyaltyRatePayments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMjEzOQ_28ee6d1f-2183-4dfd-8bf6-80bbdf62074e">14</ix:nonFraction>%. We are obligated to pay to Novartis tiered royalties in the low single-digits on future JAKAFI net sales within the United States contingent on certain conditions. During the three and nine months ended September&#160;30, 2022, such royalties on net sales within the United States totaled $<ix:nonFraction unitRef="usd" contextRef="i2abac4d4d9084b0cbd214384a0bdd136_D20220701-20220930" decimals="-5" name="us-gaap:IncreaseDecreaseInRoyaltiesPayable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMjM5OQ_d8124bc7-696d-42ba-a5d5-f9120d0e6de9">30.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ifa4602ca397f4df8b24c50991489996f_D20220101-20220930" decimals="-5" name="us-gaap:IncreaseDecreaseInRoyaltiesPayable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMjQwNg_c6b5b176-deeb-4d12-b3a1-20a84babb333">81.3</ix:nonFraction> million, respectively, and were reflected in cost of product revenues on the condensed consolidated statements of operations. During the three and nine months ended September&#160;30, 2021, such royalties on net sales within the United States totaled $<ix:nonFraction unitRef="usd" contextRef="i829cf684375a4486846e54a47708b378_D20210701-20210930" decimals="-5" name="us-gaap:IncreaseDecreaseInRoyaltiesPayable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMjYxOQ_4338cd59-a7a4-4fc4-accd-95b37e288ca7">26.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i02be7adafa9342b0a09344a3239b2392_D20210101-20210930" decimals="-5" name="us-gaap:IncreaseDecreaseInRoyaltiesPayable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMjYyNw_b0f81238-dc2d-4ad5-9310-84e0e0c307ba">70.6</ix:nonFraction> million, respectively, and were reflected in cost of product revenues on the condensed consolidated statements of operations. At September&#160;30, 2022 and December&#160;31, 2021, $<ix:nonFraction unitRef="usd" contextRef="i6881c415becd47fa9f89334bb95c5996_I20220930" decimals="-5" name="incy:RoyaltiesPayable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMjc2Mg_b6f1ecb0-1e68-4214-83d6-af6483937098">221.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ifbfff633ca0a4e9ea1abbaec86cf758b_I20211231" decimals="-5" name="incy:RoyaltiesPayable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMjc2OQ_c2da91bf-7341-44f7-8473-0bf70e49634e">148.1</ix:nonFraction> million, respectively, of accrued royalties were included in accrued and other current liabilities on the condensed consolidated balance sheets. Each company is responsible for costs relating to the development and commercialization of ruxolitinib in its respective territories, with costs of collaborative studies shared equally. Novartis is also responsible for all costs relating to the development and commercialization of capmatinib.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had <ix:nonFraction unitRef="usd" contextRef="ic15fa27e6524408cb2ade84bf1015e8a_D20220701-20220930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMTY0OTI2NzU2MDE1Ng_6701459b-e25d-4e22-ab29-4ed5841548e4">no</ix:nonFraction> milestone and contract revenue under the Novartis agreement for the three months ended September&#160;30, 2022, and we had $<ix:nonFraction unitRef="usd" contextRef="i5aa252a5e50f412c987b6f82e79e1f2d_D20220101-20220930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMzI2OA_6f54ce1f-cef0-4f95-aafe-54600d4f0566">60.0</ix:nonFraction> million for the nine months ended September&#160;30, 2022. Product royalty revenue related to Novartis net sales of JAKAVI outside of the United States for the three and nine months ended September&#160;30, 2022 was $<ix:nonFraction unitRef="usd" contextRef="iab260328ac9041409b390a6d753ed302_D20220701-20220930" decimals="-5" name="us-gaap:IncreaseDecreaseInRoyaltiesPayable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMTY0OTI2NzU2MjkzNA_195feef1-4413-4eeb-8436-01141ab6e9c3">85.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i51a40b9a674c444c9eabfee9d2524c4a_D20220101-20220930" decimals="-5" name="us-gaap:IncreaseDecreaseInRoyaltiesPayable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMTY0OTI2NzU2Mjk0Mg_59315349-e32b-4bfa-8caf-58312a861b66">240.4</ix:nonFraction> million, respectively. Product royalty revenue related to Novartis net sales of JAKAVI outside of the United States for the three and nine months ended September&#160;30, 2021 was $<ix:nonFraction unitRef="usd" contextRef="ia6dcb750836e4de6b839dbd19f02184f_D20210701-20210930" decimals="-5" name="us-gaap:IncreaseDecreaseInRoyaltiesPayable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMTY0OTI2NzU2Mjk1MA_705ccb3d-3961-4cad-b664-2b882f5b4c72">94.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ife40116eb76549f19cb03e7d7d84733b_D20210101-20210930" decimals="-5" name="us-gaap:IncreaseDecreaseInRoyaltiesPayable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMTY0OTI2NzU2Mjk1NA_788de323-3808-4aa3-abc2-cc20a034f461">242.3</ix:nonFraction> million, respectively. Product royalty revenue related to Novartis net sales of TABRECTA worldwide for the three and nine months ended September&#160;30, 2022 was $<ix:nonFraction unitRef="usd" contextRef="iff64b50b378d484492f7f8d0962ecace_D20220701-20220930" decimals="-5" name="us-gaap:IncreaseDecreaseInRoyaltiesPayable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMTY0OTI2NzU2Mjk2Ng_ca585b35-583d-469f-a51a-e15b222d5f57">4.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i2d83cfa285a94cdf9e3c412825e16ed7_D20220101-20220930" decimals="-5" name="us-gaap:IncreaseDecreaseInRoyaltiesPayable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMTY0OTI2NzU2Mjk3MA_88fa8d63-0b4c-41d0-b966-cceaa150fc79">11.2</ix:nonFraction> million, respectively. Product royalty revenue related to Novartis net sales of TABRECTA worldwide for the three and nine months ended September&#160;30, 2021 was $<ix:nonFraction unitRef="usd" contextRef="i51a445bbbf1c4bb2b3b6e0b802471593_D20210701-20210930" decimals="-5" name="us-gaap:IncreaseDecreaseInRoyaltiesPayable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMTY0OTI2NzU2Mjk3NA_22f0e6d4-bcb9-4808-92bf-bc2b5936e4e8">2.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i30a2ee091dab4a71840f5db6371badf9_D20210101-20210930" decimals="-5" name="us-gaap:IncreaseDecreaseInRoyaltiesPayable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMTY0OTI2NzU2Mjk3OA_178e03dd-bed5-4f35-91ec-beb1dc97ea57">7.3</ix:nonFraction> million, respectively.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Lilly &#8211; Baricitinib</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2009, we entered into a License, Development and Commercialization Agreement with Lilly. Under the terms of the agreement, Lilly received exclusive worldwide development and commercialization rights to our JAK inhibitor baricitinib, and certain back-up compounds for inflammatory and autoimmune diseases.</span></div></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie2ffba3ee5384c86becdb38ff117ca9a_7">Table of Contents</a></span></div></div><ix:continuation id="icdae8bb3b8364921a1ea14c8b7d9ef86" continuedAt="ic2821d123b7242f0a7cb7168061e5b48"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under this agreement, we were initially eligible to receive up to $<ix:nonFraction unitRef="usd" contextRef="idadd52c621494f53a41ccc71303f0944_D20091201-20091231" decimals="-5" name="incy:LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfNDI1OQ_1b7243ff-9618-4b2a-9555-82a6be30d5de">150.0</ix:nonFraction> million for the achievement of development milestones, up to $<ix:nonFraction unitRef="usd" contextRef="i5da7cd5ffebe4fc2b3889b38d5a3dd8f_D20091201-20091231" decimals="-5" name="incy:LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfNDMxNQ_b2fc3d72-5572-4551-a9d5-29a51c2a5068">365.0</ix:nonFraction> million for the achievement of regulatory milestones and up to $<ix:nonFraction unitRef="usd" contextRef="i1a1df5969f734568b13fa48eb0fff053_D20091201-20091231" decimals="-5" name="incy:LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfNDM3Mw_90085308-e8f1-4a76-b982-246598da733a">150.0</ix:nonFraction> million for the achievement of sales milestones. We have recognized and received, in aggregate, $<ix:nonFraction unitRef="usd" contextRef="i03d9a6dbc0bb43aaa8228030c1e90e5c_D20091201-20220930" decimals="-5" name="incy:LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfNDQ2NA_9fd2ac0d-6587-47cd-bb7e-f466051ac9d4">149.0</ix:nonFraction> million for the achievement of development milestones, $<ix:nonFraction unitRef="usd" contextRef="i4562ffe6c4de4f0c8852be62011ecaa1_D20091201-20220930" decimals="-5" name="incy:LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfNDUxNA_84e9dc49-c52d-47a4-aede-6bf98020309e">335.0</ix:nonFraction> million for the achievement of regulatory milestones and $<ix:nonFraction unitRef="usd" contextRef="ib271257c3c244c8491614777e365abbd_D20091201-20220930" decimals="-5" name="incy:LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfNDU2Ng_3f39f4fc-9aee-4913-b74a-bfd73ff299f9">50.0</ix:nonFraction> million for the achievement of sales milestones through September&#160;30, 2022. We are also eligible to receive tiered, double-digit royalty payments on future global sales with rates ranging up to the mid-twenties if a product is successfully commercialized. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, we amended our agreement with Lilly to enable Lilly to develop and commercialize baricitinib for the treatment of COVID-19. As part of the amended agreement, in addition to the royalties described above, we will be entitled to receive additional royalty payments with rates in the low teens on global net sales of baricitinib for the treatment of COVID-19 that exceed a specified aggregate global net sales threshold.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2022, we recognized a $<ix:nonFraction unitRef="usd" contextRef="iaa7f2cb6de4b491abfc72a3a790e6c24_D20220601-20220630" decimals="-5" name="incy:LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfNTI1Mg_c181d209-012c-48a5-b24d-de8333e3a6e5">40.0</ix:nonFraction> million regulatory milestone for the FDA approval of OLUMIANT as a first-in-disease systemic treatment for adults with severe alopecia areata. Additionally, in June 2022 we recognized a $<ix:nonFraction unitRef="usd" contextRef="if3576f8af5d9438f8a88daefbfe6e46c_D20220601-20220630" decimals="-5" name="incy:LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfNTQyNg_a715d0cc-93fc-40c4-afa0-d382ab574c2e">20.0</ix:nonFraction> million regulatory milestone for the European Commission&#8217;s approval for OLUMIANT for the treatment of adults with severe alopecia areata, and a $<ix:nonFraction unitRef="usd" contextRef="id7fe066d0c744249bf7ad5af413886e0_D20220601-20220630" decimals="-5" name="incy:LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfNTU2NQ_6248ba08-3745-4033-b61c-24b45eb1a67a">10.0</ix:nonFraction> million regulatory milestone for the Ministry of Health, Labour and Welfare of Japan&#8217;s approval for OLUMIANT for the treatment of adults with severe alopecia areata in Japan.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had <ix:nonFraction unitRef="usd" contextRef="if134f6ece59c4973a0b3eb0c742df2b4_D20220701-20220930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMTY0OTI2NzU2MDI1Mw_3d7b3767-f112-4617-8a69-01e7fdefe58b">no</ix:nonFraction> milestone and contract revenue under the Lilly agreement for the three months ended September&#160;30, 2022, and we had $<ix:nonFraction unitRef="usd" contextRef="i9c21ab11171944d088ad94775faa82d3_D20220101-20220930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfNTc5Ng_c8d93d48-1012-4479-ac85-fe4d61d0c480">70.0</ix:nonFraction> million for the nine months ended September&#160;30, 2022. Product royalty revenue related to Lilly net sales of OLUMIANT outside of the United States for the three and nine months ended September&#160;30, 2022 was $<ix:nonFraction unitRef="usd" contextRef="i773d88ed6ec246e38116cf7dcfe2b613_D20220701-20220930" decimals="-5" name="us-gaap:IncreaseDecreaseInRoyaltiesPayable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMTY0OTI2NzU2MzAwMg_3cd8a57d-9131-4454-9686-0a0915558323">20.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i67b271a11f4749eca413dadc55b898ff_D20220101-20220930" decimals="-5" name="us-gaap:IncreaseDecreaseInRoyaltiesPayable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMTY0OTI2NzU2MzAwNg_8d8d2bcd-e901-4a91-b722-cc65f2583903">98.7</ix:nonFraction> million, respectively. Product royalty revenue related to Lilly net sales of OLUMIANT outside of the United States for the three and nine months ended September&#160;30, 2021 was $<ix:nonFraction unitRef="usd" contextRef="i95f4766b35c44fb7bd203becd9f77ad2_D20210701-20210930" decimals="-5" name="us-gaap:IncreaseDecreaseInRoyaltiesPayable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMTY0OTI2NzU2MzAxMA_5dd7b9ac-ab3b-4f5a-9ae0-ad318f08db54">86.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i332c91272a044c69bed32a22f727d46f_D20210101-20210930" decimals="-5" name="us-gaap:IncreaseDecreaseInRoyaltiesPayable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMTY0OTI2NzU2MzAxNA_7ec7bb2e-9434-4bd3-a38b-a46a7b1c871b">154.9</ix:nonFraction> million, respectively. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Lilly - Ruxolitinib</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2016, we entered into an amendment to the agreement with Lilly that amended the non-compete provision of the agreement to allow us to engage in the development and commercialization of ruxolitinib in the GVHD field. Lilly is eligible to receive up to $<ix:nonFraction unitRef="usd" contextRef="i6a0eb481719843cb8e92803e3eabf444_I20160630" decimals="-5" name="incy:LicenseAgreementAdditionalMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfNjQwMQ_f9436196-f759-4e28-811c-9cc8373609ef">40.0</ix:nonFraction> million in regulatory milestone payments relating to ruxolitinib in the GVHD field. In May 2019, the approval of JAKAFI in steroid-refractory acute GVHD triggered a $<ix:nonFraction unitRef="usd" contextRef="ic8ef5df1d4014903a83c4bd9313a8063_D20190501-20190531" decimals="-5" name="incy:LicenseAgreementMilestonePaymentAmountPaid" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfNjU1NQ_4fad3e88-aa56-44c7-bf0a-b8243bb7f1c3">20.0</ix:nonFraction> million milestone payment to Lilly. In March 2022, the positive recommendation from the European Medicines Agency for regulatory approval of ruxolitinib in the GVHD field triggered an additional $<ix:nonFraction unitRef="usd" contextRef="i27b0ba8514fd434a9cc2954162a2955e_D20220301-20220331" decimals="-5" name="incy:LicenseAgreementMilestonePaymentAmountPaid" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfNjczNw_678aff54-6e94-460e-b229-439a4bd99f3d">20.0</ix:nonFraction> million milestone payment to Lilly, which was recorded as research and development expense in our condensed consolidated statements of operations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Agenus</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2015, we entered into a License, Development and Commercialization Agreement with Agenus Inc. and its wholly-owned subsidiary, 4-Antibody AG (now known as Agenus Switzerland Inc.), which we collectively refer to as Agenus. Under this agreement, which was amended in February 2017, the parties have agreed to collaborate on the discovery of novel immuno-therapeutics using Agenus&#8217; antibody discovery platforms. Under the terms of the amended agreement, we received exclusive worldwide development and commercialization rights to four checkpoint modulators directed against GITR, OX40, LAG-3 and TIM-3 as well as two undisclosed targets. Targets may be designated profit-share programs, where all costs and profits are shared equally by us and Agenus, or royalty-bearing programs, where we are responsible for all costs associated with discovery, preclinical, clinical development and commercialization activities. There are currently no profit-share programs. For each royalty-bearing product other than GITR and one undisclosed target, Agenus will be eligible to receive tiered royalties on global net sales ranging from <ix:nonFraction unitRef="number" contextRef="ie98f2f82461347b486999bb44539bcea_D20170201-20170228" decimals="2" name="incy:PercentageOfRoyaltyRatePayments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfODAyNA_8f52c278-858b-4865-9976-cdf41b518f59">6</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i77e092a0d9e54838988930228ca59678_D20170201-20170228" decimals="2" name="incy:PercentageOfRoyaltyRatePayments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfODAzMA_d0c7b198-dcf8-4cfd-83df-15f8de47cc0a">12</ix:nonFraction>%. For GITR and one undisclosed target, Agenus will be eligible to receive <ix:nonFraction unitRef="number" contextRef="i322b83e81195460e8c7931fafc090d9a_D20170201-20170228" decimals="2" name="incy:PercentageOfRoyaltyRatePayments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfODExMg_f93bb8db-379f-4c4b-b7e6-f7919d2aefdb">15</ix:nonFraction>% royalties on global net sales. The agreement may be terminated by us for convenience upon <ix:nonNumeric contextRef="i5094eb7ec3484534bab11f2216427143_D20170201-20170228" name="incy:LicenseAgreementTerminationNoticePeriod" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfODIwNQ_67973603-2436-4b9b-a695-f6378a4fdfcb">12</ix:nonNumeric> months&#8217; notice and may also be terminated under certain other circumstances, including material breach. On October 19, 2022 we notified Agenus that we were terminating the OX40 project.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2022, we have paid Agenus milestones totaling $<ix:nonFraction unitRef="usd" contextRef="i0c8cef81f270473fadccddb9df52f115_D20150101-20220930" decimals="-5" name="incy:LicenseAgreementMilestonePaymentAmountPaid" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfODM1NQ_1e5c086c-908d-4794-be33-6bfed4d6721e">30.0</ix:nonFraction> million and Agenus is eligible to receive up to an additional $<ix:nonFraction unitRef="usd" contextRef="id92745e544bc4129ab3571e6e1882924_I20220930" decimals="-5" name="incy:LicenseAgreementAdditionalMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfODQxMg_5dc082e0-a4e4-4a6d-b7fb-fbd08e92083c">500.0</ix:nonFraction> million in future contingent development, regulatory and commercialization milestones across all programs in the collaboration.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie2ffba3ee5384c86becdb38ff117ca9a_7">Table of Contents</a></span></div></div><ix:continuation id="ic2821d123b7242f0a7cb7168061e5b48" continuedAt="i40a60552b57448289a8c7450ee0048e1"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in 2017 we purchased <ix:nonFraction unitRef="shares" contextRef="i6c3197a1985e4c74a433c4e949b9a513_D20170101-20171231" decimals="-5" name="incy:PurchaseOfCommonStockUnderStockPurchaseAgreementInShares" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfODU2Nw_14196459-7f6b-47a3-bf6f-60e157cf7795">10.0</ix:nonFraction>&#160;million shares of Agenus Inc.&#8217;s common stock for an aggregate purchase price of $<ix:nonFraction unitRef="usd" contextRef="i5eaa2a7f03b24bb684bd8c6d31d0037c_I20171231" decimals="-5" name="us-gaap:EquityMethodInvestmentAggregateCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfODY0Mw_f3fd0edd-773e-4b6c-b6a5-ad825a92cd62">60.0</ix:nonFraction> million in cash, or $<ix:nonFraction unitRef="usdPerShare" contextRef="i5eaa2a7f03b24bb684bd8c6d31d0037c_I20171231" decimals="2" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfODY1OQ_82792910-4d89-4af0-84d8-a78d859ea6f9">6.00</ix:nonFraction> per share. In 2020, we sold an aggregate of approximately <ix:nonFraction unitRef="shares" contextRef="iac9dda7781924f1c941a441ab2e2b22e_D20200101-20201231" decimals="-5" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfODcxOA_ea32b2ad-82e3-4e1a-bd4a-b8cc3b8d23fc">3.7</ix:nonFraction>&#160;million shares of Agenus Inc.&#8217;s common stock resulting in gross proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="iac9dda7781924f1c941a441ab2e2b22e_D20200101-20201231" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfODgwNA_4faac56b-12d1-4962-884e-e7538ce83bae">17.2</ix:nonFraction> million. In 2021, we sold an aggregate of approximately <ix:nonFraction unitRef="shares" contextRef="i181b872577d8409197ea188e8c75e75e_D20210101-20211231" decimals="-5" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfODg1NA_0360cc81-9b74-4a3d-8b60-5be085e428de">2.0</ix:nonFraction>&#160;million shares of Agenus Inc.&#8217;s common stock resulting in gross proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="i181b872577d8409197ea188e8c75e75e_D20210101-20211231" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfODkzOQ_8e7821fd-a517-41af-be00-5e741071436e">10.5</ix:nonFraction> million. The fair market value of our long term investment in Agenus Inc. at September&#160;30, 2022 and December&#160;31, 2021 was $<ix:nonFraction unitRef="usd" contextRef="i75f5d515a0904070a5f78ec1c95a20f5_I20220930" decimals="-5" name="us-gaap:LongTermInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfOTAyNg_3a977b1d-a43b-417c-803b-12e5ec99447c">24.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ib46ef2e3f9964aa1ae70251f66606bb7_I20211231" decimals="-5" name="us-gaap:LongTermInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfOTAzMw_e8a51482-40c8-46ba-a0de-f11f024af68c">38.9</ix:nonFraction> million, respectively.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to hold the investment in Agenus Inc. for the foreseeable future and therefore, are accounting for our shares held in Agenus Inc. at fair value whereby the investment is marked to market through earnings in each reporting period. Given our intent to hold the investment for the foreseeable future, we have classified the investment within long term investments on the accompanying condensed consolidated balance sheets. For the three and nine months ended September&#160;30, 2022, we recorded an unrealized gain of $<ix:nonFraction unitRef="usd" contextRef="i0fde4e1ee3904f46bc27b6433525d662_D20220701-20220930" decimals="-5" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfOTYzMg_07e388d6-a7de-4c5f-a002-bdd616a53040">1.3</ix:nonFraction> million and an unrealized loss of $<ix:nonFraction unitRef="usd" contextRef="i6737e877e1fd425cadb82670cc929c9d_D20220101-20220930" decimals="-5" sign="-" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfOTYzOQ_aca92aba-6b65-4197-8a44-1e73173866dd">14.1</ix:nonFraction> million, respectively, based on the change in fair value of Agenus Inc.&#8217;s common stock during the respective periods. For the three and nine months ended September&#160;30, 2021, we recorded an unrealized loss of $<ix:nonFraction unitRef="usd" contextRef="i595a69e029b4481b8df26f1ffe67629c_D20210701-20210930" decimals="-5" sign="-" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfOTgxNA_7c2148ab-b050-4911-b313-92507546869a">2.8</ix:nonFraction> million and an unrealized gain of $<ix:nonFraction unitRef="usd" contextRef="i9682bdfe1eb449eca0f0c2c52870768b_D20210101-20210930" decimals="-5" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfOTgyMg_8e818c06-cc4b-4bf6-bfc4-cce1a98d58ca">29.1</ix:nonFraction> million, respectively, based on the change in fair value of Agenus Inc.&#8217;s common stock during the respective periods. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Merus</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2016, we entered into a Collaboration and License Agreement with Merus N.V. (&#8220;Merus&#8221;). Under this agreement, the parties have agreed to collaborate with respect to the research, discovery and development of bispecific antibodies utilizing Merus&#8217; technology platform. The collaboration encompasses up to <ix:nonFraction unitRef="item" contextRef="i9334ed3cba224fde929ed123a17c88d3_D20161201-20161231" decimals="INF" name="incy:LicenseAgreementMaximumNumberOfIndependentPrograms" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMTAyNDc_4b413e53-2cb9-4a15-843c-d5d47c83fc86">ten</ix:nonFraction> independent programs. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2022, we decided to opt-out of the continued development of MCLA-145, a bispecific antibody targeting PD-L1 and CD137. We continue to collaborate with Merus and leverage the Merus platform to develop a pipeline of novel agents, as we continue to hold worldwide exclusive development and commercialization rights to up to <ix:nonFraction unitRef="item" contextRef="i9011187ffb7d41f38db3ce85ad7e7768_D20220101-20220131" decimals="INF" name="incy:LicenseAgreementNumberOfAdditionalPreclinicalDiscoveryPrograms" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMTA1OTY_29317eff-173e-4da0-856d-826a0230f636">ten</ix:nonFraction> additional programs. Of these <ix:nonFraction unitRef="item" contextRef="i9011187ffb7d41f38db3ce85ad7e7768_D20220101-20220131" decimals="INF" name="incy:LicenseAgreementNumberOfAdditionalPreclinicalDiscoveryPrograms" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMTA2MzA_29317eff-173e-4da0-856d-826a0230f636">ten</ix:nonFraction> additional programs, Merus retained the option, subject to certain conditions, to co-fund development of up to <ix:nonFraction unitRef="item" contextRef="i9011187ffb7d41f38db3ce85ad7e7768_D20220101-20220131" decimals="INF" name="incy:NumberOfProgramsUnderWhichResultingProductsAreCoFundedForDevelopment" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMTA3NDQ_6812575c-ad80-4c01-ad22-4f98bf4b1554">two</ix:nonFraction> such programs. If Merus exercises its co-funding option for a program, Merus would be responsible for funding <ix:nonFraction unitRef="number" contextRef="i9011187ffb7d41f38db3ce85ad7e7768_D20220101-20220131" decimals="2" name="incy:PercentageFundingOnCostOnPossibleElectionOfCodevelopmentOfCompounds" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMTA4NTc_ca9d82b6-388a-4c42-beda-b7ab69ca32d4">35</ix:nonFraction>% of the associated future global development costs and, for certain of such programs, would be responsible for reimbursing us for certain development costs incurred prior to the option exercise. Merus will also have the right to participate in a specified proportion of detailing activities in the United States for one of those co-developed programs. All costs related to the co-funded collaboration programs are subject to joint research and development plans and overseen by a joint development committee, but we will have final determination as to such plans in cases of dispute. We will be responsible for all research, development and commercialization costs relating to all other programs. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For each program as to which Merus does not have commercialization or development co-funding rights, Merus is eligible to receive up to $<ix:nonFraction unitRef="usd" contextRef="i3734c8248498448d986bbd533587971e_I20220930" decimals="-5" name="incy:LicenseAgreementAdditionalMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMTE2OTM_3b6382ce-2c7b-426b-b377-e718b8721cc0">100.0</ix:nonFraction> million in future contingent development and regulatory milestones, and up to $<ix:nonFraction unitRef="usd" contextRef="id2a299f69c6442bebb13283c32eb5495_I20220930" decimals="-5" name="incy:LicenseAgreementAdditionalMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMTE3NjY_ba5491bd-e36e-484a-b4fb-549032efa7ba">250.0</ix:nonFraction> million in commercialization milestones as well as tiered royalties ranging from <ix:nonFraction unitRef="number" contextRef="i68cb2d0ea17a41489814062745e1a6d8_D20161201-20220930" decimals="2" name="incy:PercentageOfRoyaltyRatePayments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMTE4NDI_02cad6e3-e2f7-453c-9372-41b7972ccbe0">6</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="ida045afcbce447a1922f7d64f607e199_D20161201-20220930" decimals="2" name="incy:PercentageOfRoyaltyRatePayments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMTE4NDg_57a6e4e4-45e5-4b17-a823-dc23a587d806">10</ix:nonFraction>% of global net sales. For each program as to which Merus exercises its option to co-fund development, Merus is eligible to receive a <ix:nonFraction unitRef="number" contextRef="ic6746d80cb784b16bb25e182d074023d_D20161201-20220930" decimals="2" name="incy:CollaborationAgreementProfitSharingPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMTE5ODM_963b4172-4fdf-40b5-8c6e-9ef381d71fc5">50</ix:nonFraction>% share of profits (or sustain <ix:nonFraction unitRef="number" contextRef="ic6746d80cb784b16bb25e182d074023d_D20161201-20220930" decimals="2" name="incy:PercentageOfProfitsLosses" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMTIwMTY_326a4398-86b0-4950-a682-b18ac21210fe">50</ix:nonFraction>% of any losses) in the United States and be eligible to receive tiered royalties ranging from <ix:nonFraction unitRef="number" contextRef="i3fda94064174414ba40e5f53bd348807_D20161201-20220930" decimals="2" name="incy:PercentageOfRoyaltyRatePayments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMTIxMTI_87d01eea-1181-4e98-a826-9d3c3cbbd785">6</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i7ab2a3895a964a1292f9330cada8a771_D20161201-20220930" decimals="2" name="incy:PercentageOfRoyaltyRatePayments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMTIxMTg_5d2c7eab-c4b4-419a-aaba-23b9322d847c">10</ix:nonFraction>% of net sales of products outside of the United States. If Merus opts to cease co-funding a program as to which it exercised its co-development option, then Merus will no longer receive a share of profits in the United States but will be eligible to receive the same milestones from the co-funding termination date and the same tiered royalties described above with respect to programs where Merus does not have a right to co-fund development and, depending on the stage at which Merus chose to cease co-funding development costs, Merus will be eligible to receive additional royalties ranging up to <ix:nonFraction unitRef="number" contextRef="i8440f47d04e64df1b565b9e18146f65e_D20161201-20220930" decimals="2" name="incy:PercentageOfRoyaltyRatePayments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMTI3MjE_0e830723-e24a-4ecb-b7fe-880a78b52b30">4</ix:nonFraction>% of net sales in the United States. As of September&#160;30, 2022, we have paid Merus milestones totaling $<ix:nonFraction unitRef="usd" contextRef="idad439e73b814d62ac3f923adfd04e2a_D20161201-20220930" decimals="-5" name="incy:LicenseAgreementMilestonePaymentAmountPaid" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMTI4MDg_6ba2c56e-2577-4ea3-8d1f-e6dc5a7e9092">3.0</ix:nonFraction> million.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in 2016 we entered into a Share Subscription Agreement with Merus, pursuant to which we purchased <ix:nonFraction unitRef="shares" contextRef="i1a445305a100467ca73640bc7fefa6b1_D20160101-20161231" decimals="-5" name="incy:PurchaseOfCommonStockUnderStockPurchaseAgreementInShares" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMTI5MjE_5d16f035-c3ff-4ab9-8c8f-84fbfa512581">3.2</ix:nonFraction>&#160;million common shares of Merus for an aggregate purchase price of $<ix:nonFraction unitRef="usd" contextRef="i68df7b52e15747f7ae8531c9b598597e_I20161231" decimals="-5" name="us-gaap:EquityMethodInvestmentAggregateCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMTI5ODM_0a877a22-1f40-4b09-a240-25f8036b4170">80.0</ix:nonFraction> million in cash, or $<ix:nonFraction unitRef="usdPerShare" contextRef="i68df7b52e15747f7ae8531c9b598597e_I20161231" decimals="2" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMTI5OTg_411acfad-b326-4131-aefb-040013157700">25.00</ix:nonFraction> per share. In January 2021, we purchased <ix:nonFraction unitRef="shares" contextRef="i372a75620ad046e48dae561ae27ead65_D20210101-20210131" decimals="INF" name="incy:EquityMethodInvestmentSharesPurchased" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMTMwMzI_69724b78-7ebd-4e6b-a7ca-55be1f4ee3fb">350,000</ix:nonFraction> common shares in Merus&#8217; underwritten public offering of <ix:nonFraction unitRef="shares" contextRef="i372a75620ad046e48dae561ae27ead65_D20210101-20210131" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMTMwOTE_86beeed0-7680-42e0-8e6a-6977d3026f8e">4,848,485</ix:nonFraction> common shares at the public offering price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i4725ae58984b44c88c59c206c45fa1d2_I20210131" decimals="2" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMTMxNDA_3c92d28d-b407-4b6d-9358-7c20d835c8fe">24.75</ix:nonFraction> per share, or an aggregate purchase price of $<ix:nonFraction unitRef="usd" contextRef="i4725ae58984b44c88c59c206c45fa1d2_I20210131" decimals="-5" name="us-gaap:EquityMethodInvestmentQuotedMarketValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMTMxODg_eca02933-3ef3-4880-8ba0-a6cafd56ed06">8.7</ix:nonFraction> million. The fair market value of our total long term investment in Merus at September&#160;30, 2022 and December&#160;31, 2021 was $<ix:nonFraction unitRef="usd" contextRef="idc8b97af450a4ea5ad6a270978aca78f_I20220930" decimals="-5" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMTMyNzQ_ed1d75de-3290-433d-b947-6717b92bc09c">71.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i9eec6fea7a9943da8efef567ce22965f_I20211231" decimals="-5" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMTMyODE_3e1677e9-3065-4024-b85e-dfa68d70325e">112.9</ix:nonFraction> million, respectively. As of September&#160;30, 2022, we owned approximately <ix:nonFraction unitRef="number" contextRef="idc8b97af450a4ea5ad6a270978aca78f_I20220930" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMTMzMzI_9a6a5edd-40fe-484d-80aa-c62711079cf2">8</ix:nonFraction>% of the outstanding common shares of Merus.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie2ffba3ee5384c86becdb38ff117ca9a_7">Table of Contents</a></span></div></div><ix:continuation id="i40a60552b57448289a8c7450ee0048e1" continuedAt="ib4236fe9371e4b2e840d59afc00810b0"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have concluded that we have the ability to exercise significant influence, but not control, over Merus based primarily on our ownership interest, the level of intra-entity transactions between us and Merus related to development expenses, as well as other qualitative factors. We have elected the fair value option to account for our long term investment in Merus whereby the investment is marked to market through earnings in each reporting period. We believe the fair value option to be the most appropriate accounting method to account for securities in publicly held collaborators for which we have significant influence. For the three and nine months ended September&#160;30, 2022, we recorded an unrealized loss of $<ix:nonFraction unitRef="usd" contextRef="i223beeaf3ff34be8ac561d2f33d4ee03_D20220701-20220930" decimals="-5" sign="-" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMTQwNjk_ba86cf9b-add7-4273-8a3a-73c871856d53">9.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i2c2d69aa47e742379d1cce352dedd9ae_D20220101-20220930" decimals="-5" sign="-" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMTQwNzY_c635bc29-f6c8-4b20-adb4-1d7d9ca8fa9d">41.8</ix:nonFraction> million, respectively, based on the change in fair value of Merus&#8217; common shares during the respective periods. For the three and nine months ended September&#160;30, 2021, we recorded an unrealized gain of $<ix:nonFraction unitRef="usd" contextRef="i3700fa75a23a4f7eb6dcb20a8debd956_D20210701-20210930" decimals="-5" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMTQyNDU_59048e50-b21e-473f-b6f8-e350170d1ebe">3.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i2665334fe7184425872feb9740fab18e_D20210101-20210930" decimals="-5" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMTQyNTI_02c0c7b5-07ae-446f-8042-5abc4d99f713">13.3</ix:nonFraction> million, respectively, based on the change in fair value of Merus&#8217; common shares during the respective periods. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Calithera</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2017, we entered into a Collaboration and License Agreement with Calithera Biosciences, Inc. (&#8220;Calithera&#8221;). Under this agreement, we received an exclusive, worldwide license to develop and commercialize small molecule arginase inhibitors, including INCB01158. We had initially agreed to co-fund <ix:nonFraction unitRef="number" contextRef="i4764998569344819b699915846b00247_D20170101-20170131" decimals="2" name="incy:LicenseAgreementPercentageOfFutureGlobalDevelopmentCostsFunded" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMTY0OTI2NzU1Njk5OA_51e8c286-32d8-4399-987c-cb888f803030">70</ix:nonFraction>% of the global development costs for the development of the licensed products for hematology and oncology indications, but effective September 30, 2020 Calithera opted out of its co-funding obligation, and we became responsible for funding all of the development costs of INCB01158 and any other licensed products. In September 2022, we notified Calithera of our exercise of our right to terminate the Collaboration and License Agreement for convenience, effective in December 2022. As a result of the termination, rights to INCB01158 and the other licensed products will revert to Calithera.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in 2017, we entered into a Stock Purchase Agreement with Calithera, pursuant to which we purchased <ix:nonFraction unitRef="shares" contextRef="i7d98c2063e874805b3cd156154e95b6a_D20170101-20171231" decimals="-5" name="incy:PurchaseOfCommonStockUnderStockPurchaseAgreementInShares" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMTY0NTU_375aed82-cdd3-4824-ae56-3493d580425c">1.7</ix:nonFraction>&#160;million shares of Calithera common stock for an aggregate purchase price of $<ix:nonFraction unitRef="usd" contextRef="i040b9736a2b34584b9200ad4e2e9a3fa_I20170131" decimals="-5" name="us-gaap:EquityMethodInvestmentAggregateCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMTY1MjY_3174e569-17cb-4566-9c93-0ada39e0bc5e">8.0</ix:nonFraction> million in cash, or $<ix:nonFraction unitRef="usdPerShare" contextRef="i040b9736a2b34584b9200ad4e2e9a3fa_I20170131" decimals="2" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMTY1NDE_33e9c95c-7666-45ed-b909-03cf60367c3f">4.65</ix:nonFraction> per share. In June 2022, Calithera effected a one-for-twenty stock split of its outstanding common stock, adjusting our ownership to <ix:nonFraction unitRef="shares" contextRef="i3851ace877124ec6913ece53ee3910da_I20220630" decimals="INF" name="us-gaap:InvestmentOwnedBalanceShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMTY2NzA_e35f7c44-9239-4b50-9afb-a6e399fca7ab">86,021</ix:nonFraction> shares of Calithera&#8217;s common stock. The fair market value of our long term investment in Calithera at September&#160;30, 2022 and December&#160;31, 2021 was $<ix:nonFraction unitRef="usd" contextRef="i976bcd6e91034b90afc59a80f582f14d_I20220930" decimals="-5" name="us-gaap:LongTermInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMTY3ODk_e14c1b07-7d44-44fa-a12b-6299a611d55d">0.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i14a2cf26acb6415995411f908d84bb40_I20211231" decimals="-5" name="us-gaap:LongTermInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMTY3OTY_5150b1e4-45a5-45a0-aaf6-9dc4e4676b9d">1.1</ix:nonFraction> million, respectively.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to hold the investment in Calithera for the foreseeable future and therefore, are accounting for our shares held in Calithera at fair value whereby the investment is marked to market through earnings in each reporting period. Given our intent to hold the investment for the foreseeable future, we have classified the investment within long term investments on the accompanying condensed consolidated balance sheets. For the three months ended September&#160;30, 2022 we recorded a <ix:nonFraction unitRef="usd" contextRef="i73a305e484884469b7b72fee3888f57d_D20220701-20220930" decimals="-5" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMTczOTE_8af2b665-9e84-46b0-88df-85eed7866226">nominal</ix:nonFraction> unrealized gain, and for the nine months ended September&#160;30, 2022 we recorded an unrealized loss of $<ix:nonFraction unitRef="usd" contextRef="ibf490fff4c3b444c824506cac379e2c3_D20220101-20220930" decimals="-5" sign="-" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMTczOTg_5edaa1db-092b-4a95-abef-0e50009a035c">0.9</ix:nonFraction> million, based on the change in fair value of Calithera&#8217;s common stock during the respective periods. For the three and nine months ended September&#160;30, 2021 we recorded an unrealized gain of $<ix:nonFraction unitRef="usd" contextRef="ia0e5eed879114b4fb4f2900138c56b8c_D20210701-20210930" decimals="-5" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMTc1NzE_0425eb40-29b2-40db-9358-a048095fb61b">0.2</ix:nonFraction> million and an unrealized loss of $<ix:nonFraction unitRef="usd" contextRef="ibb93f3e466f7462fb5aade7477f8d7d9_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMTc1Nzg_56394181-84ae-4712-8582-81b8ce72b41b">4.6</ix:nonFraction> million, respectively, based on the change in fair value of Calithera&#8217;s common stock during the respective periods.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">MacroGenics</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2017, we entered into a Global Collaboration and License Agreement with MacroGenics, Inc. (&#8220;MacroGenics&#8221;). Under this agreement, we received exclusive development and commercialization rights worldwide to MacroGenics&#8217; INCMGA0012 (formerly MGA012), an investigational monoclonal antibody that inhibits PD-1. Except as set forth in the succeeding sentence, we have sole authority over and bear all costs and expenses in connection with the development and commercialization of INCMGA0012 in all indications, whether as a monotherapy or as part of a combination regimen. MacroGenics has retained the right to develop and commercialize, at its cost and expense, its pipeline assets in combination with INCMGA0012. In addition, MacroGenics has the right to manufacture a portion of both companies&#8217; global clinical and commercial supply needs of INCMGA0012.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2022, we amended our agreement with MacroGenics to reflect changes related to the payment of certain milestones and paid MacroGenics $<ix:nonFraction unitRef="usd" contextRef="ied65757537b34a7aa71eb6babf067549_D20220701-20220731" decimals="-5" name="incy:LicenseAgreementMilestonePaymentAmountPaid" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMTg5OTg_a5ac1b00-b673-4bd6-b918-22ada3827a91">30.0</ix:nonFraction> million. As of September 30, 2022, we have paid MacroGenics developmental milestones totaling $<ix:nonFraction unitRef="usd" contextRef="ibd823a98e80f479cb6963127d5b61c4f_D20171001-20220630" decimals="-5" name="incy:LicenseAgreementMilestonePaymentAmountPaid" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMjE5OTAyMzM3NDQwOA_42850a07-4594-4baf-94ea-83c92f04a153">100.0</ix:nonFraction> million. After the amendment, MacroGenics will be eligible to receive up to an additional $<ix:nonFraction unitRef="usd" contextRef="ieca316d43e864d6c9e1338c719db09da_I20220930" decimals="-5" name="incy:LicenseAgreementAdditionalMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMTkwOTc_4685e3d4-4992-4657-bc09-dce98484c860">335.0</ix:nonFraction> million in future contingent development and regulatory milestones, and up to $<ix:nonFraction unitRef="usd" contextRef="id5aed6962c28461aa5a91abb86e50e12_I20220630" decimals="-5" name="incy:LicenseAgreementAdditionalMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMjE5OTAyMzM3NDQ3MQ_0adcc62f-887b-4284-97e9-ba592751918f">330.0</ix:nonFraction> million in sales milestones as well as tiered royalties ranging from <ix:nonFraction unitRef="number" contextRef="ic18f95fb157047e8b27cafc65fd5af9c_D20171001-20220630" decimals="2" name="incy:PercentageOfRoyaltyRatePayments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMjE5OTAyMzM3NDUzNg_2b373cb2-cd94-4a9c-b2b6-f802e42a76f5">15</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="ie6e53682249b48c2b89c302c106844f5_D20171001-20220630" decimals="2" name="incy:PercentageOfRoyaltyRatePayments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMjE5OTAyMzM3NDU0Mw_ccabf42c-de9f-4eac-94b5-d6092d12deb7">24</ix:nonFraction>% of global net sales.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie2ffba3ee5384c86becdb38ff117ca9a_7">Table of Contents</a></span></div></div><ix:continuation id="ib4236fe9371e4b2e840d59afc00810b0" continuedAt="i6f7c465e6cdf4756a34e92edf663148a"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses for the three and nine months ended September&#160;30, 2022 also included $<ix:nonFraction unitRef="usd" contextRef="icf19c78006d9495182f71ef7c21fe380_D20220701-20220930" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMTkyOTA_09340265-5a81-41b8-ad0b-20fe3c95baa4">41.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i3985fee19ddf43a38f40f8f7a256fbdf_D20220101-20220930" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMTkyOTc_027e7249-8bce-4f74-b451-405786bb0ef9">69.9</ix:nonFraction> million, respectively, of development costs incurred pursuant to the MacroGenics agreement. Research and development expenses for the three and nine months ended September&#160;30, 2021 also included $<ix:nonFraction unitRef="usd" contextRef="icb1732c8fda74656b87657355bf486ce_D20210701-20210930" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMTk0NTk_cffb66fa-473f-4b21-b75e-e81264d01a04">17.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i73db6105ad88412f9de49662c370a570_D20210101-20210930" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMTk0NjY_e6a10ab8-2f87-49f7-901a-1d53ae406d6d">49.0</ix:nonFraction> million, respectively, of development costs incurred pursuant to the MacroGenics agreement. At September&#160;30, 2022 and December&#160;31, 2021, a total of $<ix:nonFraction unitRef="usd" contextRef="ieaa2a400ed804a53b1afde32908c0c07_I20220930" decimals="-5" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMTk1Nzg_6a28f845-aa02-4eaf-b3e9-b2304a095968">2.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i2dbf58f06d2f47308c3bad5301982ece_I20211231" decimals="-5" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMTk1ODU_cee79967-8757-452b-9ac3-e6cd150a5d16">0.7</ix:nonFraction> million of such costs were included in accrued and other liabilities on the condensed consolidated balance sheets.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Syros</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2018, we entered into a Target Discovery, Research Collaboration and Option Agreement with Syros Pharmaceuticals, Inc. (&#8220;Syros&#8221;). Under this agreement, Syros will use its proprietary gene control platform to identify novel therapeutic targets with a focus in myeloproliferative neoplasms and we have received options to obtain exclusive worldwide rights to intellectual property resulting from the collaboration for up to <ix:nonFraction unitRef="item" contextRef="i70fb3b0153d340f5aab70006b97df6d0_D20180101-20180131" decimals="INF" name="incy:NumberOfProgramTargets" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMjAxMjQ_e7f44c25-deac-4476-978d-c37acfa4e49d">seven</ix:nonFraction> validated targets. We will have exclusive worldwide rights to develop and commercialize any therapies under the collaboration that modulate those validated targets. We have agreed to pay Syros up to $<ix:nonFraction unitRef="usd" contextRef="i152e5989713548879ee454b4d94dc97d_I20180131" decimals="-5" name="incy:LicenseAgreementTargetSelectionAndOptionExerciseFeePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMjAzMjY_ded90122-f7b8-47bd-8393-c9302d2e1b83">54.0</ix:nonFraction> million in target selection and option exercise fees should we decide to exercise all of our options under the agreement. For products resulting from the collaboration against each of the <ix:nonFraction unitRef="item" contextRef="i70fb3b0153d340f5aab70006b97df6d0_D20180101-20180131" decimals="INF" name="incy:NumberOfProgramTargets" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMjA1MDk_e7f44c25-deac-4476-978d-c37acfa4e49d">seven</ix:nonFraction> selected and validated targets, we have agreed to pay up to $<ix:nonFraction unitRef="usd" contextRef="icafda92b12fb4c439f26f3cbf5162d94_I20180131" decimals="-5" name="incy:LicenseAgreementAdditionalMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMjA1NzI_f202e2af-0858-443d-aad0-ed2a94d64f97">50.0</ix:nonFraction> million in potential development and regulatory milestones and up to $<ix:nonFraction unitRef="usd" contextRef="i9b71fd409f444f9ab70ba536a99e012b_I20180131" decimals="-5" name="incy:LicenseAgreementAdditionalMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMjA2MzY_76333360-00fe-4c9f-b100-4706aeff4733">65.0</ix:nonFraction> million in potential sales milestones. Syros is also eligible to receive low single-digit royalties on net sales of products resulting from the collaboration.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in 2018, we entered into a Stock Purchase Agreement with Syros, pursuant to which we purchased <ix:nonFraction unitRef="shares" contextRef="i4802cd742cea475fa7d4e4c77f6ed61f_D20180101-20181231" decimals="-5" name="incy:PurchaseOfCommonStockUnderStockPurchaseAgreementInShares" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMjA4OTk_681cca77-e42e-4204-afe4-4b38be697f36">0.8</ix:nonFraction>&#160;million shares of Syros common stock for an aggregate purchase price of $<ix:nonFraction unitRef="usd" contextRef="i8cf0a385b080416f8c84cece61770144_I20181231" decimals="-5" name="us-gaap:EquityMethodInvestmentAggregateCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMjA5NjY_f0d7f23a-1db3-4748-8ccb-d54cd46b4da3">10.0</ix:nonFraction> million in cash, or $<ix:nonFraction unitRef="usdPerShare" contextRef="i8cf0a385b080416f8c84cece61770144_I20181231" decimals="2" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMjA5ODI_48b9457f-c1af-4a3e-80d8-3023d9b0253a">12.61</ix:nonFraction> per share. Subsequently in 2018, we entered into an Amended Stock Purchase Agreement with Syros, pursuant to which we purchased an additional <ix:nonFraction unitRef="shares" contextRef="i56216a9c32c046e293518645fa59581e_D20180101-20181231" decimals="-5" name="incy:PurchaseOfCommonStockUnderStockPurchaseAgreementInShares" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMjExMjg_aedbab66-84d3-4f2e-bf34-22264e307d01">0.1</ix:nonFraction>&#160;million shares of Syros common stock for an aggregate purchase price of $<ix:nonFraction unitRef="usd" contextRef="i84229a0cf41042c4af314a95d0c76e40_I20181231" decimals="-5" name="us-gaap:EquityMethodInvestmentAggregateCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMjExOTY_e8bdc782-bc7e-4d3e-8b35-8e3d4d5784e7">1.4</ix:nonFraction> million in cash, or $<ix:nonFraction unitRef="usdPerShare" contextRef="i84229a0cf41042c4af314a95d0c76e40_I20181231" decimals="2" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMjEyMTI_a59b8406-e74c-4a97-90f2-9346e24c38e1">9.55</ix:nonFraction> per share. In September 2022, Syros effected a one-for-ten stock split of its outstanding common stock, adjusting our ownership to <ix:nonFraction unitRef="shares" contextRef="icc792aa24edf4db4b607a35782e9f099_I20220930" decimals="INF" name="us-gaap:InvestmentOwnedBalanceShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMjE5OTAyMzM2MzAxNA_7179ada7-6160-425e-ad71-b36e0d056faa">93,753</ix:nonFraction> shares of Syros&#8217;s common stock. The fair market value of our long term investment in Syros as of September&#160;30, 2022 and December&#160;31, 2021 was $<ix:nonFraction unitRef="usd" contextRef="ia7d2cecabe5d473b9e10bcd188d283ba_I20220930" decimals="-5" name="us-gaap:LongTermInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMjEzMDU_903a7518-6b01-4d6d-9cb6-aaa15fea7db5">0.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i8210542f8d5e44b9852bd20e5f5e3854_I20211231" decimals="-5" name="us-gaap:LongTermInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMjEzMTI_6b103f73-a8bb-4754-bf0b-a8f5bb609ead">3.1</ix:nonFraction> million, respectively.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to hold the investment in Syros for the foreseeable future and therefore, are accounting for our shares held in Syros at fair value whereby the investment is marked to market through earnings in each reporting period. Given our intent to hold the investment for the foreseeable future, we have classified the investment within long term investments on the accompanying condensed consolidated balance sheets. For the three and nine months ended September&#160;30, 2022, we recorded an unrealized loss of $<ix:nonFraction unitRef="usd" contextRef="ic8f331242d08460fbf44354246d36f87_D20220701-20220930" decimals="-5" sign="-" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMjE4OTM_2d7a6c88-cfb2-4b6f-b808-880484b2b904">0.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i7c697b731e83449fa55119d8b2fbba64_D20220101-20220930" decimals="-5" sign="-" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMjE5MDA_93c4fb6d-1f04-416b-865b-56e0f00b3992">2.5</ix:nonFraction> million, respectively, based on the change in fair value of Syros&#8217; common stock during the respective periods. For the three and nine months ended September&#160;30, 2021, we recorded an unrealized loss of $<ix:nonFraction unitRef="usd" contextRef="i6adb3d95448a44468d8489293e1ea749_D20210701-20210930" decimals="-5" sign="-" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMjIwNjk_cb38310c-2f02-4b71-b82e-f2ab9273a59b">0.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i09a141eea49e49258b3beebd24497e7e_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMjIwNzc_556a7eb2-50a3-4ae1-9b0b-79ab98c64af1">6.0</ix:nonFraction> million, respectively, based on the change in fair value of Syros&#8217; common stock during the respective periods.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Innovent </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">n December 2018, we entered into a Research Collaboration and Licensing Agreement with Innovent. Under the terms of this agreement, Innovent received exclusive development and commercialization rights to our clinical-stage product candidates pemigatinib, itacitinib and parsaclisib in hematology and oncology in mainland China, Hong Kong, Macau and Taiwan. We are eligible to receive up to an additional $<ix:nonFraction unitRef="usd" contextRef="ic09f0ce12baa4ba48de314895f364fc0_D20220101-20220930" decimals="-5" name="incy:LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMjI1ODc_19bae5a4-28f8-459e-ab91-d50ab2573035">94.0</ix:nonFraction> million in potential development and regulatory milestones.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize development and regulatory milestones upon confirmation of achievement of the event, as development and regulatory approvals are events not controllable by us but rather development activities of Innovent and decisions made by regulatory agencies. In March 2022, we recognized a $<ix:nonFraction unitRef="usd" contextRef="idf1c0108786a4620836caeb03784ce6c_D20220301-20220331" decimals="-5" name="incy:LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMjI5MjY_f23c10a3-9799-4d20-a86d-274fc010346a">5.0</ix:nonFraction> million milestone for approval of PEMAZYRE (pemigatinib) in China.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event of commercialization of the licensed molecule, we are eligible to receive up to $<ix:nonFraction unitRef="usd" contextRef="ie995745d247a45d38430829bee3187e8_D20220101-20220930" decimals="-5" name="incy:LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMjMwODE_a3ea809a-63ca-465c-bf47-959852a0c50e">202.5</ix:nonFraction> million in potential sales milestones from Innovent. We will recognize sales milestones in the corresponding period of the product sale upon confirmation of net sales milestone threshold achievement by Innovent. We are also eligible to receive tiered royalties from the high-teens to the low-twenties on future sales of products resulting from the collaboration. We retain an option to assist in the promotion of the three product candidates in the Innovent territories.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie2ffba3ee5384c86becdb38ff117ca9a_7">Table of Contents</a></span></div></div><ix:continuation id="i6f7c465e6cdf4756a34e92edf663148a" continuedAt="icbccd06636604c6d8de7b9c01f8f259a"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Zai Lab</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2019, we entered into a Collaboration and License Agreement with Zai Lab. Under the terms of this agreement, Zai Lab received development and exclusive commercialization rights to INCMGA0012 in hematology and oncology in mainland China, Hong Kong, Macau and Taiwan.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The agreement allows for Zai Lab to continue development of the licensed molecule and to submit the licensed molecule to authorities for regulatory approval within the agreement territory, upon which we are eligible for up to $<ix:nonFraction unitRef="usd" contextRef="i96f4281beb534126a1eef106e0789ece_D20190701-20190731" decimals="-5" name="incy:LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMjQwNTU_b4101689-40a4-43c1-9db4-1f9bd40204a6">22.5</ix:nonFraction> million in potential development and regulatory milestones. We recognize development and regulatory milestones upon confirmation of achievement of the event, as development and regulatory approvals are events not controllable by us but rather development activities of Zai Lab and decisions made by regulatory agencies.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event of commercialization of the licensed molecule, we are eligible to receive up to $<ix:nonFraction unitRef="usd" contextRef="iebdcdab801a74c27a6126ac544405996_D20190701-20190731" decimals="-5" name="incy:LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMjQ0NjM_932fb58e-d01e-411c-a9f3-739b424bf198">37.5</ix:nonFraction> million in potential sales milestones from Zai Lab. We will recognize sales milestones in the corresponding period of the product sale upon confirmation of net sales milestone threshold achievement by Zai Lab. We are also eligible to receive tiered royalties from the low to mid-twenties on future product sales resulting from the collaboration. We also retain an option to assist in the promotion of INCMGA0012 in Zai Lab&#8217;s licensed territories.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">MorphoSys</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2020, we entered into a Collaboration and License Agreement with MorphoSys AG and MorphoSys US Inc., a wholly-owned subsidiary of MorphoSys AG (together with MorphoSys AG, &#8220;MorphoSys&#8221;), covering the worldwide development and commercialization of MOR208 (tafasitamab), an investigational Fc engineered monoclonal antibody directed against the target molecule CD19 that is currently in clinical development by MorphoSys. MorphoSys has exclusive worldwide development and commercialization rights to tafasitamab under a June 2010 collaboration and license agreement with Xencor, Inc.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the agreement, we received exclusive commercialization rights outside of the United States, and MorphoSys and we have co-commercialization rights in the United States, with respect to tafasitamab. MorphoSys is responsible for leading the commercialization strategy and booking all revenue from sales of tafasitamab in the United States, and we and MorphoSys are both responsible for commercialization efforts in the United States and will share equally the profits and losses from the co-commercialization efforts. We will lead the commercialization strategy outside of the United States, and will be responsible for commercialization efforts and book all revenue from sales of tafasitamab outside of the United States, subject to our royalty payment obligations set forth below. We and MorphoSys have agreed to co-develop tafasitamab and to share development costs associated with global and U.S.-specific clinical trials, with Incyte responsible for <ix:nonFraction unitRef="number" contextRef="i900f0ac816ab4775ab2106619f594870_D20220101-20220930" decimals="2" name="incy:LicenseAgreementPercentageOfFutureGlobalDevelopmentCostsFunded" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMjY0Nzg_8e7202fa-9c53-484d-9b58-ad6c4e1f4f1c">55</ix:nonFraction>% of such costs and MorphoSys responsible for <ix:nonFraction unitRef="number" contextRef="i591cacee8aca4012a248fa2c96cea301_D20220101-20220930" decimals="2" name="incy:LicenseAgreementPercentageOfFutureGlobalDevelopmentCostsFunded" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMjY1MjU_6404916a-7cb5-4b93-a821-8aeecb61533f">45</ix:nonFraction>% of such costs. Each company is responsible for funding any independent development activities, and we are responsible for funding development activities specific to territories outside of the United States. All development costs related to the collaboration are subject to a joint development plan. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MorphoSys is eligible to receive up to $<ix:nonFraction unitRef="usd" contextRef="i6aecf3dce21d42e7851bf481a425bc46_I20200131" decimals="-5" name="incy:LicenseAgreementAdditionalMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMjY4Njc_57b257d2-4f90-4e89-a2b2-3c2d794d66d0">737.5</ix:nonFraction> million in future contingent development and regulatory milestones and up to $<ix:nonFraction unitRef="usd" contextRef="i8d1b83baba194bed8477bb9ea0de3df7_I20200131" decimals="-5" name="incy:LicenseAgreementAdditionalMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMjY5Mzk_c4f8298e-158e-495d-9c0c-0c64d3616cb5">315.0</ix:nonFraction> million in commercialization milestones as well as tiered royalties ranging from the mid-teens to mid-twenties of net sales outside of the United States. MorphoSys&#8217; right to receive royalties in any particular country will expire upon the last to occur of (a) the expiration of patent rights in that particular country, (b) a specified period of time after the first post-marketing authorization sale of a licensed product comprising tafasitamab in that country, and (c) the expiration of any regulatory exclusivity for that licensed product in that country. As of September&#160;30, 2022, we have paid MorphoSys milestones totaling $<ix:nonFraction unitRef="usd" contextRef="ifecd0798049d402f9683bec43016bf55_D20200101-20220930" decimals="-5" name="incy:LicenseAgreementMilestonePaymentAmountPaid" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMjE5OTAyMzM3NTExMw_af743f64-9346-47af-8187-b18fa27440ce">2.5</ix:nonFraction> million.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, under the terms of the agreement and pursuant to a related purchase agreement, we purchased American Depositary Shares (&#8220;ADSs&#8221;), each representing <ix:nonFraction unitRef="number" contextRef="i7acbcf60ab2042008f713a4d43e83de9_I20200131" decimals="2" name="incy:SubsidiaryStockConversionRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMjc2NTM_948c84b9-bc21-47a0-9d83-49fd8812923f">0.25</ix:nonFraction> of an ordinary share of MorphoSys AG, for an aggregate purchase price of $<ix:nonFraction unitRef="usd" contextRef="i7acbcf60ab2042008f713a4d43e83de9_I20200131" decimals="-5" name="us-gaap:EquityMethodInvestmentAggregateCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMjc3Mjk_02e44de7-a619-42dd-92f2-5075a37d7f94">150.0</ix:nonFraction> million or $<ix:nonFraction unitRef="usdPerShare" contextRef="i7acbcf60ab2042008f713a4d43e83de9_I20200131" decimals="2" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMjc3MzU_ebf8058d-d024-4573-a963-7dc1345f562f">41.33</ix:nonFraction> per ADS (such ADSs to be purchased, the &#8220;New ADSs&#8221;). The fair market value of our long term investment in MorphoSys as of September&#160;30, 2022 and December&#160;31, 2021 was $<ix:nonFraction unitRef="usd" contextRef="i2ed4e89797ba4aaf9b7ebc41ec200ef4_I20220930" decimals="-5" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMjc4NzQ_8ef6afce-bbbf-431b-b7a0-0d776a0ba8ea">18.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ia375a7c89bc74d8bbfbae792527a8710_I20211231" decimals="-5" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMjc4ODE_01f45f8b-5bc4-4102-a418-8e54d8b1b76f">34.2</ix:nonFraction> million, respectively.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie2ffba3ee5384c86becdb38ff117ca9a_7">Table of Contents</a></span></div></div><ix:continuation id="icbccd06636604c6d8de7b9c01f8f259a" continuedAt="i34e3b18898e54d08bc62aada12e18407"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to hold the investment in MorphoSys for the foreseeable future and therefore, are accounting for our shares held in MorphoSys at fair value whereby the investment is marked to market through earnings in each reporting period. Given our intent to hold the investment for the foreseeable future, we have classified the investment within long term investments on the accompanying condensed consolidated balance sheets. For the three and nine months ended September&#160;30, 2022, we recorded an unrealized gain of $<ix:nonFraction unitRef="usd" contextRef="i743d644eae334843b9ede7cb71b9c67d_D20220701-20220930" decimals="-5" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMjg0NzI_4ed8502c-773e-40f8-85f9-bab6f490a874">0.8</ix:nonFraction> million and an unrealized loss of $<ix:nonFraction unitRef="usd" contextRef="i9415bb6d6cbd4c08a203ce650cc97142_D20220101-20220930" decimals="-5" sign="-" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMjg0Nzk_296632a7-11b8-42f8-a09a-e1113e2e700e">15.9</ix:nonFraction> million, respectively, based on the change in fair value of MorphoSys&#8217; ordinary shares during the respective periods. For the three and nine months ended September&#160;30, 2021, we recorded an unrealized loss of $<ix:nonFraction unitRef="usd" contextRef="i5c84e3647ab24388b648b9a8ab264afa_D20210701-20210930" decimals="-5" sign="-" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMjg2NTQ_3b834a63-cd0a-486b-9172-5ce1998e00dd">27.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="idaa0f5c512544ed5bb9ed44eff567a1b_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMjg2NjE_0f4cf5b3-1b71-445f-bf1e-363f22ae1845">60.2</ix:nonFraction> million, respectively, based on the change in fair value of MorphoSys&#8217; ordinary shares during the respective periods. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our <ix:nonFraction unitRef="number" contextRef="ie043e97a1aa74373b87fb3609b47dd3c_D20220101-20220930" decimals="2" name="incy:CollaborationAgreementProfitLossSharingRatio" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMjg3Nzk_117c7714-2562-48bf-ab42-287e0b60aefa"><ix:nonFraction unitRef="number" contextRef="ie686f463b19c46aea6f673458c296cfa_D20220701-20220930" decimals="2" name="incy:CollaborationAgreementProfitLossSharingRatio" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMjg3Nzk_c9fb1329-6c2d-4e02-a83d-05f1954c6a14">50</ix:nonFraction></ix:nonFraction>% share of the United States loss for the commercialization of tafasitamab for the three and nine months ended September&#160;30, 2022 was $<ix:nonFraction unitRef="usd" contextRef="i49acad92f3dd479a8b0f38d89cfdd456_D20220701-20220930" decimals="-3" name="incy:CollaborationLossSharingExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMTY0OTI2NzU2MzAzNA_93f8e007-0ed9-47fe-8c6b-47214778c14c">1.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ibf40aaa491714d97a2353162af92483b_D20220101-20220930" decimals="-3" name="incy:CollaborationLossSharingExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMTY0OTI2NzU2MzAzOA_ff2682ae-5643-4fc8-a708-906f9303689e">9.1</ix:nonFraction> million, respectively, and is recorded as collaboration loss sharing on the condensed consolidated statement of operations. Our <ix:nonFraction unitRef="number" contextRef="ie043e97a1aa74373b87fb3609b47dd3c_D20220101-20220930" decimals="2" name="incy:CollaborationAgreementProfitLossSharingRatio" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMTY0OTI2NzUzMTE2Mg_117c7714-2562-48bf-ab42-287e0b60aefa"><ix:nonFraction unitRef="number" contextRef="ie686f463b19c46aea6f673458c296cfa_D20220701-20220930" decimals="2" name="incy:CollaborationAgreementProfitLossSharingRatio" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMTY0OTI2NzUzMTE2Mg_c9fb1329-6c2d-4e02-a83d-05f1954c6a14">50</ix:nonFraction></ix:nonFraction>% share of the United States loss for the commercialization of tafasitamab for the three and nine months ended September&#160;30, 2021 was $<ix:nonFraction unitRef="usd" contextRef="i52bb96abc5854205a71aecc9f552d0a1_D20210701-20210930" decimals="-3" name="incy:CollaborationLossSharingExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMTY0OTI2NzU2MzA0Mg_4da9328f-136b-4300-a87f-396ad0b44815">9.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i052ba28ba496497ba9474f71db32c295_D20210101-20210930" decimals="-3" name="incy:CollaborationLossSharingExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMTY0OTI2NzU2MzA0Ng_d1ad0eae-09ac-4875-99e5-de5cb874d7a6">29.5</ix:nonFraction> million, respectively, and is recorded as collaboration loss sharing on the condensed consolidated statement of operations. Research and development expenses for the three and nine months ended September&#160;30, 2022, includes $<ix:nonFraction unitRef="usd" contextRef="i8d57ef7a2a5e4baea3532431671ef13c_D20220701-20220930" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMjkzMjA_7e381838-ead2-4377-ac3d-78fe76055a85">21.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i339dc7a864644d6fa19c079e6c5c35f2_D20220101-20220930" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMjkzMjc_bc0e5fd9-efd1-4bc8-9aa3-b382d79bb7fc">70.4</ix:nonFraction> million, respectively, related to our <ix:nonFraction unitRef="number" contextRef="i900f0ac816ab4775ab2106619f594870_D20220101-20220930" decimals="2" name="incy:LicenseAgreementPercentageOfFutureGlobalDevelopmentCostsFunded" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMTY0OTI2NzUzMTE1NA_8e7202fa-9c53-484d-9b58-ad6c4e1f4f1c">55</ix:nonFraction>% share of the co-development costs for tafasitamab. Research and development expenses for the three and nine months ended September&#160;30, 2021, includes $<ix:nonFraction unitRef="usd" contextRef="ib8a2da8278cb46e5a34861f79068cd18_D20210701-20210930" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMjk0ODU_e9db3092-d5bb-464c-9191-be1a4a0d5c26">21.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="iaffe85fc70e4417eb1de69b0992095b4_D20210101-20210930" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMjk0OTI_fe9b0a46-0cd4-4767-91c4-2df7fb0b1d79">55.8</ix:nonFraction> million, respectively, related to our <ix:nonFraction unitRef="number" contextRef="i900f0ac816ab4775ab2106619f594870_D20220101-20220930" decimals="2" name="incy:LicenseAgreementPercentageOfFutureGlobalDevelopmentCostsFunded" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMTY0OTI2NzUzMTE1OA_8e7202fa-9c53-484d-9b58-ad6c4e1f4f1c">55</ix:nonFraction>% share of the co-development costs for tafasitamab. At September&#160;30, 2022 and December&#160;31, 2021, $<ix:nonFraction unitRef="usd" contextRef="i058a1a9cef2b4e36bcbc453963f518d2_I20220930" decimals="-5" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMjk1OTM_83eb6406-bdba-4b49-b92a-35650bf21556">72.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i8ea67dc6fe88438cbc0a45ad09002fec_I20211231" decimals="-5" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMjk2MDA_e78a98c8-b30b-4230-8b40-f8567f1e5fae">21.5</ix:nonFraction> million, respectively, was included in accrued and other liabilities on the condensed consolidated balance sheets for amounts due to MorphoSys under the agreement.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Nimble</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, we entered into a Collaboration and License Agreement with Nimble Therapeutics, Inc. (&#8220;Nimble&#8221;). Under the terms of this agreement, Nimble will utilize their peptide synthesis, screening and optimization platform for discovery and validation of peptides against specified targets. Under the agreement, Nimble is eligible to receive up to $<ix:nonFraction unitRef="usd" contextRef="i68d610f80f7e4dd1b7076852e33351b9_I20220930" decimals="-5" name="incy:LicenseAgreementAdditionalMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMzAxMTE_4debf633-fd21-408d-9090-7218c64e69da">8.0</ix:nonFraction> million in future contingent discovery milestones and up to $<ix:nonFraction unitRef="usd" contextRef="if241609d783147a2a65ee7d8f3cfab8e_I20220930" decimals="-5" name="incy:LicenseAgreementAdditionalMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMzAxNjY_47bd9251-d374-4b55-955d-29d4105bf083">127.0</ix:nonFraction> million in future contingent development and regulatory milestones. Additionally, in the event of successful commercialization, Nimble is eligible to receive up to $<ix:nonFraction unitRef="usd" contextRef="i0c67636b0e5c40e3bccf2287aa2dd24e_I20220930" decimals="-5" name="incy:LicenseAgreementAdditionalMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMzAzMjU_f582fc9d-aaaa-4da4-83c8-6eecc4f02589">130.0</ix:nonFraction> million in future contingent sales milestones and tiered royalties on net sales in the low single digits.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">InnoCare</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2021, we entered into a Collaboration and License Agreement with Sunny Investments Limited, a wholly-owned subsidiary of InnoCare Pharma Limited (&#8220;InnoCare&#8221;). InnoCare received development and exclusive commercialization rights to tafasitamab in hematology and oncology in mainland China, Hong Kong, Macau and Taiwan. In September 2021, we recognized an upfront payment under this agreement of $<ix:nonFraction unitRef="usd" contextRef="i54911354715749fdbd74f62ce9dd1ad8_D20210901-20210930" decimals="-5" name="incy:LicenseAgreementUpfrontPaymentReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMzA4MTg_459bd0a0-4f34-45d9-81b4-7ec9ff50b28a">35.0</ix:nonFraction> million upon our transfer of technology related to the licensed product candidate to InnoCare, which was recorded in milestone and contract revenues on the consolidated statement of operations for the year ended December 31, 2021. Under the terms of this agreement, we are eligible to receive up to an additional $<ix:nonFraction unitRef="usd" contextRef="i7e81499535aa4d19aae8e5cfa7cac860_D20220930-20220930" decimals="-5" name="incy:LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMzExMjY_af6fad5a-6ddc-4530-9d9a-22f0732d8e96">82.5</ix:nonFraction> million in potential development, regulatory and commercial milestones. We recognize development and regulatory milestones upon confirmation of achievement of the event, as development and regulatory approvals are events not controllable by us but rather development activities of InnoCare and decisions made by regulatory agencies. In the event of commercialization, we will recognize sales milestones in the corresponding period of the product sale upon confirmation of net sales milestone threshold achievement by InnoCare.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Syndax</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2021, we entered into a Collaboration and License Agreement with Syndax Pharmaceuticals, Inc. (&#8220;Syndax&#8221;), covering the worldwide development and commercialization of SNDX-6352 (&#8220;axatilimab&#8221;). Axatilimab, currently in clinical development by Syndax, is a monoclonal antibody that blocks the colony stimulating factor-1 (CSF-1) receptor. Syndax has exclusive worldwide development and commercialization rights to axatilimab under a June 2016 license agreement with UCB Biopharma Sprl. The agreement became effective in December 2021.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie2ffba3ee5384c86becdb38ff117ca9a_7">Table of Contents</a></span></div></div><ix:continuation id="i34e3b18898e54d08bc62aada12e18407"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the agreement, we received exclusive commercialization rights outside of the United States, and Syndax and we have co-commercialization rights in the United States, with respect to axatilimab. We will be responsible for leading the commercialization strategy and booking all revenue from sales of axatilimab globally, and Syndax will have the option to co-commercialization axatilimab with Incyte in the United States. Incyte and Syndax will share equally the profits and losses from the co-commercialization efforts in the United States. Sales of axatilimab outside the United States will be subject to our royalty payment obligations to Syndax, as set forth below. We and Syndax have agreed to co-develop axatilimab and to share development costs associated with global and U.S.-specific clinical trials, with Incyte responsible for <ix:nonFraction unitRef="number" contextRef="ic4b6bf4c21e94e4e8eac1ce2ff2aca3c_D20210901-20210930" decimals="2" name="incy:LicenseAgreementPercentageOfFutureGlobalDevelopmentCostsFunded" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMzMwNDM_fb0b58a2-968f-4f47-b96d-c9b639e85856">55</ix:nonFraction>% of such costs and Syndax responsible for <ix:nonFraction unitRef="number" contextRef="i2fc0a1b5bbc34643b361651b2d12a002_D20210901-20210930" decimals="2" name="incy:LicenseAgreementPercentageOfFutureGlobalDevelopmentCostsFunded" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMzMwODc_a3bb9425-63e2-4d4b-8042-b9cbe7c9a5e7">45</ix:nonFraction>% of such costs. Each company is responsible for funding any independent development activities. All development costs related to the collaboration are subject to a joint development plan. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021, we paid Syndax an upfront, non-refundable payment of $<ix:nonFraction unitRef="usd" contextRef="ice2384877b1e441482f1b13c9a8dae52_D20211201-20211231" decimals="-5" name="incy:LicenseAgreementUpfrontPaymentAmountPaid" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMzMzMzg_4237e32e-0b68-4fd6-b4ae-d6b0402307b0">117.0</ix:nonFraction> million, which was recorded in research and development expense on the consolidated statement of operations for the year ended December 31, 2021. Syndax is eligible to receive up to $<ix:nonFraction unitRef="usd" contextRef="i381ad8904ad94b698038402e2dbae630_I20220930" decimals="-5" name="incy:LicenseAgreementAdditionalMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMzM1MDA_b50845c5-8d6a-4d12-9fec-ec11eff2c413">220.0</ix:nonFraction> million in future contingent development and regulatory milestones and up to $<ix:nonFraction unitRef="usd" contextRef="i9c8cc765b77d4e319490794de2d57720_I20220930" decimals="-5" name="incy:LicenseAgreementAdditionalMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMzM1NzM_eb96498f-a658-47c3-bd61-a73692404c8c">230.0</ix:nonFraction> million in sales milestones as well as tiered royalties ranging in the mid-teens on net sales in Europe and Japan and low double digit percentage on net sales in the rest of the world outside of the United States. Syndax&#8217; right to receive royalties in any particular country will expire upon the last to occur of (a) the expiration of patent rights in that particular country, (b) a specified period of time after the first post-marketing authorization sale of a licensed product comprising axatilimab in that country, and (c) the expiration of any regulatory exclusivity for that licensed product in that country.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, under the terms of the agreement and pursuant to a related stock purchase agreement, we purchased approximately <ix:nonFraction unitRef="shares" contextRef="ic75be732674a48cc932a3908c0f0125f_D20210901-20210930" decimals="-5" name="incy:PurchaseOfCommonStockUnderStockPurchaseAgreementInShares" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMzQzMDg_fc3c0ac1-59dd-4239-86ed-4833ba1481ac">1.4</ix:nonFraction>&#160;million shares of Syndax common stock for an aggregate purchase price of $<ix:nonFraction unitRef="usd" contextRef="iab65428e773d4e1f81be1d9a26ea6741_I20220930" decimals="-5" name="us-gaap:EquityMethodInvestmentAggregateCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMzQzNzY_e6663e3a-97d0-4bbd-b87a-d9f3d93c1553">35.0</ix:nonFraction> million, or $<ix:nonFraction unitRef="usdPerShare" contextRef="i8fa5c0ac0f304b3f986fce0cfbaa390d_I20210930" decimals="2" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMzQzODM_ec278ac5-e8b8-4b8b-9fab-c1ec9d74b48a">24.62</ix:nonFraction> per share. We completed the purchase of the shares on December 9, 2021 when the closing price on The Nasdaq Stock Market was $<ix:nonFraction unitRef="usdPerShare" contextRef="i5ae4ff1b717c42c4b158977281cf10aa_I20211209" decimals="2" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMzQ0OTc_9b5c8fb6-f531-4d61-a0e3-b162bb75b238">17.48</ix:nonFraction> per share. Of the $<ix:nonFraction unitRef="usd" contextRef="i5ae4ff1b717c42c4b158977281cf10aa_I20211209" decimals="-5" name="us-gaap:EquityMethodInvestmentAggregateCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMTY0OTI2NzU2MzA4Mw_7f7047b9-8237-417e-a326-092eac9020ad">35.0</ix:nonFraction> million aggregate purchase price paid, $<ix:nonFraction unitRef="usd" contextRef="i5ae4ff1b717c42c4b158977281cf10aa_I20211209" decimals="-5" name="us-gaap:LongTermInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMzQ1NTI_c434401e-ffb6-49ce-9c51-64618209b24c">24.8</ix:nonFraction> million was allocated to our stock purchase and was recorded within long term investments and $<ix:nonFraction unitRef="usd" contextRef="ib136551050f34038b1062509c10fd644_D20211209-20211209" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMzQ2NDE_f8a9e4ea-e422-4f02-91da-cf00b31ea9ae">10.2</ix:nonFraction> million, representing premium paid on the purchase, was allocated to research and development expense on the consolidated statement of operations for the year ended December 31, 2021. The fair market value of our long term investment in Syndax as of September&#160;30, 2022 and December&#160;31, 2021 was $<ix:nonFraction unitRef="usd" contextRef="i8a234f090f5e47568ec964b185b6ea18_I20220930" decimals="-5" name="us-gaap:LongTermInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMzQ4ODU_f5d1a61a-5624-4210-967b-10bcab93fe3b">34.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i8f65aa20c7b04a3aa4af35f8d8783e0d_I20211231" decimals="-5" name="us-gaap:LongTermInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMzQ4OTI_ff958607-bc16-475d-86ca-0607c1b92cac">31.1</ix:nonFraction> million.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to hold the investment in Syndax for the foreseeable future and therefore, are accounting for our shares held in Syndax at fair value whereby the investment is marked to market through earnings in each reporting period. Given our intent to hold the investment for the foreseeable future, we have classified the investment within long term investments on the accompanying condensed consolidated balance sheets. For the three and nine months ended September&#160;30, 2022, we recorded an unrealized gain of $<ix:nonFraction unitRef="usd" contextRef="i0eb6eb6c67a046c99cb82fbf4c1e3ab3_D20220701-20220930" decimals="-5" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMzU0NjA_297cc7b9-cd5b-4c0b-befb-c1a0a719f6c6">6.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i91c3988b9dd7488dbbd895a2cfde280d_D20220101-20220930" decimals="-5" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMzU0ODk_8c642c54-0b62-4248-aa7e-e524fa61a919">3.1</ix:nonFraction> million, respectively, based on the change in fair value of Syndax&#8217;s common stock during the respective periods.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Maruho</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2022, we entered into a strategic alliance agreement with Maruho, Co., Ltd (&#8220;Maruho&#8221;) for the development, manufacturing and exclusive commercialization of ruxolitinib cream, for treatment of autoimmune and inflammatory dermatology indications in Japan. Maruho will receive the rights to develop, manufacture and exclusively commercialize ruxolitinib cream, and other potential future topical formulations of ruxolitinib, in autoimmune and inflammatory dermatologic diseases, including vitiligo and atopic dermatitis, in Japan. Under the terms of the agreement, we received an upfront payment from Maruho which was deferred and recorded in other liabilities on the condensed consolidated balance sheet and we are eligible to receive additional potential development, regulatory and commercial milestones and royalties on net sales of the licensed product in Japan.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">21</span></div></div></div><div id="ie2ffba3ee5384c86becdb38ff117ca9a_58"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie2ffba3ee5384c86becdb38ff117ca9a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 8. Property and Equipment, net</span></div><ix:nonNumeric contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81OC9mcmFnOjU3NjUyN2FlNjcwYTRkOTFhOTFlNGY3MmIxZjA0ZTI4L3RleHRyZWdpb246NTc2NTI3YWU2NzBhNGQ5MWE5MWU0ZjcyYjFmMDRlMjhfMTkxNg_d44e7b40-0da4-4fe3-8de7-eb03f075de5e" escape="true"><ix:nonNumeric contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81OC9mcmFnOjU3NjUyN2FlNjcwYTRkOTFhOTFlNGY3MmIxZjA0ZTI4L3RleHRyZWdpb246NTc2NTI3YWU2NzBhNGQ5MWE5MWU0ZjcyYjFmMDRlMjhfMTkxNw_012c23bd-a4e6-454f-916a-991cae0ab49e" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consists of the following (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Office equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a62ea7776234ba0824931335a0d4825_I20220930" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81OC9mcmFnOjU3NjUyN2FlNjcwYTRkOTFhOTFlNGY3MmIxZjA0ZTI4L3RhYmxlOjA5YjE0NDQwYTQ3MTQyNTliMTNkZWVlYjE3OTVlOTMyL3RhYmxlcmFuZ2U6MDliMTQ0NDBhNDcxNDI1OWIxM2RlZWViMTc5NWU5MzJfMS0xLTEtMS04MQ_69520d85-accc-4ad4-b499-cf32e927686f">22,527</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i132cda3dcfdc4ce6853fafa85f1782e7_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81OC9mcmFnOjU3NjUyN2FlNjcwYTRkOTFhOTFlNGY3MmIxZjA0ZTI4L3RhYmxlOjA5YjE0NDQwYTQ3MTQyNTliMTNkZWVlYjE3OTVlOTMyL3RhYmxlcmFuZ2U6MDliMTQ0NDBhNDcxNDI1OWIxM2RlZWViMTc5NWU5MzJfMS0zLTEtMS04MQ_78f7b62a-4774-493b-ba99-603f324db1ee">22,554</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Laboratory equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie059b8e396a34f60beab49836d33d129_I20220930" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81OC9mcmFnOjU3NjUyN2FlNjcwYTRkOTFhOTFlNGY3MmIxZjA0ZTI4L3RhYmxlOjA5YjE0NDQwYTQ3MTQyNTliMTNkZWVlYjE3OTVlOTMyL3RhYmxlcmFuZ2U6MDliMTQ0NDBhNDcxNDI1OWIxM2RlZWViMTc5NWU5MzJfMi0xLTEtMS04MQ_98572c18-afef-4cd9-b8d0-221aec7fc395">115,507</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2df7a55feb96443a96a33b7ff9a2e1a5_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81OC9mcmFnOjU3NjUyN2FlNjcwYTRkOTFhOTFlNGY3MmIxZjA0ZTI4L3RhYmxlOjA5YjE0NDQwYTQ3MTQyNTliMTNkZWVlYjE3OTVlOTMyL3RhYmxlcmFuZ2U6MDliMTQ0NDBhNDcxNDI1OWIxM2RlZWViMTc5NWU5MzJfMi0zLTEtMS04MQ_7a8d141e-e46c-4053-802c-ba3186d9a84f">105,040</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Computer equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ffd71f442ea4f50bb5fe72e558fe509_I20220930" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81OC9mcmFnOjU3NjUyN2FlNjcwYTRkOTFhOTFlNGY3MmIxZjA0ZTI4L3RhYmxlOjA5YjE0NDQwYTQ3MTQyNTliMTNkZWVlYjE3OTVlOTMyL3RhYmxlcmFuZ2U6MDliMTQ0NDBhNDcxNDI1OWIxM2RlZWViMTc5NWU5MzJfMy0xLTEtMS04MQ_af24db96-6545-4307-bafc-da6ef54feac4">88,239</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b31e55bf720475390b524cce573a3d0_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81OC9mcmFnOjU3NjUyN2FlNjcwYTRkOTFhOTFlNGY3MmIxZjA0ZTI4L3RhYmxlOjA5YjE0NDQwYTQ3MTQyNTliMTNkZWVlYjE3OTVlOTMyL3RhYmxlcmFuZ2U6MDliMTQ0NDBhNDcxNDI1OWIxM2RlZWViMTc5NWU5MzJfMy0zLTEtMS04MQ_b216feef-2ada-4f18-a5c0-06665e1d37dd">79,871</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Land</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i706ab952dd37469eaeedc74245929deb_I20220930" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81OC9mcmFnOjU3NjUyN2FlNjcwYTRkOTFhOTFlNGY3MmIxZjA0ZTI4L3RhYmxlOjA5YjE0NDQwYTQ3MTQyNTliMTNkZWVlYjE3OTVlOTMyL3RhYmxlcmFuZ2U6MDliMTQ0NDBhNDcxNDI1OWIxM2RlZWViMTc5NWU5MzJfNC0xLTEtMS04MQ_4be0ddd9-3110-4fd7-a209-f3638feed77e">10,139</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15460e5c3abd492e81486c9dd98ed0f9_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81OC9mcmFnOjU3NjUyN2FlNjcwYTRkOTFhOTFlNGY3MmIxZjA0ZTI4L3RhYmxlOjA5YjE0NDQwYTQ3MTQyNTliMTNkZWVlYjE3OTVlOTMyL3RhYmxlcmFuZ2U6MDliMTQ0NDBhNDcxNDI1OWIxM2RlZWViMTc5NWU5MzJfNC0zLTEtMS04MQ_67d53221-d4e3-4f34-9757-3fd2d6b200b4">10,494</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Building and leasehold improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7d77528a6e8420e9064a4b8b5c0de47_I20220930" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81OC9mcmFnOjU3NjUyN2FlNjcwYTRkOTFhOTFlNGY3MmIxZjA0ZTI4L3RhYmxlOjA5YjE0NDQwYTQ3MTQyNTliMTNkZWVlYjE3OTVlOTMyL3RhYmxlcmFuZ2U6MDliMTQ0NDBhNDcxNDI1OWIxM2RlZWViMTc5NWU5MzJfNS0xLTEtMS04MQ_22c80cbd-37c5-4bb9-9ffc-39cb9c677ded">432,748</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3fdcc8f5ffb478da66863c12a1b6a68_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81OC9mcmFnOjU3NjUyN2FlNjcwYTRkOTFhOTFlNGY3MmIxZjA0ZTI4L3RhYmxlOjA5YjE0NDQwYTQ3MTQyNTliMTNkZWVlYjE3OTVlOTMyL3RhYmxlcmFuZ2U6MDliMTQ0NDBhNDcxNDI1OWIxM2RlZWViMTc5NWU5MzJfNS0zLTEtMS04MQ_17bf5350-049d-4c17-8c88-89b4b424a962">434,321</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4b01aa79b8543cb89e4d2fe5b5782db_I20220930" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81OC9mcmFnOjU3NjUyN2FlNjcwYTRkOTFhOTFlNGY3MmIxZjA0ZTI4L3RhYmxlOjA5YjE0NDQwYTQ3MTQyNTliMTNkZWVlYjE3OTVlOTMyL3RhYmxlcmFuZ2U6MDliMTQ0NDBhNDcxNDI1OWIxM2RlZWViMTc5NWU5MzJfNi0xLTEtMS04MQ_a3bc336f-ff3d-4c46-913a-c3237150b9bb">23,111</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id090587fece240a682b2eb53308bef79_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81OC9mcmFnOjU3NjUyN2FlNjcwYTRkOTFhOTFlNGY3MmIxZjA0ZTI4L3RhYmxlOjA5YjE0NDQwYTQ3MTQyNTliMTNkZWVlYjE3OTVlOTMyL3RhYmxlcmFuZ2U6MDliMTQ0NDBhNDcxNDI1OWIxM2RlZWViMTc5NWU5MzJfNi0zLTEtMS04MQ_7087a382-dda1-4c83-a486-f72f9d9f32fb">27,308</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51126f0e89df4b60bd2aacb656a90f1a_I20220930" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81OC9mcmFnOjU3NjUyN2FlNjcwYTRkOTFhOTFlNGY3MmIxZjA0ZTI4L3RhYmxlOjA5YjE0NDQwYTQ3MTQyNTliMTNkZWVlYjE3OTVlOTMyL3RhYmxlcmFuZ2U6MDliMTQ0NDBhNDcxNDI1OWIxM2RlZWViMTc5NWU5MzJfNy0xLTEtMS04MQ_98a076fe-4bd6-4e37-937f-9d07c00fb263">225,442</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fa10fd48d3a49168a51c3085f8e84c2_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81OC9mcmFnOjU3NjUyN2FlNjcwYTRkOTFhOTFlNGY3MmIxZjA0ZTI4L3RhYmxlOjA5YjE0NDQwYTQ3MTQyNTliMTNkZWVlYjE3OTVlOTMyL3RhYmxlcmFuZ2U6MDliMTQ0NDBhNDcxNDI1OWIxM2RlZWViMTc5NWU5MzJfNy0zLTEtMS04MQ_3bbccb1c-5c6d-4f78-8222-5698d13d2fa4">220,052</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b4376f8fc614de98c9cf647198c504e_I20220930" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81OC9mcmFnOjU3NjUyN2FlNjcwYTRkOTFhOTFlNGY3MmIxZjA0ZTI4L3RhYmxlOjA5YjE0NDQwYTQ3MTQyNTliMTNkZWVlYjE3OTVlOTMyL3RhYmxlcmFuZ2U6MDliMTQ0NDBhNDcxNDI1OWIxM2RlZWViMTc5NWU5MzJfOC0xLTEtMS04MQ_df536d46-f7c6-4434-afbb-3f90afb5233c">917,713</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab26fe441f0d4ab984456365a7f7cff0_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81OC9mcmFnOjU3NjUyN2FlNjcwYTRkOTFhOTFlNGY3MmIxZjA0ZTI4L3RhYmxlOjA5YjE0NDQwYTQ3MTQyNTliMTNkZWVlYjE3OTVlOTMyL3RhYmxlcmFuZ2U6MDliMTQ0NDBhNDcxNDI1OWIxM2RlZWViMTc5NWU5MzJfOC0zLTEtMS04MQ_17abe797-8def-4316-b441-03b0e003ceab">899,640</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b4376f8fc614de98c9cf647198c504e_I20220930" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81OC9mcmFnOjU3NjUyN2FlNjcwYTRkOTFhOTFlNGY3MmIxZjA0ZTI4L3RhYmxlOjA5YjE0NDQwYTQ3MTQyNTliMTNkZWVlYjE3OTVlOTMyL3RhYmxlcmFuZ2U6MDliMTQ0NDBhNDcxNDI1OWIxM2RlZWViMTc5NWU5MzJfOS0xLTEtMS04MQ_e2530b54-253c-43fb-8e1c-22c82e07973d">201,980</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iab26fe441f0d4ab984456365a7f7cff0_I20211231" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81OC9mcmFnOjU3NjUyN2FlNjcwYTRkOTFhOTFlNGY3MmIxZjA0ZTI4L3RhYmxlOjA5YjE0NDQwYTQ3MTQyNTliMTNkZWVlYjE3OTVlOTMyL3RhYmxlcmFuZ2U6MDliMTQ0NDBhNDcxNDI1OWIxM2RlZWViMTc5NWU5MzJfOS0zLTEtMS04MQ_f8bfc1d0-5e2b-4793-998c-5850017cd44f">175,720</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b4376f8fc614de98c9cf647198c504e_I20220930" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81OC9mcmFnOjU3NjUyN2FlNjcwYTRkOTFhOTFlNGY3MmIxZjA0ZTI4L3RhYmxlOjA5YjE0NDQwYTQ3MTQyNTliMTNkZWVlYjE3OTVlOTMyL3RhYmxlcmFuZ2U6MDliMTQ0NDBhNDcxNDI1OWIxM2RlZWViMTc5NWU5MzJfMTAtMS0xLTEtODE_3aafd813-5d68-4624-8b09-081364e4344c">715,733</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab26fe441f0d4ab984456365a7f7cff0_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81OC9mcmFnOjU3NjUyN2FlNjcwYTRkOTFhOTFlNGY3MmIxZjA0ZTI4L3RhYmxlOjA5YjE0NDQwYTQ3MTQyNTliMTNkZWVlYjE3OTVlOTMyL3RhYmxlcmFuZ2U6MDliMTQ0NDBhNDcxNDI1OWIxM2RlZWViMTc5NWU5MzJfMTAtMy0xLTEtODE_5f66a3d6-adfe-4c63-a21b-6ad97e73191a">723,920</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2017, we acquired additional adjacent buildings to our global headquarters in Wilmington, Delaware and in 2019, began demolition of these buildings and construction of a new laboratory and office building totaling approximately <ix:nonFraction unitRef="sqft" contextRef="i1b500a53ba8b41b09f796fe4eaf76bef_I20191231" decimals="-5" name="us-gaap:AreaOfRealEstateProperty" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81OC9mcmFnOjU3NjUyN2FlNjcwYTRkOTFhOTFlNGY3MmIxZjA0ZTI4L3RleHRyZWdpb246NTc2NTI3YWU2NzBhNGQ5MWE5MWU0ZjcyYjFmMDRlMjhfMzUw_c271d9c6-d13e-41b4-8c22-aed1e2b3ee96">200,000</ix:nonFraction> square feet. The certificate of occupancy was received in December 2021 and we capitalized approximately $<ix:nonFraction unitRef="usd" contextRef="i2370b8e265a34d1aa69e4cb0d71b393f_I20211231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81OC9mcmFnOjU3NjUyN2FlNjcwYTRkOTFhOTFlNGY3MmIxZjA0ZTI4L3RleHRyZWdpb246NTc2NTI3YWU2NzBhNGQ5MWE5MWU0ZjcyYjFmMDRlMjhfNDQ3_daf95d58-cc57-4a55-97e4-a4c8ce92b4bb">158.2</ix:nonFraction> million in building and office equipment that was previously included in construction in progress as of December&#160;31, 2021.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2018, we signed an agreement to rent a building in Morges, Switzerland for an initial term of <ix:nonNumeric contextRef="i3e022afff69a4662b44f01a7c0e13f2b_I20180228" name="us-gaap:LesseeFinanceLeaseTermOfContract1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81OC9mcmFnOjU3NjUyN2FlNjcwYTRkOTFhOTFlNGY3MmIxZjA0ZTI4L3RleHRyZWdpb246NTc2NTI3YWU2NzBhNGQ5MWE5MWU0ZjcyYjFmMDRlMjhfNjQ1_750e04d7-ef84-4589-a84d-f8582908caef">15</ix:nonNumeric> years plus <ix:nonNumeric contextRef="i98615f967e4d480b8209d68fbee3cb04_D20220101-20220930" name="us-gaap:LesseeFinanceLeaseExistenceOfOptionToExtend" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81OC9mcmFnOjU3NjUyN2FlNjcwYTRkOTFhOTFlNGY3MmIxZjA0ZTI4L3RleHRyZWdpb246NTc2NTI3YWU2NzBhNGQ5MWE5MWU0ZjcyYjFmMDRlMjhfNjUz_eee59fee-30e3-4141-9ee4-9b3be7b6fab6">one year</ix:nonNumeric> of free rent, with multiple options to extend for an additional <ix:nonNumeric contextRef="i3e022afff69a4662b44f01a7c0e13f2b_I20180228" name="us-gaap:LesseeFinanceLeaseRenewalTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81OC9mcmFnOjU3NjUyN2FlNjcwYTRkOTFhOTFlNGY3MmIxZjA0ZTI4L3RleHRyZWdpb246NTc2NTI3YWU2NzBhNGQ5MWE5MWU0ZjcyYjFmMDRlMjhfNzIw_b725e206-34d9-4061-b33a-1ba6d3ec244c">20</ix:nonNumeric> years. The building serves as our new European headquarters and consists of approximately <ix:nonFraction unitRef="sqft" contextRef="i5b1c37d431a944d2bedb8074e5a6d652_I20220930" decimals="-5" name="us-gaap:AreaOfRealEstateProperty" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81OC9mcmFnOjU3NjUyN2FlNjcwYTRkOTFhOTFlNGY3MmIxZjA0ZTI4L3RleHRyZWdpb246NTc2NTI3YWU2NzBhNGQ5MWE5MWU0ZjcyYjFmMDRlMjhfODA3_3dd474a9-4784-4eed-a01c-5737ecac5c94">100,000</ix:nonFraction> square feet of office space. This building allowed for consolidation of our European operations that were located in Geneva and Lausanne, Switzerland. In June 2019, we obtained control of the Morges building to begin our construction activity, which was completed in 2020. At that time, we determined the lease to be a finance lease and recorded a lease liability of $<ix:nonFraction unitRef="usd" contextRef="ia946998af0fa49ddb26d6ca660cd4f96_I20190930" decimals="-5" name="us-gaap:FinanceLeaseLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81OC9mcmFnOjU3NjUyN2FlNjcwYTRkOTFhOTFlNGY3MmIxZjA0ZTI4L3RleHRyZWdpb246NTc2NTI3YWU2NzBhNGQ5MWE5MWU0ZjcyYjFmMDRlMjhfMTE2OA_c023e40c-8fbe-414f-907c-c47e7737fda4">31.1</ix:nonFraction> million and a finance lease right-of-use asset of $<ix:nonFraction unitRef="usd" contextRef="ia946998af0fa49ddb26d6ca660cd4f96_I20190930" decimals="-5" name="us-gaap:FinanceLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81OC9mcmFnOjU3NjUyN2FlNjcwYTRkOTFhOTFlNGY3MmIxZjA0ZTI4L3RleHRyZWdpb246NTc2NTI3YWU2NzBhNGQ5MWE5MWU0ZjcyYjFmMDRlMjhfMTIxMw_02da30ce-8abb-4599-b034-6009410fd936">29.1</ix:nonFraction> million, net of a lease incentive from our landlord of $<ix:nonFraction unitRef="usd" contextRef="ia946998af0fa49ddb26d6ca660cd4f96_I20190930" decimals="-5" name="incy:FinanceLeaseLeaseIncentiveReceivable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81OC9mcmFnOjU3NjUyN2FlNjcwYTRkOTFhOTFlNGY3MmIxZjA0ZTI4L3RleHRyZWdpb246NTc2NTI3YWU2NzBhNGQ5MWE5MWU0ZjcyYjFmMDRlMjhfMTI2Mw_4fbff588-1caa-4135-88a5-156ba518ea81">2.0</ix:nonFraction> million. We have capitalized approximately $<ix:nonFraction unitRef="usd" contextRef="i5f74da13198248b88b7490d0362d5443_I20220930" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81OC9mcmFnOjU3NjUyN2FlNjcwYTRkOTFhOTFlNGY3MmIxZjA0ZTI4L3RleHRyZWdpb246NTc2NTI3YWU2NzBhNGQ5MWE5MWU0ZjcyYjFmMDRlMjhfMTMwMQ_8937a92e-ea45-4440-8e65-ef192fc2f3ae">19.5</ix:nonFraction> million in leasehold improvements as of September&#160;30, 2022 relating to Morges.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2018, we signed an agreement to purchase land located in Yverdon, Switzerland. The land was purchased, in cash, for approximately $<ix:nonFraction unitRef="usd" contextRef="ied0dbe564f15462a80f773631b1b4a84_D20180701-20180731" decimals="-5" name="us-gaap:PaymentsToAcquireRealEstate" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81OC9mcmFnOjU3NjUyN2FlNjcwYTRkOTFhOTFlNGY3MmIxZjA0ZTI4L3RleHRyZWdpb246NTc2NTI3YWU2NzBhNGQ5MWE5MWU0ZjcyYjFmMDRlMjhfMTQ5MA_6240eaab-220f-48bc-9d81-08796bf8b7eb">4.8</ix:nonFraction> million. Upon this parcel, we are constructing a large molecule production facility. Construction activity commenced in July 2018, and as of September&#160;30, 2022, we have capitalized approximately $<ix:nonFraction unitRef="usd" contextRef="if65cebf5f28640cc97c1750992f7d09c_I20220930" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81OC9mcmFnOjU3NjUyN2FlNjcwYTRkOTFhOTFlNGY3MmIxZjA0ZTI4L3RleHRyZWdpb246NTc2NTI3YWU2NzBhNGQ5MWE5MWU0ZjcyYjFmMDRlMjhfMTY2NA_d9050097-c6c7-43ce-bd6a-4d7925e30d65">190.5</ix:nonFraction> million in costs for construction, ground preparation and architectural and engineering studies. Inspection from competent authorities was finalized in March 2022, and in June 2022 Swissmedic authorities granted the GMP drug manufacturing license for this facility.</span></div></ix:nonNumeric><div id="ie2ffba3ee5384c86becdb38ff117ca9a_61"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 9. Accrued and Other Current Liabilities</span></div><ix:nonNumeric contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930" name="us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82MS9mcmFnOjc0YjUwYTRkZjA5YTQ0M2Q4ODE1ZTk1ZDk2YTlmZjRjL3RleHRyZWdpb246NzRiNTBhNGRmMDlhNDQzZDg4MTVlOTVkOTZhOWZmNGNfMTMy_8aeaea41-b5ec-46ba-af0d-11574888116e" escape="true"><ix:nonNumeric contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82MS9mcmFnOjc0YjUwYTRkZjA5YTQ0M2Q4ODE1ZTk1ZDk2YTlmZjRjL3RleHRyZWdpb246NzRiNTBhNGRmMDlhNDQzZDg4MTVlOTVkOTZhOWZmNGNfMTMz_6a0d7f94-e8c6-4b87-ad1c-ad49a7cd24da" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued and other current liabilities consisted of the following (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.778%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Royalties</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1.97pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i3b4376f8fc614de98c9cf647198c504e_I20220930" decimals="-3" name="us-gaap:AccruedRoyaltiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82MS9mcmFnOjc0YjUwYTRkZjA5YTQ0M2Q4ODE1ZTk1ZDk2YTlmZjRjL3RhYmxlOjZhZTQxMzg4MGEzYjQyNGZiYjY1OGM4OGViZDQ3YmNhL3RhYmxlcmFuZ2U6NmFlNDEzODgwYTNiNDI0ZmJiNjU4Yzg4ZWJkNDdiY2FfMS0xLTEtMS04MQ_ae0acdc3-370c-4ddb-9674-57ea43d4b69c">248,455</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1.97pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="iab26fe441f0d4ab984456365a7f7cff0_I20211231" decimals="-3" name="us-gaap:AccruedRoyaltiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82MS9mcmFnOjc0YjUwYTRkZjA5YTQ0M2Q4ODE1ZTk1ZDk2YTlmZjRjL3RhYmxlOjZhZTQxMzg4MGEzYjQyNGZiYjY1OGM4OGViZDQ3YmNhL3RhYmxlcmFuZ2U6NmFlNDEzODgwYTNiNDI0ZmJiNjU4Yzg4ZWJkNDdiY2FfMS0zLTEtMS04MQ_1bf422bd-02a6-4e0d-9251-d105a63f1f34">168,412</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical related costs</span></td><td colspan="3" style="padding:2px 1.97pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i3b4376f8fc614de98c9cf647198c504e_I20220930" decimals="-3" name="incy:AccruedClinicalRelatedCostsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82MS9mcmFnOjc0YjUwYTRkZjA5YTQ0M2Q4ODE1ZTk1ZDk2YTlmZjRjL3RhYmxlOjZhZTQxMzg4MGEzYjQyNGZiYjY1OGM4OGViZDQ3YmNhL3RhYmxlcmFuZ2U6NmFlNDEzODgwYTNiNDI0ZmJiNjU4Yzg4ZWJkNDdiY2FfMi0xLTEtMS04MQ_02d50681-eb87-4a02-b20e-03689a7854b9">152,764</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1.97pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="iab26fe441f0d4ab984456365a7f7cff0_I20211231" decimals="-3" name="incy:AccruedClinicalRelatedCostsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82MS9mcmFnOjc0YjUwYTRkZjA5YTQ0M2Q4ODE1ZTk1ZDk2YTlmZjRjL3RhYmxlOjZhZTQxMzg4MGEzYjQyNGZiYjY1OGM4OGViZDQ3YmNhL3RhYmxlcmFuZ2U6NmFlNDEzODgwYTNiNDI0ZmJiNjU4Yzg4ZWJkNDdiY2FfMi0zLTEtMS04MQ_944130c7-c23d-4ba2-8b96-b87fd14db4e1">109,486</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Sales allowances</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.97pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i3b4376f8fc614de98c9cf647198c504e_I20220930" decimals="-3" name="us-gaap:ProvisionForLossOnContracts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82MS9mcmFnOjc0YjUwYTRkZjA5YTQ0M2Q4ODE1ZTk1ZDk2YTlmZjRjL3RhYmxlOjZhZTQxMzg4MGEzYjQyNGZiYjY1OGM4OGViZDQ3YmNhL3RhYmxlcmFuZ2U6NmFlNDEzODgwYTNiNDI0ZmJiNjU4Yzg4ZWJkNDdiY2FfMy0xLTEtMS04MQ_ee5e4dfe-b64d-49a7-bf71-71eeed33702d">186,112</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.97pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="iab26fe441f0d4ab984456365a7f7cff0_I20211231" decimals="-3" name="us-gaap:ProvisionForLossOnContracts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82MS9mcmFnOjc0YjUwYTRkZjA5YTQ0M2Q4ODE1ZTk1ZDk2YTlmZjRjL3RhYmxlOjZhZTQxMzg4MGEzYjQyNGZiYjY1OGM4OGViZDQ3YmNhL3RhYmxlcmFuZ2U6NmFlNDEzODgwYTNiNDI0ZmJiNjU4Yzg4ZWJkNDdiY2FfMy0zLTEtMS04MQ_5fbe2fa4-628e-4229-84a8-83255610c741">136,541</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales and marketing</span></td><td colspan="3" style="padding:2px 1.97pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i3b4376f8fc614de98c9cf647198c504e_I20220930" decimals="-3" name="us-gaap:AccruedMarketingCostsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82MS9mcmFnOjc0YjUwYTRkZjA5YTQ0M2Q4ODE1ZTk1ZDk2YTlmZjRjL3RhYmxlOjZhZTQxMzg4MGEzYjQyNGZiYjY1OGM4OGViZDQ3YmNhL3RhYmxlcmFuZ2U6NmFlNDEzODgwYTNiNDI0ZmJiNjU4Yzg4ZWJkNDdiY2FfNC0xLTEtMS04MQ_8243f0f5-ecc2-43db-a04a-b5cb16fa651c">31,001</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1.97pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="iab26fe441f0d4ab984456365a7f7cff0_I20211231" decimals="-3" name="us-gaap:AccruedMarketingCostsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82MS9mcmFnOjc0YjUwYTRkZjA5YTQ0M2Q4ODE1ZTk1ZDk2YTlmZjRjL3RhYmxlOjZhZTQxMzg4MGEzYjQyNGZiYjY1OGM4OGViZDQ3YmNhL3RhYmxlcmFuZ2U6NmFlNDEzODgwYTNiNDI0ZmJiNjU4Yzg4ZWJkNDdiY2FfNC0zLTEtMS04MQ_415a6aef-15e1-4126-a5d0-5ac3858250df">35,750</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Construction in progress</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.97pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i3b4376f8fc614de98c9cf647198c504e_I20220930" decimals="-3" name="us-gaap:ConstructionPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82MS9mcmFnOjc0YjUwYTRkZjA5YTQ0M2Q4ODE1ZTk1ZDk2YTlmZjRjL3RhYmxlOjZhZTQxMzg4MGEzYjQyNGZiYjY1OGM4OGViZDQ3YmNhL3RhYmxlcmFuZ2U6NmFlNDEzODgwYTNiNDI0ZmJiNjU4Yzg4ZWJkNDdiY2FfNS0xLTEtMS04MQ_b487cebe-a338-474a-a26f-b115759dea80">8,836</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.97pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="iab26fe441f0d4ab984456365a7f7cff0_I20211231" decimals="-3" name="us-gaap:ConstructionPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82MS9mcmFnOjc0YjUwYTRkZjA5YTQ0M2Q4ODE1ZTk1ZDk2YTlmZjRjL3RhYmxlOjZhZTQxMzg4MGEzYjQyNGZiYjY1OGM4OGViZDQ3YmNhL3RhYmxlcmFuZ2U6NmFlNDEzODgwYTNiNDI0ZmJiNjU4Yzg4ZWJkNDdiY2FfNS0zLTEtMS04MQ_b54001b6-b732-4f07-8437-65a0c0fadbb7">27,098</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating lease liabilities</span></td><td colspan="3" style="padding:2px 1.97pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i3b4376f8fc614de98c9cf647198c504e_I20220930" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82MS9mcmFnOjc0YjUwYTRkZjA5YTQ0M2Q4ODE1ZTk1ZDk2YTlmZjRjL3RhYmxlOjZhZTQxMzg4MGEzYjQyNGZiYjY1OGM4OGViZDQ3YmNhL3RhYmxlcmFuZ2U6NmFlNDEzODgwYTNiNDI0ZmJiNjU4Yzg4ZWJkNDdiY2FfNi0xLTEtMS04MQ_f48f57f4-2f68-404b-a5b9-65041e3e3aac">8,492</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1.97pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="iab26fe441f0d4ab984456365a7f7cff0_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82MS9mcmFnOjc0YjUwYTRkZjA5YTQ0M2Q4ODE1ZTk1ZDk2YTlmZjRjL3RhYmxlOjZhZTQxMzg4MGEzYjQyNGZiYjY1OGM4OGViZDQ3YmNhL3RhYmxlcmFuZ2U6NmFlNDEzODgwYTNiNDI0ZmJiNjU4Yzg4ZWJkNDdiY2FfNi0zLTEtMS04MQ_6af6d329-2e66-42a9-a71c-4d94b2d9821c">10,554</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.97pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i3b4376f8fc614de98c9cf647198c504e_I20220930" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82MS9mcmFnOjc0YjUwYTRkZjA5YTQ0M2Q4ODE1ZTk1ZDk2YTlmZjRjL3RhYmxlOjZhZTQxMzg4MGEzYjQyNGZiYjY1OGM4OGViZDQ3YmNhL3RhYmxlcmFuZ2U6NmFlNDEzODgwYTNiNDI0ZmJiNjU4Yzg4ZWJkNDdiY2FfNy0xLTEtMS04MQ_eadb0bf6-13be-439d-9215-5eacb98cfb2e">64,154</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.97pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="iab26fe441f0d4ab984456365a7f7cff0_I20211231" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82MS9mcmFnOjc0YjUwYTRkZjA5YTQ0M2Q4ODE1ZTk1ZDk2YTlmZjRjL3RhYmxlOjZhZTQxMzg4MGEzYjQyNGZiYjY1OGM4OGViZDQ3YmNhL3RhYmxlcmFuZ2U6NmFlNDEzODgwYTNiNDI0ZmJiNjU4Yzg4ZWJkNDdiY2FfNy0zLTEtMS04MQ_4a88afb6-6979-4af0-8193-a24f637444a5">45,754</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total accrued and other current liabilities</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1.97pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i3b4376f8fc614de98c9cf647198c504e_I20220930" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82MS9mcmFnOjc0YjUwYTRkZjA5YTQ0M2Q4ODE1ZTk1ZDk2YTlmZjRjL3RhYmxlOjZhZTQxMzg4MGEzYjQyNGZiYjY1OGM4OGViZDQ3YmNhL3RhYmxlcmFuZ2U6NmFlNDEzODgwYTNiNDI0ZmJiNjU4Yzg4ZWJkNDdiY2FfOC0xLTEtMS04MQ_5e504513-4f82-4378-8e28-e1fa6b016994">699,814</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1.97pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="iab26fe441f0d4ab984456365a7f7cff0_I20211231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82MS9mcmFnOjc0YjUwYTRkZjA5YTQ0M2Q4ODE1ZTk1ZDk2YTlmZjRjL3RhYmxlOjZhZTQxMzg4MGEzYjQyNGZiYjY1OGM4OGViZDQ3YmNhL3RhYmxlcmFuZ2U6NmFlNDEzODgwYTNiNDI0ZmJiNjU4Yzg4ZWJkNDdiY2FfOC0zLTEtMS04MQ_7e7dd0c9-90a4-47ff-bc05-976ffc1b3f43">533,595</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">22</span></div></div></div><div id="ie2ffba3ee5384c86becdb38ff117ca9a_64"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie2ffba3ee5384c86becdb38ff117ca9a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 10. Stock Compensation</span></div><ix:nonNumeric contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RleHRyZWdpb246ZmFlNDc5YmVlYzk3NGU3Njk4MDJlOTE5MjQ4MDEwYzRfNDkzMA_41f3d2a3-5e8b-493b-a94b-03e0c5e8b09a" continuedAt="i3cffdd2c976642e282c148a7d1b86908" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recorded $<ix:nonFraction unitRef="usd" contextRef="id673d80f31e74643a241d2f62db94ca9_D20220701-20220930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RleHRyZWdpb246ZmFlNDc5YmVlYzk3NGU3Njk4MDJlOTE5MjQ4MDEwYzRfNDU_94dbb63b-d340-4620-b4b0-f499d20e1c18">45.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RleHRyZWdpb246ZmFlNDc5YmVlYzk3NGU3Njk4MDJlOTE5MjQ4MDEwYzRfNTI_77269058-c8d5-4d99-a677-835161cb99be">135.7</ix:nonFraction> million of stock compensation expense on our condensed consolidated statements of operations for the three and nine months ended September&#160;30, 2022, respectively. We recorded $<ix:nonFraction unitRef="usd" contextRef="i313b15d35b7045babd1ba61f84a077dd_D20210701-20210930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RleHRyZWdpb246ZmFlNDc5YmVlYzk3NGU3Njk4MDJlOTE5MjQ4MDEwYzRfMTk0_a6724285-2381-4881-84a1-0552e445143e">42.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i0faaba5fcd6b485781cadacae8b2fd8e_D20210101-20210930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RleHRyZWdpb246ZmFlNDc5YmVlYzk3NGU3Njk4MDJlOTE5MjQ4MDEwYzRfMjAy_b5698e30-e255-4780-a17b-e5a71d5c12aa">134.8</ix:nonFraction> million of stock compensation expense on our condensed consolidated statements of operations for the three and nine months ended September&#160;30, 2021, respectively. Stock compensation expense included within our condensed consolidated statements of operations included research and development expense of $<ix:nonFraction unitRef="usd" contextRef="i70b041b0d1e8409a9b019c7f878e45a2_D20220701-20220930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RleHRyZWdpb246ZmFlNDc5YmVlYzk3NGU3Njk4MDJlOTE5MjQ4MDEwYzRfNDcy_b70fcb63-e0bf-40c6-a067-28ad6f892f6d">25.8</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i49a1f92f5e85446da96c93ad448dbab8_D20220101-20220930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RleHRyZWdpb246ZmFlNDc5YmVlYzk3NGU3Njk4MDJlOTE5MjQ4MDEwYzRfNDc2_137831cf-9286-4fd9-98ed-4a0c7b054b38">80.2</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="ia4fb38d378634c26b981ddc5c86f5524_D20210701-20210930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RleHRyZWdpb246ZmFlNDc5YmVlYzk3NGU3Njk4MDJlOTE5MjQ4MDEwYzRfNDgw_8e15fafb-4a4d-4822-9ef8-0029bb7cc9b1">26.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i383fc0ace0f847c4a6eb8bb43c13caff_D20210101-20210930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RleHRyZWdpb246ZmFlNDc5YmVlYzk3NGU3Njk4MDJlOTE5MjQ4MDEwYzRfNDg4_e6230a0c-dcb4-4864-88f9-a08698d59d0d">84.2</ix:nonFraction> million for the three and nine months ended September&#160;30, 2022 and 2021, respectively. Stock compensation expense included within our condensed consolidated statements of operations also included selling, general and administrative expense of $<ix:nonFraction unitRef="usd" contextRef="i5835316ce7724afea3bdb29dcb3a2253_D20220701-20220930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RleHRyZWdpb246ZmFlNDc5YmVlYzk3NGU3Njk4MDJlOTE5MjQ4MDEwYzRfNjk2_ee7199e7-1fef-4d99-af7d-502bf0f5c0ff">18.9</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="ib017a2d350ba431d9ba79b402e1cfb7f_D20220101-20220930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RleHRyZWdpb246ZmFlNDc5YmVlYzk3NGU3Njk4MDJlOTE5MjQ4MDEwYzRfNzAw_aa451054-e2e4-4eac-963f-8eaa3f454c5c">53.5</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i89ed3c93c92745279b334fa5c4526831_D20210701-20210930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RleHRyZWdpb246ZmFlNDc5YmVlYzk3NGU3Njk4MDJlOTE5MjQ4MDEwYzRfNzA0_206fb634-f4b4-4f54-9f70-00ce959ff6dd">15.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i7f29ae45641b4afcab178d487b406c8b_D20210101-20210930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RleHRyZWdpb246ZmFlNDc5YmVlYzk3NGU3Njk4MDJlOTE5MjQ4MDEwYzRfNzEx_91080fd0-0d35-4a60-b228-1d0ed5c347f6">49.5</ix:nonFraction> million for the three and nine months ended September&#160;30, 2022 and 2021, respectively. Stock compensation expense included within our condensed consolidated statements of operations also included cost of product revenues of $<ix:nonFraction unitRef="usd" contextRef="icce988e289034a3fb382746bd6fb055e_D20220701-20220930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RleHRyZWdpb246ZmFlNDc5YmVlYzk3NGU3Njk4MDJlOTE5MjQ4MDEwYzRfOTAw_12769d50-e126-45a1-a95e-47d5453f57da">0.7</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="idcbe2a87e3f1451b8c00c0d575bc9286_D20220101-20220930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RleHRyZWdpb246ZmFlNDc5YmVlYzk3NGU3Njk4MDJlOTE5MjQ4MDEwYzRfOTA0_3fcff9bb-fb71-4f3b-b7cf-3a0f518cbbee">2.0</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i743fbd319cfc457b9da040d45ac71e11_D20210701-20210930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RleHRyZWdpb246ZmFlNDc5YmVlYzk3NGU3Njk4MDJlOTE5MjQ4MDEwYzRfOTA4_58ecc451-66a9-4f76-82fd-d382529ba12e">0.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i29928027a77447828aad4cf785a73286_D20210101-20210930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RleHRyZWdpb246ZmFlNDc5YmVlYzk3NGU3Njk4MDJlOTE5MjQ4MDEwYzRfOTE1_857ec78a-2a61-472c-89af-c8009c00122c">1.1</ix:nonFraction> million, respectively, for the three and nine months ended September&#160;30, 2022 and 2021.</span></div><ix:nonNumeric contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930" name="incy:ScheduleOfShareBasedPaymentAwardStockOptionsAndEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RleHRyZWdpb246ZmFlNDc5YmVlYzk3NGU3Njk4MDJlOTE5MjQ4MDEwYzRfNDkzMQ_ca94d15a-666f-42ca-8b65-529f7421e5a8" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We utilized the Black-Scholes valuation model for estimating the fair value of the stock compensation granted, with the following weighted-average assumptions:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:21.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.998%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Employee Stock Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Employee Stock Purchase Plan</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average risk-free interest rates</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id3db81cbe7d44bf4b59daffdc638772b_D20220701-20220930" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RhYmxlOjJjNWRmMDU2OTZiNDRhMmViMGNlOGIxM2NlMzJlZjdhL3RhYmxlcmFuZ2U6MmM1ZGYwNTY5NmI0NGEyZWIwY2U4YjEzY2UzMmVmN2FfNC0xLTEtMS04MQ_c8a715f1-b690-435c-8e54-fa201b5e0e9b">2.90</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i18064623ae8c40b0b87d8d75806827d8_D20210701-20210930" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RhYmxlOjJjNWRmMDU2OTZiNDRhMmViMGNlOGIxM2NlMzJlZjdhL3RhYmxlcmFuZ2U6MmM1ZGYwNTY5NmI0NGEyZWIwY2U4YjEzY2UzMmVmN2FfNC0zLTEtMS04MQ_a2e44b72-acee-4595-84fe-3074963ca34e">0.76</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i88f8a540b3d94b20983f8902eae30ae2_D20220101-20220930" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RhYmxlOjJjNWRmMDU2OTZiNDRhMmViMGNlOGIxM2NlMzJlZjdhL3RhYmxlcmFuZ2U6MmM1ZGYwNTY5NmI0NGEyZWIwY2U4YjEzY2UzMmVmN2FfNC01LTEtMS04MQ_059d373f-38cb-42e6-8ccd-680e415d7ddd">2.03</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id7acb0824a524ce2b1a6d6eeb3f5b6b8_D20210101-20210930" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RhYmxlOjJjNWRmMDU2OTZiNDRhMmViMGNlOGIxM2NlMzJlZjdhL3RhYmxlcmFuZ2U6MmM1ZGYwNTY5NmI0NGEyZWIwY2U4YjEzY2UzMmVmN2FfNC03LTEtMS04MQ_86652c2d-4222-42df-b3aa-b39c65995845">0.60</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia05518f1a01d4291b4add6208b75e939_D20220701-20220930" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RhYmxlOjJjNWRmMDU2OTZiNDRhMmViMGNlOGIxM2NlMzJlZjdhL3RhYmxlcmFuZ2U6MmM1ZGYwNTY5NmI0NGEyZWIwY2U4YjEzY2UzMmVmN2FfNC05LTEtMS04MQ_3ed65a4f-9972-43be-8c3b-b9a4ae5be875">4.22</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie12951e0177049569a4eaac01ed75693_D20210701-20210930" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RhYmxlOjJjNWRmMDU2OTZiNDRhMmViMGNlOGIxM2NlMzJlZjdhL3RhYmxlcmFuZ2U6MmM1ZGYwNTY5NmI0NGEyZWIwY2U4YjEzY2UzMmVmN2FfNC0xMS0xLTEtODE_7d23ca57-7c52-4286-b3af-ccc03f0c9b51">0.28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icaf56e010147488ebeb835f2e5b31900_D20220101-20220930" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RhYmxlOjJjNWRmMDU2OTZiNDRhMmViMGNlOGIxM2NlMzJlZjdhL3RhYmxlcmFuZ2U6MmM1ZGYwNTY5NmI0NGEyZWIwY2U4YjEzY2UzMmVmN2FfNC0xMy0xLTEtODE_19e7a41a-c872-43e0-8d4e-790d29af52b2">3.44</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6c730d6b5a3349088cf01b0df9f09e86_D20210101-20210930" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RhYmxlOjJjNWRmMDU2OTZiNDRhMmViMGNlOGIxM2NlMzJlZjdhL3RhYmxlcmFuZ2U6MmM1ZGYwNTY5NmI0NGEyZWIwY2U4YjEzY2UzMmVmN2FfNC0xNS0xLTEtODE_6addcd47-8518-4c95-a2ba-df2b5e42b36b">0.22</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average expected life (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id3db81cbe7d44bf4b59daffdc638772b_D20220701-20220930" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RhYmxlOjJjNWRmMDU2OTZiNDRhMmViMGNlOGIxM2NlMzJlZjdhL3RhYmxlcmFuZ2U6MmM1ZGYwNTY5NmI0NGEyZWIwY2U4YjEzY2UzMmVmN2FfNS0xLTEtMS04MQ_75098eff-10b0-4de5-8e3e-6c9d083c844a">5.17</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i18064623ae8c40b0b87d8d75806827d8_D20210701-20210930" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RhYmxlOjJjNWRmMDU2OTZiNDRhMmViMGNlOGIxM2NlMzJlZjdhL3RhYmxlcmFuZ2U6MmM1ZGYwNTY5NmI0NGEyZWIwY2U4YjEzY2UzMmVmN2FfNS0zLTEtMS04MQ_d371da05-30fb-4f42-b2af-1b4a34846c3b">5.16</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i88f8a540b3d94b20983f8902eae30ae2_D20220101-20220930" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RhYmxlOjJjNWRmMDU2OTZiNDRhMmViMGNlOGIxM2NlMzJlZjdhL3RhYmxlcmFuZ2U6MmM1ZGYwNTY5NmI0NGEyZWIwY2U4YjEzY2UzMmVmN2FfNS01LTEtMS04MQ_ca0f57dc-ef5f-4de5-ba7d-a1536acb6225">4.88</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id7acb0824a524ce2b1a6d6eeb3f5b6b8_D20210101-20210930" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RhYmxlOjJjNWRmMDU2OTZiNDRhMmViMGNlOGIxM2NlMzJlZjdhL3RhYmxlcmFuZ2U6MmM1ZGYwNTY5NmI0NGEyZWIwY2U4YjEzY2UzMmVmN2FfNS03LTEtMS04MQ_5c607da5-3160-4022-a2e7-5f44855b7f13">5.00</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia05518f1a01d4291b4add6208b75e939_D20220701-20220930" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RhYmxlOjJjNWRmMDU2OTZiNDRhMmViMGNlOGIxM2NlMzJlZjdhL3RhYmxlcmFuZ2U6MmM1ZGYwNTY5NmI0NGEyZWIwY2U4YjEzY2UzMmVmN2FfNS05LTEtMS04MQ_98689577-db6d-48e0-8be3-7e66e4ba1ead">0.50</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie12951e0177049569a4eaac01ed75693_D20210701-20210930" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RhYmxlOjJjNWRmMDU2OTZiNDRhMmViMGNlOGIxM2NlMzJlZjdhL3RhYmxlcmFuZ2U6MmM1ZGYwNTY5NmI0NGEyZWIwY2U4YjEzY2UzMmVmN2FfNS0xMS0xLTEtODE_0cf380b9-0cc9-4c1d-b993-b87a45fcdcb6">0.50</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="icaf56e010147488ebeb835f2e5b31900_D20220101-20220930" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RhYmxlOjJjNWRmMDU2OTZiNDRhMmViMGNlOGIxM2NlMzJlZjdhL3RhYmxlcmFuZ2U6MmM1ZGYwNTY5NmI0NGEyZWIwY2U4YjEzY2UzMmVmN2FfNS0xMy0xLTEtODE_d2084140-5820-49c3-82e1-254c049ffdfc">0.50</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6c730d6b5a3349088cf01b0df9f09e86_D20210101-20210930" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RhYmxlOjJjNWRmMDU2OTZiNDRhMmViMGNlOGIxM2NlMzJlZjdhL3RhYmxlcmFuZ2U6MmM1ZGYwNTY5NmI0NGEyZWIwY2U4YjEzY2UzMmVmN2FfNS0xNS0xLTEtODE_05acc9dd-00aa-4b57-935b-5b7a5229dcdc">0.50</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id3db81cbe7d44bf4b59daffdc638772b_D20220701-20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RhYmxlOjJjNWRmMDU2OTZiNDRhMmViMGNlOGIxM2NlMzJlZjdhL3RhYmxlcmFuZ2U6MmM1ZGYwNTY5NmI0NGEyZWIwY2U4YjEzY2UzMmVmN2FfNi0xLTEtMS04MQ_80ecb2dc-d8c0-4e6c-a1aa-0a72e0810e6f">35</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i18064623ae8c40b0b87d8d75806827d8_D20210701-20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RhYmxlOjJjNWRmMDU2OTZiNDRhMmViMGNlOGIxM2NlMzJlZjdhL3RhYmxlcmFuZ2U6MmM1ZGYwNTY5NmI0NGEyZWIwY2U4YjEzY2UzMmVmN2FfNi0zLTEtMS04MQ_a4bb9ac7-09c3-4a6a-be6d-aed8ff9b4bba">38</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i88f8a540b3d94b20983f8902eae30ae2_D20220101-20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RhYmxlOjJjNWRmMDU2OTZiNDRhMmViMGNlOGIxM2NlMzJlZjdhL3RhYmxlcmFuZ2U6MmM1ZGYwNTY5NmI0NGEyZWIwY2U4YjEzY2UzMmVmN2FfNi01LTEtMS04MQ_85176926-7dc9-4d16-8569-ce22f308cbdf">36</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id7acb0824a524ce2b1a6d6eeb3f5b6b8_D20210101-20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RhYmxlOjJjNWRmMDU2OTZiNDRhMmViMGNlOGIxM2NlMzJlZjdhL3RhYmxlcmFuZ2U6MmM1ZGYwNTY5NmI0NGEyZWIwY2U4YjEzY2UzMmVmN2FfNi03LTEtMS04MQ_dc43027c-8d4a-4bda-9246-9f9b7f6ec34b">39</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia05518f1a01d4291b4add6208b75e939_D20220701-20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RhYmxlOjJjNWRmMDU2OTZiNDRhMmViMGNlOGIxM2NlMzJlZjdhL3RhYmxlcmFuZ2U6MmM1ZGYwNTY5NmI0NGEyZWIwY2U4YjEzY2UzMmVmN2FfNi05LTEtMS04MQ_4160abcb-8ac4-4343-9ebc-8b09e837b918">31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie12951e0177049569a4eaac01ed75693_D20210701-20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RhYmxlOjJjNWRmMDU2OTZiNDRhMmViMGNlOGIxM2NlMzJlZjdhL3RhYmxlcmFuZ2U6MmM1ZGYwNTY5NmI0NGEyZWIwY2U4YjEzY2UzMmVmN2FfNi0xMS0xLTEtODE_7845db89-c37d-48b6-8167-979b3d96d380">25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icaf56e010147488ebeb835f2e5b31900_D20220101-20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RhYmxlOjJjNWRmMDU2OTZiNDRhMmViMGNlOGIxM2NlMzJlZjdhL3RhYmxlcmFuZ2U6MmM1ZGYwNTY5NmI0NGEyZWIwY2U4YjEzY2UzMmVmN2FfNi0xMy0xLTEtODE_d4213e69-0ee2-4e16-9ffd-73b949ef7a5c">27</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6c730d6b5a3349088cf01b0df9f09e86_D20210101-20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RhYmxlOjJjNWRmMDU2OTZiNDRhMmViMGNlOGIxM2NlMzJlZjdhL3RhYmxlcmFuZ2U6MmM1ZGYwNTY5NmI0NGEyZWIwY2U4YjEzY2UzMmVmN2FfNi0xNS0xLTEtODE_2397b2b1-1b96-4acc-a9bb-043e3f4d6c50">31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average fair value (in dollars)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id3db81cbe7d44bf4b59daffdc638772b_D20220701-20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RhYmxlOjJjNWRmMDU2OTZiNDRhMmViMGNlOGIxM2NlMzJlZjdhL3RhYmxlcmFuZ2U6MmM1ZGYwNTY5NmI0NGEyZWIwY2U4YjEzY2UzMmVmN2FfNy0xLTEtMS04MQ_9e5d8866-c443-4cb8-af97-c602e51e21dc">27.57</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i18064623ae8c40b0b87d8d75806827d8_D20210701-20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RhYmxlOjJjNWRmMDU2OTZiNDRhMmViMGNlOGIxM2NlMzJlZjdhL3RhYmxlcmFuZ2U6MmM1ZGYwNTY5NmI0NGEyZWIwY2U4YjEzY2UzMmVmN2FfNy0zLTEtMS04MQ_b778dfc3-dad3-44e1-94ef-6d57195b012c">28.84</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i88f8a540b3d94b20983f8902eae30ae2_D20220101-20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RhYmxlOjJjNWRmMDU2OTZiNDRhMmViMGNlOGIxM2NlMzJlZjdhL3RhYmxlcmFuZ2U6MmM1ZGYwNTY5NmI0NGEyZWIwY2U4YjEzY2UzMmVmN2FfNy01LTEtMS04MQ_29de48ec-44c0-42ef-883b-e0f9a01d04a0">25.96</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id7acb0824a524ce2b1a6d6eeb3f5b6b8_D20210101-20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RhYmxlOjJjNWRmMDU2OTZiNDRhMmViMGNlOGIxM2NlMzJlZjdhL3RhYmxlcmFuZ2U6MmM1ZGYwNTY5NmI0NGEyZWIwY2U4YjEzY2UzMmVmN2FfNy03LTEtMS04MQ_576342e8-d943-4e06-850f-b75d4ad8e958">29.32</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia05518f1a01d4291b4add6208b75e939_D20220701-20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RhYmxlOjJjNWRmMDU2OTZiNDRhMmViMGNlOGIxM2NlMzJlZjdhL3RhYmxlcmFuZ2U6MmM1ZGYwNTY5NmI0NGEyZWIwY2U4YjEzY2UzMmVmN2FfNy05LTEtMS04MQ_935d9cea-15e0-4c3e-b61b-3d555b425ed0">16.46</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie12951e0177049569a4eaac01ed75693_D20210701-20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RhYmxlOjJjNWRmMDU2OTZiNDRhMmViMGNlOGIxM2NlMzJlZjdhL3RhYmxlcmFuZ2U6MmM1ZGYwNTY5NmI0NGEyZWIwY2U4YjEzY2UzMmVmN2FfNy0xMS0xLTEtODE_f784f131-38ba-4c3f-a058-81ea2aa758e2">18.20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="icaf56e010147488ebeb835f2e5b31900_D20220101-20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RhYmxlOjJjNWRmMDU2OTZiNDRhMmViMGNlOGIxM2NlMzJlZjdhL3RhYmxlcmFuZ2U6MmM1ZGYwNTY5NmI0NGEyZWIwY2U4YjEzY2UzMmVmN2FfNy0xMy0xLTEtODE_ad921593-cac4-4b02-a9d0-41b412c595a5">15.38</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6c730d6b5a3349088cf01b0df9f09e86_D20210101-20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RhYmxlOjJjNWRmMDU2OTZiNDRhMmViMGNlOGIxM2NlMzJlZjdhL3RhYmxlcmFuZ2U6MmM1ZGYwNTY5NmI0NGEyZWIwY2U4YjEzY2UzMmVmN2FfNy0xNS0xLTEtODE_a7227e70-ed3f-45c2-b0b8-cfa4d6a4920b">18.82</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The risk-free interest rate is derived from the U.S. Federal Reserve rate in effect at the time of grant. The expected life calculation is based on the observed and expected time to the exercise of options by our employees based on historical exercise patterns for similar type options. Expected volatility is based on the historical volatility of our common stock over the period commensurate with the expected life of the options. A dividend yield of <ix:nonFraction unitRef="number" contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RleHRyZWdpb246ZmFlNDc5YmVlYzk3NGU3Njk4MDJlOTE5MjQ4MDEwYzRfMTU1Ng_32b7e63e-c92c-4c7c-9b6c-3b9f7134b0e2">zero</ix:nonFraction> is assumed based on the fact that we have never paid cash dividends and have no present intention to pay cash dividends. Nonemployee awards are measured on the grant date by estimating the fair value of the equity instruments to be issued using the expected term, similar to our employee awards.</span></div><ix:nonNumeric contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RleHRyZWdpb246ZmFlNDc5YmVlYzk3NGU3Njk4MDJlOTE5MjQ4MDEwYzRfNDkyNw_877736fa-406d-4e32-a891-ae27871cf2ed" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Option activity under our 2010 Stock Incentive Plan (the &#8220;2010 Stock Plan&#8221;) was as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares Subject to<br/>Outstanding Options</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average<br/>Exercise Price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ica61680f037f4dedb0e7d3fa6de64097_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RhYmxlOjQ5NWIwY2MyNzUyYjRkNWU4ZWM5NGY0MWRmYTdkYzI2L3RhYmxlcmFuZ2U6NDk1YjBjYzI3NTJiNGQ1ZThlYzk0ZjQxZGZhN2RjMjZfMi0xLTEtMS04MQ_d4622f95-1301-41f6-b2d6-38d815dd0d8c">12,763,460</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ica61680f037f4dedb0e7d3fa6de64097_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RhYmxlOjQ5NWIwY2MyNzUyYjRkNWU4ZWM5NGY0MWRmYTdkYzI2L3RhYmxlcmFuZ2U6NDk1YjBjYzI3NTJiNGQ1ZThlYzk0ZjQxZGZhN2RjMjZfMi0zLTEtMS04MQ_5fc55be3-d2bf-44a4-a310-3d8c055f1415">88.39</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options granted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i88f8a540b3d94b20983f8902eae30ae2_D20220101-20220930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RhYmxlOjQ5NWIwY2MyNzUyYjRkNWU4ZWM5NGY0MWRmYTdkYzI2L3RhYmxlcmFuZ2U6NDk1YjBjYzI3NTJiNGQ1ZThlYzk0ZjQxZGZhN2RjMjZfMy0xLTEtMS04MQ_31d2022b-d9de-462b-bea4-e78baf09bdc2">1,755,963</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i88f8a540b3d94b20983f8902eae30ae2_D20220101-20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RhYmxlOjQ5NWIwY2MyNzUyYjRkNWU4ZWM5NGY0MWRmYTdkYzI2L3RhYmxlcmFuZ2U6NDk1YjBjYzI3NTJiNGQ1ZThlYzk0ZjQxZGZhN2RjMjZfMy0zLTEtMS04MQ_e2a73acf-e71e-43bb-bbff-9001916e9621">75.32</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i88f8a540b3d94b20983f8902eae30ae2_D20220101-20220930" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RhYmxlOjQ5NWIwY2MyNzUyYjRkNWU4ZWM5NGY0MWRmYTdkYzI2L3RhYmxlcmFuZ2U6NDk1YjBjYzI3NTJiNGQ1ZThlYzk0ZjQxZGZhN2RjMjZfNC0xLTEtMS04MQ_c3d00e27-3fe5-470f-991d-caaf28ad3032">477,371</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i88f8a540b3d94b20983f8902eae30ae2_D20220101-20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RhYmxlOjQ5NWIwY2MyNzUyYjRkNWU4ZWM5NGY0MWRmYTdkYzI2L3RhYmxlcmFuZ2U6NDk1YjBjYzI3NTJiNGQ1ZThlYzk0ZjQxZGZhN2RjMjZfNC0zLTEtMS04MQ_6e98de4a-d865-4659-b72c-ab0c02896af9">66.69</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options cancelled</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i88f8a540b3d94b20983f8902eae30ae2_D20220101-20220930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RhYmxlOjQ5NWIwY2MyNzUyYjRkNWU4ZWM5NGY0MWRmYTdkYzI2L3RhYmxlcmFuZ2U6NDk1YjBjYzI3NTJiNGQ1ZThlYzk0ZjQxZGZhN2RjMjZfNS0xLTEtMS04MQ_080417ef-f910-4bcf-81b3-89cffff963a4">989,465</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i88f8a540b3d94b20983f8902eae30ae2_D20220101-20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RhYmxlOjQ5NWIwY2MyNzUyYjRkNWU4ZWM5NGY0MWRmYTdkYzI2L3RhYmxlcmFuZ2U6NDk1YjBjYzI3NTJiNGQ1ZThlYzk0ZjQxZGZhN2RjMjZfNS0zLTEtMS04MQ_cb18677c-c7bd-457f-bf1d-42792a8c815f">88.60</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i63709951184741bbb03325606fc77885_I20220930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RhYmxlOjQ5NWIwY2MyNzUyYjRkNWU4ZWM5NGY0MWRmYTdkYzI2L3RhYmxlcmFuZ2U6NDk1YjBjYzI3NTJiNGQ1ZThlYzk0ZjQxZGZhN2RjMjZfNi0xLTEtMS04MQ_d35c603c-4bee-42a8-a47f-bda95e551fc2">13,052,587</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i63709951184741bbb03325606fc77885_I20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RhYmxlOjQ5NWIwY2MyNzUyYjRkNWU4ZWM5NGY0MWRmYTdkYzI2L3RhYmxlcmFuZ2U6NDk1YjBjYzI3NTJiNGQ1ZThlYzk0ZjQxZGZhN2RjMjZfNi0zLTEtMS04MQ_0d88809e-01e2-4527-8bab-7d3f3af05092">87.41</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our annual stock option grants generally have a <ix:nonNumeric contextRef="i88f8a540b3d94b20983f8902eae30ae2_D20220101-20220930" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RleHRyZWdpb246ZmFlNDc5YmVlYzk3NGU3Njk4MDJlOTE5MjQ4MDEwYzRfMTk5Nw_9be6d543-df6d-49c2-bf0f-0b6cb5e1b6dc">10</ix:nonNumeric>-year term and vest over <ix:nonNumeric contextRef="i88f8a540b3d94b20983f8902eae30ae2_D20220101-20220930" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RleHRyZWdpb246ZmFlNDc5YmVlYzk3NGU3Njk4MDJlOTE5MjQ4MDEwYzRfMjAyNA_5acc6b02-5917-4088-933a-71fb9d991358">four years</ix:nonNumeric>, with <ix:nonFraction unitRef="number" contextRef="i88f8a540b3d94b20983f8902eae30ae2_D20220101-20220930" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RleHRyZWdpb246ZmFlNDc5YmVlYzk3NGU3Njk4MDJlOTE5MjQ4MDEwYzRfMjAzMw_c41627f0-fbf6-49a7-83e9-8ca8350517e2">25</ix:nonFraction>% vesting after <ix:nonNumeric contextRef="i48621c6db4cc4ac9ad02fc57e325cfda_D20220101-20220930" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RleHRyZWdpb246ZmFlNDc5YmVlYzk3NGU3Njk4MDJlOTE5MjQ4MDEwYzRfMjA1MA_b086a7cb-ca01-45a6-adcb-597c0b791951">one year</ix:nonNumeric> and the remainder vesting in <ix:nonNumeric contextRef="i04c8ff8acdef44f4b58b1deff299fcc5_D20220101-20220930" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RleHRyZWdpb246ZmFlNDc5YmVlYzk3NGU3Njk4MDJlOTE5MjQ4MDEwYzRfMjA4Mg_318609a9-3b7a-4af8-9a09-8bbaf562b30e">36</ix:nonNumeric> equal monthly installments.</span></div></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie2ffba3ee5384c86becdb38ff117ca9a_7">Table of Contents</a></span></div></div><ix:continuation id="i3cffdd2c976642e282c148a7d1b86908" continuedAt="i7ecee333dc1b40e3bd786be1b95b0e9e"><ix:nonNumeric contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930" name="incy:ScheduleOfShareBasedCompensationOtherThanStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RleHRyZWdpb246ZmFlNDc5YmVlYzk3NGU3Njk4MDJlOTE5MjQ4MDEwYzRfMzg0ODI5MDcwMjIzOA_7af86c5e-890c-4552-abca-749cd47bb432" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock unit (&#8220;RSU&#8221;) and performance share (&#8220;PSU&#8221;) award activity under the 2010 Stock Plan was as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares Subject to<br/>Outstanding Awards</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Grant Date Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iab26fe441f0d4ab984456365a7f7cff0_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RhYmxlOmRiMmY0YzhiNGUzOTRlOTg4NDMyMjRiZThmNGJhODI1L3RhYmxlcmFuZ2U6ZGIyZjRjOGI0ZTM5NGU5ODg0MzIyNGJlOGY0YmE4MjVfMi0xLTEtMS04MQ_24f2ab48-fef7-4665-af8e-cb16e00a048d">3,966,888</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iab26fe441f0d4ab984456365a7f7cff0_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RhYmxlOmRiMmY0YzhiNGUzOTRlOTg4NDMyMjRiZThmNGJhODI1L3RhYmxlcmFuZ2U6ZGIyZjRjOGI0ZTM5NGU5ODg0MzIyNGJlOGY0YmE4MjVfMi0zLTEtMS04MQ_be369b35-fa0f-4dc9-a3e4-dd4d93e3b570">84.91</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs granted </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6a259c2680304a099d7306f0be37ed62_D20220101-20220930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RhYmxlOmRiMmY0YzhiNGUzOTRlOTg4NDMyMjRiZThmNGJhODI1L3RhYmxlcmFuZ2U6ZGIyZjRjOGI0ZTM5NGU5ODg0MzIyNGJlOGY0YmE4MjVfMy0xLTEtMS04MQ_70188805-a0a1-4fe9-b6d9-10aca48d1f49">2,473,892</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6a259c2680304a099d7306f0be37ed62_D20220101-20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RhYmxlOmRiMmY0YzhiNGUzOTRlOTg4NDMyMjRiZThmNGJhODI1L3RhYmxlcmFuZ2U6ZGIyZjRjOGI0ZTM5NGU5ODg0MzIyNGJlOGY0YmE4MjVfMy0zLTEtMS04MQ_af9a280d-67cc-4c5c-83b2-2bd91e47815b">77.14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PSUs granted</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie5ac7148ca1b4e0cac828a4f764cc338_D20220101-20220930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RhYmxlOmRiMmY0YzhiNGUzOTRlOTg4NDMyMjRiZThmNGJhODI1L3RhYmxlcmFuZ2U6ZGIyZjRjOGI0ZTM5NGU5ODg0MzIyNGJlOGY0YmE4MjVfNC0xLTEtMS01MTY1_bfafa54d-18f1-495f-ab32-fe04f75c96da">154,685</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie5ac7148ca1b4e0cac828a4f764cc338_D20220101-20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RhYmxlOmRiMmY0YzhiNGUzOTRlOTg4NDMyMjRiZThmNGJhODI1L3RhYmxlcmFuZ2U6ZGIyZjRjOGI0ZTM5NGU5ODg0MzIyNGJlOGY0YmE4MjVfNC0zLTEtMS01MTY1_ac85576b-9af7-4fec-8a79-7648c69c46d9">77.67</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs released</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i6a259c2680304a099d7306f0be37ed62_D20220101-20220930" decimals="INF" name="incy:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RhYmxlOmRiMmY0YzhiNGUzOTRlOTg4NDMyMjRiZThmNGJhODI1L3RhYmxlcmFuZ2U6ZGIyZjRjOGI0ZTM5NGU5ODg0MzIyNGJlOGY0YmE4MjVfNC0xLTEtMS04MQ_4959bd94-823b-47fe-ae4d-944c965538bd">845,095</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6a259c2680304a099d7306f0be37ed62_D20220101-20220930" decimals="2" name="incy:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedIntrinsicValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RhYmxlOmRiMmY0YzhiNGUzOTRlOTg4NDMyMjRiZThmNGJhODI1L3RhYmxlcmFuZ2U6ZGIyZjRjOGI0ZTM5NGU5ODg0MzIyNGJlOGY0YmE4MjVfNC0zLTEtMS04MQ_00984ce6-9eed-437c-b31e-f0e34458695b">87.06</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PSUs released</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ie5ac7148ca1b4e0cac828a4f764cc338_D20220101-20220930" decimals="INF" name="incy:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RhYmxlOmRiMmY0YzhiNGUzOTRlOTg4NDMyMjRiZThmNGJhODI1L3RhYmxlcmFuZ2U6ZGIyZjRjOGI0ZTM5NGU5ODg0MzIyNGJlOGY0YmE4MjVfNS0xLTEtMS04MQ_a5a38164-ab12-4852-be57-448f728ce9f8">184,401</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie5ac7148ca1b4e0cac828a4f764cc338_D20220101-20220930" decimals="2" name="incy:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedIntrinsicValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RhYmxlOmRiMmY0YzhiNGUzOTRlOTg4NDMyMjRiZThmNGJhODI1L3RhYmxlcmFuZ2U6ZGIyZjRjOGI0ZTM5NGU5ODg0MzIyNGJlOGY0YmE4MjVfNS0zLTEtMS04MQ_85777c7b-4b54-41a0-a712-2e863eed8ed7">69.25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs cancelled </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i6a259c2680304a099d7306f0be37ed62_D20220101-20220930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RhYmxlOmRiMmY0YzhiNGUzOTRlOTg4NDMyMjRiZThmNGJhODI1L3RhYmxlcmFuZ2U6ZGIyZjRjOGI0ZTM5NGU5ODg0MzIyNGJlOGY0YmE4MjVfNi0xLTEtMS04MQ_905059fa-88cd-4b97-be82-40298e5edf65">337,265</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6a259c2680304a099d7306f0be37ed62_D20220101-20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RhYmxlOmRiMmY0YzhiNGUzOTRlOTg4NDMyMjRiZThmNGJhODI1L3RhYmxlcmFuZ2U6ZGIyZjRjOGI0ZTM5NGU5ODg0MzIyNGJlOGY0YmE4MjVfNi0zLTEtMS04MQ_2cce5492-49ae-485e-a809-7ceaa3ec9dee">83.94</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PSUs cancelled</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ie5ac7148ca1b4e0cac828a4f764cc338_D20220101-20220930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RhYmxlOmRiMmY0YzhiNGUzOTRlOTg4NDMyMjRiZThmNGJhODI1L3RhYmxlcmFuZ2U6ZGIyZjRjOGI0ZTM5NGU5ODg0MzIyNGJlOGY0YmE4MjVfNy0xLTEtMS04MQ_39f700ef-fd33-4fdc-9c4d-4e2cc786412d">1,720</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie5ac7148ca1b4e0cac828a4f764cc338_D20220101-20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RhYmxlOmRiMmY0YzhiNGUzOTRlOTg4NDMyMjRiZThmNGJhODI1L3RhYmxlcmFuZ2U6ZGIyZjRjOGI0ZTM5NGU5ODg0MzIyNGJlOGY0YmE4MjVfNy0zLTEtMS04MQ_bdf7cbc7-de22-4f43-ade8-e8d7ca771e32">65.76</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30, 2022</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3b4376f8fc614de98c9cf647198c504e_I20220930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RhYmxlOmRiMmY0YzhiNGUzOTRlOTg4NDMyMjRiZThmNGJhODI1L3RhYmxlcmFuZ2U6ZGIyZjRjOGI0ZTM5NGU5ODg0MzIyNGJlOGY0YmE4MjVfOC0xLTEtMS04MQ_f76df767-e157-4748-bb85-e929790822a0">5,226,984</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3b4376f8fc614de98c9cf647198c504e_I20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RhYmxlOmRiMmY0YzhiNGUzOTRlOTg4NDMyMjRiZThmNGJhODI1L3RhYmxlcmFuZ2U6ZGIyZjRjOGI0ZTM5NGU5ODg0MzIyNGJlOGY0YmE4MjVfOC0zLTEtMS04MQ_aab0f7bf-0473-4ac8-b938-a83e08425aeb">81.29</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RSUs and PSUs are granted to our employees at the share price on the date of grant. Each RSU represents the right to acquire <ix:nonFraction unitRef="shares" contextRef="i6a259c2680304a099d7306f0be37ed62_D20220101-20220930" decimals="INF" name="incy:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesPerRestrictedStockUnits" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RleHRyZWdpb246ZmFlNDc5YmVlYzk3NGU3Njk4MDJlOTE5MjQ4MDEwYzRfMjM1Nw_97d1ac4a-c111-4e56-8c26-edd057ea89cf">one</ix:nonFraction> share of our common stock. Each RSU granted in connection with our annual equity awards will vest <ix:nonFraction unitRef="number" contextRef="i6a259c2680304a099d7306f0be37ed62_D20220101-20220930" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RleHRyZWdpb246ZmFlNDc5YmVlYzk3NGU3Njk4MDJlOTE5MjQ4MDEwYzRfMjQ1OQ_9b5488de-10e0-4c1d-bec6-5f5f90777f6c">25</ix:nonFraction>% annually over <ix:nonNumeric contextRef="i6a259c2680304a099d7306f0be37ed62_D20220101-20220930" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RleHRyZWdpb246ZmFlNDc5YmVlYzk3NGU3Njk4MDJlOTE5MjQ4MDEwYzRfMjQ3Ng_5d9645d6-f14a-4398-961b-85f5e7e4cbe9">four years</ix:nonNumeric>, while each RSU granted as outstanding merit awards or as part of retention award programs will vest in a single installment at the end of <ix:nonNumeric contextRef="i6a259c2680304a099d7306f0be37ed62_D20220101-20220930" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RleHRyZWdpb246ZmFlNDc5YmVlYzk3NGU3Njk4MDJlOTE5MjQ4MDEwYzRfMjYxOA_47ece34c-bb88-4791-af82-f9267a633ab7">four years</ix:nonNumeric>.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We grant PSUs with performance and/or service-based milestones with graded and/or cliff vesting over <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RleHRyZWdpb246ZmFlNDc5YmVlYzk3NGU3Njk4MDJlOTE5MjQ4MDEwYzRfMjcyMw_f68315b0-93a7-445d-8854-3803f7e59595">three</span> to <ix:nonNumeric contextRef="id70f31d4f5454cf2a35efe177f68fc3a_D20220101-20220930" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RleHRyZWdpb246ZmFlNDc5YmVlYzk3NGU3Njk4MDJlOTE5MjQ4MDEwYzRfMjczMA_e551f03b-b006-4e6d-af3c-db0b56a0ae76">four years</ix:nonNumeric>. The shares of our common stock into which each PSU may convert is subject to a multiplier based on the level at which the financial, developmental and market performance conditions are achieved over the service period. Compensation expense for PSUs with financial and developmental performance conditions is recorded over the estimated service period for each milestone when the performance conditions are deemed probable of achievement. For PSUs containing performance conditions which were not deemed probable of achievement, no stock compensation expense is recorded. Compensation expense for PSUs with market performance conditions is calculated using a Monte Carlo simulation model as of the date of grant and recorded over the requisite service period. For the three and nine months ended September&#160;30, 2022 we recorded $<ix:nonFraction unitRef="usd" contextRef="ibf315c942d3a4e75bf4c724b522cbd2a_D20220701-20220930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RleHRyZWdpb246ZmFlNDc5YmVlYzk3NGU3Njk4MDJlOTE5MjQ4MDEwYzRfMzUzMg_d07ba07a-db8c-4e51-89fa-8fa1424409e7">3.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ie5ac7148ca1b4e0cac828a4f764cc338_D20220101-20220930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RleHRyZWdpb246ZmFlNDc5YmVlYzk3NGU3Njk4MDJlOTE5MjQ4MDEwYzRfMzUzOQ_2b6d3bc9-404f-41a2-be82-1495af266fb9">5.1</ix:nonFraction> million, respectively, of stock compensation expense for PSUs on our condensed consolidated statements of operations. For the three and nine months ended September&#160;30, 2021 we recorded $<ix:nonFraction unitRef="usd" contextRef="i815d3de20f4a4db7baa12ac1511dc801_D20210701-20210930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RleHRyZWdpb246ZmFlNDc5YmVlYzk3NGU3Njk4MDJlOTE5MjQ4MDEwYzRfMzY5MQ_d906033e-61b0-4541-a4ea-8a4d57112813">1.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ib0879ceff7714c68a441c12f87a02bb6_D20210101-20210930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RleHRyZWdpb246ZmFlNDc5YmVlYzk3NGU3Njk4MDJlOTE5MjQ4MDEwYzRfMzY5OA_97db18fe-5b19-4b94-ab00-a3bd927d3aa9">5.0</ix:nonFraction> million of stock compensation expense for PSUs on our condensed consolidated statements of operations.</span></div><ix:nonNumeric contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930" name="us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RleHRyZWdpb246ZmFlNDc5YmVlYzk3NGU3Njk4MDJlOTE5MjQ4MDEwYzRfNDkyOQ_3cae79b0-35fa-4bcd-916a-3ffd05ed6df3" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our shares available for grant under the 2010 Stock Plan. Each RSU and PSU grant reduces the available share pool by 2 shares.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Shares Available<br/>for Grant</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Balance at December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1.97pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="iab26fe441f0d4ab984456365a7f7cff0_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RhYmxlOjYwZjdiNTJlMzBiMjQ2OWQ5NjA0NmJhZmRkYTRjZjhmL3RhYmxlcmFuZ2U6NjBmN2I1MmUzMGIyNDY5ZDk2MDQ2YmFmZGRhNGNmOGZfMS0xLTEtMS04MQ_13a4c123-7ad1-401e-9936-7d9754ee639d">10,113,298</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Options, RSUs and PSUs granted</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="shares" contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930" decimals="INF" name="incy:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGranted" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RhYmxlOjYwZjdiNTJlMzBiMjQ2OWQ5NjA0NmJhZmRkYTRjZjhmL3RhYmxlcmFuZ2U6NjBmN2I1MmUzMGIyNDY5ZDk2MDQ2YmFmZGRhNGNmOGZfMi0xLTEtMS04MQ_04b5f21d-8c7d-4aaa-9d8d-9f8c2f1b6e25">7,013,475</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Options, RSUs and PSUs cancelled</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.97pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930" decimals="INF" name="incy:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCanceled" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RhYmxlOjYwZjdiNTJlMzBiMjQ2OWQ5NjA0NmJhZmRkYTRjZjhmL3RhYmxlcmFuZ2U6NjBmN2I1MmUzMGIyNDY5ZDk2MDQ2YmFmZGRhNGNmOGZfMy0xLTEtMS04MQ_4879474b-60f0-43a6-ba76-7a9eb6821836">1,680,482</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Balance at September 30, 2022</span></td><td colspan="3" style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1.97pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="i3b4376f8fc614de98c9cf647198c504e_I20220930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RhYmxlOjYwZjdiNTJlMzBiMjQ2OWQ5NjA0NmJhZmRkYTRjZjhmL3RhYmxlcmFuZ2U6NjBmN2I1MmUzMGIyNDY5ZDk2MDQ2YmFmZGRhNGNmOGZfNC0xLTEtMS04MQ_d4160612-3c50-44e7-a120-8d97855e52da">4,780,305</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on our historical experience of employee turnover, we have assumed an annualized forfeiture rate of <ix:nonFraction unitRef="number" contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930" decimals="2" name="incy:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedAnnualizedForfeitureRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RleHRyZWdpb246ZmFlNDc5YmVlYzk3NGU3Njk4MDJlOTE5MjQ4MDEwYzRfNDA2Mg_3c4f98c9-2215-4640-a5f0-75317c218d49">5</ix:nonFraction>% for our options, RSUs and PSUs. Under the true-up provisions of the stock compensation guidance, we will record additional expense if the actual forfeiture rate is lower than we estimated, and will record a recovery of prior expense if the actual forfeiture is higher than we estimated.</span></div></ix:continuation><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i7ecee333dc1b40e3bd786be1b95b0e9e">Total compensation cost of options granted but not yet vested, as of September&#160;30, 2022, was $<ix:nonFraction unitRef="usd" contextRef="i63709951184741bbb03325606fc77885_I20220930" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RleHRyZWdpb246ZmFlNDc5YmVlYzk3NGU3Njk4MDJlOTE5MjQ4MDEwYzRfNDQyOQ_1128a7c2-f6c0-4c7e-a7fa-0d05bf55b19b">51.2</ix:nonFraction> million, which is expected to be recognized over the weighted average period of approximately <ix:nonNumeric contextRef="i88f8a540b3d94b20983f8902eae30ae2_D20220101-20220930" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RleHRyZWdpb246ZmFlNDc5YmVlYzk3NGU3Njk4MDJlOTE5MjQ4MDEwYzRfNDUxOA_bfcfd8df-9948-4647-83e4-101da884e53f">1.1</ix:nonNumeric> years. Total compensation cost of RSUs granted but not yet vested, as of September&#160;30, 2022, was $<ix:nonFraction unitRef="usd" contextRef="i6afeedfad1cd4882a7d671b04f209a35_I20220930" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RleHRyZWdpb246ZmFlNDc5YmVlYzk3NGU3Njk4MDJlOTE5MjQ4MDEwYzRfNDYwMg_f81d4a66-11d2-47a3-8d86-6cef342b131f">235.5</ix:nonFraction> million, which is expected to be recognized over the weighted average period of approximately <ix:nonNumeric contextRef="i6a259c2680304a099d7306f0be37ed62_D20220101-20220930" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RleHRyZWdpb246ZmFlNDc5YmVlYzk3NGU3Njk4MDJlOTE5MjQ4MDEwYzRfNDY5MQ_ed9e8914-c170-42de-af87-427f3e235aa2">2.0</ix:nonNumeric> years. Total compensation cost of PSUs granted but not yet vested, as of September&#160;30, 2022, was $<ix:nonFraction unitRef="usd" contextRef="if444048235584a2399361851f892f5df_I20220930" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RleHRyZWdpb246ZmFlNDc5YmVlYzk3NGU3Njk4MDJlOTE5MjQ4MDEwYzRfNDc2OQ_19abb64c-a6d8-4f27-b39c-74ac8278c0d3">19.6</ix:nonFraction> million, which is expected to be recognized over the weighted average period of <ix:nonNumeric contextRef="ie5ac7148ca1b4e0cac828a4f764cc338_D20220101-20220930" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RleHRyZWdpb246ZmFlNDc5YmVlYzk3NGU3Njk4MDJlOTE5MjQ4MDEwYzRfNDg0NA_76609b24-3170-4e51-aab3-1529dd2c8804">2.2</ix:nonNumeric> years, should the underlying performance conditions be deemed probable of achievement.</ix:continuation> </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">24</span></div></div></div><div id="ie2ffba3ee5384c86becdb38ff117ca9a_67"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie2ffba3ee5384c86becdb38ff117ca9a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 11. Income Taxes </span></div><ix:nonNumeric contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82Ny9mcmFnOjk4ZDFkMDFmNDQ0YjRmMWRhYTAwMmY1YjM2YjRkNTlkL3RleHRyZWdpb246OThkMWQwMWY0NDRiNGYxZGFhMDAyZjViMzZiNGQ1OWRfMTg5Ng_ae4e25f7-775b-4761-9ba7-e8684ea58a2e" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September&#160;30, 2022, we recorded income tax expense of approximately $<ix:nonFraction unitRef="usd" contextRef="id673d80f31e74643a241d2f62db94ca9_D20220701-20220930" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82Ny9mcmFnOjk4ZDFkMDFmNDQ0YjRmMWRhYTAwMmY1YjM2YjRkNTlkL3RleHRyZWdpb246OThkMWQwMWY0NDRiNGYxZGFhMDAyZjViMzZiNGQ1OWRfMTA0_1bf08831-f9e4-4b7d-a68d-0496219d7d9e">35.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82Ny9mcmFnOjk4ZDFkMDFmNDQ0YjRmMWRhYTAwMmY1YjM2YjRkNTlkL3RleHRyZWdpb246OThkMWQwMWY0NDRiNGYxZGFhMDAyZjViMzZiNGQ1OWRfMTEx_804a46e3-fe1d-49e5-822f-cf6fc6b43dab">136.3</ix:nonFraction> million, respectively. For the three and nine months ended September&#160;30, 2021, we recorded income tax expense of approximately $<ix:nonFraction unitRef="usd" contextRef="i313b15d35b7045babd1ba61f84a077dd_D20210701-20210930" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82Ny9mcmFnOjk4ZDFkMDFmNDQ0YjRmMWRhYTAwMmY1YjM2YjRkNTlkL3RleHRyZWdpb246OThkMWQwMWY0NDRiNGYxZGFhMDAyZjViMzZiNGQ1OWRfMjA1_475dc974-66a8-4c78-bd83-8e4294fd0aa1">27.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i0faaba5fcd6b485781cadacae8b2fd8e_D20210101-20210930" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82Ny9mcmFnOjk4ZDFkMDFmNDQ0YjRmMWRhYTAwMmY1YjM2YjRkNTlkL3RleHRyZWdpb246OThkMWQwMWY0NDRiNGYxZGFhMDAyZjViMzZiNGQ1OWRfMjEy_5b1a998d-5ca6-4838-926f-e6fe7b74180f">65.7</ix:nonFraction> million, respectively. The tax expense for the three and nine months ended September&#160;30, 2022 increased as compared to that for the prior year periods due to the release of our valuation allowance against a majority of our U.S. research and development tax credit carryforwards and other deferred tax assets at December&#160;31, 2021.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the fourth quarter of 2021, we assessed the valuation allowance and considered positive evidence, including significant cumulative consolidated and U.S. income over the three years ended December&#160;31, 2021, consistent growth in product revenues, and expectations regarding future profitability. We also assessed negative evidence, including the potential impact of competition, clinical failures and patent expirations on our projections. After assessing both the positive evidence and negative evidence, we determined it was more likely than not that the majority of our U.S. deferred tax assets would be realized in the future and released the associated valuation allowance as of December&#160;31, 2021. This resulted in a benefit of $<ix:nonFraction unitRef="usd" contextRef="i0efcc1efa4d94a789080eb3693e147ff_D20211001-20211231" decimals="-5" sign="-" name="us-gaap:IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82Ny9mcmFnOjk4ZDFkMDFmNDQ0YjRmMWRhYTAwMmY1YjM2YjRkNTlkL3RleHRyZWdpb246OThkMWQwMWY0NDRiNGYxZGFhMDAyZjViMzZiNGQ1OWRfMTE5Nw_8cfcfba2-178c-4d30-a397-d1a184768d6c">569.0</ix:nonFraction> million. As of December&#160;31, 2021, we maintained a valuation allowance of $<ix:nonFraction unitRef="usd" contextRef="iab26fe441f0d4ab984456365a7f7cff0_I20211231" decimals="-5" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82Ny9mcmFnOjk4ZDFkMDFmNDQ0YjRmMWRhYTAwMmY1YjM2YjRkNTlkL3RleHRyZWdpb246OThkMWQwMWY0NDRiNGYxZGFhMDAyZjViMzZiNGQ1OWRfMTI1MA_e07066ab-a2ad-43b3-9a6d-5a513c0d010a">408.2</ix:nonFraction> million against a portion of our remaining U.S. deferred tax assets as well as select state and foreign deferred tax assets. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The balance of our unrecognized tax benefits (including penalties and interest) increased by approximately $<ix:nonFraction unitRef="usd" contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsPeriodIncreaseDecrease" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82Ny9mcmFnOjk4ZDFkMDFmNDQ0YjRmMWRhYTAwMmY1YjM2YjRkNTlkL3RleHRyZWdpb246OThkMWQwMWY0NDRiNGYxZGFhMDAyZjViMzZiNGQ1OWRfMTQ3OA_b8133689-fd8a-402c-bb64-9c11610bed09">11.2</ix:nonFraction> million during the nine months ended September&#160;30, 2022, resulting in movements to other liabilities and deferred income tax asset on the condensed consolidated balance sheet. The overall increase is primarily driven by unrecognized tax benefits related to current year operations and research and development tax credits. We accrue interest and penalties related to unrecognized tax benefits as a component of its provision for income taxes.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2022, the Inflation Reduction Act of 2022 (&#8220;IRA&#8221;) was enacted into law. The IRA includes a 15% corporate alternative minimum tax and a 1% excise tax on share repurchases. We do not expect the IRA to have a material impact on our consolidated financial statements.</span></div></ix:nonNumeric><div id="ie2ffba3ee5384c86becdb38ff117ca9a_70"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 12. Net Income Per Share</span></div><ix:nonNumeric contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV83MC9mcmFnOjU3ZWMzMTQ0ODQwYjQwZjI5ZWIzODQzYTg4ZDgxYjFkL3RleHRyZWdpb246NTdlYzMxNDQ4NDBiNDBmMjllYjM4NDNhODhkODFiMWRfMjMy_6f595d0e-e8ae-4980-82dd-7499e97822cb" continuedAt="icdcc2a0dea8b4661b30bc9d8372b4cc5" escape="true"><ix:nonNumeric contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV83MC9mcmFnOjU3ZWMzMTQ0ODQwYjQwZjI5ZWIzODQzYTg4ZDgxYjFkL3RleHRyZWdpb246NTdlYzMxNDQ4NDBiNDBmMjllYjM4NDNhODhkODFiMWRfMjMw_f351d487-73f8-43d6-a091-4b36c9a5f268" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income per share was calculated as follows for the periods indicated below:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id673d80f31e74643a241d2f62db94ca9_D20220701-20220930" decimals="-3" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV83MC9mcmFnOjU3ZWMzMTQ0ODQwYjQwZjI5ZWIzODQzYTg4ZDgxYjFkL3RhYmxlOmMwN2IyNDkzMWM1ZTRjMmQ5ODM3MjNmMGYwYzRiNzAxL3RhYmxlcmFuZ2U6YzA3YjI0OTMxYzVlNGMyZDk4MzcyM2YwZjBjNGI3MDFfMi0xLTEtMS04MQ_d875d86c-0f08-4319-9f87-d30d8491c6ff">112,775</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i313b15d35b7045babd1ba61f84a077dd_D20210701-20210930" decimals="-3" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV83MC9mcmFnOjU3ZWMzMTQ0ODQwYjQwZjI5ZWIzODQzYTg4ZDgxYjFkL3RhYmxlOmMwN2IyNDkzMWM1ZTRjMmQ5ODM3MjNmMGYwYzRiNzAxL3RhYmxlcmFuZ2U6YzA3YjI0OTMxYzVlNGMyZDk4MzcyM2YwZjBjNGI3MDFfMi0zLTEtMS04MQ_155eec71-464c-4522-9363-ec73b2048488">181,739</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930" decimals="-3" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV83MC9mcmFnOjU3ZWMzMTQ0ODQwYjQwZjI5ZWIzODQzYTg4ZDgxYjFkL3RhYmxlOmMwN2IyNDkzMWM1ZTRjMmQ5ODM3MjNmMGYwYzRiNzAxL3RhYmxlcmFuZ2U6YzA3YjI0OTMxYzVlNGMyZDk4MzcyM2YwZjBjNGI3MDFfMi01LTEtMS04MQ_81133bf9-e978-4185-984e-250ec059d283">312,199</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0faaba5fcd6b485781cadacae8b2fd8e_D20210101-20210930" decimals="-3" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV83MC9mcmFnOjU3ZWMzMTQ0ODQwYjQwZjI5ZWIzODQzYTg4ZDgxYjFkL3RhYmxlOmMwN2IyNDkzMWM1ZTRjMmQ5ODM3MjNmMGYwYzRiNzAxL3RhYmxlcmFuZ2U6YzA3YjI0OTMxYzVlNGMyZDk4MzcyM2YwZjBjNGI3MDFfMi03LTEtMS04MQ_234631f3-72e1-4ac5-9a4a-e38bd2cc5489">384,730</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average common shares outstanding</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id673d80f31e74643a241d2f62db94ca9_D20220701-20220930" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV83MC9mcmFnOjU3ZWMzMTQ0ODQwYjQwZjI5ZWIzODQzYTg4ZDgxYjFkL3RhYmxlOmMwN2IyNDkzMWM1ZTRjMmQ5ODM3MjNmMGYwYzRiNzAxL3RhYmxlcmFuZ2U6YzA3YjI0OTMxYzVlNGMyZDk4MzcyM2YwZjBjNGI3MDFfNC0xLTEtMS04MQ_2123c9ba-e1ad-4467-a8be-4c8418130262">222,415</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i313b15d35b7045babd1ba61f84a077dd_D20210701-20210930" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV83MC9mcmFnOjU3ZWMzMTQ0ODQwYjQwZjI5ZWIzODQzYTg4ZDgxYjFkL3RhYmxlOmMwN2IyNDkzMWM1ZTRjMmQ5ODM3MjNmMGYwYzRiNzAxL3RhYmxlcmFuZ2U6YzA3YjI0OTMxYzVlNGMyZDk4MzcyM2YwZjBjNGI3MDFfNC0zLTEtMS04MQ_5bd6a5a2-dbf5-456a-b037-394f4d8317ae">220,845</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV83MC9mcmFnOjU3ZWMzMTQ0ODQwYjQwZjI5ZWIzODQzYTg4ZDgxYjFkL3RhYmxlOmMwN2IyNDkzMWM1ZTRjMmQ5ODM3MjNmMGYwYzRiNzAxL3RhYmxlcmFuZ2U6YzA3YjI0OTMxYzVlNGMyZDk4MzcyM2YwZjBjNGI3MDFfNC01LTEtMS04MQ_7536cac3-495c-4a0c-8a85-1237d878f469">221,801</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0faaba5fcd6b485781cadacae8b2fd8e_D20210101-20210930" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV83MC9mcmFnOjU3ZWMzMTQ0ODQwYjQwZjI5ZWIzODQzYTg4ZDgxYjFkL3RhYmxlOmMwN2IyNDkzMWM1ZTRjMmQ5ODM3MjNmMGYwYzRiNzAxL3RhYmxlcmFuZ2U6YzA3YjI0OTMxYzVlNGMyZDk4MzcyM2YwZjBjNGI3MDFfNC03LTEtMS04MQ_79bb4581-06dc-48d7-a705-5a61f23b1db1">220,243</ix:nonFraction></span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic net income per share</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id673d80f31e74643a241d2f62db94ca9_D20220701-20220930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV83MC9mcmFnOjU3ZWMzMTQ0ODQwYjQwZjI5ZWIzODQzYTg4ZDgxYjFkL3RhYmxlOmMwN2IyNDkzMWM1ZTRjMmQ5ODM3MjNmMGYwYzRiNzAxL3RhYmxlcmFuZ2U6YzA3YjI0OTMxYzVlNGMyZDk4MzcyM2YwZjBjNGI3MDFfNi0xLTEtMS04MQ_872a83aa-845e-41b2-be4d-6cedc43af54b">0.51</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i313b15d35b7045babd1ba61f84a077dd_D20210701-20210930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV83MC9mcmFnOjU3ZWMzMTQ0ODQwYjQwZjI5ZWIzODQzYTg4ZDgxYjFkL3RhYmxlOmMwN2IyNDkzMWM1ZTRjMmQ5ODM3MjNmMGYwYzRiNzAxL3RhYmxlcmFuZ2U6YzA3YjI0OTMxYzVlNGMyZDk4MzcyM2YwZjBjNGI3MDFfNi0zLTEtMS04MQ_7ec30160-6df5-4e47-b06d-91c64a4917a8">0.82</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV83MC9mcmFnOjU3ZWMzMTQ0ODQwYjQwZjI5ZWIzODQzYTg4ZDgxYjFkL3RhYmxlOmMwN2IyNDkzMWM1ZTRjMmQ5ODM3MjNmMGYwYzRiNzAxL3RhYmxlcmFuZ2U6YzA3YjI0OTMxYzVlNGMyZDk4MzcyM2YwZjBjNGI3MDFfNi01LTEtMS04MQ_eac17a46-037d-4f29-807e-953c19a42858">1.41</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0faaba5fcd6b485781cadacae8b2fd8e_D20210101-20210930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV83MC9mcmFnOjU3ZWMzMTQ0ODQwYjQwZjI5ZWIzODQzYTg4ZDgxYjFkL3RhYmxlOmMwN2IyNDkzMWM1ZTRjMmQ5ODM3MjNmMGYwYzRiNzAxL3RhYmxlcmFuZ2U6YzA3YjI0OTMxYzVlNGMyZDk4MzcyM2YwZjBjNGI3MDFfNi03LTEtMS04MQ_7eda252c-dfda-48b6-83ec-24f875a9c9de">1.75</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted net income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id673d80f31e74643a241d2f62db94ca9_D20220701-20220930" decimals="-3" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV83MC9mcmFnOjU3ZWMzMTQ0ODQwYjQwZjI5ZWIzODQzYTg4ZDgxYjFkL3RhYmxlOmMwN2IyNDkzMWM1ZTRjMmQ5ODM3MjNmMGYwYzRiNzAxL3RhYmxlcmFuZ2U6YzA3YjI0OTMxYzVlNGMyZDk4MzcyM2YwZjBjNGI3MDFfOC0xLTEtMS04MQ_73eee42b-921c-4b8c-aa20-564825f2243b">112,775</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i313b15d35b7045babd1ba61f84a077dd_D20210701-20210930" decimals="-3" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV83MC9mcmFnOjU3ZWMzMTQ0ODQwYjQwZjI5ZWIzODQzYTg4ZDgxYjFkL3RhYmxlOmMwN2IyNDkzMWM1ZTRjMmQ5ODM3MjNmMGYwYzRiNzAxL3RhYmxlcmFuZ2U6YzA3YjI0OTMxYzVlNGMyZDk4MzcyM2YwZjBjNGI3MDFfOC0zLTEtMS04MQ_92f78c9e-01b0-490e-86c7-60548558da96">181,739</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930" decimals="-3" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV83MC9mcmFnOjU3ZWMzMTQ0ODQwYjQwZjI5ZWIzODQzYTg4ZDgxYjFkL3RhYmxlOmMwN2IyNDkzMWM1ZTRjMmQ5ODM3MjNmMGYwYzRiNzAxL3RhYmxlcmFuZ2U6YzA3YjI0OTMxYzVlNGMyZDk4MzcyM2YwZjBjNGI3MDFfOC01LTEtMS04MQ_3a675a31-f116-4d78-98b5-b486cf0f5c2e">312,199</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0faaba5fcd6b485781cadacae8b2fd8e_D20210101-20210930" decimals="-3" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV83MC9mcmFnOjU3ZWMzMTQ0ODQwYjQwZjI5ZWIzODQzYTg4ZDgxYjFkL3RhYmxlOmMwN2IyNDkzMWM1ZTRjMmQ5ODM3MjNmMGYwYzRiNzAxL3RhYmxlcmFuZ2U6YzA3YjI0OTMxYzVlNGMyZDk4MzcyM2YwZjBjNGI3MDFfOC03LTEtMS04MQ_e153ac2f-17b1-4630-9c03-54acfbd2a008">384,730</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id673d80f31e74643a241d2f62db94ca9_D20220701-20220930" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV83MC9mcmFnOjU3ZWMzMTQ0ODQwYjQwZjI5ZWIzODQzYTg4ZDgxYjFkL3RhYmxlOmMwN2IyNDkzMWM1ZTRjMmQ5ODM3MjNmMGYwYzRiNzAxL3RhYmxlcmFuZ2U6YzA3YjI0OTMxYzVlNGMyZDk4MzcyM2YwZjBjNGI3MDFfMTAtMS0xLTEtODE_9e0c61af-9055-43fa-ba4d-d7c0529635db">222,415</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i313b15d35b7045babd1ba61f84a077dd_D20210701-20210930" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV83MC9mcmFnOjU3ZWMzMTQ0ODQwYjQwZjI5ZWIzODQzYTg4ZDgxYjFkL3RhYmxlOmMwN2IyNDkzMWM1ZTRjMmQ5ODM3MjNmMGYwYzRiNzAxL3RhYmxlcmFuZ2U6YzA3YjI0OTMxYzVlNGMyZDk4MzcyM2YwZjBjNGI3MDFfMTAtMy0xLTEtODE_5dad9b28-2a9a-4e52-a6e9-d47709d2f127">220,845</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV83MC9mcmFnOjU3ZWMzMTQ0ODQwYjQwZjI5ZWIzODQzYTg4ZDgxYjFkL3RhYmxlOmMwN2IyNDkzMWM1ZTRjMmQ5ODM3MjNmMGYwYzRiNzAxL3RhYmxlcmFuZ2U6YzA3YjI0OTMxYzVlNGMyZDk4MzcyM2YwZjBjNGI3MDFfMTAtNS0xLTEtODE_ef623ab0-d91f-4cba-93a3-b10eb71edc00">221,801</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0faaba5fcd6b485781cadacae8b2fd8e_D20210101-20210930" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV83MC9mcmFnOjU3ZWMzMTQ0ODQwYjQwZjI5ZWIzODQzYTg4ZDgxYjFkL3RhYmxlOmMwN2IyNDkzMWM1ZTRjMmQ5ODM3MjNmMGYwYzRiNzAxL3RhYmxlcmFuZ2U6YzA3YjI0OTMxYzVlNGMyZDk4MzcyM2YwZjBjNGI3MDFfMTAtNy0xLTEtODE_bbd6a8e8-68dd-4cba-abbc-2cc10d67a96d">220,243</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive stock options and awards</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id673d80f31e74643a241d2f62db94ca9_D20220701-20220930" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV83MC9mcmFnOjU3ZWMzMTQ0ODQwYjQwZjI5ZWIzODQzYTg4ZDgxYjFkL3RhYmxlOmMwN2IyNDkzMWM1ZTRjMmQ5ODM3MjNmMGYwYzRiNzAxL3RhYmxlcmFuZ2U6YzA3YjI0OTMxYzVlNGMyZDk4MzcyM2YwZjBjNGI3MDFfMTEtMS0xLTEtODE_09b090d4-284b-4833-851b-7d30282b15a9">1,760</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i313b15d35b7045babd1ba61f84a077dd_D20210701-20210930" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV83MC9mcmFnOjU3ZWMzMTQ0ODQwYjQwZjI5ZWIzODQzYTg4ZDgxYjFkL3RhYmxlOmMwN2IyNDkzMWM1ZTRjMmQ5ODM3MjNmMGYwYzRiNzAxL3RhYmxlcmFuZ2U6YzA3YjI0OTMxYzVlNGMyZDk4MzcyM2YwZjBjNGI3MDFfMTEtMy0xLTEtODE_8f01af22-a328-4ea6-b150-fbdc6093a3e6">1,403</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV83MC9mcmFnOjU3ZWMzMTQ0ODQwYjQwZjI5ZWIzODQzYTg4ZDgxYjFkL3RhYmxlOmMwN2IyNDkzMWM1ZTRjMmQ5ODM3MjNmMGYwYzRiNzAxL3RhYmxlcmFuZ2U6YzA3YjI0OTMxYzVlNGMyZDk4MzcyM2YwZjBjNGI3MDFfMTEtNS0xLTEtODE_8dfe6654-fa3f-4e88-adcf-d524e76f9657">1,825</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0faaba5fcd6b485781cadacae8b2fd8e_D20210101-20210930" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV83MC9mcmFnOjU3ZWMzMTQ0ODQwYjQwZjI5ZWIzODQzYTg4ZDgxYjFkL3RhYmxlOmMwN2IyNDkzMWM1ZTRjMmQ5ODM3MjNmMGYwYzRiNzAxL3RhYmxlcmFuZ2U6YzA3YjI0OTMxYzVlNGMyZDk4MzcyM2YwZjBjNGI3MDFfMTEtNy0xLTEtODE_aa051aa9-9bf5-4d8d-938f-5b4b26911960">1,870</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average shares used to compute diluted net income per share </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id673d80f31e74643a241d2f62db94ca9_D20220701-20220930" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV83MC9mcmFnOjU3ZWMzMTQ0ODQwYjQwZjI5ZWIzODQzYTg4ZDgxYjFkL3RhYmxlOmMwN2IyNDkzMWM1ZTRjMmQ5ODM3MjNmMGYwYzRiNzAxL3RhYmxlcmFuZ2U6YzA3YjI0OTMxYzVlNGMyZDk4MzcyM2YwZjBjNGI3MDFfMTItMS0xLTEtODE_7403eb44-612f-4347-b500-3cd293f3f0b6">224,175</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i313b15d35b7045babd1ba61f84a077dd_D20210701-20210930" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV83MC9mcmFnOjU3ZWMzMTQ0ODQwYjQwZjI5ZWIzODQzYTg4ZDgxYjFkL3RhYmxlOmMwN2IyNDkzMWM1ZTRjMmQ5ODM3MjNmMGYwYzRiNzAxL3RhYmxlcmFuZ2U6YzA3YjI0OTMxYzVlNGMyZDk4MzcyM2YwZjBjNGI3MDFfMTItMy0xLTEtODE_470f850d-3005-4a13-8433-976876d22aef">222,248</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV83MC9mcmFnOjU3ZWMzMTQ0ODQwYjQwZjI5ZWIzODQzYTg4ZDgxYjFkL3RhYmxlOmMwN2IyNDkzMWM1ZTRjMmQ5ODM3MjNmMGYwYzRiNzAxL3RhYmxlcmFuZ2U6YzA3YjI0OTMxYzVlNGMyZDk4MzcyM2YwZjBjNGI3MDFfMTItNS0xLTEtODE_0d6e88b3-1922-43b7-b004-c880b943dbaa">223,626</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0faaba5fcd6b485781cadacae8b2fd8e_D20210101-20210930" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV83MC9mcmFnOjU3ZWMzMTQ0ODQwYjQwZjI5ZWIzODQzYTg4ZDgxYjFkL3RhYmxlOmMwN2IyNDkzMWM1ZTRjMmQ5ODM3MjNmMGYwYzRiNzAxL3RhYmxlcmFuZ2U6YzA3YjI0OTMxYzVlNGMyZDk4MzcyM2YwZjBjNGI3MDFfMTItNy0xLTEtODE_c38829b3-5e07-4d95-8ff9-f8950c0e4a07">222,113</ix:nonFraction></span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Diluted net income per share</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id673d80f31e74643a241d2f62db94ca9_D20220701-20220930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV83MC9mcmFnOjU3ZWMzMTQ0ODQwYjQwZjI5ZWIzODQzYTg4ZDgxYjFkL3RhYmxlOmMwN2IyNDkzMWM1ZTRjMmQ5ODM3MjNmMGYwYzRiNzAxL3RhYmxlcmFuZ2U6YzA3YjI0OTMxYzVlNGMyZDk4MzcyM2YwZjBjNGI3MDFfMTQtMS0xLTEtODE_5d4f5551-fd13-4b5b-a158-e78f52f17b96">0.50</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i313b15d35b7045babd1ba61f84a077dd_D20210701-20210930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV83MC9mcmFnOjU3ZWMzMTQ0ODQwYjQwZjI5ZWIzODQzYTg4ZDgxYjFkL3RhYmxlOmMwN2IyNDkzMWM1ZTRjMmQ5ODM3MjNmMGYwYzRiNzAxL3RhYmxlcmFuZ2U6YzA3YjI0OTMxYzVlNGMyZDk4MzcyM2YwZjBjNGI3MDFfMTQtMy0xLTEtODE_e4598fc6-e143-4244-baed-40bd2942c3b5">0.82</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV83MC9mcmFnOjU3ZWMzMTQ0ODQwYjQwZjI5ZWIzODQzYTg4ZDgxYjFkL3RhYmxlOmMwN2IyNDkzMWM1ZTRjMmQ5ODM3MjNmMGYwYzRiNzAxL3RhYmxlcmFuZ2U6YzA3YjI0OTMxYzVlNGMyZDk4MzcyM2YwZjBjNGI3MDFfMTQtNS0xLTEtODE_7e77e1ec-f234-4a9f-80be-50e1827aacbd">1.40</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0faaba5fcd6b485781cadacae8b2fd8e_D20210101-20210930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV83MC9mcmFnOjU3ZWMzMTQ0ODQwYjQwZjI5ZWIzODQzYTg4ZDgxYjFkL3RhYmxlOmMwN2IyNDkzMWM1ZTRjMmQ5ODM3MjNmMGYwYzRiNzAxL3RhYmxlcmFuZ2U6YzA3YjI0OTMxYzVlNGMyZDk4MzcyM2YwZjBjNGI3MDFfMTQtNy0xLTEtODE_7246d545-6874-43bd-ac5d-250eb19dd4fb">1.73</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV83MC9mcmFnOjU3ZWMzMTQ0ODQwYjQwZjI5ZWIzODQzYTg4ZDgxYjFkL3RleHRyZWdpb246NTdlYzMxNDQ4NDBiNDBmMjllYjM4NDNhODhkODFiMWRfMjMx_16b66089-12e9-4614-93e4-275685129f84" continuedAt="i70662e2009274c07ac64d739a76bc2b0" escape="true">The potential common shares that were excluded from the diluted net income per share computation are as follows:</ix:nonNumeric></span></div></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie2ffba3ee5384c86becdb38ff117ca9a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><ix:continuation id="icdcc2a0dea8b4661b30bc9d8372b4cc5"><ix:continuation id="i70662e2009274c07ac64d739a76bc2b0"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding stock options and awards</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4265039234524ff8ba29f3a4b5d9b5b7_D20220701-20220930" decimals="INF" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV83MC9mcmFnOjU3ZWMzMTQ0ODQwYjQwZjI5ZWIzODQzYTg4ZDgxYjFkL3RhYmxlOjViODcxNGQxOTNmZjQzMmQ4M2U4NmIzNzdiN2YwMzc1L3RhYmxlcmFuZ2U6NWI4NzE0ZDE5M2ZmNDMyZDgzZTg2YjM3N2I3ZjAzNzVfMi0xLTEtMS04MQ_8c1e39ce-8577-46df-8714-38ad85cca7aa">11,150,022</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6fd8c5827aa44407ac99325c6ecd1dcd_D20210701-20210930" decimals="INF" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV83MC9mcmFnOjU3ZWMzMTQ0ODQwYjQwZjI5ZWIzODQzYTg4ZDgxYjFkL3RhYmxlOjViODcxNGQxOTNmZjQzMmQ4M2U4NmIzNzdiN2YwMzc1L3RhYmxlcmFuZ2U6NWI4NzE0ZDE5M2ZmNDMyZDgzZTg2YjM3N2I3ZjAzNzVfMi0zLTEtMS04MQ_8b82bd14-bff2-4de7-8805-ad960ab89d6f">11,841,440</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i09060caa1e0a470da42482940ed7fad9_D20220101-20220930" decimals="INF" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV83MC9mcmFnOjU3ZWMzMTQ0ODQwYjQwZjI5ZWIzODQzYTg4ZDgxYjFkL3RhYmxlOjViODcxNGQxOTNmZjQzMmQ4M2U4NmIzNzdiN2YwMzc1L3RhYmxlcmFuZ2U6NWI4NzE0ZDE5M2ZmNDMyZDgzZTg2YjM3N2I3ZjAzNzVfMi01LTEtMS04MQ_5be23014-f18e-48a2-9edb-76bd4269a059">10,979,096</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i45da57132f0b4b1baefd68fba20589ad_D20210101-20210930" decimals="INF" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV83MC9mcmFnOjU3ZWMzMTQ0ODQwYjQwZjI5ZWIzODQzYTg4ZDgxYjFkL3RhYmxlOjViODcxNGQxOTNmZjQzMmQ4M2U4NmIzNzdiN2YwMzc1L3RhYmxlcmFuZ2U6NWI4NzE0ZDE5M2ZmNDMyZDgzZTg2YjM3N2I3ZjAzNzVfMi03LTEtMS04MQ_5122a78f-bfc3-42a0-aa16-636a51a4b7a0">9,917,824</ix:nonFraction></span></td></tr></table></ix:continuation></ix:continuation></div><div id="ie2ffba3ee5384c86becdb38ff117ca9a_73"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 13. Employee Benefit Plans</span></div><ix:nonNumeric contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV83My9mcmFnOjlkZDZlNTZmNWEzYzQwY2VhZDY2OWZjZDZjZmEzNDhiL3RleHRyZWdpb246OWRkNmU1NmY1YTNjNDBjZWFkNjY5ZmNkNmNmYTM0OGJfMTMxNg_ae5257c1-81a9-466e-800f-e5c954d4a039" continuedAt="i9243e512b975467d9017b8de62070cd5" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Defined Contribution Plans</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a defined contribution plan qualified under Section 401(k) of the Internal Revenue Code covering all U.S. employees and defined contribution plans for other Incyte employees in Europe and Japan. Employees may contribute a portion of their compensation, which is then matched by us, subject to certain limitations. Defined contribution expense for the three and nine months ended September&#160;30, 2022 was $<ix:nonFraction unitRef="usd" contextRef="id673d80f31e74643a241d2f62db94ca9_D20220701-20220930" decimals="-5" name="us-gaap:DefinedContributionPlanCostRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV83My9mcmFnOjlkZDZlNTZmNWEzYzQwY2VhZDY2OWZjZDZjZmEzNDhiL3RleHRyZWdpb246OWRkNmU1NmY1YTNjNDBjZWFkNjY5ZmNkNmNmYTM0OGJfNDQ3_590e7f5f-a6ff-4fe9-ac2a-b7e9904656ad">5.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930" decimals="-5" name="us-gaap:DefinedContributionPlanCostRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV83My9mcmFnOjlkZDZlNTZmNWEzYzQwY2VhZDY2OWZjZDZjZmEzNDhiL3RleHRyZWdpb246OWRkNmU1NmY1YTNjNDBjZWFkNjY5ZmNkNmNmYTM0OGJfNDU0_5330c57c-05f8-4ea5-a6fc-6adf72dec224">14.7</ix:nonFraction> million, respectively. Defined contribution expense for the three and nine months ended September&#160;30, 2021 was $<ix:nonFraction unitRef="usd" contextRef="i313b15d35b7045babd1ba61f84a077dd_D20210701-20210930" decimals="-5" name="us-gaap:DefinedContributionPlanCostRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV83My9mcmFnOjlkZDZlNTZmNWEzYzQwY2VhZDY2OWZjZDZjZmEzNDhiL3RleHRyZWdpb246OWRkNmU1NmY1YTNjNDBjZWFkNjY5ZmNkNmNmYTM0OGJfNTMy_72450f3c-b8f0-4c33-b742-7aeef648cb96">4.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i0faaba5fcd6b485781cadacae8b2fd8e_D20210101-20210930" decimals="-5" name="us-gaap:DefinedContributionPlanCostRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV83My9mcmFnOjlkZDZlNTZmNWEzYzQwY2VhZDY2OWZjZDZjZmEzNDhiL3RleHRyZWdpb246OWRkNmU1NmY1YTNjNDBjZWFkNjY5ZmNkNmNmYTM0OGJfNTM5_18bd2aea-25ef-419e-928a-767355e4c029">12.8</ix:nonFraction> million, respectively. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Defined Benefit Pension Plans</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have defined benefit pension plans for our employees in Europe which provide benefits to employees upon retirement, death or disability. The assets of the pension plans are held in collective investment accounts represented by the cash surrender value of an insurance policy and are classified as Level 2 within the fair value hierarchy.</span></div><ix:nonNumeric contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930" name="us-gaap:ScheduleOfNetBenefitCostsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV83My9mcmFnOjlkZDZlNTZmNWEzYzQwY2VhZDY2OWZjZDZjZmEzNDhiL3RleHRyZWdpb246OWRkNmU1NmY1YTNjNDBjZWFkNjY5ZmNkNmNmYTM0OGJfMTMxNw_22ceaa82-9816-47b1-8303-66fa91fcbe44" escape="true"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net periodic benefit cost was as follows (in thousands): </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id673d80f31e74643a241d2f62db94ca9_D20220701-20220930" decimals="-3" name="us-gaap:DefinedBenefitPlanServiceCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV83My9mcmFnOjlkZDZlNTZmNWEzYzQwY2VhZDY2OWZjZDZjZmEzNDhiL3RhYmxlOmIzOTBjYWUzNzEwYzRiMGFhZWMxNTA0NGFkOTNlYzQ3L3RhYmxlcmFuZ2U6YjM5MGNhZTM3MTBjNGIwYWFlYzE1MDQ0YWQ5M2VjNDdfMi0xLTEtMS04MQ_e925c116-ddf7-43d3-b66a-49f226a78572">2,376</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i313b15d35b7045babd1ba61f84a077dd_D20210701-20210930" decimals="-3" name="us-gaap:DefinedBenefitPlanServiceCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV83My9mcmFnOjlkZDZlNTZmNWEzYzQwY2VhZDY2OWZjZDZjZmEzNDhiL3RhYmxlOmIzOTBjYWUzNzEwYzRiMGFhZWMxNTA0NGFkOTNlYzQ3L3RhYmxlcmFuZ2U6YjM5MGNhZTM3MTBjNGIwYWFlYzE1MDQ0YWQ5M2VjNDdfMi0zLTEtMS04MQ_8df81eae-35b6-479e-bfa5-9160676aebb1">1,975</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930" decimals="-3" name="us-gaap:DefinedBenefitPlanServiceCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV83My9mcmFnOjlkZDZlNTZmNWEzYzQwY2VhZDY2OWZjZDZjZmEzNDhiL3RhYmxlOmIzOTBjYWUzNzEwYzRiMGFhZWMxNTA0NGFkOTNlYzQ3L3RhYmxlcmFuZ2U6YjM5MGNhZTM3MTBjNGIwYWFlYzE1MDQ0YWQ5M2VjNDdfMi01LTEtMS04MQ_187add67-4d63-4381-b5ca-b0b0dd7056c3">7,336</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0faaba5fcd6b485781cadacae8b2fd8e_D20210101-20210930" decimals="-3" name="us-gaap:DefinedBenefitPlanServiceCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV83My9mcmFnOjlkZDZlNTZmNWEzYzQwY2VhZDY2OWZjZDZjZmEzNDhiL3RhYmxlOmIzOTBjYWUzNzEwYzRiMGFhZWMxNTA0NGFkOTNlYzQ3L3RhYmxlcmFuZ2U6YjM5MGNhZTM3MTBjNGIwYWFlYzE1MDQ0YWQ5M2VjNDdfMi03LTEtMS04MQ_1a388701-72bd-4183-b313-b79ab09456aa">5,927</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id673d80f31e74643a241d2f62db94ca9_D20220701-20220930" decimals="-3" name="us-gaap:DefinedBenefitPlanInterestCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV83My9mcmFnOjlkZDZlNTZmNWEzYzQwY2VhZDY2OWZjZDZjZmEzNDhiL3RhYmxlOmIzOTBjYWUzNzEwYzRiMGFhZWMxNTA0NGFkOTNlYzQ3L3RhYmxlcmFuZ2U6YjM5MGNhZTM3MTBjNGIwYWFlYzE1MDQ0YWQ5M2VjNDdfMy0xLTEtMS04MQ_552fd83d-c21a-4fe4-981c-1f2de8007b98">61</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i313b15d35b7045babd1ba61f84a077dd_D20210701-20210930" decimals="-3" name="us-gaap:DefinedBenefitPlanInterestCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV83My9mcmFnOjlkZDZlNTZmNWEzYzQwY2VhZDY2OWZjZDZjZmEzNDhiL3RhYmxlOmIzOTBjYWUzNzEwYzRiMGFhZWMxNTA0NGFkOTNlYzQ3L3RhYmxlcmFuZ2U6YjM5MGNhZTM3MTBjNGIwYWFlYzE1MDQ0YWQ5M2VjNDdfMy0zLTEtMS04MQ_54c4b414-5448-4b6d-b6e3-b7c8ddf6aef0">23</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930" decimals="-3" name="us-gaap:DefinedBenefitPlanInterestCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV83My9mcmFnOjlkZDZlNTZmNWEzYzQwY2VhZDY2OWZjZDZjZmEzNDhiL3RhYmxlOmIzOTBjYWUzNzEwYzRiMGFhZWMxNTA0NGFkOTNlYzQ3L3RhYmxlcmFuZ2U6YjM5MGNhZTM3MTBjNGIwYWFlYzE1MDQ0YWQ5M2VjNDdfMy01LTEtMS04MQ_aff3f740-01bf-42d9-9ddf-700a96f53702">187</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0faaba5fcd6b485781cadacae8b2fd8e_D20210101-20210930" decimals="-3" name="us-gaap:DefinedBenefitPlanInterestCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV83My9mcmFnOjlkZDZlNTZmNWEzYzQwY2VhZDY2OWZjZDZjZmEzNDhiL3RhYmxlOmIzOTBjYWUzNzEwYzRiMGFhZWMxNTA0NGFkOTNlYzQ3L3RhYmxlcmFuZ2U6YjM5MGNhZTM3MTBjNGIwYWFlYzE1MDQ0YWQ5M2VjNDdfMy03LTEtMS04MQ_f3688557-78c1-43e2-b3bf-4675fa7a3018">68</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id673d80f31e74643a241d2f62db94ca9_D20220701-20220930" decimals="-3" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV83My9mcmFnOjlkZDZlNTZmNWEzYzQwY2VhZDY2OWZjZDZjZmEzNDhiL3RhYmxlOmIzOTBjYWUzNzEwYzRiMGFhZWMxNTA0NGFkOTNlYzQ3L3RhYmxlcmFuZ2U6YjM5MGNhZTM3MTBjNGIwYWFlYzE1MDQ0YWQ5M2VjNDdfNC0xLTEtMS04MQ_3cff4304-c613-4696-ab20-ae1a7f8388b2">1,008</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i313b15d35b7045babd1ba61f84a077dd_D20210701-20210930" decimals="-3" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV83My9mcmFnOjlkZDZlNTZmNWEzYzQwY2VhZDY2OWZjZDZjZmEzNDhiL3RhYmxlOmIzOTBjYWUzNzEwYzRiMGFhZWMxNTA0NGFkOTNlYzQ3L3RhYmxlcmFuZ2U6YjM5MGNhZTM3MTBjNGIwYWFlYzE1MDQ0YWQ5M2VjNDdfNC0zLTEtMS04MQ_ab94bb6c-49a4-4f76-8ab3-eaea602b19a0">15</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930" decimals="-3" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV83My9mcmFnOjlkZDZlNTZmNWEzYzQwY2VhZDY2OWZjZDZjZmEzNDhiL3RhYmxlOmIzOTBjYWUzNzEwYzRiMGFhZWMxNTA0NGFkOTNlYzQ3L3RhYmxlcmFuZ2U6YjM5MGNhZTM3MTBjNGIwYWFlYzE1MDQ0YWQ5M2VjNDdfNC01LTEtMS04MQ_5e8cdf0c-46fc-4496-a257-312dfda120de">3,114</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0faaba5fcd6b485781cadacae8b2fd8e_D20210101-20210930" decimals="-3" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV83My9mcmFnOjlkZDZlNTZmNWEzYzQwY2VhZDY2OWZjZDZjZmEzNDhiL3RhYmxlOmIzOTBjYWUzNzEwYzRiMGFhZWMxNTA0NGFkOTNlYzQ3L3RhYmxlcmFuZ2U6YjM5MGNhZTM3MTBjNGIwYWFlYzE1MDQ0YWQ5M2VjNDdfNC03LTEtMS04MQ_db580ebb-047a-43e6-9015-f49534564c62">45</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of prior service cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id673d80f31e74643a241d2f62db94ca9_D20220701-20220930" decimals="-3" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV83My9mcmFnOjlkZDZlNTZmNWEzYzQwY2VhZDY2OWZjZDZjZmEzNDhiL3RhYmxlOmIzOTBjYWUzNzEwYzRiMGFhZWMxNTA0NGFkOTNlYzQ3L3RhYmxlcmFuZ2U6YjM5MGNhZTM3MTBjNGIwYWFlYzE1MDQ0YWQ5M2VjNDdfNS0xLTEtMS04MQ_ea0dde9f-d187-4bd7-bb19-c92f1f8fb815">193</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i313b15d35b7045babd1ba61f84a077dd_D20210701-20210930" decimals="-3" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV83My9mcmFnOjlkZDZlNTZmNWEzYzQwY2VhZDY2OWZjZDZjZmEzNDhiL3RhYmxlOmIzOTBjYWUzNzEwYzRiMGFhZWMxNTA0NGFkOTNlYzQ3L3RhYmxlcmFuZ2U6YjM5MGNhZTM3MTBjNGIwYWFlYzE1MDQ0YWQ5M2VjNDdfNS0zLTEtMS04MQ_51a84e99-b7dc-4f28-aafc-05216f458571">54</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930" decimals="-3" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV83My9mcmFnOjlkZDZlNTZmNWEzYzQwY2VhZDY2OWZjZDZjZmEzNDhiL3RhYmxlOmIzOTBjYWUzNzEwYzRiMGFhZWMxNTA0NGFkOTNlYzQ3L3RhYmxlcmFuZ2U6YjM5MGNhZTM3MTBjNGIwYWFlYzE1MDQ0YWQ5M2VjNDdfNS01LTEtMS04MQ_3a6a5f37-a597-44f0-84db-fdd75a6c2c8f">580</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0faaba5fcd6b485781cadacae8b2fd8e_D20210101-20210930" decimals="-3" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV83My9mcmFnOjlkZDZlNTZmNWEzYzQwY2VhZDY2OWZjZDZjZmEzNDhiL3RhYmxlOmIzOTBjYWUzNzEwYzRiMGFhZWMxNTA0NGFkOTNlYzQ3L3RhYmxlcmFuZ2U6YjM5MGNhZTM3MTBjNGIwYWFlYzE1MDQ0YWQ5M2VjNDdfNS03LTEtMS04MQ_132ba763-4de1-4785-aa75-c61306eb5ffe">162</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of actuarial losses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id673d80f31e74643a241d2f62db94ca9_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:DefinedBenefitPlanActuarialGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV83My9mcmFnOjlkZDZlNTZmNWEzYzQwY2VhZDY2OWZjZDZjZmEzNDhiL3RhYmxlOmIzOTBjYWUzNzEwYzRiMGFhZWMxNTA0NGFkOTNlYzQ3L3RhYmxlcmFuZ2U6YjM5MGNhZTM3MTBjNGIwYWFlYzE1MDQ0YWQ5M2VjNDdfNi0xLTEtMS04MQ_c6403f34-4c69-41ab-8c64-2bcdc7e31662">89</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i313b15d35b7045babd1ba61f84a077dd_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:DefinedBenefitPlanActuarialGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV83My9mcmFnOjlkZDZlNTZmNWEzYzQwY2VhZDY2OWZjZDZjZmEzNDhiL3RhYmxlOmIzOTBjYWUzNzEwYzRiMGFhZWMxNTA0NGFkOTNlYzQ3L3RhYmxlcmFuZ2U6YjM5MGNhZTM3MTBjNGIwYWFlYzE1MDQ0YWQ5M2VjNDdfNi0zLTEtMS04MQ_2bdcfcae-e9e2-4739-b9e3-6a1b533b8cc1">288</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:DefinedBenefitPlanActuarialGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV83My9mcmFnOjlkZDZlNTZmNWEzYzQwY2VhZDY2OWZjZDZjZmEzNDhiL3RhYmxlOmIzOTBjYWUzNzEwYzRiMGFhZWMxNTA0NGFkOTNlYzQ3L3RhYmxlcmFuZ2U6YjM5MGNhZTM3MTBjNGIwYWFlYzE1MDQ0YWQ5M2VjNDdfNi01LTEtMS04MQ_1f57476c-a902-4aaf-8df3-c494fd5656ae">266</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0faaba5fcd6b485781cadacae8b2fd8e_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:DefinedBenefitPlanActuarialGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV83My9mcmFnOjlkZDZlNTZmNWEzYzQwY2VhZDY2OWZjZDZjZmEzNDhiL3RhYmxlOmIzOTBjYWUzNzEwYzRiMGFhZWMxNTA0NGFkOTNlYzQ3L3RhYmxlcmFuZ2U6YjM5MGNhZTM3MTBjNGIwYWFlYzE1MDQ0YWQ5M2VjNDdfNi03LTEtMS04MQ_e3f8b210-e745-4d3a-a50a-b34be67d5d55">864</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic benefit cost</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id673d80f31e74643a241d2f62db94ca9_D20220701-20220930" decimals="-3" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV83My9mcmFnOjlkZDZlNTZmNWEzYzQwY2VhZDY2OWZjZDZjZmEzNDhiL3RhYmxlOmIzOTBjYWUzNzEwYzRiMGFhZWMxNTA0NGFkOTNlYzQ3L3RhYmxlcmFuZ2U6YjM5MGNhZTM3MTBjNGIwYWFlYzE1MDQ0YWQ5M2VjNDdfNy0xLTEtMS04MQ_14189936-f6da-434b-94da-51e50d75bc8b">1,711</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i313b15d35b7045babd1ba61f84a077dd_D20210701-20210930" decimals="-3" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV83My9mcmFnOjlkZDZlNTZmNWEzYzQwY2VhZDY2OWZjZDZjZmEzNDhiL3RhYmxlOmIzOTBjYWUzNzEwYzRiMGFhZWMxNTA0NGFkOTNlYzQ3L3RhYmxlcmFuZ2U6YjM5MGNhZTM3MTBjNGIwYWFlYzE1MDQ0YWQ5M2VjNDdfNy0zLTEtMS04MQ_f9df3853-e1c3-4c22-b432-d91a0154341f">2,325</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930" decimals="-3" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV83My9mcmFnOjlkZDZlNTZmNWEzYzQwY2VhZDY2OWZjZDZjZmEzNDhiL3RhYmxlOmIzOTBjYWUzNzEwYzRiMGFhZWMxNTA0NGFkOTNlYzQ3L3RhYmxlcmFuZ2U6YjM5MGNhZTM3MTBjNGIwYWFlYzE1MDQ0YWQ5M2VjNDdfNy01LTEtMS04MQ_a49bec3f-9552-4a07-ba47-b2a3ee6e5383">5,255</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0faaba5fcd6b485781cadacae8b2fd8e_D20210101-20210930" decimals="-3" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV83My9mcmFnOjlkZDZlNTZmNWEzYzQwY2VhZDY2OWZjZDZjZmEzNDhiL3RhYmxlOmIzOTBjYWUzNzEwYzRiMGFhZWMxNTA0NGFkOTNlYzQ3L3RhYmxlcmFuZ2U6YjM5MGNhZTM3MTBjNGIwYWFlYzE1MDQ0YWQ5M2VjNDdfNy03LTEtMS04MQ_e0420025-e55e-42d1-80ea-44797309952a">6,976</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:nonNumeric><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i9243e512b975467d9017b8de62070cd5">The components of net periodic benefit cost other than the service cost component are included in <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV83My9mcmFnOjlkZDZlNTZmNWEzYzQwY2VhZDY2OWZjZDZjZmEzNDhiL3RleHRyZWdpb246OWRkNmU1NmY1YTNjNDBjZWFkNjY5ZmNkNmNmYTM0OGJfNjA0NzMxMzk1NDEzMQ_cd32c16f-4695-4a46-9bef-320c5c331b0a">other income (expense), net</span> on the condensed consolidated statements of operations. We expect to contribute a total of $<ix:nonFraction unitRef="usd" contextRef="i3b4376f8fc614de98c9cf647198c504e_I20220930" decimals="-5" name="us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsCurrentFiscalYear" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV83My9mcmFnOjlkZDZlNTZmNWEzYzQwY2VhZDY2OWZjZDZjZmEzNDhiL3RleHRyZWdpb246OWRkNmU1NmY1YTNjNDBjZWFkNjY5ZmNkNmNmYTM0OGJfMTIxMQ_a7873449-fc3f-403f-9315-f08a38725afe">6.4</ix:nonFraction> million to the pension plans in 2022 inclusive of the amounts contributed to the plan during the current period.</ix:continuation> </span></div><div id="ie2ffba3ee5384c86becdb38ff117ca9a_79"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 14. Commitments and Contingencies</span></div><ix:nonNumeric contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV83OS9mcmFnOmY0ZjhhYWQ5YmI0NDRmNGNhYjI5ZTc0ZDFiODIwNGU3L3RleHRyZWdpb246ZjRmOGFhZDliYjQ0NGY0Y2FiMjllNzRkMWI4MjA0ZTdfOTM4_09ec0565-9c0b-4e1d-9d33-7d6dacd8708a" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into the collaboration agreements described in Note 7, as well as various other collaboration agreements that are not individually, or in the aggregate, significant to our operating results or financial condition at this time. We may in the future seek to license additional rights relating to technologies or drug development candidates in connection with our drug discovery and development programs. Under these agreements, we may be required to pay upfront fees, milestone payments, and royalties on sales of future products.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of our business, we may become involved in lawsuits, proceedings, and other disputes, including commercial, intellectual property, regulatory, employment, and other matters. We record a reserve for these matters when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated.</span></div></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">26</span></div></div></div><div id="ie2ffba3ee5384c86becdb38ff117ca9a_470"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie2ffba3ee5384c86becdb38ff117ca9a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 15. Subsequent Event</span></div><ix:nonNumeric contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930" name="us-gaap:SubsequentEventsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80NzAvZnJhZzoyMjQ4NGIyOWNjZGY0Y2VmYjgzNDg5Y2RlMjY5ZTQ3ZC90ZXh0cmVnaW9uOjIyNDg0YjI5Y2NkZjRjZWZiODM0ODljZGUyNjllNDdkXzM4NDgyOTA2OTgyMzU_2e7e7035-4c7e-467e-b40f-c9ad9cee1943" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Villaris</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2022, we announced that we entered into an agreement to acquire Villaris Therapeutics, Inc. ("Villaris"), a biopharmaceutical company focused on the development of novel antibody therapeutics for vitiligo. Under the terms of the agreement, Incyte will acquire Villaris and the exclusive global rights to develop and commercialize auremolimab (VM6), an anti-IL-15R&#946; monoclonal antibody, for all uses, including in vitiligo and other autoimmune and inflammatory diseases. Upon effectiveness of the agreement, Incyte will make an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i1c305a826fd9438ab670f7c9b7fa8ab4_D20221001-20221031" decimals="-5" name="incy:LicenseAgreementUpfrontPaymentAmountPaid" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80NzAvZnJhZzoyMjQ4NGIyOWNjZGY0Y2VmYjgzNDg5Y2RlMjY5ZTQ3ZC90ZXh0cmVnaW9uOjIyNDg0YjI5Y2NkZjRjZWZiODM0ODljZGUyNjllNDdkXzE2NDkyNjc0NDIxOTU_e7ce6795-dedd-4bfa-9120-a2544fc6a101">70.0</ix:nonFraction> million, and Villaris shareholders will be eligible for up to $<ix:nonFraction unitRef="usd" contextRef="if0d0cff0ce394041bc79b1987d42f3cd_D20221001-20221031" decimals="-5" name="incy:LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80NzAvZnJhZzoyMjQ4NGIyOWNjZGY0Y2VmYjgzNDg5Y2RlMjY5ZTQ3ZC90ZXh0cmVnaW9uOjIyNDg0YjI5Y2NkZjRjZWZiODM0ODljZGUyNjllNDdkXzE2NDkyNjc0NDIyNTM_21093b74-9b49-428d-8e15-623b19b55030">310.0</ix:nonFraction> million upon achievement of certain development and regulatory milestones, as well as up to an additional $<ix:nonFraction unitRef="usd" contextRef="i2aa7c5f2196a496abe03ba33b71612a9_D20221001-20221031" decimals="-7" name="incy:LicenseAgreementMilestoneOnNetSalesOfProduct" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80NzAvZnJhZzoyMjQ4NGIyOWNjZGY0Y2VmYjgzNDg5Y2RlMjY5ZTQ3ZC90ZXh0cmVnaW9uOjIyNDg0YjI5Y2NkZjRjZWZiODM0ODljZGUyNjllNDdkXzE2NDkyNjc0NDIzNTU_0e156dce-18b5-4c13-901a-eb9801d464cc">1.05</ix:nonFraction> billion in commercial milestones on net sales of the product. The agreement is subject to clearance by the U.S. antitrust authorities under the Hart-Scott-Rodino Act and will become effective as soon as this condition has been met.</span></div></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">27</span></div></div></div><div id="ie2ffba3ee5384c86becdb38ff117ca9a_82"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie2ffba3ee5384c86becdb38ff117ca9a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following discussion of our financial condition and results of operations as of and for the three and nine months ended September&#160;30, 2022 should be read in conjunction with the unaudited condensed consolidated financial statements and notes to those statements included elsewhere in this Quarterly Report on Form 10-Q and our audited consolidated financial statements as of and for the year ended December&#160;31, 2021 included in our Annual Report on Form 10-K for the year ended December&#160;31, 2021 previously filed with the SEC.</span></div><div id="ie2ffba3ee5384c86becdb38ff117ca9a_85"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Forward-Looking Statements</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">This report contains forward-looking statements that involve risks and uncertainties. These statements relate to future periods, future events or our future operating or financial plans or performance. Often, these statements include the words &#8220;believe,&#8221; &#8220;expect,&#8221; &#8220;target,&#8221; &#8220;anticipate,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;seek,&#8221; &#8220;estimate,&#8221; &#8220;potential,&#8221; or words of similar meaning, or future or conditional verbs such as &#8220;will,&#8221; &#8220;would,&#8221; &#8220;should,&#8221; &#8220;could,&#8221; &#8220;might,&#8221; or &#8220;may,&#8221; or the negative of these terms, and other similar expressions. These forward-looking statements include statements as to:</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the discovery, development, formulation, manufacturing and commercialization of our compounds, our drug candidates and JAKAFI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">/JAKAVI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> (ruxolitinib), PEMAZYRE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> (pemigatinib), ICLUSIG</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> (ponatinib), MONJUVI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(tafasitamab-cxix)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">/MINJUVI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> (tafasitamab), and OPZELURA&#8482; (ruxolitinib) cream;</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">our plans to further develop our operations outside of the United States;</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">conducting clinical trials internally, with collaborators, or with clinical research organizations;</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">our collaboration and strategic relationship strategy, and anticipated benefits and disadvantages of entering into collaboration agreements;</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">our licensing, investment and commercialization strategies, including our plans to commercialize our drug products and drug candidates;</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the regulatory approval process, including obtaining U.S. Food and Drug Administration and other international regulatory authorities&#8217; approval for our products in the United States and abroad;</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the safety, effectiveness and potential benefits and indications of our drug candidates and other compounds under development;</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the timing and size of our clinical trials; the compounds expected to enter clinical trials; timing of clinical trial results;</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to manage expansion of our drug discovery and development operations;</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">future required expertise relating to clinical trials, manufacturing, sales and marketing;</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">obtaining and terminating licenses to products, drug candidates or technology, or other intellectual property rights;</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the receipt from or payments pursuant to collaboration or license agreements resulting from milestones or royalties;</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">plans to develop and commercialize products on our own;</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">plans to use third-party manufacturers; </span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">plans for our manufacturing operations;</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">expected expenses and expenditure levels; expected uses of cash; expected revenues and sources of revenues, including milestone payments; expectations with respect to inventory;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie2ffba3ee5384c86becdb38ff117ca9a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">expectations with respect to reimbursement for our products;</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the expected impact of recent accounting pronouncements and changes in tax laws;</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">expected losses; fluctuation of losses; currency translation impact associated with non-U.S. operations and collaboration royalties;</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">our profitability; the adequacy of our capital resources to continue operations;</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the need to raise additional capital;</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the costs associated with resolving matters in litigation and governmental proceedings;</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">our expectations regarding competition;</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">our investments, including anticipated expenditures, losses and expenses; </span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">our patent prosecution and maintenance efforts; and</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the potential effects of the COVID-19 pandemic and efforts undertaken or to be undertaken by us or applicable governmental authorities on local and global economic conditions, and on our business, results of operations and financial condition.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">These forward-looking statements reflect our current views with respect to future events, are based on assumptions and are subject to risks and uncertainties. These risks and uncertainties could cause actual results to differ materially from those projected and include, but are not limited to:</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to successfully commercialize our drug products and drug candidates;</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain, or maintain at anticipated levels, coverage and reimbursement for our products from government health administration authorities, private health insurers and other organizations;</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to establish and maintain effective sales, marketing and distribution capabilities;</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the risk of reliance on other parties to manufacture our products, which could result in a short supply of our products, increased costs, and withdrawal of regulatory approval;</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to maintain regulatory approvals to market our products;</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to achieve a significant market share in order to achieve or maintain profitability;</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the risk of civil or criminal penalties if we market our products in a manner that violates health care fraud and abuse and other applicable laws, rules and regulations;</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to discover, develop, formulate, manufacture and commercialize our drug candidates;</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the risk of unanticipated delays in, or discontinuations of, research and development efforts;</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the risk that previous preclinical testing or clinical trial results are not necessarily indicative of future clinical trial results;</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">risks relating to the conduct of our clinical trials;</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">changing regulatory requirements;</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the risk of adverse safety findings;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie2ffba3ee5384c86becdb38ff117ca9a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the risk that results of our clinical trials do not support submission of a marketing approval application for our drug candidates;</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the risk of significant delays or costs in obtaining regulatory approvals;</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">risks relating to our reliance on third-party manufacturers, collaborators, and clinical research organizations;</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">risks relating to the development of new products and their use by us and our current and potential collaborators;</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">risks relating to our inability to control the development of out-licensed compounds or drug candidates;</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">risks relating to our collaborators&#8217; ability to develop and commercialize JAKAVI, OLUMIANT, TABRECTA and the drug candidates licensed from us;</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">costs associated with prosecuting, maintaining, defending and enforcing patent claims and other intellectual property rights;</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to maintain or obtain adequate product liability and other insurance coverage;</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the risk that our drug candidates may not obtain or maintain regulatory approval;</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of technological advances and competition, including potential generic competition;</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to compete against third parties with greater resources than ours;</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">risks relating to changes in pricing and reimbursement in the markets in which we may compete;</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">risks relating to governmental healthcare reform efforts, including efforts to control, set or cap pricing for our commercial drugs in the U.S and abroad;</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">competition to develop and commercialize similar drug products;</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain and maintain patent protection and freedom to operate for our discoveries and to continue to be effective in expanding our patent coverage;</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of changing laws on our patent portfolio;</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">developments in and expenses relating to litigation;</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to in-license drug candidates or other technology;</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">unanticipated delays or changes in plans or regulatory agency interactions or other issues relating to our large molecule production facility;</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to integrate successfully acquired businesses, development programs or technology;</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain additional capital when needed;</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">fluctuations in net cash provided and used by operating, financing and investing activities;</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to analyze the effects of new accounting pronouncements and apply new accounting rules;</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">risks relating to our ability to sustain profitability; </span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">risks related to public health pandemics such as the COVID-19 pandemic, natural disasters, or geopolitical events such as the Russian invasion of Ukraine; and</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie2ffba3ee5384c86becdb38ff117ca9a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the risks set forth under &#8220;Risk Factors.&#8221;</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Given these risks and uncertainties, you should not place undue reliance on these forward-looking statements. Except as required by federal securities laws, we undertake no obligation to update any forward-looking statements for any reason, even if new information becomes available or other events occur in the future.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In this report all references to &#8220;Incyte,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our&#8221; or the &#8220;Company&#8221; mean Incyte Corporation and our subsidiaries, except where it is made clear that the term means only the parent company.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Incyte, JAKAFI and PEMAZYRE are our registered trademarks and OPZELURA is our trademark. We also refer to trademarks of other corporations and organizations in this Quarterly Report on Form 10-Q.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">31</span></div></div></div><div id="ie2ffba3ee5384c86becdb38ff117ca9a_88"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie2ffba3ee5384c86becdb38ff117ca9a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summary Risk Factors</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business is subject to numerous risks and uncertainties that could affect our ability to successfully implement our business strategy and affect our financial results. You should carefully consider all of the information in this report and, in particular, the following principal risks and all of the other specific factors described in Item 1A. of this report, &#8220;Risk Factors,&#8221; before deciding whether to invest in our company.</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We depend heavily on JAKAFI/JAKAVI (ruxolitinib), and if we are not able to maintain revenues from JAKAFI/JAKAVI or those revenues decrease, our business may be materially harmed. </span></div><div style="margin-top:9pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we or our collaborators are unable to obtain, or maintain at anticipated levels, coverage and reimbursement for our products from government and other third-party payors, our results of operations and financial condition could be harmed.</span></div><div style="margin-top:9pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A limited number of specialty pharmacies and wholesalers represent a significant portion of revenues from JAKAFI and most of our other products, and the loss of, or significant reduction in sales to, any one of these specialty pharmacies or wholesalers could harm our operations and financial condition.</span></div><div style="margin-top:9pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we are unable to establish and maintain effective sales, marketing and distribution capabilities, or to enter into agreements with third parties to do so, we will not be able to successfully commercialize our products.</span></div><div style="margin-top:9pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we fail to comply with applicable laws and regulations, we could lose our approval to market our products or be subject to other governmental enforcement activity.</span></div><div style="margin-top:9pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If the use of our products harms or is perceived to harm patients, our regulatory approvals could be revoked or otherwise negatively impacted or we could be subject to costly product liability claims.</span></div><div style="margin-top:9pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we market our products in a manner that violates various laws and regulations, we may be subject to civil or criminal penalties.</span></div><div style="margin-top:9pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Competition for our products could harm our business and result in a decrease in our revenue.</span></div><div style="margin-top:9pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The COVID-19 pandemic and measures to address the pandemic, as well as other geopolitical events, have adversely affected and could in the future adversely affect our business and results of operations.</span></div><div style="margin-top:9pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We or our collaborators may be unsuccessful in discovering and developing drug candidates, and we may spend significant time and money attempting to do so, in particular with our later stage drug candidates.</span></div><div style="margin-top:9pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we or our collaborators are unable to obtain regulatory approval in and outside of the United States for drug candidates, we and our collaborators will be unable to commercialize those drug candidates.</span></div><div style="margin-top:9pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Health care reform measures could impact the pricing and profitability of pharmaceuticals, and adversely affect the commercial viability of our or our collaborators&#8217; products and drug candidates. </span></div><div style="margin-top:9pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Conflicts between us and our collaborators or termination of our collaboration agreements could limit future development and commercialization of our drug candidates and harm our business.</span></div><div style="margin-top:9pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we are unable to establish collaborations to fully exploit our drug discovery and development capabilities or if future collaborations are unsuccessful, our future revenue prospects could be diminished.</span></div><div style="margin-top:9pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we fail to enter into additional in-licensing agreements or if these arrangements are unsuccessful, we may be unable to increase our number of successfully marketed products and our revenues.</span></div><div style="margin-top:9pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Even if one of our drug candidates receives regulatory approval, we may determine that commercialization would not be worth the investment.</span></div><div style="margin-top:9pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Any approved drug product that we bring to the market may not gain market acceptance by physicians, patients, healthcare payors and others in the medical community.</span></div><div style="margin-top:9pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have limited capacity to conduct preclinical testing and clinical trials, and our resulting dependence on other parties could result in delays in and additional costs for our drug development efforts.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie2ffba3ee5384c86becdb38ff117ca9a_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We face significant competition for our drug discovery and development efforts, and if we do not compete effectively, our commercial opportunities will be reduced or eliminated.</span></div><div style="margin-top:9pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our reliance on others to manufacture our drug products and drug candidates could result in drug supply constraints, delays in clinical trials, increased costs, and withdrawal or denial of regulatory approvals.</span></div><div style="margin-top:9pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we fail to comply with the extensive legal and regulatory requirements affecting the health care industry, we could face increased costs, penalties and a loss of business.</span></div><div style="margin-top:9pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The illegal distribution and sale by third parties of counterfeit or unfit versions of our or our collaborators&#8217; products or stolen products could harm our business and reputation.</span></div><div style="margin-top:9pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">As most of our drug discovery and development operations are conducted at our headquarters in Wilmington, Delaware, the loss of access to this facility would negatively impact our business.</span></div><div style="margin-top:9pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we lose any of our key employees or are unable to attract and retain additional personnel, our business and ability to achieve our objectives could be harmed.</span></div><div style="margin-top:9pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we fail to manage our growth effectively, our ability to develop and commercialize products could suffer.</span></div><div style="margin-top:9pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may acquire businesses or assets, form joint ventures or make investments in other companies that may be unsuccessful, divert our management&#8217;s attention and harm our operating results and prospects.</span></div><div style="margin-top:9pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Risks associated with our operations outside of the United States could adversely affect our business.</span></div><div style="margin-top:9pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If product liability lawsuits are brought against us, we could face substantial liabilities and may be required to limit commercialization of our products, and our results of operations could be harmed.</span></div><div style="margin-top:9pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Because our activities involve the use of hazardous materials, we may be subject to claims relating to improper handling, storage or disposal of these materials that could be time consuming and costly.</span></div><div style="margin-top:9pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We expect to continue to incur significant expenses to discover and develop drugs, which could result in future losses and impair our achievement of and ability to sustain profitability in the future.</span></div><div style="margin-top:9pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we are unable to raise additional capital in the future when we require it, our efforts to broaden our product portfolio or commercialization efforts could be limited.</span></div><div style="margin-top:9pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our marketable securities and long term investments are subject to risks that could adversely affect our overall financial position, and tax law changes could adversely affect our results of operations and financial condition.</span></div><div style="margin-top:9pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we are unable to achieve milestones, develop product candidates to license or renew or enter into new collaborations, our royalty and milestone revenues and future prospects for those revenues may decrease.</span></div><div style="margin-top:9pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Any arbitration or litigation involving us and regarding intellectual property infringement claims could be costly and disrupt our drug discovery and development efforts.</span></div><div style="margin-top:9pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our inability to adequately protect or enforce our proprietary information may result in loss of revenues or otherwise reduce our ability to compete.</span></div><div style="margin-top:9pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If the effective term of our patents is decreased or if we need to refile some of our patent applications, the value of our patent portfolio and the revenues we derive from it may be decreased.</span></div><div style="margin-top:9pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">International patent protection is particularly uncertain and costly, and our involvement in opposition proceedings may result in the expenditure of substantial sums and management resources.</span></div><div style="margin-top:9pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Significant disruptions of information technology systems, breaches of data security, or unauthorized disclosures of sensitive data could harm our business and subject us to liability or reputational damage. </span></div><div style="margin-top:9pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Increasing use of social media could give rise to liability, breaches of data security, or reputational damage, which could harm our business and results of operations.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">33</span></div></div></div><div id="ie2ffba3ee5384c86becdb38ff117ca9a_91"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie2ffba3ee5384c86becdb38ff117ca9a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Incyte is a biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics. Our global headquarters is located in Wilmington, Delaware, where we conduct global clinical development and commercial operations. We also conduct clinical development and commercial operations from our country offices across Europe, including our European headquarters in Morges, Switzerland, our Japanese office in Tokyo and our Canadian headquarters in Montreal.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described in more detail below, we operate in two therapeutic areas that are defined by the indications of our approved medicines and the diseases for which our clinical candidates are being developed. One therapeutic area is Hematology/Oncology, which is comprised of Myeloproliferative Neoplasms (MPNs), Graft-Versus-Host Disease (GVHD), as well as solid tumors and hematologic malignancies. The other therapeutic area is Inflammation and Autoimmunity (IAI), which includes our newly established Dermatology commercial franchise. We are also eligible to receive milestones and royalties on molecules discovered by us and licensed to third parties. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Hematology and Oncology</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our hematology and oncology franchise is comprised of four approved products, which are JAKAFI (ruxolitinib), MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), PEMAZYRE (pemigatinib) and ICLUSIG (ponatinib), as well as numerous clinical development programs. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">JAKAFI (ruxolitinib)</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">JAKAFI (ruxolitinib) is our first product to be approved for sale in the United States. It was approved by the U.S. Food and Drug Administration (FDA) in November 2011 for the treatment of adults with intermediate or high-risk myelofibrosis (MF), in December 2014 for the treatment of adults with polycythemia vera (PV) who have had an inadequate response to or are intolerant of hydroxyurea, in May 2019 </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for the treatment of steroid-refractory acute graft-versus-host disease (GVHD) in adult and pediatric patients 12 years and older and in September 2021 for the treatment of chronic GVHD after failure of one or two lines of systemic therapy in adult and pediatric patients 12 years and older</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Myelofibrosis and polycythemia vera are both myeloproliferative neoplasms (MPNs), a type of rare blood cancer, and GVHD is an adverse immune response to an allogeneic hematopoietic stem cell transplant (HSCT). Under our collaboration agreement with our collaboration partner Novartis Pharmaceutical International Ltd., Novartis received exclusive development and commercialization rights to ruxolitinib outside of the United States for all hematologic and oncologic indications and sells ruxolitinib outside of the United States under the name JAKAVI.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2003, we initiated a research and development program to explore the inhibition of enzymes called janus associated kinases (JAK). The JAK family is composed of four tyrosine kinases&#8212;JAK1, JAK2, JAK3 and Tyk2&#8212;that are involved in the signaling of a number of cytokines and growth factors. JAKs are central to a number of biologic processes, including the formation and development of blood cells and the regulation of immune functions. Dysregulation of the JAK-STAT signaling pathway has been associated with a number of diseases, including myeloproliferative neoplasms, other hematological malignancies, rheumatoid arthritis and other chronic inflammatory diseases. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have discovered multiple potent, selective and orally bioavailable JAK inhibitors that are selective for JAK1 or JAK1 and JAK2. JAKAFI is the most advanced compound in our JAK program. It is an oral JAK1 and JAK2 inhibitor.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">JAKAFI is marketed in the United States through our own specialty sales force and commercial team. JAKAFI was the first FDA-approved JAK inhibitor for any indication, was the first FDA-approved product in MF, PV and steroid-refractory acute GVHD, and was recently approved in steroid-refractory chronic GVHD. JAKAFI remains the first-line standard of care in MF and remains the only FDA-approved product for steroid-refractory acute GVHD. The FDA has granted JAKAFI orphan drug status for MF, PV and GVHD.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">JAKAFI is distributed primarily through a network of specialty pharmacy providers and wholesalers that allow for efficient delivery of the medication by mail directly to patients or direct delivery to the patient&#8217;s pharmacy. Our distribution process uses a model that is well-established and familiar to physicians who practice within the oncology field.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To further support appropriate use and future development of JAKAFI, our U.S. Medical Affairs department is responsible for providing appropriate scientific and medical education and information to physicians, preparing scientific presentations and publications, and overseeing the process for supporting investigator sponsored trials.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie2ffba3ee5384c86becdb38ff117ca9a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Myelofibrosis.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> MF is a rare, life-threatening condition. MF, considered the most serious of the myeloproliferative neoplasms, can occur either as primary MF, or as secondary MF that develops in some patients who previously had polycythemia vera or essential thrombocythemia. We estimate there are between 16,000 and 18,500 patients with MF in the United States. Based on the modern prognostic scoring systems referred to as International Prognostic Scoring System and Dynamic International Prognostic Scoring System, we believe intermediate and high-risk patients represent 80% to 90% of all patients with MF in the United States and encompass patients over the age of 65, or patients who have or have ever had any of the following: anemia, constitutional symptoms, elevated white blood cell or blast counts, or platelet counts less than 100,000 per microliter of blood.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Most MF patients have enlarged spleens and many suffer from debilitating symptoms, including abdominal discomfort, pruritus (itching), night sweats and cachexia (involuntary weight loss). There were no FDA approved therapies for MF until the approval of JAKAFI.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA approval was based on results from two randomized Phase III trials (COMFORT-I and COMFORT-II), which demonstrated that patients treated with JAKAFI experienced significant reductions in splenomegaly (enlarged spleen). COMFORT-I also demonstrated improvements in symptoms. The most common hematologic adverse reactions in both trials were thrombocytopenia and anemia. These events rarely led to discontinuation of JAKAFI treatment. The most common non-hematologic adverse reactions were bruising, dizziness and headache.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2014, the FDA approved supplemental labeling for JAKAFI to include Kaplan-Meier overall survival curves as well as additional safety and dosing information. The overall survival information is based on three-year data from COMFORT-I and II, and shows that at three years the probability of survival for patients treated with JAKAFI in COMFORT-I was 70% and for those patients originally randomized to placebo it was 61%. In COMFORT-II, at three years the probability of survival for patients treated with JAKAFI was 79% and for patients originally randomized to best available therapy it was 59%. In December 2016, we announced an exploratory pooled analysis of data from the five-year follow-up of the COMFORT-I and COMFORT-II trials of patients treated with JAKAFI, which further supported previously published overall survival findings.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2016, we announced that JAKAFI had been included as a recommended treatment in the latest National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology for myelofibrosis, underscoring the important and long-term clinical benefits seen in patients treated with JAKAFI.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2017, the FDA approved updated labeling for JAKAFI to include the addition of new patient-reported outcome (PRO) data from the COMFORT-I study, as well as updating the warning related to progressive multifocal leukoencephalopathy. An exploratory analysis of PRO data of patients with myelofibrosis receiving JAKAFI showed improvement in fatigue-related symptoms at Week 24. Fatigue response (defined as a reduction of 4.5 points or more from baseline in the PROMIS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Fatigue total score) was reported in 35% of patients treated with JAKAFI versus 14% of the patients treated with placebo.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Polycythemia Vera.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> PV is a myeloproliferative neoplasm typically characterized by elevated hematocrit, the volume percentage of red blood cells in whole blood, which can lead to a thickening of the blood and an increased risk of blood clots, as well as an elevated white blood cell and platelet count. When phlebotomy can no longer control PV, chemotherapy such as hydroxyurea, or interferon, is utilized. Approximately 25,000 patients with PV in the United States are considered uncontrolled because they have an inadequate response to or are intolerant of hydroxyurea, the most commonly used chemotherapeutic agent for the treatment of PV.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2014, the FDA approved JAKAFI for the treatment of patients with PV who have had an inadequate response to or are intolerant of hydroxyurea. The approval of JAKAFI for PV was based on data from the pivotal Phase III RESPONSE trial. In this trial, patients treated with JAKAFI demonstrated superior hematocrit control and reductions in spleen volume compared to best available therapy. In addition, a greater proportion of patients treated with JAKAFI achieved complete hematologic remission&#8212;which was defined as achieving hematocrit control, and lowering platelet and white blood cell counts. In the RESPONSE trial, the most common hematologic adverse reactions (incidence &gt; 20%) were thrombocytopenia and anemia. The most common non-hematologic adverse events (incidence &gt;10%) were headache, abdominal pain, diarrhea, dizziness, fatigue, pruritus, dyspnea and muscle spasms.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie2ffba3ee5384c86becdb38ff117ca9a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2016, the FDA approved supplemental labeling for JAKAFI to include additional safety data as well as efficacy analyses from the RESPONSE trial to assess the durability of response in JAKAFI treated patients after 80 weeks. At this time, 83% patients were still on treatment, and 76% of the responders at 32 weeks maintained their response through 80 weeks.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, we announced data from the Phase III RESPONSE-2 study of JAKAFI in patients with inadequately controlled PV that was resistant to or intolerant of hydroxyurea who did not have an enlarged spleen. These data showed that JAKAFI was superior to best available therapy in maintaining hematocrit control (62.2% vs. 18.7%, respectively; P&lt;0.0001) without the need for phlebotomy.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2017, we announced that JAKAFI had been included as a recommended treatment in the latest NCCN Guidelines for patients with polycythemia vera who have had an inadequate response to first-line therapies, such as hydroxyurea.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Graft-versus-host disease.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> GVHD is a condition that can occur after an allogeneic HSCT (the transfer of genetically dissimilar stem cells or tissue). In GVHD, the donated bone marrow or peripheral blood stem cells view the recipient&#8217;s body as foreign and attack various tissues. 12-month survival rates in patients with Grade III or IV steroid-refractory acute GVHD are 50% or less, and the incidence of steroid-refractory acute and chronic GVHD is approximately 3,000 per year in the United States.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, we announced that the FDA granted Breakthrough Therapy designation for ruxolitinib in patients with acute GVHD. In May 2019, the FDA approved JAKAFI for the treatment of steroid-refractory acute GVHD in adult and pediatric patients 12 years and older. The approval was based on data from REACH1, an open-label, single-arm, multicenter study of JAKAFI in combination with corticosteroids in patients with steroid-refractory grade II-IV acute GVHD. The overall response rate (ORR) in patients refractory to steroids alone was 57% with a complete response (CR) rate of 31%. The most frequently reported adverse reactions among all study participants were infections (55%) and edema (51%), and the most common laboratory abnormalities were anemia (75%), thrombocytopenia (75%) and neutropenia (58%).</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2021, the FDA approved JAKAFI for the treatment of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">chronic GVHD after failure of one or two lines of systemic therapy in adult and pediatric patients 12 years and older. This approval was based on data from REACH3, a Phase III, randomized, open-label, multicenter study of JAKAFI in comparison to best available therapy for treatment of steroid-refractory chronic GVHD after allogeneic stem cell transplantation. The overall response rate through Cycle 7 Day 1 was 70% for JAKAFI compared to 57% for best available therapy. The most common hematologic adverse reactions (incidence &gt; 35%) were anemia and thrombocytopenia. The most common non-hematologic adverse reactions (incidence &#8805; 20%) were infections (pathogen not specified) and viral infection. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the FDA updated labeling for JAKAFI to include warnings of increased risk of major adverse cardiovascular events, thrombosis, and secondary malignancies related to another JAK-inhibitor treating rheumatoid arthritis, a condition for which JAKAFI is not indicated. In patients with MF and PV treated with JAKAFI in clinical trials, the rates of thromboembolic events were similar in JAKAFI and control treated patients.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have retained all development and commercialization rights to JAKAFI in the United States and are eligible to receive development and sales milestones as well as royalties from product sales outside the United States. We hold patents that cover the composition of matter and use of ruxolitinib. These patents, including applicable extensions, currently expire in mid-2028. A determination of pediatric exclusivity would add six months to the expiration.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">MONJUVI (tafasitamab-cxix) / MINJUVI (tafasitamab)</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2020, we and MorphoSys AG entered into a collaboration and license agreement to further develop and commercialize MorphoSys' proprietary anti-CD19 antibody tafasitamab (MOR208) globally. The agreement became effective March 2020. Tafasitamab is an Fc-engineered antibody against CD19 currently in clinical development for the treatment of B cell malignancies. We have rights to co-commercialize tafasitamab in the United States with MorphoSys, and we have exclusive development and commercialization rights outside of the United States. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie2ffba3ee5384c86becdb38ff117ca9a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2020, we and MorphoSys announced that the FDA approved MONJUVI (tafasitamab-cxix), which is indicated in combination with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from low grade lymphoma, and who are not eligible for autologous stem cell transplant (ASCT). MONJUVI was approved under accelerated approval based on overall response rate from the MorphoSys-sponsored Phase II L-MIND study, an open label, multicenter, single arm trial of MONJUVI in combination with lenalidomide as a treatment for adult patients with r/r DLBCL. Results from the study showed an objective response rate (ORR) of 55% (39 out of 71 patients; primary endpoint) and a complete response (CR) rate of 37% (26 out of 71 patients). The median duration of response (mDOR) was 21.7 months. The most frequent serious adverse reactions were infections (26%), including pneumonia (7%) and febrile neutropenia (6%). Updated three-year data from L-MIND were presented at the American Society of Clinical Oncology (ASCO) 2021.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, we and MorphoSys announced that MONJUVI in combination with lenalidomide had been included in the latest National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology for B-cell Lymphomas. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2021, we and MorphoSys announced that the European Commission granted conditional marketing authorization for MINJUVI (tafasitamab) in combination with lenalidomide, followed by MINJUVI monotherapy, for the treatment of adult patients with relapsed or refractory DLBCL who are not eligible for autologous stem cell transplant (ASCT). The conditional approval was based on the three-year results from the L-MIND study evaluating the safety and efficacy of MINJUVI in combination with lenalidomide as a treatment for patients with r/r DLBCL who are not eligible for ASCT. The results showed best objective response rate (ORR) of 56.8% (primary endpoint), including a complete response (CR) rate of 39.5% and a partial response rate (PR) of 17.3%, as assessed by an independent review committee. The median duration of response (mDOR) was 43.9 months after a minimum follow up of 35 months (secondary endpoint). MINJUVI together with lenalidomide was shown to provide a clinically meaningful response and the side effects were manageable. Warnings and precautions for MINJUVI include infusion-related reactions, myelosuppression, including neutropenia and thrombocytopenia, infections and tumour lysis syndrome.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DLBCL is the most common type of non-Hodgkin lymphoma in adults worldwide, comprising 40% of all cases. DLBCL is characterized by rapidly growing masses of malignant B-cells in the lymph nodes, spleen, liver, bone marrow or other organs. It is an aggressive disease with ~40% of patients not responding to initial therapy or relapsing thereafter. We estimate that there are ~10,000 patients diagnosed in the United States each year with r/r DLBCL who are not eligible for ASCT. In the EU, we estimate there are ~14,000 patients diagnosed each year with r/r DLBCL who are not eligible for ASCT.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">PEMAZYRE (pemigatinib)</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PEMAZYRE is the first internally discovered product to be internationally commercialized by us.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020, we announced that the FDA approved PEMAZYRE (pemigatinib), a selective fibroblast growth factor receptor (FGFR) kinase inhibitor, for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with an FGFR2 fusion or other rearrangement as detected by an FDA-approved test. PEMAZYRE is the first FDA-approved treatment for this indication, which was approved under accelerated approval based on overall response rate and duration of response (DOR). </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2021, PEMAZYRE was approved by the Japanese Ministry of Health, Labour and Welfare (MHLW) for the treatment of patients with unresectable biliary tract cancer (BTC) with an FGFR2 fusion gene, worsening after cancer chemotherapy. Also in March 2021, PEMAZYRE was approved by the European Commission (EC) for the treatment of adults with locally advanced or metastatic cholangiocarcinoma with an FGFR2 fusion or rearrangement that have progressed after at least one prior line of systemic therapy. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2021, the UK&#8217;s National Institute for Health and Care Excellence (NICE) recommended PEMAZYRE for patients with cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement that have progressed after at least one prior line of systemic therapy. NICE&#8217;s guidance enables all eligible patients in England and Wales to have access to PEMAZYRE through the National Health Service (NHS).</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cholangiocarcinoma is a rare cancer that arises from the cells within the bile ducts. It is often diagnosed late (stages III and IV) and the prognosis is poor. The incidence of cholangiocarcinoma with FGFR2 fusions or rearrangements is increasing, and it is currently estimated that there are 2,000-3,000 patients in the United States, Europe and Japan.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie2ffba3ee5384c86becdb38ff117ca9a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The approval of PEMAZYRE was based on data from FIGHT-202, a multi-center, open-label, single-arm study evaluating PEMAZYRE as a treatment for adults with cholangiocarcinoma. In FIGHT-202, and in patients harboring FGFR2 fusions or rearrangements (Cohort A), PEMAZYRE monotherapy resulted in an overall response rate of 36% (primary endpoint), and median DOR of 9.1 months (secondary endpoint). FIGHT-302, a Phase III trial of pemigatinib for the first-line treatment of patients with cholangiocarcinoma and FGFR2 fusions or rearrangements, is ongoing.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2022, PEMAZYRE was approved by the National Medical Products Administration (NMPA) of the People</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8217;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s Republic of China for the treatment of adults with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth receptor 2 (FGFR2) fusion or rearrangement as confirmed by a validated diagnostic test that have progressed after at least one prior line of systemic therapy. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2022, PEMAZYRE was approved by the FDA as the first and only targeted treatment for myeloid/lymphoid neoplasms (MLNs) with FGFR1 rearrangement. MLNs with FGFR1 rearrangement are extremely rare and aggressive blood cancers. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ICLUSIG (ponatinib)</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, we acquired the European operations of ARIAD Pharmaceuticals, Inc. and obtained an exclusive license to develop and commercialize ICLUSIG (ponatinib) in Europe and other select countries. ICLUSIG is a kinase inhibitor. The primary target for ICLUSIG is BCR-ABL, an abnormal tyrosine kinase that is expressed in chronic myeloid leukemia (CML) and Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ ALL).</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the European Union, ICLUSIG is approved for the treatment of adult patients with chronic phase, accelerated phase or blast phase CML who are resistant to dasatinib or nilotinib; who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I mutation, or the treatment of adult patients with Ph+ ALL who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I mutation. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical Programs in Hematology and Oncology</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Ruxolitinib </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of our ongoing LIMBER (Leadership In MPNs BEyond Ruxolitinib) clinical development initiative, which is designed to improve and expand therapeutic options for patients with myeloproliferative neoplasms, we are evaluating combinations of ruxolitinib with other therapeutic modalities, as well as developing a once-a-day formulation of ruxolitinib for potential use as monotherapy and combination therapy. Bioavailability and bioequivalence data were published for ruxolitinib&#8217;s once-daily (QD) extended release (XR) formulation at the European Hematology Association (EHA) 2021 Virtual Congress in June 2021. The FDA accepted the New Drug Application (NDA) for QD ruxolitinib with a Prescription Drug User Fee Act (PDUFA) target action date of March 23, 2023.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on positive Phase II data, we opened two pivotal trials of ruxolitinib in combination with parsaclisib (PI3K&#948;) in first-line MF (LIMBER-313) and in MF patients with a suboptimal response to ruxolitinib monotherapy (LIMBER-304), and both trials are ongoing. Additional Phase II trials combining ruxolitinib with investigational agents from our portfolio such as INCB57643 (BET) and INCB00928 (ALK2) in patients with MF are ongoing, and additional discovery and development initiatives are also ongoing within the LIMBER program, which are evaluating internally-discovered compounds and candidates from collaboration partners. </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Itacitinib</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We no longer intend to develop itacitinib, a selective JAK1 inhibitor, in treatment-na&#239;ve chronic GVHD (cGVHD). Based on efficacy data from Part I of the Phase II/II GRAVITAS-309 trial, we determined that a pivotal trial was unlikely to be successful.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie2ffba3ee5384c86becdb38ff117ca9a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Axatilimab</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2021, we and Syndax Pharmaceuticals, Inc. announced an exclusive worldwide collaboration and license agreement to develop and commercialize axatilimab, Syndax&#8217;s anti-CSF-1R monoclonal antibody. Together, we plan to develop axatilimab as a therapy for patients with chronic GVHD as well as in additional immune-mediated diseases where CSF-1R-dependent monocytes and macrophages are believed to contribute to organ fibrosis. In December 2021, updated positive data were presented at ASH from the Phase I/II trial evaluating axatilimab as a monotherapy in patients with recurrent or refractory chronic GVHD after two or more prior lines of therapy. A 68% overall response rate and broad clinical benefit across multiple organs were observed at doses being assessed in AGAVE-201, a global pivotal trial evaluating axatilimab monotherapy in patients with chronic GVHD in the third line setting. Additional trials of axatilimab are planned in patients with chronic GVHD, including a Phase II trial in combination with ruxolitinib in patients with newly-diagnosed cGVHD. In May 2022, Syndax announced that axatilimab was granted fast-track designation by the FDA for the treatment of patients with chronic GVHD after failure of two or more lines of systemic therapy.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Tafasitamab </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tafasitamab is an anti-CD19 antibody and is being investigated as a therapeutic option in B cell malignancies in a number of ongoing and planned combination trials. An open-label Phase II combination trial (L-MIND) is investigating the safety and efficacy of tafasitamab in combination with lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL), and the ongoing Phase III B-MIND trial is assessing the combination of tafasitamab and bendamustine versus rituximab and bendamustine in r/r DLBCL. firstMIND is a Phase Ib safety trial of tafasitamab as a first-line therapy for patients with DLBCL, and frontMIND, a placebo-controlled Phase III trial evaluating tafasitamab in combination with lenalidomide added to rituximab plus chemotherapy (R-CHOP) as a first-line therapy for patients with DLBCL, is ongoing. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A placebo-controlled Phase III trial (inMIND) of tafasitamab added to lenalidomide plus rituximab (R</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) in patients with relapsed or refractory follicular or marginal zone lymphomas is ongoing. A proof-of-concept study of tafasitamab, lenalidomide and plamotamab in patients with r/r DLBCL is also ongoing. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, the FDA granted orphan drug designation to tafasitamab as a treatment for patients with follicular lymphoma.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pemigatinib </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pemigatinib is a potent and selective inhibitor of the fibroblast growth factor receptor (FGFR) isoforms 1, 2 and 3 with demonstrated activity in preclinical studies. The FGFR family of receptor tyrosine kinases can act as oncogenic drivers in a number of liquid and solid tumor types. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We initiated the FIGHT clinical program to evaluate pemigatinib across a spectrum of cancers that are driven by FGF/FGFR alterations. The program initially included three Phase II trials &#8211; FIGHT-201 in patients with bladder cancer, FIGHT-202 in patients with cholangiocarcinoma, and FIGHT-203 in patients with myeloid/lymphoid neoplasms with FGFR1 rearrangement. Based on data generated from these trials, we have initiated additional trials including FIGHT-302, a Phase III study in first-line cholangiocarcinoma. FIGHT-207, a solid tumor-agnostic trial evaluating pemigatinib in patients with driver-alterations of FGF/FGFR, is now closed to recruitment. Based on findings from this study, we have identified populations that may potentially benefit from treatment with pemigatinib and have initiated two Phase II trials &#8211; FIGHT-209 in patients with glioblastoma and FIGHT-210 in patients with non-small cell lung cancer.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pemigatinib has Breakthrough Therapy designation as a treatment for patients with myeloid/lymphoid neoplasms (MLN) with FGFR1 rearrangement who have relapsed or are refractory to initial chemotherapy. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Parsaclisib </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The PI3K&#948; pathway mediates oncogenic signaling in B cell malignancies. Parsaclisib is a PI3K&#948; inhibitor that has demonstrated potency and selectivity in preclinical studies and has potential therapeutic utility in the treatment of patients with lymphoma. We initiated the CITADEL clinical program to evaluate parsaclisib in non-Hodgkin lymphomas, including Phase II trials in follicular lymphoma, marginal zone lymphoma and mantle cell lymphoma. The FDA granted orphan drug designation and Fast Track designation to parsaclisib as a treatment for patients with follicular lymphoma, marginal zone lymphoma and mantle cell lymphoma.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie2ffba3ee5384c86becdb38ff117ca9a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, we announced preliminary results from the ongoing CITADEL monotherapy development program, which was designed to enable registration of parsaclisib. Results from four cohorts were presented at the American Society of Hematology (ASH), including in r/r follicular lymphoma (CITADEL-203), in BTK-na&#239;ve r/r marginal zone lymphoma (CITADEL-204) and in both BTK-na&#239;ve and BTK-experienced r/r mantle cell lymphoma (CITADEL-205). </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, we announced the FDA acceptance of an NDA seeking approval of parsaclisib for the treatment of patients with relapsed or refractory follicular lymphoma, marginal zone lymphoma and mantle cell lymphoma. The submission was based on data from several Phase II studies (CITADEL-203, -204 and -205) evaluating parsaclisib as a treatment for relapsed or refractory non-Hodgkin lymphomas (follicular, marginal zone and mantle cell). In January 2022, we announced that we withdrew the NDA seeking approval of parsaclisib for the three indications in non-Hodgkin lymphoma. The decision to withdraw the NDA followed discussions with FDA regarding confirmatory studies that we determined cannot be completed within a reasonable time period to support an accelerated approval. In July 2022, we withdrew the Marketing Authorization Application (MAA) seeking approval of parsaclisib in marginal zone lymphoma following discussions with the European Medicines Agency (EMA) regarding the confirmatory study needed to support the approval which we determined were not feasible.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A Phase II trial of parsaclisib in patients with autoimmune hemolytic anemia (AIHA), a rare red blood cell disorder, is ongoing. In June 2021, data from the Phase II trial were presented at EHA. The majority of patients achieved a response with parsaclisib over the initial 12-week treatment period and treatment with parsaclisib was generally well tolerated. Based on these results, we initiated a Phase III trial (PATHWAY) in warm AIHA. The FDA has granted orphan drug designation to parsaclisib as a treatment for patients with AIHA.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Retifanlimab </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2017, we and MacroGenics, Inc. announced an exclusive global collaboration and license agreement for MacroGenics&#8217; retifanlimab (formerly INCMGA0012), an investigational monoclonal antibody that inhibits PD-1. Under this collaboration, we obtained exclusive worldwide rights for the development and commercialization of retifanlimab in all indications. The molecule is currently being evaluated both as monotherapy and in combination therapy across various tumor types. Potentially registration-enabling trials in microsatellite instability-high (MSI-H) endometrial cancer and Merkel cell carcinoma are ongoing.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Phase III POD1UM-303 trial of retifanlimab in combination with platinum-based chemotherapy as a first-line treatment for patients with squamous cell carcinoma of the anal canal (SCAC) is underway. In July 2021, we announced that the FDA issued a complete response letter (CRL) for the BLA of retifanlimab for the treatment of SCAC. In October 2021, we announced that we withdrew the MAA seeking approval of retifanlimab in SCAC. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Phase III POD1UM-304 trial is evaluating retifanlimab in combination with platinum-based chemotherapy as a first-line treatment for patients with non-small cell lung cancer (NSCLC), and in October 2020, our collaboration partner Zai Lab announced dosing of the first patient in China. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie2ffba3ee5384c86becdb38ff117ca9a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Retifanlimab has been granted Fast Track designation for the treatment of certain patients with advanced or metastatic MSI-H or DNA mismatch repair (dMMR) endometrial cancer, for the treatment of certain patients with locally advanced or metastatic SCAC and for the treatment of Merkel cell carcinoma (MCC). The FDA and EMA have granted orphan drug designation to retifanlimab as a treatment for patients with locally advanced or metastatic SCAC and the FDA has granted orphan drug designation to retifanlimab as a treatment for patients with MCC.</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.060%"><tr><td style="width:1.0%"></td><td style="width:25.240%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:72.560%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Indication and status</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Once-a-day ruxolitinib (JAK1/JAK2)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Myelofibrosis, polycythemia vera and GVHD: NDA under review</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ruxolitinib + parsaclisib </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(JAK1/JAK2 + PI3K&#948;)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Myelofibrosis: Phase III (first-line therapy) (LIMBER-313)<br/>Myelofibrosis: Phase III (suboptimal responders to ruxolitinib) (LIMBER-304)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ruxolitinib + INCB57643</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(JAK1/JAK2 + BET)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Myelofibrosis: Phase II</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ruxolitinib + INCB00928 <br/>(JAK1/JAK2 + ALK2)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Myelofibrosis: Phase II</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ruxolitinib + CK0804</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">1</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(JAK1/JAK2 + CB-Tregs)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Myelofibrosis: PoC (LIMBER-TREG108)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">axatilimab (anti-CSF-1R)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">2</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chronic GVHD: Pivotal Phase II (third-line plus therapy) (AGAVE-201)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">tafasitamab (CD19)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">3</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">r/r DLBCL: Phase II (L-MIND); Phase III (B-MIND) </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1L DLBCL: Phase III (frontMIND)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">r/r follicular &amp; marginal zone lymphomas: Phase III (inMIND) </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">r/r B-cell malignancies: PoC with lenalidomide and plamotamab</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">4</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">pemigatinib (FGFR1/2/3)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CCA: Phase III (FIGHT-302)<br/>Myeloid/lymphoid neoplasms (MLN): Phase II (FIGHT-203); approved in the United States<br/>Glioblastoma: Phase II (FIGHT-209) <br/>NSCLC: Phase II (FIGHT-210) </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">parsaclisib (PI3K&#948;)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warm autoimmune hemolytic anemia: Phase III (PATHWAY)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">retifanlimab (PD-1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">5</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SCAC: Phase III (PODIUM-303) <br/>MSI-high endometrial cancer: Phase II (POD1UM-101, POD1UM-204)<br/>Merkel cell carcinoma: Phase II (POD1UM-201)<br/>NSCLC: Phase III (POD1UM-304)</span></td></tr></table></div><div style="margin-top:6pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.13pt">Development collaboration with Cellenkos, Inc.</span></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.13pt">axatilimab development in collaboration with Syndax.</span></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.13pt"> tafasitamab development in collaboration with MorphoSys.</span></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">4.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.13pt">Clinical collaboration with MorphoSys and Xencor, Inc. to investigate the combination of tafasitamab plus lenalidomide in combination with Xencor&#8217;s CD20xCD3 XmAb bispecific antibody, plamotamab.</span></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">5.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.13pt">retifanlimab licensed from MacroGenics.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Earlier-Stage Development Programs in Hematology and Oncology</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Oral PD-L1</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2021, we highlighted Phase I clinical safety and efficacy data for our oral PD-L1 program which included three compounds, INCB86550, INCB99280 and INCB99318. Tumor shrinkage was observed for all three oral PD-L1 inhibitors. With regard to safety, both INCB99280 and INCB99318 did not show peripheral neuropathy seen with INCB86550. In May 2022, the decision was made to prioritize the development of INCB99280 and INCB99318 based on positive therapeutic ratios.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie2ffba3ee5384c86becdb38ff117ca9a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">INCB123667 (CDK2)</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the cell cycle, the serine threonine kinase, CDK2, regulates the transition from the G1 phase (cell growth) to the S-phase (DNA replication). INCB123667 is a novel, potent and selective oral small molecule inhibitor of CDK2 which has been shown to suppress tumor growth as monotherapy and in combination with standard of care, in Cyclin E amplified tumor models, in vivo. In July 2022, we initiated a Phase I dose-escalation and dose-expansion study evaluating INCB123667 in adults with selected advanced or metastatic solid tumors.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">INCA32459 (LAG-3xPD-1)</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In collaboration with Merus we have developed INCA32459, a novel LAG3xPD-1 bispecific antibody that is planned to enter clinical studies later this year. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our earlier-stage clinical programs in hematology and oncology are included in the table below.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We intend to describe these programs more fully if we obtain clinical proof-of-concept and establish that a program warrants further development in a specific indication or group of indications.</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.203%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:73.597%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Modality</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Candidates</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Small molecules</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INCB81776 (AXL/MER), INCB99280 (PD-L1), INCB99318 (PD-L1), INCB106385 (A2A/A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:1.41pt;vertical-align:baseline">2B</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), INCB123667 (CDK2)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Monoclonal antibodies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INCAGN1876 (GITR), INCAGN2385 (LAG-3), INCAGN2390 (TIM-3), INCA00186 (CD73)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Bispecific antibodies</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INCA32459 (LAG-3xPD-1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">2</span></div></td></tr></table></div><div style="margin-top:6pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.13pt">Discovery collaboration with Agenus Inc.</span></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.13pt">Development collaboration with Merus</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inflammation and AutoImmunity (IAI)</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Incyte Dermatology launched its first approved product, OPZELURA (ruxolitinib) cream, in October 2021, following FDA approval in September 2021. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Incyte&#8217;s IAI efforts also include numerous clinical development programs. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">OPZELURA (ruxolitinib) cream</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Atopic Dermatitis. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2021, we announced that the FDA approved OPZELURA (ruxolitinib) cream, a novel cream formulation of Incyte&#8217;s selective JAK1/JAK2 inhibitor ruxolitinib, for the topical short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis (AD) in non-immunocompromised patients 12 years of age and older whose disease is not adequately controlled with topical prescription therapies, or when those therapies are not advisable.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AD is a skin disorder that causes long term inflammation of the skin resulting in itchy, red, swollen and cracked skin. Onset can occur at any age, but is more common in infants and children. In the United States, we estimate that there are approximately 10 million diagnosed adolescent and adult patients with AD.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The approval of OPZELURA was based on data from two randomized, double-blind, vehicle-controlled Phase III studies (TRuE-AD1 and TRuE-AD 2) evaluating the safety and efficacy of OPZELURA in adolescents and adults with mild to moderate AD. Significantly more patients treated with OPZELURA achieved Investigator&#8217;s Global Assessment (IGA) Treatment Success at Week 8 (defined as an IGA score of 0 or 1 with at least a 2-point improvement from baseline, the primary endpoint: 53.8% in TRuE-AD1 and 51.3% in TRuE-AD2, compared to vehicle (15.1% in TRuE-AD1, 7.6% in TRuE-AD2; P&lt;0.0001). Significantly more patients treated with OPZELURA experienced a clinically meaningful reduction in itch from baseline at Week 8, as measured by a &#8805;4-point reduction in the itch Numerical Rating Scale (itch NRS4): 52.2% in TRuE-AD1 and 50.7% in TRuE-AD2, compared to vehicle (15.4% in TRuE-AD1, 16.3% in TRuE-AD2; P&lt;0.0001), among patients with an NRS score of at least 4 at baseline. The most common (&#8805;1%) treatment-emergent adverse reactions in patients treated with OPZELURA were nasopharyngitis, diarrhea, bronchitis, ear infection, eosinophil count increased, urticaria, folliculitis, tonsillitis and rhinorrhea.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie2ffba3ee5384c86becdb38ff117ca9a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Vitiligo. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2022, we announced that the FDA approved OPZELURA for the topical treatment of nonsegmental vitiligo in adult and pediatric patients 12 years of age and older. OPZELURA was approved for continuous use and no limits to duration as a treatment for nonsegmental vitiligo.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vitiligo is a chronic autoimmune depigmenting skin disease characterized by patches of the skin losing their pigment. It is estimated that there are at least 1.5 million patients diagnosed with vitiligo in the United States, with the majority of patients (approximately 85%) suffering from nonsegmental vitiligo. OPZELURA is the first and only FDA approved treatment for repigmentation of vitiligo lesions.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The approval of OPZELURA in vitiligo was based on two randomized, double-blind, vehicle-controlled Phase III studies (TRuE-V1 and TRuE-V2) evaluating the safety and efficacy of OPZELURA in adolescents and adults with nonsegmental vitiligo. Treatment with 1.5% ruxolitinib cream twice daily (BID) resulted in greater improvement versus vehicle for the primary and all key secondary endpoints in both the TRuE-V1 and TRuE-V2 studies. Results, which were consistent across both studies, showed that 29.9% of patients applying ruxolitinib cream achieved &gt;75% improvement from baseline in the facial Vitiligo Area Scoring Index (F-VASI75) at Week 24, the primary endpoint. At Week 52, approximately 50% of patients achieved F-VASI75. The most common (&gt;1%) treatment-emergent adverse reactions in patients treated with OPZELURA were application site acne, application site pruritus, nasopharyngitis, headache, urinary tract infection, application site erythema and pyrexia.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical Programs in Dermatology</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Ruxolitinib cream</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ruxolitinib cream is a potent, selective inhibitor of JAK1 and JAK2 that provides the opportunity to directly target diverse pathogenic pathways that underlie certain dermatologic conditions, including atopic dermatitis, vitiligo, chronic hand eczema, lichen planus and lichen sclerosus. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, we announced the validation of the MAA for ruxolitinib cream as a potential treatment for adolescents and adults (age &#8805;12 years) with nonsegmental vitiligo with facial involvement. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Two Phase 2 trials evaluating ruxolitinib cream in lichen planus and lichen sclerosus are in preparation. Lichen planus is a recurrent inflammatory condition affecting the skin and mucosal surfaces and can result in itchy, purple bumps on the skin. Lichen sclerosus is a chronic inflammatory skin disease most commonly affecting women and can result in painful ulcers and intense itching. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Povorcitinib</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also developing povorcitinib (formerly INCB54707), which is an oral small molecule selective JAK1 inhibitor. Povorcitinib is undergoing evaluation in patients with hidradenitis suppurativa (HS), a chronic skin condition where lesions develop as a result of inflammation and infection of the sweat glands. In October 2020, initial results from the clinical program were presented and a randomized Phase IIb trial of povorcitinib is underway in patients with HS.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2021, we initiated a Phase II trial evaluating povorcitinib in patients with vitiligo. A Phase II trial evaluating povorcitinib in patients with prurigo nodularis is ongoing. In August 2022, we presented results from the Phase II trial of povorcitinib in HS and based on positive results, we plan to initiate a Phase III study in HS. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie2ffba3ee5384c86becdb38ff117ca9a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:27.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:70.567%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Indication and status</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ruxolitinib cream</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(JAK1/JAK2)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Atopic dermatitis: Phase III pediatric study (TRuE-AD3)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vitiligo: Phase III (TRuE-V1, TRuE-V2); approved by FDA; MAA under review</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ruxolitinib cream + NB-UVB (JAK1/JAK2 + phototherapy)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vitiligo: Phase II </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">povorcitinib (JAK1)</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.77pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Hidradenitis suppurativa: Phase II; Phase III in preparation</span></div><div style="padding-right:2.77pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vitiligo: Phase II</span></div><div style="padding-right:2.77pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prurigo nodularis: Phase II</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Novartis&#8217; rights for ruxolitinib outside of the United States under our Collaboration and License Agreement with Novartis do not include topical administration.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical Programs in Other IAI</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2022, we initiated a Phase II trial evaluating INCB00928 in patients with fibrodysplasia ossificans progressiva (FOP), a disorder in which muscle tissue and connective tissue are gradually replaced by bone. The FDA has granted Fast Track designation and orphan drug designation to INCB00928 as a treatment for patients with FOP.</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:27.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:70.567%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Indication and status</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">INCB00928 (ALK2)</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fibrodysplasia ossificans progressiva: Phase II </span></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Collaborative Partnered Programs</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described below under &#8220;&#8212;License Agreements and Business Relationships,&#8221; we are eligible for milestone payments and royalties on certain products that we licensed to third parties. These include OLUMIANT (baricitinib), which is licensed to our collaborative partner Eli Lilly and Company, and JAKAVI (ruxolitinib) and TABRECTA (capmatinib), which are licensed to Novartis. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Baricitinib</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a second JAK1 and JAK2 inhibitor, baricitinib, which is subject to our collaboration agreement with Lilly, in which Lilly received exclusive worldwide development and commercialization rights to the compound for inflammatory and autoimmune diseases. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rheumatoid Arthritis.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Rheumatoid arthritis is an autoimmune disease characterized by aberrant or abnormal immune mechanisms that lead to joint inflammation and swelling and, in some patients, the progressive destruction of joints. Rheumatoid arthritis can also affect connective tissue in the skin and organs of the body.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current rheumatoid arthritis treatments include the use of non-steroidal anti-inflammatory drugs, disease-modifying anti-rheumatic drugs, such as methotrexate, and the newer biological response modifiers that target pro-inflammatory cytokines, such as tumor necrosis factor, implicated in the pathogenesis of rheumatoid arthritis. None of these approaches to treatment is curative; therefore, there remains an unmet need for new safe and effective treatment options for these patients. Rheumatoid arthritis is estimated to affect about 1% of the world&#8217;s population.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Phase III program of baricitinib in patients with rheumatoid arthritis incorporated all three rheumatoid arthritis populations (methotrexate na&#239;ve, biologic na&#239;ve, and tumor necrosis factor (TNF) inhibitor inadequate responders); used event rates to fully power the baricitinib program for structural comparison and non-inferiority vs. adalimumab; and evaluated patient-reported outcomes. All four Phase III trials met their respective primary endpoints.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie2ffba3ee5384c86becdb38ff117ca9a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2016, Lilly submitted an NDA to the FDA and an MAA to the EMA for baricitinib as treatment for rheumatoid arthritis. In February 2017, we and Lilly announced that the European Commission approved baricitinib as OLUMIANT for the treatment of moderate-to-severe rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to, one or more disease-modifying antirheumatic drugs (DMARDs). In July 2017, the Japanese Ministry of Health, Labour and Welfare (MHLW) granted marketing approval for OLUMIANT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for the treatment of rheumatoid arthritis (including the prevention of structural injury of joints) in patients with inadequate response to standard-of-care therapies. In June 2018, the FDA approved the 2mg dose of OLUMIANT for the treatment of adults with moderately-to-severely active rheumatoid arthritis (RA) who have had an inadequate response to one or more tumor necrosis factor (TNF) inhibitor therapies.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Atopic Dermatitis. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lilly has conducted a Phase IIa trial and a Phase III program to evaluate the safety and efficacy of baricitinib in patients with moderate-to-severe atopic dermatitis. The JAK-STAT pathway has been shown to play an essential role in the dysregulation of immune responses in atopic dermatitis. Therefore, we believe that inhibiting cytokine pathways dependent on JAK1 and JAK2 may lead to positive clinical outcomes in AD. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2019, we and Lilly announced that baricitinib met the primary endpoint in BREEZE-AD1 and BREEZE-AD2, two Phase III studies evaluating the efficacy and safety of baricitinib monotherapy for the treatment of adult patients with moderate-to-severe AD and, in August 2019, we and Lilly announced that baricitinib met the primary endpoint in BREEZE-AD7, a Phase III study evaluating the efficacy and safety of baricitinib in combination with standard-of-care topical corticosteroids in patients with moderate-to-severe AD. In January 2020, we and Lilly announced that baricitinib met the primary endpoint in both BREEZE-AD4 and BREEZE-AD5, the results of which completed the placebo-controlled data program intended to support global registrations. A supplemental New Drug Application (sNDA) for baricitinib was submitted by Lilly for the treatment of patients with moderate to severe AD. In April 2021, we and Lilly announced the FDA extended the review period for the sNDA for baricitinib for the treatment of moderate to severe AD by three months to allow time for additional data analyses. In July 2021, we and Lilly announced that the FDA will not meet the PDUFA action date for the sNDA for baricitinib for the treatment of adults with moderate to severe AD due to the FDA's ongoing assessment of JAK inhibitors. In January 2022, Lilly provided a regulatory update on the sNDA based on ongoing discussions with the FDA. Lilly announced that alignment with the FDA on the indicated population had not yet been reached and given the FDA&#8217;s position, there would be the possibility of a Complete Response Letter (CRL).</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2020, Lilly announced that baricitinib had been submitted for regulatory review in Europe as a treatment for patients with moderate-to-severe AD. In October 2020, Lilly announced that the European Commission approved baricitinib as OLUMIANT for the treatment of moderate-to-severe AD in adult patients who are candidates for systemic therapy. In December 2020, baricitinib was approved by the MHLW for the treatment of patients with moderate-to-severe AD.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Alopecia Areata</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Alopecia areata is an autoimmune disorder in which the immune system attacks the hair follicles, causing hair loss in patches. In March 2020, Lilly announced that baricitinib received Breakthrough Therapy designation for the treatment of alopecia areata, based on the positive Phase II results of Lilly&#8217;s adaptive Phase II/III study BRAVE-AA1. In March 2021, we and Lilly announced positive results from BRAVE-AA2, the Phase III trial evaluating the efficacy and safety of once-daily baricitinib in adults with severe alopecia areata. In April 2021, we and Lilly announced positive results from the Phase III portion of BRAVE-AA1. In September 2021, we and Lilly announced detailed results from BRAVE-AA1 and BRAVE-AA2 at the European Academy of Dermatology and Venereology Congress (EADV). The two studies showed statistically significant improvement in scalp hair regrowth across both baricitinib dosing groups when compared to placebo. In March 2022, we and Lilly announced positive 52 week results from BRAVE-AA1 and BRAVE-AA2 at the American Academy of Dermatology (AAD) annual meeting showing 40% of adults saw at least 80% scalp coverage. In June 2022, the FDA approved 2mg, and 4mg doses of OLUMIANT for the treatment of adults with severe alopecia areata, becoming the first and only systemic treatment in the indication. In June 2022, OLUMIANT was approved as a treatment for alopecia areata in Europe and Japan.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Systemic Lupus Erythematosus.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Systemic lupus erythematosus (SLE) is a chronic disease that causes inflammation. In addition to affecting the skin and joints, it can affect other organs in the body such as the kidneys, the tissue lining the lungs and heart, and the brain. Lilly has conducted a Phase II trial to evaluate the safety and efficacy of baricitinib in patients with SLE. Baricitinib&#8217;s activity profile suggests that it inhibits cytokines implicated in SLE such as type I interferon (IFN), type II IFN-&#947;, IL-6, and IL-23 as well as other cytokines that may have a role in SLE, including granulocyte macrophage colony stimulating factor (GM-CSF) and IL-12. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie2ffba3ee5384c86becdb38ff117ca9a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2022, Lilly announced the discontinuation of the Phase III development program for baricitinib in SLE based on top-line efficacy results from two pivotal Phase III trials (SLE-BRAVE-I and &#8211;II). The primary endpoint of SRI-4 response was reached in SLE-BRAVE-I but was not reached in SLE-BRAVE-II and key secondary endpoints were not met in either study.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">COVID-19.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In May 2020, we amended our agreement with Lilly to enable Lilly to commercialize baricitinib for the treatment of COVID-19. In November 2020, we and Lilly announced that the FDA issued an Emergency Use Authorization (EUA) for the distribution and emergency use of baricitinib to be used in combination with remdesivir in hospitalized adult and pediatric patients two years of age or older with suspected or laboratory confirmed COVID-19 who require supplemental oxygen, invasive mechanical ventilation, or extracorporeal membrane oxygenation. In December 2020, we and Lilly announced that data from ACTT-2 supportive of the EUA were published in the New England Journal of Medicine. In July 2021, we and Lilly announced that the FDA broadened the EUA for baricitinib to allow for treatment with or without remdesivir. The EUA now provides for the use of baricitinib for treatment of COVID-19 in hospitalized adults and pediatric patients two years of age or older requiring supplemental oxygen, non-invasive or invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO). In June 2022, we and Lilly announced the FDA approved baricitinib as OLUMIANT for the treatment of COVID-19 in hospitalized adults requiring supplemental oxygen, non-invasive or invasive mechanical ventilation, or ECMO.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Capmatinib</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Capmatinib is a potent and highly selective MET inhibitor. The investigational compound has demonstrated inhibitory activity in cell-based biochemical and functional assays that measure MET signaling and MET dependent cell proliferation, survival and migration. Under our agreement, Novartis received worldwide exclusive development and commercialization rights to capmatinib and certain back-up compounds in all indications. Capmatinib is being evaluated in patients with hepatocellular carcinoma, non-small cell lung cancer and other solid tumors, and may have potential utility as a combination agent.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MET is a clinically validated receptor kinase cancer target. Abnormal MET activation in cancer correlates with poor prognosis. Dysregulation of the MET pathway triggers tumor growth, formation of new blood vessels that supply the tumor with nutrients, and causes cancer to spread to other organs. Dysregulation of the MET pathway is seen in many types of cancers, including lung, kidney, liver, stomach, breast and brain.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, we and Novartis announced the FDA approval of capmatinib as TABRECTA for the treatment of adult patients with metastatic NSCLC whose tumors have a mutation that leads to MET exon 14 skipping (METex14) as detected by an FDA-approved test. TABRECTA is the first and only treatment approved to specifically target NSCLC with this driver mutation and is approved for first-line and previously treated patients regardless of prior treatment type. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA approval of TABRECTA was based on results from the pivotal GEOMETRY mono-1 study. In the METex14 population (n=97), the confirmed overall response rate was 68% and 41% among treatment-naive (n=28) and previously treated patients (n=69), respectively, based on the Blinded Independent Review Committee (BIRC) assessment per RECIST v1.1. In patients taking TABRECTA, the study also demonstrated a median duration of response of 12.6 months in treatment-naive patients (19 responders) and 9.7 months in previously treated patients (28 responders). The most common treatment-related adverse events (AEs) (incidence &#8805;20%) are peripheral edema, nausea, fatigue, vomiting, dyspnea, and decreased appetite. In September 2020, we and Novartis announced that GEOMETRY mono-1 results were published in The New England Journal of Medicine.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, we and Novartis announced that the MHLW approved TABRECTA for METex14 mutation-positive advanced and/or recurrent unresectable NSCLC. In April 2022, we and Novartis announced a positive opinion from the CHMP based on data from the Phase II GEOMETRY mono-1 study showing an overall response rate (ORR) of 51.6% in a cohort evaluating second-line patients only and 44% in all previously-treated patients with advanced non-small cell lung cancer (NSCLC) harboring alterations leading to MET exon 14 skipping.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2022, we and Novartis announced the European Commission approval of capmatinib as TABRECTA as monotherapy treatment of adults with advanced non-small cell lung cancer (NSCLC) harboring alterations leading to mesenchymal-epithelial-transition factor gene (MET) exon 14 (METex14) skipping who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie2ffba3ee5384c86becdb38ff117ca9a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NSCLC is the most common type of lung cancer, impacting more than 2 million people per year globally. Approximately 3-4 percent of all patients with NSCLC have tumors with a mutation that leads to MET exon 14 skipping. Though rare, this mutation is an indicator of especially poor prognosis and poor responses to standard therapies, including immunotherapy. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Ruxolitinib</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Graft-versus-host disease.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In March 2022, we and Novartis announced a positive opinion from the CHMP for ruxolitinib in acute and chronic GVHD, based on data from the Phase III REACH2 and REACH3 trials. GVHD is a life-threatening complication of stem cell transplants, with no established standard of care in Europe for patients who do not adequately respond to first-line steroid treatment. In May 2022, we and Novartis announced the EC approval of ruxolitinib as JAKAVI for the treatment of acute or chronic GVHD in patients aged 12 years and older who have inadequate response to corticosteroids or other systemic therapies.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:27.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:70.567%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Indication and status</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">baricitinib (JAK1/JAK2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Atopic dermatitis: Phase III (BREEZE-AD); approved in Europe and Japan</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Severe alopecia areata: Phase III (BRAVE-AA1, BRAVE-AA2); approved in the United States, Europe and Japan</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">capmatinib (MET)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">2</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NSCLC (with MET exon 14 skipping mutations): approved in the United States, Europe and Japan</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ruxolitinib (JAK1/JAK2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">3</span></div></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acute and chronic GVHD: approved in Europe; J-NDA under review</span></td></tr></table></div><div style="margin-top:6pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.13pt">baricitinib licensed to Lilly.</span></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.13pt">capmatinib licensed to Novartis.</span></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.13pt">ruxolitinib licensed to Novartis ex-US for use in hematology and oncology excluding topical administration.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">License Agreements and Business Relationships</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We establish business relationships, including collaborative arrangements with other companies and medical research institutions to assist in the clinical development and/or commercialization of certain of our drugs and drug candidates and to provide support for our research programs. We also evaluate opportunities for acquiring products or rights to products and technologies that are complementary to our business from other companies and medical research institutions.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Below is a brief description of our significant business relationships and collaborations and related license agreements that expand our pipeline and provide us with certain rights to existing and potential new products and technologies. Additional information regarding our collaboration agreements, including their financial and accounting impact on our business and results of operations, can be found in Note 7 of notes to the condensed consolidated financial statements.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Out-License Agreements</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Novartis</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2009, we entered into a Collaboration and License Agreement with Novartis. Under the terms of the agreement, Novartis received exclusive development and commercialization rights outside of the United States to ruxolitinib and certain back up compounds for hematologic and oncology indications, including all hematological malignancies, solid tumors and myeloproliferative diseases. We retained exclusive development and commercialization rights to JAKAFI (ruxolitinib) in the United States and in certain other indications. Novartis also received worldwide exclusive development and commercialization rights to our MET inhibitor compound capmatinib and certain back up compounds in all indications. We retained options to co-develop and to co-promote capmatinib in the United States. In April 2016, we amended this agreement to provide that Novartis has exclusive research, development and commercialization rights outside of the United States to ruxolitinib (excluding topical formulations) in the GVHD field.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie2ffba3ee5384c86becdb38ff117ca9a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Lilly</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2009, we entered into a License, Development and Commercialization Agreement with Lilly. Under the terms of the agreement, Lilly received exclusive worldwide development and commercialization rights to baricitinib and certain back up compounds for inflammatory and autoimmune diseases. In March 2016, we entered into an amendment to the agreement with Lilly that allows us to engage in the development and commercialization of ruxolitinib in the GVHD field. In May 2020, we amended our agreement with Lilly to enable Lilly to commercialize baricitinib for the treatment of COVID-19. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Innovent</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2018, we entered into a Research Collaboration and Licensing Agreement with Innovent Biologics, Inc. Under the terms of this agreement, Innovent received exclusive development and commercialization rights to pemigatinib and our clinical-stage product candidates itacitinib and parsaclisib in hematology and oncology indications in mainland China, Hong Kong, Macau and Taiwan. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Zai Lab</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2019, we entered into a Collaboration and License Agreement with a subsidiary of Zai Lab Limited. Under the terms of this agreement, Zai Lab&#8217;s subsidiary received development and exclusive commercialization rights to retifanlimab in hematology and oncology in mainland China, Hong Kong, Macau and Taiwan. We retained an option to assist in the promotion of retifanlimab in Zai Lab&#8217;s licensed territories. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">InnoCare</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2021, we entered into a Collaboration and License Agreement with a subsidiary of InnoCare Pharma Limited. Under the terms of this agreement, InnoCare&#8217;s subsidiary received development and exclusive commercialization rights to tafasitamab in hematology and oncology in mainland China, Hong Kong, Macau and Taiwan.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Maruho</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2022, we entered into a Strategic Alliance Agreement with Maruho Co., Ltd. Under the terms of this agreement, Maruho received development, manufacturing and exclusive commercialization rights to ruxolitinib cream, and other potential future topical formulations of ruxolitinib, in autoimmune and inflammatory dermatologic diseases in Japan.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">In-License Agreements</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Agenus</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2015, we entered into a License, Development and Commercialization Agreement with Agenus Inc. and its wholly-owned subsidiary, 4-Antibody AG (now known as Agenus Switzerland Inc.), which we collectively refer to as Agenus. Under this agreement, the parties have agreed to collaborate on the discovery of novel immuno-therapeutics using Agenus&#8217; antibody discovery platforms. Under the terms of this agreement, as amended in February 2017, we received exclusive worldwide development and commercialization rights to four checkpoint modulators directed against GITR, OX40, LAG-3 and TIM-3. In addition to the initial four program targets, we and Agenus have the option to jointly nominate and pursue additional targets within the framework of the collaboration, and in November 2015, three more targets were added, two of which were removed from the collaboration under the February 2017 amendments.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Takeda (ARIAD) </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, we acquired from ARIAD Pharmaceuticals, Inc. all of the outstanding shares of ARIAD Pharmaceuticals (Luxembourg) S.&#224;.r.l., the parent company of ARIAD&#8217;s European subsidiaries responsible for the development and commercialization of ICLUSIG in the European Union and other countries. We obtained an exclusive license to develop and commercialize ICLUSIG in Europe and other select countries. ARIAD was subsequently acquired by Takeda Pharmaceutical Company Limited in 2017. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie2ffba3ee5384c86becdb38ff117ca9a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Merus</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2016, we entered into a Collaboration and License Agreement with Merus N.V. Under this agreement, which became effective in January 2017, the parties have agreed to collaborate with respect to the research, discovery and development of bispecific antibodies utilizing Merus&#8217; technology platform. The collaboration encompasses up to eleven independent programs. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2022, we decided to opt-out of the continued development of MCLA-145, a bispecific antibody targeting PD-L1 and CD137. We continue to collaborate with Merus and leverage the Merus platform to develop a pipeline of novel agents, as we continue to hold worldwide exclusive development and commercialization rights to up to ten additional programs.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Calithera</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2017, we entered into a Collaboration and License Agreement with Calithera Biosciences, Inc. Under this agreement, we received an exclusive, worldwide license to develop and commercialize small molecule arginase inhibitors, including INCB01158 (CB-1158), which is currently in Phase II clinical trials, for multiple myeloma. In September 2022, we notified Calithera of our exercise of our right to terminate the Collaboration and License Agreement for convenience, effective in December 2022. As a result of the termination, rights to INCB01158 and the other licensed products will revert to Calithera. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">MacroGenics</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2017, we entered into a Global Collaboration and License Agreement with MacroGenics. Under this agreement, we received exclusive development and commercialization rights worldwide to MacroGenics&#8217; INCMGA0012, an investigational monoclonal antibody that inhibits PD-1. MacroGenics has retained the right to develop and commercialize, at its cost and expense, its pipeline assets in combination with INCMGA0012. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Syros</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2018, we entered into a Target Discovery, Research Collaboration and Option Agreement with Syros Pharmaceuticals, Inc. Under this agreement, Syros will use its proprietary gene control platform to identify novel therapeutic targets with a focus in myeloproliferative neoplasms and we have received options to obtain exclusive worldwide rights to intellectual property resulting from the collaboration for up to seven validated targets. We will have exclusive worldwide rights to develop and commercialize any therapies under the collaboration that modulate those validated targets. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">MorphoSys</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2020, we entered into a Collaboration and License Agreement with MorphoSys AG and MorphoSys US Inc., a wholly-owned subsidiary of MorphoSys AG, covering the worldwide development and commercialization of MOR208 (tafasitamab), an investigational Fc engineered monoclonal antibody directed against the target molecule CD19. Under the terms of this agreement, we received exclusive commercialization rights outside of the United States, and MorphoSys and we have co-commercialization rights in the United States, with respect to tafasitamab. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Syndax</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2021, we entered into a Collaboration and License Agreement with Syndax covering the worldwide development and commercialization of SNDX-6352 (axatilimab), Syndax&#8217;s anti-CSF-1R monoclonal antibody. In March 2021, axatilimab was granted Orphan Drug Designation by the FDA for the treatment of chronic GVHD and a second designation in April 2021 for treatment of idiopathic pulmonary fibrosis. Under the terms of this agreement, we received exclusive commercialization rights outside of the United States, and Syndax has co-commercialization rights in the United States with respect to axatilimab.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie2ffba3ee5384c86becdb38ff117ca9a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COVID-19 </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, coronavirus disease of 2019, or COVID-19, was first reported in Wuhan, China. In March 2020, the World Health Organization declared COVID-19 a pandemic. We and our collaboration partners Lilly and Novartis initiated a number of clinical trials to address COVID-19.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020, we announced the initiation of a Phase III clinical trial (RUXCOVID) to evaluate the efficacy and safety of ruxolitinib plus standard-of-care (SoC), compared to SoC therapy alone, in patients not on mechanical ventilation and who have COVID-19 associated cytokine storm. We sponsored this collaborative study in the United States and our collaboration partner Novartis International Pharmaceutical Ltd. sponsored the study outside of the United States. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, we announced initial results from RUXCOVID, where treatment with ruxolitinib plus SoC did not prevent complications compared to SoC treatment alone in patients with COVID-19 associated cytokine storm.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2021, results from a second Phase III clinical trial to evaluate the efficacy and safety of ruxolitinib plus SoC, compared to SoC therapy alone, in COVID-19 patients on mechanical ventilation and who have acute respiratory distress syndrome (ARDS), a type of respiratory failure characterized by rapid onset of widespread inflammation in the lungs were announced. Ruxolitinib failed to reduce mortality due to any cause through Day 29 although in the U.S. study population (91% of total study patients), there was a clinically and statistically significant improvement in mortality in each of the 5mg and 15mg ruxolitinib arms. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020, Lilly announced that it has entered into an agreement with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, to study baricitinib as an arm in NIAID's Adaptive COVID-19 Treatment Trial (ACTT-2). The study is investigating the efficacy and safety of baricitinib as a potential treatment for hospitalized patients diagnosed with COVID-19 in the United States, and Lilly is also planning an expansion to include Europe and Asia. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, we and Lilly announced initial results from ACTT-2, where baricitinib in combination with remdesivir reduced the time to recovery in comparison with remdesivir alone. Additional data announced in October 2020 showed that baricitinib plus remdesivir resulted in a numerical decrease in mortality through Day 29 compared to remdesivir alone, with a more pronounced reduction seen in more severely ill patients.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2020, we and Lilly announced that the FDA issued an Emergency Use Authorization (EUA) for the distribution and emergency use of baricitinib to be used in combination with remdesivir in hospitalized adult and pediatric patients two years of age or older with suspected or laboratory confirmed COVID-19 who require supplemental oxygen, invasive mechanical ventilation, or extracorporeal membrane oxygenation. In December 2020, we and Lilly announced that data from ACTT-2 supportive of the EUA were published in the New England Journal of Medicine. In July 2021, we and Lilly announced that the FDA broadened the EUA for baricitinib to allow for treatment with or without remdesivir. The EUA now provides for the use of baricitinib for treatment of COVID-19 in hospitalized adults and pediatric patients two years of age or older requiring supplemental oxygen, non-invasive or invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO).</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021, we and Lilly announced that the primary endpoint was not met in COV-BARRIER, the Phase III randomized, double-blind, placebo&#8211;controlled study to evaluate the efficacy and safety of baricitinib in hospitalized adults not on mechanical ventilation and who have COVID-19. There was, however, a 38% reduction in mortality by Day 28 in patients treated with baricitinib in addition to SoC. In August 2021, we and Lilly announced new data from an additional cohort of 101 adult patients from the COV-BARRIER trial. In this sub-study, patients with COVID-19 on mechanical ventilation or ECMO who received baricitinib plus standard of care were 46% less likely to die by Day 28 compared to patients who received placebo plus standard of care.</span></div><div id="ie2ffba3ee5384c86becdb38ff117ca9a_109"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Significant Estimates</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements requires us to make estimates, assumptions and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosures of contingent assets and liabilities. On an ongoing basis, we evaluate our estimates. We base our estimates on historical experience and various other assumptions that we believe to be reasonable under the circumstances, the results of which form our basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from those estimates under different assumptions or conditions.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie2ffba3ee5384c86becdb38ff117ca9a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a discussion of our critical accounting policies, refer to &#8220;Item 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; in our 2021 Form 10-K. There have been no significant changes to our critical accounting policies or estimates during the nine months ended September&#160;30, 2022.</span></div><div id="ie2ffba3ee5384c86becdb38ff117ca9a_112"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no new accounting pronouncements issued nor adopted since our filing of the Annual Report on Form 10-K for the year ended December&#160;31, 2021, which could have a significant effect on our condensed consolidated financial statements.</span></div><div id="ie2ffba3ee5384c86becdb38ff117ca9a_115"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recorded net income of $112.8 million and basic net income per share of $0.51 and diluted net income per share of $0.50 for the three months ended September&#160;30, 2022, as compared to net income of $181.7 million and basic and diluted net income per share of $0.82 in the corresponding period in 2021. We recorded net income of $312.2 million and basic net income per share of $1.41 and diluted net income per share of $1.40 for the nine months ended September&#160;30, 2022, as compared to net income of $384.7 million and basic net income per share of $1.75 and diluted net income per share of $1.73 in the corresponding period in 2021. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenues</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">JAKAFI revenues, net</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">619.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">547.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,761.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,542.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">ICLUSIG revenues, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">25.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">28.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">78.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">82.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">PEMAZYRE revenues, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">23.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">17.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">60.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">48.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">MINJUVI revenues, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">14.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">OPZELURA revenues, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">38.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">67.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total product revenues, net</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">713.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">594.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,982.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,673.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">JAKAVI product royalty revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">85.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">94.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">240.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">242.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">OLUMIANT product royalty revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">20.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">86.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">98.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">154.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">TABRECTA product royalty revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">11.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total product royalty revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">110.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">184.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">350.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">404.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Milestone and contract revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">35.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">135.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">45.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total revenues</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">823.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">813.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,467.9&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,123.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in JAKAFI product revenues for the three months ended September&#160;30, 2022 as compared to the corresponding period in 2021 was comprised of a volume increase of $30.9 million and a price increase of $41.3 million. The increase in JAKAFI product revenues for the nine months ended September&#160;30, 2022 as compared to the corresponding period in 2021 was comprised of a volume increase of $125.7 million and a price increase of $93.9 million. Additionally, our product revenues may fluctuate from quarter to quarter due to our customers&#8217; purchasing patterns over the course of the year, including as a result of increased inventory building by customers in advance of expected or announced price increases. Product revenues are recorded net of estimated product returns, pricing discounts including rebates offered pursuant to mandatory federal and state government programs and chargebacks, prompt pay discounts and distribution fees and co-pay assistance. Our revenue recognition policies require estimates of the aforementioned sales allowances each period. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie2ffba3ee5384c86becdb38ff117ca9a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a summary of activity with respect to our sales allowances and accruals (in thousands):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.869%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.023%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Nine Months Ended September 30, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Discounts and <br/>Distribution<br/>Fees</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Government<br/>Rebates and<br/>Chargebacks</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Co-Pay<br/>Assistance<br/>and Other<br/>Discounts</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Product<br/>Returns</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Balance at January 1, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">14,678&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">99,304&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">24,074&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4,740&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">142,796&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Allowances for current period sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">87,898&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">445,112&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">214,823&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,776&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">751,609&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Allowances for prior period sales</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(94)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(2,702)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(2,801)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Credits/payments for current period sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(66,388)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(363,943)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(185,780)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(616,111)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Credits/payments for prior period sales</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(12,095)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(58,696)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(8,230)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(2,229)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(81,250)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Balance at September 30, 2022</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">23,999&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">119,075&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">44,882&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6,287&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">194,243&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government rebates and chargebacks are the most significant component of our sales allowances. Increases in certain government reimbursement rates are limited to a measure of inflation, and when the price of a drug increases faster than this measure of inflation it will result in a penalty adjustment factor that causes a larger sales allowance to those government related entities. We expect government rebates and chargebacks as a percentage of our gross product sales will continue to increase in connection with any future product price increases greater than the rate of inflation, and any such increase in these government rebates and chargebacks will have a negative impact on our reported product revenues, net. We adjust our estimates for government rebates and chargebacks based on new information regarding actual rebates as it becomes available. Claims by third-party payors for rebates and chargebacks are frequently submitted after the period in which the related sales occurred, which may result in adjustments to prior period accrual balances in the period in which the new information becomes available. We also adjust our allowance for product returns based on new information regarding actual returns as it becomes available. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect our sales allowances to fluctuate from quarter to quarter as a result of the Medicare Part D Coverage Gap, the volume of purchases eligible for government mandated discounts and rebates as well as changes in discount percentages which are impacted by potential future price increases, rate of inflation, and other factors.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product royalty revenues on commercial sales of JAKAVI and TABRECTA by Novartis are based on net sales of licensed products in licensed territories as provided by Novartis. Product royalty revenues on commercial sales of OLUMIANT by Lilly are based on net sales of licensed products in licensed territor</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ies as provided by Lilly. The decrease in OLUMIANT product royalty revenues for the nine months ended September&#160;30, 2022 as compared to the corresponding period in 2021 reflects unfavorable changes in foreign currency exchange rates, a decrease in net product sales of OLUMIANT for use as a treatment for COVID-19 and a </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">one-time deduction related to securing intellectual property rights. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our milestone and contract revenues for the nine months ended September&#160;30, 2022, were derived from total regulatory milestones of $60.0 million </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">under the Novartis </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">collaboration and license agreement, regulatory milestones of $70.0 million under the license, development and commercialization agreement with Lilly, and a $5.0 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> regulatory milestone under the Innovent </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">research collaboration and licensing agreement. Our milestone and contract revenues for the nine months ended September&#160;30, 2021, were derived from a $10.0 million milestone under the Innovent research collaboration and licensing agreement and a $35.0 million upfront payment under the InnoCare collaboration and license agreement..</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie2ffba3ee5384c86becdb38ff117ca9a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Product Revenues </span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Product costs</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">14.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">39.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">14.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Salary and benefits related</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Stock compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Royalty expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">31.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">26.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">83.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">70.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Amortization of definite-lived intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">16.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">16.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total cost of product revenues</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">54.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">39.9&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">147.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">107.1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of product revenues includes all product related costs, employee personnel costs, including stock compensation, for those employees dedicated to the production of our commercial products, royalties under our collaborative agreements and amortization of our licensed intellectual property rights for ICLUSIG. The increase in cost of product revenues for the three and nine months ended September&#160;30, 2022 as compared to the same periods in 2021 was primarily due to product related costs for our commercial products including OPZELURA.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Expenses</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development expenses</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Salary and benefits related</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">82.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">75.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">250.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">229.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Stock compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">25.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">26.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">80.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">84.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Clinical research and outside services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">242.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">196.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">650.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">576.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Occupancy and all other costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">33.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">36.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">103.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">95.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total research and development expenses</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">384.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">334.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,084.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">985.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for research and development costs by natural expense line and not costs by project. The increase in salary and benefits related expense for the three and nine months ended September&#160;30, 2022 as compared to the corresponding periods in 2021 was due primarily to increased development headcount to sustain our development pipeline. Stock compensation expense may fluctuate from period to period based on the number of awards granted, stock price volatility and expected award lives, as well as expected award forfeiture rates which are used to value equity-based compensation. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in clinical research and outside services expense for the three and nine months ended September&#160;30, 2022 as compared to the corresponding period in 2021 was primarily due to continued investment in our late stage development assets. Research and development expenses include upfront and milestone expenses related to our collaborative agreements of $33.5 million and $56.0 million, respectively, for the three and nine months ended September&#160;30, 2022. Research and development expenses include upfront and milestone expenses related to our collaborative agreements of $4.3 million and $20.8 million, respectively, for the three and nine months ended September&#160;30, 2021. Research and development expenses for the three and nine months ended September&#160;30, 2022 and 2021 were net of $8.7 million, $43.3 million, $3.2 million and $15.7 million, respectively, of costs reimbursed by our collaborative partners. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie2ffba3ee5384c86becdb38ff117ca9a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to one-time expenses resulting from upfront fees in connection with the entry into any new or amended collaboration agreements and payment of milestones under those agreements, research and development expenses may fluctuate from period to period depending upon the stage of certain projects and the level of preclinical and clinical trial related activities. Many factors can affect the cost and timing of our clinical trials, including requests by regulatory agencies for more information, inconclusive results requiring additional clinical trials, slow patient enrollment, adverse side effects among patients, insufficient supplies for our clinical trials, timing of drug supply, including API, and real or perceived lack of effectiveness or safety of our investigational drugs in our clinical trials. In addition, the development of all of our products will be subject to extensive governmental regulation. These factors make it difficult for us to predict the timing and costs of the further development and approval of our products.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, general and administrative expenses</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.960%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.932%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Salary and benefits related</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">64.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">58.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">197.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">163.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Stock compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">18.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">15.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">53.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">49.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other contract services and outside costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">183.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">116.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">478.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">300.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total selling, general and administrative expenses</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">266.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">190.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">729.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">513.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in salary and benefits related expense for the three and nine months ended September&#160;30, 2022 as compared to the corresponding period in 2021 was due primarily to increased headcount. This increased headcount was due primarily to the establishment of our dermatology commercial organization and activities to support the launch of OPZELURA for the treatment of atopic dermatitis. Stock compensation expense may fluctuate from period to period based on the number of awards granted, stock price volatility and expected award lives, as well as expected award forfeiture rates which are used to value equity-based compensation. The increase in other contract services and outside costs for the three and nine months ended September&#160;30, 2022, as compared to the corresponding periods in 2021, was due primarily to expenses related to our dermatology commercial organization and activities to support the launch of OPZELURA for the treatments of atopic dermatitis and vitiligo.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(Gain) loss on change in fair value of acquisition-related contingent consideration</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquisition-related contingent consideration, which consists of our future royalty obligations to ARIAD/Takeda, was recorded on the acquisition date, June 1, 2016, at the estimated fair value of the obligation, in accordance with the acquisition method of accounting. The fair value of the acquisition-related contingent consideration is remeasured quarterly. The gain on change in fair value of the acquisition-related contingent consideration for the three and nine months ended September&#160;30, 2022 was $21.9 million and $12.2 million, respectively, which is recorded in (gain) loss on change in fair value of acquisition-related contingent consideration on the condensed consolidated statements of operations. The loss on change in fair value of the acquisition-related contingent consideration for the three and nine months ended September&#160;30, 2021 was $2.9 million and $13.1 million, respectively, which is recorded in (gain) loss on change in fair value of acquisition-related contingent consideration on the condensed consolidated statements of operations. The change in fair value for the three and nine months ended September&#160;30, 2022 was due primarily to the changes in foreign currency exchange rates included within the updated projections of future net revenues of ICLUSIG.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaboration loss sharing</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the collaboration and license agreement with MorphoSys, which was executed in March 2020, we and MorphoSys are both responsible for the commercialization efforts of tafasitamab in the United States and will share equally the profits and losses from the co-commercialization efforts. For the three and nine months ended September&#160;30, 2022, our 50% share of the losses for tafasitamab was $1.8 million and $9.1 million, respectively, as recorded in collaboration loss sharing on the condensed consolidated statement of operations. For the three and nine months ended September&#160;30, 2021, our 50% share of the losses for tafasitamab was $9.1 million and $29.5 million, respectively, as recorded in collaboration loss sharing on the condensed consolidated statement of operations. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie2ffba3ee5384c86becdb38ff117ca9a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other income (expense)</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other income (expense), net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Other income (expense), net for the three and nine months ended September&#160;30, 2022 was $11.5 million and $13.3 million, respectively. Other income (expense), net for the three and nine months ended September&#160;30, 2021 was $1.9 million and $4.9 million, respectively. The increase in other income (expense), net for the three and nine months ended September&#160;30, 2022 primarily relates to an increase in interest income.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Unrealized loss on long term investments. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrealized gains and losses on long term investments will fluctuate from period to period, based on the change in fair value of the securities we hold in our publicly held collaboration partners. The following table provides a summary of those unrealized losses: </span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Agenus</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 1.97pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(2.8)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(14.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 1.97pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">29.1</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Calithera</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(0.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(4.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Merus</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(9.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.97pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(41.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.97pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">13.3</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">MorphoSys</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(27.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(15.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(60.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Syndax</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.97pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6.8</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.97pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.97pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Syros</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(0.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(2.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(6.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total unrealized loss on long term investments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(0.7)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1.97pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(27.5)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(72.1)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(28.4)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Provision for income taxes. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes for the three and nine months ended September&#160;30, 2022 was $35.8 million and $136.3 million, respectively. The provision for income taxes for the three and nine months ended September&#160;30, 2021 was $27.7 million and $65.7 million, respectively. The provision for income taxes increased in 2022 as compared to that for the prior year period due to the release of our valuation allowance against a majority of our U.S. research and development tax credit carryforwards and other deferred tax assets at December&#160;31, 2021.</span></div><div id="ie2ffba3ee5384c86becdb38ff117ca9a_118"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to historical net losses, we had an accumulated deficit of $0.5 billion as of September&#160;30, 2022. We have funded our research and development operations through cash received from customers, sales of equity securities, the issuance of convertible notes, and collaborative arrangements. At September&#160;30, 2022, we had available cash, cash equivalents and marketable securities of $3.0&#160;billion. Our cash and marketable securities balances are held in a variety of interest-bearing instruments, including money market accounts, and U.S. government debt securities. Available cash is invested in accordance with our investment policy&#8217;s primary objectives of liquidity, safety of principal and diversity of investments.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by operating activities for the nine months ended September&#160;30, 2022 and 2021 was $686.3 million and $634.1 million, respectively. The increase in cash provided by operating activities was due primarily to changes in working capital.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our investing activities, other than purchases, sales and maturities of marketable securities, have consisted predominantly of capital expenditures and purchases of long term investments. Net cash used in investing activities was $57.6 million for the nine months ended September&#160;30, 2022, which represented purchases of marketable securities of $59.1 million and capital expenditures of $56.6 million, offset in part by the sale and maturities of marketable securities of $58.0 million. Net cash used in investing activities was $141.7 million for the nine months ended September&#160;30, 2021, which represented purchases of marketable securities of $228.2 million, capital expenditures of $146.5 million, and purchases of long term equity investments of $8.7 million, offset in part by the sale of long term investment of $10.5 million and the sales and maturities of marketable securities of $231.3 million. In the future, net cash used by investing activities may fluctuate significantly from period to period due to the timing of strategic equity investments, acquisitions, and capital expenditures and maturities/sales and purchases of marketable securities.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie2ffba3ee5384c86becdb38ff117ca9a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities was $1.7 million for the nine months ended September&#160;30, 2022 and net cash used in financing activities was $2.8 million for the nine months ended September&#160;30, 2021, primarily representing proceeds from the issuance of common stock under our stock plans, offset in part by cash paid to ARIAD/Takeda for contingent consideration. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our capital expenditures for construction activities are discussed in Note 8 of notes to our condensed consolidated financial statements. In addition, in October 2019, we entered into an agreement with Wilmington Friends School Inc., to purchase property for $50.0&#160;million to expand our global headquarters. Under that agreement, closing of the purchase is subject to certain standard closing conditions, including an initial diligence period and a subsequent approval period. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2021, we entered into a $500.0 million, three-year senior unsecured revolving credit facility. We may increase the maximum revolving commitments or add one or more incremental term loan facilities, subject to obtaining commitments from any participating lenders and certain other conditions, in an amount not to exceed $250.0 million plus a contingent additional amount that is dependent on our pro forma consolidated leverage ratio. As of September&#160;30, 2022, we had no outstanding borrowings and were in compliance with all covenants under this facility.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our U.S. income tax payments will increase significantly due to the mandatory capitalization and amortization of research and development expenses for tax years beginning after December 31, 2021, as required under the Tax Cuts and Jobs Act of 2017, which eliminated the immediate expensing of such expenses.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our cash flow from operations, together with our cash, cash equivalents and marketable securities and funds available under our revolving credit facility, will be adequate to satisfy our capital needs for the foreseeable future. Our cash requirements depend on numerous factors, including our expenditures in connection with our drug discovery and development programs and commercialization operations; expenditures in connection with litigation or other legal proceedings; costs for future facility requirements; and expenditures for future strategic equity investments or potential acquisitions. We have entered into and may in the future seek to license additional rights relating to technologies or drug development candidates in connection with our drug discovery and development programs. Under these licenses, we may be required to pay upfront fees, milestone payments, and royalties on sales of future products. These contingent future payments are discussed in detail in Note 7 of notes to the condensed consolidated financial statements.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent we seek to augment our existing cash resources and cash flow from operations to satisfy our cash requirements for future acquisitions or other strategic purposes, we expect that additional funding can be obtained through equity or debt financings or from other sources. The sale of equity or convertible debt securities in the future may be dilutive to our stockholders, and may provide for rights, preferences or privileges senior to those of our holders of common stock. Debt financing arrangements may require us to pledge certain assets or enter into covenants that could restrict our operations or our ability to incur further indebtedness.</span></div><div id="ie2ffba3ee5384c86becdb38ff117ca9a_121"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Quantitative and Qualitative Disclosures About Market Risk</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our investments in marketable securities, which are composed primarily of U.S. government debt securities, are subject to default, changes in credit rating and changes in market value. These investments are also subject to interest rate risk and will decrease in value if market interest rates increase. As of September&#160;30, 2022, marketable securities were $286.5 million. Due to the nature of these investments, if market interest rates were to increase immediately and uniformly by 10% from levels as of September&#160;30, 2022, the decline in fair value would not be material.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">56</span></div></div></div><div id="ie2ffba3ee5384c86becdb38ff117ca9a_124"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie2ffba3ee5384c86becdb38ff117ca9a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Controls and Procedures</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Evaluation of disclosure controls and procedures.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We maintain &#8220;disclosure controls and procedures,&#8221; as such term is defined in Rule 13a-15(e) under the Securities Exchange Act of 1934 (the &#8220;Exchange Act&#8221;), that are designed to ensure that information required to be disclosed by us in reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in Securities and Exchange Commission rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating our disclosure controls and procedures, management recognized that disclosure controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the disclosure controls and procedures are met. Our disclosure controls and procedures have been designed to meet reasonable assurance standards. Additionally, in designing disclosure controls and procedures, our management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible disclosure controls and procedures. The design of any disclosure controls and procedures also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on their evaluation as of the end of the period covered by this Quarterly Report on Form 10-Q, our Chief Executive Officer and Chief Financial Officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in internal control over financial reporting</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. There were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) for the three months ended September&#160;30, 2022, that materially affected or are reasonably likely to materially affect our internal control over financial reporting. </span></div><div id="ie2ffba3ee5384c86becdb38ff117ca9a_127"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OTHER INFORMATION</span></div><div id="ie2ffba3ee5384c86becdb38ff117ca9a_130"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risk Factors </span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RISKS RELATING TO COMMERCIALIZATION OF OUR PRODUCTS</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We depend heavily on our lead product, JAKAFI (ruxolitinib), which is marketed as JAKAVI outside the United States. If we are unable to maintain revenues from JAKAFI or those revenues decrease, our business may be materially harmed.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">JAKAFI is our first product marketed by us that is approved for sale in the United States. JAKAFI was approved by the U.S. Food and Drug Administration, or FDA, in November 2011 for the treatment of patients with intermediate or high-risk myelofibrosis, in December 2014 for the treatment of patients with polycythemia vera who have had an inadequate response to or are intolerant of hydroxyurea, which we refer to as uncontrolled polycythemia vera, in May 2019 for the treatment of steroid-refractory acute graft-versus-host disease in adult and pediatric patients 12 years and older </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and in September 2021 for the treatment of steroid-refractory chronic </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">graft-versus-host disease </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in adult and pediatric patients 12 years and older</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Although we have received regulatory approval for these indications, such approval does not guarantee future revenues. While we also sell ICLUSIG in the European Union, or EU, and other countries for the treatment of certain types of leukemia, PEMAZYRE in the United States, Europe and Japan for the treatment of certain metastatic cholangiocarcinoma indications, as well as for certain blood cancer indications in the United States, MONJUVI in the United States and MINJUVI in the European Union for the treatment of certain lymphoma indications, and OPZELURA in the Unites States for the treatment of certain indications of atopic dermatitis and vitiligo, and our exclusive licensees sell OLUMIANT (baricitinib) for the treatment of specified rheumatoid arthritis and atopic dermatitis indications and TABRECTA for the treatment of a certain type of non-small cell lung cancer, we anticipate that JAKAFI product sales will continue to contribute a significant percentage of our total revenues over the next several years.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The commercial success of JAKAFI and our ability to maintain and continue to increase revenues from the sale of JAKAFI will depend on a number of factors, including:</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the number of patients with intermediate or high-risk myelofibrosis, uncontrolled polycythemia vera or steroid-refractory graft-versus-host disease who are diagnosed with the diseases and the number of such patients that may be treated with JAKAFI;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie2ffba3ee5384c86becdb38ff117ca9a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the acceptance of JAKAFI by patients and the healthcare community;</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">whether physicians, patients and healthcare payors view JAKAFI as therapeutically effective and safe relative to cost and any alternative therapies, as well as whether patients will continue to use JAKAFI;</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ability to obtain and maintain sufficient coverage or reimbursement by third-party payors and pricing;</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ability of our third-party manufacturers to manufacture JAKAFI in sufficient quantities that meet all applicable quality standards;</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ability of our company and our third-party providers to provide marketing and distribution support for JAKAFI;</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the effects of the COVID-19 pandemic, any associated quarantine, travel restriction, stay-at-home or shutdown orders, guidelines or practices, and any disruption in our supply chain for JAKAFI on our ability to provide marketing and distribution support for JAKAFI, our ability to produce sufficient quantities of JAKAFI that meet all applicable quality standards, patient demand (including new patient prescriptions and hesitancy of patients to make office visits) and other risks detailed further below under &#8220;&#8212;Other Risks Relating to our Business&#8212;Public health epidemics, such as the COVID-19 pandemic, could adversely affect our business, results of operations, and financial condition&#8221;;</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the label and promotional claims allowed by the FDA;</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the maintenance of regulatory approval for the approved indications in the United States; and</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to develop, obtain regulatory approval for and commercialize ruxolitinib in the United States for additional indications or in combination with other therapeutic modalities.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are not able to maintain revenues from JAKAFI in the United States, or our revenues from JAKAFI decrease, our business may be materially harmed and we may need to delay other drug discovery, development and commercialization initiatives or even significantly curtail operations, and our ability to license or acquire new products to diversify our revenue base could be limited.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, revenues from our other products and our receipt of royalties under our collaboration agreements, including our agreements with Novartis for sales of JAKAVI outside the United States and TABRECTA globally and with Eli Lilly and Company for worldwide sales of OLUMIANT, will depend on factors similar to those listed above, with similar regulatory, pricing and reimbursement issues driven by applicable regulatory authorities and governmental and third-party payors affecting jurisdictions outside the United States.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to obtain, or maintain at anticipated levels, coverage and reimbursement for our products from government health administration authorities, private health insurers and other organizations, our pricing may be affected and our product sales, results of operations and financial condition could be harmed.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to commercialize our current and any future approved products successfully will depend in part on the prices we are able to charge for these products and the extent to which adequate coverage and reimbursement levels for the cost of our products and related treatment are obtained from third-party payors, such as private insurers, government insurance programs, including Medicare and Medicaid, health maintenance organizations (HMOs) and other health care related organizations in the United States and abroad. We may not be able to sell our products on a profitable basis or our profitability may be reduced if we are required to sell our products at lower than anticipated prices or reimbursement is unavailable or limited in scope or amount. The costs of JAKAFI, ICLUSIG, PEMAZYRE, MONJUVI/MINJUVI and OPZELURA are not insignificant and almost all patients will require some form of third-party coverage to afford their cost. Our future revenues and profitability will be adversely affected if we cannot depend on government and other third-party payors to defray the cost of our products to the patient.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie2ffba3ee5384c86becdb38ff117ca9a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Governments and other third-party payors continue to pursue initiatives to manage drug costs. Pricing and reimbursement for our products may be adversely affected by a number of factors, including;</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">actions of federal, state and foreign governments and other third-party payors to implement or modify laws, regulations or policies addressing payment and reimbursement for drugs;</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">pressure by employers on private health insurance plans to reduce costs or moderate cost increases, as well as continued public scrutiny of the price of drugs and other healthcare costs; and</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">consolidation of third-party payors and continued initiatives of government and other third-party payors to reduce costs by seeking price discounts or rebates, reducing reimbursement rates or imposing restrictions on access to or coverage of particular drugs based on perceived value.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In many markets outside of the United States, including countries of the EU, drug pricing and reimbursement are subject to government control, and government authorities are making greater efforts to limit or regulate the price of drug products. Reimbursement systems in international markets vary significantly by country and by region, and reimbursement approvals must be obtained on a country-by-country basis. Reimbursement in the EU must be negotiated on a country-by-country basis and in many countries a drug product cannot be commercially launched until reimbursement is approved. The timing to complete the negotiation process in each country is highly uncertain, and in some countries, we expect that it may exceed 12 months. Some countries set prices by reference to prices in other countries, and countries may refuse to reimburse or may restrict the reimbursed population for a drug product based on their national health technology assessments and cost effectiveness thresholds. In addition, governmental authorities in many countries may reduce prices for approved drug products from previously established prices. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third-party payors are increasingly challenging the prices charged for medical products and services, and payors and employers are adopting benefit plan changes that shift a greater portion of prescription drug costs to patients. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third party pharmacy benefit managers, or PBMs,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> other similar organizations </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and payors can limit coverage to specific products on an approved list, or formulary, which might not include all of the approved products for a particular indication, and to exclude drugs from their formularies in favor of competitor drugs or alternative treatments, or place drugs on formulary tiers with higher patient co-pay obligations, and/or to mandate stricter utilization criteria. Formulary exclusion effectively encourages patients and providers to seek alternative treatments, make a complex and time-intensive request for medical exemptions, or pay 100% of the cost of a drug. In addition, in many instances, certain PBMs, other similar organizations and third party payors may exert negotiating leverage by requiring incremental rebates, discounts or other concessions from manufacturers in order to maintain formulary positions, which could continue to result in higher gross to net deductions for affected products.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> There has been significant consolidation in the health insurance industry, resulting in large insurers and PBMs exerting greater pressure and leverage in pricing and usage negotiations with drug manufacturers. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In this regard, we are in the process of negotiating agreements with PBMs and payor accounts to provide rebates to those entities related to formulary coverage for OPZELURA, but we cannot guarantee that we will be able to agree to coverage terms with these PBMs and other third party payors.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> P</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ayors could decide to exclude </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">OPZELURA from formulary coverage lists, impose step edits that require patients to try alternative, including generic, treatments before authorizing payment for OPZELURA, limit the types of diagnoses for which coverage will be provided or impose a moratorium on coverage for products while the payor makes a coverage decision.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An inability to maintain adequate formulary positions could increase patient cost-sharing for OPZELURA and cause some patients to determine not to use OPZELURA. Any delays or unforeseen difficulties in reimbursement approvals could limit patient access, depress therapy adherence rates, and adversely impact our ability to successfully commercialize OPZELURA.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unsuccessful in obtaining and maintaining broad coverage and reimbursement for OPZELURA, our anticipated revenue from and growth prospects for OPZELURA could be negatively affected.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If third parties institute high co-payment amounts or other benefit limits for our products, the demand for our products and, accordingly, our revenues and results of operations, could be adversely affected. Our patient assistance programs have provided support for non-profit organizations that provide financial assistance to eligible patients or in some cases, we have provided our products without charge to eligible patients who have no insurance coverage or are underinsured. Substantial support in this manner could harm our profitability in the future. Further, non-profit organizations&#8217; ability to provide assistance to patients is dependent on funding from external sources, and we cannot guarantee that such funding will be provided at adequate levels, or at all. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie2ffba3ee5384c86becdb38ff117ca9a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risks related to proposed changes in government regulations and health care reform measures are described below under &#8220;&#8212;Other Risks Relating to our Business&#8212;Health care reform measures could impact the pricing and profitability of pharmaceuticals, and adversely affect the commercial viability of our or our collaborators&#8217; products and drug candidates. &#8221; If government and other third-party payors refuse to provide coverage and reimbursement with respect to our products, determine to provide a lower level of coverage and reimbursement than anticipated, reduce previously approved levels of coverage and reimbursement, or delay reimbursement payments due to budgetary constraints relating to the COVID-19 pandemic, then our pricing or reimbursement for our products may be affected and our product sales, results of operations or financial condition could be harmed. Our collaborators Novartis and Eli Lilly are affected by similar considerations for the drugs that they market and for which we may receive royalties. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We depend upon a limited number of specialty pharmacies and wholesalers for a significant portion of any revenues from JAKAFI and most of our other drug products, and the loss of, or significant reduction in sales to, any one of these specialty pharmacies or wholesalers could adversely affect our operations and financial condition.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We sell JAKAFI and our other drug products other than OPZELURA primarily to specialty pharmacies and wholesalers. Specialty pharmacies dispense JAKAFI and our other drug products to patients in fulfillment of prescriptions and wholesalers sell JAKAFI and our other drug products to hospitals and physician offices. We do not promote JAKAFI or our other drug products to specialty pharmacies or wholesalers, and they do not set or determine demand for JAKAFI or our other drug products. Our ability to successfully commercialize JAKAFI and our other drug products will depend, in part, on the extent to which we are able to provide adequate distribution of JAKAFI and our other drug products to patients. Although we have contracted with a number of specialty pharmacies and wholesalers, they are expected generally to carry a very limited inventory and may be reluctant to be part of our distribution network in the future if demand for the product does not increase. Further, it is possible that these specialty pharmacies and wholesalers could decide to change their policies or fees, or both, at some time in the future. This could result in their refusal to carry smaller volume products such as JAKAFI and our other drug products, or lower margins or the need to find alternative methods of distributing our product. Although we believe we can find alternative channels to distribute JAKAFI or our other drug products on relatively short notice, our revenue during that period of time may suffer and we may incur additional costs to replace any such specialty pharmacy or wholesaler. The loss of any large specialty pharmacy or wholesaler as part of our distribution network, a significant reduction in sales we make to specialty pharmacies or wholesalers, or any failure to pay for the products we have shipped to them could materially and adversely affect our results of operations and financial condition.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to establish and maintain effective sales, marketing and distribution capabilities, or to enter into agreements with third parties to do so, we will not be able to successfully commercialize our products.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have established commercial capabilities in the United States and outside of the United States, but cannot guarantee that we will be able to enter into and maintain any marketing, distribution or third-party logistics agreements with third-party providers on acceptable terms, if at all. We may not be able to correctly judge the size and experience of the sales and marketing force and the scale of distribution capabilities necessary to successfully market and sell any new products. Establishing and maintaining sales, marketing and distribution capabilities are expensive and time-consuming. Competition for personnel with experience in sales and marketing can be high. Our expenses associated with building and maintaining the sales force and distribution capabilities may be disproportional compared to the revenues we may be able to generate on sales of our products.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are working to establish and maintain sales, marketing and distribution capabilities for OPZELURA that will generally be separate from our existing capabilities for oncology indications, and we have no prior experience in commercializing products for dermatology indications. Successful commercialization of our drug candidates for dermatology indications requires us to establish new physician and payor relationships, PBM and pharmacy network relationships, reimbursement strategies and governmental interactions. Our inability to commercialize successfully products in indications outside of oncology could harm our business and operating results.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie2ffba3ee5384c86becdb38ff117ca9a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to comply with applicable laws and regulations, we could lose our approval to market our products or be subject to other governmental enforcement activity.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot guarantee that we will be able to maintain regulatory approval to market our products in the jurisdictions in which they are currently marketed. If we do not maintain our regulatory approval to market our products, in particular JAKAFI, our results of operations will be materially harmed. We and our collaborators, third-party manufacturers and suppliers are subject to rigorous and extensive regulation by the FDA and other federal and state agencies as well as foreign governmental agencies. These regulations continue to apply after product marketing approval, and cover, among other things, testing, manufacturing, quality control and assurance, labeling, advertising, promotion, risk mitigation, and adverse event reporting requirements.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The commercialization of our products is subject to post-regulatory approval product surveillance, and our products may have to be withdrawn from the market or subject to restrictions if previously unknown problems occur. Regulatory agencies may also require additional clinical trials or testing for our products, and our products may be recalled or may be subject to reformulation, additional studies, changes in labeling, warnings to the public and negative publicity. For example, from late 2013 through 2014, ICLUSIG was subject to review by the European Medicines Agency, or EMA, of the benefits and risks of ICLUSIG to better understand the nature, frequency and severity of events obstructing the arteries or veins, the potential mechanism that leads to these side effects and whether there needed to be a revision in the dosing recommendation, patient monitoring and a risk management plan for ICLUSIG. This review was completed in January 2015, with additional warnings in the product information but without any change in the approved indications. The EMA could take additional actions in the future that reduce the commercial potential of ICLUSIG. In addition, in September 2021, the FDA approved a labeling update for JAKAFI, adding warnings of increased risk of major adverse cardiovascular events, thrombosis, and secondary malignancies related to another JAK-inhibitor treating rheumatoid arthritis, a condition for which JAKAFI is not indicated. As part of the FDA labeling update for oral JAK inhibitors in treating inflammatory conditions, class &#8220;boxed&#8221; warnings were also included in the OPZELURA label. We cannot predict the effects on sales of JAKAFI with the updated warnings or OPZELURA as a result of the &#8220;boxed&#8221; warnings, but it is possible that future sales of JAKAFI and OPZELURA can be negatively affected, which could have a material and adverse effect on our business, results of operations and prospects.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Failure to comply with the laws and regulations administered by the FDA or other agencies could result in:</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">administrative and judicial sanctions, including warning letters;</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fines and other civil penalties;</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">suspension or withdrawal of regulatory approval to market or manufacture our products;</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">interruption of production;</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">operating restrictions;</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product recall or seizure;</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">injunctions; and</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">criminal prosecution.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The occurrence of any such event may have a material adverse effect on our business.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie2ffba3ee5384c86becdb38ff117ca9a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If the use of our products harms patients, or is perceived to harm patients even when such harm is unrelated to our products, our regulatory approvals could be revoked or otherwise negatively impacted or we could be subject to costly and damaging product liability claims.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The testing of JAKAFI, ICLUSIG, PEMAZYRE, MONJUVI/MINJUVI and OPZELURA, the manufacturing, marketing and sale of JAKAFI, PEMAZYRE and OPZELURA and the marketing and sale of ICLUSIG and MONJUVI MINJUVI expose us to product liability and other risks. Side effects and other problems experienced by patients from the use of our products</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">could:</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">lessen the frequency with which physicians decide to prescribe our products;</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">encourage physicians to stop prescribing our products to their patients who previously had been prescribed our products;</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">cause serious harm to patients that may give rise to product liability claims against us; and</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">result in our need to withdraw or recall our products from the marketplace.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our products are used by a wide patient population, new risks and side effects may be discovered, the rate of known risks or side effects may increase, and risks previously viewed as less significant could be determined to be significant.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Previously unknown risks and adverse effects of our products may also be discovered in connection with unapproved, or off-label, uses of our products. We are prohibited by law from promoting or in any way supporting or encouraging the promotion of our products for off-label uses, but physicians are permitted to use products for off-label purposes. In addition, we are studying and expect to continue to study JAKAFI in diseases for potential additional indications in controlled clinical settings, and independent investigators are doing so as well. In the event of any new risks or adverse effects discovered as new patients are treated for intermediate or high-risk myelofibrosis, uncontrolled polycythemia vera or acute graft-versus-host disease and as JAKAFI is studied in or used by patients for off-label indications, regulatory authorities may delay or revoke their approvals, we may be required to conduct additional clinical trials, make changes in labeling of JAKAFI, reformulate JAKAFI or make changes and obtain new approvals. We may also experience a significant drop in the sales of JAKAFI, experience harm to our reputation and the reputation of JAKAFI in the marketplace or become subject to lawsuits, including class actions. Any of these results could decrease or prevent sales of JAKAFI or substantially increase the costs and expenses of commercializing JAKAFI. Similar results could occur with respect to our commercialization of ICLUSIG, PEMAZYRE, MONJUVI/MINJUVI and OPZELURA.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patients who have been enrolled in our clinical trials or who may use our products in the future often have severe and advanced stages of disease and known as well as unknown significant pre-existing and potentially life-threatening health risks. During the course of treatment, patients may suffer adverse events, including death, for reasons that may or may not be related to our products. Such events could subject us to costly litigation, require us to pay substantial amounts of money to injured patients, delay, negatively impact or end our opportunity to receive or maintain regulatory approval to market our products, or require us to suspend or abandon our commercialization efforts. Even in a circumstance in which we do not believe that an adverse event is related to our products, the investigation into the circumstance may be time consuming or inconclusive. These investigations may interrupt our sales efforts, impact and limit the type of regulatory approvals our products receive or maintain, or delay the regulatory approval process in other countries.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Factors similar to those listed above also apply to our collaborator Novartis for jurisdictions in which it has development and commercialization rights, to ICLUSIG for jurisdictions outside the United States, to our collaborator Lilly for all jurisdictions and to our collaborator Innovent for PEMAZYRE in the jurisdictions in which it has development and commercialization rights.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie2ffba3ee5384c86becdb38ff117ca9a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we market our products in a manner that violates various laws and regulations, we may be subject to civil or criminal penalties.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to FDA and related regulatory requirements, we are subject to health care &#8220;fraud and abuse&#8221; laws, such as the federal False Claims Act, the anti-kickback provisions of the federal Social Security Act, and other state and federal laws and regulations. Federal and state anti-kickback laws prohibit, among other things, knowingly and willfully offering, paying, soliciting or receiving remuneration to induce, or in return for purchasing, leasing, ordering or arranging for the purchase, lease or order of any health care item or service reimbursable under Medicare, Medicaid, or other federally- or state-financed health care programs. Federal false claims laws prohibit any person from knowingly presenting, or causing to be presented, a false claim for payment to the federal government, or knowingly making, or causing to be made, a false statement to get a false claim paid. Pharmaceutical companies have been prosecuted under these laws for a variety of alleged promotional and marketing activities.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although physicians are permitted, based on their medical judgment, to prescribe products for indications other than those approved by the FDA, manufacturers are prohibited from promoting their products for such off-label uses. We market JAKAFI for intermediate or high-risk myelofibrosis, uncontrolled polycythemia vera and acute graft-versus-host disease and provide promotional materials to physicians regarding the use of JAKAFI for these indications. Although we believe that our promotional materials for physicians do not constitute improper promotion of JAKAFI, the FDA or other agencies may disagree. If the FDA or another agency determines that our promotional materials or other activities constitute improper promotion of JAKAFI, it could request that we modify our promotional materials or other activities or subject us to regulatory enforcement actions, including the issuance of a warning letter, injunction, seizure, civil fine and criminal penalties. It is also possible that other federal, state or foreign enforcement authorities might take action if they believe that the alleged improper promotion led to the submission and payment of claims for an unapproved use, which could result in significant fines or penalties under other statutory authorities, such as laws prohibiting false claims for reimbursement. Even if it is later determined we are not in violation of these laws, we may be faced with negative publicity, incur significant expenses defending our position and have to divert significant management resources from other matters. Similar risks exist for our marketing of PEMAZYRE and OPZELURA and our collaborator MorphoSys&#8217;s marketing of MONJUVI.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The European Union and member countries, as well as governmental authorities in other countries, impose similar strict restrictions on the promotion and marketing of drug products. The off-label promotion of medicinal products is prohibited in the EU and in other territories, and the EU also maintains strict controls on advertising and promotional materials. The promotion of medicinal products that are not subject to a marketing authorization is also prohibited in the EU. Violations of the rules governing the promotion of medicinal products in the EU and in other territories could be penalized by administrative measures, fines and imprisonment.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of states also have statutes or regulations similar to the federal anti-kickback law and false claims laws, which apply to items and services reimbursed under Medicaid and other state programs, or, in several states, apply regardless of the payor. Numerous states and localities have enacted or are considering enacting legislation requiring pharmaceutical companies to establish marketing compliance programs, file periodic reports or make periodic public disclosures on sales, marketing, pricing, clinical trials, and other activities. Additionally, as part of the Patient Protection and Affordable Care Act, the federal government has enacted the Physician Payment Sunshine provisions. The Sunshine provisions and similar laws and regulations in other jurisdictions where we do business require manufacturers to publicly report certain payments or other transfers of value made to physicians and teaching hospitals. Many of these requirements are new and uncertain, and the penalties for failure to comply with these requirements are unclear. Nonetheless, if we are found not to be in full compliance with these laws, we could face enforcement action and fines and other penalties, which could be significant in amount or result in exclusion from federal healthcare programs such as Medicare and Medicaid. Any action initiated against us for violation of these laws, even if we successfully defend against it, could require the expenditure of significant resources and generate negative publicity, which could harm our business and operating results, and any settlement of such action initiated against us, regardless of the merits, could result in the payment of significant amounts, which could harm our financial condition and operating results. See also &#8220;&#8212;Other Risks Relating to our Business&#8212;If we fail to comply with the extensive legal and regulatory requirements affecting the health care industry, we could face increased costs, penalties and a loss of business&#8221; below.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie2ffba3ee5384c86becdb38ff117ca9a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Competition for our products could harm our business and result in a decrease in our revenue.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our products compete, and our product candidates may in the future compete, with currently existing therapies, including generic drugs, product candidates currently under development by us and others, or future product candidates, including new chemical entities that may be safer or more effective or more convenient than our products. Any products that we develop may be commercialized in competitive markets, and our competitors, which include large global pharmaceutical and biopharmaceutical companies and smaller research-based biotechnology companies, may succeed in developing products that render our products obsolete or noncompetitive. Many of our competitors, particularly large pharmaceutical and biopharmaceutical companies, have substantially greater financial, operational and human resources than we do. Smaller or earlier stage companies may also prove to be significant competitors, particularly through focused development programs and collaborative arrangements with large, established companies. In addition, many of our competitors deploy more personnel to market and sell their products than we do, and we compete with other companies to recruit, hire, train and retain pharmaceutical sales and marketing personnel. If our sales force and sales support organization are not appropriately resourced and sized to adequately promote our products, the commercial potential of our current and any future products may be diminished. In any event, the commercial potential of our current products and any future products may be reduced or eliminated if our competitors develop or acquire and commercialize generic or branded products that are safer or more effective, are more convenient or are less expensive than our products. See &#8220;Item 1. Business &#8212;Competition&#8221; in our Annual Report on Form 10-K for the year ended December&#160;31, 2021 for additional information regarding the effects of competition. If we are unable to compete successfully, our commercial opportunities will be reduced and our business, results of operations and financial conditions may be materially harmed.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Present and potential competitors for JAKAFI include major pharmaceutical and biotechnology companies, as well as specialty pharmaceutical firms. In addition, JAKAFI could face competition from generic products. As a result of the Drug Price Competition and Patent Term Restoration Act of 1984, commonly known as the Hatch-Waxman Act, in the United States, generic manufacturers may seek approval of a generic version of an innovative pharmaceutical by filing with the FDA an Abbreviated New Drug Application, or ANDA. The Hatch-Waxman Act provides significant incentives to generic manufacturers to challenge U.S. patents on successful innovative pharmaceutical products. In February 2016, we received a notice letter regarding an ANDA that requested approval to market a generic version of JAKAFI and purported to challenge patents covering ruxolitinib phosphate and its use that expire in 2028. The notice letter does not challenge the ruxolitinib composition of matter patent, which expires in December 2027. To date, to our knowledge, the FDA has taken no action with respect to this ANDA. Separately, in January 2018 the Patent Trial and Appeal Board (PTAB) of United States Patent and Trademark Office denied a petition challenging our patent covering deuterated ruxolitinib analogs and the PTAB subsequently denied the petitioner&#8217;s request for rehearing in May 2018. Nevertheless, the petitioner still has the right separately to challenge the validity of our patent in federal court. There can be no assurance that our patents will be upheld or that any litigation in which we might engage with any such generic manufacturer would be successful in protecting JAKAFI&#8217;s exclusivity. The entry of a competitive drug product from another company or a generic version of JAKAFI could result in a decrease in JAKAFI sales and materially harm our business, operating results and financial condition.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ICLUSIG currently competes with existing therapies that are approved for the treatment of patients with chronic myeloid leukemia, or CML, who are resistant or intolerant to prior tyrosine kinase inhibitor, or TKI, therapies, on the basis of, among other things, efficacy, cost, breadth of approved use and the safety and side-effect profile. In addition, generic versions of imatinib are available and, while we currently believe that generic versions of imatinib will not materially impact our commercialization of ICLUSIG, given ICLUSIG&#8217;s various indication statements globally that are currently focused on resistant or intolerant CML, we cannot be certain how physicians, payors, patients, regulatory authorities and other market participants will respond to the availability of generic versions of imatinib. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MONJUVI/MINJUVI currently competes with existing therapies that are approved for the treatment of patients with diffuse large B-cell lymphoma on the basis of, among other things, efficacy, cost, breadth of approved use and the safety and side-effect profile. These existing therapies are offered by major pharmaceutical and biotechnology companies, as well as specialty pharmaceutical firms. Competitors and potential competitors for PEMAZYRE include major pharmaceutical and biotechnology companies, as well as specialty pharmaceutical firms. Competitors for OPZELURA include existing over-the-counter topical treatments, prescription topical treatments, including generic versions, such as tacrolimus, pimecrolimus, topical steroids, and EUCRISA (crisaborole) from Pfizer Inc., as well as oral and injectable therapies such as prednisone and other oral steroids, injectable DUPIXENT (dupilimab) from Sanofi and Regeneron Pharmaceuticals, Inc., and oral CIBINQO (abrocitinib) from Pfizer Inc. and RINVOQ (upadacitinib) from AbbVie Inc.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie2ffba3ee5384c86becdb38ff117ca9a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OTHER RISKS RELATING TO OUR BUSINESS</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Public health epidemics and pandemics, such as the COVID-19 pandemic, have adversely affected and could in the future adversely affect our business, results of operations, and financial condition.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our global operations expose us to risks associated with public health epidemics and pandemics, such as the COVID-19 pandemic that has spread globally and continues with the proliferation of new variants. The extent to which the COVID-19 pandemic and the measures taken to limit COVID-19&#8217;s spread impact our operations and those of our suppliers, collaborators, service providers and healthcare organizations serving patients, as well as demand for our drug products, will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration of the outbreak and any future resurgence of the outbreak, additional or modified government actions, including any further restrictions or reopening of local, state or national social or economic activity, new information that may emerge concerning the severity of COVID-19 and the actions taken to contain COVID-19 or treat its impact, among others.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the COVID-19 pandemic, we have experienced and may in the future experience disruptions that could severely impact our business, results of operations and financial condition, including the following: </span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">When the COVID-19 pandemic commenced, to protect the health of our employees and their families, and our communities, in accordance with &#8211; and in some cases in advance of &#8211; direction from state and local government authorities, we limited access to our facilities and a significant percentage of our personnel worked remotely. In the event that governmental authorities were to re-establish workplace restrictions, our employees conducting research and development activities may not be able to access our laboratory space or access may be limited, and our research and development activities may be significantly limited or curtailed, possibly for an extended period of time. These research and development activities could include completing Investigational New Drug (IND)/Clinical Trial Application (CTA)-enabling studies, our ability to select future development candidates, and initiation of additional clinical trials for our development programs. Having a significant portion of our employees work from home can strain our information technology infrastructure, which may affect our ability to operate effectively, may make us more susceptible to communications disruptions, and expose us to greater cybersecurity risks. </span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our sales and marketing activities, including our interactions with healthcare professionals, have been limited and made more difficult by government or employer imposed work from home orders and travel and workplace visitor restrictions resulting from measures to address the COVID-19 pandemic, as well as employee-initiated remote work and travel limitations resulting from, among other things, the spread of the COVID-19 variants. In addition, demand for our products has been affected by decreases in new patients, which we believe resulted in large part from decreases in patient visits to healthcare professionals and prioritization of hospital resources for the COVID-19 pandemic, resulting in decreases in disease screening and diagnosis. We cannot predict the effects on patient demand or future sales if there are prolonged quarantines, work from home orders, travel restrictions or surges in COVID-19 cases. </span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our clinical trials have been and will likely continue to be affected by delays in site initiation, patient screening, patient enrollment, and monitoring and data collection as a result of prioritization of hospital resources for the COVID-19 pandemic, difficulty in recruiting and retaining healthcare providers and staff due to their diversion toward treating COVID-19 patients, the potential unwillingness of patients to enroll or continue in clinical trials for fear of exposure to COVID-19 at sites, and the inability to access sites for initiation and monitoring. In addition, some patients may be unable to comply with clinical trial protocols if quarantines or travel restrictions impede patient movement or interrupt health services, we may be unable to obtain blood samples for testing, and we may not be able to provide the trial drug candidate to patients. Also, we rely on independent clinical investigators, contract research organizations and other third-party service providers to assist us in managing, monitoring and otherwise carrying out our preclinical studies and clinical trials, and the COVID-19 pandemic has affected and may continue to affect their ability to devote sufficient time and resources to our programs or to travel to sites to perform work for us.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie2ffba3ee5384c86becdb38ff117ca9a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Regulatory agencies globally have experienced disruptions in their operations as a result of the coronavirus pandemic. The FDA and comparable foreign regulatory agencies may have slower response times or be under-resourced to continue to monitor our clinical trials and, as a result, review, inspection, and other timelines may be materially delayed. If any of these disruptions occur or continue to occur, we cannot predict how long they may last. Our drug candidate application reviews and potential approvals could be impacted or delayed by these disruptions, if they occur or continue to occur. </span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The outbreak and measures taken to limit the spread of the outbreak, especially if prolonged, could also disrupt our supply chain or limit our ability to obtain sufficient materials for our drug products and product candidates, which could adversely affect our revenues and clinical trial timelines. Currently, our supply chain for our drug products and product candidates depends on operations by us and by other companies in multiple countries around the world, and the effects of the COVID-19 pandemic on any or all of these countries is uncertain and unpredictable and potential disruption is possible. In addition, our third-party manufacturers might experience capacity constraints and delays in producing materials for our drug products and product candidates if they are required, under the U.S. Defense Production Act or similar governmental mandates, to prioritize production of raw materials, supplies, drugs or vaccines to address COVID-19. And, for JAKAFI, while our strategy is to maintain a 24 month stock of active pharmaceutical ingredient, or API, inclusive of finished product, ruxolitinib phosphate might be used by us either to make JAKAFI or for ruxolitinib drug candidates in clinical trials. </span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Any deterioration of worldwide credit and financial markets could result in losses on our holdings of cash and investments due to failures of financial institutions and other parties, and interruptions and delays in our ability to collect, or potential losses on, our accounts receivable. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our collaborators could be affected by similar factors as those that have or could affect our business. The ultimate impact of the COVID-19 pandemic or a similar health epidemic is highly uncertain and subject to change. We do not yet know the full extent of potential impacts or delays on our or our collaborators&#8217; businesses, our revenues, including milestone and royalty revenues from our collaborators, our and our collaborators&#8217; clinical trials, healthcare systems or the global economy as a whole. However, these effects could have a material adverse impact on our business, results of operations, and financial condition.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be unsuccessful in our efforts to discover and develop drug candidates and commercialize drug products.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our long-term success, revenue growth and diversification of revenues depends on our ability to obtain regulatory approval for new drug products and additional indications for our existing drug products. Our ability to discover and develop drug candidates and to commercialize additional drug products and indications will depend on our ability to:</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">hire and retain key employees;</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">identify high quality therapeutic targets;</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">identify potential drug candidates;</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">develop products internally or license or acquire drug candidates from others;</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">identify and enroll suitable human subjects, either in the United States or abroad, for our clinical trials;</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">complete laboratory testing;</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">commence, conduct and complete safe and effective clinical trials on humans;</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtain and maintain necessary intellectual property rights to our products;</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtain and maintain necessary regulatory approvals for our products, both in the United States and abroad;</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">enter into arrangements with third parties to provide services or to manufacture our products on our behalf;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie2ffba3ee5384c86becdb38ff117ca9a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">deploy sales, marketing, distribution and manufacturing resources effectively or enter into arrangements with third parties to provide these functions in compliance with all applicable laws;</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtain appropriate coverage and reimbursement levels for the cost of our products from governmental authorities, private health insurers and other third-party payors;</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">lease facilities at reasonable rates to support our growth; and</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">enter into arrangements with third parties to license and commercialize our products.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not be successful in discovering, developing, or commercializing additional drug products or our existing drug products in new indications. Discovery and development of drug candidates are expensive, uncertain and time-consuming, and we do not know if our efforts will lead to discovery of any drug candidates that can be successfully developed and marketed. Of the compounds or biologics that we identify as potential drug products or that we may in-license from other companies, including potential products for which we are conducting clinical trials, only a few, if any, are likely to lead to successful drug development programs and commercialized drug products.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We depend heavily on the success of our most advanced drug candidates. We and our collaborators might not be able to commercialize any of our or their drug candidates successfully, and we may spend significant time and money attempting to do so.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have invested significant resources in the development of our most advanced drug candidates. We have a number of drug candidates in Phase III clinical trials as monotherapies or in combination with other drugs and drug candidates, including parsaclisib, pemigatinib, retifanlimab, ruxolitinib, ruxolitinib cream and tafasitamab. Our ability to generate product revenues will depend on the successful development and eventual commercialization of our most advanced drug candidates. We, or our collaborators or licensees, may decide to discontinue development of any or all of our drug candidates at any time for commercial, scientific or other reasons. For example, in April 2018, we along with Merck stopped the ECHO-301 study with epacadostat, and we also significantly downsized the epacadostat development program. If a product is developed but not approved or marketed, or becomes approved for a narrower set of indications than those for which we initially conducted clinical trials, we may have spent significant amounts of time and money on it without achieving potential returns initially anticipated, which could adversely affect our operating results and financial condition as well as our business plans. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we or our collaborators are unable to obtain regulatory approval for our drug candidates in the United States and foreign jurisdictions, we or our collaborators will not be permitted to commercialize products resulting from our research.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to commercialize drug products in the United States, drug candidates will have to obtain regulatory approval from the FDA. Satisfaction of regulatory requirements typically takes many years. To obtain regulatory approval, we or our collaborators, as the case may be, must first show that our or our collaborators&#8217; drug candidates are safe and effective for target indications through preclinical testing (animal testing) and clinical trials (human testing). Preclinical testing and clinical development are long, expensive and uncertain processes, and we do not know whether the FDA will allow us or our collaborators to undertake clinical trials of any drug candidates in addition to our or our collaborators&#8217; compounds currently in clinical trials. If regulatory approval of a product is granted, this approval will be limited to those disease states and conditions for which the product is demonstrated through clinical trials to be safe and effective.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Completion of clinical trials may take several years and failure may occur at any stage of testing. The length of time required varies substantially according to the type, complexity, novelty and intended use of the drug candidate. Interim results of a preclinical test or clinical trial do not necessarily predict final results, and acceptable results in early clinical trials may not be repeated in later clinical trials. For example, a drug candidate that is successful at the preclinical level may cause harmful or dangerous side effects when tested at the clinical level. Our rate of commencement and completion of clinical trials may be delayed, and existing clinical trials with our or our collaborators&#8217; drug candidates may be stopped, due to many potential factors, including:</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the high degree of risk and uncertainty associated with drug development;</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our inability to formulate or manufacture sufficient quantities of materials for use in clinical trials;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie2ffba3ee5384c86becdb38ff117ca9a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">variability in the number and types of patients available for each study;</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">difficulty in maintaining contact with patients after treatment, resulting in incomplete data;</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">unforeseen safety issues or side effects;</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">poor or unanticipated effectiveness of drug candidates during the clinical trials; or</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">government or regulatory delays.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Data obtained from clinical trials are susceptible to varying interpretation, which may delay, limit or prevent regulatory approval. Many companies in the pharmaceutical and biopharmaceutical industry, including our company, have suffered significant setbacks in advanced clinical trials, even after achieving promising results in earlier clinical trials. In addition, regulatory authorities may refuse or delay approval as a result of other factors, such as changes in regulatory policy during the period of product development and regulatory agency review. For example, the FDA has in the past required, and could in the future require, that we or our collaborators conduct additional trials of any of our drug candidates, which would result in delays. In April 2017, we and our collaborator Lilly announced that the FDA had issued a complete response letter for the New Drug Application, or NDA, of OLUMIANT as a once-daily oral medication for the treatment of moderate-to-severe rheumatoid arthritis. The letter indicated that additional clinical data were needed to determine the most appropriate doses and to further characterize safety concerns across treatment arms. In June 2018, after a resubmission of the NDA, the FDA approved the 2mg dose of OLUMIANT for the treatment of adults with moderately-to-severely active rheumatoid arthritis who have had an inadequate response to one or more tumor necrosis factor inhibitor therapies. The FDA did not at that time approve any higher dose of OLUMIANT and required a warning label in connection with its approval. In addition, in January 2022, we announced that we withdrew the NDA seeking approval of parsaclisib for the treatment of patients with relapsed or refractory follicular lymphoma, marginal zone lymphoma and mantle cell lymphoma. The decision to withdraw the NDA followed discussions with FDA regarding confirmatory clinical trials that we determined cannot be completed within the time period to support the investment.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compounds or biologics developed by us or with or by our collaborators and licensees may not prove to be safe and effective in clinical trials and may not meet all of the applicable regulatory requirements needed to receive marketing approval. For example, in January 2016, a Phase II trial that was evaluating ruxolitinib in combination with regorafenib in patients with relapsed or refractory metastatic colorectal cancer and high C-reactive protein was stopped early after a planned analysis of interim efficacy data determined that the likelihood of the trial meeting its efficacy endpoint was insufficient. In addition, in February 2016, we made a decision to discontinue our JANUS 1 study, our JANUS 2 study, our other studies of ruxolitinib in colorectal, breast and lung cancer, and our study of INCB39110 in pancreatic cancer after a planned analysis of interim efficacy data of JANUS 1 demonstrated that ruxolitinib plus capecitabine did not show a sufficient level of efficacy to warrant continuation. Also, in April 2018, we along with Merck announced that the ECHO-301 study had been stopped and we also significantly downsized the epacadostat development program and in January 2020 we stopped our Phase III trial of itacitinib for the treatment of acute graft-versus-host-disease. If clinical trials of any of our or our collaborators&#8217; compounds or biologics are stopped for safety, efficacy or other reasons or fail to meet their respective endpoints, our overall development plans, business, prospects, expected operating results and financial condition could be materially harmed and the value of our company could be negatively affected. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if any of our applications receives an FDA Fast Track or priority review designation (including based on a priority review voucher, one of which we recently acquired and used in connection with our submission seeking FDA approval of ruxolitinib cream for atopic dermatitis), these designations may not result in faster review or approval for our product candidate compared to product candidates considered for approval under conventional FDA procedures and, in any event, do not assure ultimate approval of our product candidate by FDA. For example, in June 2021 we were informed by the FDA that the FDA had extended by three months the review period for the NDA for ruxolitinib cream for atopic dermatitis. Also, in July 2021, we announced that the FDA issued a complete response letter for the BLA of retifanlimab for the treatment of squamous cell carcinoma of the anal canal, in which the FDA stated it cannot approve the BLA and that additional data are needed. In addition, while the FDA had granted orphan drug designation and Fast Track designation to parsaclisib as a treatment for patients with follicular lymphoma, marginal zone lymphoma and mantle cell lymphoma, as discussed above we withdrew our NDA seeking approval for treatment of patients with those lymphomas. The FDA has recently increased its attention on mandated confirmatory trials for oncology drug candidates with accelerated approvals, and the logistics, cost and timing required for confirmatory trials may conflict with the investment thesis for drug candidates, resulting in withdrawal of approval applications. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie2ffba3ee5384c86becdb38ff117ca9a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outside the United States, our and our collaborators&#8217; ability to market a product is contingent upon receiving a marketing authorization from the appropriate regulatory authorities. This foreign regulatory approval process typically includes all of the risks associated with the FDA approval process described above and may also include additional risks. The requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement vary greatly from country to country and may require us to perform additional testing and expend additional resources. Approval by the FDA does not ensure approval by regulatory authorities in other countries, and approval by one foreign regulatory authority does not ensure approval by regulatory authorities in other countries or by the FDA.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Health care reform measures could impact the pricing and profitability of pharmaceuticals, and adversely affect the commercial viability of our or our collaborators&#8217; products and drug candidates. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In recent years, through legislative and regulatory actions and executive orders, the U.S. federal government has made substantial changes to various payment systems under the Medicare and other federal health care programs. Comprehensive reforms to the U.S. healthcare system were enacted, including changes to the methods for, and amounts of, Medicare reimbursement. For example, a provision in the American Rescue Plan Act of 2021 that is expected to be implemented in 2024 will have the effect of increasing the Medicaid rebate liability for some medicines that increase prices in excess of inflation. Further, in August 2022, the Inflation Reduction Act of 2022 was enacted, which includes provisions allowing the federal government to negotiate prices for certain high-priced single source Medicare drugs, to impose penalties and to implement a potential excise tax for manufacturers that fail to comply with the legislation by offering a price that is not equal to or less than the negotiated &#8220;maximum fair price&#8221; under the law or for taking price increases that exceed inflation. The new law also reduced the out-of-pocket prescription drug costs for Medicare beneficiaries. The Inflation Reduction Act includes certain exemptions for small biotech drug manufacturers, including Incyte, which exempt those drugs from negotiation through 2028 and permit phased-in discounts under the new Part D benefit. While there is currently significant uncertainty regarding the implementation of some of these reforms or the scope of amended or additional reforms, the implementation of reforms could significantly reduce payments from Medicare and Medicaid or otherwise place limitations on the prices that manufacturers may charge for their products. Reforms or other changes to these payment systems may change the availability, methods and rates of reimbursements from Medicare, private insurers and other third-party payors for our current and any future approved products. Some of these changes and proposed changes could result in reduced reimbursement rates or in eliminating dual sources of payment, which could reduce the price that we or any of our collaborators or licensees receive for any products in the future, and which would adversely affect our business strategy, operations and financial results. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, there has been an increasing legislative and enforcement interest in the United States with respect to drug pricing practices. This has resulted in significant legislative activity and proposals from the prior and current Administrations relating to prescription drug prices and reimbursement, any of which, if enacted, could impose downward pressure on the prices that we can charge for our products and may further limit the commercial viability of our products and drug candidates. Specifically, there have been ongoing federal congressional inquiries and proposed and enacted federal and state legislation, executive orders and administrative agency rules designed to, among other things, bring more transparency to drug pricing, reduce drug prices, reform government program reimbursement methodologies for prescription drugs, expand access to government-mandated discounted pricing (known as 340B pricing) through broader contract pharmacy arrangements, allow importation of drugs into the United States from other countries, and limit allowable prices for drugs through reference to an average price from foreign markets that may be substantially lower than what we currently or would otherwise charge. In certain foreign markets, pricing or profitability of prescription pharmaceuticals is subject to government control. We expect that the health care reform measures that have been adopted in the United States and in foreign markets, and further reforms that may be adopted in the future, could result in more rigorous coverage criteria and additional downward pressure on the prices that we may receive for our approved products. If reimbursement for our products is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, our business could be materially harmed, including by our revenue potentially being materially adversely affected and our research and development efforts potentially being materially curtailed or, in some cases, ceasing. There may be future changes that result in reductions in current prices, coverage and reimbursement levels for our current or any future approved products, and we cannot predict the scope of any future changes or the impact that those changes would have on our operations.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consequences of the COVID-19 pandemic, including the economic effect on government budgets in the United States and elsewhere, may accelerate any of the healthcare reform efforts described above or result in future reform efforts, any of which could have adverse effects on our business, including higher costs for us, lower reimbursement rates for our products and lower demand for our products.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie2ffba3ee5384c86becdb38ff117ca9a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, if we become the subject of any governmental or other regulatory hearing or investigation with respect to the pricing of our products or other business practices, we could incur significant expenses and could be distracted from the operation of our business and execution of our business strategy. Any such hearing or investigation could also result in significant negative publicity and harm to our reputation, reduced market acceptance and demand, which could adversely affect our financial results and growth prospects. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the trend toward managed health care in the United States, the organizations for which could control or significantly influence the purchase of health care services and products, as well as legislative and regulatory proposals to reform health care or address the cost of government insurance programs, may all result in lower prices for or rejection of our products. Adoption of our products by the medical community and patients may be limited without adequate reimbursement for those products. Cost control initiatives may decrease coverage and payment levels for our products and, in turn, the price that we will be able to charge for any product. Our products may not be considered cost-effective, and coverage and reimbursement may not be available or sufficient to allow us to sell our products on a profitable basis. We are unable to predict all changes to the coverage or reimbursement methodologies that will be applied by private or government payors to our current and any future approved products. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The continuing efforts of legislatures, health agencies and third-party payors to contain or reduce the costs of health care, any denial of private or government payor coverage or inadequate reimbursement for our drug candidates could materially and adversely affect our business strategy, operations, future revenues and profitability, and the future revenues and profitability of our potential customers, suppliers, collaborators and licensees and the availability of capital. The same risks apply to our compounds developed and marketed by our collaborators, and our future potential milestone and royalty revenues could be affected in a similar manner.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We depend on our collaborators and licensees for the future development and commercialization of some of our drug candidates. Conflicts may arise between our collaborators and licensees and us, or our collaborators and licensees may choose to terminate their agreements with us, which may adversely affect our business.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have licensed to Novartis rights to ruxolitinib outside of the United States and worldwide rights to our MET inhibitor compounds, including TABRECTA, and licensed to Lilly worldwide rights to baricitinib. In addition, we have licensed to Innovent, Zai Lab, InnoCare and Maruho certain Asian rights to some of our drug products and clinical stage compounds. Under the terms of our agreements with these collaborators, we have no or limited control over the further clinical development of these drug candidates in the relevant territories and any revenues we may receive if these drug candidates receive regulatory approval and are commercialized in the relevant territories will depend primarily on the development and commercialization efforts of others. While OLUMIANT was approved by the European Commission in February 2017 for the treatment of moderate-to-severe rheumatoid arthritis in adult patients and by Japan&#8217;s Ministry of Health, Labor and Welfare in July 2017 for the treatment of rheumatoid arthritis in patients with inadequate response to standard-of-care therapies, the NDA for OLUMIANT for the treatment of moderate-to-severe rheumatoid arthritis was approved in June 2018, and only in the lower dosage tablet and with a warning label. Delays in any marketing approval by the FDA, European or other regulatory authorities, or any label modifications or restrictions in connection with any such approval, or the existence of other risks relating to approved drug products, including those described under &#8220;Risks Relating to Commercialization of Our Products,&#8221; could delay the receipt of and reduce resulting potential royalty and milestone revenue from baricitinib or any of our other out-licensed drug candidates. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Conflicts may arise with our collaborators and licensees if they pursue alternative technologies or develop alternative products either on their own or in collaboration with others as a means for developing treatments for the diseases that we have targeted. Competing products and product opportunities may lead our collaborators and licensees to withdraw their support for our drug candidates. Any failure of our collaborators and licensees to perform their obligations under our agreements with them or otherwise to support our drug candidates could negatively impact the development of our drug candidates, lead to our loss of potential revenues from product sales and milestones and delay our achievement, if any, of profitability. Additionally, conflicts have from time to time occurred, and may in the future arise, relating to, among other things, disputes about the achievement and payment of milestone amounts and royalties owed, the ownership of intellectual property that is developed during the course of a collaborative relationship or the operation or interpretation of other provisions in our collaboration agreements. These disputes have led and could in the future lead to litigation or arbitration, which could be costly and divert the efforts of our management and scientific staff, and could diminish the expected effectiveness of the collaboration. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">70</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie2ffba3ee5384c86becdb38ff117ca9a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our existing collaborative and license agreements can be terminated by our collaborators and licensees for convenience, among other circumstances. If any of our collaborators or licensees terminates its agreement with us, or terminates its rights with respect to certain indications or drug candidates, we may not be able to find a new collaborator for them, and our business could be adversely affected. Should an agreement be terminated before we have realized the benefits of the collaboration or license, our reputation could be harmed, we may not obtain revenues that we anticipated receiving, and our business could be adversely affected.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The success of our drug discovery and development efforts may depend on our ability to find suitable collaborators to fully exploit our capabilities. If we are unable to establish collaborations or if these future collaborations are unsuccessful in the development and commercialization of our drug candidates, our research, development and commercialization efforts may be unsuccessful, which could adversely affect our results of operations, financial condition and future revenue prospects.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An element of our business strategy is to enter into collaborative or license arrangements with other parties, under which we license our drug candidates to those parties for development and commercialization or under which we study our drug candidates in combination with other parties&#8217; compounds or biologics. For example, in addition to our Novartis, Lilly, Innovent, Zai Lab, InnoCare and Maruho collaborations, we are evaluating strategic relationships with respect to several of our other programs. However, because collaboration and license arrangements are complex to negotiate, we may not be successful in our attempts to establish these arrangements. Also, we may not have drug candidates that are desirable to other parties, or we may be unwilling to license a drug candidate to a particular party because such party interested in it is a competitor or for other reasons. The terms of any such arrangements that we establish may not be favorable to us. Alternatively, potential collaborators may decide against entering into an agreement with us because of our financial, regulatory or intellectual property position or for scientific, commercial or other reasons. If we are not able to establish collaboration or license arrangements, we may not be able to develop and commercialize a drug product, which could adversely affect our business, our revenues and our future revenue prospects.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will likely not be able to control the amount and timing of resources that our collaborators or licensees devote to our programs or drug candidates. If our collaborators or licensees prove difficult to work with, are less skilled than we originally expected, do not devote adequate resources to the program, are unable to obtain regulatory approval of our drug candidates, pursue alternative technologies or develop alternative products, or do not agree with our approach to development or manufacturing of the drug candidate, the relationship could be unsuccessful. Our collaborations with respect to epacadostat involved the study of our collaborators&#8217; drugs used in combination with epacadostat on a number of indications or tumor types, many of which were the same across multiple collaborations. We cannot assure you that potential conflicts will not arise or be alleged among these or future collaborations. If a business combination involving a collaborator or licensee and a third-party were to occur, the effect could be to terminate or cause delays in development of a drug candidate.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to enter into additional licensing agreements or if these arrangements are unsuccessful, our business and operations might be adversely affected.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to establishing collaborative or license arrangements under which other parties license our drug candidates for development and commercialization or under which we study our drug candidates in combination with such parties&#8217; compounds or biologics, we may explore opportunities to develop our clinical pipeline by in-licensing drug candidates or therapeutics targets that fit within our focus on oncology, such as our collaborations with Agenus Inc., MacroGenics, Inc., Merus N.V., MorphoSys, Syros Pharmaceuticals, Inc., and Syndax Pharmaceuticals, Inc., or explore additional opportunities to further develop and commercialize existing drug candidates in specific jurisdictions, such as our June 2016 acquisition of the development and commercialization rights to ICLUSIG in certain countries. We may be unable to enter into any additional in-licensing agreements because suitable drug candidates that are within our expertise may not be available to us on terms that are acceptable to us or because competitors with greater resources seek to in-license the same drug candidates. Drug candidates that we would like to develop or commercialize may not be available to us because they are controlled by competitors who are unwilling to license the rights to the drug candidate to us. In addition, we may enter into license agreements that are unsuccessful and our business and operations might be adversely affected if we are unable to realize the expected economic benefits of a collaboration or other licensing arrangement, by the termination of a drug candidate and termination and winding down of the related license agreement, or due to other business or regulatory issues, including financial difficulties, that may adversely affect a licensor&#8217;s ability to continue to perform its obligations under an in-license agreement. For example, in January 2022, we decided to opt-out of the continued development with Merus of MCLA-145, which was the most advanced compound under our collaboration with Merus, and in September 2022, we decided to terminate our collaboration with Calithera Biosciences, Inc. If we make or </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie2ffba3ee5384c86becdb38ff117ca9a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">incur contractual obligations to make significant upfront payments in connection with licenses for late-stage drug candidates, as we did in March 2020 in connection with the effectiveness of our collaboration agreement with MorphoSys, and if any of those drug candidates do not receive marketing approval or commercial sales as anticipated or we have to fund additional clinical trials before marketing approval can be obtained, we will have expended significant funds that might otherwise be applied for other uses or have to expend funds that were not otherwise budgeted or anticipated in connection with the collaboration, and such developments could have a material adverse effect on our stock price and our ability to pursue other transactions. As discussed above under &#8220;We depend on our collaborators and licensees for the future development and commercialization of some of our drug candidates. Conflicts may arise between our collaborators and licensees and us, or our collaborators and licensees may choose to terminate their agreements with us, which may adversely affect our business,&#8221; conflicts or other issues may arise with our licensors. Those conflicts could result in delays in our plans to develop drug candidates or result in the expenditure of additional funds to resolve those conflicts that could have an adverse effect on our results of operations. We may also need to license drug delivery or other technology in order to continue to develop our drug candidates. If we are unable to enter into additional agreements to license drug candidates, drug delivery technology or other technology or if these arrangements are unsuccessful, our research and development efforts could be adversely affected, and we may be unable to increase our number of successfully marketed products and our revenues.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if a drug candidate that we develop receives regulatory approval, we may decide not to commercialize it if we determine that commercialization of that product would require more money and time than we are willing to invest.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if any of our drug candidates receives regulatory approval, it could be subject to post-regulatory surveillance, and may have to be withdrawn from the market or subject to restrictions if previously unknown problems occur. Regulatory agencies may also require additional clinical trials or testing, and the drug product may be recalled or may be subject to reformulation, additional studies, changes in labeling, warnings to the public and negative publicity. As a result, we may not continue to commercialize a product even though it has obtained regulatory approval. Further, we may decide not to continue to commercialize a product if the market does not accept the product because it is too expensive or because third parties such as insurance companies or Medicare, will not cover it for substantial reimbursement. In addition, we may decide not to continue to commercialize a product if competitors develop and commercialize similar or superior products or have proprietary rights that preclude us from ultimately marketing our products.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Any approved drug product that we bring to the market may not gain market acceptance by physicians, patients, healthcare payors and others in the medical community.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we or our collaborators are successful in gaining regulatory approval of any of our or our collaborators&#8217; drug candidates in addition to JAKAFI, OLUMIANT, PEMAZYRE, MONJUVI/MINJUVI and OPZELURA or acquire rights to approved drug products in addition to ICLUSIG, we may not generate significant product revenues if these drug products do not achieve an adequate level of acceptance. Physicians may not recommend our or our collaborators&#8217; drug products until longer-term clinical data or other factors demonstrate the safety and efficacy of our or our collaborators&#8217; drug products as compared to other alternative treatments. Even if the clinical safety and efficacy of our or our collaborators&#8217; drug products is established, physicians may elect not to prescribe these drug products for a variety of reasons, including the reimbursement policies of government and other third-party payors and the effectiveness of our or our collaborators&#8217; competitors in marketing their products.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Market acceptance of our drug products, if approved for commercial sale, will depend on a number of factors, including the following, and market acceptance of our collaborators&#8217; drug products will depend on similar factors:</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the willingness and ability of patients and the healthcare community to use our drug products;</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ability to manufacture our drug products in sufficient quantities that meet all applicable quality standards and to offer our drug products for sale at competitive prices;</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the perception of patients and the healthcare community, including third-party payors, regarding the safety, efficacy and benefits of our drug products compared to those of competing products or therapies;</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the label and promotional claims allowed by the FDA;</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the pricing and reimbursement of our drug products relative to existing treatments; and</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie2ffba3ee5384c86becdb38ff117ca9a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">marketing and distribution support for our drug products.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2021, the FDA updated labeling for JAKAFI and other JAK-inhibitor drugs to include warnings of increased risk of major adverse cardiovascular events, thrombosis, and secondary malignancies related to another JAK-inhibitor treating rheumatoid arthritis, a condition for which JAKAFI is not indicated. The label for OPZELURA contains similar warnings seen with JAK inhibitors for inflammatory conditions. We cannot predict the effects on sales of JAKAFI as a result of the labeling change or OPZELURA as a result of warning included in its label, but it is possible that future sales of JAKAFI and the commercial success of OPZELURA can be negatively affected by the updated labeling, which could have a material and adverse effect on our business, results of operations and prospects.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have limited capacity to conduct preclinical testing and clinical trials, and our resulting dependence on other parties could result in delays in and additional costs for our drug development efforts.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have limited internal resources and capacity to perform preclinical testing and clinical trials. As part of our development strategy, we often hire contract research organizations, or CROs, to perform preclinical testing and clinical trials for drug candidates. If the CROs that we hire to perform our preclinical testing and clinical trials do not meet deadlines, do not follow proper procedures, or a conflict arises between us and our CROs, our preclinical testing and clinical trials may take longer than expected, may cost more, may be delayed or may be terminated. If we were forced to find a replacement entity to perform any of our preclinical testing or clinical trials, we may not be able to find a suitable entity on favorable terms, or at all. Even if we were able to find another company to perform a preclinical test or clinical trial, the delay in the test or trial may result in significant additional expenditures. Events such as these may result in delays in our obtaining regulatory approval for our drug candidates or our ability to commercialize our products and could result in increased expenditures that would adversely affect our operating results.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face significant competition for our drug discovery and development efforts, and if we do not compete effectively, our commercial opportunities will be reduced or eliminated.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The biotechnology and pharmaceutical industries are intensely competitive and subject to rapid and significant technological change. Our drug discovery and development efforts may target diseases and conditions that are already subject to existing therapies or that are being developed by our competitors, many of which have substantially greater resources, larger research and development staffs and facilities, more experience in completing preclinical testing and clinical trials, and formulation, marketing and manufacturing capabilities. As a result of these resources, our competitors may develop drug products that render our products obsolete or noncompetitive by developing more effective drugs, developing their products more efficiently or pricing their products more competitively. Our ability to develop competitive products would be limited if our competitors succeeded in obtaining regulatory approvals for drug candidates more rapidly than we were able to or in obtaining patent protection or other intellectual property rights that limited our drug development efforts. Any drug products resulting from our research and development efforts, or from our joint efforts with collaborators or licensees, might not be able to compete successfully with our competitors&#8217; existing and future products, or obtain regulatory approval in the United States or elsewhere. The development of products or processes by our competitors with significant advantages over those that we are developing could harm our future revenues and profitability.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">73</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie2ffba3ee5384c86becdb38ff117ca9a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our reliance on other parties to manufacture our drug products and drug candidates could result in a short supply of the drugs, delays in clinical trials or drug development, increased costs, and withdrawal or denial of a regulatory authority&#8217;s approval.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not currently operate manufacturing facilities for clinical or commercial production of JAKAFI, PEMAZYRE, OPZELURA and most of our other drug candidates or for ICLUSIG. We currently hire third parties to manufacture the raw materials, API and finished drug product of JAKAFI, ICLUSIG, PEMAZYRE, OPZELURA and our other drug candidates for clinical trials and our collaborator MorphoSys is currently responsible for sourcing manufacturing of MONJUVI/MINJUVI. In addition, we expect to continue to rely on third parties for the manufacture of commercial supplies of raw materials, API and finished drug product for any drugs that we successfully develop. We also hire third parties to package and label the finished product. The FDA requires that the raw materials, API and finished product for drug products such as JAKAFI, PEMAZYRE and OPZELURA and our other drug candidates be manufactured according to its current Good Manufacturing Practices regulations and regulatory authorities in other countries have similar requirements. There are only a limited number of manufacturers that comply with these requirements. Failure to comply with current Good Manufacturing Practices and the applicable regulatory requirements of other countries in the manufacture of our drug candidates and products could result in the FDA or a foreign regulatory authority halting our clinical trials, withdrawing or denying regulatory approval of our drug product, enforcing product recalls or other enforcement actions, which could have a material adverse effect on our business.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not be able to obtain sufficient quantities of our drug candidates or any drug products we may develop if our designated manufacturers do not have the capacity or capability to manufacture them according to our schedule and specifications. Manufacturers of pharmaceutical products often encounter difficulties in production, especially in scaling up initial production to commercial quantities from clinical quantities. These problems include difficulties with production costs and yields, quality control and assurance and shortages of qualified personnel. To the extent problems are experienced, we could encounter difficulties in supplying sufficient product to meet demand or incur additional costs to remedy the problems or to recall defective products. Any such recall could also harm our sales efforts and our reputation. To the extent our supply chain involves parties in China or materials originating in areas of China that are or could be affected by disease outbreaks such as the COVID-19 pandemic or geopolitical events such as the Russian invasion of Ukraine, we could see disruptions to our supply chain. Currently, our supply chain for our drug products and product candidates depends on operations by us and by other companies in multiple countries around the world, and the effects of the COVID-19 pandemic and measures to address the COVID-19 pandemic, as well as the effects resulting from the Russian invasion of Ukraine and related sanctions and other actions, on any or all of these countries is uncertain and unpredictable and potential disruption is possible. And, for JAKAFI, while our strategy is to maintain a 24 months stock of API, inclusive of finished product, ruxolitinib phosphate might be used by us either to make JAKAFI or for ruxolitinib drug candidates in clinical trials. In addition, we may not be able to arrange for our drug candidates or any drug products that we may develop to be manufactured by one of these parties on reasonable terms, if at all. We generally have a single source or a limited number of suppliers that are qualified to supply each of the API and finished product of our drug products and our other drug candidates and, in the case of JAKAFI, we only have a single source for its raw materials. If any of these suppliers were to become unable or unwilling to supply us with raw materials, API or finished product that complies with applicable regulatory requirements, we could incur significant delays in our clinical trials or interruption of commercial supply that could have a material adverse effect on our business. If we have promised delivery of a drug candidate or drug product and are unable to meet the delivery requirement due to manufacturing difficulties, our development programs could be delayed, we may have to expend additional sums in order to ensure that manufacturing capacity is available when we need it even if we do not use all of the manufacturing capacity, and our business and operating results could be harmed.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not be able to adequately manage and oversee the manufacturers we choose, they may not perform as agreed or they may terminate their agreements with us. Foreign manufacturing approval processes typically include all of the risks associated with the FDA approval process for manufacturing and may also include additional risks.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">74</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie2ffba3ee5384c86becdb38ff117ca9a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A number of our collaborations involve the manufacture of antibodies. Either we or our collaborators have primary responsibility for manufacturing activities, and we intend to continue to use third-party contract manufacturing organizations for the manufacture of antibodies in conjunction with our manufacturing facility in Switzerland, which became accredited by the Swiss Health Authority in June 2022. Manufacturing antibodies and products containing antibodies is a more complex process than manufacturing small molecule drugs and subject to additional risks. The process of manufacturing antibodies and products containing antibodies is highly susceptible to product loss due to contamination, equipment failure or improper installation or operation of equipment, vendor or operator error, inconsistency in yields, variability in product characteristics, and difficulties in scaling up the production process. Even minor deviations from normal manufacturing processes could result in reduced production yields, product defects and other supply disruptions. If microbial, viral or other contaminations are discovered in our product candidates or in the manufacturing facilities in which our product candidates are made, such manufacturing facilities may need to be closed for an extended period of time to investigate and remedy the contamination. We may encounter delays and difficulties in scaling up production at our new facility.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to comply with the extensive legal and regulatory requirements affecting the health care industry, we could face increased costs, penalties and a loss of business.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our activities, and the activities of our collaborators, partners and third-party providers, are subject to extensive government regulation and oversight both in the United States and in foreign jurisdictions. The FDA and comparable agencies in other jurisdictions directly regulate many of our most critical business activities, including the conduct of preclinical and clinical studies, product manufacturing, advertising and promotion, product distribution, adverse event reporting and product risk management. States increasingly have been placing greater restrictions on the marketing practices of healthcare companies and have instituted pricing disclosure and other requirements for companies selling pharmaceuticals. In addition, pharmaceutical and biotechnology companies have been the target of lawsuits and investigations alleging violations of government regulations, including claims asserting submission of incorrect pricing information, improper promotion of pharmaceutical products, payments intended to influence the referral of federal or state healthcare business, submission of false claims for government reimbursement, antitrust violations, violations of the U.S. Foreign Corrupt Practices Act, the U.K. Bribery Act and similar anti-bribery or anti-corruption laws, or violations related to environmental matters. There is also enhanced scrutiny of company-sponsored patient assistance programs, including insurance premium and co-pay assistance programs and donations to third-party charities that provide such assistance. In December 2018, we received a civil investigative demand from the U.S. Department of Justice, or DOJ, for documents and information relating to our speaker programs and patient assistance programs, including our support of non-profit organizations that provide financial assistance to eligible patients and in November 2019, the qui tam complaint underlying the DOJ inquiry was unsealed, at which time we learned that a former employee whom we had terminated had made certain allegations relating to the programs described above. While we deny that any improper claims were submitted to government payers, we agreed in May 2021 to settle the matter with the DOJ Civil Division for $12.6 million, plus certain statutory fees. Violations of governmental regulation by us, our vendors or donation recipients may be punishable by criminal and civil sanctions, including damages, fines and penalties and exclusion from participation in government programs, including Medicare and Medicaid. In addition to damages, fines and penalties for violation of laws and regulations, we could be required to repay amounts we received from government payors, or pay additional rebates and interest if we are found to have miscalculated the pricing information we have submitted to the government. Actions taken by federal or local governments, legislative bodies and enforcement agencies with respect to these legal and regulatory compliance matters could also result in reduced demand for our products, reduced coverage of our products by health care payors, or both. We cannot ensure that our compliance controls, policies, and procedures will in every instance protect us from acts committed by our employees, collaborators, partners or third-party providers that would violate the laws or regulations of the jurisdictions in which we operate. Whether or not we have complied with the law, an investigation into alleged unlawful conduct could increase our expenses, damage our reputation, divert management time and attention and adversely affect our business, and any settlement of these proceedings could result in significant payments by us. Risks relating to compliance with laws and regulations may be heightened as we continue to expand our global operations and enter new therapeutic areas with different patient populations, which due to different product distribution methods, marketing programs or patient assistance programs may result in additional regulatory burdens and obligations.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">75</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie2ffba3ee5384c86becdb38ff117ca9a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The illegal distribution and sale by third parties of counterfeit or unfit versions of our or our collaborators&#8217; products or stolen products could harm our business and reputation.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are aware that counterfeit versions of our products have been distributed or sold by entities not authorized by us using product packaging suggesting that the product was provided by us. If unauthorized third parties illegally distribute and sell counterfeit versions of our or our collaborators&#8217; products, those products may not meet our or our collaborators&#8217; rigorous manufacturing, distribution and handling standards. In addition, inventory that is stolen from warehouses, plants or while in-transit, and that is subsequently improperly stored and sold through unauthorized channels, may not meet our or our collaborators&#8217; distribution and handling standards. A patient who receives a counterfeit or unfit drug may suffer dangerous health consequences. Our reputation and business could suffer harm as a result of counterfeit or unfit drugs sold under our brand name and could result in lost sales for us and decreased revenues. If counterfeit or unfit drugs are sold under our or our collaborators&#8217; brand names, our reputation and business could suffer harm and we could experience decreased royalty revenues. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">As most of our drug discovery and development operations are conducted at our headquarters in Wilmington, Delaware, the loss of access to this facility would negatively impact our business.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our facility in Wilmington, Delaware is our headquarters and is also where we conduct most of our drug discovery, research, development and marketing activities. In addition, natural disasters, the effects of or measures taken to limit the effects of health epidemics such as the COVID-19 pandemic, or actions of activists opposed to aspects of pharmaceutical research may disrupt our experiments or our ability to access or use our facility. The loss of access to or use of our Wilmington, Delaware facility, either on a temporary or permanent basis, would result in an interruption of our business and, consequently, would adversely affect our overall business.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We depend on key employees in a competitive market for skilled personnel, and the loss of the services of any of our key employees or our inability to attract and retain additional personnel would affect our ability to expand our drug discovery and development programs and achieve our objectives.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are highly dependent on the members of our executive management team and principal members of our commercial, development, medical, operations and scientific staff. We experience intense competition for qualified personnel. Our future success also depends in part on the continued service of our executive management team and key personnel and our ability to recruit, train and retain essential personnel for our drug discovery and development programs, and for our medical affairs and commercialization activities. If we lose the services of any of these people or if we are unable to recruit sufficient qualified personnel, our research and product development goals, and our commercialization efforts could be delayed or curtailed. We do not maintain &#8220;key person&#8221; insurance on any of our employees.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to manage our growth effectively, our ability to develop and commercialize products could suffer.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that if our drug discovery efforts continue to generate drug candidates, our clinical drug candidates continue to progress in development, and we continue to build our development, medical and commercial organizations, we will require significant additional investment in personnel, management and resources. Our ability to achieve our research, development and commercialization objectives depends on our ability to respond effectively to these demands and expand our internal organization, systems, controls and facilities to accommodate additional anticipated growth. If we are unable to manage our growth effectively, our business could be harmed and our ability to execute our business strategy could suffer.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">76</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie2ffba3ee5384c86becdb38ff117ca9a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may acquire businesses or assets, form joint ventures or make investments in other companies that may be unsuccessful, divert our management&#8217;s attention and harm our operating results and prospects.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of our business strategy, we may pursue additional acquisitions of what we believe to be complementary businesses or assets or seek to enter into joint ventures. We also may pursue strategic alliances in an effort to leverage our existing infrastructure and industry experience to expand our product offerings or distribution, or make investments in other companies. For example, in June 2016, we completed the acquisition of the European operations of ARIAD. The success of our acquisitions, joint ventures, strategic alliances and investments will depend on our ability to identify, negotiate, complete and, in the case of acquisitions, integrate those transactions and, if necessary, obtain satisfactory debt or equity financing to fund those transactions. We may not realize the anticipated benefits of any acquisition, joint venture, strategic alliance or investment. We may not be able to integrate acquisitions successfully into our existing business, achieve planned synergies or cost savings, maintain the key business relationships of businesses we acquire, or retain key personnel of an acquired business, and we could assume unknown or contingent liabilities or incur unanticipated expenses. Integration of acquired companies or businesses also may require management resources that otherwise would be available for ongoing development of our existing business. Any acquisitions or investments made by us also could result in significant write-offs or the incurrence of debt and contingent liabilities, any of which could harm our operating results. For example, for the year ended December&#160;31, 2021 and for the three and nine months ended September&#160;30, 2022, we recorded unrealized losses related to our investments in our collaboration partners,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and we may in experience additional losses related to our investments in future period. In addition, if we choose to issue shares of our stock as consideration for any acquisition, dilution to our stockholders could result.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks associated with our operations outside of the United States could adversely affect our business.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our acquisition of ARIAD&#8217;s European operations significantly expanded our operations in Europe, and we plan to continue to expand our operations and conduct certain development activities outside of the United States. For example, as part of our plans to expand our activities outside of the United States, we now conduct some of our operations in Canada, commercial and clinical development activities in Japan and have opened an office in China. International operations and business expansion plans are subject to numerous additional risks, including:</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">multiple, conflicting and changing laws and regulations such as tax laws, privacy regulations, tariffs, export and import restrictions, employment, immigration and labor laws, regulatory requirements, and other governmental approvals, permits and licenses, compliance with which can increase in complexity as we enter into additional jurisdictions;</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">difficulties in staffing and managing operations in diverse countries and difficulties in connection with assimilating and integrating any operations and personnel we might acquire into our company;</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">risks associated with obtaining and maintaining, or the failure to obtain or maintain, regulatory approvals for the sale or use of our products in various countries;</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">complexities associated with managing government payor systems, multiple payor-reimbursement regimes or patient self-pay systems;</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">financial risks, such as longer payment cycles, difficulty obtaining financing in foreign markets, difficulty enforcing contracts and intellectual property rights, difficulty collecting accounts receivable and exposure to foreign currency exchange rate fluctuations;</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">general political and economic conditions in the countries in which we operate, including terrorism and political unrest, geopolitical events such as the Russian invasion of Ukraine, curtailment of trade and other business restrictions, and uncertainties associated with the implementation of the relationship between the United Kingdom and the European Union; </span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">public health risks, such as the effects of the COVID-19 pandemic, and related effects on new patient starts, clinical trial activity, regulatory agency response times, supply chain, travel and employee health and availability; and</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">77</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie2ffba3ee5384c86becdb38ff117ca9a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory and compliance risks that relate to maintaining accurate information and control over activities that may fall within the purview of the U.S. Foreign Corrupt Practices Act, its books and records provisions or its anti-bribery provisions, or similar anti-bribery or anti-corruption laws and regulations in other countries, such as the U.K. Anti-Bribery Act and the U.K. Criminal Finances Act, which may have similarly broad extraterritorial reach.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our revenues are subject to foreign currency exchange rate fluctuations due to the global nature of our operations and unfavorable changes in foreign currency exchange rates may adversely affect our revenues and net income. To the extent that our non-U.S. source revenues represent a more significant portion of our total revenues, these fluctuations could materially affect our operating results. Any of the risks described above, if encountered, could significantly increase our costs of operating internationally, prevent us from operating in certain jurisdictions, or otherwise significantly harm our future international expansion and operations, which could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If product liability lawsuits are brought against us, we could face substantial liabilities and may be required to limit commercialization of our products and our results of operations could be harmed.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the risks described above under &#8220;&#8212;Risks Relating to Commercialization of Our Products&#8212;If the use of our products harms patients, or is perceived to harm patients even when such harm is unrelated to our products, our regulatory approvals could be revoked or otherwise negatively impacted or we could be subject to costly and damaging product liability claims,&#8221; the conduct of clinical trials of medical products that are intended for human use entails an inherent risk of product liability. If any product that we or any of our collaborators or licensees develops causes or is alleged to cause injury during clinical trials or commercialization, we may be held liable. If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities, including substantial damages to be paid to the plaintiffs and legal costs, or we may be required to limit further development and commercialization of our products. Additionally, any product liability lawsuit could cause injury to our reputation, participants and investigators to withdraw from clinical trials, and potential collaborators or licensees to seek other partners, any of which could impact our results of operations.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product liability insurance policy may not fully cover our potential liabilities. In addition, we may determine that we should increase our coverage, and this insurance may be prohibitively expensive to us or our collaborators or licensees and may not fully cover our potential liabilities. Since December 30, 2017, we elected to self-insure a portion of our exposure to product liability risks through our wholly-owned captive insurance subsidiary, in tandem with third-party insurance policies. Our inability to obtain sufficient product liability insurance at an acceptable cost to protect against potential product liability claims could prevent or inhibit the development or commercialization of our drug candidates and products, and if our liabilities from any such claims exceed our third-party insurance limits and self-insurance reserves, our results of operations, cash flows and financial condition could be adversely impacted.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Because our activities involve the use of hazardous materials, we may be subject to claims relating to improper handling, storage or disposal of these materials that could be time consuming and costly.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to various environmental, health and safety laws and regulations governing, among other things, the use, handling, storage and disposal of regulated substances and the health and safety of our employees. Our research and development processes involve the controlled use of hazardous and radioactive materials and biological waste resulting in the production of hazardous waste products. We cannot completely eliminate the risk of accidental contamination or discharge and any resultant injury from these materials. If any injury or contamination results from our use or the use by our collaborators or licensees of these materials, we may be sued and our liability may exceed our insurance coverage and our total assets. Further, we may be required to indemnify our collaborators or licensees against all damages and other liabilities arising out of our development activities or products produced in connection with these collaborations or licenses. Compliance with the applicable environmental and workplace laws and regulations is expensive. Future changes to environmental, health, workplace and safety laws could cause us to incur additional expense or may restrict our operations or impair our research, development and production efforts.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">78</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie2ffba3ee5384c86becdb38ff117ca9a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business disruptions could seriously harm our operations, future revenues and financial condition and increase our costs and expenses.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations, and those of our CROs, suppliers, and other contractors and consultants, could be subject to geopolitical events, natural disasters, power and other infrastructure failures or shortages, public health pandemics or epidemics, and other natural or man-made disasters or business interruptions. In addition, geopolitical and other events, such as the Russian invasion of Ukraine, could lead to sanctions, embargoes, supply shortages, regional instability, geopolitical shifts, cyberattacks, other retaliatory actions, and adverse effects on macroeconomic conditions, currency exchange rates, and financial markets, which could adversely impact our operations and financial results, as well as those of third parties with whom we conduct business. The occurrence of any of these business disruptions could seriously harm our operations, future revenues and financial condition and increase our costs and expenses. We have engaged CROs to conduct clinical trials outside the United States, including a limited number of trials in Ukraine and Russia. We may not be able to complete any additional dosing or follow-up visits of patients in Ukraine and Russia who are participating in these clinical trials. We may also be unable to ship additional clinical drug and other supplies necessary to complete the clinical trials in Ukraine and Russia. Although the impact of Russia&#8217;s invasion is highly unpredictable, certain clinical trial activities have already been changed or suspended, and may continue to be changed, suspended or terminated, which could potentially increase our costs, slow down our product candidate development and approval process and jeopardize our ability to commence product sales and generate revenues. </span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RISKS RELATING TO OUR FINANCIAL RESULTS</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may incur losses in the future, and we expect to continue to incur significant expenses to discover and develop drugs, which may make it difficult for us to achieve sustained profitability on a quarterly or annual basis in the future.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to historical net losses, we had an accumulated deficit of $0.5 billion as of September&#160;30, 2022. We intend to continue to spend significant amounts on our efforts to discover and develop drugs. As a result, we may incur losses in future periods as well. Our revenues, expenses and net income (loss) may fluctuate, even significantly, due to the risks described in these &#8220;Risk Factors&#8221; and factors discussed in &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; as well as the timing of charges and expenses that we may take, including those relating to transactions such as acquisitions and the entry into collaborative agreements. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We anticipate that our drug discovery and development efforts and related expenditures will increase as we focus on the studies, including preclinical tests and clinical trials prior to seeking regulatory approval, that are required before we can sell a drug product.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The development of drug products will require us to spend significant funds on research, development, testing, obtaining regulatory approvals, manufacturing and marketing. To date, we do not have any drug products that have generated significant revenues other than from sales of JAKAFI and we cannot assure you that we will generate substantial revenues from the drug candidates that we license or develop, including ICLUSIG, PEMAZYRE, MONJUVI/MINJUVI, and OPZELURA, for several years, if ever.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot be certain whether or when we will achieve sustained or increased profitability on a quarterly or annual basis because of the factors discussed under &#8220;Risks Relating to Commercialization of our Products&#8221; and in the above paragraphs and the significant uncertainties relating to our ability to generate commercially successful drug products. Even if we are successful in obtaining regulatory approvals for manufacturing and commercializing drug products in addition to JAKAFI, ICLUSIG, PEMAZYRE, MONJUVI/MINJUVI, and OPZELURA, we may incur losses if our drug products do not generate significant revenues. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may need additional capital in the future. If we are unable to generate sufficient funds from operations, the capital markets may not permit us to raise additional capital at the time that we require it, which could result in limitations on our research and development or commercialization efforts or the loss of certain of our rights in our technologies or drug candidates.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future funding requirements will depend on many factors and we anticipate that we may need to raise additional capital to fund our business plan and research and development efforts going-forward.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">79</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie2ffba3ee5384c86becdb38ff117ca9a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional factors that may affect our future funding requirements include:</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the acquisition of businesses, technologies, or drug candidates, or the licensing of technologies or drug candidates, if any;</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the amount of revenues generated from our business activities;</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any changes in the breadth of our research and development programs;</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the results of research and development, preclinical testing and clinical trials conducted by us or our current or future collaborators or licensees, if any;</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our exercise of any co-development options with collaborators that may require us to fund future development;</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs for future facility requirements;</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to maintain and establish new corporate relationships and research collaborations;</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">competing technological and market developments;</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the time and costs involved in filing, prosecuting, defending and enforcing patent and intellectual property claims;</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the receipt or payment of contingent licensing or milestone fees or royalties on product sales from our current or future collaborative and license arrangements, if established; and</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing of regulatory approvals, if any.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we require additional capital at a time when investment in companies such as ours, or in the marketplace generally, is limited due to the then prevailing market or other conditions, we may have to scale back our operations, eliminate one or more of our research or development programs, or attempt to obtain funds by entering into an agreement with a collaborator or licensee that would result in terms that are not favorable to us or relinquishing our rights in certain of our proprietary technologies or drug candidates. If we are unable to raise funds at the time that we desire or at any time thereafter on acceptable terms, we may not be able to continue to develop our drug candidates. The sale of equity or equity-linked securities in the future may be dilutive to our stockholders and may provide for rights, preferences or privileges senior to those of our holders of common stock, and debt financing arrangements may require us to pledge certain assets or enter into covenants that could restrict our operations or our ability to pay dividends or other distributions on our common stock or incur further indebtedness.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our marketable securities and long term investments are subject to risks that could adversely affect our overall financial position.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We invest our cash in accordance with an established internal policy and customarily in short-term instruments, money market funds, U.S. government backed-funds and Treasury securities, which are investment grade and historically have been highly liquid and carried relatively low risk. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Should a portion of our cash or marketable securities lose value or have their liquidity impaired, it could adversely affect our overall financial position by imperiling our ability to fund our operations and forcing us to seek additional financing sooner than we would otherwise. Such financing, if available, may not be available on commercially attractive terms.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed under &#8220;Other Risks Relating to Our Business&#8212; We may acquire businesses or assets, form joint ventures or make investments in other companies that may be unsuccessful, divert our management&#8217;s attention and harm our operating results and prospects,&#8221; any investments that we may make in companies with which we have strategic alliances, such as Agenus, Merus and MorphoSys, could result in our recognition of losses on those investments. In addition, to the extent we may seek to sell or otherwise monetize those investments, we may not be able to do so at our desired price or valuation levels, or at all, due to the limited liquidity of some or all of those investments.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">80</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie2ffba3ee5384c86becdb38ff117ca9a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any loss in value of our long term investments could adversely affect our financial position on the consolidated balance sheets and consolidated statements of operations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in tax laws or regulations could adversely affect our results of operations, business and financial condition.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">New tax laws or regulations could be enacted at any time, and existing tax laws or regulations could be interpreted, modified or applied in a manner that is adverse to us or our customers, which could adversely affect our results of operations, business and financial condition. In August 2022, the Inflation Reduction Act of 2022 was enacted, which includes tax provisions implementing a 15% corporate alternative minimum tax on a corporation&#8217;s adjusted financial statement income if it exceeds its regular tax liability for tax years beginning after December 31, 2022, and a 1% excise tax on share repurchases occurring after December 31, 2022. At this time, we believe it is unlikely, to have a material impact on our tax provision and financial results in future years. In addition, the Organisation for Economic Co-Operation and Development (OECD) in October 2021 announced an agreement on an outline for new tax rules that would align countries on a minimum corporate tax rate and an expansion of the taxing rights of market countries. If enacted by member countries, this agreement could result in tax increases in both the United States and many foreign jurisdictions where we operate or have a presence. These initiatives not only could significantly increase our tax provision, cash tax liabilities, and effective tax rate, but could also significantly increase tax uncertainty due to differing interpretations and increased audit scrutiny. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We derive a substantial portion of our revenues from royalties, milestone payments and other payments under our collaboration agreements. If we are unable to achieve milestones, develop product candidates to license or renew or enter into new collaborations, our revenues may decrease, and future milestone and royalty payments may not contribute significantly to revenues for several years, and may never result in revenues.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We derived a substantial portion of our revenues for the year ended December 31, 2021 and the three and nine months ended September&#160;30, 2022 from JAKAVI and OLUMIANT product royalties and from milestone payments under our collaboration agreements. Future revenues from research and development collaborations depend upon continuation of the collaborations, the achievement of milestones and royalties we earn from any future products developed from our research. If we are unable to successfully achieve milestones or our collaborators fail to develop successful products, we will not earn the future revenues contemplated under our collaborative agreements. For example, delays in or other limitations with respect to the approval of baricitinib in the United States for the treatment of moderate-to-severe rheumatoid arthritis, or the failure to obtain such approval as a first line therapy, as discussed under &#8220;&#8212;We depend on our collaborators and licensees for the future development and commercialization of some of our drug candidates. Conflicts may arise between our collaborators and licensees and us, or our collaborators and licensees may choose to terminate their agreements with us, which may adversely affect our business.&#8221; could affect potential future royalty and milestone and contract revenue. </span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RISKS RELATING TO INTELLECTUAL PROPERTY AND LEGAL MATTERS</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are subject to arbitration, litigation and infringement claims, they could be costly and disrupt our drug discovery and development efforts.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The technology that we use to make and develop our drug products, the technology that we incorporate in our products, and the products we are developing may be subject to claims that they infringe the patents or proprietary rights of others. The success of our drug discovery and development efforts will also depend on our ability to develop new compounds, drugs and technologies without infringing or misappropriating the proprietary rights of others. We are aware of patents and patent applications filed in certain countries claiming intellectual property relating to some of our drug discovery targets and drug candidates. While the validity of issued patents, patentability of pending patent applications and applicability of any of them to our programs are uncertain, if any of these patents are asserted against us or if we choose to license any of these patents, our ability to commercialize our products could be harmed or the potential return to us from any product that may be successfully commercialized could be diminished.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time we have received, and we may in the future receive, notices from third parties offering licenses to technology or alleging patent, trademark, or copyright infringement, claims regarding trade secrets or other contract claims. Receipt of these notices could result in significant costs as a result of the diversion of the attention of management from our drug discovery and development efforts. Parties sending these notices may have brought and in the future may bring litigation against us or seek arbitration relating to contract claims.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">81</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie2ffba3ee5384c86becdb38ff117ca9a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may be involved in future lawsuits or other legal proceedings alleging patent infringement or other intellectual property rights or contract violations. In addition, litigation or other legal proceedings may be necessary to:</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">assert claims of infringement;</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">enforce our patents or trademarks;</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">protect our trade secrets or know-how; or</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">determine the enforceability, scope and validity of the proprietary rights of others.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may be unsuccessful in defending or pursuing these lawsuits, claims or other legal proceedings. Regardless of the outcome, litigation or other legal proceedings can be very costly and can divert management&#8217;s efforts. An adverse determination may subject us to significant liabilities or require us or our collaborators or licensees to seek licenses to other parties&#8217; patents or proprietary rights. We or our collaborators or licensees may also be restricted or prevented from manufacturing or selling a drug or other product that we or they develop. Further, we or our future collaborators or licensees may not be able to obtain any necessary licenses on acceptable terms, if at all. If we are unable to develop non-infringing technology or license technology on a timely basis or on reasonable terms, our business could be harmed.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be unable to adequately protect or enforce our proprietary information, which may result in its unauthorized use, a loss of revenue under a collaboration agreement or loss of sales to generic versions of our products or otherwise reduce our ability to compete in developing and commercializing products.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business and competitive position depends in significant part upon our ability to protect our proprietary technology, including any drug products that we create. Despite our efforts to protect this information, unauthorized parties may attempt to obtain and use information that we regard as proprietary. For example, one of our collaborators may disclose proprietary information pertaining to our drug discovery efforts. In addition, while we have filed numerous patent applications with respect to ruxolitinib and our drug candidates in the United States and in foreign countries, our patent applications may fail to result in issued patents. In addition, because patent applications can take several years to issue as patents, there may be pending patent applications of others that may later issue as patents that cover some aspect of ruxolitinib and our drug candidates. Our existing patents and any future patents we may obtain may not be broad enough to protect our products or all of the potential uses of our products, or otherwise prevent others from developing competing products or technologies. In addition, our patents may be challenged and invalidated or may fail to provide us with any competitive advantages if, for example, others were first to invent or first to file a patent application for the technologies and products covered by our patents. As noted above under &#8220;&#8212;Risks Relating to Commercialization of Our Products&#8212;Competition for our products could potentially harm our business and result in a decrease in our revenue,&#8221; a potential generic drug company competitor has challenged certain patents relating to JAKAFI.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, when we do not control the prosecution, maintenance and enforcement of certain important intellectual property, such as a drug candidate in-licensed to us or subject to a collaboration with a third-party, the protection of the intellectual property rights may not be in our hands. If we do not control the intellectual property rights in-licensed to us with respect to a drug candidate and the entity that controls the intellectual property rights does not adequately protect those rights, our rights may be impaired, which may impact our ability to develop, market and commercialize the in-licensed drug candidate.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our means of protecting our proprietary rights may not be adequate, and our competitors may:</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">independently develop substantially equivalent proprietary information, products and techniques;</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">otherwise gain access to our proprietary information; or</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">design around patents issued to us or our other intellectual property.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We pursue a policy of having our employees, consultants and advisors execute proprietary information and invention agreements when they begin working for us. However, these agreements may not provide meaningful protection for our trade secrets or other proprietary information in the event of unauthorized use or disclosure. If we fail to maintain trade secret and patent protection, our potential future revenues may be decreased.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">82</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie2ffba3ee5384c86becdb38ff117ca9a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If the effective term of our patents is decreased due to changes in the United States patent laws or if we need to refile some of our patent applications, the value of our patent portfolio and the revenues we derive from it may be decreased.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The value of our patents depends, in part, on their duration. A shorter period of patent protection could lessen the value of our rights under any patents that we obtain and may decrease the revenues we derive from our patents. The United States patent laws provide a term of patent protection of 20 years from the earliest effective filing date of the patent application. Because the time from filing to issuance of biotechnology applications may be more than three years depending on the subject matter, a 20-year patent term from the filing date may result in substantially shorter patent protection.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, United States patent laws were amended in 2011 with the enactment of the America Invents Act and third parties are now able to challenge the validity of issued U.S. patents through various review proceedings; thus rendering the validity of U.S. patents more uncertain. We may be obligated to participate in review proceedings to determine the validity of our U.S. patents. We cannot predict the ultimate outcome of these proceedings, the conduct of which could result in substantial costs and diversion of our efforts and resources. If we are unsuccessful in these proceedings some or all of our claims in the patents may be narrowed or invalidated and the patent protection for our products and drug candidates in the United States could be substantially shortened. Further, if all of the patents covering one of our products are invalidated, the FDA could approve requests to manufacture a generic version of that product prior to the expiration date of those patents.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other changes in the United States patent laws or changes in the interpretation of patent laws could diminish the value of our patents or narrow the scope of our patent protection. For example, the Supreme Court of the United States resolved a split among the circuit courts of appeals regarding antitrust challenges to settlements of patent infringement lawsuits under the Hatch-Waxman Act between brand-name drug companies and generic drug companies. The Court rejected the &#8220;scope of the patent&#8221; test and ruled that settlements involving &#8220;reverse payments&#8221; from brand-name drug companies to generic drug companies should be analyzed under the rule of reason. This ruling may create uncertainty and make it more difficult to settle patent litigation if a company seeking to manufacture a generic version of one of our products challenges the patents covering that product prior to the expiration date of those patents.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">International patent protection is particularly uncertain and costly, and our involvement in opposition proceedings in foreign countries may result in the expenditure of substantial sums and management resources.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Biotechnology and pharmaceutical patent law outside the United States is even more uncertain and costly than in the United States and is currently undergoing review and revision in many countries. Further, the laws of some foreign countries may not protect our intellectual property rights to the same extent as United States laws. For example, certain countries do not grant patent claims that are directed to the treatment of humans. We have participated, and may in the future participate, in opposition proceedings to determine the validity of our foreign patents or our competitors&#8217; foreign patents, which could result in substantial costs and diversion of our efforts. Successful challenges to our patent or other intellectual property rights through these proceedings could result in a loss of rights in the relevant jurisdiction and allow third parties to use our proprietary technologies without a license from us or our collaborators, which may also result in loss of future royalty payments. In addition, successful challenges may jeopardize or delay our ability to enter into new collaborations or commercialize potential products, which could harm our business and results of operations.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RISKS RELATING TO INFORMATION TECHNOLOGY AND DATA PRIVACY </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Significant disruptions of information technology systems, breaches of data security, or unauthorized disclosures of sensitive data or personally identifiable information or individually identifiable health information could adversely affect our business,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">and could</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">subject us to liability or reputational damage. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business is increasingly dependent on critical, complex, and interdependent information technology (IT) systems, including Internet-based systems, some of which are managed or hosted by third parties, to support business processes as well as internal and external communications. The size and complexity of our IT systems make us potentially vulnerable to IT system breakdowns, malicious intrusion, and computer viruses, which may result in the impairment of our ability to operate our business effectively. In addition, having a significant portion of our employees work remotely due to the COVID-19 pandemic or otherwise can strain our information technology infrastructure, which may affect our ability to operate effectively, may make us more susceptible to communications disruptions, and expose us to greater cybersecurity risks.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">83</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie2ffba3ee5384c86becdb38ff117ca9a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are continuously evaluating and, where appropriate, enhancing our IT systems to address our planned growth, including to support our planned manufacturing operations. In particular, we are currently in the process of implementing a new enterprise resource planning system. There are inherent costs and risks associated with implementing the enhancements to our IT systems, including potential delays in access to, or errors in, critical business and financial information, substantial capital expenditures, additional administrative time and operating expenses, retention of sufficiently skilled personnel to implement and operate the enhanced systems, demands on management time, and costs of delays or difficulties in transitioning to the enhanced systems, any of which could harm our business and results of operations. In addition, the implementation of enhancements to our IT systems may not result in productivity improvements at a level that outweighs the costs of implementation, or at all. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our systems and the systems of our third-party providers and collaborators are potentially vulnerable to data security breaches which may expose sensitive data to unauthorized persons or to the public. Such data security breaches could lead to the loss of confidential information, trade secrets or other intellectual property, could lead to the public exposure of personal information (including personally identifiable information or individually identifiable health information) of our employees, clinical trial patients, customers, business partners, and others, could lead to potential identity theft, or could lead to reputational harm. Data security breaches could also result in loss of clinical trial data or damage to the integrity of that data. In addition, the increased use of social media by our employees and contractors could result in inadvertent disclosure of sensitive data or personal information, including but not limited to, confidential information, trade secrets and other intellectual property.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any such disruption or security breach, as well as any action by us or our employees or contractors that might be inconsistent with the rapidly evolving data privacy and security laws and regulations applicable within the United States and elsewhere where we conduct business, could result in enforcement actions by U.S. states, the U.S. Federal government or foreign governments, liability or sanctions under data privacy laws, including healthcare laws such as HIPAA, that protect certain types of sensitive information, regulatory penalties, other legal proceedings such as but not limited to private litigation, the incurrence of significant remediation costs, disruptions to our development programs, business operations and collaborations, diversion of management efforts and damage to our reputation, which could harm our business and operations. Because of the rapidly moving nature of technology and the increasing sophistication of cybersecurity threats, our measures to prevent, respond to and minimize such risks may be unsuccessful. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the European Parliament and the Council of the European Union has adopted a comprehensive general data privacy regulation, known as the GDPR, which governs the collection and use of personal data in the European Union. The GDPR, which is wide-ranging in scope, imposes several requirements relating to the consent of the individuals to whom the personal data relates, the information provided to the individuals, the security and confidentiality of the personal data, data breach notification and the use of third party processors in connection with the processing of the personal data. The GDPR also imposes strict rules on the transfer of personal data out of the European Union to the United States, provides an enforcement authority and imposes large penalties for noncompliance, including the potential for fines of up to &#8364;20 million or 4% of the annual global revenues of the infringer, whichever is greater. The United Kingdom has enacted legislation similar to the GDPR, the UK GDPR, which provides for potential fines of up to the greater of &#163;17.5 million or 4% of the annual global revenue. Moreover, the European Court of Justice in July 2020 invalidated the Privacy Shield framework that had been in place between the European Union and the United States, which invalidation has created uncertainty about how data can now be shared in a compliant manner. Additionally, the California Consumer Privacy Act (CCPA) affords a private right of action to such consumers if certain data breaches result in the loss or theft of their personal information. The GDPR, UK GDPR, CCPA and other similar laws or regulations enacted or proposed to be enacted in the United States or other jurisdictions associated with the enhanced protection of certain types of sensitive data, including healthcare data or other personal information, may increase our costs of doing business, and the differing requirements of these laws and regulations can complicate our compliance efforts.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">84</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie2ffba3ee5384c86becdb38ff117ca9a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Increasing use of social media could give rise to liability, breaches of data security, or reputational damage.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and our employees are increasingly utilizing social media tools as a means of communication both internally and externally. Despite our efforts to monitor evolving social media communication guidelines and comply with applicable rules, there is risk that the use of social media by us or our employees to communicate about our products or business may cause us to be found in violation of applicable requirements. In addition, our employees may knowingly or inadvertently make use of social media in ways that may not comply with our social media policy or other legal or contractual requirements, which may give rise to liability, lead to the loss of trade secrets or other intellectual property, or result in public exposure of personal information of our employees, clinical trial patients, customers, and others. Furthermore, negative posts or comments about us or our products in social media could seriously damage our reputation, brand image, and goodwill.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">85</span></div></div></div><div id="ie2ffba3ee5384c86becdb38ff117ca9a_133"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie2ffba3ee5384c86becdb38ff117ca9a_7">Table of Contents</a></span></div></div><div style="-sec-extract:summary;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 6.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibits</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:86.173%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit<br/>Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Description of Document</span></td></tr><tr><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.1&#8224;*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="exhibit101_amendment3toglo.htm">Amendment No. 3, dated as of July 14, 2022, to Global Collaboration and License Agreement, dated October 24, 2017, by and between the Company and MacroGenics, Inc.</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">31.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="incy-9302022xex311.htm">Rule 13a-14(a) Certification of Chief Executive Officer</a></span><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">.</span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">31.2*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="incy-9302022xex312.htm">Rule 13a-14(a) Certification of Chief Financial Officer</a></span><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">.</span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">32.1**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="incy-9302022xex321.htm">Statement of the Chief Executive Officer under Section 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. Section 1350)</a></span><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">.</span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">32.2**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="incy-9302022xex322.htm">Statement of the Chief Financial Officer under Section 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. Section 1350)</a></span><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">.</span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">101.INS*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">XBRL Instance Document &#8211; the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">101.SCH*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">XBRL Taxonomy Extension Schema Document.</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">101.CAL*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">XBRL Taxonomy Extension Calculation Linkbase Document.</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">101.LAB*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">XBRL Taxonomy Extension Label Linkbase Document.</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">101.PRE*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">XBRL Taxonomy Presentation Linkbase Document.</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">101.DEF*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">XBRL Taxonomy Definition Linkbase Document.</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Cover Page Interactive Data File (embedded within the Inline XBRL document).</span></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_____________________________</span></div><div style="margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;Filed herewith.</span></div><div style="margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">**&#160;&#160;&#160;&#160;In accordance with Item 601(b)(32)(ii) of Regulation S-K and SEC Release No. 34-47986, the certifications furnished in Exhibits 32.1 and 32.2 hereto are deemed to accompany this Form 10-Q and will not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Exchange Act. Such certifications will not be deemed to be incorporated by reference into any filing under the Securities Act or the Exchange Act.</span></div><div style="margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8224;&#160;&#160;&#160;&#160;Portions</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of this exhibit have been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">86</span></div></div></div><div id="ie2ffba3ee5384c86becdb38ff117ca9a_136"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie2ffba3ee5384c86becdb38ff117ca9a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.356%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">INCYTE CORPORATION</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Dated: November&#160;1, 2022</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">/s/ HERV&#201; HOPPENOT</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Herv&#233; Hoppenot</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Chairman, President, and Chief Executive Officer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(Principal Executive Officer)</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Dated: November&#160;1, 2022</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">/s/ CHRISTIANA STAMOULIS</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Christiana Stamoulis</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Chief Financial Officer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(Principal Financial Officer)</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">87</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>exhibit101_amendment3toglo.htm
<DESCRIPTION>EX-10.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i23e85eb1012746c286d19894ccdbe76b_1"></div><div style="min-height:99.36pt;width:100%"><div style="padding-left:396pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Exhibit 10.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Certain identified information, marked by &#91;***&#93;, has been excluded from the exhibit because it is both not material and is the type that the Company treats as private or confidential.</font></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><font><br></font></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">AMENDMENT NO. 3 TO GLOBAL COLLABORATION AND LICENSE AGREEMENT</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Amendment No. 3 to Global Collaboration and License Agreement (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Amendment No. 3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) is dated as of July 14, 2022, by and between </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">INCYTE CORPORATION</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, a Delaware corporation, having its principal place of business at 1801 Augustine Cut-Off, Wilmington, DE 19803 (hereinafter &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Incyte</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">MACROGENICS, INC.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, a Delaware corporation, having its principal place of business at 9704 Medical Center Drive, Rockville, MD 20850 (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">MacroGenics</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;, together with Incyte, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; and each separately, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), and is meant to amend that certain Global Collaboration and License Agreement, dated as of October 24, 2017, between Incyte and MacroGenics and amended on March 15, 2018 (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Amendment No. 1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) and April 7, 2022 (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Amendment No. 2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). The Global Collaboration and License Agreement, Amendment No. 1, and Amendment No. 2 are referred to herein collectively as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;.  Capitalized terms used and not otherwise defined herein shall have the meanings ascribed to such terms in the Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">WHEREAS, the Parties wish to modify the Agreement to reflect changes agreed to between the Parties with respect to (a) the acceleration of payment for certain Milestones with respect to </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and (b) the </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of certain Milestones with respect to </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">NOW, THEREFORE, IN CONSIDERATION of the mutual covenants contained herein, and for other good and valuable consideration the receipt and adequacy of which are hereby acknowledged, the Parties agree as follows&#58;</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Acceleration of First Development Milestones with respect to </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Indications</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Parties agree that the first Development Milestone set forth in Section 8.2(b) of the Agreement, </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (including Incyte Monotherapy Studies and Incyte Combination Studies) </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Milestone</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) shall be deemed to have been achieved with respect to the Indications </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Incyte shall pay MacroGenics within </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Business Days of the date hereof the amount of </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, representing payment for the achievement of such </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93; Milestones</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Parties agree that only </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> remains unachieved and potentially payable by Incyte in the future.</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Removal of Certain Milestones and Payments for </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Parties agree that&#58;</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9.68pt">The </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall not apply with respect to the Indication </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, and </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> for the </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> with respect to the Indication of </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, whether by reason of (i) actually </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in the Indication </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> or (ii) the occurrence of any of the events set forth in the final sentence in the first paragraph of Section 8.2 stating, &#8220;In addition, except with respect to the Breakthrough Designation Milestone, if for any reason any other Development Milestone corresponding to a Milestone payment does not occur prior to the occurrence of Regulatory Approval, then such prior non-occurring Development Milestone shall be deemed to occur concurrently with Regulatory Approval, and the applicable Milestone payments for the applicable Development Milestones shall become due and payable in accordance with this Section 8.2.&#8221;  For clarity, </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> by Incyte, its Affiliates, or sublicensees for a Monotherapy Regimen or Incyte Combination Regimen in the </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> any such Milestone payment.</font></div><div style="padding-left:72pt;padding-right:17.85pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:99.36pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">The Regulatory Filing Milestone </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> set forth in Section 8.2(c) of the Agreement </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> respect to the Indication </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, and </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93; </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of such</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Milestone </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">with respect to the </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="padding-left:83pt;padding-right:17.85pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9.68pt">The Approval Milestone </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> set forth in Section 8.2(d) of the Agreement </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> with respect to the Indication of </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, and </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> for the </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Milestone shall </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> with respect to the Indication </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="padding-left:83pt;padding-right:17.85pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="margin-bottom:12pt;padding-left:54pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Entire Agreement&#59; Remaining Provisions of the Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Agreement, as supplemented and modified by this Amendment No. 3, contains the entire understanding of the parties with respect to the subject matter hereof and supersedes all prior agreements and understandings, oral or written, with respect to such matters, which the parties acknowledge have been merged into the Agreement.  Upon the effectiveness of this Amendment No. 3, on and after the date hereof, each reference in the Agreement to &#8220;this Agreement,&#8221; &#8220;hereunder,&#8221; &#8220;hereof,&#8221; &#8220;herein&#8221; or words of like import shall mean and be a reference to the Agreement, as amended hereby.  Except as provided herein, each of the other provisions of the Agreement shall remain in full force and effect.</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Governing Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This Amendment No. 3 shall be governed by and construed under the laws of the State of New York, without giving effect to any choice of law principles that would require the application of the laws of a different state.</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Execution in Counterparts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This Amendment No. 3 may be executed in two (2) or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. This Amendment No. 3 may be executed by .pdf or other electronically transmitted signatures and such signatures shall be deemed to bind each Party as if they were the original signatures.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">&#91;remainder of page intentionally blank&#93;</font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:99.36pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">IN WITNESS WHEREOF, the parties hereto have caused this Amendment No. 3 to Global Collaboration and License Agreement to be duly executed by their respective authorized signatories effective as of the date first indicated above.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.179%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">MACROGENICS, INC.</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:230.2pt;text-align:justify"><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58; </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Scott Koenig&#160;&#160;&#160;&#160;</font></div><div style="padding-left:2.75pt;padding-right:230.2pt;text-align:justify;text-indent:21.35pt"><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58; Scott Koenig</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:21.35pt"><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58; President and Chief Executive Officer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td></tr><tr style="height:44pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">INCYTE CORPORATION</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Vijay Iyengar&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:21.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58;  Vijay Iyengar</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:21.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;  EVP, Global Strategy &#38; Corporate Development </font></div></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3</font></div><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>incy-9302022xex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i266b26e15e5c49a99f77086b156cafce_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Herv&#233; Hoppenot, certify that&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">I have reviewed this quarterly report on Form 10-Q of Incyte Corporation&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.24pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.24pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.24pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr style="height:0pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; HERV&#201; HOPPENOT</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Herv&#233; Hoppenot</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">November&#160;1, 2022</font></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>incy-9302022xex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ie062772e37fd4747b483a40712b366d7_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Christiana Stamoulis, certify that&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">I have reviewed this quarterly report on Form 10-Q of Incyte Corporation&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.24pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.24pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.24pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr style="height:0pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; CHRISTIANA STAMOULIS</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Christiana Stamoulis</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">November&#160;1, 2022</font></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>incy-9302022xex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ic786100b2469404c862a3de1889bc16b_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">STATEMENT PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With reference to the Quarterly Report of Incyte Corporation (the &#8220;Company&#8221;) on Form 10-Q for the quarter ended September&#160;30, 2022, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Herv&#233; Hoppenot, Chief Executive Officer of the Company, certify, for the purposes of 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge&#58;</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">the Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:119%">&#47;s&#47; HERV&#201; HOPPENOT</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:119%">Herv&#233; Hoppenot</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:119%">November 1, 2022</font></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>6
<FILENAME>incy-9302022xex322.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i6b56f7d634ba44b09ce2e9390f853498_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.2</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">STATEMENT PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With reference to the Quarterly Report of Incyte Corporation (the &#8220;Company&#8221;) on Form 10-Q for the quarter ended September&#160;30, 2022, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Christiana Stamoulis, Chief Financial Officer of the Company, certify, for the purposes of 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge&#58;</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">the Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:119%">&#47;s&#47; CHRISTIANA STAMOULIS</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:119%">Christiana Stamoulis</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:119%">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:119%">November 1, 2022</font></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>incy-20220930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:4b736358-c29a-4c12-bfe7-729e80c7c631,g:94be2257-4ebc-4637-90cb-08232abb2695-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:incy="http://www.incyte.com/20220930" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.incyte.com/20220930">
  <xs:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2022" schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="incy-20220930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="incy-20220930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="incy-20220930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="incy-20220930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="DocumentandEntityInformation" roleURI="http://www.incyte.com/role/DocumentandEntityInformation">
        <link:definition>0000001 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDBALANCESHEETS" roleURI="http://www.incyte.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS">
        <link:definition>0000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" roleURI="http://www.incyte.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical">
        <link:definition>0000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" roleURI="http://www.incyte.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS">
        <link:definition>0000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" roleURI="http://www.incyte.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS">
        <link:definition>0000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" roleURI="http://www.incyte.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY">
        <link:definition>0000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical" roleURI="http://www.incyte.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical">
        <link:definition>0000007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" roleURI="http://www.incyte.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>0000008 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandBusiness" roleURI="http://www.incyte.com/role/OrganizationandBusiness">
        <link:definition>0000009 - Disclosure - Organization and Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://www.incyte.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>0000010 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Revenues" roleURI="http://www.incyte.com/role/Revenues">
        <link:definition>0000011 - Disclosure - Revenues</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueofFinancialInstruments" roleURI="http://www.incyte.com/role/FairValueofFinancialInstruments">
        <link:definition>0000012 - Disclosure - Fair Value of Financial Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConcentrationsofCreditRiskandCurrentExpectedCreditLosses" roleURI="http://www.incyte.com/role/ConcentrationsofCreditRiskandCurrentExpectedCreditLosses">
        <link:definition>0000013 - Disclosure - Concentrations of Credit Risk and Current Expected Credit Losses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Inventory" roleURI="http://www.incyte.com/role/Inventory">
        <link:definition>0000014 - Disclosure - Inventory</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicenseAgreements" roleURI="http://www.incyte.com/role/LicenseAgreements">
        <link:definition>0000015 - Disclosure - License Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentnet" roleURI="http://www.incyte.com/role/PropertyandEquipmentnet">
        <link:definition>0000016 - Disclosure - Property and Equipment, net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedandOtherCurrentLiabilities" roleURI="http://www.incyte.com/role/AccruedandOtherCurrentLiabilities">
        <link:definition>0000017 - Disclosure - Accrued and Other Current Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockCompensation" roleURI="http://www.incyte.com/role/StockCompensation">
        <link:definition>0000018 - Disclosure - Stock Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.incyte.com/role/IncomeTaxes">
        <link:definition>0000019 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomePerShare" roleURI="http://www.incyte.com/role/NetIncomePerShare">
        <link:definition>0000020 - Disclosure - Net Income Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlans" roleURI="http://www.incyte.com/role/EmployeeBenefitPlans">
        <link:definition>0000021 - Disclosure - Employee Benefit Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.incyte.com/role/CommitmentsandContingencies">
        <link:definition>0000022 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvents" roleURI="http://www.incyte.com/role/SubsequentEvents">
        <link:definition>0000023 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.incyte.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>0000024 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesTables" roleURI="http://www.incyte.com/role/RevenuesTables">
        <link:definition>0000025 - Disclosure - Revenues (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueofFinancialInstrumentsTables" roleURI="http://www.incyte.com/role/FairValueofFinancialInstrumentsTables">
        <link:definition>0000026 - Disclosure - Fair Value of Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConcentrationsofCreditRiskandCurrentExpectedCreditLossesTables" roleURI="http://www.incyte.com/role/ConcentrationsofCreditRiskandCurrentExpectedCreditLossesTables">
        <link:definition>0000027 - Disclosure - Concentrations of Credit Risk and Current Expected Credit Losses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryTables" roleURI="http://www.incyte.com/role/InventoryTables">
        <link:definition>0000028 - Disclosure - Inventory (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentnetTables" roleURI="http://www.incyte.com/role/PropertyandEquipmentnetTables">
        <link:definition>0000029 - Disclosure - Property and Equipment, net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedandOtherCurrentLiabilitiesTables" roleURI="http://www.incyte.com/role/AccruedandOtherCurrentLiabilitiesTables">
        <link:definition>0000030 - Disclosure - Accrued and Other Current Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockcompensationTables" roleURI="http://www.incyte.com/role/StockcompensationTables">
        <link:definition>0000031 - Disclosure - Stock compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomePerShareTables" roleURI="http://www.incyte.com/role/NetIncomePerShareTables">
        <link:definition>0000032 - Disclosure - Net Income Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlansTables" roleURI="http://www.incyte.com/role/EmployeeBenefitPlansTables">
        <link:definition>0000033 - Disclosure - Employee Benefit Plans (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandBusinessDetails" roleURI="http://www.incyte.com/role/OrganizationandBusinessDetails">
        <link:definition>0000034 - Disclosure - Organization and Business (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesDetails" roleURI="http://www.incyte.com/role/RevenuesDetails">
        <link:definition>0000035 - Disclosure - Revenues (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueofFinancialInstrumentsMarketablesecuritiesportfolioDetails" roleURI="http://www.incyte.com/role/FairValueofFinancialInstrumentsMarketablesecuritiesportfolioDetails">
        <link:definition>0000036 - Disclosure - Fair Value of Financial Instruments - Marketable securities portfolio (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueofFinancialInstrumentsAssetsmeasuredonarecurringbasisDetails" roleURI="http://www.incyte.com/role/FairValueofFinancialInstrumentsAssetsmeasuredonarecurringbasisDetails">
        <link:definition>0000037 - Disclosure - Fair Value of Financial Instruments - Assets measured on a recurring basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueofFinancialInstrumentsLiabilitiesmeasuredonarecurringbasisDetails" roleURI="http://www.incyte.com/role/FairValueofFinancialInstrumentsLiabilitiesmeasuredonarecurringbasisDetails">
        <link:definition>0000038 - Disclosure - Fair Value of Financial Instruments - Liabilities measured on a recurring basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueofFinancialInstrumentsLevel3liabilitiesDetails" roleURI="http://www.incyte.com/role/FairValueofFinancialInstrumentsLevel3liabilitiesDetails">
        <link:definition>0000039 - Disclosure - Fair Value of Financial Instruments - Level 3 liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueofFinancialInstrumentsNarrativeDetails" roleURI="http://www.incyte.com/role/FairValueofFinancialInstrumentsNarrativeDetails">
        <link:definition>0000040 - Disclosure - Fair Value of Financial Instruments - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConcentrationsofCreditRiskandCurrentExpectedCreditLossesDetails" roleURI="http://www.incyte.com/role/ConcentrationsofCreditRiskandCurrentExpectedCreditLossesDetails">
        <link:definition>0000041 - Disclosure - Concentrations of Credit Risk and Current Expected Credit Losses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryDetails" roleURI="http://www.incyte.com/role/InventoryDetails">
        <link:definition>0000042 - Disclosure - Inventory (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicenseAgreementsNovartisDetails" roleURI="http://www.incyte.com/role/LicenseAgreementsNovartisDetails">
        <link:definition>0000043 - Disclosure - License Agreements - Novartis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicenseAgreementsLillyDetails" roleURI="http://www.incyte.com/role/LicenseAgreementsLillyDetails">
        <link:definition>0000044 - Disclosure - License Agreements - Lilly (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicenseAgreementsAgenusDetails" roleURI="http://www.incyte.com/role/LicenseAgreementsAgenusDetails">
        <link:definition>0000045 - Disclosure - License Agreements - Agenus (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicenseAgreementsMerusDetails" roleURI="http://www.incyte.com/role/LicenseAgreementsMerusDetails">
        <link:definition>0000046 - Disclosure - License Agreements - Merus (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicenseAgreementsCalitheraDetails" roleURI="http://www.incyte.com/role/LicenseAgreementsCalitheraDetails">
        <link:definition>0000047 - Disclosure - License Agreements - Calithera (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicenseAgreementsMacroGenicsDetails" roleURI="http://www.incyte.com/role/LicenseAgreementsMacroGenicsDetails">
        <link:definition>0000048 - Disclosure - License Agreements - MacroGenics (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicenseAgreementsSyrosDetails" roleURI="http://www.incyte.com/role/LicenseAgreementsSyrosDetails">
        <link:definition>0000049 - Disclosure - License Agreements - Syros (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicenseAgreementsInnoventDetails" roleURI="http://www.incyte.com/role/LicenseAgreementsInnoventDetails">
        <link:definition>0000050 - Disclosure - License Agreements - Innovent (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicenseAgreementsZaiLabDetails" roleURI="http://www.incyte.com/role/LicenseAgreementsZaiLabDetails">
        <link:definition>0000051 - Disclosure - License Agreements - Zai Lab (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicenseAgreementsMorphoSysDetails" roleURI="http://www.incyte.com/role/LicenseAgreementsMorphoSysDetails">
        <link:definition>0000052 - Disclosure - License Agreements - MorphoSys (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicenseAgreementsNimbleDetails" roleURI="http://www.incyte.com/role/LicenseAgreementsNimbleDetails">
        <link:definition>0000053 - Disclosure - License Agreements - Nimble (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicenseAgreementsInnoCareDetails" roleURI="http://www.incyte.com/role/LicenseAgreementsInnoCareDetails">
        <link:definition>0000054 - Disclosure - License Agreements - InnoCare (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicenseAgreementsSyndaxDetails" roleURI="http://www.incyte.com/role/LicenseAgreementsSyndaxDetails">
        <link:definition>0000055 - Disclosure - License Agreements - Syndax (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentnetPropertyandequipmentnetDetails" roleURI="http://www.incyte.com/role/PropertyandEquipmentnetPropertyandequipmentnetDetails">
        <link:definition>0000056 - Disclosure - Property and Equipment, net - Property and equipment, net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentnetBuildingsandconstructionDetails" roleURI="http://www.incyte.com/role/PropertyandEquipmentnetBuildingsandconstructionDetails">
        <link:definition>0000057 - Disclosure - Property and Equipment, net - Buildings and construction (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedandOtherCurrentLiabilitiesDetails" roleURI="http://www.incyte.com/role/AccruedandOtherCurrentLiabilitiesDetails">
        <link:definition>0000058 - Disclosure - Accrued and Other Current Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockCompensationNarrativeDetails" roleURI="http://www.incyte.com/role/StockCompensationNarrativeDetails">
        <link:definition>0000059 - Disclosure - Stock Compensation - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockCompensationValuationassumptionsusedforvalueofstockcompensationgrantedDetails" roleURI="http://www.incyte.com/role/StockCompensationValuationassumptionsusedforvalueofstockcompensationgrantedDetails">
        <link:definition>0000060 - Disclosure - Stock Compensation - Valuation assumptions used for value of stock compensation granted (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockCompensationOptionactivityunderthe2010stockplanDetails" roleURI="http://www.incyte.com/role/StockCompensationOptionactivityunderthe2010stockplanDetails">
        <link:definition>0000061 - Disclosure - Stock Compensation - Option activity under the 2010 stock plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockCompensationRSUawardandPSUactivityunderthe2010stockplanDetails" roleURI="http://www.incyte.com/role/StockCompensationRSUawardandPSUactivityunderthe2010stockplanDetails">
        <link:definition>0000062 - Disclosure - Stock Compensation - RSU award and PSU activity under the 2010 stock plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockCompensationSharesavailableforgrantDetails" roleURI="http://www.incyte.com/role/StockCompensationSharesavailableforgrantDetails">
        <link:definition>0000063 - Disclosure - Stock Compensation - Shares available for grant (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncometaxesDetails" roleURI="http://www.incyte.com/role/IncometaxesDetails">
        <link:definition>0000064 - Disclosure - Income taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomePerShareNetincomelosspershareDetails" roleURI="http://www.incyte.com/role/NetIncomePerShareNetincomelosspershareDetails">
        <link:definition>0000065 - Disclosure - Net Income Per Share - Net income (loss) per share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomePerShareAntidilutivesecuritiesDetails" roleURI="http://www.incyte.com/role/NetIncomePerShareAntidilutivesecuritiesDetails">
        <link:definition>0000066 - Disclosure - Net Income Per Share - Antidilutive securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlansNarrativeDetails" roleURI="http://www.incyte.com/role/EmployeeBenefitPlansNarrativeDetails">
        <link:definition>0000067 - Disclosure - Employee Benefit Plans - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitplansNetperiodicbenefitcostDetails" roleURI="http://www.incyte.com/role/EmployeeBenefitplansNetperiodicbenefitcostDetails">
        <link:definition>0000068 - Disclosure - Employee Benefit plans - Net periodic benefit cost (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEventsNarrativeDetails" roleURI="http://www.incyte.com/role/SubsequentEventsNarrativeDetails">
        <link:definition>0000069 - Disclosure - Subsequent Events - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="incy_CorporateAndGovernmentDebtSecuritiesMember" abstract="true" name="CorporateAndGovernmentDebtSecuritiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="incy_PercentageFundingOnCostOnPossibleElectionOfCodevelopmentOfCompounds" abstract="false" name="PercentageFundingOnCostOnPossibleElectionOfCodevelopmentOfCompounds" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="incy_CustomerBMember" abstract="true" name="CustomerBMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="incy_AmendedStockPurchaseAgreementMember" abstract="true" name="AmendedStockPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="incy_JakaviRoyaltyRevenuesMember" abstract="true" name="JakaviRoyaltyRevenuesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="incy_SchedulesOfConcentrationOfRiskByRiskFactorRelatedToCollaborativePartnersTableTextBlock" abstract="false" name="SchedulesOfConcentrationOfRiskByRiskFactorRelatedToCollaborativePartnersTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="incy_AccruedAndOtherCurrentLiabilityMember" abstract="true" name="AccruedAndOtherCurrentLiabilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="incy_TabrectaMember" abstract="true" name="TabrectaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="incy_MINJUVIMember" abstract="true" name="MINJUVIMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="incy_BuildingAndLeaseholdImprovementsMember" abstract="true" name="BuildingAndLeaseholdImprovementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="incy_CollaborationAgreementProfitLossSharingRatio" abstract="false" name="CollaborationAgreementProfitLossSharingRatio" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="incy_OpzeluraMember" abstract="true" name="OpzeluraMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="incy_LicenseAgreementNumberOfAdditionalPreclinicalDiscoveryPrograms" abstract="false" name="LicenseAgreementNumberOfAdditionalPreclinicalDiscoveryPrograms" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="incy_DevelopmentRegulatoryAndCommercializationMilestonesMember" abstract="true" name="DevelopmentRegulatoryAndCommercializationMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGranted" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGranted" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="incy_DevelopmentMilestonesMember" abstract="true" name="DevelopmentMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="incy_LicenseAgreementMilestoneOnNetSalesOfProduct" abstract="false" name="LicenseAgreementMilestoneOnNetSalesOfProduct" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="incy_TafasitamabMember" abstract="true" name="TafasitamabMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="incy_RegulatoryMilestonesMember" abstract="true" name="RegulatoryMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="incy_TafasitamabProductAndServiceMember" abstract="true" name="TafasitamabProductAndServiceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="incy_CommercializationMilestonesMember" abstract="true" name="CommercializationMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="incy_NovartisMember" abstract="true" name="NovartisMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="incy_ScheduleOfInventoryTableTextBlock" abstract="false" name="ScheduleOfInventoryTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="incy_LicenseAgreementUpfrontPaymentReceived" abstract="false" name="LicenseAgreementUpfrontPaymentReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="incy_OlumiantMember" abstract="true" name="OlumiantMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="incy_AgenusMember" abstract="true" name="AgenusMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="incy_StockIssuedDuringPeriodValueStockOptionsAndRestrictedStockUnitsExercisedAndEmployeeStockPurchasePlan" abstract="false" name="StockIssuedDuringPeriodValueStockOptionsAndRestrictedStockUnitsExercisedAndEmployeeStockPurchasePlan" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="incy_NumberOfProgramTargets" abstract="false" name="NumberOfProgramTargets" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="incy_PemazyreMember" abstract="true" name="PemazyreMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="incy_LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived" abstract="false" name="LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="incy_LicenseAgreementTerminationNoticePeriod" abstract="false" name="LicenseAgreementTerminationNoticePeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="incy_PaymentOfContingentConsideration" abstract="false" name="PaymentOfContingentConsideration" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="incy_OfficeBuildingMorgesSwitzerlandMember" abstract="true" name="OfficeBuildingMorgesSwitzerlandMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="incy_AmericanDepositarySharesMember" abstract="true" name="AmericanDepositarySharesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="incy_ScheduleOfShareBasedCompensationOtherThanStockOptionsActivityTableTextBlock" abstract="false" name="ScheduleOfShareBasedCompensationOtherThanStockOptionsActivityTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="incy_ProductGroupOneMember" abstract="true" name="ProductGroupOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="incy_LicenseAgreementMaximumNumberOfIndependentPrograms" abstract="false" name="LicenseAgreementMaximumNumberOfIndependentPrograms" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="incy_InnocarePharmaLimitedMember" abstract="true" name="InnocarePharmaLimitedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="incy_TabrectaRoyaltyRevenuesMember" abstract="true" name="TabrectaRoyaltyRevenuesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="incy_PeriodOfDeviationFromAverageCostOfGoodsSold" abstract="false" name="PeriodOfDeviationFromAverageCostOfGoodsSold" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="incy_FairValueInputsCashFlowsEstimatedPeriod" abstract="false" name="FairValueInputsCashFlowsEstimatedPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="incy_NimbleMember" abstract="true" name="NimbleMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="incy_InventoryNetCurrentAndNoncurrent" abstract="false" name="InventoryNetCurrentAndNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="incy_InventoryRecordedAsResearchAndDevelopmentExpense" abstract="false" name="InventoryRecordedAsResearchAndDevelopmentExpense" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="incy_EquityMethodInvestmentSharesPurchased" abstract="false" name="EquityMethodInvestmentSharesPurchased" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="incy_DevelopmentAndRegulatoryMilestonesMember" abstract="true" name="DevelopmentAndRegulatoryMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="incy_CollaborationAndLicenseAgreementWithZaiLabLtdMember" abstract="true" name="CollaborationAndLicenseAgreementWithZaiLabLtdMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="incy_EliLillyMember" abstract="true" name="EliLillyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="incy_AchievementOfMilestoneAxis" abstract="true" name="AchievementOfMilestoneAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="incy_SyrosPharmaceuticalsIncMember" abstract="true" name="SyrosPharmaceuticalsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="incy_FinanceLeaseLeaseIncentiveReceivable" abstract="false" name="FinanceLeaseLeaseIncentiveReceivable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="incy_AggregateConcentrationCustomersMember" abstract="true" name="AggregateConcentrationCustomersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="incy_InnoventBiologicsIncMember" abstract="true" name="InnoventBiologicsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="incy_PercentageOfRoyaltyRatePayments" abstract="false" name="PercentageOfRoyaltyRatePayments" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="incy_ProductGroupTwoMember" abstract="true" name="ProductGroupTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="incy_CalitheraBiosciencesIncMember" abstract="true" name="CalitheraBiosciencesIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="incy_LicenseAgreementsTextBlock" abstract="false" name="LicenseAgreementsTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="incy_VillarisMember" abstract="true" name="VillarisMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="incy_ScheduleOfShareBasedPaymentAwardStockOptionsAndEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" abstract="false" name="ScheduleOfShareBasedPaymentAwardStockOptionsAndEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="incy_MacrogenicsMember" abstract="true" name="MacrogenicsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="incy_LicenseAgreementPercentageOfFutureGlobalDevelopmentCostsFunded" abstract="false" name="LicenseAgreementPercentageOfFutureGlobalDevelopmentCostsFunded" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="incy_LicenseAgreementsDisclosureAbstract" abstract="true" name="LicenseAgreementsDisclosureAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="incy_LicenseAgreementUpfrontPaymentAmountPaid" abstract="false" name="LicenseAgreementUpfrontPaymentAmountPaid" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="incy_OperatingLeaseRightOfUseAssetsMember" abstract="true" name="OperatingLeaseRightOfUseAssetsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="incy_CustomerCMember" abstract="true" name="CustomerCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="incy_PurchaseOfCommonStockUnderStockPurchaseAgreementInShares" abstract="false" name="PurchaseOfCommonStockUnderStockPurchaseAgreementInShares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="incy_NumberOfProgramsUnderWhichResultingProductsAreCoFundedForDevelopment" abstract="false" name="NumberOfProgramsUnderWhichResultingProductsAreCoFundedForDevelopment" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="incy_OfficeBuildingWilmingtonDelawareMember" abstract="true" name="OfficeBuildingWilmingtonDelawareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCanceled" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCanceled" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="incy_InvestmentInSyndaxPharmaceuticalsIncMember" abstract="true" name="InvestmentInSyndaxPharmaceuticalsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="incy_LandLocatedWithinYParcSwitzerlandsLargestTechnologyParkInYverdonMember" abstract="true" name="LandLocatedWithinYParcSwitzerlandsLargestTechnologyParkInYverdonMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="incy_AchievementOfMilestoneDomain" abstract="true" name="AchievementOfMilestoneDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="incy_SyndaxPharmaceuticalsIncMember" abstract="true" name="SyndaxPharmaceuticalsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="incy_CustomerEMember" abstract="true" name="CustomerEMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="incy_StockPurchaseAgreementMember" abstract="true" name="StockPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="incy_MorphosysAgMember" abstract="true" name="MorphosysAgMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="incy_AriadPharmaceuticalsMember" abstract="true" name="AriadPharmaceuticalsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedIntrinsicValue" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedIntrinsicValue" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="incy_LicenseAgreementTargetSelectionAndOptionExerciseFeePayments" abstract="false" name="LicenseAgreementTargetSelectionAndOptionExerciseFeePayments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="incy_PreSeptember2022StockSplitSharesMember" abstract="true" name="PreSeptember2022StockSplitSharesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="incy_CustomerAMember" abstract="true" name="CustomerAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesPerRestrictedStockUnits" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesPerRestrictedStockUnits" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="incy_JakaviMember" abstract="true" name="JakaviMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="incy_ICLUSIGMember" abstract="true" name="ICLUSIGMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="incy_OlumiantRoyaltyMember" abstract="true" name="OlumiantRoyaltyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedAnnualizedForfeitureRate" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedAnnualizedForfeitureRate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="incy_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityConsiderationEarned" abstract="false" name="BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityConsiderationEarned" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="incy_JAKAFIMember" abstract="true" name="JAKAFIMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="incy_SubsidiaryStockConversionRatio" abstract="false" name="SubsidiaryStockConversionRatio" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="incy_LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone" abstract="false" name="LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="incy_RoyaltiesPayable" abstract="false" name="RoyaltiesPayable" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="incy_AccruedClinicalRelatedCostsCurrent" abstract="false" name="AccruedClinicalRelatedCostsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="incy_GvhdMember" abstract="true" name="GvhdMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="incy_CollaborationPartnersaBCAndDMember" abstract="true" name="CollaborationPartnersaBCAndDMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="incy_CustomerDMember" abstract="true" name="CustomerDMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="incy_TABRECTAPRODUCTANDSERVICESMember" abstract="true" name="TABRECTAPRODUCTANDSERVICESMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="incy_MerusNVMember" abstract="true" name="MerusNVMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="incy_LicenseAgreementAdditionalMilestonePayments" abstract="false" name="LicenseAgreementAdditionalMilestonePayments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="incy_MilestoneRevenueMember" abstract="true" name="MilestoneRevenueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="incy_MilestoneAndContractRevenueMember" abstract="true" name="MilestoneAndContractRevenueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="incy_CollaborationLossSharingExpense" abstract="false" name="CollaborationLossSharingExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="incy_PercentageOfProfitsLosses" abstract="false" name="PercentageOfProfitsLosses" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="incy_CollaborationAgreementProfitSharingPercentage" abstract="false" name="CollaborationAgreementProfitSharingPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="incy_IncyteMember" abstract="true" name="IncyteMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="incy_LicenseAgreementMilestonePaymentAmountPaid" abstract="false" name="LicenseAgreementMilestonePaymentAmountPaid" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="incy_FutureContingentDiscoveryMilestoneMember" abstract="true" name="FutureContingentDiscoveryMilestoneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>incy-20220930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:4b736358-c29a-4c12-bfe7-729e80c7c631,g:94be2257-4ebc-4637-90cb-08232abb2695-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.incyte.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="incy-20220930.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://www.incyte.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_788ad4ee-eeac-4333-b986-a3c30c66ddb5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_3b3570df-b06d-41ec-9f67-0927a87ec08b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_788ad4ee-eeac-4333-b986-a3c30c66ddb5" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_3b3570df-b06d-41ec-9f67-0927a87ec08b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_47c65465-500a-4445-9de0-f9bd4468c688" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_788ad4ee-eeac-4333-b986-a3c30c66ddb5" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_47c65465-500a-4445-9de0-f9bd4468c688" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNet_1a943f77-87cb-4b2d-82f5-93899f3f1555" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_788ad4ee-eeac-4333-b986-a3c30c66ddb5" xlink:to="loc_us-gaap_AccountsReceivableNet_1a943f77-87cb-4b2d-82f5-93899f3f1555" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_a602eede-3aa5-4565-984b-5f3f7dc37f66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_788ad4ee-eeac-4333-b986-a3c30c66ddb5" xlink:to="loc_us-gaap_InventoryNet_a602eede-3aa5-4565-984b-5f3f7dc37f66" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_fe50378f-e4c3-4107-b551-da64a27e093f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_788ad4ee-eeac-4333-b986-a3c30c66ddb5" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_fe50378f-e4c3-4107-b551-da64a27e093f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_4a46a74e-4192-4c00-ba2d-d912c2f31e4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_be1e5bea-9c89-4d43-9de1-974fc659c43e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_4a46a74e-4192-4c00-ba2d-d912c2f31e4a" xlink:to="loc_us-gaap_Liabilities_be1e5bea-9c89-4d43-9de1-974fc659c43e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_82dc6e6c-8866-4e42-8ae0-fa2fc49067ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_4a46a74e-4192-4c00-ba2d-d912c2f31e4a" xlink:to="loc_us-gaap_StockholdersEquity_82dc6e6c-8866-4e42-8ae0-fa2fc49067ce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_d31754f6-12fb-4aeb-b9ce-f16932d2af8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_207c89a6-103a-4092-a458-fc5ee935919e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_d31754f6-12fb-4aeb-b9ce-f16932d2af8d" xlink:to="loc_us-gaap_CommitmentsAndContingencies_207c89a6-103a-4092-a458-fc5ee935919e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_4a871bf0-4a00-4f04-9f81-3d46dcc5c058" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_d31754f6-12fb-4aeb-b9ce-f16932d2af8d" xlink:to="loc_us-gaap_PreferredStockValue_4a871bf0-4a00-4f04-9f81-3d46dcc5c058" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_bf31bc19-8690-48e2-aea1-4778810789d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_d31754f6-12fb-4aeb-b9ce-f16932d2af8d" xlink:to="loc_us-gaap_CommonStockValue_bf31bc19-8690-48e2-aea1-4778810789d8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_854d58a2-e140-4cab-a435-2697c8155503" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_d31754f6-12fb-4aeb-b9ce-f16932d2af8d" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_854d58a2-e140-4cab-a435-2697c8155503" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_15da44b0-05ff-464b-b0e6-f8deeb4042de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_d31754f6-12fb-4aeb-b9ce-f16932d2af8d" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_15da44b0-05ff-464b-b0e6-f8deeb4042de" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_9acdc074-f898-43cd-92a1-c4e07ac2c075" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_d31754f6-12fb-4aeb-b9ce-f16932d2af8d" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_9acdc074-f898-43cd-92a1-c4e07ac2c075" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_ccf113dc-5bad-403e-949f-7c7c624d6d19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_bbc77050-86e6-4b44-9bba-3294ce794368" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_ccf113dc-5bad-403e-949f-7c7c624d6d19" xlink:to="loc_us-gaap_AccountsPayableCurrent_bbc77050-86e6-4b44-9bba-3294ce794368" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_cc8bfb7b-7258-4bbe-9bde-57359af2982d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_ccf113dc-5bad-403e-949f-7c7c624d6d19" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_cc8bfb7b-7258-4bbe-9bde-57359af2982d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_017f0af0-4cd1-43e9-8f19-9f4882cc55f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_ccf113dc-5bad-403e-949f-7c7c624d6d19" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_017f0af0-4cd1-43e9-8f19-9f4882cc55f1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_04fb398e-28ea-47d0-ac33-428b609a516f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_ccf113dc-5bad-403e-949f-7c7c624d6d19" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_04fb398e-28ea-47d0-ac33-428b609a516f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_529a5918-357e-4920-9c5e-4fa0ea5ff9b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_ccf113dc-5bad-403e-949f-7c7c624d6d19" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_529a5918-357e-4920-9c5e-4fa0ea5ff9b3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_d4d98b9b-fef0-45a8-9e44-0feee1cd4fcd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_a69f731b-5119-4caf-b6d7-9c33cb4995d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_d4d98b9b-fef0-45a8-9e44-0feee1cd4fcd" xlink:to="loc_us-gaap_AssetsCurrent_a69f731b-5119-4caf-b6d7-9c33cb4995d2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndInvestmentsNoncurrent_0a19d132-5180-4e32-9a74-eba9286e7663" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndInvestmentsNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_d4d98b9b-fef0-45a8-9e44-0feee1cd4fcd" xlink:to="loc_us-gaap_RestrictedCashAndInvestmentsNoncurrent_0a19d132-5180-4e32-9a74-eba9286e7663" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments_9612ef51-1ca2-4925-ba95-c45da12c829c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermInvestments"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_d4d98b9b-fef0-45a8-9e44-0feee1cd4fcd" xlink:to="loc_us-gaap_LongTermInvestments_9612ef51-1ca2-4925-ba95-c45da12c829c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent_be403572-d31a-46c5-b7f2-45f90499f34c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_d4d98b9b-fef0-45a8-9e44-0feee1cd4fcd" xlink:to="loc_us-gaap_InventoryNoncurrent_be403572-d31a-46c5-b7f2-45f90499f34c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_40ec4640-85cd-4b85-a62b-5fe8e9a58e06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_d4d98b9b-fef0-45a8-9e44-0feee1cd4fcd" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_40ec4640-85cd-4b85-a62b-5fe8e9a58e06" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset_f8b78788-c657-4f18-bdfd-6397a29c294e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_d4d98b9b-fef0-45a8-9e44-0feee1cd4fcd" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAsset_f8b78788-c657-4f18-bdfd-6397a29c294e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsNet_15adedae-3d03-4938-8e5f-362509c3d486" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIntangibleAssetsNet"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_d4d98b9b-fef0-45a8-9e44-0feee1cd4fcd" xlink:to="loc_us-gaap_OtherIntangibleAssetsNet_15adedae-3d03-4938-8e5f-362509c3d486" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_6ddfce69-7d6c-4046-95fe-7a9b25c3d280" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_d4d98b9b-fef0-45a8-9e44-0feee1cd4fcd" xlink:to="loc_us-gaap_Goodwill_6ddfce69-7d6c-4046-95fe-7a9b25c3d280" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_80f51b9b-1a22-4fcf-992b-6a4561d3f193" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_d4d98b9b-fef0-45a8-9e44-0feee1cd4fcd" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_80f51b9b-1a22-4fcf-992b-6a4561d3f193" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_b40ac4a8-6f1a-432b-8c6b-434726c220d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_d4d98b9b-fef0-45a8-9e44-0feee1cd4fcd" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_b40ac4a8-6f1a-432b-8c6b-434726c220d0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_b142cbe8-b26a-4947-a13f-6976978791c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_1563484c-0958-44ba-b1d8-5d4110a17448" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_b142cbe8-b26a-4947-a13f-6976978791c7" xlink:to="loc_us-gaap_LiabilitiesCurrent_1563484c-0958-44ba-b1d8-5d4110a17448" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_fbeccb71-6b0a-4249-a818-8d4803ca6cf2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_b142cbe8-b26a-4947-a13f-6976978791c7" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_fbeccb71-6b0a-4249-a818-8d4803ca6cf2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_37627a88-434a-4e99-8b1f-bdf81572398f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_b142cbe8-b26a-4947-a13f-6976978791c7" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_37627a88-434a-4e99-8b1f-bdf81572398f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_c896b7a5-88f0-47f3-9541-21acd4198cc9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_b142cbe8-b26a-4947-a13f-6976978791c7" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_c896b7a5-88f0-47f3-9541-21acd4198cc9" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.incyte.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="incy-20220930.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:calculationLink xlink:role="http://www.incyte.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_427f46c3-f189-4755-b369-f9a07482c133" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_53dd84f1-7d34-42b7-83ef-74d27f90c15b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_427f46c3-f189-4755-b369-f9a07482c133" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_53dd84f1-7d34-42b7-83ef-74d27f90c15b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_ce6a3719-feb2-4d06-89c5-6758251a31de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_427f46c3-f189-4755-b369-f9a07482c133" xlink:to="loc_us-gaap_CostsAndExpenses_ce6a3719-feb2-4d06-89c5-6758251a31de" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_98f68af5-bbc9-46c2-9940-ecf4e2a241eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_6f7ba0fd-8a08-453a-96b4-a4b9803cf965" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_98f68af5-bbc9-46c2-9940-ecf4e2a241eb" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_6f7ba0fd-8a08-453a-96b4-a4b9803cf965" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_41524a3e-b55a-4bd1-abaa-68d85cd3091a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_98f68af5-bbc9-46c2-9940-ecf4e2a241eb" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_41524a3e-b55a-4bd1-abaa-68d85cd3091a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_dc326f12-e426-412f-8f0b-95da153b6678" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue_94575206-1fd0-47b0-9a34-368719125eb4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfRevenue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_dc326f12-e426-412f-8f0b-95da153b6678" xlink:to="loc_us-gaap_CostOfRevenue_94575206-1fd0-47b0-9a34-368719125eb4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_9dfec9dd-1920-4115-a449-ef2e8696456a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_dc326f12-e426-412f-8f0b-95da153b6678" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_9dfec9dd-1920-4115-a449-ef2e8696456a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_9dc196df-a6e3-4673-bb03-c75b0ef96176" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_dc326f12-e426-412f-8f0b-95da153b6678" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_9dc196df-a6e3-4673-bb03-c75b0ef96176" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_f7a02454-e047-49b8-98c8-0278970f0da1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_dc326f12-e426-412f-8f0b-95da153b6678" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_f7a02454-e047-49b8-98c8-0278970f0da1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_CollaborationLossSharingExpense_d3297e12-e96f-417c-9359-35284e4c1622" xlink:href="incy-20220930.xsd#incy_CollaborationLossSharingExpense"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_dc326f12-e426-412f-8f0b-95da153b6678" xlink:to="loc_incy_CollaborationLossSharingExpense_d3297e12-e96f-417c-9359-35284e4c1622" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7c4f8c68-e814-4eaa-ba75-8a7f72f72127" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_1a60dce8-7815-478e-80ae-a2cda5cceb1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7c4f8c68-e814-4eaa-ba75-8a7f72f72127" xlink:to="loc_us-gaap_OperatingIncomeLoss_1a60dce8-7815-478e-80ae-a2cda5cceb1b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_3ea04210-960c-44c0-ae62-5e96b85dca5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7c4f8c68-e814-4eaa-ba75-8a7f72f72127" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_3ea04210-960c-44c0-ae62-5e96b85dca5e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_fccfb24f-29bc-4bc8-996f-9cd36a387cc2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7c4f8c68-e814-4eaa-ba75-8a7f72f72127" xlink:to="loc_us-gaap_InterestExpense_fccfb24f-29bc-4bc8-996f-9cd36a387cc2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_3a4c5a0a-6bd5-466a-90a7-87850355bd03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7c4f8c68-e814-4eaa-ba75-8a7f72f72127" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_3a4c5a0a-6bd5-466a-90a7-87850355bd03" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.incyte.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" xlink:type="simple" xlink:href="incy-20220930.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"/>
  <link:calculationLink xlink:role="http://www.incyte.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_b776edb3-b865-44b0-a976-f45513dd8e85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_8b616a26-e675-4bd6-b043-e4ec8d601b08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_b776edb3-b865-44b0-a976-f45513dd8e85" xlink:to="loc_us-gaap_NetIncomeLoss_8b616a26-e675-4bd6-b043-e4ec8d601b08" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_809a310c-2ff8-479e-af1d-c9b2556edc36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_b776edb3-b865-44b0-a976-f45513dd8e85" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_809a310c-2ff8-479e-af1d-c9b2556edc36" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_4af4fadf-b2b4-45cc-ad88-1b2fc0eaece1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_46034cf6-a245-48dd-b899-d92ab5a03c37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_4af4fadf-b2b4-45cc-ad88-1b2fc0eaece1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_46034cf6-a245-48dd-b899-d92ab5a03c37" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_8674eb0e-ae8f-4922-b6ef-40f386a10670" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_4af4fadf-b2b4-45cc-ad88-1b2fc0eaece1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_8674eb0e-ae8f-4922-b6ef-40f386a10670" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_054e195d-db28-467a-bfee-89dba942851d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_4af4fadf-b2b4-45cc-ad88-1b2fc0eaece1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_054e195d-db28-467a-bfee-89dba942851d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.incyte.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="incy-20220930.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://www.incyte.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0360452d-ba67-4e72-974e-f11439c2ce66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_7c0ea0a8-c8bb-4ea3-af17-73e67bf6ead8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0360452d-ba67-4e72-974e-f11439c2ce66" xlink:to="loc_us-gaap_ProfitLoss_7c0ea0a8-c8bb-4ea3-af17-73e67bf6ead8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_f170c7ff-17ee-4669-a2cc-4c65a172ab88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0360452d-ba67-4e72-974e-f11439c2ce66" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_f170c7ff-17ee-4669-a2cc-4c65a172ab88" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_ffd943fc-382f-46c9-a9f8-b6eeeaf384a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0360452d-ba67-4e72-974e-f11439c2ce66" xlink:to="loc_us-gaap_ShareBasedCompensation_ffd943fc-382f-46c9-a9f8-b6eeeaf384a4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_e49461a3-7480-4ddd-b923-5692a933ae0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0360452d-ba67-4e72-974e-f11439c2ce66" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_e49461a3-7480-4ddd-b923-5692a933ae0b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_c6cbf57b-2790-4cf6-b919-1907e7aed363" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0360452d-ba67-4e72-974e-f11439c2ce66" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_c6cbf57b-2790-4cf6-b919-1907e7aed363" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_1cba82dc-df5f-42a9-a443-3b51da173132" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0360452d-ba67-4e72-974e-f11439c2ce66" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_1cba82dc-df5f-42a9-a443-3b51da173132" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_e6aba2d0-4b6a-485e-9988-03a199504d8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0360452d-ba67-4e72-974e-f11439c2ce66" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_e6aba2d0-4b6a-485e-9988-03a199504d8a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_b260c2aa-d90c-4ce0-a7ff-53c607d50409" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0360452d-ba67-4e72-974e-f11439c2ce66" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_b260c2aa-d90c-4ce0-a7ff-53c607d50409" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_a449e76d-1abe-4ea7-88d2-205fc25d9d13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0360452d-ba67-4e72-974e-f11439c2ce66" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_a449e76d-1abe-4ea7-88d2-205fc25d9d13" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_9c7e59a8-6f66-4d2c-a3e8-50aa10f17f4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0360452d-ba67-4e72-974e-f11439c2ce66" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_9c7e59a8-6f66-4d2c-a3e8-50aa10f17f4b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_536844d3-67c9-4d3a-8918-985fe5ae457a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0360452d-ba67-4e72-974e-f11439c2ce66" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_536844d3-67c9-4d3a-8918-985fe5ae457a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_a241c171-1511-4e09-b388-8e10602b30c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0360452d-ba67-4e72-974e-f11439c2ce66" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_a241c171-1511-4e09-b388-8e10602b30c6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_78170309-2d08-47e4-8e68-fe803977b2cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireLongtermInvestments_c3f1a298-ed36-45e1-b323-26193b8fcd8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireLongtermInvestments"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_78170309-2d08-47e4-8e68-fe803977b2cd" xlink:to="loc_us-gaap_PaymentsToAcquireLongtermInvestments_c3f1a298-ed36-45e1-b323-26193b8fcd8b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfLongtermInvestments_d301893f-da31-459a-8546-44b540765e8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfLongtermInvestments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_78170309-2d08-47e4-8e68-fe803977b2cd" xlink:to="loc_us-gaap_ProceedsFromSaleOfLongtermInvestments_d301893f-da31-459a-8546-44b540765e8d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets_84d5f291-ce6d-4d78-b4ea-7cd73e5e353e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireProductiveAssets"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_78170309-2d08-47e4-8e68-fe803977b2cd" xlink:to="loc_us-gaap_PaymentsToAcquireProductiveAssets_84d5f291-ce6d-4d78-b4ea-7cd73e5e353e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_83686854-c028-4202-bbe5-afb513901198" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_78170309-2d08-47e4-8e68-fe803977b2cd" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_83686854-c028-4202-bbe5-afb513901198" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_21278fc2-0c7f-4552-8558-a3e1ccdd035c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_78170309-2d08-47e4-8e68-fe803977b2cd" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_21278fc2-0c7f-4552-8558-a3e1ccdd035c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a6ed7cae-cd7a-4fb5-b511-b4e3b7f91fb5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans_bb960ef7-33a8-42ef-9068-aae04cbbda7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a6ed7cae-cd7a-4fb5-b511-b4e3b7f91fb5" xlink:to="loc_us-gaap_ProceedsFromStockPlans_bb960ef7-33a8-42ef-9068-aae04cbbda7b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_0c4b9a87-dad9-4148-ae69-79b0411fbaa0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a6ed7cae-cd7a-4fb5-b511-b4e3b7f91fb5" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_0c4b9a87-dad9-4148-ae69-79b0411fbaa0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_6cbd3141-ece2-427f-875c-b4b674aec540" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a6ed7cae-cd7a-4fb5-b511-b4e3b7f91fb5" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_6cbd3141-ece2-427f-875c-b4b674aec540" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_PaymentOfContingentConsideration_a181eac5-8873-412e-a419-71c5544566a4" xlink:href="incy-20220930.xsd#incy_PaymentOfContingentConsideration"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a6ed7cae-cd7a-4fb5-b511-b4e3b7f91fb5" xlink:to="loc_incy_PaymentOfContingentConsideration_a181eac5-8873-412e-a419-71c5544566a4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_75696370-3bec-4349-9d27-850716737c4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_787ed3dc-43c4-42be-86f1-be25fd10eec8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_75696370-3bec-4349-9d27-850716737c4b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_787ed3dc-43c4-42be-86f1-be25fd10eec8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_97f0417a-8f03-41d2-b4e6-1e2d80c688d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_75696370-3bec-4349-9d27-850716737c4b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_97f0417a-8f03-41d2-b4e6-1e2d80c688d1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_cddfc50b-ea4f-4a6f-8f77-c0cdc19def2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_75696370-3bec-4349-9d27-850716737c4b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_cddfc50b-ea4f-4a6f-8f77-c0cdc19def2d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_37bc3ccf-aa95-44c3-885f-ebac00f71fe4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_75696370-3bec-4349-9d27-850716737c4b" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_37bc3ccf-aa95-44c3-885f-ebac00f71fe4" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.incyte.com/role/FairValueofFinancialInstrumentsMarketablesecuritiesportfolioDetails" xlink:type="simple" xlink:href="incy-20220930.xsd#FairValueofFinancialInstrumentsMarketablesecuritiesportfolioDetails"/>
  <link:calculationLink xlink:role="http://www.incyte.com/role/FairValueofFinancialInstrumentsMarketablesecuritiesportfolioDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_92fcca07-2ccb-43cd-9651-2d1fca7ff706" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_2592bd99-0fd9-438c-9e0b-243c93aa9bd0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_92fcca07-2ccb-43cd-9651-2d1fca7ff706" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_2592bd99-0fd9-438c-9e0b-243c93aa9bd0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax_195e3cd2-778f-4530-82e0-44f63f85e895" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_92fcca07-2ccb-43cd-9651-2d1fca7ff706" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax_195e3cd2-778f-4530-82e0-44f63f85e895" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.incyte.com/role/FairValueofFinancialInstrumentsAssetsmeasuredonarecurringbasisDetails" xlink:type="simple" xlink:href="incy-20220930.xsd#FairValueofFinancialInstrumentsAssetsmeasuredonarecurringbasisDetails"/>
  <link:calculationLink xlink:role="http://www.incyte.com/role/FairValueofFinancialInstrumentsAssetsmeasuredonarecurringbasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_6a0c7d18-dcbf-4d3d-843b-f2df48737b52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_ec423f62-0bd8-4f39-be41-a01924f3a5d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_6a0c7d18-dcbf-4d3d-843b-f2df48737b52" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_ec423f62-0bd8-4f39-be41-a01924f3a5d5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_d3c05ef7-3a40-49e2-8908-988a5fdf1214" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_6a0c7d18-dcbf-4d3d-843b-f2df48737b52" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_d3c05ef7-3a40-49e2-8908-988a5fdf1214" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments_75e237b6-3176-40ee-a9c4-537af775d551" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermInvestments"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_6a0c7d18-dcbf-4d3d-843b-f2df48737b52" xlink:to="loc_us-gaap_LongTermInvestments_75e237b6-3176-40ee-a9c4-537af775d551" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.incyte.com/role/FairValueofFinancialInstrumentsLiabilitiesmeasuredonarecurringbasisDetails" xlink:type="simple" xlink:href="incy-20220930.xsd#FairValueofFinancialInstrumentsLiabilitiesmeasuredonarecurringbasisDetails"/>
  <link:calculationLink xlink:role="http://www.incyte.com/role/FairValueofFinancialInstrumentsLiabilitiesmeasuredonarecurringbasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_b2be85fb-03ea-4860-aff7-127664bead44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_0f9278e5-a833-4d5a-9b9b-2dc1e2b60fba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_b2be85fb-03ea-4860-aff7-127664bead44" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_0f9278e5-a833-4d5a-9b9b-2dc1e2b60fba" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.incyte.com/role/InventoryDetails" xlink:type="simple" xlink:href="incy-20220930.xsd#InventoryDetails"/>
  <link:calculationLink xlink:role="http://www.incyte.com/role/InventoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_incy_InventoryNetCurrentAndNoncurrent_b98fb719-15a7-425d-8a8a-100fdfe2531c" xlink:href="incy-20220930.xsd#incy_InventoryNetCurrentAndNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_44033e05-6cca-4553-909b-b3178ca94ace" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_incy_InventoryNetCurrentAndNoncurrent_b98fb719-15a7-425d-8a8a-100fdfe2531c" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_44033e05-6cca-4553-909b-b3178ca94ace" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_3c4a1e47-789d-4fba-9e00-f7f250394101" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_incy_InventoryNetCurrentAndNoncurrent_b98fb719-15a7-425d-8a8a-100fdfe2531c" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_3c4a1e47-789d-4fba-9e00-f7f250394101" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_8106a6ab-d04e-4a23-b452-0e2dde1a0d79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_incy_InventoryNetCurrentAndNoncurrent_b98fb719-15a7-425d-8a8a-100fdfe2531c" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_8106a6ab-d04e-4a23-b452-0e2dde1a0d79" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.incyte.com/role/PropertyandEquipmentnetPropertyandequipmentnetDetails" xlink:type="simple" xlink:href="incy-20220930.xsd#PropertyandEquipmentnetPropertyandequipmentnetDetails"/>
  <link:calculationLink xlink:role="http://www.incyte.com/role/PropertyandEquipmentnetPropertyandequipmentnetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_e77fba72-58ac-4dab-8abf-1933ea27d6b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_82c2bd6d-773b-4e0e-bf9b-f9179045cf12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_e77fba72-58ac-4dab-8abf-1933ea27d6b8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_82c2bd6d-773b-4e0e-bf9b-f9179045cf12" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_538b08b3-857d-4d77-a6d6-dd544da56462" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_e77fba72-58ac-4dab-8abf-1933ea27d6b8" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_538b08b3-857d-4d77-a6d6-dd544da56462" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.incyte.com/role/AccruedandOtherCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="incy-20220930.xsd#AccruedandOtherCurrentLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.incyte.com/role/AccruedandOtherCurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_1aeac593-78e0-41bf-aa60-4fadd3e68fde" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent_590f86c8-f14d-4ad7-9c7f-ce0461427309" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedRoyaltiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_1aeac593-78e0-41bf-aa60-4fadd3e68fde" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrent_590f86c8-f14d-4ad7-9c7f-ce0461427309" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_AccruedClinicalRelatedCostsCurrent_22398970-b299-4bd7-b71f-9a279c03fb21" xlink:href="incy-20220930.xsd#incy_AccruedClinicalRelatedCostsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_1aeac593-78e0-41bf-aa60-4fadd3e68fde" xlink:to="loc_incy_AccruedClinicalRelatedCostsCurrent_22398970-b299-4bd7-b71f-9a279c03fb21" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForLossOnContracts_84d670a2-6abb-46de-badb-2cfe3b8a1536" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForLossOnContracts"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_1aeac593-78e0-41bf-aa60-4fadd3e68fde" xlink:to="loc_us-gaap_ProvisionForLossOnContracts_84d670a2-6abb-46de-badb-2cfe3b8a1536" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedMarketingCostsCurrent_7e1c86d7-4945-4f3f-8e7d-dfc842e9b37d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedMarketingCostsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_1aeac593-78e0-41bf-aa60-4fadd3e68fde" xlink:to="loc_us-gaap_AccruedMarketingCostsCurrent_7e1c86d7-4945-4f3f-8e7d-dfc842e9b37d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionPayableCurrent_77a89714-c3fe-4f13-bdd1-55dc865e7472" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionPayableCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_1aeac593-78e0-41bf-aa60-4fadd3e68fde" xlink:to="loc_us-gaap_ConstructionPayableCurrent_77a89714-c3fe-4f13-bdd1-55dc865e7472" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_624c8ec2-fe9e-4cbb-86e3-cc87fd88957a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_1aeac593-78e0-41bf-aa60-4fadd3e68fde" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_624c8ec2-fe9e-4cbb-86e3-cc87fd88957a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_d937f096-e280-4a84-a4d8-ad666f4e8db2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_1aeac593-78e0-41bf-aa60-4fadd3e68fde" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_d937f096-e280-4a84-a4d8-ad666f4e8db2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.incyte.com/role/EmployeeBenefitplansNetperiodicbenefitcostDetails" xlink:type="simple" xlink:href="incy-20220930.xsd#EmployeeBenefitplansNetperiodicbenefitcostDetails"/>
  <link:calculationLink xlink:role="http://www.incyte.com/role/EmployeeBenefitplansNetperiodicbenefitcostDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_1cbb9abc-33de-43e0-bf28-85ab9e998328" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_5e54fa67-dfb2-421b-968d-fc1bfc817c09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_1cbb9abc-33de-43e0-bf28-85ab9e998328" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_5e54fa67-dfb2-421b-968d-fc1bfc817c09" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_545efb08-9ec3-420a-8b92-55653bfd3f5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_1cbb9abc-33de-43e0-bf28-85ab9e998328" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_545efb08-9ec3-420a-8b92-55653bfd3f5a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_c9a786e9-0cd0-4bc4-b6fc-af7e6484983c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_1cbb9abc-33de-43e0-bf28-85ab9e998328" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_c9a786e9-0cd0-4bc4-b6fc-af7e6484983c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActuarialGainLoss_c11ba9f0-fadb-4010-8479-7f8fd07371cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanActuarialGainLoss"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_1cbb9abc-33de-43e0-bf28-85ab9e998328" xlink:to="loc_us-gaap_DefinedBenefitPlanActuarialGainLoss_c11ba9f0-fadb-4010-8479-7f8fd07371cf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_e5285385-4fd1-4c54-89a0-290c25c3797c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_1cbb9abc-33de-43e0-bf28-85ab9e998328" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_e5285385-4fd1-4c54-89a0-290c25c3797c" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>incy-20220930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:4b736358-c29a-4c12-bfe7-729e80c7c631,g:94be2257-4ebc-4637-90cb-08232abb2695-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.incyte.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="incy-20220930.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:definitionLink xlink:role="http://www.incyte.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended" id="i8d621f57a7e14580a385ae0a3fa15bef_CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_3f835ea6-43db-4659-9aca-2f5e4d369094" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_8fd9a696-34c1-4869-ba76-43e30d66a7df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3f835ea6-43db-4659-9aca-2f5e4d369094" xlink:to="loc_us-gaap_RevenuesAbstract_8fd9a696-34c1-4869-ba76-43e30d66a7df" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_0623bbe5-afea-436a-bd5a-ce04b700e68f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_8fd9a696-34c1-4869-ba76-43e30d66a7df" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_0623bbe5-afea-436a-bd5a-ce04b700e68f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_39ce49de-bf25-4177-acc8-8d1f6a7c70c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3f835ea6-43db-4659-9aca-2f5e4d369094" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_39ce49de-bf25-4177-acc8-8d1f6a7c70c2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue_a79059a9-1180-47d5-8bf7-9f175b6bb36c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_39ce49de-bf25-4177-acc8-8d1f6a7c70c2" xlink:to="loc_us-gaap_CostOfRevenue_a79059a9-1180-47d5-8bf7-9f175b6bb36c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_97ef9964-111f-43f4-ba1f-f4f9b4111677" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_39ce49de-bf25-4177-acc8-8d1f6a7c70c2" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_97ef9964-111f-43f4-ba1f-f4f9b4111677" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_b3e42080-0edc-4f89-82de-bc79e0a6e537" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_39ce49de-bf25-4177-acc8-8d1f6a7c70c2" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_b3e42080-0edc-4f89-82de-bc79e0a6e537" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_ce3db27d-b50e-4866-8917-2dc1d264d5ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_39ce49de-bf25-4177-acc8-8d1f6a7c70c2" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_ce3db27d-b50e-4866-8917-2dc1d264d5ff" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_CollaborationLossSharingExpense_03691cb6-8680-4fb3-98a7-3354237f6485" xlink:href="incy-20220930.xsd#incy_CollaborationLossSharingExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_39ce49de-bf25-4177-acc8-8d1f6a7c70c2" xlink:to="loc_incy_CollaborationLossSharingExpense_03691cb6-8680-4fb3-98a7-3354237f6485" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_d6526bc9-f878-46f2-81db-7eb9a41ded85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_39ce49de-bf25-4177-acc8-8d1f6a7c70c2" xlink:to="loc_us-gaap_CostsAndExpenses_d6526bc9-f878-46f2-81db-7eb9a41ded85" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_cf0f7bde-80f0-4e90-9ce2-45318edb1a72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3f835ea6-43db-4659-9aca-2f5e4d369094" xlink:to="loc_us-gaap_OperatingIncomeLoss_cf0f7bde-80f0-4e90-9ce2-45318edb1a72" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_6a307fd4-58ad-438d-8b4e-cc2556fde619" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3f835ea6-43db-4659-9aca-2f5e4d369094" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_6a307fd4-58ad-438d-8b4e-cc2556fde619" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_168b1ad0-61f4-415f-af6b-979a1aa77856" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3f835ea6-43db-4659-9aca-2f5e4d369094" xlink:to="loc_us-gaap_InterestExpense_168b1ad0-61f4-415f-af6b-979a1aa77856" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_6fd20c77-70ea-4220-8b60-7c4b6edbe05c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3f835ea6-43db-4659-9aca-2f5e4d369094" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_6fd20c77-70ea-4220-8b60-7c4b6edbe05c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_c0bc8e0d-762e-4dae-91ba-ffb014ec3c13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3f835ea6-43db-4659-9aca-2f5e4d369094" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_c0bc8e0d-762e-4dae-91ba-ffb014ec3c13" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_0cdf8ed2-9e9a-4189-a5c4-b4d052fc429a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3f835ea6-43db-4659-9aca-2f5e4d369094" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_0cdf8ed2-9e9a-4189-a5c4-b4d052fc429a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_41da1552-fa73-43f5-afde-4f6586073d74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3f835ea6-43db-4659-9aca-2f5e4d369094" xlink:to="loc_us-gaap_NetIncomeLoss_41da1552-fa73-43f5-afde-4f6586073d74" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_4ad5e8cc-7ca2-424f-90dc-7c6fbca1a341" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3f835ea6-43db-4659-9aca-2f5e4d369094" xlink:to="loc_us-gaap_EarningsPerShareAbstract_4ad5e8cc-7ca2-424f-90dc-7c6fbca1a341" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_3a696d53-98e7-421f-a3b0-766c4f92d31c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_4ad5e8cc-7ca2-424f-90dc-7c6fbca1a341" xlink:to="loc_us-gaap_EarningsPerShareBasic_3a696d53-98e7-421f-a3b0-766c4f92d31c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_c314d313-51a7-469b-8280-c878bdf340d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_4ad5e8cc-7ca2-424f-90dc-7c6fbca1a341" xlink:to="loc_us-gaap_EarningsPerShareDiluted_c314d313-51a7-469b-8280-c878bdf340d7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_2ce33b12-a4cf-4135-9cb0-6b717f470a8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3f835ea6-43db-4659-9aca-2f5e4d369094" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_2ce33b12-a4cf-4135-9cb0-6b717f470a8c" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_75acc23f-ab04-4421-938b-bf06325da53b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_2ce33b12-a4cf-4135-9cb0-6b717f470a8c" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_75acc23f-ab04-4421-938b-bf06325da53b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_63c964a0-28d3-4b70-999b-7a0067551a69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_2ce33b12-a4cf-4135-9cb0-6b717f470a8c" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_63c964a0-28d3-4b70-999b-7a0067551a69" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_7453cee5-7838-4ab2-9f90-e306f901da87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_3f835ea6-43db-4659-9aca-2f5e4d369094" xlink:to="loc_us-gaap_StatementTable_7453cee5-7838-4ab2-9f90-e306f901da87" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_1e53b431-7831-4617-820e-0d8397046a6c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_7453cee5-7838-4ab2-9f90-e306f901da87" xlink:to="loc_srt_ProductOrServiceAxis_1e53b431-7831-4617-820e-0d8397046a6c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_1e53b431-7831-4617-820e-0d8397046a6c_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_1e53b431-7831-4617-820e-0d8397046a6c" xlink:to="loc_srt_ProductsAndServicesDomain_1e53b431-7831-4617-820e-0d8397046a6c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_03bbb0f3-e415-47f7-a359-e5343f623bda" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_1e53b431-7831-4617-820e-0d8397046a6c" xlink:to="loc_srt_ProductsAndServicesDomain_03bbb0f3-e415-47f7-a359-e5343f623bda" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_fae63add-7555-422f-9fb7-20ede28d207a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_03bbb0f3-e415-47f7-a359-e5343f623bda" xlink:to="loc_us-gaap_ProductMember_fae63add-7555-422f-9fb7-20ede28d207a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_48f60bf7-16b7-4556-b6ed-db90fb72870e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_03bbb0f3-e415-47f7-a359-e5343f623bda" xlink:to="loc_us-gaap_RoyaltyMember_48f60bf7-16b7-4556-b6ed-db90fb72870e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_MilestoneRevenueMember_2ccef12a-4501-4837-a8f4-01d23255b3b7" xlink:href="incy-20220930.xsd#incy_MilestoneRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_03bbb0f3-e415-47f7-a359-e5343f623bda" xlink:to="loc_incy_MilestoneRevenueMember_2ccef12a-4501-4837-a8f4-01d23255b3b7" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.incyte.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="incy-20220930.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"/>
  <link:definitionLink xlink:role="http://www.incyte.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="extended" id="iaa24bdc8ac97445d905af378e460f3b0_CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_ee715633-9591-4ef5-a632-6cf4c4a21a37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ae8d21f2-ca6f-42ec-a5c6-eda9cc96776a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ee715633-9591-4ef5-a632-6cf4c4a21a37" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ae8d21f2-ca6f-42ec-a5c6-eda9cc96776a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_71919a70-5e49-4702-8318-7f988e78e270" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ae8d21f2-ca6f-42ec-a5c6-eda9cc96776a" xlink:to="loc_us-gaap_StockholdersEquity_71919a70-5e49-4702-8318-7f988e78e270" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_3372da0c-4376-497c-a3bc-2feaca9b4d55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ae8d21f2-ca6f-42ec-a5c6-eda9cc96776a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_3372da0c-4376-497c-a3bc-2feaca9b4d55" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_StockIssuedDuringPeriodValueStockOptionsAndRestrictedStockUnitsExercisedAndEmployeeStockPurchasePlan_188f25ca-b7d9-4311-9298-bfdd1ed1c07c" xlink:href="incy-20220930.xsd#incy_StockIssuedDuringPeriodValueStockOptionsAndRestrictedStockUnitsExercisedAndEmployeeStockPurchasePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ae8d21f2-ca6f-42ec-a5c6-eda9cc96776a" xlink:to="loc_incy_StockIssuedDuringPeriodValueStockOptionsAndRestrictedStockUnitsExercisedAndEmployeeStockPurchasePlan_188f25ca-b7d9-4311-9298-bfdd1ed1c07c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_89d4ed10-442a-4e00-8985-485fbb81d071" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ae8d21f2-ca6f-42ec-a5c6-eda9cc96776a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_89d4ed10-442a-4e00-8985-485fbb81d071" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_9d671aca-26ec-4609-b601-b1b3797c63d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ae8d21f2-ca6f-42ec-a5c6-eda9cc96776a" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_9d671aca-26ec-4609-b601-b1b3797c63d2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_e0f1047f-4ed8-4fe8-8605-49fcccb47b75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ae8d21f2-ca6f-42ec-a5c6-eda9cc96776a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_e0f1047f-4ed8-4fe8-8605-49fcccb47b75" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_039dd9a0-fd0b-48f8-b261-a4d5d4e6b442" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ae8d21f2-ca6f-42ec-a5c6-eda9cc96776a" xlink:to="loc_us-gaap_NetIncomeLoss_039dd9a0-fd0b-48f8-b261-a4d5d4e6b442" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_65670155-da83-4dac-80ad-410312d4ad44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_ee21be5b-d677-47db-a0f9-29ac8e40c3d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_ee715633-9591-4ef5-a632-6cf4c4a21a37" xlink:to="loc_us-gaap_StatementTable_ee21be5b-d677-47db-a0f9-29ac8e40c3d0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_d7889845-0f34-4b1a-b57b-2acaf189b05d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_ee21be5b-d677-47db-a0f9-29ac8e40c3d0" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_d7889845-0f34-4b1a-b57b-2acaf189b05d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_d7889845-0f34-4b1a-b57b-2acaf189b05d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_d7889845-0f34-4b1a-b57b-2acaf189b05d" xlink:to="loc_us-gaap_EquityComponentDomain_d7889845-0f34-4b1a-b57b-2acaf189b05d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_5c4d2718-b5c6-48e8-ba1f-7e3be608f95a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_d7889845-0f34-4b1a-b57b-2acaf189b05d" xlink:to="loc_us-gaap_EquityComponentDomain_5c4d2718-b5c6-48e8-ba1f-7e3be608f95a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_28c203d0-8f01-4182-ac82-35a3deab76c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_5c4d2718-b5c6-48e8-ba1f-7e3be608f95a" xlink:to="loc_us-gaap_CommonStockMember_28c203d0-8f01-4182-ac82-35a3deab76c5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_97885e66-7314-46fd-a81c-579e2a6808c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_5c4d2718-b5c6-48e8-ba1f-7e3be608f95a" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_97885e66-7314-46fd-a81c-579e2a6808c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_5cfcbd80-b7c8-46e9-8964-c74e0a55a902" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_5c4d2718-b5c6-48e8-ba1f-7e3be608f95a" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_5cfcbd80-b7c8-46e9-8964-c74e0a55a902" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_31c63857-2cc8-4618-857a-4ca8d3dabc08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_5c4d2718-b5c6-48e8-ba1f-7e3be608f95a" xlink:to="loc_us-gaap_RetainedEarningsMember_31c63857-2cc8-4618-857a-4ca8d3dabc08" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.incyte.com/role/RevenuesDetails" xlink:type="simple" xlink:href="incy-20220930.xsd#RevenuesDetails"/>
  <link:definitionLink xlink:role="http://www.incyte.com/role/RevenuesDetails" xlink:type="extended" id="iedd5cdc25751485b9662ffa914e4815a_RevenuesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_3188f2a8-794b-4cde-9dc3-6ad4eef0359c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8fcbce7e-6489-408f-b28e-35998d9d36ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_3188f2a8-794b-4cde-9dc3-6ad4eef0359c" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8fcbce7e-6489-408f-b28e-35998d9d36ca" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_c657dc9f-8a2a-4bf9-ba5c-c7b73322424b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_3188f2a8-794b-4cde-9dc3-6ad4eef0359c" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_c657dc9f-8a2a-4bf9-ba5c-c7b73322424b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_f2116b3d-4546-43d2-9839-370ae9dc6e0f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_c657dc9f-8a2a-4bf9-ba5c-c7b73322424b" xlink:to="loc_srt_ProductOrServiceAxis_f2116b3d-4546-43d2-9839-370ae9dc6e0f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_f2116b3d-4546-43d2-9839-370ae9dc6e0f_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_f2116b3d-4546-43d2-9839-370ae9dc6e0f" xlink:to="loc_srt_ProductsAndServicesDomain_f2116b3d-4546-43d2-9839-370ae9dc6e0f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_46fa1634-f039-4d7f-97e1-35658fba7278" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_f2116b3d-4546-43d2-9839-370ae9dc6e0f" xlink:to="loc_srt_ProductsAndServicesDomain_46fa1634-f039-4d7f-97e1-35658fba7278" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_c4f9f688-3f83-4c00-870c-e878805608f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_46fa1634-f039-4d7f-97e1-35658fba7278" xlink:to="loc_us-gaap_ProductMember_c4f9f688-3f83-4c00-870c-e878805608f1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_JAKAFIMember_003b708b-ba32-4d85-9a0a-b1ceedb8b6f1" xlink:href="incy-20220930.xsd#incy_JAKAFIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_c4f9f688-3f83-4c00-870c-e878805608f1" xlink:to="loc_incy_JAKAFIMember_003b708b-ba32-4d85-9a0a-b1ceedb8b6f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_ICLUSIGMember_ac07f1e7-fb13-4211-9a24-44d2ce910021" xlink:href="incy-20220930.xsd#incy_ICLUSIGMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_c4f9f688-3f83-4c00-870c-e878805608f1" xlink:to="loc_incy_ICLUSIGMember_ac07f1e7-fb13-4211-9a24-44d2ce910021" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_PemazyreMember_90762525-31c0-479c-8f3d-dea02f68ed19" xlink:href="incy-20220930.xsd#incy_PemazyreMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_c4f9f688-3f83-4c00-870c-e878805608f1" xlink:to="loc_incy_PemazyreMember_90762525-31c0-479c-8f3d-dea02f68ed19" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_MINJUVIMember_b7b2ad77-2098-4550-90d6-919940994ca5" xlink:href="incy-20220930.xsd#incy_MINJUVIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_c4f9f688-3f83-4c00-870c-e878805608f1" xlink:to="loc_incy_MINJUVIMember_b7b2ad77-2098-4550-90d6-919940994ca5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_OpzeluraMember_3441684e-bbd1-4654-9933-5997d75099d1" xlink:href="incy-20220930.xsd#incy_OpzeluraMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_c4f9f688-3f83-4c00-870c-e878805608f1" xlink:to="loc_incy_OpzeluraMember_3441684e-bbd1-4654-9933-5997d75099d1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_b8441ef3-f834-43a9-9921-5e8daab85cf0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_46fa1634-f039-4d7f-97e1-35658fba7278" xlink:to="loc_us-gaap_RoyaltyMember_b8441ef3-f834-43a9-9921-5e8daab85cf0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_JakaviRoyaltyRevenuesMember_64a0c82f-6a71-4c09-ba38-9511e8acec6c" xlink:href="incy-20220930.xsd#incy_JakaviRoyaltyRevenuesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RoyaltyMember_b8441ef3-f834-43a9-9921-5e8daab85cf0" xlink:to="loc_incy_JakaviRoyaltyRevenuesMember_64a0c82f-6a71-4c09-ba38-9511e8acec6c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_OlumiantRoyaltyMember_a659b557-83ee-4552-b9c6-02608e7b014e" xlink:href="incy-20220930.xsd#incy_OlumiantRoyaltyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RoyaltyMember_b8441ef3-f834-43a9-9921-5e8daab85cf0" xlink:to="loc_incy_OlumiantRoyaltyMember_a659b557-83ee-4552-b9c6-02608e7b014e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_TabrectaRoyaltyRevenuesMember_b22c191a-f160-4189-bfd9-2262b6b653a3" xlink:href="incy-20220930.xsd#incy_TabrectaRoyaltyRevenuesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RoyaltyMember_b8441ef3-f834-43a9-9921-5e8daab85cf0" xlink:to="loc_incy_TabrectaRoyaltyRevenuesMember_b22c191a-f160-4189-bfd9-2262b6b653a3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_MilestoneAndContractRevenueMember_6a0b3401-1dfc-4458-9c96-578cfd04f9a2" xlink:href="incy-20220930.xsd#incy_MilestoneAndContractRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_46fa1634-f039-4d7f-97e1-35658fba7278" xlink:to="loc_incy_MilestoneAndContractRevenueMember_6a0b3401-1dfc-4458-9c96-578cfd04f9a2" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.incyte.com/role/FairValueofFinancialInstrumentsMarketablesecuritiesportfolioDetails" xlink:type="simple" xlink:href="incy-20220930.xsd#FairValueofFinancialInstrumentsMarketablesecuritiesportfolioDetails"/>
  <link:definitionLink xlink:role="http://www.incyte.com/role/FairValueofFinancialInstrumentsMarketablesecuritiesportfolioDetails" xlink:type="extended" id="ie307c1ddf66b426ab0d244fc6c47a323_FairValueofFinancialInstrumentsMarketablesecuritiesportfolioDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1b3501d0-0ff1-4b5a-af7d-d462f00079d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_6618979b-9e31-4fe4-834c-c11271425c53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1b3501d0-0ff1-4b5a-af7d-d462f00079d0" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_6618979b-9e31-4fe4-834c-c11271425c53" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax_dedfe8ef-c914-45d2-8bc2-3a3432771153" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1b3501d0-0ff1-4b5a-af7d-d462f00079d0" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax_dedfe8ef-c914-45d2-8bc2-3a3432771153" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_ad59dd9e-e6ed-49fc-8194-eb76ee3c1613" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1b3501d0-0ff1-4b5a-af7d-d462f00079d0" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_ad59dd9e-e6ed-49fc-8194-eb76ee3c1613" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_c67fc0fb-875e-45b9-9771-1b937a25dbd2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1b3501d0-0ff1-4b5a-af7d-d462f00079d0" xlink:to="loc_us-gaap_DebtInstrumentTerm_c67fc0fb-875e-45b9-9771-1b937a25dbd2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_d94ea39b-a6a3-40d3-859e-aedb1042f9bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1b3501d0-0ff1-4b5a-af7d-d462f00079d0" xlink:to="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_d94ea39b-a6a3-40d3-859e-aedb1042f9bf" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_0bc304b2-e116-4f2a-85f1-18388915d06f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_d94ea39b-a6a3-40d3-859e-aedb1042f9bf" xlink:to="loc_us-gaap_FinancialInstrumentAxis_0bc304b2-e116-4f2a-85f1-18388915d06f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0bc304b2-e116-4f2a-85f1-18388915d06f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_0bc304b2-e116-4f2a-85f1-18388915d06f" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0bc304b2-e116-4f2a-85f1-18388915d06f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c0a975b2-67d7-425b-9789-57eee18c3934" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_0bc304b2-e116-4f2a-85f1-18388915d06f" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c0a975b2-67d7-425b-9789-57eee18c3934" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_CorporateAndGovernmentDebtSecuritiesMember_fbd9f46d-5939-47cc-8ee2-51d8d6a08864" xlink:href="incy-20220930.xsd#incy_CorporateAndGovernmentDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c0a975b2-67d7-425b-9789-57eee18c3934" xlink:to="loc_incy_CorporateAndGovernmentDebtSecuritiesMember_fbd9f46d-5939-47cc-8ee2-51d8d6a08864" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_b3bac3b6-6149-45c6-88da-fc54b7b4cb19" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_d94ea39b-a6a3-40d3-859e-aedb1042f9bf" xlink:to="loc_srt_RangeAxis_b3bac3b6-6149-45c6-88da-fc54b7b4cb19" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b3bac3b6-6149-45c6-88da-fc54b7b4cb19_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_b3bac3b6-6149-45c6-88da-fc54b7b4cb19" xlink:to="loc_srt_RangeMember_b3bac3b6-6149-45c6-88da-fc54b7b4cb19_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_33698828-679b-4c97-a5bf-eea546634e36" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_b3bac3b6-6149-45c6-88da-fc54b7b4cb19" xlink:to="loc_srt_RangeMember_33698828-679b-4c97-a5bf-eea546634e36" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_b354d531-6f07-4f1c-803f-47fce7c5b0aa" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_33698828-679b-4c97-a5bf-eea546634e36" xlink:to="loc_srt_MinimumMember_b354d531-6f07-4f1c-803f-47fce7c5b0aa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_b0dfe0e1-3609-44c1-8951-3af0924e99a0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_33698828-679b-4c97-a5bf-eea546634e36" xlink:to="loc_srt_MaximumMember_b0dfe0e1-3609-44c1-8951-3af0924e99a0" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.incyte.com/role/FairValueofFinancialInstrumentsAssetsmeasuredonarecurringbasisDetails" xlink:type="simple" xlink:href="incy-20220930.xsd#FairValueofFinancialInstrumentsAssetsmeasuredonarecurringbasisDetails"/>
  <link:definitionLink xlink:role="http://www.incyte.com/role/FairValueofFinancialInstrumentsAssetsmeasuredonarecurringbasisDetails" xlink:type="extended" id="i98c3a10445fd4c59bdd953d5be5a1180_FairValueofFinancialInstrumentsAssetsmeasuredonarecurringbasisDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_63174807-49ea-4953-b87d-2b8a87c3e069" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_b775fc24-a8f3-4a22-be78-2c932b4da191" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_63174807-49ea-4953-b87d-2b8a87c3e069" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_b775fc24-a8f3-4a22-be78-2c932b4da191" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_1dad85fc-19fe-41b4-8ad8-59eea43d069a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_63174807-49ea-4953-b87d-2b8a87c3e069" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_1dad85fc-19fe-41b4-8ad8-59eea43d069a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments_3a7fc2b6-e110-42f4-985e-3988fe5a6cf5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_63174807-49ea-4953-b87d-2b8a87c3e069" xlink:to="loc_us-gaap_LongTermInvestments_3a7fc2b6-e110-42f4-985e-3988fe5a6cf5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_7a015ce4-48e4-4e29-9c91-8cc5c341cb0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_63174807-49ea-4953-b87d-2b8a87c3e069" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_7a015ce4-48e4-4e29-9c91-8cc5c341cb0a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9aae8baf-f994-485f-b5a0-9d24aa8614d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_63174807-49ea-4953-b87d-2b8a87c3e069" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9aae8baf-f994-485f-b5a0-9d24aa8614d9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_24085a2e-010d-45d1-9656-799d51eeab4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9aae8baf-f994-485f-b5a0-9d24aa8614d9" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_24085a2e-010d-45d1-9656-799d51eeab4a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_24085a2e-010d-45d1-9656-799d51eeab4a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_24085a2e-010d-45d1-9656-799d51eeab4a" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_24085a2e-010d-45d1-9656-799d51eeab4a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_ac454348-4fc4-4315-b068-312d784343e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_24085a2e-010d-45d1-9656-799d51eeab4a" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_ac454348-4fc4-4315-b068-312d784343e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_1a5e4745-b6dc-4181-8da8-b43c7cc85a8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_ac454348-4fc4-4315-b068-312d784343e5" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_1a5e4745-b6dc-4181-8da8-b43c7cc85a8d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_01bd4608-4305-4904-ae2e-97189ffab344" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9aae8baf-f994-485f-b5a0-9d24aa8614d9" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_01bd4608-4305-4904-ae2e-97189ffab344" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_01bd4608-4305-4904-ae2e-97189ffab344_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_01bd4608-4305-4904-ae2e-97189ffab344" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_01bd4608-4305-4904-ae2e-97189ffab344_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a33e648e-9f5a-4b5a-a645-812db0e7525f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_01bd4608-4305-4904-ae2e-97189ffab344" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a33e648e-9f5a-4b5a-a645-812db0e7525f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_3646aca0-a598-4f52-9da4-203438f47245" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a33e648e-9f5a-4b5a-a645-812db0e7525f" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_3646aca0-a598-4f52-9da4-203438f47245" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_012dd472-dee0-4757-b98e-afdb1c7b75cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a33e648e-9f5a-4b5a-a645-812db0e7525f" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_012dd472-dee0-4757-b98e-afdb1c7b75cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_0b7eb7ce-0472-434c-b0b2-d0f3fc1c61d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a33e648e-9f5a-4b5a-a645-812db0e7525f" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_0b7eb7ce-0472-434c-b0b2-d0f3fc1c61d4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_81228a74-95c9-4db0-81df-5aa4e54d13e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9aae8baf-f994-485f-b5a0-9d24aa8614d9" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_81228a74-95c9-4db0-81df-5aa4e54d13e5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_81228a74-95c9-4db0-81df-5aa4e54d13e5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_81228a74-95c9-4db0-81df-5aa4e54d13e5" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_81228a74-95c9-4db0-81df-5aa4e54d13e5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_23a4c2c4-6f73-47fe-9052-8c67d86c098b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_81228a74-95c9-4db0-81df-5aa4e54d13e5" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_23a4c2c4-6f73-47fe-9052-8c67d86c098b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_81904af2-6455-4a53-9310-7d2350cd8c7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_23a4c2c4-6f73-47fe-9052-8c67d86c098b" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_81904af2-6455-4a53-9310-7d2350cd8c7e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_0a886f13-dae2-4fb8-8323-3da9b4615143" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_81904af2-6455-4a53-9310-7d2350cd8c7e" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_0a886f13-dae2-4fb8-8323-3da9b4615143" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.incyte.com/role/FairValueofFinancialInstrumentsLiabilitiesmeasuredonarecurringbasisDetails" xlink:type="simple" xlink:href="incy-20220930.xsd#FairValueofFinancialInstrumentsLiabilitiesmeasuredonarecurringbasisDetails"/>
  <link:definitionLink xlink:role="http://www.incyte.com/role/FairValueofFinancialInstrumentsLiabilitiesmeasuredonarecurringbasisDetails" xlink:type="extended" id="ie235561d587743a4963d30fb2df62bf3_FairValueofFinancialInstrumentsLiabilitiesmeasuredonarecurringbasisDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3cf4220a-ced8-41df-9821-830d43d858b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_80380f3d-bfd4-4b9d-8856-aad987481151" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3cf4220a-ced8-41df-9821-830d43d858b2" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_80380f3d-bfd4-4b9d-8856-aad987481151" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_740e6713-c2c9-406e-a76a-7de9c0b371dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3cf4220a-ced8-41df-9821-830d43d858b2" xlink:to="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_740e6713-c2c9-406e-a76a-7de9c0b371dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0500a01c-ce95-4cd9-85f4-b569bf6a38b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3cf4220a-ced8-41df-9821-830d43d858b2" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0500a01c-ce95-4cd9-85f4-b569bf6a38b3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_9c489704-7500-41ab-910d-faff377b40fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0500a01c-ce95-4cd9-85f4-b569bf6a38b3" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_9c489704-7500-41ab-910d-faff377b40fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_9c489704-7500-41ab-910d-faff377b40fc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_9c489704-7500-41ab-910d-faff377b40fc" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_9c489704-7500-41ab-910d-faff377b40fc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_1d5ed20d-ade0-4048-a9d8-260aeda7c8ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_9c489704-7500-41ab-910d-faff377b40fc" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_1d5ed20d-ade0-4048-a9d8-260aeda7c8ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_a0d0bdc8-3e4a-47ed-a408-a08fc40c603b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_1d5ed20d-ade0-4048-a9d8-260aeda7c8ed" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_a0d0bdc8-3e4a-47ed-a408-a08fc40c603b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_48846e3a-13bf-4b17-b54e-8f912e7bdb6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0500a01c-ce95-4cd9-85f4-b569bf6a38b3" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_48846e3a-13bf-4b17-b54e-8f912e7bdb6a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_48846e3a-13bf-4b17-b54e-8f912e7bdb6a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_48846e3a-13bf-4b17-b54e-8f912e7bdb6a" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_48846e3a-13bf-4b17-b54e-8f912e7bdb6a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6244f415-2e9c-4323-b3b5-37a6a68aa9fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_48846e3a-13bf-4b17-b54e-8f912e7bdb6a" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6244f415-2e9c-4323-b3b5-37a6a68aa9fb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_35762760-053e-4aa3-9250-97ede82df62e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6244f415-2e9c-4323-b3b5-37a6a68aa9fb" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_35762760-053e-4aa3-9250-97ede82df62e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_48a18f39-4073-43cf-8d20-c68f8d620dea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6244f415-2e9c-4323-b3b5-37a6a68aa9fb" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_48a18f39-4073-43cf-8d20-c68f8d620dea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_d71efd51-d5a1-4bc8-9eda-9a118f76a476" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6244f415-2e9c-4323-b3b5-37a6a68aa9fb" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_d71efd51-d5a1-4bc8-9eda-9a118f76a476" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_1a7c4494-06c7-4adb-bce3-fdebf608b1a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0500a01c-ce95-4cd9-85f4-b569bf6a38b3" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_1a7c4494-06c7-4adb-bce3-fdebf608b1a1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_1a7c4494-06c7-4adb-bce3-fdebf608b1a1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_1a7c4494-06c7-4adb-bce3-fdebf608b1a1" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_1a7c4494-06c7-4adb-bce3-fdebf608b1a1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_95ba834c-9035-4a0f-ae5e-805338eb33ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_1a7c4494-06c7-4adb-bce3-fdebf608b1a1" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_95ba834c-9035-4a0f-ae5e-805338eb33ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_c5eb4b0e-d100-4982-821b-e2e0a43c9452" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_95ba834c-9035-4a0f-ae5e-805338eb33ac" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_c5eb4b0e-d100-4982-821b-e2e0a43c9452" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_762890b2-56a2-4d3f-b3b8-10d7fa60c875" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_c5eb4b0e-d100-4982-821b-e2e0a43c9452" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_762890b2-56a2-4d3f-b3b8-10d7fa60c875" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.incyte.com/role/FairValueofFinancialInstrumentsLevel3liabilitiesDetails" xlink:type="simple" xlink:href="incy-20220930.xsd#FairValueofFinancialInstrumentsLevel3liabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.incyte.com/role/FairValueofFinancialInstrumentsLevel3liabilitiesDetails" xlink:type="extended" id="ice00f0bc2fdd4f3a87a8fbd60ba7e5e5_FairValueofFinancialInstrumentsLevel3liabilitiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_4006a91a-bed4-4cd2-b6b2-69873531a149" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_85f750a4-0b32-4577-844f-a08fe32c2c6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_4006a91a-bed4-4cd2-b6b2-69873531a149" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_85f750a4-0b32-4577-844f-a08fe32c2c6e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_7f17c896-4f6c-45ae-a668-f9aae60b2960" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_85f750a4-0b32-4577-844f-a08fe32c2c6e" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_7f17c896-4f6c-45ae-a668-f9aae60b2960" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityConsiderationEarned_6be5cb2d-4858-4e12-9191-f0d12b9bcb75" xlink:href="incy-20220930.xsd#incy_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityConsiderationEarned"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_85f750a4-0b32-4577-844f-a08fe32c2c6e" xlink:to="loc_incy_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityConsiderationEarned_6be5cb2d-4858-4e12-9191-f0d12b9bcb75" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_ae568a9b-2183-418b-8319-0e7fa9c5d533" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_85f750a4-0b32-4577-844f-a08fe32c2c6e" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_ae568a9b-2183-418b-8319-0e7fa9c5d533" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_3c737c60-7ec8-4ba1-8461-bd802837e752" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1c711a85-53cb-404c-86b2-541c3ec61675" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_4006a91a-bed4-4cd2-b6b2-69873531a149" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1c711a85-53cb-404c-86b2-541c3ec61675" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_40dd2a62-dc1b-4228-83f9-5266fb211ddd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1c711a85-53cb-404c-86b2-541c3ec61675" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_40dd2a62-dc1b-4228-83f9-5266fb211ddd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_40dd2a62-dc1b-4228-83f9-5266fb211ddd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_40dd2a62-dc1b-4228-83f9-5266fb211ddd" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_40dd2a62-dc1b-4228-83f9-5266fb211ddd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4ca53e55-8860-4783-8958-0d4664bfb6ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_40dd2a62-dc1b-4228-83f9-5266fb211ddd" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4ca53e55-8860-4783-8958-0d4664bfb6ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_f975e33b-9161-4a58-983f-ee719ae91c79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4ca53e55-8860-4783-8958-0d4664bfb6ac" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_f975e33b-9161-4a58-983f-ee719ae91c79" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_8c16395f-70d0-4f90-b7c9-c7744817f7c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1c711a85-53cb-404c-86b2-541c3ec61675" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_8c16395f-70d0-4f90-b7c9-c7744817f7c4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_8c16395f-70d0-4f90-b7c9-c7744817f7c4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_8c16395f-70d0-4f90-b7c9-c7744817f7c4" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_8c16395f-70d0-4f90-b7c9-c7744817f7c4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_9e84fa91-0c72-4ad6-b583-0aa4b7d14de7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_8c16395f-70d0-4f90-b7c9-c7744817f7c4" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_9e84fa91-0c72-4ad6-b583-0aa4b7d14de7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_556cc0ac-59ce-418e-bda9-636c40de070b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_9e84fa91-0c72-4ad6-b583-0aa4b7d14de7" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_556cc0ac-59ce-418e-bda9-636c40de070b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_e57a9af7-2d0d-43c8-b7f5-9e1032f8e869" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_556cc0ac-59ce-418e-bda9-636c40de070b" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_e57a9af7-2d0d-43c8-b7f5-9e1032f8e869" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.incyte.com/role/FairValueofFinancialInstrumentsNarrativeDetails" xlink:type="simple" xlink:href="incy-20220930.xsd#FairValueofFinancialInstrumentsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.incyte.com/role/FairValueofFinancialInstrumentsNarrativeDetails" xlink:type="extended" id="i49d66b8d14a7448a915684b776235266_FairValueofFinancialInstrumentsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1069dd49-1bae-4e67-a930-b4a18273dd67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_FairValueInputsCashFlowsEstimatedPeriod_725ee388-b406-4bff-ba32-53dd0d84f0e0" xlink:href="incy-20220930.xsd#incy_FairValueInputsCashFlowsEstimatedPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1069dd49-1bae-4e67-a930-b4a18273dd67" xlink:to="loc_incy_FairValueInputsCashFlowsEstimatedPeriod_725ee388-b406-4bff-ba32-53dd0d84f0e0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_93dcc21d-8157-4d75-870a-a6cdbd4cd72a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1069dd49-1bae-4e67-a930-b4a18273dd67" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_93dcc21d-8157-4d75-870a-a6cdbd4cd72a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityConsiderationEarned_77dd784a-f42f-4d55-b7b4-9c8a7b825576" xlink:href="incy-20220930.xsd#incy_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityConsiderationEarned"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1069dd49-1bae-4e67-a930-b4a18273dd67" xlink:to="loc_incy_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityConsiderationEarned_77dd784a-f42f-4d55-b7b4-9c8a7b825576" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_41e28847-4c1f-48bb-bbeb-a0bddc3c418b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1069dd49-1bae-4e67-a930-b4a18273dd67" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_41e28847-4c1f-48bb-bbeb-a0bddc3c418b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_b30ca789-fe19-4a56-a359-732ebcfaebd3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_41e28847-4c1f-48bb-bbeb-a0bddc3c418b" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_b30ca789-fe19-4a56-a359-732ebcfaebd3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b30ca789-fe19-4a56-a359-732ebcfaebd3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_b30ca789-fe19-4a56-a359-732ebcfaebd3" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b30ca789-fe19-4a56-a359-732ebcfaebd3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ed197254-dc92-417a-a2ba-68cc68b9d79b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_b30ca789-fe19-4a56-a359-732ebcfaebd3" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ed197254-dc92-417a-a2ba-68cc68b9d79b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_AriadPharmaceuticalsMember_8465ed6a-bbc7-4a5e-bb16-13beb17f92bc" xlink:href="incy-20220930.xsd#incy_AriadPharmaceuticalsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ed197254-dc92-417a-a2ba-68cc68b9d79b" xlink:to="loc_incy_AriadPharmaceuticalsMember_8465ed6a-bbc7-4a5e-bb16-13beb17f92bc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_107d7a5c-8e9c-4f68-b161-9a6076a2e3c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_41e28847-4c1f-48bb-bbeb-a0bddc3c418b" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_107d7a5c-8e9c-4f68-b161-9a6076a2e3c7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_107d7a5c-8e9c-4f68-b161-9a6076a2e3c7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_107d7a5c-8e9c-4f68-b161-9a6076a2e3c7" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_107d7a5c-8e9c-4f68-b161-9a6076a2e3c7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_9c48c37b-58a0-43a6-b371-ad5a41070ad9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_107d7a5c-8e9c-4f68-b161-9a6076a2e3c7" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_9c48c37b-58a0-43a6-b371-ad5a41070ad9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityMember_b5f2308b-a6ee-4a5b-9048-bb7d8d2fdcec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_9c48c37b-58a0-43a6-b371-ad5a41070ad9" xlink:to="loc_us-gaap_LiabilityMember_b5f2308b-a6ee-4a5b-9048-bb7d8d2fdcec" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_8eb37d15-beab-4584-b4bc-0fc52692bc4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_41e28847-4c1f-48bb-bbeb-a0bddc3c418b" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_8eb37d15-beab-4584-b4bc-0fc52692bc4a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_8eb37d15-beab-4584-b4bc-0fc52692bc4a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_8eb37d15-beab-4584-b4bc-0fc52692bc4a" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_8eb37d15-beab-4584-b4bc-0fc52692bc4a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_45f69e77-69d7-4a42-91cb-cb74f6c96b35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_8eb37d15-beab-4584-b4bc-0fc52692bc4a" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_45f69e77-69d7-4a42-91cb-cb74f6c96b35" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_4cbc3883-dd75-415c-a83f-97514d097a0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_45f69e77-69d7-4a42-91cb-cb74f6c96b35" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_4cbc3883-dd75-415c-a83f-97514d097a0f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_e35b8498-c1b5-499e-854e-d39491b91aa2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_41e28847-4c1f-48bb-bbeb-a0bddc3c418b" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_e35b8498-c1b5-499e-854e-d39491b91aa2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_e35b8498-c1b5-499e-854e-d39491b91aa2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_e35b8498-c1b5-499e-854e-d39491b91aa2" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_e35b8498-c1b5-499e-854e-d39491b91aa2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_5b180383-07b9-4ec6-9b33-b3a9af56ff9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_e35b8498-c1b5-499e-854e-d39491b91aa2" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_5b180383-07b9-4ec6-9b33-b3a9af56ff9c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_AccruedAndOtherCurrentLiabilityMember_dc395618-1d67-4439-b25c-aad08b1d1c12" xlink:href="incy-20220930.xsd#incy_AccruedAndOtherCurrentLiabilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_5b180383-07b9-4ec6-9b33-b3a9af56ff9c" xlink:to="loc_incy_AccruedAndOtherCurrentLiabilityMember_dc395618-1d67-4439-b25c-aad08b1d1c12" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.incyte.com/role/ConcentrationsofCreditRiskandCurrentExpectedCreditLossesDetails" xlink:type="simple" xlink:href="incy-20220930.xsd#ConcentrationsofCreditRiskandCurrentExpectedCreditLossesDetails"/>
  <link:definitionLink xlink:role="http://www.incyte.com/role/ConcentrationsofCreditRiskandCurrentExpectedCreditLossesDetails" xlink:type="extended" id="i8511120df4cf4f94875f66eb5518514e_ConcentrationsofCreditRiskandCurrentExpectedCreditLossesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_c6eb0bf3-fcf0-4531-ac4a-1a4560a90ea4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_46412ea9-26ac-407f-a50d-9fd8dec09428" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_c6eb0bf3-fcf0-4531-ac4a-1a4560a90ea4" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_46412ea9-26ac-407f-a50d-9fd8dec09428" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_579b99af-c517-4aa8-8c68-f4708d76fd2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_c6eb0bf3-fcf0-4531-ac4a-1a4560a90ea4" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_579b99af-c517-4aa8-8c68-f4708d76fd2e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_2b43dc23-abd7-47f2-b047-06bec4cd8608" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_c6eb0bf3-fcf0-4531-ac4a-1a4560a90ea4" xlink:to="loc_us-gaap_ConcentrationRiskTable_2b43dc23-abd7-47f2-b047-06bec4cd8608" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_4accd5e1-c4b0-40af-bef5-b0abfce8877d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_2b43dc23-abd7-47f2-b047-06bec4cd8608" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_4accd5e1-c4b0-40af-bef5-b0abfce8877d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_4accd5e1-c4b0-40af-bef5-b0abfce8877d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_4accd5e1-c4b0-40af-bef5-b0abfce8877d" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_4accd5e1-c4b0-40af-bef5-b0abfce8877d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_0b3ea35b-9d5d-45b3-b20a-24e540d3fd66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_4accd5e1-c4b0-40af-bef5-b0abfce8877d" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_0b3ea35b-9d5d-45b3-b20a-24e540d3fd66" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueProductLineMember_5ec2ed12-e6c0-4624-a7d3-5e1d2c77fdaa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueProductLineMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_0b3ea35b-9d5d-45b3-b20a-24e540d3fd66" xlink:to="loc_us-gaap_SalesRevenueProductLineMember_5ec2ed12-e6c0-4624-a7d3-5e1d2c77fdaa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_c67a79f5-c103-48b7-895e-8686736a0766" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_0b3ea35b-9d5d-45b3-b20a-24e540d3fd66" xlink:to="loc_us-gaap_AccountsReceivableMember_c67a79f5-c103-48b7-895e-8686736a0766" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_0f196539-32cb-4a2e-a930-59dadf1394df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_2b43dc23-abd7-47f2-b047-06bec4cd8608" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_0f196539-32cb-4a2e-a930-59dadf1394df" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_0f196539-32cb-4a2e-a930-59dadf1394df_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_0f196539-32cb-4a2e-a930-59dadf1394df" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_0f196539-32cb-4a2e-a930-59dadf1394df_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_bfe41d78-6070-4e64-beca-ea5571869ea1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_0f196539-32cb-4a2e-a930-59dadf1394df" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_bfe41d78-6070-4e64-beca-ea5571869ea1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_e2e00d6f-af46-44bc-9879-c5b9d17094e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_bfe41d78-6070-4e64-beca-ea5571869ea1" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_e2e00d6f-af46-44bc-9879-c5b9d17094e6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditConcentrationRiskMember_486078ca-eca1-42a6-b9e1-11ae451f6cd3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_bfe41d78-6070-4e64-beca-ea5571869ea1" xlink:to="loc_us-gaap_CreditConcentrationRiskMember_486078ca-eca1-42a6-b9e1-11ae451f6cd3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_cbe2b171-8e0b-4398-88ce-43fb3db3e6c0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_2b43dc23-abd7-47f2-b047-06bec4cd8608" xlink:to="loc_srt_MajorCustomersAxis_cbe2b171-8e0b-4398-88ce-43fb3db3e6c0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_cbe2b171-8e0b-4398-88ce-43fb3db3e6c0_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_cbe2b171-8e0b-4398-88ce-43fb3db3e6c0" xlink:to="loc_srt_NameOfMajorCustomerDomain_cbe2b171-8e0b-4398-88ce-43fb3db3e6c0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_cba832ef-9f54-4536-ba06-34fb963b4481" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_cbe2b171-8e0b-4398-88ce-43fb3db3e6c0" xlink:to="loc_srt_NameOfMajorCustomerDomain_cba832ef-9f54-4536-ba06-34fb963b4481" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_CollaborationPartnersaBCAndDMember_a06d92bc-98bf-4694-bac1-28a155d392fb" xlink:href="incy-20220930.xsd#incy_CollaborationPartnersaBCAndDMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_cba832ef-9f54-4536-ba06-34fb963b4481" xlink:to="loc_incy_CollaborationPartnersaBCAndDMember_a06d92bc-98bf-4694-bac1-28a155d392fb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_CustomerAMember_797e8c82-0cb0-443e-9e4a-f9d278611a6d" xlink:href="incy-20220930.xsd#incy_CustomerAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_cba832ef-9f54-4536-ba06-34fb963b4481" xlink:to="loc_incy_CustomerAMember_797e8c82-0cb0-443e-9e4a-f9d278611a6d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_CustomerBMember_8377a27a-7c4e-4bc6-83d1-c521d3d915f1" xlink:href="incy-20220930.xsd#incy_CustomerBMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_cba832ef-9f54-4536-ba06-34fb963b4481" xlink:to="loc_incy_CustomerBMember_8377a27a-7c4e-4bc6-83d1-c521d3d915f1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_CustomerCMember_50e41098-3276-41ad-87bf-4c091f2a8dbd" xlink:href="incy-20220930.xsd#incy_CustomerCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_cba832ef-9f54-4536-ba06-34fb963b4481" xlink:to="loc_incy_CustomerCMember_50e41098-3276-41ad-87bf-4c091f2a8dbd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_CustomerDMember_e7ccb333-4357-4b2e-a58e-15160076ec72" xlink:href="incy-20220930.xsd#incy_CustomerDMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_cba832ef-9f54-4536-ba06-34fb963b4481" xlink:to="loc_incy_CustomerDMember_e7ccb333-4357-4b2e-a58e-15160076ec72" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_CustomerEMember_94607352-0566-4bb9-922f-8da13f40e727" xlink:href="incy-20220930.xsd#incy_CustomerEMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_cba832ef-9f54-4536-ba06-34fb963b4481" xlink:to="loc_incy_CustomerEMember_94607352-0566-4bb9-922f-8da13f40e727" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_AggregateConcentrationCustomersMember_403f42db-67e6-4eac-b3e4-5bad511f91ee" xlink:href="incy-20220930.xsd#incy_AggregateConcentrationCustomersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_cba832ef-9f54-4536-ba06-34fb963b4481" xlink:to="loc_incy_AggregateConcentrationCustomersMember_403f42db-67e6-4eac-b3e4-5bad511f91ee" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.incyte.com/role/InventoryDetails" xlink:type="simple" xlink:href="incy-20220930.xsd#InventoryDetails"/>
  <link:definitionLink xlink:role="http://www.incyte.com/role/InventoryDetails" xlink:type="extended" id="i7301688ac3dd409082d70277c54af6ba_InventoryDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_fa275af3-da12-40c8-9456-67fffa3c39ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_d43fcf97-7789-4c11-88cd-8b54cf0586c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_fa275af3-da12-40c8-9456-67fffa3c39ac" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_d43fcf97-7789-4c11-88cd-8b54cf0586c2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_621dd2fb-4483-43c8-b939-79a1024c5288" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_fa275af3-da12-40c8-9456-67fffa3c39ac" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_621dd2fb-4483-43c8-b939-79a1024c5288" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_26997c25-32a4-404e-89c3-7a62340c4fcd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_fa275af3-da12-40c8-9456-67fffa3c39ac" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_26997c25-32a4-404e-89c3-7a62340c4fcd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_InventoryNetCurrentAndNoncurrent_910cfdcc-9c4c-4cc0-82a5-93cd792bc742" xlink:href="incy-20220930.xsd#incy_InventoryNetCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_fa275af3-da12-40c8-9456-67fffa3c39ac" xlink:to="loc_incy_InventoryNetCurrentAndNoncurrent_910cfdcc-9c4c-4cc0-82a5-93cd792bc742" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_1c6745b4-ec33-435b-9c1d-c8c2df118f68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_fa275af3-da12-40c8-9456-67fffa3c39ac" xlink:to="loc_us-gaap_InventoryNet_1c6745b4-ec33-435b-9c1d-c8c2df118f68" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent_aa17c9a1-115c-4b3f-abc7-8ebd18b3a023" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_fa275af3-da12-40c8-9456-67fffa3c39ac" xlink:to="loc_us-gaap_InventoryNoncurrent_aa17c9a1-115c-4b3f-abc7-8ebd18b3a023" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_InventoryRecordedAsResearchAndDevelopmentExpense_59c65c30-5f7c-44ea-90a1-5af60060cb0c" xlink:href="incy-20220930.xsd#incy_InventoryRecordedAsResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_fa275af3-da12-40c8-9456-67fffa3c39ac" xlink:to="loc_incy_InventoryRecordedAsResearchAndDevelopmentExpense_59c65c30-5f7c-44ea-90a1-5af60060cb0c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_PeriodOfDeviationFromAverageCostOfGoodsSold_be9159b5-de03-4076-8b0b-ff00ee68c38d" xlink:href="incy-20220930.xsd#incy_PeriodOfDeviationFromAverageCostOfGoodsSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_fa275af3-da12-40c8-9456-67fffa3c39ac" xlink:to="loc_incy_PeriodOfDeviationFromAverageCostOfGoodsSold_be9159b5-de03-4076-8b0b-ff00ee68c38d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryCurrentTable_bb34abde-b203-4801-b22d-36cf9d83027c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryCurrentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_fa275af3-da12-40c8-9456-67fffa3c39ac" xlink:to="loc_us-gaap_InventoryCurrentTable_bb34abde-b203-4801-b22d-36cf9d83027c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_9a676599-9b87-401b-a981-f0d1688286e9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_InventoryCurrentTable_bb34abde-b203-4801-b22d-36cf9d83027c" xlink:to="loc_srt_RangeAxis_9a676599-9b87-401b-a981-f0d1688286e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9a676599-9b87-401b-a981-f0d1688286e9_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_9a676599-9b87-401b-a981-f0d1688286e9" xlink:to="loc_srt_RangeMember_9a676599-9b87-401b-a981-f0d1688286e9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a79c3f5d-b052-4f71-84c8-07554e8808c3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_9a676599-9b87-401b-a981-f0d1688286e9" xlink:to="loc_srt_RangeMember_a79c3f5d-b052-4f71-84c8-07554e8808c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_9d356d46-522b-4bf4-9c89-321f59dd4962" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_a79c3f5d-b052-4f71-84c8-07554e8808c3" xlink:to="loc_srt_MaximumMember_9d356d46-522b-4bf4-9c89-321f59dd4962" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.incyte.com/role/LicenseAgreementsNovartisDetails" xlink:type="simple" xlink:href="incy-20220930.xsd#LicenseAgreementsNovartisDetails"/>
  <link:definitionLink xlink:role="http://www.incyte.com/role/LicenseAgreementsNovartisDetails" xlink:type="extended" id="i1509c0311b4746858d75d0dbbfc66bfb_LicenseAgreementsNovartisDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_862e195f-6339-49aa-a7d8-f10cfe829c70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived_d6f2fe25-c26c-49e0-b3e2-50391cd19a6f" xlink:href="incy-20220930.xsd#incy_LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_862e195f-6339-49aa-a7d8-f10cfe829c70" xlink:to="loc_incy_LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived_d6f2fe25-c26c-49e0-b3e2-50391cd19a6f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone_d175d63a-739d-4647-bfba-8339b704927e" xlink:href="incy-20220930.xsd#incy_LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_862e195f-6339-49aa-a7d8-f10cfe829c70" xlink:to="loc_incy_LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone_d175d63a-739d-4647-bfba-8339b704927e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_PercentageOfRoyaltyRatePayments_1740a817-e912-4543-ac6b-67fc8ee9392f" xlink:href="incy-20220930.xsd#incy_PercentageOfRoyaltyRatePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_862e195f-6339-49aa-a7d8-f10cfe829c70" xlink:to="loc_incy_PercentageOfRoyaltyRatePayments_1740a817-e912-4543-ac6b-67fc8ee9392f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInRoyaltiesPayable_099d7144-41b6-4645-b29a-d1663ee442d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInRoyaltiesPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_862e195f-6339-49aa-a7d8-f10cfe829c70" xlink:to="loc_us-gaap_IncreaseDecreaseInRoyaltiesPayable_099d7144-41b6-4645-b29a-d1663ee442d4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_RoyaltiesPayable_db43567a-3a34-4fab-87c9-773471fedb9a" xlink:href="incy-20220930.xsd#incy_RoyaltiesPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_862e195f-6339-49aa-a7d8-f10cfe829c70" xlink:to="loc_incy_RoyaltiesPayable_db43567a-3a34-4fab-87c9-773471fedb9a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c22785e6-fb51-4119-90cf-bf29bc051885" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_862e195f-6339-49aa-a7d8-f10cfe829c70" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c22785e6-fb51-4119-90cf-bf29bc051885" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_edef712f-1b8a-4b4f-8c3d-e6d0c8204977" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_862e195f-6339-49aa-a7d8-f10cfe829c70" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_edef712f-1b8a-4b4f-8c3d-e6d0c8204977" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_06c525a4-afc3-4458-8348-6ba686b85b4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_edef712f-1b8a-4b4f-8c3d-e6d0c8204977" xlink:to="loc_us-gaap_TypeOfArrangementAxis_06c525a4-afc3-4458-8348-6ba686b85b4d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_06c525a4-afc3-4458-8348-6ba686b85b4d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_06c525a4-afc3-4458-8348-6ba686b85b4d" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_06c525a4-afc3-4458-8348-6ba686b85b4d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f6cb8589-c23c-428f-9023-9ead7951077d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_06c525a4-afc3-4458-8348-6ba686b85b4d" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f6cb8589-c23c-428f-9023-9ead7951077d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_NovartisMember_8edc7014-8330-405d-980d-0b26a4a3ad7c" xlink:href="incy-20220930.xsd#incy_NovartisMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f6cb8589-c23c-428f-9023-9ead7951077d" xlink:to="loc_incy_NovartisMember_8edc7014-8330-405d-980d-0b26a4a3ad7c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_AchievementOfMilestoneAxis_00ec18fd-2e82-433c-9c7b-14f1acc7c6b3" xlink:href="incy-20220930.xsd#incy_AchievementOfMilestoneAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_edef712f-1b8a-4b4f-8c3d-e6d0c8204977" xlink:to="loc_incy_AchievementOfMilestoneAxis_00ec18fd-2e82-433c-9c7b-14f1acc7c6b3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_AchievementOfMilestoneDomain_00ec18fd-2e82-433c-9c7b-14f1acc7c6b3_default" xlink:href="incy-20220930.xsd#incy_AchievementOfMilestoneDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_incy_AchievementOfMilestoneAxis_00ec18fd-2e82-433c-9c7b-14f1acc7c6b3" xlink:to="loc_incy_AchievementOfMilestoneDomain_00ec18fd-2e82-433c-9c7b-14f1acc7c6b3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_AchievementOfMilestoneDomain_568d2516-b7de-4529-9f1a-ef05bbde32ad" xlink:href="incy-20220930.xsd#incy_AchievementOfMilestoneDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_incy_AchievementOfMilestoneAxis_00ec18fd-2e82-433c-9c7b-14f1acc7c6b3" xlink:to="loc_incy_AchievementOfMilestoneDomain_568d2516-b7de-4529-9f1a-ef05bbde32ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_DevelopmentMilestonesMember_e203d233-c766-402c-b9e6-672f47049cc5" xlink:href="incy-20220930.xsd#incy_DevelopmentMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_incy_AchievementOfMilestoneDomain_568d2516-b7de-4529-9f1a-ef05bbde32ad" xlink:to="loc_incy_DevelopmentMilestonesMember_e203d233-c766-402c-b9e6-672f47049cc5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_RegulatoryMilestonesMember_7d8ca3d2-b1a3-4126-a940-8122bd62fe7f" xlink:href="incy-20220930.xsd#incy_RegulatoryMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_incy_AchievementOfMilestoneDomain_568d2516-b7de-4529-9f1a-ef05bbde32ad" xlink:to="loc_incy_RegulatoryMilestonesMember_7d8ca3d2-b1a3-4126-a940-8122bd62fe7f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_CommercializationMilestonesMember_f696d245-7a08-4bde-833f-3742832f4f2d" xlink:href="incy-20220930.xsd#incy_CommercializationMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_incy_AchievementOfMilestoneDomain_568d2516-b7de-4529-9f1a-ef05bbde32ad" xlink:to="loc_incy_CommercializationMilestonesMember_f696d245-7a08-4bde-833f-3742832f4f2d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_DevelopmentAndRegulatoryMilestonesMember_838d14fa-f9b0-4144-a7a5-f7c5c80b6476" xlink:href="incy-20220930.xsd#incy_DevelopmentAndRegulatoryMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_incy_AchievementOfMilestoneDomain_568d2516-b7de-4529-9f1a-ef05bbde32ad" xlink:to="loc_incy_DevelopmentAndRegulatoryMilestonesMember_838d14fa-f9b0-4144-a7a5-f7c5c80b6476" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_9fefdfee-3609-478a-8846-b5e8b4b16b8f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_edef712f-1b8a-4b4f-8c3d-e6d0c8204977" xlink:to="loc_srt_ProductOrServiceAxis_9fefdfee-3609-478a-8846-b5e8b4b16b8f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_9fefdfee-3609-478a-8846-b5e8b4b16b8f_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_9fefdfee-3609-478a-8846-b5e8b4b16b8f" xlink:to="loc_srt_ProductsAndServicesDomain_9fefdfee-3609-478a-8846-b5e8b4b16b8f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_ca08a919-7e00-499f-950b-0f0afce3c8bd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_9fefdfee-3609-478a-8846-b5e8b4b16b8f" xlink:to="loc_srt_ProductsAndServicesDomain_ca08a919-7e00-499f-950b-0f0afce3c8bd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_aefef99a-bb20-4917-92f6-649569cdeef1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_ca08a919-7e00-499f-950b-0f0afce3c8bd" xlink:to="loc_us-gaap_RoyaltyMember_aefef99a-bb20-4917-92f6-649569cdeef1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_TabrectaMember_ef1f9cbe-893c-47cc-ada4-aad416902c31" xlink:href="incy-20220930.xsd#incy_TabrectaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RoyaltyMember_aefef99a-bb20-4917-92f6-649569cdeef1" xlink:to="loc_incy_TabrectaMember_ef1f9cbe-893c-47cc-ada4-aad416902c31" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_JakaviMember_0205bb45-9b02-47cc-b528-e33f8d544d24" xlink:href="incy-20220930.xsd#incy_JakaviMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RoyaltyMember_aefef99a-bb20-4917-92f6-649569cdeef1" xlink:to="loc_incy_JakaviMember_0205bb45-9b02-47cc-b528-e33f8d544d24" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_JAKAFIMember_8e1cb252-fb10-4134-a493-f89b114ceadc" xlink:href="incy-20220930.xsd#incy_JAKAFIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_ca08a919-7e00-499f-950b-0f0afce3c8bd" xlink:to="loc_incy_JAKAFIMember_8e1cb252-fb10-4134-a493-f89b114ceadc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_MilestoneAndContractRevenueMember_40970cc6-bfc9-4fc4-bedd-46b96f4d91ff" xlink:href="incy-20220930.xsd#incy_MilestoneAndContractRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_ca08a919-7e00-499f-950b-0f0afce3c8bd" xlink:to="loc_incy_MilestoneAndContractRevenueMember_40970cc6-bfc9-4fc4-bedd-46b96f4d91ff" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_TABRECTAPRODUCTANDSERVICESMember_1fb6a4e1-1e8b-4053-94d7-8c2317b6df19" xlink:href="incy-20220930.xsd#incy_TABRECTAPRODUCTANDSERVICESMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_ca08a919-7e00-499f-950b-0f0afce3c8bd" xlink:to="loc_incy_TABRECTAPRODUCTANDSERVICESMember_1fb6a4e1-1e8b-4053-94d7-8c2317b6df19" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_83175ff1-9be5-40de-af08-c1e6f3e292d5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_edef712f-1b8a-4b4f-8c3d-e6d0c8204977" xlink:to="loc_srt_RangeAxis_83175ff1-9be5-40de-af08-c1e6f3e292d5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_83175ff1-9be5-40de-af08-c1e6f3e292d5_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_83175ff1-9be5-40de-af08-c1e6f3e292d5" xlink:to="loc_srt_RangeMember_83175ff1-9be5-40de-af08-c1e6f3e292d5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_11ac3d00-3544-43c2-b7cc-6595744bdb91" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_83175ff1-9be5-40de-af08-c1e6f3e292d5" xlink:to="loc_srt_RangeMember_11ac3d00-3544-43c2-b7cc-6595744bdb91" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_4c8e37d2-58ea-489c-952a-0c881694d8b8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_11ac3d00-3544-43c2-b7cc-6595744bdb91" xlink:to="loc_srt_MinimumMember_4c8e37d2-58ea-489c-952a-0c881694d8b8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_42601a6d-ef1b-4064-a518-ad49b2dbf80f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_11ac3d00-3544-43c2-b7cc-6595744bdb91" xlink:to="loc_srt_MaximumMember_42601a6d-ef1b-4064-a518-ad49b2dbf80f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_4e58ccba-b17e-4f89-9686-bd80853f10f0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_edef712f-1b8a-4b4f-8c3d-e6d0c8204977" xlink:to="loc_srt_StatementGeographicalAxis_4e58ccba-b17e-4f89-9686-bd80853f10f0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_4e58ccba-b17e-4f89-9686-bd80853f10f0_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_4e58ccba-b17e-4f89-9686-bd80853f10f0" xlink:to="loc_srt_SegmentGeographicalDomain_4e58ccba-b17e-4f89-9686-bd80853f10f0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_2226464d-e773-4e6c-b15f-da1b76fec2bb" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_4e58ccba-b17e-4f89-9686-bd80853f10f0" xlink:to="loc_srt_SegmentGeographicalDomain_2226464d-e773-4e6c-b15f-da1b76fec2bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_e8cf1f5f-f2be-4f86-80a5-5c8fceaf6c39" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_2226464d-e773-4e6c-b15f-da1b76fec2bb" xlink:to="loc_country_US_e8cf1f5f-f2be-4f86-80a5-5c8fceaf6c39" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_27a1bb9a-556b-4e08-b691-17a580861830" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_2226464d-e773-4e6c-b15f-da1b76fec2bb" xlink:to="loc_us-gaap_NonUsMember_27a1bb9a-556b-4e08-b691-17a580861830" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.incyte.com/role/LicenseAgreementsLillyDetails" xlink:type="simple" xlink:href="incy-20220930.xsd#LicenseAgreementsLillyDetails"/>
  <link:definitionLink xlink:role="http://www.incyte.com/role/LicenseAgreementsLillyDetails" xlink:type="extended" id="i42720318696d46f08c6446c1e6bc1d2b_LicenseAgreementsLillyDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_94b44a1c-6420-4bb0-b858-8d31b6542f2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived_7de89e80-d3e5-4775-a969-21431c605b1c" xlink:href="incy-20220930.xsd#incy_LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_94b44a1c-6420-4bb0-b858-8d31b6542f2d" xlink:to="loc_incy_LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived_7de89e80-d3e5-4775-a969-21431c605b1c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone_69736be1-33cc-40f3-b9cc-9244adf67c2f" xlink:href="incy-20220930.xsd#incy_LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_94b44a1c-6420-4bb0-b858-8d31b6542f2d" xlink:to="loc_incy_LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone_69736be1-33cc-40f3-b9cc-9244adf67c2f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_23845319-a06b-4dd1-b9e2-d2868ffdb758" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_94b44a1c-6420-4bb0-b858-8d31b6542f2d" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_23845319-a06b-4dd1-b9e2-d2868ffdb758" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInRoyaltiesPayable_7fdc523e-9099-43e4-baad-262c3ec4a362" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInRoyaltiesPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_94b44a1c-6420-4bb0-b858-8d31b6542f2d" xlink:to="loc_us-gaap_IncreaseDecreaseInRoyaltiesPayable_7fdc523e-9099-43e4-baad-262c3ec4a362" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_LicenseAgreementAdditionalMilestonePayments_4cc1d314-75ba-4f83-b58a-f9b41e910dd3" xlink:href="incy-20220930.xsd#incy_LicenseAgreementAdditionalMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_94b44a1c-6420-4bb0-b858-8d31b6542f2d" xlink:to="loc_incy_LicenseAgreementAdditionalMilestonePayments_4cc1d314-75ba-4f83-b58a-f9b41e910dd3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_LicenseAgreementMilestonePaymentAmountPaid_3b6d9e7f-d7f7-448d-98d0-d0530c072359" xlink:href="incy-20220930.xsd#incy_LicenseAgreementMilestonePaymentAmountPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_94b44a1c-6420-4bb0-b858-8d31b6542f2d" xlink:to="loc_incy_LicenseAgreementMilestonePaymentAmountPaid_3b6d9e7f-d7f7-448d-98d0-d0530c072359" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_572226ea-d424-43ef-8f0b-29988f6f9b1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_94b44a1c-6420-4bb0-b858-8d31b6542f2d" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_572226ea-d424-43ef-8f0b-29988f6f9b1e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_752bf19c-db97-43ae-8987-5f416fe27535" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_572226ea-d424-43ef-8f0b-29988f6f9b1e" xlink:to="loc_us-gaap_TypeOfArrangementAxis_752bf19c-db97-43ae-8987-5f416fe27535" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_752bf19c-db97-43ae-8987-5f416fe27535_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_752bf19c-db97-43ae-8987-5f416fe27535" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_752bf19c-db97-43ae-8987-5f416fe27535_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_52fa2bf6-0098-4340-b565-63c037fd9346" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_752bf19c-db97-43ae-8987-5f416fe27535" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_52fa2bf6-0098-4340-b565-63c037fd9346" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_EliLillyMember_5c9978b2-92ca-43d6-98b8-8db6b2c176a9" xlink:href="incy-20220930.xsd#incy_EliLillyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_52fa2bf6-0098-4340-b565-63c037fd9346" xlink:to="loc_incy_EliLillyMember_5c9978b2-92ca-43d6-98b8-8db6b2c176a9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_863ca883-8209-4e07-b2c2-9533e0f89df6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_572226ea-d424-43ef-8f0b-29988f6f9b1e" xlink:to="loc_srt_ProductOrServiceAxis_863ca883-8209-4e07-b2c2-9533e0f89df6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_863ca883-8209-4e07-b2c2-9533e0f89df6_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_863ca883-8209-4e07-b2c2-9533e0f89df6" xlink:to="loc_srt_ProductsAndServicesDomain_863ca883-8209-4e07-b2c2-9533e0f89df6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_502d74cb-0e6c-41d6-9cb8-26cecbd56951" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_863ca883-8209-4e07-b2c2-9533e0f89df6" xlink:to="loc_srt_ProductsAndServicesDomain_502d74cb-0e6c-41d6-9cb8-26cecbd56951" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_OlumiantMember_4837c7ab-e2a8-435b-a25a-249027a575ac" xlink:href="incy-20220930.xsd#incy_OlumiantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_502d74cb-0e6c-41d6-9cb8-26cecbd56951" xlink:to="loc_incy_OlumiantMember_4837c7ab-e2a8-435b-a25a-249027a575ac" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_OlumiantRoyaltyMember_72ee6cef-a303-4ec4-93b5-0f2188ae040b" xlink:href="incy-20220930.xsd#incy_OlumiantRoyaltyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_502d74cb-0e6c-41d6-9cb8-26cecbd56951" xlink:to="loc_incy_OlumiantRoyaltyMember_72ee6cef-a303-4ec4-93b5-0f2188ae040b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_GvhdMember_ed979290-6d32-4e0c-a3ba-b4c780e97980" xlink:href="incy-20220930.xsd#incy_GvhdMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_502d74cb-0e6c-41d6-9cb8-26cecbd56951" xlink:to="loc_incy_GvhdMember_ed979290-6d32-4e0c-a3ba-b4c780e97980" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_AchievementOfMilestoneAxis_0ac12d09-7e73-45db-b814-e324187dc9dd" xlink:href="incy-20220930.xsd#incy_AchievementOfMilestoneAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_572226ea-d424-43ef-8f0b-29988f6f9b1e" xlink:to="loc_incy_AchievementOfMilestoneAxis_0ac12d09-7e73-45db-b814-e324187dc9dd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_AchievementOfMilestoneDomain_0ac12d09-7e73-45db-b814-e324187dc9dd_default" xlink:href="incy-20220930.xsd#incy_AchievementOfMilestoneDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_incy_AchievementOfMilestoneAxis_0ac12d09-7e73-45db-b814-e324187dc9dd" xlink:to="loc_incy_AchievementOfMilestoneDomain_0ac12d09-7e73-45db-b814-e324187dc9dd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_AchievementOfMilestoneDomain_1e6d963f-ac87-4551-96d5-9fb75daccaf2" xlink:href="incy-20220930.xsd#incy_AchievementOfMilestoneDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_incy_AchievementOfMilestoneAxis_0ac12d09-7e73-45db-b814-e324187dc9dd" xlink:to="loc_incy_AchievementOfMilestoneDomain_1e6d963f-ac87-4551-96d5-9fb75daccaf2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_DevelopmentMilestonesMember_1bed7a60-4e1c-466e-8b60-20a7fa17a189" xlink:href="incy-20220930.xsd#incy_DevelopmentMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_incy_AchievementOfMilestoneDomain_1e6d963f-ac87-4551-96d5-9fb75daccaf2" xlink:to="loc_incy_DevelopmentMilestonesMember_1bed7a60-4e1c-466e-8b60-20a7fa17a189" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_RegulatoryMilestonesMember_25681fba-06ab-45bb-9968-18800f26ed21" xlink:href="incy-20220930.xsd#incy_RegulatoryMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_incy_AchievementOfMilestoneDomain_1e6d963f-ac87-4551-96d5-9fb75daccaf2" xlink:to="loc_incy_RegulatoryMilestonesMember_25681fba-06ab-45bb-9968-18800f26ed21" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_CommercializationMilestonesMember_f4191d2f-9fd3-41e7-bfe8-147c4fd19d32" xlink:href="incy-20220930.xsd#incy_CommercializationMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_incy_AchievementOfMilestoneDomain_1e6d963f-ac87-4551-96d5-9fb75daccaf2" xlink:to="loc_incy_CommercializationMilestonesMember_f4191d2f-9fd3-41e7-bfe8-147c4fd19d32" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_657edd6a-a51b-4bf6-b3d3-59d0c0622fa3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_572226ea-d424-43ef-8f0b-29988f6f9b1e" xlink:to="loc_srt_RangeAxis_657edd6a-a51b-4bf6-b3d3-59d0c0622fa3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_657edd6a-a51b-4bf6-b3d3-59d0c0622fa3_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_657edd6a-a51b-4bf6-b3d3-59d0c0622fa3" xlink:to="loc_srt_RangeMember_657edd6a-a51b-4bf6-b3d3-59d0c0622fa3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ccd07ff7-b7db-44d4-a6a5-ed30b02fa20c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_657edd6a-a51b-4bf6-b3d3-59d0c0622fa3" xlink:to="loc_srt_RangeMember_ccd07ff7-b7db-44d4-a6a5-ed30b02fa20c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_b09befa0-0e80-42f6-95cc-e4ef9f5e6234" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_ccd07ff7-b7db-44d4-a6a5-ed30b02fa20c" xlink:to="loc_srt_MaximumMember_b09befa0-0e80-42f6-95cc-e4ef9f5e6234" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_8c25c760-8957-4782-af07-23c7378a3bf7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_572226ea-d424-43ef-8f0b-29988f6f9b1e" xlink:to="loc_srt_StatementGeographicalAxis_8c25c760-8957-4782-af07-23c7378a3bf7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_8c25c760-8957-4782-af07-23c7378a3bf7_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_8c25c760-8957-4782-af07-23c7378a3bf7" xlink:to="loc_srt_SegmentGeographicalDomain_8c25c760-8957-4782-af07-23c7378a3bf7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_4d2d1641-c522-4aba-b35d-335f6df8d8c6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_8c25c760-8957-4782-af07-23c7378a3bf7" xlink:to="loc_srt_SegmentGeographicalDomain_4d2d1641-c522-4aba-b35d-335f6df8d8c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_330e9898-63ef-4e1e-8a9c-1860bca860b2" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_4d2d1641-c522-4aba-b35d-335f6df8d8c6" xlink:to="loc_country_US_330e9898-63ef-4e1e-8a9c-1860bca860b2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember_c9f1e257-88f1-403a-ba08-1e6793fd2f3b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EuropeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_4d2d1641-c522-4aba-b35d-335f6df8d8c6" xlink:to="loc_srt_EuropeMember_c9f1e257-88f1-403a-ba08-1e6793fd2f3b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_JP_2886e706-6fc5-4b4b-9304-97cbdbe6ecfd" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_JP"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_4d2d1641-c522-4aba-b35d-335f6df8d8c6" xlink:to="loc_country_JP_2886e706-6fc5-4b4b-9304-97cbdbe6ecfd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_52d21724-3477-4388-b6bb-06219f770666" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_4d2d1641-c522-4aba-b35d-335f6df8d8c6" xlink:to="loc_us-gaap_NonUsMember_52d21724-3477-4388-b6bb-06219f770666" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.incyte.com/role/LicenseAgreementsAgenusDetails" xlink:type="simple" xlink:href="incy-20220930.xsd#LicenseAgreementsAgenusDetails"/>
  <link:definitionLink xlink:role="http://www.incyte.com/role/LicenseAgreementsAgenusDetails" xlink:type="extended" id="i0d7fdb35ed45470e928454b481c44a13_LicenseAgreementsAgenusDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_095b2c32-7bb8-4262-bdef-a55bd7d35ee8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_PercentageOfRoyaltyRatePayments_cdab4097-9b85-4900-8028-52e6c5a9e6ca" xlink:href="incy-20220930.xsd#incy_PercentageOfRoyaltyRatePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_095b2c32-7bb8-4262-bdef-a55bd7d35ee8" xlink:to="loc_incy_PercentageOfRoyaltyRatePayments_cdab4097-9b85-4900-8028-52e6c5a9e6ca" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_LicenseAgreementTerminationNoticePeriod_1bb17072-9866-4ea5-963a-7abfa0c1e179" xlink:href="incy-20220930.xsd#incy_LicenseAgreementTerminationNoticePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_095b2c32-7bb8-4262-bdef-a55bd7d35ee8" xlink:to="loc_incy_LicenseAgreementTerminationNoticePeriod_1bb17072-9866-4ea5-963a-7abfa0c1e179" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_LicenseAgreementMilestonePaymentAmountPaid_39ce6768-8815-45a5-a238-b9c1a57b1f98" xlink:href="incy-20220930.xsd#incy_LicenseAgreementMilestonePaymentAmountPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_095b2c32-7bb8-4262-bdef-a55bd7d35ee8" xlink:to="loc_incy_LicenseAgreementMilestonePaymentAmountPaid_39ce6768-8815-45a5-a238-b9c1a57b1f98" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_LicenseAgreementAdditionalMilestonePayments_09d0760f-6faf-488c-9bfa-2e8b4b987ff2" xlink:href="incy-20220930.xsd#incy_LicenseAgreementAdditionalMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_095b2c32-7bb8-4262-bdef-a55bd7d35ee8" xlink:to="loc_incy_LicenseAgreementAdditionalMilestonePayments_09d0760f-6faf-488c-9bfa-2e8b4b987ff2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_PurchaseOfCommonStockUnderStockPurchaseAgreementInShares_6b8b94a9-e48f-4001-88cf-8990c97c4a3c" xlink:href="incy-20220930.xsd#incy_PurchaseOfCommonStockUnderStockPurchaseAgreementInShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_095b2c32-7bb8-4262-bdef-a55bd7d35ee8" xlink:to="loc_incy_PurchaseOfCommonStockUnderStockPurchaseAgreementInShares_6b8b94a9-e48f-4001-88cf-8990c97c4a3c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentAggregateCost_df51160a-5e89-4dff-b2cb-80a3340cdd04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentAggregateCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_095b2c32-7bb8-4262-bdef-a55bd7d35ee8" xlink:to="loc_us-gaap_EquityMethodInvestmentAggregateCost_df51160a-5e89-4dff-b2cb-80a3340cdd04" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_db9a3674-96f7-46ed-89cb-e249845f05c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_095b2c32-7bb8-4262-bdef-a55bd7d35ee8" xlink:to="loc_us-gaap_SharePrice_db9a3674-96f7-46ed-89cb-e249845f05c9" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_6ed40526-68eb-47c4-86ff-dfe27f08f0ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_095b2c32-7bb8-4262-bdef-a55bd7d35ee8" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_6ed40526-68eb-47c4-86ff-dfe27f08f0ab" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_3fc93bb0-f2d5-4449-a5a1-3c29d1152114" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_095b2c32-7bb8-4262-bdef-a55bd7d35ee8" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_3fc93bb0-f2d5-4449-a5a1-3c29d1152114" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments_dd9b618c-cbdd-4494-8823-17d7ba4addeb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_095b2c32-7bb8-4262-bdef-a55bd7d35ee8" xlink:to="loc_us-gaap_LongTermInvestments_dd9b618c-cbdd-4494-8823-17d7ba4addeb" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_8b484277-2845-4260-b6db-96b899e93d62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_095b2c32-7bb8-4262-bdef-a55bd7d35ee8" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_8b484277-2845-4260-b6db-96b899e93d62" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_6b4b9aeb-a498-4d21-a984-734482aafdd4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_095b2c32-7bb8-4262-bdef-a55bd7d35ee8" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_6b4b9aeb-a498-4d21-a984-734482aafdd4" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_fd745af2-1da6-485a-94a6-823c6d9c2c58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_095b2c32-7bb8-4262-bdef-a55bd7d35ee8" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_fd745af2-1da6-485a-94a6-823c6d9c2c58" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_8d2c57cb-c00f-43f0-8e5d-7038795d28de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_fd745af2-1da6-485a-94a6-823c6d9c2c58" xlink:to="loc_us-gaap_TypeOfArrangementAxis_8d2c57cb-c00f-43f0-8e5d-7038795d28de" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8d2c57cb-c00f-43f0-8e5d-7038795d28de_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_8d2c57cb-c00f-43f0-8e5d-7038795d28de" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8d2c57cb-c00f-43f0-8e5d-7038795d28de_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d3f84bc9-a105-4eea-99a7-af5a911758ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_8d2c57cb-c00f-43f0-8e5d-7038795d28de" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d3f84bc9-a105-4eea-99a7-af5a911758ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_AgenusMember_150181b4-7a07-4eb9-a84e-ec55f39dd304" xlink:href="incy-20220930.xsd#incy_AgenusMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d3f84bc9-a105-4eea-99a7-af5a911758ac" xlink:to="loc_incy_AgenusMember_150181b4-7a07-4eb9-a84e-ec55f39dd304" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_StockPurchaseAgreementMember_4eae7046-527a-4e6a-8440-d3dca6bd4d1d" xlink:href="incy-20220930.xsd#incy_StockPurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d3f84bc9-a105-4eea-99a7-af5a911758ac" xlink:to="loc_incy_StockPurchaseAgreementMember_4eae7046-527a-4e6a-8440-d3dca6bd4d1d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_AchievementOfMilestoneAxis_3c55cb92-856e-47a0-9652-19fa540671af" xlink:href="incy-20220930.xsd#incy_AchievementOfMilestoneAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_fd745af2-1da6-485a-94a6-823c6d9c2c58" xlink:to="loc_incy_AchievementOfMilestoneAxis_3c55cb92-856e-47a0-9652-19fa540671af" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_AchievementOfMilestoneDomain_3c55cb92-856e-47a0-9652-19fa540671af_default" xlink:href="incy-20220930.xsd#incy_AchievementOfMilestoneDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_incy_AchievementOfMilestoneAxis_3c55cb92-856e-47a0-9652-19fa540671af" xlink:to="loc_incy_AchievementOfMilestoneDomain_3c55cb92-856e-47a0-9652-19fa540671af_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_AchievementOfMilestoneDomain_8d67c7f5-9b80-4211-b00a-59d7a6076880" xlink:href="incy-20220930.xsd#incy_AchievementOfMilestoneDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_incy_AchievementOfMilestoneAxis_3c55cb92-856e-47a0-9652-19fa540671af" xlink:to="loc_incy_AchievementOfMilestoneDomain_8d67c7f5-9b80-4211-b00a-59d7a6076880" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_DevelopmentRegulatoryAndCommercializationMilestonesMember_df77e68a-4aa8-44f9-b474-f5199e46e13f" xlink:href="incy-20220930.xsd#incy_DevelopmentRegulatoryAndCommercializationMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_incy_AchievementOfMilestoneDomain_8d67c7f5-9b80-4211-b00a-59d7a6076880" xlink:to="loc_incy_DevelopmentRegulatoryAndCommercializationMilestonesMember_df77e68a-4aa8-44f9-b474-f5199e46e13f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_5c70a62f-cc55-4caa-88b9-da70d193157f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_fd745af2-1da6-485a-94a6-823c6d9c2c58" xlink:to="loc_srt_ProductOrServiceAxis_5c70a62f-cc55-4caa-88b9-da70d193157f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_5c70a62f-cc55-4caa-88b9-da70d193157f_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_5c70a62f-cc55-4caa-88b9-da70d193157f" xlink:to="loc_srt_ProductsAndServicesDomain_5c70a62f-cc55-4caa-88b9-da70d193157f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_d94950d9-4a13-4340-80dc-a23d224c90e6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_5c70a62f-cc55-4caa-88b9-da70d193157f" xlink:to="loc_srt_ProductsAndServicesDomain_d94950d9-4a13-4340-80dc-a23d224c90e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_ProductGroupOneMember_f7d36bfb-e573-464d-b28c-93708f5be873" xlink:href="incy-20220930.xsd#incy_ProductGroupOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d94950d9-4a13-4340-80dc-a23d224c90e6" xlink:to="loc_incy_ProductGroupOneMember_f7d36bfb-e573-464d-b28c-93708f5be873" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_ProductGroupTwoMember_70c3433d-76fa-4b5a-ad78-edbed53ab2ee" xlink:href="incy-20220930.xsd#incy_ProductGroupTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d94950d9-4a13-4340-80dc-a23d224c90e6" xlink:to="loc_incy_ProductGroupTwoMember_70c3433d-76fa-4b5a-ad78-edbed53ab2ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_7ae8570e-7521-43a4-8b60-255b4a1cd933" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_fd745af2-1da6-485a-94a6-823c6d9c2c58" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_7ae8570e-7521-43a4-8b60-255b4a1cd933" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_7ae8570e-7521-43a4-8b60-255b4a1cd933_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_7ae8570e-7521-43a4-8b60-255b4a1cd933" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_7ae8570e-7521-43a4-8b60-255b4a1cd933_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_0b4b350d-e067-4ee2-8af7-ee5b0dff0d2d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_7ae8570e-7521-43a4-8b60-255b4a1cd933" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_0b4b350d-e067-4ee2-8af7-ee5b0dff0d2d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_AgenusMember_768ec690-2ec4-4210-8ed8-2dad5d22ed60" xlink:href="incy-20220930.xsd#incy_AgenusMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_0b4b350d-e067-4ee2-8af7-ee5b0dff0d2d" xlink:to="loc_incy_AgenusMember_768ec690-2ec4-4210-8ed8-2dad5d22ed60" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_e226616c-9d89-4a94-91e0-b6a222d5f4d2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_fd745af2-1da6-485a-94a6-823c6d9c2c58" xlink:to="loc_srt_RangeAxis_e226616c-9d89-4a94-91e0-b6a222d5f4d2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e226616c-9d89-4a94-91e0-b6a222d5f4d2_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_e226616c-9d89-4a94-91e0-b6a222d5f4d2" xlink:to="loc_srt_RangeMember_e226616c-9d89-4a94-91e0-b6a222d5f4d2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_aa25c351-779c-4bb3-b591-e2c89642fc98" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_e226616c-9d89-4a94-91e0-b6a222d5f4d2" xlink:to="loc_srt_RangeMember_aa25c351-779c-4bb3-b591-e2c89642fc98" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_0868cb89-4254-436d-801f-c285ef96c76e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_aa25c351-779c-4bb3-b591-e2c89642fc98" xlink:to="loc_srt_MinimumMember_0868cb89-4254-436d-801f-c285ef96c76e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_dcde7e26-e318-445c-a6a9-5c3fa030211d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_aa25c351-779c-4bb3-b591-e2c89642fc98" xlink:to="loc_srt_MaximumMember_dcde7e26-e318-445c-a6a9-5c3fa030211d" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.incyte.com/role/LicenseAgreementsMerusDetails" xlink:type="simple" xlink:href="incy-20220930.xsd#LicenseAgreementsMerusDetails"/>
  <link:definitionLink xlink:role="http://www.incyte.com/role/LicenseAgreementsMerusDetails" xlink:type="extended" id="i63159100208e4a8a892bca441058ab83_LicenseAgreementsMerusDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_ce56eb54-980e-4b85-846d-d6adbf26aa6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_LicenseAgreementMaximumNumberOfIndependentPrograms_95f85d83-4b88-4b7e-8969-9d8541a7cdf0" xlink:href="incy-20220930.xsd#incy_LicenseAgreementMaximumNumberOfIndependentPrograms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_ce56eb54-980e-4b85-846d-d6adbf26aa6c" xlink:to="loc_incy_LicenseAgreementMaximumNumberOfIndependentPrograms_95f85d83-4b88-4b7e-8969-9d8541a7cdf0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_LicenseAgreementNumberOfAdditionalPreclinicalDiscoveryPrograms_618252f4-8b88-411d-b073-4f426e91c2bb" xlink:href="incy-20220930.xsd#incy_LicenseAgreementNumberOfAdditionalPreclinicalDiscoveryPrograms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_ce56eb54-980e-4b85-846d-d6adbf26aa6c" xlink:to="loc_incy_LicenseAgreementNumberOfAdditionalPreclinicalDiscoveryPrograms_618252f4-8b88-411d-b073-4f426e91c2bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_NumberOfProgramsUnderWhichResultingProductsAreCoFundedForDevelopment_0782f8c0-dd6a-411d-ab3a-f0e5c0c85768" xlink:href="incy-20220930.xsd#incy_NumberOfProgramsUnderWhichResultingProductsAreCoFundedForDevelopment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_ce56eb54-980e-4b85-846d-d6adbf26aa6c" xlink:to="loc_incy_NumberOfProgramsUnderWhichResultingProductsAreCoFundedForDevelopment_0782f8c0-dd6a-411d-ab3a-f0e5c0c85768" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_PercentageFundingOnCostOnPossibleElectionOfCodevelopmentOfCompounds_99203220-ca76-4263-a3d4-bc23d27960f0" xlink:href="incy-20220930.xsd#incy_PercentageFundingOnCostOnPossibleElectionOfCodevelopmentOfCompounds"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_ce56eb54-980e-4b85-846d-d6adbf26aa6c" xlink:to="loc_incy_PercentageFundingOnCostOnPossibleElectionOfCodevelopmentOfCompounds_99203220-ca76-4263-a3d4-bc23d27960f0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_LicenseAgreementAdditionalMilestonePayments_0b4f1d07-bdf5-4753-bf44-211027cde7c1" xlink:href="incy-20220930.xsd#incy_LicenseAgreementAdditionalMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_ce56eb54-980e-4b85-846d-d6adbf26aa6c" xlink:to="loc_incy_LicenseAgreementAdditionalMilestonePayments_0b4f1d07-bdf5-4753-bf44-211027cde7c1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_PercentageOfRoyaltyRatePayments_f913a354-4af9-4250-8c39-36767f7f110b" xlink:href="incy-20220930.xsd#incy_PercentageOfRoyaltyRatePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_ce56eb54-980e-4b85-846d-d6adbf26aa6c" xlink:to="loc_incy_PercentageOfRoyaltyRatePayments_f913a354-4af9-4250-8c39-36767f7f110b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_CollaborationAgreementProfitSharingPercentage_a1a3d6a4-4f73-4ace-bad2-370902c0d150" xlink:href="incy-20220930.xsd#incy_CollaborationAgreementProfitSharingPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_ce56eb54-980e-4b85-846d-d6adbf26aa6c" xlink:to="loc_incy_CollaborationAgreementProfitSharingPercentage_a1a3d6a4-4f73-4ace-bad2-370902c0d150" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_PercentageOfProfitsLosses_7f6560c1-63cd-482e-9a74-9488f50571b6" xlink:href="incy-20220930.xsd#incy_PercentageOfProfitsLosses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_ce56eb54-980e-4b85-846d-d6adbf26aa6c" xlink:to="loc_incy_PercentageOfProfitsLosses_7f6560c1-63cd-482e-9a74-9488f50571b6" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_LicenseAgreementMilestonePaymentAmountPaid_7506d442-50f0-4ec1-b5c5-5f291c5ac946" xlink:href="incy-20220930.xsd#incy_LicenseAgreementMilestonePaymentAmountPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_ce56eb54-980e-4b85-846d-d6adbf26aa6c" xlink:to="loc_incy_LicenseAgreementMilestonePaymentAmountPaid_7506d442-50f0-4ec1-b5c5-5f291c5ac946" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_PurchaseOfCommonStockUnderStockPurchaseAgreementInShares_c5489234-6371-455b-8cbf-c25b9ee216b4" xlink:href="incy-20220930.xsd#incy_PurchaseOfCommonStockUnderStockPurchaseAgreementInShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_ce56eb54-980e-4b85-846d-d6adbf26aa6c" xlink:to="loc_incy_PurchaseOfCommonStockUnderStockPurchaseAgreementInShares_c5489234-6371-455b-8cbf-c25b9ee216b4" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentAggregateCost_30f12511-edf6-4661-af07-00176685a90e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentAggregateCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_ce56eb54-980e-4b85-846d-d6adbf26aa6c" xlink:to="loc_us-gaap_EquityMethodInvestmentAggregateCost_30f12511-edf6-4661-af07-00176685a90e" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_4a32403d-5e81-4520-ab6b-612dd58aeff9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_ce56eb54-980e-4b85-846d-d6adbf26aa6c" xlink:to="loc_us-gaap_SharePrice_4a32403d-5e81-4520-ab6b-612dd58aeff9" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_EquityMethodInvestmentSharesPurchased_fe751eea-4d12-4d82-82c8-db7a0c705abd" xlink:href="incy-20220930.xsd#incy_EquityMethodInvestmentSharesPurchased"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_ce56eb54-980e-4b85-846d-d6adbf26aa6c" xlink:to="loc_incy_EquityMethodInvestmentSharesPurchased_fe751eea-4d12-4d82-82c8-db7a0c705abd" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_4f1ce03d-5b59-4627-96c2-d421f0c7a75f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_ce56eb54-980e-4b85-846d-d6adbf26aa6c" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_4f1ce03d-5b59-4627-96c2-d421f0c7a75f" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentQuotedMarketValue_bf876e3f-36a7-437b-9341-ec327d2b4892" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentQuotedMarketValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_ce56eb54-980e-4b85-846d-d6adbf26aa6c" xlink:to="loc_us-gaap_EquityMethodInvestmentQuotedMarketValue_bf876e3f-36a7-437b-9341-ec327d2b4892" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_5bb14032-2af4-4c81-91f0-a9dd29a425ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_ce56eb54-980e-4b85-846d-d6adbf26aa6c" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_5bb14032-2af4-4c81-91f0-a9dd29a425ce" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_0e82322d-4dd6-4598-b630-067aca1eda53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_ce56eb54-980e-4b85-846d-d6adbf26aa6c" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_0e82322d-4dd6-4598-b630-067aca1eda53" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_f806fbc3-11f4-46a4-8e55-414d53a0b8d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_ce56eb54-980e-4b85-846d-d6adbf26aa6c" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_f806fbc3-11f4-46a4-8e55-414d53a0b8d5" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_952ea747-9ca0-4454-b2a5-2082f3609da4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_ce56eb54-980e-4b85-846d-d6adbf26aa6c" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_952ea747-9ca0-4454-b2a5-2082f3609da4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_e6158c73-6a8a-4a3b-9bdb-4a5775d22804" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_952ea747-9ca0-4454-b2a5-2082f3609da4" xlink:to="loc_us-gaap_TypeOfArrangementAxis_e6158c73-6a8a-4a3b-9bdb-4a5775d22804" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e6158c73-6a8a-4a3b-9bdb-4a5775d22804_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_e6158c73-6a8a-4a3b-9bdb-4a5775d22804" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e6158c73-6a8a-4a3b-9bdb-4a5775d22804_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2c528aad-a7e8-4448-9357-722ba58d29cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_e6158c73-6a8a-4a3b-9bdb-4a5775d22804" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2c528aad-a7e8-4448-9357-722ba58d29cb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_MerusNVMember_d7981488-8c75-43ed-aff0-80e9df15222b" xlink:href="incy-20220930.xsd#incy_MerusNVMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2c528aad-a7e8-4448-9357-722ba58d29cb" xlink:to="loc_incy_MerusNVMember_d7981488-8c75-43ed-aff0-80e9df15222b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_StockPurchaseAgreementMember_5a7cb356-7977-4938-a02f-e6befa6ca5b9" xlink:href="incy-20220930.xsd#incy_StockPurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2c528aad-a7e8-4448-9357-722ba58d29cb" xlink:to="loc_incy_StockPurchaseAgreementMember_5a7cb356-7977-4938-a02f-e6befa6ca5b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_6a0e7f91-07b9-4c60-bb5c-353b26e99f27" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_952ea747-9ca0-4454-b2a5-2082f3609da4" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_6a0e7f91-07b9-4c60-bb5c-353b26e99f27" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_6a0e7f91-07b9-4c60-bb5c-353b26e99f27_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_6a0e7f91-07b9-4c60-bb5c-353b26e99f27" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_6a0e7f91-07b9-4c60-bb5c-353b26e99f27_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_fde2177c-46f5-41d9-9b73-3aa6f6f79fc9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_6a0e7f91-07b9-4c60-bb5c-353b26e99f27" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_fde2177c-46f5-41d9-9b73-3aa6f6f79fc9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_MerusNVMember_26830916-5611-4db8-bfa3-adb33c04f168" xlink:href="incy-20220930.xsd#incy_MerusNVMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_fde2177c-46f5-41d9-9b73-3aa6f6f79fc9" xlink:to="loc_incy_MerusNVMember_26830916-5611-4db8-bfa3-adb33c04f168" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_f24b64ae-1a97-4bc7-9456-aaea0a04c7ec" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_952ea747-9ca0-4454-b2a5-2082f3609da4" xlink:to="loc_srt_RangeAxis_f24b64ae-1a97-4bc7-9456-aaea0a04c7ec" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f24b64ae-1a97-4bc7-9456-aaea0a04c7ec_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_f24b64ae-1a97-4bc7-9456-aaea0a04c7ec" xlink:to="loc_srt_RangeMember_f24b64ae-1a97-4bc7-9456-aaea0a04c7ec_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e7a8cbfb-de5f-455b-ae76-8b79f31f3a0b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_f24b64ae-1a97-4bc7-9456-aaea0a04c7ec" xlink:to="loc_srt_RangeMember_e7a8cbfb-de5f-455b-ae76-8b79f31f3a0b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_d7122f7b-c05b-4bcc-bf8e-a5b20aa85626" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_e7a8cbfb-de5f-455b-ae76-8b79f31f3a0b" xlink:to="loc_srt_MinimumMember_d7122f7b-c05b-4bcc-bf8e-a5b20aa85626" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_50a45661-2d19-4499-97c9-145cbefd27f2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_e7a8cbfb-de5f-455b-ae76-8b79f31f3a0b" xlink:to="loc_srt_MaximumMember_50a45661-2d19-4499-97c9-145cbefd27f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_AchievementOfMilestoneAxis_af24478c-25fd-41bc-940f-3bc1e9a2cb50" xlink:href="incy-20220930.xsd#incy_AchievementOfMilestoneAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_952ea747-9ca0-4454-b2a5-2082f3609da4" xlink:to="loc_incy_AchievementOfMilestoneAxis_af24478c-25fd-41bc-940f-3bc1e9a2cb50" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_AchievementOfMilestoneDomain_af24478c-25fd-41bc-940f-3bc1e9a2cb50_default" xlink:href="incy-20220930.xsd#incy_AchievementOfMilestoneDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_incy_AchievementOfMilestoneAxis_af24478c-25fd-41bc-940f-3bc1e9a2cb50" xlink:to="loc_incy_AchievementOfMilestoneDomain_af24478c-25fd-41bc-940f-3bc1e9a2cb50_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_AchievementOfMilestoneDomain_5d98d41a-bbac-405b-9e43-53e6739436cc" xlink:href="incy-20220930.xsd#incy_AchievementOfMilestoneDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_incy_AchievementOfMilestoneAxis_af24478c-25fd-41bc-940f-3bc1e9a2cb50" xlink:to="loc_incy_AchievementOfMilestoneDomain_5d98d41a-bbac-405b-9e43-53e6739436cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_DevelopmentAndRegulatoryMilestonesMember_833db91c-a2a8-4518-bad5-50233df21082" xlink:href="incy-20220930.xsd#incy_DevelopmentAndRegulatoryMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_incy_AchievementOfMilestoneDomain_5d98d41a-bbac-405b-9e43-53e6739436cc" xlink:to="loc_incy_DevelopmentAndRegulatoryMilestonesMember_833db91c-a2a8-4518-bad5-50233df21082" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_CommercializationMilestonesMember_17896e74-b81e-4c7b-b878-a52e2200cb4f" xlink:href="incy-20220930.xsd#incy_CommercializationMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_incy_AchievementOfMilestoneDomain_5d98d41a-bbac-405b-9e43-53e6739436cc" xlink:to="loc_incy_CommercializationMilestonesMember_17896e74-b81e-4c7b-b878-a52e2200cb4f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_e6ac5b67-60f4-49f1-b7f0-5f862ebca5ef" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_952ea747-9ca0-4454-b2a5-2082f3609da4" xlink:to="loc_srt_StatementGeographicalAxis_e6ac5b67-60f4-49f1-b7f0-5f862ebca5ef" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_e6ac5b67-60f4-49f1-b7f0-5f862ebca5ef_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_e6ac5b67-60f4-49f1-b7f0-5f862ebca5ef" xlink:to="loc_srt_SegmentGeographicalDomain_e6ac5b67-60f4-49f1-b7f0-5f862ebca5ef_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_19e7574e-01a1-4d87-a2a7-86fa7e34e2dc" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_e6ac5b67-60f4-49f1-b7f0-5f862ebca5ef" xlink:to="loc_srt_SegmentGeographicalDomain_19e7574e-01a1-4d87-a2a7-86fa7e34e2dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_21979ea9-1b19-4192-b209-8c63d78e7e36" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_19e7574e-01a1-4d87-a2a7-86fa7e34e2dc" xlink:to="loc_country_US_21979ea9-1b19-4192-b209-8c63d78e7e36" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_7dc1eae6-19a4-4819-ae31-e9832e258dc2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_19e7574e-01a1-4d87-a2a7-86fa7e34e2dc" xlink:to="loc_us-gaap_NonUsMember_7dc1eae6-19a4-4819-ae31-e9832e258dc2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_aff3b52a-3800-4d5f-9b32-bf454154fff8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_952ea747-9ca0-4454-b2a5-2082f3609da4" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_aff3b52a-3800-4d5f-9b32-bf454154fff8" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_aff3b52a-3800-4d5f-9b32-bf454154fff8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_aff3b52a-3800-4d5f-9b32-bf454154fff8" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_aff3b52a-3800-4d5f-9b32-bf454154fff8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0cfda52c-2904-45ee-9386-bfaaa1600c63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_aff3b52a-3800-4d5f-9b32-bf454154fff8" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0cfda52c-2904-45ee-9386-bfaaa1600c63" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_9974f949-fc23-4c1c-91c4-0c8d0332003c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0cfda52c-2904-45ee-9386-bfaaa1600c63" xlink:to="loc_us-gaap_IPOMember_9974f949-fc23-4c1c-91c4-0c8d0332003c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.incyte.com/role/LicenseAgreementsCalitheraDetails" xlink:type="simple" xlink:href="incy-20220930.xsd#LicenseAgreementsCalitheraDetails"/>
  <link:definitionLink xlink:role="http://www.incyte.com/role/LicenseAgreementsCalitheraDetails" xlink:type="extended" id="ibdbed01103ed4e00a2c59a497b09b4eb_LicenseAgreementsCalitheraDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_146c3790-0692-4127-8d15-c1196a4d3707" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_LicenseAgreementPercentageOfFutureGlobalDevelopmentCostsFunded_dfe26632-2e4e-4f47-ad04-3320dba3ef68" xlink:href="incy-20220930.xsd#incy_LicenseAgreementPercentageOfFutureGlobalDevelopmentCostsFunded"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_146c3790-0692-4127-8d15-c1196a4d3707" xlink:to="loc_incy_LicenseAgreementPercentageOfFutureGlobalDevelopmentCostsFunded_dfe26632-2e4e-4f47-ad04-3320dba3ef68" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_PercentageOfProfitsLosses_0568aaae-4441-4f60-a0da-54dff0419a04" xlink:href="incy-20220930.xsd#incy_PercentageOfProfitsLosses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_146c3790-0692-4127-8d15-c1196a4d3707" xlink:to="loc_incy_PercentageOfProfitsLosses_0568aaae-4441-4f60-a0da-54dff0419a04" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_LicenseAgreementMilestonePaymentAmountPaid_c7f9a5fc-369a-47df-b840-9315eb4a374a" xlink:href="incy-20220930.xsd#incy_LicenseAgreementMilestonePaymentAmountPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_146c3790-0692-4127-8d15-c1196a4d3707" xlink:to="loc_incy_LicenseAgreementMilestonePaymentAmountPaid_c7f9a5fc-369a-47df-b840-9315eb4a374a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_PurchaseOfCommonStockUnderStockPurchaseAgreementInShares_aad52ca2-0c69-4f41-9c98-df29cd3dbc1a" xlink:href="incy-20220930.xsd#incy_PurchaseOfCommonStockUnderStockPurchaseAgreementInShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_146c3790-0692-4127-8d15-c1196a4d3707" xlink:to="loc_incy_PurchaseOfCommonStockUnderStockPurchaseAgreementInShares_aad52ca2-0c69-4f41-9c98-df29cd3dbc1a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentAggregateCost_de7d4d89-5466-4f42-9f6a-5a7dfbbd5143" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentAggregateCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_146c3790-0692-4127-8d15-c1196a4d3707" xlink:to="loc_us-gaap_EquityMethodInvestmentAggregateCost_de7d4d89-5466-4f42-9f6a-5a7dfbbd5143" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_131049d1-5488-437b-9b93-c980a5806d0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_146c3790-0692-4127-8d15-c1196a4d3707" xlink:to="loc_us-gaap_SharePrice_131049d1-5488-437b-9b93-c980a5806d0a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_364f8c86-7128-4e4b-95f0-c1866d11c863" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_146c3790-0692-4127-8d15-c1196a4d3707" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_364f8c86-7128-4e4b-95f0-c1866d11c863" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedBalanceShares_3714f86e-f3be-44a0-b548-b2452e214622" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentOwnedBalanceShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_146c3790-0692-4127-8d15-c1196a4d3707" xlink:to="loc_us-gaap_InvestmentOwnedBalanceShares_3714f86e-f3be-44a0-b548-b2452e214622" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments_505eb4b5-c1a4-41d8-8fa9-bff62f920047" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_146c3790-0692-4127-8d15-c1196a4d3707" xlink:to="loc_us-gaap_LongTermInvestments_505eb4b5-c1a4-41d8-8fa9-bff62f920047" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_ebd2683d-f399-41e5-95a3-e15f36a76d78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_146c3790-0692-4127-8d15-c1196a4d3707" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_ebd2683d-f399-41e5-95a3-e15f36a76d78" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_75966512-9a83-4e1a-a13b-e56f14821890" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_146c3790-0692-4127-8d15-c1196a4d3707" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_75966512-9a83-4e1a-a13b-e56f14821890" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_2fdf7f32-0e87-4021-9a16-050a46cc5840" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_146c3790-0692-4127-8d15-c1196a4d3707" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_2fdf7f32-0e87-4021-9a16-050a46cc5840" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_a66828fc-c1f3-4f1d-b11c-94ec4c1c0863" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_2fdf7f32-0e87-4021-9a16-050a46cc5840" xlink:to="loc_us-gaap_TypeOfArrangementAxis_a66828fc-c1f3-4f1d-b11c-94ec4c1c0863" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a66828fc-c1f3-4f1d-b11c-94ec4c1c0863_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_a66828fc-c1f3-4f1d-b11c-94ec4c1c0863" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a66828fc-c1f3-4f1d-b11c-94ec4c1c0863_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e13b8578-bc0a-4fa8-8138-1c113832b9cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_a66828fc-c1f3-4f1d-b11c-94ec4c1c0863" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e13b8578-bc0a-4fa8-8138-1c113832b9cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_CalitheraBiosciencesIncMember_dbc4039f-d1b8-44bd-9455-cc364941c464" xlink:href="incy-20220930.xsd#incy_CalitheraBiosciencesIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e13b8578-bc0a-4fa8-8138-1c113832b9cf" xlink:to="loc_incy_CalitheraBiosciencesIncMember_dbc4039f-d1b8-44bd-9455-cc364941c464" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_StockPurchaseAgreementMember_65111b63-f902-48c5-b8dd-762e1a354fed" xlink:href="incy-20220930.xsd#incy_StockPurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e13b8578-bc0a-4fa8-8138-1c113832b9cf" xlink:to="loc_incy_StockPurchaseAgreementMember_65111b63-f902-48c5-b8dd-762e1a354fed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_AchievementOfMilestoneAxis_dedacfcf-0211-464b-8a5d-d824269cb34b" xlink:href="incy-20220930.xsd#incy_AchievementOfMilestoneAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_2fdf7f32-0e87-4021-9a16-050a46cc5840" xlink:to="loc_incy_AchievementOfMilestoneAxis_dedacfcf-0211-464b-8a5d-d824269cb34b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_AchievementOfMilestoneDomain_dedacfcf-0211-464b-8a5d-d824269cb34b_default" xlink:href="incy-20220930.xsd#incy_AchievementOfMilestoneDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_incy_AchievementOfMilestoneAxis_dedacfcf-0211-464b-8a5d-d824269cb34b" xlink:to="loc_incy_AchievementOfMilestoneDomain_dedacfcf-0211-464b-8a5d-d824269cb34b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_AchievementOfMilestoneDomain_bd0a645f-87bf-4f46-80c0-b353bf9f2bae" xlink:href="incy-20220930.xsd#incy_AchievementOfMilestoneDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_incy_AchievementOfMilestoneAxis_dedacfcf-0211-464b-8a5d-d824269cb34b" xlink:to="loc_incy_AchievementOfMilestoneDomain_bd0a645f-87bf-4f46-80c0-b353bf9f2bae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_DevelopmentRegulatoryAndCommercializationMilestonesMember_0c7ad4f9-6f94-434b-a562-5d71eb0a85f5" xlink:href="incy-20220930.xsd#incy_DevelopmentRegulatoryAndCommercializationMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_incy_AchievementOfMilestoneDomain_bd0a645f-87bf-4f46-80c0-b353bf9f2bae" xlink:to="loc_incy_DevelopmentRegulatoryAndCommercializationMilestonesMember_0c7ad4f9-6f94-434b-a562-5d71eb0a85f5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_0796bac2-85ed-4cb7-8993-a82052193bfc" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_2fdf7f32-0e87-4021-9a16-050a46cc5840" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_0796bac2-85ed-4cb7-8993-a82052193bfc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_0796bac2-85ed-4cb7-8993-a82052193bfc_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_0796bac2-85ed-4cb7-8993-a82052193bfc" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_0796bac2-85ed-4cb7-8993-a82052193bfc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_a753c6cf-d1f0-4f67-b599-ba4c450cec6a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_0796bac2-85ed-4cb7-8993-a82052193bfc" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_a753c6cf-d1f0-4f67-b599-ba4c450cec6a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_CalitheraBiosciencesIncMember_c913e6f9-1016-43ce-bcf1-ed9effd25275" xlink:href="incy-20220930.xsd#incy_CalitheraBiosciencesIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_a753c6cf-d1f0-4f67-b599-ba4c450cec6a" xlink:to="loc_incy_CalitheraBiosciencesIncMember_c913e6f9-1016-43ce-bcf1-ed9effd25275" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_7159a15b-3210-4b85-88b4-0f5b5b819c4b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_2fdf7f32-0e87-4021-9a16-050a46cc5840" xlink:to="loc_srt_StatementGeographicalAxis_7159a15b-3210-4b85-88b4-0f5b5b819c4b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_7159a15b-3210-4b85-88b4-0f5b5b819c4b_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_7159a15b-3210-4b85-88b4-0f5b5b819c4b" xlink:to="loc_srt_SegmentGeographicalDomain_7159a15b-3210-4b85-88b4-0f5b5b819c4b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_d5729871-9b74-4738-9f1d-95b81ccef8ba" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_7159a15b-3210-4b85-88b4-0f5b5b819c4b" xlink:to="loc_srt_SegmentGeographicalDomain_d5729871-9b74-4738-9f1d-95b81ccef8ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_0c8f8457-bc78-41ef-90f9-78710bf83f5e" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_d5729871-9b74-4738-9f1d-95b81ccef8ba" xlink:to="loc_country_US_0c8f8457-bc78-41ef-90f9-78710bf83f5e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_801ffd10-fa3f-4aa8-b090-5ac2f0d56041" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_2fdf7f32-0e87-4021-9a16-050a46cc5840" xlink:to="loc_srt_RangeAxis_801ffd10-fa3f-4aa8-b090-5ac2f0d56041" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_801ffd10-fa3f-4aa8-b090-5ac2f0d56041_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_801ffd10-fa3f-4aa8-b090-5ac2f0d56041" xlink:to="loc_srt_RangeMember_801ffd10-fa3f-4aa8-b090-5ac2f0d56041_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_652743e9-8edd-4d47-a456-f5869d033505" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_801ffd10-fa3f-4aa8-b090-5ac2f0d56041" xlink:to="loc_srt_RangeMember_652743e9-8edd-4d47-a456-f5869d033505" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_bd89a51a-bc70-4ca9-ab8f-dc7761bfb2e0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_652743e9-8edd-4d47-a456-f5869d033505" xlink:to="loc_srt_MaximumMember_bd89a51a-bc70-4ca9-ab8f-dc7761bfb2e0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_64dd776f-080c-46e5-ac3d-3c88516e7063" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_2fdf7f32-0e87-4021-9a16-050a46cc5840" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_64dd776f-080c-46e5-ac3d-3c88516e7063" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_64dd776f-080c-46e5-ac3d-3c88516e7063_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_64dd776f-080c-46e5-ac3d-3c88516e7063" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_64dd776f-080c-46e5-ac3d-3c88516e7063_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_6d600d7d-f187-4d97-8de3-2e90d997f522" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_64dd776f-080c-46e5-ac3d-3c88516e7063" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_6d600d7d-f187-4d97-8de3-2e90d997f522" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeMember_b8e1dd19-fe0b-46bf-8b3d-a39ee304d5ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_6d600d7d-f187-4d97-8de3-2e90d997f522" xlink:to="loc_us-gaap_OtherComprehensiveIncomeMember_b8e1dd19-fe0b-46bf-8b3d-a39ee304d5ba" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.incyte.com/role/LicenseAgreementsMacroGenicsDetails" xlink:type="simple" xlink:href="incy-20220930.xsd#LicenseAgreementsMacroGenicsDetails"/>
  <link:definitionLink xlink:role="http://www.incyte.com/role/LicenseAgreementsMacroGenicsDetails" xlink:type="extended" id="ie8c8b7af8bf14273ac052e392f025190_LicenseAgreementsMacroGenicsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_0f45310a-80e4-44dd-b9f7-764cf9ec843e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_LicenseAgreementMilestonePaymentAmountPaid_8bf6e729-b764-4eeb-a3d8-19aafbc1e2ea" xlink:href="incy-20220930.xsd#incy_LicenseAgreementMilestonePaymentAmountPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0f45310a-80e4-44dd-b9f7-764cf9ec843e" xlink:to="loc_incy_LicenseAgreementMilestonePaymentAmountPaid_8bf6e729-b764-4eeb-a3d8-19aafbc1e2ea" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_LicenseAgreementAdditionalMilestonePayments_28225e2d-2a38-4dac-96bd-7df704d63919" xlink:href="incy-20220930.xsd#incy_LicenseAgreementAdditionalMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0f45310a-80e4-44dd-b9f7-764cf9ec843e" xlink:to="loc_incy_LicenseAgreementAdditionalMilestonePayments_28225e2d-2a38-4dac-96bd-7df704d63919" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_PercentageOfRoyaltyRatePayments_ebbffdc4-6b9f-41a3-8b23-701405153e26" xlink:href="incy-20220930.xsd#incy_PercentageOfRoyaltyRatePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0f45310a-80e4-44dd-b9f7-764cf9ec843e" xlink:to="loc_incy_PercentageOfRoyaltyRatePayments_ebbffdc4-6b9f-41a3-8b23-701405153e26" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_b0fc3ad8-ff66-4ff2-b5fe-e1885c1b0658" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0f45310a-80e4-44dd-b9f7-764cf9ec843e" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_b0fc3ad8-ff66-4ff2-b5fe-e1885c1b0658" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_4d747b6c-edda-448b-864e-114986b5a609" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0f45310a-80e4-44dd-b9f7-764cf9ec843e" xlink:to="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_4d747b6c-edda-448b-864e-114986b5a609" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_95519167-3f5a-4901-9c6e-543717444b41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0f45310a-80e4-44dd-b9f7-764cf9ec843e" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_95519167-3f5a-4901-9c6e-543717444b41" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_a15c625a-319e-412f-a463-f6bf4f8b7fe3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_95519167-3f5a-4901-9c6e-543717444b41" xlink:to="loc_us-gaap_TypeOfArrangementAxis_a15c625a-319e-412f-a463-f6bf4f8b7fe3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a15c625a-319e-412f-a463-f6bf4f8b7fe3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_a15c625a-319e-412f-a463-f6bf4f8b7fe3" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a15c625a-319e-412f-a463-f6bf4f8b7fe3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_915fab5c-fca6-4d3b-9201-38ea2d53381b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_a15c625a-319e-412f-a463-f6bf4f8b7fe3" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_915fab5c-fca6-4d3b-9201-38ea2d53381b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_MacrogenicsMember_b16c3813-c5b1-41c3-9d2a-aee94e166b79" xlink:href="incy-20220930.xsd#incy_MacrogenicsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_915fab5c-fca6-4d3b-9201-38ea2d53381b" xlink:to="loc_incy_MacrogenicsMember_b16c3813-c5b1-41c3-9d2a-aee94e166b79" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_AchievementOfMilestoneAxis_441404f2-2e42-4a04-bdbb-2074f60bfb4a" xlink:href="incy-20220930.xsd#incy_AchievementOfMilestoneAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_95519167-3f5a-4901-9c6e-543717444b41" xlink:to="loc_incy_AchievementOfMilestoneAxis_441404f2-2e42-4a04-bdbb-2074f60bfb4a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_AchievementOfMilestoneDomain_441404f2-2e42-4a04-bdbb-2074f60bfb4a_default" xlink:href="incy-20220930.xsd#incy_AchievementOfMilestoneDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_incy_AchievementOfMilestoneAxis_441404f2-2e42-4a04-bdbb-2074f60bfb4a" xlink:to="loc_incy_AchievementOfMilestoneDomain_441404f2-2e42-4a04-bdbb-2074f60bfb4a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_AchievementOfMilestoneDomain_dba948c6-b07f-425f-acb3-1f017cccf4e4" xlink:href="incy-20220930.xsd#incy_AchievementOfMilestoneDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_incy_AchievementOfMilestoneAxis_441404f2-2e42-4a04-bdbb-2074f60bfb4a" xlink:to="loc_incy_AchievementOfMilestoneDomain_dba948c6-b07f-425f-acb3-1f017cccf4e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_DevelopmentAndRegulatoryMilestonesMember_cb82f568-55f4-4dd3-a46f-4f2c72f44d3d" xlink:href="incy-20220930.xsd#incy_DevelopmentAndRegulatoryMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_incy_AchievementOfMilestoneDomain_dba948c6-b07f-425f-acb3-1f017cccf4e4" xlink:to="loc_incy_DevelopmentAndRegulatoryMilestonesMember_cb82f568-55f4-4dd3-a46f-4f2c72f44d3d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_DevelopmentMilestonesMember_9b7de504-0362-4bfd-bf2f-0fda18728fa3" xlink:href="incy-20220930.xsd#incy_DevelopmentMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_incy_DevelopmentAndRegulatoryMilestonesMember_cb82f568-55f4-4dd3-a46f-4f2c72f44d3d" xlink:to="loc_incy_DevelopmentMilestonesMember_9b7de504-0362-4bfd-bf2f-0fda18728fa3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_CommercializationMilestonesMember_8b3ab3f2-3dd9-4ac0-a86c-d4332398c7a1" xlink:href="incy-20220930.xsd#incy_CommercializationMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_incy_AchievementOfMilestoneDomain_dba948c6-b07f-425f-acb3-1f017cccf4e4" xlink:to="loc_incy_CommercializationMilestonesMember_8b3ab3f2-3dd9-4ac0-a86c-d4332398c7a1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_077388e1-96de-420f-8f52-b00ac53a4287" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_95519167-3f5a-4901-9c6e-543717444b41" xlink:to="loc_srt_RangeAxis_077388e1-96de-420f-8f52-b00ac53a4287" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_077388e1-96de-420f-8f52-b00ac53a4287_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_077388e1-96de-420f-8f52-b00ac53a4287" xlink:to="loc_srt_RangeMember_077388e1-96de-420f-8f52-b00ac53a4287_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_54fc2885-2991-427c-b57a-2e0a87c8bcd0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_077388e1-96de-420f-8f52-b00ac53a4287" xlink:to="loc_srt_RangeMember_54fc2885-2991-427c-b57a-2e0a87c8bcd0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_bfba5af6-ccd7-45df-b218-0c9659fcd46d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_54fc2885-2991-427c-b57a-2e0a87c8bcd0" xlink:to="loc_srt_MinimumMember_bfba5af6-ccd7-45df-b218-0c9659fcd46d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_4307279a-6085-4149-a339-4c5a8aeebbf9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_54fc2885-2991-427c-b57a-2e0a87c8bcd0" xlink:to="loc_srt_MaximumMember_4307279a-6085-4149-a339-4c5a8aeebbf9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_72b01aae-a680-4957-96ee-210da7b8a7e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_95519167-3f5a-4901-9c6e-543717444b41" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_72b01aae-a680-4957-96ee-210da7b8a7e7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_72b01aae-a680-4957-96ee-210da7b8a7e7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_72b01aae-a680-4957-96ee-210da7b8a7e7" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_72b01aae-a680-4957-96ee-210da7b8a7e7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_19111d2f-7934-472e-8383-6fda30ab9b62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_72b01aae-a680-4957-96ee-210da7b8a7e7" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_19111d2f-7934-472e-8383-6fda30ab9b62" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesMember_23a97f6f-05ec-4ea4-8e74-93f2d1d7043c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_19111d2f-7934-472e-8383-6fda30ab9b62" xlink:to="loc_us-gaap_AccruedLiabilitiesMember_23a97f6f-05ec-4ea4-8e74-93f2d1d7043c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.incyte.com/role/LicenseAgreementsSyrosDetails" xlink:type="simple" xlink:href="incy-20220930.xsd#LicenseAgreementsSyrosDetails"/>
  <link:definitionLink xlink:role="http://www.incyte.com/role/LicenseAgreementsSyrosDetails" xlink:type="extended" id="i4db5b44f0e0e429da4fe44e659f2cfea_LicenseAgreementsSyrosDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_d7987a38-0ad2-4151-93f8-d9c08592ca50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_NumberOfProgramTargets_6d9c2035-cbad-43cd-a58a-bb492ada3834" xlink:href="incy-20220930.xsd#incy_NumberOfProgramTargets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_d7987a38-0ad2-4151-93f8-d9c08592ca50" xlink:to="loc_incy_NumberOfProgramTargets_6d9c2035-cbad-43cd-a58a-bb492ada3834" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_LicenseAgreementTargetSelectionAndOptionExerciseFeePayments_2d00f464-1939-4968-9441-b1f30264235f" xlink:href="incy-20220930.xsd#incy_LicenseAgreementTargetSelectionAndOptionExerciseFeePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_d7987a38-0ad2-4151-93f8-d9c08592ca50" xlink:to="loc_incy_LicenseAgreementTargetSelectionAndOptionExerciseFeePayments_2d00f464-1939-4968-9441-b1f30264235f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_LicenseAgreementAdditionalMilestonePayments_266118fb-d5d0-47b5-9f43-68b4b6533931" xlink:href="incy-20220930.xsd#incy_LicenseAgreementAdditionalMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_d7987a38-0ad2-4151-93f8-d9c08592ca50" xlink:to="loc_incy_LicenseAgreementAdditionalMilestonePayments_266118fb-d5d0-47b5-9f43-68b4b6533931" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_PurchaseOfCommonStockUnderStockPurchaseAgreementInShares_a783cc28-757f-4ca4-babd-82c5502df95d" xlink:href="incy-20220930.xsd#incy_PurchaseOfCommonStockUnderStockPurchaseAgreementInShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_d7987a38-0ad2-4151-93f8-d9c08592ca50" xlink:to="loc_incy_PurchaseOfCommonStockUnderStockPurchaseAgreementInShares_a783cc28-757f-4ca4-babd-82c5502df95d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentAggregateCost_c4471c61-a958-4286-ba26-a91088ec267c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentAggregateCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_d7987a38-0ad2-4151-93f8-d9c08592ca50" xlink:to="loc_us-gaap_EquityMethodInvestmentAggregateCost_c4471c61-a958-4286-ba26-a91088ec267c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_2d6e8506-1360-4d14-b35d-fc70353ab933" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_d7987a38-0ad2-4151-93f8-d9c08592ca50" xlink:to="loc_us-gaap_SharePrice_2d6e8506-1360-4d14-b35d-fc70353ab933" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedBalanceShares_cecbb8f7-de7b-4e11-ba51-4970bd4f7e31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentOwnedBalanceShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_d7987a38-0ad2-4151-93f8-d9c08592ca50" xlink:to="loc_us-gaap_InvestmentOwnedBalanceShares_cecbb8f7-de7b-4e11-ba51-4970bd4f7e31" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments_6a5d20b5-3c64-4baf-b044-7040e3298c4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_d7987a38-0ad2-4151-93f8-d9c08592ca50" xlink:to="loc_us-gaap_LongTermInvestments_6a5d20b5-3c64-4baf-b044-7040e3298c4a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_7fee696e-09d8-4483-8b36-527eaf357c6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_d7987a38-0ad2-4151-93f8-d9c08592ca50" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_7fee696e-09d8-4483-8b36-527eaf357c6a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_2b8591b2-028c-4fff-a56a-381342267396" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_d7987a38-0ad2-4151-93f8-d9c08592ca50" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_2b8591b2-028c-4fff-a56a-381342267396" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_f164e6f0-d67b-43dc-9942-3605001326f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_d7987a38-0ad2-4151-93f8-d9c08592ca50" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_f164e6f0-d67b-43dc-9942-3605001326f0" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_d238b633-16fe-48cf-b0c8-6eda3d5d9de6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_d7987a38-0ad2-4151-93f8-d9c08592ca50" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_d238b633-16fe-48cf-b0c8-6eda3d5d9de6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_f2880edd-24a7-4875-a26a-6ff962ddd769" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_d238b633-16fe-48cf-b0c8-6eda3d5d9de6" xlink:to="loc_us-gaap_TypeOfArrangementAxis_f2880edd-24a7-4875-a26a-6ff962ddd769" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f2880edd-24a7-4875-a26a-6ff962ddd769_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_f2880edd-24a7-4875-a26a-6ff962ddd769" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f2880edd-24a7-4875-a26a-6ff962ddd769_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c59db323-f125-48cf-9b7c-91297fc4444a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_f2880edd-24a7-4875-a26a-6ff962ddd769" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c59db323-f125-48cf-9b7c-91297fc4444a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_SyrosPharmaceuticalsIncMember_ca929414-5a97-439d-b355-42c542d69c25" xlink:href="incy-20220930.xsd#incy_SyrosPharmaceuticalsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c59db323-f125-48cf-9b7c-91297fc4444a" xlink:to="loc_incy_SyrosPharmaceuticalsIncMember_ca929414-5a97-439d-b355-42c542d69c25" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_StockPurchaseAgreementMember_6f12d16a-a195-4b7e-ac9b-0d2416c26afc" xlink:href="incy-20220930.xsd#incy_StockPurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c59db323-f125-48cf-9b7c-91297fc4444a" xlink:to="loc_incy_StockPurchaseAgreementMember_6f12d16a-a195-4b7e-ac9b-0d2416c26afc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_AmendedStockPurchaseAgreementMember_1a68902f-e3ab-485b-9537-75aa4081f6a3" xlink:href="incy-20220930.xsd#incy_AmendedStockPurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c59db323-f125-48cf-9b7c-91297fc4444a" xlink:to="loc_incy_AmendedStockPurchaseAgreementMember_1a68902f-e3ab-485b-9537-75aa4081f6a3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_AchievementOfMilestoneAxis_53842b6f-6697-4601-a97f-b69fbfa7afb2" xlink:href="incy-20220930.xsd#incy_AchievementOfMilestoneAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_d238b633-16fe-48cf-b0c8-6eda3d5d9de6" xlink:to="loc_incy_AchievementOfMilestoneAxis_53842b6f-6697-4601-a97f-b69fbfa7afb2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_AchievementOfMilestoneDomain_53842b6f-6697-4601-a97f-b69fbfa7afb2_default" xlink:href="incy-20220930.xsd#incy_AchievementOfMilestoneDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_incy_AchievementOfMilestoneAxis_53842b6f-6697-4601-a97f-b69fbfa7afb2" xlink:to="loc_incy_AchievementOfMilestoneDomain_53842b6f-6697-4601-a97f-b69fbfa7afb2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_AchievementOfMilestoneDomain_3070a6bf-1888-496c-9cd5-0d7f1d21519c" xlink:href="incy-20220930.xsd#incy_AchievementOfMilestoneDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_incy_AchievementOfMilestoneAxis_53842b6f-6697-4601-a97f-b69fbfa7afb2" xlink:to="loc_incy_AchievementOfMilestoneDomain_3070a6bf-1888-496c-9cd5-0d7f1d21519c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_DevelopmentAndRegulatoryMilestonesMember_3f83b37b-91fe-4024-b9bb-164f3e24e287" xlink:href="incy-20220930.xsd#incy_DevelopmentAndRegulatoryMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_incy_AchievementOfMilestoneDomain_3070a6bf-1888-496c-9cd5-0d7f1d21519c" xlink:to="loc_incy_DevelopmentAndRegulatoryMilestonesMember_3f83b37b-91fe-4024-b9bb-164f3e24e287" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_CommercializationMilestonesMember_d49460d9-3b44-4026-b0b0-7f164ef2cde1" xlink:href="incy-20220930.xsd#incy_CommercializationMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_incy_AchievementOfMilestoneDomain_3070a6bf-1888-496c-9cd5-0d7f1d21519c" xlink:to="loc_incy_CommercializationMilestonesMember_d49460d9-3b44-4026-b0b0-7f164ef2cde1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_494ea434-5774-4f1e-bda7-117d9a6e6780" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_d238b633-16fe-48cf-b0c8-6eda3d5d9de6" xlink:to="loc_srt_RangeAxis_494ea434-5774-4f1e-bda7-117d9a6e6780" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_494ea434-5774-4f1e-bda7-117d9a6e6780_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_494ea434-5774-4f1e-bda7-117d9a6e6780" xlink:to="loc_srt_RangeMember_494ea434-5774-4f1e-bda7-117d9a6e6780_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9e6b9038-7f65-42a6-8fd9-5da4c9c351c6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_494ea434-5774-4f1e-bda7-117d9a6e6780" xlink:to="loc_srt_RangeMember_9e6b9038-7f65-42a6-8fd9-5da4c9c351c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_8ae139b0-0624-4a7f-98e6-44d5f4c48ae3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_9e6b9038-7f65-42a6-8fd9-5da4c9c351c6" xlink:to="loc_srt_MaximumMember_8ae139b0-0624-4a7f-98e6-44d5f4c48ae3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_a5b89487-6e14-4fb8-b409-8e7271e8808f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_d238b633-16fe-48cf-b0c8-6eda3d5d9de6" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_a5b89487-6e14-4fb8-b409-8e7271e8808f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_a5b89487-6e14-4fb8-b409-8e7271e8808f_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_a5b89487-6e14-4fb8-b409-8e7271e8808f" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_a5b89487-6e14-4fb8-b409-8e7271e8808f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_ccb535e8-89b5-49cf-8436-71a1969c350e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_a5b89487-6e14-4fb8-b409-8e7271e8808f" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_ccb535e8-89b5-49cf-8436-71a1969c350e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_SyrosPharmaceuticalsIncMember_042e25aa-21ed-48a4-9262-3b5efec93a32" xlink:href="incy-20220930.xsd#incy_SyrosPharmaceuticalsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_ccb535e8-89b5-49cf-8436-71a1969c350e" xlink:to="loc_incy_SyrosPharmaceuticalsIncMember_042e25aa-21ed-48a4-9262-3b5efec93a32" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_326cdf90-e5f1-4460-a4fe-b8839f9402f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_d238b633-16fe-48cf-b0c8-6eda3d5d9de6" xlink:to="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_326cdf90-e5f1-4460-a4fe-b8839f9402f0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockNameDomain_326cdf90-e5f1-4460-a4fe-b8839f9402f0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_326cdf90-e5f1-4460-a4fe-b8839f9402f0" xlink:to="loc_us-gaap_ConversionOfStockNameDomain_326cdf90-e5f1-4460-a4fe-b8839f9402f0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockNameDomain_f49c5e23-8676-4b17-b504-2b9dd229f870" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_326cdf90-e5f1-4460-a4fe-b8839f9402f0" xlink:to="loc_us-gaap_ConversionOfStockNameDomain_f49c5e23-8676-4b17-b504-2b9dd229f870" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_PreSeptember2022StockSplitSharesMember_095ec29e-541e-4c64-a750-34d07298d6ba" xlink:href="incy-20220930.xsd#incy_PreSeptember2022StockSplitSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConversionOfStockNameDomain_f49c5e23-8676-4b17-b504-2b9dd229f870" xlink:to="loc_incy_PreSeptember2022StockSplitSharesMember_095ec29e-541e-4c64-a750-34d07298d6ba" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.incyte.com/role/LicenseAgreementsInnoventDetails" xlink:type="simple" xlink:href="incy-20220930.xsd#LicenseAgreementsInnoventDetails"/>
  <link:definitionLink xlink:role="http://www.incyte.com/role/LicenseAgreementsInnoventDetails" xlink:type="extended" id="ice840dc17ea34e6c9b7f85fdcb3ac046_LicenseAgreementsInnoventDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_11756cf2-37c6-43f2-9e0d-713dbbdc9154" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived_b996b5e5-05e5-48f1-ba4d-b24ffc675171" xlink:href="incy-20220930.xsd#incy_LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_11756cf2-37c6-43f2-9e0d-713dbbdc9154" xlink:to="loc_incy_LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived_b996b5e5-05e5-48f1-ba4d-b24ffc675171" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone_4cb351fb-ab40-4193-bbbc-e9ceddf817f0" xlink:href="incy-20220930.xsd#incy_LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_11756cf2-37c6-43f2-9e0d-713dbbdc9154" xlink:to="loc_incy_LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone_4cb351fb-ab40-4193-bbbc-e9ceddf817f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_7f2b0d47-eeed-4dda-aac6-fff2525f65ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_11756cf2-37c6-43f2-9e0d-713dbbdc9154" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_7f2b0d47-eeed-4dda-aac6-fff2525f65ba" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_9d36f102-e0ac-4415-8415-ef330945e9b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_7f2b0d47-eeed-4dda-aac6-fff2525f65ba" xlink:to="loc_us-gaap_TypeOfArrangementAxis_9d36f102-e0ac-4415-8415-ef330945e9b2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9d36f102-e0ac-4415-8415-ef330945e9b2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_9d36f102-e0ac-4415-8415-ef330945e9b2" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9d36f102-e0ac-4415-8415-ef330945e9b2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_950cf8ba-9248-454d-8407-9129731fd6d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_9d36f102-e0ac-4415-8415-ef330945e9b2" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_950cf8ba-9248-454d-8407-9129731fd6d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_InnoventBiologicsIncMember_dde04994-e603-4b57-b987-16492a1920ff" xlink:href="incy-20220930.xsd#incy_InnoventBiologicsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_950cf8ba-9248-454d-8407-9129731fd6d0" xlink:to="loc_incy_InnoventBiologicsIncMember_dde04994-e603-4b57-b987-16492a1920ff" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_AchievementOfMilestoneAxis_b9d98271-0a9a-41bc-8323-08d58a300e0d" xlink:href="incy-20220930.xsd#incy_AchievementOfMilestoneAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_7f2b0d47-eeed-4dda-aac6-fff2525f65ba" xlink:to="loc_incy_AchievementOfMilestoneAxis_b9d98271-0a9a-41bc-8323-08d58a300e0d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_AchievementOfMilestoneDomain_b9d98271-0a9a-41bc-8323-08d58a300e0d_default" xlink:href="incy-20220930.xsd#incy_AchievementOfMilestoneDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_incy_AchievementOfMilestoneAxis_b9d98271-0a9a-41bc-8323-08d58a300e0d" xlink:to="loc_incy_AchievementOfMilestoneDomain_b9d98271-0a9a-41bc-8323-08d58a300e0d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_AchievementOfMilestoneDomain_f8824953-1a53-4082-9425-78ee202b2d8e" xlink:href="incy-20220930.xsd#incy_AchievementOfMilestoneDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_incy_AchievementOfMilestoneAxis_b9d98271-0a9a-41bc-8323-08d58a300e0d" xlink:to="loc_incy_AchievementOfMilestoneDomain_f8824953-1a53-4082-9425-78ee202b2d8e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_DevelopmentAndRegulatoryMilestonesMember_171164bd-40ef-40f3-99bc-b2ba6a6828d9" xlink:href="incy-20220930.xsd#incy_DevelopmentAndRegulatoryMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_incy_AchievementOfMilestoneDomain_f8824953-1a53-4082-9425-78ee202b2d8e" xlink:to="loc_incy_DevelopmentAndRegulatoryMilestonesMember_171164bd-40ef-40f3-99bc-b2ba6a6828d9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_RegulatoryMilestonesMember_09315e31-f354-4eaa-9f52-42958fe2dc8a" xlink:href="incy-20220930.xsd#incy_RegulatoryMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_incy_AchievementOfMilestoneDomain_f8824953-1a53-4082-9425-78ee202b2d8e" xlink:to="loc_incy_RegulatoryMilestonesMember_09315e31-f354-4eaa-9f52-42958fe2dc8a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_CommercializationMilestonesMember_50fb9693-81f1-482c-93e2-f41f4899e5ac" xlink:href="incy-20220930.xsd#incy_CommercializationMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_incy_AchievementOfMilestoneDomain_f8824953-1a53-4082-9425-78ee202b2d8e" xlink:to="loc_incy_CommercializationMilestonesMember_50fb9693-81f1-482c-93e2-f41f4899e5ac" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_87193bec-b304-4ec4-8658-de6587224133" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_7f2b0d47-eeed-4dda-aac6-fff2525f65ba" xlink:to="loc_srt_ProductOrServiceAxis_87193bec-b304-4ec4-8658-de6587224133" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_87193bec-b304-4ec4-8658-de6587224133_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_87193bec-b304-4ec4-8658-de6587224133" xlink:to="loc_srt_ProductsAndServicesDomain_87193bec-b304-4ec4-8658-de6587224133_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_d167298e-4f61-4c2e-aa12-690cac6772d6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_87193bec-b304-4ec4-8658-de6587224133" xlink:to="loc_srt_ProductsAndServicesDomain_d167298e-4f61-4c2e-aa12-690cac6772d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_PemazyreMember_78ceffc8-148f-4ffa-b41d-36e595a01407" xlink:href="incy-20220930.xsd#incy_PemazyreMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d167298e-4f61-4c2e-aa12-690cac6772d6" xlink:to="loc_incy_PemazyreMember_78ceffc8-148f-4ffa-b41d-36e595a01407" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_f517eb42-5861-414f-a9d8-87e2eff491a4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_7f2b0d47-eeed-4dda-aac6-fff2525f65ba" xlink:to="loc_srt_RangeAxis_f517eb42-5861-414f-a9d8-87e2eff491a4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f517eb42-5861-414f-a9d8-87e2eff491a4_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_f517eb42-5861-414f-a9d8-87e2eff491a4" xlink:to="loc_srt_RangeMember_f517eb42-5861-414f-a9d8-87e2eff491a4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_74923e9c-ce2b-492e-bac2-259cd14d9751" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_f517eb42-5861-414f-a9d8-87e2eff491a4" xlink:to="loc_srt_RangeMember_74923e9c-ce2b-492e-bac2-259cd14d9751" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_7f2ff037-1aa8-46d2-81fb-b342130d1efe" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_74923e9c-ce2b-492e-bac2-259cd14d9751" xlink:to="loc_srt_MaximumMember_7f2ff037-1aa8-46d2-81fb-b342130d1efe" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.incyte.com/role/LicenseAgreementsZaiLabDetails" xlink:type="simple" xlink:href="incy-20220930.xsd#LicenseAgreementsZaiLabDetails"/>
  <link:definitionLink xlink:role="http://www.incyte.com/role/LicenseAgreementsZaiLabDetails" xlink:type="extended" id="i37b5a6f23ab14a2ab688033b1fd1be8b_LicenseAgreementsZaiLabDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_17775bf3-d102-4a39-a9ad-d9e550b47d07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived_4612342c-670d-4b90-b443-b32d863d8806" xlink:href="incy-20220930.xsd#incy_LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_17775bf3-d102-4a39-a9ad-d9e550b47d07" xlink:to="loc_incy_LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived_4612342c-670d-4b90-b443-b32d863d8806" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_59a3e4b4-8277-40d9-95d2-e1c0c831e663" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_17775bf3-d102-4a39-a9ad-d9e550b47d07" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_59a3e4b4-8277-40d9-95d2-e1c0c831e663" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_dfe6c7dd-75ae-46ee-96ef-4ccbe4d54aaf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_59a3e4b4-8277-40d9-95d2-e1c0c831e663" xlink:to="loc_us-gaap_TypeOfArrangementAxis_dfe6c7dd-75ae-46ee-96ef-4ccbe4d54aaf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_dfe6c7dd-75ae-46ee-96ef-4ccbe4d54aaf_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_dfe6c7dd-75ae-46ee-96ef-4ccbe4d54aaf" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_dfe6c7dd-75ae-46ee-96ef-4ccbe4d54aaf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_976847e6-a982-4539-9fd5-02f780cc5d5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_dfe6c7dd-75ae-46ee-96ef-4ccbe4d54aaf" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_976847e6-a982-4539-9fd5-02f780cc5d5f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_CollaborationAndLicenseAgreementWithZaiLabLtdMember_d71c46b7-27a2-4e55-884d-bd54158e8b08" xlink:href="incy-20220930.xsd#incy_CollaborationAndLicenseAgreementWithZaiLabLtdMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_976847e6-a982-4539-9fd5-02f780cc5d5f" xlink:to="loc_incy_CollaborationAndLicenseAgreementWithZaiLabLtdMember_d71c46b7-27a2-4e55-884d-bd54158e8b08" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_AchievementOfMilestoneAxis_0830664d-aa91-456c-9161-75a56046c525" xlink:href="incy-20220930.xsd#incy_AchievementOfMilestoneAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_59a3e4b4-8277-40d9-95d2-e1c0c831e663" xlink:to="loc_incy_AchievementOfMilestoneAxis_0830664d-aa91-456c-9161-75a56046c525" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_AchievementOfMilestoneDomain_0830664d-aa91-456c-9161-75a56046c525_default" xlink:href="incy-20220930.xsd#incy_AchievementOfMilestoneDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_incy_AchievementOfMilestoneAxis_0830664d-aa91-456c-9161-75a56046c525" xlink:to="loc_incy_AchievementOfMilestoneDomain_0830664d-aa91-456c-9161-75a56046c525_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_AchievementOfMilestoneDomain_dae088b1-9f33-4223-8a37-0dbd253399a8" xlink:href="incy-20220930.xsd#incy_AchievementOfMilestoneDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_incy_AchievementOfMilestoneAxis_0830664d-aa91-456c-9161-75a56046c525" xlink:to="loc_incy_AchievementOfMilestoneDomain_dae088b1-9f33-4223-8a37-0dbd253399a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_DevelopmentAndRegulatoryMilestonesMember_ca9a0282-9873-4971-a5ba-e5bbe7b7f37c" xlink:href="incy-20220930.xsd#incy_DevelopmentAndRegulatoryMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_incy_AchievementOfMilestoneDomain_dae088b1-9f33-4223-8a37-0dbd253399a8" xlink:to="loc_incy_DevelopmentAndRegulatoryMilestonesMember_ca9a0282-9873-4971-a5ba-e5bbe7b7f37c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_CommercializationMilestonesMember_ced7a169-3433-4648-93f0-d573ae379056" xlink:href="incy-20220930.xsd#incy_CommercializationMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_incy_AchievementOfMilestoneDomain_dae088b1-9f33-4223-8a37-0dbd253399a8" xlink:to="loc_incy_CommercializationMilestonesMember_ced7a169-3433-4648-93f0-d573ae379056" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_401b4e0d-8f36-46f2-adbf-2fc050bedc16" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_59a3e4b4-8277-40d9-95d2-e1c0c831e663" xlink:to="loc_srt_RangeAxis_401b4e0d-8f36-46f2-adbf-2fc050bedc16" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_401b4e0d-8f36-46f2-adbf-2fc050bedc16_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_401b4e0d-8f36-46f2-adbf-2fc050bedc16" xlink:to="loc_srt_RangeMember_401b4e0d-8f36-46f2-adbf-2fc050bedc16_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_884d79e0-9501-41ae-bbf2-bc4aab3cf8ec" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_401b4e0d-8f36-46f2-adbf-2fc050bedc16" xlink:to="loc_srt_RangeMember_884d79e0-9501-41ae-bbf2-bc4aab3cf8ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_7009a3f6-6efa-4659-a751-183fc1b772e7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_884d79e0-9501-41ae-bbf2-bc4aab3cf8ec" xlink:to="loc_srt_MaximumMember_7009a3f6-6efa-4659-a751-183fc1b772e7" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.incyte.com/role/LicenseAgreementsMorphoSysDetails" xlink:type="simple" xlink:href="incy-20220930.xsd#LicenseAgreementsMorphoSysDetails"/>
  <link:definitionLink xlink:role="http://www.incyte.com/role/LicenseAgreementsMorphoSysDetails" xlink:type="extended" id="ic59755d709634d908c9c3bc37e03724d_LicenseAgreementsMorphoSysDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_89104dc8-f2ca-4c9f-ac88-c2cd5d64a41b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_LicenseAgreementPercentageOfFutureGlobalDevelopmentCostsFunded_d172a122-4976-428b-ad6f-95de9cf934ea" xlink:href="incy-20220930.xsd#incy_LicenseAgreementPercentageOfFutureGlobalDevelopmentCostsFunded"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_89104dc8-f2ca-4c9f-ac88-c2cd5d64a41b" xlink:to="loc_incy_LicenseAgreementPercentageOfFutureGlobalDevelopmentCostsFunded_d172a122-4976-428b-ad6f-95de9cf934ea" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_LicenseAgreementAdditionalMilestonePayments_d6970105-8563-4bdf-80fd-cafa2a750e38" xlink:href="incy-20220930.xsd#incy_LicenseAgreementAdditionalMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_89104dc8-f2ca-4c9f-ac88-c2cd5d64a41b" xlink:to="loc_incy_LicenseAgreementAdditionalMilestonePayments_d6970105-8563-4bdf-80fd-cafa2a750e38" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_LicenseAgreementMilestonePaymentAmountPaid_f2a8e86a-5cea-4108-a9fc-1f6f5d282413" xlink:href="incy-20220930.xsd#incy_LicenseAgreementMilestonePaymentAmountPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_89104dc8-f2ca-4c9f-ac88-c2cd5d64a41b" xlink:to="loc_incy_LicenseAgreementMilestonePaymentAmountPaid_f2a8e86a-5cea-4108-a9fc-1f6f5d282413" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_SubsidiaryStockConversionRatio_6d3495d6-b55b-4881-9291-f7ac834d3d63" xlink:href="incy-20220930.xsd#incy_SubsidiaryStockConversionRatio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_89104dc8-f2ca-4c9f-ac88-c2cd5d64a41b" xlink:to="loc_incy_SubsidiaryStockConversionRatio_6d3495d6-b55b-4881-9291-f7ac834d3d63" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentAggregateCost_d11694ec-1ba1-4ed7-bc5f-aa7201034aa4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentAggregateCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_89104dc8-f2ca-4c9f-ac88-c2cd5d64a41b" xlink:to="loc_us-gaap_EquityMethodInvestmentAggregateCost_d11694ec-1ba1-4ed7-bc5f-aa7201034aa4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_a304f85c-500f-4d4a-a5ef-fb06b2e13b49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_89104dc8-f2ca-4c9f-ac88-c2cd5d64a41b" xlink:to="loc_us-gaap_SharePrice_a304f85c-500f-4d4a-a5ef-fb06b2e13b49" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_16c7ab54-0d0f-4435-8cec-68222aaa09ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_89104dc8-f2ca-4c9f-ac88-c2cd5d64a41b" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_16c7ab54-0d0f-4435-8cec-68222aaa09ef" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_68d796a9-8c1a-4081-b42b-24f40d182e60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_89104dc8-f2ca-4c9f-ac88-c2cd5d64a41b" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_68d796a9-8c1a-4081-b42b-24f40d182e60" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_CollaborationAgreementProfitLossSharingRatio_2dd6cc81-a2d9-4c1a-8db5-1819bbeed4b8" xlink:href="incy-20220930.xsd#incy_CollaborationAgreementProfitLossSharingRatio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_89104dc8-f2ca-4c9f-ac88-c2cd5d64a41b" xlink:to="loc_incy_CollaborationAgreementProfitLossSharingRatio_2dd6cc81-a2d9-4c1a-8db5-1819bbeed4b8" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_CollaborationLossSharingExpense_0d5a1dca-2e1e-4beb-815d-7c634847c5d3" xlink:href="incy-20220930.xsd#incy_CollaborationLossSharingExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_89104dc8-f2ca-4c9f-ac88-c2cd5d64a41b" xlink:to="loc_incy_CollaborationLossSharingExpense_0d5a1dca-2e1e-4beb-815d-7c634847c5d3" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_d76c2961-bd1b-4837-968b-2ea576cb2b2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_89104dc8-f2ca-4c9f-ac88-c2cd5d64a41b" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_d76c2961-bd1b-4837-968b-2ea576cb2b2b" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_674e44c7-f611-45cf-a292-c092cb3eb6ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_89104dc8-f2ca-4c9f-ac88-c2cd5d64a41b" xlink:to="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_674e44c7-f611-45cf-a292-c092cb3eb6ec" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_a081b942-4194-4b24-9b1f-f4cecfddae86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_89104dc8-f2ca-4c9f-ac88-c2cd5d64a41b" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_a081b942-4194-4b24-9b1f-f4cecfddae86" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_b19c0807-9f8f-4e33-864e-ea699e7787c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_a081b942-4194-4b24-9b1f-f4cecfddae86" xlink:to="loc_us-gaap_TypeOfArrangementAxis_b19c0807-9f8f-4e33-864e-ea699e7787c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b19c0807-9f8f-4e33-864e-ea699e7787c7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_b19c0807-9f8f-4e33-864e-ea699e7787c7" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b19c0807-9f8f-4e33-864e-ea699e7787c7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_921cbd3c-b32f-40b8-af7e-2b88105e1975" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_b19c0807-9f8f-4e33-864e-ea699e7787c7" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_921cbd3c-b32f-40b8-af7e-2b88105e1975" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_MorphosysAgMember_fde66d46-ac3e-4a98-b21e-e957ad3236b3" xlink:href="incy-20220930.xsd#incy_MorphosysAgMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_921cbd3c-b32f-40b8-af7e-2b88105e1975" xlink:to="loc_incy_MorphosysAgMember_fde66d46-ac3e-4a98-b21e-e957ad3236b3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_AmericanDepositarySharesMember_27708db4-467c-4720-bb6c-1323c98dc573" xlink:href="incy-20220930.xsd#incy_AmericanDepositarySharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_incy_MorphosysAgMember_fde66d46-ac3e-4a98-b21e-e957ad3236b3" xlink:to="loc_incy_AmericanDepositarySharesMember_27708db4-467c-4720-bb6c-1323c98dc573" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_adffbb5a-19d1-4748-899b-b36cee6bf9e3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_a081b942-4194-4b24-9b1f-f4cecfddae86" xlink:to="loc_dei_LegalEntityAxis_adffbb5a-19d1-4748-899b-b36cee6bf9e3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_adffbb5a-19d1-4748-899b-b36cee6bf9e3_default" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_adffbb5a-19d1-4748-899b-b36cee6bf9e3" xlink:to="loc_dei_EntityDomain_adffbb5a-19d1-4748-899b-b36cee6bf9e3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_734a5dfb-b322-43a4-8c54-5f2843b56d03" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_adffbb5a-19d1-4748-899b-b36cee6bf9e3" xlink:to="loc_dei_EntityDomain_734a5dfb-b322-43a4-8c54-5f2843b56d03" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_IncyteMember_e2432295-c565-4fbc-96a6-8360221a5546" xlink:href="incy-20220930.xsd#incy_IncyteMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_734a5dfb-b322-43a4-8c54-5f2843b56d03" xlink:to="loc_incy_IncyteMember_e2432295-c565-4fbc-96a6-8360221a5546" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_b1ccc5ee-a138-48db-a7db-322a3ab81e14" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_a081b942-4194-4b24-9b1f-f4cecfddae86" xlink:to="loc_srt_CounterpartyNameAxis_b1ccc5ee-a138-48db-a7db-322a3ab81e14" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b1ccc5ee-a138-48db-a7db-322a3ab81e14_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_b1ccc5ee-a138-48db-a7db-322a3ab81e14" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b1ccc5ee-a138-48db-a7db-322a3ab81e14_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5957461e-97b4-46d9-96b3-99516502c8a7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_b1ccc5ee-a138-48db-a7db-322a3ab81e14" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5957461e-97b4-46d9-96b3-99516502c8a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_MorphosysAgMember_b910dd4d-fd0e-4e71-a9e8-b73d7184069f" xlink:href="incy-20220930.xsd#incy_MorphosysAgMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5957461e-97b4-46d9-96b3-99516502c8a7" xlink:to="loc_incy_MorphosysAgMember_b910dd4d-fd0e-4e71-a9e8-b73d7184069f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_AmericanDepositarySharesMember_4437d0d4-db3d-4d35-a2d0-0109be0b52e7" xlink:href="incy-20220930.xsd#incy_AmericanDepositarySharesMember"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_AchievementOfMilestoneAxis_15473efc-f4f3-4b26-a9bb-81b31c310680" xlink:href="incy-20220930.xsd#incy_AchievementOfMilestoneAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_a081b942-4194-4b24-9b1f-f4cecfddae86" xlink:to="loc_incy_AchievementOfMilestoneAxis_15473efc-f4f3-4b26-a9bb-81b31c310680" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_AchievementOfMilestoneDomain_15473efc-f4f3-4b26-a9bb-81b31c310680_default" xlink:href="incy-20220930.xsd#incy_AchievementOfMilestoneDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_incy_AchievementOfMilestoneAxis_15473efc-f4f3-4b26-a9bb-81b31c310680" xlink:to="loc_incy_AchievementOfMilestoneDomain_15473efc-f4f3-4b26-a9bb-81b31c310680_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_AchievementOfMilestoneDomain_4825a541-1928-4ff6-bfc6-e15b7d7e3027" xlink:href="incy-20220930.xsd#incy_AchievementOfMilestoneDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_incy_AchievementOfMilestoneAxis_15473efc-f4f3-4b26-a9bb-81b31c310680" xlink:to="loc_incy_AchievementOfMilestoneDomain_4825a541-1928-4ff6-bfc6-e15b7d7e3027" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_DevelopmentAndRegulatoryMilestonesMember_9aa2cab3-d350-421f-9a18-be86875d6d79" xlink:href="incy-20220930.xsd#incy_DevelopmentAndRegulatoryMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_incy_AchievementOfMilestoneDomain_4825a541-1928-4ff6-bfc6-e15b7d7e3027" xlink:to="loc_incy_DevelopmentAndRegulatoryMilestonesMember_9aa2cab3-d350-421f-9a18-be86875d6d79" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_CommercializationMilestonesMember_e8e82a2e-e2a3-4814-a548-e9f980710cd9" xlink:href="incy-20220930.xsd#incy_CommercializationMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_incy_AchievementOfMilestoneDomain_4825a541-1928-4ff6-bfc6-e15b7d7e3027" xlink:to="loc_incy_CommercializationMilestonesMember_e8e82a2e-e2a3-4814-a548-e9f980710cd9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_9c79003d-e69b-4d80-8438-3b8c77e628a0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_a081b942-4194-4b24-9b1f-f4cecfddae86" xlink:to="loc_srt_RangeAxis_9c79003d-e69b-4d80-8438-3b8c77e628a0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9c79003d-e69b-4d80-8438-3b8c77e628a0_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_9c79003d-e69b-4d80-8438-3b8c77e628a0" xlink:to="loc_srt_RangeMember_9c79003d-e69b-4d80-8438-3b8c77e628a0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b3dfe461-d991-4a6d-9eb5-28cdb798549a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_9c79003d-e69b-4d80-8438-3b8c77e628a0" xlink:to="loc_srt_RangeMember_b3dfe461-d991-4a6d-9eb5-28cdb798549a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_52d579df-d70d-4f94-b596-33c1a5d89ed3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_b3dfe461-d991-4a6d-9eb5-28cdb798549a" xlink:to="loc_srt_MaximumMember_52d579df-d70d-4f94-b596-33c1a5d89ed3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_26611813-00a7-4534-be9d-291c9f7332be" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_a081b942-4194-4b24-9b1f-f4cecfddae86" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_26611813-00a7-4534-be9d-291c9f7332be" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_26611813-00a7-4534-be9d-291c9f7332be_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_26611813-00a7-4534-be9d-291c9f7332be" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_26611813-00a7-4534-be9d-291c9f7332be_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_207ac105-b739-4498-826e-cb5b3d3ad360" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_26611813-00a7-4534-be9d-291c9f7332be" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_207ac105-b739-4498-826e-cb5b3d3ad360" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_MorphosysAgMember_c975a830-2468-40c1-90fb-b28f125952ed" xlink:href="incy-20220930.xsd#incy_MorphosysAgMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_207ac105-b739-4498-826e-cb5b3d3ad360" xlink:to="loc_incy_MorphosysAgMember_c975a830-2468-40c1-90fb-b28f125952ed" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_AmericanDepositarySharesMember_862513b9-9dff-4710-ae14-37978d0cc4a1" xlink:href="incy-20220930.xsd#incy_AmericanDepositarySharesMember"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_bc2ef739-4096-4222-b39e-84aed8ef7893" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_a081b942-4194-4b24-9b1f-f4cecfddae86" xlink:to="loc_srt_StatementGeographicalAxis_bc2ef739-4096-4222-b39e-84aed8ef7893" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_bc2ef739-4096-4222-b39e-84aed8ef7893_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_bc2ef739-4096-4222-b39e-84aed8ef7893" xlink:to="loc_srt_SegmentGeographicalDomain_bc2ef739-4096-4222-b39e-84aed8ef7893_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_1909a468-99d3-46fa-a724-56cf1c805f94" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_bc2ef739-4096-4222-b39e-84aed8ef7893" xlink:to="loc_srt_SegmentGeographicalDomain_1909a468-99d3-46fa-a724-56cf1c805f94" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_d58aa87c-fb04-456b-bd32-53bffa82eb98" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_1909a468-99d3-46fa-a724-56cf1c805f94" xlink:to="loc_country_US_d58aa87c-fb04-456b-bd32-53bffa82eb98" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_c4b2c428-03d6-4e54-b562-2cd75a340524" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_a081b942-4194-4b24-9b1f-f4cecfddae86" xlink:to="loc_srt_ProductOrServiceAxis_c4b2c428-03d6-4e54-b562-2cd75a340524" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_c4b2c428-03d6-4e54-b562-2cd75a340524_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_c4b2c428-03d6-4e54-b562-2cd75a340524" xlink:to="loc_srt_ProductsAndServicesDomain_c4b2c428-03d6-4e54-b562-2cd75a340524_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_c32ae3b3-9ae7-43b7-b9c7-3694b71a284a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_c4b2c428-03d6-4e54-b562-2cd75a340524" xlink:to="loc_srt_ProductsAndServicesDomain_c32ae3b3-9ae7-43b7-b9c7-3694b71a284a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_TafasitamabProductAndServiceMember_b61a4d46-bc74-4278-afd0-a1c49a050b07" xlink:href="incy-20220930.xsd#incy_TafasitamabProductAndServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c32ae3b3-9ae7-43b7-b9c7-3694b71a284a" xlink:to="loc_incy_TafasitamabProductAndServiceMember_b61a4d46-bc74-4278-afd0-a1c49a050b07" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.incyte.com/role/LicenseAgreementsNimbleDetails" xlink:type="simple" xlink:href="incy-20220930.xsd#LicenseAgreementsNimbleDetails"/>
  <link:definitionLink xlink:role="http://www.incyte.com/role/LicenseAgreementsNimbleDetails" xlink:type="extended" id="if52e2796d41c4f979440fc496eecd419_LicenseAgreementsNimbleDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_53c1b115-3a41-4098-afc1-8d6ed40a40ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_LicenseAgreementAdditionalMilestonePayments_470b9ac9-369b-45c2-8621-b0a92ad29991" xlink:href="incy-20220930.xsd#incy_LicenseAgreementAdditionalMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_53c1b115-3a41-4098-afc1-8d6ed40a40ca" xlink:to="loc_incy_LicenseAgreementAdditionalMilestonePayments_470b9ac9-369b-45c2-8621-b0a92ad29991" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_80b11f27-689e-4069-9044-b94cff5b9ec6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_53c1b115-3a41-4098-afc1-8d6ed40a40ca" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_80b11f27-689e-4069-9044-b94cff5b9ec6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_057d95f1-8985-4cc3-bb8d-b01b91e9f81a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_80b11f27-689e-4069-9044-b94cff5b9ec6" xlink:to="loc_us-gaap_TypeOfArrangementAxis_057d95f1-8985-4cc3-bb8d-b01b91e9f81a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_057d95f1-8985-4cc3-bb8d-b01b91e9f81a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_057d95f1-8985-4cc3-bb8d-b01b91e9f81a" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_057d95f1-8985-4cc3-bb8d-b01b91e9f81a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_60188738-e511-4d6c-8975-9126f1b24aff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_057d95f1-8985-4cc3-bb8d-b01b91e9f81a" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_60188738-e511-4d6c-8975-9126f1b24aff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_NimbleMember_3406cb1c-b2ee-480c-9ec3-55dc6f22f398" xlink:href="incy-20220930.xsd#incy_NimbleMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_60188738-e511-4d6c-8975-9126f1b24aff" xlink:to="loc_incy_NimbleMember_3406cb1c-b2ee-480c-9ec3-55dc6f22f398" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_AchievementOfMilestoneAxis_a0a0ac4c-33af-4bd2-8d8e-065eaad91ee6" xlink:href="incy-20220930.xsd#incy_AchievementOfMilestoneAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_80b11f27-689e-4069-9044-b94cff5b9ec6" xlink:to="loc_incy_AchievementOfMilestoneAxis_a0a0ac4c-33af-4bd2-8d8e-065eaad91ee6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_AchievementOfMilestoneDomain_a0a0ac4c-33af-4bd2-8d8e-065eaad91ee6_default" xlink:href="incy-20220930.xsd#incy_AchievementOfMilestoneDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_incy_AchievementOfMilestoneAxis_a0a0ac4c-33af-4bd2-8d8e-065eaad91ee6" xlink:to="loc_incy_AchievementOfMilestoneDomain_a0a0ac4c-33af-4bd2-8d8e-065eaad91ee6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_AchievementOfMilestoneDomain_1b38707c-0297-45d8-855e-ac0c265faac6" xlink:href="incy-20220930.xsd#incy_AchievementOfMilestoneDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_incy_AchievementOfMilestoneAxis_a0a0ac4c-33af-4bd2-8d8e-065eaad91ee6" xlink:to="loc_incy_AchievementOfMilestoneDomain_1b38707c-0297-45d8-855e-ac0c265faac6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_FutureContingentDiscoveryMilestoneMember_affdd0cb-ef15-4951-94c1-2f0a2d80131a" xlink:href="incy-20220930.xsd#incy_FutureContingentDiscoveryMilestoneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_incy_AchievementOfMilestoneDomain_1b38707c-0297-45d8-855e-ac0c265faac6" xlink:to="loc_incy_FutureContingentDiscoveryMilestoneMember_affdd0cb-ef15-4951-94c1-2f0a2d80131a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_DevelopmentAndRegulatoryMilestonesMember_840327f0-ac73-4135-8ba7-5f7ec10867f6" xlink:href="incy-20220930.xsd#incy_DevelopmentAndRegulatoryMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_incy_AchievementOfMilestoneDomain_1b38707c-0297-45d8-855e-ac0c265faac6" xlink:to="loc_incy_DevelopmentAndRegulatoryMilestonesMember_840327f0-ac73-4135-8ba7-5f7ec10867f6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_CommercializationMilestonesMember_f2bd6549-67a7-4960-98eb-9c0ae7a5275f" xlink:href="incy-20220930.xsd#incy_CommercializationMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_incy_AchievementOfMilestoneDomain_1b38707c-0297-45d8-855e-ac0c265faac6" xlink:to="loc_incy_CommercializationMilestonesMember_f2bd6549-67a7-4960-98eb-9c0ae7a5275f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_758c32ee-3697-43cc-bafe-1954bf23e031" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_80b11f27-689e-4069-9044-b94cff5b9ec6" xlink:to="loc_srt_RangeAxis_758c32ee-3697-43cc-bafe-1954bf23e031" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_758c32ee-3697-43cc-bafe-1954bf23e031_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_758c32ee-3697-43cc-bafe-1954bf23e031" xlink:to="loc_srt_RangeMember_758c32ee-3697-43cc-bafe-1954bf23e031_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_36e65a72-a18b-4600-a781-0cae8c3b85c5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_758c32ee-3697-43cc-bafe-1954bf23e031" xlink:to="loc_srt_RangeMember_36e65a72-a18b-4600-a781-0cae8c3b85c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_bb46797c-e405-498c-82bd-90a9bbe4523c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_36e65a72-a18b-4600-a781-0cae8c3b85c5" xlink:to="loc_srt_MaximumMember_bb46797c-e405-498c-82bd-90a9bbe4523c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.incyte.com/role/LicenseAgreementsInnoCareDetails" xlink:type="simple" xlink:href="incy-20220930.xsd#LicenseAgreementsInnoCareDetails"/>
  <link:definitionLink xlink:role="http://www.incyte.com/role/LicenseAgreementsInnoCareDetails" xlink:type="extended" id="i24e35c1746af41dbbcee1ab32ff32507_LicenseAgreementsInnoCareDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_0a13a9eb-292a-4170-b81a-7598956c0d90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_LicenseAgreementUpfrontPaymentReceived_5067d799-b397-4ee5-9f66-da97ef605bf0" xlink:href="incy-20220930.xsd#incy_LicenseAgreementUpfrontPaymentReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0a13a9eb-292a-4170-b81a-7598956c0d90" xlink:to="loc_incy_LicenseAgreementUpfrontPaymentReceived_5067d799-b397-4ee5-9f66-da97ef605bf0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived_b069ddca-dd5b-4856-9d3c-4d5855b7d3d5" xlink:href="incy-20220930.xsd#incy_LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0a13a9eb-292a-4170-b81a-7598956c0d90" xlink:to="loc_incy_LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived_b069ddca-dd5b-4856-9d3c-4d5855b7d3d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_730c6b1a-79d1-49a4-8afa-c31c019ae350" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0a13a9eb-292a-4170-b81a-7598956c0d90" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_730c6b1a-79d1-49a4-8afa-c31c019ae350" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_ad3c90e8-3f8d-4579-b13d-c80697c7b8d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_730c6b1a-79d1-49a4-8afa-c31c019ae350" xlink:to="loc_us-gaap_TypeOfArrangementAxis_ad3c90e8-3f8d-4579-b13d-c80697c7b8d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ad3c90e8-3f8d-4579-b13d-c80697c7b8d0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_ad3c90e8-3f8d-4579-b13d-c80697c7b8d0" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ad3c90e8-3f8d-4579-b13d-c80697c7b8d0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a4649c1e-9adb-410e-96a0-07c6cfd21475" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_ad3c90e8-3f8d-4579-b13d-c80697c7b8d0" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a4649c1e-9adb-410e-96a0-07c6cfd21475" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_InnocarePharmaLimitedMember_81c9c51e-a5f0-4434-9099-79e2a82c3e23" xlink:href="incy-20220930.xsd#incy_InnocarePharmaLimitedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a4649c1e-9adb-410e-96a0-07c6cfd21475" xlink:to="loc_incy_InnocarePharmaLimitedMember_81c9c51e-a5f0-4434-9099-79e2a82c3e23" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_ef9eb24a-cc08-40b8-ab43-1061a6480cb9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_730c6b1a-79d1-49a4-8afa-c31c019ae350" xlink:to="loc_srt_ProductOrServiceAxis_ef9eb24a-cc08-40b8-ab43-1061a6480cb9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_ef9eb24a-cc08-40b8-ab43-1061a6480cb9_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_ef9eb24a-cc08-40b8-ab43-1061a6480cb9" xlink:to="loc_srt_ProductsAndServicesDomain_ef9eb24a-cc08-40b8-ab43-1061a6480cb9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_6e3a13ad-ccf9-4775-ba11-c100ee20e363" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_ef9eb24a-cc08-40b8-ab43-1061a6480cb9" xlink:to="loc_srt_ProductsAndServicesDomain_6e3a13ad-ccf9-4775-ba11-c100ee20e363" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_TafasitamabMember_d81bcf69-8f53-44f3-afdf-4cf0c53c143b" xlink:href="incy-20220930.xsd#incy_TafasitamabMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_6e3a13ad-ccf9-4775-ba11-c100ee20e363" xlink:to="loc_incy_TafasitamabMember_d81bcf69-8f53-44f3-afdf-4cf0c53c143b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_657c5344-cf33-4aaa-bae7-af04d10f14e9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_730c6b1a-79d1-49a4-8afa-c31c019ae350" xlink:to="loc_srt_RangeAxis_657c5344-cf33-4aaa-bae7-af04d10f14e9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_657c5344-cf33-4aaa-bae7-af04d10f14e9_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_657c5344-cf33-4aaa-bae7-af04d10f14e9" xlink:to="loc_srt_RangeMember_657c5344-cf33-4aaa-bae7-af04d10f14e9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_17c8bdc0-ba5e-4397-9819-e3ae600105d8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_657c5344-cf33-4aaa-bae7-af04d10f14e9" xlink:to="loc_srt_RangeMember_17c8bdc0-ba5e-4397-9819-e3ae600105d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_7f7179e1-fa94-45ad-b896-5c93a8336c29" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_17c8bdc0-ba5e-4397-9819-e3ae600105d8" xlink:to="loc_srt_MaximumMember_7f7179e1-fa94-45ad-b896-5c93a8336c29" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.incyte.com/role/LicenseAgreementsSyndaxDetails" xlink:type="simple" xlink:href="incy-20220930.xsd#LicenseAgreementsSyndaxDetails"/>
  <link:definitionLink xlink:role="http://www.incyte.com/role/LicenseAgreementsSyndaxDetails" xlink:type="extended" id="ic397e04729034fb9813523c15e915c5a_LicenseAgreementsSyndaxDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_5a08e409-b5c1-4143-81b6-9c0c72caac26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_LicenseAgreementPercentageOfFutureGlobalDevelopmentCostsFunded_d144e5b1-e993-4b86-bce8-11d417e2081e" xlink:href="incy-20220930.xsd#incy_LicenseAgreementPercentageOfFutureGlobalDevelopmentCostsFunded"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_5a08e409-b5c1-4143-81b6-9c0c72caac26" xlink:to="loc_incy_LicenseAgreementPercentageOfFutureGlobalDevelopmentCostsFunded_d144e5b1-e993-4b86-bce8-11d417e2081e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_LicenseAgreementUpfrontPaymentAmountPaid_eed7be00-347f-4f1a-8fb8-ce3de1db2e70" xlink:href="incy-20220930.xsd#incy_LicenseAgreementUpfrontPaymentAmountPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_5a08e409-b5c1-4143-81b6-9c0c72caac26" xlink:to="loc_incy_LicenseAgreementUpfrontPaymentAmountPaid_eed7be00-347f-4f1a-8fb8-ce3de1db2e70" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_LicenseAgreementAdditionalMilestonePayments_899568ce-a31d-412e-a176-3c7e137138df" xlink:href="incy-20220930.xsd#incy_LicenseAgreementAdditionalMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_5a08e409-b5c1-4143-81b6-9c0c72caac26" xlink:to="loc_incy_LicenseAgreementAdditionalMilestonePayments_899568ce-a31d-412e-a176-3c7e137138df" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_PurchaseOfCommonStockUnderStockPurchaseAgreementInShares_05dd2a6e-a509-4e52-9db2-5559661210f7" xlink:href="incy-20220930.xsd#incy_PurchaseOfCommonStockUnderStockPurchaseAgreementInShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_5a08e409-b5c1-4143-81b6-9c0c72caac26" xlink:to="loc_incy_PurchaseOfCommonStockUnderStockPurchaseAgreementInShares_05dd2a6e-a509-4e52-9db2-5559661210f7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentAggregateCost_e208f8a6-eea2-4ba4-8357-738a6ccc519b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentAggregateCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_5a08e409-b5c1-4143-81b6-9c0c72caac26" xlink:to="loc_us-gaap_EquityMethodInvestmentAggregateCost_e208f8a6-eea2-4ba4-8357-738a6ccc519b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_0130cb1b-be8b-4c58-b5d4-140f1ae4a0bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_5a08e409-b5c1-4143-81b6-9c0c72caac26" xlink:to="loc_us-gaap_SharePrice_0130cb1b-be8b-4c58-b5d4-140f1ae4a0bc" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments_58ce414b-48fb-4d83-8a81-99fb62b27407" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_5a08e409-b5c1-4143-81b6-9c0c72caac26" xlink:to="loc_us-gaap_LongTermInvestments_58ce414b-48fb-4d83-8a81-99fb62b27407" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_8598686f-7c70-49eb-8329-0e1b1c03c2fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_5a08e409-b5c1-4143-81b6-9c0c72caac26" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_8598686f-7c70-49eb-8329-0e1b1c03c2fb" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_fb810e82-d9fa-483f-9238-05d9006e7b9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_5a08e409-b5c1-4143-81b6-9c0c72caac26" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_fb810e82-d9fa-483f-9238-05d9006e7b9d" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_3781b2f9-1b2c-4abf-8344-81274a32024a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_5a08e409-b5c1-4143-81b6-9c0c72caac26" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_3781b2f9-1b2c-4abf-8344-81274a32024a" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_f5e5e011-9982-4ddd-b98a-1d632beb6e4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_5a08e409-b5c1-4143-81b6-9c0c72caac26" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_f5e5e011-9982-4ddd-b98a-1d632beb6e4b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_9e33d4e6-92ac-477a-9bef-fe1ec06e5200" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_f5e5e011-9982-4ddd-b98a-1d632beb6e4b" xlink:to="loc_us-gaap_TypeOfArrangementAxis_9e33d4e6-92ac-477a-9bef-fe1ec06e5200" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9e33d4e6-92ac-477a-9bef-fe1ec06e5200_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_9e33d4e6-92ac-477a-9bef-fe1ec06e5200" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9e33d4e6-92ac-477a-9bef-fe1ec06e5200_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_31ac57a8-01f4-47c2-93b2-36f3da6918a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_9e33d4e6-92ac-477a-9bef-fe1ec06e5200" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_31ac57a8-01f4-47c2-93b2-36f3da6918a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_SyndaxPharmaceuticalsIncMember_c36420d8-e767-4ee3-9dad-c45811b534aa" xlink:href="incy-20220930.xsd#incy_SyndaxPharmaceuticalsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_31ac57a8-01f4-47c2-93b2-36f3da6918a0" xlink:to="loc_incy_SyndaxPharmaceuticalsIncMember_c36420d8-e767-4ee3-9dad-c45811b534aa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_StockPurchaseAgreementMember_1c5a67e2-178d-4026-a7e5-955ca5e79091" xlink:href="incy-20220930.xsd#incy_StockPurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_31ac57a8-01f4-47c2-93b2-36f3da6918a0" xlink:to="loc_incy_StockPurchaseAgreementMember_1c5a67e2-178d-4026-a7e5-955ca5e79091" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_e81b3a74-5fd7-4b8c-87f5-6baaac4bfcca" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_f5e5e011-9982-4ddd-b98a-1d632beb6e4b" xlink:to="loc_dei_LegalEntityAxis_e81b3a74-5fd7-4b8c-87f5-6baaac4bfcca" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_e81b3a74-5fd7-4b8c-87f5-6baaac4bfcca_default" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_e81b3a74-5fd7-4b8c-87f5-6baaac4bfcca" xlink:to="loc_dei_EntityDomain_e81b3a74-5fd7-4b8c-87f5-6baaac4bfcca_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_edcc82ff-5e9e-4fbd-841c-f634e84b31e6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_e81b3a74-5fd7-4b8c-87f5-6baaac4bfcca" xlink:to="loc_dei_EntityDomain_edcc82ff-5e9e-4fbd-841c-f634e84b31e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_IncyteMember_2ed6ae07-0c9d-4a8e-bc67-b4d5afa4d0b0" xlink:href="incy-20220930.xsd#incy_IncyteMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_edcc82ff-5e9e-4fbd-841c-f634e84b31e6" xlink:to="loc_incy_IncyteMember_2ed6ae07-0c9d-4a8e-bc67-b4d5afa4d0b0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_a93e867d-6462-42ae-93ee-e18e283a91ef" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_f5e5e011-9982-4ddd-b98a-1d632beb6e4b" xlink:to="loc_srt_CounterpartyNameAxis_a93e867d-6462-42ae-93ee-e18e283a91ef" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a93e867d-6462-42ae-93ee-e18e283a91ef_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_a93e867d-6462-42ae-93ee-e18e283a91ef" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a93e867d-6462-42ae-93ee-e18e283a91ef_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ce062758-23e1-48e2-9c1c-8604dd4a7328" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_a93e867d-6462-42ae-93ee-e18e283a91ef" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ce062758-23e1-48e2-9c1c-8604dd4a7328" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_SyndaxPharmaceuticalsIncMember_e1312d54-934f-4815-8e1b-80c439192ba0" xlink:href="incy-20220930.xsd#incy_SyndaxPharmaceuticalsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ce062758-23e1-48e2-9c1c-8604dd4a7328" xlink:to="loc_incy_SyndaxPharmaceuticalsIncMember_e1312d54-934f-4815-8e1b-80c439192ba0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_e338852a-fa7f-4859-a358-f98149da2144" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_f5e5e011-9982-4ddd-b98a-1d632beb6e4b" xlink:to="loc_srt_StatementGeographicalAxis_e338852a-fa7f-4859-a358-f98149da2144" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_e338852a-fa7f-4859-a358-f98149da2144_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_e338852a-fa7f-4859-a358-f98149da2144" xlink:to="loc_srt_SegmentGeographicalDomain_e338852a-fa7f-4859-a358-f98149da2144_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_03174750-d659-42dc-a3de-9d8c9f734c60" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_e338852a-fa7f-4859-a358-f98149da2144" xlink:to="loc_srt_SegmentGeographicalDomain_03174750-d659-42dc-a3de-9d8c9f734c60" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_baab5556-466a-44a1-a426-8886f6e22005" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_03174750-d659-42dc-a3de-9d8c9f734c60" xlink:to="loc_country_US_baab5556-466a-44a1-a426-8886f6e22005" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_AchievementOfMilestoneAxis_bcf903d4-6b04-400d-be9c-28635ca66fdf" xlink:href="incy-20220930.xsd#incy_AchievementOfMilestoneAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_f5e5e011-9982-4ddd-b98a-1d632beb6e4b" xlink:to="loc_incy_AchievementOfMilestoneAxis_bcf903d4-6b04-400d-be9c-28635ca66fdf" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_AchievementOfMilestoneDomain_bcf903d4-6b04-400d-be9c-28635ca66fdf_default" xlink:href="incy-20220930.xsd#incy_AchievementOfMilestoneDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_incy_AchievementOfMilestoneAxis_bcf903d4-6b04-400d-be9c-28635ca66fdf" xlink:to="loc_incy_AchievementOfMilestoneDomain_bcf903d4-6b04-400d-be9c-28635ca66fdf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_AchievementOfMilestoneDomain_ddb0e2e4-3f95-41af-b9a0-ffb986211422" xlink:href="incy-20220930.xsd#incy_AchievementOfMilestoneDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_incy_AchievementOfMilestoneAxis_bcf903d4-6b04-400d-be9c-28635ca66fdf" xlink:to="loc_incy_AchievementOfMilestoneDomain_ddb0e2e4-3f95-41af-b9a0-ffb986211422" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_DevelopmentAndRegulatoryMilestonesMember_e210f047-a868-4046-9175-31ac35bec196" xlink:href="incy-20220930.xsd#incy_DevelopmentAndRegulatoryMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_incy_AchievementOfMilestoneDomain_ddb0e2e4-3f95-41af-b9a0-ffb986211422" xlink:to="loc_incy_DevelopmentAndRegulatoryMilestonesMember_e210f047-a868-4046-9175-31ac35bec196" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_CommercializationMilestonesMember_b86fc870-9d2e-4649-8af5-d062e4b0f96d" xlink:href="incy-20220930.xsd#incy_CommercializationMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_incy_AchievementOfMilestoneDomain_ddb0e2e4-3f95-41af-b9a0-ffb986211422" xlink:to="loc_incy_CommercializationMilestonesMember_b86fc870-9d2e-4649-8af5-d062e4b0f96d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_bffd3625-2d1c-4374-a755-f6b71e6f94ab" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_f5e5e011-9982-4ddd-b98a-1d632beb6e4b" xlink:to="loc_srt_RangeAxis_bffd3625-2d1c-4374-a755-f6b71e6f94ab" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_bffd3625-2d1c-4374-a755-f6b71e6f94ab_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_bffd3625-2d1c-4374-a755-f6b71e6f94ab" xlink:to="loc_srt_RangeMember_bffd3625-2d1c-4374-a755-f6b71e6f94ab_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_00868818-5e1c-4cfc-b596-c153adff67c6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_bffd3625-2d1c-4374-a755-f6b71e6f94ab" xlink:to="loc_srt_RangeMember_00868818-5e1c-4cfc-b596-c153adff67c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_92a0cb54-b49b-440f-812b-ee922b1cb7e7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_00868818-5e1c-4cfc-b596-c153adff67c6" xlink:to="loc_srt_MaximumMember_92a0cb54-b49b-440f-812b-ee922b1cb7e7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_31a88bfc-a0b2-4576-b69d-367e7d394064" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_f5e5e011-9982-4ddd-b98a-1d632beb6e4b" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_31a88bfc-a0b2-4576-b69d-367e7d394064" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_31a88bfc-a0b2-4576-b69d-367e7d394064_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_31a88bfc-a0b2-4576-b69d-367e7d394064" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_31a88bfc-a0b2-4576-b69d-367e7d394064_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_cf442d8a-4fd0-43fa-a03b-c0ad9ccdde55" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_31a88bfc-a0b2-4576-b69d-367e7d394064" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_cf442d8a-4fd0-43fa-a03b-c0ad9ccdde55" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_InvestmentInSyndaxPharmaceuticalsIncMember_c570f887-d5cf-4b75-a700-058c9326f79e" xlink:href="incy-20220930.xsd#incy_InvestmentInSyndaxPharmaceuticalsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_cf442d8a-4fd0-43fa-a03b-c0ad9ccdde55" xlink:to="loc_incy_InvestmentInSyndaxPharmaceuticalsIncMember_c570f887-d5cf-4b75-a700-058c9326f79e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.incyte.com/role/PropertyandEquipmentnetPropertyandequipmentnetDetails" xlink:type="simple" xlink:href="incy-20220930.xsd#PropertyandEquipmentnetPropertyandequipmentnetDetails"/>
  <link:definitionLink xlink:role="http://www.incyte.com/role/PropertyandEquipmentnetPropertyandequipmentnetDetails" xlink:type="extended" id="iae708958c01e4808b649ffb267b09a6d_PropertyandEquipmentnetPropertyandequipmentnetDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9f748e36-0ff6-4e1f-909b-42cc36da29fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_1750bf8c-7e70-4cb0-8fec-c85eb0508ad5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9f748e36-0ff6-4e1f-909b-42cc36da29fb" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_1750bf8c-7e70-4cb0-8fec-c85eb0508ad5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_24dee932-1b2d-4ba2-90e3-8c840b044c01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9f748e36-0ff6-4e1f-909b-42cc36da29fb" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_24dee932-1b2d-4ba2-90e3-8c840b044c01" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_20bf751c-5d08-428a-b032-6840f0a1b200" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9f748e36-0ff6-4e1f-909b-42cc36da29fb" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_20bf751c-5d08-428a-b032-6840f0a1b200" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_aca44067-fde2-4ef8-9806-0c1d9cd2b392" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9f748e36-0ff6-4e1f-909b-42cc36da29fb" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_aca44067-fde2-4ef8-9806-0c1d9cd2b392" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_dd17f082-9097-409f-80be-60a6ca863e72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_aca44067-fde2-4ef8-9806-0c1d9cd2b392" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_dd17f082-9097-409f-80be-60a6ca863e72" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_dd17f082-9097-409f-80be-60a6ca863e72_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_dd17f082-9097-409f-80be-60a6ca863e72" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_dd17f082-9097-409f-80be-60a6ca863e72_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_115543a7-3a96-403b-91bc-200d9415cc0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_dd17f082-9097-409f-80be-60a6ca863e72" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_115543a7-3a96-403b-91bc-200d9415cc0b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember_64aebe57-c931-482b-bf78-759065f111cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OfficeEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_115543a7-3a96-403b-91bc-200d9415cc0b" xlink:to="loc_us-gaap_OfficeEquipmentMember_64aebe57-c931-482b-bf78-759065f111cf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_ad730301-4ac6-4e23-aba0-ce404cfc7d2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_115543a7-3a96-403b-91bc-200d9415cc0b" xlink:to="loc_us-gaap_EquipmentMember_ad730301-4ac6-4e23-aba0-ce404cfc7d2b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_41a9f74b-0782-4162-b745-b953457177ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_115543a7-3a96-403b-91bc-200d9415cc0b" xlink:to="loc_us-gaap_ComputerEquipmentMember_41a9f74b-0782-4162-b745-b953457177ea" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandMember_750bba4f-22dd-45fc-8684-195155ad5644" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LandMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_115543a7-3a96-403b-91bc-200d9415cc0b" xlink:to="loc_us-gaap_LandMember_750bba4f-22dd-45fc-8684-195155ad5644" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_BuildingAndLeaseholdImprovementsMember_8e87163f-71a9-4cf3-8e77-6e42e77b3514" xlink:href="incy-20220930.xsd#incy_BuildingAndLeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_115543a7-3a96-403b-91bc-200d9415cc0b" xlink:to="loc_incy_BuildingAndLeaseholdImprovementsMember_8e87163f-71a9-4cf3-8e77-6e42e77b3514" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_OperatingLeaseRightOfUseAssetsMember_c719a136-4769-4489-8e5d-6bc70283565e" xlink:href="incy-20220930.xsd#incy_OperatingLeaseRightOfUseAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_115543a7-3a96-403b-91bc-200d9415cc0b" xlink:to="loc_incy_OperatingLeaseRightOfUseAssetsMember_c719a136-4769-4489-8e5d-6bc70283565e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_c5d6a3ce-bfe1-4f4c-856d-3ef931264fd1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_115543a7-3a96-403b-91bc-200d9415cc0b" xlink:to="loc_us-gaap_ConstructionInProgressMember_c5d6a3ce-bfe1-4f4c-856d-3ef931264fd1" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.incyte.com/role/PropertyandEquipmentnetBuildingsandconstructionDetails" xlink:type="simple" xlink:href="incy-20220930.xsd#PropertyandEquipmentnetBuildingsandconstructionDetails"/>
  <link:definitionLink xlink:role="http://www.incyte.com/role/PropertyandEquipmentnetBuildingsandconstructionDetails" xlink:type="extended" id="i5d5f6b9f42c24fa6b576c047a085a294_PropertyandEquipmentnetBuildingsandconstructionDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ebc60995-865d-458f-ba41-34f4bb82f2f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfRealEstateProperty_9513d0a8-20c8-4a32-b130-23494681d189" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AreaOfRealEstateProperty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ebc60995-865d-458f-ba41-34f4bb82f2f6" xlink:to="loc_us-gaap_AreaOfRealEstateProperty_9513d0a8-20c8-4a32-b130-23494681d189" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_649b3d7f-e457-487f-bd3c-c2911340f7a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ebc60995-865d-458f-ba41-34f4bb82f2f6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_649b3d7f-e457-487f-bd3c-c2911340f7a9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeaseTermOfContract1_3f610c8b-99a9-4e33-ace2-a74d5a387e4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeFinanceLeaseTermOfContract1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ebc60995-865d-458f-ba41-34f4bb82f2f6" xlink:to="loc_us-gaap_LesseeFinanceLeaseTermOfContract1_3f610c8b-99a9-4e33-ace2-a74d5a387e4b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeaseExistenceOfOptionToExtend_67748da1-c494-4799-8c6c-3f273ef37408" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeFinanceLeaseExistenceOfOptionToExtend"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ebc60995-865d-458f-ba41-34f4bb82f2f6" xlink:to="loc_us-gaap_LesseeFinanceLeaseExistenceOfOptionToExtend_67748da1-c494-4799-8c6c-3f273ef37408" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeaseRenewalTerm1_d226fe22-d249-4460-ac2a-22048e0d35e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeFinanceLeaseRenewalTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ebc60995-865d-458f-ba41-34f4bb82f2f6" xlink:to="loc_us-gaap_LesseeFinanceLeaseRenewalTerm1_d226fe22-d249-4460-ac2a-22048e0d35e7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_17a3ffb1-a4c4-4f5a-a81b-1f942a6f2282" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ebc60995-865d-458f-ba41-34f4bb82f2f6" xlink:to="loc_us-gaap_FinanceLeaseLiability_17a3ffb1-a4c4-4f5a-a81b-1f942a6f2282" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset_310d3591-e244-4d28-9e7f-df0a6ad4fd79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ebc60995-865d-458f-ba41-34f4bb82f2f6" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAsset_310d3591-e244-4d28-9e7f-df0a6ad4fd79" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_FinanceLeaseLeaseIncentiveReceivable_860b6ffa-9b66-4af4-91e5-43d0159aca88" xlink:href="incy-20220930.xsd#incy_FinanceLeaseLeaseIncentiveReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ebc60995-865d-458f-ba41-34f4bb82f2f6" xlink:to="loc_incy_FinanceLeaseLeaseIncentiveReceivable_860b6ffa-9b66-4af4-91e5-43d0159aca88" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireRealEstate_2aac361d-689a-41be-820b-9b950ce75561" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireRealEstate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ebc60995-865d-458f-ba41-34f4bb82f2f6" xlink:to="loc_us-gaap_PaymentsToAcquireRealEstate_2aac361d-689a-41be-820b-9b950ce75561" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3dbb24c1-b5e2-4214-96ed-5979af2357f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ebc60995-865d-458f-ba41-34f4bb82f2f6" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3dbb24c1-b5e2-4214-96ed-5979af2357f4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealEstatePropertiesAxis_be66fadd-3fd4-44a4-a9b7-5d05d732f0fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RealEstatePropertiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3dbb24c1-b5e2-4214-96ed-5979af2357f4" xlink:to="loc_us-gaap_RealEstatePropertiesAxis_be66fadd-3fd4-44a4-a9b7-5d05d732f0fb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealEstatePropertiesDomain_be66fadd-3fd4-44a4-a9b7-5d05d732f0fb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RealEstatePropertiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RealEstatePropertiesAxis_be66fadd-3fd4-44a4-a9b7-5d05d732f0fb" xlink:to="loc_us-gaap_RealEstatePropertiesDomain_be66fadd-3fd4-44a4-a9b7-5d05d732f0fb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealEstatePropertiesDomain_9f119c25-611d-4694-8ea3-69c370093f02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RealEstatePropertiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RealEstatePropertiesAxis_be66fadd-3fd4-44a4-a9b7-5d05d732f0fb" xlink:to="loc_us-gaap_RealEstatePropertiesDomain_9f119c25-611d-4694-8ea3-69c370093f02" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_OfficeBuildingWilmingtonDelawareMember_4ee5f635-cf92-42cc-abbb-430c2b861354" xlink:href="incy-20220930.xsd#incy_OfficeBuildingWilmingtonDelawareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RealEstatePropertiesDomain_9f119c25-611d-4694-8ea3-69c370093f02" xlink:to="loc_incy_OfficeBuildingWilmingtonDelawareMember_4ee5f635-cf92-42cc-abbb-430c2b861354" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_OfficeBuildingMorgesSwitzerlandMember_ccf09e63-dc97-4a98-b7ec-e260820279a5" xlink:href="incy-20220930.xsd#incy_OfficeBuildingMorgesSwitzerlandMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RealEstatePropertiesDomain_9f119c25-611d-4694-8ea3-69c370093f02" xlink:to="loc_incy_OfficeBuildingMorgesSwitzerlandMember_ccf09e63-dc97-4a98-b7ec-e260820279a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_LandLocatedWithinYParcSwitzerlandsLargestTechnologyParkInYverdonMember_5f7ba981-ee5f-41b5-9043-38fdd9d0e4ec" xlink:href="incy-20220930.xsd#incy_LandLocatedWithinYParcSwitzerlandsLargestTechnologyParkInYverdonMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RealEstatePropertiesDomain_9f119c25-611d-4694-8ea3-69c370093f02" xlink:to="loc_incy_LandLocatedWithinYParcSwitzerlandsLargestTechnologyParkInYverdonMember_5f7ba981-ee5f-41b5-9043-38fdd9d0e4ec" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8f62a0b5-d072-4aac-a73f-db1494fe3bb7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3dbb24c1-b5e2-4214-96ed-5979af2357f4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8f62a0b5-d072-4aac-a73f-db1494fe3bb7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8f62a0b5-d072-4aac-a73f-db1494fe3bb7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8f62a0b5-d072-4aac-a73f-db1494fe3bb7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8f62a0b5-d072-4aac-a73f-db1494fe3bb7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c32f6589-46cf-4003-875f-13fca2848e4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8f62a0b5-d072-4aac-a73f-db1494fe3bb7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c32f6589-46cf-4003-875f-13fca2848e4d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_BuildingAndLeaseholdImprovementsMember_3e21aaf6-c068-4c54-89da-9cebf1694c2d" xlink:href="incy-20220930.xsd#incy_BuildingAndLeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c32f6589-46cf-4003-875f-13fca2848e4d" xlink:to="loc_incy_BuildingAndLeaseholdImprovementsMember_3e21aaf6-c068-4c54-89da-9cebf1694c2d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_ff6348fd-53f7-4ad6-9f1b-79321f5031da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c32f6589-46cf-4003-875f-13fca2848e4d" xlink:to="loc_us-gaap_ConstructionInProgressMember_ff6348fd-53f7-4ad6-9f1b-79321f5031da" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.incyte.com/role/StockCompensationNarrativeDetails" xlink:type="simple" xlink:href="incy-20220930.xsd#StockCompensationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.incyte.com/role/StockCompensationNarrativeDetails" xlink:type="extended" id="ia3c922d544574f8595812b1484e6b269_StockCompensationNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cdb54f4e-c9d4-4cbe-a460-10a6976c3899" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_cb8c1d4b-0dbc-4ad2-a361-d196e1704c00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cdb54f4e-c9d4-4cbe-a460-10a6976c3899" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_cb8c1d4b-0dbc-4ad2-a361-d196e1704c00" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_2a95d824-6997-4488-8937-93fb404cbc25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cdb54f4e-c9d4-4cbe-a460-10a6976c3899" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_2a95d824-6997-4488-8937-93fb404cbc25" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_2c5d4d81-81a4-421a-a2d9-55de2d8f0d7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cdb54f4e-c9d4-4cbe-a460-10a6976c3899" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_2c5d4d81-81a4-421a-a2d9-55de2d8f0d7a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_f93e8c0f-b7dc-4128-a533-d1d1db6f3b9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cdb54f4e-c9d4-4cbe-a460-10a6976c3899" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_f93e8c0f-b7dc-4128-a533-d1d1db6f3b9f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_068f76a0-a76f-40a8-bb17-d5f59ccaee86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cdb54f4e-c9d4-4cbe-a460-10a6976c3899" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_068f76a0-a76f-40a8-bb17-d5f59ccaee86" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesPerRestrictedStockUnits_8c532157-3493-45a4-93e2-9fcb7c48e58d" xlink:href="incy-20220930.xsd#incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesPerRestrictedStockUnits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cdb54f4e-c9d4-4cbe-a460-10a6976c3899" xlink:to="loc_incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesPerRestrictedStockUnits_8c532157-3493-45a4-93e2-9fcb7c48e58d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedAnnualizedForfeitureRate_f4b52741-6c57-4a6e-bc84-0dd0028c4b3a" xlink:href="incy-20220930.xsd#incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedAnnualizedForfeitureRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cdb54f4e-c9d4-4cbe-a460-10a6976c3899" xlink:to="loc_incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedAnnualizedForfeitureRate_f4b52741-6c57-4a6e-bc84-0dd0028c4b3a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract_adb97ad0-9092-420b-a1b9-4bdd4b3b638b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cdb54f4e-c9d4-4cbe-a460-10a6976c3899" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract_adb97ad0-9092-420b-a1b9-4bdd4b3b638b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_ce024c61-ea62-4cba-ab21-4b7ece9b965e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract_adb97ad0-9092-420b-a1b9-4bdd4b3b638b" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_ce024c61-ea62-4cba-ab21-4b7ece9b965e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_b7427dfb-f2be-42f9-8d99-3f746e8f1b33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract_adb97ad0-9092-420b-a1b9-4bdd4b3b638b" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_b7427dfb-f2be-42f9-8d99-3f746e8f1b33" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ab3ed9e9-8d00-4d82-a6f9-7097819d75e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cdb54f4e-c9d4-4cbe-a460-10a6976c3899" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ab3ed9e9-8d00-4d82-a6f9-7097819d75e0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_d7958f40-9ed1-4bb3-a9c4-b7ad84fbd4c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ab3ed9e9-8d00-4d82-a6f9-7097819d75e0" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_d7958f40-9ed1-4bb3-a9c4-b7ad84fbd4c2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_d7958f40-9ed1-4bb3-a9c4-b7ad84fbd4c2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_d7958f40-9ed1-4bb3-a9c4-b7ad84fbd4c2" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_d7958f40-9ed1-4bb3-a9c4-b7ad84fbd4c2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_3d241c68-3cf8-4bb4-9047-ddae95c091e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_d7958f40-9ed1-4bb3-a9c4-b7ad84fbd4c2" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_3d241c68-3cf8-4bb4-9047-ddae95c091e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_ac7f1ed8-88d1-4716-bbfd-99a108a9678d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_3d241c68-3cf8-4bb4-9047-ddae95c091e5" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_ac7f1ed8-88d1-4716-bbfd-99a108a9678d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_826a9094-1ced-4bb8-be5d-a2b207439ecc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_3d241c68-3cf8-4bb4-9047-ddae95c091e5" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_826a9094-1ced-4bb8-be5d-a2b207439ecc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_07e12994-f08a-4330-8a46-e8f1906e070a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_3d241c68-3cf8-4bb4-9047-ddae95c091e5" xlink:to="loc_us-gaap_CostOfSalesMember_07e12994-f08a-4330-8a46-e8f1906e070a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_d10a43a1-4898-43b5-b1d4-c4070ea1d1d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ab3ed9e9-8d00-4d82-a6f9-7097819d75e0" xlink:to="loc_us-gaap_AwardTypeAxis_d10a43a1-4898-43b5-b1d4-c4070ea1d1d6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d10a43a1-4898-43b5-b1d4-c4070ea1d1d6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_d10a43a1-4898-43b5-b1d4-c4070ea1d1d6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d10a43a1-4898-43b5-b1d4-c4070ea1d1d6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_09cb2792-f4ba-4b87-aeda-0059191d16bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_d10a43a1-4898-43b5-b1d4-c4070ea1d1d6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_09cb2792-f4ba-4b87-aeda-0059191d16bd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_1974e3b0-bc03-4967-9897-884974cac38a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_09cb2792-f4ba-4b87-aeda-0059191d16bd" xlink:to="loc_us-gaap_EmployeeStockOptionMember_1974e3b0-bc03-4967-9897-884974cac38a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_b6f4cbfe-0ff0-4bb7-b6a5-40c854dfd678" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_09cb2792-f4ba-4b87-aeda-0059191d16bd" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_b6f4cbfe-0ff0-4bb7-b6a5-40c854dfd678" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_7cd083f9-cbd7-421f-97e9-56ebfbc4095f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_09cb2792-f4ba-4b87-aeda-0059191d16bd" xlink:to="loc_us-gaap_PerformanceSharesMember_7cd083f9-cbd7-421f-97e9-56ebfbc4095f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_885a7666-d354-4e3d-92b6-da59066938d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ab3ed9e9-8d00-4d82-a6f9-7097819d75e0" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_885a7666-d354-4e3d-92b6-da59066938d5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_885a7666-d354-4e3d-92b6-da59066938d5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_885a7666-d354-4e3d-92b6-da59066938d5" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_885a7666-d354-4e3d-92b6-da59066938d5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_de4d89d6-8c5a-48b5-b7e5-103e0c737002" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_885a7666-d354-4e3d-92b6-da59066938d5" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_de4d89d6-8c5a-48b5-b7e5-103e0c737002" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_caad79ce-a66d-44c7-901e-49b9ff6c79c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_de4d89d6-8c5a-48b5-b7e5-103e0c737002" xlink:to="loc_us-gaap_EmployeeStockMember_caad79ce-a66d-44c7-901e-49b9ff6c79c9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_764a2c92-d7eb-4932-9eaa-56d84b7bcb75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ab3ed9e9-8d00-4d82-a6f9-7097819d75e0" xlink:to="loc_us-gaap_VestingAxis_764a2c92-d7eb-4932-9eaa-56d84b7bcb75" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_764a2c92-d7eb-4932-9eaa-56d84b7bcb75_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_764a2c92-d7eb-4932-9eaa-56d84b7bcb75" xlink:to="loc_us-gaap_VestingDomain_764a2c92-d7eb-4932-9eaa-56d84b7bcb75_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_b976cc96-fdc4-498f-be89-f820e8e50fef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_764a2c92-d7eb-4932-9eaa-56d84b7bcb75" xlink:to="loc_us-gaap_VestingDomain_b976cc96-fdc4-498f-be89-f820e8e50fef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_e6bdc0fc-dbf8-46c2-baf0-e67fb0e8b5b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_b976cc96-fdc4-498f-be89-f820e8e50fef" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_e6bdc0fc-dbf8-46c2-baf0-e67fb0e8b5b3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_d8019c27-28d2-42d2-9e5e-20b27dbe2f45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_b976cc96-fdc4-498f-be89-f820e8e50fef" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_d8019c27-28d2-42d2-9e5e-20b27dbe2f45" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_2d9136e2-9fe4-4a41-8edb-bd231dc59dd5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ab3ed9e9-8d00-4d82-a6f9-7097819d75e0" xlink:to="loc_srt_RangeAxis_2d9136e2-9fe4-4a41-8edb-bd231dc59dd5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_2d9136e2-9fe4-4a41-8edb-bd231dc59dd5_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_2d9136e2-9fe4-4a41-8edb-bd231dc59dd5" xlink:to="loc_srt_RangeMember_2d9136e2-9fe4-4a41-8edb-bd231dc59dd5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f06d5a0a-5151-4a20-a374-d847b1522518" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_2d9136e2-9fe4-4a41-8edb-bd231dc59dd5" xlink:to="loc_srt_RangeMember_f06d5a0a-5151-4a20-a374-d847b1522518" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_24958ac1-92b4-43c9-8636-8b1dcc81d2ba" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_f06d5a0a-5151-4a20-a374-d847b1522518" xlink:to="loc_srt_MinimumMember_24958ac1-92b4-43c9-8636-8b1dcc81d2ba" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_9f5bb04c-dd26-44c7-8f64-64abd407eaf2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_f06d5a0a-5151-4a20-a374-d847b1522518" xlink:to="loc_srt_MaximumMember_9f5bb04c-dd26-44c7-8f64-64abd407eaf2" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.incyte.com/role/StockCompensationValuationassumptionsusedforvalueofstockcompensationgrantedDetails" xlink:type="simple" xlink:href="incy-20220930.xsd#StockCompensationValuationassumptionsusedforvalueofstockcompensationgrantedDetails"/>
  <link:definitionLink xlink:role="http://www.incyte.com/role/StockCompensationValuationassumptionsusedforvalueofstockcompensationgrantedDetails" xlink:type="extended" id="i25824706948e4600a908fed9324384b3_StockCompensationValuationassumptionsusedforvalueofstockcompensationgrantedDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_51790044-a746-4633-8977-a8e7d6b4f5c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_85121fd5-0af0-4fed-92c4-8c100fdd4aaa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_51790044-a746-4633-8977-a8e7d6b4f5c2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_85121fd5-0af0-4fed-92c4-8c100fdd4aaa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_998f0b0a-d405-444a-a9c5-dde990d86907" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_85121fd5-0af0-4fed-92c4-8c100fdd4aaa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_998f0b0a-d405-444a-a9c5-dde990d86907" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_c030cc17-9d3b-4bfb-9dd9-f701868dca81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_85121fd5-0af0-4fed-92c4-8c100fdd4aaa" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_c030cc17-9d3b-4bfb-9dd9-f701868dca81" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_b8b0bc5c-c701-43e0-a2cb-eb49494e207a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_85121fd5-0af0-4fed-92c4-8c100fdd4aaa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_b8b0bc5c-c701-43e0-a2cb-eb49494e207a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_fa0c5a35-8f04-469f-ba21-0c506efdd88c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_85121fd5-0af0-4fed-92c4-8c100fdd4aaa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_fa0c5a35-8f04-469f-ba21-0c506efdd88c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_17868112-6c05-42d7-88fd-382a16380b32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_51790044-a746-4633-8977-a8e7d6b4f5c2" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_17868112-6c05-42d7-88fd-382a16380b32" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_1b7b6ee4-3db4-49fa-abc0-6fef3b49c2fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_17868112-6c05-42d7-88fd-382a16380b32" xlink:to="loc_us-gaap_AwardTypeAxis_1b7b6ee4-3db4-49fa-abc0-6fef3b49c2fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1b7b6ee4-3db4-49fa-abc0-6fef3b49c2fa_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_1b7b6ee4-3db4-49fa-abc0-6fef3b49c2fa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1b7b6ee4-3db4-49fa-abc0-6fef3b49c2fa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d68f8e47-7e9c-4b87-935f-bbda06d1d8e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_1b7b6ee4-3db4-49fa-abc0-6fef3b49c2fa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d68f8e47-7e9c-4b87-935f-bbda06d1d8e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_46c604dd-c9ed-466f-9345-3ec7a960c56b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d68f8e47-7e9c-4b87-935f-bbda06d1d8e4" xlink:to="loc_us-gaap_EmployeeStockOptionMember_46c604dd-c9ed-466f-9345-3ec7a960c56b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_da6d8f44-fae9-4c9d-b9c4-2714e39be690" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_17868112-6c05-42d7-88fd-382a16380b32" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_da6d8f44-fae9-4c9d-b9c4-2714e39be690" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_da6d8f44-fae9-4c9d-b9c4-2714e39be690_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_da6d8f44-fae9-4c9d-b9c4-2714e39be690" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_da6d8f44-fae9-4c9d-b9c4-2714e39be690_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_316b424b-cdac-4dc2-8369-0cf57a616df8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_da6d8f44-fae9-4c9d-b9c4-2714e39be690" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_316b424b-cdac-4dc2-8369-0cf57a616df8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_1eaaa7dd-1b44-4047-9359-e11f06f2c57a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_316b424b-cdac-4dc2-8369-0cf57a616df8" xlink:to="loc_us-gaap_EmployeeStockMember_1eaaa7dd-1b44-4047-9359-e11f06f2c57a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.incyte.com/role/StockCompensationOptionactivityunderthe2010stockplanDetails" xlink:type="simple" xlink:href="incy-20220930.xsd#StockCompensationOptionactivityunderthe2010stockplanDetails"/>
  <link:definitionLink xlink:role="http://www.incyte.com/role/StockCompensationOptionactivityunderthe2010stockplanDetails" xlink:type="extended" id="i9080012853944fb5b6564c70d173024d_StockCompensationOptionactivityunderthe2010stockplanDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_987d2851-d2bf-4fd9-a918-26b408503228" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ea8e02ab-dfec-48c3-bbf7-12b2013484b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_987d2851-d2bf-4fd9-a918-26b408503228" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ea8e02ab-dfec-48c3-bbf7-12b2013484b9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_fdad73bd-c032-4626-b8a2-6fc69159a62a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ea8e02ab-dfec-48c3-bbf7-12b2013484b9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_fdad73bd-c032-4626-b8a2-6fc69159a62a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_25b3c3c7-e3c2-42b3-953c-6d11a15e044c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ea8e02ab-dfec-48c3-bbf7-12b2013484b9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_25b3c3c7-e3c2-42b3-953c-6d11a15e044c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_90a346af-de82-4f71-899b-e013d46673f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ea8e02ab-dfec-48c3-bbf7-12b2013484b9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_90a346af-de82-4f71-899b-e013d46673f8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_658b884a-3fe8-4d7d-94e6-5a70e72dabd5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ea8e02ab-dfec-48c3-bbf7-12b2013484b9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_658b884a-3fe8-4d7d-94e6-5a70e72dabd5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_be973f09-d335-46f3-9f72-edde23205734" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7d6db9ac-6fac-4622-a09b-586c04a1034e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_987d2851-d2bf-4fd9-a918-26b408503228" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7d6db9ac-6fac-4622-a09b-586c04a1034e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_dcdd516b-3dcc-452d-9070-6ded7744863b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7d6db9ac-6fac-4622-a09b-586c04a1034e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_dcdd516b-3dcc-452d-9070-6ded7744863b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_26d94238-a68d-4824-8f89-6a813d04bbe0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7d6db9ac-6fac-4622-a09b-586c04a1034e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_26d94238-a68d-4824-8f89-6a813d04bbe0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_18202f0e-4683-4eef-9e45-b62cc0423a93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7d6db9ac-6fac-4622-a09b-586c04a1034e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_18202f0e-4683-4eef-9e45-b62cc0423a93" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_a9b344bf-f7bb-48a8-a0c9-2f29a97bf394" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7d6db9ac-6fac-4622-a09b-586c04a1034e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_a9b344bf-f7bb-48a8-a0c9-2f29a97bf394" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c37bef69-f6a0-41a3-8be1-77817586b661" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_987d2851-d2bf-4fd9-a918-26b408503228" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c37bef69-f6a0-41a3-8be1-77817586b661" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_6e409546-f038-4d3e-a79a-218ca129f7d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c37bef69-f6a0-41a3-8be1-77817586b661" xlink:to="loc_us-gaap_AwardTypeAxis_6e409546-f038-4d3e-a79a-218ca129f7d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6e409546-f038-4d3e-a79a-218ca129f7d1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_6e409546-f038-4d3e-a79a-218ca129f7d1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6e409546-f038-4d3e-a79a-218ca129f7d1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_549eaa4d-b78a-4426-b7cd-64cdd90eadc5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_6e409546-f038-4d3e-a79a-218ca129f7d1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_549eaa4d-b78a-4426-b7cd-64cdd90eadc5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_d5721a15-f44e-4b8f-ab9e-662f913307b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_549eaa4d-b78a-4426-b7cd-64cdd90eadc5" xlink:to="loc_us-gaap_EmployeeStockOptionMember_d5721a15-f44e-4b8f-ab9e-662f913307b3" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.incyte.com/role/StockCompensationRSUawardandPSUactivityunderthe2010stockplanDetails" xlink:type="simple" xlink:href="incy-20220930.xsd#StockCompensationRSUawardandPSUactivityunderthe2010stockplanDetails"/>
  <link:definitionLink xlink:role="http://www.incyte.com/role/StockCompensationRSUawardandPSUactivityunderthe2010stockplanDetails" xlink:type="extended" id="i1b57f93b97124064bb7b63a8bccb272e_StockCompensationRSUawardandPSUactivityunderthe2010stockplanDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e9d1ac1e-5e1a-454e-90e6-7a9628cdf898" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_194aded8-2b72-47ce-a1e8-5ff969f26a39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e9d1ac1e-5e1a-454e-90e6-7a9628cdf898" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_194aded8-2b72-47ce-a1e8-5ff969f26a39" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_02c928b7-eebc-4624-9dc8-5c9bdbb17bd0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_194aded8-2b72-47ce-a1e8-5ff969f26a39" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_02c928b7-eebc-4624-9dc8-5c9bdbb17bd0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_a53ebcfc-90b7-4cf0-b792-21f4109cfcf2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_194aded8-2b72-47ce-a1e8-5ff969f26a39" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_a53ebcfc-90b7-4cf0-b792-21f4109cfcf2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod_f8ed6fe4-dcd1-482e-b659-bc27bc3b56c2" xlink:href="incy-20220930.xsd#incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_194aded8-2b72-47ce-a1e8-5ff969f26a39" xlink:to="loc_incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod_f8ed6fe4-dcd1-482e-b659-bc27bc3b56c2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_376a76b9-f0e8-475d-9a6d-994cd30a38af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_194aded8-2b72-47ce-a1e8-5ff969f26a39" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_376a76b9-f0e8-475d-9a6d-994cd30a38af" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_581682e5-4e17-44a8-ae27-0423bfad79fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_9e71d677-0deb-4f95-a6c7-31110105bf2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e9d1ac1e-5e1a-454e-90e6-7a9628cdf898" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_9e71d677-0deb-4f95-a6c7-31110105bf2f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_5b96be09-b281-400a-a852-05e04c88df6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_9e71d677-0deb-4f95-a6c7-31110105bf2f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_5b96be09-b281-400a-a852-05e04c88df6a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue_a977cc81-d655-4781-ac3a-826dcfb2efef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_9e71d677-0deb-4f95-a6c7-31110105bf2f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue_a977cc81-d655-4781-ac3a-826dcfb2efef" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedIntrinsicValue_52711e85-57b5-438e-98e9-b16f4dc91461" xlink:href="incy-20220930.xsd#incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_9e71d677-0deb-4f95-a6c7-31110105bf2f" xlink:to="loc_incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedIntrinsicValue_52711e85-57b5-438e-98e9-b16f4dc91461" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue_0fc04e24-d52d-4bcc-b68f-8bd74a62f172" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_9e71d677-0deb-4f95-a6c7-31110105bf2f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue_0fc04e24-d52d-4bcc-b68f-8bd74a62f172" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ede23d4b-8e10-4c1d-b77b-a32ba4adb269" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e9d1ac1e-5e1a-454e-90e6-7a9628cdf898" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ede23d4b-8e10-4c1d-b77b-a32ba4adb269" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_ca02f58e-00d5-43b5-afe2-fd5ffc228d28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ede23d4b-8e10-4c1d-b77b-a32ba4adb269" xlink:to="loc_us-gaap_AwardTypeAxis_ca02f58e-00d5-43b5-afe2-fd5ffc228d28" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ca02f58e-00d5-43b5-afe2-fd5ffc228d28_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_ca02f58e-00d5-43b5-afe2-fd5ffc228d28" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ca02f58e-00d5-43b5-afe2-fd5ffc228d28_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_faf337a6-7fa2-4bab-9bf7-6d2bf500fe01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_ca02f58e-00d5-43b5-afe2-fd5ffc228d28" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_faf337a6-7fa2-4bab-9bf7-6d2bf500fe01" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_6e1ce3bf-3192-488e-af8f-7e92fc7abef5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_faf337a6-7fa2-4bab-9bf7-6d2bf500fe01" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_6e1ce3bf-3192-488e-af8f-7e92fc7abef5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_80f261ed-b667-4240-b301-9098715b711a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_faf337a6-7fa2-4bab-9bf7-6d2bf500fe01" xlink:to="loc_us-gaap_PerformanceSharesMember_80f261ed-b667-4240-b301-9098715b711a" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.incyte.com/role/NetIncomePerShareAntidilutivesecuritiesDetails" xlink:type="simple" xlink:href="incy-20220930.xsd#NetIncomePerShareAntidilutivesecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.incyte.com/role/NetIncomePerShareAntidilutivesecuritiesDetails" xlink:type="extended" id="if8c18ce983914628b150c08120232cad_NetIncomePerShareAntidilutivesecuritiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicLineItems_ed828240-5482-4192-ac52-30085f445460" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasicLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract_4bd036fa-435c-431e-9f43-0115f404b8c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_ed828240-5482-4192-ac52-30085f445460" xlink:to="loc_us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract_4bd036fa-435c-431e-9f43-0115f404b8c7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_a93bb5d7-7adb-40a7-a503-49a87abf8eaf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract_4bd036fa-435c-431e-9f43-0115f404b8c7" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_a93bb5d7-7adb-40a7-a503-49a87abf8eaf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_37802a85-df5b-433e-be27-fc729a23245f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_ed828240-5482-4192-ac52-30085f445460" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_37802a85-df5b-433e-be27-fc729a23245f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_51b57e75-1368-478f-962f-90b7ca8baeea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_37802a85-df5b-433e-be27-fc729a23245f" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_51b57e75-1368-478f-962f-90b7ca8baeea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_51b57e75-1368-478f-962f-90b7ca8baeea_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_51b57e75-1368-478f-962f-90b7ca8baeea" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_51b57e75-1368-478f-962f-90b7ca8baeea_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_e3d2be47-9755-479e-8ea8-5bd5cf727e58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_51b57e75-1368-478f-962f-90b7ca8baeea" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_e3d2be47-9755-479e-8ea8-5bd5cf727e58" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember_43a46766-97b8-4152-aef7-ae266e49fc9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_e3d2be47-9755-479e-8ea8-5bd5cf727e58" xlink:to="loc_us-gaap_StockCompensationPlanMember_43a46766-97b8-4152-aef7-ae266e49fc9d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.incyte.com/role/SubsequentEventsNarrativeDetails" xlink:type="simple" xlink:href="incy-20220930.xsd#SubsequentEventsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.incyte.com/role/SubsequentEventsNarrativeDetails" xlink:type="extended" id="i9d6a0170b7b94119929cefeb0ea03b9b_SubsequentEventsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_8f12b7e0-abf3-4477-9b56-e2656b5ca4fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_LicenseAgreementUpfrontPaymentAmountPaid_62fc38a2-8513-4b2a-8d53-30f11c2d4b5d" xlink:href="incy-20220930.xsd#incy_LicenseAgreementUpfrontPaymentAmountPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_8f12b7e0-abf3-4477-9b56-e2656b5ca4fc" xlink:to="loc_incy_LicenseAgreementUpfrontPaymentAmountPaid_62fc38a2-8513-4b2a-8d53-30f11c2d4b5d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived_4f21c966-4a91-4d50-a8f4-fbd8d315b4fb" xlink:href="incy-20220930.xsd#incy_LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_8f12b7e0-abf3-4477-9b56-e2656b5ca4fc" xlink:to="loc_incy_LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived_4f21c966-4a91-4d50-a8f4-fbd8d315b4fb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_LicenseAgreementMilestoneOnNetSalesOfProduct_68f2db0d-4e70-45b9-a408-7cec770bae20" xlink:href="incy-20220930.xsd#incy_LicenseAgreementMilestoneOnNetSalesOfProduct"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_8f12b7e0-abf3-4477-9b56-e2656b5ca4fc" xlink:to="loc_incy_LicenseAgreementMilestoneOnNetSalesOfProduct_68f2db0d-4e70-45b9-a408-7cec770bae20" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_66ac0aae-1500-4bd9-994b-90ee0fe4c502" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_8f12b7e0-abf3-4477-9b56-e2656b5ca4fc" xlink:to="loc_us-gaap_SubsequentEventTable_66ac0aae-1500-4bd9-994b-90ee0fe4c502" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_d5764d65-ec53-481f-94fc-d3e8664a6422" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_66ac0aae-1500-4bd9-994b-90ee0fe4c502" xlink:to="loc_us-gaap_TypeOfArrangementAxis_d5764d65-ec53-481f-94fc-d3e8664a6422" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d5764d65-ec53-481f-94fc-d3e8664a6422_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_d5764d65-ec53-481f-94fc-d3e8664a6422" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d5764d65-ec53-481f-94fc-d3e8664a6422_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f7dd8715-e027-4463-a6fe-304a457322b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_d5764d65-ec53-481f-94fc-d3e8664a6422" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f7dd8715-e027-4463-a6fe-304a457322b2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_VillarisMember_50ff75ee-c427-4de0-8583-14b1b1c37893" xlink:href="incy-20220930.xsd#incy_VillarisMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f7dd8715-e027-4463-a6fe-304a457322b2" xlink:to="loc_incy_VillarisMember_50ff75ee-c427-4de0-8583-14b1b1c37893" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_AchievementOfMilestoneAxis_daf2379b-20cb-4c5e-b563-e3e68b8d9474" xlink:href="incy-20220930.xsd#incy_AchievementOfMilestoneAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_66ac0aae-1500-4bd9-994b-90ee0fe4c502" xlink:to="loc_incy_AchievementOfMilestoneAxis_daf2379b-20cb-4c5e-b563-e3e68b8d9474" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_AchievementOfMilestoneDomain_daf2379b-20cb-4c5e-b563-e3e68b8d9474_default" xlink:href="incy-20220930.xsd#incy_AchievementOfMilestoneDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_incy_AchievementOfMilestoneAxis_daf2379b-20cb-4c5e-b563-e3e68b8d9474" xlink:to="loc_incy_AchievementOfMilestoneDomain_daf2379b-20cb-4c5e-b563-e3e68b8d9474_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_AchievementOfMilestoneDomain_b4143921-d5bb-4c10-956f-515f7b22b908" xlink:href="incy-20220930.xsd#incy_AchievementOfMilestoneDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_incy_AchievementOfMilestoneAxis_daf2379b-20cb-4c5e-b563-e3e68b8d9474" xlink:to="loc_incy_AchievementOfMilestoneDomain_b4143921-d5bb-4c10-956f-515f7b22b908" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_DevelopmentAndRegulatoryMilestonesMember_2e2c87b2-1efd-43f9-9d95-f1b198f00b05" xlink:href="incy-20220930.xsd#incy_DevelopmentAndRegulatoryMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_incy_AchievementOfMilestoneDomain_b4143921-d5bb-4c10-956f-515f7b22b908" xlink:to="loc_incy_DevelopmentAndRegulatoryMilestonesMember_2e2c87b2-1efd-43f9-9d95-f1b198f00b05" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_CommercializationMilestonesMember_87ae1b43-c51c-48b3-a040-7c10c81eed9b" xlink:href="incy-20220930.xsd#incy_CommercializationMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_incy_AchievementOfMilestoneDomain_b4143921-d5bb-4c10-956f-515f7b22b908" xlink:to="loc_incy_CommercializationMilestonesMember_87ae1b43-c51c-48b3-a040-7c10c81eed9b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_8aaeeabd-76bb-4d34-80e9-61a241984a45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_66ac0aae-1500-4bd9-994b-90ee0fe4c502" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_8aaeeabd-76bb-4d34-80e9-61a241984a45" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_8aaeeabd-76bb-4d34-80e9-61a241984a45_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_8aaeeabd-76bb-4d34-80e9-61a241984a45" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_8aaeeabd-76bb-4d34-80e9-61a241984a45_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_c6fe7777-501a-4343-acbc-329f2552a0cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_8aaeeabd-76bb-4d34-80e9-61a241984a45" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_c6fe7777-501a-4343-acbc-329f2552a0cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_5519d62b-95e7-4ee8-bfd7-35de129edb02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_c6fe7777-501a-4343-acbc-329f2552a0cc" xlink:to="loc_us-gaap_SubsequentEventMember_5519d62b-95e7-4ee8-bfd7-35de129edb02" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>incy-20220930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:4b736358-c29a-4c12-bfe7-729e80c7c631,g:94be2257-4ebc-4637-90cb-08232abb2695-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_incy_RoyaltiesPayable_5640d1fb-d1b9-4b38-bade-6b6e1349096b_terseLabel_en-US" xlink:label="lab_incy_RoyaltiesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalties payable</link:label>
    <link:label id="lab_incy_RoyaltiesPayable_label_en-US" xlink:label="lab_incy_RoyaltiesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalties Payable</link:label>
    <link:label id="lab_incy_RoyaltiesPayable_documentation_en-US" xlink:label="lab_incy_RoyaltiesPayable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the amount of royalties payable.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_incy_RoyaltiesPayable" xlink:href="incy-20220930.xsd#incy_RoyaltiesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_incy_RoyaltiesPayable" xlink:to="lab_incy_RoyaltiesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_60810d26-b832-42cf-9be8-daf0c1280078_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1a4518da-eea2-4bd2-8441-f73e8bd42e54_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_9948294e-c824-45e4-91c2-737e94eb887f_verboseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_incy_FairValueInputsCashFlowsEstimatedPeriod_3b0d8854-a410-4d4c-b7d6-0f7987910758_terseLabel_en-US" xlink:label="lab_incy_FairValueInputsCashFlowsEstimatedPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Projected cash flows period</link:label>
    <link:label id="lab_incy_FairValueInputsCashFlowsEstimatedPeriod_label_en-US" xlink:label="lab_incy_FairValueInputsCashFlowsEstimatedPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Inputs Cash Flows Estimated Period</link:label>
    <link:label id="lab_incy_FairValueInputsCashFlowsEstimatedPeriod_documentation_en-US" xlink:label="lab_incy_FairValueInputsCashFlowsEstimatedPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period of time used to measure cash flows to find the present value of an amount to be paid or received in the future as an input to measure fair value.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_incy_FairValueInputsCashFlowsEstimatedPeriod" xlink:href="incy-20220930.xsd#incy_FairValueInputsCashFlowsEstimatedPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_incy_FairValueInputsCashFlowsEstimatedPeriod" xlink:to="lab_incy_FairValueInputsCashFlowsEstimatedPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_9585063f-2db5-442c-b3fd-e9a248d788c4_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income tax asset</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_9cc621e8-e87c-4ee8-93ad-46fc7b0931a3_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAsset_d0c51723-9e6c-495a-9b9b-7a8a720436e1_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease right-of-use assets, net</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, after Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAsset" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AreaOfRealEstateProperty_1eb89898-6b03-4b27-a86f-0e8042626aba_terseLabel_en-US" xlink:label="lab_us-gaap_AreaOfRealEstateProperty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Square footage</link:label>
    <link:label id="lab_us-gaap_AreaOfRealEstateProperty_label_en-US" xlink:label="lab_us-gaap_AreaOfRealEstateProperty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Area of Real Estate Property</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfRealEstateProperty" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AreaOfRealEstateProperty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AreaOfRealEstateProperty" xlink:to="lab_us-gaap_AreaOfRealEstateProperty" xlink:type="arc" order="1"/>
    <link:label id="lab_incy_SyrosPharmaceuticalsIncMember_b5c1d7c0-a6b8-41bf-91cd-874bcc2f04bb_terseLabel_en-US" xlink:label="lab_incy_SyrosPharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Syros Pharmaceuticals, Inc.</link:label>
    <link:label id="lab_incy_SyrosPharmaceuticalsIncMember_label_en-US" xlink:label="lab_incy_SyrosPharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Syros Pharmaceuticals, Inc.</link:label>
    <link:label id="lab_incy_SyrosPharmaceuticalsIncMember_documentation_en-US" xlink:label="lab_incy_SyrosPharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents details pertaining to Syros Pharmaceuticals, Inc with whom we have entered into a target discovery, research collaboration and option agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_incy_SyrosPharmaceuticalsIncMember" xlink:href="incy-20220930.xsd#incy_SyrosPharmaceuticalsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_incy_SyrosPharmaceuticalsIncMember" xlink:to="lab_incy_SyrosPharmaceuticalsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_incy_NumberOfProgramTargets_c15bc6fb-6c85-4d44-8414-edad8c78e61d_terseLabel_en-US" xlink:label="lab_incy_NumberOfProgramTargets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of program targets</link:label>
    <link:label id="lab_incy_NumberOfProgramTargets_label_en-US" xlink:label="lab_incy_NumberOfProgramTargets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Program Targets</link:label>
    <link:label id="lab_incy_NumberOfProgramTargets_documentation_en-US" xlink:label="lab_incy_NumberOfProgramTargets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the number of program targets identified.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_incy_NumberOfProgramTargets" xlink:href="incy-20220930.xsd#incy_NumberOfProgramTargets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_incy_NumberOfProgramTargets" xlink:to="lab_incy_NumberOfProgramTargets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_8d4a50b7-d1e3-4e02-8d0c-8d5a767f4a86_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_2a65fb11-49e1-4ad3-8e85-182f96319625_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_incy_StockIssuedDuringPeriodValueStockOptionsAndRestrictedStockUnitsExercisedAndEmployeeStockPurchasePlan_5c51b14d-164f-4433-9922-1c71c1ec5b50_verboseLabel_en-US" xlink:label="lab_incy_StockIssuedDuringPeriodValueStockOptionsAndRestrictedStockUnitsExercisedAndEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of shares of Common Stock upon exercise of stock options and settlement of employee restricted stock units and performance shares, net of shares withheld for taxes and shares of Common Stock under the ESPP</link:label>
    <link:label id="lab_incy_StockIssuedDuringPeriodValueStockOptionsAndRestrictedStockUnitsExercisedAndEmployeeStockPurchasePlan_label_en-US" xlink:label="lab_incy_StockIssuedDuringPeriodValueStockOptionsAndRestrictedStockUnitsExercisedAndEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period Value Stock Options and Restricted Stock Units Exercised and Employee Stock Purchase Plan</link:label>
    <link:label id="lab_incy_StockIssuedDuringPeriodValueStockOptionsAndRestrictedStockUnitsExercisedAndEmployeeStockPurchasePlan_documentation_en-US" xlink:label="lab_incy_StockIssuedDuringPeriodValueStockOptionsAndRestrictedStockUnitsExercisedAndEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Value stock issued during the period as a result of the exercise of stock options and restricted stock units and the aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_incy_StockIssuedDuringPeriodValueStockOptionsAndRestrictedStockUnitsExercisedAndEmployeeStockPurchasePlan" xlink:href="incy-20220930.xsd#incy_StockIssuedDuringPeriodValueStockOptionsAndRestrictedStockUnitsExercisedAndEmployeeStockPurchasePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_incy_StockIssuedDuringPeriodValueStockOptionsAndRestrictedStockUnitsExercisedAndEmployeeStockPurchasePlan" xlink:to="lab_incy_StockIssuedDuringPeriodValueStockOptionsAndRestrictedStockUnitsExercisedAndEmployeeStockPurchasePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_cd45ce26-c076-4f65-b43b-1caddd9554fd_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair market value of our long term investments</link:label>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsFairValueDisclosure" xlink:to="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiability_c9602c8a-4015-488a-9058-f464410aa2b3_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiability_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiability" xlink:to="lab_us-gaap_FinanceLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_75825f56-d09e-4623-960b-48f536818132_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment, gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_incy_OfficeBuildingWilmingtonDelawareMember_7603cb06-59c3-4ab3-bbe9-44a6fa8af137_terseLabel_en-US" xlink:label="lab_incy_OfficeBuildingWilmingtonDelawareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office Building in Wilmington, Delaware</link:label>
    <link:label id="lab_incy_OfficeBuildingWilmingtonDelawareMember_label_en-US" xlink:label="lab_incy_OfficeBuildingWilmingtonDelawareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office Building in Wilmington, Delaware</link:label>
    <link:label id="lab_incy_OfficeBuildingWilmingtonDelawareMember_documentation_en-US" xlink:label="lab_incy_OfficeBuildingWilmingtonDelawareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information relating to the office building located in Wilmington, Delaware.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_incy_OfficeBuildingWilmingtonDelawareMember" xlink:href="incy-20220930.xsd#incy_OfficeBuildingWilmingtonDelawareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_incy_OfficeBuildingWilmingtonDelawareMember" xlink:to="lab_incy_OfficeBuildingWilmingtonDelawareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_c380de83-3e40-4a0a-8b82-32bcae061886_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod_9e09e9c4-7c48-4e1c-9795-37c30f196993_terseLabel_en-US" xlink:label="lab_incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Released (in shares)</link:label>
    <link:label id="lab_incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod_label_en-US" xlink:label="lab_incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Released In Period</link:label>
    <link:label id="lab_incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod_documentation_en-US" xlink:label="lab_incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the number of shares of employee compensation programs, other than options, released during the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod" xlink:href="incy-20220930.xsd#incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod" xlink:to="lab_incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_incy_LicenseAgreementTargetSelectionAndOptionExerciseFeePayments_42bf740e-f55f-48c9-b97c-86355ecbe260_terseLabel_en-US" xlink:label="lab_incy_LicenseAgreementTargetSelectionAndOptionExerciseFeePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Target selection and option exercise fee payment</link:label>
    <link:label id="lab_incy_LicenseAgreementTargetSelectionAndOptionExerciseFeePayments_label_en-US" xlink:label="lab_incy_LicenseAgreementTargetSelectionAndOptionExerciseFeePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement Target Selection and Option Exercise Fee Payments</link:label>
    <link:label id="lab_incy_LicenseAgreementTargetSelectionAndOptionExerciseFeePayments_documentation_en-US" xlink:label="lab_incy_LicenseAgreementTargetSelectionAndOptionExerciseFeePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the target selection and option exercise fee payments to be made under the license agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_incy_LicenseAgreementTargetSelectionAndOptionExerciseFeePayments" xlink:href="incy-20220930.xsd#incy_LicenseAgreementTargetSelectionAndOptionExerciseFeePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_incy_LicenseAgreementTargetSelectionAndOptionExerciseFeePayments" xlink:to="lab_incy_LicenseAgreementTargetSelectionAndOptionExerciseFeePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_incy_StockPurchaseAgreementMember_8f14b8d7-c0f6-41a4-8aab-5615ab486ded_terseLabel_en-US" xlink:label="lab_incy_StockPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock purchase agreement</link:label>
    <link:label id="lab_incy_StockPurchaseAgreementMember_label_en-US" xlink:label="lab_incy_StockPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock purchase agreement</link:label>
    <link:label id="lab_incy_StockPurchaseAgreementMember_documentation_en-US" xlink:label="lab_incy_StockPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents stock purchase agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_incy_StockPurchaseAgreementMember" xlink:href="incy-20220930.xsd#incy_StockPurchaseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_incy_StockPurchaseAgreementMember" xlink:to="lab_incy_StockPurchaseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_764dedea-a956-467e-a7ef-edb244186ec4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_98481dcf-3817-4227-b38b-6550f117f20d_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_incy_OperatingLeaseRightOfUseAssetsMember_21f6ae8c-7406-44c1-9338-f7b4a005db21_terseLabel_en-US" xlink:label="lab_incy_OperatingLeaseRightOfUseAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_incy_OperatingLeaseRightOfUseAssetsMember_label_en-US" xlink:label="lab_incy_OperatingLeaseRightOfUseAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_incy_OperatingLeaseRightOfUseAssetsMember_documentation_en-US" xlink:label="lab_incy_OperatingLeaseRightOfUseAssetsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual agreement that stipulates the lessee pay the lessor for use of an asset under operating lease.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_incy_OperatingLeaseRightOfUseAssetsMember" xlink:href="incy-20220930.xsd#incy_OperatingLeaseRightOfUseAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_incy_OperatingLeaseRightOfUseAssetsMember" xlink:to="lab_incy_OperatingLeaseRightOfUseAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_f22e3f32-7fce-49fd-aaef-e1fb0b185b58_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_af30cc3b-f9bc-45cf-a747-e1f45b9d6835_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_incy_LicenseAgreementUpfrontPaymentAmountPaid_ed7bce16-a224-4d84-8263-de2db717aca7_terseLabel_en-US" xlink:label="lab_incy_LicenseAgreementUpfrontPaymentAmountPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront payment under license agreement</link:label>
    <link:label id="lab_incy_LicenseAgreementUpfrontPaymentAmountPaid_label_en-US" xlink:label="lab_incy_LicenseAgreementUpfrontPaymentAmountPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement Upfront Payment Amount Paid</link:label>
    <link:label id="lab_incy_LicenseAgreementUpfrontPaymentAmountPaid_documentation_en-US" xlink:label="lab_incy_LicenseAgreementUpfrontPaymentAmountPaid" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the amount of the upfront payment made under the license agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_incy_LicenseAgreementUpfrontPaymentAmountPaid" xlink:href="incy-20220930.xsd#incy_LicenseAgreementUpfrontPaymentAmountPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_incy_LicenseAgreementUpfrontPaymentAmountPaid" xlink:to="lab_incy_LicenseAgreementUpfrontPaymentAmountPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_3b09fac3-5264-4571-a0a1-a6aaab39fe62_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale and maturities of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale and Maturity of Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2f7c7085-3e51-40fd-a48a-6a04985a080e_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsCurrentFiscalYear_29612671-85e1-4b8b-90a6-8d97fc8161be_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsCurrentFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current year expected contributions total</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsCurrentFiscalYear_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsCurrentFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Future Employer Contributions, Current Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsCurrentFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsCurrentFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsCurrentFiscalYear" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsCurrentFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability_fad58a6d-d0d2-4556-a6b5-b0e646893f1e_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One-time benefit from associated valuation allowance</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit), Continuing Operations, Adjustment of Deferred Tax (Asset) Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_50a4b77c-9fd7-4fbb-afd1-dba836734f36_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_incy_LicenseAgreementTerminationNoticePeriod_28576496-44df-4deb-9b96-6d77331872d3_terseLabel_en-US" xlink:label="lab_incy_LicenseAgreementTerminationNoticePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period of notice for termination of license agreement</link:label>
    <link:label id="lab_incy_LicenseAgreementTerminationNoticePeriod_label_en-US" xlink:label="lab_incy_LicenseAgreementTerminationNoticePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Termination Notice, Period</link:label>
    <link:label id="lab_incy_LicenseAgreementTerminationNoticePeriod_documentation_en-US" xlink:label="lab_incy_LicenseAgreementTerminationNoticePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the notice period for the termination of license agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_incy_LicenseAgreementTerminationNoticePeriod" xlink:href="incy-20220930.xsd#incy_LicenseAgreementTerminationNoticePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_incy_LicenseAgreementTerminationNoticePeriod" xlink:to="lab_incy_LicenseAgreementTerminationNoticePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_52373cf7-2336-4d89-b449-ad13d9557b7e_totalLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net periodic benefit cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Net Periodic Benefit Cost (Credit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:to="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:type="arc" order="1"/>
    <link:label id="lab_incy_ScheduleOfInventoryTableTextBlock_7b7c2f27-851a-4048-a14c-89f9fe240710_terseLabel_en-US" xlink:label="lab_incy_ScheduleOfInventoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of inventory</link:label>
    <link:label id="lab_incy_ScheduleOfInventoryTableTextBlock_label_en-US" xlink:label="lab_incy_ScheduleOfInventoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory [Table Text Block]</link:label>
    <link:label id="lab_incy_ScheduleOfInventoryTableTextBlock_documentation_en-US" xlink:label="lab_incy_ScheduleOfInventoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tabular disclosure of carrying amount of inventories as of the balance sheet date.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_incy_ScheduleOfInventoryTableTextBlock" xlink:href="incy-20220930.xsd#incy_ScheduleOfInventoryTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_incy_ScheduleOfInventoryTableTextBlock" xlink:to="lab_incy_ScheduleOfInventoryTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_54113739-2e4d-466f-af0f-42250cc9eec7_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RealEstatePropertiesDomain_aaeaf8a0-8105-4f85-97b7-8a29a5d7dfe9_terseLabel_en-US" xlink:label="lab_us-gaap_RealEstatePropertiesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Real Estate Properties [Domain]</link:label>
    <link:label id="lab_us-gaap_RealEstatePropertiesDomain_label_en-US" xlink:label="lab_us-gaap_RealEstatePropertiesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Real Estate Properties [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealEstatePropertiesDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RealEstatePropertiesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RealEstatePropertiesDomain" xlink:to="lab_us-gaap_RealEstatePropertiesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_10bcacdb-5b1f-45cd-94ee-c310039ee7b6_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_eef7b561-2764-44f9-8da7-435e4693316b_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_bdd2ecda-5cd1-4ef8-b237-5b4e21ebc27f_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_03ae7582-5ac7-45cd-b173-d1dbaecf900c_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential common shares excluded from diluted net income (loss) per share computation ( in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_165f8ca5-2989-4e93-913a-1a801024d7b7_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_988a6eb9-df03-498a-abfa-03ca38367632_verboseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of prior service cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Amortization of Prior Service Cost (Credit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:to="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_11584ab2-6c5e-4274-973a-c5d50d7f5bda_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesPerRestrictedStockUnits_9be9bf96-7b72-43b3-8303-f56c22255bd7_terseLabel_en-US" xlink:label="lab_incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesPerRestrictedStockUnits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares awarded for each RSU (in shares)</link:label>
    <link:label id="lab_incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesPerRestrictedStockUnits_label_en-US" xlink:label="lab_incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesPerRestrictedStockUnits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement by Share Based Payment Award Number of Shares Per Restricted Stock Units</link:label>
    <link:label id="lab_incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesPerRestrictedStockUnits_documentation_en-US" xlink:label="lab_incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesPerRestrictedStockUnits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the number of shares awarded for each restricted share units.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesPerRestrictedStockUnits" xlink:href="incy-20220930.xsd#incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesPerRestrictedStockUnits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesPerRestrictedStockUnits" xlink:to="lab_incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesPerRestrictedStockUnits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_38db3c94-3114-4038-99b1-37278245c9cc_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_8f426b77-e463-407a-ac38-2427e713bc99_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Discount Rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Discount Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:to="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_e80e19df-1391-455c-bc19-5ef6de6710b9_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_fe1cfe7f-ce55-418f-b905-f619dde5238e_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of units vesting at the end of each calendar year (as a percent)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_4a68278a-32ef-4b56-9fea-7460f543b2c5_terseLabel_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_label_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EquityMethodInvesteeNameDomain" xlink:to="lab_srt_EquityMethodInvesteeNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_425239c8-0bca-40d2-b78a-b856a42b3fb4_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Schedule of Cash Flow Information</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_39043ac4-c9dc-4f73-bd2b-e6edb5e84a28_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cancelled (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_incy_PaymentOfContingentConsideration_e703bfc2-0e4a-4b5b-aad4-7d5ac5850503_negatedLabel_en-US" xlink:label="lab_incy_PaymentOfContingentConsideration" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of contingent consideration</link:label>
    <link:label id="lab_incy_PaymentOfContingentConsideration_label_en-US" xlink:label="lab_incy_PaymentOfContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of Contingent Consideration</link:label>
    <link:label id="lab_incy_PaymentOfContingentConsideration_documentation_en-US" xlink:label="lab_incy_PaymentOfContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The cash outflow with regard to the contingent consideration during the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_incy_PaymentOfContingentConsideration" xlink:href="incy-20220930.xsd#incy_PaymentOfContingentConsideration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_incy_PaymentOfContingentConsideration" xlink:to="lab_incy_PaymentOfContingentConsideration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_8a7fbc4d-840f-4401-8192-aaa82896bb7e_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_incy_PemazyreMember_47a60ebb-18d2-4619-b5e9-4f1e20361734_terseLabel_en-US" xlink:label="lab_incy_PemazyreMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PEMAZYRE</link:label>
    <link:label id="lab_incy_PemazyreMember_label_en-US" xlink:label="lab_incy_PemazyreMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PEMAZYRE</link:label>
    <link:label id="lab_incy_PemazyreMember_documentation_en-US" xlink:label="lab_incy_PemazyreMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to PEMAZYRE (pemigatinib), a selective fibroblast growth factor receptor (FGFR) inhibitor, for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with an FGFR2 fusion or other rearrangement as detected by an FDA-approved test.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_incy_PemazyreMember" xlink:href="incy-20220930.xsd#incy_PemazyreMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_incy_PemazyreMember" xlink:to="lab_incy_PemazyreMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_c5ceb209-32cb-4df3-a206-8739f136fa4f_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_incy_CustomerDMember_d5a9b229-6824-4bb8-b145-30e2fcec81f1_terseLabel_en-US" xlink:label="lab_incy_CustomerDMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer D</link:label>
    <link:label id="lab_incy_CustomerDMember_label_en-US" xlink:label="lab_incy_CustomerDMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer D [Member]</link:label>
    <link:label id="lab_incy_CustomerDMember_documentation_en-US" xlink:label="lab_incy_CustomerDMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to the customer D.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_incy_CustomerDMember" xlink:href="incy-20220930.xsd#incy_CustomerDMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_incy_CustomerDMember" xlink:to="lab_incy_CustomerDMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_a708eff6-624c-4133-b58b-73c7b886b062_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_4898c37d-8280-4a65-af67-bee1d8818cb0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockMember_8a1a70fa-03b2-4d16-a243-7f0a89b709e5_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember" xlink:to="lab_us-gaap_EmployeeStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_incy_LicenseAgreementMilestoneOnNetSalesOfProduct_8a17a2c4-dee5-487e-b689-4220f595b388_terseLabel_en-US" xlink:label="lab_incy_LicenseAgreementMilestoneOnNetSalesOfProduct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payments for net sales of product</link:label>
    <link:label id="lab_incy_LicenseAgreementMilestoneOnNetSalesOfProduct_label_en-US" xlink:label="lab_incy_LicenseAgreementMilestoneOnNetSalesOfProduct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Milestone on Net Sales of Product</link:label>
    <link:label id="lab_incy_LicenseAgreementMilestoneOnNetSalesOfProduct_documentation_en-US" xlink:label="lab_incy_LicenseAgreementMilestoneOnNetSalesOfProduct" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Milestone on Net Sales of Product</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_incy_LicenseAgreementMilestoneOnNetSalesOfProduct" xlink:href="incy-20220930.xsd#incy_LicenseAgreementMilestoneOnNetSalesOfProduct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_incy_LicenseAgreementMilestoneOnNetSalesOfProduct" xlink:to="lab_incy_LicenseAgreementMilestoneOnNetSalesOfProduct" xlink:type="arc" order="1"/>
    <link:label id="lab_incy_AccruedClinicalRelatedCostsCurrent_5e9e4a5c-fca6-4816-9805-f72ba6de63c4_terseLabel_en-US" xlink:label="lab_incy_AccruedClinicalRelatedCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical related costs</link:label>
    <link:label id="lab_incy_AccruedClinicalRelatedCostsCurrent_label_en-US" xlink:label="lab_incy_AccruedClinicalRelatedCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Clinical Related Costs Current</link:label>
    <link:label id="lab_incy_AccruedClinicalRelatedCostsCurrent_documentation_en-US" xlink:label="lab_incy_AccruedClinicalRelatedCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying value as of the balance sheet date of obligations incurred through that date and payable for clinical related costs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_incy_AccruedClinicalRelatedCostsCurrent" xlink:href="incy-20220930.xsd#incy_AccruedClinicalRelatedCostsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_incy_AccruedClinicalRelatedCostsCurrent" xlink:to="lab_incy_AccruedClinicalRelatedCostsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_6275af5b-7718-4767-9b8c-8fa9fc60d30e_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanActuarialGainLoss_71aeb7de-e0f3-4d2e-acf9-a7242163613f_negatedLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanActuarialGainLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of actuarial losses</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanActuarialGainLoss_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanActuarialGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActuarialGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanActuarialGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanActuarialGainLoss" xlink:to="lab_us-gaap_DefinedBenefitPlanActuarialGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_f6ef80d0-9859-415b-ae9c-420e377da19f_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_972b728f-7bc5-43ff-b34d-06ba6d22390c_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_9b673a76-249d-4ce9-be1b-aaca48c9ea95_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of marketable securities portfolio</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_cec80a79-b292-47c1-89ce-0e98b2521ee3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_02347920-2ec3-48f5-a6ca-e52284f1c678_terseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and expenses:</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract" xlink:to="lab_us-gaap_CostsAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_6d3ca35a-9a9e-44a8-a598-cd3aba9bbb7e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options cancelled (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LegalEntityAxis_1f96eedd-e1c3-47dd-b2b5-a05bd9416d6f_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_label_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_f7600b67-e2cf-44f4-9608-2dbf1ea815fa_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:to="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_incy_LicenseAgreementAdditionalMilestonePayments_6924a3fe-7667-4ce0-ba5c-f3b9934c7317_terseLabel_en-US" xlink:label="lab_incy_LicenseAgreementAdditionalMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional milestone payments under the license agreement</link:label>
    <link:label id="lab_incy_LicenseAgreementAdditionalMilestonePayments_label_en-US" xlink:label="lab_incy_LicenseAgreementAdditionalMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement Additional Milestone Payments</link:label>
    <link:label id="lab_incy_LicenseAgreementAdditionalMilestonePayments_documentation_en-US" xlink:label="lab_incy_LicenseAgreementAdditionalMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the additional milestone payments to be made under the license agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_incy_LicenseAgreementAdditionalMilestonePayments" xlink:href="incy-20220930.xsd#incy_LicenseAgreementAdditionalMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_incy_LicenseAgreementAdditionalMilestonePayments" xlink:to="lab_incy_LicenseAgreementAdditionalMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_bc567cdc-6da2-44b1-884f-47ebadd14347_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_150815ec-1af8-42dd-a8cf-4c079b21be46_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_48348eb9-98c6-4ded-bfa4-d3f7955e002e_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_incy_InventoryNetCurrentAndNoncurrent_4add57e5-37f7-4e50-86a9-601cf9751d77_totalLabel_en-US" xlink:label="lab_incy_InventoryNetCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total inventory</link:label>
    <link:label id="lab_incy_InventoryNetCurrentAndNoncurrent_label_en-US" xlink:label="lab_incy_InventoryNetCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Net Current and Noncurrent</link:label>
    <link:label id="lab_incy_InventoryNetCurrentAndNoncurrent_documentation_en-US" xlink:label="lab_incy_InventoryNetCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the aggregate carrying amount of current and noncurrent portion, net of valuation reserves and allowances, as of the balance sheet date of inventories.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_incy_InventoryNetCurrentAndNoncurrent" xlink:href="incy-20220930.xsd#incy_InventoryNetCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_incy_InventoryNetCurrentAndNoncurrent" xlink:to="lab_incy_InventoryNetCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_2fe478bd-fec6-42b5-913c-a51875206993_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeFinanceLeaseRenewalTerm1_c2525f03-6932-4e50-bcce-a18a2964d376_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeaseRenewalTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Renewal term of agreement to rent</link:label>
    <link:label id="lab_us-gaap_LesseeFinanceLeaseRenewalTerm1_label_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeaseRenewalTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Finance Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeaseRenewalTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeFinanceLeaseRenewalTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeFinanceLeaseRenewalTerm1" xlink:to="lab_us-gaap_LesseeFinanceLeaseRenewalTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_9bd8d0bb-56b8-4cf8-b483-87cd44b9647f_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_49df2a74-dddd-4354-b429-459461af9625_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RisksAndUncertaintiesAbstract_5a1a2d38-2c9b-4ef3-90e2-dddf1e767c50_terseLabel_en-US" xlink:label="lab_us-gaap_RisksAndUncertaintiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risks and Uncertainties [Abstract]</link:label>
    <link:label id="lab_us-gaap_RisksAndUncertaintiesAbstract_label_en-US" xlink:label="lab_us-gaap_RisksAndUncertaintiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risks and Uncertainties [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RisksAndUncertaintiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RisksAndUncertaintiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RisksAndUncertaintiesAbstract" xlink:to="lab_us-gaap_RisksAndUncertaintiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_56697742-db38-4805-914f-f911303251b4_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities-amortized cost</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_incy_PurchaseOfCommonStockUnderStockPurchaseAgreementInShares_6dede3d1-f653-45ae-a672-f1ff5f5750d2_terseLabel_en-US" xlink:label="lab_incy_PurchaseOfCommonStockUnderStockPurchaseAgreementInShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of common stock under Stock Purchase Agreement (in shares )</link:label>
    <link:label id="lab_incy_PurchaseOfCommonStockUnderStockPurchaseAgreementInShares_label_en-US" xlink:label="lab_incy_PurchaseOfCommonStockUnderStockPurchaseAgreementInShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of common stock under stock purchase agreement in shares</link:label>
    <link:label id="lab_incy_PurchaseOfCommonStockUnderStockPurchaseAgreementInShares_documentation_en-US" xlink:label="lab_incy_PurchaseOfCommonStockUnderStockPurchaseAgreementInShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the purchase of common stock under Stock Purchase Agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_incy_PurchaseOfCommonStockUnderStockPurchaseAgreementInShares" xlink:href="incy-20220930.xsd#incy_PurchaseOfCommonStockUnderStockPurchaseAgreementInShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_incy_PurchaseOfCommonStockUnderStockPurchaseAgreementInShares" xlink:to="lab_incy_PurchaseOfCommonStockUnderStockPurchaseAgreementInShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_7ac19aa2-cacf-4801-9864-31da0235845a_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_599236db-ba14-4b56-aac7-5b38dea9008d_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities&#8212;available-for-sale (amortized cost $292,941 and $291,871 as of September&#160;30, 2022 and December&#160;31, 2021, respectively; allowance for credit losses $0 as of September&#160;30, 2022 and December&#160;31, 2021)</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_36920421-b13f-43a0-93f2-cedf452ec627_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares issued</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_4c64ad4f-c965-4809-9d02-6a644ae6cdfa_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_3205b6b9-921e-4ebd-a301-927372352a31_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options Weighted Average Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConversionOfStockByUniqueDescriptionAxis_fdbf4d46-18e2-4af1-8474-a55210c174a6_terseLabel_en-US" xlink:label="lab_us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Conversion Description [Axis]</link:label>
    <link:label id="lab_us-gaap_ConversionOfStockByUniqueDescriptionAxis_label_en-US" xlink:label="lab_us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Conversion Description [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="lab_us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_86bacae5-d36f-4305-a066-a51c0a984f0d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSU and PSU Activity Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_a46b8ba0-bfd4-4295-adcd-e71655ceab74_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_c19ea53c-854f-4b8e-9e3f-66e72b185fb8_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_c8b6c2e9-38d6-438c-91f4-8d83cd0c523f_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_incy_LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived_0bc05256-b41d-40b4-8a70-08bd66297268_terseLabel_en-US" xlink:label="lab_incy_LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront and immediate milestone payment to be received under license agreement</link:label>
    <link:label id="lab_incy_LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived_label_en-US" xlink:label="lab_incy_LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Upfront Payment and Immediate Milestone Payment to be Received</link:label>
    <link:label id="lab_incy_LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived_documentation_en-US" xlink:label="lab_incy_LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the upfront and immediate milestone payment received under the license agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_incy_LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived" xlink:href="incy-20220930.xsd#incy_LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_incy_LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived" xlink:to="lab_incy_LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_a56ff5ca-0d39-45ab-8861-584d310aa679_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued and other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_01e8404a-7aaf-4372-9937-2b01a44228f7_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTable" xlink:to="lab_us-gaap_ConcentrationRiskTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentQuotedMarketValue_a6198a7a-e86d-4f02-bf6e-754f1821be96_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentQuotedMarketValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Value of shares acquired</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentQuotedMarketValue_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentQuotedMarketValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Quoted Market Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentQuotedMarketValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentQuotedMarketValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentQuotedMarketValue" xlink:to="lab_us-gaap_EquityMethodInvestmentQuotedMarketValue" xlink:type="arc" order="1"/>
    <link:label id="lab_incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGranted_358fe977-6dd4-4c45-9ee4-492cd7e39aa9_negatedTerseLabel_en-US" xlink:label="lab_incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGranted" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, RSUs and PSUs granted (in shares)</link:label>
    <link:label id="lab_incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGranted_label_en-US" xlink:label="lab_incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement by Share Based Payment Award Number of Shares Granted</link:label>
    <link:label id="lab_incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGranted_documentation_en-US" xlink:label="lab_incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGranted" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares granted under an established share-based compensation plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGranted" xlink:href="incy-20220930.xsd#incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGranted" xlink:to="lab_incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_9d603394-5e46-44d7-b51e-ae99b01544d8_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_13da3223-afbc-4f69-b823-11fafbba96f8_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_52303828-a6ba-46b0-a780-5fc5530e89fd_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_72059aa3-00a5-46fb-8988-2ccee4b0064e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Tranche One</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Tranche One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_4d6e5d20-0e33-4c76-a610-ab29ab1e1922_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_d529627f-1fe6-438c-bc0f-4a76494b1dff_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income per share:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_4274d839-19ba-4870-8022-d5f31e878471_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_c02767ad-0eb5-4080-9cbb-b4bcc83d987b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_b3f54e46-34a7-4039-891d-74aa1061e4b1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average fair value assumptions</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionPayableCurrent_f919f3d0-4ffb-481f-b990-2a2ae1df581b_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in progress</link:label>
    <link:label id="lab_us-gaap_ConstructionPayableCurrent_label_en-US" xlink:label="lab_us-gaap_ConstructionPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionPayableCurrent" xlink:to="lab_us-gaap_ConstructionPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_b39d0342-1cdc-4aab-83b4-0b64675f9aef_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PerformanceSharesMember_2a0d9a05-e400-4785-9545-ec701fd2e574_terseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Shares</link:label>
    <link:label id="lab_us-gaap_PerformanceSharesMember_label_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Shares [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PerformanceSharesMember" xlink:to="lab_us-gaap_PerformanceSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_00463ec1-a080-4278-abb9-351aaf970c13_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued and other current liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_40b2ac48-8300-4df9-a888-cd5bdcdff497_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total accrued and other current liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditConcentrationRiskMember_2cf4138e-7733-4a1f-8c3d-4833580fec8a_terseLabel_en-US" xlink:label="lab_us-gaap_CreditConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Concentration Risk</link:label>
    <link:label id="lab_us-gaap_CreditConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CreditConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditConcentrationRiskMember" xlink:to="lab_us-gaap_CreditConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_3aa76444-ecd3-4d25-9609-19f47774262d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_incy_InvestmentInSyndaxPharmaceuticalsIncMember_22042ac0-658b-4b62-a749-7d75c31e60fa_terseLabel_en-US" xlink:label="lab_incy_InvestmentInSyndaxPharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in Syndax</link:label>
    <link:label id="lab_incy_InvestmentInSyndaxPharmaceuticalsIncMember_label_en-US" xlink:label="lab_incy_InvestmentInSyndaxPharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in Syndax</link:label>
    <link:label id="lab_incy_InvestmentInSyndaxPharmaceuticalsIncMember_documentation_en-US" xlink:label="lab_incy_InvestmentInSyndaxPharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents investment information pertaining to Syndax Pharmaceuticals Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_incy_InvestmentInSyndaxPharmaceuticalsIncMember" xlink:href="incy-20220930.xsd#incy_InvestmentInSyndaxPharmaceuticalsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_incy_InvestmentInSyndaxPharmaceuticalsIncMember" xlink:to="lab_incy_InvestmentInSyndaxPharmaceuticalsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_fbc8c5ff-5f04-48e4-b32a-678b0e3c5809_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_9abb2f30-815b-4d82-88d5-5f010264c811_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermInvestments_70a9de45-7971-4766-84bd-752a70ae9ddc_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Investments</link:label>
    <link:label id="lab_us-gaap_LongTermInvestments_2150b6c6-05f1-47c4-a430-a227e3751d18_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermInvestments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair market long term investments</link:label>
    <link:label id="lab_us-gaap_LongTermInvestments_label_en-US" xlink:label="lab_us-gaap_LongTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermInvestments" xlink:to="lab_us-gaap_LongTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_incy_FutureContingentDiscoveryMilestoneMember_f25eb5e6-a513-4a6d-9fad-e31251daf5d3_terseLabel_en-US" xlink:label="lab_incy_FutureContingentDiscoveryMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future contingent discovery milestones</link:label>
    <link:label id="lab_incy_FutureContingentDiscoveryMilestoneMember_label_en-US" xlink:label="lab_incy_FutureContingentDiscoveryMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future contingent discovery milestones</link:label>
    <link:label id="lab_incy_FutureContingentDiscoveryMilestoneMember_documentation_en-US" xlink:label="lab_incy_FutureContingentDiscoveryMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to future contingent discovery milestone.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_incy_FutureContingentDiscoveryMilestoneMember" xlink:href="incy-20220930.xsd#incy_FutureContingentDiscoveryMilestoneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_incy_FutureContingentDiscoveryMilestoneMember" xlink:to="lab_incy_FutureContingentDiscoveryMilestoneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_incy_TabrectaMember_7f5c5eca-9473-4631-935d-328bab5a3f4a_terseLabel_en-US" xlink:label="lab_incy_TabrectaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TABRECTA</link:label>
    <link:label id="lab_incy_TabrectaMember_label_en-US" xlink:label="lab_incy_TabrectaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TABRECTA</link:label>
    <link:label id="lab_incy_TabrectaMember_documentation_en-US" xlink:label="lab_incy_TabrectaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to TABRECTA, treatment of adult patients with metastatic NSCLC whose tumors have a mutation that leads to MET exon 14 skipping (METex14).</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_incy_TabrectaMember" xlink:href="incy-20220930.xsd#incy_TabrectaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_incy_TabrectaMember" xlink:to="lab_incy_TabrectaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_c76e60b0-60f0-4114-b69e-458751439908_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_37c04c1a-1ee1-467e-ab32-2836d2846c16_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income before provision for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_3e4fe53c-2b87-4685-8e3d-3803911c6f2c_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_70b7f861-931e-4863-bf5e-a74ec2da2419_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_9bd4b2f2-b0f9-452e-896c-04d6872dbdc4_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_dc79b8bc-a44a-4d59-a481-d22a0fee0945_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanInterestCost_3c1eb50f-a89b-4918-b367-615d4da19211_verboseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanInterestCost" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanInterestCost_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanInterestCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Interest Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanInterestCost" xlink:to="lab_us-gaap_DefinedBenefitPlanInterestCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_5bd464d9-ac72-476c-abf1-c60e3265c57a_verboseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_incy_SyndaxPharmaceuticalsIncMember_4b2226ea-e2b1-4370-89aa-3364c67d7fdd_terseLabel_en-US" xlink:label="lab_incy_SyndaxPharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Syndax</link:label>
    <link:label id="lab_incy_SyndaxPharmaceuticalsIncMember_label_en-US" xlink:label="lab_incy_SyndaxPharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Syndax</link:label>
    <link:label id="lab_incy_SyndaxPharmaceuticalsIncMember_documentation_en-US" xlink:label="lab_incy_SyndaxPharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents member information pertaining to Syndax Pharmaceuticals Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_incy_SyndaxPharmaceuticalsIncMember" xlink:href="incy-20220930.xsd#incy_SyndaxPharmaceuticalsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_incy_SyndaxPharmaceuticalsIncMember" xlink:to="lab_incy_SyndaxPharmaceuticalsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_4cd95c1f-bc43-4f8e-b833-8adcaba540ce_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreements</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_17cb7f89-6ec8-4f6d-81ed-6f1a6995f155_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_1f9522c9-e0c9-4e29-a70a-1925a31f24ae_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting period of recognition of the unrecognized compensation cost of nonvested awards</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockPlans_73fb7b33-3f22-48ac-9a9b-493c19387d03_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock under stock plans</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockPlans_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockPlans" xlink:to="lab_us-gaap_ProceedsFromStockPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_3073a024-1cc0-4d23-9c4c-abac956d6df8_terseLabel_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Equipment</link:label>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_label_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerEquipmentMember" xlink:to="lab_us-gaap_ComputerEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_1dd5227c-a953-4cd8-9d94-20102e6c73ac_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_incy_ScheduleOfShareBasedPaymentAwardStockOptionsAndEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_389ba637-6db0-485b-8e09-660633157aa8_terseLabel_en-US" xlink:label="lab_incy_ScheduleOfShareBasedPaymentAwardStockOptionsAndEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of valuation assumptions used for valuation of fair value of stock compensation granted</link:label>
    <link:label id="lab_incy_ScheduleOfShareBasedPaymentAwardStockOptionsAndEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_incy_ScheduleOfShareBasedPaymentAwardStockOptionsAndEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share Based Payment Award, Stock Options and Employee Stock Purchase Plan Valuation Assumptions [Table Text Block]</link:label>
    <link:label id="lab_incy_ScheduleOfShareBasedPaymentAwardStockOptionsAndEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_documentation_en-US" xlink:label="lab_incy_ScheduleOfShareBasedPaymentAwardStockOptionsAndEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock options plan and employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_incy_ScheduleOfShareBasedPaymentAwardStockOptionsAndEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:href="incy-20220930.xsd#incy_ScheduleOfShareBasedPaymentAwardStockOptionsAndEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_incy_ScheduleOfShareBasedPaymentAwardStockOptionsAndEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:to="lab_incy_ScheduleOfShareBasedPaymentAwardStockOptionsAndEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_b6167c57-e6f9-42e0-81e6-16b09c084ff6_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_incy_PercentageOfProfitsLosses_1626bb17-6033-4b66-b5c2-c24b57d985b7_terseLabel_en-US" xlink:label="lab_incy_PercentageOfProfitsLosses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of profit (losses)</link:label>
    <link:label id="lab_incy_PercentageOfProfitsLosses_label_en-US" xlink:label="lab_incy_PercentageOfProfitsLosses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of Profits (Losses)</link:label>
    <link:label id="lab_incy_PercentageOfProfitsLosses_documentation_en-US" xlink:label="lab_incy_PercentageOfProfitsLosses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the percentage of profits (losses).</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_incy_PercentageOfProfitsLosses" xlink:href="incy-20220930.xsd#incy_PercentageOfProfitsLosses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_incy_PercentageOfProfitsLosses" xlink:to="lab_incy_PercentageOfProfitsLosses" xlink:type="arc" order="1"/>
    <link:label id="lab_incy_JakaviMember_32365001-3202-4190-96c6-ea0bab7f47a9_terseLabel_en-US" xlink:label="lab_incy_JakaviMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">JAKAVI</link:label>
    <link:label id="lab_incy_JakaviMember_label_en-US" xlink:label="lab_incy_JakaviMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">JAKAVI</link:label>
    <link:label id="lab_incy_JakaviMember_documentation_en-US" xlink:label="lab_incy_JakaviMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to JAKAVI (ruxolitinib), an oral Janus associate kinase (JAK) inhibitor sold outside the United State of America.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_incy_JakaviMember" xlink:href="incy-20220930.xsd#incy_JakaviMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_incy_JakaviMember" xlink:to="lab_incy_JakaviMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_4d2ea6dc-3c06-4534-85a0-1669097dc6be_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend yield (as a percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_5ff97e00-9aaa-489f-b641-e11ecc4a2b60_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_4dacc1cb-8e38-4639-a82b-746ac70f1598_terseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Benefit Plans</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_incy_LicenseAgreementNumberOfAdditionalPreclinicalDiscoveryPrograms_1fb92ffc-0c2e-4865-be99-9444b59283a0_terseLabel_en-US" xlink:label="lab_incy_LicenseAgreementNumberOfAdditionalPreclinicalDiscoveryPrograms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of additional preclinical discovery programs</link:label>
    <link:label id="lab_incy_LicenseAgreementNumberOfAdditionalPreclinicalDiscoveryPrograms_label_en-US" xlink:label="lab_incy_LicenseAgreementNumberOfAdditionalPreclinicalDiscoveryPrograms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Number of Additional Preclinical Discovery Programs</link:label>
    <link:label id="lab_incy_LicenseAgreementNumberOfAdditionalPreclinicalDiscoveryPrograms_documentation_en-US" xlink:label="lab_incy_LicenseAgreementNumberOfAdditionalPreclinicalDiscoveryPrograms" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the number of additional preclinical discovery programs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_incy_LicenseAgreementNumberOfAdditionalPreclinicalDiscoveryPrograms" xlink:href="incy-20220930.xsd#incy_LicenseAgreementNumberOfAdditionalPreclinicalDiscoveryPrograms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_incy_LicenseAgreementNumberOfAdditionalPreclinicalDiscoveryPrograms" xlink:to="lab_incy_LicenseAgreementNumberOfAdditionalPreclinicalDiscoveryPrograms" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease_498b374e-8ac3-4303-9c13-5130f1eecaa3_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Period Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_f2ffa8e5-168a-4a2d-922a-60a861c5c625_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principles of Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_1caa8312-b28f-445b-b4bb-5b5eaead9baf_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_49c546f7-9d89-4b03-a8ce-3fb74d7688bb_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_80db9937-e9c8-4dc3-9ebb-ebe9f3e65e96_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RoyaltyMember_5942bf99-3ad7-4353-a5e0-97c7e7483f1c_terseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product royalty revenues</link:label>
    <link:label id="lab_us-gaap_RoyaltyMember_label_en-US" xlink:label="lab_us-gaap_RoyaltyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyMember" xlink:to="lab_us-gaap_RoyaltyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_80a64a3b-10cc-4e3a-ab83-6c45a4b1d8d2_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in USD per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_026bf6be-522b-45ce-82fe-578b6b587510_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_58929168-2160-4855-b28c-9b9ab3175175_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_fc5b4da5-8883-40a5-8054-ed3f89908e5c_terseLabel_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_label_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_192397a7-5a5d-48af-a30c-0890c2023380_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharePrice_60be4306-def3-4b03-9e07-ecf9967bb063_terseLabel_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Per share price (In USD per share)</link:label>
    <link:label id="lab_us-gaap_SharePrice_label_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice" xlink:to="lab_us-gaap_SharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_89804937-a9bb-462c-8e41-cb65ca73cd0b_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_3cf02c46-487e-4e4c-9c64-d234071e5c7e_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_incy_MacrogenicsMember_c7295846-4196-497f-bb93-b34b9ca39ed0_terseLabel_en-US" xlink:label="lab_incy_MacrogenicsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MacroGenics</link:label>
    <link:label id="lab_incy_MacrogenicsMember_label_en-US" xlink:label="lab_incy_MacrogenicsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MacroGenics</link:label>
    <link:label id="lab_incy_MacrogenicsMember_documentation_en-US" xlink:label="lab_incy_MacrogenicsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents details pertaining to MacroGenics with whom we have entered into an exclusive global collaboration and license agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_incy_MacrogenicsMember" xlink:href="incy-20220930.xsd#incy_MacrogenicsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_incy_MacrogenicsMember" xlink:to="lab_incy_MacrogenicsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_incy_DevelopmentRegulatoryAndCommercializationMilestonesMember_90d006fc-3df0-4e91-bf5a-6d1cbaae1584_terseLabel_en-US" xlink:label="lab_incy_DevelopmentRegulatoryAndCommercializationMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development, Regulatory and Commercialization Milestones</link:label>
    <link:label id="lab_incy_DevelopmentRegulatoryAndCommercializationMilestonesMember_label_en-US" xlink:label="lab_incy_DevelopmentRegulatoryAndCommercializationMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development, Regulatory and Commercialization Milestones</link:label>
    <link:label id="lab_incy_DevelopmentRegulatoryAndCommercializationMilestonesMember_documentation_en-US" xlink:label="lab_incy_DevelopmentRegulatoryAndCommercializationMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents development regulatory and commercialization milestones.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_incy_DevelopmentRegulatoryAndCommercializationMilestonesMember" xlink:href="incy-20220930.xsd#incy_DevelopmentRegulatoryAndCommercializationMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_incy_DevelopmentRegulatoryAndCommercializationMilestonesMember" xlink:to="lab_incy_DevelopmentRegulatoryAndCommercializationMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeMember_4a35659e-34c7-46a4-a483-bb5bbf3e5e3b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_OtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_a62ec285-73f9-4b14-aa32-2a8de22b4b80_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_a9589e22-872a-4bd1-861a-942962846ec2_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquipmentMember_9504096f-94f9-41c1-9f8b-9b5eeda16424_terseLabel_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment</link:label>
    <link:label id="lab_us-gaap_EquipmentMember_label_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquipmentMember" xlink:to="lab_us-gaap_EquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_dff99f46-6f8a-4e7b-946c-ee37e747851d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_incy_FinanceLeaseLeaseIncentiveReceivable_7e3af5a7-cb8a-48a4-918a-bf4cb564de7a_terseLabel_en-US" xlink:label="lab_incy_FinanceLeaseLeaseIncentiveReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease, lease incentive receivable</link:label>
    <link:label id="lab_incy_FinanceLeaseLeaseIncentiveReceivable_label_en-US" xlink:label="lab_incy_FinanceLeaseLeaseIncentiveReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Lease Incentive Receivable</link:label>
    <link:label id="lab_incy_FinanceLeaseLeaseIncentiveReceivable_documentation_en-US" xlink:label="lab_incy_FinanceLeaseLeaseIncentiveReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The amount of lease incentive receivable from landlord under finance leases.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_incy_FinanceLeaseLeaseIncentiveReceivable" xlink:href="incy-20220930.xsd#incy_FinanceLeaseLeaseIncentiveReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_incy_FinanceLeaseLeaseIncentiveReceivable" xlink:to="lab_incy_FinanceLeaseLeaseIncentiveReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_8701c063-4293-44fd-8307-9dcdf98f76ca_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_7cee22ec-daa7-4b85-a5eb-ee6e806b749a_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs)</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_dfc9814b-fafa-467e-9000-74774702de5b_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_incy_ICLUSIGMember_059c1679-5517-41d6-b301-b6e17e693995_terseLabel_en-US" xlink:label="lab_incy_ICLUSIGMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICLUSIG</link:label>
    <link:label id="lab_incy_ICLUSIGMember_label_en-US" xlink:label="lab_incy_ICLUSIGMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICLUSIG</link:label>
    <link:label id="lab_incy_ICLUSIGMember_documentation_en-US" xlink:label="lab_incy_ICLUSIGMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to ICLUSIG, a kinase inhibitor.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_incy_ICLUSIGMember" xlink:href="incy-20220930.xsd#incy_ICLUSIGMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_incy_ICLUSIGMember" xlink:to="lab_incy_ICLUSIGMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_eda8ceae-a68e-4c05-ae17-56fa0c898dcd_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_b0f2c032-9f28-49f4-985b-b25cc6c8c06b_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_065cc7d8-2898-4798-a5ee-e097ec35e7c5_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive loss:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_incy_LicenseAgreementMaximumNumberOfIndependentPrograms_046da408-13da-475a-9e41-01b6d053795c_terseLabel_en-US" xlink:label="lab_incy_LicenseAgreementMaximumNumberOfIndependentPrograms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of independent programs</link:label>
    <link:label id="lab_incy_LicenseAgreementMaximumNumberOfIndependentPrograms_label_en-US" xlink:label="lab_incy_LicenseAgreementMaximumNumberOfIndependentPrograms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Maximum Number Of Independent Programs</link:label>
    <link:label id="lab_incy_LicenseAgreementMaximumNumberOfIndependentPrograms_documentation_en-US" xlink:label="lab_incy_LicenseAgreementMaximumNumberOfIndependentPrograms" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the maximum number of independent programs encompassed under the collaboration agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_incy_LicenseAgreementMaximumNumberOfIndependentPrograms" xlink:href="incy-20220930.xsd#incy_LicenseAgreementMaximumNumberOfIndependentPrograms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_incy_LicenseAgreementMaximumNumberOfIndependentPrograms" xlink:to="lab_incy_LicenseAgreementMaximumNumberOfIndependentPrograms" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_be6a1f85-cd3a-4d57-b485-0728d1260f4c_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_34bef136-4739-4661-a908-5fa62a21911e_verboseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization and Business</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_c9b2d593-cc2d-43e9-9e51-3217ebd64288_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at the beginning of the period</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_33102e91-92aa-4583-aa3c-1115bc0fae72_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at the end of the period</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_53fdce64-cbcf-46c8-9b9a-e2de39aaa828_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of concentration risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_1423a0a5-7b16-4802-89d9-d56d846a3182_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_60ac22bb-1daf-4210-9811-ca6bfe92bce0_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_de19eab6-6291-4502-b041-1063ee371c21_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Trading, and Equity Securities, FV-NI [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Trading, and Equity Securities, FV-NI [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable" xlink:to="lab_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_incy_AriadPharmaceuticalsMember_0a45e897-bb9e-4757-9245-cceb97da955d_terseLabel_en-US" xlink:label="lab_incy_AriadPharmaceuticalsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ARIAD</link:label>
    <link:label id="lab_incy_AriadPharmaceuticalsMember_label_en-US" xlink:label="lab_incy_AriadPharmaceuticalsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ARIAD</link:label>
    <link:label id="lab_incy_AriadPharmaceuticalsMember_documentation_en-US" xlink:label="lab_incy_AriadPharmaceuticalsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to ARIAD Pharmaceuticals.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_incy_AriadPharmaceuticalsMember" xlink:href="incy-20220930.xsd#incy_AriadPharmaceuticalsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_incy_AriadPharmaceuticalsMember" xlink:to="lab_incy_AriadPharmaceuticalsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_8fefb31d-d5de-454b-abe8-f55039a9ef6f_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in USD per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_4bb1064f-6531-42b2-bec4-7b530de91955_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic net income per share ( in USD per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_incy_AchievementOfMilestoneDomain_61dae9a9-b011-45ab-a837-025355cd0e8e_terseLabel_en-US" xlink:label="lab_incy_AchievementOfMilestoneDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement of Milestone [Domain]</link:label>
    <link:label id="lab_incy_AchievementOfMilestoneDomain_label_en-US" xlink:label="lab_incy_AchievementOfMilestoneDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement of Milestone [Domain]</link:label>
    <link:label id="lab_incy_AchievementOfMilestoneDomain_documentation_en-US" xlink:label="lab_incy_AchievementOfMilestoneDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Different categories of achievement of milestones.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_incy_AchievementOfMilestoneDomain" xlink:href="incy-20220930.xsd#incy_AchievementOfMilestoneDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_incy_AchievementOfMilestoneDomain" xlink:to="lab_incy_AchievementOfMilestoneDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_ff9f670a-d461-4692-8840-a32a1006b045_totalLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_3e03f0e6-bf4f-43c7-b9f8-5838073c179d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Excluding Accrued Interest, after Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_fd8973e8-d3ff-4a3b-9adf-8936eb47c342_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_956199bb-cedd-480e-bdb0-eefaa3bcbc47_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProvisionForLossOnContracts_3e50c74b-3459-4718-a3c9-8951bcc7e5bc_terseLabel_en-US" xlink:label="lab_us-gaap_ProvisionForLossOnContracts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales allowances</link:label>
    <link:label id="lab_us-gaap_ProvisionForLossOnContracts_label_en-US" xlink:label="lab_us-gaap_ProvisionForLossOnContracts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for Loss on Contracts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForLossOnContracts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForLossOnContracts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProvisionForLossOnContracts" xlink:to="lab_us-gaap_ProvisionForLossOnContracts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_43aceb89-fd2a-4742-a69a-b11a13843b9e_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_a3ec61ee-6333-4703-8e66-ed398e7c3a68_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_d805b703-b142-4f93-b5ab-864f700dd300_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_39f869bf-1822-4bd9-8501-568845b1bfad_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leased assets obtained in exchange for new finance lease liabilities</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Finance Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingDomain_5ec5fab1-a6c7-4e53-92d1-8f9b9057e866_terseLabel_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:label id="lab_us-gaap_VestingDomain_label_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingDomain" xlink:to="lab_us-gaap_VestingDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_ec2e8187-160e-4db0-8b3a-4f1437f92d19_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities-allowance for credit losses</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_2e5536f8-ed11-4eea-8fba-9ffb5e1207dd_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_9355baf0-7952-4042-930f-fec3f60ff59e_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares divested (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_5ce94a35-a0f9-4f01-bb05-4aa6b34aa40d_verboseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares in underwritten public offering (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_b8e0688f-2911-4c7f-a66e-c1baa4b83075_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_incy_MorphosysAgMember_b32cf751-e745-4e31-ba1a-4bd8bd0d941e_terseLabel_en-US" xlink:label="lab_incy_MorphosysAgMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MorphoSys AG</link:label>
    <link:label id="lab_incy_MorphosysAgMember_label_en-US" xlink:label="lab_incy_MorphosysAgMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MorphoSys AG</link:label>
    <link:label id="lab_incy_MorphosysAgMember_documentation_en-US" xlink:label="lab_incy_MorphosysAgMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents member information pertaining to MorphoSys AG.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_incy_MorphosysAgMember" xlink:href="incy-20220930.xsd#incy_MorphosysAgMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_incy_MorphosysAgMember" xlink:to="lab_incy_MorphosysAgMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8fa3eaf4-46e3-445b-987b-9444a3b06cf1_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_714a0bbe-2ec7-44bc-a406-325551041aaf_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of roll forward of Level 3 liabilities</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_91588750-c45d-40ce-8bf9-8eeabef0469e_terseLabel_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion at Fair Value Measurement</link:label>
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion at Fair Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:to="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_595b4cf3-e1db-42ef-8954-74b46e651647_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_incy_CommercializationMilestonesMember_dfab7539-0961-4f65-965e-2beec71fa0a0_terseLabel_en-US" xlink:label="lab_incy_CommercializationMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercialization Milestones</link:label>
    <link:label id="lab_incy_CommercializationMilestonesMember_label_en-US" xlink:label="lab_incy_CommercializationMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercialization Milestones</link:label>
    <link:label id="lab_incy_CommercializationMilestonesMember_documentation_en-US" xlink:label="lab_incy_CommercializationMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to certain commercialized events on the basis of which certain milestones are achieved.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_incy_CommercializationMilestonesMember" xlink:href="incy-20220930.xsd#incy_CommercializationMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_incy_CommercializationMilestonesMember" xlink:to="lab_incy_CommercializationMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_incy_PreSeptember2022StockSplitSharesMember_877fb60f-8d9a-47b9-9d31-dd0f1a1c36cc_terseLabel_en-US" xlink:label="lab_incy_PreSeptember2022StockSplitSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre September 2022 -Stock Split Shares</link:label>
    <link:label id="lab_incy_PreSeptember2022StockSplitSharesMember_label_en-US" xlink:label="lab_incy_PreSeptember2022StockSplitSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre September 2022 -Stock Split Shares [Member]</link:label>
    <link:label id="lab_incy_PreSeptember2022StockSplitSharesMember_documentation_en-US" xlink:label="lab_incy_PreSeptember2022StockSplitSharesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre September 2022 -Stock Split Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_incy_PreSeptember2022StockSplitSharesMember" xlink:href="incy-20220930.xsd#incy_PreSeptember2022StockSplitSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_incy_PreSeptember2022StockSplitSharesMember" xlink:to="lab_incy_PreSeptember2022StockSplitSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_incy_InnocarePharmaLimitedMember_7513b868-b0f5-4364-bf93-4c6a08deac5c_terseLabel_en-US" xlink:label="lab_incy_InnocarePharmaLimitedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">InnoCare</link:label>
    <link:label id="lab_incy_InnocarePharmaLimitedMember_label_en-US" xlink:label="lab_incy_InnocarePharmaLimitedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">InnoCare</link:label>
    <link:label id="lab_incy_InnocarePharmaLimitedMember_documentation_en-US" xlink:label="lab_incy_InnocarePharmaLimitedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to InnoCare Pharma Limited ("InnoCare").</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_incy_InnocarePharmaLimitedMember" xlink:href="incy-20220930.xsd#incy_InnocarePharmaLimitedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_incy_InnocarePharmaLimitedMember" xlink:to="lab_incy_InnocarePharmaLimitedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_16d4df97-6fba-4c84-bac8-9f97d61a00e1_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_incy_CollaborationAgreementProfitSharingPercentage_d48441cb-0677-4847-87eb-44c9375dcdb0_terseLabel_en-US" xlink:label="lab_incy_CollaborationAgreementProfitSharingPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Profit sharing (as a percent)</link:label>
    <link:label id="lab_incy_CollaborationAgreementProfitSharingPercentage_label_en-US" xlink:label="lab_incy_CollaborationAgreementProfitSharingPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement Profit Sharing Percentage</link:label>
    <link:label id="lab_incy_CollaborationAgreementProfitSharingPercentage_documentation_en-US" xlink:label="lab_incy_CollaborationAgreementProfitSharingPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the percentage of profits and losses shared under the collaboration agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_incy_CollaborationAgreementProfitSharingPercentage" xlink:href="incy-20220930.xsd#incy_CollaborationAgreementProfitSharingPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_incy_CollaborationAgreementProfitSharingPercentage" xlink:to="lab_incy_CollaborationAgreementProfitSharingPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_d1306ae1-4b37-4865-9514-603176f707fa_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_86d52559-effb-4097-a6bb-4a9746efc16f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_bda300bc-6fc8-430c-9da6-0412091038d8_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of shares of Common Stock upon exercise of stock options and settlement of employee restricted stock units, net of shares withheld for taxes</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedIntrinsicValue_723542c8-3550-4aa9-8915-dd2779231dc4_terseLabel_en-US" xlink:label="lab_incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Released (in USD per share)</link:label>
    <link:label id="lab_incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedIntrinsicValue_label_en-US" xlink:label="lab_incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Released Intrinsic Value</link:label>
    <link:label id="lab_incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedIntrinsicValue_documentation_en-US" xlink:label="lab_incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Per share weighted average intrinsic value of equity-based compensation awards released. Excludes stock and unit options.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedIntrinsicValue" xlink:href="incy-20220930.xsd#incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedIntrinsicValue" xlink:to="lab_incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_625ecc16-0c75-4962-86f8-b1c58c0fb64f_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_b1508522-4a38-4093-b708-0377b8674863_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_e10c1e0d-8be5-4e80-b861-0cc7593b29a2_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition-related contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_f7fac9be-e855-452b-b3e1-3e0f61234421_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_incy_OpzeluraMember_47aee4d4-c2c9-41b8-bd7e-c8108703c053_terseLabel_en-US" xlink:label="lab_incy_OpzeluraMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OPZELURA</link:label>
    <link:label id="lab_incy_OpzeluraMember_label_en-US" xlink:label="lab_incy_OpzeluraMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OPZELURA</link:label>
    <link:label id="lab_incy_OpzeluraMember_documentation_en-US" xlink:label="lab_incy_OpzeluraMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to OPZELURA (ruxolitinib) cream, a novel cream formulation of Incyte's selective JAK1/JAK2 inhibitor ruxolitinib.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_incy_OpzeluraMember" xlink:href="incy-20220930.xsd#incy_OpzeluraMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_incy_OpzeluraMember" xlink:to="lab_incy_OpzeluraMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_969a28b3-b73d-48e2-ab1e-a9b697c54a88_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_44cdc5cf-1045-4887-b98b-828457e0013e_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_incy_LicenseAgreementUpfrontPaymentReceived_6504e061-7c06-46dc-baec-1b624713dc2d_terseLabel_en-US" xlink:label="lab_incy_LicenseAgreementUpfrontPaymentReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront payment received under license agreement</link:label>
    <link:label id="lab_incy_LicenseAgreementUpfrontPaymentReceived_label_en-US" xlink:label="lab_incy_LicenseAgreementUpfrontPaymentReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Upfront Payment Received</link:label>
    <link:label id="lab_incy_LicenseAgreementUpfrontPaymentReceived_documentation_en-US" xlink:label="lab_incy_LicenseAgreementUpfrontPaymentReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the upfront payment received under the license agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_incy_LicenseAgreementUpfrontPaymentReceived" xlink:href="incy-20220930.xsd#incy_LicenseAgreementUpfrontPaymentReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_incy_LicenseAgreementUpfrontPaymentReceived" xlink:to="lab_incy_LicenseAgreementUpfrontPaymentReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_08f5ace9-cfd2-43db-9ead-99638aa3a107_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined contribution expense</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:to="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_5ee6dc61-502c-41b5-95e2-fddc1b005141_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfLongtermInvestments_cc95c247-c9e7-442a-af86-1da7f0103bfe_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfLongtermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of long term investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfLongtermInvestments_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfLongtermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Long-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfLongtermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfLongtermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfLongtermInvestments" xlink:to="lab_us-gaap_ProceedsFromSaleOfLongtermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_6c3ceb1e-b3c7-431c-b236-3f282de12898_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityMember_ddb54fa9-b267-4448-9d6b-c5c3f106b5f8_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability</link:label>
    <link:label id="lab_us-gaap_LiabilityMember_label_en-US" xlink:label="lab_us-gaap_LiabilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityMember" xlink:to="lab_us-gaap_LiabilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_19a6eb9e-2304-4839-93e9-b73e634c2c70_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_241b9858-c7c0-404a-8fad-c2c2aa7d7f54_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_34467e40-f273-4106-b4a3-37bac9a81ad2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_incy_IncyteMember_8b9567c7-0364-4d85-973d-f921fab103d5_terseLabel_en-US" xlink:label="lab_incy_IncyteMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incyte</link:label>
    <link:label id="lab_incy_IncyteMember_label_en-US" xlink:label="lab_incy_IncyteMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incyte</link:label>
    <link:label id="lab_incy_IncyteMember_documentation_en-US" xlink:label="lab_incy_IncyteMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents member information pertaining to Incyte.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_incy_IncyteMember" xlink:href="incy-20220930.xsd#incy_IncyteMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_incy_IncyteMember" xlink:to="lab_incy_IncyteMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_7858b44f-3043-42c7-894d-28d9bac0cd1c_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_7eaedf10-ba69-4ae0-89eb-f63db668cc0d_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_c7a9deff-78a3-4e29-91b8-7d9bc098abce_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_debff023-77a8-499d-b39b-50e35f9239c9_negatedLabel_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of finance lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_label_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Principal Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:to="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_incy_PeriodOfDeviationFromAverageCostOfGoodsSold_3099b7af-f08f-4466-939f-e32f1b7b6821_terseLabel_en-US" xlink:label="lab_incy_PeriodOfDeviationFromAverageCostOfGoodsSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period of lower average per unit cost of materials</link:label>
    <link:label id="lab_incy_PeriodOfDeviationFromAverageCostOfGoodsSold_label_en-US" xlink:label="lab_incy_PeriodOfDeviationFromAverageCostOfGoodsSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period Of Deviation From Average, Cost Of Goods Sold</link:label>
    <link:label id="lab_incy_PeriodOfDeviationFromAverageCostOfGoodsSold_documentation_en-US" xlink:label="lab_incy_PeriodOfDeviationFromAverageCostOfGoodsSold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the length of time in which cost of goods sold will deviate from average due to unusual and/or infrequent conditions.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_incy_PeriodOfDeviationFromAverageCostOfGoodsSold" xlink:href="incy-20220930.xsd#incy_PeriodOfDeviationFromAverageCostOfGoodsSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_incy_PeriodOfDeviationFromAverageCostOfGoodsSold" xlink:to="lab_incy_PeriodOfDeviationFromAverageCostOfGoodsSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_1838d655-71b3-4ea8-8f50-b93498da60a4_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition-related contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_7163d862-5ed6-4c4d-8017-e96ed923862c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_cf018b7b-7c89-46f6-9989-adef39fc92cf_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_incy_AgenusMember_f524e322-320b-4f40-b404-156e9804b281_terseLabel_en-US" xlink:label="lab_incy_AgenusMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agenus</link:label>
    <link:label id="lab_incy_AgenusMember_label_en-US" xlink:label="lab_incy_AgenusMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agenus</link:label>
    <link:label id="lab_incy_AgenusMember_documentation_en-US" xlink:label="lab_incy_AgenusMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents details pertaining to Agenus with whom we have entered into a License, Development and Commercialization Agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_incy_AgenusMember" xlink:href="incy-20220930.xsd#incy_AgenusMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_incy_AgenusMember" xlink:to="lab_incy_AgenusMember" xlink:type="arc" order="1"/>
    <link:label id="lab_incy_NimbleMember_b8e1df02-f881-4d69-8631-37b6214b677f_terseLabel_en-US" xlink:label="lab_incy_NimbleMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nimble</link:label>
    <link:label id="lab_incy_NimbleMember_label_en-US" xlink:label="lab_incy_NimbleMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nimble</link:label>
    <link:label id="lab_incy_NimbleMember_documentation_en-US" xlink:label="lab_incy_NimbleMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to Nimble.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_incy_NimbleMember" xlink:href="incy-20220930.xsd#incy_NimbleMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_incy_NimbleMember" xlink:to="lab_incy_NimbleMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_8b0e4455-18e2-4ed0-8e8f-00e4c0501729_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Gain) loss on change in fair value of acquisition-related contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrent_97028db7-2673-45ef-b247-dde77faabee5_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalties</link:label>
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Royalties, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedRoyaltiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedRoyaltiesCurrent" xlink:to="lab_us-gaap_AccruedRoyaltiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductMember_6470bd51-dbb6-484e-9ffa-ec17cf555943_terseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product revenues, net</link:label>
    <link:label id="lab_us-gaap_ProductMember_label_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember" xlink:to="lab_us-gaap_ProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_incy_MilestoneAndContractRevenueMember_5207c409-9ac6-4f66-83cc-7d3b43859fb3_terseLabel_en-US" xlink:label="lab_incy_MilestoneAndContractRevenueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone and contract revenues</link:label>
    <link:label id="lab_incy_MilestoneAndContractRevenueMember_label_en-US" xlink:label="lab_incy_MilestoneAndContractRevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone and contract revenues</link:label>
    <link:label id="lab_incy_MilestoneAndContractRevenueMember_documentation_en-US" xlink:label="lab_incy_MilestoneAndContractRevenueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to milestone and contract revenues.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_incy_MilestoneAndContractRevenueMember" xlink:href="incy-20220930.xsd#incy_MilestoneAndContractRevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_incy_MilestoneAndContractRevenueMember" xlink:to="lab_incy_MilestoneAndContractRevenueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_a2be02db-d24f-4528-a9ec-59bae78fb12a_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireProductiveAssets_9a61bbe2-bb08-4c1c-bf55-26e2771ae635_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireProductiveAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital expenditures</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireProductiveAssets_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Productive Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireProductiveAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireProductiveAssets" xlink:to="lab_us-gaap_PaymentsToAcquireProductiveAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_3cbdf6ee-69d2-48ba-a8f9-29d9b55d53c8_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_e852714b-b223-45af-b3a4-025494e1a3e8_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_incy_BuildingAndLeaseholdImprovementsMember_ce6d8b5e-b95d-4d04-86f6-d8ccab53c4cc_terseLabel_en-US" xlink:label="lab_incy_BuildingAndLeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Building and leasehold improvements</link:label>
    <link:label id="lab_incy_BuildingAndLeaseholdImprovementsMember_label_en-US" xlink:label="lab_incy_BuildingAndLeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Building and leasehold improvements</link:label>
    <link:label id="lab_incy_BuildingAndLeaseholdImprovementsMember_documentation_en-US" xlink:label="lab_incy_BuildingAndLeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information relating to building and leasehold improvements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_incy_BuildingAndLeaseholdImprovementsMember" xlink:href="incy-20220930.xsd#incy_BuildingAndLeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_incy_BuildingAndLeaseholdImprovementsMember" xlink:to="lab_incy_BuildingAndLeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_a0fa9426-b34c-4e3e-827b-0e4e251b888d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of option activity under the 2010 Stock Plan</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_29804db9-ede6-4584-a6f9-e02fb0888bf2_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_34b19941-a85b-4e8c-9442-2a59ad4b567b_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_incy_CalitheraBiosciencesIncMember_3b6d7857-9099-4383-830a-4eba88c8fcb4_terseLabel_en-US" xlink:label="lab_incy_CalitheraBiosciencesIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Calithera</link:label>
    <link:label id="lab_incy_CalitheraBiosciencesIncMember_label_en-US" xlink:label="lab_incy_CalitheraBiosciencesIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Calithera</link:label>
    <link:label id="lab_incy_CalitheraBiosciencesIncMember_documentation_en-US" xlink:label="lab_incy_CalitheraBiosciencesIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents details pertaining to our long-term investment in Calithera Biosciences, Inc with whom we have entered into a License and Commercialization Agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_incy_CalitheraBiosciencesIncMember" xlink:href="incy-20220930.xsd#incy_CalitheraBiosciencesIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_incy_CalitheraBiosciencesIncMember" xlink:to="lab_incy_CalitheraBiosciencesIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_06c64772-592f-428f-9702-63577eb47fe6_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_3bff2980-7335-4c46-a951-49459843eef2_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities_62fda5ad-8d0a-4a9a-b4e1-edb9307d4303_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued and other liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities and Other Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_ef28fc87-7f8d-451d-8121-610306b86e17_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_fb6aa436-852b-47d4-8afe-4ea2620b71bf_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_incy_OfficeBuildingMorgesSwitzerlandMember_1322ed04-a27c-4ec6-bb24-d3d642a74dfc_terseLabel_en-US" xlink:label="lab_incy_OfficeBuildingMorgesSwitzerlandMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office Building in Morges, Switzerland</link:label>
    <link:label id="lab_incy_OfficeBuildingMorgesSwitzerlandMember_label_en-US" xlink:label="lab_incy_OfficeBuildingMorgesSwitzerlandMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office Building in Morges, Switzerland</link:label>
    <link:label id="lab_incy_OfficeBuildingMorgesSwitzerlandMember_documentation_en-US" xlink:label="lab_incy_OfficeBuildingMorgesSwitzerlandMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information relating to the office building located in Morges, Switzerland.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_incy_OfficeBuildingMorgesSwitzerlandMember" xlink:href="incy-20220930.xsd#incy_OfficeBuildingMorgesSwitzerlandMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_incy_OfficeBuildingMorgesSwitzerlandMember" xlink:to="lab_incy_OfficeBuildingMorgesSwitzerlandMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_c8b142a4-4957-4dd8-9419-0927bbd28a19_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a440d838-d3bb-4277-96fb-3bd950c1e831_verboseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net income to net cash provided by operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_9e75ce24-a852-4cc1-a838-be64d623d0bf_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_b1870bd8-3f73-44a1-b84a-b42371b182fd_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax (benefit) expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_f71bb41b-14e1-4c17-979a-6adfb49feb01_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_incy_CustomerCMember_e7a14eae-9fb6-4ac2-9a99-6bdb33e2bf10_terseLabel_en-US" xlink:label="lab_incy_CustomerCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer C</link:label>
    <link:label id="lab_incy_CustomerCMember_label_en-US" xlink:label="lab_incy_CustomerCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer C [Member]</link:label>
    <link:label id="lab_incy_CustomerCMember_documentation_en-US" xlink:label="lab_incy_CustomerCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to the customer C.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_incy_CustomerCMember" xlink:href="incy-20220930.xsd#incy_CustomerCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_incy_CustomerCMember" xlink:to="lab_incy_CustomerCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_b4853bcc-bc66-4668-ad5a-953552a9235e_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_incy_CorporateAndGovernmentDebtSecuritiesMember_8385a4de-bb51-4478-a510-136fd24d35de_terseLabel_en-US" xlink:label="lab_incy_CorporateAndGovernmentDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities (government)</link:label>
    <link:label id="lab_incy_CorporateAndGovernmentDebtSecuritiesMember_label_en-US" xlink:label="lab_incy_CorporateAndGovernmentDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities (government)</link:label>
    <link:label id="lab_incy_CorporateAndGovernmentDebtSecuritiesMember_documentation_en-US" xlink:label="lab_incy_CorporateAndGovernmentDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities issued by government or corporate business, banks and other entities with a promise of repayment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_incy_CorporateAndGovernmentDebtSecuritiesMember" xlink:href="incy-20220930.xsd#incy_CorporateAndGovernmentDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_incy_CorporateAndGovernmentDebtSecuritiesMember" xlink:to="lab_incy_CorporateAndGovernmentDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_cecbcea8-1631-4a03-bc61-786e0f972ca1_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in USD per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_ace3e6c9-d8bd-45d1-801e-c342853eaeb7_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_e255cb16-9d96-4942-8389-e460831e06e3_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_a0c02f9d-6d85-41ba-8b12-65e623856c52_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_fb88f441-dca0-48ed-803e-59b08edcfdaa_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_e0bdc3a5-0982-4faf-8a03-5b9b9d5de19d_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic Net Income (Loss) Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_75a815cc-8de7-4cad-8e70-46ddedd30f8c_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_c14d6f82-5368-42d4-a712-07cb774bebb6_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average shares used to compute diluted net income per share ( in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_dc2b5a69-116b-46fc-a4fa-cc020b34be2e_negatedLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less accumulated depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskDisclosureTextBlock_6d7cbd92-c16e-4c60-9a94-2ea952f9b609_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentrations of Credit Risk and Current Expected Credit Losses</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:to="lab_us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_fe42cb1c-0840-4f26-8f09-7771d46a4efa_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average expected life (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_049e912f-6815-4a2b-a035-97765cdd75f1_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RealEstatePropertiesAxis_838f2b3f-bee6-42cb-88f5-a06b7369a519_terseLabel_en-US" xlink:label="lab_us-gaap_RealEstatePropertiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Real Estate Property Ownership [Axis]</link:label>
    <link:label id="lab_us-gaap_RealEstatePropertiesAxis_label_en-US" xlink:label="lab_us-gaap_RealEstatePropertiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Real Estate Property Ownership [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealEstatePropertiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RealEstatePropertiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RealEstatePropertiesAxis" xlink:to="lab_us-gaap_RealEstatePropertiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b7839b70-9234-4d4c-8535-ff2d53d9e1d5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of marketable security portfolio</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableMember_b9d1be28-4f57-41eb-99db-56c157ae4cc0_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember" xlink:to="lab_us-gaap_AccountsReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCanceled_3b3070ea-6e9d-4722-8625-6785f5786fd9_terseLabel_en-US" xlink:label="lab_incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCanceled" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, RSUs and PSUs cancelled (in shares)</link:label>
    <link:label id="lab_incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCanceled_label_en-US" xlink:label="lab_incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCanceled" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement by Share Based Payment Award Number of Shares Canceled</link:label>
    <link:label id="lab_incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCanceled_documentation_en-US" xlink:label="lab_incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCanceled" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares canceled under an established share-based compensation plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCanceled" xlink:href="incy-20220930.xsd#incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCanceled"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCanceled" xlink:to="lab_incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCanceled" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_ce442df4-91b7-4d10-9159-2418aabffcfa_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.001 par value; 400,000,000 shares authorized; 222,454,839 and 221,084,433 shares issued and outstanding as of September&#160;30, 2022 and December&#160;31, 2021, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue_28380706-9904-4a0a-9f20-422d9684e85d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cancelled (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Intrinsic Value, Amount Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_52e76da9-ccbb-425f-9a27-bf8f0027d20f_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_bafbb047-6f18-42ff-bdf6-740692d68b1c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of antidilutive securities excluded from the computation of earnings per share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_e3381096-f2aa-471b-b278-2203c405e22f_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicLineItems_e575957d-640d-409a-b7dc-fe398c0a62e2_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income per share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicLineItems_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasicLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems" xlink:to="lab_us-gaap_EarningsPerShareBasicLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_19903924-1bc7-4055-9407-5cc6498ad6d3_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, restricted cash and investments at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6910712f-cee1-4a47-a7fc-3b81cd79c4bb_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, restricted cash and investments at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentOwnedBalanceShares_e695566b-b62e-4811-80a0-64e876be5bc9_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentOwnedBalanceShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership (in shares)</link:label>
    <link:label id="lab_us-gaap_InvestmentOwnedBalanceShares_label_en-US" xlink:label="lab_us-gaap_InvestmentOwnedBalanceShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Owned, Balance, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedBalanceShares" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentOwnedBalanceShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentOwnedBalanceShares" xlink:to="lab_us-gaap_InvestmentOwnedBalanceShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_4c763001-5166-4836-8dfd-167630482038_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_63820195-40a2-4a77-a8f3-5df510eea7f2_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_d909d0de-4c7d-4824-9c57-faa0f61fdba7_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic net income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_b67e94e7-19c0-4e85-a2c9-25018de889a3_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_incy_LicenseAgreementMilestonePaymentAmountPaid_5097f1a6-3444-463b-ada4-b3414c541c6c_terseLabel_en-US" xlink:label="lab_incy_LicenseAgreementMilestonePaymentAmountPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payment made under license agreement</link:label>
    <link:label id="lab_incy_LicenseAgreementMilestonePaymentAmountPaid_label_en-US" xlink:label="lab_incy_LicenseAgreementMilestonePaymentAmountPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement Milestone Payment Amount Paid</link:label>
    <link:label id="lab_incy_LicenseAgreementMilestonePaymentAmountPaid_documentation_en-US" xlink:label="lab_incy_LicenseAgreementMilestonePaymentAmountPaid" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the amount of the milestone payment made under the license agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_incy_LicenseAgreementMilestonePaymentAmountPaid" xlink:href="incy-20220930.xsd#incy_LicenseAgreementMilestonePaymentAmountPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_incy_LicenseAgreementMilestonePaymentAmountPaid" xlink:to="lab_incy_LicenseAgreementMilestonePaymentAmountPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_6ebddbea-b7d8-4d50-b49c-6c9dd37593e4_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration of risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskLineItems" xlink:to="lab_us-gaap_ConcentrationRiskLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_incy_TabrectaRoyaltyRevenuesMember_05ea75d1-b29b-4bc4-9faa-f88da16e54a2_terseLabel_en-US" xlink:label="lab_incy_TabrectaRoyaltyRevenuesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TABRECTA Royalty Revenues</link:label>
    <link:label id="lab_incy_TabrectaRoyaltyRevenuesMember_label_en-US" xlink:label="lab_incy_TabrectaRoyaltyRevenuesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TABRECTA Royalty Revenues</link:label>
    <link:label id="lab_incy_TabrectaRoyaltyRevenuesMember_documentation_en-US" xlink:label="lab_incy_TabrectaRoyaltyRevenuesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to TABRECTA royalty revenues, treatment of adult patients with metastatic NSCLC whose tumors have a mutation that leads to MET exon 14 skipping (METex14).</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_incy_TabrectaRoyaltyRevenuesMember" xlink:href="incy-20220930.xsd#incy_TabrectaRoyaltyRevenuesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_incy_TabrectaRoyaltyRevenuesMember" xlink:to="lab_incy_TabrectaRoyaltyRevenuesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_incy_InventoryRecordedAsResearchAndDevelopmentExpense_3b9977ea-d7b8-4748-9375-8f32963f1ddf_terseLabel_en-US" xlink:label="lab_incy_InventoryRecordedAsResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory incurred prior to FDA approval</link:label>
    <link:label id="lab_incy_InventoryRecordedAsResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_incy_InventoryRecordedAsResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Recorded as Research and Development Expense</link:label>
    <link:label id="lab_incy_InventoryRecordedAsResearchAndDevelopmentExpense_documentation_en-US" xlink:label="lab_incy_InventoryRecordedAsResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the aggregate carrying amount of current and noncurrent portion, net of valuation reserves and allowances, as of the balance sheet date of inventories recorded as research and development expense.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_incy_InventoryRecordedAsResearchAndDevelopmentExpense" xlink:href="incy-20220930.xsd#incy_InventoryRecordedAsResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_incy_InventoryRecordedAsResearchAndDevelopmentExpense" xlink:to="lab_incy_InventoryRecordedAsResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_35a80b48-44f6-4335-aa2d-39a394c9d35e_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unpaid purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_d2228b18-0716-432f-af8a-ab8a10caa6ad_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_incy_GvhdMember_0e17b5d6-6c41-4363-8803-4e26e2295add_terseLabel_en-US" xlink:label="lab_incy_GvhdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GVHD</link:label>
    <link:label id="lab_incy_GvhdMember_label_en-US" xlink:label="lab_incy_GvhdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GVHD</link:label>
    <link:label id="lab_incy_GvhdMember_documentation_en-US" xlink:label="lab_incy_GvhdMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to GVHD, an Graft-Versus-Host Disease field.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_incy_GvhdMember" xlink:href="incy-20220930.xsd#incy_GvhdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_incy_GvhdMember" xlink:to="lab_incy_GvhdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_907e6f2c-61ba-49c5-9647-19874a05f024_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a5667c95-01b1-400e-b206-9e6318da0a40_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of financial instruments</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_48cea8ee-5374-4215-9953-6e8e5b43c53c_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_8dcc7a0f-1d47-406e-9e52-012de698ec31_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_ff6d172c-eb67-4c1a-b9db-dd70a8204f9a_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_f280d875-8d5d-4378-9a79-1ae936bec7c2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of fair value of liabilities measured on recurring basis</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_5f2375ea-577d-40bf-91d0-bece5471e39b_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in Progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in Progress [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressMember" xlink:to="lab_us-gaap_ConstructionInProgressMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_a3e1bc72-7532-486c-9802-87335cf05790_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_7b536227-547b-4457-a008-cf54d92f18a1_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_fbcdaeb7-45b5-4c35-85a8-ba8b3a85aac9_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets, net</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_incy_ProductGroupTwoMember_b8890f90-d5dd-4660-a657-5b34923a1f1e_terseLabel_en-US" xlink:label="lab_incy_ProductGroupTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty-bearing product GITR, OX40 and one undisclosed target</link:label>
    <link:label id="lab_incy_ProductGroupTwoMember_label_en-US" xlink:label="lab_incy_ProductGroupTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty-bearing product GITR, OX40 and one undisclosed target</link:label>
    <link:label id="lab_incy_ProductGroupTwoMember_documentation_en-US" xlink:label="lab_incy_ProductGroupTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the royalty-bearing product GITR, OX40 and one undisclosed target.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_incy_ProductGroupTwoMember" xlink:href="incy-20220930.xsd#incy_ProductGroupTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_incy_ProductGroupTwoMember" xlink:to="lab_incy_ProductGroupTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_461c2c12-6424-40ce-b4a1-64f9a9adc579_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_incy_CollaborationAgreementProfitLossSharingRatio_40f0be01-9b31-4450-9cf3-3ab3de154638_terseLabel_en-US" xlink:label="lab_incy_CollaborationAgreementProfitLossSharingRatio" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Profit (loss) sharing ratio</link:label>
    <link:label id="lab_incy_CollaborationAgreementProfitLossSharingRatio_label_en-US" xlink:label="lab_incy_CollaborationAgreementProfitLossSharingRatio" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement Profit Loss Sharing Ratio</link:label>
    <link:label id="lab_incy_CollaborationAgreementProfitLossSharingRatio_documentation_en-US" xlink:label="lab_incy_CollaborationAgreementProfitLossSharingRatio" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ratio of sharing profit and losses under the collaboration agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_incy_CollaborationAgreementProfitLossSharingRatio" xlink:href="incy-20220930.xsd#incy_CollaborationAgreementProfitLossSharingRatio"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_incy_CollaborationAgreementProfitLossSharingRatio" xlink:to="lab_incy_CollaborationAgreementProfitLossSharingRatio" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_bbc6ac8a-328f-49b5-a909-e9a2b120b631_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_a7bb65a1-39fe-4a3b-89d4-ef5656fbcb9b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Fair Value</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Excluding Accrued Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_country_JP_2b01db05-bafb-45d6-bb84-85f2f9f71d6e_terseLabel_en-US" xlink:label="lab_country_JP" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">JAPAN</link:label>
    <link:label id="lab_country_JP_label_en-US" xlink:label="lab_country_JP" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">JAPAN</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_JP" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_JP"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_JP" xlink:to="lab_country_JP" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_6cd3cbfb-741a-4025-a284-85c4b97485df_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of shares of Common Stock under the ESPP</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_49711e46-7864-472e-954c-16a1e345076a_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_aa1bf5b5-ec3b-407f-9d2c-ecad959d76f5_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at the beginning of the period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c6b1a96b-5096-4f24-a57d-6a0aa55d62db_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at the end of the period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_incy_SubsidiaryStockConversionRatio_4df28928-ca7e-417e-b272-efe6dc935e3f_terseLabel_en-US" xlink:label="lab_incy_SubsidiaryStockConversionRatio" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share conversion</link:label>
    <link:label id="lab_incy_SubsidiaryStockConversionRatio_label_en-US" xlink:label="lab_incy_SubsidiaryStockConversionRatio" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary Stock, Conversion Ratio</link:label>
    <link:label id="lab_incy_SubsidiaryStockConversionRatio_documentation_en-US" xlink:label="lab_incy_SubsidiaryStockConversionRatio" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of parent common shares issuable upon conversion for each share of subsidiary stock to be converted.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_incy_SubsidiaryStockConversionRatio" xlink:href="incy-20220930.xsd#incy_SubsidiaryStockConversionRatio"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_incy_SubsidiaryStockConversionRatio" xlink:to="lab_incy_SubsidiaryStockConversionRatio" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_56841c8d-9dda-4c5d-9a78-db0fcb01ce40_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued and Other Current Liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedMarketingCostsCurrent_db4978d4-dcff-416b-854d-190816047c28_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedMarketingCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales and marketing</link:label>
    <link:label id="lab_us-gaap_AccruedMarketingCostsCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedMarketingCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Marketing Costs, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedMarketingCostsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedMarketingCostsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedMarketingCostsCurrent" xlink:to="lab_us-gaap_AccruedMarketingCostsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IPOMember_8fb15216-3d7c-41cc-b09b-0d9378330227_terseLabel_en-US" xlink:label="lab_us-gaap_IPOMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPO</link:label>
    <link:label id="lab_us-gaap_IPOMember_label_en-US" xlink:label="lab_us-gaap_IPOMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IPOMember" xlink:to="lab_us-gaap_IPOMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_377750da-c000-4c4f-9f6a-2ee5aac793e3_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_incy_CollaborationAndLicenseAgreementWithZaiLabLtdMember_94359dac-7a47-4421-b242-ef80c7c39289_terseLabel_en-US" xlink:label="lab_incy_CollaborationAndLicenseAgreementWithZaiLabLtdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zai Lab Ltd</link:label>
    <link:label id="lab_incy_CollaborationAndLicenseAgreementWithZaiLabLtdMember_label_en-US" xlink:label="lab_incy_CollaborationAndLicenseAgreementWithZaiLabLtdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zai Lab Ltd</link:label>
    <link:label id="lab_incy_CollaborationAndLicenseAgreementWithZaiLabLtdMember_documentation_en-US" xlink:label="lab_incy_CollaborationAndLicenseAgreementWithZaiLabLtdMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the collaboration and license agreement with Zai Lab Ltd.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_incy_CollaborationAndLicenseAgreementWithZaiLabLtdMember" xlink:href="incy-20220930.xsd#incy_CollaborationAndLicenseAgreementWithZaiLabLtdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_incy_CollaborationAndLicenseAgreementWithZaiLabLtdMember" xlink:to="lab_incy_CollaborationAndLicenseAgreementWithZaiLabLtdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_2741ee1b-cba0-42b9-acb1-649d40165cdc_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ad614ed1-b557-423f-9e7c-3a29e61f3aaa_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rates on cash, cash equivalents, restricted cash and investments</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_612513bb-c5b0-42b4-89f9-dda3ec0f000e_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_af998fb2-4000-4a69-9192-6d58977052c1_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OfficeEquipmentMember_98e0d0fe-56fe-43be-b748-df07fff21711_terseLabel_en-US" xlink:label="lab_us-gaap_OfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office Equipment</link:label>
    <link:label id="lab_us-gaap_OfficeEquipmentMember_label_en-US" xlink:label="lab_us-gaap_OfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OfficeEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OfficeEquipmentMember" xlink:to="lab_us-gaap_OfficeEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_d827460c-3fb5-4fba-a569-27d6647ff206_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of contingent consideration</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_025cdc8f-c0b8-459c-9938-54073c274539_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_d3a9ba22-73df-47c9-8b5e-f4e11cf8c14f_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined benefit pension gain, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_7420834b-7354-429b-baed-fbb23515b113_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Volatility (as a percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_incy_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityConsiderationEarned_9c76efdd-d2ad-47e1-ac3b-11b1b4690f98_negatedLabel_en-US" xlink:label="lab_incy_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityConsiderationEarned" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration earned during the period but not yet paid</link:label>
    <link:label id="lab_incy_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityConsiderationEarned_label_en-US" xlink:label="lab_incy_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityConsiderationEarned" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Change In Amount Of Contingent Consideration Liability, Consideration Earned</link:label>
    <link:label id="lab_incy_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityConsiderationEarned_documentation_en-US" xlink:label="lab_incy_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityConsiderationEarned" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of decrease in the value of a contingent consideration liability attributable to consideration earned by the acquiree in a business combination.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_incy_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityConsiderationEarned" xlink:href="incy-20220930.xsd#incy_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityConsiderationEarned"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_incy_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityConsiderationEarned" xlink:to="lab_incy_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityConsiderationEarned" xlink:type="arc" order="1"/>
    <link:label id="lab_incy_DevelopmentAndRegulatoryMilestonesMember_2c010bd8-fd99-449d-b468-f3b416956be2_terseLabel_en-US" xlink:label="lab_incy_DevelopmentAndRegulatoryMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development and Regulatory Milestones</link:label>
    <link:label id="lab_incy_DevelopmentAndRegulatoryMilestonesMember_label_en-US" xlink:label="lab_incy_DevelopmentAndRegulatoryMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development and Regulatory Milestones</link:label>
    <link:label id="lab_incy_DevelopmentAndRegulatoryMilestonesMember_documentation_en-US" xlink:label="lab_incy_DevelopmentAndRegulatoryMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to certain development and regulatory events on the basis of which certain milestones are achieved.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_incy_DevelopmentAndRegulatoryMilestonesMember" xlink:href="incy-20220930.xsd#incy_DevelopmentAndRegulatoryMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_incy_DevelopmentAndRegulatoryMilestonesMember" xlink:to="lab_incy_DevelopmentAndRegulatoryMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_1221c4c4-5507-40cf-addd-182e6fb3abd0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cancelled (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_7433857d-8d48-45c0-bdba-29ce10e4f2f9_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense), net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_f7d35b8f-dbc9-4382-8dc1-0e3951a533ae_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_4e5a2daf-b114-458d-b378-34d9762591b5_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_2e0d1790-98d9-4f9b-bd5e-6d724eed1a7f_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition-related contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_d9059ced-508a-4a7f-a055-d38a521041a0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_incy_LandLocatedWithinYParcSwitzerlandsLargestTechnologyParkInYverdonMember_f294c361-b4d1-43a8-9045-a76a0c313eef_terseLabel_en-US" xlink:label="lab_incy_LandLocatedWithinYParcSwitzerlandsLargestTechnologyParkInYverdonMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land in Y-PARC, Switzerland's largest technology park, Yverdon</link:label>
    <link:label id="lab_incy_LandLocatedWithinYParcSwitzerlandsLargestTechnologyParkInYverdonMember_label_en-US" xlink:label="lab_incy_LandLocatedWithinYParcSwitzerlandsLargestTechnologyParkInYverdonMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land in Y-PARC, Switzerland's largest technology park, Yverdon</link:label>
    <link:label id="lab_incy_LandLocatedWithinYParcSwitzerlandsLargestTechnologyParkInYverdonMember_documentation_en-US" xlink:label="lab_incy_LandLocatedWithinYParcSwitzerlandsLargestTechnologyParkInYverdonMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to land located with Y-PARC, Switzerland's largest technology park in Yverdon.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_incy_LandLocatedWithinYParcSwitzerlandsLargestTechnologyParkInYverdonMember" xlink:href="incy-20220930.xsd#incy_LandLocatedWithinYParcSwitzerlandsLargestTechnologyParkInYverdonMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_incy_LandLocatedWithinYParcSwitzerlandsLargestTechnologyParkInYverdonMember" xlink:to="lab_incy_LandLocatedWithinYParcSwitzerlandsLargestTechnologyParkInYverdonMember" xlink:type="arc" order="1"/>
    <link:label id="lab_incy_JAKAFIMember_ecac860c-8f0a-437f-b7d8-d0441fe79f04_terseLabel_en-US" xlink:label="lab_incy_JAKAFIMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">JAKAFI</link:label>
    <link:label id="lab_incy_JAKAFIMember_e88b395f-725a-4516-8d06-4b60dfc740ab_verboseLabel_en-US" xlink:label="lab_incy_JAKAFIMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">JAKAFI</link:label>
    <link:label id="lab_incy_JAKAFIMember_label_en-US" xlink:label="lab_incy_JAKAFIMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">JAKAFI</link:label>
    <link:label id="lab_incy_JAKAFIMember_documentation_en-US" xlink:label="lab_incy_JAKAFIMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to JAKAFI (ruxolitinib), an oral Janus associate kinase (JAK) inhibitor sold within the United State of America.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_incy_JAKAFIMember" xlink:href="incy-20220930.xsd#incy_JAKAFIMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_incy_JAKAFIMember" xlink:to="lab_incy_JAKAFIMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostCreditExcludingServiceCostStatementOfIncomeOrComprehensiveIncomeExtensibleList_be327522-4795-429b-a726-c57069bdca25_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostCreditExcludingServiceCostStatementOfIncomeOrComprehensiveIncomeExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Location of costs excluding the service component</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostCreditExcludingServiceCostStatementOfIncomeOrComprehensiveIncomeExtensibleList_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostCreditExcludingServiceCostStatementOfIncomeOrComprehensiveIncomeExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Net Periodic Benefit Cost (Credit) Excluding Service Cost, Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostCreditExcludingServiceCostStatementOfIncomeOrComprehensiveIncomeExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostCreditExcludingServiceCostStatementOfIncomeOrComprehensiveIncomeExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostCreditExcludingServiceCostStatementOfIncomeOrComprehensiveIncomeExtensibleList" xlink:to="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostCreditExcludingServiceCostStatementOfIncomeOrComprehensiveIncomeExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_c08b54ae-219c-4ccd-8697-18d6749f511a_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_413d6157-ebb6-40a4-ba17-acb076c50651_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_96c50b01-d159-4e5c-9061-101a6823d4bc_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_incy_VillarisMember_6665fdb5-71f7-4124-856c-17ba34d95e26_terseLabel_en-US" xlink:label="lab_incy_VillarisMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Villaris</link:label>
    <link:label id="lab_incy_VillarisMember_label_en-US" xlink:label="lab_incy_VillarisMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Villaris [Member]</link:label>
    <link:label id="lab_incy_VillarisMember_documentation_en-US" xlink:label="lab_incy_VillarisMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Villaris</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_incy_VillarisMember" xlink:href="incy-20220930.xsd#incy_VillarisMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_incy_VillarisMember" xlink:to="lab_incy_VillarisMember" xlink:type="arc" order="1"/>
    <link:label id="lab_incy_OlumiantRoyaltyMember_ddd6b9f4-60b1-4e6d-9c1f-e55665dacddf_terseLabel_en-US" xlink:label="lab_incy_OlumiantRoyaltyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OLUMIANT Royalty Revenues</link:label>
    <link:label id="lab_incy_OlumiantRoyaltyMember_label_en-US" xlink:label="lab_incy_OlumiantRoyaltyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OLUMIANT Royalty Revenues</link:label>
    <link:label id="lab_incy_OlumiantRoyaltyMember_documentation_en-US" xlink:label="lab_incy_OlumiantRoyaltyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to OLUMIANT royalty revenues, a treatment of adults with moderately-to-severely active rheumatoid arthritis.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_incy_OlumiantRoyaltyMember" xlink:href="incy-20220930.xsd#incy_OlumiantRoyaltyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_incy_OlumiantRoyaltyMember" xlink:to="lab_incy_OlumiantRoyaltyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockCompensationPlanMember_612a0be2-7a15-4e9b-8087-b090e42c263a_terseLabel_en-US" xlink:label="lab_us-gaap_StockCompensationPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement</link:label>
    <link:label id="lab_us-gaap_StockCompensationPlanMember_label_en-US" xlink:label="lab_us-gaap_StockCompensationPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockCompensationPlanMember" xlink:to="lab_us-gaap_StockCompensationPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_f1c43dd2-2bb4-416d-b65b-1ea8873674c5_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_48a6c64c-c867-422b-826d-6aedfd15b55c_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_34e22c9d-3b82-4af1-b55a-24ea93ea9cad_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes paid</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Paid, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaidNet" xlink:to="lab_us-gaap_IncomeTaxesPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_b20dd574-c9ee-4bdb-9113-75ff946e5dbd_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_b7336ee9-4604-42b6-9b89-bc9a405fb67f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Basis [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Basis [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis" xlink:to="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndInvestmentsNoncurrent_b91100d8-c03b-4b4a-936c-e6dcc9b9f4d3_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndInvestmentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash and investments</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndInvestmentsNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndInvestmentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Investments, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndInvestmentsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndInvestmentsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndInvestmentsNoncurrent" xlink:to="lab_us-gaap_RestrictedCashAndInvestmentsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_d0cbf28b-1592-4166-b4ac-fc14bb1b5a4c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_d27acca7-5ee5-497b-bbbe-b13a45656a84_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of net periodic benefit cost</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Net Benefit Costs [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNetBenefitCostsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_a91d0df9-ca11-4a08-8ed9-91157709da91_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_incy_LicenseAgreementPercentageOfFutureGlobalDevelopmentCostsFunded_dbd378ba-ba8a-4d02-8fbd-4908f0936f8f_terseLabel_en-US" xlink:label="lab_incy_LicenseAgreementPercentageOfFutureGlobalDevelopmentCostsFunded" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funding of future development costs (as a percent)</link:label>
    <link:label id="lab_incy_LicenseAgreementPercentageOfFutureGlobalDevelopmentCostsFunded_label_en-US" xlink:label="lab_incy_LicenseAgreementPercentageOfFutureGlobalDevelopmentCostsFunded" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement Percentage of Future Global Development Costs Funded</link:label>
    <link:label id="lab_incy_LicenseAgreementPercentageOfFutureGlobalDevelopmentCostsFunded_documentation_en-US" xlink:label="lab_incy_LicenseAgreementPercentageOfFutureGlobalDevelopmentCostsFunded" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the percentage of future global development costs funded under the license agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_incy_LicenseAgreementPercentageOfFutureGlobalDevelopmentCostsFunded" xlink:href="incy-20220930.xsd#incy_LicenseAgreementPercentageOfFutureGlobalDevelopmentCostsFunded"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_incy_LicenseAgreementPercentageOfFutureGlobalDevelopmentCostsFunded" xlink:to="lab_incy_LicenseAgreementPercentageOfFutureGlobalDevelopmentCostsFunded" xlink:type="arc" order="1"/>
    <link:label id="lab_incy_PercentageOfRoyaltyRatePayments_586dfd9d-5ce3-46b3-ae62-bd61fdf7258d_terseLabel_en-US" xlink:label="lab_incy_PercentageOfRoyaltyRatePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty payments on future global net sales (as a percent)</link:label>
    <link:label id="lab_incy_PercentageOfRoyaltyRatePayments_label_en-US" xlink:label="lab_incy_PercentageOfRoyaltyRatePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Royalty Rate Payments</link:label>
    <link:label id="lab_incy_PercentageOfRoyaltyRatePayments_documentation_en-US" xlink:label="lab_incy_PercentageOfRoyaltyRatePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents range of tiered, double-digit royalty payments on future global sales if product is successfully commercialized.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_incy_PercentageOfRoyaltyRatePayments" xlink:href="incy-20220930.xsd#incy_PercentageOfRoyaltyRatePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_incy_PercentageOfRoyaltyRatePayments" xlink:to="lab_incy_PercentageOfRoyaltyRatePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_27e696a8-f4fa-4fae-982f-bac78de4540e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of fair value of assets measured on recurring basis</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax_08746923-44dd-4e2c-b9ac-4a6bb15d698a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain (Loss), before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_7e84f085-5dc5-47b7-a943-eb44565610f4_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_d1bd98b7-01fd-463f-bec3-5827f7e4120d_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation cost for nonvested option (in dollars)</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6fce2036-9650-49fe-825f-696daefe6ffa_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option Activity Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_a652c984-6d71-49ed-b004-c391ba303352_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_f9aec156-dde9-4921-901e-725f519a7551_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_614c71a6-2ca6-4484-9f7d-1593fe376130_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_2481509f-5a2c-4f7a-88e2-b045a29f7d29_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeFinanceLeaseExistenceOfOptionToExtend_8c4c092e-1622-4b1b-a623-d1d985846da4_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeaseExistenceOfOptionToExtend" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options to extend</link:label>
    <link:label id="lab_us-gaap_LesseeFinanceLeaseExistenceOfOptionToExtend_label_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeaseExistenceOfOptionToExtend" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Finance Lease, Existence of Option to Extend [true false]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeaseExistenceOfOptionToExtend" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeFinanceLeaseExistenceOfOptionToExtend"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeFinanceLeaseExistenceOfOptionToExtend" xlink:to="lab_us-gaap_LesseeFinanceLeaseExistenceOfOptionToExtend" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_a80a5546-3f6e-42e6-adec-7fc071c89f04_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total costs and expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_08a88a62-8319-45fb-8997-a72dd4e9f514_terseLabel_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_70ea53c0-fca9-4ce3-8e0b-49a56b75aac9_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_48f32d92-5e26-4f1c-a05c-c4cb31bced1d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_efb58595-c3bd-4bea-af82-52b69c1d2e01_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of shares of Common Stock upon exercise of stock options and settlement of employee restricted stock units and performance shares</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireRealEstate_af4b8d8a-fc9c-4836-9e8d-fbe39a6ba4f7_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireRealEstate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase price</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireRealEstate_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireRealEstate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Real Estate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireRealEstate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireRealEstate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireRealEstate" xlink:to="lab_us-gaap_PaymentsToAcquireRealEstate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_3aacbf70-9221-4cbc-8fd8-b61c8d29d9a0_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expenses</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeFinanceLeaseTermOfContract1_a18d98d8-4db7-41f5-b6c9-9e2858506274_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeaseTermOfContract1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial lease term</link:label>
    <link:label id="lab_us-gaap_LesseeFinanceLeaseTermOfContract1_label_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeaseTermOfContract1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Finance Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeaseTermOfContract1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeFinanceLeaseTermOfContract1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeFinanceLeaseTermOfContract1" xlink:to="lab_us-gaap_LesseeFinanceLeaseTermOfContract1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b7892b9a-ab72-446d-9d32-7427df788a69_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_ac98ffea-569b-4824-99a3-ee64989fa99e_terseLabel_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimate of Fair Value Measurement</link:label>
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimate of Fair Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:to="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_e3d879e7-0845-411a-b012-db4989de009b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation loss</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_0c6b261f-4694-410b-9caf-ee7b581070b7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_fe21fd0e-cb4b-4833-bd50-7623c16a3fa9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_6dc08d53-f383-4db2-a5b3-0aaacd873b85_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares used in computing net income per share:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_24bcb731-b3f0-4cc3-9d3a-4434c3382776_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross proceeds from sale of stock</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_f98ed613-0735-431e-b4b6-74305db6b09e_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNet_cf32561e-d4bf-47ff-8229-971d31a9a510_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories - current</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_incy_AccruedAndOtherCurrentLiabilityMember_0fa3ba51-698f-4f02-aafc-969e02b44856_terseLabel_en-US" xlink:label="lab_incy_AccruedAndOtherCurrentLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued and other current liabilities</link:label>
    <link:label id="lab_incy_AccruedAndOtherCurrentLiabilityMember_label_en-US" xlink:label="lab_incy_AccruedAndOtherCurrentLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued and other current liabilities</link:label>
    <link:label id="lab_incy_AccruedAndOtherCurrentLiabilityMember_documentation_en-US" xlink:label="lab_incy_AccruedAndOtherCurrentLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Primary financial statement caption encompassing accrued and other current liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_incy_AccruedAndOtherCurrentLiabilityMember" xlink:href="incy-20220930.xsd#incy_AccruedAndOtherCurrentLiabilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_incy_AccruedAndOtherCurrentLiabilityMember" xlink:to="lab_incy_AccruedAndOtherCurrentLiabilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_fb6414d0-f481-41e4-b814-dec007c79f15_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_incy_TABRECTAPRODUCTANDSERVICESMember_7b6d5de1-927d-48df-a819-08f1d55ad877_terseLabel_en-US" xlink:label="lab_incy_TABRECTAPRODUCTANDSERVICESMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TABRECTA PROD SERV</link:label>
    <link:label id="lab_incy_TABRECTAPRODUCTANDSERVICESMember_label_en-US" xlink:label="lab_incy_TABRECTAPRODUCTANDSERVICESMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TABRECTA PRODUCT AND SERVICES [Member]</link:label>
    <link:label id="lab_incy_TABRECTAPRODUCTANDSERVICESMember_documentation_en-US" xlink:label="lab_incy_TABRECTAPRODUCTANDSERVICESMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TABRECTA PRODUCT AND SERVICES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_incy_TABRECTAPRODUCTANDSERVICESMember" xlink:href="incy-20220930.xsd#incy_TABRECTAPRODUCTANDSERVICESMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_incy_TABRECTAPRODUCTANDSERVICESMember" xlink:to="lab_incy_TABRECTAPRODUCTANDSERVICESMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesRevenueProductLineMember_4a7855f9-a033-46ee-ae9c-e6e1dcfda64d_terseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueProductLineMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Product and Service Benchmark</link:label>
    <link:label id="lab_us-gaap_SalesRevenueProductLineMember_label_en-US" xlink:label="lab_us-gaap_SalesRevenueProductLineMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Product and Service Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueProductLineMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueProductLineMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueProductLineMember" xlink:to="lab_us-gaap_SalesRevenueProductLineMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_581a34df-b724-4cd3-8290-99fbec55fa64_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_913ee8c9-c586-4e08-801b-76f7575ff021_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0109e46b-d9e6-4ef0-9c1a-196d84a06e80_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average common shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_d5547014-2894-4635-82e0-17747993e5d4_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrentAbstract_d02d31ba-67ad-4285-b68e-a78f970d2253_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued and Other Current Liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_b86d6103-1bc5-4ba6-ac05-dec05b39ed9f_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership percentage (as a percent)</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Ownership Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_40f19a7a-4925-4b42-ae55-44ddeeceec79_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_cbf49170-3226-4e26-bee5-01fb031a6b34_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies (Note 14)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_9e82e195-4628-4028-9d58-fd2c7fa9a02f_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_9ccc940c-aff2-4b5c-82b5-b13d768b1c21_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise prices of options outstanding (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNet_f35d7726-54dc-45f3-b445-235d5ae3248d_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNet_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNet" xlink:to="lab_us-gaap_AccountsReceivableNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_9a66a223-8306-4b0a-961b-5ffb56618db6_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, $0.001 par value; 5,000,000 shares authorized; none issued or outstanding</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_incy_AmendedStockPurchaseAgreementMember_e879aebd-59ee-4ddc-8d05-0905f98cc736_terseLabel_en-US" xlink:label="lab_incy_AmendedStockPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended stock purchase agreement</link:label>
    <link:label id="lab_incy_AmendedStockPurchaseAgreementMember_label_en-US" xlink:label="lab_incy_AmendedStockPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended stock purchase agreement</link:label>
    <link:label id="lab_incy_AmendedStockPurchaseAgreementMember_documentation_en-US" xlink:label="lab_incy_AmendedStockPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents amended stock purchase agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_incy_AmendedStockPurchaseAgreementMember" xlink:href="incy-20220930.xsd#incy_AmendedStockPurchaseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_incy_AmendedStockPurchaseAgreementMember" xlink:to="lab_incy_AmendedStockPurchaseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_incy_AchievementOfMilestoneAxis_4b072840-6e8a-4e93-b7b5-67a6f4437346_terseLabel_en-US" xlink:label="lab_incy_AchievementOfMilestoneAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement of Milestone [Axis]</link:label>
    <link:label id="lab_incy_AchievementOfMilestoneAxis_label_en-US" xlink:label="lab_incy_AchievementOfMilestoneAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement of Milestone [Axis]</link:label>
    <link:label id="lab_incy_AchievementOfMilestoneAxis_documentation_en-US" xlink:label="lab_incy_AchievementOfMilestoneAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information by different categories of achievement of milestones.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_incy_AchievementOfMilestoneAxis" xlink:href="incy-20220930.xsd#incy_AchievementOfMilestoneAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_incy_AchievementOfMilestoneAxis" xlink:to="lab_incy_AchievementOfMilestoneAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_d08fc7b3-3202-402c-9be5-5f91da968114_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of shares of Common Stock for services rendered</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Issued for Services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_d1f0c0a8-abb8-42ac-95cb-d53ee62e84c4_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1d582025-7c0e-4389-bb03-7407c28a230e_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e099f6ab-2f05-4add-8ce2-2598fb1a0a13_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_incy_CollaborationPartnersaBCAndDMember_f61e6148-7cc3-4f41-84cf-c2637eb1085b_terseLabel_en-US" xlink:label="lab_incy_CollaborationPartnersaBCAndDMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Partner A, B, C and D</link:label>
    <link:label id="lab_incy_CollaborationPartnersaBCAndDMember_label_en-US" xlink:label="lab_incy_CollaborationPartnersaBCAndDMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Partner A, B, C and D</link:label>
    <link:label id="lab_incy_CollaborationPartnersaBCAndDMember_documentation_en-US" xlink:label="lab_incy_CollaborationPartnersaBCAndDMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to both the Collaboration partners A, B, C and D.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_incy_CollaborationPartnersaBCAndDMember" xlink:href="incy-20220930.xsd#incy_CollaborationPartnersaBCAndDMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_incy_CollaborationPartnersaBCAndDMember" xlink:to="lab_incy_CollaborationPartnersaBCAndDMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanServiceCost_2ec27e64-c4b5-4ad2-b068-119d25c1c94d_verboseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanServiceCost" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employer service cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanServiceCost_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanServiceCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Service Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanServiceCost" xlink:to="lab_us-gaap_DefinedBenefitPlanServiceCost" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_8c54538d-98ca-4176-8d89-4e84ec29f0d1_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_incy_TafasitamabProductAndServiceMember_647effbe-8f2e-4cfd-93bb-4b9c5d274176_terseLabel_en-US" xlink:label="lab_incy_TafasitamabProductAndServiceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tafasitamab Product and Service</link:label>
    <link:label id="lab_incy_TafasitamabProductAndServiceMember_label_en-US" xlink:label="lab_incy_TafasitamabProductAndServiceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tafasitamab Product and Service [Member]</link:label>
    <link:label id="lab_incy_TafasitamabProductAndServiceMember_documentation_en-US" xlink:label="lab_incy_TafasitamabProductAndServiceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tafasitamab Product and Service</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_incy_TafasitamabProductAndServiceMember" xlink:href="incy-20220930.xsd#incy_TafasitamabProductAndServiceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_incy_TafasitamabProductAndServiceMember" xlink:to="lab_incy_TafasitamabProductAndServiceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_696942d9-128b-4107-86a9-e24bfc7d649e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireLongtermInvestments_c86ddb2d-5141-45ca-b83c-9a7d3ef499e3_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireLongtermInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of long term investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireLongtermInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireLongtermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Long-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireLongtermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireLongtermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireLongtermInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireLongtermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_18466269-ca26-4bf1-bad5-b5e5a3b79542_verboseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_297a7119-f328-4e13-9afb-86a02593deae_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for doubtful accounts</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_incy_TafasitamabMember_8d2272f4-9a0d-4d87-bce2-f6cca6fca4ae_terseLabel_en-US" xlink:label="lab_incy_TafasitamabMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">tafasitamab</link:label>
    <link:label id="lab_incy_TafasitamabMember_label_en-US" xlink:label="lab_incy_TafasitamabMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">tafasitamab</link:label>
    <link:label id="lab_incy_TafasitamabMember_documentation_en-US" xlink:label="lab_incy_TafasitamabMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to tafasitamab.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_incy_TafasitamabMember" xlink:href="incy-20220930.xsd#incy_TafasitamabMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_incy_TafasitamabMember" xlink:to="lab_incy_TafasitamabMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_a800e779-75e8-45b9-9ca2-a5ee7abdf8ec_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Work-in-process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_fa251fec-fe9c-4639-acd3-432589ff027b_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Deferred Income Taxes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:to="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_22716ac5-5d1b-4e9f-a253-25d85e766232_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_incy_CustomerEMember_aca0b921-7c89-40aa-9c63-601f6c549687_terseLabel_en-US" xlink:label="lab_incy_CustomerEMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer E</link:label>
    <link:label id="lab_incy_CustomerEMember_label_en-US" xlink:label="lab_incy_CustomerEMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer E</link:label>
    <link:label id="lab_incy_CustomerEMember_documentation_en-US" xlink:label="lab_incy_CustomerEMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to the customer E.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_incy_CustomerEMember" xlink:href="incy-20220930.xsd#incy_CustomerEMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_incy_CustomerEMember" xlink:to="lab_incy_CustomerEMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_3cebaa19-65c1-4d06-a294-32381e888916_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average risk-free interest rates (as a percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_incy_PercentageFundingOnCostOnPossibleElectionOfCodevelopmentOfCompounds_8b07a0b9-d8ba-415d-b27e-2ab96faafd66_verboseLabel_en-US" xlink:label="lab_incy_PercentageFundingOnCostOnPossibleElectionOfCodevelopmentOfCompounds" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Associated future global development costs , if elected to co-develop (as a percent)</link:label>
    <link:label id="lab_incy_PercentageFundingOnCostOnPossibleElectionOfCodevelopmentOfCompounds_label_en-US" xlink:label="lab_incy_PercentageFundingOnCostOnPossibleElectionOfCodevelopmentOfCompounds" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Funding on Cost on Possible Election of Co-development of Compounds</link:label>
    <link:label id="lab_incy_PercentageFundingOnCostOnPossibleElectionOfCodevelopmentOfCompounds_documentation_en-US" xlink:label="lab_incy_PercentageFundingOnCostOnPossibleElectionOfCodevelopmentOfCompounds" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the percentage of associated future global development costs from the initiation of a Phase IIb trial provided the entity elects to co-develop any compounds and/or indications.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_incy_PercentageFundingOnCostOnPossibleElectionOfCodevelopmentOfCompounds" xlink:href="incy-20220930.xsd#incy_PercentageFundingOnCostOnPossibleElectionOfCodevelopmentOfCompounds"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_incy_PercentageFundingOnCostOnPossibleElectionOfCodevelopmentOfCompounds" xlink:to="lab_incy_PercentageFundingOnCostOnPossibleElectionOfCodevelopmentOfCompounds" xlink:type="arc" order="1"/>
    <link:label id="lab_incy_LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone_6b76d93c-adb3-448d-beaf-f3abc674fe22_terseLabel_en-US" xlink:label="lab_incy_LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount recognized and received for the achievement of a predefined milestone</link:label>
    <link:label id="lab_incy_LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone_label_en-US" xlink:label="lab_incy_LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Amount Recognized and Received for Achievement of a Predefined Milestone</link:label>
    <link:label id="lab_incy_LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone_documentation_en-US" xlink:label="lab_incy_LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the earning recognized and the payment received for the achievement of a predefined milestone under the license agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_incy_LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone" xlink:href="incy-20220930.xsd#incy_LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_incy_LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone" xlink:to="lab_incy_LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_8b94e033-26c7-43b6-a730-45e68bb90697_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax withholdings related to restricted and performance share vesting</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment, Tax Withholding, Share-Based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_1a1e08fb-a260-405b-a798-ccff25a9fbf4_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInRoyaltiesPayable_b3b31969-5cd6-499e-8e78-83eeccbe7087_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInRoyaltiesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalties payable on net sales</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInRoyaltiesPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInRoyaltiesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Royalties Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInRoyaltiesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInRoyaltiesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInRoyaltiesPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInRoyaltiesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_8c1a7391-1e24-484f-b977-2bf4a7af5415_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual maturity dates</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTerm" xlink:to="lab_us-gaap_DebtInstrumentTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_1f650a38-7ac2-4143-9f9a-c79fb48c2a7b_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LandMember_194c560f-0fa0-444d-8179-eb247f376132_terseLabel_en-US" xlink:label="lab_us-gaap_LandMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land</link:label>
    <link:label id="lab_us-gaap_LandMember_label_en-US" xlink:label="lab_us-gaap_LandMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LandMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LandMember" xlink:to="lab_us-gaap_LandMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_1c12a077-d321-41d4-99fd-54f98035d4eb_verboseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dilutive stock options and awards ( in shares)</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDilutedAbstract_1896cc30-0358-4d00-8728-379dbdaea80a_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted Net Income (Loss) Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDilutedAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDilutedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract" xlink:to="lab_us-gaap_EarningsPerShareDilutedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonUsMember_8f97fc2d-a41b-41b7-83ea-a8f12cf0b427_terseLabel_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-US</link:label>
    <link:label id="lab_us-gaap_NonUsMember_label_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-US [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonUsMember" xlink:to="lab_us-gaap_NonUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_36b40176-ea8a-4d68-b911-3ce81d82f7bd_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_incy_AmericanDepositarySharesMember_66572d3a-b2be-4914-a502-13b9ff5a96d5_terseLabel_en-US" xlink:label="lab_incy_AmericanDepositarySharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ADSs</link:label>
    <link:label id="lab_incy_AmericanDepositarySharesMember_label_en-US" xlink:label="lab_incy_AmericanDepositarySharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ADSs</link:label>
    <link:label id="lab_incy_AmericanDepositarySharesMember_documentation_en-US" xlink:label="lab_incy_AmericanDepositarySharesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents American Depositary Shares.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_incy_AmericanDepositarySharesMember" xlink:href="incy-20220930.xsd#incy_AmericanDepositarySharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_incy_AmericanDepositarySharesMember" xlink:to="lab_incy_AmericanDepositarySharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_cf5baf2f-91a0-4cd1-adc9-0965ef6ab658_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_fb5e20bf-2689-4605-99bf-84eb9801279c_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_3486e7b6-eee6-4cbb-af1f-9683b21337d0_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted net income (loss)</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingAxis_208de2f2-fc96-459e-8043-8c857430de42_terseLabel_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:label id="lab_us-gaap_VestingAxis_label_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingAxis" xlink:to="lab_us-gaap_VestingAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_ad36e934-58c6-4d74-8c4a-cb7f762d44c3_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in USD per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_dfc21024-742c-4291-9520-6a44553df0b9_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted net income per share ( in USD per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_71504110-d071-47a3-b6b3-ce9b337b356e_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_a2ce9f51-0e60-4a19-a5d2-5c92c289d9eb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Tranche Two</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Tranche Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_6dbf4e42-2f49-46a9-90cf-16d00c254350_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effected stock split (as a percent)</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note, Stock Split, Conversion Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_8dfa4979-8120-4af5-8279-1272414d3f28_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_incy_LicenseAgreementsDisclosureAbstract_ef0c0267-fd14-4800-be2b-d272ca4f4ca7_terseLabel_en-US" xlink:label="lab_incy_LicenseAgreementsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreements</link:label>
    <link:label id="lab_incy_LicenseAgreementsDisclosureAbstract_label_en-US" xlink:label="lab_incy_LicenseAgreementsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreements</link:label>
    <link:label id="lab_incy_LicenseAgreementsDisclosureAbstract_documentation_en-US" xlink:label="lab_incy_LicenseAgreementsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_incy_LicenseAgreementsDisclosureAbstract" xlink:href="incy-20220930.xsd#incy_LicenseAgreementsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_incy_LicenseAgreementsDisclosureAbstract" xlink:to="lab_incy_LicenseAgreementsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_914e9f05-4927-4ef7-a878-c405609e04f2_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract_bb8cbb45-cffa-4613-93ea-089f3eb3aaa4_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Additional Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_06ef89bb-2560-4e39-98d5-1d9ce25b755b_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_18f6d523-4284-40b3-89fc-04f203c4b8d4_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryCurrentTable_657c0507-2f0b-4a25-91f5-0393425e3219_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryCurrentTable" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Current [Table]</link:label>
    <link:label id="lab_us-gaap_InventoryCurrentTable_label_en-US" xlink:label="lab_us-gaap_InventoryCurrentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Current [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryCurrentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryCurrentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryCurrentTable" xlink:to="lab_us-gaap_InventoryCurrentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract_46259b81-9091-4bb5-b54b-0bb7609c6685_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Anti-dilutive securities</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted, Other Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:to="lab_us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_8f3c8c64-2099-48c9-9ed5-8d6561bf72db_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_incy_EquityMethodInvestmentSharesPurchased_8d906c2e-5ec5-4267-813e-2bf69db20ea4_terseLabel_en-US" xlink:label="lab_incy_EquityMethodInvestmentSharesPurchased" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common shares purchased (in shares)</link:label>
    <link:label id="lab_incy_EquityMethodInvestmentSharesPurchased_label_en-US" xlink:label="lab_incy_EquityMethodInvestmentSharesPurchased" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Shares Purchased</link:label>
    <link:label id="lab_incy_EquityMethodInvestmentSharesPurchased_documentation_en-US" xlink:label="lab_incy_EquityMethodInvestmentSharesPurchased" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">This element represents the aggregate shares purchased of investments accounted for under the equity method of accounting.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_incy_EquityMethodInvestmentSharesPurchased" xlink:href="incy-20220930.xsd#incy_EquityMethodInvestmentSharesPurchased"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_incy_EquityMethodInvestmentSharesPurchased" xlink:to="lab_incy_EquityMethodInvestmentSharesPurchased" xlink:type="arc" order="1"/>
    <link:label id="lab_incy_EliLillyMember_ba32e39a-04d5-4873-a31b-e8c68daddb3c_terseLabel_en-US" xlink:label="lab_incy_EliLillyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eli Lilly</link:label>
    <link:label id="lab_incy_EliLillyMember_label_en-US" xlink:label="lab_incy_EliLillyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eli Lilly</link:label>
    <link:label id="lab_incy_EliLillyMember_documentation_en-US" xlink:label="lab_incy_EliLillyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents details pertaining to Eli Lilly with whom we have entered into a License, Development and Commercialization Agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_incy_EliLillyMember" xlink:href="incy-20220930.xsd#incy_EliLillyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_incy_EliLillyMember" xlink:to="lab_incy_EliLillyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_incy_LicenseAgreementsTextBlock_d97c7866-94b2-44af-ab48-e88a19df2419_terseLabel_en-US" xlink:label="lab_incy_LicenseAgreementsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreements</link:label>
    <link:label id="lab_incy_LicenseAgreementsTextBlock_label_en-US" xlink:label="lab_incy_LicenseAgreementsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreements [Text Block]</link:label>
    <link:label id="lab_incy_LicenseAgreementsTextBlock_documentation_en-US" xlink:label="lab_incy_LicenseAgreementsTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">This element may be used to describe all significant license agreements of the reporting entity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_incy_LicenseAgreementsTextBlock" xlink:href="incy-20220930.xsd#incy_LicenseAgreementsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_incy_LicenseAgreementsTextBlock" xlink:to="lab_incy_LicenseAgreementsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_cb392fea-95d3-47e4-8919-41c57e2d4f8e_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of shares of Common Stock for services rendered</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Issued for Services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_f67c6ed3-c224-46ef-8428-39a1bd1e2bd0_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock option grant term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_7f67062f-5062-444e-9a19-94a83946abe1_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized loss on long term investments</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_1d275188-c55d-4802-bb95-372fbcccb7c1_negatedLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized loss on long term investments</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_749dadb8-d105-4d0f-a28c-0e97f5a80f17_verboseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain (loss) on long term investments</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Unrealized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:to="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_d2afb04c-6e4d-4dfc-9b0e-da4071ed4594_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfRevenue_516ae926-8c63-47ee-bea7-a01e430798cd_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of product revenues (including definite-lived intangible amortization)</link:label>
    <link:label id="lab_us-gaap_CostOfRevenue_label_en-US" xlink:label="lab_us-gaap_CostOfRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfRevenue" xlink:to="lab_us-gaap_CostOfRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_incy_InnoventBiologicsIncMember_54be347e-bd3d-4d29-ae08-69ffabda6ebd_terseLabel_en-US" xlink:label="lab_incy_InnoventBiologicsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Innovent</link:label>
    <link:label id="lab_incy_InnoventBiologicsIncMember_label_en-US" xlink:label="lab_incy_InnoventBiologicsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Innovent</link:label>
    <link:label id="lab_incy_InnoventBiologicsIncMember_documentation_en-US" xlink:label="lab_incy_InnoventBiologicsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents details pertaining to Innovent Biologics, Inc with whom we have entered into a research collaboration and licensing agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_incy_InnoventBiologicsIncMember" xlink:href="incy-20220930.xsd#incy_InnoventBiologicsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_incy_InnoventBiologicsIncMember" xlink:to="lab_incy_InnoventBiologicsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_1daa554b-c724-491f-9658-8a530ab4cc02_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EuropeMember_7f601974-6228-41b1-8f32-1e1fc9a9fcc9_terseLabel_en-US" xlink:label="lab_srt_EuropeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Europe</link:label>
    <link:label id="lab_srt_EuropeMember_label_en-US" xlink:label="lab_srt_EuropeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Europe [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EuropeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EuropeMember" xlink:to="lab_srt_EuropeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_a331d503-44f1-4efa-9a1b-7e848bf578b2_negatedLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected return on plan assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Return (Loss) on Plan Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_incy_ScheduleOfShareBasedCompensationOtherThanStockOptionsActivityTableTextBlock_616cc050-2056-4512-ab70-fb1104d8d09f_terseLabel_en-US" xlink:label="lab_incy_ScheduleOfShareBasedCompensationOtherThanStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of RSU award and PSU activity under the 2010 Stock Plan</link:label>
    <link:label id="lab_incy_ScheduleOfShareBasedCompensationOtherThanStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_incy_ScheduleOfShareBasedCompensationOtherThanStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of RSU award and PSU activity under the 2010 Stock Plan</link:label>
    <link:label id="lab_incy_ScheduleOfShareBasedCompensationOtherThanStockOptionsActivityTableTextBlock_documentation_en-US" xlink:label="lab_incy_ScheduleOfShareBasedCompensationOtherThanStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tabular disclosure represents the schedule of share based compensation other than stock options activity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_incy_ScheduleOfShareBasedCompensationOtherThanStockOptionsActivityTableTextBlock" xlink:href="incy-20220930.xsd#incy_ScheduleOfShareBasedCompensationOtherThanStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_incy_ScheduleOfShareBasedCompensationOtherThanStockOptionsActivityTableTextBlock" xlink:to="lab_incy_ScheduleOfShareBasedCompensationOtherThanStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_incy_AggregateConcentrationCustomersMember_744dfb39-9db1-4a62-88c4-e8a2b8e997f2_terseLabel_en-US" xlink:label="lab_incy_AggregateConcentrationCustomersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer A, B, C, D and E</link:label>
    <link:label id="lab_incy_AggregateConcentrationCustomersMember_label_en-US" xlink:label="lab_incy_AggregateConcentrationCustomersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer A, B, C D, and E</link:label>
    <link:label id="lab_incy_AggregateConcentrationCustomersMember_documentation_en-US" xlink:label="lab_incy_AggregateConcentrationCustomersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to the aggregate list of concentration customers.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_incy_AggregateConcentrationCustomersMember" xlink:href="incy-20220930.xsd#incy_AggregateConcentrationCustomersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_incy_AggregateConcentrationCustomersMember" xlink:to="lab_incy_AggregateConcentrationCustomersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_2f1be28e-7dcf-4e7f-a830-01f140640ffd_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_4c5cdb84-8a6f-4f67-9642-29606a1b91b9_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_0e83cda0-629e-44b4-89c9-2e6d704e8298_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized loss on marketable securities, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNoncurrent_c22bc764-caa3-4877-b623-12b211f3961b_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNoncurrent_c41fb8a6-e68f-4f6d-af0f-4119648ff9f0_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories-noncurrent</link:label>
    <link:label id="lab_us-gaap_InventoryNoncurrent_label_en-US" xlink:label="lab_us-gaap_InventoryNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNoncurrent" xlink:to="lab_us-gaap_InventoryNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_31f30ac3-0aa2-452f-bdd0-b493428ec997_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of accrued and other current liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_24520a9d-0ae6-4b29-83e6-2ad6d5188d00_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTable_88e97d65-4a5c-40a1-8cf1-398d6842bbc4_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue_65469aa4-6e62-45c5-bd62-ffcf01864b47_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Intrinsic Value, Amount Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedAnnualizedForfeitureRate_e72868f9-186c-40d1-8c8c-372a903c6636_terseLabel_en-US" xlink:label="lab_incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedAnnualizedForfeitureRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assumed annualized forfeiture rate (as a percent)</link:label>
    <link:label id="lab_incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedAnnualizedForfeitureRate_label_en-US" xlink:label="lab_incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedAnnualizedForfeitureRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions Expected Annualized Forfeiture Rate</link:label>
    <link:label id="lab_incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedAnnualizedForfeitureRate_documentation_en-US" xlink:label="lab_incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedAnnualizedForfeitureRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the expected annualized forfeiture rate for options granted.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedAnnualizedForfeitureRate" xlink:href="incy-20220930.xsd#incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedAnnualizedForfeitureRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedAnnualizedForfeitureRate" xlink:to="lab_incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedAnnualizedForfeitureRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_15282847-9d2e-4327-9b3f-dd4098f5ffde_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_06b7fd51-d8ea-4311-bec2-ff5b1cf4949f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available Shares for Grant</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Additional General Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_79a71955-8414-4f1c-ace7-74c941bd7616_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_82452c85-303b-4453-91e6-f9edf91e5b1f_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSU and PSU Grant Price</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_844dafc3-fe02-40d3-a71d-45dc6939353b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of shares available for grant</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Nonvested Share Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_7faf373c-13e6-47bd-ac18-1366ac64f1fc_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at the beginning of the period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_231a89b9-6884-4aa5-a740-4e9de4754b0a_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at the end of the period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_incy_CustomerBMember_8f7925d8-6541-408d-a26e-7f41505b4787_terseLabel_en-US" xlink:label="lab_incy_CustomerBMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer B</link:label>
    <link:label id="lab_incy_CustomerBMember_label_en-US" xlink:label="lab_incy_CustomerBMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer B [Member]</link:label>
    <link:label id="lab_incy_CustomerBMember_documentation_en-US" xlink:label="lab_incy_CustomerBMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to the customer B.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_incy_CustomerBMember" xlink:href="incy-20220930.xsd#incy_CustomerBMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_incy_CustomerBMember" xlink:to="lab_incy_CustomerBMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_0e6100cb-bd42-4a82-b5d5-de78456a4676_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of disaggregated revenue</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_incy_RegulatoryMilestonesMember_6a8e950b-42b0-49fd-87df-c13dbc9de84d_terseLabel_en-US" xlink:label="lab_incy_RegulatoryMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regulatory Milestones</link:label>
    <link:label id="lab_incy_RegulatoryMilestonesMember_label_en-US" xlink:label="lab_incy_RegulatoryMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regulatory Milestones</link:label>
    <link:label id="lab_incy_RegulatoryMilestonesMember_documentation_en-US" xlink:label="lab_incy_RegulatoryMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to certain regulatory events on the basis of which certain milestones are achieved.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_incy_RegulatoryMilestonesMember" xlink:href="incy-20220930.xsd#incy_RegulatoryMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_incy_RegulatoryMilestonesMember" xlink:to="lab_incy_RegulatoryMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_incy_DevelopmentMilestonesMember_d2f13121-4d43-4efe-9206-ee0260f279ac_terseLabel_en-US" xlink:label="lab_incy_DevelopmentMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development Milestones</link:label>
    <link:label id="lab_incy_DevelopmentMilestonesMember_label_en-US" xlink:label="lab_incy_DevelopmentMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development Milestones</link:label>
    <link:label id="lab_incy_DevelopmentMilestonesMember_documentation_en-US" xlink:label="lab_incy_DevelopmentMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to certain development events on the basis of which certain milestones are achieved.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_incy_DevelopmentMilestonesMember" xlink:href="incy-20220930.xsd#incy_DevelopmentMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_incy_DevelopmentMilestonesMember" xlink:to="lab_incy_DevelopmentMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_860486bf-30d3-409a-be09-b321ae517856_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_incy_NumberOfProgramsUnderWhichResultingProductsAreCoFundedForDevelopment_3ab825c3-3114-45d4-afdf-5d9656fa7769_terseLabel_en-US" xlink:label="lab_incy_NumberOfProgramsUnderWhichResultingProductsAreCoFundedForDevelopment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of programs under the resulting products are co-funded for development</link:label>
    <link:label id="lab_incy_NumberOfProgramsUnderWhichResultingProductsAreCoFundedForDevelopment_label_en-US" xlink:label="lab_incy_NumberOfProgramsUnderWhichResultingProductsAreCoFundedForDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Programs Under Which The Resulting Products Are Co-Funded For Development</link:label>
    <link:label id="lab_incy_NumberOfProgramsUnderWhichResultingProductsAreCoFundedForDevelopment_documentation_en-US" xlink:label="lab_incy_NumberOfProgramsUnderWhichResultingProductsAreCoFundedForDevelopment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the number of programs in which the resulting products are co-funded for development.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_incy_NumberOfProgramsUnderWhichResultingProductsAreCoFundedForDevelopment" xlink:href="incy-20220930.xsd#incy_NumberOfProgramsUnderWhichResultingProductsAreCoFundedForDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_incy_NumberOfProgramsUnderWhichResultingProductsAreCoFundedForDevelopment" xlink:to="lab_incy_NumberOfProgramsUnderWhichResultingProductsAreCoFundedForDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_0278d8ae-8325-4d22-a5c7-2708a4a3e6cf_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share price of shares available (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instrument Other than Option, Nonvested, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_c36f950f-d291-49f2-9562-3cd1b16c135d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Roll forward of Level 3 liabilities</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_incy_MINJUVIMember_177eca6d-69d2-4ffa-a65c-fd535ee0d0ef_terseLabel_en-US" xlink:label="lab_incy_MINJUVIMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MINJUVI</link:label>
    <link:label id="lab_incy_MINJUVIMember_label_en-US" xlink:label="lab_incy_MINJUVIMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MINJUVI</link:label>
    <link:label id="lab_incy_MINJUVIMember_documentation_en-US" xlink:label="lab_incy_MINJUVIMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to MONJUVI/MINJUVI (tafasitamab-cxix).</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_incy_MINJUVIMember" xlink:href="incy-20220930.xsd#incy_MINJUVIMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_incy_MINJUVIMember" xlink:to="lab_incy_MINJUVIMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_90a0efdc-292d-4831-bd80-7fe84a4f6e56_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase in cash, cash equivalents, restricted cash and investments</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_incy_MilestoneRevenueMember_e61f25d7-a454-4d27-9489-fe8f12b6a264_terseLabel_en-US" xlink:label="lab_incy_MilestoneRevenueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone and contract revenues</link:label>
    <link:label id="lab_incy_MilestoneRevenueMember_label_en-US" xlink:label="lab_incy_MilestoneRevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone revenues</link:label>
    <link:label id="lab_incy_MilestoneRevenueMember_documentation_en-US" xlink:label="lab_incy_MilestoneRevenueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to milestone revenue.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_incy_MilestoneRevenueMember" xlink:href="incy-20220930.xsd#incy_MilestoneRevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_incy_MilestoneRevenueMember" xlink:to="lab_incy_MilestoneRevenueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesMember_60221450-f3f6-4faa-b30e-06c312e9a630_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesMember" xlink:to="lab_us-gaap_AccruedLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_92ff4597-819e-43fa-86f7-13c22fbf5e48_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation input (as a percent)</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_incy_OlumiantMember_1d6d4cc3-e706-4fd8-8210-ea9c8d306082_terseLabel_en-US" xlink:label="lab_incy_OlumiantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OLUMIANT</link:label>
    <link:label id="lab_incy_OlumiantMember_label_en-US" xlink:label="lab_incy_OlumiantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OLUMIANT</link:label>
    <link:label id="lab_incy_OlumiantMember_documentation_en-US" xlink:label="lab_incy_OlumiantMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Baricitinib for the treatment of moderate-to-severe rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to, one or more disease-modifying antirheumatic drugs (DMARDs).</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_incy_OlumiantMember" xlink:href="incy-20220930.xsd#incy_OlumiantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_incy_OlumiantMember" xlink:to="lab_incy_OlumiantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIntangibleAssetsNet_89312eed-7a74-457c-8ac6-a37ca7ba8691_terseLabel_en-US" xlink:label="lab_us-gaap_OtherIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other intangible assets, net</link:label>
    <link:label id="lab_us-gaap_OtherIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_OtherIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIntangibleAssetsNet" xlink:to="lab_us-gaap_OtherIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_4004712a-e66a-4748-9e18-08b0a8a709c0_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_961122d1-413a-4b4b-ba35-7a513e25ea02_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_incy_JakaviRoyaltyRevenuesMember_01a6bfbf-2c6a-4d0c-9b99-8e794aadec4c_terseLabel_en-US" xlink:label="lab_incy_JakaviRoyaltyRevenuesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">JAKAVI Royalty Revenues</link:label>
    <link:label id="lab_incy_JakaviRoyaltyRevenuesMember_label_en-US" xlink:label="lab_incy_JakaviRoyaltyRevenuesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">JAKAVI Royalty Revenues</link:label>
    <link:label id="lab_incy_JakaviRoyaltyRevenuesMember_documentation_en-US" xlink:label="lab_incy_JakaviRoyaltyRevenuesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to JAKAVI royalty revenues, an oral Janus associate kinase (JAK) inhibitor sold within the United State of America.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_incy_JakaviRoyaltyRevenuesMember" xlink:href="incy-20220930.xsd#incy_JakaviRoyaltyRevenuesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_incy_JakaviRoyaltyRevenuesMember" xlink:to="lab_incy_JakaviRoyaltyRevenuesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_3dca7ced-7661-4d2b-9649-aa4d5f4f7e5e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_21fd58c0-53a5-4e2e-82f9-7f429408a5e3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_incy_ProductGroupOneMember_44fc0d8d-5c57-4bb4-9135-a23ff59ed644_terseLabel_en-US" xlink:label="lab_incy_ProductGroupOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty-bearing product other than GITR, OX40 and one undisclosed target</link:label>
    <link:label id="lab_incy_ProductGroupOneMember_label_en-US" xlink:label="lab_incy_ProductGroupOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty-bearing product other than GITR, OX40 and one undisclosed target</link:label>
    <link:label id="lab_incy_ProductGroupOneMember_documentation_en-US" xlink:label="lab_incy_ProductGroupOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the royalty-bearing product other than GITR, OX40 and one undisclosed target.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_incy_ProductGroupOneMember" xlink:href="incy-20220930.xsd#incy_ProductGroupOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_incy_ProductGroupOneMember" xlink:to="lab_incy_ProductGroupOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_7ca9c319-e2f0-4825-a160-b20c466cec1e_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityDomain_526d4894-26eb-44d0-bc9e-c0c9a5cf2301_terseLabel_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_label_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_b88c8802-a1d7-4ae8-acd6-ac38b33bce81_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_3020e26d-90f2-4690-b9c7-5be8e3d56eff_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_0c502f3c-98c7-42ff-a9c2-f935d1d4e46d_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_f65a8a3c-0465-46a2-a0d8-52a1bfc24223_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_db957ba7-e02a-4616-a322-c1448767ae91_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_78917f1f-c05b-4ff2-9b50-7f560092d2ff_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure_a3840eca-2f22-467f-8cd9-b430efeefa4f_totalLabel_en-US" xlink:label="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Liabilities Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_incy_SchedulesOfConcentrationOfRiskByRiskFactorRelatedToCollaborativePartnersTableTextBlock_19db7c5e-c614-417f-8ce3-e633547b662b_terseLabel_en-US" xlink:label="lab_incy_SchedulesOfConcentrationOfRiskByRiskFactorRelatedToCollaborativePartnersTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of concentration of credit risk related to collaborative partners</link:label>
    <link:label id="lab_incy_SchedulesOfConcentrationOfRiskByRiskFactorRelatedToCollaborativePartnersTableTextBlock_label_en-US" xlink:label="lab_incy_SchedulesOfConcentrationOfRiskByRiskFactorRelatedToCollaborativePartnersTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedules of Concentration of Risk by Risk Factor Related to Collaborative Partners [Table Text Block]</link:label>
    <link:label id="lab_incy_SchedulesOfConcentrationOfRiskByRiskFactorRelatedToCollaborativePartnersTableTextBlock_documentation_en-US" xlink:label="lab_incy_SchedulesOfConcentrationOfRiskByRiskFactorRelatedToCollaborativePartnersTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark, related to the collaborative partners.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_incy_SchedulesOfConcentrationOfRiskByRiskFactorRelatedToCollaborativePartnersTableTextBlock" xlink:href="incy-20220930.xsd#incy_SchedulesOfConcentrationOfRiskByRiskFactorRelatedToCollaborativePartnersTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_incy_SchedulesOfConcentrationOfRiskByRiskFactorRelatedToCollaborativePartnersTableTextBlock" xlink:to="lab_incy_SchedulesOfConcentrationOfRiskByRiskFactorRelatedToCollaborativePartnersTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_ce779850-1394-43e7-a1ee-365420fb0cf7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_a4723909-cae5-4b8f-8d22-160a4df7932f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average fair value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_incy_CollaborationLossSharingExpense_0c142a53-e297-4eaa-b7a7-3080adb7d802_terseLabel_en-US" xlink:label="lab_incy_CollaborationLossSharingExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration loss sharing</link:label>
    <link:label id="lab_incy_CollaborationLossSharingExpense_label_en-US" xlink:label="lab_incy_CollaborationLossSharingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Loss Sharing Expense</link:label>
    <link:label id="lab_incy_CollaborationLossSharingExpense_documentation_en-US" xlink:label="lab_incy_CollaborationLossSharingExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The expense recognized during the reporting period for collaboration loss sharing.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_incy_CollaborationLossSharingExpense" xlink:href="incy-20220930.xsd#incy_CollaborationLossSharingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_incy_CollaborationLossSharingExpense" xlink:to="lab_incy_CollaborationLossSharingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_9e91f49d-3fd5-4658-ac8c-73a1d54f7f93_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_82011240-ef5c-4f92-830a-b5bad59c2a20_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_incy_MerusNVMember_d1ec4b34-6596-432f-aae4-0bdb4ee0f94a_terseLabel_en-US" xlink:label="lab_incy_MerusNVMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Merus</link:label>
    <link:label id="lab_incy_MerusNVMember_label_en-US" xlink:label="lab_incy_MerusNVMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Merus</link:label>
    <link:label id="lab_incy_MerusNVMember_documentation_en-US" xlink:label="lab_incy_MerusNVMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to Merus N. V.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_incy_MerusNVMember" xlink:href="incy-20220930.xsd#incy_MerusNVMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_incy_MerusNVMember" xlink:to="lab_incy_MerusNVMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_2f57fc4f-b0b3-4750-8a55-3bbc0be68f49_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_b51db8f3-0f50-4aba-9784-16c5442f66ba_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of calculation of net income (loss) per share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentAggregateCost_38f4eecd-be2c-4abb-82bd-ad3c35a5a7a3_verboseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentAggregateCost" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase price of common stock</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentAggregateCost_13acf28e-71b4-4371-86d5-d3ecaa4c92c3_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentAggregateCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Aggregate Cost</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentAggregateCost_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentAggregateCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Aggregate Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentAggregateCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentAggregateCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentAggregateCost" xlink:to="lab_us-gaap_EquityMethodInvestmentAggregateCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConversionOfStockNameDomain_10a1b95e-c794-4be4-b8a5-922341f233f1_terseLabel_en-US" xlink:label="lab_us-gaap_ConversionOfStockNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of Stock, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_ConversionOfStockNameDomain_label_en-US" xlink:label="lab_us-gaap_ConversionOfStockNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of Stock, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockNameDomain" xlink:to="lab_us-gaap_ConversionOfStockNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_incy_CustomerAMember_34a069ed-c2a8-4cc6-b753-052955502f9c_terseLabel_en-US" xlink:label="lab_incy_CustomerAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer A</link:label>
    <link:label id="lab_incy_CustomerAMember_label_en-US" xlink:label="lab_incy_CustomerAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer A [Member]</link:label>
    <link:label id="lab_incy_CustomerAMember_documentation_en-US" xlink:label="lab_incy_CustomerAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to the customer A.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_incy_CustomerAMember" xlink:href="incy-20220930.xsd#incy_CustomerAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_incy_CustomerAMember" xlink:to="lab_incy_CustomerAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_d70532ac-3046-4db9-a1a3-3633c451b7d5_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leased assets obtained in exchange for new operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfSalesMember_59b5235d-b754-43ee-b0b9-32d4bb3af921_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Sales</link:label>
    <link:label id="lab_us-gaap_CostOfSalesMember_label_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Sales [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesMember" xlink:to="lab_us-gaap_CostOfSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_incy_NovartisMember_ce70aa07-583a-4d94-b648-9ef33318e0fb_terseLabel_en-US" xlink:label="lab_incy_NovartisMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Novartis</link:label>
    <link:label id="lab_incy_NovartisMember_label_en-US" xlink:label="lab_incy_NovartisMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Novartis</link:label>
    <link:label id="lab_incy_NovartisMember_documentation_en-US" xlink:label="lab_incy_NovartisMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents details pertaining to Novartis with whom we have entered into a Collaboration and License Agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_incy_NovartisMember" xlink:href="incy-20220930.xsd#incy_NovartisMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_incy_NovartisMember" xlink:to="lab_incy_NovartisMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_661c7e3c-cb72-4b1f-9eaa-ce0db65f677b_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>incy-20220930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:4b736358-c29a-4c12-bfe7-729e80c7c631,g:94be2257-4ebc-4637-90cb-08232abb2695-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.incyte.com/role/DocumentandEntityInformation" xlink:type="simple" xlink:href="incy-20220930.xsd#DocumentandEntityInformation"/>
  <link:presentationLink xlink:role="http://www.incyte.com/role/DocumentandEntityInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_d0618bc5-33d4-41a9-8984-d18d916f55e1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_5485a609-1575-430f-b57b-a9a63031c8e4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d0618bc5-33d4-41a9-8984-d18d916f55e1" xlink:to="loc_dei_DocumentType_5485a609-1575-430f-b57b-a9a63031c8e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_30f42c7e-3d3f-4d6c-a512-0f48c448f0fd" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d0618bc5-33d4-41a9-8984-d18d916f55e1" xlink:to="loc_dei_DocumentQuarterlyReport_30f42c7e-3d3f-4d6c-a512-0f48c448f0fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_b1e5af2d-0f17-4ca8-b848-f5dce8aae550" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d0618bc5-33d4-41a9-8984-d18d916f55e1" xlink:to="loc_dei_DocumentPeriodEndDate_b1e5af2d-0f17-4ca8-b848-f5dce8aae550" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_223ac563-7df7-4744-9fb8-9df1f7f9df4d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d0618bc5-33d4-41a9-8984-d18d916f55e1" xlink:to="loc_dei_DocumentTransitionReport_223ac563-7df7-4744-9fb8-9df1f7f9df4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_8647d3aa-634a-4770-a359-b22d3d9b2404" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d0618bc5-33d4-41a9-8984-d18d916f55e1" xlink:to="loc_dei_EntityFileNumber_8647d3aa-634a-4770-a359-b22d3d9b2404" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_bd0f8005-d0f0-470d-a774-6aa1c23d345b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d0618bc5-33d4-41a9-8984-d18d916f55e1" xlink:to="loc_dei_EntityRegistrantName_bd0f8005-d0f0-470d-a774-6aa1c23d345b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_27d4b627-decc-4156-aab8-a61124cc72f6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d0618bc5-33d4-41a9-8984-d18d916f55e1" xlink:to="loc_dei_EntityIncorporationStateCountryCode_27d4b627-decc-4156-aab8-a61124cc72f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_bbb71d9d-9019-479d-86ab-c8899ab80632" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d0618bc5-33d4-41a9-8984-d18d916f55e1" xlink:to="loc_dei_EntityTaxIdentificationNumber_bbb71d9d-9019-479d-86ab-c8899ab80632" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_781c9316-da5c-4bbf-81c6-1b68926936f1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d0618bc5-33d4-41a9-8984-d18d916f55e1" xlink:to="loc_dei_EntityAddressAddressLine1_781c9316-da5c-4bbf-81c6-1b68926936f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_f7e2de38-1182-4b6c-83af-6373214195a3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d0618bc5-33d4-41a9-8984-d18d916f55e1" xlink:to="loc_dei_EntityAddressCityOrTown_f7e2de38-1182-4b6c-83af-6373214195a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_4f3f67a5-3e44-4547-b44d-2dc154519cd6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d0618bc5-33d4-41a9-8984-d18d916f55e1" xlink:to="loc_dei_EntityAddressStateOrProvince_4f3f67a5-3e44-4547-b44d-2dc154519cd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_7d33a619-845a-4428-80c8-8e8f7adb1263" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d0618bc5-33d4-41a9-8984-d18d916f55e1" xlink:to="loc_dei_EntityAddressPostalZipCode_7d33a619-845a-4428-80c8-8e8f7adb1263" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_5f62452e-983b-4b15-8b2a-3a62380ef4e0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d0618bc5-33d4-41a9-8984-d18d916f55e1" xlink:to="loc_dei_CityAreaCode_5f62452e-983b-4b15-8b2a-3a62380ef4e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_63c64478-c870-4dca-a009-e642eb9c8a1d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d0618bc5-33d4-41a9-8984-d18d916f55e1" xlink:to="loc_dei_LocalPhoneNumber_63c64478-c870-4dca-a009-e642eb9c8a1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_76857b70-2213-47e0-af2a-d5848043527c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d0618bc5-33d4-41a9-8984-d18d916f55e1" xlink:to="loc_dei_Security12bTitle_76857b70-2213-47e0-af2a-d5848043527c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_eed6ecad-9c11-4809-90de-1c4005df00e6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d0618bc5-33d4-41a9-8984-d18d916f55e1" xlink:to="loc_dei_TradingSymbol_eed6ecad-9c11-4809-90de-1c4005df00e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_0cd1b0cb-4197-4820-98b9-90e869635a13" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d0618bc5-33d4-41a9-8984-d18d916f55e1" xlink:to="loc_dei_SecurityExchangeName_0cd1b0cb-4197-4820-98b9-90e869635a13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_6567861a-6796-42c0-8aa1-900e43836e91" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d0618bc5-33d4-41a9-8984-d18d916f55e1" xlink:to="loc_dei_EntityCurrentReportingStatus_6567861a-6796-42c0-8aa1-900e43836e91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_c77df3bd-e64e-4d81-9ad3-0850b52f1e4c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d0618bc5-33d4-41a9-8984-d18d916f55e1" xlink:to="loc_dei_EntityInteractiveDataCurrent_c77df3bd-e64e-4d81-9ad3-0850b52f1e4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_d4aa3f59-2a05-492c-96c2-f8f77855e068" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d0618bc5-33d4-41a9-8984-d18d916f55e1" xlink:to="loc_dei_EntityFilerCategory_d4aa3f59-2a05-492c-96c2-f8f77855e068" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_21e3958e-8ace-48d9-8bb0-19f3050f1d5a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d0618bc5-33d4-41a9-8984-d18d916f55e1" xlink:to="loc_dei_EntitySmallBusiness_21e3958e-8ace-48d9-8bb0-19f3050f1d5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_582081ab-9d3f-4f4c-b97e-f0234fbd639b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d0618bc5-33d4-41a9-8984-d18d916f55e1" xlink:to="loc_dei_EntityEmergingGrowthCompany_582081ab-9d3f-4f4c-b97e-f0234fbd639b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_a4066819-292c-4e9a-99ec-f73bf1c0a2f2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d0618bc5-33d4-41a9-8984-d18d916f55e1" xlink:to="loc_dei_EntityShellCompany_a4066819-292c-4e9a-99ec-f73bf1c0a2f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_d92269fc-31f6-423e-8d2d-5fe7c375258c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d0618bc5-33d4-41a9-8984-d18d916f55e1" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_d92269fc-31f6-423e-8d2d-5fe7c375258c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_671bf618-ee8c-4885-98c5-e93316af2535" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d0618bc5-33d4-41a9-8984-d18d916f55e1" xlink:to="loc_dei_CurrentFiscalYearEndDate_671bf618-ee8c-4885-98c5-e93316af2535" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_07ea1bb3-076b-490b-99b5-f4e54dcce35a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d0618bc5-33d4-41a9-8984-d18d916f55e1" xlink:to="loc_dei_DocumentFiscalYearFocus_07ea1bb3-076b-490b-99b5-f4e54dcce35a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_82431f46-de04-4dc4-ac27-57f6d9b41af5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d0618bc5-33d4-41a9-8984-d18d916f55e1" xlink:to="loc_dei_DocumentFiscalPeriodFocus_82431f46-de04-4dc4-ac27-57f6d9b41af5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_e5bec933-7bed-45a2-a1cb-7e6521ecd553" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d0618bc5-33d4-41a9-8984-d18d916f55e1" xlink:to="loc_dei_EntityCentralIndexKey_e5bec933-7bed-45a2-a1cb-7e6521ecd553" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_f5718c91-af97-466f-8376-8d5b7223a8bf" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d0618bc5-33d4-41a9-8984-d18d916f55e1" xlink:to="loc_dei_AmendmentFlag_f5718c91-af97-466f-8376-8d5b7223a8bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.incyte.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="incy-20220930.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETS"/>
  <link:presentationLink xlink:role="http://www.incyte.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_ffc4f111-4ec6-4eef-8e1d-d220c8542eb8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_c1a0130f-4135-4d94-8281-e0aaa9f0e339" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_ffc4f111-4ec6-4eef-8e1d-d220c8542eb8" xlink:to="loc_us-gaap_AssetsAbstract_c1a0130f-4135-4d94-8281-e0aaa9f0e339" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_309a92a2-32e3-431f-bc58-680f69f2e833" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_c1a0130f-4135-4d94-8281-e0aaa9f0e339" xlink:to="loc_us-gaap_AssetsCurrentAbstract_309a92a2-32e3-431f-bc58-680f69f2e833" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_9e663d75-1b84-4a58-823a-f8a4a9f19215" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_309a92a2-32e3-431f-bc58-680f69f2e833" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_9e663d75-1b84-4a58-823a-f8a4a9f19215" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_c4d08196-0b17-4814-b530-c43fa5e99f64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_309a92a2-32e3-431f-bc58-680f69f2e833" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_c4d08196-0b17-4814-b530-c43fa5e99f64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNet_31502214-aae3-4fec-8b15-8ec1dfffa831" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_309a92a2-32e3-431f-bc58-680f69f2e833" xlink:to="loc_us-gaap_AccountsReceivableNet_31502214-aae3-4fec-8b15-8ec1dfffa831" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_2b22ff50-e43c-4a88-88c7-5c210efe40ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_309a92a2-32e3-431f-bc58-680f69f2e833" xlink:to="loc_us-gaap_InventoryNet_2b22ff50-e43c-4a88-88c7-5c210efe40ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_54f9db06-8729-418f-94a7-22eb20e73d3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_309a92a2-32e3-431f-bc58-680f69f2e833" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_54f9db06-8729-418f-94a7-22eb20e73d3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_1fb8b411-9c35-411a-be55-d355c697b51e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_309a92a2-32e3-431f-bc58-680f69f2e833" xlink:to="loc_us-gaap_AssetsCurrent_1fb8b411-9c35-411a-be55-d355c697b51e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndInvestmentsNoncurrent_e410adb4-1199-4092-8885-d322d976cebb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndInvestmentsNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_c1a0130f-4135-4d94-8281-e0aaa9f0e339" xlink:to="loc_us-gaap_RestrictedCashAndInvestmentsNoncurrent_e410adb4-1199-4092-8885-d322d976cebb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments_63a67157-30df-4519-8af0-953411817729" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_c1a0130f-4135-4d94-8281-e0aaa9f0e339" xlink:to="loc_us-gaap_LongTermInvestments_63a67157-30df-4519-8af0-953411817729" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent_95b95c47-cb2d-45f6-bb92-5432a62e800c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_c1a0130f-4135-4d94-8281-e0aaa9f0e339" xlink:to="loc_us-gaap_InventoryNoncurrent_95b95c47-cb2d-45f6-bb92-5432a62e800c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_963389d0-34db-4b33-92d4-7a0ac1d7e9d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_c1a0130f-4135-4d94-8281-e0aaa9f0e339" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_963389d0-34db-4b33-92d4-7a0ac1d7e9d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset_6fe41221-3390-41fd-b6ca-51b3f6b2412c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_c1a0130f-4135-4d94-8281-e0aaa9f0e339" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAsset_6fe41221-3390-41fd-b6ca-51b3f6b2412c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsNet_88d5fe54-5284-4287-a07b-d9bf39bda626" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIntangibleAssetsNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_c1a0130f-4135-4d94-8281-e0aaa9f0e339" xlink:to="loc_us-gaap_OtherIntangibleAssetsNet_88d5fe54-5284-4287-a07b-d9bf39bda626" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_fd48209a-89f8-4eb7-81da-aed07525ac2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_c1a0130f-4135-4d94-8281-e0aaa9f0e339" xlink:to="loc_us-gaap_Goodwill_fd48209a-89f8-4eb7-81da-aed07525ac2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_7b65a5e2-b200-473c-917f-a1091ca12590" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_c1a0130f-4135-4d94-8281-e0aaa9f0e339" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_7b65a5e2-b200-473c-917f-a1091ca12590" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_ba103a5e-1ac9-4109-9b0e-c1e596905606" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_c1a0130f-4135-4d94-8281-e0aaa9f0e339" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_ba103a5e-1ac9-4109-9b0e-c1e596905606" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_83dbf251-96ed-40e7-b476-008d9171fd4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_c1a0130f-4135-4d94-8281-e0aaa9f0e339" xlink:to="loc_us-gaap_Assets_83dbf251-96ed-40e7-b476-008d9171fd4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_aeeaf3a1-81a3-4d96-bc2a-e6db158572e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_ffc4f111-4ec6-4eef-8e1d-d220c8542eb8" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_aeeaf3a1-81a3-4d96-bc2a-e6db158572e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_2031fc3f-1922-4526-9265-c5d28c369ed6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_aeeaf3a1-81a3-4d96-bc2a-e6db158572e5" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_2031fc3f-1922-4526-9265-c5d28c369ed6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_ac425e89-212f-46a2-92ca-c728377eaeda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_2031fc3f-1922-4526-9265-c5d28c369ed6" xlink:to="loc_us-gaap_AccountsPayableCurrent_ac425e89-212f-46a2-92ca-c728377eaeda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_fa32d3f9-0955-4339-8814-6f8a1d578c30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_2031fc3f-1922-4526-9265-c5d28c369ed6" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_fa32d3f9-0955-4339-8814-6f8a1d578c30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_8443eb1d-dc67-4424-9a5d-31eee77f67b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_2031fc3f-1922-4526-9265-c5d28c369ed6" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_8443eb1d-dc67-4424-9a5d-31eee77f67b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_e831fc55-1965-4ed5-9d28-283163795be7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_2031fc3f-1922-4526-9265-c5d28c369ed6" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_e831fc55-1965-4ed5-9d28-283163795be7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_2d1ab65c-b49f-476b-a14c-a4bb4a8888a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_2031fc3f-1922-4526-9265-c5d28c369ed6" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_2d1ab65c-b49f-476b-a14c-a4bb4a8888a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_a0fbdced-5637-46f0-9167-11f12ce1a0f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_2031fc3f-1922-4526-9265-c5d28c369ed6" xlink:to="loc_us-gaap_LiabilitiesCurrent_a0fbdced-5637-46f0-9167-11f12ce1a0f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_0f3b85a9-c739-4cd6-9ceb-337b2ad0dd26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_aeeaf3a1-81a3-4d96-bc2a-e6db158572e5" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_0f3b85a9-c739-4cd6-9ceb-337b2ad0dd26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_881bb9ca-50c3-4271-aa02-4a337862006e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_aeeaf3a1-81a3-4d96-bc2a-e6db158572e5" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_881bb9ca-50c3-4271-aa02-4a337862006e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_47de15a2-0ed7-4451-a96d-30a9509651b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_aeeaf3a1-81a3-4d96-bc2a-e6db158572e5" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_47de15a2-0ed7-4451-a96d-30a9509651b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_e93731fc-f238-424d-8635-9421319c26df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_aeeaf3a1-81a3-4d96-bc2a-e6db158572e5" xlink:to="loc_us-gaap_Liabilities_e93731fc-f238-424d-8635-9421319c26df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_f514533d-7592-4c1b-9b88-d85223a17a2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_aeeaf3a1-81a3-4d96-bc2a-e6db158572e5" xlink:to="loc_us-gaap_CommitmentsAndContingencies_f514533d-7592-4c1b-9b88-d85223a17a2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_03f343ee-4550-449b-8b4f-1ebf880afad7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_aeeaf3a1-81a3-4d96-bc2a-e6db158572e5" xlink:to="loc_us-gaap_StockholdersEquityAbstract_03f343ee-4550-449b-8b4f-1ebf880afad7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_70345041-44b9-49e4-99db-dc1422e456cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_03f343ee-4550-449b-8b4f-1ebf880afad7" xlink:to="loc_us-gaap_PreferredStockValue_70345041-44b9-49e4-99db-dc1422e456cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_d7c7e89b-e2f5-4090-a585-624e24a2d224" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_03f343ee-4550-449b-8b4f-1ebf880afad7" xlink:to="loc_us-gaap_CommonStockValue_d7c7e89b-e2f5-4090-a585-624e24a2d224" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_3c2dc882-085b-4168-9895-c5e184e9e167" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_03f343ee-4550-449b-8b4f-1ebf880afad7" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_3c2dc882-085b-4168-9895-c5e184e9e167" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_5d620043-8a04-48a4-a5e1-e7d64ae524e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_03f343ee-4550-449b-8b4f-1ebf880afad7" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_5d620043-8a04-48a4-a5e1-e7d64ae524e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_b50d7d3a-2d7a-4ff1-903d-cb8f24983fe3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_03f343ee-4550-449b-8b4f-1ebf880afad7" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_b50d7d3a-2d7a-4ff1-903d-cb8f24983fe3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_540b2602-2eda-469e-8763-a89757cb2804" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_03f343ee-4550-449b-8b4f-1ebf880afad7" xlink:to="loc_us-gaap_StockholdersEquity_540b2602-2eda-469e-8763-a89757cb2804" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_7dcc9a29-0d5f-4847-a529-c5d05b417b7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_aeeaf3a1-81a3-4d96-bc2a-e6db158572e5" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_7dcc9a29-0d5f-4847-a529-c5d05b417b7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.incyte.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="incy-20220930.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:presentationLink xlink:role="http://www.incyte.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_dad64f92-e50c-4fba-9fa9-730110925bd4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_89abd15c-6adf-4fc1-9c1d-11ab83876ab3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_dad64f92-e50c-4fba-9fa9-730110925bd4" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_89abd15c-6adf-4fc1-9c1d-11ab83876ab3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_c821de34-ac51-4376-94ff-f3af8a48af5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_dad64f92-e50c-4fba-9fa9-730110925bd4" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_c821de34-ac51-4376-94ff-f3af8a48af5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_4ac8670a-fe1a-4052-937d-a88722976a3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_dad64f92-e50c-4fba-9fa9-730110925bd4" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_4ac8670a-fe1a-4052-937d-a88722976a3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_2b0c9610-6641-41cc-9506-ed7aa1bc1563" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_dad64f92-e50c-4fba-9fa9-730110925bd4" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_2b0c9610-6641-41cc-9506-ed7aa1bc1563" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_22a8ce88-34f4-4b2c-a747-d259f7d8844b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_dad64f92-e50c-4fba-9fa9-730110925bd4" xlink:to="loc_us-gaap_PreferredStockSharesIssued_22a8ce88-34f4-4b2c-a747-d259f7d8844b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_cced7d89-ffb7-42db-af67-ed63712c6fde" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_dad64f92-e50c-4fba-9fa9-730110925bd4" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_cced7d89-ffb7-42db-af67-ed63712c6fde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_5c543f1e-ed6e-4099-b144-d8e9c8fd4351" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_dad64f92-e50c-4fba-9fa9-730110925bd4" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_5c543f1e-ed6e-4099-b144-d8e9c8fd4351" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_3e3c1bbc-0775-4a0b-9fd4-87a458948c83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_dad64f92-e50c-4fba-9fa9-730110925bd4" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_3e3c1bbc-0775-4a0b-9fd4-87a458948c83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_27d42c17-2a1f-49a2-a39e-ac3668347b6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_dad64f92-e50c-4fba-9fa9-730110925bd4" xlink:to="loc_us-gaap_CommonStockSharesIssued_27d42c17-2a1f-49a2-a39e-ac3668347b6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_de446ad1-94f1-4511-9e70-a8798262bff5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_dad64f92-e50c-4fba-9fa9-730110925bd4" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_de446ad1-94f1-4511-9e70-a8798262bff5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.incyte.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="incy-20220930.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:presentationLink xlink:role="http://www.incyte.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_7f904211-4887-4a5e-aa23-269c6c53a562" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_7453cee5-7838-4ab2-9f90-e306f901da87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_7f904211-4887-4a5e-aa23-269c6c53a562" xlink:to="loc_us-gaap_StatementTable_7453cee5-7838-4ab2-9f90-e306f901da87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_1e53b431-7831-4617-820e-0d8397046a6c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_7453cee5-7838-4ab2-9f90-e306f901da87" xlink:to="loc_srt_ProductOrServiceAxis_1e53b431-7831-4617-820e-0d8397046a6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_03bbb0f3-e415-47f7-a359-e5343f623bda" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_1e53b431-7831-4617-820e-0d8397046a6c" xlink:to="loc_srt_ProductsAndServicesDomain_03bbb0f3-e415-47f7-a359-e5343f623bda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_fae63add-7555-422f-9fb7-20ede28d207a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_03bbb0f3-e415-47f7-a359-e5343f623bda" xlink:to="loc_us-gaap_ProductMember_fae63add-7555-422f-9fb7-20ede28d207a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_48f60bf7-16b7-4556-b6ed-db90fb72870e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_03bbb0f3-e415-47f7-a359-e5343f623bda" xlink:to="loc_us-gaap_RoyaltyMember_48f60bf7-16b7-4556-b6ed-db90fb72870e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_MilestoneRevenueMember_2ccef12a-4501-4837-a8f4-01d23255b3b7" xlink:href="incy-20220930.xsd#incy_MilestoneRevenueMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_03bbb0f3-e415-47f7-a359-e5343f623bda" xlink:to="loc_incy_MilestoneRevenueMember_2ccef12a-4501-4837-a8f4-01d23255b3b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_3f835ea6-43db-4659-9aca-2f5e4d369094" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_7453cee5-7838-4ab2-9f90-e306f901da87" xlink:to="loc_us-gaap_StatementLineItems_3f835ea6-43db-4659-9aca-2f5e4d369094" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_8fd9a696-34c1-4869-ba76-43e30d66a7df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3f835ea6-43db-4659-9aca-2f5e4d369094" xlink:to="loc_us-gaap_RevenuesAbstract_8fd9a696-34c1-4869-ba76-43e30d66a7df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_0623bbe5-afea-436a-bd5a-ce04b700e68f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_8fd9a696-34c1-4869-ba76-43e30d66a7df" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_0623bbe5-afea-436a-bd5a-ce04b700e68f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_39ce49de-bf25-4177-acc8-8d1f6a7c70c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3f835ea6-43db-4659-9aca-2f5e4d369094" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_39ce49de-bf25-4177-acc8-8d1f6a7c70c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue_a79059a9-1180-47d5-8bf7-9f175b6bb36c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfRevenue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_39ce49de-bf25-4177-acc8-8d1f6a7c70c2" xlink:to="loc_us-gaap_CostOfRevenue_a79059a9-1180-47d5-8bf7-9f175b6bb36c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_97ef9964-111f-43f4-ba1f-f4f9b4111677" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_39ce49de-bf25-4177-acc8-8d1f6a7c70c2" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_97ef9964-111f-43f4-ba1f-f4f9b4111677" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_b3e42080-0edc-4f89-82de-bc79e0a6e537" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_39ce49de-bf25-4177-acc8-8d1f6a7c70c2" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_b3e42080-0edc-4f89-82de-bc79e0a6e537" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_ce3db27d-b50e-4866-8917-2dc1d264d5ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_39ce49de-bf25-4177-acc8-8d1f6a7c70c2" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_ce3db27d-b50e-4866-8917-2dc1d264d5ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_CollaborationLossSharingExpense_03691cb6-8680-4fb3-98a7-3354237f6485" xlink:href="incy-20220930.xsd#incy_CollaborationLossSharingExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_39ce49de-bf25-4177-acc8-8d1f6a7c70c2" xlink:to="loc_incy_CollaborationLossSharingExpense_03691cb6-8680-4fb3-98a7-3354237f6485" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_d6526bc9-f878-46f2-81db-7eb9a41ded85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_39ce49de-bf25-4177-acc8-8d1f6a7c70c2" xlink:to="loc_us-gaap_CostsAndExpenses_d6526bc9-f878-46f2-81db-7eb9a41ded85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_cf0f7bde-80f0-4e90-9ce2-45318edb1a72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3f835ea6-43db-4659-9aca-2f5e4d369094" xlink:to="loc_us-gaap_OperatingIncomeLoss_cf0f7bde-80f0-4e90-9ce2-45318edb1a72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_6a307fd4-58ad-438d-8b4e-cc2556fde619" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3f835ea6-43db-4659-9aca-2f5e4d369094" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_6a307fd4-58ad-438d-8b4e-cc2556fde619" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_168b1ad0-61f4-415f-af6b-979a1aa77856" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3f835ea6-43db-4659-9aca-2f5e4d369094" xlink:to="loc_us-gaap_InterestExpense_168b1ad0-61f4-415f-af6b-979a1aa77856" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_6fd20c77-70ea-4220-8b60-7c4b6edbe05c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3f835ea6-43db-4659-9aca-2f5e4d369094" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_6fd20c77-70ea-4220-8b60-7c4b6edbe05c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_c0bc8e0d-762e-4dae-91ba-ffb014ec3c13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3f835ea6-43db-4659-9aca-2f5e4d369094" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_c0bc8e0d-762e-4dae-91ba-ffb014ec3c13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_0cdf8ed2-9e9a-4189-a5c4-b4d052fc429a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3f835ea6-43db-4659-9aca-2f5e4d369094" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_0cdf8ed2-9e9a-4189-a5c4-b4d052fc429a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_41da1552-fa73-43f5-afde-4f6586073d74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3f835ea6-43db-4659-9aca-2f5e4d369094" xlink:to="loc_us-gaap_NetIncomeLoss_41da1552-fa73-43f5-afde-4f6586073d74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_4ad5e8cc-7ca2-424f-90dc-7c6fbca1a341" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3f835ea6-43db-4659-9aca-2f5e4d369094" xlink:to="loc_us-gaap_EarningsPerShareAbstract_4ad5e8cc-7ca2-424f-90dc-7c6fbca1a341" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_3a696d53-98e7-421f-a3b0-766c4f92d31c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_4ad5e8cc-7ca2-424f-90dc-7c6fbca1a341" xlink:to="loc_us-gaap_EarningsPerShareBasic_3a696d53-98e7-421f-a3b0-766c4f92d31c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_c314d313-51a7-469b-8280-c878bdf340d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_4ad5e8cc-7ca2-424f-90dc-7c6fbca1a341" xlink:to="loc_us-gaap_EarningsPerShareDiluted_c314d313-51a7-469b-8280-c878bdf340d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_2ce33b12-a4cf-4135-9cb0-6b717f470a8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3f835ea6-43db-4659-9aca-2f5e4d369094" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_2ce33b12-a4cf-4135-9cb0-6b717f470a8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_75acc23f-ab04-4421-938b-bf06325da53b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_2ce33b12-a4cf-4135-9cb0-6b717f470a8c" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_75acc23f-ab04-4421-938b-bf06325da53b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_63c964a0-28d3-4b70-999b-7a0067551a69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_2ce33b12-a4cf-4135-9cb0-6b717f470a8c" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_63c964a0-28d3-4b70-999b-7a0067551a69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.incyte.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" xlink:type="simple" xlink:href="incy-20220930.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"/>
  <link:presentationLink xlink:role="http://www.incyte.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_12cd21d0-54f5-45f5-a95e-3b123a0fc7ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_66e4147e-18a6-4e3d-a44a-4ed04e7d46aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_12cd21d0-54f5-45f5-a95e-3b123a0fc7ce" xlink:to="loc_us-gaap_NetIncomeLoss_66e4147e-18a6-4e3d-a44a-4ed04e7d46aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_a060c4e4-ab32-41d6-a41c-2878206dbbd8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_12cd21d0-54f5-45f5-a95e-3b123a0fc7ce" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_a060c4e4-ab32-41d6-a41c-2878206dbbd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_ddef66c6-ceb8-4fec-a7df-3ca3511d55b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_a060c4e4-ab32-41d6-a41c-2878206dbbd8" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_ddef66c6-ceb8-4fec-a7df-3ca3511d55b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_8c21cf65-e1ae-42e0-9b5c-13f4a70851e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_a060c4e4-ab32-41d6-a41c-2878206dbbd8" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_8c21cf65-e1ae-42e0-9b5c-13f4a70851e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_95cc0fa6-7b9d-466f-86f5-ea475c01bd5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_a060c4e4-ab32-41d6-a41c-2878206dbbd8" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_95cc0fa6-7b9d-466f-86f5-ea475c01bd5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_059f9bbc-1824-4526-8504-e24ec7a38d96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_a060c4e4-ab32-41d6-a41c-2878206dbbd8" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_059f9bbc-1824-4526-8504-e24ec7a38d96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_3fda4647-ab39-43b1-bc20-df4218254b13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_12cd21d0-54f5-45f5-a95e-3b123a0fc7ce" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_3fda4647-ab39-43b1-bc20-df4218254b13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.incyte.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="incy-20220930.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"/>
  <link:presentationLink xlink:role="http://www.incyte.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_11e56048-66f5-43ba-9985-d36e5ba5b627" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_ee21be5b-d677-47db-a0f9-29ac8e40c3d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_11e56048-66f5-43ba-9985-d36e5ba5b627" xlink:to="loc_us-gaap_StatementTable_ee21be5b-d677-47db-a0f9-29ac8e40c3d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_d7889845-0f34-4b1a-b57b-2acaf189b05d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_ee21be5b-d677-47db-a0f9-29ac8e40c3d0" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_d7889845-0f34-4b1a-b57b-2acaf189b05d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_5c4d2718-b5c6-48e8-ba1f-7e3be608f95a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_d7889845-0f34-4b1a-b57b-2acaf189b05d" xlink:to="loc_us-gaap_EquityComponentDomain_5c4d2718-b5c6-48e8-ba1f-7e3be608f95a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_28c203d0-8f01-4182-ac82-35a3deab76c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_5c4d2718-b5c6-48e8-ba1f-7e3be608f95a" xlink:to="loc_us-gaap_CommonStockMember_28c203d0-8f01-4182-ac82-35a3deab76c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_97885e66-7314-46fd-a81c-579e2a6808c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_5c4d2718-b5c6-48e8-ba1f-7e3be608f95a" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_97885e66-7314-46fd-a81c-579e2a6808c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_5cfcbd80-b7c8-46e9-8964-c74e0a55a902" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_5c4d2718-b5c6-48e8-ba1f-7e3be608f95a" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_5cfcbd80-b7c8-46e9-8964-c74e0a55a902" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_31c63857-2cc8-4618-857a-4ca8d3dabc08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_5c4d2718-b5c6-48e8-ba1f-7e3be608f95a" xlink:to="loc_us-gaap_RetainedEarningsMember_31c63857-2cc8-4618-857a-4ca8d3dabc08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_ee715633-9591-4ef5-a632-6cf4c4a21a37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_ee21be5b-d677-47db-a0f9-29ac8e40c3d0" xlink:to="loc_us-gaap_StatementLineItems_ee715633-9591-4ef5-a632-6cf4c4a21a37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ae8d21f2-ca6f-42ec-a5c6-eda9cc96776a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ee715633-9591-4ef5-a632-6cf4c4a21a37" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ae8d21f2-ca6f-42ec-a5c6-eda9cc96776a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_71919a70-5e49-4702-8318-7f988e78e270" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ae8d21f2-ca6f-42ec-a5c6-eda9cc96776a" xlink:to="loc_us-gaap_StockholdersEquity_71919a70-5e49-4702-8318-7f988e78e270" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_3372da0c-4376-497c-a3bc-2feaca9b4d55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ae8d21f2-ca6f-42ec-a5c6-eda9cc96776a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_3372da0c-4376-497c-a3bc-2feaca9b4d55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_StockIssuedDuringPeriodValueStockOptionsAndRestrictedStockUnitsExercisedAndEmployeeStockPurchasePlan_188f25ca-b7d9-4311-9298-bfdd1ed1c07c" xlink:href="incy-20220930.xsd#incy_StockIssuedDuringPeriodValueStockOptionsAndRestrictedStockUnitsExercisedAndEmployeeStockPurchasePlan"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ae8d21f2-ca6f-42ec-a5c6-eda9cc96776a" xlink:to="loc_incy_StockIssuedDuringPeriodValueStockOptionsAndRestrictedStockUnitsExercisedAndEmployeeStockPurchasePlan_188f25ca-b7d9-4311-9298-bfdd1ed1c07c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_89d4ed10-442a-4e00-8985-485fbb81d071" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ae8d21f2-ca6f-42ec-a5c6-eda9cc96776a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_89d4ed10-442a-4e00-8985-485fbb81d071" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_9d671aca-26ec-4609-b601-b1b3797c63d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ae8d21f2-ca6f-42ec-a5c6-eda9cc96776a" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_9d671aca-26ec-4609-b601-b1b3797c63d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_e0f1047f-4ed8-4fe8-8605-49fcccb47b75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ae8d21f2-ca6f-42ec-a5c6-eda9cc96776a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_e0f1047f-4ed8-4fe8-8605-49fcccb47b75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_039dd9a0-fd0b-48f8-b261-a4d5d4e6b442" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ae8d21f2-ca6f-42ec-a5c6-eda9cc96776a" xlink:to="loc_us-gaap_NetIncomeLoss_039dd9a0-fd0b-48f8-b261-a4d5d4e6b442" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_65670155-da83-4dac-80ad-410312d4ad44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ae8d21f2-ca6f-42ec-a5c6-eda9cc96776a" xlink:to="loc_us-gaap_StockholdersEquity_65670155-da83-4dac-80ad-410312d4ad44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.incyte.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical" xlink:type="simple" xlink:href="incy-20220930.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical"/>
  <link:presentationLink xlink:role="http://www.incyte.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_f7d88526-6bcf-4352-8843-a514ab07223c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_d600b15f-1f8e-48d5-a8f0-fb61ab2d2ef6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_f7d88526-6bcf-4352-8843-a514ab07223c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_d600b15f-1f8e-48d5-a8f0-fb61ab2d2ef6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_7236b349-6a6c-4e2b-a9c9-e672d0290ce1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_f7d88526-6bcf-4352-8843-a514ab07223c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_7236b349-6a6c-4e2b-a9c9-e672d0290ce1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_79ac942b-8740-44aa-b69f-abd5977238d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_f7d88526-6bcf-4352-8843-a514ab07223c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_79ac942b-8740-44aa-b69f-abd5977238d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.incyte.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="incy-20220930.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://www.incyte.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_a7628438-b7b9-4f2f-80f3-0134b1629a0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_e3717ca1-4178-4bf6-a9e2-0946a55ffb84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_a7628438-b7b9-4f2f-80f3-0134b1629a0e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_e3717ca1-4178-4bf6-a9e2-0946a55ffb84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_379e867d-2edb-4c1b-a85b-38a354847e69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_e3717ca1-4178-4bf6-a9e2-0946a55ffb84" xlink:to="loc_us-gaap_ProfitLoss_379e867d-2edb-4c1b-a85b-38a354847e69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_64672408-a516-4f3a-8c09-21641a5c1f58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_e3717ca1-4178-4bf6-a9e2-0946a55ffb84" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_64672408-a516-4f3a-8c09-21641a5c1f58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_5df373ba-be93-4bc1-9621-459946022ba5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_64672408-a516-4f3a-8c09-21641a5c1f58" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_5df373ba-be93-4bc1-9621-459946022ba5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_7dbb8840-bfba-4d2e-b2db-8f0e11879e6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_64672408-a516-4f3a-8c09-21641a5c1f58" xlink:to="loc_us-gaap_ShareBasedCompensation_7dbb8840-bfba-4d2e-b2db-8f0e11879e6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_4698b4d1-b1a6-42f4-aa52-66469baf6b92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_64672408-a516-4f3a-8c09-21641a5c1f58" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_4698b4d1-b1a6-42f4-aa52-66469baf6b92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_24d46acb-2a48-40ac-8568-7235b9231caa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_64672408-a516-4f3a-8c09-21641a5c1f58" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_24d46acb-2a48-40ac-8568-7235b9231caa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_5bc695f4-04b3-4bd1-984c-04aff26705a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_64672408-a516-4f3a-8c09-21641a5c1f58" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_5bc695f4-04b3-4bd1-984c-04aff26705a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_ee499999-d3ba-4cc6-839c-0353686149fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_64672408-a516-4f3a-8c09-21641a5c1f58" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_ee499999-d3ba-4cc6-839c-0353686149fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8a8a841d-eaea-4bc7-aa06-00bbfeb5e73b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_64672408-a516-4f3a-8c09-21641a5c1f58" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8a8a841d-eaea-4bc7-aa06-00bbfeb5e73b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_f765f39b-05bf-4336-beec-c8f7c18ac363" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8a8a841d-eaea-4bc7-aa06-00bbfeb5e73b" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_f765f39b-05bf-4336-beec-c8f7c18ac363" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_b17cc52e-43e2-4fb7-a72f-1d88c280b4ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8a8a841d-eaea-4bc7-aa06-00bbfeb5e73b" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_b17cc52e-43e2-4fb7-a72f-1d88c280b4ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_3112c18f-8054-4383-8751-a13ed552ec34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8a8a841d-eaea-4bc7-aa06-00bbfeb5e73b" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_3112c18f-8054-4383-8751-a13ed552ec34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_1163a9b6-5d29-4065-8e56-5eefc01549ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8a8a841d-eaea-4bc7-aa06-00bbfeb5e73b" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_1163a9b6-5d29-4065-8e56-5eefc01549ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_04091f15-0fef-49a1-aaef-16c93ed923af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8a8a841d-eaea-4bc7-aa06-00bbfeb5e73b" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_04091f15-0fef-49a1-aaef-16c93ed923af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3382e55b-50c8-4a96-a750-748b5a6c9b10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_e3717ca1-4178-4bf6-a9e2-0946a55ffb84" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3382e55b-50c8-4a96-a750-748b5a6c9b10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4f2c333a-9336-40de-ad7e-94385f60d5d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_a7628438-b7b9-4f2f-80f3-0134b1629a0e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4f2c333a-9336-40de-ad7e-94385f60d5d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireLongtermInvestments_1d1434ee-bfeb-42a7-a085-a6de318c29ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireLongtermInvestments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4f2c333a-9336-40de-ad7e-94385f60d5d8" xlink:to="loc_us-gaap_PaymentsToAcquireLongtermInvestments_1d1434ee-bfeb-42a7-a085-a6de318c29ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfLongtermInvestments_7e3b02c3-7a08-4495-b4c6-0281030afb1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfLongtermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4f2c333a-9336-40de-ad7e-94385f60d5d8" xlink:to="loc_us-gaap_ProceedsFromSaleOfLongtermInvestments_7e3b02c3-7a08-4495-b4c6-0281030afb1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets_32a49332-1f27-4473-99c7-791ce24813c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireProductiveAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4f2c333a-9336-40de-ad7e-94385f60d5d8" xlink:to="loc_us-gaap_PaymentsToAcquireProductiveAssets_32a49332-1f27-4473-99c7-791ce24813c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_63219fa9-376e-4a4b-b82f-0922a2eae5f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4f2c333a-9336-40de-ad7e-94385f60d5d8" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_63219fa9-376e-4a4b-b82f-0922a2eae5f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_14438509-ba90-4d56-be36-3af66d7316ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4f2c333a-9336-40de-ad7e-94385f60d5d8" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_14438509-ba90-4d56-be36-3af66d7316ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7f29440b-3e1e-4223-9d63-28afda514a40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4f2c333a-9336-40de-ad7e-94385f60d5d8" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7f29440b-3e1e-4223-9d63-28afda514a40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0d27c53d-f689-43d0-97c3-e978f89e9499" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_a7628438-b7b9-4f2f-80f3-0134b1629a0e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0d27c53d-f689-43d0-97c3-e978f89e9499" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans_8eb561e3-6dad-45fb-8b87-b143be248572" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0d27c53d-f689-43d0-97c3-e978f89e9499" xlink:to="loc_us-gaap_ProceedsFromStockPlans_8eb561e3-6dad-45fb-8b87-b143be248572" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_1ac8410c-02b0-41f4-9fbb-853c6bc53dea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0d27c53d-f689-43d0-97c3-e978f89e9499" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_1ac8410c-02b0-41f4-9fbb-853c6bc53dea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_e7bd2bf5-4b6d-4777-86d2-d27b9f2b7d0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0d27c53d-f689-43d0-97c3-e978f89e9499" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_e7bd2bf5-4b6d-4777-86d2-d27b9f2b7d0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_PaymentOfContingentConsideration_75c7aeb1-9e50-444a-a698-d9c8e37f1442" xlink:href="incy-20220930.xsd#incy_PaymentOfContingentConsideration"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0d27c53d-f689-43d0-97c3-e978f89e9499" xlink:to="loc_incy_PaymentOfContingentConsideration_75c7aeb1-9e50-444a-a698-d9c8e37f1442" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_95d93f0f-fe12-4227-9575-bd25780522bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0d27c53d-f689-43d0-97c3-e978f89e9499" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_95d93f0f-fe12-4227-9575-bd25780522bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3c3ba791-3e30-46d9-9757-85a67ed42a1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0d27c53d-f689-43d0-97c3-e978f89e9499" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3c3ba791-3e30-46d9-9757-85a67ed42a1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_13e77a34-084b-4741-bafa-81daee03ff1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0d27c53d-f689-43d0-97c3-e978f89e9499" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_13e77a34-084b-4741-bafa-81daee03ff1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5d4961eb-82c5-45bf-a07e-5d9d08be9042" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0d27c53d-f689-43d0-97c3-e978f89e9499" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5d4961eb-82c5-45bf-a07e-5d9d08be9042" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_aa63dc0d-963d-4f8b-ba27-9240b8e2589f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0d27c53d-f689-43d0-97c3-e978f89e9499" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_aa63dc0d-963d-4f8b-ba27-9240b8e2589f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_8497f8ec-bca0-4805-bd9f-4de37b6f32a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_a7628438-b7b9-4f2f-80f3-0134b1629a0e" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_8497f8ec-bca0-4805-bd9f-4de37b6f32a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_387f0bdd-6392-412c-b645-8250e6c15b4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_8497f8ec-bca0-4805-bd9f-4de37b6f32a7" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_387f0bdd-6392-412c-b645-8250e6c15b4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_92e85895-c0a9-4fb9-abca-a382edeec885" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_8497f8ec-bca0-4805-bd9f-4de37b6f32a7" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_92e85895-c0a9-4fb9-abca-a382edeec885" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_d37e081f-af22-410f-88de-0f30ef0dcc15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_8497f8ec-bca0-4805-bd9f-4de37b6f32a7" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_d37e081f-af22-410f-88de-0f30ef0dcc15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_da4c92e5-47d6-4b48-a64a-956790b0a263" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_8497f8ec-bca0-4805-bd9f-4de37b6f32a7" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_da4c92e5-47d6-4b48-a64a-956790b0a263" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.incyte.com/role/OrganizationandBusiness" xlink:type="simple" xlink:href="incy-20220930.xsd#OrganizationandBusiness"/>
  <link:presentationLink xlink:role="http://www.incyte.com/role/OrganizationandBusiness" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_541b497f-6105-464c-bec1-0448705a66a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_e27a7bc6-8f66-4c11-9224-367dc96f8ef3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_541b497f-6105-464c-bec1-0448705a66a4" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_e27a7bc6-8f66-4c11-9224-367dc96f8ef3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.incyte.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="incy-20220930.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.incyte.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_a538fe85-3193-471b-8359-6b953e225e13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_46f67b8d-a91a-47e6-8057-15cf1f4cbde9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a538fe85-3193-471b-8359-6b953e225e13" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_46f67b8d-a91a-47e6-8057-15cf1f4cbde9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.incyte.com/role/Revenues" xlink:type="simple" xlink:href="incy-20220930.xsd#Revenues"/>
  <link:presentationLink xlink:role="http://www.incyte.com/role/Revenues" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_2725425e-8cf1-4b0c-bb26-ce9fca2ee1c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_4c0ab173-09de-46d1-991b-087ac2e33180" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_2725425e-8cf1-4b0c-bb26-ce9fca2ee1c1" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_4c0ab173-09de-46d1-991b-087ac2e33180" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.incyte.com/role/FairValueofFinancialInstruments" xlink:type="simple" xlink:href="incy-20220930.xsd#FairValueofFinancialInstruments"/>
  <link:presentationLink xlink:role="http://www.incyte.com/role/FairValueofFinancialInstruments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_3fa2deb5-0e48-4a7d-a213-86ee905a5ce8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_cf20e105-ac40-4228-8891-828eca5e08a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_3fa2deb5-0e48-4a7d-a213-86ee905a5ce8" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_cf20e105-ac40-4228-8891-828eca5e08a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.incyte.com/role/ConcentrationsofCreditRiskandCurrentExpectedCreditLosses" xlink:type="simple" xlink:href="incy-20220930.xsd#ConcentrationsofCreditRiskandCurrentExpectedCreditLosses"/>
  <link:presentationLink xlink:role="http://www.incyte.com/role/ConcentrationsofCreditRiskandCurrentExpectedCreditLosses" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RisksAndUncertaintiesAbstract_0f728e60-5411-47dc-b9c5-c0f29a9fb802" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RisksAndUncertaintiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskDisclosureTextBlock_f03f0af5-767f-49fe-8036-8dc549a81e12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RisksAndUncertaintiesAbstract_0f728e60-5411-47dc-b9c5-c0f29a9fb802" xlink:to="loc_us-gaap_ConcentrationRiskDisclosureTextBlock_f03f0af5-767f-49fe-8036-8dc549a81e12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.incyte.com/role/Inventory" xlink:type="simple" xlink:href="incy-20220930.xsd#Inventory"/>
  <link:presentationLink xlink:role="http://www.incyte.com/role/Inventory" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_aa43e56a-2d52-4a86-8b2c-ff4030b831c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_7e167431-af33-4ee4-ab51-f43fb6de3f1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_aa43e56a-2d52-4a86-8b2c-ff4030b831c9" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_7e167431-af33-4ee4-ab51-f43fb6de3f1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.incyte.com/role/LicenseAgreements" xlink:type="simple" xlink:href="incy-20220930.xsd#LicenseAgreements"/>
  <link:presentationLink xlink:role="http://www.incyte.com/role/LicenseAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_incy_LicenseAgreementsDisclosureAbstract_87a42152-c1c1-440f-80f5-43b7c896085f" xlink:href="incy-20220930.xsd#incy_LicenseAgreementsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_LicenseAgreementsTextBlock_86367a2a-af75-4591-bf7a-db318889c125" xlink:href="incy-20220930.xsd#incy_LicenseAgreementsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_incy_LicenseAgreementsDisclosureAbstract_87a42152-c1c1-440f-80f5-43b7c896085f" xlink:to="loc_incy_LicenseAgreementsTextBlock_86367a2a-af75-4591-bf7a-db318889c125" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.incyte.com/role/PropertyandEquipmentnet" xlink:type="simple" xlink:href="incy-20220930.xsd#PropertyandEquipmentnet"/>
  <link:presentationLink xlink:role="http://www.incyte.com/role/PropertyandEquipmentnet" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_d9f28c93-91f8-4bf5-b225-59a9717c73e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_2c7393b8-a938-4dc4-bc06-9062d538a837" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_d9f28c93-91f8-4bf5-b225-59a9717c73e4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_2c7393b8-a938-4dc4-bc06-9062d538a837" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.incyte.com/role/AccruedandOtherCurrentLiabilities" xlink:type="simple" xlink:href="incy-20220930.xsd#AccruedandOtherCurrentLiabilities"/>
  <link:presentationLink xlink:role="http://www.incyte.com/role/AccruedandOtherCurrentLiabilities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_d574bdd1-f770-47cd-9b78-3204622a3ae5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_dbc05779-b735-4801-b039-a52d2c7faa45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_d574bdd1-f770-47cd-9b78-3204622a3ae5" xlink:to="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_dbc05779-b735-4801-b039-a52d2c7faa45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.incyte.com/role/StockCompensation" xlink:type="simple" xlink:href="incy-20220930.xsd#StockCompensation"/>
  <link:presentationLink xlink:role="http://www.incyte.com/role/StockCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_013576a9-79c8-4491-93c8-594241781c20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_9cf6f37a-65d7-4844-b990-c4985a90fd9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_013576a9-79c8-4491-93c8-594241781c20" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_9cf6f37a-65d7-4844-b990-c4985a90fd9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.incyte.com/role/IncomeTaxes" xlink:type="simple" xlink:href="incy-20220930.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.incyte.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_e24ffda3-b7eb-4f17-b81f-2c5f69c98ed0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_0d5e12bd-5525-44cd-80f2-d12627633a7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_e24ffda3-b7eb-4f17-b81f-2c5f69c98ed0" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_0d5e12bd-5525-44cd-80f2-d12627633a7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.incyte.com/role/NetIncomePerShare" xlink:type="simple" xlink:href="incy-20220930.xsd#NetIncomePerShare"/>
  <link:presentationLink xlink:role="http://www.incyte.com/role/NetIncomePerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_845faea6-d232-4d3a-adc7-81eb3159415a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_55e05dd6-3921-4af3-aea6-0e614d795bc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_845faea6-d232-4d3a-adc7-81eb3159415a" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_55e05dd6-3921-4af3-aea6-0e614d795bc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.incyte.com/role/EmployeeBenefitPlans" xlink:type="simple" xlink:href="incy-20220930.xsd#EmployeeBenefitPlans"/>
  <link:presentationLink xlink:role="http://www.incyte.com/role/EmployeeBenefitPlans" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_2585a23a-c910-40d3-917b-d8c192370407" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_f6909a5c-bebd-4fd6-9984-4299a7a50027" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_2585a23a-c910-40d3-917b-d8c192370407" xlink:to="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_f6909a5c-bebd-4fd6-9984-4299a7a50027" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.incyte.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="incy-20220930.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.incyte.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_efdc3163-b981-4622-9f4d-94d1c9ceb473" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_97e43735-f0de-4ec5-a45d-3ffc8dda73eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_efdc3163-b981-4622-9f4d-94d1c9ceb473" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_97e43735-f0de-4ec5-a45d-3ffc8dda73eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.incyte.com/role/SubsequentEvents" xlink:type="simple" xlink:href="incy-20220930.xsd#SubsequentEvents"/>
  <link:presentationLink xlink:role="http://www.incyte.com/role/SubsequentEvents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_b22ee849-e538-455e-8263-5fa3156624ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_227413ae-3db4-41ea-9371-69909c2fecdd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_b22ee849-e538-455e-8263-5fa3156624ba" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_227413ae-3db4-41ea-9371-69909c2fecdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.incyte.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="incy-20220930.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.incyte.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_a1e6c7fe-b4cc-4bb3-b380-d0e1993f4188" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_b0d303e6-ea9d-4495-838e-9f131c6cb642" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a1e6c7fe-b4cc-4bb3-b380-d0e1993f4188" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_b0d303e6-ea9d-4495-838e-9f131c6cb642" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_be7d33cb-df79-4a68-aea1-12acfcc3bb01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a1e6c7fe-b4cc-4bb3-b380-d0e1993f4188" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_be7d33cb-df79-4a68-aea1-12acfcc3bb01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_c5ae087f-fd55-4003-9d0c-e827684a6c83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a1e6c7fe-b4cc-4bb3-b380-d0e1993f4188" xlink:to="loc_us-gaap_UseOfEstimates_c5ae087f-fd55-4003-9d0c-e827684a6c83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_c9777e5c-207a-4f1f-88e1-bd55b93d8781" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a1e6c7fe-b4cc-4bb3-b380-d0e1993f4188" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_c9777e5c-207a-4f1f-88e1-bd55b93d8781" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.incyte.com/role/RevenuesTables" xlink:type="simple" xlink:href="incy-20220930.xsd#RevenuesTables"/>
  <link:presentationLink xlink:role="http://www.incyte.com/role/RevenuesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_f623ccbc-40f1-43f4-b405-b9a1c1eb25f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_03ae6c0e-14d7-41b3-a73b-7a1d386d9abc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_f623ccbc-40f1-43f4-b405-b9a1c1eb25f3" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_03ae6c0e-14d7-41b3-a73b-7a1d386d9abc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.incyte.com/role/FairValueofFinancialInstrumentsTables" xlink:type="simple" xlink:href="incy-20220930.xsd#FairValueofFinancialInstrumentsTables"/>
  <link:presentationLink xlink:role="http://www.incyte.com/role/FairValueofFinancialInstrumentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_49cbcbfe-4183-4cc5-856f-fe5714b6edd0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_09da134e-f27d-4777-b438-92a527fe108c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_49cbcbfe-4183-4cc5-856f-fe5714b6edd0" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_09da134e-f27d-4777-b438-92a527fe108c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_f0375e35-cd49-404b-9150-aa9328c89ff4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_49cbcbfe-4183-4cc5-856f-fe5714b6edd0" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_f0375e35-cd49-404b-9150-aa9328c89ff4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_c1e1ca81-2ab8-446d-a03d-a980e592ca94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_49cbcbfe-4183-4cc5-856f-fe5714b6edd0" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_c1e1ca81-2ab8-446d-a03d-a980e592ca94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_11ae29a3-8b0a-4638-a6de-791c2b89d6c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_49cbcbfe-4183-4cc5-856f-fe5714b6edd0" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_11ae29a3-8b0a-4638-a6de-791c2b89d6c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.incyte.com/role/ConcentrationsofCreditRiskandCurrentExpectedCreditLossesTables" xlink:type="simple" xlink:href="incy-20220930.xsd#ConcentrationsofCreditRiskandCurrentExpectedCreditLossesTables"/>
  <link:presentationLink xlink:role="http://www.incyte.com/role/ConcentrationsofCreditRiskandCurrentExpectedCreditLossesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RisksAndUncertaintiesAbstract_ad3b8539-15a9-499b-a455-3a1b1db15104" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RisksAndUncertaintiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_SchedulesOfConcentrationOfRiskByRiskFactorRelatedToCollaborativePartnersTableTextBlock_2e413723-c088-443e-95de-72683ced39fc" xlink:href="incy-20220930.xsd#incy_SchedulesOfConcentrationOfRiskByRiskFactorRelatedToCollaborativePartnersTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RisksAndUncertaintiesAbstract_ad3b8539-15a9-499b-a455-3a1b1db15104" xlink:to="loc_incy_SchedulesOfConcentrationOfRiskByRiskFactorRelatedToCollaborativePartnersTableTextBlock_2e413723-c088-443e-95de-72683ced39fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.incyte.com/role/InventoryTables" xlink:type="simple" xlink:href="incy-20220930.xsd#InventoryTables"/>
  <link:presentationLink xlink:role="http://www.incyte.com/role/InventoryTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_031d59f1-90b7-4471-82d0-461415d69ab5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_ScheduleOfInventoryTableTextBlock_a5fe84f7-0f07-493b-b7f4-e5af1a931ae7" xlink:href="incy-20220930.xsd#incy_ScheduleOfInventoryTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_031d59f1-90b7-4471-82d0-461415d69ab5" xlink:to="loc_incy_ScheduleOfInventoryTableTextBlock_a5fe84f7-0f07-493b-b7f4-e5af1a931ae7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.incyte.com/role/PropertyandEquipmentnetTables" xlink:type="simple" xlink:href="incy-20220930.xsd#PropertyandEquipmentnetTables"/>
  <link:presentationLink xlink:role="http://www.incyte.com/role/PropertyandEquipmentnetTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_8d52885b-68a1-4524-986b-1f7d509f3014" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_bbcc435b-bdb3-4265-addf-462f51629d9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_8d52885b-68a1-4524-986b-1f7d509f3014" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_bbcc435b-bdb3-4265-addf-462f51629d9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.incyte.com/role/AccruedandOtherCurrentLiabilitiesTables" xlink:type="simple" xlink:href="incy-20220930.xsd#AccruedandOtherCurrentLiabilitiesTables"/>
  <link:presentationLink xlink:role="http://www.incyte.com/role/AccruedandOtherCurrentLiabilitiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_16a772cd-e0a8-4d3a-9f31-3668e6bb9d0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_c10bcd86-6b46-439b-8fd2-6fa8647f3e26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_16a772cd-e0a8-4d3a-9f31-3668e6bb9d0e" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_c10bcd86-6b46-439b-8fd2-6fa8647f3e26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.incyte.com/role/StockcompensationTables" xlink:type="simple" xlink:href="incy-20220930.xsd#StockcompensationTables"/>
  <link:presentationLink xlink:role="http://www.incyte.com/role/StockcompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2a394f46-99ff-4052-90f0-13cd3fc3d9eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_ScheduleOfShareBasedPaymentAwardStockOptionsAndEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_1da2dab1-27a0-4036-9452-6cf222ddfe4c" xlink:href="incy-20220930.xsd#incy_ScheduleOfShareBasedPaymentAwardStockOptionsAndEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2a394f46-99ff-4052-90f0-13cd3fc3d9eb" xlink:to="loc_incy_ScheduleOfShareBasedPaymentAwardStockOptionsAndEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_1da2dab1-27a0-4036-9452-6cf222ddfe4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_ab9b4f7d-e3ce-400e-a955-cb4390af9723" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2a394f46-99ff-4052-90f0-13cd3fc3d9eb" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_ab9b4f7d-e3ce-400e-a955-cb4390af9723" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_ScheduleOfShareBasedCompensationOtherThanStockOptionsActivityTableTextBlock_c3badd43-9e54-4fc1-8e66-a9debd2fecc7" xlink:href="incy-20220930.xsd#incy_ScheduleOfShareBasedCompensationOtherThanStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2a394f46-99ff-4052-90f0-13cd3fc3d9eb" xlink:to="loc_incy_ScheduleOfShareBasedCompensationOtherThanStockOptionsActivityTableTextBlock_c3badd43-9e54-4fc1-8e66-a9debd2fecc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_8b323f3d-97af-47f3-9691-946e6be4cdb7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2a394f46-99ff-4052-90f0-13cd3fc3d9eb" xlink:to="loc_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_8b323f3d-97af-47f3-9691-946e6be4cdb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.incyte.com/role/NetIncomePerShareTables" xlink:type="simple" xlink:href="incy-20220930.xsd#NetIncomePerShareTables"/>
  <link:presentationLink xlink:role="http://www.incyte.com/role/NetIncomePerShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_dce16a77-fe49-4c7a-98e1-e7ac6534a2f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_b7d88fa9-0ebd-4943-a6a1-da43927f46c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_dce16a77-fe49-4c7a-98e1-e7ac6534a2f6" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_b7d88fa9-0ebd-4943-a6a1-da43927f46c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_b4666307-ada7-4f10-b431-718f1e55a5be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_dce16a77-fe49-4c7a-98e1-e7ac6534a2f6" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_b4666307-ada7-4f10-b431-718f1e55a5be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.incyte.com/role/EmployeeBenefitPlansTables" xlink:type="simple" xlink:href="incy-20220930.xsd#EmployeeBenefitPlansTables"/>
  <link:presentationLink xlink:role="http://www.incyte.com/role/EmployeeBenefitPlansTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_decb4e8a-3e11-4d02-bb51-83e41de8e786" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_d6b26d75-1038-454f-8cbf-10012e24056c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNetBenefitCostsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_decb4e8a-3e11-4d02-bb51-83e41de8e786" xlink:to="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_d6b26d75-1038-454f-8cbf-10012e24056c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.incyte.com/role/OrganizationandBusinessDetails" xlink:type="simple" xlink:href="incy-20220930.xsd#OrganizationandBusinessDetails"/>
  <link:presentationLink xlink:role="http://www.incyte.com/role/OrganizationandBusinessDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ba71281a-bd29-477a-823e-0019ac7c3f2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_ab1bace9-ffda-45c3-828c-a75fe58df49a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ba71281a-bd29-477a-823e-0019ac7c3f2e" xlink:to="loc_us-gaap_NumberOfOperatingSegments_ab1bace9-ffda-45c3-828c-a75fe58df49a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.incyte.com/role/RevenuesDetails" xlink:type="simple" xlink:href="incy-20220930.xsd#RevenuesDetails"/>
  <link:presentationLink xlink:role="http://www.incyte.com/role/RevenuesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_e6bca67b-2b1f-4b8c-ab76-e25387d623d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_c657dc9f-8a2a-4bf9-ba5c-c7b73322424b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_e6bca67b-2b1f-4b8c-ab76-e25387d623d3" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_c657dc9f-8a2a-4bf9-ba5c-c7b73322424b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_f2116b3d-4546-43d2-9839-370ae9dc6e0f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_c657dc9f-8a2a-4bf9-ba5c-c7b73322424b" xlink:to="loc_srt_ProductOrServiceAxis_f2116b3d-4546-43d2-9839-370ae9dc6e0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_46fa1634-f039-4d7f-97e1-35658fba7278" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_f2116b3d-4546-43d2-9839-370ae9dc6e0f" xlink:to="loc_srt_ProductsAndServicesDomain_46fa1634-f039-4d7f-97e1-35658fba7278" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_c4f9f688-3f83-4c00-870c-e878805608f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_46fa1634-f039-4d7f-97e1-35658fba7278" xlink:to="loc_us-gaap_ProductMember_c4f9f688-3f83-4c00-870c-e878805608f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_JAKAFIMember_003b708b-ba32-4d85-9a0a-b1ceedb8b6f1" xlink:href="incy-20220930.xsd#incy_JAKAFIMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_c4f9f688-3f83-4c00-870c-e878805608f1" xlink:to="loc_incy_JAKAFIMember_003b708b-ba32-4d85-9a0a-b1ceedb8b6f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_ICLUSIGMember_ac07f1e7-fb13-4211-9a24-44d2ce910021" xlink:href="incy-20220930.xsd#incy_ICLUSIGMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_c4f9f688-3f83-4c00-870c-e878805608f1" xlink:to="loc_incy_ICLUSIGMember_ac07f1e7-fb13-4211-9a24-44d2ce910021" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_PemazyreMember_90762525-31c0-479c-8f3d-dea02f68ed19" xlink:href="incy-20220930.xsd#incy_PemazyreMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_c4f9f688-3f83-4c00-870c-e878805608f1" xlink:to="loc_incy_PemazyreMember_90762525-31c0-479c-8f3d-dea02f68ed19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_MINJUVIMember_b7b2ad77-2098-4550-90d6-919940994ca5" xlink:href="incy-20220930.xsd#incy_MINJUVIMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_c4f9f688-3f83-4c00-870c-e878805608f1" xlink:to="loc_incy_MINJUVIMember_b7b2ad77-2098-4550-90d6-919940994ca5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_OpzeluraMember_3441684e-bbd1-4654-9933-5997d75099d1" xlink:href="incy-20220930.xsd#incy_OpzeluraMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_c4f9f688-3f83-4c00-870c-e878805608f1" xlink:to="loc_incy_OpzeluraMember_3441684e-bbd1-4654-9933-5997d75099d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_b8441ef3-f834-43a9-9921-5e8daab85cf0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_46fa1634-f039-4d7f-97e1-35658fba7278" xlink:to="loc_us-gaap_RoyaltyMember_b8441ef3-f834-43a9-9921-5e8daab85cf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_JakaviRoyaltyRevenuesMember_64a0c82f-6a71-4c09-ba38-9511e8acec6c" xlink:href="incy-20220930.xsd#incy_JakaviRoyaltyRevenuesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RoyaltyMember_b8441ef3-f834-43a9-9921-5e8daab85cf0" xlink:to="loc_incy_JakaviRoyaltyRevenuesMember_64a0c82f-6a71-4c09-ba38-9511e8acec6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_OlumiantRoyaltyMember_a659b557-83ee-4552-b9c6-02608e7b014e" xlink:href="incy-20220930.xsd#incy_OlumiantRoyaltyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RoyaltyMember_b8441ef3-f834-43a9-9921-5e8daab85cf0" xlink:to="loc_incy_OlumiantRoyaltyMember_a659b557-83ee-4552-b9c6-02608e7b014e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_TabrectaRoyaltyRevenuesMember_b22c191a-f160-4189-bfd9-2262b6b653a3" xlink:href="incy-20220930.xsd#incy_TabrectaRoyaltyRevenuesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RoyaltyMember_b8441ef3-f834-43a9-9921-5e8daab85cf0" xlink:to="loc_incy_TabrectaRoyaltyRevenuesMember_b22c191a-f160-4189-bfd9-2262b6b653a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_MilestoneAndContractRevenueMember_6a0b3401-1dfc-4458-9c96-578cfd04f9a2" xlink:href="incy-20220930.xsd#incy_MilestoneAndContractRevenueMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_46fa1634-f039-4d7f-97e1-35658fba7278" xlink:to="loc_incy_MilestoneAndContractRevenueMember_6a0b3401-1dfc-4458-9c96-578cfd04f9a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_3188f2a8-794b-4cde-9dc3-6ad4eef0359c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_c657dc9f-8a2a-4bf9-ba5c-c7b73322424b" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_3188f2a8-794b-4cde-9dc3-6ad4eef0359c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8fcbce7e-6489-408f-b28e-35998d9d36ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_3188f2a8-794b-4cde-9dc3-6ad4eef0359c" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8fcbce7e-6489-408f-b28e-35998d9d36ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.incyte.com/role/FairValueofFinancialInstrumentsMarketablesecuritiesportfolioDetails" xlink:type="simple" xlink:href="incy-20220930.xsd#FairValueofFinancialInstrumentsMarketablesecuritiesportfolioDetails"/>
  <link:presentationLink xlink:role="http://www.incyte.com/role/FairValueofFinancialInstrumentsMarketablesecuritiesportfolioDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_e5991625-a8c3-46bb-b32d-bf5ff441f7d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_d94ea39b-a6a3-40d3-859e-aedb1042f9bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_e5991625-a8c3-46bb-b32d-bf5ff441f7d9" xlink:to="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_d94ea39b-a6a3-40d3-859e-aedb1042f9bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_0bc304b2-e116-4f2a-85f1-18388915d06f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_d94ea39b-a6a3-40d3-859e-aedb1042f9bf" xlink:to="loc_us-gaap_FinancialInstrumentAxis_0bc304b2-e116-4f2a-85f1-18388915d06f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c0a975b2-67d7-425b-9789-57eee18c3934" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_0bc304b2-e116-4f2a-85f1-18388915d06f" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c0a975b2-67d7-425b-9789-57eee18c3934" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_CorporateAndGovernmentDebtSecuritiesMember_fbd9f46d-5939-47cc-8ee2-51d8d6a08864" xlink:href="incy-20220930.xsd#incy_CorporateAndGovernmentDebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c0a975b2-67d7-425b-9789-57eee18c3934" xlink:to="loc_incy_CorporateAndGovernmentDebtSecuritiesMember_fbd9f46d-5939-47cc-8ee2-51d8d6a08864" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_b3bac3b6-6149-45c6-88da-fc54b7b4cb19" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_d94ea39b-a6a3-40d3-859e-aedb1042f9bf" xlink:to="loc_srt_RangeAxis_b3bac3b6-6149-45c6-88da-fc54b7b4cb19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_33698828-679b-4c97-a5bf-eea546634e36" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_b3bac3b6-6149-45c6-88da-fc54b7b4cb19" xlink:to="loc_srt_RangeMember_33698828-679b-4c97-a5bf-eea546634e36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_b354d531-6f07-4f1c-803f-47fce7c5b0aa" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_33698828-679b-4c97-a5bf-eea546634e36" xlink:to="loc_srt_MinimumMember_b354d531-6f07-4f1c-803f-47fce7c5b0aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_b0dfe0e1-3609-44c1-8951-3af0924e99a0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_33698828-679b-4c97-a5bf-eea546634e36" xlink:to="loc_srt_MaximumMember_b0dfe0e1-3609-44c1-8951-3af0924e99a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1b3501d0-0ff1-4b5a-af7d-d462f00079d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_d94ea39b-a6a3-40d3-859e-aedb1042f9bf" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1b3501d0-0ff1-4b5a-af7d-d462f00079d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_6618979b-9e31-4fe4-834c-c11271425c53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1b3501d0-0ff1-4b5a-af7d-d462f00079d0" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_6618979b-9e31-4fe4-834c-c11271425c53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax_dedfe8ef-c914-45d2-8bc2-3a3432771153" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1b3501d0-0ff1-4b5a-af7d-d462f00079d0" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax_dedfe8ef-c914-45d2-8bc2-3a3432771153" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_ad59dd9e-e6ed-49fc-8194-eb76ee3c1613" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1b3501d0-0ff1-4b5a-af7d-d462f00079d0" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_ad59dd9e-e6ed-49fc-8194-eb76ee3c1613" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_c67fc0fb-875e-45b9-9771-1b937a25dbd2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1b3501d0-0ff1-4b5a-af7d-d462f00079d0" xlink:to="loc_us-gaap_DebtInstrumentTerm_c67fc0fb-875e-45b9-9771-1b937a25dbd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.incyte.com/role/FairValueofFinancialInstrumentsAssetsmeasuredonarecurringbasisDetails" xlink:type="simple" xlink:href="incy-20220930.xsd#FairValueofFinancialInstrumentsAssetsmeasuredonarecurringbasisDetails"/>
  <link:presentationLink xlink:role="http://www.incyte.com/role/FairValueofFinancialInstrumentsAssetsmeasuredonarecurringbasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_df7fba6c-1322-4c9e-81c3-ab0c455d4602" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9aae8baf-f994-485f-b5a0-9d24aa8614d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_df7fba6c-1322-4c9e-81c3-ab0c455d4602" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9aae8baf-f994-485f-b5a0-9d24aa8614d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_24085a2e-010d-45d1-9656-799d51eeab4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9aae8baf-f994-485f-b5a0-9d24aa8614d9" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_24085a2e-010d-45d1-9656-799d51eeab4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_ac454348-4fc4-4315-b068-312d784343e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_24085a2e-010d-45d1-9656-799d51eeab4a" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_ac454348-4fc4-4315-b068-312d784343e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_1a5e4745-b6dc-4181-8da8-b43c7cc85a8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_ac454348-4fc4-4315-b068-312d784343e5" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_1a5e4745-b6dc-4181-8da8-b43c7cc85a8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_01bd4608-4305-4904-ae2e-97189ffab344" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9aae8baf-f994-485f-b5a0-9d24aa8614d9" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_01bd4608-4305-4904-ae2e-97189ffab344" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a33e648e-9f5a-4b5a-a645-812db0e7525f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_01bd4608-4305-4904-ae2e-97189ffab344" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a33e648e-9f5a-4b5a-a645-812db0e7525f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_3646aca0-a598-4f52-9da4-203438f47245" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a33e648e-9f5a-4b5a-a645-812db0e7525f" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_3646aca0-a598-4f52-9da4-203438f47245" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_012dd472-dee0-4757-b98e-afdb1c7b75cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a33e648e-9f5a-4b5a-a645-812db0e7525f" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_012dd472-dee0-4757-b98e-afdb1c7b75cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_0b7eb7ce-0472-434c-b0b2-d0f3fc1c61d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a33e648e-9f5a-4b5a-a645-812db0e7525f" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_0b7eb7ce-0472-434c-b0b2-d0f3fc1c61d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_81228a74-95c9-4db0-81df-5aa4e54d13e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9aae8baf-f994-485f-b5a0-9d24aa8614d9" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_81228a74-95c9-4db0-81df-5aa4e54d13e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_23a4c2c4-6f73-47fe-9052-8c67d86c098b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_81228a74-95c9-4db0-81df-5aa4e54d13e5" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_23a4c2c4-6f73-47fe-9052-8c67d86c098b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_81904af2-6455-4a53-9310-7d2350cd8c7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_23a4c2c4-6f73-47fe-9052-8c67d86c098b" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_81904af2-6455-4a53-9310-7d2350cd8c7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_0a886f13-dae2-4fb8-8323-3da9b4615143" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_81904af2-6455-4a53-9310-7d2350cd8c7e" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_0a886f13-dae2-4fb8-8323-3da9b4615143" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_63174807-49ea-4953-b87d-2b8a87c3e069" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9aae8baf-f994-485f-b5a0-9d24aa8614d9" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_63174807-49ea-4953-b87d-2b8a87c3e069" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_b775fc24-a8f3-4a22-be78-2c932b4da191" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_63174807-49ea-4953-b87d-2b8a87c3e069" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_b775fc24-a8f3-4a22-be78-2c932b4da191" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_1dad85fc-19fe-41b4-8ad8-59eea43d069a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_63174807-49ea-4953-b87d-2b8a87c3e069" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_1dad85fc-19fe-41b4-8ad8-59eea43d069a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments_3a7fc2b6-e110-42f4-985e-3988fe5a6cf5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_63174807-49ea-4953-b87d-2b8a87c3e069" xlink:to="loc_us-gaap_LongTermInvestments_3a7fc2b6-e110-42f4-985e-3988fe5a6cf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_7a015ce4-48e4-4e29-9c91-8cc5c341cb0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_63174807-49ea-4953-b87d-2b8a87c3e069" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_7a015ce4-48e4-4e29-9c91-8cc5c341cb0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.incyte.com/role/FairValueofFinancialInstrumentsLiabilitiesmeasuredonarecurringbasisDetails" xlink:type="simple" xlink:href="incy-20220930.xsd#FairValueofFinancialInstrumentsLiabilitiesmeasuredonarecurringbasisDetails"/>
  <link:presentationLink xlink:role="http://www.incyte.com/role/FairValueofFinancialInstrumentsLiabilitiesmeasuredonarecurringbasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_9bb7b160-bcc0-42a9-b118-3106c0cd4abf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0500a01c-ce95-4cd9-85f4-b569bf6a38b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_9bb7b160-bcc0-42a9-b118-3106c0cd4abf" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0500a01c-ce95-4cd9-85f4-b569bf6a38b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_9c489704-7500-41ab-910d-faff377b40fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0500a01c-ce95-4cd9-85f4-b569bf6a38b3" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_9c489704-7500-41ab-910d-faff377b40fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_1d5ed20d-ade0-4048-a9d8-260aeda7c8ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_9c489704-7500-41ab-910d-faff377b40fc" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_1d5ed20d-ade0-4048-a9d8-260aeda7c8ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_a0d0bdc8-3e4a-47ed-a408-a08fc40c603b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_1d5ed20d-ade0-4048-a9d8-260aeda7c8ed" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_a0d0bdc8-3e4a-47ed-a408-a08fc40c603b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_48846e3a-13bf-4b17-b54e-8f912e7bdb6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0500a01c-ce95-4cd9-85f4-b569bf6a38b3" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_48846e3a-13bf-4b17-b54e-8f912e7bdb6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6244f415-2e9c-4323-b3b5-37a6a68aa9fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_48846e3a-13bf-4b17-b54e-8f912e7bdb6a" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6244f415-2e9c-4323-b3b5-37a6a68aa9fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_35762760-053e-4aa3-9250-97ede82df62e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6244f415-2e9c-4323-b3b5-37a6a68aa9fb" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_35762760-053e-4aa3-9250-97ede82df62e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_48a18f39-4073-43cf-8d20-c68f8d620dea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6244f415-2e9c-4323-b3b5-37a6a68aa9fb" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_48a18f39-4073-43cf-8d20-c68f8d620dea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_d71efd51-d5a1-4bc8-9eda-9a118f76a476" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6244f415-2e9c-4323-b3b5-37a6a68aa9fb" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_d71efd51-d5a1-4bc8-9eda-9a118f76a476" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_1a7c4494-06c7-4adb-bce3-fdebf608b1a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0500a01c-ce95-4cd9-85f4-b569bf6a38b3" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_1a7c4494-06c7-4adb-bce3-fdebf608b1a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_95ba834c-9035-4a0f-ae5e-805338eb33ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_1a7c4494-06c7-4adb-bce3-fdebf608b1a1" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_95ba834c-9035-4a0f-ae5e-805338eb33ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_c5eb4b0e-d100-4982-821b-e2e0a43c9452" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_95ba834c-9035-4a0f-ae5e-805338eb33ac" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_c5eb4b0e-d100-4982-821b-e2e0a43c9452" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_762890b2-56a2-4d3f-b3b8-10d7fa60c875" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_c5eb4b0e-d100-4982-821b-e2e0a43c9452" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_762890b2-56a2-4d3f-b3b8-10d7fa60c875" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3cf4220a-ced8-41df-9821-830d43d858b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0500a01c-ce95-4cd9-85f4-b569bf6a38b3" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3cf4220a-ced8-41df-9821-830d43d858b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_80380f3d-bfd4-4b9d-8856-aad987481151" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3cf4220a-ced8-41df-9821-830d43d858b2" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_80380f3d-bfd4-4b9d-8856-aad987481151" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_740e6713-c2c9-406e-a76a-7de9c0b371dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3cf4220a-ced8-41df-9821-830d43d858b2" xlink:to="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_740e6713-c2c9-406e-a76a-7de9c0b371dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.incyte.com/role/FairValueofFinancialInstrumentsLevel3liabilitiesDetails" xlink:type="simple" xlink:href="incy-20220930.xsd#FairValueofFinancialInstrumentsLevel3liabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.incyte.com/role/FairValueofFinancialInstrumentsLevel3liabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_d05eae2b-22b6-4803-8a9b-782fd2a54419" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1c711a85-53cb-404c-86b2-541c3ec61675" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_d05eae2b-22b6-4803-8a9b-782fd2a54419" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1c711a85-53cb-404c-86b2-541c3ec61675" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_40dd2a62-dc1b-4228-83f9-5266fb211ddd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1c711a85-53cb-404c-86b2-541c3ec61675" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_40dd2a62-dc1b-4228-83f9-5266fb211ddd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4ca53e55-8860-4783-8958-0d4664bfb6ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_40dd2a62-dc1b-4228-83f9-5266fb211ddd" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4ca53e55-8860-4783-8958-0d4664bfb6ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_f975e33b-9161-4a58-983f-ee719ae91c79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4ca53e55-8860-4783-8958-0d4664bfb6ac" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_f975e33b-9161-4a58-983f-ee719ae91c79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_8c16395f-70d0-4f90-b7c9-c7744817f7c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1c711a85-53cb-404c-86b2-541c3ec61675" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_8c16395f-70d0-4f90-b7c9-c7744817f7c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_9e84fa91-0c72-4ad6-b583-0aa4b7d14de7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_8c16395f-70d0-4f90-b7c9-c7744817f7c4" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_9e84fa91-0c72-4ad6-b583-0aa4b7d14de7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_556cc0ac-59ce-418e-bda9-636c40de070b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_9e84fa91-0c72-4ad6-b583-0aa4b7d14de7" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_556cc0ac-59ce-418e-bda9-636c40de070b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_e57a9af7-2d0d-43c8-b7f5-9e1032f8e869" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_556cc0ac-59ce-418e-bda9-636c40de070b" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_e57a9af7-2d0d-43c8-b7f5-9e1032f8e869" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_4006a91a-bed4-4cd2-b6b2-69873531a149" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1c711a85-53cb-404c-86b2-541c3ec61675" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_4006a91a-bed4-4cd2-b6b2-69873531a149" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_85f750a4-0b32-4577-844f-a08fe32c2c6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_4006a91a-bed4-4cd2-b6b2-69873531a149" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_85f750a4-0b32-4577-844f-a08fe32c2c6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_7f17c896-4f6c-45ae-a668-f9aae60b2960" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_85f750a4-0b32-4577-844f-a08fe32c2c6e" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_7f17c896-4f6c-45ae-a668-f9aae60b2960" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityConsiderationEarned_6be5cb2d-4858-4e12-9191-f0d12b9bcb75" xlink:href="incy-20220930.xsd#incy_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityConsiderationEarned"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_85f750a4-0b32-4577-844f-a08fe32c2c6e" xlink:to="loc_incy_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityConsiderationEarned_6be5cb2d-4858-4e12-9191-f0d12b9bcb75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_ae568a9b-2183-418b-8319-0e7fa9c5d533" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_85f750a4-0b32-4577-844f-a08fe32c2c6e" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_ae568a9b-2183-418b-8319-0e7fa9c5d533" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_3c737c60-7ec8-4ba1-8461-bd802837e752" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_85f750a4-0b32-4577-844f-a08fe32c2c6e" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_3c737c60-7ec8-4ba1-8461-bd802837e752" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.incyte.com/role/FairValueofFinancialInstrumentsNarrativeDetails" xlink:type="simple" xlink:href="incy-20220930.xsd#FairValueofFinancialInstrumentsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.incyte.com/role/FairValueofFinancialInstrumentsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_b4b85dc0-3b38-467a-91eb-ec710009f690" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_41e28847-4c1f-48bb-bbeb-a0bddc3c418b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_b4b85dc0-3b38-467a-91eb-ec710009f690" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_41e28847-4c1f-48bb-bbeb-a0bddc3c418b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_b30ca789-fe19-4a56-a359-732ebcfaebd3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_41e28847-4c1f-48bb-bbeb-a0bddc3c418b" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_b30ca789-fe19-4a56-a359-732ebcfaebd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ed197254-dc92-417a-a2ba-68cc68b9d79b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_b30ca789-fe19-4a56-a359-732ebcfaebd3" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ed197254-dc92-417a-a2ba-68cc68b9d79b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_AriadPharmaceuticalsMember_8465ed6a-bbc7-4a5e-bb16-13beb17f92bc" xlink:href="incy-20220930.xsd#incy_AriadPharmaceuticalsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ed197254-dc92-417a-a2ba-68cc68b9d79b" xlink:to="loc_incy_AriadPharmaceuticalsMember_8465ed6a-bbc7-4a5e-bb16-13beb17f92bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_107d7a5c-8e9c-4f68-b161-9a6076a2e3c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_41e28847-4c1f-48bb-bbeb-a0bddc3c418b" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_107d7a5c-8e9c-4f68-b161-9a6076a2e3c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_9c48c37b-58a0-43a6-b371-ad5a41070ad9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_107d7a5c-8e9c-4f68-b161-9a6076a2e3c7" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_9c48c37b-58a0-43a6-b371-ad5a41070ad9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityMember_b5f2308b-a6ee-4a5b-9048-bb7d8d2fdcec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_9c48c37b-58a0-43a6-b371-ad5a41070ad9" xlink:to="loc_us-gaap_LiabilityMember_b5f2308b-a6ee-4a5b-9048-bb7d8d2fdcec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_8eb37d15-beab-4584-b4bc-0fc52692bc4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_41e28847-4c1f-48bb-bbeb-a0bddc3c418b" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_8eb37d15-beab-4584-b4bc-0fc52692bc4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_45f69e77-69d7-4a42-91cb-cb74f6c96b35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_8eb37d15-beab-4584-b4bc-0fc52692bc4a" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_45f69e77-69d7-4a42-91cb-cb74f6c96b35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_4cbc3883-dd75-415c-a83f-97514d097a0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_45f69e77-69d7-4a42-91cb-cb74f6c96b35" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_4cbc3883-dd75-415c-a83f-97514d097a0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_e35b8498-c1b5-499e-854e-d39491b91aa2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_41e28847-4c1f-48bb-bbeb-a0bddc3c418b" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_e35b8498-c1b5-499e-854e-d39491b91aa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_5b180383-07b9-4ec6-9b33-b3a9af56ff9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_e35b8498-c1b5-499e-854e-d39491b91aa2" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_5b180383-07b9-4ec6-9b33-b3a9af56ff9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_AccruedAndOtherCurrentLiabilityMember_dc395618-1d67-4439-b25c-aad08b1d1c12" xlink:href="incy-20220930.xsd#incy_AccruedAndOtherCurrentLiabilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_5b180383-07b9-4ec6-9b33-b3a9af56ff9c" xlink:to="loc_incy_AccruedAndOtherCurrentLiabilityMember_dc395618-1d67-4439-b25c-aad08b1d1c12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1069dd49-1bae-4e67-a930-b4a18273dd67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_41e28847-4c1f-48bb-bbeb-a0bddc3c418b" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1069dd49-1bae-4e67-a930-b4a18273dd67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_FairValueInputsCashFlowsEstimatedPeriod_725ee388-b406-4bff-ba32-53dd0d84f0e0" xlink:href="incy-20220930.xsd#incy_FairValueInputsCashFlowsEstimatedPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1069dd49-1bae-4e67-a930-b4a18273dd67" xlink:to="loc_incy_FairValueInputsCashFlowsEstimatedPeriod_725ee388-b406-4bff-ba32-53dd0d84f0e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_93dcc21d-8157-4d75-870a-a6cdbd4cd72a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1069dd49-1bae-4e67-a930-b4a18273dd67" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_93dcc21d-8157-4d75-870a-a6cdbd4cd72a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityConsiderationEarned_77dd784a-f42f-4d55-b7b4-9c8a7b825576" xlink:href="incy-20220930.xsd#incy_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityConsiderationEarned"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1069dd49-1bae-4e67-a930-b4a18273dd67" xlink:to="loc_incy_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityConsiderationEarned_77dd784a-f42f-4d55-b7b4-9c8a7b825576" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.incyte.com/role/ConcentrationsofCreditRiskandCurrentExpectedCreditLossesDetails" xlink:type="simple" xlink:href="incy-20220930.xsd#ConcentrationsofCreditRiskandCurrentExpectedCreditLossesDetails"/>
  <link:presentationLink xlink:role="http://www.incyte.com/role/ConcentrationsofCreditRiskandCurrentExpectedCreditLossesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RisksAndUncertaintiesAbstract_427b98f4-2763-40d5-8f91-8e9f720e0913" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RisksAndUncertaintiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_2b43dc23-abd7-47f2-b047-06bec4cd8608" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RisksAndUncertaintiesAbstract_427b98f4-2763-40d5-8f91-8e9f720e0913" xlink:to="loc_us-gaap_ConcentrationRiskTable_2b43dc23-abd7-47f2-b047-06bec4cd8608" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_4accd5e1-c4b0-40af-bef5-b0abfce8877d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_2b43dc23-abd7-47f2-b047-06bec4cd8608" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_4accd5e1-c4b0-40af-bef5-b0abfce8877d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_0b3ea35b-9d5d-45b3-b20a-24e540d3fd66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_4accd5e1-c4b0-40af-bef5-b0abfce8877d" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_0b3ea35b-9d5d-45b3-b20a-24e540d3fd66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueProductLineMember_5ec2ed12-e6c0-4624-a7d3-5e1d2c77fdaa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueProductLineMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_0b3ea35b-9d5d-45b3-b20a-24e540d3fd66" xlink:to="loc_us-gaap_SalesRevenueProductLineMember_5ec2ed12-e6c0-4624-a7d3-5e1d2c77fdaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_c67a79f5-c103-48b7-895e-8686736a0766" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_0b3ea35b-9d5d-45b3-b20a-24e540d3fd66" xlink:to="loc_us-gaap_AccountsReceivableMember_c67a79f5-c103-48b7-895e-8686736a0766" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_0f196539-32cb-4a2e-a930-59dadf1394df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_2b43dc23-abd7-47f2-b047-06bec4cd8608" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_0f196539-32cb-4a2e-a930-59dadf1394df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_bfe41d78-6070-4e64-beca-ea5571869ea1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_0f196539-32cb-4a2e-a930-59dadf1394df" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_bfe41d78-6070-4e64-beca-ea5571869ea1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_e2e00d6f-af46-44bc-9879-c5b9d17094e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_bfe41d78-6070-4e64-beca-ea5571869ea1" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_e2e00d6f-af46-44bc-9879-c5b9d17094e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditConcentrationRiskMember_486078ca-eca1-42a6-b9e1-11ae451f6cd3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditConcentrationRiskMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_bfe41d78-6070-4e64-beca-ea5571869ea1" xlink:to="loc_us-gaap_CreditConcentrationRiskMember_486078ca-eca1-42a6-b9e1-11ae451f6cd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_cbe2b171-8e0b-4398-88ce-43fb3db3e6c0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_2b43dc23-abd7-47f2-b047-06bec4cd8608" xlink:to="loc_srt_MajorCustomersAxis_cbe2b171-8e0b-4398-88ce-43fb3db3e6c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_cba832ef-9f54-4536-ba06-34fb963b4481" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_cbe2b171-8e0b-4398-88ce-43fb3db3e6c0" xlink:to="loc_srt_NameOfMajorCustomerDomain_cba832ef-9f54-4536-ba06-34fb963b4481" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_CollaborationPartnersaBCAndDMember_a06d92bc-98bf-4694-bac1-28a155d392fb" xlink:href="incy-20220930.xsd#incy_CollaborationPartnersaBCAndDMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_cba832ef-9f54-4536-ba06-34fb963b4481" xlink:to="loc_incy_CollaborationPartnersaBCAndDMember_a06d92bc-98bf-4694-bac1-28a155d392fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_CustomerAMember_797e8c82-0cb0-443e-9e4a-f9d278611a6d" xlink:href="incy-20220930.xsd#incy_CustomerAMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_cba832ef-9f54-4536-ba06-34fb963b4481" xlink:to="loc_incy_CustomerAMember_797e8c82-0cb0-443e-9e4a-f9d278611a6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_CustomerBMember_8377a27a-7c4e-4bc6-83d1-c521d3d915f1" xlink:href="incy-20220930.xsd#incy_CustomerBMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_cba832ef-9f54-4536-ba06-34fb963b4481" xlink:to="loc_incy_CustomerBMember_8377a27a-7c4e-4bc6-83d1-c521d3d915f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_CustomerCMember_50e41098-3276-41ad-87bf-4c091f2a8dbd" xlink:href="incy-20220930.xsd#incy_CustomerCMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_cba832ef-9f54-4536-ba06-34fb963b4481" xlink:to="loc_incy_CustomerCMember_50e41098-3276-41ad-87bf-4c091f2a8dbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_CustomerDMember_e7ccb333-4357-4b2e-a58e-15160076ec72" xlink:href="incy-20220930.xsd#incy_CustomerDMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_cba832ef-9f54-4536-ba06-34fb963b4481" xlink:to="loc_incy_CustomerDMember_e7ccb333-4357-4b2e-a58e-15160076ec72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_CustomerEMember_94607352-0566-4bb9-922f-8da13f40e727" xlink:href="incy-20220930.xsd#incy_CustomerEMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_cba832ef-9f54-4536-ba06-34fb963b4481" xlink:to="loc_incy_CustomerEMember_94607352-0566-4bb9-922f-8da13f40e727" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_AggregateConcentrationCustomersMember_403f42db-67e6-4eac-b3e4-5bad511f91ee" xlink:href="incy-20220930.xsd#incy_AggregateConcentrationCustomersMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_cba832ef-9f54-4536-ba06-34fb963b4481" xlink:to="loc_incy_AggregateConcentrationCustomersMember_403f42db-67e6-4eac-b3e4-5bad511f91ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_c6eb0bf3-fcf0-4531-ac4a-1a4560a90ea4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_2b43dc23-abd7-47f2-b047-06bec4cd8608" xlink:to="loc_us-gaap_ConcentrationRiskLineItems_c6eb0bf3-fcf0-4531-ac4a-1a4560a90ea4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_46412ea9-26ac-407f-a50d-9fd8dec09428" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_c6eb0bf3-fcf0-4531-ac4a-1a4560a90ea4" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_46412ea9-26ac-407f-a50d-9fd8dec09428" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_579b99af-c517-4aa8-8c68-f4708d76fd2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_c6eb0bf3-fcf0-4531-ac4a-1a4560a90ea4" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_579b99af-c517-4aa8-8c68-f4708d76fd2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.incyte.com/role/InventoryDetails" xlink:type="simple" xlink:href="incy-20220930.xsd#InventoryDetails"/>
  <link:presentationLink xlink:role="http://www.incyte.com/role/InventoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_42dd7db4-1d27-4dd5-8f2b-66cdf360b628" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryCurrentTable_bb34abde-b203-4801-b22d-36cf9d83027c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryCurrentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_42dd7db4-1d27-4dd5-8f2b-66cdf360b628" xlink:to="loc_us-gaap_InventoryCurrentTable_bb34abde-b203-4801-b22d-36cf9d83027c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_9a676599-9b87-401b-a981-f0d1688286e9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryCurrentTable_bb34abde-b203-4801-b22d-36cf9d83027c" xlink:to="loc_srt_RangeAxis_9a676599-9b87-401b-a981-f0d1688286e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a79c3f5d-b052-4f71-84c8-07554e8808c3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_9a676599-9b87-401b-a981-f0d1688286e9" xlink:to="loc_srt_RangeMember_a79c3f5d-b052-4f71-84c8-07554e8808c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_9d356d46-522b-4bf4-9c89-321f59dd4962" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_a79c3f5d-b052-4f71-84c8-07554e8808c3" xlink:to="loc_srt_MaximumMember_9d356d46-522b-4bf4-9c89-321f59dd4962" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_fa275af3-da12-40c8-9456-67fffa3c39ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryCurrentTable_bb34abde-b203-4801-b22d-36cf9d83027c" xlink:to="loc_us-gaap_StatementLineItems_fa275af3-da12-40c8-9456-67fffa3c39ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_d43fcf97-7789-4c11-88cd-8b54cf0586c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_fa275af3-da12-40c8-9456-67fffa3c39ac" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_d43fcf97-7789-4c11-88cd-8b54cf0586c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_621dd2fb-4483-43c8-b939-79a1024c5288" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_fa275af3-da12-40c8-9456-67fffa3c39ac" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_621dd2fb-4483-43c8-b939-79a1024c5288" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_26997c25-32a4-404e-89c3-7a62340c4fcd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_fa275af3-da12-40c8-9456-67fffa3c39ac" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_26997c25-32a4-404e-89c3-7a62340c4fcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_InventoryNetCurrentAndNoncurrent_910cfdcc-9c4c-4cc0-82a5-93cd792bc742" xlink:href="incy-20220930.xsd#incy_InventoryNetCurrentAndNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_fa275af3-da12-40c8-9456-67fffa3c39ac" xlink:to="loc_incy_InventoryNetCurrentAndNoncurrent_910cfdcc-9c4c-4cc0-82a5-93cd792bc742" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_1c6745b4-ec33-435b-9c1d-c8c2df118f68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_fa275af3-da12-40c8-9456-67fffa3c39ac" xlink:to="loc_us-gaap_InventoryNet_1c6745b4-ec33-435b-9c1d-c8c2df118f68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent_aa17c9a1-115c-4b3f-abc7-8ebd18b3a023" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_fa275af3-da12-40c8-9456-67fffa3c39ac" xlink:to="loc_us-gaap_InventoryNoncurrent_aa17c9a1-115c-4b3f-abc7-8ebd18b3a023" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_InventoryRecordedAsResearchAndDevelopmentExpense_59c65c30-5f7c-44ea-90a1-5af60060cb0c" xlink:href="incy-20220930.xsd#incy_InventoryRecordedAsResearchAndDevelopmentExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_fa275af3-da12-40c8-9456-67fffa3c39ac" xlink:to="loc_incy_InventoryRecordedAsResearchAndDevelopmentExpense_59c65c30-5f7c-44ea-90a1-5af60060cb0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_PeriodOfDeviationFromAverageCostOfGoodsSold_be9159b5-de03-4076-8b0b-ff00ee68c38d" xlink:href="incy-20220930.xsd#incy_PeriodOfDeviationFromAverageCostOfGoodsSold"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_fa275af3-da12-40c8-9456-67fffa3c39ac" xlink:to="loc_incy_PeriodOfDeviationFromAverageCostOfGoodsSold_be9159b5-de03-4076-8b0b-ff00ee68c38d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.incyte.com/role/LicenseAgreementsNovartisDetails" xlink:type="simple" xlink:href="incy-20220930.xsd#LicenseAgreementsNovartisDetails"/>
  <link:presentationLink xlink:role="http://www.incyte.com/role/LicenseAgreementsNovartisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_incy_LicenseAgreementsDisclosureAbstract_85c168b6-8dc7-4bd9-a65c-ea92161a0792" xlink:href="incy-20220930.xsd#incy_LicenseAgreementsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_edef712f-1b8a-4b4f-8c3d-e6d0c8204977" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_incy_LicenseAgreementsDisclosureAbstract_85c168b6-8dc7-4bd9-a65c-ea92161a0792" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_edef712f-1b8a-4b4f-8c3d-e6d0c8204977" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_06c525a4-afc3-4458-8348-6ba686b85b4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_edef712f-1b8a-4b4f-8c3d-e6d0c8204977" xlink:to="loc_us-gaap_TypeOfArrangementAxis_06c525a4-afc3-4458-8348-6ba686b85b4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f6cb8589-c23c-428f-9023-9ead7951077d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_06c525a4-afc3-4458-8348-6ba686b85b4d" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f6cb8589-c23c-428f-9023-9ead7951077d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_NovartisMember_8edc7014-8330-405d-980d-0b26a4a3ad7c" xlink:href="incy-20220930.xsd#incy_NovartisMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f6cb8589-c23c-428f-9023-9ead7951077d" xlink:to="loc_incy_NovartisMember_8edc7014-8330-405d-980d-0b26a4a3ad7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_AchievementOfMilestoneAxis_00ec18fd-2e82-433c-9c7b-14f1acc7c6b3" xlink:href="incy-20220930.xsd#incy_AchievementOfMilestoneAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_edef712f-1b8a-4b4f-8c3d-e6d0c8204977" xlink:to="loc_incy_AchievementOfMilestoneAxis_00ec18fd-2e82-433c-9c7b-14f1acc7c6b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_AchievementOfMilestoneDomain_568d2516-b7de-4529-9f1a-ef05bbde32ad" xlink:href="incy-20220930.xsd#incy_AchievementOfMilestoneDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_incy_AchievementOfMilestoneAxis_00ec18fd-2e82-433c-9c7b-14f1acc7c6b3" xlink:to="loc_incy_AchievementOfMilestoneDomain_568d2516-b7de-4529-9f1a-ef05bbde32ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_DevelopmentMilestonesMember_e203d233-c766-402c-b9e6-672f47049cc5" xlink:href="incy-20220930.xsd#incy_DevelopmentMilestonesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_incy_AchievementOfMilestoneDomain_568d2516-b7de-4529-9f1a-ef05bbde32ad" xlink:to="loc_incy_DevelopmentMilestonesMember_e203d233-c766-402c-b9e6-672f47049cc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_RegulatoryMilestonesMember_7d8ca3d2-b1a3-4126-a940-8122bd62fe7f" xlink:href="incy-20220930.xsd#incy_RegulatoryMilestonesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_incy_AchievementOfMilestoneDomain_568d2516-b7de-4529-9f1a-ef05bbde32ad" xlink:to="loc_incy_RegulatoryMilestonesMember_7d8ca3d2-b1a3-4126-a940-8122bd62fe7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_CommercializationMilestonesMember_f696d245-7a08-4bde-833f-3742832f4f2d" xlink:href="incy-20220930.xsd#incy_CommercializationMilestonesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_incy_AchievementOfMilestoneDomain_568d2516-b7de-4529-9f1a-ef05bbde32ad" xlink:to="loc_incy_CommercializationMilestonesMember_f696d245-7a08-4bde-833f-3742832f4f2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_DevelopmentAndRegulatoryMilestonesMember_838d14fa-f9b0-4144-a7a5-f7c5c80b6476" xlink:href="incy-20220930.xsd#incy_DevelopmentAndRegulatoryMilestonesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_incy_AchievementOfMilestoneDomain_568d2516-b7de-4529-9f1a-ef05bbde32ad" xlink:to="loc_incy_DevelopmentAndRegulatoryMilestonesMember_838d14fa-f9b0-4144-a7a5-f7c5c80b6476" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_9fefdfee-3609-478a-8846-b5e8b4b16b8f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_edef712f-1b8a-4b4f-8c3d-e6d0c8204977" xlink:to="loc_srt_ProductOrServiceAxis_9fefdfee-3609-478a-8846-b5e8b4b16b8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_ca08a919-7e00-499f-950b-0f0afce3c8bd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_9fefdfee-3609-478a-8846-b5e8b4b16b8f" xlink:to="loc_srt_ProductsAndServicesDomain_ca08a919-7e00-499f-950b-0f0afce3c8bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_aefef99a-bb20-4917-92f6-649569cdeef1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_ca08a919-7e00-499f-950b-0f0afce3c8bd" xlink:to="loc_us-gaap_RoyaltyMember_aefef99a-bb20-4917-92f6-649569cdeef1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_TabrectaMember_ef1f9cbe-893c-47cc-ada4-aad416902c31" xlink:href="incy-20220930.xsd#incy_TabrectaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RoyaltyMember_aefef99a-bb20-4917-92f6-649569cdeef1" xlink:to="loc_incy_TabrectaMember_ef1f9cbe-893c-47cc-ada4-aad416902c31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_JakaviMember_0205bb45-9b02-47cc-b528-e33f8d544d24" xlink:href="incy-20220930.xsd#incy_JakaviMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RoyaltyMember_aefef99a-bb20-4917-92f6-649569cdeef1" xlink:to="loc_incy_JakaviMember_0205bb45-9b02-47cc-b528-e33f8d544d24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_JAKAFIMember_8e1cb252-fb10-4134-a493-f89b114ceadc" xlink:href="incy-20220930.xsd#incy_JAKAFIMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_ca08a919-7e00-499f-950b-0f0afce3c8bd" xlink:to="loc_incy_JAKAFIMember_8e1cb252-fb10-4134-a493-f89b114ceadc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_MilestoneAndContractRevenueMember_40970cc6-bfc9-4fc4-bedd-46b96f4d91ff" xlink:href="incy-20220930.xsd#incy_MilestoneAndContractRevenueMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_ca08a919-7e00-499f-950b-0f0afce3c8bd" xlink:to="loc_incy_MilestoneAndContractRevenueMember_40970cc6-bfc9-4fc4-bedd-46b96f4d91ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_TABRECTAPRODUCTANDSERVICESMember_1fb6a4e1-1e8b-4053-94d7-8c2317b6df19" xlink:href="incy-20220930.xsd#incy_TABRECTAPRODUCTANDSERVICESMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_ca08a919-7e00-499f-950b-0f0afce3c8bd" xlink:to="loc_incy_TABRECTAPRODUCTANDSERVICESMember_1fb6a4e1-1e8b-4053-94d7-8c2317b6df19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_83175ff1-9be5-40de-af08-c1e6f3e292d5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_edef712f-1b8a-4b4f-8c3d-e6d0c8204977" xlink:to="loc_srt_RangeAxis_83175ff1-9be5-40de-af08-c1e6f3e292d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_11ac3d00-3544-43c2-b7cc-6595744bdb91" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_83175ff1-9be5-40de-af08-c1e6f3e292d5" xlink:to="loc_srt_RangeMember_11ac3d00-3544-43c2-b7cc-6595744bdb91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_4c8e37d2-58ea-489c-952a-0c881694d8b8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_11ac3d00-3544-43c2-b7cc-6595744bdb91" xlink:to="loc_srt_MinimumMember_4c8e37d2-58ea-489c-952a-0c881694d8b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_42601a6d-ef1b-4064-a518-ad49b2dbf80f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_11ac3d00-3544-43c2-b7cc-6595744bdb91" xlink:to="loc_srt_MaximumMember_42601a6d-ef1b-4064-a518-ad49b2dbf80f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_4e58ccba-b17e-4f89-9686-bd80853f10f0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_edef712f-1b8a-4b4f-8c3d-e6d0c8204977" xlink:to="loc_srt_StatementGeographicalAxis_4e58ccba-b17e-4f89-9686-bd80853f10f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_2226464d-e773-4e6c-b15f-da1b76fec2bb" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_4e58ccba-b17e-4f89-9686-bd80853f10f0" xlink:to="loc_srt_SegmentGeographicalDomain_2226464d-e773-4e6c-b15f-da1b76fec2bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_e8cf1f5f-f2be-4f86-80a5-5c8fceaf6c39" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_2226464d-e773-4e6c-b15f-da1b76fec2bb" xlink:to="loc_country_US_e8cf1f5f-f2be-4f86-80a5-5c8fceaf6c39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_27a1bb9a-556b-4e08-b691-17a580861830" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonUsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_2226464d-e773-4e6c-b15f-da1b76fec2bb" xlink:to="loc_us-gaap_NonUsMember_27a1bb9a-556b-4e08-b691-17a580861830" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_862e195f-6339-49aa-a7d8-f10cfe829c70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_edef712f-1b8a-4b4f-8c3d-e6d0c8204977" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_862e195f-6339-49aa-a7d8-f10cfe829c70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived_d6f2fe25-c26c-49e0-b3e2-50391cd19a6f" xlink:href="incy-20220930.xsd#incy_LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_862e195f-6339-49aa-a7d8-f10cfe829c70" xlink:to="loc_incy_LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived_d6f2fe25-c26c-49e0-b3e2-50391cd19a6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone_d175d63a-739d-4647-bfba-8339b704927e" xlink:href="incy-20220930.xsd#incy_LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_862e195f-6339-49aa-a7d8-f10cfe829c70" xlink:to="loc_incy_LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone_d175d63a-739d-4647-bfba-8339b704927e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_PercentageOfRoyaltyRatePayments_1740a817-e912-4543-ac6b-67fc8ee9392f" xlink:href="incy-20220930.xsd#incy_PercentageOfRoyaltyRatePayments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_862e195f-6339-49aa-a7d8-f10cfe829c70" xlink:to="loc_incy_PercentageOfRoyaltyRatePayments_1740a817-e912-4543-ac6b-67fc8ee9392f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInRoyaltiesPayable_099d7144-41b6-4645-b29a-d1663ee442d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInRoyaltiesPayable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_862e195f-6339-49aa-a7d8-f10cfe829c70" xlink:to="loc_us-gaap_IncreaseDecreaseInRoyaltiesPayable_099d7144-41b6-4645-b29a-d1663ee442d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_RoyaltiesPayable_db43567a-3a34-4fab-87c9-773471fedb9a" xlink:href="incy-20220930.xsd#incy_RoyaltiesPayable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_862e195f-6339-49aa-a7d8-f10cfe829c70" xlink:to="loc_incy_RoyaltiesPayable_db43567a-3a34-4fab-87c9-773471fedb9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c22785e6-fb51-4119-90cf-bf29bc051885" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_862e195f-6339-49aa-a7d8-f10cfe829c70" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c22785e6-fb51-4119-90cf-bf29bc051885" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.incyte.com/role/LicenseAgreementsLillyDetails" xlink:type="simple" xlink:href="incy-20220930.xsd#LicenseAgreementsLillyDetails"/>
  <link:presentationLink xlink:role="http://www.incyte.com/role/LicenseAgreementsLillyDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_incy_LicenseAgreementsDisclosureAbstract_db4440f3-a144-4d5a-9ad3-266a76662047" xlink:href="incy-20220930.xsd#incy_LicenseAgreementsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_572226ea-d424-43ef-8f0b-29988f6f9b1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_incy_LicenseAgreementsDisclosureAbstract_db4440f3-a144-4d5a-9ad3-266a76662047" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_572226ea-d424-43ef-8f0b-29988f6f9b1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_752bf19c-db97-43ae-8987-5f416fe27535" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_572226ea-d424-43ef-8f0b-29988f6f9b1e" xlink:to="loc_us-gaap_TypeOfArrangementAxis_752bf19c-db97-43ae-8987-5f416fe27535" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_52fa2bf6-0098-4340-b565-63c037fd9346" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_752bf19c-db97-43ae-8987-5f416fe27535" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_52fa2bf6-0098-4340-b565-63c037fd9346" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_EliLillyMember_5c9978b2-92ca-43d6-98b8-8db6b2c176a9" xlink:href="incy-20220930.xsd#incy_EliLillyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_52fa2bf6-0098-4340-b565-63c037fd9346" xlink:to="loc_incy_EliLillyMember_5c9978b2-92ca-43d6-98b8-8db6b2c176a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_863ca883-8209-4e07-b2c2-9533e0f89df6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_572226ea-d424-43ef-8f0b-29988f6f9b1e" xlink:to="loc_srt_ProductOrServiceAxis_863ca883-8209-4e07-b2c2-9533e0f89df6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_502d74cb-0e6c-41d6-9cb8-26cecbd56951" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_863ca883-8209-4e07-b2c2-9533e0f89df6" xlink:to="loc_srt_ProductsAndServicesDomain_502d74cb-0e6c-41d6-9cb8-26cecbd56951" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_OlumiantMember_4837c7ab-e2a8-435b-a25a-249027a575ac" xlink:href="incy-20220930.xsd#incy_OlumiantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_502d74cb-0e6c-41d6-9cb8-26cecbd56951" xlink:to="loc_incy_OlumiantMember_4837c7ab-e2a8-435b-a25a-249027a575ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_OlumiantRoyaltyMember_72ee6cef-a303-4ec4-93b5-0f2188ae040b" xlink:href="incy-20220930.xsd#incy_OlumiantRoyaltyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_502d74cb-0e6c-41d6-9cb8-26cecbd56951" xlink:to="loc_incy_OlumiantRoyaltyMember_72ee6cef-a303-4ec4-93b5-0f2188ae040b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_GvhdMember_ed979290-6d32-4e0c-a3ba-b4c780e97980" xlink:href="incy-20220930.xsd#incy_GvhdMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_502d74cb-0e6c-41d6-9cb8-26cecbd56951" xlink:to="loc_incy_GvhdMember_ed979290-6d32-4e0c-a3ba-b4c780e97980" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_AchievementOfMilestoneAxis_0ac12d09-7e73-45db-b814-e324187dc9dd" xlink:href="incy-20220930.xsd#incy_AchievementOfMilestoneAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_572226ea-d424-43ef-8f0b-29988f6f9b1e" xlink:to="loc_incy_AchievementOfMilestoneAxis_0ac12d09-7e73-45db-b814-e324187dc9dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_AchievementOfMilestoneDomain_1e6d963f-ac87-4551-96d5-9fb75daccaf2" xlink:href="incy-20220930.xsd#incy_AchievementOfMilestoneDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_incy_AchievementOfMilestoneAxis_0ac12d09-7e73-45db-b814-e324187dc9dd" xlink:to="loc_incy_AchievementOfMilestoneDomain_1e6d963f-ac87-4551-96d5-9fb75daccaf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_DevelopmentMilestonesMember_1bed7a60-4e1c-466e-8b60-20a7fa17a189" xlink:href="incy-20220930.xsd#incy_DevelopmentMilestonesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_incy_AchievementOfMilestoneDomain_1e6d963f-ac87-4551-96d5-9fb75daccaf2" xlink:to="loc_incy_DevelopmentMilestonesMember_1bed7a60-4e1c-466e-8b60-20a7fa17a189" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_RegulatoryMilestonesMember_25681fba-06ab-45bb-9968-18800f26ed21" xlink:href="incy-20220930.xsd#incy_RegulatoryMilestonesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_incy_AchievementOfMilestoneDomain_1e6d963f-ac87-4551-96d5-9fb75daccaf2" xlink:to="loc_incy_RegulatoryMilestonesMember_25681fba-06ab-45bb-9968-18800f26ed21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_CommercializationMilestonesMember_f4191d2f-9fd3-41e7-bfe8-147c4fd19d32" xlink:href="incy-20220930.xsd#incy_CommercializationMilestonesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_incy_AchievementOfMilestoneDomain_1e6d963f-ac87-4551-96d5-9fb75daccaf2" xlink:to="loc_incy_CommercializationMilestonesMember_f4191d2f-9fd3-41e7-bfe8-147c4fd19d32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_657edd6a-a51b-4bf6-b3d3-59d0c0622fa3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_572226ea-d424-43ef-8f0b-29988f6f9b1e" xlink:to="loc_srt_RangeAxis_657edd6a-a51b-4bf6-b3d3-59d0c0622fa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ccd07ff7-b7db-44d4-a6a5-ed30b02fa20c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_657edd6a-a51b-4bf6-b3d3-59d0c0622fa3" xlink:to="loc_srt_RangeMember_ccd07ff7-b7db-44d4-a6a5-ed30b02fa20c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_b09befa0-0e80-42f6-95cc-e4ef9f5e6234" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_ccd07ff7-b7db-44d4-a6a5-ed30b02fa20c" xlink:to="loc_srt_MaximumMember_b09befa0-0e80-42f6-95cc-e4ef9f5e6234" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_8c25c760-8957-4782-af07-23c7378a3bf7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_572226ea-d424-43ef-8f0b-29988f6f9b1e" xlink:to="loc_srt_StatementGeographicalAxis_8c25c760-8957-4782-af07-23c7378a3bf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_4d2d1641-c522-4aba-b35d-335f6df8d8c6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_8c25c760-8957-4782-af07-23c7378a3bf7" xlink:to="loc_srt_SegmentGeographicalDomain_4d2d1641-c522-4aba-b35d-335f6df8d8c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_330e9898-63ef-4e1e-8a9c-1860bca860b2" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_4d2d1641-c522-4aba-b35d-335f6df8d8c6" xlink:to="loc_country_US_330e9898-63ef-4e1e-8a9c-1860bca860b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember_c9f1e257-88f1-403a-ba08-1e6793fd2f3b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EuropeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_4d2d1641-c522-4aba-b35d-335f6df8d8c6" xlink:to="loc_srt_EuropeMember_c9f1e257-88f1-403a-ba08-1e6793fd2f3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_JP_2886e706-6fc5-4b4b-9304-97cbdbe6ecfd" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_JP"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_4d2d1641-c522-4aba-b35d-335f6df8d8c6" xlink:to="loc_country_JP_2886e706-6fc5-4b4b-9304-97cbdbe6ecfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_52d21724-3477-4388-b6bb-06219f770666" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonUsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_4d2d1641-c522-4aba-b35d-335f6df8d8c6" xlink:to="loc_us-gaap_NonUsMember_52d21724-3477-4388-b6bb-06219f770666" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_94b44a1c-6420-4bb0-b858-8d31b6542f2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_572226ea-d424-43ef-8f0b-29988f6f9b1e" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_94b44a1c-6420-4bb0-b858-8d31b6542f2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived_7de89e80-d3e5-4775-a969-21431c605b1c" xlink:href="incy-20220930.xsd#incy_LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_94b44a1c-6420-4bb0-b858-8d31b6542f2d" xlink:to="loc_incy_LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived_7de89e80-d3e5-4775-a969-21431c605b1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone_69736be1-33cc-40f3-b9cc-9244adf67c2f" xlink:href="incy-20220930.xsd#incy_LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_94b44a1c-6420-4bb0-b858-8d31b6542f2d" xlink:to="loc_incy_LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone_69736be1-33cc-40f3-b9cc-9244adf67c2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_23845319-a06b-4dd1-b9e2-d2868ffdb758" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_94b44a1c-6420-4bb0-b858-8d31b6542f2d" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_23845319-a06b-4dd1-b9e2-d2868ffdb758" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInRoyaltiesPayable_7fdc523e-9099-43e4-baad-262c3ec4a362" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInRoyaltiesPayable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_94b44a1c-6420-4bb0-b858-8d31b6542f2d" xlink:to="loc_us-gaap_IncreaseDecreaseInRoyaltiesPayable_7fdc523e-9099-43e4-baad-262c3ec4a362" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_LicenseAgreementAdditionalMilestonePayments_4cc1d314-75ba-4f83-b58a-f9b41e910dd3" xlink:href="incy-20220930.xsd#incy_LicenseAgreementAdditionalMilestonePayments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_94b44a1c-6420-4bb0-b858-8d31b6542f2d" xlink:to="loc_incy_LicenseAgreementAdditionalMilestonePayments_4cc1d314-75ba-4f83-b58a-f9b41e910dd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_LicenseAgreementMilestonePaymentAmountPaid_3b6d9e7f-d7f7-448d-98d0-d0530c072359" xlink:href="incy-20220930.xsd#incy_LicenseAgreementMilestonePaymentAmountPaid"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_94b44a1c-6420-4bb0-b858-8d31b6542f2d" xlink:to="loc_incy_LicenseAgreementMilestonePaymentAmountPaid_3b6d9e7f-d7f7-448d-98d0-d0530c072359" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.incyte.com/role/LicenseAgreementsAgenusDetails" xlink:type="simple" xlink:href="incy-20220930.xsd#LicenseAgreementsAgenusDetails"/>
  <link:presentationLink xlink:role="http://www.incyte.com/role/LicenseAgreementsAgenusDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_incy_LicenseAgreementsDisclosureAbstract_d2e8a76c-4c56-498e-aa4f-1dc3fe304f8b" xlink:href="incy-20220930.xsd#incy_LicenseAgreementsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_fd745af2-1da6-485a-94a6-823c6d9c2c58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_incy_LicenseAgreementsDisclosureAbstract_d2e8a76c-4c56-498e-aa4f-1dc3fe304f8b" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_fd745af2-1da6-485a-94a6-823c6d9c2c58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_8d2c57cb-c00f-43f0-8e5d-7038795d28de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_fd745af2-1da6-485a-94a6-823c6d9c2c58" xlink:to="loc_us-gaap_TypeOfArrangementAxis_8d2c57cb-c00f-43f0-8e5d-7038795d28de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d3f84bc9-a105-4eea-99a7-af5a911758ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_8d2c57cb-c00f-43f0-8e5d-7038795d28de" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d3f84bc9-a105-4eea-99a7-af5a911758ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_AgenusMember_150181b4-7a07-4eb9-a84e-ec55f39dd304" xlink:href="incy-20220930.xsd#incy_AgenusMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d3f84bc9-a105-4eea-99a7-af5a911758ac" xlink:to="loc_incy_AgenusMember_150181b4-7a07-4eb9-a84e-ec55f39dd304" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_StockPurchaseAgreementMember_4eae7046-527a-4e6a-8440-d3dca6bd4d1d" xlink:href="incy-20220930.xsd#incy_StockPurchaseAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d3f84bc9-a105-4eea-99a7-af5a911758ac" xlink:to="loc_incy_StockPurchaseAgreementMember_4eae7046-527a-4e6a-8440-d3dca6bd4d1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_AchievementOfMilestoneAxis_3c55cb92-856e-47a0-9652-19fa540671af" xlink:href="incy-20220930.xsd#incy_AchievementOfMilestoneAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_fd745af2-1da6-485a-94a6-823c6d9c2c58" xlink:to="loc_incy_AchievementOfMilestoneAxis_3c55cb92-856e-47a0-9652-19fa540671af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_AchievementOfMilestoneDomain_8d67c7f5-9b80-4211-b00a-59d7a6076880" xlink:href="incy-20220930.xsd#incy_AchievementOfMilestoneDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_incy_AchievementOfMilestoneAxis_3c55cb92-856e-47a0-9652-19fa540671af" xlink:to="loc_incy_AchievementOfMilestoneDomain_8d67c7f5-9b80-4211-b00a-59d7a6076880" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_DevelopmentRegulatoryAndCommercializationMilestonesMember_df77e68a-4aa8-44f9-b474-f5199e46e13f" xlink:href="incy-20220930.xsd#incy_DevelopmentRegulatoryAndCommercializationMilestonesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_incy_AchievementOfMilestoneDomain_8d67c7f5-9b80-4211-b00a-59d7a6076880" xlink:to="loc_incy_DevelopmentRegulatoryAndCommercializationMilestonesMember_df77e68a-4aa8-44f9-b474-f5199e46e13f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_5c70a62f-cc55-4caa-88b9-da70d193157f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_fd745af2-1da6-485a-94a6-823c6d9c2c58" xlink:to="loc_srt_ProductOrServiceAxis_5c70a62f-cc55-4caa-88b9-da70d193157f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_d94950d9-4a13-4340-80dc-a23d224c90e6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_5c70a62f-cc55-4caa-88b9-da70d193157f" xlink:to="loc_srt_ProductsAndServicesDomain_d94950d9-4a13-4340-80dc-a23d224c90e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_ProductGroupOneMember_f7d36bfb-e573-464d-b28c-93708f5be873" xlink:href="incy-20220930.xsd#incy_ProductGroupOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d94950d9-4a13-4340-80dc-a23d224c90e6" xlink:to="loc_incy_ProductGroupOneMember_f7d36bfb-e573-464d-b28c-93708f5be873" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_ProductGroupTwoMember_70c3433d-76fa-4b5a-ad78-edbed53ab2ee" xlink:href="incy-20220930.xsd#incy_ProductGroupTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d94950d9-4a13-4340-80dc-a23d224c90e6" xlink:to="loc_incy_ProductGroupTwoMember_70c3433d-76fa-4b5a-ad78-edbed53ab2ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_7ae8570e-7521-43a4-8b60-255b4a1cd933" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_fd745af2-1da6-485a-94a6-823c6d9c2c58" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_7ae8570e-7521-43a4-8b60-255b4a1cd933" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_0b4b350d-e067-4ee2-8af7-ee5b0dff0d2d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_7ae8570e-7521-43a4-8b60-255b4a1cd933" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_0b4b350d-e067-4ee2-8af7-ee5b0dff0d2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_AgenusMember_768ec690-2ec4-4210-8ed8-2dad5d22ed60" xlink:href="incy-20220930.xsd#incy_AgenusMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_0b4b350d-e067-4ee2-8af7-ee5b0dff0d2d" xlink:to="loc_incy_AgenusMember_768ec690-2ec4-4210-8ed8-2dad5d22ed60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_e226616c-9d89-4a94-91e0-b6a222d5f4d2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_fd745af2-1da6-485a-94a6-823c6d9c2c58" xlink:to="loc_srt_RangeAxis_e226616c-9d89-4a94-91e0-b6a222d5f4d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_aa25c351-779c-4bb3-b591-e2c89642fc98" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_e226616c-9d89-4a94-91e0-b6a222d5f4d2" xlink:to="loc_srt_RangeMember_aa25c351-779c-4bb3-b591-e2c89642fc98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_0868cb89-4254-436d-801f-c285ef96c76e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_aa25c351-779c-4bb3-b591-e2c89642fc98" xlink:to="loc_srt_MinimumMember_0868cb89-4254-436d-801f-c285ef96c76e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_dcde7e26-e318-445c-a6a9-5c3fa030211d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_aa25c351-779c-4bb3-b591-e2c89642fc98" xlink:to="loc_srt_MaximumMember_dcde7e26-e318-445c-a6a9-5c3fa030211d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_095b2c32-7bb8-4262-bdef-a55bd7d35ee8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_fd745af2-1da6-485a-94a6-823c6d9c2c58" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_095b2c32-7bb8-4262-bdef-a55bd7d35ee8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_PercentageOfRoyaltyRatePayments_cdab4097-9b85-4900-8028-52e6c5a9e6ca" xlink:href="incy-20220930.xsd#incy_PercentageOfRoyaltyRatePayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_095b2c32-7bb8-4262-bdef-a55bd7d35ee8" xlink:to="loc_incy_PercentageOfRoyaltyRatePayments_cdab4097-9b85-4900-8028-52e6c5a9e6ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_LicenseAgreementTerminationNoticePeriod_1bb17072-9866-4ea5-963a-7abfa0c1e179" xlink:href="incy-20220930.xsd#incy_LicenseAgreementTerminationNoticePeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_095b2c32-7bb8-4262-bdef-a55bd7d35ee8" xlink:to="loc_incy_LicenseAgreementTerminationNoticePeriod_1bb17072-9866-4ea5-963a-7abfa0c1e179" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_LicenseAgreementMilestonePaymentAmountPaid_39ce6768-8815-45a5-a238-b9c1a57b1f98" xlink:href="incy-20220930.xsd#incy_LicenseAgreementMilestonePaymentAmountPaid"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_095b2c32-7bb8-4262-bdef-a55bd7d35ee8" xlink:to="loc_incy_LicenseAgreementMilestonePaymentAmountPaid_39ce6768-8815-45a5-a238-b9c1a57b1f98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_LicenseAgreementAdditionalMilestonePayments_09d0760f-6faf-488c-9bfa-2e8b4b987ff2" xlink:href="incy-20220930.xsd#incy_LicenseAgreementAdditionalMilestonePayments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_095b2c32-7bb8-4262-bdef-a55bd7d35ee8" xlink:to="loc_incy_LicenseAgreementAdditionalMilestonePayments_09d0760f-6faf-488c-9bfa-2e8b4b987ff2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_PurchaseOfCommonStockUnderStockPurchaseAgreementInShares_6b8b94a9-e48f-4001-88cf-8990c97c4a3c" xlink:href="incy-20220930.xsd#incy_PurchaseOfCommonStockUnderStockPurchaseAgreementInShares"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_095b2c32-7bb8-4262-bdef-a55bd7d35ee8" xlink:to="loc_incy_PurchaseOfCommonStockUnderStockPurchaseAgreementInShares_6b8b94a9-e48f-4001-88cf-8990c97c4a3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentAggregateCost_df51160a-5e89-4dff-b2cb-80a3340cdd04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentAggregateCost"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_095b2c32-7bb8-4262-bdef-a55bd7d35ee8" xlink:to="loc_us-gaap_EquityMethodInvestmentAggregateCost_df51160a-5e89-4dff-b2cb-80a3340cdd04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_db9a3674-96f7-46ed-89cb-e249845f05c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_095b2c32-7bb8-4262-bdef-a55bd7d35ee8" xlink:to="loc_us-gaap_SharePrice_db9a3674-96f7-46ed-89cb-e249845f05c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_6ed40526-68eb-47c4-86ff-dfe27f08f0ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_095b2c32-7bb8-4262-bdef-a55bd7d35ee8" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_6ed40526-68eb-47c4-86ff-dfe27f08f0ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_3fc93bb0-f2d5-4449-a5a1-3c29d1152114" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_095b2c32-7bb8-4262-bdef-a55bd7d35ee8" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_3fc93bb0-f2d5-4449-a5a1-3c29d1152114" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments_dd9b618c-cbdd-4494-8823-17d7ba4addeb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermInvestments"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_095b2c32-7bb8-4262-bdef-a55bd7d35ee8" xlink:to="loc_us-gaap_LongTermInvestments_dd9b618c-cbdd-4494-8823-17d7ba4addeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_8b484277-2845-4260-b6db-96b899e93d62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_095b2c32-7bb8-4262-bdef-a55bd7d35ee8" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_8b484277-2845-4260-b6db-96b899e93d62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_6b4b9aeb-a498-4d21-a984-734482aafdd4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_095b2c32-7bb8-4262-bdef-a55bd7d35ee8" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_6b4b9aeb-a498-4d21-a984-734482aafdd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.incyte.com/role/LicenseAgreementsMerusDetails" xlink:type="simple" xlink:href="incy-20220930.xsd#LicenseAgreementsMerusDetails"/>
  <link:presentationLink xlink:role="http://www.incyte.com/role/LicenseAgreementsMerusDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_incy_LicenseAgreementsDisclosureAbstract_085c0767-bddf-42fd-b2c8-f43b4c1a9285" xlink:href="incy-20220930.xsd#incy_LicenseAgreementsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_952ea747-9ca0-4454-b2a5-2082f3609da4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_incy_LicenseAgreementsDisclosureAbstract_085c0767-bddf-42fd-b2c8-f43b4c1a9285" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_952ea747-9ca0-4454-b2a5-2082f3609da4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_e6158c73-6a8a-4a3b-9bdb-4a5775d22804" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_952ea747-9ca0-4454-b2a5-2082f3609da4" xlink:to="loc_us-gaap_TypeOfArrangementAxis_e6158c73-6a8a-4a3b-9bdb-4a5775d22804" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2c528aad-a7e8-4448-9357-722ba58d29cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_e6158c73-6a8a-4a3b-9bdb-4a5775d22804" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2c528aad-a7e8-4448-9357-722ba58d29cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_MerusNVMember_d7981488-8c75-43ed-aff0-80e9df15222b" xlink:href="incy-20220930.xsd#incy_MerusNVMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2c528aad-a7e8-4448-9357-722ba58d29cb" xlink:to="loc_incy_MerusNVMember_d7981488-8c75-43ed-aff0-80e9df15222b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_StockPurchaseAgreementMember_5a7cb356-7977-4938-a02f-e6befa6ca5b9" xlink:href="incy-20220930.xsd#incy_StockPurchaseAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2c528aad-a7e8-4448-9357-722ba58d29cb" xlink:to="loc_incy_StockPurchaseAgreementMember_5a7cb356-7977-4938-a02f-e6befa6ca5b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_6a0e7f91-07b9-4c60-bb5c-353b26e99f27" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_952ea747-9ca0-4454-b2a5-2082f3609da4" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_6a0e7f91-07b9-4c60-bb5c-353b26e99f27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_fde2177c-46f5-41d9-9b73-3aa6f6f79fc9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_6a0e7f91-07b9-4c60-bb5c-353b26e99f27" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_fde2177c-46f5-41d9-9b73-3aa6f6f79fc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_MerusNVMember_26830916-5611-4db8-bfa3-adb33c04f168" xlink:href="incy-20220930.xsd#incy_MerusNVMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_fde2177c-46f5-41d9-9b73-3aa6f6f79fc9" xlink:to="loc_incy_MerusNVMember_26830916-5611-4db8-bfa3-adb33c04f168" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_f24b64ae-1a97-4bc7-9456-aaea0a04c7ec" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_952ea747-9ca0-4454-b2a5-2082f3609da4" xlink:to="loc_srt_RangeAxis_f24b64ae-1a97-4bc7-9456-aaea0a04c7ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e7a8cbfb-de5f-455b-ae76-8b79f31f3a0b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_f24b64ae-1a97-4bc7-9456-aaea0a04c7ec" xlink:to="loc_srt_RangeMember_e7a8cbfb-de5f-455b-ae76-8b79f31f3a0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_d7122f7b-c05b-4bcc-bf8e-a5b20aa85626" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_e7a8cbfb-de5f-455b-ae76-8b79f31f3a0b" xlink:to="loc_srt_MinimumMember_d7122f7b-c05b-4bcc-bf8e-a5b20aa85626" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_50a45661-2d19-4499-97c9-145cbefd27f2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_e7a8cbfb-de5f-455b-ae76-8b79f31f3a0b" xlink:to="loc_srt_MaximumMember_50a45661-2d19-4499-97c9-145cbefd27f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_AchievementOfMilestoneAxis_af24478c-25fd-41bc-940f-3bc1e9a2cb50" xlink:href="incy-20220930.xsd#incy_AchievementOfMilestoneAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_952ea747-9ca0-4454-b2a5-2082f3609da4" xlink:to="loc_incy_AchievementOfMilestoneAxis_af24478c-25fd-41bc-940f-3bc1e9a2cb50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_AchievementOfMilestoneDomain_5d98d41a-bbac-405b-9e43-53e6739436cc" xlink:href="incy-20220930.xsd#incy_AchievementOfMilestoneDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_incy_AchievementOfMilestoneAxis_af24478c-25fd-41bc-940f-3bc1e9a2cb50" xlink:to="loc_incy_AchievementOfMilestoneDomain_5d98d41a-bbac-405b-9e43-53e6739436cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_DevelopmentAndRegulatoryMilestonesMember_833db91c-a2a8-4518-bad5-50233df21082" xlink:href="incy-20220930.xsd#incy_DevelopmentAndRegulatoryMilestonesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_incy_AchievementOfMilestoneDomain_5d98d41a-bbac-405b-9e43-53e6739436cc" xlink:to="loc_incy_DevelopmentAndRegulatoryMilestonesMember_833db91c-a2a8-4518-bad5-50233df21082" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_CommercializationMilestonesMember_17896e74-b81e-4c7b-b878-a52e2200cb4f" xlink:href="incy-20220930.xsd#incy_CommercializationMilestonesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_incy_AchievementOfMilestoneDomain_5d98d41a-bbac-405b-9e43-53e6739436cc" xlink:to="loc_incy_CommercializationMilestonesMember_17896e74-b81e-4c7b-b878-a52e2200cb4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_e6ac5b67-60f4-49f1-b7f0-5f862ebca5ef" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_952ea747-9ca0-4454-b2a5-2082f3609da4" xlink:to="loc_srt_StatementGeographicalAxis_e6ac5b67-60f4-49f1-b7f0-5f862ebca5ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_19e7574e-01a1-4d87-a2a7-86fa7e34e2dc" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_e6ac5b67-60f4-49f1-b7f0-5f862ebca5ef" xlink:to="loc_srt_SegmentGeographicalDomain_19e7574e-01a1-4d87-a2a7-86fa7e34e2dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_21979ea9-1b19-4192-b209-8c63d78e7e36" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_19e7574e-01a1-4d87-a2a7-86fa7e34e2dc" xlink:to="loc_country_US_21979ea9-1b19-4192-b209-8c63d78e7e36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_7dc1eae6-19a4-4819-ae31-e9832e258dc2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonUsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_19e7574e-01a1-4d87-a2a7-86fa7e34e2dc" xlink:to="loc_us-gaap_NonUsMember_7dc1eae6-19a4-4819-ae31-e9832e258dc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_aff3b52a-3800-4d5f-9b32-bf454154fff8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_952ea747-9ca0-4454-b2a5-2082f3609da4" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_aff3b52a-3800-4d5f-9b32-bf454154fff8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0cfda52c-2904-45ee-9386-bfaaa1600c63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_aff3b52a-3800-4d5f-9b32-bf454154fff8" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0cfda52c-2904-45ee-9386-bfaaa1600c63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_9974f949-fc23-4c1c-91c4-0c8d0332003c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0cfda52c-2904-45ee-9386-bfaaa1600c63" xlink:to="loc_us-gaap_IPOMember_9974f949-fc23-4c1c-91c4-0c8d0332003c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_ce56eb54-980e-4b85-846d-d6adbf26aa6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_952ea747-9ca0-4454-b2a5-2082f3609da4" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_ce56eb54-980e-4b85-846d-d6adbf26aa6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_LicenseAgreementMaximumNumberOfIndependentPrograms_95f85d83-4b88-4b7e-8969-9d8541a7cdf0" xlink:href="incy-20220930.xsd#incy_LicenseAgreementMaximumNumberOfIndependentPrograms"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_ce56eb54-980e-4b85-846d-d6adbf26aa6c" xlink:to="loc_incy_LicenseAgreementMaximumNumberOfIndependentPrograms_95f85d83-4b88-4b7e-8969-9d8541a7cdf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_LicenseAgreementNumberOfAdditionalPreclinicalDiscoveryPrograms_618252f4-8b88-411d-b073-4f426e91c2bb" xlink:href="incy-20220930.xsd#incy_LicenseAgreementNumberOfAdditionalPreclinicalDiscoveryPrograms"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_ce56eb54-980e-4b85-846d-d6adbf26aa6c" xlink:to="loc_incy_LicenseAgreementNumberOfAdditionalPreclinicalDiscoveryPrograms_618252f4-8b88-411d-b073-4f426e91c2bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_NumberOfProgramsUnderWhichResultingProductsAreCoFundedForDevelopment_0782f8c0-dd6a-411d-ab3a-f0e5c0c85768" xlink:href="incy-20220930.xsd#incy_NumberOfProgramsUnderWhichResultingProductsAreCoFundedForDevelopment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_ce56eb54-980e-4b85-846d-d6adbf26aa6c" xlink:to="loc_incy_NumberOfProgramsUnderWhichResultingProductsAreCoFundedForDevelopment_0782f8c0-dd6a-411d-ab3a-f0e5c0c85768" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_PercentageFundingOnCostOnPossibleElectionOfCodevelopmentOfCompounds_99203220-ca76-4263-a3d4-bc23d27960f0" xlink:href="incy-20220930.xsd#incy_PercentageFundingOnCostOnPossibleElectionOfCodevelopmentOfCompounds"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_ce56eb54-980e-4b85-846d-d6adbf26aa6c" xlink:to="loc_incy_PercentageFundingOnCostOnPossibleElectionOfCodevelopmentOfCompounds_99203220-ca76-4263-a3d4-bc23d27960f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_LicenseAgreementAdditionalMilestonePayments_0b4f1d07-bdf5-4753-bf44-211027cde7c1" xlink:href="incy-20220930.xsd#incy_LicenseAgreementAdditionalMilestonePayments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_ce56eb54-980e-4b85-846d-d6adbf26aa6c" xlink:to="loc_incy_LicenseAgreementAdditionalMilestonePayments_0b4f1d07-bdf5-4753-bf44-211027cde7c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_PercentageOfRoyaltyRatePayments_f913a354-4af9-4250-8c39-36767f7f110b" xlink:href="incy-20220930.xsd#incy_PercentageOfRoyaltyRatePayments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_ce56eb54-980e-4b85-846d-d6adbf26aa6c" xlink:to="loc_incy_PercentageOfRoyaltyRatePayments_f913a354-4af9-4250-8c39-36767f7f110b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_CollaborationAgreementProfitSharingPercentage_a1a3d6a4-4f73-4ace-bad2-370902c0d150" xlink:href="incy-20220930.xsd#incy_CollaborationAgreementProfitSharingPercentage"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_ce56eb54-980e-4b85-846d-d6adbf26aa6c" xlink:to="loc_incy_CollaborationAgreementProfitSharingPercentage_a1a3d6a4-4f73-4ace-bad2-370902c0d150" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_PercentageOfProfitsLosses_7f6560c1-63cd-482e-9a74-9488f50571b6" xlink:href="incy-20220930.xsd#incy_PercentageOfProfitsLosses"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_ce56eb54-980e-4b85-846d-d6adbf26aa6c" xlink:to="loc_incy_PercentageOfProfitsLosses_7f6560c1-63cd-482e-9a74-9488f50571b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_LicenseAgreementMilestonePaymentAmountPaid_7506d442-50f0-4ec1-b5c5-5f291c5ac946" xlink:href="incy-20220930.xsd#incy_LicenseAgreementMilestonePaymentAmountPaid"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_ce56eb54-980e-4b85-846d-d6adbf26aa6c" xlink:to="loc_incy_LicenseAgreementMilestonePaymentAmountPaid_7506d442-50f0-4ec1-b5c5-5f291c5ac946" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_PurchaseOfCommonStockUnderStockPurchaseAgreementInShares_c5489234-6371-455b-8cbf-c25b9ee216b4" xlink:href="incy-20220930.xsd#incy_PurchaseOfCommonStockUnderStockPurchaseAgreementInShares"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_ce56eb54-980e-4b85-846d-d6adbf26aa6c" xlink:to="loc_incy_PurchaseOfCommonStockUnderStockPurchaseAgreementInShares_c5489234-6371-455b-8cbf-c25b9ee216b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentAggregateCost_30f12511-edf6-4661-af07-00176685a90e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentAggregateCost"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_ce56eb54-980e-4b85-846d-d6adbf26aa6c" xlink:to="loc_us-gaap_EquityMethodInvestmentAggregateCost_30f12511-edf6-4661-af07-00176685a90e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_4a32403d-5e81-4520-ab6b-612dd58aeff9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_ce56eb54-980e-4b85-846d-d6adbf26aa6c" xlink:to="loc_us-gaap_SharePrice_4a32403d-5e81-4520-ab6b-612dd58aeff9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_EquityMethodInvestmentSharesPurchased_fe751eea-4d12-4d82-82c8-db7a0c705abd" xlink:href="incy-20220930.xsd#incy_EquityMethodInvestmentSharesPurchased"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_ce56eb54-980e-4b85-846d-d6adbf26aa6c" xlink:to="loc_incy_EquityMethodInvestmentSharesPurchased_fe751eea-4d12-4d82-82c8-db7a0c705abd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_4f1ce03d-5b59-4627-96c2-d421f0c7a75f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_ce56eb54-980e-4b85-846d-d6adbf26aa6c" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_4f1ce03d-5b59-4627-96c2-d421f0c7a75f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentQuotedMarketValue_bf876e3f-36a7-437b-9341-ec327d2b4892" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentQuotedMarketValue"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_ce56eb54-980e-4b85-846d-d6adbf26aa6c" xlink:to="loc_us-gaap_EquityMethodInvestmentQuotedMarketValue_bf876e3f-36a7-437b-9341-ec327d2b4892" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_5bb14032-2af4-4c81-91f0-a9dd29a425ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_ce56eb54-980e-4b85-846d-d6adbf26aa6c" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_5bb14032-2af4-4c81-91f0-a9dd29a425ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_0e82322d-4dd6-4598-b630-067aca1eda53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_ce56eb54-980e-4b85-846d-d6adbf26aa6c" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_0e82322d-4dd6-4598-b630-067aca1eda53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_f806fbc3-11f4-46a4-8e55-414d53a0b8d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_ce56eb54-980e-4b85-846d-d6adbf26aa6c" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_f806fbc3-11f4-46a4-8e55-414d53a0b8d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.incyte.com/role/LicenseAgreementsCalitheraDetails" xlink:type="simple" xlink:href="incy-20220930.xsd#LicenseAgreementsCalitheraDetails"/>
  <link:presentationLink xlink:role="http://www.incyte.com/role/LicenseAgreementsCalitheraDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_incy_LicenseAgreementsDisclosureAbstract_470c24a1-0c83-4552-8f8d-f118b15b50e8" xlink:href="incy-20220930.xsd#incy_LicenseAgreementsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_2fdf7f32-0e87-4021-9a16-050a46cc5840" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_incy_LicenseAgreementsDisclosureAbstract_470c24a1-0c83-4552-8f8d-f118b15b50e8" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_2fdf7f32-0e87-4021-9a16-050a46cc5840" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_a66828fc-c1f3-4f1d-b11c-94ec4c1c0863" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_2fdf7f32-0e87-4021-9a16-050a46cc5840" xlink:to="loc_us-gaap_TypeOfArrangementAxis_a66828fc-c1f3-4f1d-b11c-94ec4c1c0863" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e13b8578-bc0a-4fa8-8138-1c113832b9cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_a66828fc-c1f3-4f1d-b11c-94ec4c1c0863" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e13b8578-bc0a-4fa8-8138-1c113832b9cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_CalitheraBiosciencesIncMember_dbc4039f-d1b8-44bd-9455-cc364941c464" xlink:href="incy-20220930.xsd#incy_CalitheraBiosciencesIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e13b8578-bc0a-4fa8-8138-1c113832b9cf" xlink:to="loc_incy_CalitheraBiosciencesIncMember_dbc4039f-d1b8-44bd-9455-cc364941c464" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_StockPurchaseAgreementMember_65111b63-f902-48c5-b8dd-762e1a354fed" xlink:href="incy-20220930.xsd#incy_StockPurchaseAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e13b8578-bc0a-4fa8-8138-1c113832b9cf" xlink:to="loc_incy_StockPurchaseAgreementMember_65111b63-f902-48c5-b8dd-762e1a354fed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_AchievementOfMilestoneAxis_dedacfcf-0211-464b-8a5d-d824269cb34b" xlink:href="incy-20220930.xsd#incy_AchievementOfMilestoneAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_2fdf7f32-0e87-4021-9a16-050a46cc5840" xlink:to="loc_incy_AchievementOfMilestoneAxis_dedacfcf-0211-464b-8a5d-d824269cb34b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_AchievementOfMilestoneDomain_bd0a645f-87bf-4f46-80c0-b353bf9f2bae" xlink:href="incy-20220930.xsd#incy_AchievementOfMilestoneDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_incy_AchievementOfMilestoneAxis_dedacfcf-0211-464b-8a5d-d824269cb34b" xlink:to="loc_incy_AchievementOfMilestoneDomain_bd0a645f-87bf-4f46-80c0-b353bf9f2bae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_DevelopmentRegulatoryAndCommercializationMilestonesMember_0c7ad4f9-6f94-434b-a562-5d71eb0a85f5" xlink:href="incy-20220930.xsd#incy_DevelopmentRegulatoryAndCommercializationMilestonesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_incy_AchievementOfMilestoneDomain_bd0a645f-87bf-4f46-80c0-b353bf9f2bae" xlink:to="loc_incy_DevelopmentRegulatoryAndCommercializationMilestonesMember_0c7ad4f9-6f94-434b-a562-5d71eb0a85f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_0796bac2-85ed-4cb7-8993-a82052193bfc" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_2fdf7f32-0e87-4021-9a16-050a46cc5840" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_0796bac2-85ed-4cb7-8993-a82052193bfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_a753c6cf-d1f0-4f67-b599-ba4c450cec6a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_0796bac2-85ed-4cb7-8993-a82052193bfc" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_a753c6cf-d1f0-4f67-b599-ba4c450cec6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_CalitheraBiosciencesIncMember_c913e6f9-1016-43ce-bcf1-ed9effd25275" xlink:href="incy-20220930.xsd#incy_CalitheraBiosciencesIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_a753c6cf-d1f0-4f67-b599-ba4c450cec6a" xlink:to="loc_incy_CalitheraBiosciencesIncMember_c913e6f9-1016-43ce-bcf1-ed9effd25275" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_7159a15b-3210-4b85-88b4-0f5b5b819c4b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_2fdf7f32-0e87-4021-9a16-050a46cc5840" xlink:to="loc_srt_StatementGeographicalAxis_7159a15b-3210-4b85-88b4-0f5b5b819c4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_d5729871-9b74-4738-9f1d-95b81ccef8ba" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_7159a15b-3210-4b85-88b4-0f5b5b819c4b" xlink:to="loc_srt_SegmentGeographicalDomain_d5729871-9b74-4738-9f1d-95b81ccef8ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_0c8f8457-bc78-41ef-90f9-78710bf83f5e" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_d5729871-9b74-4738-9f1d-95b81ccef8ba" xlink:to="loc_country_US_0c8f8457-bc78-41ef-90f9-78710bf83f5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_801ffd10-fa3f-4aa8-b090-5ac2f0d56041" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_2fdf7f32-0e87-4021-9a16-050a46cc5840" xlink:to="loc_srt_RangeAxis_801ffd10-fa3f-4aa8-b090-5ac2f0d56041" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_652743e9-8edd-4d47-a456-f5869d033505" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_801ffd10-fa3f-4aa8-b090-5ac2f0d56041" xlink:to="loc_srt_RangeMember_652743e9-8edd-4d47-a456-f5869d033505" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_bd89a51a-bc70-4ca9-ab8f-dc7761bfb2e0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_652743e9-8edd-4d47-a456-f5869d033505" xlink:to="loc_srt_MaximumMember_bd89a51a-bc70-4ca9-ab8f-dc7761bfb2e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_64dd776f-080c-46e5-ac3d-3c88516e7063" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_2fdf7f32-0e87-4021-9a16-050a46cc5840" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_64dd776f-080c-46e5-ac3d-3c88516e7063" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_6d600d7d-f187-4d97-8de3-2e90d997f522" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_64dd776f-080c-46e5-ac3d-3c88516e7063" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_6d600d7d-f187-4d97-8de3-2e90d997f522" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeMember_b8e1dd19-fe0b-46bf-8b3d-a39ee304d5ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_6d600d7d-f187-4d97-8de3-2e90d997f522" xlink:to="loc_us-gaap_OtherComprehensiveIncomeMember_b8e1dd19-fe0b-46bf-8b3d-a39ee304d5ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_146c3790-0692-4127-8d15-c1196a4d3707" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_2fdf7f32-0e87-4021-9a16-050a46cc5840" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_146c3790-0692-4127-8d15-c1196a4d3707" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_LicenseAgreementPercentageOfFutureGlobalDevelopmentCostsFunded_dfe26632-2e4e-4f47-ad04-3320dba3ef68" xlink:href="incy-20220930.xsd#incy_LicenseAgreementPercentageOfFutureGlobalDevelopmentCostsFunded"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_146c3790-0692-4127-8d15-c1196a4d3707" xlink:to="loc_incy_LicenseAgreementPercentageOfFutureGlobalDevelopmentCostsFunded_dfe26632-2e4e-4f47-ad04-3320dba3ef68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_PercentageOfProfitsLosses_0568aaae-4441-4f60-a0da-54dff0419a04" xlink:href="incy-20220930.xsd#incy_PercentageOfProfitsLosses"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_146c3790-0692-4127-8d15-c1196a4d3707" xlink:to="loc_incy_PercentageOfProfitsLosses_0568aaae-4441-4f60-a0da-54dff0419a04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_LicenseAgreementMilestonePaymentAmountPaid_c7f9a5fc-369a-47df-b840-9315eb4a374a" xlink:href="incy-20220930.xsd#incy_LicenseAgreementMilestonePaymentAmountPaid"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_146c3790-0692-4127-8d15-c1196a4d3707" xlink:to="loc_incy_LicenseAgreementMilestonePaymentAmountPaid_c7f9a5fc-369a-47df-b840-9315eb4a374a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_PurchaseOfCommonStockUnderStockPurchaseAgreementInShares_aad52ca2-0c69-4f41-9c98-df29cd3dbc1a" xlink:href="incy-20220930.xsd#incy_PurchaseOfCommonStockUnderStockPurchaseAgreementInShares"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_146c3790-0692-4127-8d15-c1196a4d3707" xlink:to="loc_incy_PurchaseOfCommonStockUnderStockPurchaseAgreementInShares_aad52ca2-0c69-4f41-9c98-df29cd3dbc1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentAggregateCost_de7d4d89-5466-4f42-9f6a-5a7dfbbd5143" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentAggregateCost"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_146c3790-0692-4127-8d15-c1196a4d3707" xlink:to="loc_us-gaap_EquityMethodInvestmentAggregateCost_de7d4d89-5466-4f42-9f6a-5a7dfbbd5143" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_131049d1-5488-437b-9b93-c980a5806d0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_146c3790-0692-4127-8d15-c1196a4d3707" xlink:to="loc_us-gaap_SharePrice_131049d1-5488-437b-9b93-c980a5806d0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_364f8c86-7128-4e4b-95f0-c1866d11c863" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_146c3790-0692-4127-8d15-c1196a4d3707" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_364f8c86-7128-4e4b-95f0-c1866d11c863" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedBalanceShares_3714f86e-f3be-44a0-b548-b2452e214622" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentOwnedBalanceShares"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_146c3790-0692-4127-8d15-c1196a4d3707" xlink:to="loc_us-gaap_InvestmentOwnedBalanceShares_3714f86e-f3be-44a0-b548-b2452e214622" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments_505eb4b5-c1a4-41d8-8fa9-bff62f920047" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermInvestments"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_146c3790-0692-4127-8d15-c1196a4d3707" xlink:to="loc_us-gaap_LongTermInvestments_505eb4b5-c1a4-41d8-8fa9-bff62f920047" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_ebd2683d-f399-41e5-95a3-e15f36a76d78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_146c3790-0692-4127-8d15-c1196a4d3707" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_ebd2683d-f399-41e5-95a3-e15f36a76d78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_75966512-9a83-4e1a-a13b-e56f14821890" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_146c3790-0692-4127-8d15-c1196a4d3707" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_75966512-9a83-4e1a-a13b-e56f14821890" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.incyte.com/role/LicenseAgreementsMacroGenicsDetails" xlink:type="simple" xlink:href="incy-20220930.xsd#LicenseAgreementsMacroGenicsDetails"/>
  <link:presentationLink xlink:role="http://www.incyte.com/role/LicenseAgreementsMacroGenicsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_incy_LicenseAgreementsDisclosureAbstract_5020b39b-2d1c-490e-8188-3168bd7e1dca" xlink:href="incy-20220930.xsd#incy_LicenseAgreementsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_95519167-3f5a-4901-9c6e-543717444b41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_incy_LicenseAgreementsDisclosureAbstract_5020b39b-2d1c-490e-8188-3168bd7e1dca" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_95519167-3f5a-4901-9c6e-543717444b41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_a15c625a-319e-412f-a463-f6bf4f8b7fe3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_95519167-3f5a-4901-9c6e-543717444b41" xlink:to="loc_us-gaap_TypeOfArrangementAxis_a15c625a-319e-412f-a463-f6bf4f8b7fe3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_915fab5c-fca6-4d3b-9201-38ea2d53381b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_a15c625a-319e-412f-a463-f6bf4f8b7fe3" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_915fab5c-fca6-4d3b-9201-38ea2d53381b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_MacrogenicsMember_b16c3813-c5b1-41c3-9d2a-aee94e166b79" xlink:href="incy-20220930.xsd#incy_MacrogenicsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_915fab5c-fca6-4d3b-9201-38ea2d53381b" xlink:to="loc_incy_MacrogenicsMember_b16c3813-c5b1-41c3-9d2a-aee94e166b79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_AchievementOfMilestoneAxis_441404f2-2e42-4a04-bdbb-2074f60bfb4a" xlink:href="incy-20220930.xsd#incy_AchievementOfMilestoneAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_95519167-3f5a-4901-9c6e-543717444b41" xlink:to="loc_incy_AchievementOfMilestoneAxis_441404f2-2e42-4a04-bdbb-2074f60bfb4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_AchievementOfMilestoneDomain_dba948c6-b07f-425f-acb3-1f017cccf4e4" xlink:href="incy-20220930.xsd#incy_AchievementOfMilestoneDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_incy_AchievementOfMilestoneAxis_441404f2-2e42-4a04-bdbb-2074f60bfb4a" xlink:to="loc_incy_AchievementOfMilestoneDomain_dba948c6-b07f-425f-acb3-1f017cccf4e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_DevelopmentAndRegulatoryMilestonesMember_cb82f568-55f4-4dd3-a46f-4f2c72f44d3d" xlink:href="incy-20220930.xsd#incy_DevelopmentAndRegulatoryMilestonesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_incy_AchievementOfMilestoneDomain_dba948c6-b07f-425f-acb3-1f017cccf4e4" xlink:to="loc_incy_DevelopmentAndRegulatoryMilestonesMember_cb82f568-55f4-4dd3-a46f-4f2c72f44d3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_DevelopmentMilestonesMember_9b7de504-0362-4bfd-bf2f-0fda18728fa3" xlink:href="incy-20220930.xsd#incy_DevelopmentMilestonesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_incy_DevelopmentAndRegulatoryMilestonesMember_cb82f568-55f4-4dd3-a46f-4f2c72f44d3d" xlink:to="loc_incy_DevelopmentMilestonesMember_9b7de504-0362-4bfd-bf2f-0fda18728fa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_CommercializationMilestonesMember_8b3ab3f2-3dd9-4ac0-a86c-d4332398c7a1" xlink:href="incy-20220930.xsd#incy_CommercializationMilestonesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_incy_AchievementOfMilestoneDomain_dba948c6-b07f-425f-acb3-1f017cccf4e4" xlink:to="loc_incy_CommercializationMilestonesMember_8b3ab3f2-3dd9-4ac0-a86c-d4332398c7a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_077388e1-96de-420f-8f52-b00ac53a4287" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_95519167-3f5a-4901-9c6e-543717444b41" xlink:to="loc_srt_RangeAxis_077388e1-96de-420f-8f52-b00ac53a4287" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_54fc2885-2991-427c-b57a-2e0a87c8bcd0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_077388e1-96de-420f-8f52-b00ac53a4287" xlink:to="loc_srt_RangeMember_54fc2885-2991-427c-b57a-2e0a87c8bcd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_bfba5af6-ccd7-45df-b218-0c9659fcd46d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_54fc2885-2991-427c-b57a-2e0a87c8bcd0" xlink:to="loc_srt_MinimumMember_bfba5af6-ccd7-45df-b218-0c9659fcd46d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_4307279a-6085-4149-a339-4c5a8aeebbf9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_54fc2885-2991-427c-b57a-2e0a87c8bcd0" xlink:to="loc_srt_MaximumMember_4307279a-6085-4149-a339-4c5a8aeebbf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_72b01aae-a680-4957-96ee-210da7b8a7e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_95519167-3f5a-4901-9c6e-543717444b41" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_72b01aae-a680-4957-96ee-210da7b8a7e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_19111d2f-7934-472e-8383-6fda30ab9b62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_72b01aae-a680-4957-96ee-210da7b8a7e7" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_19111d2f-7934-472e-8383-6fda30ab9b62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesMember_23a97f6f-05ec-4ea4-8e74-93f2d1d7043c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_19111d2f-7934-472e-8383-6fda30ab9b62" xlink:to="loc_us-gaap_AccruedLiabilitiesMember_23a97f6f-05ec-4ea4-8e74-93f2d1d7043c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_0f45310a-80e4-44dd-b9f7-764cf9ec843e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_95519167-3f5a-4901-9c6e-543717444b41" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_0f45310a-80e4-44dd-b9f7-764cf9ec843e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_LicenseAgreementMilestonePaymentAmountPaid_8bf6e729-b764-4eeb-a3d8-19aafbc1e2ea" xlink:href="incy-20220930.xsd#incy_LicenseAgreementMilestonePaymentAmountPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0f45310a-80e4-44dd-b9f7-764cf9ec843e" xlink:to="loc_incy_LicenseAgreementMilestonePaymentAmountPaid_8bf6e729-b764-4eeb-a3d8-19aafbc1e2ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_LicenseAgreementAdditionalMilestonePayments_28225e2d-2a38-4dac-96bd-7df704d63919" xlink:href="incy-20220930.xsd#incy_LicenseAgreementAdditionalMilestonePayments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0f45310a-80e4-44dd-b9f7-764cf9ec843e" xlink:to="loc_incy_LicenseAgreementAdditionalMilestonePayments_28225e2d-2a38-4dac-96bd-7df704d63919" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_PercentageOfRoyaltyRatePayments_ebbffdc4-6b9f-41a3-8b23-701405153e26" xlink:href="incy-20220930.xsd#incy_PercentageOfRoyaltyRatePayments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0f45310a-80e4-44dd-b9f7-764cf9ec843e" xlink:to="loc_incy_PercentageOfRoyaltyRatePayments_ebbffdc4-6b9f-41a3-8b23-701405153e26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_b0fc3ad8-ff66-4ff2-b5fe-e1885c1b0658" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0f45310a-80e4-44dd-b9f7-764cf9ec843e" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_b0fc3ad8-ff66-4ff2-b5fe-e1885c1b0658" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_4d747b6c-edda-448b-864e-114986b5a609" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0f45310a-80e4-44dd-b9f7-764cf9ec843e" xlink:to="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_4d747b6c-edda-448b-864e-114986b5a609" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.incyte.com/role/LicenseAgreementsSyrosDetails" xlink:type="simple" xlink:href="incy-20220930.xsd#LicenseAgreementsSyrosDetails"/>
  <link:presentationLink xlink:role="http://www.incyte.com/role/LicenseAgreementsSyrosDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_incy_LicenseAgreementsDisclosureAbstract_a233e143-f906-477a-b268-d535c2a0ee51" xlink:href="incy-20220930.xsd#incy_LicenseAgreementsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_d238b633-16fe-48cf-b0c8-6eda3d5d9de6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_incy_LicenseAgreementsDisclosureAbstract_a233e143-f906-477a-b268-d535c2a0ee51" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_d238b633-16fe-48cf-b0c8-6eda3d5d9de6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_f2880edd-24a7-4875-a26a-6ff962ddd769" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_d238b633-16fe-48cf-b0c8-6eda3d5d9de6" xlink:to="loc_us-gaap_TypeOfArrangementAxis_f2880edd-24a7-4875-a26a-6ff962ddd769" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c59db323-f125-48cf-9b7c-91297fc4444a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_f2880edd-24a7-4875-a26a-6ff962ddd769" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c59db323-f125-48cf-9b7c-91297fc4444a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_SyrosPharmaceuticalsIncMember_ca929414-5a97-439d-b355-42c542d69c25" xlink:href="incy-20220930.xsd#incy_SyrosPharmaceuticalsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c59db323-f125-48cf-9b7c-91297fc4444a" xlink:to="loc_incy_SyrosPharmaceuticalsIncMember_ca929414-5a97-439d-b355-42c542d69c25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_StockPurchaseAgreementMember_6f12d16a-a195-4b7e-ac9b-0d2416c26afc" xlink:href="incy-20220930.xsd#incy_StockPurchaseAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c59db323-f125-48cf-9b7c-91297fc4444a" xlink:to="loc_incy_StockPurchaseAgreementMember_6f12d16a-a195-4b7e-ac9b-0d2416c26afc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_AmendedStockPurchaseAgreementMember_1a68902f-e3ab-485b-9537-75aa4081f6a3" xlink:href="incy-20220930.xsd#incy_AmendedStockPurchaseAgreementMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c59db323-f125-48cf-9b7c-91297fc4444a" xlink:to="loc_incy_AmendedStockPurchaseAgreementMember_1a68902f-e3ab-485b-9537-75aa4081f6a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_AchievementOfMilestoneAxis_53842b6f-6697-4601-a97f-b69fbfa7afb2" xlink:href="incy-20220930.xsd#incy_AchievementOfMilestoneAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_d238b633-16fe-48cf-b0c8-6eda3d5d9de6" xlink:to="loc_incy_AchievementOfMilestoneAxis_53842b6f-6697-4601-a97f-b69fbfa7afb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_AchievementOfMilestoneDomain_3070a6bf-1888-496c-9cd5-0d7f1d21519c" xlink:href="incy-20220930.xsd#incy_AchievementOfMilestoneDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_incy_AchievementOfMilestoneAxis_53842b6f-6697-4601-a97f-b69fbfa7afb2" xlink:to="loc_incy_AchievementOfMilestoneDomain_3070a6bf-1888-496c-9cd5-0d7f1d21519c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_DevelopmentAndRegulatoryMilestonesMember_3f83b37b-91fe-4024-b9bb-164f3e24e287" xlink:href="incy-20220930.xsd#incy_DevelopmentAndRegulatoryMilestonesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_incy_AchievementOfMilestoneDomain_3070a6bf-1888-496c-9cd5-0d7f1d21519c" xlink:to="loc_incy_DevelopmentAndRegulatoryMilestonesMember_3f83b37b-91fe-4024-b9bb-164f3e24e287" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_CommercializationMilestonesMember_d49460d9-3b44-4026-b0b0-7f164ef2cde1" xlink:href="incy-20220930.xsd#incy_CommercializationMilestonesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_incy_AchievementOfMilestoneDomain_3070a6bf-1888-496c-9cd5-0d7f1d21519c" xlink:to="loc_incy_CommercializationMilestonesMember_d49460d9-3b44-4026-b0b0-7f164ef2cde1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_494ea434-5774-4f1e-bda7-117d9a6e6780" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_d238b633-16fe-48cf-b0c8-6eda3d5d9de6" xlink:to="loc_srt_RangeAxis_494ea434-5774-4f1e-bda7-117d9a6e6780" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9e6b9038-7f65-42a6-8fd9-5da4c9c351c6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_494ea434-5774-4f1e-bda7-117d9a6e6780" xlink:to="loc_srt_RangeMember_9e6b9038-7f65-42a6-8fd9-5da4c9c351c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_8ae139b0-0624-4a7f-98e6-44d5f4c48ae3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_9e6b9038-7f65-42a6-8fd9-5da4c9c351c6" xlink:to="loc_srt_MaximumMember_8ae139b0-0624-4a7f-98e6-44d5f4c48ae3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_a5b89487-6e14-4fb8-b409-8e7271e8808f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_d238b633-16fe-48cf-b0c8-6eda3d5d9de6" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_a5b89487-6e14-4fb8-b409-8e7271e8808f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_ccb535e8-89b5-49cf-8436-71a1969c350e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_a5b89487-6e14-4fb8-b409-8e7271e8808f" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_ccb535e8-89b5-49cf-8436-71a1969c350e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_SyrosPharmaceuticalsIncMember_042e25aa-21ed-48a4-9262-3b5efec93a32" xlink:href="incy-20220930.xsd#incy_SyrosPharmaceuticalsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_ccb535e8-89b5-49cf-8436-71a1969c350e" xlink:to="loc_incy_SyrosPharmaceuticalsIncMember_042e25aa-21ed-48a4-9262-3b5efec93a32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_326cdf90-e5f1-4460-a4fe-b8839f9402f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_d238b633-16fe-48cf-b0c8-6eda3d5d9de6" xlink:to="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_326cdf90-e5f1-4460-a4fe-b8839f9402f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockNameDomain_f49c5e23-8676-4b17-b504-2b9dd229f870" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_326cdf90-e5f1-4460-a4fe-b8839f9402f0" xlink:to="loc_us-gaap_ConversionOfStockNameDomain_f49c5e23-8676-4b17-b504-2b9dd229f870" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_PreSeptember2022StockSplitSharesMember_095ec29e-541e-4c64-a750-34d07298d6ba" xlink:href="incy-20220930.xsd#incy_PreSeptember2022StockSplitSharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockNameDomain_f49c5e23-8676-4b17-b504-2b9dd229f870" xlink:to="loc_incy_PreSeptember2022StockSplitSharesMember_095ec29e-541e-4c64-a750-34d07298d6ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_d7987a38-0ad2-4151-93f8-d9c08592ca50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_d238b633-16fe-48cf-b0c8-6eda3d5d9de6" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_d7987a38-0ad2-4151-93f8-d9c08592ca50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_NumberOfProgramTargets_6d9c2035-cbad-43cd-a58a-bb492ada3834" xlink:href="incy-20220930.xsd#incy_NumberOfProgramTargets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_d7987a38-0ad2-4151-93f8-d9c08592ca50" xlink:to="loc_incy_NumberOfProgramTargets_6d9c2035-cbad-43cd-a58a-bb492ada3834" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_LicenseAgreementTargetSelectionAndOptionExerciseFeePayments_2d00f464-1939-4968-9441-b1f30264235f" xlink:href="incy-20220930.xsd#incy_LicenseAgreementTargetSelectionAndOptionExerciseFeePayments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_d7987a38-0ad2-4151-93f8-d9c08592ca50" xlink:to="loc_incy_LicenseAgreementTargetSelectionAndOptionExerciseFeePayments_2d00f464-1939-4968-9441-b1f30264235f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_LicenseAgreementAdditionalMilestonePayments_266118fb-d5d0-47b5-9f43-68b4b6533931" xlink:href="incy-20220930.xsd#incy_LicenseAgreementAdditionalMilestonePayments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_d7987a38-0ad2-4151-93f8-d9c08592ca50" xlink:to="loc_incy_LicenseAgreementAdditionalMilestonePayments_266118fb-d5d0-47b5-9f43-68b4b6533931" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_PurchaseOfCommonStockUnderStockPurchaseAgreementInShares_a783cc28-757f-4ca4-babd-82c5502df95d" xlink:href="incy-20220930.xsd#incy_PurchaseOfCommonStockUnderStockPurchaseAgreementInShares"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_d7987a38-0ad2-4151-93f8-d9c08592ca50" xlink:to="loc_incy_PurchaseOfCommonStockUnderStockPurchaseAgreementInShares_a783cc28-757f-4ca4-babd-82c5502df95d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentAggregateCost_c4471c61-a958-4286-ba26-a91088ec267c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentAggregateCost"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_d7987a38-0ad2-4151-93f8-d9c08592ca50" xlink:to="loc_us-gaap_EquityMethodInvestmentAggregateCost_c4471c61-a958-4286-ba26-a91088ec267c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_2d6e8506-1360-4d14-b35d-fc70353ab933" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_d7987a38-0ad2-4151-93f8-d9c08592ca50" xlink:to="loc_us-gaap_SharePrice_2d6e8506-1360-4d14-b35d-fc70353ab933" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedBalanceShares_cecbb8f7-de7b-4e11-ba51-4970bd4f7e31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentOwnedBalanceShares"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_d7987a38-0ad2-4151-93f8-d9c08592ca50" xlink:to="loc_us-gaap_InvestmentOwnedBalanceShares_cecbb8f7-de7b-4e11-ba51-4970bd4f7e31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments_6a5d20b5-3c64-4baf-b044-7040e3298c4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermInvestments"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_d7987a38-0ad2-4151-93f8-d9c08592ca50" xlink:to="loc_us-gaap_LongTermInvestments_6a5d20b5-3c64-4baf-b044-7040e3298c4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_7fee696e-09d8-4483-8b36-527eaf357c6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_d7987a38-0ad2-4151-93f8-d9c08592ca50" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_7fee696e-09d8-4483-8b36-527eaf357c6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_2b8591b2-028c-4fff-a56a-381342267396" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_d7987a38-0ad2-4151-93f8-d9c08592ca50" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_2b8591b2-028c-4fff-a56a-381342267396" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_f164e6f0-d67b-43dc-9942-3605001326f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_d7987a38-0ad2-4151-93f8-d9c08592ca50" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_f164e6f0-d67b-43dc-9942-3605001326f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.incyte.com/role/LicenseAgreementsInnoventDetails" xlink:type="simple" xlink:href="incy-20220930.xsd#LicenseAgreementsInnoventDetails"/>
  <link:presentationLink xlink:role="http://www.incyte.com/role/LicenseAgreementsInnoventDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_incy_LicenseAgreementsDisclosureAbstract_b2f9adbb-582f-4bf9-a90b-f31137970d4f" xlink:href="incy-20220930.xsd#incy_LicenseAgreementsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_7f2b0d47-eeed-4dda-aac6-fff2525f65ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_incy_LicenseAgreementsDisclosureAbstract_b2f9adbb-582f-4bf9-a90b-f31137970d4f" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_7f2b0d47-eeed-4dda-aac6-fff2525f65ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_9d36f102-e0ac-4415-8415-ef330945e9b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_7f2b0d47-eeed-4dda-aac6-fff2525f65ba" xlink:to="loc_us-gaap_TypeOfArrangementAxis_9d36f102-e0ac-4415-8415-ef330945e9b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_950cf8ba-9248-454d-8407-9129731fd6d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_9d36f102-e0ac-4415-8415-ef330945e9b2" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_950cf8ba-9248-454d-8407-9129731fd6d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_InnoventBiologicsIncMember_dde04994-e603-4b57-b987-16492a1920ff" xlink:href="incy-20220930.xsd#incy_InnoventBiologicsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_950cf8ba-9248-454d-8407-9129731fd6d0" xlink:to="loc_incy_InnoventBiologicsIncMember_dde04994-e603-4b57-b987-16492a1920ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_AchievementOfMilestoneAxis_b9d98271-0a9a-41bc-8323-08d58a300e0d" xlink:href="incy-20220930.xsd#incy_AchievementOfMilestoneAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_7f2b0d47-eeed-4dda-aac6-fff2525f65ba" xlink:to="loc_incy_AchievementOfMilestoneAxis_b9d98271-0a9a-41bc-8323-08d58a300e0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_AchievementOfMilestoneDomain_f8824953-1a53-4082-9425-78ee202b2d8e" xlink:href="incy-20220930.xsd#incy_AchievementOfMilestoneDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_incy_AchievementOfMilestoneAxis_b9d98271-0a9a-41bc-8323-08d58a300e0d" xlink:to="loc_incy_AchievementOfMilestoneDomain_f8824953-1a53-4082-9425-78ee202b2d8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_DevelopmentAndRegulatoryMilestonesMember_171164bd-40ef-40f3-99bc-b2ba6a6828d9" xlink:href="incy-20220930.xsd#incy_DevelopmentAndRegulatoryMilestonesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_incy_AchievementOfMilestoneDomain_f8824953-1a53-4082-9425-78ee202b2d8e" xlink:to="loc_incy_DevelopmentAndRegulatoryMilestonesMember_171164bd-40ef-40f3-99bc-b2ba6a6828d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_RegulatoryMilestonesMember_09315e31-f354-4eaa-9f52-42958fe2dc8a" xlink:href="incy-20220930.xsd#incy_RegulatoryMilestonesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_incy_AchievementOfMilestoneDomain_f8824953-1a53-4082-9425-78ee202b2d8e" xlink:to="loc_incy_RegulatoryMilestonesMember_09315e31-f354-4eaa-9f52-42958fe2dc8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_CommercializationMilestonesMember_50fb9693-81f1-482c-93e2-f41f4899e5ac" xlink:href="incy-20220930.xsd#incy_CommercializationMilestonesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_incy_AchievementOfMilestoneDomain_f8824953-1a53-4082-9425-78ee202b2d8e" xlink:to="loc_incy_CommercializationMilestonesMember_50fb9693-81f1-482c-93e2-f41f4899e5ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_87193bec-b304-4ec4-8658-de6587224133" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_7f2b0d47-eeed-4dda-aac6-fff2525f65ba" xlink:to="loc_srt_ProductOrServiceAxis_87193bec-b304-4ec4-8658-de6587224133" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_d167298e-4f61-4c2e-aa12-690cac6772d6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_87193bec-b304-4ec4-8658-de6587224133" xlink:to="loc_srt_ProductsAndServicesDomain_d167298e-4f61-4c2e-aa12-690cac6772d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_PemazyreMember_78ceffc8-148f-4ffa-b41d-36e595a01407" xlink:href="incy-20220930.xsd#incy_PemazyreMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d167298e-4f61-4c2e-aa12-690cac6772d6" xlink:to="loc_incy_PemazyreMember_78ceffc8-148f-4ffa-b41d-36e595a01407" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_f517eb42-5861-414f-a9d8-87e2eff491a4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_7f2b0d47-eeed-4dda-aac6-fff2525f65ba" xlink:to="loc_srt_RangeAxis_f517eb42-5861-414f-a9d8-87e2eff491a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_74923e9c-ce2b-492e-bac2-259cd14d9751" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_f517eb42-5861-414f-a9d8-87e2eff491a4" xlink:to="loc_srt_RangeMember_74923e9c-ce2b-492e-bac2-259cd14d9751" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_7f2ff037-1aa8-46d2-81fb-b342130d1efe" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_74923e9c-ce2b-492e-bac2-259cd14d9751" xlink:to="loc_srt_MaximumMember_7f2ff037-1aa8-46d2-81fb-b342130d1efe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_11756cf2-37c6-43f2-9e0d-713dbbdc9154" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_7f2b0d47-eeed-4dda-aac6-fff2525f65ba" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_11756cf2-37c6-43f2-9e0d-713dbbdc9154" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived_b996b5e5-05e5-48f1-ba4d-b24ffc675171" xlink:href="incy-20220930.xsd#incy_LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_11756cf2-37c6-43f2-9e0d-713dbbdc9154" xlink:to="loc_incy_LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived_b996b5e5-05e5-48f1-ba4d-b24ffc675171" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone_4cb351fb-ab40-4193-bbbc-e9ceddf817f0" xlink:href="incy-20220930.xsd#incy_LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_11756cf2-37c6-43f2-9e0d-713dbbdc9154" xlink:to="loc_incy_LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone_4cb351fb-ab40-4193-bbbc-e9ceddf817f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.incyte.com/role/LicenseAgreementsZaiLabDetails" xlink:type="simple" xlink:href="incy-20220930.xsd#LicenseAgreementsZaiLabDetails"/>
  <link:presentationLink xlink:role="http://www.incyte.com/role/LicenseAgreementsZaiLabDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_incy_LicenseAgreementsDisclosureAbstract_401036e5-3082-4b35-aa4a-2b1b72717d8f" xlink:href="incy-20220930.xsd#incy_LicenseAgreementsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_59a3e4b4-8277-40d9-95d2-e1c0c831e663" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_incy_LicenseAgreementsDisclosureAbstract_401036e5-3082-4b35-aa4a-2b1b72717d8f" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_59a3e4b4-8277-40d9-95d2-e1c0c831e663" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_dfe6c7dd-75ae-46ee-96ef-4ccbe4d54aaf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_59a3e4b4-8277-40d9-95d2-e1c0c831e663" xlink:to="loc_us-gaap_TypeOfArrangementAxis_dfe6c7dd-75ae-46ee-96ef-4ccbe4d54aaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_976847e6-a982-4539-9fd5-02f780cc5d5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_dfe6c7dd-75ae-46ee-96ef-4ccbe4d54aaf" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_976847e6-a982-4539-9fd5-02f780cc5d5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_CollaborationAndLicenseAgreementWithZaiLabLtdMember_d71c46b7-27a2-4e55-884d-bd54158e8b08" xlink:href="incy-20220930.xsd#incy_CollaborationAndLicenseAgreementWithZaiLabLtdMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_976847e6-a982-4539-9fd5-02f780cc5d5f" xlink:to="loc_incy_CollaborationAndLicenseAgreementWithZaiLabLtdMember_d71c46b7-27a2-4e55-884d-bd54158e8b08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_AchievementOfMilestoneAxis_0830664d-aa91-456c-9161-75a56046c525" xlink:href="incy-20220930.xsd#incy_AchievementOfMilestoneAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_59a3e4b4-8277-40d9-95d2-e1c0c831e663" xlink:to="loc_incy_AchievementOfMilestoneAxis_0830664d-aa91-456c-9161-75a56046c525" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_AchievementOfMilestoneDomain_dae088b1-9f33-4223-8a37-0dbd253399a8" xlink:href="incy-20220930.xsd#incy_AchievementOfMilestoneDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_incy_AchievementOfMilestoneAxis_0830664d-aa91-456c-9161-75a56046c525" xlink:to="loc_incy_AchievementOfMilestoneDomain_dae088b1-9f33-4223-8a37-0dbd253399a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_DevelopmentAndRegulatoryMilestonesMember_ca9a0282-9873-4971-a5ba-e5bbe7b7f37c" xlink:href="incy-20220930.xsd#incy_DevelopmentAndRegulatoryMilestonesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_incy_AchievementOfMilestoneDomain_dae088b1-9f33-4223-8a37-0dbd253399a8" xlink:to="loc_incy_DevelopmentAndRegulatoryMilestonesMember_ca9a0282-9873-4971-a5ba-e5bbe7b7f37c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_CommercializationMilestonesMember_ced7a169-3433-4648-93f0-d573ae379056" xlink:href="incy-20220930.xsd#incy_CommercializationMilestonesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_incy_AchievementOfMilestoneDomain_dae088b1-9f33-4223-8a37-0dbd253399a8" xlink:to="loc_incy_CommercializationMilestonesMember_ced7a169-3433-4648-93f0-d573ae379056" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_401b4e0d-8f36-46f2-adbf-2fc050bedc16" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_59a3e4b4-8277-40d9-95d2-e1c0c831e663" xlink:to="loc_srt_RangeAxis_401b4e0d-8f36-46f2-adbf-2fc050bedc16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_884d79e0-9501-41ae-bbf2-bc4aab3cf8ec" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_401b4e0d-8f36-46f2-adbf-2fc050bedc16" xlink:to="loc_srt_RangeMember_884d79e0-9501-41ae-bbf2-bc4aab3cf8ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_7009a3f6-6efa-4659-a751-183fc1b772e7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_884d79e0-9501-41ae-bbf2-bc4aab3cf8ec" xlink:to="loc_srt_MaximumMember_7009a3f6-6efa-4659-a751-183fc1b772e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_17775bf3-d102-4a39-a9ad-d9e550b47d07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_59a3e4b4-8277-40d9-95d2-e1c0c831e663" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_17775bf3-d102-4a39-a9ad-d9e550b47d07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived_4612342c-670d-4b90-b443-b32d863d8806" xlink:href="incy-20220930.xsd#incy_LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_17775bf3-d102-4a39-a9ad-d9e550b47d07" xlink:to="loc_incy_LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived_4612342c-670d-4b90-b443-b32d863d8806" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.incyte.com/role/LicenseAgreementsMorphoSysDetails" xlink:type="simple" xlink:href="incy-20220930.xsd#LicenseAgreementsMorphoSysDetails"/>
  <link:presentationLink xlink:role="http://www.incyte.com/role/LicenseAgreementsMorphoSysDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_incy_LicenseAgreementsDisclosureAbstract_87e07bb7-a94d-46be-a328-8111878ab2dd" xlink:href="incy-20220930.xsd#incy_LicenseAgreementsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_a081b942-4194-4b24-9b1f-f4cecfddae86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_incy_LicenseAgreementsDisclosureAbstract_87e07bb7-a94d-46be-a328-8111878ab2dd" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_a081b942-4194-4b24-9b1f-f4cecfddae86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_b19c0807-9f8f-4e33-864e-ea699e7787c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_a081b942-4194-4b24-9b1f-f4cecfddae86" xlink:to="loc_us-gaap_TypeOfArrangementAxis_b19c0807-9f8f-4e33-864e-ea699e7787c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_921cbd3c-b32f-40b8-af7e-2b88105e1975" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_b19c0807-9f8f-4e33-864e-ea699e7787c7" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_921cbd3c-b32f-40b8-af7e-2b88105e1975" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_MorphosysAgMember_fde66d46-ac3e-4a98-b21e-e957ad3236b3" xlink:href="incy-20220930.xsd#incy_MorphosysAgMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_921cbd3c-b32f-40b8-af7e-2b88105e1975" xlink:to="loc_incy_MorphosysAgMember_fde66d46-ac3e-4a98-b21e-e957ad3236b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_AmericanDepositarySharesMember_27708db4-467c-4720-bb6c-1323c98dc573" xlink:href="incy-20220930.xsd#incy_AmericanDepositarySharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_incy_MorphosysAgMember_fde66d46-ac3e-4a98-b21e-e957ad3236b3" xlink:to="loc_incy_AmericanDepositarySharesMember_27708db4-467c-4720-bb6c-1323c98dc573" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_adffbb5a-19d1-4748-899b-b36cee6bf9e3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_a081b942-4194-4b24-9b1f-f4cecfddae86" xlink:to="loc_dei_LegalEntityAxis_adffbb5a-19d1-4748-899b-b36cee6bf9e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_734a5dfb-b322-43a4-8c54-5f2843b56d03" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_adffbb5a-19d1-4748-899b-b36cee6bf9e3" xlink:to="loc_dei_EntityDomain_734a5dfb-b322-43a4-8c54-5f2843b56d03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_IncyteMember_e2432295-c565-4fbc-96a6-8360221a5546" xlink:href="incy-20220930.xsd#incy_IncyteMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_734a5dfb-b322-43a4-8c54-5f2843b56d03" xlink:to="loc_incy_IncyteMember_e2432295-c565-4fbc-96a6-8360221a5546" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_b1ccc5ee-a138-48db-a7db-322a3ab81e14" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_a081b942-4194-4b24-9b1f-f4cecfddae86" xlink:to="loc_srt_CounterpartyNameAxis_b1ccc5ee-a138-48db-a7db-322a3ab81e14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5957461e-97b4-46d9-96b3-99516502c8a7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_b1ccc5ee-a138-48db-a7db-322a3ab81e14" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5957461e-97b4-46d9-96b3-99516502c8a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_MorphosysAgMember_b910dd4d-fd0e-4e71-a9e8-b73d7184069f" xlink:href="incy-20220930.xsd#incy_MorphosysAgMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5957461e-97b4-46d9-96b3-99516502c8a7" xlink:to="loc_incy_MorphosysAgMember_b910dd4d-fd0e-4e71-a9e8-b73d7184069f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_AmericanDepositarySharesMember_4437d0d4-db3d-4d35-a2d0-0109be0b52e7" xlink:href="incy-20220930.xsd#incy_AmericanDepositarySharesMember"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_AchievementOfMilestoneAxis_15473efc-f4f3-4b26-a9bb-81b31c310680" xlink:href="incy-20220930.xsd#incy_AchievementOfMilestoneAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_a081b942-4194-4b24-9b1f-f4cecfddae86" xlink:to="loc_incy_AchievementOfMilestoneAxis_15473efc-f4f3-4b26-a9bb-81b31c310680" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_AchievementOfMilestoneDomain_4825a541-1928-4ff6-bfc6-e15b7d7e3027" xlink:href="incy-20220930.xsd#incy_AchievementOfMilestoneDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_incy_AchievementOfMilestoneAxis_15473efc-f4f3-4b26-a9bb-81b31c310680" xlink:to="loc_incy_AchievementOfMilestoneDomain_4825a541-1928-4ff6-bfc6-e15b7d7e3027" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_DevelopmentAndRegulatoryMilestonesMember_9aa2cab3-d350-421f-9a18-be86875d6d79" xlink:href="incy-20220930.xsd#incy_DevelopmentAndRegulatoryMilestonesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_incy_AchievementOfMilestoneDomain_4825a541-1928-4ff6-bfc6-e15b7d7e3027" xlink:to="loc_incy_DevelopmentAndRegulatoryMilestonesMember_9aa2cab3-d350-421f-9a18-be86875d6d79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_CommercializationMilestonesMember_e8e82a2e-e2a3-4814-a548-e9f980710cd9" xlink:href="incy-20220930.xsd#incy_CommercializationMilestonesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_incy_AchievementOfMilestoneDomain_4825a541-1928-4ff6-bfc6-e15b7d7e3027" xlink:to="loc_incy_CommercializationMilestonesMember_e8e82a2e-e2a3-4814-a548-e9f980710cd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_9c79003d-e69b-4d80-8438-3b8c77e628a0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_a081b942-4194-4b24-9b1f-f4cecfddae86" xlink:to="loc_srt_RangeAxis_9c79003d-e69b-4d80-8438-3b8c77e628a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b3dfe461-d991-4a6d-9eb5-28cdb798549a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_9c79003d-e69b-4d80-8438-3b8c77e628a0" xlink:to="loc_srt_RangeMember_b3dfe461-d991-4a6d-9eb5-28cdb798549a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_52d579df-d70d-4f94-b596-33c1a5d89ed3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_b3dfe461-d991-4a6d-9eb5-28cdb798549a" xlink:to="loc_srt_MaximumMember_52d579df-d70d-4f94-b596-33c1a5d89ed3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_26611813-00a7-4534-be9d-291c9f7332be" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_a081b942-4194-4b24-9b1f-f4cecfddae86" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_26611813-00a7-4534-be9d-291c9f7332be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_207ac105-b739-4498-826e-cb5b3d3ad360" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_26611813-00a7-4534-be9d-291c9f7332be" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_207ac105-b739-4498-826e-cb5b3d3ad360" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_MorphosysAgMember_c975a830-2468-40c1-90fb-b28f125952ed" xlink:href="incy-20220930.xsd#incy_MorphosysAgMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_207ac105-b739-4498-826e-cb5b3d3ad360" xlink:to="loc_incy_MorphosysAgMember_c975a830-2468-40c1-90fb-b28f125952ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_AmericanDepositarySharesMember_862513b9-9dff-4710-ae14-37978d0cc4a1" xlink:href="incy-20220930.xsd#incy_AmericanDepositarySharesMember"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_bc2ef739-4096-4222-b39e-84aed8ef7893" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_a081b942-4194-4b24-9b1f-f4cecfddae86" xlink:to="loc_srt_StatementGeographicalAxis_bc2ef739-4096-4222-b39e-84aed8ef7893" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_1909a468-99d3-46fa-a724-56cf1c805f94" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_bc2ef739-4096-4222-b39e-84aed8ef7893" xlink:to="loc_srt_SegmentGeographicalDomain_1909a468-99d3-46fa-a724-56cf1c805f94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_d58aa87c-fb04-456b-bd32-53bffa82eb98" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_1909a468-99d3-46fa-a724-56cf1c805f94" xlink:to="loc_country_US_d58aa87c-fb04-456b-bd32-53bffa82eb98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_c4b2c428-03d6-4e54-b562-2cd75a340524" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_a081b942-4194-4b24-9b1f-f4cecfddae86" xlink:to="loc_srt_ProductOrServiceAxis_c4b2c428-03d6-4e54-b562-2cd75a340524" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_c32ae3b3-9ae7-43b7-b9c7-3694b71a284a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_c4b2c428-03d6-4e54-b562-2cd75a340524" xlink:to="loc_srt_ProductsAndServicesDomain_c32ae3b3-9ae7-43b7-b9c7-3694b71a284a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_TafasitamabProductAndServiceMember_b61a4d46-bc74-4278-afd0-a1c49a050b07" xlink:href="incy-20220930.xsd#incy_TafasitamabProductAndServiceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_c32ae3b3-9ae7-43b7-b9c7-3694b71a284a" xlink:to="loc_incy_TafasitamabProductAndServiceMember_b61a4d46-bc74-4278-afd0-a1c49a050b07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_89104dc8-f2ca-4c9f-ac88-c2cd5d64a41b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_a081b942-4194-4b24-9b1f-f4cecfddae86" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_89104dc8-f2ca-4c9f-ac88-c2cd5d64a41b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_LicenseAgreementPercentageOfFutureGlobalDevelopmentCostsFunded_d172a122-4976-428b-ad6f-95de9cf934ea" xlink:href="incy-20220930.xsd#incy_LicenseAgreementPercentageOfFutureGlobalDevelopmentCostsFunded"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_89104dc8-f2ca-4c9f-ac88-c2cd5d64a41b" xlink:to="loc_incy_LicenseAgreementPercentageOfFutureGlobalDevelopmentCostsFunded_d172a122-4976-428b-ad6f-95de9cf934ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_LicenseAgreementAdditionalMilestonePayments_d6970105-8563-4bdf-80fd-cafa2a750e38" xlink:href="incy-20220930.xsd#incy_LicenseAgreementAdditionalMilestonePayments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_89104dc8-f2ca-4c9f-ac88-c2cd5d64a41b" xlink:to="loc_incy_LicenseAgreementAdditionalMilestonePayments_d6970105-8563-4bdf-80fd-cafa2a750e38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_LicenseAgreementMilestonePaymentAmountPaid_f2a8e86a-5cea-4108-a9fc-1f6f5d282413" xlink:href="incy-20220930.xsd#incy_LicenseAgreementMilestonePaymentAmountPaid"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_89104dc8-f2ca-4c9f-ac88-c2cd5d64a41b" xlink:to="loc_incy_LicenseAgreementMilestonePaymentAmountPaid_f2a8e86a-5cea-4108-a9fc-1f6f5d282413" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_SubsidiaryStockConversionRatio_6d3495d6-b55b-4881-9291-f7ac834d3d63" xlink:href="incy-20220930.xsd#incy_SubsidiaryStockConversionRatio"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_89104dc8-f2ca-4c9f-ac88-c2cd5d64a41b" xlink:to="loc_incy_SubsidiaryStockConversionRatio_6d3495d6-b55b-4881-9291-f7ac834d3d63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentAggregateCost_d11694ec-1ba1-4ed7-bc5f-aa7201034aa4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentAggregateCost"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_89104dc8-f2ca-4c9f-ac88-c2cd5d64a41b" xlink:to="loc_us-gaap_EquityMethodInvestmentAggregateCost_d11694ec-1ba1-4ed7-bc5f-aa7201034aa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_a304f85c-500f-4d4a-a5ef-fb06b2e13b49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_89104dc8-f2ca-4c9f-ac88-c2cd5d64a41b" xlink:to="loc_us-gaap_SharePrice_a304f85c-500f-4d4a-a5ef-fb06b2e13b49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_16c7ab54-0d0f-4435-8cec-68222aaa09ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_89104dc8-f2ca-4c9f-ac88-c2cd5d64a41b" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_16c7ab54-0d0f-4435-8cec-68222aaa09ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_68d796a9-8c1a-4081-b42b-24f40d182e60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_89104dc8-f2ca-4c9f-ac88-c2cd5d64a41b" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_68d796a9-8c1a-4081-b42b-24f40d182e60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_CollaborationAgreementProfitLossSharingRatio_2dd6cc81-a2d9-4c1a-8db5-1819bbeed4b8" xlink:href="incy-20220930.xsd#incy_CollaborationAgreementProfitLossSharingRatio"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_89104dc8-f2ca-4c9f-ac88-c2cd5d64a41b" xlink:to="loc_incy_CollaborationAgreementProfitLossSharingRatio_2dd6cc81-a2d9-4c1a-8db5-1819bbeed4b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_CollaborationLossSharingExpense_0d5a1dca-2e1e-4beb-815d-7c634847c5d3" xlink:href="incy-20220930.xsd#incy_CollaborationLossSharingExpense"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_89104dc8-f2ca-4c9f-ac88-c2cd5d64a41b" xlink:to="loc_incy_CollaborationLossSharingExpense_0d5a1dca-2e1e-4beb-815d-7c634847c5d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_d76c2961-bd1b-4837-968b-2ea576cb2b2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_89104dc8-f2ca-4c9f-ac88-c2cd5d64a41b" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_d76c2961-bd1b-4837-968b-2ea576cb2b2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_674e44c7-f611-45cf-a292-c092cb3eb6ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_89104dc8-f2ca-4c9f-ac88-c2cd5d64a41b" xlink:to="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_674e44c7-f611-45cf-a292-c092cb3eb6ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.incyte.com/role/LicenseAgreementsNimbleDetails" xlink:type="simple" xlink:href="incy-20220930.xsd#LicenseAgreementsNimbleDetails"/>
  <link:presentationLink xlink:role="http://www.incyte.com/role/LicenseAgreementsNimbleDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_incy_LicenseAgreementsDisclosureAbstract_641e5f48-c6a2-4e51-8eec-321ef5a71495" xlink:href="incy-20220930.xsd#incy_LicenseAgreementsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_80b11f27-689e-4069-9044-b94cff5b9ec6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_incy_LicenseAgreementsDisclosureAbstract_641e5f48-c6a2-4e51-8eec-321ef5a71495" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_80b11f27-689e-4069-9044-b94cff5b9ec6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_057d95f1-8985-4cc3-bb8d-b01b91e9f81a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_80b11f27-689e-4069-9044-b94cff5b9ec6" xlink:to="loc_us-gaap_TypeOfArrangementAxis_057d95f1-8985-4cc3-bb8d-b01b91e9f81a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_60188738-e511-4d6c-8975-9126f1b24aff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_057d95f1-8985-4cc3-bb8d-b01b91e9f81a" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_60188738-e511-4d6c-8975-9126f1b24aff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_NimbleMember_3406cb1c-b2ee-480c-9ec3-55dc6f22f398" xlink:href="incy-20220930.xsd#incy_NimbleMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_60188738-e511-4d6c-8975-9126f1b24aff" xlink:to="loc_incy_NimbleMember_3406cb1c-b2ee-480c-9ec3-55dc6f22f398" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_AchievementOfMilestoneAxis_a0a0ac4c-33af-4bd2-8d8e-065eaad91ee6" xlink:href="incy-20220930.xsd#incy_AchievementOfMilestoneAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_80b11f27-689e-4069-9044-b94cff5b9ec6" xlink:to="loc_incy_AchievementOfMilestoneAxis_a0a0ac4c-33af-4bd2-8d8e-065eaad91ee6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_AchievementOfMilestoneDomain_1b38707c-0297-45d8-855e-ac0c265faac6" xlink:href="incy-20220930.xsd#incy_AchievementOfMilestoneDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_incy_AchievementOfMilestoneAxis_a0a0ac4c-33af-4bd2-8d8e-065eaad91ee6" xlink:to="loc_incy_AchievementOfMilestoneDomain_1b38707c-0297-45d8-855e-ac0c265faac6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_FutureContingentDiscoveryMilestoneMember_affdd0cb-ef15-4951-94c1-2f0a2d80131a" xlink:href="incy-20220930.xsd#incy_FutureContingentDiscoveryMilestoneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_incy_AchievementOfMilestoneDomain_1b38707c-0297-45d8-855e-ac0c265faac6" xlink:to="loc_incy_FutureContingentDiscoveryMilestoneMember_affdd0cb-ef15-4951-94c1-2f0a2d80131a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_DevelopmentAndRegulatoryMilestonesMember_840327f0-ac73-4135-8ba7-5f7ec10867f6" xlink:href="incy-20220930.xsd#incy_DevelopmentAndRegulatoryMilestonesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_incy_AchievementOfMilestoneDomain_1b38707c-0297-45d8-855e-ac0c265faac6" xlink:to="loc_incy_DevelopmentAndRegulatoryMilestonesMember_840327f0-ac73-4135-8ba7-5f7ec10867f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_CommercializationMilestonesMember_f2bd6549-67a7-4960-98eb-9c0ae7a5275f" xlink:href="incy-20220930.xsd#incy_CommercializationMilestonesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_incy_AchievementOfMilestoneDomain_1b38707c-0297-45d8-855e-ac0c265faac6" xlink:to="loc_incy_CommercializationMilestonesMember_f2bd6549-67a7-4960-98eb-9c0ae7a5275f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_758c32ee-3697-43cc-bafe-1954bf23e031" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_80b11f27-689e-4069-9044-b94cff5b9ec6" xlink:to="loc_srt_RangeAxis_758c32ee-3697-43cc-bafe-1954bf23e031" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_36e65a72-a18b-4600-a781-0cae8c3b85c5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_758c32ee-3697-43cc-bafe-1954bf23e031" xlink:to="loc_srt_RangeMember_36e65a72-a18b-4600-a781-0cae8c3b85c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_bb46797c-e405-498c-82bd-90a9bbe4523c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_36e65a72-a18b-4600-a781-0cae8c3b85c5" xlink:to="loc_srt_MaximumMember_bb46797c-e405-498c-82bd-90a9bbe4523c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_53c1b115-3a41-4098-afc1-8d6ed40a40ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_80b11f27-689e-4069-9044-b94cff5b9ec6" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_53c1b115-3a41-4098-afc1-8d6ed40a40ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_LicenseAgreementAdditionalMilestonePayments_470b9ac9-369b-45c2-8621-b0a92ad29991" xlink:href="incy-20220930.xsd#incy_LicenseAgreementAdditionalMilestonePayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_53c1b115-3a41-4098-afc1-8d6ed40a40ca" xlink:to="loc_incy_LicenseAgreementAdditionalMilestonePayments_470b9ac9-369b-45c2-8621-b0a92ad29991" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.incyte.com/role/LicenseAgreementsInnoCareDetails" xlink:type="simple" xlink:href="incy-20220930.xsd#LicenseAgreementsInnoCareDetails"/>
  <link:presentationLink xlink:role="http://www.incyte.com/role/LicenseAgreementsInnoCareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_incy_LicenseAgreementsDisclosureAbstract_b9b1668f-14d4-4800-8e9b-df105cb18053" xlink:href="incy-20220930.xsd#incy_LicenseAgreementsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_730c6b1a-79d1-49a4-8afa-c31c019ae350" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_incy_LicenseAgreementsDisclosureAbstract_b9b1668f-14d4-4800-8e9b-df105cb18053" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_730c6b1a-79d1-49a4-8afa-c31c019ae350" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_ad3c90e8-3f8d-4579-b13d-c80697c7b8d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_730c6b1a-79d1-49a4-8afa-c31c019ae350" xlink:to="loc_us-gaap_TypeOfArrangementAxis_ad3c90e8-3f8d-4579-b13d-c80697c7b8d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a4649c1e-9adb-410e-96a0-07c6cfd21475" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_ad3c90e8-3f8d-4579-b13d-c80697c7b8d0" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a4649c1e-9adb-410e-96a0-07c6cfd21475" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_InnocarePharmaLimitedMember_81c9c51e-a5f0-4434-9099-79e2a82c3e23" xlink:href="incy-20220930.xsd#incy_InnocarePharmaLimitedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a4649c1e-9adb-410e-96a0-07c6cfd21475" xlink:to="loc_incy_InnocarePharmaLimitedMember_81c9c51e-a5f0-4434-9099-79e2a82c3e23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_ef9eb24a-cc08-40b8-ab43-1061a6480cb9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_730c6b1a-79d1-49a4-8afa-c31c019ae350" xlink:to="loc_srt_ProductOrServiceAxis_ef9eb24a-cc08-40b8-ab43-1061a6480cb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_6e3a13ad-ccf9-4775-ba11-c100ee20e363" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_ef9eb24a-cc08-40b8-ab43-1061a6480cb9" xlink:to="loc_srt_ProductsAndServicesDomain_6e3a13ad-ccf9-4775-ba11-c100ee20e363" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_TafasitamabMember_d81bcf69-8f53-44f3-afdf-4cf0c53c143b" xlink:href="incy-20220930.xsd#incy_TafasitamabMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_6e3a13ad-ccf9-4775-ba11-c100ee20e363" xlink:to="loc_incy_TafasitamabMember_d81bcf69-8f53-44f3-afdf-4cf0c53c143b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_657c5344-cf33-4aaa-bae7-af04d10f14e9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_730c6b1a-79d1-49a4-8afa-c31c019ae350" xlink:to="loc_srt_RangeAxis_657c5344-cf33-4aaa-bae7-af04d10f14e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_17c8bdc0-ba5e-4397-9819-e3ae600105d8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_657c5344-cf33-4aaa-bae7-af04d10f14e9" xlink:to="loc_srt_RangeMember_17c8bdc0-ba5e-4397-9819-e3ae600105d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_7f7179e1-fa94-45ad-b896-5c93a8336c29" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_17c8bdc0-ba5e-4397-9819-e3ae600105d8" xlink:to="loc_srt_MaximumMember_7f7179e1-fa94-45ad-b896-5c93a8336c29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_0a13a9eb-292a-4170-b81a-7598956c0d90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_730c6b1a-79d1-49a4-8afa-c31c019ae350" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_0a13a9eb-292a-4170-b81a-7598956c0d90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_LicenseAgreementUpfrontPaymentReceived_5067d799-b397-4ee5-9f66-da97ef605bf0" xlink:href="incy-20220930.xsd#incy_LicenseAgreementUpfrontPaymentReceived"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0a13a9eb-292a-4170-b81a-7598956c0d90" xlink:to="loc_incy_LicenseAgreementUpfrontPaymentReceived_5067d799-b397-4ee5-9f66-da97ef605bf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived_b069ddca-dd5b-4856-9d3c-4d5855b7d3d5" xlink:href="incy-20220930.xsd#incy_LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0a13a9eb-292a-4170-b81a-7598956c0d90" xlink:to="loc_incy_LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived_b069ddca-dd5b-4856-9d3c-4d5855b7d3d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.incyte.com/role/LicenseAgreementsSyndaxDetails" xlink:type="simple" xlink:href="incy-20220930.xsd#LicenseAgreementsSyndaxDetails"/>
  <link:presentationLink xlink:role="http://www.incyte.com/role/LicenseAgreementsSyndaxDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_incy_LicenseAgreementsDisclosureAbstract_7148eb3c-1820-44f7-a593-fc87accf1d8e" xlink:href="incy-20220930.xsd#incy_LicenseAgreementsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_f5e5e011-9982-4ddd-b98a-1d632beb6e4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_incy_LicenseAgreementsDisclosureAbstract_7148eb3c-1820-44f7-a593-fc87accf1d8e" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_f5e5e011-9982-4ddd-b98a-1d632beb6e4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_9e33d4e6-92ac-477a-9bef-fe1ec06e5200" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_f5e5e011-9982-4ddd-b98a-1d632beb6e4b" xlink:to="loc_us-gaap_TypeOfArrangementAxis_9e33d4e6-92ac-477a-9bef-fe1ec06e5200" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_31ac57a8-01f4-47c2-93b2-36f3da6918a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_9e33d4e6-92ac-477a-9bef-fe1ec06e5200" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_31ac57a8-01f4-47c2-93b2-36f3da6918a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_SyndaxPharmaceuticalsIncMember_c36420d8-e767-4ee3-9dad-c45811b534aa" xlink:href="incy-20220930.xsd#incy_SyndaxPharmaceuticalsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_31ac57a8-01f4-47c2-93b2-36f3da6918a0" xlink:to="loc_incy_SyndaxPharmaceuticalsIncMember_c36420d8-e767-4ee3-9dad-c45811b534aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_StockPurchaseAgreementMember_1c5a67e2-178d-4026-a7e5-955ca5e79091" xlink:href="incy-20220930.xsd#incy_StockPurchaseAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_31ac57a8-01f4-47c2-93b2-36f3da6918a0" xlink:to="loc_incy_StockPurchaseAgreementMember_1c5a67e2-178d-4026-a7e5-955ca5e79091" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_e81b3a74-5fd7-4b8c-87f5-6baaac4bfcca" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_f5e5e011-9982-4ddd-b98a-1d632beb6e4b" xlink:to="loc_dei_LegalEntityAxis_e81b3a74-5fd7-4b8c-87f5-6baaac4bfcca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_edcc82ff-5e9e-4fbd-841c-f634e84b31e6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_e81b3a74-5fd7-4b8c-87f5-6baaac4bfcca" xlink:to="loc_dei_EntityDomain_edcc82ff-5e9e-4fbd-841c-f634e84b31e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_IncyteMember_2ed6ae07-0c9d-4a8e-bc67-b4d5afa4d0b0" xlink:href="incy-20220930.xsd#incy_IncyteMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_edcc82ff-5e9e-4fbd-841c-f634e84b31e6" xlink:to="loc_incy_IncyteMember_2ed6ae07-0c9d-4a8e-bc67-b4d5afa4d0b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_a93e867d-6462-42ae-93ee-e18e283a91ef" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_f5e5e011-9982-4ddd-b98a-1d632beb6e4b" xlink:to="loc_srt_CounterpartyNameAxis_a93e867d-6462-42ae-93ee-e18e283a91ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ce062758-23e1-48e2-9c1c-8604dd4a7328" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_a93e867d-6462-42ae-93ee-e18e283a91ef" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ce062758-23e1-48e2-9c1c-8604dd4a7328" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_SyndaxPharmaceuticalsIncMember_e1312d54-934f-4815-8e1b-80c439192ba0" xlink:href="incy-20220930.xsd#incy_SyndaxPharmaceuticalsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ce062758-23e1-48e2-9c1c-8604dd4a7328" xlink:to="loc_incy_SyndaxPharmaceuticalsIncMember_e1312d54-934f-4815-8e1b-80c439192ba0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_e338852a-fa7f-4859-a358-f98149da2144" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_f5e5e011-9982-4ddd-b98a-1d632beb6e4b" xlink:to="loc_srt_StatementGeographicalAxis_e338852a-fa7f-4859-a358-f98149da2144" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_03174750-d659-42dc-a3de-9d8c9f734c60" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_e338852a-fa7f-4859-a358-f98149da2144" xlink:to="loc_srt_SegmentGeographicalDomain_03174750-d659-42dc-a3de-9d8c9f734c60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_baab5556-466a-44a1-a426-8886f6e22005" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_03174750-d659-42dc-a3de-9d8c9f734c60" xlink:to="loc_country_US_baab5556-466a-44a1-a426-8886f6e22005" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_AchievementOfMilestoneAxis_bcf903d4-6b04-400d-be9c-28635ca66fdf" xlink:href="incy-20220930.xsd#incy_AchievementOfMilestoneAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_f5e5e011-9982-4ddd-b98a-1d632beb6e4b" xlink:to="loc_incy_AchievementOfMilestoneAxis_bcf903d4-6b04-400d-be9c-28635ca66fdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_AchievementOfMilestoneDomain_ddb0e2e4-3f95-41af-b9a0-ffb986211422" xlink:href="incy-20220930.xsd#incy_AchievementOfMilestoneDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_incy_AchievementOfMilestoneAxis_bcf903d4-6b04-400d-be9c-28635ca66fdf" xlink:to="loc_incy_AchievementOfMilestoneDomain_ddb0e2e4-3f95-41af-b9a0-ffb986211422" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_DevelopmentAndRegulatoryMilestonesMember_e210f047-a868-4046-9175-31ac35bec196" xlink:href="incy-20220930.xsd#incy_DevelopmentAndRegulatoryMilestonesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_incy_AchievementOfMilestoneDomain_ddb0e2e4-3f95-41af-b9a0-ffb986211422" xlink:to="loc_incy_DevelopmentAndRegulatoryMilestonesMember_e210f047-a868-4046-9175-31ac35bec196" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_CommercializationMilestonesMember_b86fc870-9d2e-4649-8af5-d062e4b0f96d" xlink:href="incy-20220930.xsd#incy_CommercializationMilestonesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_incy_AchievementOfMilestoneDomain_ddb0e2e4-3f95-41af-b9a0-ffb986211422" xlink:to="loc_incy_CommercializationMilestonesMember_b86fc870-9d2e-4649-8af5-d062e4b0f96d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_bffd3625-2d1c-4374-a755-f6b71e6f94ab" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_f5e5e011-9982-4ddd-b98a-1d632beb6e4b" xlink:to="loc_srt_RangeAxis_bffd3625-2d1c-4374-a755-f6b71e6f94ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_00868818-5e1c-4cfc-b596-c153adff67c6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_bffd3625-2d1c-4374-a755-f6b71e6f94ab" xlink:to="loc_srt_RangeMember_00868818-5e1c-4cfc-b596-c153adff67c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_92a0cb54-b49b-440f-812b-ee922b1cb7e7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_00868818-5e1c-4cfc-b596-c153adff67c6" xlink:to="loc_srt_MaximumMember_92a0cb54-b49b-440f-812b-ee922b1cb7e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_31a88bfc-a0b2-4576-b69d-367e7d394064" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_f5e5e011-9982-4ddd-b98a-1d632beb6e4b" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_31a88bfc-a0b2-4576-b69d-367e7d394064" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_cf442d8a-4fd0-43fa-a03b-c0ad9ccdde55" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_31a88bfc-a0b2-4576-b69d-367e7d394064" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_cf442d8a-4fd0-43fa-a03b-c0ad9ccdde55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_InvestmentInSyndaxPharmaceuticalsIncMember_c570f887-d5cf-4b75-a700-058c9326f79e" xlink:href="incy-20220930.xsd#incy_InvestmentInSyndaxPharmaceuticalsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_cf442d8a-4fd0-43fa-a03b-c0ad9ccdde55" xlink:to="loc_incy_InvestmentInSyndaxPharmaceuticalsIncMember_c570f887-d5cf-4b75-a700-058c9326f79e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_5a08e409-b5c1-4143-81b6-9c0c72caac26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_f5e5e011-9982-4ddd-b98a-1d632beb6e4b" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_5a08e409-b5c1-4143-81b6-9c0c72caac26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_LicenseAgreementPercentageOfFutureGlobalDevelopmentCostsFunded_d144e5b1-e993-4b86-bce8-11d417e2081e" xlink:href="incy-20220930.xsd#incy_LicenseAgreementPercentageOfFutureGlobalDevelopmentCostsFunded"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_5a08e409-b5c1-4143-81b6-9c0c72caac26" xlink:to="loc_incy_LicenseAgreementPercentageOfFutureGlobalDevelopmentCostsFunded_d144e5b1-e993-4b86-bce8-11d417e2081e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_LicenseAgreementUpfrontPaymentAmountPaid_eed7be00-347f-4f1a-8fb8-ce3de1db2e70" xlink:href="incy-20220930.xsd#incy_LicenseAgreementUpfrontPaymentAmountPaid"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_5a08e409-b5c1-4143-81b6-9c0c72caac26" xlink:to="loc_incy_LicenseAgreementUpfrontPaymentAmountPaid_eed7be00-347f-4f1a-8fb8-ce3de1db2e70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_LicenseAgreementAdditionalMilestonePayments_899568ce-a31d-412e-a176-3c7e137138df" xlink:href="incy-20220930.xsd#incy_LicenseAgreementAdditionalMilestonePayments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_5a08e409-b5c1-4143-81b6-9c0c72caac26" xlink:to="loc_incy_LicenseAgreementAdditionalMilestonePayments_899568ce-a31d-412e-a176-3c7e137138df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_PurchaseOfCommonStockUnderStockPurchaseAgreementInShares_05dd2a6e-a509-4e52-9db2-5559661210f7" xlink:href="incy-20220930.xsd#incy_PurchaseOfCommonStockUnderStockPurchaseAgreementInShares"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_5a08e409-b5c1-4143-81b6-9c0c72caac26" xlink:to="loc_incy_PurchaseOfCommonStockUnderStockPurchaseAgreementInShares_05dd2a6e-a509-4e52-9db2-5559661210f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentAggregateCost_e208f8a6-eea2-4ba4-8357-738a6ccc519b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentAggregateCost"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_5a08e409-b5c1-4143-81b6-9c0c72caac26" xlink:to="loc_us-gaap_EquityMethodInvestmentAggregateCost_e208f8a6-eea2-4ba4-8357-738a6ccc519b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_0130cb1b-be8b-4c58-b5d4-140f1ae4a0bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_5a08e409-b5c1-4143-81b6-9c0c72caac26" xlink:to="loc_us-gaap_SharePrice_0130cb1b-be8b-4c58-b5d4-140f1ae4a0bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments_58ce414b-48fb-4d83-8a81-99fb62b27407" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermInvestments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_5a08e409-b5c1-4143-81b6-9c0c72caac26" xlink:to="loc_us-gaap_LongTermInvestments_58ce414b-48fb-4d83-8a81-99fb62b27407" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_8598686f-7c70-49eb-8329-0e1b1c03c2fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_5a08e409-b5c1-4143-81b6-9c0c72caac26" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_8598686f-7c70-49eb-8329-0e1b1c03c2fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_fb810e82-d9fa-483f-9238-05d9006e7b9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_5a08e409-b5c1-4143-81b6-9c0c72caac26" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_fb810e82-d9fa-483f-9238-05d9006e7b9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_3781b2f9-1b2c-4abf-8344-81274a32024a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_5a08e409-b5c1-4143-81b6-9c0c72caac26" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_3781b2f9-1b2c-4abf-8344-81274a32024a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.incyte.com/role/PropertyandEquipmentnetPropertyandequipmentnetDetails" xlink:type="simple" xlink:href="incy-20220930.xsd#PropertyandEquipmentnetPropertyandequipmentnetDetails"/>
  <link:presentationLink xlink:role="http://www.incyte.com/role/PropertyandEquipmentnetPropertyandequipmentnetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_2880da65-da39-4390-87e9-247dfe7b88b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_aca44067-fde2-4ef8-9806-0c1d9cd2b392" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_2880da65-da39-4390-87e9-247dfe7b88b8" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_aca44067-fde2-4ef8-9806-0c1d9cd2b392" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_dd17f082-9097-409f-80be-60a6ca863e72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_aca44067-fde2-4ef8-9806-0c1d9cd2b392" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_dd17f082-9097-409f-80be-60a6ca863e72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_115543a7-3a96-403b-91bc-200d9415cc0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_dd17f082-9097-409f-80be-60a6ca863e72" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_115543a7-3a96-403b-91bc-200d9415cc0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember_64aebe57-c931-482b-bf78-759065f111cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OfficeEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_115543a7-3a96-403b-91bc-200d9415cc0b" xlink:to="loc_us-gaap_OfficeEquipmentMember_64aebe57-c931-482b-bf78-759065f111cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_ad730301-4ac6-4e23-aba0-ce404cfc7d2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_115543a7-3a96-403b-91bc-200d9415cc0b" xlink:to="loc_us-gaap_EquipmentMember_ad730301-4ac6-4e23-aba0-ce404cfc7d2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_41a9f74b-0782-4162-b745-b953457177ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_115543a7-3a96-403b-91bc-200d9415cc0b" xlink:to="loc_us-gaap_ComputerEquipmentMember_41a9f74b-0782-4162-b745-b953457177ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandMember_750bba4f-22dd-45fc-8684-195155ad5644" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LandMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_115543a7-3a96-403b-91bc-200d9415cc0b" xlink:to="loc_us-gaap_LandMember_750bba4f-22dd-45fc-8684-195155ad5644" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_BuildingAndLeaseholdImprovementsMember_8e87163f-71a9-4cf3-8e77-6e42e77b3514" xlink:href="incy-20220930.xsd#incy_BuildingAndLeaseholdImprovementsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_115543a7-3a96-403b-91bc-200d9415cc0b" xlink:to="loc_incy_BuildingAndLeaseholdImprovementsMember_8e87163f-71a9-4cf3-8e77-6e42e77b3514" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_OperatingLeaseRightOfUseAssetsMember_c719a136-4769-4489-8e5d-6bc70283565e" xlink:href="incy-20220930.xsd#incy_OperatingLeaseRightOfUseAssetsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_115543a7-3a96-403b-91bc-200d9415cc0b" xlink:to="loc_incy_OperatingLeaseRightOfUseAssetsMember_c719a136-4769-4489-8e5d-6bc70283565e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_c5d6a3ce-bfe1-4f4c-856d-3ef931264fd1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_115543a7-3a96-403b-91bc-200d9415cc0b" xlink:to="loc_us-gaap_ConstructionInProgressMember_c5d6a3ce-bfe1-4f4c-856d-3ef931264fd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9f748e36-0ff6-4e1f-909b-42cc36da29fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_aca44067-fde2-4ef8-9806-0c1d9cd2b392" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9f748e36-0ff6-4e1f-909b-42cc36da29fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_1750bf8c-7e70-4cb0-8fec-c85eb0508ad5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9f748e36-0ff6-4e1f-909b-42cc36da29fb" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_1750bf8c-7e70-4cb0-8fec-c85eb0508ad5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_24dee932-1b2d-4ba2-90e3-8c840b044c01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9f748e36-0ff6-4e1f-909b-42cc36da29fb" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_24dee932-1b2d-4ba2-90e3-8c840b044c01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_20bf751c-5d08-428a-b032-6840f0a1b200" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9f748e36-0ff6-4e1f-909b-42cc36da29fb" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_20bf751c-5d08-428a-b032-6840f0a1b200" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.incyte.com/role/PropertyandEquipmentnetBuildingsandconstructionDetails" xlink:type="simple" xlink:href="incy-20220930.xsd#PropertyandEquipmentnetBuildingsandconstructionDetails"/>
  <link:presentationLink xlink:role="http://www.incyte.com/role/PropertyandEquipmentnetBuildingsandconstructionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_4fe42e8e-0f2b-4831-bf04-4170562d4b0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3dbb24c1-b5e2-4214-96ed-5979af2357f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_4fe42e8e-0f2b-4831-bf04-4170562d4b0f" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3dbb24c1-b5e2-4214-96ed-5979af2357f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealEstatePropertiesAxis_be66fadd-3fd4-44a4-a9b7-5d05d732f0fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RealEstatePropertiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3dbb24c1-b5e2-4214-96ed-5979af2357f4" xlink:to="loc_us-gaap_RealEstatePropertiesAxis_be66fadd-3fd4-44a4-a9b7-5d05d732f0fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealEstatePropertiesDomain_9f119c25-611d-4694-8ea3-69c370093f02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RealEstatePropertiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RealEstatePropertiesAxis_be66fadd-3fd4-44a4-a9b7-5d05d732f0fb" xlink:to="loc_us-gaap_RealEstatePropertiesDomain_9f119c25-611d-4694-8ea3-69c370093f02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_OfficeBuildingWilmingtonDelawareMember_4ee5f635-cf92-42cc-abbb-430c2b861354" xlink:href="incy-20220930.xsd#incy_OfficeBuildingWilmingtonDelawareMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RealEstatePropertiesDomain_9f119c25-611d-4694-8ea3-69c370093f02" xlink:to="loc_incy_OfficeBuildingWilmingtonDelawareMember_4ee5f635-cf92-42cc-abbb-430c2b861354" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_OfficeBuildingMorgesSwitzerlandMember_ccf09e63-dc97-4a98-b7ec-e260820279a5" xlink:href="incy-20220930.xsd#incy_OfficeBuildingMorgesSwitzerlandMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RealEstatePropertiesDomain_9f119c25-611d-4694-8ea3-69c370093f02" xlink:to="loc_incy_OfficeBuildingMorgesSwitzerlandMember_ccf09e63-dc97-4a98-b7ec-e260820279a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_LandLocatedWithinYParcSwitzerlandsLargestTechnologyParkInYverdonMember_5f7ba981-ee5f-41b5-9043-38fdd9d0e4ec" xlink:href="incy-20220930.xsd#incy_LandLocatedWithinYParcSwitzerlandsLargestTechnologyParkInYverdonMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RealEstatePropertiesDomain_9f119c25-611d-4694-8ea3-69c370093f02" xlink:to="loc_incy_LandLocatedWithinYParcSwitzerlandsLargestTechnologyParkInYverdonMember_5f7ba981-ee5f-41b5-9043-38fdd9d0e4ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8f62a0b5-d072-4aac-a73f-db1494fe3bb7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3dbb24c1-b5e2-4214-96ed-5979af2357f4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8f62a0b5-d072-4aac-a73f-db1494fe3bb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c32f6589-46cf-4003-875f-13fca2848e4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8f62a0b5-d072-4aac-a73f-db1494fe3bb7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c32f6589-46cf-4003-875f-13fca2848e4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_BuildingAndLeaseholdImprovementsMember_3e21aaf6-c068-4c54-89da-9cebf1694c2d" xlink:href="incy-20220930.xsd#incy_BuildingAndLeaseholdImprovementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c32f6589-46cf-4003-875f-13fca2848e4d" xlink:to="loc_incy_BuildingAndLeaseholdImprovementsMember_3e21aaf6-c068-4c54-89da-9cebf1694c2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_ff6348fd-53f7-4ad6-9f1b-79321f5031da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c32f6589-46cf-4003-875f-13fca2848e4d" xlink:to="loc_us-gaap_ConstructionInProgressMember_ff6348fd-53f7-4ad6-9f1b-79321f5031da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ebc60995-865d-458f-ba41-34f4bb82f2f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3dbb24c1-b5e2-4214-96ed-5979af2357f4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ebc60995-865d-458f-ba41-34f4bb82f2f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfRealEstateProperty_9513d0a8-20c8-4a32-b130-23494681d189" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AreaOfRealEstateProperty"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ebc60995-865d-458f-ba41-34f4bb82f2f6" xlink:to="loc_us-gaap_AreaOfRealEstateProperty_9513d0a8-20c8-4a32-b130-23494681d189" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_649b3d7f-e457-487f-bd3c-c2911340f7a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ebc60995-865d-458f-ba41-34f4bb82f2f6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_649b3d7f-e457-487f-bd3c-c2911340f7a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeaseTermOfContract1_3f610c8b-99a9-4e33-ace2-a74d5a387e4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeFinanceLeaseTermOfContract1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ebc60995-865d-458f-ba41-34f4bb82f2f6" xlink:to="loc_us-gaap_LesseeFinanceLeaseTermOfContract1_3f610c8b-99a9-4e33-ace2-a74d5a387e4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeaseExistenceOfOptionToExtend_67748da1-c494-4799-8c6c-3f273ef37408" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeFinanceLeaseExistenceOfOptionToExtend"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ebc60995-865d-458f-ba41-34f4bb82f2f6" xlink:to="loc_us-gaap_LesseeFinanceLeaseExistenceOfOptionToExtend_67748da1-c494-4799-8c6c-3f273ef37408" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeaseRenewalTerm1_d226fe22-d249-4460-ac2a-22048e0d35e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeFinanceLeaseRenewalTerm1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ebc60995-865d-458f-ba41-34f4bb82f2f6" xlink:to="loc_us-gaap_LesseeFinanceLeaseRenewalTerm1_d226fe22-d249-4460-ac2a-22048e0d35e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_17a3ffb1-a4c4-4f5a-a81b-1f942a6f2282" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ebc60995-865d-458f-ba41-34f4bb82f2f6" xlink:to="loc_us-gaap_FinanceLeaseLiability_17a3ffb1-a4c4-4f5a-a81b-1f942a6f2282" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset_310d3591-e244-4d28-9e7f-df0a6ad4fd79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ebc60995-865d-458f-ba41-34f4bb82f2f6" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAsset_310d3591-e244-4d28-9e7f-df0a6ad4fd79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_FinanceLeaseLeaseIncentiveReceivable_860b6ffa-9b66-4af4-91e5-43d0159aca88" xlink:href="incy-20220930.xsd#incy_FinanceLeaseLeaseIncentiveReceivable"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ebc60995-865d-458f-ba41-34f4bb82f2f6" xlink:to="loc_incy_FinanceLeaseLeaseIncentiveReceivable_860b6ffa-9b66-4af4-91e5-43d0159aca88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireRealEstate_2aac361d-689a-41be-820b-9b950ce75561" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireRealEstate"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ebc60995-865d-458f-ba41-34f4bb82f2f6" xlink:to="loc_us-gaap_PaymentsToAcquireRealEstate_2aac361d-689a-41be-820b-9b950ce75561" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.incyte.com/role/AccruedandOtherCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="incy-20220930.xsd#AccruedandOtherCurrentLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.incyte.com/role/AccruedandOtherCurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_feeba185-383c-45b2-ac59-0d444976ea4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_ecdc2612-bd6e-4dcf-825c-6c842843093f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_feeba185-383c-45b2-ac59-0d444976ea4e" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_ecdc2612-bd6e-4dcf-825c-6c842843093f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent_fe0cb9cb-ef02-42f2-9a49-a0536cd4d4ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedRoyaltiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_ecdc2612-bd6e-4dcf-825c-6c842843093f" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrent_fe0cb9cb-ef02-42f2-9a49-a0536cd4d4ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_AccruedClinicalRelatedCostsCurrent_1652eed6-4c7e-4db6-8cdc-c33ed43cee6d" xlink:href="incy-20220930.xsd#incy_AccruedClinicalRelatedCostsCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_ecdc2612-bd6e-4dcf-825c-6c842843093f" xlink:to="loc_incy_AccruedClinicalRelatedCostsCurrent_1652eed6-4c7e-4db6-8cdc-c33ed43cee6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForLossOnContracts_fac2c34b-bdf7-4515-bf78-19eeb68c5965" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForLossOnContracts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_ecdc2612-bd6e-4dcf-825c-6c842843093f" xlink:to="loc_us-gaap_ProvisionForLossOnContracts_fac2c34b-bdf7-4515-bf78-19eeb68c5965" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedMarketingCostsCurrent_832664a9-403e-4d72-aa56-63ef180b2629" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedMarketingCostsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_ecdc2612-bd6e-4dcf-825c-6c842843093f" xlink:to="loc_us-gaap_AccruedMarketingCostsCurrent_832664a9-403e-4d72-aa56-63ef180b2629" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionPayableCurrent_032c70bd-8b1d-46ba-b4c5-36adfaf08054" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionPayableCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_ecdc2612-bd6e-4dcf-825c-6c842843093f" xlink:to="loc_us-gaap_ConstructionPayableCurrent_032c70bd-8b1d-46ba-b4c5-36adfaf08054" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_6952705d-f7d3-4ea6-a6ab-f88d0d920a92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_ecdc2612-bd6e-4dcf-825c-6c842843093f" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_6952705d-f7d3-4ea6-a6ab-f88d0d920a92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_47819103-0184-4d27-9d82-0ff96caa392b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_ecdc2612-bd6e-4dcf-825c-6c842843093f" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_47819103-0184-4d27-9d82-0ff96caa392b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_4eda6180-4865-40a3-8702-ba50924fe325" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_ecdc2612-bd6e-4dcf-825c-6c842843093f" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_4eda6180-4865-40a3-8702-ba50924fe325" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.incyte.com/role/StockCompensationNarrativeDetails" xlink:type="simple" xlink:href="incy-20220930.xsd#StockCompensationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.incyte.com/role/StockCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e17fb26c-7749-4927-970f-77bc733d0e09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ab3ed9e9-8d00-4d82-a6f9-7097819d75e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e17fb26c-7749-4927-970f-77bc733d0e09" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ab3ed9e9-8d00-4d82-a6f9-7097819d75e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_d7958f40-9ed1-4bb3-a9c4-b7ad84fbd4c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ab3ed9e9-8d00-4d82-a6f9-7097819d75e0" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_d7958f40-9ed1-4bb3-a9c4-b7ad84fbd4c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_3d241c68-3cf8-4bb4-9047-ddae95c091e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_d7958f40-9ed1-4bb3-a9c4-b7ad84fbd4c2" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_3d241c68-3cf8-4bb4-9047-ddae95c091e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_ac7f1ed8-88d1-4716-bbfd-99a108a9678d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_3d241c68-3cf8-4bb4-9047-ddae95c091e5" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_ac7f1ed8-88d1-4716-bbfd-99a108a9678d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_826a9094-1ced-4bb8-be5d-a2b207439ecc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_3d241c68-3cf8-4bb4-9047-ddae95c091e5" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_826a9094-1ced-4bb8-be5d-a2b207439ecc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_07e12994-f08a-4330-8a46-e8f1906e070a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_3d241c68-3cf8-4bb4-9047-ddae95c091e5" xlink:to="loc_us-gaap_CostOfSalesMember_07e12994-f08a-4330-8a46-e8f1906e070a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_d10a43a1-4898-43b5-b1d4-c4070ea1d1d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ab3ed9e9-8d00-4d82-a6f9-7097819d75e0" xlink:to="loc_us-gaap_AwardTypeAxis_d10a43a1-4898-43b5-b1d4-c4070ea1d1d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_09cb2792-f4ba-4b87-aeda-0059191d16bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_d10a43a1-4898-43b5-b1d4-c4070ea1d1d6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_09cb2792-f4ba-4b87-aeda-0059191d16bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_1974e3b0-bc03-4967-9897-884974cac38a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_09cb2792-f4ba-4b87-aeda-0059191d16bd" xlink:to="loc_us-gaap_EmployeeStockOptionMember_1974e3b0-bc03-4967-9897-884974cac38a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_b6f4cbfe-0ff0-4bb7-b6a5-40c854dfd678" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_09cb2792-f4ba-4b87-aeda-0059191d16bd" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_b6f4cbfe-0ff0-4bb7-b6a5-40c854dfd678" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_7cd083f9-cbd7-421f-97e9-56ebfbc4095f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_09cb2792-f4ba-4b87-aeda-0059191d16bd" xlink:to="loc_us-gaap_PerformanceSharesMember_7cd083f9-cbd7-421f-97e9-56ebfbc4095f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_885a7666-d354-4e3d-92b6-da59066938d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ab3ed9e9-8d00-4d82-a6f9-7097819d75e0" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_885a7666-d354-4e3d-92b6-da59066938d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_de4d89d6-8c5a-48b5-b7e5-103e0c737002" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_885a7666-d354-4e3d-92b6-da59066938d5" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_de4d89d6-8c5a-48b5-b7e5-103e0c737002" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_caad79ce-a66d-44c7-901e-49b9ff6c79c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_de4d89d6-8c5a-48b5-b7e5-103e0c737002" xlink:to="loc_us-gaap_EmployeeStockMember_caad79ce-a66d-44c7-901e-49b9ff6c79c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_764a2c92-d7eb-4932-9eaa-56d84b7bcb75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ab3ed9e9-8d00-4d82-a6f9-7097819d75e0" xlink:to="loc_us-gaap_VestingAxis_764a2c92-d7eb-4932-9eaa-56d84b7bcb75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_b976cc96-fdc4-498f-be89-f820e8e50fef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_764a2c92-d7eb-4932-9eaa-56d84b7bcb75" xlink:to="loc_us-gaap_VestingDomain_b976cc96-fdc4-498f-be89-f820e8e50fef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_e6bdc0fc-dbf8-46c2-baf0-e67fb0e8b5b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_b976cc96-fdc4-498f-be89-f820e8e50fef" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_e6bdc0fc-dbf8-46c2-baf0-e67fb0e8b5b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_d8019c27-28d2-42d2-9e5e-20b27dbe2f45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_b976cc96-fdc4-498f-be89-f820e8e50fef" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_d8019c27-28d2-42d2-9e5e-20b27dbe2f45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_2d9136e2-9fe4-4a41-8edb-bd231dc59dd5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ab3ed9e9-8d00-4d82-a6f9-7097819d75e0" xlink:to="loc_srt_RangeAxis_2d9136e2-9fe4-4a41-8edb-bd231dc59dd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f06d5a0a-5151-4a20-a374-d847b1522518" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_2d9136e2-9fe4-4a41-8edb-bd231dc59dd5" xlink:to="loc_srt_RangeMember_f06d5a0a-5151-4a20-a374-d847b1522518" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_24958ac1-92b4-43c9-8636-8b1dcc81d2ba" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_f06d5a0a-5151-4a20-a374-d847b1522518" xlink:to="loc_srt_MinimumMember_24958ac1-92b4-43c9-8636-8b1dcc81d2ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_9f5bb04c-dd26-44c7-8f64-64abd407eaf2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_f06d5a0a-5151-4a20-a374-d847b1522518" xlink:to="loc_srt_MaximumMember_9f5bb04c-dd26-44c7-8f64-64abd407eaf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cdb54f4e-c9d4-4cbe-a460-10a6976c3899" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ab3ed9e9-8d00-4d82-a6f9-7097819d75e0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cdb54f4e-c9d4-4cbe-a460-10a6976c3899" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_cb8c1d4b-0dbc-4ad2-a361-d196e1704c00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cdb54f4e-c9d4-4cbe-a460-10a6976c3899" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_cb8c1d4b-0dbc-4ad2-a361-d196e1704c00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_2a95d824-6997-4488-8937-93fb404cbc25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cdb54f4e-c9d4-4cbe-a460-10a6976c3899" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_2a95d824-6997-4488-8937-93fb404cbc25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_2c5d4d81-81a4-421a-a2d9-55de2d8f0d7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cdb54f4e-c9d4-4cbe-a460-10a6976c3899" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_2c5d4d81-81a4-421a-a2d9-55de2d8f0d7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_f93e8c0f-b7dc-4128-a533-d1d1db6f3b9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cdb54f4e-c9d4-4cbe-a460-10a6976c3899" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_f93e8c0f-b7dc-4128-a533-d1d1db6f3b9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_068f76a0-a76f-40a8-bb17-d5f59ccaee86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cdb54f4e-c9d4-4cbe-a460-10a6976c3899" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_068f76a0-a76f-40a8-bb17-d5f59ccaee86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesPerRestrictedStockUnits_8c532157-3493-45a4-93e2-9fcb7c48e58d" xlink:href="incy-20220930.xsd#incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesPerRestrictedStockUnits"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cdb54f4e-c9d4-4cbe-a460-10a6976c3899" xlink:to="loc_incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesPerRestrictedStockUnits_8c532157-3493-45a4-93e2-9fcb7c48e58d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedAnnualizedForfeitureRate_f4b52741-6c57-4a6e-bc84-0dd0028c4b3a" xlink:href="incy-20220930.xsd#incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedAnnualizedForfeitureRate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cdb54f4e-c9d4-4cbe-a460-10a6976c3899" xlink:to="loc_incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedAnnualizedForfeitureRate_f4b52741-6c57-4a6e-bc84-0dd0028c4b3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract_adb97ad0-9092-420b-a1b9-4bdd4b3b638b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cdb54f4e-c9d4-4cbe-a460-10a6976c3899" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract_adb97ad0-9092-420b-a1b9-4bdd4b3b638b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_ce024c61-ea62-4cba-ab21-4b7ece9b965e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract_adb97ad0-9092-420b-a1b9-4bdd4b3b638b" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_ce024c61-ea62-4cba-ab21-4b7ece9b965e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_b7427dfb-f2be-42f9-8d99-3f746e8f1b33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract_adb97ad0-9092-420b-a1b9-4bdd4b3b638b" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_b7427dfb-f2be-42f9-8d99-3f746e8f1b33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.incyte.com/role/StockCompensationValuationassumptionsusedforvalueofstockcompensationgrantedDetails" xlink:type="simple" xlink:href="incy-20220930.xsd#StockCompensationValuationassumptionsusedforvalueofstockcompensationgrantedDetails"/>
  <link:presentationLink xlink:role="http://www.incyte.com/role/StockCompensationValuationassumptionsusedforvalueofstockcompensationgrantedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_be9acd5e-d9bf-4e28-b84a-18f982661ced" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_17868112-6c05-42d7-88fd-382a16380b32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_be9acd5e-d9bf-4e28-b84a-18f982661ced" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_17868112-6c05-42d7-88fd-382a16380b32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_1b7b6ee4-3db4-49fa-abc0-6fef3b49c2fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_17868112-6c05-42d7-88fd-382a16380b32" xlink:to="loc_us-gaap_AwardTypeAxis_1b7b6ee4-3db4-49fa-abc0-6fef3b49c2fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d68f8e47-7e9c-4b87-935f-bbda06d1d8e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_1b7b6ee4-3db4-49fa-abc0-6fef3b49c2fa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d68f8e47-7e9c-4b87-935f-bbda06d1d8e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_46c604dd-c9ed-466f-9345-3ec7a960c56b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d68f8e47-7e9c-4b87-935f-bbda06d1d8e4" xlink:to="loc_us-gaap_EmployeeStockOptionMember_46c604dd-c9ed-466f-9345-3ec7a960c56b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_da6d8f44-fae9-4c9d-b9c4-2714e39be690" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_17868112-6c05-42d7-88fd-382a16380b32" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_da6d8f44-fae9-4c9d-b9c4-2714e39be690" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_316b424b-cdac-4dc2-8369-0cf57a616df8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_da6d8f44-fae9-4c9d-b9c4-2714e39be690" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_316b424b-cdac-4dc2-8369-0cf57a616df8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_1eaaa7dd-1b44-4047-9359-e11f06f2c57a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_316b424b-cdac-4dc2-8369-0cf57a616df8" xlink:to="loc_us-gaap_EmployeeStockMember_1eaaa7dd-1b44-4047-9359-e11f06f2c57a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_51790044-a746-4633-8977-a8e7d6b4f5c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_17868112-6c05-42d7-88fd-382a16380b32" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_51790044-a746-4633-8977-a8e7d6b4f5c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_85121fd5-0af0-4fed-92c4-8c100fdd4aaa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_51790044-a746-4633-8977-a8e7d6b4f5c2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_85121fd5-0af0-4fed-92c4-8c100fdd4aaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_998f0b0a-d405-444a-a9c5-dde990d86907" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_85121fd5-0af0-4fed-92c4-8c100fdd4aaa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_998f0b0a-d405-444a-a9c5-dde990d86907" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_c030cc17-9d3b-4bfb-9dd9-f701868dca81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_85121fd5-0af0-4fed-92c4-8c100fdd4aaa" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_c030cc17-9d3b-4bfb-9dd9-f701868dca81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_b8b0bc5c-c701-43e0-a2cb-eb49494e207a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_85121fd5-0af0-4fed-92c4-8c100fdd4aaa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_b8b0bc5c-c701-43e0-a2cb-eb49494e207a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_fa0c5a35-8f04-469f-ba21-0c506efdd88c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_85121fd5-0af0-4fed-92c4-8c100fdd4aaa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_fa0c5a35-8f04-469f-ba21-0c506efdd88c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.incyte.com/role/StockCompensationOptionactivityunderthe2010stockplanDetails" xlink:type="simple" xlink:href="incy-20220930.xsd#StockCompensationOptionactivityunderthe2010stockplanDetails"/>
  <link:presentationLink xlink:role="http://www.incyte.com/role/StockCompensationOptionactivityunderthe2010stockplanDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2f4632b6-0b6e-4288-a421-b90ea9d55a33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c37bef69-f6a0-41a3-8be1-77817586b661" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2f4632b6-0b6e-4288-a421-b90ea9d55a33" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c37bef69-f6a0-41a3-8be1-77817586b661" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_6e409546-f038-4d3e-a79a-218ca129f7d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c37bef69-f6a0-41a3-8be1-77817586b661" xlink:to="loc_us-gaap_AwardTypeAxis_6e409546-f038-4d3e-a79a-218ca129f7d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_549eaa4d-b78a-4426-b7cd-64cdd90eadc5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_6e409546-f038-4d3e-a79a-218ca129f7d1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_549eaa4d-b78a-4426-b7cd-64cdd90eadc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_d5721a15-f44e-4b8f-ab9e-662f913307b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_549eaa4d-b78a-4426-b7cd-64cdd90eadc5" xlink:to="loc_us-gaap_EmployeeStockOptionMember_d5721a15-f44e-4b8f-ab9e-662f913307b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_987d2851-d2bf-4fd9-a918-26b408503228" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c37bef69-f6a0-41a3-8be1-77817586b661" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_987d2851-d2bf-4fd9-a918-26b408503228" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ea8e02ab-dfec-48c3-bbf7-12b2013484b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_987d2851-d2bf-4fd9-a918-26b408503228" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ea8e02ab-dfec-48c3-bbf7-12b2013484b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_fdad73bd-c032-4626-b8a2-6fc69159a62a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ea8e02ab-dfec-48c3-bbf7-12b2013484b9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_fdad73bd-c032-4626-b8a2-6fc69159a62a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_25b3c3c7-e3c2-42b3-953c-6d11a15e044c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ea8e02ab-dfec-48c3-bbf7-12b2013484b9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_25b3c3c7-e3c2-42b3-953c-6d11a15e044c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_90a346af-de82-4f71-899b-e013d46673f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ea8e02ab-dfec-48c3-bbf7-12b2013484b9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_90a346af-de82-4f71-899b-e013d46673f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_658b884a-3fe8-4d7d-94e6-5a70e72dabd5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ea8e02ab-dfec-48c3-bbf7-12b2013484b9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_658b884a-3fe8-4d7d-94e6-5a70e72dabd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_be973f09-d335-46f3-9f72-edde23205734" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ea8e02ab-dfec-48c3-bbf7-12b2013484b9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_be973f09-d335-46f3-9f72-edde23205734" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7d6db9ac-6fac-4622-a09b-586c04a1034e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_987d2851-d2bf-4fd9-a918-26b408503228" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7d6db9ac-6fac-4622-a09b-586c04a1034e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_dcdd516b-3dcc-452d-9070-6ded7744863b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7d6db9ac-6fac-4622-a09b-586c04a1034e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_dcdd516b-3dcc-452d-9070-6ded7744863b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_26d94238-a68d-4824-8f89-6a813d04bbe0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7d6db9ac-6fac-4622-a09b-586c04a1034e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_26d94238-a68d-4824-8f89-6a813d04bbe0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_18202f0e-4683-4eef-9e45-b62cc0423a93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7d6db9ac-6fac-4622-a09b-586c04a1034e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_18202f0e-4683-4eef-9e45-b62cc0423a93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_a9b344bf-f7bb-48a8-a0c9-2f29a97bf394" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7d6db9ac-6fac-4622-a09b-586c04a1034e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_a9b344bf-f7bb-48a8-a0c9-2f29a97bf394" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.incyte.com/role/StockCompensationRSUawardandPSUactivityunderthe2010stockplanDetails" xlink:type="simple" xlink:href="incy-20220930.xsd#StockCompensationRSUawardandPSUactivityunderthe2010stockplanDetails"/>
  <link:presentationLink xlink:role="http://www.incyte.com/role/StockCompensationRSUawardandPSUactivityunderthe2010stockplanDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_fd3e319c-e41f-4697-98f0-618f619ef99a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ede23d4b-8e10-4c1d-b77b-a32ba4adb269" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_fd3e319c-e41f-4697-98f0-618f619ef99a" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ede23d4b-8e10-4c1d-b77b-a32ba4adb269" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_ca02f58e-00d5-43b5-afe2-fd5ffc228d28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ede23d4b-8e10-4c1d-b77b-a32ba4adb269" xlink:to="loc_us-gaap_AwardTypeAxis_ca02f58e-00d5-43b5-afe2-fd5ffc228d28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_faf337a6-7fa2-4bab-9bf7-6d2bf500fe01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_ca02f58e-00d5-43b5-afe2-fd5ffc228d28" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_faf337a6-7fa2-4bab-9bf7-6d2bf500fe01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_6e1ce3bf-3192-488e-af8f-7e92fc7abef5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_faf337a6-7fa2-4bab-9bf7-6d2bf500fe01" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_6e1ce3bf-3192-488e-af8f-7e92fc7abef5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_80f261ed-b667-4240-b301-9098715b711a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_faf337a6-7fa2-4bab-9bf7-6d2bf500fe01" xlink:to="loc_us-gaap_PerformanceSharesMember_80f261ed-b667-4240-b301-9098715b711a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e9d1ac1e-5e1a-454e-90e6-7a9628cdf898" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ede23d4b-8e10-4c1d-b77b-a32ba4adb269" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e9d1ac1e-5e1a-454e-90e6-7a9628cdf898" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_194aded8-2b72-47ce-a1e8-5ff969f26a39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e9d1ac1e-5e1a-454e-90e6-7a9628cdf898" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_194aded8-2b72-47ce-a1e8-5ff969f26a39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_02c928b7-eebc-4624-9dc8-5c9bdbb17bd0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_194aded8-2b72-47ce-a1e8-5ff969f26a39" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_02c928b7-eebc-4624-9dc8-5c9bdbb17bd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_a53ebcfc-90b7-4cf0-b792-21f4109cfcf2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_194aded8-2b72-47ce-a1e8-5ff969f26a39" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_a53ebcfc-90b7-4cf0-b792-21f4109cfcf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod_f8ed6fe4-dcd1-482e-b659-bc27bc3b56c2" xlink:href="incy-20220930.xsd#incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_194aded8-2b72-47ce-a1e8-5ff969f26a39" xlink:to="loc_incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod_f8ed6fe4-dcd1-482e-b659-bc27bc3b56c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_376a76b9-f0e8-475d-9a6d-994cd30a38af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_194aded8-2b72-47ce-a1e8-5ff969f26a39" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_376a76b9-f0e8-475d-9a6d-994cd30a38af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_581682e5-4e17-44a8-ae27-0423bfad79fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_194aded8-2b72-47ce-a1e8-5ff969f26a39" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_581682e5-4e17-44a8-ae27-0423bfad79fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_9e71d677-0deb-4f95-a6c7-31110105bf2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e9d1ac1e-5e1a-454e-90e6-7a9628cdf898" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_9e71d677-0deb-4f95-a6c7-31110105bf2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_5b96be09-b281-400a-a852-05e04c88df6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_9e71d677-0deb-4f95-a6c7-31110105bf2f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_5b96be09-b281-400a-a852-05e04c88df6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue_a977cc81-d655-4781-ac3a-826dcfb2efef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_9e71d677-0deb-4f95-a6c7-31110105bf2f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue_a977cc81-d655-4781-ac3a-826dcfb2efef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedIntrinsicValue_52711e85-57b5-438e-98e9-b16f4dc91461" xlink:href="incy-20220930.xsd#incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedIntrinsicValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_9e71d677-0deb-4f95-a6c7-31110105bf2f" xlink:to="loc_incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedIntrinsicValue_52711e85-57b5-438e-98e9-b16f4dc91461" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue_0fc04e24-d52d-4bcc-b68f-8bd74a62f172" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_9e71d677-0deb-4f95-a6c7-31110105bf2f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue_0fc04e24-d52d-4bcc-b68f-8bd74a62f172" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.incyte.com/role/StockCompensationSharesavailableforgrantDetails" xlink:type="simple" xlink:href="incy-20220930.xsd#StockCompensationSharesavailableforgrantDetails"/>
  <link:presentationLink xlink:role="http://www.incyte.com/role/StockCompensationSharesavailableforgrantDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ef898eda-f389-4ab0-b42c-c2c8c82d006a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_ec402b22-b11f-407c-9326-8e71a5475473" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ef898eda-f389-4ab0-b42c-c2c8c82d006a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_ec402b22-b11f-407c-9326-8e71a5475473" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_2e9cc23b-0c5f-4f4d-940d-8bf87ca71231" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_ec402b22-b11f-407c-9326-8e71a5475473" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_2e9cc23b-0c5f-4f4d-940d-8bf87ca71231" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGranted_526390f6-b032-4a88-a35c-077ab619095f" xlink:href="incy-20220930.xsd#incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGranted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_ec402b22-b11f-407c-9326-8e71a5475473" xlink:to="loc_incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGranted_526390f6-b032-4a88-a35c-077ab619095f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCanceled_43c877a8-2992-45b7-8d8e-64581351fde0" xlink:href="incy-20220930.xsd#incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCanceled"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_ec402b22-b11f-407c-9326-8e71a5475473" xlink:to="loc_incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCanceled_43c877a8-2992-45b7-8d8e-64581351fde0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_1bced322-7284-4dfd-898e-f2604c974cd5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_ec402b22-b11f-407c-9326-8e71a5475473" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_1bced322-7284-4dfd-898e-f2604c974cd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.incyte.com/role/IncometaxesDetails" xlink:type="simple" xlink:href="incy-20220930.xsd#IncometaxesDetails"/>
  <link:presentationLink xlink:role="http://www.incyte.com/role/IncometaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_412b2105-f866-4b61-b10c-18d217001d3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_ed84d4b1-2b63-4490-ba4f-3f39d16299ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_412b2105-f866-4b61-b10c-18d217001d3c" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_ed84d4b1-2b63-4490-ba4f-3f39d16299ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability_3a10206e-dbd2-4850-977b-8644ae52a183" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_412b2105-f866-4b61-b10c-18d217001d3c" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability_3a10206e-dbd2-4850-977b-8644ae52a183" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_5491166b-c003-4e3e-b1b9-4ab151a0b7ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_412b2105-f866-4b61-b10c-18d217001d3c" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_5491166b-c003-4e3e-b1b9-4ab151a0b7ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease_226e68f3-4225-4ad0-b1e4-b627f0f1e4aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_412b2105-f866-4b61-b10c-18d217001d3c" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease_226e68f3-4225-4ad0-b1e4-b627f0f1e4aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.incyte.com/role/NetIncomePerShareNetincomelosspershareDetails" xlink:type="simple" xlink:href="incy-20220930.xsd#NetIncomePerShareNetincomelosspershareDetails"/>
  <link:presentationLink xlink:role="http://www.incyte.com/role/NetIncomePerShareNetincomelosspershareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_5c225729-f057-4e3c-9bed-affd0d1a4249" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract_b79bb5a6-806e-4a5b-af9c-065a7652a699" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_5c225729-f057-4e3c-9bed-affd0d1a4249" xlink:to="loc_us-gaap_EarningsPerShareBasicAbstract_b79bb5a6-806e-4a5b-af9c-065a7652a699" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_eb004730-717d-4081-a361-5965291e10ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_b79bb5a6-806e-4a5b-af9c-065a7652a699" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_eb004730-717d-4081-a361-5965291e10ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_80c78334-837b-4efb-86a3-0f06967b6f52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_b79bb5a6-806e-4a5b-af9c-065a7652a699" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_80c78334-837b-4efb-86a3-0f06967b6f52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_f9876f44-47ae-4c87-b171-d46939515bc5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_b79bb5a6-806e-4a5b-af9c-065a7652a699" xlink:to="loc_us-gaap_EarningsPerShareBasic_f9876f44-47ae-4c87-b171-d46939515bc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedAbstract_c50bfcb5-d7c8-4522-9f62-3841347cec22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDilutedAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_5c225729-f057-4e3c-9bed-affd0d1a4249" xlink:to="loc_us-gaap_EarningsPerShareDilutedAbstract_c50bfcb5-d7c8-4522-9f62-3841347cec22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_aec78092-3352-44b9-9c77-afc3df4974a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_c50bfcb5-d7c8-4522-9f62-3841347cec22" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_aec78092-3352-44b9-9c77-afc3df4974a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_7a3fedc1-e64a-4a02-86c0-1fe3d66430db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_c50bfcb5-d7c8-4522-9f62-3841347cec22" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_7a3fedc1-e64a-4a02-86c0-1fe3d66430db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_a84ab16c-2ffd-4af1-b7bb-021902ee17f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_c50bfcb5-d7c8-4522-9f62-3841347cec22" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_a84ab16c-2ffd-4af1-b7bb-021902ee17f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_cb370a08-a48d-4223-a33a-2fdd69fc6062" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_c50bfcb5-d7c8-4522-9f62-3841347cec22" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_cb370a08-a48d-4223-a33a-2fdd69fc6062" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_e967bc12-868c-44e7-9a68-95d192edb87c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_c50bfcb5-d7c8-4522-9f62-3841347cec22" xlink:to="loc_us-gaap_EarningsPerShareDiluted_e967bc12-868c-44e7-9a68-95d192edb87c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.incyte.com/role/NetIncomePerShareAntidilutivesecuritiesDetails" xlink:type="simple" xlink:href="incy-20220930.xsd#NetIncomePerShareAntidilutivesecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.incyte.com/role/NetIncomePerShareAntidilutivesecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_562cb582-d562-49eb-8e1d-9f280b5ecce9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_37802a85-df5b-433e-be27-fc729a23245f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_562cb582-d562-49eb-8e1d-9f280b5ecce9" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_37802a85-df5b-433e-be27-fc729a23245f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_51b57e75-1368-478f-962f-90b7ca8baeea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_37802a85-df5b-433e-be27-fc729a23245f" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_51b57e75-1368-478f-962f-90b7ca8baeea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_e3d2be47-9755-479e-8ea8-5bd5cf727e58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_51b57e75-1368-478f-962f-90b7ca8baeea" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_e3d2be47-9755-479e-8ea8-5bd5cf727e58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember_43a46766-97b8-4152-aef7-ae266e49fc9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_e3d2be47-9755-479e-8ea8-5bd5cf727e58" xlink:to="loc_us-gaap_StockCompensationPlanMember_43a46766-97b8-4152-aef7-ae266e49fc9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicLineItems_ed828240-5482-4192-ac52-30085f445460" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasicLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_37802a85-df5b-433e-be27-fc729a23245f" xlink:to="loc_us-gaap_EarningsPerShareBasicLineItems_ed828240-5482-4192-ac52-30085f445460" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract_4bd036fa-435c-431e-9f43-0115f404b8c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_ed828240-5482-4192-ac52-30085f445460" xlink:to="loc_us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract_4bd036fa-435c-431e-9f43-0115f404b8c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_a93bb5d7-7adb-40a7-a503-49a87abf8eaf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract_4bd036fa-435c-431e-9f43-0115f404b8c7" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_a93bb5d7-7adb-40a7-a503-49a87abf8eaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.incyte.com/role/EmployeeBenefitPlansNarrativeDetails" xlink:type="simple" xlink:href="incy-20220930.xsd#EmployeeBenefitPlansNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.incyte.com/role/EmployeeBenefitPlansNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_c3f0e6e3-c8ef-43df-acb4-293966eb87f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_1b7704fa-9347-4807-9803-bd05475e2467" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_c3f0e6e3-c8ef-43df-acb4-293966eb87f9" xlink:to="loc_us-gaap_DefinedContributionPlanCostRecognized_1b7704fa-9347-4807-9803-bd05475e2467" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostCreditExcludingServiceCostStatementOfIncomeOrComprehensiveIncomeExtensibleList_e09bde48-a94b-49bf-b177-b63c1a43215e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostCreditExcludingServiceCostStatementOfIncomeOrComprehensiveIncomeExtensibleList"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_c3f0e6e3-c8ef-43df-acb4-293966eb87f9" xlink:to="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostCreditExcludingServiceCostStatementOfIncomeOrComprehensiveIncomeExtensibleList_e09bde48-a94b-49bf-b177-b63c1a43215e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsCurrentFiscalYear_155df5c0-e8c0-460a-b1c6-197379ada583" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsCurrentFiscalYear"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_c3f0e6e3-c8ef-43df-acb4-293966eb87f9" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsCurrentFiscalYear_155df5c0-e8c0-460a-b1c6-197379ada583" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.incyte.com/role/EmployeeBenefitplansNetperiodicbenefitcostDetails" xlink:type="simple" xlink:href="incy-20220930.xsd#EmployeeBenefitplansNetperiodicbenefitcostDetails"/>
  <link:presentationLink xlink:role="http://www.incyte.com/role/EmployeeBenefitplansNetperiodicbenefitcostDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_e63fb40c-7482-4079-89af-2f87b59de407" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_a4c7e866-42d3-41ff-ad5b-635bb277a7bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_e63fb40c-7482-4079-89af-2f87b59de407" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_a4c7e866-42d3-41ff-ad5b-635bb277a7bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_d792bd0e-0b4f-44f9-ba02-ed92b47a00c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_e63fb40c-7482-4079-89af-2f87b59de407" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_d792bd0e-0b4f-44f9-ba02-ed92b47a00c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_b01c75d8-fb50-4c38-a622-6c64a947885c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_e63fb40c-7482-4079-89af-2f87b59de407" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_b01c75d8-fb50-4c38-a622-6c64a947885c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_f214b3b9-7cb3-4875-be7e-835155673d83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_e63fb40c-7482-4079-89af-2f87b59de407" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_f214b3b9-7cb3-4875-be7e-835155673d83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActuarialGainLoss_ce99f1ca-ba2c-4d51-a688-08c08aa80b03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanActuarialGainLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_e63fb40c-7482-4079-89af-2f87b59de407" xlink:to="loc_us-gaap_DefinedBenefitPlanActuarialGainLoss_ce99f1ca-ba2c-4d51-a688-08c08aa80b03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_6ae2ed85-d62a-4506-a6db-9b5fbe9f2274" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_e63fb40c-7482-4079-89af-2f87b59de407" xlink:to="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_6ae2ed85-d62a-4506-a6db-9b5fbe9f2274" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.incyte.com/role/SubsequentEventsNarrativeDetails" xlink:type="simple" xlink:href="incy-20220930.xsd#SubsequentEventsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.incyte.com/role/SubsequentEventsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_e43ba66e-b658-4a8a-87d2-ec4760ebab8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_66ac0aae-1500-4bd9-994b-90ee0fe4c502" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_e43ba66e-b658-4a8a-87d2-ec4760ebab8c" xlink:to="loc_us-gaap_SubsequentEventTable_66ac0aae-1500-4bd9-994b-90ee0fe4c502" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_d5764d65-ec53-481f-94fc-d3e8664a6422" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_66ac0aae-1500-4bd9-994b-90ee0fe4c502" xlink:to="loc_us-gaap_TypeOfArrangementAxis_d5764d65-ec53-481f-94fc-d3e8664a6422" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f7dd8715-e027-4463-a6fe-304a457322b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_d5764d65-ec53-481f-94fc-d3e8664a6422" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f7dd8715-e027-4463-a6fe-304a457322b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_VillarisMember_50ff75ee-c427-4de0-8583-14b1b1c37893" xlink:href="incy-20220930.xsd#incy_VillarisMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f7dd8715-e027-4463-a6fe-304a457322b2" xlink:to="loc_incy_VillarisMember_50ff75ee-c427-4de0-8583-14b1b1c37893" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_AchievementOfMilestoneAxis_daf2379b-20cb-4c5e-b563-e3e68b8d9474" xlink:href="incy-20220930.xsd#incy_AchievementOfMilestoneAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_66ac0aae-1500-4bd9-994b-90ee0fe4c502" xlink:to="loc_incy_AchievementOfMilestoneAxis_daf2379b-20cb-4c5e-b563-e3e68b8d9474" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_AchievementOfMilestoneDomain_b4143921-d5bb-4c10-956f-515f7b22b908" xlink:href="incy-20220930.xsd#incy_AchievementOfMilestoneDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_incy_AchievementOfMilestoneAxis_daf2379b-20cb-4c5e-b563-e3e68b8d9474" xlink:to="loc_incy_AchievementOfMilestoneDomain_b4143921-d5bb-4c10-956f-515f7b22b908" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_DevelopmentAndRegulatoryMilestonesMember_2e2c87b2-1efd-43f9-9d95-f1b198f00b05" xlink:href="incy-20220930.xsd#incy_DevelopmentAndRegulatoryMilestonesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_incy_AchievementOfMilestoneDomain_b4143921-d5bb-4c10-956f-515f7b22b908" xlink:to="loc_incy_DevelopmentAndRegulatoryMilestonesMember_2e2c87b2-1efd-43f9-9d95-f1b198f00b05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_CommercializationMilestonesMember_87ae1b43-c51c-48b3-a040-7c10c81eed9b" xlink:href="incy-20220930.xsd#incy_CommercializationMilestonesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_incy_AchievementOfMilestoneDomain_b4143921-d5bb-4c10-956f-515f7b22b908" xlink:to="loc_incy_CommercializationMilestonesMember_87ae1b43-c51c-48b3-a040-7c10c81eed9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_8aaeeabd-76bb-4d34-80e9-61a241984a45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_66ac0aae-1500-4bd9-994b-90ee0fe4c502" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_8aaeeabd-76bb-4d34-80e9-61a241984a45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_c6fe7777-501a-4343-acbc-329f2552a0cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_8aaeeabd-76bb-4d34-80e9-61a241984a45" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_c6fe7777-501a-4343-acbc-329f2552a0cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_5519d62b-95e7-4ee8-bfd7-35de129edb02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_c6fe7777-501a-4343-acbc-329f2552a0cc" xlink:to="loc_us-gaap_SubsequentEventMember_5519d62b-95e7-4ee8-bfd7-35de129edb02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_8f12b7e0-abf3-4477-9b56-e2656b5ca4fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_66ac0aae-1500-4bd9-994b-90ee0fe4c502" xlink:to="loc_us-gaap_SubsequentEventLineItems_8f12b7e0-abf3-4477-9b56-e2656b5ca4fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_LicenseAgreementUpfrontPaymentAmountPaid_62fc38a2-8513-4b2a-8d53-30f11c2d4b5d" xlink:href="incy-20220930.xsd#incy_LicenseAgreementUpfrontPaymentAmountPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_8f12b7e0-abf3-4477-9b56-e2656b5ca4fc" xlink:to="loc_incy_LicenseAgreementUpfrontPaymentAmountPaid_62fc38a2-8513-4b2a-8d53-30f11c2d4b5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived_4f21c966-4a91-4d50-a8f4-fbd8d315b4fb" xlink:href="incy-20220930.xsd#incy_LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_8f12b7e0-abf3-4477-9b56-e2656b5ca4fc" xlink:to="loc_incy_LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived_4f21c966-4a91-4d50-a8f4-fbd8d315b4fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_incy_LicenseAgreementMilestoneOnNetSalesOfProduct_68f2db0d-4e70-45b9-a408-7cec770bae20" xlink:href="incy-20220930.xsd#incy_LicenseAgreementMilestoneOnNetSalesOfProduct"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_8f12b7e0-abf3-4477-9b56-e2656b5ca4fc" xlink:to="loc_incy_LicenseAgreementMilestoneOnNetSalesOfProduct_68f2db0d-4e70-45b9-a408-7cec770bae20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139808197962608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Oct. 25, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-12400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">INCYTE CORPORATION<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">94-3136539<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1801 Augustine Cut-Off<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Wilmington<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">19803<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">302<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">498-6700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $.001 par value per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">INCY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">222,475,468<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000879169<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139808194792992">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 2,690,622,000<span></span>
</td>
<td class="nump">$ 2,057,440,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Marketable securities&#8212;available-for-sale (amortized cost $292,941 and $291,871 as of September&#160;30, 2022 and December&#160;31, 2021, respectively; allowance for credit losses $0 as of September&#160;30, 2022 and December&#160;31, 2021)</a></td>
<td class="nump">286,500,000<span></span>
</td>
<td class="nump">290,752,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNet', window );">Accounts receivable</a></td>
<td class="nump">618,188,000<span></span>
</td>
<td class="nump">616,300,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">45,869,000<span></span>
</td>
<td class="nump">27,904,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">179,932,000<span></span>
</td>
<td class="nump">126,278,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">3,821,111,000<span></span>
</td>
<td class="nump">3,118,674,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndInvestmentsNoncurrent', window );">Restricted cash and investments</a></td>
<td class="nump">1,601,000<span></span>
</td>
<td class="nump">1,720,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Long-Term Investments</a></td>
<td class="nump">149,124,000<span></span>
</td>
<td class="nump">221,266,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNoncurrent', window );">Inventory</a></td>
<td class="nump">55,264,000<span></span>
</td>
<td class="nump">29,034,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">715,733,000<span></span>
</td>
<td class="nump">723,920,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Finance lease right-of-use assets, net</a></td>
<td class="nump">26,679,000<span></span>
</td>
<td class="nump">27,548,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIntangibleAssetsNet', window );">Other intangible assets, net</a></td>
<td class="nump">134,603,000<span></span>
</td>
<td class="nump">150,755,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">155,593,000<span></span>
</td>
<td class="nump">155,593,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred income tax asset</a></td>
<td class="nump">426,840,000<span></span>
</td>
<td class="nump">467,538,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets, net</a></td>
<td class="nump">23,666,000<span></span>
</td>
<td class="nump">37,304,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">5,510,214,000<span></span>
</td>
<td class="nump">4,933,352,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">163,175,000<span></span>
</td>
<td class="nump">172,110,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation</a></td>
<td class="nump">106,309,000<span></span>
</td>
<td class="nump">108,962,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued and other current liabilities</a></td>
<td class="nump">699,814,000<span></span>
</td>
<td class="nump">533,595,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Finance lease liabilities</a></td>
<td class="nump">3,112,000<span></span>
</td>
<td class="nump">2,635,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Acquisition-related contingent consideration</a></td>
<td class="nump">34,186,000<span></span>
</td>
<td class="nump">37,006,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">1,006,596,000<span></span>
</td>
<td class="nump">854,308,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Acquisition-related contingent consideration</a></td>
<td class="nump">171,814,000<span></span>
</td>
<td class="nump">206,994,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Finance lease liabilities</a></td>
<td class="nump">30,476,000<span></span>
</td>
<td class="nump">31,632,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other liabilities</a></td>
<td class="nump">74,677,000<span></span>
</td>
<td class="nump">70,414,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">1,283,563,000<span></span>
</td>
<td class="nump">1,163,348,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 14)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value; 5,000,000 shares authorized; none issued or outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 400,000,000 shares authorized; 222,454,839 and 221,084,433 shares issued and outstanding as of September&#160;30, 2022 and December&#160;31, 2021, respectively</a></td>
<td class="nump">222,000<span></span>
</td>
<td class="nump">221,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">4,721,166,000<span></span>
</td>
<td class="nump">4,567,111,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(29,062,000)<span></span>
</td>
<td class="num">(19,454,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(465,675,000)<span></span>
</td>
<td class="num">(777,874,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">4,226,651,000<span></span>
</td>
<td class="nump">3,770,004,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 5,510,214,000<span></span>
</td>
<td class="nump">$ 4,933,352,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 310<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126942793&amp;loc=d3e3073-115593<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI https://asc.fasb.org/extlink&amp;oid=126966325&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI https://asc.fasb.org/extlink&amp;oid=126966325&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated amortization of finite-lived and indefinite-lived intangible assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndInvestmentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The noncurrent cash, cash equivalents and investments that is restricted as to withdrawal or usage. Restrictions may include legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or entity statements of intention with regard to particular deposits classified as long-term; that is not expected to be released from such existing restrictions within one year of the balance sheet date or operating cycle, whichever is longer. Excludes compensating balance arrangements that are not agreements which legally restrict the use of cash amounts shown on the balance sheet. Includes noncurrent cash equivalents and investments that are similarly restricted as to withdrawal, usage or disposal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL6242262-115580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=127002003&amp;loc=SL6242269-115581<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndInvestmentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139808199015728">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent', window );">Marketable securities-amortized cost</a></td>
<td class="nump">$ 292,941<span></span>
</td>
<td class="nump">$ 291,871<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss', window );">Marketable securities-allowance for credit losses</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in USD per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in USD per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">400,000,000<span></span>
</td>
<td class="nump">400,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">222,454,839<span></span>
</td>
<td class="nump">221,084,433<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">222,454,839<span></span>
</td>
<td class="nump">221,084,433<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922900-210455<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922900-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139808195625648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 823,303<span></span>
</td>
<td class="nump">$ 812,987<span></span>
</td>
<td class="nump">$ 2,467,935<span></span>
</td>
<td class="nump">$ 2,123,414<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Costs and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of product revenues (including definite-lived intangible amortization)</a></td>
<td class="nump">54,584<span></span>
</td>
<td class="nump">39,869<span></span>
</td>
<td class="nump">147,834<span></span>
</td>
<td class="nump">107,117<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">384,007<span></span>
</td>
<td class="nump">334,945<span></span>
</td>
<td class="nump">1,084,576<span></span>
</td>
<td class="nump">985,352<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">266,460<span></span>
</td>
<td class="nump">190,704<span></span>
</td>
<td class="nump">729,321<span></span>
</td>
<td class="nump">513,358<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">(Gain) loss on change in fair value of acquisition-related contingent consideration</a></td>
<td class="num">(21,893)<span></span>
</td>
<td class="nump">2,910<span></span>
</td>
<td class="num">(12,198)<span></span>
</td>
<td class="nump">13,068<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_incy_CollaborationLossSharingExpense', window );">Collaboration loss sharing</a></td>
<td class="nump">1,769<span></span>
</td>
<td class="nump">9,149<span></span>
</td>
<td class="nump">9,055<span></span>
</td>
<td class="nump">29,476<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total costs and expenses</a></td>
<td class="nump">684,927<span></span>
</td>
<td class="nump">577,577<span></span>
</td>
<td class="nump">1,958,588<span></span>
</td>
<td class="nump">1,648,371<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income from operations</a></td>
<td class="nump">138,376<span></span>
</td>
<td class="nump">235,410<span></span>
</td>
<td class="nump">509,347<span></span>
</td>
<td class="nump">475,043<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="nump">11,513<span></span>
</td>
<td class="nump">1,948<span></span>
</td>
<td class="nump">13,295<span></span>
</td>
<td class="nump">4,931<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(641)<span></span>
</td>
<td class="num">(439)<span></span>
</td>
<td class="num">(1,999)<span></span>
</td>
<td class="num">(1,156)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Unrealized loss on long term investments</a></td>
<td class="num">(660)<span></span>
</td>
<td class="num">(27,450)<span></span>
</td>
<td class="num">(72,142)<span></span>
</td>
<td class="num">(28,394)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income before provision for income taxes</a></td>
<td class="nump">148,588<span></span>
</td>
<td class="nump">209,469<span></span>
</td>
<td class="nump">448,501<span></span>
</td>
<td class="nump">450,424<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">35,813<span></span>
</td>
<td class="nump">27,730<span></span>
</td>
<td class="nump">136,302<span></span>
</td>
<td class="nump">65,694<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 112,775<span></span>
</td>
<td class="nump">$ 181,739<span></span>
</td>
<td class="nump">$ 312,199<span></span>
</td>
<td class="nump">$ 384,730<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net income per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in USD per share)</a></td>
<td class="nump">$ 0.51<span></span>
</td>
<td class="nump">$ 0.82<span></span>
</td>
<td class="nump">$ 1.41<span></span>
</td>
<td class="nump">$ 1.75<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in USD per share)</a></td>
<td class="nump">$ 0.50<span></span>
</td>
<td class="nump">$ 0.82<span></span>
</td>
<td class="nump">$ 1.40<span></span>
</td>
<td class="nump">$ 1.73<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Shares used in computing net income per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in shares)</a></td>
<td class="nump">222,415<span></span>
</td>
<td class="nump">220,845<span></span>
</td>
<td class="nump">221,801<span></span>
</td>
<td class="nump">220,243<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in shares)</a></td>
<td class="nump">224,175<span></span>
</td>
<td class="nump">222,248<span></span>
</td>
<td class="nump">223,626<span></span>
</td>
<td class="nump">222,113<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product revenues, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 713,010<span></span>
</td>
<td class="nump">$ 594,013<span></span>
</td>
<td class="nump">$ 1,982,682<span></span>
</td>
<td class="nump">$ 1,673,974<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember', window );">Product royalty revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">110,293<span></span>
</td>
<td class="nump">183,974<span></span>
</td>
<td class="nump">350,253<span></span>
</td>
<td class="nump">404,440<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=incy_MilestoneRevenueMember', window );">Milestone and contract revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 35,000<span></span>
</td>
<td class="nump">$ 135,000<span></span>
</td>
<td class="nump">$ 45,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_CollaborationLossSharingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The expense recognized during the reporting period for collaboration loss sharing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_CollaborationLossSharingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126980263&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_RoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=incy_MilestoneRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=incy_MilestoneRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139808194738080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 112,775<span></span>
</td>
<td class="nump">$ 181,739<span></span>
</td>
<td class="nump">$ 312,199<span></span>
</td>
<td class="nump">$ 384,730<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation loss</a></td>
<td class="num">(2,513)<span></span>
</td>
<td class="num">(629)<span></span>
</td>
<td class="num">(5,132)<span></span>
</td>
<td class="num">(4,061)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized loss on marketable securities, net of tax</a></td>
<td class="num">(1,135)<span></span>
</td>
<td class="num">(86)<span></span>
</td>
<td class="num">(5,322)<span></span>
</td>
<td class="num">(251)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax', window );">Defined benefit pension gain, net of tax</a></td>
<td class="nump">282<span></span>
</td>
<td class="nump">342<span></span>
</td>
<td class="nump">846<span></span>
</td>
<td class="nump">1,026<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive loss</a></td>
<td class="num">(3,366)<span></span>
</td>
<td class="num">(373)<span></span>
</td>
<td class="num">(9,608)<span></span>
</td>
<td class="num">(3,286)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income</a></td>
<td class="nump">$ 109,409<span></span>
</td>
<td class="nump">$ 181,366<span></span>
</td>
<td class="nump">$ 302,591<span></span>
</td>
<td class="nump">$ 381,444<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i-k)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139808193867008">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Loss</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Dec. 31, 2020</a></td>
<td class="nump">$ 2,611,268<span></span>
</td>
<td class="nump">$ 219<span></span>
</td>
<td class="nump">$ 4,352,864<span></span>
</td>
<td class="num">$ (15,360)<span></span>
</td>
<td class="num">$ (1,726,455)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of shares of Common Stock upon exercise of stock options and settlement of employee restricted stock units, net of shares withheld for taxes</a></td>
<td class="nump">20,028<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">20,027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of shares of Common Stock for services rendered</a></td>
<td class="nump">108<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">108<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock compensation</a></td>
<td class="nump">47,903<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,903<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss)</a></td>
<td class="num">(4,998)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,998)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">53,535<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53,535<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Mar. 31, 2021</a></td>
<td class="nump">2,727,844<span></span>
</td>
<td class="nump">220<span></span>
</td>
<td class="nump">4,420,902<span></span>
</td>
<td class="num">(20,358)<span></span>
</td>
<td class="num">(1,672,920)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Dec. 31, 2020</a></td>
<td class="nump">2,611,268<span></span>
</td>
<td class="nump">219<span></span>
</td>
<td class="nump">4,352,864<span></span>
</td>
<td class="num">(15,360)<span></span>
</td>
<td class="num">(1,726,455)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss)</a></td>
<td class="num">(3,286)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">384,730<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Sep. 30, 2021</a></td>
<td class="nump">3,148,657<span></span>
</td>
<td class="nump">221<span></span>
</td>
<td class="nump">4,508,807<span></span>
</td>
<td class="num">(18,646)<span></span>
</td>
<td class="num">(1,341,725)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Mar. 31, 2021</a></td>
<td class="nump">2,727,844<span></span>
</td>
<td class="nump">220<span></span>
</td>
<td class="nump">4,420,902<span></span>
</td>
<td class="num">(20,358)<span></span>
</td>
<td class="num">(1,672,920)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_incy_StockIssuedDuringPeriodValueStockOptionsAndRestrictedStockUnitsExercisedAndEmployeeStockPurchasePlan', window );">Issuance of shares of Common Stock upon exercise of stock options and settlement of employee restricted stock units and performance shares, net of shares withheld for taxes and shares of Common Stock under the ESPP</a></td>
<td class="nump">11,016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of shares of Common Stock for services rendered</a></td>
<td class="nump">109<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">109<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock compensation</a></td>
<td class="nump">45,351<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,351<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss)</a></td>
<td class="nump">2,085<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,085<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">149,456<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">149,456<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Jun. 30, 2021</a></td>
<td class="nump">2,935,861<span></span>
</td>
<td class="nump">220<span></span>
</td>
<td class="nump">4,477,378<span></span>
</td>
<td class="num">(18,273)<span></span>
</td>
<td class="num">(1,523,464)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of shares of Common Stock upon exercise of stock options and settlement of employee restricted stock units, net of shares withheld for taxes</a></td>
<td class="num">(11,992)<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="num">(11,993)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of shares of Common Stock for services rendered</a></td>
<td class="nump">108<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">108<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock compensation</a></td>
<td class="nump">43,314<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,314<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss)</a></td>
<td class="num">(373)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(373)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">181,739<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">181,739<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Sep. 30, 2021</a></td>
<td class="nump">3,148,657<span></span>
</td>
<td class="nump">221<span></span>
</td>
<td class="nump">4,508,807<span></span>
</td>
<td class="num">(18,646)<span></span>
</td>
<td class="num">(1,341,725)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Dec. 31, 2021</a></td>
<td class="nump">3,770,004<span></span>
</td>
<td class="nump">221<span></span>
</td>
<td class="nump">4,567,111<span></span>
</td>
<td class="num">(19,454)<span></span>
</td>
<td class="num">(777,874)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of shares of Common Stock upon exercise of stock options and settlement of employee restricted stock units, net of shares withheld for taxes</a></td>
<td class="nump">14,237<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,237<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of shares of Common Stock for services rendered</a></td>
<td class="nump">112<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">112<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock compensation</a></td>
<td class="nump">44,320<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,320<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss)</a></td>
<td class="num">(3,593)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,593)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">37,992<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,992<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Mar. 31, 2022</a></td>
<td class="nump">3,863,072<span></span>
</td>
<td class="nump">221<span></span>
</td>
<td class="nump">4,625,780<span></span>
</td>
<td class="num">(23,047)<span></span>
</td>
<td class="num">(739,882)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Dec. 31, 2021</a></td>
<td class="nump">3,770,004<span></span>
</td>
<td class="nump">221<span></span>
</td>
<td class="nump">4,567,111<span></span>
</td>
<td class="num">(19,454)<span></span>
</td>
<td class="num">(777,874)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss)</a></td>
<td class="num">(9,608)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">312,199<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Sep. 30, 2022</a></td>
<td class="nump">4,226,651<span></span>
</td>
<td class="nump">222<span></span>
</td>
<td class="nump">4,721,166<span></span>
</td>
<td class="num">(29,062)<span></span>
</td>
<td class="num">(465,675)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Mar. 31, 2022</a></td>
<td class="nump">3,863,072<span></span>
</td>
<td class="nump">221<span></span>
</td>
<td class="nump">4,625,780<span></span>
</td>
<td class="num">(23,047)<span></span>
</td>
<td class="num">(739,882)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_incy_StockIssuedDuringPeriodValueStockOptionsAndRestrictedStockUnitsExercisedAndEmployeeStockPurchasePlan', window );">Issuance of shares of Common Stock upon exercise of stock options and settlement of employee restricted stock units and performance shares, net of shares withheld for taxes and shares of Common Stock under the ESPP</a></td>
<td class="nump">16,601<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">16,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of shares of Common Stock for services rendered</a></td>
<td class="nump">109<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">109<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock compensation</a></td>
<td class="nump">46,496<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46,496<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss)</a></td>
<td class="num">(2,649)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,649)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">161,432<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">161,432<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Jun. 30, 2022</a></td>
<td class="nump">4,085,061<span></span>
</td>
<td class="nump">222<span></span>
</td>
<td class="nump">4,688,985<span></span>
</td>
<td class="num">(25,696)<span></span>
</td>
<td class="num">(578,450)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of shares of Common Stock upon exercise of stock options and settlement of employee restricted stock units, net of shares withheld for taxes</a></td>
<td class="num">(13,572)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(13,572)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of shares of Common Stock for services rendered</a></td>
<td class="nump">94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock compensation</a></td>
<td class="nump">45,659<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,659<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss)</a></td>
<td class="num">(3,366)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,366)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">112,775<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">112,775<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Sep. 30, 2022</a></td>
<td class="nump">$ 4,226,651<span></span>
</td>
<td class="nump">$ 222<span></span>
</td>
<td class="nump">$ 4,721,166<span></span>
</td>
<td class="num">$ (29,062)<span></span>
</td>
<td class="num">$ (465,675)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_StockIssuedDuringPeriodValueStockOptionsAndRestrictedStockUnitsExercisedAndEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value stock issued during the period as a result of the exercise of stock options and restricted stock units and the aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_StockIssuedDuringPeriodValueStockOptionsAndRestrictedStockUnitsExercisedAndEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139808195745328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical) - shares<br></strong></div></th>
<th class="th" colspan="6">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement of Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of shares of Common Stock upon exercise of stock options and settlement of employee restricted stock units and performance shares</a></td>
<td class="nump">578,106<span></span>
</td>
<td class="nump">274,693<span></span>
</td>
<td class="nump">323,582<span></span>
</td>
<td class="nump">459,084<span></span>
</td>
<td class="nump">390,001<span></span>
</td>
<td class="nump">389,512<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of shares of Common Stock under the ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">189,684<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">153,082<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of shares of Common Stock for services rendered</a></td>
<td class="nump">1,337<span></span>
</td>
<td class="nump">1,469<span></span>
</td>
<td class="nump">1,535<span></span>
</td>
<td class="nump">1,466<span></span>
</td>
<td class="nump">1,288<span></span>
</td>
<td class="nump">1,357<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139808195421392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">$ 312,199<span></span>
</td>
<td class="nump">$ 384,730<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income to net cash provided by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">49,637<span></span>
</td>
<td class="nump">42,986<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">135,741<span></span>
</td>
<td class="nump">134,784<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes', window );">Deferred income taxes</a></td>
<td class="nump">40,432<span></span>
</td>
<td class="num">(178)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other, net</a></td>
<td class="nump">15,097<span></span>
</td>
<td class="nump">5,268<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Unrealized loss on long term investments</a></td>
<td class="nump">72,142<span></span>
</td>
<td class="nump">28,394<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">(Gain) loss on change in fair value of acquisition-related contingent consideration</a></td>
<td class="num">(12,198)<span></span>
</td>
<td class="nump">13,068<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(1,888)<span></span>
</td>
<td class="num">(34,695)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="num">(40,016)<span></span>
</td>
<td class="num">(24,784)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="num">(48,316)<span></span>
</td>
<td class="num">(16,215)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(8,935)<span></span>
</td>
<td class="nump">15,742<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued and other liabilities</a></td>
<td class="nump">172,384<span></span>
</td>
<td class="nump">85,037<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by operating activities</a></td>
<td class="nump">686,279<span></span>
</td>
<td class="nump">634,137<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireLongtermInvestments', window );">Purchase of long term investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(8,662)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfLongtermInvestments', window );">Sale of long term investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">10,473<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireProductiveAssets', window );">Capital expenditures</a></td>
<td class="num">(56,560)<span></span>
</td>
<td class="num">(146,543)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchases of marketable securities</a></td>
<td class="num">(59,058)<span></span>
</td>
<td class="num">(228,170)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Sale and maturities of marketable securities</a></td>
<td class="nump">57,988<span></span>
</td>
<td class="nump">231,250<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(57,630)<span></span>
</td>
<td class="num">(141,652)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockPlans', window );">Proceeds from issuance of common stock under stock plans</a></td>
<td class="nump">42,989<span></span>
</td>
<td class="nump">48,432<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Tax withholdings related to restricted and performance share vesting</a></td>
<td class="num">(25,724)<span></span>
</td>
<td class="num">(29,380)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Payment of finance lease liabilities</a></td>
<td class="num">(2,106)<span></span>
</td>
<td class="num">(1,788)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_incy_PaymentOfContingentConsideration', window );">Payment of contingent consideration</a></td>
<td class="num">(13,473)<span></span>
</td>
<td class="num">(20,093)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by (used in) financing activities</a></td>
<td class="nump">1,686<span></span>
</td>
<td class="num">(2,829)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rates on cash, cash equivalents, restricted cash and investments</a></td>
<td class="nump">2,728<span></span>
</td>
<td class="num">(3,718)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase in cash, cash equivalents, restricted cash and investments</a></td>
<td class="nump">633,063<span></span>
</td>
<td class="nump">485,938<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, restricted cash and investments at beginning of period</a></td>
<td class="nump">2,059,160<span></span>
</td>
<td class="nump">1,514,765<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, restricted cash and investments at end of period</a></td>
<td class="nump">2,692,223<span></span>
</td>
<td class="nump">2,000,703<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental Schedule of Cash Flow Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Income taxes paid</a></td>
<td class="nump">116,537<span></span>
</td>
<td class="nump">45,872<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Unpaid purchases of property and equipment</a></td>
<td class="nump">8,836<span></span>
</td>
<td class="nump">23,892<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Leased assets obtained in exchange for new operating lease liabilities</a></td>
<td class="nump">3,650<span></span>
</td>
<td class="nump">9,068<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability', window );">Leased assets obtained in exchange for new finance lease liabilities</a></td>
<td class="nump">$ 1,448<span></span>
</td>
<td class="nump">$ 455<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_PaymentOfContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow with regard to the contingent consideration during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_PaymentOfContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126980263&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireLongtermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, beyond the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the long-term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireLongtermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126928898&amp;loc=d3e9212-128498<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126928898&amp;loc=d3e9215-128498<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=127000608&amp;loc=d3e9135-128495<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfLongtermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sales of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, beyond the current operating cycle.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfLongtermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the stock plan during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139808196525040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Business<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock', window );">Organization and Business</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Incyte Corporation (including its subsidiaries, &#8220;Incyte,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; or &#8220;our&#8221;) is a biopharmaceutical company focused on developing and commercializing proprietary therapeutics. Our portfolio includes compounds in various stages, ranging from preclinical to late stage development, and commercialized products JAKAFI&#174; (ruxolitinib), ICLUSIG&#174; (ponatinib), PEMAZYRE&#174; (pemigatinib), OPZELURA&#8482; (ruxolitinib cream),</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MINJUVI&#174; (tafasitamab) and MONJUVI&#174; (tafasitamab-cxix), which is co-commercialized. Our operations are treated as one operating segment.</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI https://asc.fasb.org/topic&amp;trid=2197479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI https://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139808196460640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of presentation</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. The condensed consolidated balance sheet as of September&#160;30, 2022, the condensed consolidated statements of operations, comprehensive income (loss), and stockholders&#8217; equity for the three and nine months ended September&#160;30, 2022 and 2021, and the condensed consolidated statements of cash flows for the nine months ended September&#160;30, 2022 and 2021, are unaudited, but include all adjustments, consisting only of normal recurring adjustments, which we consider necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented. The condensed consolidated balance sheet at December&#160;31, 2021 has been derived from our audited consolidated financial statements.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we believe that the disclosures in these financial statements are adequate to make the information presented not misleading, certain information and footnote information normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States (&#8220;U.S. GAAP&#8221;) have been condensed or omitted pursuant to the rules and regulations of the Securities and Exchange Commission.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Results for any interim period are not necessarily indicative of results for any future interim period or for the entire year. The accompanying financial statements should be read in conjunction with the financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December&#160;31, 2021.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Principles of Consolidation.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The condensed consolidated financial statements include the accounts of Incyte Corporation and our wholly owned subsidiaries. All inter-company accounts, transactions, and profits have been eliminated in consolidation.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of Estimates.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div>There were no new accounting pronouncements issued nor adopted since our filing of the Annual Report on Form 10-K for the year ended December&#160;31, 2021, which could have a significant effect on our condensed consolidated financial statements.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139808196414768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Revenues</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues are recognized under guidance within ASC 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The following table presents our disaggregated revenue for the periods presented (in thousands):  </span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">JAKAFI revenues, net</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">619,595&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">547,373&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,761,732&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,542,138&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ICLUSIG revenues, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,929&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,522&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,222&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,356&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PEMAZYRE revenues, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,414&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,562&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,429&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,924&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MINJUVI revenues, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,932&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">556&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,845&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">556&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OPZELURA revenues, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,140&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,454&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total product revenues, net</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">713,010&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">594,013&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,982,682&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,673,974&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">JAKAVI product royalty revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,808&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,655&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240,386&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">242,295&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OLUMIANT product royalty revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,371&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,572&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,689&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154,875&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TABRECTA product royalty revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,114&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,747&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,178&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,270&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total product royalty revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110,293&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183,974&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350,253&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">404,440&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Milestone and contract revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">823,303&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">812,987&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,467,935&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,123,414&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For further information on our revenue-generating contracts,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">refer to Note 7.</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI https://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130551-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130556-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130550-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130558-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139808196460640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of our marketable security portfolio for the periods presented (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities (government)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">292,941&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,441)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">286,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities (government)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">291,871&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,119)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">290,752&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our available-for-sale debt securities generally have contractual maturity dates of between 12 to 18 months. Debt security assets were assessed for risk of expected credit losses. As of September&#160;30, 2022 and December&#160;31, 2021, the available-for-sale debt securities were held in U.S.-government backed securities and in Treasury bonds and were assessed on an individual security basis to have a de minimis risk of credit loss.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FASB accounting guidance defines fair value as the price that would be received to sell an asset or paid to transfer a liability (&#8220;the exit price&#8221;) in an orderly transaction between market participants at the measurement date. The standard outlines a valuation framework and creates a fair value hierarchy in order to increase the consistency and comparability of fair value measurements and the related disclosures. In determining fair value we use quoted prices and observable inputs. Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of us. The fair value hierarchy is broken down into three levels based on the source of inputs as follows:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1&#8212;Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2&#8212;Valuations based on observable inputs and quoted prices in active markets for similar assets and liabilities.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3&#8212;Valuations based on inputs that are unobservable and models that are significant to the overall fair value measurement.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recurring Fair Value Measurements</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our marketable securities consist of investments in U.S. government debt securities that are classified as available-for-sale. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September&#160;30, 2022 and December&#160;31, 2021, our Level 2 U.S. government debt securities were valued using readily available pricing sources which utilize market observable inputs, including the current interest rate and other characteristics for similar types of investments. Our long term investments classified as Level 1 were valued using their respective closing stock prices on The Nasdaq Stock Market. We did not experience any transfers of financial instruments between the fair value hierarchy levels during the nine months ended September&#160;30, 2022.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following fair value hierarchy table presents information about each major category of our financial assets measured at fair value on a recurring basis (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurement at Reporting Date Using:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Quoted Prices in<br/>Active Markets for<br/>Identical Assets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Significant Other<br/>Observable<br/>Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance as of <br/>September 30, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,690,622&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,690,622&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities (government)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">286,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">286,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long term investments (Note 7)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149,124&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149,124&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,839,746&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">286,500&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,126,246&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurement at Reporting Date Using:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Quoted Prices in<br/>Active Markets for<br/>Identical Assets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Significant Other<br/>Observable<br/>Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Balance as of<br/>December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,057,440&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,057,440&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities (government)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">290,752&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">290,752&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long term investments (Note 7)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221,266&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221,266&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,278,706&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">290,752&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,569,458&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following fair value hierarchy table presents information about each major category of our financial liabilities measured at fair value on a recurring basis as (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurement at Reporting Date Using:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Quoted Prices in<br/>Active Markets for<br/>Identical Liabilities<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Significant Other<br/>Observable<br/>Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance as of<br/>September 30, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition-related contingent consideration</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurement at Reporting Date Using:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices in<br/>Active Markets for<br/>Identical Liabilities<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Other<br/>Observable<br/>Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance as of<br/>December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition-related contingent consideration</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">244,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">244,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">244,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">244,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a rollforward of our Level 3 liabilities (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.082%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January 1, </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">244,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration earned during the period but not yet paid</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,802)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,198)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30,</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the contingent consideration was determined on the date of acquisition, June&#160;1, 2016, using an income approach based on projected future net revenues of ICLUSIG in the European Union and other countries for the approved third line treatment over 18 years, and discounted to present value at a rate of 10%. The fair value of the contingent consideration is remeasured each reporting period, with changes in fair value recorded in the condensed consolidated statements of operations. The valuation inputs utilized to estimate the fair value of the contingent consideration as of September&#160;30, 2022 and December&#160;31, 2021 included a discount rate of 10% and updated projections of future net revenues of ICLUSIG in the European Union and other countries for the approved third line treatment. The gain on change in fair value of the contingent consideration during the three and nine months ended September&#160;30, 2022 was due primarily to the changes in foreign currency exchange rates included within the updated projections of future net revenues of ICLUSIG.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generally make payments to Takeda Pharmaceutical Company Limited quarterly based on the royalties or any additional milestone payments earned in the previous quarter. At September&#160;30, 2022 and December&#160;31, 2021, contingent consideration earned but not yet paid was $25.8 million and $19.6 million, respectively, and was included in accrued and other current liabilities.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139808196447232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Concentrations of Credit Risk and Current Expected Credit Losses<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RisksAndUncertaintiesAbstract', window );"><strong>Risks and Uncertainties [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskDisclosureTextBlock', window );">Concentrations of Credit Risk and Current Expected Credit Losses</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2009, we entered into a collaboration and license agreement with Novartis Pharmaceutical International Ltd. (&#8220;Novartis&#8221;). In December 2009, we entered into a license, development and commercialization agreement with Eli Lilly and Company (&#8220;Lilly&#8221;). In December 2018, we entered into a research collaboration and licensing agreement with Innovent Biologics, Inc. (&#8220;Innovent&#8221;). In July 2019, we entered into a collaboration and license agreement with Zai Lab (Shanghai) Co., Ltd., a subsidiary of Zai Lab Limited (collectively, &#8220;Zai Lab&#8221;). The above collaboration partners comprised, in aggregate, 19% and 36% of the accounts receivable balance as of September&#160;30, 2022 and December&#160;31, 2021, respectively. For further information relating to these collaboration and license agreements,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">refer to Note 7.</span><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2011, we began commercialization and distribution of JAKAFI, in April 2020, we began commercialization and distribution of PEMAZYRE, and in October 2021, we began commercialization and distribution of OPZELURA. Our product revenues are concentrated in a number of these customers. The concentration of credit risk related to our JAKAFI, PEMAZYRE and OPZELURA product revenues is as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Percentage of Total Net<br/>Product Revenues for the<br/>Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Percentage of Total Net<br/>Product Revenues for the<br/>Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer A</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer B</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer C</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer D</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer E</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to risks associated with extending credit to customers related to the sale of products. Customers A, B, C, D and E comprised, in aggregate, 36% and 31% of the accounts receivable balance as of September&#160;30, 2022 and December&#160;31, 2021, respectively. The concentration of credit risk relating to our other product revenues or accounts receivable is not significant.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assessed our collaborative and customer receivable assets as of September&#160;30, 2022 according to our accounting policy for applying reserves for expected credit losses, noting minimal history of uncollectible receivables and the continued perceived creditworthiness of our third party sales relationships, upon which the expected credit losses were considered de minimis. As of September&#160;30, 2022 and December&#160;31, 2021, we had no allowance for doubtful accounts.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI https://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RisksAndUncertaintiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RisksAndUncertaintiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139808196391008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventory</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our inventory balance consists of the following (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,289&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,275&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,465&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,895&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,379&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,768&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventory</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101,133&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,938&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories, stated at the lower of cost and net realizable value, consist of raw materials, work in process and finished goods. At September&#160;30, 2022, $45.9 million of inventory was classified as current on the condensed consolidated balance sheet as we expect this inventory to be consumed for commercial use within the next twelve months. At September&#160;30, 2022, $55.3 million of inventory was classified as non-current on the condensed consolidated balance sheet as we did not expect this inventory to be consumed for commercial use within the next twelve months. We obtain some inventory components from a limited number of suppliers due to technology, availability, price, quality or other considerations. The loss of a supplier, the deterioration of our relationship with a supplier, or any unilateral violation of the contractual terms under which we are supplied components by a supplier could adversely affect our total revenues and gross margins.</span></div>We capitalize inventory after U.S. Food and Drug Administration (FDA) approval as the related costs are expected to be recoverable through the commercialization of the product. Costs incurred prior to FDA approval are recorded as research and development expense in our statements of operations. At September&#160;30, 2022, inventory with approximately $56.8 million of product costs incurred prior to FDA approval had not yet been sold. We expect to sell the pre-commercialization inventory over the next 28 months and, as a result, cost of product revenues will reflect a lower average per unit cost of materials.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI https://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139808196447232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License Agreements<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_incy_LicenseAgreementsDisclosureAbstract', window );"><strong>License Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_incy_LicenseAgreementsTextBlock', window );">License Agreements</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Novartis</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2009, we entered into a Collaboration and License Agreement with Novartis. Under the terms of the agreement, Novartis received exclusive development and commercialization rights outside of the United States to our JAK inhibitor ruxolitinib and certain back-up compounds for hematologic and oncology indications, including all hematological malignancies, solid tumors and myeloproliferative diseases. We retained exclusive development and commercialization rights to JAKAFI (ruxolitinib) in the United States and in certain other indications. Novartis also received worldwide exclusive development and commercialization rights to our MET inhibitor compound capmatinib and certain back-up compounds in all indications.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under this agreement, we were initially eligible to receive up to $174.0 million for the achievement of development milestones, up to $495.0 million for the achievement of regulatory milestones and up to $500.0 million for the achievement of sales milestones. In addition, under an amendment to this agreement, we were initially eligible to receive up to $75.0 million of additional potential development and regulatory milestones relating to graft-versus-host-disease (&#8220;GVHD&#8221;). We have recognized and received, in the aggregate, $157.0 million for the achievement of development milestones, $340.0 million for the achievement of regulatory milestones, and $200.0 million for the achievement of sales milestones through September&#160;30, 2022. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2022, we recognized a $15.0 million regulatory milestone for the positive opinion issued by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) that recommends granting marketing authorization for capmatinib (TABRECTA) as a monotherapy for the treatment of adults with advanced non-small cell lung cancer. Additionally, in May 2022, we recognized a $45.0 million regulatory milestone as a result of the European Commission&#8217;s approval of JAKAVI (ruxolitinib) as the first post-steroid treatment for acute and chronic GVHD.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also are eligible to receive tiered, double-digit royalties ranging from the upper-teens to the mid-twenties on future JAKAVI net sales outside of the United States, and tiered, worldwide royalties on TABRECTA net sales that range from 12% to 14%. We are obligated to pay to Novartis tiered royalties in the low single-digits on future JAKAFI net sales within the United States contingent on certain conditions. During the three and nine months ended September&#160;30, 2022, such royalties on net sales within the United States totaled $30.3 million and $81.3 million, respectively, and were reflected in cost of product revenues on the condensed consolidated statements of operations. During the three and nine months ended September&#160;30, 2021, such royalties on net sales within the United States totaled $26.9 million and $70.6 million, respectively, and were reflected in cost of product revenues on the condensed consolidated statements of operations. At September&#160;30, 2022 and December&#160;31, 2021, $221.7 million and $148.1 million, respectively, of accrued royalties were included in accrued and other current liabilities on the condensed consolidated balance sheets. Each company is responsible for costs relating to the development and commercialization of ruxolitinib in its respective territories, with costs of collaborative studies shared equally. Novartis is also responsible for all costs relating to the development and commercialization of capmatinib.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had no milestone and contract revenue under the Novartis agreement for the three months ended September&#160;30, 2022, and we had $60.0 million for the nine months ended September&#160;30, 2022. Product royalty revenue related to Novartis net sales of JAKAVI outside of the United States for the three and nine months ended September&#160;30, 2022 was $85.8 million and $240.4 million, respectively. Product royalty revenue related to Novartis net sales of JAKAVI outside of the United States for the three and nine months ended September&#160;30, 2021 was $94.7 million and $242.3 million, respectively. Product royalty revenue related to Novartis net sales of TABRECTA worldwide for the three and nine months ended September&#160;30, 2022 was $4.1 million and $11.2 million, respectively. Product royalty revenue related to Novartis net sales of TABRECTA worldwide for the three and nine months ended September&#160;30, 2021 was $2.7 million and $7.3 million, respectively.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Lilly &#8211; Baricitinib</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2009, we entered into a License, Development and Commercialization Agreement with Lilly. Under the terms of the agreement, Lilly received exclusive worldwide development and commercialization rights to our JAK inhibitor baricitinib, and certain back-up compounds for inflammatory and autoimmune diseases.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under this agreement, we were initially eligible to receive up to $150.0 million for the achievement of development milestones, up to $365.0 million for the achievement of regulatory milestones and up to $150.0 million for the achievement of sales milestones. We have recognized and received, in aggregate, $149.0 million for the achievement of development milestones, $335.0 million for the achievement of regulatory milestones and $50.0 million for the achievement of sales milestones through September&#160;30, 2022. We are also eligible to receive tiered, double-digit royalty payments on future global sales with rates ranging up to the mid-twenties if a product is successfully commercialized. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, we amended our agreement with Lilly to enable Lilly to develop and commercialize baricitinib for the treatment of COVID-19. As part of the amended agreement, in addition to the royalties described above, we will be entitled to receive additional royalty payments with rates in the low teens on global net sales of baricitinib for the treatment of COVID-19 that exceed a specified aggregate global net sales threshold.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2022, we recognized a $40.0 million regulatory milestone for the FDA approval of OLUMIANT as a first-in-disease systemic treatment for adults with severe alopecia areata. Additionally, in June 2022 we recognized a $20.0 million regulatory milestone for the European Commission&#8217;s approval for OLUMIANT for the treatment of adults with severe alopecia areata, and a $10.0 million regulatory milestone for the Ministry of Health, Labour and Welfare of Japan&#8217;s approval for OLUMIANT for the treatment of adults with severe alopecia areata in Japan.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had no milestone and contract revenue under the Lilly agreement for the three months ended September&#160;30, 2022, and we had $70.0 million for the nine months ended September&#160;30, 2022. Product royalty revenue related to Lilly net sales of OLUMIANT outside of the United States for the three and nine months ended September&#160;30, 2022 was $20.4 million and $98.7 million, respectively. Product royalty revenue related to Lilly net sales of OLUMIANT outside of the United States for the three and nine months ended September&#160;30, 2021 was $86.6 million and $154.9 million, respectively. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Lilly - Ruxolitinib</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2016, we entered into an amendment to the agreement with Lilly that amended the non-compete provision of the agreement to allow us to engage in the development and commercialization of ruxolitinib in the GVHD field. Lilly is eligible to receive up to $40.0 million in regulatory milestone payments relating to ruxolitinib in the GVHD field. In May 2019, the approval of JAKAFI in steroid-refractory acute GVHD triggered a $20.0 million milestone payment to Lilly. In March 2022, the positive recommendation from the European Medicines Agency for regulatory approval of ruxolitinib in the GVHD field triggered an additional $20.0 million milestone payment to Lilly, which was recorded as research and development expense in our condensed consolidated statements of operations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Agenus</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2015, we entered into a License, Development and Commercialization Agreement with Agenus Inc. and its wholly-owned subsidiary, 4-Antibody AG (now known as Agenus Switzerland Inc.), which we collectively refer to as Agenus. Under this agreement, which was amended in February 2017, the parties have agreed to collaborate on the discovery of novel immuno-therapeutics using Agenus&#8217; antibody discovery platforms. Under the terms of the amended agreement, we received exclusive worldwide development and commercialization rights to four checkpoint modulators directed against GITR, OX40, LAG-3 and TIM-3 as well as two undisclosed targets. Targets may be designated profit-share programs, where all costs and profits are shared equally by us and Agenus, or royalty-bearing programs, where we are responsible for all costs associated with discovery, preclinical, clinical development and commercialization activities. There are currently no profit-share programs. For each royalty-bearing product other than GITR and one undisclosed target, Agenus will be eligible to receive tiered royalties on global net sales ranging from 6% to 12%. For GITR and one undisclosed target, Agenus will be eligible to receive 15% royalties on global net sales. The agreement may be terminated by us for convenience upon 12 months&#8217; notice and may also be terminated under certain other circumstances, including material breach. On October 19, 2022 we notified Agenus that we were terminating the OX40 project.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2022, we have paid Agenus milestones totaling $30.0 million and Agenus is eligible to receive up to an additional $500.0 million in future contingent development, regulatory and commercialization milestones across all programs in the collaboration.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in 2017 we purchased 10.0&#160;million shares of Agenus Inc.&#8217;s common stock for an aggregate purchase price of $60.0 million in cash, or $6.00 per share. In 2020, we sold an aggregate of approximately 3.7&#160;million shares of Agenus Inc.&#8217;s common stock resulting in gross proceeds of approximately $17.2 million. In 2021, we sold an aggregate of approximately 2.0&#160;million shares of Agenus Inc.&#8217;s common stock resulting in gross proceeds of approximately $10.5 million. The fair market value of our long term investment in Agenus Inc. at September&#160;30, 2022 and December&#160;31, 2021 was $24.8 million and $38.9 million, respectively.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to hold the investment in Agenus Inc. for the foreseeable future and therefore, are accounting for our shares held in Agenus Inc. at fair value whereby the investment is marked to market through earnings in each reporting period. Given our intent to hold the investment for the foreseeable future, we have classified the investment within long term investments on the accompanying condensed consolidated balance sheets. For the three and nine months ended September&#160;30, 2022, we recorded an unrealized gain of $1.3 million and an unrealized loss of $14.1 million, respectively, based on the change in fair value of Agenus Inc.&#8217;s common stock during the respective periods. For the three and nine months ended September&#160;30, 2021, we recorded an unrealized loss of $2.8 million and an unrealized gain of $29.1 million, respectively, based on the change in fair value of Agenus Inc.&#8217;s common stock during the respective periods. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Merus</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2016, we entered into a Collaboration and License Agreement with Merus N.V. (&#8220;Merus&#8221;). Under this agreement, the parties have agreed to collaborate with respect to the research, discovery and development of bispecific antibodies utilizing Merus&#8217; technology platform. The collaboration encompasses up to ten independent programs. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2022, we decided to opt-out of the continued development of MCLA-145, a bispecific antibody targeting PD-L1 and CD137. We continue to collaborate with Merus and leverage the Merus platform to develop a pipeline of novel agents, as we continue to hold worldwide exclusive development and commercialization rights to up to ten additional programs. Of these ten additional programs, Merus retained the option, subject to certain conditions, to co-fund development of up to two such programs. If Merus exercises its co-funding option for a program, Merus would be responsible for funding 35% of the associated future global development costs and, for certain of such programs, would be responsible for reimbursing us for certain development costs incurred prior to the option exercise. Merus will also have the right to participate in a specified proportion of detailing activities in the United States for one of those co-developed programs. All costs related to the co-funded collaboration programs are subject to joint research and development plans and overseen by a joint development committee, but we will have final determination as to such plans in cases of dispute. We will be responsible for all research, development and commercialization costs relating to all other programs. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For each program as to which Merus does not have commercialization or development co-funding rights, Merus is eligible to receive up to $100.0 million in future contingent development and regulatory milestones, and up to $250.0 million in commercialization milestones as well as tiered royalties ranging from 6% to 10% of global net sales. For each program as to which Merus exercises its option to co-fund development, Merus is eligible to receive a 50% share of profits (or sustain 50% of any losses) in the United States and be eligible to receive tiered royalties ranging from 6% to 10% of net sales of products outside of the United States. If Merus opts to cease co-funding a program as to which it exercised its co-development option, then Merus will no longer receive a share of profits in the United States but will be eligible to receive the same milestones from the co-funding termination date and the same tiered royalties described above with respect to programs where Merus does not have a right to co-fund development and, depending on the stage at which Merus chose to cease co-funding development costs, Merus will be eligible to receive additional royalties ranging up to 4% of net sales in the United States. As of September&#160;30, 2022, we have paid Merus milestones totaling $3.0 million.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in 2016 we entered into a Share Subscription Agreement with Merus, pursuant to which we purchased 3.2&#160;million common shares of Merus for an aggregate purchase price of $80.0 million in cash, or $25.00 per share. In January 2021, we purchased 350,000 common shares in Merus&#8217; underwritten public offering of 4,848,485 common shares at the public offering price of $24.75 per share, or an aggregate purchase price of $8.7 million. The fair market value of our total long term investment in Merus at September&#160;30, 2022 and December&#160;31, 2021 was $71.1 million and $112.9 million, respectively. As of September&#160;30, 2022, we owned approximately 8% of the outstanding common shares of Merus.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have concluded that we have the ability to exercise significant influence, but not control, over Merus based primarily on our ownership interest, the level of intra-entity transactions between us and Merus related to development expenses, as well as other qualitative factors. We have elected the fair value option to account for our long term investment in Merus whereby the investment is marked to market through earnings in each reporting period. We believe the fair value option to be the most appropriate accounting method to account for securities in publicly held collaborators for which we have significant influence. For the three and nine months ended September&#160;30, 2022, we recorded an unrealized loss of $9.3 million and $41.8 million, respectively, based on the change in fair value of Merus&#8217; common shares during the respective periods. For the three and nine months ended September&#160;30, 2021, we recorded an unrealized gain of $3.3 million and $13.3 million, respectively, based on the change in fair value of Merus&#8217; common shares during the respective periods. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Calithera</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2017, we entered into a Collaboration and License Agreement with Calithera Biosciences, Inc. (&#8220;Calithera&#8221;). Under this agreement, we received an exclusive, worldwide license to develop and commercialize small molecule arginase inhibitors, including INCB01158. We had initially agreed to co-fund 70% of the global development costs for the development of the licensed products for hematology and oncology indications, but effective September 30, 2020 Calithera opted out of its co-funding obligation, and we became responsible for funding all of the development costs of INCB01158 and any other licensed products. In September 2022, we notified Calithera of our exercise of our right to terminate the Collaboration and License Agreement for convenience, effective in December 2022. As a result of the termination, rights to INCB01158 and the other licensed products will revert to Calithera.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in 2017, we entered into a Stock Purchase Agreement with Calithera, pursuant to which we purchased 1.7&#160;million shares of Calithera common stock for an aggregate purchase price of $8.0 million in cash, or $4.65 per share. In June 2022, Calithera effected a one-for-twenty stock split of its outstanding common stock, adjusting our ownership to 86,021 shares of Calithera&#8217;s common stock. The fair market value of our long term investment in Calithera at September&#160;30, 2022 and December&#160;31, 2021 was $0.3 million and $1.1 million, respectively.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to hold the investment in Calithera for the foreseeable future and therefore, are accounting for our shares held in Calithera at fair value whereby the investment is marked to market through earnings in each reporting period. Given our intent to hold the investment for the foreseeable future, we have classified the investment within long term investments on the accompanying condensed consolidated balance sheets. For the three months ended September&#160;30, 2022 we recorded a nominal unrealized gain, and for the nine months ended September&#160;30, 2022 we recorded an unrealized loss of $0.9 million, based on the change in fair value of Calithera&#8217;s common stock during the respective periods. For the three and nine months ended September&#160;30, 2021 we recorded an unrealized gain of $0.2 million and an unrealized loss of $4.6 million, respectively, based on the change in fair value of Calithera&#8217;s common stock during the respective periods.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">MacroGenics</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2017, we entered into a Global Collaboration and License Agreement with MacroGenics, Inc. (&#8220;MacroGenics&#8221;). Under this agreement, we received exclusive development and commercialization rights worldwide to MacroGenics&#8217; INCMGA0012 (formerly MGA012), an investigational monoclonal antibody that inhibits PD-1. Except as set forth in the succeeding sentence, we have sole authority over and bear all costs and expenses in connection with the development and commercialization of INCMGA0012 in all indications, whether as a monotherapy or as part of a combination regimen. MacroGenics has retained the right to develop and commercialize, at its cost and expense, its pipeline assets in combination with INCMGA0012. In addition, MacroGenics has the right to manufacture a portion of both companies&#8217; global clinical and commercial supply needs of INCMGA0012.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2022, we amended our agreement with MacroGenics to reflect changes related to the payment of certain milestones and paid MacroGenics $30.0 million. As of September 30, 2022, we have paid MacroGenics developmental milestones totaling $100.0 million. After the amendment, MacroGenics will be eligible to receive up to an additional $335.0 million in future contingent development and regulatory milestones, and up to $330.0 million in sales milestones as well as tiered royalties ranging from 15% to 24% of global net sales.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses for the three and nine months ended September&#160;30, 2022 also included $41.6 million and $69.9 million, respectively, of development costs incurred pursuant to the MacroGenics agreement. Research and development expenses for the three and nine months ended September&#160;30, 2021 also included $17.8 million and $49.0 million, respectively, of development costs incurred pursuant to the MacroGenics agreement. At September&#160;30, 2022 and December&#160;31, 2021, a total of $2.7 million and $0.7 million of such costs were included in accrued and other liabilities on the condensed consolidated balance sheets.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Syros</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2018, we entered into a Target Discovery, Research Collaboration and Option Agreement with Syros Pharmaceuticals, Inc. (&#8220;Syros&#8221;). Under this agreement, Syros will use its proprietary gene control platform to identify novel therapeutic targets with a focus in myeloproliferative neoplasms and we have received options to obtain exclusive worldwide rights to intellectual property resulting from the collaboration for up to seven validated targets. We will have exclusive worldwide rights to develop and commercialize any therapies under the collaboration that modulate those validated targets. We have agreed to pay Syros up to $54.0 million in target selection and option exercise fees should we decide to exercise all of our options under the agreement. For products resulting from the collaboration against each of the seven selected and validated targets, we have agreed to pay up to $50.0 million in potential development and regulatory milestones and up to $65.0 million in potential sales milestones. Syros is also eligible to receive low single-digit royalties on net sales of products resulting from the collaboration.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in 2018, we entered into a Stock Purchase Agreement with Syros, pursuant to which we purchased 0.8&#160;million shares of Syros common stock for an aggregate purchase price of $10.0 million in cash, or $12.61 per share. Subsequently in 2018, we entered into an Amended Stock Purchase Agreement with Syros, pursuant to which we purchased an additional 0.1&#160;million shares of Syros common stock for an aggregate purchase price of $1.4 million in cash, or $9.55 per share. In September 2022, Syros effected a one-for-ten stock split of its outstanding common stock, adjusting our ownership to 93,753 shares of Syros&#8217;s common stock. The fair market value of our long term investment in Syros as of September&#160;30, 2022 and December&#160;31, 2021 was $0.6 million and $3.1 million, respectively.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to hold the investment in Syros for the foreseeable future and therefore, are accounting for our shares held in Syros at fair value whereby the investment is marked to market through earnings in each reporting period. Given our intent to hold the investment for the foreseeable future, we have classified the investment within long term investments on the accompanying condensed consolidated balance sheets. For the three and nine months ended September&#160;30, 2022, we recorded an unrealized loss of $0.3 million and $2.5 million, respectively, based on the change in fair value of Syros&#8217; common stock during the respective periods. For the three and nine months ended September&#160;30, 2021, we recorded an unrealized loss of $0.9 million and $6.0 million, respectively, based on the change in fair value of Syros&#8217; common stock during the respective periods.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Innovent </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">n December 2018, we entered into a Research Collaboration and Licensing Agreement with Innovent. Under the terms of this agreement, Innovent received exclusive development and commercialization rights to our clinical-stage product candidates pemigatinib, itacitinib and parsaclisib in hematology and oncology in mainland China, Hong Kong, Macau and Taiwan. We are eligible to receive up to an additional $94.0 million in potential development and regulatory milestones.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize development and regulatory milestones upon confirmation of achievement of the event, as development and regulatory approvals are events not controllable by us but rather development activities of Innovent and decisions made by regulatory agencies. In March 2022, we recognized a $5.0 million milestone for approval of PEMAZYRE (pemigatinib) in China.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event of commercialization of the licensed molecule, we are eligible to receive up to $202.5 million in potential sales milestones from Innovent. We will recognize sales milestones in the corresponding period of the product sale upon confirmation of net sales milestone threshold achievement by Innovent. We are also eligible to receive tiered royalties from the high-teens to the low-twenties on future sales of products resulting from the collaboration. We retain an option to assist in the promotion of the three product candidates in the Innovent territories.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Zai Lab</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2019, we entered into a Collaboration and License Agreement with Zai Lab. Under the terms of this agreement, Zai Lab received development and exclusive commercialization rights to INCMGA0012 in hematology and oncology in mainland China, Hong Kong, Macau and Taiwan.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The agreement allows for Zai Lab to continue development of the licensed molecule and to submit the licensed molecule to authorities for regulatory approval within the agreement territory, upon which we are eligible for up to $22.5 million in potential development and regulatory milestones. We recognize development and regulatory milestones upon confirmation of achievement of the event, as development and regulatory approvals are events not controllable by us but rather development activities of Zai Lab and decisions made by regulatory agencies.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event of commercialization of the licensed molecule, we are eligible to receive up to $37.5 million in potential sales milestones from Zai Lab. We will recognize sales milestones in the corresponding period of the product sale upon confirmation of net sales milestone threshold achievement by Zai Lab. We are also eligible to receive tiered royalties from the low to mid-twenties on future product sales resulting from the collaboration. We also retain an option to assist in the promotion of INCMGA0012 in Zai Lab&#8217;s licensed territories.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">MorphoSys</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2020, we entered into a Collaboration and License Agreement with MorphoSys AG and MorphoSys US Inc., a wholly-owned subsidiary of MorphoSys AG (together with MorphoSys AG, &#8220;MorphoSys&#8221;), covering the worldwide development and commercialization of MOR208 (tafasitamab), an investigational Fc engineered monoclonal antibody directed against the target molecule CD19 that is currently in clinical development by MorphoSys. MorphoSys has exclusive worldwide development and commercialization rights to tafasitamab under a June 2010 collaboration and license agreement with Xencor, Inc.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the agreement, we received exclusive commercialization rights outside of the United States, and MorphoSys and we have co-commercialization rights in the United States, with respect to tafasitamab. MorphoSys is responsible for leading the commercialization strategy and booking all revenue from sales of tafasitamab in the United States, and we and MorphoSys are both responsible for commercialization efforts in the United States and will share equally the profits and losses from the co-commercialization efforts. We will lead the commercialization strategy outside of the United States, and will be responsible for commercialization efforts and book all revenue from sales of tafasitamab outside of the United States, subject to our royalty payment obligations set forth below. We and MorphoSys have agreed to co-develop tafasitamab and to share development costs associated with global and U.S.-specific clinical trials, with Incyte responsible for 55% of such costs and MorphoSys responsible for 45% of such costs. Each company is responsible for funding any independent development activities, and we are responsible for funding development activities specific to territories outside of the United States. All development costs related to the collaboration are subject to a joint development plan. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MorphoSys is eligible to receive up to $737.5 million in future contingent development and regulatory milestones and up to $315.0 million in commercialization milestones as well as tiered royalties ranging from the mid-teens to mid-twenties of net sales outside of the United States. MorphoSys&#8217; right to receive royalties in any particular country will expire upon the last to occur of (a) the expiration of patent rights in that particular country, (b) a specified period of time after the first post-marketing authorization sale of a licensed product comprising tafasitamab in that country, and (c) the expiration of any regulatory exclusivity for that licensed product in that country. As of September&#160;30, 2022, we have paid MorphoSys milestones totaling $2.5 million.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, under the terms of the agreement and pursuant to a related purchase agreement, we purchased American Depositary Shares (&#8220;ADSs&#8221;), each representing 0.25 of an ordinary share of MorphoSys AG, for an aggregate purchase price of $150.0 million or $41.33 per ADS (such ADSs to be purchased, the &#8220;New ADSs&#8221;). The fair market value of our long term investment in MorphoSys as of September&#160;30, 2022 and December&#160;31, 2021 was $18.3 million and $34.2 million, respectively.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to hold the investment in MorphoSys for the foreseeable future and therefore, are accounting for our shares held in MorphoSys at fair value whereby the investment is marked to market through earnings in each reporting period. Given our intent to hold the investment for the foreseeable future, we have classified the investment within long term investments on the accompanying condensed consolidated balance sheets. For the three and nine months ended September&#160;30, 2022, we recorded an unrealized gain of $0.8 million and an unrealized loss of $15.9 million, respectively, based on the change in fair value of MorphoSys&#8217; ordinary shares during the respective periods. For the three and nine months ended September&#160;30, 2021, we recorded an unrealized loss of $27.3 million and $60.2 million, respectively, based on the change in fair value of MorphoSys&#8217; ordinary shares during the respective periods. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our 50% share of the United States loss for the commercialization of tafasitamab for the three and nine months ended September&#160;30, 2022 was $1.8 million and $9.1 million, respectively, and is recorded as collaboration loss sharing on the condensed consolidated statement of operations. Our 50% share of the United States loss for the commercialization of tafasitamab for the three and nine months ended September&#160;30, 2021 was $9.1 million and $29.5 million, respectively, and is recorded as collaboration loss sharing on the condensed consolidated statement of operations. Research and development expenses for the three and nine months ended September&#160;30, 2022, includes $21.9 million and $70.4 million, respectively, related to our 55% share of the co-development costs for tafasitamab. Research and development expenses for the three and nine months ended September&#160;30, 2021, includes $21.5 million and $55.8 million, respectively, related to our 55% share of the co-development costs for tafasitamab. At September&#160;30, 2022 and December&#160;31, 2021, $72.5 million and $21.5 million, respectively, was included in accrued and other liabilities on the condensed consolidated balance sheets for amounts due to MorphoSys under the agreement.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Nimble</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, we entered into a Collaboration and License Agreement with Nimble Therapeutics, Inc. (&#8220;Nimble&#8221;). Under the terms of this agreement, Nimble will utilize their peptide synthesis, screening and optimization platform for discovery and validation of peptides against specified targets. Under the agreement, Nimble is eligible to receive up to $8.0 million in future contingent discovery milestones and up to $127.0 million in future contingent development and regulatory milestones. Additionally, in the event of successful commercialization, Nimble is eligible to receive up to $130.0 million in future contingent sales milestones and tiered royalties on net sales in the low single digits.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">InnoCare</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2021, we entered into a Collaboration and License Agreement with Sunny Investments Limited, a wholly-owned subsidiary of InnoCare Pharma Limited (&#8220;InnoCare&#8221;). InnoCare received development and exclusive commercialization rights to tafasitamab in hematology and oncology in mainland China, Hong Kong, Macau and Taiwan. In September 2021, we recognized an upfront payment under this agreement of $35.0 million upon our transfer of technology related to the licensed product candidate to InnoCare, which was recorded in milestone and contract revenues on the consolidated statement of operations for the year ended December 31, 2021. Under the terms of this agreement, we are eligible to receive up to an additional $82.5 million in potential development, regulatory and commercial milestones. We recognize development and regulatory milestones upon confirmation of achievement of the event, as development and regulatory approvals are events not controllable by us but rather development activities of InnoCare and decisions made by regulatory agencies. In the event of commercialization, we will recognize sales milestones in the corresponding period of the product sale upon confirmation of net sales milestone threshold achievement by InnoCare.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Syndax</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2021, we entered into a Collaboration and License Agreement with Syndax Pharmaceuticals, Inc. (&#8220;Syndax&#8221;), covering the worldwide development and commercialization of SNDX-6352 (&#8220;axatilimab&#8221;). Axatilimab, currently in clinical development by Syndax, is a monoclonal antibody that blocks the colony stimulating factor-1 (CSF-1) receptor. Syndax has exclusive worldwide development and commercialization rights to axatilimab under a June 2016 license agreement with UCB Biopharma Sprl. The agreement became effective in December 2021.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the agreement, we received exclusive commercialization rights outside of the United States, and Syndax and we have co-commercialization rights in the United States, with respect to axatilimab. We will be responsible for leading the commercialization strategy and booking all revenue from sales of axatilimab globally, and Syndax will have the option to co-commercialization axatilimab with Incyte in the United States. Incyte and Syndax will share equally the profits and losses from the co-commercialization efforts in the United States. Sales of axatilimab outside the United States will be subject to our royalty payment obligations to Syndax, as set forth below. We and Syndax have agreed to co-develop axatilimab and to share development costs associated with global and U.S.-specific clinical trials, with Incyte responsible for 55% of such costs and Syndax responsible for 45% of such costs. Each company is responsible for funding any independent development activities. All development costs related to the collaboration are subject to a joint development plan. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021, we paid Syndax an upfront, non-refundable payment of $117.0 million, which was recorded in research and development expense on the consolidated statement of operations for the year ended December 31, 2021. Syndax is eligible to receive up to $220.0 million in future contingent development and regulatory milestones and up to $230.0 million in sales milestones as well as tiered royalties ranging in the mid-teens on net sales in Europe and Japan and low double digit percentage on net sales in the rest of the world outside of the United States. Syndax&#8217; right to receive royalties in any particular country will expire upon the last to occur of (a) the expiration of patent rights in that particular country, (b) a specified period of time after the first post-marketing authorization sale of a licensed product comprising axatilimab in that country, and (c) the expiration of any regulatory exclusivity for that licensed product in that country.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, under the terms of the agreement and pursuant to a related stock purchase agreement, we purchased approximately 1.4&#160;million shares of Syndax common stock for an aggregate purchase price of $35.0 million, or $24.62 per share. We completed the purchase of the shares on December 9, 2021 when the closing price on The Nasdaq Stock Market was $17.48 per share. Of the $35.0 million aggregate purchase price paid, $24.8 million was allocated to our stock purchase and was recorded within long term investments and $10.2 million, representing premium paid on the purchase, was allocated to research and development expense on the consolidated statement of operations for the year ended December 31, 2021. The fair market value of our long term investment in Syndax as of September&#160;30, 2022 and December&#160;31, 2021 was $34.2 million and $31.1 million.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to hold the investment in Syndax for the foreseeable future and therefore, are accounting for our shares held in Syndax at fair value whereby the investment is marked to market through earnings in each reporting period. Given our intent to hold the investment for the foreseeable future, we have classified the investment within long term investments on the accompanying condensed consolidated balance sheets. For the three and nine months ended September&#160;30, 2022, we recorded an unrealized gain of $6.8 million and $3.1 million, respectively, based on the change in fair value of Syndax&#8217;s common stock during the respective periods.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Maruho</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2022, we entered into a strategic alliance agreement with Maruho, Co., Ltd (&#8220;Maruho&#8221;) for the development, manufacturing and exclusive commercialization of ruxolitinib cream, for treatment of autoimmune and inflammatory dermatology indications in Japan. Maruho will receive the rights to develop, manufacture and exclusively commercialize ruxolitinib cream, and other potential future topical formulations of ruxolitinib, in autoimmune and inflammatory dermatologic diseases, including vitiligo and atopic dermatitis, in Japan. Under the terms of the agreement, we received an upfront payment from Maruho which was deferred and recorded in other liabilities on the condensed consolidated balance sheet and we are eligible to receive additional potential development, regulatory and commercial milestones and royalties on net sales of the licensed product in Japan.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_LicenseAgreementsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License Agreements</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_LicenseAgreementsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_LicenseAgreementsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element may be used to describe all significant license agreements of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_LicenseAgreementsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139808196582880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, net<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment, net</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consists of the following (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Office equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,527&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,554&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Laboratory equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,507&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,040&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Computer equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,239&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,871&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Land</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,139&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,494&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Building and leasehold improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">432,748&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">434,321&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,111&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,308&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225,442&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220,052&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">917,713&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">899,640&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(201,980)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(175,720)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">715,733&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">723,920&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2017, we acquired additional adjacent buildings to our global headquarters in Wilmington, Delaware and in 2019, began demolition of these buildings and construction of a new laboratory and office building totaling approximately 200,000 square feet. The certificate of occupancy was received in December 2021 and we capitalized approximately $158.2 million in building and office equipment that was previously included in construction in progress as of December&#160;31, 2021.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2018, we signed an agreement to rent a building in Morges, Switzerland for an initial term of 15 years plus one year of free rent, with multiple options to extend for an additional 20 years. The building serves as our new European headquarters and consists of approximately 100,000 square feet of office space. This building allowed for consolidation of our European operations that were located in Geneva and Lausanne, Switzerland. In June 2019, we obtained control of the Morges building to begin our construction activity, which was completed in 2020. At that time, we determined the lease to be a finance lease and recorded a lease liability of $31.1 million and a finance lease right-of-use asset of $29.1 million, net of a lease incentive from our landlord of $2.0 million. We have capitalized approximately $19.5 million in leasehold improvements as of September&#160;30, 2022 relating to Morges.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2018, we signed an agreement to purchase land located in Yverdon, Switzerland. The land was purchased, in cash, for approximately $4.8 million. Upon this parcel, we are constructing a large molecule production facility. Construction activity commenced in July 2018, and as of September&#160;30, 2022, we have capitalized approximately $190.5 million in costs for construction, ground preparation and architectural and engineering studies. Inspection from competent authorities was finalized in March 2022, and in June 2022 Swissmedic authorities granted the GMP drug manufacturing license for this facility.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI https://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139808196426784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued and Other Current Liabilities<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">Accrued and Other Current Liabilities</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued and other current liabilities consisted of the following (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.778%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Royalties</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1.97pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">248,455</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1.97pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">168,412</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical related costs</span></td><td colspan="3" style="padding:2px 1.97pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">152,764</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1.97pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">109,486</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Sales allowances</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.97pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">186,112</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1.97pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">136,541</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales and marketing</span></td><td colspan="3" style="padding:2px 1.97pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">31,001</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1.97pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">35,750</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Construction in progress</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.97pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">8,836</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1.97pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">27,098</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating lease liabilities</span></td><td colspan="3" style="padding:2px 1.97pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">8,492</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1.97pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10,554</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.97pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">64,154</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1.97pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">45,754</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total accrued and other current liabilities</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1.97pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">699,814</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1.97pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">533,595</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139808196507120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Compensation<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock Compensation</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recorded $45.4 million and $135.7 million of stock compensation expense on our condensed consolidated statements of operations for the three and nine months ended September&#160;30, 2022, respectively. We recorded $42.7 million and $134.8 million of stock compensation expense on our condensed consolidated statements of operations for the three and nine months ended September&#160;30, 2021, respectively. Stock compensation expense included within our condensed consolidated statements of operations included research and development expense of $25.8 million, $80.2 million, $26.3 million and $84.2 million for the three and nine months ended September&#160;30, 2022 and 2021, respectively. Stock compensation expense included within our condensed consolidated statements of operations also included selling, general and administrative expense of $18.9 million, $53.5 million, $15.9 million and $49.5 million for the three and nine months ended September&#160;30, 2022 and 2021, respectively. Stock compensation expense included within our condensed consolidated statements of operations also included cost of product revenues of $0.7 million, $2.0 million, $0.5 million and $1.1 million, respectively, for the three and nine months ended September&#160;30, 2022 and 2021.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We utilized the Black-Scholes valuation model for estimating the fair value of the stock compensation granted, with the following weighted-average assumptions:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:21.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.998%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Employee Stock Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Employee Stock Purchase Plan</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average risk-free interest rates</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.90&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.76&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.03&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.60&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.22&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.28&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.44&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.22&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average expected life (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.17</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.16</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.88</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.00</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.50</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.50</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.50</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.50</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average fair value (in dollars)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.57&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.84&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.96&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.46&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.82&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The risk-free interest rate is derived from the U.S. Federal Reserve rate in effect at the time of grant. The expected life calculation is based on the observed and expected time to the exercise of options by our employees based on historical exercise patterns for similar type options. Expected volatility is based on the historical volatility of our common stock over the period commensurate with the expected life of the options. A dividend yield of zero is assumed based on the fact that we have never paid cash dividends and have no present intention to pay cash dividends. Nonemployee awards are measured on the grant date by estimating the fair value of the equity instruments to be issued using the expected term, similar to our employee awards.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Option activity under our 2010 Stock Incentive Plan (the &#8220;2010 Stock Plan&#8221;) was as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares Subject to<br/>Outstanding Options</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average<br/>Exercise Price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,763,460</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88.39&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options granted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,755,963</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(477,371)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.69&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options cancelled</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(989,465)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88.60&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,052,587</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87.41&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our annual stock option grants generally have a 10-year term and vest over four years, with 25% vesting after one year and the remainder vesting in 36 equal monthly installments.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock unit (&#8220;RSU&#8221;) and performance share (&#8220;PSU&#8221;) award activity under the 2010 Stock Plan was as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares Subject to<br/>Outstanding Awards</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Grant Date Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,966,888</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84.91&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs granted </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,473,892</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77.14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PSUs granted</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154,685</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77.67&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs released</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(845,095)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87.06&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PSUs released</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(184,401)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69.25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs cancelled </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(337,265)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83.94&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PSUs cancelled</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,720)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65.76&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30, 2022</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,226,984</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RSUs and PSUs are granted to our employees at the share price on the date of grant. Each RSU represents the right to acquire one share of our common stock. Each RSU granted in connection with our annual equity awards will vest 25% annually over four years, while each RSU granted as outstanding merit awards or as part of retention award programs will vest in a single installment at the end of four years.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We grant PSUs with performance and/or service-based milestones with graded and/or cliff vesting over <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RleHRyZWdpb246ZmFlNDc5YmVlYzk3NGU3Njk4MDJlOTE5MjQ4MDEwYzRfMjcyMw_f68315b0-93a7-445d-8854-3803f7e59595">three</span> to four years. The shares of our common stock into which each PSU may convert is subject to a multiplier based on the level at which the financial, developmental and market performance conditions are achieved over the service period. Compensation expense for PSUs with financial and developmental performance conditions is recorded over the estimated service period for each milestone when the performance conditions are deemed probable of achievement. For PSUs containing performance conditions which were not deemed probable of achievement, no stock compensation expense is recorded. Compensation expense for PSUs with market performance conditions is calculated using a Monte Carlo simulation model as of the date of grant and recorded over the requisite service period. For the three and nine months ended September&#160;30, 2022 we recorded $3.2 million and $5.1 million, respectively, of stock compensation expense for PSUs on our condensed consolidated statements of operations. For the three and nine months ended September&#160;30, 2021 we recorded $1.7 million and $5.0 million of stock compensation expense for PSUs on our condensed consolidated statements of operations.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our shares available for grant under the 2010 Stock Plan. Each RSU and PSU grant reduces the available share pool by 2 shares.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.082%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Shares Available<br/>for Grant</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Balance at December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1.97pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10,113,298</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Options, RSUs and PSUs granted</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(7,013,475)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Options, RSUs and PSUs cancelled</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.97pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,680,482</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Balance at September 30, 2022</span></td><td colspan="3" style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1.97pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4,780,305</span></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on our historical experience of employee turnover, we have assumed an annualized forfeiture rate of 5% for our options, RSUs and PSUs. Under the true-up provisions of the stock compensation guidance, we will record additional expense if the actual forfeiture rate is lower than we estimated, and will record a recovery of prior expense if the actual forfeiture is higher than we estimated.</span></div>Total compensation cost of options granted but not yet vested, as of September&#160;30, 2022, was $51.2 million, which is expected to be recognized over the weighted average period of approximately 1.1 years. Total compensation cost of RSUs granted but not yet vested, as of September&#160;30, 2022, was $235.5 million, which is expected to be recognized over the weighted average period of approximately 2.0 years. Total compensation cost of PSUs granted but not yet vested, as of September&#160;30, 2022, was $19.6 million, which is expected to be recognized over the weighted average period of 2.2 years, should the underlying performance conditions be deemed probable of achievement.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139808196418496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September&#160;30, 2022, we recorded income tax expense of approximately $35.8 million and $136.3 million, respectively. For the three and nine months ended September&#160;30, 2021, we recorded income tax expense of approximately $27.7 million and $65.7 million, respectively. The tax expense for the three and nine months ended September&#160;30, 2022 increased as compared to that for the prior year periods due to the release of our valuation allowance against a majority of our U.S. research and development tax credit carryforwards and other deferred tax assets at December&#160;31, 2021.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the fourth quarter of 2021, we assessed the valuation allowance and considered positive evidence, including significant cumulative consolidated and U.S. income over the three years ended December&#160;31, 2021, consistent growth in product revenues, and expectations regarding future profitability. We also assessed negative evidence, including the potential impact of competition, clinical failures and patent expirations on our projections. After assessing both the positive evidence and negative evidence, we determined it was more likely than not that the majority of our U.S. deferred tax assets would be realized in the future and released the associated valuation allowance as of December&#160;31, 2021. This resulted in a benefit of $569.0 million. As of December&#160;31, 2021, we maintained a valuation allowance of $408.2 million against a portion of our remaining U.S. deferred tax assets as well as select state and foreign deferred tax assets. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The balance of our unrecognized tax benefits (including penalties and interest) increased by approximately $11.2 million during the nine months ended September&#160;30, 2022, resulting in movements to other liabilities and deferred income tax asset on the condensed consolidated balance sheet. The overall increase is primarily driven by unrecognized tax benefits related to current year operations and research and development tax credits. We accrue interest and penalties related to unrecognized tax benefits as a component of its provision for income taxes.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2022, the Inflation Reduction Act of 2022 (&#8220;IRA&#8221;) was enacted into law. The IRA includes a 15% corporate alternative minimum tax and a 1% excise tax on share repurchases. We do not expect the IRA to have a material impact on our consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139808196472560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income Per Share<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Income Per Share</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income per share was calculated as follows for the periods indicated below:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112,775&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181,739&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">312,199&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">384,730&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average common shares outstanding</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222,415</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220,845</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221,801</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220,243</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic net income per share</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.51&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.82&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.41&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.75&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted net income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112,775&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181,739&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">312,199&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">384,730&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222,415</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220,845</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221,801</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220,243</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive stock options and awards</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,760</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,403</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,825</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,870</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average shares used to compute diluted net income per share </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224,175</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222,248</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223,626</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222,113</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Diluted net income per share</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.50&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.82&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.40&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.73&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The potential common shares that were excluded from the diluted net income per share computation are as follows:</span></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding stock options and awards</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,150,022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,841,440</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,979,096</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,917,824</span></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI https://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139808196320352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Employee Benefit Plans</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Defined Contribution Plans</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a defined contribution plan qualified under Section 401(k) of the Internal Revenue Code covering all U.S. employees and defined contribution plans for other Incyte employees in Europe and Japan. Employees may contribute a portion of their compensation, which is then matched by us, subject to certain limitations. Defined contribution expense for the three and nine months ended September&#160;30, 2022 was $5.1 million and $14.7 million, respectively. Defined contribution expense for the three and nine months ended September&#160;30, 2021 was $4.4 million and $12.8 million, respectively. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Defined Benefit Pension Plans</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have defined benefit pension plans for our employees in Europe which provide benefits to employees upon retirement, death or disability. The assets of the pension plans are held in collective investment accounts represented by the cash surrender value of an insurance policy and are classified as Level 2 within the fair value hierarchy.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net periodic benefit cost was as follows (in thousands): </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,376&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,975&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,336&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,927&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,008)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,114)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of prior service cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">580&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of actuarial losses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">288&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">266&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">864&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic benefit cost</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,711&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,325&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,255&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,976&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>The components of net periodic benefit cost other than the service cost component are included in <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV83My9mcmFnOjlkZDZlNTZmNWEzYzQwY2VhZDY2OWZjZDZjZmEzNDhiL3RleHRyZWdpb246OWRkNmU1NmY1YTNjNDBjZWFkNjY5ZmNkNmNmYTM0OGJfNjA0NzMxMzk1NDEzMQ_cd32c16f-4695-4a46-9bef-320c5c331b0a">other income (expense), net</span> on the condensed consolidated statements of operations. We expect to contribute a total of $6.4 million to the pension plans in 2022 inclusive of the amounts contributed to the plan during the current period.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section S99<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=21916913&amp;loc=d3e273930-122802<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI https://asc.fasb.org/topic&amp;trid=2235017<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39689-114964<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139808196414768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into the collaboration agreements described in Note 7, as well as various other collaboration agreements that are not individually, or in the aggregate, significant to our operating results or financial condition at this time. We may in the future seek to license additional rights relating to technologies or drug development candidates in connection with our drug discovery and development programs. Under these agreements, we may be required to pay upfront fees, milestone payments, and royalties on sales of future products.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of our business, we may become involved in lawsuits, proceedings, and other disputes, including commercial, intellectual property, regulatory, employment, and other matters. We record a reserve for these matters when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139808196507936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Villaris</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2022, we announced that we entered into an agreement to acquire Villaris Therapeutics, Inc. ("Villaris"), a biopharmaceutical company focused on the development of novel antibody therapeutics for vitiligo. Under the terms of the agreement, Incyte will acquire Villaris and the exclusive global rights to develop and commercialize auremolimab (VM6), an anti-IL-15R&#946; monoclonal antibody, for all uses, including in vitiligo and other autoimmune and inflammatory diseases. Upon effectiveness of the agreement, Incyte will make an upfront payment of $70.0 million, and Villaris shareholders will be eligible for up to $310.0 million upon achievement of certain development and regulatory milestones, as well as up to an additional $1.05 billion in commercial milestones on net sales of the product. The agreement is subject to clearance by the U.S. antitrust authorities under the Hart-Scott-Rodino Act and will become effective as soon as this condition has been met.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI https://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139808194782576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of presentation</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of presentation</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. The condensed consolidated balance sheet as of September&#160;30, 2022, the condensed consolidated statements of operations, comprehensive income (loss), and stockholders&#8217; equity for the three and nine months ended September&#160;30, 2022 and 2021, and the condensed consolidated statements of cash flows for the nine months ended September&#160;30, 2022 and 2021, are unaudited, but include all adjustments, consisting only of normal recurring adjustments, which we consider necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented. The condensed consolidated balance sheet at December&#160;31, 2021 has been derived from our audited consolidated financial statements.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we believe that the disclosures in these financial statements are adequate to make the information presented not misleading, certain information and footnote information normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States (&#8220;U.S. GAAP&#8221;) have been condensed or omitted pursuant to the rules and regulations of the Securities and Exchange Commission.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Results for any interim period are not necessarily indicative of results for any future interim period or for the entire year. The accompanying financial statements should be read in conjunction with the financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December&#160;31, 2021.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Principles of Consolidation.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The condensed consolidated financial statements include the accounts of Incyte Corporation and our wholly owned subsidiaries. All inter-company accounts, transactions, and profits have been eliminated in consolidation.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of Estimates.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text">Recent Accounting PronouncementsThere were no new accounting pronouncements issued nor adopted since our filing of the Annual Report on Form 10-K for the year ended December&#160;31, 2021, which could have a significant effect on our condensed consolidated financial statements.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139808190804272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Schedule of disaggregated revenue</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues are recognized under guidance within ASC 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The following table presents our disaggregated revenue for the periods presented (in thousands):  </span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">JAKAFI revenues, net</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">619,595&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">547,373&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,761,732&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,542,138&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ICLUSIG revenues, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,929&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,522&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,222&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,356&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PEMAZYRE revenues, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,414&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,562&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,429&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,924&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MINJUVI revenues, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,932&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">556&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,845&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">556&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OPZELURA revenues, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,140&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,454&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total product revenues, net</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">713,010&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">594,013&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,982,682&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,673,974&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">JAKAVI product royalty revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,808&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,655&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240,386&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">242,295&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OLUMIANT product royalty revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,371&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,572&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,689&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154,875&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TABRECTA product royalty revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,114&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,747&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,178&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,270&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total product royalty revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110,293&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183,974&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350,253&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">404,440&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Milestone and contract revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">823,303&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">812,987&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,467,935&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,123,414&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139808195460928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Summary of marketable securities portfolio</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of our marketable security portfolio for the periods presented (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities (government)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">292,941&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,441)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">286,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities (government)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">291,871&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,119)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">290,752&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Schedule of fair value of assets measured on recurring basis</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following fair value hierarchy table presents information about each major category of our financial assets measured at fair value on a recurring basis (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurement at Reporting Date Using:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Quoted Prices in<br/>Active Markets for<br/>Identical Assets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Significant Other<br/>Observable<br/>Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance as of <br/>September 30, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,690,622&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,690,622&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities (government)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">286,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">286,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long term investments (Note 7)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149,124&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149,124&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,839,746&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">286,500&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,126,246&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurement at Reporting Date Using:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Quoted Prices in<br/>Active Markets for<br/>Identical Assets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Significant Other<br/>Observable<br/>Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Balance as of<br/>December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,057,440&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,057,440&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities (government)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">290,752&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">290,752&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long term investments (Note 7)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221,266&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221,266&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,278,706&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">290,752&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,569,458&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock', window );">Schedule of fair value of liabilities measured on recurring basis</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following fair value hierarchy table presents information about each major category of our financial liabilities measured at fair value on a recurring basis as (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurement at Reporting Date Using:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Quoted Prices in<br/>Active Markets for<br/>Identical Liabilities<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Significant Other<br/>Observable<br/>Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance as of<br/>September 30, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition-related contingent consideration</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurement at Reporting Date Using:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices in<br/>Active Markets for<br/>Identical Liabilities<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Other<br/>Observable<br/>Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance as of<br/>December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition-related contingent consideration</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">244,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">244,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">244,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">244,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Schedule of roll forward of Level 3 liabilities</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a rollforward of our Level 3 liabilities (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.082%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January 1, </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">244,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration earned during the period but not yet paid</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,802)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,198)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30,</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI https://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139808196605216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Concentrations of Credit Risk and Current Expected Credit Losses (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RisksAndUncertaintiesAbstract', window );"><strong>Risks and Uncertainties [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_incy_SchedulesOfConcentrationOfRiskByRiskFactorRelatedToCollaborativePartnersTableTextBlock', window );">Schedule of concentration of credit risk related to collaborative partners</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2011, we began commercialization and distribution of JAKAFI, in April 2020, we began commercialization and distribution of PEMAZYRE, and in October 2021, we began commercialization and distribution of OPZELURA. Our product revenues are concentrated in a number of these customers. The concentration of credit risk related to our JAKAFI, PEMAZYRE and OPZELURA product revenues is as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Percentage of Total Net<br/>Product Revenues for the<br/>Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Percentage of Total Net<br/>Product Revenues for the<br/>Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer A</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer B</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer C</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer D</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer E</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_SchedulesOfConcentrationOfRiskByRiskFactorRelatedToCollaborativePartnersTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark, related to the collaborative partners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_SchedulesOfConcentrationOfRiskByRiskFactorRelatedToCollaborativePartnersTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RisksAndUncertaintiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RisksAndUncertaintiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139808196629072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_incy_ScheduleOfInventoryTableTextBlock', window );">Schedule of inventory</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our inventory balance consists of the following (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,289&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,275&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,465&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,895&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,379&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,768&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventory</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101,133&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,938&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_ScheduleOfInventoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of carrying amount of inventories as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_ScheduleOfInventoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139808196631680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, net (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of property and equipment, net</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consists of the following (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Office equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,527&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,554&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Laboratory equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,507&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,040&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Computer equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,239&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,871&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Land</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,139&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,494&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Building and leasehold improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">432,748&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">434,321&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,111&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,308&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225,442&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220,052&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">917,713&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">899,640&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(201,980)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(175,720)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">715,733&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">723,920&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139808193719312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued and Other Current Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of accrued and other current liabilities</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued and other current liabilities consisted of the following (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.778%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Royalties</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1.97pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">248,455</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1.97pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">168,412</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical related costs</span></td><td colspan="3" style="padding:2px 1.97pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">152,764</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1.97pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">109,486</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Sales allowances</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.97pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">186,112</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1.97pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">136,541</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales and marketing</span></td><td colspan="3" style="padding:2px 1.97pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">31,001</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1.97pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">35,750</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Construction in progress</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.97pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">8,836</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1.97pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">27,098</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating lease liabilities</span></td><td colspan="3" style="padding:2px 1.97pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">8,492</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1.97pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10,554</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.97pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">64,154</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1.97pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">45,754</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total accrued and other current liabilities</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1.97pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">699,814</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1.97pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">533,595</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139808194790144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_incy_ScheduleOfShareBasedPaymentAwardStockOptionsAndEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock', window );">Schedule of valuation assumptions used for valuation of fair value of stock compensation granted</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We utilized the Black-Scholes valuation model for estimating the fair value of the stock compensation granted, with the following weighted-average assumptions:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:21.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.998%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Employee Stock Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Employee Stock Purchase Plan</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average risk-free interest rates</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.90&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.76&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.03&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.60&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.22&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.28&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.44&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.22&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average expected life (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.17</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.16</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.88</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.00</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.50</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.50</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.50</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.50</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average fair value (in dollars)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.57&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.84&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.96&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.46&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.82&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of option activity under the 2010 Stock Plan</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Option activity under our 2010 Stock Incentive Plan (the &#8220;2010 Stock Plan&#8221;) was as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares Subject to<br/>Outstanding Options</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average<br/>Exercise Price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,763,460</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88.39&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options granted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,755,963</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(477,371)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.69&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options cancelled</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(989,465)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88.60&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,052,587</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87.41&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_incy_ScheduleOfShareBasedCompensationOtherThanStockOptionsActivityTableTextBlock', window );">Schedule of RSU award and PSU activity under the 2010 Stock Plan</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock unit (&#8220;RSU&#8221;) and performance share (&#8220;PSU&#8221;) award activity under the 2010 Stock Plan was as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares Subject to<br/>Outstanding Awards</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Grant Date Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,966,888</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84.91&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs granted </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,473,892</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77.14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PSUs granted</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154,685</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77.67&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs released</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(845,095)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87.06&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PSUs released</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(184,401)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69.25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs cancelled </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(337,265)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83.94&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PSUs cancelled</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,720)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65.76&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30, 2022</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,226,984</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock', window );">Summary of shares available for grant</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our shares available for grant under the 2010 Stock Plan. Each RSU and PSU grant reduces the available share pool by 2 shares.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.082%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Shares Available<br/>for Grant</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Balance at December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1.97pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10,113,298</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Options, RSUs and PSUs granted</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(7,013,475)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Options, RSUs and PSUs cancelled</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.97pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,680,482</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Balance at September 30, 2022</span></td><td colspan="3" style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1.97pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4,780,305</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_ScheduleOfShareBasedCompensationOtherThanStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure represents the schedule of share based compensation other than stock options activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_ScheduleOfShareBasedCompensationOtherThanStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_ScheduleOfShareBasedPaymentAwardStockOptionsAndEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock options plan and employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_ScheduleOfShareBasedPaymentAwardStockOptionsAndEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139808194730592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of calculation of net income (loss) per share</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income per share was calculated as follows for the periods indicated below:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112,775&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181,739&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">312,199&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">384,730&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average common shares outstanding</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222,415</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220,845</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221,801</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220,243</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic net income per share</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.51&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.82&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.41&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.75&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted net income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112,775&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181,739&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">312,199&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">384,730&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222,415</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220,845</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221,801</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220,243</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive stock options and awards</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,760</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,403</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,825</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,870</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average shares used to compute diluted net income per share </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224,175</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222,248</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223,626</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222,113</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Diluted net income per share</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.50&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.82&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.40&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.73&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of antidilutive securities excluded from the computation of earnings per share</a></td>
<td class="text">The potential common shares that were excluded from the diluted net income per share computation are as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding stock options and awards</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,150,022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,841,440</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,979,096</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,917,824</span></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139808196601424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock', window );">Schedule of net periodic benefit cost</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net periodic benefit cost was as follows (in thousands): </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,376&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,975&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,336&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,927&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,008)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,114)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of prior service cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">580&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of actuarial losses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">288&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">266&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">864&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic benefit cost</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,711&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,325&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,255&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,976&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net benefit costs for pension plans and/or other employee benefit plans including service cost, interest cost, expected return on plan assets, gain (loss), prior service cost or credit, transition asset or obligation, and gain (loss) recognized due to settlements or curtailments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNetBenefitCostsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139808195429472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Business (Details)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2022 </div>
<div>segment</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139808199202096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenues</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 823,303<span></span>
</td>
<td class="nump">$ 812,987<span></span>
</td>
<td class="nump">$ 2,467,935<span></span>
</td>
<td class="nump">$ 2,123,414<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product revenues, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenues</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">713,010<span></span>
</td>
<td class="nump">594,013<span></span>
</td>
<td class="nump">1,982,682<span></span>
</td>
<td class="nump">1,673,974<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=incy_JAKAFIMember', window );">JAKAFI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenues</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">619,595<span></span>
</td>
<td class="nump">547,373<span></span>
</td>
<td class="nump">1,761,732<span></span>
</td>
<td class="nump">1,542,138<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=incy_ICLUSIGMember', window );">ICLUSIG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenues</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">25,929<span></span>
</td>
<td class="nump">28,522<span></span>
</td>
<td class="nump">78,222<span></span>
</td>
<td class="nump">82,356<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=incy_PemazyreMember', window );">PEMAZYRE</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenues</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">23,414<span></span>
</td>
<td class="nump">17,562<span></span>
</td>
<td class="nump">60,429<span></span>
</td>
<td class="nump">48,924<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=incy_MINJUVIMember', window );">MINJUVI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenues</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">5,932<span></span>
</td>
<td class="nump">556<span></span>
</td>
<td class="nump">14,845<span></span>
</td>
<td class="nump">556<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=incy_OpzeluraMember', window );">OPZELURA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenues</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">38,140<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">67,454<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember', window );">Product royalty revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenues</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">110,293<span></span>
</td>
<td class="nump">183,974<span></span>
</td>
<td class="nump">350,253<span></span>
</td>
<td class="nump">404,440<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=incy_JakaviRoyaltyRevenuesMember', window );">JAKAVI Royalty Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenues</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">85,808<span></span>
</td>
<td class="nump">94,655<span></span>
</td>
<td class="nump">240,386<span></span>
</td>
<td class="nump">242,295<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=incy_OlumiantRoyaltyMember', window );">OLUMIANT Royalty Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenues</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">20,371<span></span>
</td>
<td class="nump">86,572<span></span>
</td>
<td class="nump">98,689<span></span>
</td>
<td class="nump">154,875<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=incy_TabrectaRoyaltyRevenuesMember', window );">TABRECTA Royalty Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenues</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">4,114<span></span>
</td>
<td class="nump">2,747<span></span>
</td>
<td class="nump">11,178<span></span>
</td>
<td class="nump">7,270<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=incy_MilestoneAndContractRevenueMember', window );">Milestone and contract revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenues</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 35,000<span></span>
</td>
<td class="nump">$ 135,000<span></span>
</td>
<td class="nump">$ 45,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=incy_JAKAFIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=incy_JAKAFIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=incy_ICLUSIGMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=incy_ICLUSIGMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=incy_PemazyreMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=incy_PemazyreMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=incy_MINJUVIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=incy_MINJUVIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=incy_OpzeluraMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=incy_OpzeluraMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_RoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=incy_JakaviRoyaltyRevenuesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=incy_JakaviRoyaltyRevenuesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=incy_OlumiantRoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=incy_OlumiantRoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=incy_TabrectaRoyaltyRevenuesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=incy_TabrectaRoyaltyRevenuesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=incy_MilestoneAndContractRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=incy_MilestoneAndContractRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139808198992848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Instruments - Marketable securities portfolio (Details) - Debt securities (government) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Summary of marketable security portfolio</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss', window );">Amortized Cost</a></td>
<td class="nump">$ 292,941<span></span>
</td>
<td class="nump">$ 291,871<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax', window );">Net Unrealized Losses</a></td>
<td class="num">(6,441)<span></span>
</td>
<td class="num">(1,119)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Estimated Fair Value</a></td>
<td class="nump">$ 286,500<span></span>
</td>
<td class="nump">$ 290,752<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=incy_CorporateAndGovernmentDebtSecuritiesMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Summary of marketable security portfolio</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Contractual maturity dates</a></td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=incy_CorporateAndGovernmentDebtSecuritiesMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Summary of marketable security portfolio</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Contractual maturity dates</a></td>
<td class="text">18 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain (loss) in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost excluding accrued interest, after allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount excluding accrued interest, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=incy_CorporateAndGovernmentDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=incy_CorporateAndGovernmentDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139808194099280">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value of Financial Instruments - Assets measured on a recurring basis (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair value of financial instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Fair market long term investments</a></td>
<td class="nump">$ 149,124<span></span>
</td>
<td class="nump">$ 221,266<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Estimate of Fair Value Measurement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair value of financial instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">2,690,622<span></span>
</td>
<td class="nump">2,057,440<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss', window );">Amortized Cost</a></td>
<td class="nump">286,500<span></span>
</td>
<td class="nump">290,752<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Fair market long term investments</a></td>
<td class="nump">149,124<span></span>
</td>
<td class="nump">221,266<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">3,126,246<span></span>
</td>
<td class="nump">2,569,458<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Fair Value, Inputs, Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair value of financial instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">2,690,622<span></span>
</td>
<td class="nump">2,057,440<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss', window );">Amortized Cost</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Fair market long term investments</a></td>
<td class="nump">149,124<span></span>
</td>
<td class="nump">221,266<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">2,839,746<span></span>
</td>
<td class="nump">2,278,706<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Fair Value, Inputs, Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair value of financial instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss', window );">Amortized Cost</a></td>
<td class="nump">286,500<span></span>
</td>
<td class="nump">290,752<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Fair market long term investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">286,500<span></span>
</td>
<td class="nump">290,752<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Fair Value, Inputs, Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair value of financial instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss', window );">Amortized Cost</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Fair market long term investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost excluding accrued interest, after allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139808198947040">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value of Financial Instruments - Liabilities measured on a recurring basis (Details) - Fair Value, Recurring - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Estimate of Fair Value Measurement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair value of financial instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Acquisition-related contingent consideration</a></td>
<td class="nump">$ 206,000<span></span>
</td>
<td class="nump">$ 244,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">206,000<span></span>
</td>
<td class="nump">244,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Inputs, Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair value of financial instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Acquisition-related contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Inputs, Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair value of financial instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Acquisition-related contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Inputs, Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair value of financial instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Acquisition-related contingent consideration</a></td>
<td class="nump">206,000<span></span>
</td>
<td class="nump">244,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">$ 206,000<span></span>
</td>
<td class="nump">$ 244,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126966325&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialLiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialLiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139808195500640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Instruments - Level 3 liabilities (Details) - Fair Value, Inputs, Level 3 - Estimate of Fair Value Measurement<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Roll forward of Level 3 liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance at the beginning of the period</a></td>
<td class="nump">$ 244,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_incy_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityConsiderationEarned', window );">Contingent consideration earned during the period but not yet paid</a></td>
<td class="num">(25,802)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Change in fair value of contingent consideration</a></td>
<td class="num">(12,198)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance at the end of the period</a></td>
<td class="nump">$ 206,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityConsiderationEarned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in the value of a contingent consideration liability attributable to consideration earned by the acquiree in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityConsiderationEarned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139808194077504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Instruments - Narrative (Details) - ARIAD<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 01, 2016</div></th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=incy_AriadPharmaceuticalsMember', window );">Accrued and other current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair value of financial instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_incy_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityConsiderationEarned', window );">Contingent consideration earned during the period but not yet paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (25.8)<span></span>
</td>
<td class="num">$ (19.6)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=incy_AriadPharmaceuticalsMember', window );">Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair value of financial instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_incy_FairValueInputsCashFlowsEstimatedPeriod', window );">Projected cash flows period</a></td>
<td class="text">18 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=incy_AriadPharmaceuticalsMember', window );">Liability | Measurement Input, Discount Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair value of financial instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Valuation input (as a percent)</a></td>
<td class="nump">0.10<span></span>
</td>
<td class="nump">0.10<span></span>
</td>
<td class="nump">0.10<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityConsiderationEarned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in the value of a contingent consideration liability attributable to consideration earned by the acquiree in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityConsiderationEarned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_FairValueInputsCashFlowsEstimatedPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of time used to measure cash flows to find the present value of an amount to be paid or received in the future as an input to measure fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_FairValueInputsCashFlowsEstimatedPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure contingent consideration liability from business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=incy_AriadPharmaceuticalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=incy_AriadPharmaceuticalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=incy_AccruedAndOtherCurrentLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=incy_AccruedAndOtherCurrentLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_LiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=us-gaap_LiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139808198029040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Concentrations of Credit Risk and Current Expected Credit Losses (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration of risk</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Allowance for doubtful accounts</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueProductLineMember', window );">Revenue, Product and Service Benchmark | Customer Concentration Risk | Customer A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration of risk</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of concentration risk</a></td>
<td class="nump">19.00%<span></span>
</td>
<td class="nump">19.00%<span></span>
</td>
<td class="nump">19.00%<span></span>
</td>
<td class="nump">19.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueProductLineMember', window );">Revenue, Product and Service Benchmark | Customer Concentration Risk | Customer B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration of risk</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of concentration risk</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueProductLineMember', window );">Revenue, Product and Service Benchmark | Customer Concentration Risk | Customer C</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration of risk</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of concentration risk</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="nump">17.00%<span></span>
</td>
<td class="nump">18.00%<span></span>
</td>
<td class="nump">18.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueProductLineMember', window );">Revenue, Product and Service Benchmark | Customer Concentration Risk | Customer D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration of risk</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of concentration risk</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueProductLineMember', window );">Revenue, Product and Service Benchmark | Customer Concentration Risk | Customer E</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration of risk</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of concentration risk</a></td>
<td class="nump">9.00%<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Accounts Receivable | Credit Concentration Risk | Collaboration Partner A, B, C and D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration of risk</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of concentration risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Accounts Receivable | Credit Concentration Risk | Customer A, B, C, D and E</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration of risk</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of concentration risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5074-111524<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueProductLineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueProductLineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=incy_CustomerAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=incy_CustomerAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=incy_CustomerBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=incy_CustomerBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=incy_CustomerCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=incy_CustomerCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=incy_CustomerDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=incy_CustomerDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=incy_CustomerEMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=incy_CustomerEMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CreditConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CreditConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=incy_CollaborationPartnersaBCAndDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=incy_CollaborationPartnersaBCAndDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=incy_AggregateConcentrationCustomersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=incy_AggregateConcentrationCustomersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139808194756176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
<td class="nump">$ 32,289<span></span>
</td>
<td class="nump">$ 1,275<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work-in-process</a></td>
<td class="nump">35,465<span></span>
</td>
<td class="nump">39,895<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">33,379<span></span>
</td>
<td class="nump">15,768<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_incy_InventoryNetCurrentAndNoncurrent', window );">Total inventory</a></td>
<td class="nump">101,133<span></span>
</td>
<td class="nump">56,938<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories - current</a></td>
<td class="nump">45,869<span></span>
</td>
<td class="nump">27,904<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNoncurrent', window );">Inventories-noncurrent</a></td>
<td class="nump">55,264<span></span>
</td>
<td class="nump">$ 29,034<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_incy_InventoryRecordedAsResearchAndDevelopmentExpense', window );">Inventory incurred prior to FDA approval</a></td>
<td class="nump">$ 56,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_incy_PeriodOfDeviationFromAverageCostOfGoodsSold', window );">Period of lower average per unit cost of materials</a></td>
<td class="text">28 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_InventoryNetCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the aggregate carrying amount of current and noncurrent portion, net of valuation reserves and allowances, as of the balance sheet date of inventories.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_InventoryNetCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_InventoryRecordedAsResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the aggregate carrying amount of current and noncurrent portion, net of valuation reserves and allowances, as of the balance sheet date of inventories recorded as research and development expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_InventoryRecordedAsResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_PeriodOfDeviationFromAverageCostOfGoodsSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the length of time in which cost of goods sold will deviate from average due to unusual and/or infrequent conditions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_PeriodOfDeviationFromAverageCostOfGoodsSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139808193335184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License Agreements - Novartis (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">155 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 31, 2022</div></th>
<th class="th"><div>Apr. 30, 2022</div></th>
<th class="th"><div>Nov. 30, 2009</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 823,303<span></span>
</td>
<td class="nump">$ 812,987<span></span>
</td>
<td class="nump">$ 2,467,935<span></span>
</td>
<td class="nump">$ 2,123,414<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember', window );">Product royalty revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110,293<span></span>
</td>
<td class="nump">183,974<span></span>
</td>
<td class="nump">350,253<span></span>
</td>
<td class="nump">404,440<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=incy_JAKAFIMember', window );">JAKAFI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">619,595<span></span>
</td>
<td class="nump">547,373<span></span>
</td>
<td class="nump">1,761,732<span></span>
</td>
<td class="nump">1,542,138<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=incy_MilestoneAndContractRevenueMember', window );">Milestone and contract revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">35,000<span></span>
</td>
<td class="nump">135,000<span></span>
</td>
<td class="nump">45,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=incy_NovartisMember', window );">Novartis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_incy_RoyaltiesPayable', window );">Royalties payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">221,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 221,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 221,700<span></span>
</td>
<td class="nump">$ 148,100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=incy_NovartisMember', window );">Novartis | JAKAVI | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_incy_PercentageOfRoyaltyRatePayments', window );">Royalty payments on future global net sales (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=incy_NovartisMember', window );">Novartis | JAKAVI | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_incy_PercentageOfRoyaltyRatePayments', window );">Royalty payments on future global net sales (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=incy_NovartisMember', window );">Novartis | JAKAFI | UNITED STATES</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInRoyaltiesPayable', window );">Royalties payable on net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,300<span></span>
</td>
<td class="nump">26,900<span></span>
</td>
<td class="nump">$ 81,300<span></span>
</td>
<td class="nump">70,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=incy_NovartisMember', window );">Novartis | JAKAFI | Non-US</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInRoyaltiesPayable', window );">Royalties payable on net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85,800<span></span>
</td>
<td class="nump">94,700<span></span>
</td>
<td class="nump">240,400<span></span>
</td>
<td class="nump">242,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=incy_NovartisMember', window );">Novartis | Milestone and contract revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=incy_NovartisMember', window );">Novartis | TABRECTA PROD SERV | Non-US</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInRoyaltiesPayable', window );">Royalties payable on net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,100<span></span>
</td>
<td class="nump">$ 2,700<span></span>
</td>
<td class="nump">11,200<span></span>
</td>
<td class="nump">$ 7,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=incy_NovartisMember', window );">Novartis | Development Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_incy_LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone', window );">Amount recognized and received for the achievement of a predefined milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">157,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=incy_NovartisMember', window );">Novartis | Development Milestones | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_incy_LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived', window );">Upfront and immediate milestone payment to be received under license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 174,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=incy_NovartisMember', window );">Novartis | Regulatory Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_incy_LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone', window );">Amount recognized and received for the achievement of a predefined milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">340,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=incy_NovartisMember', window );">Novartis | Regulatory Milestones | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_incy_LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived', window );">Upfront and immediate milestone payment to be received under license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">495,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=incy_NovartisMember', window );">Novartis | Regulatory Milestones | TABRECTA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_incy_LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone', window );">Amount recognized and received for the achievement of a predefined milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=incy_NovartisMember', window );">Novartis | Regulatory Milestones | JAKAVI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_incy_LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone', window );">Amount recognized and received for the achievement of a predefined milestone</a></td>
<td class="nump">$ 45,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=incy_NovartisMember', window );">Novartis | Commercialization Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_incy_LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone', window );">Amount recognized and received for the achievement of a predefined milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=incy_NovartisMember', window );">Novartis | Commercialization Milestones | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_incy_LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived', window );">Upfront and immediate milestone payment to be received under license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=incy_NovartisMember', window );">Novartis | Development and Regulatory Milestones | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_incy_LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived', window );">Upfront and immediate milestone payment to be received under license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the earning recognized and the payment received for the achievement of a predefined milestone under the license agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the upfront and immediate milestone payment received under the license agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_PercentageOfRoyaltyRatePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents range of tiered, double-digit royalty payments on future global sales if product is successfully commercialized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_PercentageOfRoyaltyRatePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_RoyaltiesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of royalties payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_RoyaltiesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInRoyaltiesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the obligations due for compensation payments related to the use of copyrights, patents, trade names, licenses, technology. Royalty payments are also paid by the lease holders for oil, gas, and mineral extraction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInRoyaltiesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_RoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=incy_JAKAFIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=incy_JAKAFIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=incy_MilestoneAndContractRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=incy_MilestoneAndContractRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=incy_NovartisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=incy_NovartisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=incy_JakaviMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=incy_JakaviMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_NonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=incy_TABRECTAPRODUCTANDSERVICESMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=incy_TABRECTAPRODUCTANDSERVICESMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_AchievementOfMilestoneAxis=incy_DevelopmentMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_AchievementOfMilestoneAxis=incy_DevelopmentMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_AchievementOfMilestoneAxis=incy_RegulatoryMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_AchievementOfMilestoneAxis=incy_RegulatoryMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=incy_TabrectaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=incy_TabrectaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_AchievementOfMilestoneAxis=incy_CommercializationMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_AchievementOfMilestoneAxis=incy_CommercializationMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_AchievementOfMilestoneAxis=incy_DevelopmentAndRegulatoryMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_AchievementOfMilestoneAxis=incy_DevelopmentAndRegulatoryMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139808193200352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License Agreements - Lilly (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">154 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>May 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2009</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 823,303<span></span>
</td>
<td class="nump">$ 812,987<span></span>
</td>
<td class="nump">$ 2,467,935<span></span>
</td>
<td class="nump">$ 2,123,414<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=incy_OlumiantRoyaltyMember', window );">OLUMIANT Royalty Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,371<span></span>
</td>
<td class="nump">86,572<span></span>
</td>
<td class="nump">98,689<span></span>
</td>
<td class="nump">154,875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=incy_EliLillyMember', window );">Eli Lilly | Development Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_incy_LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone', window );">Amount recognized and received for the achievement of a predefined milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 149,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=incy_EliLillyMember', window );">Eli Lilly | Development Milestones | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_incy_LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived', window );">Upfront and immediate milestone payment to be received under license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=incy_EliLillyMember', window );">Eli Lilly | Regulatory Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_incy_LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone', window );">Amount recognized and received for the achievement of a predefined milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">335,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=incy_EliLillyMember', window );">Eli Lilly | Regulatory Milestones | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_incy_LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived', window );">Upfront and immediate milestone payment to be received under license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">365,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=incy_EliLillyMember', window );">Eli Lilly | Commercialization Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_incy_LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone', window );">Amount recognized and received for the achievement of a predefined milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=incy_EliLillyMember', window );">Eli Lilly | Commercialization Milestones | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_incy_LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived', window );">Upfront and immediate milestone payment to be received under license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=incy_EliLillyMember', window );">Eli Lilly | OLUMIANT</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=incy_EliLillyMember', window );">Eli Lilly | OLUMIANT | Regulatory Milestones | UNITED STATES</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_incy_LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone', window );">Amount recognized and received for the achievement of a predefined milestone</a></td>
<td class="nump">$ 40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=incy_EliLillyMember', window );">Eli Lilly | OLUMIANT | Regulatory Milestones | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_incy_LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone', window );">Amount recognized and received for the achievement of a predefined milestone</a></td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=incy_EliLillyMember', window );">Eli Lilly | OLUMIANT | Regulatory Milestones | JAPAN</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_incy_LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone', window );">Amount recognized and received for the achievement of a predefined milestone</a></td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=incy_EliLillyMember', window );">Eli Lilly | OLUMIANT Royalty Revenues | Non-US</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInRoyaltiesPayable', window );">Royalties payable on net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,400<span></span>
</td>
<td class="nump">$ 86,600<span></span>
</td>
<td class="nump">$ 98,700<span></span>
</td>
<td class="nump">$ 154,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=incy_EliLillyMember', window );">Eli Lilly | GVHD | Regulatory Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_incy_LicenseAgreementMilestonePaymentAmountPaid', window );">Milestone payment made under license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=incy_EliLillyMember', window );">Eli Lilly | GVHD | Regulatory Milestones | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_incy_LicenseAgreementMilestonePaymentAmountPaid', window );">Milestone payment made under license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=incy_EliLillyMember', window );">Eli Lilly | GVHD | Regulatory Milestones | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_incy_LicenseAgreementAdditionalMilestonePayments', window );">Additional milestone payments under the license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_LicenseAgreementAdditionalMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the additional milestone payments to be made under the license agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_LicenseAgreementAdditionalMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the earning recognized and the payment received for the achievement of a predefined milestone under the license agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_LicenseAgreementMilestonePaymentAmountPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of the milestone payment made under the license agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_LicenseAgreementMilestonePaymentAmountPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the upfront and immediate milestone payment received under the license agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInRoyaltiesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the obligations due for compensation payments related to the use of copyrights, patents, trade names, licenses, technology. Royalty payments are also paid by the lease holders for oil, gas, and mineral extraction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInRoyaltiesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=incy_OlumiantRoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=incy_OlumiantRoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=incy_EliLillyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=incy_EliLillyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_AchievementOfMilestoneAxis=incy_DevelopmentMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_AchievementOfMilestoneAxis=incy_DevelopmentMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_AchievementOfMilestoneAxis=incy_RegulatoryMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_AchievementOfMilestoneAxis=incy_RegulatoryMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_AchievementOfMilestoneAxis=incy_CommercializationMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_AchievementOfMilestoneAxis=incy_CommercializationMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=incy_OlumiantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=incy_OlumiantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_EuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_EuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_JP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_JP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_NonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=incy_GvhdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=incy_GvhdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139808190297344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License Agreements - Agenus (Details) - USD ($)<br> $ / shares in Units, $ in Thousands, shares in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1">93 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 28, 2017</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Fair market long term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 149,124<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 149,124<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 221,266<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 149,124<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Unrealized gain (loss) on long term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(660)<span></span>
</td>
<td class="num">$ (27,450)<span></span>
</td>
<td class="num">(72,142)<span></span>
</td>
<td class="num">$ (28,394)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=incy_AgenusMember', window );">Agenus</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares divested (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.0<span></span>
</td>
<td class="nump">3.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Gross proceeds from sale of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,500<span></span>
</td>
<td class="nump">$ 17,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Fair market long term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 38,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Unrealized gain (loss) on long term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300<span></span>
</td>
<td class="num">$ (2,800)<span></span>
</td>
<td class="num">(14,100)<span></span>
</td>
<td class="nump">$ 29,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=incy_ProductGroupTwoMember', window );">Royalty-bearing product GITR, OX40 and one undisclosed target | Agenus | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_incy_PercentageOfRoyaltyRatePayments', window );">Royalty payments on future global net sales (as a percent)</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=incy_AgenusMember', window );">Agenus</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_incy_LicenseAgreementTerminationNoticePeriod', window );">Period of notice for termination of license agreement</a></td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=incy_AgenusMember', window );">Agenus | Royalty-bearing product other than GITR, OX40 and one undisclosed target | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_incy_PercentageOfRoyaltyRatePayments', window );">Royalty payments on future global net sales (as a percent)</a></td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=incy_AgenusMember', window );">Agenus | Royalty-bearing product other than GITR, OX40 and one undisclosed target | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_incy_PercentageOfRoyaltyRatePayments', window );">Royalty payments on future global net sales (as a percent)</a></td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=incy_AgenusMember', window );">Agenus | Development, Regulatory and Commercialization Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_incy_LicenseAgreementMilestonePaymentAmountPaid', window );">Milestone payment made under license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_incy_LicenseAgreementAdditionalMilestonePayments', window );">Additional milestone payments under the license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=incy_StockPurchaseAgreementMember', window );">Stock purchase agreement | Agenus</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_incy_PurchaseOfCommonStockUnderStockPurchaseAgreementInShares', window );">Purchase of common stock under Stock Purchase Agreement (in shares )</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentAggregateCost', window );">Purchase price of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Per share price (In USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_LicenseAgreementAdditionalMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the additional milestone payments to be made under the license agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_LicenseAgreementAdditionalMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_LicenseAgreementMilestonePaymentAmountPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of the milestone payment made under the license agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_LicenseAgreementMilestonePaymentAmountPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_LicenseAgreementTerminationNoticePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the notice period for the termination of license agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_LicenseAgreementTerminationNoticePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_PercentageOfRoyaltyRatePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents range of tiered, double-digit royalty payments on future global sales if product is successfully commercialized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_PercentageOfRoyaltyRatePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_PurchaseOfCommonStockUnderStockPurchaseAgreementInShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the purchase of common stock under Stock Purchase Agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_PurchaseOfCommonStockUnderStockPurchaseAgreementInShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentAggregateCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents the aggregate cost of investments accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentAggregateCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126980263&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=incy_AgenusMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=incy_AgenusMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=incy_ProductGroupTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=incy_ProductGroupTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=incy_AgenusMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=incy_AgenusMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=incy_ProductGroupOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=incy_ProductGroupOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_AchievementOfMilestoneAxis=incy_DevelopmentRegulatoryAndCommercializationMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_AchievementOfMilestoneAxis=incy_DevelopmentRegulatoryAndCommercializationMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=incy_StockPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=incy_StockPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139808190554784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License Agreements - Merus (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1">70 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jan. 31, 2022 </div>
<div>item</div>
</th>
<th class="th">
<div>Jan. 31, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($) </div>
<div>item </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Unrealized gain (loss) on long term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (660)<span></span>
</td>
<td class="num">$ (27,450)<span></span>
</td>
<td class="num">$ (72,142)<span></span>
</td>
<td class="num">$ (28,394)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=incy_MerusNVMember', window );">Merus</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Fair market value of our long term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 71,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 71,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 71,100<span></span>
</td>
<td class="nump">$ 112,900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Unrealized gain (loss) on long term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (9,300)<span></span>
</td>
<td class="nump">$ 3,300<span></span>
</td>
<td class="num">$ (41,800)<span></span>
</td>
<td class="nump">$ 13,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=incy_MerusNVMember', window );">Merus | IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Per share price (In USD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_incy_EquityMethodInvestmentSharesPurchased', window );">Common shares purchased (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares in underwritten public offering (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,848,485<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentQuotedMarketValue', window );">Value of shares acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=incy_MerusNVMember', window );">Merus</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_incy_LicenseAgreementMaximumNumberOfIndependentPrograms', window );">Number of independent programs | item</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_incy_LicenseAgreementNumberOfAdditionalPreclinicalDiscoveryPrograms', window );">Number of additional preclinical discovery programs | item</a></td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_incy_NumberOfProgramsUnderWhichResultingProductsAreCoFundedForDevelopment', window );">Number of programs under the resulting products are co-funded for development | item</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_incy_PercentageFundingOnCostOnPossibleElectionOfCodevelopmentOfCompounds', window );">Associated future global development costs , if elected to co-develop (as a percent)</a></td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_incy_LicenseAgreementMilestonePaymentAmountPaid', window );">Milestone payment made under license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=incy_MerusNVMember', window );">Merus | UNITED STATES</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_incy_CollaborationAgreementProfitSharingPercentage', window );">Profit sharing (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_incy_PercentageOfProfitsLosses', window );">Percentage of profit (losses)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=incy_MerusNVMember', window );">Merus | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_incy_PercentageOfRoyaltyRatePayments', window );">Royalty payments on future global net sales (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=incy_MerusNVMember', window );">Merus | Minimum | Non-US</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_incy_PercentageOfRoyaltyRatePayments', window );">Royalty payments on future global net sales (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=incy_MerusNVMember', window );">Merus | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_incy_PercentageOfRoyaltyRatePayments', window );">Royalty payments on future global net sales (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=incy_MerusNVMember', window );">Merus | Maximum | UNITED STATES</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_incy_PercentageOfRoyaltyRatePayments', window );">Royalty payments on future global net sales (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=incy_MerusNVMember', window );">Merus | Maximum | Non-US</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_incy_PercentageOfRoyaltyRatePayments', window );">Royalty payments on future global net sales (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=incy_MerusNVMember', window );">Merus | Maximum | Development and Regulatory Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_incy_LicenseAgreementAdditionalMilestonePayments', window );">Additional milestone payments under the license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=incy_MerusNVMember', window );">Merus | Maximum | Commercialization Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_incy_LicenseAgreementAdditionalMilestonePayments', window );">Additional milestone payments under the license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=incy_StockPurchaseAgreementMember', window );">Stock purchase agreement | Merus</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_incy_PurchaseOfCommonStockUnderStockPurchaseAgreementInShares', window );">Purchase of common stock under Stock Purchase Agreement (in shares ) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentAggregateCost', window );">Purchase price of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 80,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 80,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Per share price (In USD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_CollaborationAgreementProfitSharingPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of profits and losses shared under the collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_CollaborationAgreementProfitSharingPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_EquityMethodInvestmentSharesPurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents the aggregate shares purchased of investments accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_EquityMethodInvestmentSharesPurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_LicenseAgreementAdditionalMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the additional milestone payments to be made under the license agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_LicenseAgreementAdditionalMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_LicenseAgreementMaximumNumberOfIndependentPrograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the maximum number of independent programs encompassed under the collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_LicenseAgreementMaximumNumberOfIndependentPrograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_LicenseAgreementMilestonePaymentAmountPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of the milestone payment made under the license agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_LicenseAgreementMilestonePaymentAmountPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_LicenseAgreementNumberOfAdditionalPreclinicalDiscoveryPrograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of additional preclinical discovery programs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_LicenseAgreementNumberOfAdditionalPreclinicalDiscoveryPrograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_NumberOfProgramsUnderWhichResultingProductsAreCoFundedForDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of programs in which the resulting products are co-funded for development.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_NumberOfProgramsUnderWhichResultingProductsAreCoFundedForDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_PercentageFundingOnCostOnPossibleElectionOfCodevelopmentOfCompounds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of associated future global development costs from the initiation of a Phase IIb trial provided the entity elects to co-develop any compounds and/or indications.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_PercentageFundingOnCostOnPossibleElectionOfCodevelopmentOfCompounds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_PercentageOfProfitsLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of profits (losses).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_PercentageOfProfitsLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_PercentageOfRoyaltyRatePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents range of tiered, double-digit royalty payments on future global sales if product is successfully commercialized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_PercentageOfRoyaltyRatePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_PurchaseOfCommonStockUnderStockPurchaseAgreementInShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the purchase of common stock under Stock Purchase Agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_PurchaseOfCommonStockUnderStockPurchaseAgreementInShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentAggregateCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents the aggregate cost of investments accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentAggregateCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentQuotedMarketValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This item represents the aggregate value of each identified investment accounted for under the equity method of accounting based on the quoted market price for those investments in common stock for which a quoted market price is available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentQuotedMarketValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126980263&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=incy_MerusNVMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=incy_MerusNVMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=incy_MerusNVMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=incy_MerusNVMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_NonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_AchievementOfMilestoneAxis=incy_DevelopmentAndRegulatoryMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_AchievementOfMilestoneAxis=incy_DevelopmentAndRegulatoryMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_AchievementOfMilestoneAxis=incy_CommercializationMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_AchievementOfMilestoneAxis=incy_CommercializationMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=incy_StockPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=incy_StockPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139808194628000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License Agreements - Calithera (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 31, 2017 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Fair market long term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 149,124<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 149,124<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 221,266<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Unrealized gain (loss) on long term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(660)<span></span>
</td>
<td class="num">$ (27,450)<span></span>
</td>
<td class="num">(72,142)<span></span>
</td>
<td class="num">$ (28,394)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=incy_CalitheraBiosciencesIncMember', window );">Calithera</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Fair market long term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=incy_CalitheraBiosciencesIncMember', window );">Calithera | Other Comprehensive Income (Loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Unrealized gain (loss) on long term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="num">$ (900)<span></span>
</td>
<td class="num">$ (4,600)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=incy_CalitheraBiosciencesIncMember', window );">Calithera</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_incy_LicenseAgreementPercentageOfFutureGlobalDevelopmentCostsFunded', window );">Funding of future development costs (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=incy_StockPurchaseAgreementMember', window );">Stock purchase agreement | Calithera</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_incy_PurchaseOfCommonStockUnderStockPurchaseAgreementInShares', window );">Purchase of common stock under Stock Purchase Agreement (in shares ) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentAggregateCost', window );">Purchase price of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Per share price (In USD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Effected stock split (as a percent)</a></td>
<td class="nump">0.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentOwnedBalanceShares', window );">Ownership (in shares) | shares</a></td>
<td class="nump">86,021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_LicenseAgreementPercentageOfFutureGlobalDevelopmentCostsFunded">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of future global development costs funded under the license agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_LicenseAgreementPercentageOfFutureGlobalDevelopmentCostsFunded</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_PurchaseOfCommonStockUnderStockPurchaseAgreementInShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the purchase of common stock under Stock Purchase Agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_PurchaseOfCommonStockUnderStockPurchaseAgreementInShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentAggregateCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents the aggregate cost of investments accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentAggregateCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126980263&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentOwnedBalanceShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Balance held at close of period in number of shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99383244&amp;loc=d3e12121-115841<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column B))<br> -URI https://asc.fasb.org/extlink&amp;oid=122147990&amp;loc=d3e611197-123010<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentOwnedBalanceShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=incy_CalitheraBiosciencesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=incy_CalitheraBiosciencesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=incy_CalitheraBiosciencesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=incy_CalitheraBiosciencesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=incy_StockPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=incy_StockPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139808194239376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License Agreements - MacroGenics (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">57 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 384,007<span></span>
</td>
<td class="nump">$ 334,945<span></span>
</td>
<td class="nump">$ 1,084,576<span></span>
</td>
<td class="nump">$ 985,352<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=incy_MacrogenicsMember', window );">MacroGenics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,600<span></span>
</td>
<td class="nump">$ 17,800<span></span>
</td>
<td class="nump">69,900<span></span>
</td>
<td class="nump">$ 49,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=incy_MacrogenicsMember', window );">MacroGenics | Accrued Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Accrued and other liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=incy_MacrogenicsMember', window );">MacroGenics | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_incy_PercentageOfRoyaltyRatePayments', window );">Royalty payments on future global net sales (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=incy_MacrogenicsMember', window );">MacroGenics | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_incy_PercentageOfRoyaltyRatePayments', window );">Royalty payments on future global net sales (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=incy_MacrogenicsMember', window );">MacroGenics | Development and Regulatory Milestones | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_incy_LicenseAgreementAdditionalMilestonePayments', window );">Additional milestone payments under the license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 335,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 335,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=incy_MacrogenicsMember', window );">MacroGenics | Development Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_incy_LicenseAgreementMilestonePaymentAmountPaid', window );">Milestone payment made under license agreement</a></td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=incy_MacrogenicsMember', window );">MacroGenics | Commercialization Milestones | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_incy_LicenseAgreementAdditionalMilestonePayments', window );">Additional milestone payments under the license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 330,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_LicenseAgreementAdditionalMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the additional milestone payments to be made under the license agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_LicenseAgreementAdditionalMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_LicenseAgreementMilestonePaymentAmountPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of the milestone payment made under the license agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_LicenseAgreementMilestonePaymentAmountPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_PercentageOfRoyaltyRatePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents range of tiered, double-digit royalty payments on future global sales if product is successfully commercialized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_PercentageOfRoyaltyRatePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=incy_MacrogenicsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=incy_MacrogenicsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_AchievementOfMilestoneAxis=incy_DevelopmentAndRegulatoryMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_AchievementOfMilestoneAxis=incy_DevelopmentAndRegulatoryMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_AchievementOfMilestoneAxis=incy_DevelopmentMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_AchievementOfMilestoneAxis=incy_DevelopmentMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_AchievementOfMilestoneAxis=incy_CommercializationMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_AchievementOfMilestoneAxis=incy_CommercializationMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139808190393872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License Agreements - Syros (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th">
<div>Jan. 31, 2018 </div>
<div>USD ($) </div>
<div>item</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Fair market long term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 149,124<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 149,124<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 221,266<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Unrealized gain (loss) on long term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(660)<span></span>
</td>
<td class="num">$ (27,450)<span></span>
</td>
<td class="num">(72,142)<span></span>
</td>
<td class="num">$ (28,394)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=incy_SyrosPharmaceuticalsIncMember', window );">Syros Pharmaceuticals, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Fair market long term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Unrealized gain (loss) on long term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (300)<span></span>
</td>
<td class="num">$ (900)<span></span>
</td>
<td class="num">$ (2,500)<span></span>
</td>
<td class="num">$ (6,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=incy_SyrosPharmaceuticalsIncMember', window );">Syros Pharmaceuticals, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_incy_NumberOfProgramTargets', window );">Number of program targets | item</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=incy_SyrosPharmaceuticalsIncMember', window );">Syros Pharmaceuticals, Inc. | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_incy_LicenseAgreementTargetSelectionAndOptionExerciseFeePayments', window );">Target selection and option exercise fee payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 54,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=incy_SyrosPharmaceuticalsIncMember', window );">Syros Pharmaceuticals, Inc. | Development and Regulatory Milestones | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_incy_LicenseAgreementAdditionalMilestonePayments', window );">Additional milestone payments under the license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=incy_SyrosPharmaceuticalsIncMember', window );">Syros Pharmaceuticals, Inc. | Commercialization Milestones | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_incy_LicenseAgreementAdditionalMilestonePayments', window );">Additional milestone payments under the license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 65,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=incy_StockPurchaseAgreementMember', window );">Stock purchase agreement | Syros Pharmaceuticals, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentAggregateCost', window );">Purchase price of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Per share price (In USD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.61<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentOwnedBalanceShares', window );">Ownership (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93,753<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93,753<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Effected stock split (as a percent)</a></td>
<td class="nump">0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=incy_StockPurchaseAgreementMember', window );">Stock purchase agreement | Syros Pharmaceuticals, Inc. | Pre September 2022 -Stock Split Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_incy_PurchaseOfCommonStockUnderStockPurchaseAgreementInShares', window );">Purchase of common stock under Stock Purchase Agreement (in shares ) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=incy_AmendedStockPurchaseAgreementMember', window );">Amended stock purchase agreement | Syros Pharmaceuticals, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentAggregateCost', window );">Purchase price of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Per share price (In USD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=incy_AmendedStockPurchaseAgreementMember', window );">Amended stock purchase agreement | Syros Pharmaceuticals, Inc. | Pre September 2022 -Stock Split Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_incy_PurchaseOfCommonStockUnderStockPurchaseAgreementInShares', window );">Purchase of common stock under Stock Purchase Agreement (in shares ) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_LicenseAgreementAdditionalMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the additional milestone payments to be made under the license agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_LicenseAgreementAdditionalMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_LicenseAgreementTargetSelectionAndOptionExerciseFeePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the target selection and option exercise fee payments to be made under the license agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_LicenseAgreementTargetSelectionAndOptionExerciseFeePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_NumberOfProgramTargets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of program targets identified.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_NumberOfProgramTargets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_PurchaseOfCommonStockUnderStockPurchaseAgreementInShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the purchase of common stock under Stock Purchase Agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_PurchaseOfCommonStockUnderStockPurchaseAgreementInShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentAggregateCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents the aggregate cost of investments accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentAggregateCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126980263&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentOwnedBalanceShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Balance held at close of period in number of shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99383244&amp;loc=d3e12121-115841<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column B))<br> -URI https://asc.fasb.org/extlink&amp;oid=122147990&amp;loc=d3e611197-123010<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentOwnedBalanceShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=incy_SyrosPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=incy_SyrosPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=incy_SyrosPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=incy_SyrosPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_AchievementOfMilestoneAxis=incy_DevelopmentAndRegulatoryMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_AchievementOfMilestoneAxis=incy_DevelopmentAndRegulatoryMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_AchievementOfMilestoneAxis=incy_CommercializationMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_AchievementOfMilestoneAxis=incy_CommercializationMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=incy_StockPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=incy_StockPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=incy_PreSeptember2022StockSplitSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockByUniqueDescriptionAxis=incy_PreSeptember2022StockSplitSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=incy_AmendedStockPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=incy_AmendedStockPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139808194747008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License Agreements - Innovent (Details) - Innovent - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=incy_InnoventBiologicsIncMember', window );">Development and Regulatory Milestones | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_incy_LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived', window );">Upfront and immediate milestone payment to be received under license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 94.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=incy_InnoventBiologicsIncMember', window );">Regulatory Milestones | PEMAZYRE</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_incy_LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone', window );">Amount recognized and received for the achievement of a predefined milestone</a></td>
<td class="nump">$ 5.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=incy_InnoventBiologicsIncMember', window );">Commercialization Milestones | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_incy_LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived', window );">Upfront and immediate milestone payment to be received under license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 202.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the earning recognized and the payment received for the achievement of a predefined milestone under the license agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the upfront and immediate milestone payment received under the license agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=incy_InnoventBiologicsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=incy_InnoventBiologicsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_AchievementOfMilestoneAxis=incy_DevelopmentAndRegulatoryMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_AchievementOfMilestoneAxis=incy_DevelopmentAndRegulatoryMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_AchievementOfMilestoneAxis=incy_RegulatoryMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_AchievementOfMilestoneAxis=incy_RegulatoryMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=incy_PemazyreMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=incy_PemazyreMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_AchievementOfMilestoneAxis=incy_CommercializationMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_AchievementOfMilestoneAxis=incy_CommercializationMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139808200387552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License Agreements - Zai Lab (Details) - Zai Lab Ltd - Maximum<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jul. 31, 2019 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=incy_CollaborationAndLicenseAgreementWithZaiLabLtdMember', window );">Development and Regulatory Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_incy_LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived', window );">Upfront and immediate milestone payment to be received under license agreement</a></td>
<td class="nump">$ 22.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=incy_CollaborationAndLicenseAgreementWithZaiLabLtdMember', window );">Commercialization Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_incy_LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived', window );">Upfront and immediate milestone payment to be received under license agreement</a></td>
<td class="nump">$ 37.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the upfront and immediate milestone payment received under the license agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=incy_CollaborationAndLicenseAgreementWithZaiLabLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=incy_CollaborationAndLicenseAgreementWithZaiLabLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_AchievementOfMilestoneAxis=incy_DevelopmentAndRegulatoryMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_AchievementOfMilestoneAxis=incy_DevelopmentAndRegulatoryMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_AchievementOfMilestoneAxis=incy_CommercializationMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_AchievementOfMilestoneAxis=incy_CommercializationMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139808194148176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License Agreements - MorphoSys (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">33 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jan. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Unrealized gain (loss) on long term investments</a></td>
<td class="num">$ (660)<span></span>
</td>
<td class="num">$ (27,450)<span></span>
</td>
<td class="num">$ (72,142)<span></span>
</td>
<td class="num">$ (28,394)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_incy_CollaborationLossSharingExpense', window );">Collaboration loss sharing</a></td>
<td class="nump">1,769<span></span>
</td>
<td class="nump">9,149<span></span>
</td>
<td class="nump">9,055<span></span>
</td>
<td class="nump">29,476<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="nump">384,007<span></span>
</td>
<td class="nump">334,945<span></span>
</td>
<td class="nump">1,084,576<span></span>
</td>
<td class="nump">985,352<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=incy_MorphosysAgMember', window );">MorphoSys AG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Fair market value of our long term investments</a></td>
<td class="nump">18,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,300<span></span>
</td>
<td class="nump">$ 34,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Unrealized gain (loss) on long term investments</a></td>
<td class="nump">800<span></span>
</td>
<td class="num">(27,300)<span></span>
</td>
<td class="num">(15,900)<span></span>
</td>
<td class="num">(60,200)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=incy_MorphosysAgMember', window );">MorphoSys AG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="nump">21,900<span></span>
</td>
<td class="nump">21,500<span></span>
</td>
<td class="nump">70,400<span></span>
</td>
<td class="nump">55,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Accrued and other liabilities</a></td>
<td class="nump">$ 72,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 72,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72,500<span></span>
</td>
<td class="nump">$ 21,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=incy_MorphosysAgMember', window );">MorphoSys AG | UNITED STATES</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_incy_CollaborationAgreementProfitLossSharingRatio', window );">Profit (loss) sharing ratio</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=incy_MorphosysAgMember', window );">MorphoSys AG | UNITED STATES | Tafasitamab Product and Service</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_incy_CollaborationLossSharingExpense', window );">Collaboration loss sharing</a></td>
<td class="nump">$ 1,800<span></span>
</td>
<td class="nump">$ 9,100<span></span>
</td>
<td class="nump">$ 9,100<span></span>
</td>
<td class="nump">$ 29,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=incy_MorphosysAgMember', window );">MorphoSys AG | Development and Regulatory Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_incy_LicenseAgreementMilestonePaymentAmountPaid', window );">Milestone payment made under license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=incy_MorphosysAgMember', window );">MorphoSys AG | Development and Regulatory Milestones | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_incy_LicenseAgreementAdditionalMilestonePayments', window );">Additional milestone payments under the license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 737,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=incy_MorphosysAgMember', window );">MorphoSys AG | Commercialization Milestones | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_incy_LicenseAgreementAdditionalMilestonePayments', window );">Additional milestone payments under the license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 315,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=incy_MorphosysAgMember', window );">MorphoSys AG | MorphoSys AG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_incy_LicenseAgreementPercentageOfFutureGlobalDevelopmentCostsFunded', window );">Funding of future development costs (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=incy_MorphosysAgMember', window );">MorphoSys AG | Incyte</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_incy_LicenseAgreementPercentageOfFutureGlobalDevelopmentCostsFunded', window );">Funding of future development costs (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_CollaborationAgreementProfitLossSharingRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ratio of sharing profit and losses under the collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_CollaborationAgreementProfitLossSharingRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_CollaborationLossSharingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The expense recognized during the reporting period for collaboration loss sharing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_CollaborationLossSharingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_LicenseAgreementAdditionalMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the additional milestone payments to be made under the license agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_LicenseAgreementAdditionalMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_LicenseAgreementMilestonePaymentAmountPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of the milestone payment made under the license agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_LicenseAgreementMilestonePaymentAmountPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_LicenseAgreementPercentageOfFutureGlobalDevelopmentCostsFunded">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of future global development costs funded under the license agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_LicenseAgreementPercentageOfFutureGlobalDevelopmentCostsFunded</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126980263&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=incy_MorphosysAgMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=incy_MorphosysAgMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=incy_MorphosysAgMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=incy_MorphosysAgMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=incy_TafasitamabProductAndServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=incy_TafasitamabProductAndServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_AchievementOfMilestoneAxis=incy_DevelopmentAndRegulatoryMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_AchievementOfMilestoneAxis=incy_DevelopmentAndRegulatoryMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_AchievementOfMilestoneAxis=incy_CommercializationMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_AchievementOfMilestoneAxis=incy_CommercializationMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=incy_MorphosysAgMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=incy_MorphosysAgMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=incy_IncyteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=incy_IncyteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139808198144480">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>License Agreements - Nimble (Details) - Nimble - Maximum<br> $ in Millions</strong></div></th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=incy_NimbleMember', window );">Future contingent discovery milestones</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_incy_LicenseAgreementAdditionalMilestonePayments', window );">Additional milestone payments under the license agreement</a></td>
<td class="nump">$ 8.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=incy_NimbleMember', window );">Development and Regulatory Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_incy_LicenseAgreementAdditionalMilestonePayments', window );">Additional milestone payments under the license agreement</a></td>
<td class="nump">127.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=incy_NimbleMember', window );">Commercialization Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_incy_LicenseAgreementAdditionalMilestonePayments', window );">Additional milestone payments under the license agreement</a></td>
<td class="nump">$ 130.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_LicenseAgreementAdditionalMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the additional milestone payments to be made under the license agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_LicenseAgreementAdditionalMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=incy_NimbleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=incy_NimbleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_AchievementOfMilestoneAxis=incy_FutureContingentDiscoveryMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_AchievementOfMilestoneAxis=incy_FutureContingentDiscoveryMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_AchievementOfMilestoneAxis=incy_DevelopmentAndRegulatoryMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_AchievementOfMilestoneAxis=incy_DevelopmentAndRegulatoryMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_AchievementOfMilestoneAxis=incy_CommercializationMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_AchievementOfMilestoneAxis=incy_CommercializationMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139808291515440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License Agreements - InnoCare (Details) - InnoCare - tafasitamab - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_incy_LicenseAgreementUpfrontPaymentReceived', window );">Upfront payment received under license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=incy_InnocarePharmaLimitedMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_incy_LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived', window );">Upfront and immediate milestone payment to be received under license agreement</a></td>
<td class="nump">$ 82.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the upfront and immediate milestone payment received under the license agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_LicenseAgreementUpfrontPaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the upfront payment received under the license agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_LicenseAgreementUpfrontPaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=incy_InnocarePharmaLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=incy_InnocarePharmaLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=incy_TafasitamabMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=incy_TafasitamabMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139808198084656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License Agreements - Syndax (Details) - USD ($)<br> $ / shares in Units, $ in Thousands, shares in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 09, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Fair market long term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 221,266<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 149,124<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 149,124<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">384,007<span></span>
</td>
<td class="nump">$ 334,945<span></span>
</td>
<td class="nump">1,084,576<span></span>
</td>
<td class="nump">$ 985,352<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Unrealized gain (loss) on long term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(660)<span></span>
</td>
<td class="num">$ (27,450)<span></span>
</td>
<td class="num">(72,142)<span></span>
</td>
<td class="num">$ (28,394)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=incy_InvestmentInSyndaxPharmaceuticalsIncMember', window );">Investment in Syndax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Fair market long term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Unrealized gain (loss) on long term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=incy_SyndaxPharmaceuticalsIncMember', window );">Syndax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_incy_LicenseAgreementUpfrontPaymentAmountPaid', window );">Upfront payment under license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 117,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=incy_SyndaxPharmaceuticalsIncMember', window );">Syndax | Development and Regulatory Milestones | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_incy_LicenseAgreementAdditionalMilestonePayments', window );">Additional milestone payments under the license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">220,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">220,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=incy_SyndaxPharmaceuticalsIncMember', window );">Syndax | Commercialization Milestones | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_incy_LicenseAgreementAdditionalMilestonePayments', window );">Additional milestone payments under the license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">230,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">230,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=incy_SyndaxPharmaceuticalsIncMember', window );">Syndax | Syndax | UNITED STATES</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_incy_LicenseAgreementPercentageOfFutureGlobalDevelopmentCostsFunded', window );">Funding of future development costs (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=incy_SyndaxPharmaceuticalsIncMember', window );">Syndax | Incyte | UNITED STATES</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_incy_LicenseAgreementPercentageOfFutureGlobalDevelopmentCostsFunded', window );">Funding of future development costs (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=incy_StockPurchaseAgreementMember', window );">Stock purchase agreement | Investment in Syndax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_incy_PurchaseOfCommonStockUnderStockPurchaseAgreementInShares', window );">Purchase of common stock under Stock Purchase Agreement (in shares )</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentAggregateCost', window );">Purchase price of common stock</a></td>
<td class="nump">$ 35,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Per share price (In USD per share)</a></td>
<td class="nump">$ 17.48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24.62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24.62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24.62<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Fair market long term investments</a></td>
<td class="nump">$ 24,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 10,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_LicenseAgreementAdditionalMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the additional milestone payments to be made under the license agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_LicenseAgreementAdditionalMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_LicenseAgreementPercentageOfFutureGlobalDevelopmentCostsFunded">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of future global development costs funded under the license agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_LicenseAgreementPercentageOfFutureGlobalDevelopmentCostsFunded</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_LicenseAgreementUpfrontPaymentAmountPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of the upfront payment made under the license agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_LicenseAgreementUpfrontPaymentAmountPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_PurchaseOfCommonStockUnderStockPurchaseAgreementInShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the purchase of common stock under Stock Purchase Agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_PurchaseOfCommonStockUnderStockPurchaseAgreementInShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentAggregateCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents the aggregate cost of investments accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentAggregateCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126980263&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=incy_InvestmentInSyndaxPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=incy_InvestmentInSyndaxPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=incy_SyndaxPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=incy_SyndaxPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_AchievementOfMilestoneAxis=incy_DevelopmentAndRegulatoryMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_AchievementOfMilestoneAxis=incy_DevelopmentAndRegulatoryMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_AchievementOfMilestoneAxis=incy_CommercializationMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_AchievementOfMilestoneAxis=incy_CommercializationMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=incy_SyndaxPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=incy_SyndaxPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=incy_IncyteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=incy_IncyteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=incy_StockPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=incy_StockPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139808193993552">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment, net - Property and equipment, net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and Equipment, gross</a></td>
<td class="nump">$ 917,713<span></span>
</td>
<td class="nump">$ 899,640<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less accumulated depreciation and amortization</a></td>
<td class="num">(201,980)<span></span>
</td>
<td class="num">(175,720)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">715,733<span></span>
</td>
<td class="nump">723,920<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and Equipment, gross</a></td>
<td class="nump">22,527<span></span>
</td>
<td class="nump">22,554<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and Equipment, gross</a></td>
<td class="nump">115,507<span></span>
</td>
<td class="nump">105,040<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and Equipment, gross</a></td>
<td class="nump">88,239<span></span>
</td>
<td class="nump">79,871<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember', window );">Land</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and Equipment, gross</a></td>
<td class="nump">10,139<span></span>
</td>
<td class="nump">10,494<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=incy_BuildingAndLeaseholdImprovementsMember', window );">Building and leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and Equipment, gross</a></td>
<td class="nump">432,748<span></span>
</td>
<td class="nump">434,321<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=incy_OperatingLeaseRightOfUseAssetsMember', window );">Operating lease right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and Equipment, gross</a></td>
<td class="nump">23,111<span></span>
</td>
<td class="nump">27,308<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in Progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and Equipment, gross</a></td>
<td class="nump">$ 225,442<span></span>
</td>
<td class="nump">$ 220,052<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=incy_BuildingAndLeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=incy_BuildingAndLeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=incy_OperatingLeaseRightOfUseAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=incy_OperatingLeaseRightOfUseAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139808193116464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, net - Buildings and construction (Details)<br> $ in Thousands, ft&#178; in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jul. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Feb. 28, 2018</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and Equipment, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 917,713<span></span>
</td>
<td class="nump">$ 899,640<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Finance lease right-of-use assets, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,679<span></span>
</td>
<td class="nump">27,548<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=incy_BuildingAndLeaseholdImprovementsMember', window );">Building and leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and Equipment, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">432,748<span></span>
</td>
<td class="nump">434,321<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in Progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and Equipment, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 225,442<span></span>
</td>
<td class="nump">220,052<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RealEstatePropertiesAxis=incy_OfficeBuildingWilmingtonDelawareMember', window );">Office Building in Wilmington, Delaware</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Square footage | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RealEstatePropertiesAxis=incy_OfficeBuildingWilmingtonDelawareMember', window );">Office Building in Wilmington, Delaware | Building and leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and Equipment, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 158,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RealEstatePropertiesAxis=incy_OfficeBuildingMorgesSwitzerlandMember', window );">Office Building in Morges, Switzerland</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Square footage | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeaseTermOfContract1', window );">Initial lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeaseExistenceOfOptionToExtend', window );">Options to extend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeaseRenewalTerm1', window );">Renewal term of agreement to rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">20 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Financing lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Finance lease right-of-use assets, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_incy_FinanceLeaseLeaseIncentiveReceivable', window );">Finance lease, lease incentive receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RealEstatePropertiesAxis=incy_OfficeBuildingMorgesSwitzerlandMember', window );">Office Building in Morges, Switzerland | Building and leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and Equipment, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RealEstatePropertiesAxis=incy_LandLocatedWithinYParcSwitzerlandsLargestTechnologyParkInYverdonMember', window );">Land in Y-PARC, Switzerland's largest technology park, Yverdon</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireRealEstate', window );">Purchase price</a></td>
<td class="nump">$ 4,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RealEstatePropertiesAxis=incy_LandLocatedWithinYParcSwitzerlandsLargestTechnologyParkInYverdonMember', window );">Land in Y-PARC, Switzerland's largest technology park, Yverdon | Construction in Progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and Equipment, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 190,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_FinanceLeaseLeaseIncentiveReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of lease incentive receivable from landlord under finance leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_FinanceLeaseLeaseIncentiveReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfRealEstateProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area of a real estate property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfRealEstateProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeaseExistenceOfOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether lessee has option to extend finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeaseExistenceOfOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeaseRenewalTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's finance lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeaseRenewalTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeaseTermOfContract1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeaseTermOfContract1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireRealEstate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow from the acquisition of a piece of land, anything permanently fixed to it, including buildings, structures on it and so forth; includes real estate intended to generate income for the owner; excludes real estate acquired for use by the owner.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireRealEstate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=incy_BuildingAndLeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=incy_BuildingAndLeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RealEstatePropertiesAxis=incy_OfficeBuildingWilmingtonDelawareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RealEstatePropertiesAxis=incy_OfficeBuildingWilmingtonDelawareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RealEstatePropertiesAxis=incy_OfficeBuildingMorgesSwitzerlandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RealEstatePropertiesAxis=incy_OfficeBuildingMorgesSwitzerlandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RealEstatePropertiesAxis=incy_LandLocatedWithinYParcSwitzerlandsLargestTechnologyParkInYverdonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RealEstatePropertiesAxis=incy_LandLocatedWithinYParcSwitzerlandsLargestTechnologyParkInYverdonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139808197625664">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued and Other Current Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued and Other Current Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrent', window );">Royalties</a></td>
<td class="nump">$ 248,455<span></span>
</td>
<td class="nump">$ 168,412<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_incy_AccruedClinicalRelatedCostsCurrent', window );">Clinical related costs</a></td>
<td class="nump">152,764<span></span>
</td>
<td class="nump">109,486<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProvisionForLossOnContracts', window );">Sales allowances</a></td>
<td class="nump">186,112<span></span>
</td>
<td class="nump">136,541<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedMarketingCostsCurrent', window );">Sales and marketing</a></td>
<td class="nump">31,001<span></span>
</td>
<td class="nump">35,750<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConstructionPayableCurrent', window );">Construction in progress</a></td>
<td class="nump">8,836<span></span>
</td>
<td class="nump">27,098<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="nump">8,492<span></span>
</td>
<td class="nump">10,554<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">64,154<span></span>
</td>
<td class="nump">45,754<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued and other current liabilities</a></td>
<td class="nump">$ 699,814<span></span>
</td>
<td class="nump">$ 533,595<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_AccruedClinicalRelatedCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for clinical related costs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_AccruedClinicalRelatedCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedMarketingCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for the marketing, trade and selling of the entity's goods and services. Marketing costs would include expenditures for planning and executing the conception, pricing, promotion, and distribution of ideas, goods, and services; costs of public relations and corporate promotions; and obligations incurred and payable for sales discounts, rebates, price protection programs, etc. offered to customers and under government programs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedMarketingCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRoyaltiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRoyaltiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConstructionPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for the acquisition of merchandise, materials, supplies and services pertaining to construction projects such as a housing development or factory expansion not classified as trade payables. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConstructionPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForLossOnContracts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cumulative provision for contract losses not offset against related costs accumulated on the balance sheet.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 35<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126916656&amp;loc=d3e57777-111642<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForLossOnContracts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139808193932896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Compensation - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock compensation expense</a></td>
<td class="nump">$ 45.4<span></span>
</td>
<td class="nump">$ 42.7<span></span>
</td>
<td class="nump">$ 135.7<span></span>
</td>
<td class="nump">$ 134.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedAnnualizedForfeitureRate', window );">Assumed annualized forfeiture rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-based Payment Arrangement, Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Stock option grant term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Percentage of units vesting at the end of each calendar year (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract', window );"><strong>Unrecognized compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation cost for nonvested option (in dollars)</a></td>
<td class="nump">51.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 51.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Vesting period of recognition of the unrecognized compensation cost of nonvested awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-based Payment Arrangement, Option | Share-based Payment Arrangement, Tranche One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-based Payment Arrangement, Option | Share-based Payment Arrangement, Tranche Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">36 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Percentage of units vesting at the end of each calendar year (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesPerRestrictedStockUnits', window );">Number of shares awarded for each RSU (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract', window );"><strong>Unrecognized compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation cost for nonvested option (in dollars)</a></td>
<td class="nump">235.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 235.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Vesting period of recognition of the unrecognized compensation cost of nonvested awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock compensation expense</a></td>
<td class="nump">3.2<span></span>
</td>
<td class="nump">1.7<span></span>
</td>
<td class="nump">$ 5.1<span></span>
</td>
<td class="nump">5.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract', window );"><strong>Unrecognized compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation cost for nonvested option (in dollars)</a></td>
<td class="nump">19.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Vesting period of recognition of the unrecognized compensation cost of nonvested awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Shares | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Shares | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock compensation expense</a></td>
<td class="nump">25.8<span></span>
</td>
<td class="nump">26.3<span></span>
</td>
<td class="nump">$ 80.2<span></span>
</td>
<td class="nump">84.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, General and Administrative Expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock compensation expense</a></td>
<td class="nump">18.9<span></span>
</td>
<td class="nump">15.9<span></span>
</td>
<td class="nump">53.5<span></span>
</td>
<td class="nump">49.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of Sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock compensation expense</a></td>
<td class="nump">$ 0.7<span></span>
</td>
<td class="nump">$ 0.5<span></span>
</td>
<td class="nump">$ 2.0<span></span>
</td>
<td class="nump">$ 1.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedAnnualizedForfeitureRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the expected annualized forfeiture rate for options granted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedAnnualizedForfeitureRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesPerRestrictedStockUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of shares awarded for each restricted share units.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesPerRestrictedStockUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139808193203952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Compensation - Valuation assumptions used for value of stock compensation granted (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember', window );">Employee Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Weighted-average fair value assumptions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Average risk-free interest rates (as a percent)</a></td>
<td class="nump">4.22%<span></span>
</td>
<td class="nump">0.28%<span></span>
</td>
<td class="nump">3.44%<span></span>
</td>
<td class="nump">0.22%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Average expected life (in years)</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">6 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility (as a percent)</a></td>
<td class="nump">31.00%<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="nump">27.00%<span></span>
</td>
<td class="nump">31.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average fair value (in dollars per share)</a></td>
<td class="nump">$ 16.46<span></span>
</td>
<td class="nump">$ 18.20<span></span>
</td>
<td class="nump">$ 15.38<span></span>
</td>
<td class="nump">$ 18.82<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-based Payment Arrangement, Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Weighted-average fair value assumptions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Average risk-free interest rates (as a percent)</a></td>
<td class="nump">2.90%<span></span>
</td>
<td class="nump">0.76%<span></span>
</td>
<td class="nump">2.03%<span></span>
</td>
<td class="nump">0.60%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Average expected life (in years)</a></td>
<td class="text">5 years 2 months 1 day<span></span>
</td>
<td class="text">5 years 1 month 28 days<span></span>
</td>
<td class="text">4 years 10 months 17 days<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility (as a percent)</a></td>
<td class="nump">35.00%<span></span>
</td>
<td class="nump">38.00%<span></span>
</td>
<td class="nump">36.00%<span></span>
</td>
<td class="nump">39.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average fair value (in dollars per share)</a></td>
<td class="nump">$ 27.57<span></span>
</td>
<td class="nump">$ 28.84<span></span>
</td>
<td class="nump">$ 25.96<span></span>
</td>
<td class="nump">$ 29.32<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139808197549728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Compensation - Option activity under the 2010 stock plan (Details) - Share-based Payment Arrangement, Option - $ / shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Option Activity Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at the beginning of the period (in shares)</a></td>
<td class="nump">12,763,460<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Options granted (in shares)</a></td>
<td class="nump">1,755,963<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised (in shares)</a></td>
<td class="num">(477,371)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Options cancelled (in shares)</a></td>
<td class="num">(989,465)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at the end of the period (in shares)</a></td>
<td class="nump">13,052,587<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Stock Options Weighted Average Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise prices of options outstanding (in USD per share)</a></td>
<td class="nump">$ 87.41<span></span>
</td>
<td class="nump">$ 88.39<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in USD per share)</a></td>
<td class="nump">75.32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in USD per share)</a></td>
<td class="nump">66.69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Cancelled (in USD per share)</a></td>
<td class="nump">$ 88.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139808194086400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Compensation - RSU award and PSU activity under the 2010 stock plan (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>RSU and PSU Activity Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Outstanding at the beginning of the period (in shares)</a></td>
<td class="nump">3,966,888<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Outstanding at the end of the period (in shares)</a></td>
<td class="nump">5,226,984<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract', window );"><strong>RSU and PSU Grant Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue', window );">Share price of shares available (in USD per share)</a></td>
<td class="nump">$ 81.29<span></span>
</td>
<td class="nump">$ 84.91<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>RSU and PSU Activity Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">2,473,892<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod', window );">Released (in shares)</a></td>
<td class="nump">845,095<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Cancelled (in shares)</a></td>
<td class="nump">337,265<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract', window );"><strong>RSU and PSU Grant Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue', window );">Granted (in USD per share)</a></td>
<td class="nump">$ 77.14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedIntrinsicValue', window );">Released (in USD per share)</a></td>
<td class="nump">87.06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue', window );">Cancelled (in USD per share)</a></td>
<td class="nump">$ 83.94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>RSU and PSU Activity Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">154,685<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod', window );">Released (in shares)</a></td>
<td class="nump">184,401<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Cancelled (in shares)</a></td>
<td class="nump">1,720<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract', window );"><strong>RSU and PSU Grant Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue', window );">Granted (in USD per share)</a></td>
<td class="nump">$ 77.67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedIntrinsicValue', window );">Released (in USD per share)</a></td>
<td class="nump">69.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue', window );">Cancelled (in USD per share)</a></td>
<td class="nump">$ 65.76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of shares of employee compensation programs, other than options, released during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share weighted average intrinsic value of equity-based compensation awards released. Excludes stock and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average intrinsic value of award forfeited under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average intrinsic value of award granted under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average intrinsic value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of equity instruments other than options outstanding, including both vested and non-vested instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139808196390336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Compensation - Shares available for grant (Details)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2022 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract', window );"><strong>Available Shares for Grant</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Beginning Balance (in shares)</a></td>
<td class="nump">10,113,298<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGranted', window );">Options, RSUs and PSUs granted (in shares)</a></td>
<td class="num">(7,013,475)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCanceled', window );">Options, RSUs and PSUs cancelled (in shares)</a></td>
<td class="nump">1,680,482<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Ending Balance (in shares)</a></td>
<td class="nump">4,780,305<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCanceled">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares canceled under an established share-based compensation plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCanceled</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares granted under an established share-based compensation plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139808193912896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax (benefit) expense</a></td>
<td class="nump">$ 35,813<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,730<span></span>
</td>
<td class="nump">$ 136,302<span></span>
</td>
<td class="nump">$ 65,694<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability', window );">One-time benefit from associated valuation allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 569,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 408,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease', window );">Increase in unrecognized tax benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income tax expense (benefit) from continuing operations attributable to an adjustment of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in unrecognized tax benefits attributable to uncertain tax positions taken in tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139808193209168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income Per Share - Net income (loss) per share (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAbstract', window );"><strong>Basic Net Income (Loss) Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Basic net income</a></td>
<td class="nump">$ 112,775<span></span>
</td>
<td class="nump">$ 181,739<span></span>
</td>
<td class="nump">$ 312,199<span></span>
</td>
<td class="nump">$ 384,730<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common shares outstanding (in shares)</a></td>
<td class="nump">222,415<span></span>
</td>
<td class="nump">220,845<span></span>
</td>
<td class="nump">221,801<span></span>
</td>
<td class="nump">220,243<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net income per share ( in USD per share)</a></td>
<td class="nump">$ 0.51<span></span>
</td>
<td class="nump">$ 0.82<span></span>
</td>
<td class="nump">$ 1.41<span></span>
</td>
<td class="nump">$ 1.75<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedAbstract', window );"><strong>Diluted Net Income (Loss) Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Diluted net income (loss)</a></td>
<td class="nump">$ 112,775<span></span>
</td>
<td class="nump">$ 181,739<span></span>
</td>
<td class="nump">$ 312,199<span></span>
</td>
<td class="nump">$ 384,730<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common shares outstanding (in shares)</a></td>
<td class="nump">222,415<span></span>
</td>
<td class="nump">220,845<span></span>
</td>
<td class="nump">221,801<span></span>
</td>
<td class="nump">220,243<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Dilutive stock options and awards ( in shares)</a></td>
<td class="nump">1,760<span></span>
</td>
<td class="nump">1,403<span></span>
</td>
<td class="nump">1,825<span></span>
</td>
<td class="nump">1,870<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares used to compute diluted net income per share ( in shares)</a></td>
<td class="nump">224,175<span></span>
</td>
<td class="nump">222,248<span></span>
</td>
<td class="nump">223,626<span></span>
</td>
<td class="nump">222,113<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net income per share ( in USD per share)</a></td>
<td class="nump">$ 0.50<span></span>
</td>
<td class="nump">$ 0.82<span></span>
</td>
<td class="nump">$ 1.40<span></span>
</td>
<td class="nump">$ 1.73<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126962052&amp;loc=d3e4991-113900<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1707-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28A<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1500-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1757-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139808194790144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income Per Share - Antidilutive securities (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember', window );">Share-Based Payment Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract', window );"><strong>Anti-dilutive securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potential common shares excluded from diluted net income (loss) per share computation ( in shares)</a></td>
<td class="nump">11,150,022<span></span>
</td>
<td class="nump">11,841,440<span></span>
</td>
<td class="nump">10,979,096<span></span>
</td>
<td class="nump">9,917,824<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139808291515728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Defined contribution expense</a></td>
<td class="nump">$ 5.1<span></span>
</td>
<td class="nump">$ 4.4<span></span>
</td>
<td class="nump">$ 14.7<span></span>
</td>
<td class="nump">$ 12.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostCreditExcludingServiceCostStatementOfIncomeOrComprehensiveIncomeExtensibleList', window );">Location of costs excluding the service component</a></td>
<td class="text">Other income (expense), net<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsCurrentFiscalYear', window );">Current year expected contributions total</a></td>
<td class="nump">$ 6.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsCurrentFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contributions received and expected to be received by defined benefit plan from employer in current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsCurrentFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostCreditExcludingServiceCostStatementOfIncomeOrComprehensiveIncomeExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of income or comprehensive income that includes components of net periodic benefit cost (credit), excluding service cost component, for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostCreditExcludingServiceCostStatementOfIncomeOrComprehensiveIncomeExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139808193201984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit plans - Net periodic benefit cost (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanServiceCost', window );">Employer service cost</a></td>
<td class="nump">$ 2,376<span></span>
</td>
<td class="nump">$ 1,975<span></span>
</td>
<td class="nump">$ 7,336<span></span>
</td>
<td class="nump">$ 5,927<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Interest cost</a></td>
<td class="nump">61<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="nump">187<span></span>
</td>
<td class="nump">68<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets', window );">Expected return on plan assets</a></td>
<td class="num">(1,008)<span></span>
</td>
<td class="num">(15)<span></span>
</td>
<td class="num">(3,114)<span></span>
</td>
<td class="num">(45)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit', window );">Amortization of prior service cost</a></td>
<td class="nump">193<span></span>
</td>
<td class="nump">54<span></span>
</td>
<td class="nump">580<span></span>
</td>
<td class="nump">162<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActuarialGainLoss', window );">Amortization of actuarial losses</a></td>
<td class="nump">89<span></span>
</td>
<td class="nump">288<span></span>
</td>
<td class="nump">266<span></span>
</td>
<td class="nump">864<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost', window );">Net periodic benefit cost</a></td>
<td class="nump">$ 1,711<span></span>
</td>
<td class="nump">$ 2,325<span></span>
</td>
<td class="nump">$ 5,255<span></span>
</td>
<td class="nump">$ 6,976<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanActuarialGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from change in actuarial assumptions which (increases) decreases benefit obligation of defined benefit plan. Assumptions include, but are not limited to, interest, mortality, employee turnover, salary, and temporary deviation from substantive plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanActuarialGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of prior service cost (credit) recognized in net periodic benefit cost (credit) of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(5)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(5)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expected return (loss) recognized in net periodic benefit (cost) credit, calculated based on expected long-term rate of return and market-related value of plan assets of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanInterestCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost recognized for passage of time related to defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanInterestCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of net periodic benefit cost (credit) for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanServiceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanServiceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139808193694832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events - Narrative (Details) - Villaris - Subsequent Event<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr><th class="th">
<div>Oct. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_incy_LicenseAgreementUpfrontPaymentAmountPaid', window );">Upfront payment under license agreement</a></td>
<td class="nump">$ 70.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=incy_VillarisMember', window );">Development and Regulatory Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_incy_LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived', window );">Upfront and immediate milestone payment to be received under license agreement</a></td>
<td class="nump">310.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=incy_VillarisMember', window );">Commercialization Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_incy_LicenseAgreementMilestoneOnNetSalesOfProduct', window );">Milestone payments for net sales of product</a></td>
<td class="nump">$ 1,050.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_LicenseAgreementMilestoneOnNetSalesOfProduct">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Milestone on Net Sales of Product</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_LicenseAgreementMilestoneOnNetSalesOfProduct</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_LicenseAgreementUpfrontPaymentAmountPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of the upfront payment made under the license agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_LicenseAgreementUpfrontPaymentAmountPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the upfront and immediate milestone payment received under the license agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=incy_VillarisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=incy_VillarisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_AchievementOfMilestoneAxis=incy_DevelopmentAndRegulatoryMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_AchievementOfMilestoneAxis=incy_DevelopmentAndRegulatoryMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_AchievementOfMilestoneAxis=incy_CommercializationMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_AchievementOfMilestoneAxis=incy_CommercializationMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R9999.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139808196409632">
<tr>
<th class="tl" colspan="1">Label</th>
<th class="tl"><strong>Element</strong></th>
<th class="th" colspan="1">Value</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=incy_AmericanDepositarySharesMember', window );">ADSs</a></td>
<td class="th" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentAggregateCost', window );">Equity Method Investment, Aggregate Cost</a></td>
<td class="th" style="border-bottom: 0px;">us-gaap_EquityMethodInvestmentAggregateCost</td>
<td class="nump">$ 150,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share Price</a></td>
<td class="th" style="border-bottom: 0px;">us-gaap_SharePrice</td>
<td class="nump">$ 41.33<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_incy_SubsidiaryStockConversionRatio', window );">Subsidiary Stock, Conversion Ratio</a></td>
<td class="th" style="border-bottom: 0px;">incy_SubsidiaryStockConversionRatio</td>
<td class="nump">0.25<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_SubsidiaryStockConversionRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of parent common shares issuable upon conversion for each share of subsidiary stock to be converted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_SubsidiaryStockConversionRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentAggregateCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents the aggregate cost of investments accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentAggregateCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=incy_AmericanDepositarySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=incy_AmericanDepositarySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>incy-20220930_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2022"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:incy="http://www.incyte.com/20220930"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="incy-20220930.xsd" xlink:type="simple"/>
    <context id="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i2ee7afc3141240148065dcabb8761324_I20221025">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
        </entity>
        <period>
            <instant>2022-10-25</instant>
        </period>
    </context>
    <context id="i3b4376f8fc614de98c9cf647198c504e_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="iab26fe441f0d4ab984456365a7f7cff0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i85b99c1e194944f7bd3b5fb62f5a2182_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i48a86cbfb7934ea9845c79f994c08295_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ie260e1a53b734cf0a4f57af01f2e311d_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i6c3d6351306b42baba694287efd653dc_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i37c7d1d637bf4ae98b18884511c75dd9_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i5c507c58a3df413e914b6c8ae5dbf2a2_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ia628ec6831414d4f8e0d2c927a011f4a_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i3231b94f87f649139a15ad91d06d9fd2_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib5a93dd07a4f42b6ba18bf2e816dc557_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:MilestoneRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i4924faaf57ec4df5aafa757da5bce176_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:MilestoneRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i2028c66e6d814be2937c324c9b244728_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:MilestoneRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ic7c03930e4e24e0880a00b550c2d0c20_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:MilestoneRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="id673d80f31e74643a241d2f62db94ca9_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i313b15d35b7045babd1ba61f84a077dd_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i0faaba5fcd6b485781cadacae8b2fd8e_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib3978ca7e91d4a55b0da8a410f53aea4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1a13b312028f458ba711e0bcf4618c10_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic7a3e053f47b40869b9b63c44edaac78_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4cba8f9e546d4c0498d87ceb40e69a8f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6cea24b8bb274decac908bfad3a9c638_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ia3d452137b9d47e98488b6d8f51dd20b_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i05bc3079ebc64f4a9ddcc9c745ce3823_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ibabc38cb3fd14f2698896bf6570c921e_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i967717e321b54b36a61c6fc27425f9af_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ie914017719d349ea93b5d5a6cd062896_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i5bc89bf0de084e20a0006dad354ec6b3_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i1c77ebb088a04a3bb81e477173b73514_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i38aa3d9ea1274ad1a0d50c3c12756c65_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="if098df40ebae4afbb01da4049e945b36_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i92fea5bb4d2c40d19ea9af7ae6522acf_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="idff6b81e3d0245e797ebe0c300a68bfb_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i623f636b1e544597bf91776873f38e5d_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i83c026db6e174249812a82f711cb1f78_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i083ff8458e9c4ae38eb154dc7ce1f9a0_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i6f8d696d0d544a858bc29abec7dae8d2_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="if646a3c30a6b46ec8912b9038eb7f0bf_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i5b880c3983264395b93d1f6014da990c_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="if6f74963df2d4ed483d364c3eeabd8a1_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i60075c2eb5c5499f8837e239ab042889_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i1e7566ac86984c7d9bc3167d0dd68193_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i85c3cbfbb1824bc5a5e1c025e4781453_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ib6839b85b6084c339df68bc47f7cff76_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ibe1f6fcb358742d8947f8680dc7a2216_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i05520eab8e964199ad292516b1f688c5_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ie5b42e033862404b9b0eb46dcfa04cde_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i16eb58b1ed464d849f5daa9d5c452c5d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5940926f68ee4011bffeecd1cae3a5bd_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="idab40e34150649eb84f41cf937413ae9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i965f89ff7c6b4ce6bcc30af15c2742bb_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id7612db9fbac4f99a07f20a1f367748a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if318fa6e60cf4269ad7b22fe4b7d3bed_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i149762c26678449aa330b2367cbe6d4c_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i63235de3b5c048f09f04c5309d82d142_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i9f5bbbcd7a4e4865bf1cd728365c237b_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i510fae960406426aabb022789d463532_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i8b5fdbb0199e42af841de05d57267053_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i5b58a259e2444d51ab47b223d8db0cb8_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i964e4f2c4c4e458a807f09f6f17794df_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i06b27465ac7d4ce4b1fe3f0cc3e247fb_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i4b4b9892bc824ec58691624921a1e192_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="idc6cb7baa8c74e84b9abc3c83e5894f1_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="if9e03c43713740629fa4f89aa642de4f_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i7e103bce07364afa8641cfcaf9141951_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i27392d6e02284d51a27f567bf09e7d8a_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i117119ef63584701b5c25a7fdb4442e6_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i5519d29d74934b9387e13dee64f56289_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="if29697c5381c4b6dbdca657efd2afcb9_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ib314ad130b2f42d0844a18715eb4169a_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ie9e0017429a94b21b8bba302af4c6a96_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i80edfdae16f74674aa25a4584796d920_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i4a971b6abebd4be9a0d2b6015046b257_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i37e49a4f06ec4d2da555cee905623504_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i3999e65b4d434855be24ad71cc111f8d_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ifa71095b17734a079f0fd7349c7cc6a8_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i3a9436032c6c4652b5da596c702a1d2b_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i8d3e00d0fdce4dd6a33f933968e210ae_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ibf6b811e903342bb834df47cf71eeef4_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i4d97c6f523444f9aa40a206f5b9705c6_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i2be3671bbcdc48d9a2d0dd78d0bf79a1_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:JAKAFIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i5cd55b8f35884c0687d725055f17e72c_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:JAKAFIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i710215f6e6e248c4a2a3ff81e0391758_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:JAKAFIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="id03654679dfd4153b83d389aa2a13454_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:JAKAFIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib254aa03c50f46e7b589f20d3926968e_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:ICLUSIGMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i8c101f258c8f40a7aac78b3cbb764428_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:ICLUSIGMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i3326e3ff6d134bd48eeeeede0550ad3c_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:ICLUSIGMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ifa8bc47eb24948d78509e0f3fc38353b_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:ICLUSIGMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i9d0a3322355e44a99c106fd274d30424_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:PemazyreMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i5a43e9d7d97347f9b3479daaca253e61_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:PemazyreMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i1522e02430214c97807e76b9d4f39eac_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:PemazyreMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i56581712c0e948f182f555824226c56a_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:PemazyreMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i97181295a2fc4bc38ac82fa3dbaf41dc_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:MINJUVIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="id1964ea37b1844a981da5845b1efc66f_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:MINJUVIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i3e487722166b436b9b1a0d17da42afcb_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:MINJUVIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ie79dcd193dd74e2692c4841bc97d7582_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:MINJUVIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i5b0a477af03843e4a3226411276628ad_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:OpzeluraMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ibde9c5a1859245f58beebcd0ab2f8837_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:OpzeluraMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i2d64d29a0d744eada29116a65f7ee606_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:OpzeluraMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i76074454312246a08eeeb082fdac82d4_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:OpzeluraMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="id7988d7d482845398e5665259694affc_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:JakaviRoyaltyRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i2f384ac250ef439885835d9b5c193ad9_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:JakaviRoyaltyRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i45b0b732fe1e49f8a7de40384f586a9b_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:JakaviRoyaltyRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ie3424cac904843c0b18c3c76707b6e36_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:JakaviRoyaltyRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i0672ace4d6734ee8aaf270d6c484063d_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:OlumiantRoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i9a5b8b62e0a34310b286dc3fd7b2e45f_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:OlumiantRoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iae8216b0f9fa43a69bc74413e49ef99b_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:OlumiantRoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i4bf0f6ad20014e71a14b23e5dd30857a_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:OlumiantRoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ic85f6d136e8245968800b43ce0542fe8_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:TabrectaRoyaltyRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i63601b24528b4ff788ffb07ad33130f8_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:TabrectaRoyaltyRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i6088baa6c1d2446691681da562d452f9_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:TabrectaRoyaltyRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ibb19c48e81f541858b2a7dd6f03bfa27_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:TabrectaRoyaltyRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i897a57efbfea4fbeaa81a87e5862e1a7_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:MilestoneAndContractRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i46bcaf0cac964264acfc8967fb4fed3e_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:MilestoneAndContractRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i2dece6fa44fc4ba59c58b479ca510a5f_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:MilestoneAndContractRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="iae3f552bb26a4c00a17d299e8d3f716b_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:MilestoneAndContractRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ia7f2a4b8ea5a46449d5a5c254bc02074_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">incy:CorporateAndGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ia665e98c13fa47db9c644a1bccf8d1eb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">incy:CorporateAndGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i10d9e02673514259891fcd1d9b719b8c_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">incy:CorporateAndGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ibfc4e1b1be0040ea91db0d41c92a5dfe_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">incy:CorporateAndGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i449d405309c143ba85c051e549663c3a_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i06079cbfdc734317994c136835d0952f_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ie3ce7b9a2a1a476b998fe7aa7ef489e2_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i281946f958c146b0926f5dd53313b031_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ia17493513b37495cac5bb47509ffe782_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2f88761cfe5c4e21a116380b0db0c026_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4b1ac47dfe8c49068229b687c55c61c7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i09bab9220bbf47b692107d83bc042e87_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia7f1808eadf04e878f5967c1674de235_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7c9b57b7436547ed808aaf19bca65fb0_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i46f205a751e14f70bdffe84975b9278e_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i65e0cbcc9a1c4a45843cde84fd23371f_D20160601-20160601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">incy:AriadPharmaceuticalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:LiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-06-01</startDate>
            <endDate>2016-06-01</endDate>
        </period>
    </context>
    <context id="ide8e43b5e4774c2b80fc1d692ccd6c5f_I20160601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">incy:AriadPharmaceuticalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:LiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-06-01</instant>
        </period>
    </context>
    <context id="i4769291f7a5e4844bdea08699b901a87_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">incy:AriadPharmaceuticalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:LiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9dff9f829b91403384e43e22034102b6_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">incy:AriadPharmaceuticalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:LiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i651332485f95471bbc1f9997619b54c7_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">incy:AccruedAndOtherCurrentLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">incy:AriadPharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i8495b4244f744fd78c9b5dadcfa77dc2_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">incy:AccruedAndOtherCurrentLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">incy:AriadPharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i683a8a412ece4de6b78e4947fd25373a_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">incy:CollaborationPartnersaBCAndDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i1ed3ff5544594900b92ac9213a97bb21_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">incy:CollaborationPartnersaBCAndDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3dc5046f317541c88021a56d36951298_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">incy:CustomerAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ib26d36095867409f925663486648772f_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">incy:CustomerAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i162968d5dc8e4fd680e4dc463271dc4b_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">incy:CustomerAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="iefe171c3e83a4f289b8aae022d0e081b_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">incy:CustomerAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ifb602509071647998b5e683e940d1fcf_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">incy:CustomerBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ia8a7e40409944fc78088cd4baed567ac_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">incy:CustomerBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ia8ee030161c64a7e9c95b4e2fb66c573_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">incy:CustomerBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i8d5936e96208421793937f792f73038d_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">incy:CustomerBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i4b1f09000aa74166ade05d1c0dcfedd2_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">incy:CustomerCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i1df4e17ddac14778b89ab7f884e13730_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">incy:CustomerCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iab7d5e90e123422ea957f7b149d1df86_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">incy:CustomerCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i0cc4497fd77b42f18587cdf09d459c05_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">incy:CustomerCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i1fae7539f0da469083ea910f00e0898b_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">incy:CustomerDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ia675debc1ef84ae2b8ec00b9932e707b_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">incy:CustomerDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iaebef62b75f545d4bddd48699efd1ed1_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">incy:CustomerDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ie150bdc7743d4425a27721647c883684_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">incy:CustomerDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i35e2fb28114f48528d3537b9bb4d377b_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">incy:CustomerEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i7fb6ed6fc01c49089fc6fbcbb460178a_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">incy:CustomerEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i0324e502e8e841449b5689a5c7c6f0ff_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">incy:CustomerEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i589bb0c60aaa4a43b9a3cb4f9adb92ce_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">incy:CustomerEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="idb10cbad0c1345b9be3e38c62201ded7_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">incy:AggregateConcentrationCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ia6ac11b8a7e34e69a3ca81e7967cd4db_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">incy:AggregateConcentrationCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7ea3b32b349549ab8ef8819fd6f23c57_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i1be6071c11dc4f5baede897a7c3899d8_D20091101-20091130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:NovartisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:DevelopmentMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2009-11-01</startDate>
            <endDate>2009-11-30</endDate>
        </period>
    </context>
    <context id="i820b7b86437a49c2992e40c5dc8911be_D20091101-20091130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:NovartisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:RegulatoryMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2009-11-01</startDate>
            <endDate>2009-11-30</endDate>
        </period>
    </context>
    <context id="ic2d99eb0d2fc48a4a62cef1d76a3b8fa_D20091101-20091130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:NovartisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:CommercializationMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2009-11-01</startDate>
            <endDate>2009-11-30</endDate>
        </period>
    </context>
    <context id="i05006b85a9704e02902b03623fc8c5f7_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:NovartisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:DevelopmentAndRegulatoryMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ia6687beeb4034e3bbce66e159508b36e_D20091101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:NovartisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:DevelopmentMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2009-11-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ieaa23329fa064e728b6bab53e01e305b_D20091101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:NovartisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:RegulatoryMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2009-11-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i50b34d5e81624a7b80626a7696d9e0d1_D20091101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:NovartisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:CommercializationMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2009-11-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i7de6dcd9947241819b8f342b010b13b8_D20220401-20220430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:TabrectaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:NovartisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:RegulatoryMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-04-30</endDate>
        </period>
    </context>
    <context id="i3447a97d263a4e71b726a6da1a319017_D20220501-20220531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:JakaviMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:NovartisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:RegulatoryMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="if75967c7131848209fa546f5389ff144_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:JakaviMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:NovartisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i949fa939c8164aa79569420d1f965a48_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:JakaviMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:NovartisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i2abac4d4d9084b0cbd214384a0bdd136_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:JAKAFIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:NovartisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ifa4602ca397f4df8b24c50991489996f_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:JAKAFIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:NovartisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i829cf684375a4486846e54a47708b378_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:JAKAFIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:NovartisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i02be7adafa9342b0a09344a3239b2392_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:JAKAFIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:NovartisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i6881c415becd47fa9f89334bb95c5996_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:NovartisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ifbfff633ca0a4e9ea1abbaec86cf758b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:NovartisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic15fa27e6524408cb2ade84bf1015e8a_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:MilestoneAndContractRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:NovartisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i5aa252a5e50f412c987b6f82e79e1f2d_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:MilestoneAndContractRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:NovartisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="iab260328ac9041409b390a6d753ed302_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:JAKAFIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:NovartisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i51a40b9a674c444c9eabfee9d2524c4a_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:JAKAFIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:NovartisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ia6dcb750836e4de6b839dbd19f02184f_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:JAKAFIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:NovartisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ife40116eb76549f19cb03e7d7d84733b_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:JAKAFIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:NovartisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iff64b50b378d484492f7f8d0962ecace_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:TABRECTAPRODUCTANDSERVICESMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:NovartisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i2d83cfa285a94cdf9e3c412825e16ed7_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:TABRECTAPRODUCTANDSERVICESMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:NovartisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i51a445bbbf1c4bb2b3b6e0b802471593_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:TABRECTAPRODUCTANDSERVICESMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:NovartisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i30a2ee091dab4a71840f5db6371badf9_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:TABRECTAPRODUCTANDSERVICESMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:NovartisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="idadd52c621494f53a41ccc71303f0944_D20091201-20091231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:EliLillyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:DevelopmentMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2009-12-01</startDate>
            <endDate>2009-12-31</endDate>
        </period>
    </context>
    <context id="i5da7cd5ffebe4fc2b3889b38d5a3dd8f_D20091201-20091231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:EliLillyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:RegulatoryMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2009-12-01</startDate>
            <endDate>2009-12-31</endDate>
        </period>
    </context>
    <context id="i1a1df5969f734568b13fa48eb0fff053_D20091201-20091231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:EliLillyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:CommercializationMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2009-12-01</startDate>
            <endDate>2009-12-31</endDate>
        </period>
    </context>
    <context id="i03d9a6dbc0bb43aaa8228030c1e90e5c_D20091201-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:EliLillyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:DevelopmentMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2009-12-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i4562ffe6c4de4f0c8852be62011ecaa1_D20091201-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:EliLillyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:RegulatoryMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2009-12-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ib271257c3c244c8491614777e365abbd_D20091201-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:EliLillyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:CommercializationMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2009-12-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="iaa7f2cb6de4b491abfc72a3a790e6c24_D20220601-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:OlumiantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:EliLillyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:RegulatoryMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="if3576f8af5d9438f8a88daefbfe6e46c_D20220601-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:OlumiantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:EliLillyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:RegulatoryMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="id7fe066d0c744249bf7ad5af413886e0_D20220601-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:OlumiantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:EliLillyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:RegulatoryMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="if134f6ece59c4973a0b3eb0c742df2b4_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:OlumiantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:EliLillyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i9c21ab11171944d088ad94775faa82d3_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:OlumiantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:EliLillyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i773d88ed6ec246e38116cf7dcfe2b613_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:OlumiantRoyaltyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:EliLillyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i67b271a11f4749eca413dadc55b898ff_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:OlumiantRoyaltyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:EliLillyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i95f4766b35c44fb7bd203becd9f77ad2_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:OlumiantRoyaltyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:EliLillyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i332c91272a044c69bed32a22f727d46f_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:OlumiantRoyaltyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:EliLillyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i6a0eb481719843cb8e92803e3eabf444_I20160630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:GvhdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:EliLillyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:RegulatoryMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-06-30</instant>
        </period>
    </context>
    <context id="ic8ef5df1d4014903a83c4bd9313a8063_D20190501-20190531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:GvhdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:EliLillyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:RegulatoryMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-05-01</startDate>
            <endDate>2019-05-31</endDate>
        </period>
    </context>
    <context id="i27b0ba8514fd434a9cc2954162a2955e_D20220301-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:GvhdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:EliLillyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:RegulatoryMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ie98f2f82461347b486999bb44539bcea_D20170201-20170228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:ProductGroupOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:AgenusMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-02-01</startDate>
            <endDate>2017-02-28</endDate>
        </period>
    </context>
    <context id="i77e092a0d9e54838988930228ca59678_D20170201-20170228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:ProductGroupOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:AgenusMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-02-01</startDate>
            <endDate>2017-02-28</endDate>
        </period>
    </context>
    <context id="i322b83e81195460e8c7931fafc090d9a_D20170201-20170228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:ProductGroupTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:AgenusMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-02-01</startDate>
            <endDate>2017-02-28</endDate>
        </period>
    </context>
    <context id="i5094eb7ec3484534bab11f2216427143_D20170201-20170228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:AgenusMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-02-01</startDate>
            <endDate>2017-02-28</endDate>
        </period>
    </context>
    <context id="i0c8cef81f270473fadccddb9df52f115_D20150101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:AgenusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:DevelopmentRegulatoryAndCommercializationMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="id92745e544bc4129ab3571e6e1882924_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:AgenusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:DevelopmentRegulatoryAndCommercializationMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i6c3197a1985e4c74a433c4e949b9a513_D20170101-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:AgenusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:StockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="i5eaa2a7f03b24bb684bd8c6d31d0037c_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:AgenusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:StockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="iac9dda7781924f1c941a441ab2e2b22e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:AgenusMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i181b872577d8409197ea188e8c75e75e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:AgenusMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i75f5d515a0904070a5f78ec1c95a20f5_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:AgenusMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ib46ef2e3f9964aa1ae70251f66606bb7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:AgenusMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0fde4e1ee3904f46bc27b6433525d662_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:AgenusMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i6737e877e1fd425cadb82670cc929c9d_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:AgenusMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i595a69e029b4481b8df26f1ffe67629c_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:AgenusMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i9682bdfe1eb449eca0f0c2c52870768b_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:AgenusMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i9334ed3cba224fde929ed123a17c88d3_D20161201-20161231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:MerusNVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-12-01</startDate>
            <endDate>2016-12-31</endDate>
        </period>
    </context>
    <context id="i9011187ffb7d41f38db3ce85ad7e7768_D20220101-20220131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:MerusNVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="i3734c8248498448d986bbd533587971e_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:MerusNVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:DevelopmentAndRegulatoryMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="id2a299f69c6442bebb13283c32eb5495_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:MerusNVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:CommercializationMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i68cb2d0ea17a41489814062745e1a6d8_D20161201-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:MerusNVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-12-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ida045afcbce447a1922f7d64f607e199_D20161201-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:MerusNVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-12-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ic6746d80cb784b16bb25e182d074023d_D20161201-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:MerusNVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-12-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i3fda94064174414ba40e5f53bd348807_D20161201-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:MerusNVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-12-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i7ab2a3895a964a1292f9330cada8a771_D20161201-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:MerusNVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-12-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i8440f47d04e64df1b565b9e18146f65e_D20161201-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:MerusNVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-12-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="idad439e73b814d62ac3f923adfd04e2a_D20161201-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:MerusNVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-12-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i1a445305a100467ca73640bc7fefa6b1_D20160101-20161231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:MerusNVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:StockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-12-31</endDate>
        </period>
    </context>
    <context id="i68df7b52e15747f7ae8531c9b598597e_I20161231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:MerusNVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:StockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="i372a75620ad046e48dae561ae27ead65_D20210101-20210131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:MerusNVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="i4725ae58984b44c88c59c206c45fa1d2_I20210131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:MerusNVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-31</instant>
        </period>
    </context>
    <context id="idc8b97af450a4ea5ad6a270978aca78f_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:MerusNVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i9eec6fea7a9943da8efef567ce22965f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:MerusNVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i223beeaf3ff34be8ac561d2f33d4ee03_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:MerusNVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i2c2d69aa47e742379d1cce352dedd9ae_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:MerusNVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i3700fa75a23a4f7eb6dcb20a8debd956_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:MerusNVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i2665334fe7184425872feb9740fab18e_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:MerusNVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i4764998569344819b699915846b00247_D20170101-20170131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:CalitheraBiosciencesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-01-31</endDate>
        </period>
    </context>
    <context id="i7d98c2063e874805b3cd156154e95b6a_D20170101-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:CalitheraBiosciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:StockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="i040b9736a2b34584b9200ad4e2e9a3fa_I20170131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:CalitheraBiosciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:StockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-01-31</instant>
        </period>
    </context>
    <context id="i3851ace877124ec6913ece53ee3910da_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:CalitheraBiosciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:StockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i976bcd6e91034b90afc59a80f582f14d_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:CalitheraBiosciencesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i14a2cf26acb6415995411f908d84bb40_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:CalitheraBiosciencesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i73a305e484884469b7b72fee3888f57d_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:CalitheraBiosciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ibf490fff4c3b444c824506cac379e2c3_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:CalitheraBiosciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ia0e5eed879114b4fb4f2900138c56b8c_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:CalitheraBiosciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ibb93f3e466f7462fb5aade7477f8d7d9_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:CalitheraBiosciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ied65757537b34a7aa71eb6babf067549_D20220701-20220731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:MacrogenicsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:DevelopmentMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-07-31</endDate>
        </period>
    </context>
    <context id="ibd823a98e80f479cb6963127d5b61c4f_D20171001-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:MacrogenicsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:DevelopmentMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-10-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ieca316d43e864d6c9e1338c719db09da_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:MacrogenicsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:DevelopmentAndRegulatoryMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="id5aed6962c28461aa5a91abb86e50e12_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:MacrogenicsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:CommercializationMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ic18f95fb157047e8b27cafc65fd5af9c_D20171001-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:MacrogenicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-10-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ie6e53682249b48c2b89c302c106844f5_D20171001-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:MacrogenicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-10-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="icf19c78006d9495182f71ef7c21fe380_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:MacrogenicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i3985fee19ddf43a38f40f8f7a256fbdf_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:MacrogenicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="icb1732c8fda74656b87657355bf486ce_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:MacrogenicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i73db6105ad88412f9de49662c370a570_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:MacrogenicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ieaa2a400ed804a53b1afde32908c0c07_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:MacrogenicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i2dbf58f06d2f47308c3bad5301982ece_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:MacrogenicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i70fb3b0153d340f5aab70006b97df6d0_D20180101-20180131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:SyrosPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-01-31</endDate>
        </period>
    </context>
    <context id="i152e5989713548879ee454b4d94dc97d_I20180131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:SyrosPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-01-31</instant>
        </period>
    </context>
    <context id="icafda92b12fb4c439f26f3cbf5162d94_I20180131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:SyrosPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:DevelopmentAndRegulatoryMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-01-31</instant>
        </period>
    </context>
    <context id="i9b71fd409f444f9ab70ba536a99e012b_I20180131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:SyrosPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:CommercializationMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-01-31</instant>
        </period>
    </context>
    <context id="i4802cd742cea475fa7d4e4c77f6ed61f_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:SyrosPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">incy:PreSeptember2022StockSplitSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:StockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i8cf0a385b080416f8c84cece61770144_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:SyrosPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:StockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i56216a9c32c046e293518645fa59581e_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:SyrosPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">incy:PreSeptember2022StockSplitSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:AmendedStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i84229a0cf41042c4af314a95d0c76e40_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:SyrosPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:AmendedStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="icc792aa24edf4db4b607a35782e9f099_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:SyrosPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:StockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ia7d2cecabe5d473b9e10bcd188d283ba_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:SyrosPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i8210542f8d5e44b9852bd20e5f5e3854_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:SyrosPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic8f331242d08460fbf44354246d36f87_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:SyrosPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i7c697b731e83449fa55119d8b2fbba64_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:SyrosPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i6adb3d95448a44468d8489293e1ea749_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:SyrosPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i09a141eea49e49258b3beebd24497e7e_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:SyrosPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ic09f0ce12baa4ba48de314895f364fc0_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:InnoventBiologicsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:DevelopmentAndRegulatoryMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="idf1c0108786a4620836caeb03784ce6c_D20220301-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:PemazyreMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:InnoventBiologicsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:RegulatoryMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ie995745d247a45d38430829bee3187e8_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:InnoventBiologicsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:CommercializationMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i96f4281beb534126a1eef106e0789ece_D20190701-20190731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:CollaborationAndLicenseAgreementWithZaiLabLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:DevelopmentAndRegulatoryMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-07-31</endDate>
        </period>
    </context>
    <context id="iebdcdab801a74c27a6126ac544405996_D20190701-20190731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:CollaborationAndLicenseAgreementWithZaiLabLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:CommercializationMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-07-31</endDate>
        </period>
    </context>
    <context id="i900f0ac816ab4775ab2106619f594870_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:MorphosysAgMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">incy:IncyteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i591cacee8aca4012a248fa2c96cea301_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">incy:MorphosysAgMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:MorphosysAgMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i6aecf3dce21d42e7851bf481a425bc46_I20200131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:MorphosysAgMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:DevelopmentAndRegulatoryMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-31</instant>
        </period>
    </context>
    <context id="i8d1b83baba194bed8477bb9ea0de3df7_I20200131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:MorphosysAgMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:CommercializationMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-31</instant>
        </period>
    </context>
    <context id="ifecd0798049d402f9683bec43016bf55_D20200101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:MorphosysAgMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:DevelopmentAndRegulatoryMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i7acbcf60ab2042008f713a4d43e83de9_I20200131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:AmericanDepositarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-31</instant>
        </period>
    </context>
    <context id="i2ed4e89797ba4aaf9b7ebc41ec200ef4_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:MorphosysAgMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ia375a7c89bc74d8bbfbae792527a8710_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:MorphosysAgMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i743d644eae334843b9ede7cb71b9c67d_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:MorphosysAgMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i9415bb6d6cbd4c08a203ce650cc97142_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:MorphosysAgMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i5c84e3647ab24388b648b9a8ab264afa_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:MorphosysAgMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="idaa0f5c512544ed5bb9ed44eff567a1b_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:MorphosysAgMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ie043e97a1aa74373b87fb3609b47dd3c_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:MorphosysAgMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ie686f463b19c46aea6f673458c296cfa_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:MorphosysAgMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i49acad92f3dd479a8b0f38d89cfdd456_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:TafasitamabProductAndServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:MorphosysAgMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ibf40aaa491714d97a2353162af92483b_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:TafasitamabProductAndServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:MorphosysAgMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i52bb96abc5854205a71aecc9f552d0a1_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:TafasitamabProductAndServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:MorphosysAgMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i052ba28ba496497ba9474f71db32c295_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:TafasitamabProductAndServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:MorphosysAgMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i8d57ef7a2a5e4baea3532431671ef13c_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:MorphosysAgMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i339dc7a864644d6fa19c079e6c5c35f2_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:MorphosysAgMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ib8a2da8278cb46e5a34861f79068cd18_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:MorphosysAgMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iaffe85fc70e4417eb1de69b0992095b4_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:MorphosysAgMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i058a1a9cef2b4e36bcbc453963f518d2_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:MorphosysAgMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i8ea67dc6fe88438cbc0a45ad09002fec_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:MorphosysAgMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i68d610f80f7e4dd1b7076852e33351b9_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:NimbleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:FutureContingentDiscoveryMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="if241609d783147a2a65ee7d8f3cfab8e_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:NimbleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:DevelopmentAndRegulatoryMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i0c67636b0e5c40e3bccf2287aa2dd24e_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:NimbleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:CommercializationMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i54911354715749fdbd74f62ce9dd1ad8_D20210901-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:TafasitamabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:InnocarePharmaLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i7e81499535aa4d19aae8e5cfa7cac860_D20220930-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:TafasitamabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:InnocarePharmaLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-30</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ic4b6bf4c21e94e4e8eac1ce2ff2aca3c_D20210901-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:SyndaxPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">incy:IncyteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i2fc0a1b5bbc34643b361651b2d12a002_D20210901-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">incy:SyndaxPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:SyndaxPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ice2384877b1e441482f1b13c9a8dae52_D20211201-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:SyndaxPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i381ad8904ad94b698038402e2dbae630_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:SyndaxPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:DevelopmentAndRegulatoryMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i9c8cc765b77d4e319490794de2d57720_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:SyndaxPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:CommercializationMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ic75be732674a48cc932a3908c0f0125f_D20210901-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:InvestmentInSyndaxPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:StockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iab65428e773d4e1f81be1d9a26ea6741_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:InvestmentInSyndaxPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:StockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i8fa5c0ac0f304b3f986fce0cfbaa390d_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:InvestmentInSyndaxPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:StockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i5ae4ff1b717c42c4b158977281cf10aa_I20211209">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:InvestmentInSyndaxPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:StockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-09</instant>
        </period>
    </context>
    <context id="ib136551050f34038b1062509c10fd644_D20211209-20211209">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:InvestmentInSyndaxPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:StockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-09</startDate>
            <endDate>2021-12-09</endDate>
        </period>
    </context>
    <context id="i8a234f090f5e47568ec964b185b6ea18_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:InvestmentInSyndaxPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i8f65aa20c7b04a3aa4af35f8d8783e0d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:InvestmentInSyndaxPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0eb6eb6c67a046c99cb82fbf4c1e3ab3_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:InvestmentInSyndaxPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i91c3988b9dd7488dbbd895a2cfde280d_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:InvestmentInSyndaxPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i238b3f464fe541268bf3b5f8a01e1935_D20220601-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:CalitheraBiosciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:StockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ia8061bfa0edf44a5ad71ed8064f8ead3_D20220601-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:SyrosPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:StockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i6a62ea7776234ba0824931335a0d4825_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i132cda3dcfdc4ce6853fafa85f1782e7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie059b8e396a34f60beab49836d33d129_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i2df7a55feb96443a96a33b7ff9a2e1a5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8ffd71f442ea4f50bb5fe72e558fe509_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i0b31e55bf720475390b524cce573a3d0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i706ab952dd37469eaeedc74245929deb_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i15460e5c3abd492e81486c9dd98ed0f9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if7d77528a6e8420e9064a4b8b5c0de47_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">incy:BuildingAndLeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ie3fdcc8f5ffb478da66863c12a1b6a68_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">incy:BuildingAndLeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia4b01aa79b8543cb89e4d2fe5b5782db_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">incy:OperatingLeaseRightOfUseAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="id090587fece240a682b2eb53308bef79_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">incy:OperatingLeaseRightOfUseAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i51126f0e89df4b60bd2aacb656a90f1a_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i5fa10fd48d3a49168a51c3085f8e84c2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1b500a53ba8b41b09f796fe4eaf76bef_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RealEstatePropertiesAxis">incy:OfficeBuildingWilmingtonDelawareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i2370b8e265a34d1aa69e4cb0d71b393f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">incy:BuildingAndLeaseholdImprovementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RealEstatePropertiesAxis">incy:OfficeBuildingWilmingtonDelawareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3e022afff69a4662b44f01a7c0e13f2b_I20180228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RealEstatePropertiesAxis">incy:OfficeBuildingMorgesSwitzerlandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-02-28</instant>
        </period>
    </context>
    <context id="i98615f967e4d480b8209d68fbee3cb04_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RealEstatePropertiesAxis">incy:OfficeBuildingMorgesSwitzerlandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i5b1c37d431a944d2bedb8074e5a6d652_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RealEstatePropertiesAxis">incy:OfficeBuildingMorgesSwitzerlandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ia946998af0fa49ddb26d6ca660cd4f96_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RealEstatePropertiesAxis">incy:OfficeBuildingMorgesSwitzerlandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i5f74da13198248b88b7490d0362d5443_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">incy:BuildingAndLeaseholdImprovementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RealEstatePropertiesAxis">incy:OfficeBuildingMorgesSwitzerlandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ied0dbe564f15462a80f773631b1b4a84_D20180701-20180731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RealEstatePropertiesAxis">incy:LandLocatedWithinYParcSwitzerlandsLargestTechnologyParkInYverdonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-07-31</endDate>
        </period>
    </context>
    <context id="if65cebf5f28640cc97c1750992f7d09c_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RealEstatePropertiesAxis">incy:LandLocatedWithinYParcSwitzerlandsLargestTechnologyParkInYverdonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i70b041b0d1e8409a9b019c7f878e45a2_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i49a1f92f5e85446da96c93ad448dbab8_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ia4fb38d378634c26b981ddc5c86f5524_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i383fc0ace0f847c4a6eb8bb43c13caff_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i5835316ce7724afea3bdb29dcb3a2253_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ib017a2d350ba431d9ba79b402e1cfb7f_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i89ed3c93c92745279b334fa5c4526831_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i7f29ae45641b4afcab178d487b406c8b_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="icce988e289034a3fb382746bd6fb055e_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="idcbe2a87e3f1451b8c00c0d575bc9286_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i743fbd319cfc457b9da040d45ac71e11_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i29928027a77447828aad4cf785a73286_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="id3db81cbe7d44bf4b59daffdc638772b_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i18064623ae8c40b0b87d8d75806827d8_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i88f8a540b3d94b20983f8902eae30ae2_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="id7acb0824a524ce2b1a6d6eeb3f5b6b8_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ia05518f1a01d4291b4add6208b75e939_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ie12951e0177049569a4eaac01ed75693_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="icaf56e010147488ebeb835f2e5b31900_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i6c730d6b5a3349088cf01b0df9f09e86_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ica61680f037f4dedb0e7d3fa6de64097_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i63709951184741bbb03325606fc77885_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i48621c6db4cc4ac9ad02fc57e325cfda_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i04c8ff8acdef44f4b58b1deff299fcc5_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i6a259c2680304a099d7306f0be37ed62_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ie5ac7148ca1b4e0cac828a4f764cc338_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="id2d0ce091668413589b1cf8781e2c76f_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="id70f31d4f5454cf2a35efe177f68fc3a_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ibf315c942d3a4e75bf4c724b522cbd2a_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i815d3de20f4a4db7baa12ac1511dc801_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib0879ceff7714c68a441c12f87a02bb6_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i6afeedfad1cd4882a7d671b04f209a35_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="if444048235584a2399361851f892f5df_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i0efcc1efa4d94a789080eb3693e147ff_D20211001-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4265039234524ff8ba29f3a4b5d9b5b7_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i6fd8c5827aa44407ac99325c6ecd1dcd_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i09060caa1e0a470da42482940ed7fad9_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i45da57132f0b4b1baefd68fba20589ad_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i1c305a826fd9438ab670f7c9b7fa8ab4_D20221001-20221031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:VillarisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-10-31</endDate>
        </period>
    </context>
    <context id="if0d0cff0ce394041bc79b1987d42f3cd_D20221001-20221031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:VillarisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:DevelopmentAndRegulatoryMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-10-31</endDate>
        </period>
    </context>
    <context id="i2aa7c5f2196a496abe03ba33b71612a9_D20221001-20221031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:VillarisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:CommercializationMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-10-31</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="segment">
        <measure>incy:segment</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="item">
        <measure>incy:item</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <dei:CurrentFiscalYearEndDate
      contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80L2ZyYWc6YjNhNmM2NWViMzQ1NDVlYmFjOTFjZmZkNjEyZWU4YjkvdGFibGU6YmRiYmIwZTJhMTZmNDkxYThjZmFiNTIyZTRmZDI2MzYvdGFibGVyYW5nZTpiZGJiYjBlMmExNmY0OTFhOGNmYWI1MjJlNGZkMjYzNl8yLTEtMS0xLTgx_a1764b9d-0bea-4645-85f6-8e1017cbae2e">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80L2ZyYWc6YjNhNmM2NWViMzQ1NDVlYmFjOTFjZmZkNjEyZWU4YjkvdGFibGU6YmRiYmIwZTJhMTZmNDkxYThjZmFiNTIyZTRmZDI2MzYvdGFibGVyYW5nZTpiZGJiYjBlMmExNmY0OTFhOGNmYWI1MjJlNGZkMjYzNl8zLTEtMS0xLTgx_af173c83-1e16-4173-b957-f73d90cd6c54">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80L2ZyYWc6YjNhNmM2NWViMzQ1NDVlYmFjOTFjZmZkNjEyZWU4YjkvdGFibGU6YmRiYmIwZTJhMTZmNDkxYThjZmFiNTIyZTRmZDI2MzYvdGFibGVyYW5nZTpiZGJiYjBlMmExNmY0OTFhOGNmYWI1MjJlNGZkMjYzNl80LTEtMS0xLTgx_1a04a37c-c185-4d40-9216-feaba478b025">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80L2ZyYWc6YjNhNmM2NWViMzQ1NDVlYmFjOTFjZmZkNjEyZWU4YjkvdGFibGU6YmRiYmIwZTJhMTZmNDkxYThjZmFiNTIyZTRmZDI2MzYvdGFibGVyYW5nZTpiZGJiYjBlMmExNmY0OTFhOGNmYWI1MjJlNGZkMjYzNl81LTEtMS0xLTgx_11e370eb-5419-459f-95e8-33a6d24987a7">0000879169</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80L2ZyYWc6YjNhNmM2NWViMzQ1NDVlYmFjOTFjZmZkNjEyZWU4YjkvdGFibGU6YmRiYmIwZTJhMTZmNDkxYThjZmFiNTIyZTRmZDI2MzYvdGFibGVyYW5nZTpiZGJiYjBlMmExNmY0OTFhOGNmYWI1MjJlNGZkMjYzNl82LTEtMS0xLTgx_02424abc-5d61-47b4-9077-86d1af0864b9">false</dei:AmendmentFlag>
    <dei:EntityFilerCategory
      contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80L2ZyYWc6YjNhNmM2NWViMzQ1NDVlYmFjOTFjZmZkNjEyZWU4YjkvdGFibGU6YmRiYmIwZTJhMTZmNDkxYThjZmFiNTIyZTRmZDI2MzYvdGFibGVyYW5nZTpiZGJiYjBlMmExNmY0OTFhOGNmYWI1MjJlNGZkMjYzNl83LTEtMS0xLTgx_9f5877ca-3d81-432d-9ff4-aec4a1e085c5">Large Accelerated Filer</dei:EntityFilerCategory>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="i238b3f464fe541268bf3b5f8a01e1935_D20220601-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81NS9mcmFnOjc3NmEwNGVlMTUyYTQxMmNhNTZjZjlmMmUyNzMzNDQwL3RhYmxlOjlhYzA3MmFlZjAyZDRjNDM4Y2U4ZTMxZWFlMjBmMDc3L3RhYmxlcmFuZ2U6OWFjMDcyYWVmMDJkNGM0MzhjZThlMzFlYWUyMGYwNzdfMS0xLTEtMS04MQ_c9bcf3f0-f514-40a1-ab69-e226fd638de5"
      unitRef="number">0.05</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="ia8061bfa0edf44a5ad71ed8064f8ead3_D20220601-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81NS9mcmFnOjc3NmEwNGVlMTUyYTQxMmNhNTZjZjlmMmUyNzMzNDQwL3RhYmxlOjlhYzA3MmFlZjAyZDRjNDM4Y2U4ZTMxZWFlMjBmMDc3L3RhYmxlcmFuZ2U6OWFjMDcyYWVmMDJkNGM0MzhjZThlMzFlYWUyMGYwNzdfMi0xLTEtMS0xMjA0NA_a57515f4-be2f-4f4d-ad60-204304668774"
      unitRef="number">0.01</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="id2d0ce091668413589b1cf8781e2c76f_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RleHRyZWdpb246ZmFlNDc5YmVlYzk3NGU3Njk4MDJlOTE5MjQ4MDEwYzRfMjcyMw_f68315b0-93a7-445d-8854-3803f7e59595">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCostCreditExcludingServiceCostStatementOfIncomeOrComprehensiveIncomeExtensibleList
      contextRef="id673d80f31e74643a241d2f62db94ca9_D20220701-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV83My9mcmFnOjlkZDZlNTZmNWEzYzQwY2VhZDY2OWZjZDZjZmEzNDhiL3RleHRyZWdpb246OWRkNmU1NmY1YTNjNDBjZWFkNjY5ZmNkNmNmYTM0OGJfNjA0NzMxMzk1NDEzMQ_cd32c16f-4695-4a46-9bef-320c5c331b0a">http://fasb.org/us-gaap/2022#OtherNonoperatingIncomeExpense</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCostCreditExcludingServiceCostStatementOfIncomeOrComprehensiveIncomeExtensibleList>
    <dei:DocumentType
      contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xL2ZyYWc6OWIxMjlmNjc1ZjBjNGM1MThlNDlmZmRhZDg2NmVkYWMvdGV4dHJlZ2lvbjo5YjEyOWY2NzVmMGM0YzUxOGU0OWZmZGFkODY2ZWRhY18xOTYz_62487f5a-5231-4508-9339-3c1c307f2150">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xL2ZyYWc6OWIxMjlmNjc1ZjBjNGM1MThlNDlmZmRhZDg2NmVkYWMvdGFibGU6OTJkMDQ5MGEyOWUwNDZmMGI2MzAyZDhiNTQxNjg1MWUvdGFibGVyYW5nZTo5MmQwNDkwYTI5ZTA0NmYwYjYzMDJkOGI1NDE2ODUxZV8wLTAtMS0xLTgx_b2787965-606a-4c89-a866-1e69e80397fc">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xL2ZyYWc6OWIxMjlmNjc1ZjBjNGM1MThlNDlmZmRhZDg2NmVkYWMvdGV4dHJlZ2lvbjo5YjEyOWY2NzVmMGM0YzUxOGU0OWZmZGFkODY2ZWRhY18xMzU_d7d0000e-01ad-4780-998d-7fbbf003aa1e">2022-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xL2ZyYWc6OWIxMjlmNjc1ZjBjNGM1MThlNDlmZmRhZDg2NmVkYWMvdGFibGU6NGRlYjlkOWFlYjQyNDlhNjg0MmUzZGMzMjUwOWUzNjIvdGFibGVyYW5nZTo0ZGViOWQ5YWViNDI0OWE2ODQyZTNkYzMyNTA5ZTM2Ml8wLTAtMS0xLTgx_752289dc-98d7-46cb-b8da-922ec0800e9a">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xL2ZyYWc6OWIxMjlmNjc1ZjBjNGM1MThlNDlmZmRhZDg2NmVkYWMvdGV4dHJlZ2lvbjo5YjEyOWY2NzVmMGM0YzUxOGU0OWZmZGFkODY2ZWRhY18xOTY4_18913267-c7cf-4c20-8750-24720466da38">001-12400</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xL2ZyYWc6OWIxMjlmNjc1ZjBjNGM1MThlNDlmZmRhZDg2NmVkYWMvdGV4dHJlZ2lvbjo5YjEyOWY2NzVmMGM0YzUxOGU0OWZmZGFkODY2ZWRhY18zODQ4MjkwNjk5MjI5_881ffbfa-903d-4d5e-a312-ad55d4af3be3">INCYTE CORPORATION</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xL2ZyYWc6OWIxMjlmNjc1ZjBjNGM1MThlNDlmZmRhZDg2NmVkYWMvdGFibGU6ZTVkZjVkNzZmOWVjNDgzOTlkYTliZjllYTk4ODlmOWMvdGFibGVyYW5nZTplNWRmNWQ3NmY5ZWM0ODM5OWRhOWJmOWVhOTg4OWY5Y18wLTAtMS0xLTgx_0cbcbe81-7e1c-4f2f-b7d0-abdda476c3b1">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xL2ZyYWc6OWIxMjlmNjc1ZjBjNGM1MThlNDlmZmRhZDg2NmVkYWMvdGFibGU6ZTVkZjVkNzZmOWVjNDgzOTlkYTliZjllYTk4ODlmOWMvdGFibGVyYW5nZTplNWRmNWQ3NmY5ZWM0ODM5OWRhOWJmOWVhOTg4OWY5Y18wLTEtMS0xLTgx_f621b9d5-cb55-4eed-8a3a-4ef45396cc47">94-3136539</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xL2ZyYWc6OWIxMjlmNjc1ZjBjNGM1MThlNDlmZmRhZDg2NmVkYWMvdGFibGU6ZTVkZjVkNzZmOWVjNDgzOTlkYTliZjllYTk4ODlmOWMvdGFibGVyYW5nZTplNWRmNWQ3NmY5ZWM0ODM5OWRhOWJmOWVhOTg4OWY5Y18zLTAtMS0xLTgxL3RleHRyZWdpb246ZDM3MjAyNGI0MjVmNDE4NTkyYTRiZTJkZjU5MzA1MWZfNA_ed71983a-fef4-4a4b-8a5a-6c3bc2588dc1">1801 Augustine Cut-Off</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xL2ZyYWc6OWIxMjlmNjc1ZjBjNGM1MThlNDlmZmRhZDg2NmVkYWMvdGFibGU6ZTVkZjVkNzZmOWVjNDgzOTlkYTliZjllYTk4ODlmOWMvdGFibGVyYW5nZTplNWRmNWQ3NmY5ZWM0ODM5OWRhOWJmOWVhOTg4OWY5Y18zLTAtMS0xLTgxL3RleHRyZWdpb246ZDM3MjAyNGI0MjVmNDE4NTkyYTRiZTJkZjU5MzA1MWZfNw_976cedd0-4143-4c06-b92c-b4dea3c0199e">Wilmington</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xL2ZyYWc6OWIxMjlmNjc1ZjBjNGM1MThlNDlmZmRhZDg2NmVkYWMvdGFibGU6ZTVkZjVkNzZmOWVjNDgzOTlkYTliZjllYTk4ODlmOWMvdGFibGVyYW5nZTplNWRmNWQ3NmY5ZWM0ODM5OWRhOWJmOWVhOTg4OWY5Y18zLTAtMS0xLTgxL3RleHRyZWdpb246ZDM3MjAyNGI0MjVmNDE4NTkyYTRiZTJkZjU5MzA1MWZfMTA_52504e5c-a02e-4a11-92e6-f87ebab1921e">DE</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xL2ZyYWc6OWIxMjlmNjc1ZjBjNGM1MThlNDlmZmRhZDg2NmVkYWMvdGFibGU6ZTVkZjVkNzZmOWVjNDgzOTlkYTliZjllYTk4ODlmOWMvdGFibGVyYW5nZTplNWRmNWQ3NmY5ZWM0ODM5OWRhOWJmOWVhOTg4OWY5Y18zLTEtMS0xLTgx_5248b4c7-b1de-43ca-8f49-e4f9bb7b99f5">19803</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xL2ZyYWc6OWIxMjlmNjc1ZjBjNGM1MThlNDlmZmRhZDg2NmVkYWMvdGV4dHJlZ2lvbjo5YjEyOWY2NzVmMGM0YzUxOGU0OWZmZGFkODY2ZWRhY18xOTY5_035905af-c2d1-4042-bea6-cd6faba50a92">302</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xL2ZyYWc6OWIxMjlmNjc1ZjBjNGM1MThlNDlmZmRhZDg2NmVkYWMvdGV4dHJlZ2lvbjo5YjEyOWY2NzVmMGM0YzUxOGU0OWZmZGFkODY2ZWRhY18xOTY0_bb6754e9-f7e8-47d7-9cda-5985c77fa3e3">498-6700</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xL2ZyYWc6OWIxMjlmNjc1ZjBjNGM1MThlNDlmZmRhZDg2NmVkYWMvdGFibGU6NTFiNzNlZjczYzJiNDkyODlkZjFkNmMzYTA1YjU2YTMvdGFibGVyYW5nZTo1MWI3M2VmNzNjMmI0OTI4OWRmMWQ2YzNhMDViNTZhM18xLTAtMS0xLTgx_d052c83c-accd-47ce-84f8-7bf4b07130dd">Common Stock, $.001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xL2ZyYWc6OWIxMjlmNjc1ZjBjNGM1MThlNDlmZmRhZDg2NmVkYWMvdGFibGU6NTFiNzNlZjczYzJiNDkyODlkZjFkNmMzYTA1YjU2YTMvdGFibGVyYW5nZTo1MWI3M2VmNzNjMmI0OTI4OWRmMWQ2YzNhMDViNTZhM18xLTItMS0xLTgx_e95cfda4-937f-47eb-90aa-549b04a6d66c">INCY</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xL2ZyYWc6OWIxMjlmNjc1ZjBjNGM1MThlNDlmZmRhZDg2NmVkYWMvdGFibGU6NTFiNzNlZjczYzJiNDkyODlkZjFkNmMzYTA1YjU2YTMvdGFibGVyYW5nZTo1MWI3M2VmNzNjMmI0OTI4OWRmMWQ2YzNhMDViNTZhM18xLTQtMS0xLTgx_15a4f62d-d527-45dd-b11e-ed59c2c47714">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xL2ZyYWc6OWIxMjlmNjc1ZjBjNGM1MThlNDlmZmRhZDg2NmVkYWMvdGV4dHJlZ2lvbjo5YjEyOWY2NzVmMGM0YzUxOGU0OWZmZGFkODY2ZWRhY18xOTcw_52a415b6-5d1f-431b-8058-78795ca3e759">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xL2ZyYWc6OWIxMjlmNjc1ZjBjNGM1MThlNDlmZmRhZDg2NmVkYWMvdGV4dHJlZ2lvbjo5YjEyOWY2NzVmMGM0YzUxOGU0OWZmZGFkODY2ZWRhY18xOTY1_d295b60c-d749-4c0b-ae06-fefb6152d568">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntitySmallBusiness
      contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xL2ZyYWc6OWIxMjlmNjc1ZjBjNGM1MThlNDlmZmRhZDg2NmVkYWMvdGFibGU6YzQ2Y2Y2OTIzOTExNDc5ZGI3NWUzNGIwZDhlMGNkNTUvdGFibGVyYW5nZTpjNDZjZjY5MjM5MTE0NzlkYjc1ZTM0YjBkOGUwY2Q1NV8yLTEtMS0xLTgx_09d6fa81-c286-4082-bbc0-4090ee2a1c96">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xL2ZyYWc6OWIxMjlmNjc1ZjBjNGM1MThlNDlmZmRhZDg2NmVkYWMvdGFibGU6YzQ2Y2Y2OTIzOTExNDc5ZGI3NWUzNGIwZDhlMGNkNTUvdGFibGVyYW5nZTpjNDZjZjY5MjM5MTE0NzlkYjc1ZTM0YjBkOGUwY2Q1NV80LTEtMS0xLTgx_56f25325-571e-479f-9499-6353e32a920e">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xL2ZyYWc6OWIxMjlmNjc1ZjBjNGM1MThlNDlmZmRhZDg2NmVkYWMvdGV4dHJlZ2lvbjo5YjEyOWY2NzVmMGM0YzUxOGU0OWZmZGFkODY2ZWRhY18xOTY2_1028a76d-0ca9-43ca-8286-cc910831682c">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i2ee7afc3141240148065dcabb8761324_I20221025"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xL2ZyYWc6OWIxMjlmNjc1ZjBjNGM1MThlNDlmZmRhZDg2NmVkYWMvdGV4dHJlZ2lvbjo5YjEyOWY2NzVmMGM0YzUxOGU0OWZmZGFkODY2ZWRhY18yNzQ4Nzc5MDcxNDgy_2de0614a-ea2d-4e31-9db5-9e80ba6efd9f"
      unitRef="shares">222475468</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i3b4376f8fc614de98c9cf647198c504e_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xNi9mcmFnOjU2YmVmNWVkZGUxMDRjZDJiNzQxZGJmMjY2YmMwZmRmL3RhYmxlOjYzNjVkN2Y4YTZlYzQ4MzNiN2U3OTk3OWNlYjI2YWJlL3RhYmxlcmFuZ2U6NjM2NWQ3ZjhhNmVjNDgzM2I3ZTc5OTc5Y2ViMjZhYmVfNC0xLTEtMS04MQ_4b208c68-76e1-4814-9a97-967679c256d8"
      unitRef="usd">2690622000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="iab26fe441f0d4ab984456365a7f7cff0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xNi9mcmFnOjU2YmVmNWVkZGUxMDRjZDJiNzQxZGJmMjY2YmMwZmRmL3RhYmxlOjYzNjVkN2Y4YTZlYzQ4MzNiN2U3OTk3OWNlYjI2YWJlL3RhYmxlcmFuZ2U6NjM2NWQ3ZjhhNmVjNDgzM2I3ZTc5OTc5Y2ViMjZhYmVfNC0zLTEtMS04MQ_b2051533-5f4a-4494-8edf-eee6c6a2b3f2"
      unitRef="usd">2057440000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="i3b4376f8fc614de98c9cf647198c504e_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xNi9mcmFnOjU2YmVmNWVkZGUxMDRjZDJiNzQxZGJmMjY2YmMwZmRmL3RhYmxlOjYzNjVkN2Y4YTZlYzQ4MzNiN2U3OTk3OWNlYjI2YWJlL3RhYmxlcmFuZ2U6NjM2NWQ3ZjhhNmVjNDgzM2I3ZTc5OTc5Y2ViMjZhYmVfNS0wLTEtMS04MS90ZXh0cmVnaW9uOmY5NGRjMTI1YmE1YTQ2MmI5ZTBiNjM3MzgxZDRlMWE3XzYx_81cc8fd3-d933-432b-96dd-92582bab67b4"
      unitRef="usd">292941000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="iab26fe441f0d4ab984456365a7f7cff0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xNi9mcmFnOjU2YmVmNWVkZGUxMDRjZDJiNzQxZGJmMjY2YmMwZmRmL3RhYmxlOjYzNjVkN2Y4YTZlYzQ4MzNiN2U3OTk3OWNlYjI2YWJlL3RhYmxlcmFuZ2U6NjM2NWQ3ZjhhNmVjNDgzM2I3ZTc5OTc5Y2ViMjZhYmVfNS0wLTEtMS04MS90ZXh0cmVnaW9uOmY5NGRjMTI1YmE1YTQ2MmI5ZTBiNjM3MzgxZDRlMWE3XzY4_1e2982cb-922c-4e5e-8b2b-498a3ee8a165"
      unitRef="usd">291871000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="i3b4376f8fc614de98c9cf647198c504e_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xNi9mcmFnOjU2YmVmNWVkZGUxMDRjZDJiNzQxZGJmMjY2YmMwZmRmL3RhYmxlOjYzNjVkN2Y4YTZlYzQ4MzNiN2U3OTk3OWNlYjI2YWJlL3RhYmxlcmFuZ2U6NjM2NWQ3ZjhhNmVjNDgzM2I3ZTc5OTc5Y2ViMjZhYmVfNS0wLTEtMS04MS90ZXh0cmVnaW9uOmY5NGRjMTI1YmE1YTQ2MmI5ZTBiNjM3MzgxZDRlMWE3XzEzMA_7a02fcea-8a8b-4a52-8ba1-ebe24016361e"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="iab26fe441f0d4ab984456365a7f7cff0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xNi9mcmFnOjU2YmVmNWVkZGUxMDRjZDJiNzQxZGJmMjY2YmMwZmRmL3RhYmxlOjYzNjVkN2Y4YTZlYzQ4MzNiN2U3OTk3OWNlYjI2YWJlL3RhYmxlcmFuZ2U6NjM2NWQ3ZjhhNmVjNDgzM2I3ZTc5OTc5Y2ViMjZhYmVfNS0wLTEtMS04MS90ZXh0cmVnaW9uOmY5NGRjMTI1YmE1YTQ2MmI5ZTBiNjM3MzgxZDRlMWE3XzEzMA_c1dbe7de-546e-4c52-a7e6-3e5d7d2922b1"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i3b4376f8fc614de98c9cf647198c504e_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xNi9mcmFnOjU2YmVmNWVkZGUxMDRjZDJiNzQxZGJmMjY2YmMwZmRmL3RhYmxlOjYzNjVkN2Y4YTZlYzQ4MzNiN2U3OTk3OWNlYjI2YWJlL3RhYmxlcmFuZ2U6NjM2NWQ3ZjhhNmVjNDgzM2I3ZTc5OTc5Y2ViMjZhYmVfNS0xLTEtMS04MQ_39d42964-9fbb-4452-9fc7-1cd346a9eef3"
      unitRef="usd">286500000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="iab26fe441f0d4ab984456365a7f7cff0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xNi9mcmFnOjU2YmVmNWVkZGUxMDRjZDJiNzQxZGJmMjY2YmMwZmRmL3RhYmxlOjYzNjVkN2Y4YTZlYzQ4MzNiN2U3OTk3OWNlYjI2YWJlL3RhYmxlcmFuZ2U6NjM2NWQ3ZjhhNmVjNDgzM2I3ZTc5OTc5Y2ViMjZhYmVfNS0zLTEtMS04MQ_8447b428-b46a-4928-ac17-4760c2443388"
      unitRef="usd">290752000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AccountsReceivableNet
      contextRef="i3b4376f8fc614de98c9cf647198c504e_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xNi9mcmFnOjU2YmVmNWVkZGUxMDRjZDJiNzQxZGJmMjY2YmMwZmRmL3RhYmxlOjYzNjVkN2Y4YTZlYzQ4MzNiN2U3OTk3OWNlYjI2YWJlL3RhYmxlcmFuZ2U6NjM2NWQ3ZjhhNmVjNDgzM2I3ZTc5OTc5Y2ViMjZhYmVfNi0xLTEtMS04MQ_63760925-3c05-4de4-93c0-c19f4c4ff21c"
      unitRef="usd">618188000</us-gaap:AccountsReceivableNet>
    <us-gaap:AccountsReceivableNet
      contextRef="iab26fe441f0d4ab984456365a7f7cff0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xNi9mcmFnOjU2YmVmNWVkZGUxMDRjZDJiNzQxZGJmMjY2YmMwZmRmL3RhYmxlOjYzNjVkN2Y4YTZlYzQ4MzNiN2U3OTk3OWNlYjI2YWJlL3RhYmxlcmFuZ2U6NjM2NWQ3ZjhhNmVjNDgzM2I3ZTc5OTc5Y2ViMjZhYmVfNi0zLTEtMS04MQ_93372401-3097-4fb4-aba5-1515d244972a"
      unitRef="usd">616300000</us-gaap:AccountsReceivableNet>
    <us-gaap:InventoryNet
      contextRef="i3b4376f8fc614de98c9cf647198c504e_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xNi9mcmFnOjU2YmVmNWVkZGUxMDRjZDJiNzQxZGJmMjY2YmMwZmRmL3RhYmxlOjYzNjVkN2Y4YTZlYzQ4MzNiN2U3OTk3OWNlYjI2YWJlL3RhYmxlcmFuZ2U6NjM2NWQ3ZjhhNmVjNDgzM2I3ZTc5OTc5Y2ViMjZhYmVfNy0xLTEtMS04MQ_d9ef4e56-e087-4a74-8959-36aac25be7ab"
      unitRef="usd">45869000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="iab26fe441f0d4ab984456365a7f7cff0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xNi9mcmFnOjU2YmVmNWVkZGUxMDRjZDJiNzQxZGJmMjY2YmMwZmRmL3RhYmxlOjYzNjVkN2Y4YTZlYzQ4MzNiN2U3OTk3OWNlYjI2YWJlL3RhYmxlcmFuZ2U6NjM2NWQ3ZjhhNmVjNDgzM2I3ZTc5OTc5Y2ViMjZhYmVfNy0zLTEtMS04MQ_aff617bc-e83b-4e79-ba13-d5ae914094ce"
      unitRef="usd">27904000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i3b4376f8fc614de98c9cf647198c504e_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xNi9mcmFnOjU2YmVmNWVkZGUxMDRjZDJiNzQxZGJmMjY2YmMwZmRmL3RhYmxlOjYzNjVkN2Y4YTZlYzQ4MzNiN2U3OTk3OWNlYjI2YWJlL3RhYmxlcmFuZ2U6NjM2NWQ3ZjhhNmVjNDgzM2I3ZTc5OTc5Y2ViMjZhYmVfOC0xLTEtMS04MQ_91d25526-14b7-4e41-b099-a1acaf36e23e"
      unitRef="usd">179932000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="iab26fe441f0d4ab984456365a7f7cff0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xNi9mcmFnOjU2YmVmNWVkZGUxMDRjZDJiNzQxZGJmMjY2YmMwZmRmL3RhYmxlOjYzNjVkN2Y4YTZlYzQ4MzNiN2U3OTk3OWNlYjI2YWJlL3RhYmxlcmFuZ2U6NjM2NWQ3ZjhhNmVjNDgzM2I3ZTc5OTc5Y2ViMjZhYmVfOC0zLTEtMS04MQ_aed9435f-2377-4b84-9119-be8127f671c6"
      unitRef="usd">126278000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i3b4376f8fc614de98c9cf647198c504e_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xNi9mcmFnOjU2YmVmNWVkZGUxMDRjZDJiNzQxZGJmMjY2YmMwZmRmL3RhYmxlOjYzNjVkN2Y4YTZlYzQ4MzNiN2U3OTk3OWNlYjI2YWJlL3RhYmxlcmFuZ2U6NjM2NWQ3ZjhhNmVjNDgzM2I3ZTc5OTc5Y2ViMjZhYmVfOS0xLTEtMS04MQ_f7e86627-cd0d-4920-bd4e-0168bcda78fd"
      unitRef="usd">3821111000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="iab26fe441f0d4ab984456365a7f7cff0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xNi9mcmFnOjU2YmVmNWVkZGUxMDRjZDJiNzQxZGJmMjY2YmMwZmRmL3RhYmxlOjYzNjVkN2Y4YTZlYzQ4MzNiN2U3OTk3OWNlYjI2YWJlL3RhYmxlcmFuZ2U6NjM2NWQ3ZjhhNmVjNDgzM2I3ZTc5OTc5Y2ViMjZhYmVfOS0zLTEtMS04MQ_81b9eb28-02b2-4c34-bee1-9bb788316700"
      unitRef="usd">3118674000</us-gaap:AssetsCurrent>
    <us-gaap:RestrictedCashAndInvestmentsNoncurrent
      contextRef="i3b4376f8fc614de98c9cf647198c504e_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xNi9mcmFnOjU2YmVmNWVkZGUxMDRjZDJiNzQxZGJmMjY2YmMwZmRmL3RhYmxlOjYzNjVkN2Y4YTZlYzQ4MzNiN2U3OTk3OWNlYjI2YWJlL3RhYmxlcmFuZ2U6NjM2NWQ3ZjhhNmVjNDgzM2I3ZTc5OTc5Y2ViMjZhYmVfMTEtMS0xLTEtODE_69dae89f-7602-43d1-b0f1-c52d6dae8a7b"
      unitRef="usd">1601000</us-gaap:RestrictedCashAndInvestmentsNoncurrent>
    <us-gaap:RestrictedCashAndInvestmentsNoncurrent
      contextRef="iab26fe441f0d4ab984456365a7f7cff0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xNi9mcmFnOjU2YmVmNWVkZGUxMDRjZDJiNzQxZGJmMjY2YmMwZmRmL3RhYmxlOjYzNjVkN2Y4YTZlYzQ4MzNiN2U3OTk3OWNlYjI2YWJlL3RhYmxlcmFuZ2U6NjM2NWQ3ZjhhNmVjNDgzM2I3ZTc5OTc5Y2ViMjZhYmVfMTEtMy0xLTEtODE_1eb8b233-ac57-49b7-b80b-6dc5ff7e8b64"
      unitRef="usd">1720000</us-gaap:RestrictedCashAndInvestmentsNoncurrent>
    <us-gaap:LongTermInvestments
      contextRef="i3b4376f8fc614de98c9cf647198c504e_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xNi9mcmFnOjU2YmVmNWVkZGUxMDRjZDJiNzQxZGJmMjY2YmMwZmRmL3RhYmxlOjYzNjVkN2Y4YTZlYzQ4MzNiN2U3OTk3OWNlYjI2YWJlL3RhYmxlcmFuZ2U6NjM2NWQ3ZjhhNmVjNDgzM2I3ZTc5OTc5Y2ViMjZhYmVfMTItMS0xLTEtODE_5c3e4289-22c2-459c-9b2e-e27d5105a9cf"
      unitRef="usd">149124000</us-gaap:LongTermInvestments>
    <us-gaap:LongTermInvestments
      contextRef="iab26fe441f0d4ab984456365a7f7cff0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xNi9mcmFnOjU2YmVmNWVkZGUxMDRjZDJiNzQxZGJmMjY2YmMwZmRmL3RhYmxlOjYzNjVkN2Y4YTZlYzQ4MzNiN2U3OTk3OWNlYjI2YWJlL3RhYmxlcmFuZ2U6NjM2NWQ3ZjhhNmVjNDgzM2I3ZTc5OTc5Y2ViMjZhYmVfMTItMy0xLTEtODE_b323390b-adc3-44f6-9ca5-da0d1e781f1f"
      unitRef="usd">221266000</us-gaap:LongTermInvestments>
    <us-gaap:InventoryNoncurrent
      contextRef="i3b4376f8fc614de98c9cf647198c504e_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xNi9mcmFnOjU2YmVmNWVkZGUxMDRjZDJiNzQxZGJmMjY2YmMwZmRmL3RhYmxlOjYzNjVkN2Y4YTZlYzQ4MzNiN2U3OTk3OWNlYjI2YWJlL3RhYmxlcmFuZ2U6NjM2NWQ3ZjhhNmVjNDgzM2I3ZTc5OTc5Y2ViMjZhYmVfMTMtMS0xLTEtODE_897afb13-d5e8-4832-a80a-ba4997cbc1bc"
      unitRef="usd">55264000</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNoncurrent
      contextRef="iab26fe441f0d4ab984456365a7f7cff0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xNi9mcmFnOjU2YmVmNWVkZGUxMDRjZDJiNzQxZGJmMjY2YmMwZmRmL3RhYmxlOjYzNjVkN2Y4YTZlYzQ4MzNiN2U3OTk3OWNlYjI2YWJlL3RhYmxlcmFuZ2U6NjM2NWQ3ZjhhNmVjNDgzM2I3ZTc5OTc5Y2ViMjZhYmVfMTMtMy0xLTEtODE_9a27dc54-09b2-4aeb-bc2e-2812da731fba"
      unitRef="usd">29034000</us-gaap:InventoryNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i3b4376f8fc614de98c9cf647198c504e_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xNi9mcmFnOjU2YmVmNWVkZGUxMDRjZDJiNzQxZGJmMjY2YmMwZmRmL3RhYmxlOjYzNjVkN2Y4YTZlYzQ4MzNiN2U3OTk3OWNlYjI2YWJlL3RhYmxlcmFuZ2U6NjM2NWQ3ZjhhNmVjNDgzM2I3ZTc5OTc5Y2ViMjZhYmVfMTQtMS0xLTEtODE_9d48347a-7223-4785-8167-ee5c64a99716"
      unitRef="usd">715733000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="iab26fe441f0d4ab984456365a7f7cff0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xNi9mcmFnOjU2YmVmNWVkZGUxMDRjZDJiNzQxZGJmMjY2YmMwZmRmL3RhYmxlOjYzNjVkN2Y4YTZlYzQ4MzNiN2U3OTk3OWNlYjI2YWJlL3RhYmxlcmFuZ2U6NjM2NWQ3ZjhhNmVjNDgzM2I3ZTc5OTc5Y2ViMjZhYmVfMTQtMy0xLTEtODE_71b0801d-b954-45fc-84eb-ff277b2205fd"
      unitRef="usd">723920000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="i3b4376f8fc614de98c9cf647198c504e_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xNi9mcmFnOjU2YmVmNWVkZGUxMDRjZDJiNzQxZGJmMjY2YmMwZmRmL3RhYmxlOjYzNjVkN2Y4YTZlYzQ4MzNiN2U3OTk3OWNlYjI2YWJlL3RhYmxlcmFuZ2U6NjM2NWQ3ZjhhNmVjNDgzM2I3ZTc5OTc5Y2ViMjZhYmVfMTUtMS0xLTEtODE_f3d012ab-e32d-445b-8a45-e7986b47b222"
      unitRef="usd">26679000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="iab26fe441f0d4ab984456365a7f7cff0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xNi9mcmFnOjU2YmVmNWVkZGUxMDRjZDJiNzQxZGJmMjY2YmMwZmRmL3RhYmxlOjYzNjVkN2Y4YTZlYzQ4MzNiN2U3OTk3OWNlYjI2YWJlL3RhYmxlcmFuZ2U6NjM2NWQ3ZjhhNmVjNDgzM2I3ZTc5OTc5Y2ViMjZhYmVfMTUtMy0xLTEtODE_9cbf1282-7290-4660-a18c-74da206f8b29"
      unitRef="usd">27548000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:OtherIntangibleAssetsNet
      contextRef="i3b4376f8fc614de98c9cf647198c504e_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xNi9mcmFnOjU2YmVmNWVkZGUxMDRjZDJiNzQxZGJmMjY2YmMwZmRmL3RhYmxlOjYzNjVkN2Y4YTZlYzQ4MzNiN2U3OTk3OWNlYjI2YWJlL3RhYmxlcmFuZ2U6NjM2NWQ3ZjhhNmVjNDgzM2I3ZTc5OTc5Y2ViMjZhYmVfMTYtMS0xLTEtODE_9e3385ba-7bff-4db8-b8f5-67f1fd5caf73"
      unitRef="usd">134603000</us-gaap:OtherIntangibleAssetsNet>
    <us-gaap:OtherIntangibleAssetsNet
      contextRef="iab26fe441f0d4ab984456365a7f7cff0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xNi9mcmFnOjU2YmVmNWVkZGUxMDRjZDJiNzQxZGJmMjY2YmMwZmRmL3RhYmxlOjYzNjVkN2Y4YTZlYzQ4MzNiN2U3OTk3OWNlYjI2YWJlL3RhYmxlcmFuZ2U6NjM2NWQ3ZjhhNmVjNDgzM2I3ZTc5OTc5Y2ViMjZhYmVfMTYtMy0xLTEtODE_3c8bc890-fde8-4564-ac76-59c3ee25fb1a"
      unitRef="usd">150755000</us-gaap:OtherIntangibleAssetsNet>
    <us-gaap:Goodwill
      contextRef="i3b4376f8fc614de98c9cf647198c504e_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xNi9mcmFnOjU2YmVmNWVkZGUxMDRjZDJiNzQxZGJmMjY2YmMwZmRmL3RhYmxlOjYzNjVkN2Y4YTZlYzQ4MzNiN2U3OTk3OWNlYjI2YWJlL3RhYmxlcmFuZ2U6NjM2NWQ3ZjhhNmVjNDgzM2I3ZTc5OTc5Y2ViMjZhYmVfMTctMS0xLTEtODE_899b57e8-7f5e-43f2-9531-2f08affa5e52"
      unitRef="usd">155593000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="iab26fe441f0d4ab984456365a7f7cff0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xNi9mcmFnOjU2YmVmNWVkZGUxMDRjZDJiNzQxZGJmMjY2YmMwZmRmL3RhYmxlOjYzNjVkN2Y4YTZlYzQ4MzNiN2U3OTk3OWNlYjI2YWJlL3RhYmxlcmFuZ2U6NjM2NWQ3ZjhhNmVjNDgzM2I3ZTc5OTc5Y2ViMjZhYmVfMTctMy0xLTEtODE_ab21b2d1-a513-460b-aa0e-011f8c5fb90f"
      unitRef="usd">155593000</us-gaap:Goodwill>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="i3b4376f8fc614de98c9cf647198c504e_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xNi9mcmFnOjU2YmVmNWVkZGUxMDRjZDJiNzQxZGJmMjY2YmMwZmRmL3RhYmxlOjYzNjVkN2Y4YTZlYzQ4MzNiN2U3OTk3OWNlYjI2YWJlL3RhYmxlcmFuZ2U6NjM2NWQ3ZjhhNmVjNDgzM2I3ZTc5OTc5Y2ViMjZhYmVfMTgtMS0xLTEtODE_07b3e962-1300-4cb1-8cb7-aa1e724dd524"
      unitRef="usd">426840000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="iab26fe441f0d4ab984456365a7f7cff0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xNi9mcmFnOjU2YmVmNWVkZGUxMDRjZDJiNzQxZGJmMjY2YmMwZmRmL3RhYmxlOjYzNjVkN2Y4YTZlYzQ4MzNiN2U3OTk3OWNlYjI2YWJlL3RhYmxlcmFuZ2U6NjM2NWQ3ZjhhNmVjNDgzM2I3ZTc5OTc5Y2ViMjZhYmVfMTgtMy0xLTEtODE_4fe141c1-36fa-4b5a-ba12-9101a45137d3"
      unitRef="usd">467538000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i3b4376f8fc614de98c9cf647198c504e_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xNi9mcmFnOjU2YmVmNWVkZGUxMDRjZDJiNzQxZGJmMjY2YmMwZmRmL3RhYmxlOjYzNjVkN2Y4YTZlYzQ4MzNiN2U3OTk3OWNlYjI2YWJlL3RhYmxlcmFuZ2U6NjM2NWQ3ZjhhNmVjNDgzM2I3ZTc5OTc5Y2ViMjZhYmVfMTktMS0xLTEtODE_001c5dd9-42d5-4650-baa7-2fe0e9aa80f2"
      unitRef="usd">23666000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="iab26fe441f0d4ab984456365a7f7cff0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xNi9mcmFnOjU2YmVmNWVkZGUxMDRjZDJiNzQxZGJmMjY2YmMwZmRmL3RhYmxlOjYzNjVkN2Y4YTZlYzQ4MzNiN2U3OTk3OWNlYjI2YWJlL3RhYmxlcmFuZ2U6NjM2NWQ3ZjhhNmVjNDgzM2I3ZTc5OTc5Y2ViMjZhYmVfMTktMy0xLTEtODE_fdb90fb3-94e4-4c9a-bb58-460ccb3832eb"
      unitRef="usd">37304000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i3b4376f8fc614de98c9cf647198c504e_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xNi9mcmFnOjU2YmVmNWVkZGUxMDRjZDJiNzQxZGJmMjY2YmMwZmRmL3RhYmxlOjYzNjVkN2Y4YTZlYzQ4MzNiN2U3OTk3OWNlYjI2YWJlL3RhYmxlcmFuZ2U6NjM2NWQ3ZjhhNmVjNDgzM2I3ZTc5OTc5Y2ViMjZhYmVfMjAtMS0xLTEtODE_a8c0027d-86df-4f50-bb68-ed96157685b9"
      unitRef="usd">5510214000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="iab26fe441f0d4ab984456365a7f7cff0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xNi9mcmFnOjU2YmVmNWVkZGUxMDRjZDJiNzQxZGJmMjY2YmMwZmRmL3RhYmxlOjYzNjVkN2Y4YTZlYzQ4MzNiN2U3OTk3OWNlYjI2YWJlL3RhYmxlcmFuZ2U6NjM2NWQ3ZjhhNmVjNDgzM2I3ZTc5OTc5Y2ViMjZhYmVfMjAtMy0xLTEtODE_f9778eb7-1f32-44c8-85fd-d0130e80875c"
      unitRef="usd">4933352000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i3b4376f8fc614de98c9cf647198c504e_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xNi9mcmFnOjU2YmVmNWVkZGUxMDRjZDJiNzQxZGJmMjY2YmMwZmRmL3RhYmxlOjYzNjVkN2Y4YTZlYzQ4MzNiN2U3OTk3OWNlYjI2YWJlL3RhYmxlcmFuZ2U6NjM2NWQ3ZjhhNmVjNDgzM2I3ZTc5OTc5Y2ViMjZhYmVfMjQtMS0xLTEtODE_a04615b3-92f2-43fc-811d-4256e5a24a02"
      unitRef="usd">163175000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="iab26fe441f0d4ab984456365a7f7cff0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xNi9mcmFnOjU2YmVmNWVkZGUxMDRjZDJiNzQxZGJmMjY2YmMwZmRmL3RhYmxlOjYzNjVkN2Y4YTZlYzQ4MzNiN2U3OTk3OWNlYjI2YWJlL3RhYmxlcmFuZ2U6NjM2NWQ3ZjhhNmVjNDgzM2I3ZTc5OTc5Y2ViMjZhYmVfMjQtMy0xLTEtODE_40835c2b-2701-4902-ab73-88396e64c3c6"
      unitRef="usd">172110000</us-gaap:AccountsPayableCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i3b4376f8fc614de98c9cf647198c504e_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xNi9mcmFnOjU2YmVmNWVkZGUxMDRjZDJiNzQxZGJmMjY2YmMwZmRmL3RhYmxlOjYzNjVkN2Y4YTZlYzQ4MzNiN2U3OTk3OWNlYjI2YWJlL3RhYmxlcmFuZ2U6NjM2NWQ3ZjhhNmVjNDgzM2I3ZTc5OTc5Y2ViMjZhYmVfMjUtMS0xLTEtODE_36e5b2bd-82f1-417c-869f-d5ce8960c323"
      unitRef="usd">106309000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="iab26fe441f0d4ab984456365a7f7cff0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xNi9mcmFnOjU2YmVmNWVkZGUxMDRjZDJiNzQxZGJmMjY2YmMwZmRmL3RhYmxlOjYzNjVkN2Y4YTZlYzQ4MzNiN2U3OTk3OWNlYjI2YWJlL3RhYmxlcmFuZ2U6NjM2NWQ3ZjhhNmVjNDgzM2I3ZTc5OTc5Y2ViMjZhYmVfMjUtMy0xLTEtODE_8c276706-81be-4435-b85a-22f276bffe25"
      unitRef="usd">108962000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i3b4376f8fc614de98c9cf647198c504e_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xNi9mcmFnOjU2YmVmNWVkZGUxMDRjZDJiNzQxZGJmMjY2YmMwZmRmL3RhYmxlOjYzNjVkN2Y4YTZlYzQ4MzNiN2U3OTk3OWNlYjI2YWJlL3RhYmxlcmFuZ2U6NjM2NWQ3ZjhhNmVjNDgzM2I3ZTc5OTc5Y2ViMjZhYmVfMjYtMS0xLTEtODE_3c826445-0008-496d-95e6-46de75f46100"
      unitRef="usd">699814000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="iab26fe441f0d4ab984456365a7f7cff0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xNi9mcmFnOjU2YmVmNWVkZGUxMDRjZDJiNzQxZGJmMjY2YmMwZmRmL3RhYmxlOjYzNjVkN2Y4YTZlYzQ4MzNiN2U3OTk3OWNlYjI2YWJlL3RhYmxlcmFuZ2U6NjM2NWQ3ZjhhNmVjNDgzM2I3ZTc5OTc5Y2ViMjZhYmVfMjYtMy0xLTEtODE_4485d81c-8885-4ab6-a73b-2c1cd340972e"
      unitRef="usd">533595000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="i3b4376f8fc614de98c9cf647198c504e_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xNi9mcmFnOjU2YmVmNWVkZGUxMDRjZDJiNzQxZGJmMjY2YmMwZmRmL3RhYmxlOjYzNjVkN2Y4YTZlYzQ4MzNiN2U3OTk3OWNlYjI2YWJlL3RhYmxlcmFuZ2U6NjM2NWQ3ZjhhNmVjNDgzM2I3ZTc5OTc5Y2ViMjZhYmVfMjctMS0xLTEtODE_14eb8213-0b1c-46df-9024-b95e8ba1b293"
      unitRef="usd">3112000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="iab26fe441f0d4ab984456365a7f7cff0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xNi9mcmFnOjU2YmVmNWVkZGUxMDRjZDJiNzQxZGJmMjY2YmMwZmRmL3RhYmxlOjYzNjVkN2Y4YTZlYzQ4MzNiN2U3OTk3OWNlYjI2YWJlL3RhYmxlcmFuZ2U6NjM2NWQ3ZjhhNmVjNDgzM2I3ZTc5OTc5Y2ViMjZhYmVfMjctMy0xLTEtODE_0ddb063b-99fb-4074-bb5e-161346260c11"
      unitRef="usd">2635000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="i3b4376f8fc614de98c9cf647198c504e_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xNi9mcmFnOjU2YmVmNWVkZGUxMDRjZDJiNzQxZGJmMjY2YmMwZmRmL3RhYmxlOjYzNjVkN2Y4YTZlYzQ4MzNiN2U3OTk3OWNlYjI2YWJlL3RhYmxlcmFuZ2U6NjM2NWQ3ZjhhNmVjNDgzM2I3ZTc5OTc5Y2ViMjZhYmVfMjgtMS0xLTEtODE_259523bf-94d7-4203-aeeb-4b12950fb539"
      unitRef="usd">34186000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="iab26fe441f0d4ab984456365a7f7cff0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xNi9mcmFnOjU2YmVmNWVkZGUxMDRjZDJiNzQxZGJmMjY2YmMwZmRmL3RhYmxlOjYzNjVkN2Y4YTZlYzQ4MzNiN2U3OTk3OWNlYjI2YWJlL3RhYmxlcmFuZ2U6NjM2NWQ3ZjhhNmVjNDgzM2I3ZTc5OTc5Y2ViMjZhYmVfMjgtMy0xLTEtODE_3f686dc6-921a-48c9-b3b6-b5bb80ea7705"
      unitRef="usd">37006000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i3b4376f8fc614de98c9cf647198c504e_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xNi9mcmFnOjU2YmVmNWVkZGUxMDRjZDJiNzQxZGJmMjY2YmMwZmRmL3RhYmxlOjYzNjVkN2Y4YTZlYzQ4MzNiN2U3OTk3OWNlYjI2YWJlL3RhYmxlcmFuZ2U6NjM2NWQ3ZjhhNmVjNDgzM2I3ZTc5OTc5Y2ViMjZhYmVfMjktMS0xLTEtODE_811c69b4-b379-4806-b467-b3bde0f1d848"
      unitRef="usd">1006596000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="iab26fe441f0d4ab984456365a7f7cff0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xNi9mcmFnOjU2YmVmNWVkZGUxMDRjZDJiNzQxZGJmMjY2YmMwZmRmL3RhYmxlOjYzNjVkN2Y4YTZlYzQ4MzNiN2U3OTk3OWNlYjI2YWJlL3RhYmxlcmFuZ2U6NjM2NWQ3ZjhhNmVjNDgzM2I3ZTc5OTc5Y2ViMjZhYmVfMjktMy0xLTEtODE_7551f906-fdc2-4d6a-ae54-df910ab40792"
      unitRef="usd">854308000</us-gaap:LiabilitiesCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="i3b4376f8fc614de98c9cf647198c504e_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xNi9mcmFnOjU2YmVmNWVkZGUxMDRjZDJiNzQxZGJmMjY2YmMwZmRmL3RhYmxlOjYzNjVkN2Y4YTZlYzQ4MzNiN2U3OTk3OWNlYjI2YWJlL3RhYmxlcmFuZ2U6NjM2NWQ3ZjhhNmVjNDgzM2I3ZTc5OTc5Y2ViMjZhYmVfMzEtMS0xLTEtODE_00293365-c451-43a6-b69c-bbbdd79126a9"
      unitRef="usd">171814000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="iab26fe441f0d4ab984456365a7f7cff0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xNi9mcmFnOjU2YmVmNWVkZGUxMDRjZDJiNzQxZGJmMjY2YmMwZmRmL3RhYmxlOjYzNjVkN2Y4YTZlYzQ4MzNiN2U3OTk3OWNlYjI2YWJlL3RhYmxlcmFuZ2U6NjM2NWQ3ZjhhNmVjNDgzM2I3ZTc5OTc5Y2ViMjZhYmVfMzEtMy0xLTEtODE_78afe528-fbdd-41a9-8671-bea1133b8408"
      unitRef="usd">206994000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="i3b4376f8fc614de98c9cf647198c504e_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xNi9mcmFnOjU2YmVmNWVkZGUxMDRjZDJiNzQxZGJmMjY2YmMwZmRmL3RhYmxlOjYzNjVkN2Y4YTZlYzQ4MzNiN2U3OTk3OWNlYjI2YWJlL3RhYmxlcmFuZ2U6NjM2NWQ3ZjhhNmVjNDgzM2I3ZTc5OTc5Y2ViMjZhYmVfMzItMS0xLTEtODE_e02fb9cc-d267-4ed1-8fdc-8e311e94c97b"
      unitRef="usd">30476000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="iab26fe441f0d4ab984456365a7f7cff0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xNi9mcmFnOjU2YmVmNWVkZGUxMDRjZDJiNzQxZGJmMjY2YmMwZmRmL3RhYmxlOjYzNjVkN2Y4YTZlYzQ4MzNiN2U3OTk3OWNlYjI2YWJlL3RhYmxlcmFuZ2U6NjM2NWQ3ZjhhNmVjNDgzM2I3ZTc5OTc5Y2ViMjZhYmVfMzItMy0xLTEtODE_7fb409bb-4543-4991-80ed-9c1ee575422e"
      unitRef="usd">31632000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i3b4376f8fc614de98c9cf647198c504e_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xNi9mcmFnOjU2YmVmNWVkZGUxMDRjZDJiNzQxZGJmMjY2YmMwZmRmL3RhYmxlOjYzNjVkN2Y4YTZlYzQ4MzNiN2U3OTk3OWNlYjI2YWJlL3RhYmxlcmFuZ2U6NjM2NWQ3ZjhhNmVjNDgzM2I3ZTc5OTc5Y2ViMjZhYmVfMzMtMS0xLTEtODE_82c5e17e-73b6-4912-9cec-976d56bb9c94"
      unitRef="usd">74677000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="iab26fe441f0d4ab984456365a7f7cff0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xNi9mcmFnOjU2YmVmNWVkZGUxMDRjZDJiNzQxZGJmMjY2YmMwZmRmL3RhYmxlOjYzNjVkN2Y4YTZlYzQ4MzNiN2U3OTk3OWNlYjI2YWJlL3RhYmxlcmFuZ2U6NjM2NWQ3ZjhhNmVjNDgzM2I3ZTc5OTc5Y2ViMjZhYmVfMzMtMy0xLTEtODE_fb0a3293-be85-464c-b55d-e576a9479bf6"
      unitRef="usd">70414000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="i3b4376f8fc614de98c9cf647198c504e_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xNi9mcmFnOjU2YmVmNWVkZGUxMDRjZDJiNzQxZGJmMjY2YmMwZmRmL3RhYmxlOjYzNjVkN2Y4YTZlYzQ4MzNiN2U3OTk3OWNlYjI2YWJlL3RhYmxlcmFuZ2U6NjM2NWQ3ZjhhNmVjNDgzM2I3ZTc5OTc5Y2ViMjZhYmVfMzQtMS0xLTEtODE_3968a780-6aea-48e1-aafb-bda80dd87884"
      unitRef="usd">1283563000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="iab26fe441f0d4ab984456365a7f7cff0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xNi9mcmFnOjU2YmVmNWVkZGUxMDRjZDJiNzQxZGJmMjY2YmMwZmRmL3RhYmxlOjYzNjVkN2Y4YTZlYzQ4MzNiN2U3OTk3OWNlYjI2YWJlL3RhYmxlcmFuZ2U6NjM2NWQ3ZjhhNmVjNDgzM2I3ZTc5OTc5Y2ViMjZhYmVfMzQtMy0xLTEtODE_91727336-f662-48d2-993e-b2b8b0696a27"
      unitRef="usd">1163348000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i3b4376f8fc614de98c9cf647198c504e_I20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xNi9mcmFnOjU2YmVmNWVkZGUxMDRjZDJiNzQxZGJmMjY2YmMwZmRmL3RhYmxlOjYzNjVkN2Y4YTZlYzQ4MzNiN2U3OTk3OWNlYjI2YWJlL3RhYmxlcmFuZ2U6NjM2NWQ3ZjhhNmVjNDgzM2I3ZTc5OTc5Y2ViMjZhYmVfMzYtMS0xLTEtODE_aafa9975-26ff-4ffa-bad8-47cb08f36d24"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="iab26fe441f0d4ab984456365a7f7cff0_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xNi9mcmFnOjU2YmVmNWVkZGUxMDRjZDJiNzQxZGJmMjY2YmMwZmRmL3RhYmxlOjYzNjVkN2Y4YTZlYzQ4MzNiN2U3OTk3OWNlYjI2YWJlL3RhYmxlcmFuZ2U6NjM2NWQ3ZjhhNmVjNDgzM2I3ZTc5OTc5Y2ViMjZhYmVfMzYtMy0xLTEtODE_ea1762bc-f12a-4cf9-a3c2-70767c18b248"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="iab26fe441f0d4ab984456365a7f7cff0_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xNi9mcmFnOjU2YmVmNWVkZGUxMDRjZDJiNzQxZGJmMjY2YmMwZmRmL3RhYmxlOjYzNjVkN2Y4YTZlYzQ4MzNiN2U3OTk3OWNlYjI2YWJlL3RhYmxlcmFuZ2U6NjM2NWQ3ZjhhNmVjNDgzM2I3ZTc5OTc5Y2ViMjZhYmVfMzktMC0xLTEtODEvdGV4dHJlZ2lvbjo1MTMwNDVkZGU3NjQ0MTVhOGZlNjU0NDk3OWI1MjY3Zl8yMQ_083aa109-7ca1-486b-8006-897cd8e734ce"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i3b4376f8fc614de98c9cf647198c504e_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xNi9mcmFnOjU2YmVmNWVkZGUxMDRjZDJiNzQxZGJmMjY2YmMwZmRmL3RhYmxlOjYzNjVkN2Y4YTZlYzQ4MzNiN2U3OTk3OWNlYjI2YWJlL3RhYmxlcmFuZ2U6NjM2NWQ3ZjhhNmVjNDgzM2I3ZTc5OTc5Y2ViMjZhYmVfMzktMC0xLTEtODEvdGV4dHJlZ2lvbjo1MTMwNDVkZGU3NjQ0MTVhOGZlNjU0NDk3OWI1MjY3Zl8yMQ_f492395a-56e8-4c1d-a889-f855edbd70d9"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="iab26fe441f0d4ab984456365a7f7cff0_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xNi9mcmFnOjU2YmVmNWVkZGUxMDRjZDJiNzQxZGJmMjY2YmMwZmRmL3RhYmxlOjYzNjVkN2Y4YTZlYzQ4MzNiN2U3OTk3OWNlYjI2YWJlL3RhYmxlcmFuZ2U6NjM2NWQ3ZjhhNmVjNDgzM2I3ZTc5OTc5Y2ViMjZhYmVfMzktMC0xLTEtODEvdGV4dHJlZ2lvbjo1MTMwNDVkZGU3NjQ0MTVhOGZlNjU0NDk3OWI1MjY3Zl8zNQ_9f544bf8-881d-4d71-b910-67001829bcaa"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i3b4376f8fc614de98c9cf647198c504e_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xNi9mcmFnOjU2YmVmNWVkZGUxMDRjZDJiNzQxZGJmMjY2YmMwZmRmL3RhYmxlOjYzNjVkN2Y4YTZlYzQ4MzNiN2U3OTk3OWNlYjI2YWJlL3RhYmxlcmFuZ2U6NjM2NWQ3ZjhhNmVjNDgzM2I3ZTc5OTc5Y2ViMjZhYmVfMzktMC0xLTEtODEvdGV4dHJlZ2lvbjo1MTMwNDVkZGU3NjQ0MTVhOGZlNjU0NDk3OWI1MjY3Zl8zNQ_fa7b3925-05af-4963-a376-e5103a0adf9f"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="iab26fe441f0d4ab984456365a7f7cff0_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xNi9mcmFnOjU2YmVmNWVkZGUxMDRjZDJiNzQxZGJmMjY2YmMwZmRmL3RhYmxlOjYzNjVkN2Y4YTZlYzQ4MzNiN2U3OTk3OWNlYjI2YWJlL3RhYmxlcmFuZ2U6NjM2NWQ3ZjhhNmVjNDgzM2I3ZTc5OTc5Y2ViMjZhYmVfMzktMC0xLTEtODEvdGV4dHJlZ2lvbjo1MTMwNDVkZGU3NjQ0MTVhOGZlNjU0NDk3OWI1MjY3Zl81Nw_3517604c-a00b-4a87-b389-fe83e63d8693"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="iab26fe441f0d4ab984456365a7f7cff0_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xNi9mcmFnOjU2YmVmNWVkZGUxMDRjZDJiNzQxZGJmMjY2YmMwZmRmL3RhYmxlOjYzNjVkN2Y4YTZlYzQ4MzNiN2U3OTk3OWNlYjI2YWJlL3RhYmxlcmFuZ2U6NjM2NWQ3ZjhhNmVjNDgzM2I3ZTc5OTc5Y2ViMjZhYmVfMzktMC0xLTEtODEvdGV4dHJlZ2lvbjo1MTMwNDVkZGU3NjQ0MTVhOGZlNjU0NDk3OWI1MjY3Zl81Nw_593251b2-6d1d-4c05-84ac-3d6cceafcf88"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i3b4376f8fc614de98c9cf647198c504e_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xNi9mcmFnOjU2YmVmNWVkZGUxMDRjZDJiNzQxZGJmMjY2YmMwZmRmL3RhYmxlOjYzNjVkN2Y4YTZlYzQ4MzNiN2U3OTk3OWNlYjI2YWJlL3RhYmxlcmFuZ2U6NjM2NWQ3ZjhhNmVjNDgzM2I3ZTc5OTc5Y2ViMjZhYmVfMzktMC0xLTEtODEvdGV4dHJlZ2lvbjo1MTMwNDVkZGU3NjQ0MTVhOGZlNjU0NDk3OWI1MjY3Zl81Nw_9df062b2-622d-41fd-8c11-dc09d12d5bd7"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i3b4376f8fc614de98c9cf647198c504e_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xNi9mcmFnOjU2YmVmNWVkZGUxMDRjZDJiNzQxZGJmMjY2YmMwZmRmL3RhYmxlOjYzNjVkN2Y4YTZlYzQ4MzNiN2U3OTk3OWNlYjI2YWJlL3RhYmxlcmFuZ2U6NjM2NWQ3ZjhhNmVjNDgzM2I3ZTc5OTc5Y2ViMjZhYmVfMzktMC0xLTEtODEvdGV4dHJlZ2lvbjo1MTMwNDVkZGU3NjQ0MTVhOGZlNjU0NDk3OWI1MjY3Zl81Nw_ccec3e3c-7798-4518-b9b0-a8f77f39df2a"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue
      contextRef="i3b4376f8fc614de98c9cf647198c504e_I20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xNi9mcmFnOjU2YmVmNWVkZGUxMDRjZDJiNzQxZGJmMjY2YmMwZmRmL3RhYmxlOjYzNjVkN2Y4YTZlYzQ4MzNiN2U3OTk3OWNlYjI2YWJlL3RhYmxlcmFuZ2U6NjM2NWQ3ZjhhNmVjNDgzM2I3ZTc5OTc5Y2ViMjZhYmVfMzktMS0xLTEtODE_c6d336d8-9fad-4790-8205-df44b2a70731"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="iab26fe441f0d4ab984456365a7f7cff0_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xNi9mcmFnOjU2YmVmNWVkZGUxMDRjZDJiNzQxZGJmMjY2YmMwZmRmL3RhYmxlOjYzNjVkN2Y4YTZlYzQ4MzNiN2U3OTk3OWNlYjI2YWJlL3RhYmxlcmFuZ2U6NjM2NWQ3ZjhhNmVjNDgzM2I3ZTc5OTc5Y2ViMjZhYmVfMzktMy0xLTEtODE_e96915b5-acdb-463a-be5c-735c8a614d7c"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="iab26fe441f0d4ab984456365a7f7cff0_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xNi9mcmFnOjU2YmVmNWVkZGUxMDRjZDJiNzQxZGJmMjY2YmMwZmRmL3RhYmxlOjYzNjVkN2Y4YTZlYzQ4MzNiN2U3OTk3OWNlYjI2YWJlL3RhYmxlcmFuZ2U6NjM2NWQ3ZjhhNmVjNDgzM2I3ZTc5OTc5Y2ViMjZhYmVfNDAtMC0xLTEtODEvdGV4dHJlZ2lvbjozODFlN2RmNWIyOTc0OWU1YjdmMmI3YTBhODFkYjk3NV8xOA_0f1ca0e8-8a11-46ea-87d6-5ccd2192f78b"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i3b4376f8fc614de98c9cf647198c504e_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xNi9mcmFnOjU2YmVmNWVkZGUxMDRjZDJiNzQxZGJmMjY2YmMwZmRmL3RhYmxlOjYzNjVkN2Y4YTZlYzQ4MzNiN2U3OTk3OWNlYjI2YWJlL3RhYmxlcmFuZ2U6NjM2NWQ3ZjhhNmVjNDgzM2I3ZTc5OTc5Y2ViMjZhYmVfNDAtMC0xLTEtODEvdGV4dHJlZ2lvbjozODFlN2RmNWIyOTc0OWU1YjdmMmI3YTBhODFkYjk3NV8xOA_a0e0cbcc-7dd8-4cc9-bb95-76d7bc4aa1a4"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="iab26fe441f0d4ab984456365a7f7cff0_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xNi9mcmFnOjU2YmVmNWVkZGUxMDRjZDJiNzQxZGJmMjY2YmMwZmRmL3RhYmxlOjYzNjVkN2Y4YTZlYzQ4MzNiN2U3OTk3OWNlYjI2YWJlL3RhYmxlcmFuZ2U6NjM2NWQ3ZjhhNmVjNDgzM2I3ZTc5OTc5Y2ViMjZhYmVfNDAtMC0xLTEtODEvdGV4dHJlZ2lvbjozODFlN2RmNWIyOTc0OWU1YjdmMmI3YTBhODFkYjk3NV8zMg_972252c4-6463-4867-9a91-288a25c24eea"
      unitRef="shares">400000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i3b4376f8fc614de98c9cf647198c504e_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xNi9mcmFnOjU2YmVmNWVkZGUxMDRjZDJiNzQxZGJmMjY2YmMwZmRmL3RhYmxlOjYzNjVkN2Y4YTZlYzQ4MzNiN2U3OTk3OWNlYjI2YWJlL3RhYmxlcmFuZ2U6NjM2NWQ3ZjhhNmVjNDgzM2I3ZTc5OTc5Y2ViMjZhYmVfNDAtMC0xLTEtODEvdGV4dHJlZ2lvbjozODFlN2RmNWIyOTc0OWU1YjdmMmI3YTBhODFkYjk3NV8zMg_a3e53381-4c32-419a-adc9-a2888349b361"
      unitRef="shares">400000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i3b4376f8fc614de98c9cf647198c504e_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xNi9mcmFnOjU2YmVmNWVkZGUxMDRjZDJiNzQxZGJmMjY2YmMwZmRmL3RhYmxlOjYzNjVkN2Y4YTZlYzQ4MzNiN2U3OTk3OWNlYjI2YWJlL3RhYmxlcmFuZ2U6NjM2NWQ3ZjhhNmVjNDgzM2I3ZTc5OTc5Y2ViMjZhYmVfNDAtMC0xLTEtODEvdGV4dHJlZ2lvbjozODFlN2RmNWIyOTc0OWU1YjdmMmI3YTBhODFkYjk3NV81NA_66715ffa-87cc-41e8-acc8-19ca1b34c5df"
      unitRef="shares">222454839</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i3b4376f8fc614de98c9cf647198c504e_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xNi9mcmFnOjU2YmVmNWVkZGUxMDRjZDJiNzQxZGJmMjY2YmMwZmRmL3RhYmxlOjYzNjVkN2Y4YTZlYzQ4MzNiN2U3OTk3OWNlYjI2YWJlL3RhYmxlcmFuZ2U6NjM2NWQ3ZjhhNmVjNDgzM2I3ZTc5OTc5Y2ViMjZhYmVfNDAtMC0xLTEtODEvdGV4dHJlZ2lvbjozODFlN2RmNWIyOTc0OWU1YjdmMmI3YTBhODFkYjk3NV81NA_a6b9bb2d-6816-4732-b10e-d28b3bde411e"
      unitRef="shares">222454839</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="iab26fe441f0d4ab984456365a7f7cff0_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xNi9mcmFnOjU2YmVmNWVkZGUxMDRjZDJiNzQxZGJmMjY2YmMwZmRmL3RhYmxlOjYzNjVkN2Y4YTZlYzQ4MzNiN2U3OTk3OWNlYjI2YWJlL3RhYmxlcmFuZ2U6NjM2NWQ3ZjhhNmVjNDgzM2I3ZTc5OTc5Y2ViMjZhYmVfNDAtMC0xLTEtODEvdGV4dHJlZ2lvbjozODFlN2RmNWIyOTc0OWU1YjdmMmI3YTBhODFkYjk3NV82MQ_71330cf8-a38b-44b6-8aca-9fe438013b82"
      unitRef="shares">221084433</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="iab26fe441f0d4ab984456365a7f7cff0_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xNi9mcmFnOjU2YmVmNWVkZGUxMDRjZDJiNzQxZGJmMjY2YmMwZmRmL3RhYmxlOjYzNjVkN2Y4YTZlYzQ4MzNiN2U3OTk3OWNlYjI2YWJlL3RhYmxlcmFuZ2U6NjM2NWQ3ZjhhNmVjNDgzM2I3ZTc5OTc5Y2ViMjZhYmVfNDAtMC0xLTEtODEvdGV4dHJlZ2lvbjozODFlN2RmNWIyOTc0OWU1YjdmMmI3YTBhODFkYjk3NV82MQ_ad431d2b-434d-4c95-836a-2e3a7a8c98d0"
      unitRef="shares">221084433</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="i3b4376f8fc614de98c9cf647198c504e_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xNi9mcmFnOjU2YmVmNWVkZGUxMDRjZDJiNzQxZGJmMjY2YmMwZmRmL3RhYmxlOjYzNjVkN2Y4YTZlYzQ4MzNiN2U3OTk3OWNlYjI2YWJlL3RhYmxlcmFuZ2U6NjM2NWQ3ZjhhNmVjNDgzM2I3ZTc5OTc5Y2ViMjZhYmVfNDAtMS0xLTEtODE_30ec0cfc-f517-4cd6-bedb-2674a870b7ab"
      unitRef="usd">222000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="iab26fe441f0d4ab984456365a7f7cff0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xNi9mcmFnOjU2YmVmNWVkZGUxMDRjZDJiNzQxZGJmMjY2YmMwZmRmL3RhYmxlOjYzNjVkN2Y4YTZlYzQ4MzNiN2U3OTk3OWNlYjI2YWJlL3RhYmxlcmFuZ2U6NjM2NWQ3ZjhhNmVjNDgzM2I3ZTc5OTc5Y2ViMjZhYmVfNDAtMy0xLTEtODE_c35ae666-c63b-40cd-a2ad-4b928c3ec9cd"
      unitRef="usd">221000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i3b4376f8fc614de98c9cf647198c504e_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xNi9mcmFnOjU2YmVmNWVkZGUxMDRjZDJiNzQxZGJmMjY2YmMwZmRmL3RhYmxlOjYzNjVkN2Y4YTZlYzQ4MzNiN2U3OTk3OWNlYjI2YWJlL3RhYmxlcmFuZ2U6NjM2NWQ3ZjhhNmVjNDgzM2I3ZTc5OTc5Y2ViMjZhYmVfNDEtMS0xLTEtODE_7141562e-1ed2-4a9b-a83d-b64369801083"
      unitRef="usd">4721166000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="iab26fe441f0d4ab984456365a7f7cff0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xNi9mcmFnOjU2YmVmNWVkZGUxMDRjZDJiNzQxZGJmMjY2YmMwZmRmL3RhYmxlOjYzNjVkN2Y4YTZlYzQ4MzNiN2U3OTk3OWNlYjI2YWJlL3RhYmxlcmFuZ2U6NjM2NWQ3ZjhhNmVjNDgzM2I3ZTc5OTc5Y2ViMjZhYmVfNDEtMy0xLTEtODE_edae5fe7-96ea-4772-91e4-77b1ba2743d7"
      unitRef="usd">4567111000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i3b4376f8fc614de98c9cf647198c504e_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xNi9mcmFnOjU2YmVmNWVkZGUxMDRjZDJiNzQxZGJmMjY2YmMwZmRmL3RhYmxlOjYzNjVkN2Y4YTZlYzQ4MzNiN2U3OTk3OWNlYjI2YWJlL3RhYmxlcmFuZ2U6NjM2NWQ3ZjhhNmVjNDgzM2I3ZTc5OTc5Y2ViMjZhYmVfNDItMS0xLTEtODE_9cd265e3-5457-4699-9535-cc4e1bfdde85"
      unitRef="usd">-29062000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="iab26fe441f0d4ab984456365a7f7cff0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xNi9mcmFnOjU2YmVmNWVkZGUxMDRjZDJiNzQxZGJmMjY2YmMwZmRmL3RhYmxlOjYzNjVkN2Y4YTZlYzQ4MzNiN2U3OTk3OWNlYjI2YWJlL3RhYmxlcmFuZ2U6NjM2NWQ3ZjhhNmVjNDgzM2I3ZTc5OTc5Y2ViMjZhYmVfNDItMy0xLTEtODE_a036be63-ea7c-445e-8e5a-484496928793"
      unitRef="usd">-19454000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i3b4376f8fc614de98c9cf647198c504e_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xNi9mcmFnOjU2YmVmNWVkZGUxMDRjZDJiNzQxZGJmMjY2YmMwZmRmL3RhYmxlOjYzNjVkN2Y4YTZlYzQ4MzNiN2U3OTk3OWNlYjI2YWJlL3RhYmxlcmFuZ2U6NjM2NWQ3ZjhhNmVjNDgzM2I3ZTc5OTc5Y2ViMjZhYmVfNDMtMS0xLTEtODE_dc9ff207-4bb6-43b7-8038-b03b3e703f0a"
      unitRef="usd">-465675000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="iab26fe441f0d4ab984456365a7f7cff0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xNi9mcmFnOjU2YmVmNWVkZGUxMDRjZDJiNzQxZGJmMjY2YmMwZmRmL3RhYmxlOjYzNjVkN2Y4YTZlYzQ4MzNiN2U3OTk3OWNlYjI2YWJlL3RhYmxlcmFuZ2U6NjM2NWQ3ZjhhNmVjNDgzM2I3ZTc5OTc5Y2ViMjZhYmVfNDMtMy0xLTEtODE_cde9d902-f46f-4239-a6ec-8df5b9cdb2ea"
      unitRef="usd">-777874000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i3b4376f8fc614de98c9cf647198c504e_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xNi9mcmFnOjU2YmVmNWVkZGUxMDRjZDJiNzQxZGJmMjY2YmMwZmRmL3RhYmxlOjYzNjVkN2Y4YTZlYzQ4MzNiN2U3OTk3OWNlYjI2YWJlL3RhYmxlcmFuZ2U6NjM2NWQ3ZjhhNmVjNDgzM2I3ZTc5OTc5Y2ViMjZhYmVfNDQtMS0xLTEtODE_9fd51ab8-b4d2-40de-90f6-ac91a2415cde"
      unitRef="usd">4226651000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iab26fe441f0d4ab984456365a7f7cff0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xNi9mcmFnOjU2YmVmNWVkZGUxMDRjZDJiNzQxZGJmMjY2YmMwZmRmL3RhYmxlOjYzNjVkN2Y4YTZlYzQ4MzNiN2U3OTk3OWNlYjI2YWJlL3RhYmxlcmFuZ2U6NjM2NWQ3ZjhhNmVjNDgzM2I3ZTc5OTc5Y2ViMjZhYmVfNDQtMy0xLTEtODE_848dadc2-d7aa-49de-848e-f874e2d81e5c"
      unitRef="usd">3770004000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i3b4376f8fc614de98c9cf647198c504e_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xNi9mcmFnOjU2YmVmNWVkZGUxMDRjZDJiNzQxZGJmMjY2YmMwZmRmL3RhYmxlOjYzNjVkN2Y4YTZlYzQ4MzNiN2U3OTk3OWNlYjI2YWJlL3RhYmxlcmFuZ2U6NjM2NWQ3ZjhhNmVjNDgzM2I3ZTc5OTc5Y2ViMjZhYmVfNDUtMS0xLTEtODE_63b80b6e-40ca-4096-bc85-6fdbca24e113"
      unitRef="usd">5510214000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="iab26fe441f0d4ab984456365a7f7cff0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xNi9mcmFnOjU2YmVmNWVkZGUxMDRjZDJiNzQxZGJmMjY2YmMwZmRmL3RhYmxlOjYzNjVkN2Y4YTZlYzQ4MzNiN2U3OTk3OWNlYjI2YWJlL3RhYmxlcmFuZ2U6NjM2NWQ3ZjhhNmVjNDgzM2I3ZTc5OTc5Y2ViMjZhYmVfNDUtMy0xLTEtODE_6140512e-693e-4534-b6cb-bb6a4c65a5b5"
      unitRef="usd">4933352000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i85b99c1e194944f7bd3b5fb62f5a2182_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xOS9mcmFnOjg3NTU4NGVlZmQ2NzRjZGE4NDc4ZmZhOWY2MTg0NTk1L3RhYmxlOmVjMzUzMDdlY2E4YTQ4NzliNGU3NWU5ZWYyMDUzM2U5L3RhYmxlcmFuZ2U6ZWMzNTMwN2VjYThhNDg3OWI0ZTc1ZTllZjIwNTMzZTlfMy0xLTEtMS04MQ_b44e3c6c-d5d3-41ed-8a72-1b383ab36b13"
      unitRef="usd">713010000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i48a86cbfb7934ea9845c79f994c08295_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xOS9mcmFnOjg3NTU4NGVlZmQ2NzRjZGE4NDc4ZmZhOWY2MTg0NTk1L3RhYmxlOmVjMzUzMDdlY2E4YTQ4NzliNGU3NWU5ZWYyMDUzM2U5L3RhYmxlcmFuZ2U6ZWMzNTMwN2VjYThhNDg3OWI0ZTc1ZTllZjIwNTMzZTlfMy0zLTEtMS04MQ_dbf31868-355e-4546-b2e3-0b7923087494"
      unitRef="usd">594013000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie260e1a53b734cf0a4f57af01f2e311d_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xOS9mcmFnOjg3NTU4NGVlZmQ2NzRjZGE4NDc4ZmZhOWY2MTg0NTk1L3RhYmxlOmVjMzUzMDdlY2E4YTQ4NzliNGU3NWU5ZWYyMDUzM2U5L3RhYmxlcmFuZ2U6ZWMzNTMwN2VjYThhNDg3OWI0ZTc1ZTllZjIwNTMzZTlfMy01LTEtMS04MQ_574b4a1d-44dc-43ab-a4a3-67e2f0d34169"
      unitRef="usd">1982682000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6c3d6351306b42baba694287efd653dc_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xOS9mcmFnOjg3NTU4NGVlZmQ2NzRjZGE4NDc4ZmZhOWY2MTg0NTk1L3RhYmxlOmVjMzUzMDdlY2E4YTQ4NzliNGU3NWU5ZWYyMDUzM2U5L3RhYmxlcmFuZ2U6ZWMzNTMwN2VjYThhNDg3OWI0ZTc1ZTllZjIwNTMzZTlfMy03LTEtMS04MQ_3e5c2066-d007-4847-bfe5-3042c034aedd"
      unitRef="usd">1673974000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i37c7d1d637bf4ae98b18884511c75dd9_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xOS9mcmFnOjg3NTU4NGVlZmQ2NzRjZGE4NDc4ZmZhOWY2MTg0NTk1L3RhYmxlOmVjMzUzMDdlY2E4YTQ4NzliNGU3NWU5ZWYyMDUzM2U5L3RhYmxlcmFuZ2U6ZWMzNTMwN2VjYThhNDg3OWI0ZTc1ZTllZjIwNTMzZTlfNC0xLTEtMS04MQ_2e21e30c-dc2d-4d26-a454-c25ffa53e591"
      unitRef="usd">110293000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5c507c58a3df413e914b6c8ae5dbf2a2_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xOS9mcmFnOjg3NTU4NGVlZmQ2NzRjZGE4NDc4ZmZhOWY2MTg0NTk1L3RhYmxlOmVjMzUzMDdlY2E4YTQ4NzliNGU3NWU5ZWYyMDUzM2U5L3RhYmxlcmFuZ2U6ZWMzNTMwN2VjYThhNDg3OWI0ZTc1ZTllZjIwNTMzZTlfNC0zLTEtMS04MQ_e99f1259-88c7-4864-a0d5-4cd42e8a98bb"
      unitRef="usd">183974000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia628ec6831414d4f8e0d2c927a011f4a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xOS9mcmFnOjg3NTU4NGVlZmQ2NzRjZGE4NDc4ZmZhOWY2MTg0NTk1L3RhYmxlOmVjMzUzMDdlY2E4YTQ4NzliNGU3NWU5ZWYyMDUzM2U5L3RhYmxlcmFuZ2U6ZWMzNTMwN2VjYThhNDg3OWI0ZTc1ZTllZjIwNTMzZTlfNC01LTEtMS04MQ_f416a5ba-d837-4ad2-b916-3de1d2e68674"
      unitRef="usd">350253000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3231b94f87f649139a15ad91d06d9fd2_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xOS9mcmFnOjg3NTU4NGVlZmQ2NzRjZGE4NDc4ZmZhOWY2MTg0NTk1L3RhYmxlOmVjMzUzMDdlY2E4YTQ4NzliNGU3NWU5ZWYyMDUzM2U5L3RhYmxlcmFuZ2U6ZWMzNTMwN2VjYThhNDg3OWI0ZTc1ZTllZjIwNTMzZTlfNC03LTEtMS04MQ_46dfbc77-47eb-4a71-b491-090e72c88799"
      unitRef="usd">404440000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib5a93dd07a4f42b6ba18bf2e816dc557_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xOS9mcmFnOjg3NTU4NGVlZmQ2NzRjZGE4NDc4ZmZhOWY2MTg0NTk1L3RhYmxlOmVjMzUzMDdlY2E4YTQ4NzliNGU3NWU5ZWYyMDUzM2U5L3RhYmxlcmFuZ2U6ZWMzNTMwN2VjYThhNDg3OWI0ZTc1ZTllZjIwNTMzZTlfNS0xLTEtMS04MQ_ac195132-841b-4bf4-b8b9-b684a8e0008a"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4924faaf57ec4df5aafa757da5bce176_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xOS9mcmFnOjg3NTU4NGVlZmQ2NzRjZGE4NDc4ZmZhOWY2MTg0NTk1L3RhYmxlOmVjMzUzMDdlY2E4YTQ4NzliNGU3NWU5ZWYyMDUzM2U5L3RhYmxlcmFuZ2U6ZWMzNTMwN2VjYThhNDg3OWI0ZTc1ZTllZjIwNTMzZTlfNS0zLTEtMS04MQ_acad1dc4-810b-44e9-aa96-81e7307ca3d9"
      unitRef="usd">35000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2028c66e6d814be2937c324c9b244728_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xOS9mcmFnOjg3NTU4NGVlZmQ2NzRjZGE4NDc4ZmZhOWY2MTg0NTk1L3RhYmxlOmVjMzUzMDdlY2E4YTQ4NzliNGU3NWU5ZWYyMDUzM2U5L3RhYmxlcmFuZ2U6ZWMzNTMwN2VjYThhNDg3OWI0ZTc1ZTllZjIwNTMzZTlfNS01LTEtMS04MQ_1e8399ac-f48f-4bc2-9af8-60ba2bb60e77"
      unitRef="usd">135000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic7c03930e4e24e0880a00b550c2d0c20_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xOS9mcmFnOjg3NTU4NGVlZmQ2NzRjZGE4NDc4ZmZhOWY2MTg0NTk1L3RhYmxlOmVjMzUzMDdlY2E4YTQ4NzliNGU3NWU5ZWYyMDUzM2U5L3RhYmxlcmFuZ2U6ZWMzNTMwN2VjYThhNDg3OWI0ZTc1ZTllZjIwNTMzZTlfNS03LTEtMS04MQ_0e217856-c059-41ef-b7dd-b2a5759c7f02"
      unitRef="usd">45000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id673d80f31e74643a241d2f62db94ca9_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xOS9mcmFnOjg3NTU4NGVlZmQ2NzRjZGE4NDc4ZmZhOWY2MTg0NTk1L3RhYmxlOmVjMzUzMDdlY2E4YTQ4NzliNGU3NWU5ZWYyMDUzM2U5L3RhYmxlcmFuZ2U6ZWMzNTMwN2VjYThhNDg3OWI0ZTc1ZTllZjIwNTMzZTlfNy0xLTEtMS04MQ_a0fb349e-a925-460e-9ca9-544f0f8ace06"
      unitRef="usd">823303000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i313b15d35b7045babd1ba61f84a077dd_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xOS9mcmFnOjg3NTU4NGVlZmQ2NzRjZGE4NDc4ZmZhOWY2MTg0NTk1L3RhYmxlOmVjMzUzMDdlY2E4YTQ4NzliNGU3NWU5ZWYyMDUzM2U5L3RhYmxlcmFuZ2U6ZWMzNTMwN2VjYThhNDg3OWI0ZTc1ZTllZjIwNTMzZTlfNy0zLTEtMS04MQ_48cfa18b-70e1-44fd-9f05-9f7bd2144714"
      unitRef="usd">812987000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xOS9mcmFnOjg3NTU4NGVlZmQ2NzRjZGE4NDc4ZmZhOWY2MTg0NTk1L3RhYmxlOmVjMzUzMDdlY2E4YTQ4NzliNGU3NWU5ZWYyMDUzM2U5L3RhYmxlcmFuZ2U6ZWMzNTMwN2VjYThhNDg3OWI0ZTc1ZTllZjIwNTMzZTlfNy01LTEtMS04MQ_c7ae416b-83a8-40d8-8661-bc2c3db1f37f"
      unitRef="usd">2467935000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0faaba5fcd6b485781cadacae8b2fd8e_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xOS9mcmFnOjg3NTU4NGVlZmQ2NzRjZGE4NDc4ZmZhOWY2MTg0NTk1L3RhYmxlOmVjMzUzMDdlY2E4YTQ4NzliNGU3NWU5ZWYyMDUzM2U5L3RhYmxlcmFuZ2U6ZWMzNTMwN2VjYThhNDg3OWI0ZTc1ZTllZjIwNTMzZTlfNy03LTEtMS04MQ_082a664b-e6ac-4a80-af83-5ff309f55ada"
      unitRef="usd">2123414000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfRevenue
      contextRef="id673d80f31e74643a241d2f62db94ca9_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xOS9mcmFnOjg3NTU4NGVlZmQ2NzRjZGE4NDc4ZmZhOWY2MTg0NTk1L3RhYmxlOmVjMzUzMDdlY2E4YTQ4NzliNGU3NWU5ZWYyMDUzM2U5L3RhYmxlcmFuZ2U6ZWMzNTMwN2VjYThhNDg3OWI0ZTc1ZTllZjIwNTMzZTlfMTAtMS0xLTEtODE_a5f6893e-ef7a-4692-b972-ddaeadcd8b8d"
      unitRef="usd">54584000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="i313b15d35b7045babd1ba61f84a077dd_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xOS9mcmFnOjg3NTU4NGVlZmQ2NzRjZGE4NDc4ZmZhOWY2MTg0NTk1L3RhYmxlOmVjMzUzMDdlY2E4YTQ4NzliNGU3NWU5ZWYyMDUzM2U5L3RhYmxlcmFuZ2U6ZWMzNTMwN2VjYThhNDg3OWI0ZTc1ZTllZjIwNTMzZTlfMTAtMy0xLTEtODE_f9bb010c-4f42-4771-8575-14e5eed10446"
      unitRef="usd">39869000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xOS9mcmFnOjg3NTU4NGVlZmQ2NzRjZGE4NDc4ZmZhOWY2MTg0NTk1L3RhYmxlOmVjMzUzMDdlY2E4YTQ4NzliNGU3NWU5ZWYyMDUzM2U5L3RhYmxlcmFuZ2U6ZWMzNTMwN2VjYThhNDg3OWI0ZTc1ZTllZjIwNTMzZTlfMTAtNS0xLTEtODE_ef76493d-9794-4c51-b79f-fd8ff795af2c"
      unitRef="usd">147834000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="i0faaba5fcd6b485781cadacae8b2fd8e_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xOS9mcmFnOjg3NTU4NGVlZmQ2NzRjZGE4NDc4ZmZhOWY2MTg0NTk1L3RhYmxlOmVjMzUzMDdlY2E4YTQ4NzliNGU3NWU5ZWYyMDUzM2U5L3RhYmxlcmFuZ2U6ZWMzNTMwN2VjYThhNDg3OWI0ZTc1ZTllZjIwNTMzZTlfMTAtNy0xLTEtODE_a3e29e36-eadc-4fdc-93ef-97b1630942b6"
      unitRef="usd">107117000</us-gaap:CostOfRevenue>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="id673d80f31e74643a241d2f62db94ca9_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xOS9mcmFnOjg3NTU4NGVlZmQ2NzRjZGE4NDc4ZmZhOWY2MTg0NTk1L3RhYmxlOmVjMzUzMDdlY2E4YTQ4NzliNGU3NWU5ZWYyMDUzM2U5L3RhYmxlcmFuZ2U6ZWMzNTMwN2VjYThhNDg3OWI0ZTc1ZTllZjIwNTMzZTlfMTEtMS0xLTEtODE_76a529c9-b8bf-4af1-bbc0-32b730b5f676"
      unitRef="usd">384007000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i313b15d35b7045babd1ba61f84a077dd_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xOS9mcmFnOjg3NTU4NGVlZmQ2NzRjZGE4NDc4ZmZhOWY2MTg0NTk1L3RhYmxlOmVjMzUzMDdlY2E4YTQ4NzliNGU3NWU5ZWYyMDUzM2U5L3RhYmxlcmFuZ2U6ZWMzNTMwN2VjYThhNDg3OWI0ZTc1ZTllZjIwNTMzZTlfMTEtMy0xLTEtODE_f5fd1cbd-5d36-4ecc-a65e-48e3fa3ac662"
      unitRef="usd">334945000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xOS9mcmFnOjg3NTU4NGVlZmQ2NzRjZGE4NDc4ZmZhOWY2MTg0NTk1L3RhYmxlOmVjMzUzMDdlY2E4YTQ4NzliNGU3NWU5ZWYyMDUzM2U5L3RhYmxlcmFuZ2U6ZWMzNTMwN2VjYThhNDg3OWI0ZTc1ZTllZjIwNTMzZTlfMTEtNS0xLTEtODE_f25e3b4d-f986-4982-bc15-ffe45f8925af"
      unitRef="usd">1084576000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i0faaba5fcd6b485781cadacae8b2fd8e_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xOS9mcmFnOjg3NTU4NGVlZmQ2NzRjZGE4NDc4ZmZhOWY2MTg0NTk1L3RhYmxlOmVjMzUzMDdlY2E4YTQ4NzliNGU3NWU5ZWYyMDUzM2U5L3RhYmxlcmFuZ2U6ZWMzNTMwN2VjYThhNDg3OWI0ZTc1ZTllZjIwNTMzZTlfMTEtNy0xLTEtODE_9ac7722e-75e7-442a-b8c1-4693ad440ced"
      unitRef="usd">985352000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="id673d80f31e74643a241d2f62db94ca9_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xOS9mcmFnOjg3NTU4NGVlZmQ2NzRjZGE4NDc4ZmZhOWY2MTg0NTk1L3RhYmxlOmVjMzUzMDdlY2E4YTQ4NzliNGU3NWU5ZWYyMDUzM2U5L3RhYmxlcmFuZ2U6ZWMzNTMwN2VjYThhNDg3OWI0ZTc1ZTllZjIwNTMzZTlfMTItMS0xLTEtODE_44bf4a81-fa27-42e5-9f7c-ccc9fe1ab7da"
      unitRef="usd">266460000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i313b15d35b7045babd1ba61f84a077dd_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xOS9mcmFnOjg3NTU4NGVlZmQ2NzRjZGE4NDc4ZmZhOWY2MTg0NTk1L3RhYmxlOmVjMzUzMDdlY2E4YTQ4NzliNGU3NWU5ZWYyMDUzM2U5L3RhYmxlcmFuZ2U6ZWMzNTMwN2VjYThhNDg3OWI0ZTc1ZTllZjIwNTMzZTlfMTItMy0xLTEtODE_1f920e93-3194-4f15-9d5d-9ddb6ad189cb"
      unitRef="usd">190704000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xOS9mcmFnOjg3NTU4NGVlZmQ2NzRjZGE4NDc4ZmZhOWY2MTg0NTk1L3RhYmxlOmVjMzUzMDdlY2E4YTQ4NzliNGU3NWU5ZWYyMDUzM2U5L3RhYmxlcmFuZ2U6ZWMzNTMwN2VjYThhNDg3OWI0ZTc1ZTllZjIwNTMzZTlfMTItNS0xLTEtODE_224f169f-c28a-4288-9fa2-9c3f95c76a6c"
      unitRef="usd">729321000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i0faaba5fcd6b485781cadacae8b2fd8e_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xOS9mcmFnOjg3NTU4NGVlZmQ2NzRjZGE4NDc4ZmZhOWY2MTg0NTk1L3RhYmxlOmVjMzUzMDdlY2E4YTQ4NzliNGU3NWU5ZWYyMDUzM2U5L3RhYmxlcmFuZ2U6ZWMzNTMwN2VjYThhNDg3OWI0ZTc1ZTllZjIwNTMzZTlfMTItNy0xLTEtODE_ac909ccd-3726-40a0-9126-2a4122a56f0d"
      unitRef="usd">513358000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="id673d80f31e74643a241d2f62db94ca9_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xOS9mcmFnOjg3NTU4NGVlZmQ2NzRjZGE4NDc4ZmZhOWY2MTg0NTk1L3RhYmxlOmVjMzUzMDdlY2E4YTQ4NzliNGU3NWU5ZWYyMDUzM2U5L3RhYmxlcmFuZ2U6ZWMzNTMwN2VjYThhNDg3OWI0ZTc1ZTllZjIwNTMzZTlfMTMtMS0xLTEtODE_af286acb-0fec-47ac-a63d-5fd4c7f3c42d"
      unitRef="usd">-21893000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i313b15d35b7045babd1ba61f84a077dd_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xOS9mcmFnOjg3NTU4NGVlZmQ2NzRjZGE4NDc4ZmZhOWY2MTg0NTk1L3RhYmxlOmVjMzUzMDdlY2E4YTQ4NzliNGU3NWU5ZWYyMDUzM2U5L3RhYmxlcmFuZ2U6ZWMzNTMwN2VjYThhNDg3OWI0ZTc1ZTllZjIwNTMzZTlfMTMtMy0xLTEtODE_86052b7f-d534-414c-adc3-4117323fb22e"
      unitRef="usd">2910000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xOS9mcmFnOjg3NTU4NGVlZmQ2NzRjZGE4NDc4ZmZhOWY2MTg0NTk1L3RhYmxlOmVjMzUzMDdlY2E4YTQ4NzliNGU3NWU5ZWYyMDUzM2U5L3RhYmxlcmFuZ2U6ZWMzNTMwN2VjYThhNDg3OWI0ZTc1ZTllZjIwNTMzZTlfMTMtNS0xLTEtODE_21f7a01a-d2b7-473e-8d37-766b1e1aaf2d"
      unitRef="usd">-12198000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i0faaba5fcd6b485781cadacae8b2fd8e_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xOS9mcmFnOjg3NTU4NGVlZmQ2NzRjZGE4NDc4ZmZhOWY2MTg0NTk1L3RhYmxlOmVjMzUzMDdlY2E4YTQ4NzliNGU3NWU5ZWYyMDUzM2U5L3RhYmxlcmFuZ2U6ZWMzNTMwN2VjYThhNDg3OWI0ZTc1ZTllZjIwNTMzZTlfMTMtNy0xLTEtODE_3360d55b-6220-4a8f-b31b-607969c9adcf"
      unitRef="usd">13068000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <incy:CollaborationLossSharingExpense
      contextRef="id673d80f31e74643a241d2f62db94ca9_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xOS9mcmFnOjg3NTU4NGVlZmQ2NzRjZGE4NDc4ZmZhOWY2MTg0NTk1L3RhYmxlOmVjMzUzMDdlY2E4YTQ4NzliNGU3NWU5ZWYyMDUzM2U5L3RhYmxlcmFuZ2U6ZWMzNTMwN2VjYThhNDg3OWI0ZTc1ZTllZjIwNTMzZTlfMTQtMS0xLTEtODE_da7d8a77-79c9-4c58-90b3-4db5a5d7b529"
      unitRef="usd">1769000</incy:CollaborationLossSharingExpense>
    <incy:CollaborationLossSharingExpense
      contextRef="i313b15d35b7045babd1ba61f84a077dd_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xOS9mcmFnOjg3NTU4NGVlZmQ2NzRjZGE4NDc4ZmZhOWY2MTg0NTk1L3RhYmxlOmVjMzUzMDdlY2E4YTQ4NzliNGU3NWU5ZWYyMDUzM2U5L3RhYmxlcmFuZ2U6ZWMzNTMwN2VjYThhNDg3OWI0ZTc1ZTllZjIwNTMzZTlfMTQtMy0xLTEtODE_afeb2081-ae06-4e17-b02e-fe5c92367b41"
      unitRef="usd">9149000</incy:CollaborationLossSharingExpense>
    <incy:CollaborationLossSharingExpense
      contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xOS9mcmFnOjg3NTU4NGVlZmQ2NzRjZGE4NDc4ZmZhOWY2MTg0NTk1L3RhYmxlOmVjMzUzMDdlY2E4YTQ4NzliNGU3NWU5ZWYyMDUzM2U5L3RhYmxlcmFuZ2U6ZWMzNTMwN2VjYThhNDg3OWI0ZTc1ZTllZjIwNTMzZTlfMTQtNS0xLTEtODE_ac4526d9-2a73-4e8a-80d8-2153d4678a08"
      unitRef="usd">9055000</incy:CollaborationLossSharingExpense>
    <incy:CollaborationLossSharingExpense
      contextRef="i0faaba5fcd6b485781cadacae8b2fd8e_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xOS9mcmFnOjg3NTU4NGVlZmQ2NzRjZGE4NDc4ZmZhOWY2MTg0NTk1L3RhYmxlOmVjMzUzMDdlY2E4YTQ4NzliNGU3NWU5ZWYyMDUzM2U5L3RhYmxlcmFuZ2U6ZWMzNTMwN2VjYThhNDg3OWI0ZTc1ZTllZjIwNTMzZTlfMTQtNy0xLTEtODE_5aec1f6f-4f43-473b-b1f8-3f61c93c3533"
      unitRef="usd">29476000</incy:CollaborationLossSharingExpense>
    <us-gaap:CostsAndExpenses
      contextRef="id673d80f31e74643a241d2f62db94ca9_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xOS9mcmFnOjg3NTU4NGVlZmQ2NzRjZGE4NDc4ZmZhOWY2MTg0NTk1L3RhYmxlOmVjMzUzMDdlY2E4YTQ4NzliNGU3NWU5ZWYyMDUzM2U5L3RhYmxlcmFuZ2U6ZWMzNTMwN2VjYThhNDg3OWI0ZTc1ZTllZjIwNTMzZTlfMTYtMS0xLTEtODE_42cfc4f3-a3eb-4126-b4b5-c050d20c5d41"
      unitRef="usd">684927000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i313b15d35b7045babd1ba61f84a077dd_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xOS9mcmFnOjg3NTU4NGVlZmQ2NzRjZGE4NDc4ZmZhOWY2MTg0NTk1L3RhYmxlOmVjMzUzMDdlY2E4YTQ4NzliNGU3NWU5ZWYyMDUzM2U5L3RhYmxlcmFuZ2U6ZWMzNTMwN2VjYThhNDg3OWI0ZTc1ZTllZjIwNTMzZTlfMTYtMy0xLTEtODE_12839f40-0081-4064-ad6d-5ee1c13d8391"
      unitRef="usd">577577000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xOS9mcmFnOjg3NTU4NGVlZmQ2NzRjZGE4NDc4ZmZhOWY2MTg0NTk1L3RhYmxlOmVjMzUzMDdlY2E4YTQ4NzliNGU3NWU5ZWYyMDUzM2U5L3RhYmxlcmFuZ2U6ZWMzNTMwN2VjYThhNDg3OWI0ZTc1ZTllZjIwNTMzZTlfMTYtNS0xLTEtODE_658af91e-148d-464d-8a03-d7c73b457689"
      unitRef="usd">1958588000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i0faaba5fcd6b485781cadacae8b2fd8e_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xOS9mcmFnOjg3NTU4NGVlZmQ2NzRjZGE4NDc4ZmZhOWY2MTg0NTk1L3RhYmxlOmVjMzUzMDdlY2E4YTQ4NzliNGU3NWU5ZWYyMDUzM2U5L3RhYmxlcmFuZ2U6ZWMzNTMwN2VjYThhNDg3OWI0ZTc1ZTllZjIwNTMzZTlfMTYtNy0xLTEtODE_7023b39a-93d6-488b-978a-7c6a4cd65861"
      unitRef="usd">1648371000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="id673d80f31e74643a241d2f62db94ca9_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xOS9mcmFnOjg3NTU4NGVlZmQ2NzRjZGE4NDc4ZmZhOWY2MTg0NTk1L3RhYmxlOmVjMzUzMDdlY2E4YTQ4NzliNGU3NWU5ZWYyMDUzM2U5L3RhYmxlcmFuZ2U6ZWMzNTMwN2VjYThhNDg3OWI0ZTc1ZTllZjIwNTMzZTlfMTgtMS0xLTEtODE_aee15b86-d987-4d00-8d6f-70f68c118245"
      unitRef="usd">138376000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i313b15d35b7045babd1ba61f84a077dd_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xOS9mcmFnOjg3NTU4NGVlZmQ2NzRjZGE4NDc4ZmZhOWY2MTg0NTk1L3RhYmxlOmVjMzUzMDdlY2E4YTQ4NzliNGU3NWU5ZWYyMDUzM2U5L3RhYmxlcmFuZ2U6ZWMzNTMwN2VjYThhNDg3OWI0ZTc1ZTllZjIwNTMzZTlfMTgtMy0xLTEtODE_997fd35a-b632-491b-af64-6247f1ecb5e1"
      unitRef="usd">235410000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xOS9mcmFnOjg3NTU4NGVlZmQ2NzRjZGE4NDc4ZmZhOWY2MTg0NTk1L3RhYmxlOmVjMzUzMDdlY2E4YTQ4NzliNGU3NWU5ZWYyMDUzM2U5L3RhYmxlcmFuZ2U6ZWMzNTMwN2VjYThhNDg3OWI0ZTc1ZTllZjIwNTMzZTlfMTgtNS0xLTEtODE_8b9184a1-fb12-49ba-af4d-6621c5ed78d2"
      unitRef="usd">509347000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i0faaba5fcd6b485781cadacae8b2fd8e_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xOS9mcmFnOjg3NTU4NGVlZmQ2NzRjZGE4NDc4ZmZhOWY2MTg0NTk1L3RhYmxlOmVjMzUzMDdlY2E4YTQ4NzliNGU3NWU5ZWYyMDUzM2U5L3RhYmxlcmFuZ2U6ZWMzNTMwN2VjYThhNDg3OWI0ZTc1ZTllZjIwNTMzZTlfMTgtNy0xLTEtODE_7c772438-aef1-4e1f-b1e4-e75e90a7ded5"
      unitRef="usd">475043000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="id673d80f31e74643a241d2f62db94ca9_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xOS9mcmFnOjg3NTU4NGVlZmQ2NzRjZGE4NDc4ZmZhOWY2MTg0NTk1L3RhYmxlOmVjMzUzMDdlY2E4YTQ4NzliNGU3NWU5ZWYyMDUzM2U5L3RhYmxlcmFuZ2U6ZWMzNTMwN2VjYThhNDg3OWI0ZTc1ZTllZjIwNTMzZTlfMTktMS0xLTEtODE_c51e2526-84e8-4617-b227-7dde783a47fc"
      unitRef="usd">11513000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i313b15d35b7045babd1ba61f84a077dd_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xOS9mcmFnOjg3NTU4NGVlZmQ2NzRjZGE4NDc4ZmZhOWY2MTg0NTk1L3RhYmxlOmVjMzUzMDdlY2E4YTQ4NzliNGU3NWU5ZWYyMDUzM2U5L3RhYmxlcmFuZ2U6ZWMzNTMwN2VjYThhNDg3OWI0ZTc1ZTllZjIwNTMzZTlfMTktMy0xLTEtODE_ff896deb-5cb0-40af-8c4f-538f0a92a3f5"
      unitRef="usd">1948000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xOS9mcmFnOjg3NTU4NGVlZmQ2NzRjZGE4NDc4ZmZhOWY2MTg0NTk1L3RhYmxlOmVjMzUzMDdlY2E4YTQ4NzliNGU3NWU5ZWYyMDUzM2U5L3RhYmxlcmFuZ2U6ZWMzNTMwN2VjYThhNDg3OWI0ZTc1ZTllZjIwNTMzZTlfMTktNS0xLTEtODE_836d076c-a053-4d22-b8d3-fb82995e0ab4"
      unitRef="usd">13295000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i0faaba5fcd6b485781cadacae8b2fd8e_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xOS9mcmFnOjg3NTU4NGVlZmQ2NzRjZGE4NDc4ZmZhOWY2MTg0NTk1L3RhYmxlOmVjMzUzMDdlY2E4YTQ4NzliNGU3NWU5ZWYyMDUzM2U5L3RhYmxlcmFuZ2U6ZWMzNTMwN2VjYThhNDg3OWI0ZTc1ZTllZjIwNTMzZTlfMTktNy0xLTEtODE_2bab9001-74ab-482b-a0ce-6152ff0913f1"
      unitRef="usd">4931000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:InterestExpense
      contextRef="id673d80f31e74643a241d2f62db94ca9_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xOS9mcmFnOjg3NTU4NGVlZmQ2NzRjZGE4NDc4ZmZhOWY2MTg0NTk1L3RhYmxlOmVjMzUzMDdlY2E4YTQ4NzliNGU3NWU5ZWYyMDUzM2U5L3RhYmxlcmFuZ2U6ZWMzNTMwN2VjYThhNDg3OWI0ZTc1ZTllZjIwNTMzZTlfMjAtMS0xLTEtODE_d3ace7d2-9d15-4de2-850c-d65bc06beeb0"
      unitRef="usd">641000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i313b15d35b7045babd1ba61f84a077dd_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xOS9mcmFnOjg3NTU4NGVlZmQ2NzRjZGE4NDc4ZmZhOWY2MTg0NTk1L3RhYmxlOmVjMzUzMDdlY2E4YTQ4NzliNGU3NWU5ZWYyMDUzM2U5L3RhYmxlcmFuZ2U6ZWMzNTMwN2VjYThhNDg3OWI0ZTc1ZTllZjIwNTMzZTlfMjAtMy0xLTEtODE_abe4a0a9-0824-425e-9102-132ef6eeb146"
      unitRef="usd">439000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xOS9mcmFnOjg3NTU4NGVlZmQ2NzRjZGE4NDc4ZmZhOWY2MTg0NTk1L3RhYmxlOmVjMzUzMDdlY2E4YTQ4NzliNGU3NWU5ZWYyMDUzM2U5L3RhYmxlcmFuZ2U6ZWMzNTMwN2VjYThhNDg3OWI0ZTc1ZTllZjIwNTMzZTlfMjAtNS0xLTEtODE_2fd267c3-14e0-41a8-87e0-53e8d92e1eb6"
      unitRef="usd">1999000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i0faaba5fcd6b485781cadacae8b2fd8e_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xOS9mcmFnOjg3NTU4NGVlZmQ2NzRjZGE4NDc4ZmZhOWY2MTg0NTk1L3RhYmxlOmVjMzUzMDdlY2E4YTQ4NzliNGU3NWU5ZWYyMDUzM2U5L3RhYmxlcmFuZ2U6ZWMzNTMwN2VjYThhNDg3OWI0ZTc1ZTllZjIwNTMzZTlfMjAtNy0xLTEtODE_3ea5be20-68fe-43cf-a2f1-824190792707"
      unitRef="usd">1156000</us-gaap:InterestExpense>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="id673d80f31e74643a241d2f62db94ca9_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xOS9mcmFnOjg3NTU4NGVlZmQ2NzRjZGE4NDc4ZmZhOWY2MTg0NTk1L3RhYmxlOmVjMzUzMDdlY2E4YTQ4NzliNGU3NWU5ZWYyMDUzM2U5L3RhYmxlcmFuZ2U6ZWMzNTMwN2VjYThhNDg3OWI0ZTc1ZTllZjIwNTMzZTlfMjEtMS0xLTEtODE_84132301-19b1-45f9-a24a-8c862a19fb5c"
      unitRef="usd">-660000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i313b15d35b7045babd1ba61f84a077dd_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xOS9mcmFnOjg3NTU4NGVlZmQ2NzRjZGE4NDc4ZmZhOWY2MTg0NTk1L3RhYmxlOmVjMzUzMDdlY2E4YTQ4NzliNGU3NWU5ZWYyMDUzM2U5L3RhYmxlcmFuZ2U6ZWMzNTMwN2VjYThhNDg3OWI0ZTc1ZTllZjIwNTMzZTlfMjEtMy0xLTEtODE_eaf96e18-61e3-40c6-a47c-88c5aae3b174"
      unitRef="usd">-27450000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xOS9mcmFnOjg3NTU4NGVlZmQ2NzRjZGE4NDc4ZmZhOWY2MTg0NTk1L3RhYmxlOmVjMzUzMDdlY2E4YTQ4NzliNGU3NWU5ZWYyMDUzM2U5L3RhYmxlcmFuZ2U6ZWMzNTMwN2VjYThhNDg3OWI0ZTc1ZTllZjIwNTMzZTlfMjEtNS0xLTEtODE_82f47a0f-d87d-4bfd-b48a-1071765747fe"
      unitRef="usd">-72142000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i0faaba5fcd6b485781cadacae8b2fd8e_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xOS9mcmFnOjg3NTU4NGVlZmQ2NzRjZGE4NDc4ZmZhOWY2MTg0NTk1L3RhYmxlOmVjMzUzMDdlY2E4YTQ4NzliNGU3NWU5ZWYyMDUzM2U5L3RhYmxlcmFuZ2U6ZWMzNTMwN2VjYThhNDg3OWI0ZTc1ZTllZjIwNTMzZTlfMjEtNy0xLTEtODE_980ec916-5edf-4e19-9952-df656610f430"
      unitRef="usd">-28394000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="id673d80f31e74643a241d2f62db94ca9_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xOS9mcmFnOjg3NTU4NGVlZmQ2NzRjZGE4NDc4ZmZhOWY2MTg0NTk1L3RhYmxlOmVjMzUzMDdlY2E4YTQ4NzliNGU3NWU5ZWYyMDUzM2U5L3RhYmxlcmFuZ2U6ZWMzNTMwN2VjYThhNDg3OWI0ZTc1ZTllZjIwNTMzZTlfMjMtMS0xLTEtODE_3cd9bae4-b218-45d4-82eb-da3521572c39"
      unitRef="usd">148588000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i313b15d35b7045babd1ba61f84a077dd_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xOS9mcmFnOjg3NTU4NGVlZmQ2NzRjZGE4NDc4ZmZhOWY2MTg0NTk1L3RhYmxlOmVjMzUzMDdlY2E4YTQ4NzliNGU3NWU5ZWYyMDUzM2U5L3RhYmxlcmFuZ2U6ZWMzNTMwN2VjYThhNDg3OWI0ZTc1ZTllZjIwNTMzZTlfMjMtMy0xLTEtODE_bfd07b8f-1569-4918-92f5-addb37e0492b"
      unitRef="usd">209469000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xOS9mcmFnOjg3NTU4NGVlZmQ2NzRjZGE4NDc4ZmZhOWY2MTg0NTk1L3RhYmxlOmVjMzUzMDdlY2E4YTQ4NzliNGU3NWU5ZWYyMDUzM2U5L3RhYmxlcmFuZ2U6ZWMzNTMwN2VjYThhNDg3OWI0ZTc1ZTllZjIwNTMzZTlfMjMtNS0xLTEtODE_add4e3dd-c59c-424b-838c-dbe3395ee2fb"
      unitRef="usd">448501000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i0faaba5fcd6b485781cadacae8b2fd8e_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xOS9mcmFnOjg3NTU4NGVlZmQ2NzRjZGE4NDc4ZmZhOWY2MTg0NTk1L3RhYmxlOmVjMzUzMDdlY2E4YTQ4NzliNGU3NWU5ZWYyMDUzM2U5L3RhYmxlcmFuZ2U6ZWMzNTMwN2VjYThhNDg3OWI0ZTc1ZTllZjIwNTMzZTlfMjMtNy0xLTEtODE_2c7ebc4f-9316-4488-8bd9-7ba7dd344929"
      unitRef="usd">450424000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="id673d80f31e74643a241d2f62db94ca9_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xOS9mcmFnOjg3NTU4NGVlZmQ2NzRjZGE4NDc4ZmZhOWY2MTg0NTk1L3RhYmxlOmVjMzUzMDdlY2E4YTQ4NzliNGU3NWU5ZWYyMDUzM2U5L3RhYmxlcmFuZ2U6ZWMzNTMwN2VjYThhNDg3OWI0ZTc1ZTllZjIwNTMzZTlfMjUtMS0xLTEtODE_e5b62851-ab7b-49fe-8dc4-a647abf05ee3"
      unitRef="usd">35813000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i313b15d35b7045babd1ba61f84a077dd_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xOS9mcmFnOjg3NTU4NGVlZmQ2NzRjZGE4NDc4ZmZhOWY2MTg0NTk1L3RhYmxlOmVjMzUzMDdlY2E4YTQ4NzliNGU3NWU5ZWYyMDUzM2U5L3RhYmxlcmFuZ2U6ZWMzNTMwN2VjYThhNDg3OWI0ZTc1ZTllZjIwNTMzZTlfMjUtMy0xLTEtODE_f0b93b48-29cf-48b7-bd41-0e3212a0e4ac"
      unitRef="usd">27730000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xOS9mcmFnOjg3NTU4NGVlZmQ2NzRjZGE4NDc4ZmZhOWY2MTg0NTk1L3RhYmxlOmVjMzUzMDdlY2E4YTQ4NzliNGU3NWU5ZWYyMDUzM2U5L3RhYmxlcmFuZ2U6ZWMzNTMwN2VjYThhNDg3OWI0ZTc1ZTllZjIwNTMzZTlfMjUtNS0xLTEtODE_28efb929-bfe4-4f32-aa00-c5e487d735a3"
      unitRef="usd">136302000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i0faaba5fcd6b485781cadacae8b2fd8e_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xOS9mcmFnOjg3NTU4NGVlZmQ2NzRjZGE4NDc4ZmZhOWY2MTg0NTk1L3RhYmxlOmVjMzUzMDdlY2E4YTQ4NzliNGU3NWU5ZWYyMDUzM2U5L3RhYmxlcmFuZ2U6ZWMzNTMwN2VjYThhNDg3OWI0ZTc1ZTllZjIwNTMzZTlfMjUtNy0xLTEtODE_8e01b7f0-9de9-42a4-ae08-b0aed13a2c93"
      unitRef="usd">65694000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="id673d80f31e74643a241d2f62db94ca9_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xOS9mcmFnOjg3NTU4NGVlZmQ2NzRjZGE4NDc4ZmZhOWY2MTg0NTk1L3RhYmxlOmVjMzUzMDdlY2E4YTQ4NzliNGU3NWU5ZWYyMDUzM2U5L3RhYmxlcmFuZ2U6ZWMzNTMwN2VjYThhNDg3OWI0ZTc1ZTllZjIwNTMzZTlfMjctMS0xLTEtODE_e652bbb9-e0bf-47bf-b888-50da54ade24d"
      unitRef="usd">112775000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i313b15d35b7045babd1ba61f84a077dd_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xOS9mcmFnOjg3NTU4NGVlZmQ2NzRjZGE4NDc4ZmZhOWY2MTg0NTk1L3RhYmxlOmVjMzUzMDdlY2E4YTQ4NzliNGU3NWU5ZWYyMDUzM2U5L3RhYmxlcmFuZ2U6ZWMzNTMwN2VjYThhNDg3OWI0ZTc1ZTllZjIwNTMzZTlfMjctMy0xLTEtODE_190510b3-a511-41a5-90ac-ee096366eeb5"
      unitRef="usd">181739000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xOS9mcmFnOjg3NTU4NGVlZmQ2NzRjZGE4NDc4ZmZhOWY2MTg0NTk1L3RhYmxlOmVjMzUzMDdlY2E4YTQ4NzliNGU3NWU5ZWYyMDUzM2U5L3RhYmxlcmFuZ2U6ZWMzNTMwN2VjYThhNDg3OWI0ZTc1ZTllZjIwNTMzZTlfMjctNS0xLTEtODE_96bc8eaf-24ef-462a-8305-be967a0179db"
      unitRef="usd">312199000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i0faaba5fcd6b485781cadacae8b2fd8e_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xOS9mcmFnOjg3NTU4NGVlZmQ2NzRjZGE4NDc4ZmZhOWY2MTg0NTk1L3RhYmxlOmVjMzUzMDdlY2E4YTQ4NzliNGU3NWU5ZWYyMDUzM2U5L3RhYmxlcmFuZ2U6ZWMzNTMwN2VjYThhNDg3OWI0ZTc1ZTllZjIwNTMzZTlfMjctNy0xLTEtODE_221b2787-b6a2-471c-8e29-4666edfd0aef"
      unitRef="usd">384730000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="id673d80f31e74643a241d2f62db94ca9_D20220701-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xOS9mcmFnOjg3NTU4NGVlZmQ2NzRjZGE4NDc4ZmZhOWY2MTg0NTk1L3RhYmxlOmVjMzUzMDdlY2E4YTQ4NzliNGU3NWU5ZWYyMDUzM2U5L3RhYmxlcmFuZ2U6ZWMzNTMwN2VjYThhNDg3OWI0ZTc1ZTllZjIwNTMzZTlfMzAtMS0xLTEtODE_42de4210-48f4-4594-accf-240735594cd9"
      unitRef="usdPerShare">0.51</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i313b15d35b7045babd1ba61f84a077dd_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xOS9mcmFnOjg3NTU4NGVlZmQ2NzRjZGE4NDc4ZmZhOWY2MTg0NTk1L3RhYmxlOmVjMzUzMDdlY2E4YTQ4NzliNGU3NWU5ZWYyMDUzM2U5L3RhYmxlcmFuZ2U6ZWMzNTMwN2VjYThhNDg3OWI0ZTc1ZTllZjIwNTMzZTlfMzAtMy0xLTEtODE_87ffe2b2-4174-48d5-9df0-5bf7d0580d3e"
      unitRef="usdPerShare">0.82</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xOS9mcmFnOjg3NTU4NGVlZmQ2NzRjZGE4NDc4ZmZhOWY2MTg0NTk1L3RhYmxlOmVjMzUzMDdlY2E4YTQ4NzliNGU3NWU5ZWYyMDUzM2U5L3RhYmxlcmFuZ2U6ZWMzNTMwN2VjYThhNDg3OWI0ZTc1ZTllZjIwNTMzZTlfMzAtNS0xLTEtODE_12ad026d-dfb3-4f66-beee-48c7609aa8f1"
      unitRef="usdPerShare">1.41</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i0faaba5fcd6b485781cadacae8b2fd8e_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xOS9mcmFnOjg3NTU4NGVlZmQ2NzRjZGE4NDc4ZmZhOWY2MTg0NTk1L3RhYmxlOmVjMzUzMDdlY2E4YTQ4NzliNGU3NWU5ZWYyMDUzM2U5L3RhYmxlcmFuZ2U6ZWMzNTMwN2VjYThhNDg3OWI0ZTc1ZTllZjIwNTMzZTlfMzAtNy0xLTEtODE_2ede3052-a366-46c0-9c61-9895b07f85ae"
      unitRef="usdPerShare">1.75</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="id673d80f31e74643a241d2f62db94ca9_D20220701-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xOS9mcmFnOjg3NTU4NGVlZmQ2NzRjZGE4NDc4ZmZhOWY2MTg0NTk1L3RhYmxlOmVjMzUzMDdlY2E4YTQ4NzliNGU3NWU5ZWYyMDUzM2U5L3RhYmxlcmFuZ2U6ZWMzNTMwN2VjYThhNDg3OWI0ZTc1ZTllZjIwNTMzZTlfMzEtMS0xLTEtODE_60ba120a-b721-4fe7-bee1-921eb9fc152e"
      unitRef="usdPerShare">0.50</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i313b15d35b7045babd1ba61f84a077dd_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xOS9mcmFnOjg3NTU4NGVlZmQ2NzRjZGE4NDc4ZmZhOWY2MTg0NTk1L3RhYmxlOmVjMzUzMDdlY2E4YTQ4NzliNGU3NWU5ZWYyMDUzM2U5L3RhYmxlcmFuZ2U6ZWMzNTMwN2VjYThhNDg3OWI0ZTc1ZTllZjIwNTMzZTlfMzEtMy0xLTEtODE_c593e5aa-c706-426b-aa30-0590e6bffbe8"
      unitRef="usdPerShare">0.82</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xOS9mcmFnOjg3NTU4NGVlZmQ2NzRjZGE4NDc4ZmZhOWY2MTg0NTk1L3RhYmxlOmVjMzUzMDdlY2E4YTQ4NzliNGU3NWU5ZWYyMDUzM2U5L3RhYmxlcmFuZ2U6ZWMzNTMwN2VjYThhNDg3OWI0ZTc1ZTllZjIwNTMzZTlfMzEtNS0xLTEtODE_dc5d9960-7459-45ba-ae17-da3466c637d1"
      unitRef="usdPerShare">1.40</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i0faaba5fcd6b485781cadacae8b2fd8e_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xOS9mcmFnOjg3NTU4NGVlZmQ2NzRjZGE4NDc4ZmZhOWY2MTg0NTk1L3RhYmxlOmVjMzUzMDdlY2E4YTQ4NzliNGU3NWU5ZWYyMDUzM2U5L3RhYmxlcmFuZ2U6ZWMzNTMwN2VjYThhNDg3OWI0ZTc1ZTllZjIwNTMzZTlfMzEtNy0xLTEtODE_88908711-c9ad-4151-a174-656491efd3e0"
      unitRef="usdPerShare">1.73</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="id673d80f31e74643a241d2f62db94ca9_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xOS9mcmFnOjg3NTU4NGVlZmQ2NzRjZGE4NDc4ZmZhOWY2MTg0NTk1L3RhYmxlOmVjMzUzMDdlY2E4YTQ4NzliNGU3NWU5ZWYyMDUzM2U5L3RhYmxlcmFuZ2U6ZWMzNTMwN2VjYThhNDg3OWI0ZTc1ZTllZjIwNTMzZTlfMzQtMS0xLTEtODE_0035af62-0609-443c-975f-0e83402db160"
      unitRef="shares">222415000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i313b15d35b7045babd1ba61f84a077dd_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xOS9mcmFnOjg3NTU4NGVlZmQ2NzRjZGE4NDc4ZmZhOWY2MTg0NTk1L3RhYmxlOmVjMzUzMDdlY2E4YTQ4NzliNGU3NWU5ZWYyMDUzM2U5L3RhYmxlcmFuZ2U6ZWMzNTMwN2VjYThhNDg3OWI0ZTc1ZTllZjIwNTMzZTlfMzQtMy0xLTEtODE_44d7501c-b877-46ee-a3bf-ac12185b20f4"
      unitRef="shares">220845000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xOS9mcmFnOjg3NTU4NGVlZmQ2NzRjZGE4NDc4ZmZhOWY2MTg0NTk1L3RhYmxlOmVjMzUzMDdlY2E4YTQ4NzliNGU3NWU5ZWYyMDUzM2U5L3RhYmxlcmFuZ2U6ZWMzNTMwN2VjYThhNDg3OWI0ZTc1ZTllZjIwNTMzZTlfMzQtNS0xLTEtODE_8f87b66e-fbc6-4df7-a464-3dada21e87de"
      unitRef="shares">221801000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i0faaba5fcd6b485781cadacae8b2fd8e_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xOS9mcmFnOjg3NTU4NGVlZmQ2NzRjZGE4NDc4ZmZhOWY2MTg0NTk1L3RhYmxlOmVjMzUzMDdlY2E4YTQ4NzliNGU3NWU5ZWYyMDUzM2U5L3RhYmxlcmFuZ2U6ZWMzNTMwN2VjYThhNDg3OWI0ZTc1ZTllZjIwNTMzZTlfMzQtNy0xLTEtODE_0f31e097-29a5-4748-8cea-7cc6ce1cce0e"
      unitRef="shares">220243000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="id673d80f31e74643a241d2f62db94ca9_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xOS9mcmFnOjg3NTU4NGVlZmQ2NzRjZGE4NDc4ZmZhOWY2MTg0NTk1L3RhYmxlOmVjMzUzMDdlY2E4YTQ4NzliNGU3NWU5ZWYyMDUzM2U5L3RhYmxlcmFuZ2U6ZWMzNTMwN2VjYThhNDg3OWI0ZTc1ZTllZjIwNTMzZTlfMzUtMS0xLTEtODE_eb3a6437-dff3-4130-8460-51f42747ee15"
      unitRef="shares">224175000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i313b15d35b7045babd1ba61f84a077dd_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xOS9mcmFnOjg3NTU4NGVlZmQ2NzRjZGE4NDc4ZmZhOWY2MTg0NTk1L3RhYmxlOmVjMzUzMDdlY2E4YTQ4NzliNGU3NWU5ZWYyMDUzM2U5L3RhYmxlcmFuZ2U6ZWMzNTMwN2VjYThhNDg3OWI0ZTc1ZTllZjIwNTMzZTlfMzUtMy0xLTEtODE_2263b553-6b68-4577-a3c6-0b8dc27b3346"
      unitRef="shares">222248000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xOS9mcmFnOjg3NTU4NGVlZmQ2NzRjZGE4NDc4ZmZhOWY2MTg0NTk1L3RhYmxlOmVjMzUzMDdlY2E4YTQ4NzliNGU3NWU5ZWYyMDUzM2U5L3RhYmxlcmFuZ2U6ZWMzNTMwN2VjYThhNDg3OWI0ZTc1ZTllZjIwNTMzZTlfMzUtNS0xLTEtODE_b5a8edf7-f8f6-4eb7-a418-a29a7badfb4a"
      unitRef="shares">223626000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i0faaba5fcd6b485781cadacae8b2fd8e_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8xOS9mcmFnOjg3NTU4NGVlZmQ2NzRjZGE4NDc4ZmZhOWY2MTg0NTk1L3RhYmxlOmVjMzUzMDdlY2E4YTQ4NzliNGU3NWU5ZWYyMDUzM2U5L3RhYmxlcmFuZ2U6ZWMzNTMwN2VjYThhNDg3OWI0ZTc1ZTllZjIwNTMzZTlfMzUtNy0xLTEtODE_75f62574-fa07-4d3e-bc4e-0ba3a6302196"
      unitRef="shares">222113000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="id673d80f31e74643a241d2f62db94ca9_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yMi9mcmFnOmRjN2EwYjIzNGZmOTRlMDI5MDdiMjVlMTQ2ZWRiZjM2L3RhYmxlOjBhMTlhOWZiOTdlYjQ0Yjg5N2UzYmYxZmY3NDY3NWViL3RhYmxlcmFuZ2U6MGExOWE5ZmI5N2ViNDRiODk3ZTNiZjFmZjc0Njc1ZWJfMi0xLTEtMS04MQ_dbb944d3-e8c8-4a62-8f9c-70a7d862556e"
      unitRef="usd">112775000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i313b15d35b7045babd1ba61f84a077dd_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yMi9mcmFnOmRjN2EwYjIzNGZmOTRlMDI5MDdiMjVlMTQ2ZWRiZjM2L3RhYmxlOjBhMTlhOWZiOTdlYjQ0Yjg5N2UzYmYxZmY3NDY3NWViL3RhYmxlcmFuZ2U6MGExOWE5ZmI5N2ViNDRiODk3ZTNiZjFmZjc0Njc1ZWJfMi0zLTEtMS04MQ_7a0217f5-2ff7-4667-852f-f4b79504e28e"
      unitRef="usd">181739000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yMi9mcmFnOmRjN2EwYjIzNGZmOTRlMDI5MDdiMjVlMTQ2ZWRiZjM2L3RhYmxlOjBhMTlhOWZiOTdlYjQ0Yjg5N2UzYmYxZmY3NDY3NWViL3RhYmxlcmFuZ2U6MGExOWE5ZmI5N2ViNDRiODk3ZTNiZjFmZjc0Njc1ZWJfMi01LTEtMS04MQ_645f944f-926c-4fd8-812b-4e60ab7b4e92"
      unitRef="usd">312199000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i0faaba5fcd6b485781cadacae8b2fd8e_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yMi9mcmFnOmRjN2EwYjIzNGZmOTRlMDI5MDdiMjVlMTQ2ZWRiZjM2L3RhYmxlOjBhMTlhOWZiOTdlYjQ0Yjg5N2UzYmYxZmY3NDY3NWViL3RhYmxlcmFuZ2U6MGExOWE5ZmI5N2ViNDRiODk3ZTNiZjFmZjc0Njc1ZWJfMi03LTEtMS04MQ_edf8fe72-f049-4182-8bf3-70574e74b64b"
      unitRef="usd">384730000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="id673d80f31e74643a241d2f62db94ca9_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yMi9mcmFnOmRjN2EwYjIzNGZmOTRlMDI5MDdiMjVlMTQ2ZWRiZjM2L3RhYmxlOjBhMTlhOWZiOTdlYjQ0Yjg5N2UzYmYxZmY3NDY3NWViL3RhYmxlcmFuZ2U6MGExOWE5ZmI5N2ViNDRiODk3ZTNiZjFmZjc0Njc1ZWJfNS0xLTEtMS04MQ_4248e7a6-8e46-4531-a327-cf24e433900b"
      unitRef="usd">-2513000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i313b15d35b7045babd1ba61f84a077dd_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yMi9mcmFnOmRjN2EwYjIzNGZmOTRlMDI5MDdiMjVlMTQ2ZWRiZjM2L3RhYmxlOjBhMTlhOWZiOTdlYjQ0Yjg5N2UzYmYxZmY3NDY3NWViL3RhYmxlcmFuZ2U6MGExOWE5ZmI5N2ViNDRiODk3ZTNiZjFmZjc0Njc1ZWJfNS0zLTEtMS04MQ_7577e695-ab6a-442e-9f4d-bcb77d02c149"
      unitRef="usd">-629000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yMi9mcmFnOmRjN2EwYjIzNGZmOTRlMDI5MDdiMjVlMTQ2ZWRiZjM2L3RhYmxlOjBhMTlhOWZiOTdlYjQ0Yjg5N2UzYmYxZmY3NDY3NWViL3RhYmxlcmFuZ2U6MGExOWE5ZmI5N2ViNDRiODk3ZTNiZjFmZjc0Njc1ZWJfNS01LTEtMS04MQ_82e89630-6f74-4484-9b50-80c00e821600"
      unitRef="usd">-5132000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i0faaba5fcd6b485781cadacae8b2fd8e_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yMi9mcmFnOmRjN2EwYjIzNGZmOTRlMDI5MDdiMjVlMTQ2ZWRiZjM2L3RhYmxlOjBhMTlhOWZiOTdlYjQ0Yjg5N2UzYmYxZmY3NDY3NWViL3RhYmxlcmFuZ2U6MGExOWE5ZmI5N2ViNDRiODk3ZTNiZjFmZjc0Njc1ZWJfNS03LTEtMS04MQ_13650ad5-1557-43f4-a644-38c1279b8103"
      unitRef="usd">-4061000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="id673d80f31e74643a241d2f62db94ca9_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yMi9mcmFnOmRjN2EwYjIzNGZmOTRlMDI5MDdiMjVlMTQ2ZWRiZjM2L3RhYmxlOjBhMTlhOWZiOTdlYjQ0Yjg5N2UzYmYxZmY3NDY3NWViL3RhYmxlcmFuZ2U6MGExOWE5ZmI5N2ViNDRiODk3ZTNiZjFmZjc0Njc1ZWJfNi0xLTEtMS04MQ_2759dedd-8f24-4b80-b066-cb8d4d2008df"
      unitRef="usd">-1135000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i313b15d35b7045babd1ba61f84a077dd_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yMi9mcmFnOmRjN2EwYjIzNGZmOTRlMDI5MDdiMjVlMTQ2ZWRiZjM2L3RhYmxlOjBhMTlhOWZiOTdlYjQ0Yjg5N2UzYmYxZmY3NDY3NWViL3RhYmxlcmFuZ2U6MGExOWE5ZmI5N2ViNDRiODk3ZTNiZjFmZjc0Njc1ZWJfNi0zLTEtMS04MQ_6610f72c-2ecc-44fe-8b80-745f9bb3bbc7"
      unitRef="usd">-86000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yMi9mcmFnOmRjN2EwYjIzNGZmOTRlMDI5MDdiMjVlMTQ2ZWRiZjM2L3RhYmxlOjBhMTlhOWZiOTdlYjQ0Yjg5N2UzYmYxZmY3NDY3NWViL3RhYmxlcmFuZ2U6MGExOWE5ZmI5N2ViNDRiODk3ZTNiZjFmZjc0Njc1ZWJfNi01LTEtMS04MQ_ec3cb3e3-7a9c-4bd4-823b-6d2a52bea0c6"
      unitRef="usd">-5322000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i0faaba5fcd6b485781cadacae8b2fd8e_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yMi9mcmFnOmRjN2EwYjIzNGZmOTRlMDI5MDdiMjVlMTQ2ZWRiZjM2L3RhYmxlOjBhMTlhOWZiOTdlYjQ0Yjg5N2UzYmYxZmY3NDY3NWViL3RhYmxlcmFuZ2U6MGExOWE5ZmI5N2ViNDRiODk3ZTNiZjFmZjc0Njc1ZWJfNi03LTEtMS04MQ_89bd94f7-e7a0-4a0c-ac3b-80dc39d3ff34"
      unitRef="usd">-251000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
      contextRef="id673d80f31e74643a241d2f62db94ca9_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yMi9mcmFnOmRjN2EwYjIzNGZmOTRlMDI5MDdiMjVlMTQ2ZWRiZjM2L3RhYmxlOjBhMTlhOWZiOTdlYjQ0Yjg5N2UzYmYxZmY3NDY3NWViL3RhYmxlcmFuZ2U6MGExOWE5ZmI5N2ViNDRiODk3ZTNiZjFmZjc0Njc1ZWJfNy0xLTEtMS04MQ_d6a54f3c-9850-4e8f-b2eb-0281cb78e803"
      unitRef="usd">-282000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
      contextRef="i313b15d35b7045babd1ba61f84a077dd_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yMi9mcmFnOmRjN2EwYjIzNGZmOTRlMDI5MDdiMjVlMTQ2ZWRiZjM2L3RhYmxlOjBhMTlhOWZiOTdlYjQ0Yjg5N2UzYmYxZmY3NDY3NWViL3RhYmxlcmFuZ2U6MGExOWE5ZmI5N2ViNDRiODk3ZTNiZjFmZjc0Njc1ZWJfNy0zLTEtMS04MQ_92be5c74-cef0-4d74-8cff-9f3526f6c6ea"
      unitRef="usd">-342000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
      contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yMi9mcmFnOmRjN2EwYjIzNGZmOTRlMDI5MDdiMjVlMTQ2ZWRiZjM2L3RhYmxlOjBhMTlhOWZiOTdlYjQ0Yjg5N2UzYmYxZmY3NDY3NWViL3RhYmxlcmFuZ2U6MGExOWE5ZmI5N2ViNDRiODk3ZTNiZjFmZjc0Njc1ZWJfNy01LTEtMS04MQ_c79ff252-1330-434d-b393-8faa8b6bb27a"
      unitRef="usd">-846000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
      contextRef="i0faaba5fcd6b485781cadacae8b2fd8e_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yMi9mcmFnOmRjN2EwYjIzNGZmOTRlMDI5MDdiMjVlMTQ2ZWRiZjM2L3RhYmxlOjBhMTlhOWZiOTdlYjQ0Yjg5N2UzYmYxZmY3NDY3NWViL3RhYmxlcmFuZ2U6MGExOWE5ZmI5N2ViNDRiODk3ZTNiZjFmZjc0Njc1ZWJfNy03LTEtMS04MQ_ad4a08ca-629e-43e2-a260-a1cd45dac369"
      unitRef="usd">-1026000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="id673d80f31e74643a241d2f62db94ca9_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yMi9mcmFnOmRjN2EwYjIzNGZmOTRlMDI5MDdiMjVlMTQ2ZWRiZjM2L3RhYmxlOjBhMTlhOWZiOTdlYjQ0Yjg5N2UzYmYxZmY3NDY3NWViL3RhYmxlcmFuZ2U6MGExOWE5ZmI5N2ViNDRiODk3ZTNiZjFmZjc0Njc1ZWJfOC0xLTEtMS04MQ_b670fd5a-6a19-4fa1-9a99-a6f2b172bd50"
      unitRef="usd">-3366000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i313b15d35b7045babd1ba61f84a077dd_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yMi9mcmFnOmRjN2EwYjIzNGZmOTRlMDI5MDdiMjVlMTQ2ZWRiZjM2L3RhYmxlOjBhMTlhOWZiOTdlYjQ0Yjg5N2UzYmYxZmY3NDY3NWViL3RhYmxlcmFuZ2U6MGExOWE5ZmI5N2ViNDRiODk3ZTNiZjFmZjc0Njc1ZWJfOC0zLTEtMS04MQ_6f3a8e47-e4cd-4ae8-9e8f-5b2276ed7b0c"
      unitRef="usd">-373000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yMi9mcmFnOmRjN2EwYjIzNGZmOTRlMDI5MDdiMjVlMTQ2ZWRiZjM2L3RhYmxlOjBhMTlhOWZiOTdlYjQ0Yjg5N2UzYmYxZmY3NDY3NWViL3RhYmxlcmFuZ2U6MGExOWE5ZmI5N2ViNDRiODk3ZTNiZjFmZjc0Njc1ZWJfOC01LTEtMS04MQ_5c4a6337-1941-4779-922f-37df93fa3658"
      unitRef="usd">-9608000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i0faaba5fcd6b485781cadacae8b2fd8e_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yMi9mcmFnOmRjN2EwYjIzNGZmOTRlMDI5MDdiMjVlMTQ2ZWRiZjM2L3RhYmxlOjBhMTlhOWZiOTdlYjQ0Yjg5N2UzYmYxZmY3NDY3NWViL3RhYmxlcmFuZ2U6MGExOWE5ZmI5N2ViNDRiODk3ZTNiZjFmZjc0Njc1ZWJfOC03LTEtMS04MQ_dd638787-d8eb-409a-8860-a226043ab8e0"
      unitRef="usd">-3286000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="id673d80f31e74643a241d2f62db94ca9_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yMi9mcmFnOmRjN2EwYjIzNGZmOTRlMDI5MDdiMjVlMTQ2ZWRiZjM2L3RhYmxlOjBhMTlhOWZiOTdlYjQ0Yjg5N2UzYmYxZmY3NDY3NWViL3RhYmxlcmFuZ2U6MGExOWE5ZmI5N2ViNDRiODk3ZTNiZjFmZjc0Njc1ZWJfMTAtMS0xLTEtODE_5e656765-e1d7-46b1-b57a-fc1a753dc5c2"
      unitRef="usd">109409000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i313b15d35b7045babd1ba61f84a077dd_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yMi9mcmFnOmRjN2EwYjIzNGZmOTRlMDI5MDdiMjVlMTQ2ZWRiZjM2L3RhYmxlOjBhMTlhOWZiOTdlYjQ0Yjg5N2UzYmYxZmY3NDY3NWViL3RhYmxlcmFuZ2U6MGExOWE5ZmI5N2ViNDRiODk3ZTNiZjFmZjc0Njc1ZWJfMTAtMy0xLTEtODE_ed2643a5-fb2b-4a26-89b8-9ee7524a3775"
      unitRef="usd">181366000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yMi9mcmFnOmRjN2EwYjIzNGZmOTRlMDI5MDdiMjVlMTQ2ZWRiZjM2L3RhYmxlOjBhMTlhOWZiOTdlYjQ0Yjg5N2UzYmYxZmY3NDY3NWViL3RhYmxlcmFuZ2U6MGExOWE5ZmI5N2ViNDRiODk3ZTNiZjFmZjc0Njc1ZWJfMTAtNS0xLTEtODE_9183eed5-f283-4fb6-8763-8ebc2fd13b35"
      unitRef="usd">302591000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i0faaba5fcd6b485781cadacae8b2fd8e_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yMi9mcmFnOmRjN2EwYjIzNGZmOTRlMDI5MDdiMjVlMTQ2ZWRiZjM2L3RhYmxlOjBhMTlhOWZiOTdlYjQ0Yjg5N2UzYmYxZmY3NDY3NWViL3RhYmxlcmFuZ2U6MGExOWE5ZmI5N2ViNDRiODk3ZTNiZjFmZjc0Njc1ZWJfMTAtNy0xLTEtODE_58b8f89e-8ccb-412b-93ef-d373b4c89ba5"
      unitRef="usd">381444000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="ib3978ca7e91d4a55b0da8a410f53aea4_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjQ2MmI1OGU4NTY5NTRlMGJhZGRiNjYwNjMwMzVhZjFjL3RhYmxlcmFuZ2U6NDYyYjU4ZTg1Njk1NGUwYmFkZGI2NjA2MzAzNWFmMWNfMS0xLTEtMS04MQ_b1e46adb-90eb-4b64-af79-618122d9e2b1"
      unitRef="usd">221000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i1a13b312028f458ba711e0bcf4618c10_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjQ2MmI1OGU4NTY5NTRlMGJhZGRiNjYwNjMwMzVhZjFjL3RhYmxlcmFuZ2U6NDYyYjU4ZTg1Njk1NGUwYmFkZGI2NjA2MzAzNWFmMWNfMS0zLTEtMS04MQ_c068c041-f021-4750-a91f-2f3f25346b69"
      unitRef="usd">4567111000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic7a3e053f47b40869b9b63c44edaac78_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjQ2MmI1OGU4NTY5NTRlMGJhZGRiNjYwNjMwMzVhZjFjL3RhYmxlcmFuZ2U6NDYyYjU4ZTg1Njk1NGUwYmFkZGI2NjA2MzAzNWFmMWNfMS01LTEtMS04MQ_97b97847-9915-4222-84d6-32f83766b8f3"
      unitRef="usd">-19454000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4cba8f9e546d4c0498d87ceb40e69a8f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjQ2MmI1OGU4NTY5NTRlMGJhZGRiNjYwNjMwMzVhZjFjL3RhYmxlcmFuZ2U6NDYyYjU4ZTg1Njk1NGUwYmFkZGI2NjA2MzAzNWFmMWNfMS03LTEtMS04MQ_a4982fef-5a60-4dc4-b179-0c65cb42fac7"
      unitRef="usd">-777874000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iab26fe441f0d4ab984456365a7f7cff0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjQ2MmI1OGU4NTY5NTRlMGJhZGRiNjYwNjMwMzVhZjFjL3RhYmxlcmFuZ2U6NDYyYjU4ZTg1Njk1NGUwYmFkZGI2NjA2MzAzNWFmMWNfMS05LTEtMS04MQ_5e4eea8e-234e-48dd-8be1-cf7b2088e511"
      unitRef="usd">3770004000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i6cea24b8bb274decac908bfad3a9c638_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjQ2MmI1OGU4NTY5NTRlMGJhZGRiNjYwNjMwMzVhZjFjL3RhYmxlcmFuZ2U6NDYyYjU4ZTg1Njk1NGUwYmFkZGI2NjA2MzAzNWFmMWNfMi0wLTEtMS04MS90ZXh0cmVnaW9uOjIwNjAxNjFiNjA3ZTQ4MGE5NTM0MTE3ZDVlNTUxYTgyXzE2_434be87c-26e9-45c5-83a1-01c9fab1b9a8"
      unitRef="shares">323582</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ia3d452137b9d47e98488b6d8f51dd20b_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjQ2MmI1OGU4NTY5NTRlMGJhZGRiNjYwNjMwMzVhZjFjL3RhYmxlcmFuZ2U6NDYyYjU4ZTg1Njk1NGUwYmFkZGI2NjA2MzAzNWFmMWNfMi0zLTEtMS04MQ_50b35277-6fac-469a-86b0-3461712d7fc2"
      unitRef="usd">14237000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i6cea24b8bb274decac908bfad3a9c638_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjQ2MmI1OGU4NTY5NTRlMGJhZGRiNjYwNjMwMzVhZjFjL3RhYmxlcmFuZ2U6NDYyYjU4ZTg1Njk1NGUwYmFkZGI2NjA2MzAzNWFmMWNfMi05LTEtMS04MQ_c6c69ec2-ef19-4438-82b5-76342c8bdf21"
      unitRef="usd">14237000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="i6cea24b8bb274decac908bfad3a9c638_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjQ2MmI1OGU4NTY5NTRlMGJhZGRiNjYwNjMwMzVhZjFjL3RhYmxlcmFuZ2U6NDYyYjU4ZTg1Njk1NGUwYmFkZGI2NjA2MzAzNWFmMWNfMy0wLTEtMS04MS90ZXh0cmVnaW9uOjcxMDlkYWZkM2RkYTQxOGFhNGVlZTEzOTVjMzg5MTIxXzE2_eb9c1fd5-5f15-4c02-8dd9-42992d605dfb"
      unitRef="shares">1535</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="ia3d452137b9d47e98488b6d8f51dd20b_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjQ2MmI1OGU4NTY5NTRlMGJhZGRiNjYwNjMwMzVhZjFjL3RhYmxlcmFuZ2U6NDYyYjU4ZTg1Njk1NGUwYmFkZGI2NjA2MzAzNWFmMWNfMy0zLTEtMS04MQ_632f525e-5064-411c-b8e0-7956843f2b41"
      unitRef="usd">112000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="i6cea24b8bb274decac908bfad3a9c638_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjQ2MmI1OGU4NTY5NTRlMGJhZGRiNjYwNjMwMzVhZjFjL3RhYmxlcmFuZ2U6NDYyYjU4ZTg1Njk1NGUwYmFkZGI2NjA2MzAzNWFmMWNfMy05LTEtMS04MQ_eec39ccc-ade4-47f8-bf63-0a18bba3d1d3"
      unitRef="usd">112000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ia3d452137b9d47e98488b6d8f51dd20b_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjQ2MmI1OGU4NTY5NTRlMGJhZGRiNjYwNjMwMzVhZjFjL3RhYmxlcmFuZ2U6NDYyYjU4ZTg1Njk1NGUwYmFkZGI2NjA2MzAzNWFmMWNfNC0zLTEtMS04MQ_f88a8cbf-ef46-4bbd-a1d2-ca8cb57a1b44"
      unitRef="usd">44320000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i6cea24b8bb274decac908bfad3a9c638_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjQ2MmI1OGU4NTY5NTRlMGJhZGRiNjYwNjMwMzVhZjFjL3RhYmxlcmFuZ2U6NDYyYjU4ZTg1Njk1NGUwYmFkZGI2NjA2MzAzNWFmMWNfNC05LTEtMS04MQ_100bfe9a-07ba-45a1-af29-8f3bf6185f9f"
      unitRef="usd">44320000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i05bc3079ebc64f4a9ddcc9c745ce3823_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjQ2MmI1OGU4NTY5NTRlMGJhZGRiNjYwNjMwMzVhZjFjL3RhYmxlcmFuZ2U6NDYyYjU4ZTg1Njk1NGUwYmFkZGI2NjA2MzAzNWFmMWNfNS01LTEtMS04MQ_124a206f-ff26-4497-8941-35d3cf3c896e"
      unitRef="usd">-3593000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i6cea24b8bb274decac908bfad3a9c638_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjQ2MmI1OGU4NTY5NTRlMGJhZGRiNjYwNjMwMzVhZjFjL3RhYmxlcmFuZ2U6NDYyYjU4ZTg1Njk1NGUwYmFkZGI2NjA2MzAzNWFmMWNfNS05LTEtMS04MQ_bcad2773-80b5-4d81-b3b4-29c92057cc87"
      unitRef="usd">-3593000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="ibabc38cb3fd14f2698896bf6570c921e_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjQ2MmI1OGU4NTY5NTRlMGJhZGRiNjYwNjMwMzVhZjFjL3RhYmxlcmFuZ2U6NDYyYjU4ZTg1Njk1NGUwYmFkZGI2NjA2MzAzNWFmMWNfNi03LTEtMS04MQ_687d8f36-2920-43e7-92a9-886223fc8010"
      unitRef="usd">37992000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i6cea24b8bb274decac908bfad3a9c638_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjQ2MmI1OGU4NTY5NTRlMGJhZGRiNjYwNjMwMzVhZjFjL3RhYmxlcmFuZ2U6NDYyYjU4ZTg1Njk1NGUwYmFkZGI2NjA2MzAzNWFmMWNfNi05LTEtMS04MQ_1d45b454-286f-455d-8c71-ef578a987479"
      unitRef="usd">37992000</us-gaap:NetIncomeLoss>
    <us-gaap:StockholdersEquity
      contextRef="i967717e321b54b36a61c6fc27425f9af_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjQ2MmI1OGU4NTY5NTRlMGJhZGRiNjYwNjMwMzVhZjFjL3RhYmxlcmFuZ2U6NDYyYjU4ZTg1Njk1NGUwYmFkZGI2NjA2MzAzNWFmMWNfNy0xLTEtMS04MQ_a940731c-cafc-456a-992a-eee37f53278c"
      unitRef="usd">221000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie914017719d349ea93b5d5a6cd062896_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjQ2MmI1OGU4NTY5NTRlMGJhZGRiNjYwNjMwMzVhZjFjL3RhYmxlcmFuZ2U6NDYyYjU4ZTg1Njk1NGUwYmFkZGI2NjA2MzAzNWFmMWNfNy0zLTEtMS04MQ_9504dc10-7dae-4ca5-9d93-9eef8ee21692"
      unitRef="usd">4625780000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5bc89bf0de084e20a0006dad354ec6b3_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjQ2MmI1OGU4NTY5NTRlMGJhZGRiNjYwNjMwMzVhZjFjL3RhYmxlcmFuZ2U6NDYyYjU4ZTg1Njk1NGUwYmFkZGI2NjA2MzAzNWFmMWNfNy01LTEtMS04MQ_5ff5435b-87c8-410c-90d9-a1cd1eef82a2"
      unitRef="usd">-23047000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i1c77ebb088a04a3bb81e477173b73514_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjQ2MmI1OGU4NTY5NTRlMGJhZGRiNjYwNjMwMzVhZjFjL3RhYmxlcmFuZ2U6NDYyYjU4ZTg1Njk1NGUwYmFkZGI2NjA2MzAzNWFmMWNfNy03LTEtMS04MQ_95c2272c-9fc7-41a9-88a5-4e060ea0400a"
      unitRef="usd">-739882000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i38aa3d9ea1274ad1a0d50c3c12756c65_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjQ2MmI1OGU4NTY5NTRlMGJhZGRiNjYwNjMwMzVhZjFjL3RhYmxlcmFuZ2U6NDYyYjU4ZTg1Njk1NGUwYmFkZGI2NjA2MzAzNWFmMWNfNy05LTEtMS04MQ_3f4d69ca-6395-4c10-81d9-6d93c2dabee4"
      unitRef="usd">3863072000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="if098df40ebae4afbb01da4049e945b36_D20220401-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjQ2MmI1OGU4NTY5NTRlMGJhZGRiNjYwNjMwMzVhZjFjL3RhYmxlcmFuZ2U6NDYyYjU4ZTg1Njk1NGUwYmFkZGI2NjA2MzAzNWFmMWNfOC0wLTEtMS04MS90ZXh0cmVnaW9uOmY5ZWRhMTRiYTZkNzQ3Mjg4MjhhMDRjNDBkZGRjMzNiXzE2_c2ef68b4-3fb7-4675-a640-612ec73dd8a5"
      unitRef="shares">274693</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="if098df40ebae4afbb01da4049e945b36_D20220401-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjQ2MmI1OGU4NTY5NTRlMGJhZGRiNjYwNjMwMzVhZjFjL3RhYmxlcmFuZ2U6NDYyYjU4ZTg1Njk1NGUwYmFkZGI2NjA2MzAzNWFmMWNfOC0wLTEtMS04MS90ZXh0cmVnaW9uOmY5ZWRhMTRiYTZkNzQ3Mjg4MjhhMDRjNDBkZGRjMzNiXzE4NA_bcfc0efe-cab3-4da0-a38f-5fdffc336274"
      unitRef="shares">189684</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <incy:StockIssuedDuringPeriodValueStockOptionsAndRestrictedStockUnitsExercisedAndEmployeeStockPurchasePlan
      contextRef="i92fea5bb4d2c40d19ea9af7ae6522acf_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjQ2MmI1OGU4NTY5NTRlMGJhZGRiNjYwNjMwMzVhZjFjL3RhYmxlcmFuZ2U6NDYyYjU4ZTg1Njk1NGUwYmFkZGI2NjA2MzAzNWFmMWNfOC0xLTEtMS04MQ_f645c40c-d6dc-43b1-98ae-a1126da925e3"
      unitRef="usd">1000</incy:StockIssuedDuringPeriodValueStockOptionsAndRestrictedStockUnitsExercisedAndEmployeeStockPurchasePlan>
    <incy:StockIssuedDuringPeriodValueStockOptionsAndRestrictedStockUnitsExercisedAndEmployeeStockPurchasePlan
      contextRef="idff6b81e3d0245e797ebe0c300a68bfb_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjQ2MmI1OGU4NTY5NTRlMGJhZGRiNjYwNjMwMzVhZjFjL3RhYmxlcmFuZ2U6NDYyYjU4ZTg1Njk1NGUwYmFkZGI2NjA2MzAzNWFmMWNfOC0zLTEtMS04MQ_cdd3e05a-dad1-4d7a-b9bf-713853cad451"
      unitRef="usd">16600000</incy:StockIssuedDuringPeriodValueStockOptionsAndRestrictedStockUnitsExercisedAndEmployeeStockPurchasePlan>
    <incy:StockIssuedDuringPeriodValueStockOptionsAndRestrictedStockUnitsExercisedAndEmployeeStockPurchasePlan
      contextRef="if098df40ebae4afbb01da4049e945b36_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjQ2MmI1OGU4NTY5NTRlMGJhZGRiNjYwNjMwMzVhZjFjL3RhYmxlcmFuZ2U6NDYyYjU4ZTg1Njk1NGUwYmFkZGI2NjA2MzAzNWFmMWNfOC05LTEtMS04MQ_34363ad5-f57c-4cef-8284-622c3105a88f"
      unitRef="usd">16601000</incy:StockIssuedDuringPeriodValueStockOptionsAndRestrictedStockUnitsExercisedAndEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="if098df40ebae4afbb01da4049e945b36_D20220401-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjQ2MmI1OGU4NTY5NTRlMGJhZGRiNjYwNjMwMzVhZjFjL3RhYmxlcmFuZ2U6NDYyYjU4ZTg1Njk1NGUwYmFkZGI2NjA2MzAzNWFmMWNfOS0wLTEtMS04MS90ZXh0cmVnaW9uOjczYjAyZWI2YWYzNTQ0ZjRiMWQxNjQxNzQ2NThhYzI3XzE2_57965b27-deff-4fbd-b575-4cede4277821"
      unitRef="shares">1469</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="idff6b81e3d0245e797ebe0c300a68bfb_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjQ2MmI1OGU4NTY5NTRlMGJhZGRiNjYwNjMwMzVhZjFjL3RhYmxlcmFuZ2U6NDYyYjU4ZTg1Njk1NGUwYmFkZGI2NjA2MzAzNWFmMWNfOS0zLTEtMS04MQ_f6108c3c-1d59-44bf-b790-802cd0d471c6"
      unitRef="usd">109000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="if098df40ebae4afbb01da4049e945b36_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjQ2MmI1OGU4NTY5NTRlMGJhZGRiNjYwNjMwMzVhZjFjL3RhYmxlcmFuZ2U6NDYyYjU4ZTg1Njk1NGUwYmFkZGI2NjA2MzAzNWFmMWNfOS05LTEtMS04MQ_b11a2ab1-6c12-497c-9d18-c57bf1270c6d"
      unitRef="usd">109000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="idff6b81e3d0245e797ebe0c300a68bfb_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjQ2MmI1OGU4NTY5NTRlMGJhZGRiNjYwNjMwMzVhZjFjL3RhYmxlcmFuZ2U6NDYyYjU4ZTg1Njk1NGUwYmFkZGI2NjA2MzAzNWFmMWNfMTAtMy0xLTEtODE_b779a348-6e63-40ca-9c04-9c078544b809"
      unitRef="usd">46496000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="if098df40ebae4afbb01da4049e945b36_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjQ2MmI1OGU4NTY5NTRlMGJhZGRiNjYwNjMwMzVhZjFjL3RhYmxlcmFuZ2U6NDYyYjU4ZTg1Njk1NGUwYmFkZGI2NjA2MzAzNWFmMWNfMTAtOS0xLTEtODE_b8c403bb-22b6-4238-aa19-a5599547c6ae"
      unitRef="usd">46496000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i623f636b1e544597bf91776873f38e5d_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjQ2MmI1OGU4NTY5NTRlMGJhZGRiNjYwNjMwMzVhZjFjL3RhYmxlcmFuZ2U6NDYyYjU4ZTg1Njk1NGUwYmFkZGI2NjA2MzAzNWFmMWNfMTEtNS0xLTEtODE_7a521de9-7fa0-49ad-bd0a-b13c1a92280e"
      unitRef="usd">-2649000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="if098df40ebae4afbb01da4049e945b36_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjQ2MmI1OGU4NTY5NTRlMGJhZGRiNjYwNjMwMzVhZjFjL3RhYmxlcmFuZ2U6NDYyYjU4ZTg1Njk1NGUwYmFkZGI2NjA2MzAzNWFmMWNfMTEtOS0xLTEtODE_318b5e21-26d4-4c26-a90b-2bb3e9e64a06"
      unitRef="usd">-2649000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="i83c026db6e174249812a82f711cb1f78_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjQ2MmI1OGU4NTY5NTRlMGJhZGRiNjYwNjMwMzVhZjFjL3RhYmxlcmFuZ2U6NDYyYjU4ZTg1Njk1NGUwYmFkZGI2NjA2MzAzNWFmMWNfMTItNy0xLTEtODE_042e3fc6-e220-4a39-868e-044908785ab4"
      unitRef="usd">161432000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="if098df40ebae4afbb01da4049e945b36_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjQ2MmI1OGU4NTY5NTRlMGJhZGRiNjYwNjMwMzVhZjFjL3RhYmxlcmFuZ2U6NDYyYjU4ZTg1Njk1NGUwYmFkZGI2NjA2MzAzNWFmMWNfMTItOS0xLTEtODE_aa33507e-87b8-42aa-b8c9-410a8d719eec"
      unitRef="usd">161432000</us-gaap:NetIncomeLoss>
    <us-gaap:StockholdersEquity
      contextRef="i083ff8458e9c4ae38eb154dc7ce1f9a0_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjQ2MmI1OGU4NTY5NTRlMGJhZGRiNjYwNjMwMzVhZjFjL3RhYmxlcmFuZ2U6NDYyYjU4ZTg1Njk1NGUwYmFkZGI2NjA2MzAzNWFmMWNfMTMtMS0xLTEtODE_5d56415f-64e6-4fa9-bab9-246bc39c83ce"
      unitRef="usd">222000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6f8d696d0d544a858bc29abec7dae8d2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjQ2MmI1OGU4NTY5NTRlMGJhZGRiNjYwNjMwMzVhZjFjL3RhYmxlcmFuZ2U6NDYyYjU4ZTg1Njk1NGUwYmFkZGI2NjA2MzAzNWFmMWNfMTMtMy0xLTEtODE_ec820b68-b322-4700-ab8a-ecfb3381ca39"
      unitRef="usd">4688985000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if646a3c30a6b46ec8912b9038eb7f0bf_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjQ2MmI1OGU4NTY5NTRlMGJhZGRiNjYwNjMwMzVhZjFjL3RhYmxlcmFuZ2U6NDYyYjU4ZTg1Njk1NGUwYmFkZGI2NjA2MzAzNWFmMWNfMTMtNS0xLTEtODE_78a26eb4-1673-441e-b905-c187046a979e"
      unitRef="usd">-25696000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5b880c3983264395b93d1f6014da990c_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjQ2MmI1OGU4NTY5NTRlMGJhZGRiNjYwNjMwMzVhZjFjL3RhYmxlcmFuZ2U6NDYyYjU4ZTg1Njk1NGUwYmFkZGI2NjA2MzAzNWFmMWNfMTMtNy0xLTEtODE_b4517365-0591-4301-979e-d633273457b7"
      unitRef="usd">-578450000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if6f74963df2d4ed483d364c3eeabd8a1_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjQ2MmI1OGU4NTY5NTRlMGJhZGRiNjYwNjMwMzVhZjFjL3RhYmxlcmFuZ2U6NDYyYjU4ZTg1Njk1NGUwYmFkZGI2NjA2MzAzNWFmMWNfMTMtOS0xLTEtODE_47848a29-1a6e-464f-aad9-259bedf227f1"
      unitRef="usd">4085061000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="id673d80f31e74643a241d2f62db94ca9_D20220701-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjQ2MmI1OGU4NTY5NTRlMGJhZGRiNjYwNjMwMzVhZjFjL3RhYmxlcmFuZ2U6NDYyYjU4ZTg1Njk1NGUwYmFkZGI2NjA2MzAzNWFmMWNfMTQtMC0xLTEtMTU2NS90ZXh0cmVnaW9uOjQzMTY1OGZhYTVkYzRlNjA5NjI5ZjYyMzgxYjExZGVlXzI3NDg3NzkwNjk2MDA_0b7dba12-aa75-429e-9025-36cae3cef90d"
      unitRef="shares">578106</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i60075c2eb5c5499f8837e239ab042889_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjQ2MmI1OGU4NTY5NTRlMGJhZGRiNjYwNjMwMzVhZjFjL3RhYmxlcmFuZ2U6NDYyYjU4ZTg1Njk1NGUwYmFkZGI2NjA2MzAzNWFmMWNfMTQtMy0xLTEtMTU2NQ_d36f6897-733b-4852-a72d-f8e35c10919f"
      unitRef="usd">-13572000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="id673d80f31e74643a241d2f62db94ca9_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjQ2MmI1OGU4NTY5NTRlMGJhZGRiNjYwNjMwMzVhZjFjL3RhYmxlcmFuZ2U6NDYyYjU4ZTg1Njk1NGUwYmFkZGI2NjA2MzAzNWFmMWNfMTQtOS0xLTEtMTU2NQ_7cfaa583-960a-48d3-9308-a005c9806f8e"
      unitRef="usd">-13572000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="id673d80f31e74643a241d2f62db94ca9_D20220701-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjQ2MmI1OGU4NTY5NTRlMGJhZGRiNjYwNjMwMzVhZjFjL3RhYmxlcmFuZ2U6NDYyYjU4ZTg1Njk1NGUwYmFkZGI2NjA2MzAzNWFmMWNfMTUtMC0xLTEtMTU2NS90ZXh0cmVnaW9uOjhhNGQzMDg4Y2VmMjQ4ZDNhNGE3ZWY5YzM2NTNmYjA2XzI3NDg3NzkwNjk1MDc_4ba976e8-09b9-4ea1-a1e2-fca3426faeeb"
      unitRef="shares">1337</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="i60075c2eb5c5499f8837e239ab042889_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjQ2MmI1OGU4NTY5NTRlMGJhZGRiNjYwNjMwMzVhZjFjL3RhYmxlcmFuZ2U6NDYyYjU4ZTg1Njk1NGUwYmFkZGI2NjA2MzAzNWFmMWNfMTUtMy0xLTEtMTU2NQ_c44b327e-9c60-4285-a72b-c728b5244fa5"
      unitRef="usd">94000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="id673d80f31e74643a241d2f62db94ca9_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjQ2MmI1OGU4NTY5NTRlMGJhZGRiNjYwNjMwMzVhZjFjL3RhYmxlcmFuZ2U6NDYyYjU4ZTg1Njk1NGUwYmFkZGI2NjA2MzAzNWFmMWNfMTUtOS0xLTEtMTU2NQ_6164799d-d01c-466e-befc-6e624b0d6924"
      unitRef="usd">94000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i60075c2eb5c5499f8837e239ab042889_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjQ2MmI1OGU4NTY5NTRlMGJhZGRiNjYwNjMwMzVhZjFjL3RhYmxlcmFuZ2U6NDYyYjU4ZTg1Njk1NGUwYmFkZGI2NjA2MzAzNWFmMWNfMTYtMy0xLTEtMTU2NQ_d82115fa-f029-480a-b083-c808ec056298"
      unitRef="usd">45659000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="id673d80f31e74643a241d2f62db94ca9_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjQ2MmI1OGU4NTY5NTRlMGJhZGRiNjYwNjMwMzVhZjFjL3RhYmxlcmFuZ2U6NDYyYjU4ZTg1Njk1NGUwYmFkZGI2NjA2MzAzNWFmMWNfMTYtOS0xLTEtMTU2NQ_b33f7c12-e9a8-4a8e-b5a5-206e0c08ed0d"
      unitRef="usd">45659000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i1e7566ac86984c7d9bc3167d0dd68193_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjQ2MmI1OGU4NTY5NTRlMGJhZGRiNjYwNjMwMzVhZjFjL3RhYmxlcmFuZ2U6NDYyYjU4ZTg1Njk1NGUwYmFkZGI2NjA2MzAzNWFmMWNfMTctNS0xLTEtMTU2NQ_8424d83b-fdfb-432c-b1d5-40644d6ad1a5"
      unitRef="usd">-3366000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="id673d80f31e74643a241d2f62db94ca9_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjQ2MmI1OGU4NTY5NTRlMGJhZGRiNjYwNjMwMzVhZjFjL3RhYmxlcmFuZ2U6NDYyYjU4ZTg1Njk1NGUwYmFkZGI2NjA2MzAzNWFmMWNfMTctOS0xLTEtMTU2NQ_223af8a7-cc89-4ecf-aba3-25d29f817366"
      unitRef="usd">-3366000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="i85c3cbfbb1824bc5a5e1c025e4781453_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjQ2MmI1OGU4NTY5NTRlMGJhZGRiNjYwNjMwMzVhZjFjL3RhYmxlcmFuZ2U6NDYyYjU4ZTg1Njk1NGUwYmFkZGI2NjA2MzAzNWFmMWNfMTgtNy0xLTEtMTU2NQ_f2fa0c35-799b-4c3e-bcd7-e404a47c42aa"
      unitRef="usd">112775000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="id673d80f31e74643a241d2f62db94ca9_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjQ2MmI1OGU4NTY5NTRlMGJhZGRiNjYwNjMwMzVhZjFjL3RhYmxlcmFuZ2U6NDYyYjU4ZTg1Njk1NGUwYmFkZGI2NjA2MzAzNWFmMWNfMTgtOS0xLTEtMTU2NQ_dd27a6e4-b72e-4635-a3ee-c9c848ec35c2"
      unitRef="usd">112775000</us-gaap:NetIncomeLoss>
    <us-gaap:StockholdersEquity
      contextRef="ib6839b85b6084c339df68bc47f7cff76_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjQ2MmI1OGU4NTY5NTRlMGJhZGRiNjYwNjMwMzVhZjFjL3RhYmxlcmFuZ2U6NDYyYjU4ZTg1Njk1NGUwYmFkZGI2NjA2MzAzNWFmMWNfMTktMS0xLTEtMTU2NQ_7abdfe59-8d9f-4fcd-a250-517db1f87cbd"
      unitRef="usd">222000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ibe1f6fcb358742d8947f8680dc7a2216_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjQ2MmI1OGU4NTY5NTRlMGJhZGRiNjYwNjMwMzVhZjFjL3RhYmxlcmFuZ2U6NDYyYjU4ZTg1Njk1NGUwYmFkZGI2NjA2MzAzNWFmMWNfMTktMy0xLTEtMTU2NQ_b5f03867-cf5c-46c3-a064-12a23a31d535"
      unitRef="usd">4721166000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i05520eab8e964199ad292516b1f688c5_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjQ2MmI1OGU4NTY5NTRlMGJhZGRiNjYwNjMwMzVhZjFjL3RhYmxlcmFuZ2U6NDYyYjU4ZTg1Njk1NGUwYmFkZGI2NjA2MzAzNWFmMWNfMTktNS0xLTEtMTU2NQ_80080732-dfb2-4de4-b4b2-9e6840e27e1a"
      unitRef="usd">-29062000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie5b42e033862404b9b0eb46dcfa04cde_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjQ2MmI1OGU4NTY5NTRlMGJhZGRiNjYwNjMwMzVhZjFjL3RhYmxlcmFuZ2U6NDYyYjU4ZTg1Njk1NGUwYmFkZGI2NjA2MzAzNWFmMWNfMTktNy0xLTEtMTU2NQ_ce3a5a11-7227-4da9-854b-c0f7ccfa1b9c"
      unitRef="usd">-465675000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i3b4376f8fc614de98c9cf647198c504e_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjQ2MmI1OGU4NTY5NTRlMGJhZGRiNjYwNjMwMzVhZjFjL3RhYmxlcmFuZ2U6NDYyYjU4ZTg1Njk1NGUwYmFkZGI2NjA2MzAzNWFmMWNfMTktOS0xLTEtMTU2NQ_d7dfc0d9-48e2-41e5-80c9-fb9ee464030f"
      unitRef="usd">4226651000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i16eb58b1ed464d849f5daa9d5c452c5d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjE0ZjIxMDkzZTZkMzQ0YWQ4NzgxOTkyNDQ2ZTJmZmFjL3RhYmxlcmFuZ2U6MTRmMjEwOTNlNmQzNDRhZDg3ODE5OTI0NDZlMmZmYWNfMS0xLTEtMS04MQ_24bb061e-b855-4367-b1b1-fe44f27308e4"
      unitRef="usd">219000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5940926f68ee4011bffeecd1cae3a5bd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjE0ZjIxMDkzZTZkMzQ0YWQ4NzgxOTkyNDQ2ZTJmZmFjL3RhYmxlcmFuZ2U6MTRmMjEwOTNlNmQzNDRhZDg3ODE5OTI0NDZlMmZmYWNfMS0zLTEtMS04MQ_63386b72-1646-441f-b5c3-e7a95ee1fc58"
      unitRef="usd">4352864000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="idab40e34150649eb84f41cf937413ae9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjE0ZjIxMDkzZTZkMzQ0YWQ4NzgxOTkyNDQ2ZTJmZmFjL3RhYmxlcmFuZ2U6MTRmMjEwOTNlNmQzNDRhZDg3ODE5OTI0NDZlMmZmYWNfMS01LTEtMS04MQ_e08ddb5c-5d89-425c-aa33-4920ad395b0b"
      unitRef="usd">-15360000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i965f89ff7c6b4ce6bcc30af15c2742bb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjE0ZjIxMDkzZTZkMzQ0YWQ4NzgxOTkyNDQ2ZTJmZmFjL3RhYmxlcmFuZ2U6MTRmMjEwOTNlNmQzNDRhZDg3ODE5OTI0NDZlMmZmYWNfMS03LTEtMS04MQ_0de131e8-c960-4d43-9115-95be99698d26"
      unitRef="usd">-1726455000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id7612db9fbac4f99a07f20a1f367748a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjE0ZjIxMDkzZTZkMzQ0YWQ4NzgxOTkyNDQ2ZTJmZmFjL3RhYmxlcmFuZ2U6MTRmMjEwOTNlNmQzNDRhZDg3ODE5OTI0NDZlMmZmYWNfMS05LTEtMS04MQ_500af3fd-5032-4ee6-8a7b-33bb55f3247d"
      unitRef="usd">2611268000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="if318fa6e60cf4269ad7b22fe4b7d3bed_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjE0ZjIxMDkzZTZkMzQ0YWQ4NzgxOTkyNDQ2ZTJmZmFjL3RhYmxlcmFuZ2U6MTRmMjEwOTNlNmQzNDRhZDg3ODE5OTI0NDZlMmZmYWNfMi0wLTEtMS04MS90ZXh0cmVnaW9uOjY0Y2VmNGNmYjNiNzQwYjFiZDA2YzhiYTU5OWI4MmIzXzE2_d6477a7c-780a-44bb-afd5-9419f20da998"
      unitRef="shares">389512</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i149762c26678449aa330b2367cbe6d4c_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjE0ZjIxMDkzZTZkMzQ0YWQ4NzgxOTkyNDQ2ZTJmZmFjL3RhYmxlcmFuZ2U6MTRmMjEwOTNlNmQzNDRhZDg3ODE5OTI0NDZlMmZmYWNfMi0xLTEtMS04MQ_0ba64307-e525-4eb3-8f29-93a0b891181d"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i63235de3b5c048f09f04c5309d82d142_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjE0ZjIxMDkzZTZkMzQ0YWQ4NzgxOTkyNDQ2ZTJmZmFjL3RhYmxlcmFuZ2U6MTRmMjEwOTNlNmQzNDRhZDg3ODE5OTI0NDZlMmZmYWNfMi0zLTEtMS04MQ_dc6deafa-7855-403a-9a27-36d8417dbdf4"
      unitRef="usd">20027000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="if318fa6e60cf4269ad7b22fe4b7d3bed_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjE0ZjIxMDkzZTZkMzQ0YWQ4NzgxOTkyNDQ2ZTJmZmFjL3RhYmxlcmFuZ2U6MTRmMjEwOTNlNmQzNDRhZDg3ODE5OTI0NDZlMmZmYWNfMi05LTEtMS04MQ_49d1886a-2df0-4a46-83ea-32cf76ffff32"
      unitRef="usd">20028000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="if318fa6e60cf4269ad7b22fe4b7d3bed_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjE0ZjIxMDkzZTZkMzQ0YWQ4NzgxOTkyNDQ2ZTJmZmFjL3RhYmxlcmFuZ2U6MTRmMjEwOTNlNmQzNDRhZDg3ODE5OTI0NDZlMmZmYWNfMy0wLTEtMS04MS90ZXh0cmVnaW9uOjIxNjE2NWRhY2NkYTQ0MmU4MjJlMTY0NDU4ZDYyOWVjXzE2_7ffba7cf-5bc2-4aa1-bcb5-3e92cef230ee"
      unitRef="shares">1357</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="i63235de3b5c048f09f04c5309d82d142_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjE0ZjIxMDkzZTZkMzQ0YWQ4NzgxOTkyNDQ2ZTJmZmFjL3RhYmxlcmFuZ2U6MTRmMjEwOTNlNmQzNDRhZDg3ODE5OTI0NDZlMmZmYWNfMy0zLTEtMS04MQ_6812333f-f2a1-4ecb-b141-65313b5d468f"
      unitRef="usd">108000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="if318fa6e60cf4269ad7b22fe4b7d3bed_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjE0ZjIxMDkzZTZkMzQ0YWQ4NzgxOTkyNDQ2ZTJmZmFjL3RhYmxlcmFuZ2U6MTRmMjEwOTNlNmQzNDRhZDg3ODE5OTI0NDZlMmZmYWNfMy05LTEtMS04MQ_a219c25f-a029-40f0-8f98-dafb522e474f"
      unitRef="usd">108000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i63235de3b5c048f09f04c5309d82d142_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjE0ZjIxMDkzZTZkMzQ0YWQ4NzgxOTkyNDQ2ZTJmZmFjL3RhYmxlcmFuZ2U6MTRmMjEwOTNlNmQzNDRhZDg3ODE5OTI0NDZlMmZmYWNfNC0zLTEtMS04MQ_d5d04e43-6928-4ee0-a3b5-882811ac45ff"
      unitRef="usd">47903000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="if318fa6e60cf4269ad7b22fe4b7d3bed_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjE0ZjIxMDkzZTZkMzQ0YWQ4NzgxOTkyNDQ2ZTJmZmFjL3RhYmxlcmFuZ2U6MTRmMjEwOTNlNmQzNDRhZDg3ODE5OTI0NDZlMmZmYWNfNC05LTEtMS04MQ_839b246a-29b0-4276-8541-008dc224e6f5"
      unitRef="usd">47903000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i9f5bbbcd7a4e4865bf1cd728365c237b_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjE0ZjIxMDkzZTZkMzQ0YWQ4NzgxOTkyNDQ2ZTJmZmFjL3RhYmxlcmFuZ2U6MTRmMjEwOTNlNmQzNDRhZDg3ODE5OTI0NDZlMmZmYWNfNS01LTEtMS04MQ_dde41b24-fe7a-4dd1-a075-bf65e64efd34"
      unitRef="usd">-4998000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="if318fa6e60cf4269ad7b22fe4b7d3bed_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjE0ZjIxMDkzZTZkMzQ0YWQ4NzgxOTkyNDQ2ZTJmZmFjL3RhYmxlcmFuZ2U6MTRmMjEwOTNlNmQzNDRhZDg3ODE5OTI0NDZlMmZmYWNfNS05LTEtMS04MQ_14a60bd2-705d-4c50-9060-470947120f55"
      unitRef="usd">-4998000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="i510fae960406426aabb022789d463532_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjE0ZjIxMDkzZTZkMzQ0YWQ4NzgxOTkyNDQ2ZTJmZmFjL3RhYmxlcmFuZ2U6MTRmMjEwOTNlNmQzNDRhZDg3ODE5OTI0NDZlMmZmYWNfNi03LTEtMS04MQ_64268cce-2ec5-461e-bc38-d7c9621a2476"
      unitRef="usd">53535000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="if318fa6e60cf4269ad7b22fe4b7d3bed_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjE0ZjIxMDkzZTZkMzQ0YWQ4NzgxOTkyNDQ2ZTJmZmFjL3RhYmxlcmFuZ2U6MTRmMjEwOTNlNmQzNDRhZDg3ODE5OTI0NDZlMmZmYWNfNi05LTEtMS04MQ_225bb818-5afa-448d-b13a-d6e8f0c8c4a9"
      unitRef="usd">53535000</us-gaap:NetIncomeLoss>
    <us-gaap:StockholdersEquity
      contextRef="i8b5fdbb0199e42af841de05d57267053_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjE0ZjIxMDkzZTZkMzQ0YWQ4NzgxOTkyNDQ2ZTJmZmFjL3RhYmxlcmFuZ2U6MTRmMjEwOTNlNmQzNDRhZDg3ODE5OTI0NDZlMmZmYWNfNy0xLTEtMS04MQ_acadc6ec-c34a-43ea-b89a-44bcd8d1ad4d"
      unitRef="usd">220000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5b58a259e2444d51ab47b223d8db0cb8_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjE0ZjIxMDkzZTZkMzQ0YWQ4NzgxOTkyNDQ2ZTJmZmFjL3RhYmxlcmFuZ2U6MTRmMjEwOTNlNmQzNDRhZDg3ODE5OTI0NDZlMmZmYWNfNy0zLTEtMS04MQ_6eccb55b-0cbd-43c3-8d4b-bd0e002a561c"
      unitRef="usd">4420902000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i964e4f2c4c4e458a807f09f6f17794df_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjE0ZjIxMDkzZTZkMzQ0YWQ4NzgxOTkyNDQ2ZTJmZmFjL3RhYmxlcmFuZ2U6MTRmMjEwOTNlNmQzNDRhZDg3ODE5OTI0NDZlMmZmYWNfNy01LTEtMS04MQ_5a0df0b1-2912-4761-bed6-90cfc12ce5da"
      unitRef="usd">-20358000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i06b27465ac7d4ce4b1fe3f0cc3e247fb_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjE0ZjIxMDkzZTZkMzQ0YWQ4NzgxOTkyNDQ2ZTJmZmFjL3RhYmxlcmFuZ2U6MTRmMjEwOTNlNmQzNDRhZDg3ODE5OTI0NDZlMmZmYWNfNy03LTEtMS04MQ_fd8d703a-b092-432b-9f3a-53685196c0c7"
      unitRef="usd">-1672920000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4b4b9892bc824ec58691624921a1e192_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjE0ZjIxMDkzZTZkMzQ0YWQ4NzgxOTkyNDQ2ZTJmZmFjL3RhYmxlcmFuZ2U6MTRmMjEwOTNlNmQzNDRhZDg3ODE5OTI0NDZlMmZmYWNfNy05LTEtMS04MQ_8722cbf4-bdc9-4b6c-b0bb-44a1a070077a"
      unitRef="usd">2727844000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="idc6cb7baa8c74e84b9abc3c83e5894f1_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjE0ZjIxMDkzZTZkMzQ0YWQ4NzgxOTkyNDQ2ZTJmZmFjL3RhYmxlcmFuZ2U6MTRmMjEwOTNlNmQzNDRhZDg3ODE5OTI0NDZlMmZmYWNfOC0wLTEtMS04MS90ZXh0cmVnaW9uOjE5ZmI1NDM5OTJkYjRiN2VhNzM3YjhjMzRmM2QzYTdhXzE2_8614985d-c2a2-4c34-860a-67a698cbe871"
      unitRef="shares">390001</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="idc6cb7baa8c74e84b9abc3c83e5894f1_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjE0ZjIxMDkzZTZkMzQ0YWQ4NzgxOTkyNDQ2ZTJmZmFjL3RhYmxlcmFuZ2U6MTRmMjEwOTNlNmQzNDRhZDg3ODE5OTI0NDZlMmZmYWNfOC0wLTEtMS04MS90ZXh0cmVnaW9uOjE5ZmI1NDM5OTJkYjRiN2VhNzM3YjhjMzRmM2QzYTdhXzE4NA_83a73ebc-a84f-423a-a6cb-5040a3451b9f"
      unitRef="shares">153082</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <incy:StockIssuedDuringPeriodValueStockOptionsAndRestrictedStockUnitsExercisedAndEmployeeStockPurchasePlan
      contextRef="if9e03c43713740629fa4f89aa642de4f_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjE0ZjIxMDkzZTZkMzQ0YWQ4NzgxOTkyNDQ2ZTJmZmFjL3RhYmxlcmFuZ2U6MTRmMjEwOTNlNmQzNDRhZDg3ODE5OTI0NDZlMmZmYWNfOC0zLTEtMS04MQ_5dcff6f8-a42c-412c-86d3-175db64284ed"
      unitRef="usd">11016000</incy:StockIssuedDuringPeriodValueStockOptionsAndRestrictedStockUnitsExercisedAndEmployeeStockPurchasePlan>
    <incy:StockIssuedDuringPeriodValueStockOptionsAndRestrictedStockUnitsExercisedAndEmployeeStockPurchasePlan
      contextRef="idc6cb7baa8c74e84b9abc3c83e5894f1_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjE0ZjIxMDkzZTZkMzQ0YWQ4NzgxOTkyNDQ2ZTJmZmFjL3RhYmxlcmFuZ2U6MTRmMjEwOTNlNmQzNDRhZDg3ODE5OTI0NDZlMmZmYWNfOC05LTEtMS04MQ_2b28225b-9887-485b-a4dd-1939f820fe60"
      unitRef="usd">11016000</incy:StockIssuedDuringPeriodValueStockOptionsAndRestrictedStockUnitsExercisedAndEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="idc6cb7baa8c74e84b9abc3c83e5894f1_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjE0ZjIxMDkzZTZkMzQ0YWQ4NzgxOTkyNDQ2ZTJmZmFjL3RhYmxlcmFuZ2U6MTRmMjEwOTNlNmQzNDRhZDg3ODE5OTI0NDZlMmZmYWNfOS0wLTEtMS04MS90ZXh0cmVnaW9uOmZiYmNkNTM0MjNjMTRmYWI5ZTc1MDg5NmVlNjU1MDNlXzE2_4871331e-355e-492f-8ef9-ed2445afdff1"
      unitRef="shares">1288</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="if9e03c43713740629fa4f89aa642de4f_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjE0ZjIxMDkzZTZkMzQ0YWQ4NzgxOTkyNDQ2ZTJmZmFjL3RhYmxlcmFuZ2U6MTRmMjEwOTNlNmQzNDRhZDg3ODE5OTI0NDZlMmZmYWNfOS0zLTEtMS04MQ_0c5b2142-4ed3-4dd8-9f06-f3d831e3be35"
      unitRef="usd">109000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="idc6cb7baa8c74e84b9abc3c83e5894f1_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjE0ZjIxMDkzZTZkMzQ0YWQ4NzgxOTkyNDQ2ZTJmZmFjL3RhYmxlcmFuZ2U6MTRmMjEwOTNlNmQzNDRhZDg3ODE5OTI0NDZlMmZmYWNfOS05LTEtMS04MQ_246b8763-9ec8-42ba-8f3a-42606aaad2df"
      unitRef="usd">109000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="if9e03c43713740629fa4f89aa642de4f_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjE0ZjIxMDkzZTZkMzQ0YWQ4NzgxOTkyNDQ2ZTJmZmFjL3RhYmxlcmFuZ2U6MTRmMjEwOTNlNmQzNDRhZDg3ODE5OTI0NDZlMmZmYWNfMTAtMy0xLTEtODE_b994f64e-922d-44ed-bde6-10cd4896fd1d"
      unitRef="usd">45351000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="idc6cb7baa8c74e84b9abc3c83e5894f1_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjE0ZjIxMDkzZTZkMzQ0YWQ4NzgxOTkyNDQ2ZTJmZmFjL3RhYmxlcmFuZ2U6MTRmMjEwOTNlNmQzNDRhZDg3ODE5OTI0NDZlMmZmYWNfMTAtOS0xLTEtODE_2b1c7784-c0d4-4051-b164-df66cee4448c"
      unitRef="usd">45351000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i7e103bce07364afa8641cfcaf9141951_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjE0ZjIxMDkzZTZkMzQ0YWQ4NzgxOTkyNDQ2ZTJmZmFjL3RhYmxlcmFuZ2U6MTRmMjEwOTNlNmQzNDRhZDg3ODE5OTI0NDZlMmZmYWNfMTEtNS0xLTEtODE_8f47a4e9-7a6e-4777-9b69-f551e6c7187c"
      unitRef="usd">2085000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="idc6cb7baa8c74e84b9abc3c83e5894f1_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjE0ZjIxMDkzZTZkMzQ0YWQ4NzgxOTkyNDQ2ZTJmZmFjL3RhYmxlcmFuZ2U6MTRmMjEwOTNlNmQzNDRhZDg3ODE5OTI0NDZlMmZmYWNfMTEtOS0xLTEtODE_20f9ba98-faef-43d7-b5c2-638a896a39a7"
      unitRef="usd">2085000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="i27392d6e02284d51a27f567bf09e7d8a_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjE0ZjIxMDkzZTZkMzQ0YWQ4NzgxOTkyNDQ2ZTJmZmFjL3RhYmxlcmFuZ2U6MTRmMjEwOTNlNmQzNDRhZDg3ODE5OTI0NDZlMmZmYWNfMTItNy0xLTEtODE_65c92090-45bf-4eb3-9602-db9618bf31b5"
      unitRef="usd">149456000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="idc6cb7baa8c74e84b9abc3c83e5894f1_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjE0ZjIxMDkzZTZkMzQ0YWQ4NzgxOTkyNDQ2ZTJmZmFjL3RhYmxlcmFuZ2U6MTRmMjEwOTNlNmQzNDRhZDg3ODE5OTI0NDZlMmZmYWNfMTItOS0xLTEtODE_9e98d73f-df55-4f40-ba9b-d96796a9566d"
      unitRef="usd">149456000</us-gaap:NetIncomeLoss>
    <us-gaap:StockholdersEquity
      contextRef="i117119ef63584701b5c25a7fdb4442e6_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjE0ZjIxMDkzZTZkMzQ0YWQ4NzgxOTkyNDQ2ZTJmZmFjL3RhYmxlcmFuZ2U6MTRmMjEwOTNlNmQzNDRhZDg3ODE5OTI0NDZlMmZmYWNfMTMtMS0xLTEtODE_4fd2b1a8-0f89-4d76-9d99-33364aa0bdb2"
      unitRef="usd">220000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5519d29d74934b9387e13dee64f56289_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjE0ZjIxMDkzZTZkMzQ0YWQ4NzgxOTkyNDQ2ZTJmZmFjL3RhYmxlcmFuZ2U6MTRmMjEwOTNlNmQzNDRhZDg3ODE5OTI0NDZlMmZmYWNfMTMtMy0xLTEtODE_83b23ec0-8da0-463a-8d3a-60cf38c57e92"
      unitRef="usd">4477378000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if29697c5381c4b6dbdca657efd2afcb9_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjE0ZjIxMDkzZTZkMzQ0YWQ4NzgxOTkyNDQ2ZTJmZmFjL3RhYmxlcmFuZ2U6MTRmMjEwOTNlNmQzNDRhZDg3ODE5OTI0NDZlMmZmYWNfMTMtNS0xLTEtODE_18cbbd6e-9532-495b-b56b-b5518c115bb8"
      unitRef="usd">-18273000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib314ad130b2f42d0844a18715eb4169a_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjE0ZjIxMDkzZTZkMzQ0YWQ4NzgxOTkyNDQ2ZTJmZmFjL3RhYmxlcmFuZ2U6MTRmMjEwOTNlNmQzNDRhZDg3ODE5OTI0NDZlMmZmYWNfMTMtNy0xLTEtODE_ded48787-0a3a-4672-ad3d-f68c7e19d2f1"
      unitRef="usd">-1523464000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie9e0017429a94b21b8bba302af4c6a96_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjE0ZjIxMDkzZTZkMzQ0YWQ4NzgxOTkyNDQ2ZTJmZmFjL3RhYmxlcmFuZ2U6MTRmMjEwOTNlNmQzNDRhZDg3ODE5OTI0NDZlMmZmYWNfMTMtOS0xLTEtODE_8c23906a-090b-4296-8aa6-1a12a38dc273"
      unitRef="usd">2935861000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i313b15d35b7045babd1ba61f84a077dd_D20210701-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjE0ZjIxMDkzZTZkMzQ0YWQ4NzgxOTkyNDQ2ZTJmZmFjL3RhYmxlcmFuZ2U6MTRmMjEwOTNlNmQzNDRhZDg3ODE5OTI0NDZlMmZmYWNfMTQtMC0xLTEtMjA4MC90ZXh0cmVnaW9uOjc3MTliODczY2JjYzRlNWVhZjI1OGUxYmZlMDE0Njc4XzI3NDg3NzkwNjk2MDg_03ffd5c6-dbe3-4a0a-8f9c-f758ecf34e64"
      unitRef="shares">459084</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i80edfdae16f74674aa25a4584796d920_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjE0ZjIxMDkzZTZkMzQ0YWQ4NzgxOTkyNDQ2ZTJmZmFjL3RhYmxlcmFuZ2U6MTRmMjEwOTNlNmQzNDRhZDg3ODE5OTI0NDZlMmZmYWNfMTQtMS0xLTEtMjA4MA_60f9bc2b-a90b-4179-a966-39f37e54e333"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i4a971b6abebd4be9a0d2b6015046b257_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjE0ZjIxMDkzZTZkMzQ0YWQ4NzgxOTkyNDQ2ZTJmZmFjL3RhYmxlcmFuZ2U6MTRmMjEwOTNlNmQzNDRhZDg3ODE5OTI0NDZlMmZmYWNfMTQtMy0xLTEtMjA4MA_29e5b5b6-34a3-4f2b-a058-eac0d29528c0"
      unitRef="usd">-11993000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i313b15d35b7045babd1ba61f84a077dd_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjE0ZjIxMDkzZTZkMzQ0YWQ4NzgxOTkyNDQ2ZTJmZmFjL3RhYmxlcmFuZ2U6MTRmMjEwOTNlNmQzNDRhZDg3ODE5OTI0NDZlMmZmYWNfMTQtOS0xLTEtMjA4MA_6454dc96-cd5f-4122-9130-7403c9c6afec"
      unitRef="usd">-11992000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="i313b15d35b7045babd1ba61f84a077dd_D20210701-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjE0ZjIxMDkzZTZkMzQ0YWQ4NzgxOTkyNDQ2ZTJmZmFjL3RhYmxlcmFuZ2U6MTRmMjEwOTNlNmQzNDRhZDg3ODE5OTI0NDZlMmZmYWNfMTUtMC0xLTEtMjA4MC90ZXh0cmVnaW9uOmY3MGVhMjRhZmQzYjQyMGRiYzIwZTZiMTJkNjM2N2JhXzI3NDg3NzkwNjk1MTE_6a09b09e-4bc1-4c55-8eab-417d5073f26c"
      unitRef="shares">1466</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="i4a971b6abebd4be9a0d2b6015046b257_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjE0ZjIxMDkzZTZkMzQ0YWQ4NzgxOTkyNDQ2ZTJmZmFjL3RhYmxlcmFuZ2U6MTRmMjEwOTNlNmQzNDRhZDg3ODE5OTI0NDZlMmZmYWNfMTUtMy0xLTEtMjA4MA_ddec1b2d-dcc6-474f-aa8e-7d17c4e95a77"
      unitRef="usd">108000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="i313b15d35b7045babd1ba61f84a077dd_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjE0ZjIxMDkzZTZkMzQ0YWQ4NzgxOTkyNDQ2ZTJmZmFjL3RhYmxlcmFuZ2U6MTRmMjEwOTNlNmQzNDRhZDg3ODE5OTI0NDZlMmZmYWNfMTUtOS0xLTEtMjA4MA_fffb3049-6ea9-4c53-ac4e-b323d1fd7ec4"
      unitRef="usd">108000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i4a971b6abebd4be9a0d2b6015046b257_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjE0ZjIxMDkzZTZkMzQ0YWQ4NzgxOTkyNDQ2ZTJmZmFjL3RhYmxlcmFuZ2U6MTRmMjEwOTNlNmQzNDRhZDg3ODE5OTI0NDZlMmZmYWNfMTYtMy0xLTEtMjA4MA_3dfd3ffd-65ba-48fe-b3d9-a0d50910981e"
      unitRef="usd">43314000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i313b15d35b7045babd1ba61f84a077dd_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjE0ZjIxMDkzZTZkMzQ0YWQ4NzgxOTkyNDQ2ZTJmZmFjL3RhYmxlcmFuZ2U6MTRmMjEwOTNlNmQzNDRhZDg3ODE5OTI0NDZlMmZmYWNfMTYtOS0xLTEtMjA4MA_f14e645b-f5f9-421b-bdc4-041515f735ff"
      unitRef="usd">43314000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i37e49a4f06ec4d2da555cee905623504_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjE0ZjIxMDkzZTZkMzQ0YWQ4NzgxOTkyNDQ2ZTJmZmFjL3RhYmxlcmFuZ2U6MTRmMjEwOTNlNmQzNDRhZDg3ODE5OTI0NDZlMmZmYWNfMTctNS0xLTEtMjA4MA_781558b7-7a09-4489-be58-da9d8db6a0d5"
      unitRef="usd">-373000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i313b15d35b7045babd1ba61f84a077dd_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjE0ZjIxMDkzZTZkMzQ0YWQ4NzgxOTkyNDQ2ZTJmZmFjL3RhYmxlcmFuZ2U6MTRmMjEwOTNlNmQzNDRhZDg3ODE5OTI0NDZlMmZmYWNfMTctOS0xLTEtMjA4MA_56de6f6e-0e16-4282-8232-e10febf34524"
      unitRef="usd">-373000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="i3999e65b4d434855be24ad71cc111f8d_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjE0ZjIxMDkzZTZkMzQ0YWQ4NzgxOTkyNDQ2ZTJmZmFjL3RhYmxlcmFuZ2U6MTRmMjEwOTNlNmQzNDRhZDg3ODE5OTI0NDZlMmZmYWNfMTgtNy0xLTEtMjA4MA_0a22dc91-7acf-4482-a431-ee7bcd56b50f"
      unitRef="usd">181739000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i313b15d35b7045babd1ba61f84a077dd_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjE0ZjIxMDkzZTZkMzQ0YWQ4NzgxOTkyNDQ2ZTJmZmFjL3RhYmxlcmFuZ2U6MTRmMjEwOTNlNmQzNDRhZDg3ODE5OTI0NDZlMmZmYWNfMTgtOS0xLTEtMjA4MA_8db3a578-38e8-4548-946d-006ab1dafa65"
      unitRef="usd">181739000</us-gaap:NetIncomeLoss>
    <us-gaap:StockholdersEquity
      contextRef="ifa71095b17734a079f0fd7349c7cc6a8_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjE0ZjIxMDkzZTZkMzQ0YWQ4NzgxOTkyNDQ2ZTJmZmFjL3RhYmxlcmFuZ2U6MTRmMjEwOTNlNmQzNDRhZDg3ODE5OTI0NDZlMmZmYWNfMTktMS0xLTEtMjA4MA_14c10488-185a-4f4e-8404-d4d4ae441d21"
      unitRef="usd">221000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i3a9436032c6c4652b5da596c702a1d2b_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjE0ZjIxMDkzZTZkMzQ0YWQ4NzgxOTkyNDQ2ZTJmZmFjL3RhYmxlcmFuZ2U6MTRmMjEwOTNlNmQzNDRhZDg3ODE5OTI0NDZlMmZmYWNfMTktMy0xLTEtMjA4MA_cca5bead-ed4b-48ca-8371-b65fe212a64d"
      unitRef="usd">4508807000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8d3e00d0fdce4dd6a33f933968e210ae_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjE0ZjIxMDkzZTZkMzQ0YWQ4NzgxOTkyNDQ2ZTJmZmFjL3RhYmxlcmFuZ2U6MTRmMjEwOTNlNmQzNDRhZDg3ODE5OTI0NDZlMmZmYWNfMTktNS0xLTEtMjA4MA_7f527710-78f1-4e74-8faf-d02d076edb70"
      unitRef="usd">-18646000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ibf6b811e903342bb834df47cf71eeef4_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjE0ZjIxMDkzZTZkMzQ0YWQ4NzgxOTkyNDQ2ZTJmZmFjL3RhYmxlcmFuZ2U6MTRmMjEwOTNlNmQzNDRhZDg3ODE5OTI0NDZlMmZmYWNfMTktNy0xLTEtMjA4MA_b44b01c6-1a07-44e6-bfb8-ca3723c63f10"
      unitRef="usd">-1341725000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4d97c6f523444f9aa40a206f5b9705c6_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yNS9mcmFnOmY0ZWQ0ZTIwYzhmNzQ4ZjA4NzIxMDA3MzA2MDYwY2FjL3RhYmxlOjE0ZjIxMDkzZTZkMzQ0YWQ4NzgxOTkyNDQ2ZTJmZmFjL3RhYmxlcmFuZ2U6MTRmMjEwOTNlNmQzNDRhZDg3ODE5OTI0NDZlMmZmYWNfMTktOS0xLTEtMjA4MA_bcf5759e-bbff-48be-8583-a856a0e24112"
      unitRef="usd">3148657000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yOC9mcmFnOjQwYjQ0ZDhlZDA5YzQwNTI4NmY5MzVmMTk0NTBkMDdjL3RhYmxlOjRjY2I2Mjk0MmFjZDQ4MTQ5YzhmOGFjN2FkOWQ3OTQ4L3RhYmxlcmFuZ2U6NGNjYjYyOTQyYWNkNDgxNDljOGY4YWM3YWQ5ZDc5NDhfMy0xLTEtMS04MQ_6eda57e2-719f-4a3b-8713-3430a8d7a404"
      unitRef="usd">312199000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i0faaba5fcd6b485781cadacae8b2fd8e_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yOC9mcmFnOjQwYjQ0ZDhlZDA5YzQwNTI4NmY5MzVmMTk0NTBkMDdjL3RhYmxlOjRjY2I2Mjk0MmFjZDQ4MTQ5YzhmOGFjN2FkOWQ3OTQ4L3RhYmxlcmFuZ2U6NGNjYjYyOTQyYWNkNDgxNDljOGY4YWM3YWQ5ZDc5NDhfMy0zLTEtMS04MQ_7bbaaf24-9382-48e0-9941-3877ea502f2f"
      unitRef="usd">384730000</us-gaap:ProfitLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yOC9mcmFnOjQwYjQ0ZDhlZDA5YzQwNTI4NmY5MzVmMTk0NTBkMDdjL3RhYmxlOjRjY2I2Mjk0MmFjZDQ4MTQ5YzhmOGFjN2FkOWQ3OTQ4L3RhYmxlcmFuZ2U6NGNjYjYyOTQyYWNkNDgxNDljOGY4YWM3YWQ5ZDc5NDhfNS0xLTEtMS04MQ_bb569ad8-71bc-4add-a2a1-a57c833b3cd7"
      unitRef="usd">49637000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i0faaba5fcd6b485781cadacae8b2fd8e_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yOC9mcmFnOjQwYjQ0ZDhlZDA5YzQwNTI4NmY5MzVmMTk0NTBkMDdjL3RhYmxlOjRjY2I2Mjk0MmFjZDQ4MTQ5YzhmOGFjN2FkOWQ3OTQ4L3RhYmxlcmFuZ2U6NGNjYjYyOTQyYWNkNDgxNDljOGY4YWM3YWQ5ZDc5NDhfNS0zLTEtMS04MQ_eb11d18c-6ff5-4555-856a-4fee63ada8cb"
      unitRef="usd">42986000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yOC9mcmFnOjQwYjQ0ZDhlZDA5YzQwNTI4NmY5MzVmMTk0NTBkMDdjL3RhYmxlOjRjY2I2Mjk0MmFjZDQ4MTQ5YzhmOGFjN2FkOWQ3OTQ4L3RhYmxlcmFuZ2U6NGNjYjYyOTQyYWNkNDgxNDljOGY4YWM3YWQ5ZDc5NDhfNi0xLTEtMS04MQ_4b2cb9e5-1319-4c76-926c-d65e378d4ff0"
      unitRef="usd">135741000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i0faaba5fcd6b485781cadacae8b2fd8e_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yOC9mcmFnOjQwYjQ0ZDhlZDA5YzQwNTI4NmY5MzVmMTk0NTBkMDdjL3RhYmxlOjRjY2I2Mjk0MmFjZDQ4MTQ5YzhmOGFjN2FkOWQ3OTQ4L3RhYmxlcmFuZ2U6NGNjYjYyOTQyYWNkNDgxNDljOGY4YWM3YWQ5ZDc5NDhfNi0zLTEtMS04MQ_ca366b72-fd75-4cef-a6bd-89aa8e09b7b0"
      unitRef="usd">134784000</us-gaap:ShareBasedCompensation>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes
      contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yOC9mcmFnOjQwYjQ0ZDhlZDA5YzQwNTI4NmY5MzVmMTk0NTBkMDdjL3RhYmxlOjRjY2I2Mjk0MmFjZDQ4MTQ5YzhmOGFjN2FkOWQ3OTQ4L3RhYmxlcmFuZ2U6NGNjYjYyOTQyYWNkNDgxNDljOGY4YWM3YWQ5ZDc5NDhfNy0xLTEtMS04MQ_69e694b4-def7-4940-af30-fcedeea67062"
      unitRef="usd">-40432000</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes
      contextRef="i0faaba5fcd6b485781cadacae8b2fd8e_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yOC9mcmFnOjQwYjQ0ZDhlZDA5YzQwNTI4NmY5MzVmMTk0NTBkMDdjL3RhYmxlOjRjY2I2Mjk0MmFjZDQ4MTQ5YzhmOGFjN2FkOWQ3OTQ4L3RhYmxlcmFuZ2U6NGNjYjYyOTQyYWNkNDgxNDljOGY4YWM3YWQ5ZDc5NDhfNy0zLTEtMS04MQ_8996a968-1c06-45ac-8166-2c36ca1c4e18"
      unitRef="usd">178000</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yOC9mcmFnOjQwYjQ0ZDhlZDA5YzQwNTI4NmY5MzVmMTk0NTBkMDdjL3RhYmxlOjRjY2I2Mjk0MmFjZDQ4MTQ5YzhmOGFjN2FkOWQ3OTQ4L3RhYmxlcmFuZ2U6NGNjYjYyOTQyYWNkNDgxNDljOGY4YWM3YWQ5ZDc5NDhfOC0xLTEtMS04MQ_221473ec-b5d5-477f-bb93-34c8653e72cc"
      unitRef="usd">-15097000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="i0faaba5fcd6b485781cadacae8b2fd8e_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yOC9mcmFnOjQwYjQ0ZDhlZDA5YzQwNTI4NmY5MzVmMTk0NTBkMDdjL3RhYmxlOjRjY2I2Mjk0MmFjZDQ4MTQ5YzhmOGFjN2FkOWQ3OTQ4L3RhYmxlcmFuZ2U6NGNjYjYyOTQyYWNkNDgxNDljOGY4YWM3YWQ5ZDc5NDhfOC0zLTEtMS04MQ_56a2dcd3-2e7c-45b6-9401-b2c651cbe32d"
      unitRef="usd">-5268000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yOC9mcmFnOjQwYjQ0ZDhlZDA5YzQwNTI4NmY5MzVmMTk0NTBkMDdjL3RhYmxlOjRjY2I2Mjk0MmFjZDQ4MTQ5YzhmOGFjN2FkOWQ3OTQ4L3RhYmxlcmFuZ2U6NGNjYjYyOTQyYWNkNDgxNDljOGY4YWM3YWQ5ZDc5NDhfOS0xLTEtMS04MQ_5a9ffd5a-eb16-4010-ab66-8c254ec723f4"
      unitRef="usd">-72142000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i0faaba5fcd6b485781cadacae8b2fd8e_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yOC9mcmFnOjQwYjQ0ZDhlZDA5YzQwNTI4NmY5MzVmMTk0NTBkMDdjL3RhYmxlOjRjY2I2Mjk0MmFjZDQ4MTQ5YzhmOGFjN2FkOWQ3OTQ4L3RhYmxlcmFuZ2U6NGNjYjYyOTQyYWNkNDgxNDljOGY4YWM3YWQ5ZDc5NDhfOS0zLTEtMS04MQ_0f35d43c-341f-47ce-a7ff-651bdca0496a"
      unitRef="usd">-28394000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yOC9mcmFnOjQwYjQ0ZDhlZDA5YzQwNTI4NmY5MzVmMTk0NTBkMDdjL3RhYmxlOjRjY2I2Mjk0MmFjZDQ4MTQ5YzhmOGFjN2FkOWQ3OTQ4L3RhYmxlcmFuZ2U6NGNjYjYyOTQyYWNkNDgxNDljOGY4YWM3YWQ5ZDc5NDhfMTAtMS0xLTEtODE_18b4da32-9f5f-4b3b-919b-b35e5e73978e"
      unitRef="usd">-12198000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i0faaba5fcd6b485781cadacae8b2fd8e_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yOC9mcmFnOjQwYjQ0ZDhlZDA5YzQwNTI4NmY5MzVmMTk0NTBkMDdjL3RhYmxlOjRjY2I2Mjk0MmFjZDQ4MTQ5YzhmOGFjN2FkOWQ3OTQ4L3RhYmxlcmFuZ2U6NGNjYjYyOTQyYWNkNDgxNDljOGY4YWM3YWQ5ZDc5NDhfMTAtMy0xLTEtODE_5e1fd1fa-fc73-49e9-92e8-9bc349cf32db"
      unitRef="usd">13068000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yOC9mcmFnOjQwYjQ0ZDhlZDA5YzQwNTI4NmY5MzVmMTk0NTBkMDdjL3RhYmxlOjRjY2I2Mjk0MmFjZDQ4MTQ5YzhmOGFjN2FkOWQ3OTQ4L3RhYmxlcmFuZ2U6NGNjYjYyOTQyYWNkNDgxNDljOGY4YWM3YWQ5ZDc5NDhfMTItMS0xLTEtODE_9718ca01-9879-4b00-a513-d4f3d1e3d361"
      unitRef="usd">1888000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i0faaba5fcd6b485781cadacae8b2fd8e_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yOC9mcmFnOjQwYjQ0ZDhlZDA5YzQwNTI4NmY5MzVmMTk0NTBkMDdjL3RhYmxlOjRjY2I2Mjk0MmFjZDQ4MTQ5YzhmOGFjN2FkOWQ3OTQ4L3RhYmxlcmFuZ2U6NGNjYjYyOTQyYWNkNDgxNDljOGY4YWM3YWQ5ZDc5NDhfMTItMy0xLTEtODE_9f53daee-7116-4376-aee8-98f50f3f04d4"
      unitRef="usd">34695000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yOC9mcmFnOjQwYjQ0ZDhlZDA5YzQwNTI4NmY5MzVmMTk0NTBkMDdjL3RhYmxlOjRjY2I2Mjk0MmFjZDQ4MTQ5YzhmOGFjN2FkOWQ3OTQ4L3RhYmxlcmFuZ2U6NGNjYjYyOTQyYWNkNDgxNDljOGY4YWM3YWQ5ZDc5NDhfMTMtMS0xLTEtODE_3c985e0e-5786-4d87-9ea2-3dfcb4d78a52"
      unitRef="usd">40016000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i0faaba5fcd6b485781cadacae8b2fd8e_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yOC9mcmFnOjQwYjQ0ZDhlZDA5YzQwNTI4NmY5MzVmMTk0NTBkMDdjL3RhYmxlOjRjY2I2Mjk0MmFjZDQ4MTQ5YzhmOGFjN2FkOWQ3OTQ4L3RhYmxlcmFuZ2U6NGNjYjYyOTQyYWNkNDgxNDljOGY4YWM3YWQ5ZDc5NDhfMTMtMy0xLTEtODE_1b948bd0-0a1b-4cd3-9b00-ca50ed0dc832"
      unitRef="usd">24784000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yOC9mcmFnOjQwYjQ0ZDhlZDA5YzQwNTI4NmY5MzVmMTk0NTBkMDdjL3RhYmxlOjRjY2I2Mjk0MmFjZDQ4MTQ5YzhmOGFjN2FkOWQ3OTQ4L3RhYmxlcmFuZ2U6NGNjYjYyOTQyYWNkNDgxNDljOGY4YWM3YWQ5ZDc5NDhfMTQtMS0xLTEtODE_ca7634f2-1997-4fb5-bdc3-e139b6d5a151"
      unitRef="usd">48316000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i0faaba5fcd6b485781cadacae8b2fd8e_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yOC9mcmFnOjQwYjQ0ZDhlZDA5YzQwNTI4NmY5MzVmMTk0NTBkMDdjL3RhYmxlOjRjY2I2Mjk0MmFjZDQ4MTQ5YzhmOGFjN2FkOWQ3OTQ4L3RhYmxlcmFuZ2U6NGNjYjYyOTQyYWNkNDgxNDljOGY4YWM3YWQ5ZDc5NDhfMTQtMy0xLTEtODE_a294c115-4037-4ce7-8154-0fdb96c22768"
      unitRef="usd">16215000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yOC9mcmFnOjQwYjQ0ZDhlZDA5YzQwNTI4NmY5MzVmMTk0NTBkMDdjL3RhYmxlOjRjY2I2Mjk0MmFjZDQ4MTQ5YzhmOGFjN2FkOWQ3OTQ4L3RhYmxlcmFuZ2U6NGNjYjYyOTQyYWNkNDgxNDljOGY4YWM3YWQ5ZDc5NDhfMTUtMS0xLTEtODE_68181775-f2fd-4d46-a617-b9743432c59b"
      unitRef="usd">-8935000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i0faaba5fcd6b485781cadacae8b2fd8e_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yOC9mcmFnOjQwYjQ0ZDhlZDA5YzQwNTI4NmY5MzVmMTk0NTBkMDdjL3RhYmxlOjRjY2I2Mjk0MmFjZDQ4MTQ5YzhmOGFjN2FkOWQ3OTQ4L3RhYmxlcmFuZ2U6NGNjYjYyOTQyYWNkNDgxNDljOGY4YWM3YWQ5ZDc5NDhfMTUtMy0xLTEtODE_ee655b12-ae53-4959-8b92-b918eb5bfee6"
      unitRef="usd">15742000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yOC9mcmFnOjQwYjQ0ZDhlZDA5YzQwNTI4NmY5MzVmMTk0NTBkMDdjL3RhYmxlOjRjY2I2Mjk0MmFjZDQ4MTQ5YzhmOGFjN2FkOWQ3OTQ4L3RhYmxlcmFuZ2U6NGNjYjYyOTQyYWNkNDgxNDljOGY4YWM3YWQ5ZDc5NDhfMTYtMS0xLTEtODE_058d0446-e813-4d7d-838f-545997e87170"
      unitRef="usd">172384000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i0faaba5fcd6b485781cadacae8b2fd8e_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yOC9mcmFnOjQwYjQ0ZDhlZDA5YzQwNTI4NmY5MzVmMTk0NTBkMDdjL3RhYmxlOjRjY2I2Mjk0MmFjZDQ4MTQ5YzhmOGFjN2FkOWQ3OTQ4L3RhYmxlcmFuZ2U6NGNjYjYyOTQyYWNkNDgxNDljOGY4YWM3YWQ5ZDc5NDhfMTYtMy0xLTEtODE_24da13e1-2d65-4630-9ecd-0223e8f52bdf"
      unitRef="usd">85037000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yOC9mcmFnOjQwYjQ0ZDhlZDA5YzQwNTI4NmY5MzVmMTk0NTBkMDdjL3RhYmxlOjRjY2I2Mjk0MmFjZDQ4MTQ5YzhmOGFjN2FkOWQ3OTQ4L3RhYmxlcmFuZ2U6NGNjYjYyOTQyYWNkNDgxNDljOGY4YWM3YWQ5ZDc5NDhfMTctMS0xLTEtODE_4dd34bcc-73ab-4969-ac26-784f9d50c278"
      unitRef="usd">686279000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i0faaba5fcd6b485781cadacae8b2fd8e_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yOC9mcmFnOjQwYjQ0ZDhlZDA5YzQwNTI4NmY5MzVmMTk0NTBkMDdjL3RhYmxlOjRjY2I2Mjk0MmFjZDQ4MTQ5YzhmOGFjN2FkOWQ3OTQ4L3RhYmxlcmFuZ2U6NGNjYjYyOTQyYWNkNDgxNDljOGY4YWM3YWQ5ZDc5NDhfMTctMy0xLTEtODE_5aec1dd2-f4ed-4c63-8f83-b0cd335ac162"
      unitRef="usd">634137000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireLongtermInvestments
      contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yOC9mcmFnOjQwYjQ0ZDhlZDA5YzQwNTI4NmY5MzVmMTk0NTBkMDdjL3RhYmxlOjRjY2I2Mjk0MmFjZDQ4MTQ5YzhmOGFjN2FkOWQ3OTQ4L3RhYmxlcmFuZ2U6NGNjYjYyOTQyYWNkNDgxNDljOGY4YWM3YWQ5ZDc5NDhfMTktMS0xLTEtODE_94cb082b-dd2f-4697-858d-0a6a616f0cc3"
      unitRef="usd">0</us-gaap:PaymentsToAcquireLongtermInvestments>
    <us-gaap:PaymentsToAcquireLongtermInvestments
      contextRef="i0faaba5fcd6b485781cadacae8b2fd8e_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yOC9mcmFnOjQwYjQ0ZDhlZDA5YzQwNTI4NmY5MzVmMTk0NTBkMDdjL3RhYmxlOjRjY2I2Mjk0MmFjZDQ4MTQ5YzhmOGFjN2FkOWQ3OTQ4L3RhYmxlcmFuZ2U6NGNjYjYyOTQyYWNkNDgxNDljOGY4YWM3YWQ5ZDc5NDhfMTktMy0xLTEtODE_5f0e9da8-22f5-47b5-ab12-54189580bdd5"
      unitRef="usd">8662000</us-gaap:PaymentsToAcquireLongtermInvestments>
    <us-gaap:ProceedsFromSaleOfLongtermInvestments
      contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yOC9mcmFnOjQwYjQ0ZDhlZDA5YzQwNTI4NmY5MzVmMTk0NTBkMDdjL3RhYmxlOjRjY2I2Mjk0MmFjZDQ4MTQ5YzhmOGFjN2FkOWQ3OTQ4L3RhYmxlcmFuZ2U6NGNjYjYyOTQyYWNkNDgxNDljOGY4YWM3YWQ5ZDc5NDhfMjAtMS0xLTEtODE_665b6f1e-f7c1-4d04-9658-a7e0ccb7bcdc"
      unitRef="usd">0</us-gaap:ProceedsFromSaleOfLongtermInvestments>
    <us-gaap:ProceedsFromSaleOfLongtermInvestments
      contextRef="i0faaba5fcd6b485781cadacae8b2fd8e_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yOC9mcmFnOjQwYjQ0ZDhlZDA5YzQwNTI4NmY5MzVmMTk0NTBkMDdjL3RhYmxlOjRjY2I2Mjk0MmFjZDQ4MTQ5YzhmOGFjN2FkOWQ3OTQ4L3RhYmxlcmFuZ2U6NGNjYjYyOTQyYWNkNDgxNDljOGY4YWM3YWQ5ZDc5NDhfMjAtMy0xLTEtODE_f9bf3ddb-c2cb-4530-899c-aac457d52cad"
      unitRef="usd">10473000</us-gaap:ProceedsFromSaleOfLongtermInvestments>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yOC9mcmFnOjQwYjQ0ZDhlZDA5YzQwNTI4NmY5MzVmMTk0NTBkMDdjL3RhYmxlOjRjY2I2Mjk0MmFjZDQ4MTQ5YzhmOGFjN2FkOWQ3OTQ4L3RhYmxlcmFuZ2U6NGNjYjYyOTQyYWNkNDgxNDljOGY4YWM3YWQ5ZDc5NDhfMjEtMS0xLTEtODE_d360ee89-f104-4c67-a5cb-43087613f84f"
      unitRef="usd">56560000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="i0faaba5fcd6b485781cadacae8b2fd8e_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yOC9mcmFnOjQwYjQ0ZDhlZDA5YzQwNTI4NmY5MzVmMTk0NTBkMDdjL3RhYmxlOjRjY2I2Mjk0MmFjZDQ4MTQ5YzhmOGFjN2FkOWQ3OTQ4L3RhYmxlcmFuZ2U6NGNjYjYyOTQyYWNkNDgxNDljOGY4YWM3YWQ5ZDc5NDhfMjEtMy0xLTEtODE_97915135-fff2-4752-aff0-495e1ccaf688"
      unitRef="usd">146543000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yOC9mcmFnOjQwYjQ0ZDhlZDA5YzQwNTI4NmY5MzVmMTk0NTBkMDdjL3RhYmxlOjRjY2I2Mjk0MmFjZDQ4MTQ5YzhmOGFjN2FkOWQ3OTQ4L3RhYmxlcmFuZ2U6NGNjYjYyOTQyYWNkNDgxNDljOGY4YWM3YWQ5ZDc5NDhfMjItMS0xLTEtODE_2ed764c1-25ed-49cc-b73a-436936a926e8"
      unitRef="usd">59058000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="i0faaba5fcd6b485781cadacae8b2fd8e_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yOC9mcmFnOjQwYjQ0ZDhlZDA5YzQwNTI4NmY5MzVmMTk0NTBkMDdjL3RhYmxlOjRjY2I2Mjk0MmFjZDQ4MTQ5YzhmOGFjN2FkOWQ3OTQ4L3RhYmxlcmFuZ2U6NGNjYjYyOTQyYWNkNDgxNDljOGY4YWM3YWQ5ZDc5NDhfMjItMy0xLTEtODE_9927b73d-550e-4a15-986e-067c1275bc81"
      unitRef="usd">228170000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yOC9mcmFnOjQwYjQ0ZDhlZDA5YzQwNTI4NmY5MzVmMTk0NTBkMDdjL3RhYmxlOjRjY2I2Mjk0MmFjZDQ4MTQ5YzhmOGFjN2FkOWQ3OTQ4L3RhYmxlcmFuZ2U6NGNjYjYyOTQyYWNkNDgxNDljOGY4YWM3YWQ5ZDc5NDhfMjMtMS0xLTEtODE_b30d854f-64a0-4736-9bab-1de21ffc4f4f"
      unitRef="usd">57988000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="i0faaba5fcd6b485781cadacae8b2fd8e_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yOC9mcmFnOjQwYjQ0ZDhlZDA5YzQwNTI4NmY5MzVmMTk0NTBkMDdjL3RhYmxlOjRjY2I2Mjk0MmFjZDQ4MTQ5YzhmOGFjN2FkOWQ3OTQ4L3RhYmxlcmFuZ2U6NGNjYjYyOTQyYWNkNDgxNDljOGY4YWM3YWQ5ZDc5NDhfMjMtMy0xLTEtODE_a4e38d6e-46d9-40a2-aa94-fca47999d3fc"
      unitRef="usd">231250000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yOC9mcmFnOjQwYjQ0ZDhlZDA5YzQwNTI4NmY5MzVmMTk0NTBkMDdjL3RhYmxlOjRjY2I2Mjk0MmFjZDQ4MTQ5YzhmOGFjN2FkOWQ3OTQ4L3RhYmxlcmFuZ2U6NGNjYjYyOTQyYWNkNDgxNDljOGY4YWM3YWQ5ZDc5NDhfMjQtMS0xLTEtODE_40852c93-ae22-4b00-9735-0d93bc2b6168"
      unitRef="usd">-57630000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i0faaba5fcd6b485781cadacae8b2fd8e_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yOC9mcmFnOjQwYjQ0ZDhlZDA5YzQwNTI4NmY5MzVmMTk0NTBkMDdjL3RhYmxlOjRjY2I2Mjk0MmFjZDQ4MTQ5YzhmOGFjN2FkOWQ3OTQ4L3RhYmxlcmFuZ2U6NGNjYjYyOTQyYWNkNDgxNDljOGY4YWM3YWQ5ZDc5NDhfMjQtMy0xLTEtODE_6133f1d1-5696-42f6-a234-79b5f29626ba"
      unitRef="usd">-141652000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromStockPlans
      contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yOC9mcmFnOjQwYjQ0ZDhlZDA5YzQwNTI4NmY5MzVmMTk0NTBkMDdjL3RhYmxlOjRjY2I2Mjk0MmFjZDQ4MTQ5YzhmOGFjN2FkOWQ3OTQ4L3RhYmxlcmFuZ2U6NGNjYjYyOTQyYWNkNDgxNDljOGY4YWM3YWQ5ZDc5NDhfMjYtMS0xLTEtODE_b85c8606-038b-45bf-8ccf-ae05232e0cb3"
      unitRef="usd">42989000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ProceedsFromStockPlans
      contextRef="i0faaba5fcd6b485781cadacae8b2fd8e_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yOC9mcmFnOjQwYjQ0ZDhlZDA5YzQwNTI4NmY5MzVmMTk0NTBkMDdjL3RhYmxlOjRjY2I2Mjk0MmFjZDQ4MTQ5YzhmOGFjN2FkOWQ3OTQ4L3RhYmxlcmFuZ2U6NGNjYjYyOTQyYWNkNDgxNDljOGY4YWM3YWQ5ZDc5NDhfMjYtMy0xLTEtODE_10484fdb-a478-4e30-84b2-0989dab0aac5"
      unitRef="usd">48432000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yOC9mcmFnOjQwYjQ0ZDhlZDA5YzQwNTI4NmY5MzVmMTk0NTBkMDdjL3RhYmxlOjRjY2I2Mjk0MmFjZDQ4MTQ5YzhmOGFjN2FkOWQ3OTQ4L3RhYmxlcmFuZ2U6NGNjYjYyOTQyYWNkNDgxNDljOGY4YWM3YWQ5ZDc5NDhfMjctMS0xLTEtODE_6f9ef5cd-40c3-4572-b6f4-00ab120492ed"
      unitRef="usd">25724000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i0faaba5fcd6b485781cadacae8b2fd8e_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yOC9mcmFnOjQwYjQ0ZDhlZDA5YzQwNTI4NmY5MzVmMTk0NTBkMDdjL3RhYmxlOjRjY2I2Mjk0MmFjZDQ4MTQ5YzhmOGFjN2FkOWQ3OTQ4L3RhYmxlcmFuZ2U6NGNjYjYyOTQyYWNkNDgxNDljOGY4YWM3YWQ5ZDc5NDhfMjctMy0xLTEtODE_64b6cca8-e61c-4181-bff7-3a77aa6745d0"
      unitRef="usd">29380000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yOC9mcmFnOjQwYjQ0ZDhlZDA5YzQwNTI4NmY5MzVmMTk0NTBkMDdjL3RhYmxlOjRjY2I2Mjk0MmFjZDQ4MTQ5YzhmOGFjN2FkOWQ3OTQ4L3RhYmxlcmFuZ2U6NGNjYjYyOTQyYWNkNDgxNDljOGY4YWM3YWQ5ZDc5NDhfMjgtMS0xLTEtODE_749094aa-7859-4948-bbcb-d899aa3bd694"
      unitRef="usd">2106000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="i0faaba5fcd6b485781cadacae8b2fd8e_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yOC9mcmFnOjQwYjQ0ZDhlZDA5YzQwNTI4NmY5MzVmMTk0NTBkMDdjL3RhYmxlOjRjY2I2Mjk0MmFjZDQ4MTQ5YzhmOGFjN2FkOWQ3OTQ4L3RhYmxlcmFuZ2U6NGNjYjYyOTQyYWNkNDgxNDljOGY4YWM3YWQ5ZDc5NDhfMjgtMy0xLTEtODE_08adbced-cff9-4010-8669-5dcfaa537a4a"
      unitRef="usd">1788000</us-gaap:FinanceLeasePrincipalPayments>
    <incy:PaymentOfContingentConsideration
      contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yOC9mcmFnOjQwYjQ0ZDhlZDA5YzQwNTI4NmY5MzVmMTk0NTBkMDdjL3RhYmxlOjRjY2I2Mjk0MmFjZDQ4MTQ5YzhmOGFjN2FkOWQ3OTQ4L3RhYmxlcmFuZ2U6NGNjYjYyOTQyYWNkNDgxNDljOGY4YWM3YWQ5ZDc5NDhfMjktMS0xLTEtODE_b4b5a784-0dde-4eaa-b241-020852ca35e2"
      unitRef="usd">13473000</incy:PaymentOfContingentConsideration>
    <incy:PaymentOfContingentConsideration
      contextRef="i0faaba5fcd6b485781cadacae8b2fd8e_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yOC9mcmFnOjQwYjQ0ZDhlZDA5YzQwNTI4NmY5MzVmMTk0NTBkMDdjL3RhYmxlOjRjY2I2Mjk0MmFjZDQ4MTQ5YzhmOGFjN2FkOWQ3OTQ4L3RhYmxlcmFuZ2U6NGNjYjYyOTQyYWNkNDgxNDljOGY4YWM3YWQ5ZDc5NDhfMjktMy0xLTEtODE_3e4e971e-ecb4-4d0b-a96b-02851e58eec5"
      unitRef="usd">20093000</incy:PaymentOfContingentConsideration>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yOC9mcmFnOjQwYjQ0ZDhlZDA5YzQwNTI4NmY5MzVmMTk0NTBkMDdjL3RhYmxlOjRjY2I2Mjk0MmFjZDQ4MTQ5YzhmOGFjN2FkOWQ3OTQ4L3RhYmxlcmFuZ2U6NGNjYjYyOTQyYWNkNDgxNDljOGY4YWM3YWQ5ZDc5NDhfMzAtMS0xLTEtODE_fb9a5e7a-a957-4bb6-b6bf-e4453eb72aea"
      unitRef="usd">1686000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i0faaba5fcd6b485781cadacae8b2fd8e_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yOC9mcmFnOjQwYjQ0ZDhlZDA5YzQwNTI4NmY5MzVmMTk0NTBkMDdjL3RhYmxlOjRjY2I2Mjk0MmFjZDQ4MTQ5YzhmOGFjN2FkOWQ3OTQ4L3RhYmxlcmFuZ2U6NGNjYjYyOTQyYWNkNDgxNDljOGY4YWM3YWQ5ZDc5NDhfMzAtMy0xLTEtODE_2f0b1756-6431-449d-8546-8a54b18b75ce"
      unitRef="usd">-2829000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yOC9mcmFnOjQwYjQ0ZDhlZDA5YzQwNTI4NmY5MzVmMTk0NTBkMDdjL3RhYmxlOjRjY2I2Mjk0MmFjZDQ4MTQ5YzhmOGFjN2FkOWQ3OTQ4L3RhYmxlcmFuZ2U6NGNjYjYyOTQyYWNkNDgxNDljOGY4YWM3YWQ5ZDc5NDhfMzEtMS0xLTEtODE_fc5c6751-b545-4dab-a9c7-fb3a2202c19a"
      unitRef="usd">2728000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i0faaba5fcd6b485781cadacae8b2fd8e_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yOC9mcmFnOjQwYjQ0ZDhlZDA5YzQwNTI4NmY5MzVmMTk0NTBkMDdjL3RhYmxlOjRjY2I2Mjk0MmFjZDQ4MTQ5YzhmOGFjN2FkOWQ3OTQ4L3RhYmxlcmFuZ2U6NGNjYjYyOTQyYWNkNDgxNDljOGY4YWM3YWQ5ZDc5NDhfMzEtMy0xLTEtODE_a3e68b15-b31d-4d9f-adeb-66ae20fc25e9"
      unitRef="usd">-3718000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yOC9mcmFnOjQwYjQ0ZDhlZDA5YzQwNTI4NmY5MzVmMTk0NTBkMDdjL3RhYmxlOjRjY2I2Mjk0MmFjZDQ4MTQ5YzhmOGFjN2FkOWQ3OTQ4L3RhYmxlcmFuZ2U6NGNjYjYyOTQyYWNkNDgxNDljOGY4YWM3YWQ5ZDc5NDhfMzItMS0xLTEtODE_218fe7eb-6d07-4873-9e69-f54758636355"
      unitRef="usd">633063000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i0faaba5fcd6b485781cadacae8b2fd8e_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yOC9mcmFnOjQwYjQ0ZDhlZDA5YzQwNTI4NmY5MzVmMTk0NTBkMDdjL3RhYmxlOjRjY2I2Mjk0MmFjZDQ4MTQ5YzhmOGFjN2FkOWQ3OTQ4L3RhYmxlcmFuZ2U6NGNjYjYyOTQyYWNkNDgxNDljOGY4YWM3YWQ5ZDc5NDhfMzItMy0xLTEtODE_9b71705b-875d-4a04-bda8-fc47ed684bf8"
      unitRef="usd">485938000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="iab26fe441f0d4ab984456365a7f7cff0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yOC9mcmFnOjQwYjQ0ZDhlZDA5YzQwNTI4NmY5MzVmMTk0NTBkMDdjL3RhYmxlOjRjY2I2Mjk0MmFjZDQ4MTQ5YzhmOGFjN2FkOWQ3OTQ4L3RhYmxlcmFuZ2U6NGNjYjYyOTQyYWNkNDgxNDljOGY4YWM3YWQ5ZDc5NDhfMzMtMS0xLTEtODE_6f0b0a0f-c084-4834-aa91-fc55ae9d454b"
      unitRef="usd">2059160000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="id7612db9fbac4f99a07f20a1f367748a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yOC9mcmFnOjQwYjQ0ZDhlZDA5YzQwNTI4NmY5MzVmMTk0NTBkMDdjL3RhYmxlOjRjY2I2Mjk0MmFjZDQ4MTQ5YzhmOGFjN2FkOWQ3OTQ4L3RhYmxlcmFuZ2U6NGNjYjYyOTQyYWNkNDgxNDljOGY4YWM3YWQ5ZDc5NDhfMzMtMy0xLTEtODE_59a85898-c466-4fc4-a994-57cd001a9350"
      unitRef="usd">1514765000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i3b4376f8fc614de98c9cf647198c504e_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yOC9mcmFnOjQwYjQ0ZDhlZDA5YzQwNTI4NmY5MzVmMTk0NTBkMDdjL3RhYmxlOjRjY2I2Mjk0MmFjZDQ4MTQ5YzhmOGFjN2FkOWQ3OTQ4L3RhYmxlcmFuZ2U6NGNjYjYyOTQyYWNkNDgxNDljOGY4YWM3YWQ5ZDc5NDhfMzQtMS0xLTEtODE_ca9bcb24-3c4b-433c-b375-3433af020803"
      unitRef="usd">2692223000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i4d97c6f523444f9aa40a206f5b9705c6_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yOC9mcmFnOjQwYjQ0ZDhlZDA5YzQwNTI4NmY5MzVmMTk0NTBkMDdjL3RhYmxlOjRjY2I2Mjk0MmFjZDQ4MTQ5YzhmOGFjN2FkOWQ3OTQ4L3RhYmxlcmFuZ2U6NGNjYjYyOTQyYWNkNDgxNDljOGY4YWM3YWQ5ZDc5NDhfMzQtMy0xLTEtODE_d9097bbd-d61f-4d3a-bb18-575c7d3dbcc4"
      unitRef="usd">2000703000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yOC9mcmFnOjQwYjQ0ZDhlZDA5YzQwNTI4NmY5MzVmMTk0NTBkMDdjL3RhYmxlOjRjY2I2Mjk0MmFjZDQ4MTQ5YzhmOGFjN2FkOWQ3OTQ4L3RhYmxlcmFuZ2U6NGNjYjYyOTQyYWNkNDgxNDljOGY4YWM3YWQ5ZDc5NDhfMzYtMS0xLTEtODE_bef47a15-50d2-4f30-955c-ee62ad44175a"
      unitRef="usd">116537000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="i0faaba5fcd6b485781cadacae8b2fd8e_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yOC9mcmFnOjQwYjQ0ZDhlZDA5YzQwNTI4NmY5MzVmMTk0NTBkMDdjL3RhYmxlOjRjY2I2Mjk0MmFjZDQ4MTQ5YzhmOGFjN2FkOWQ3OTQ4L3RhYmxlcmFuZ2U6NGNjYjYyOTQyYWNkNDgxNDljOGY4YWM3YWQ5ZDc5NDhfMzYtMy0xLTEtODE_b4b8b9ec-6bda-4596-ab36-87ee956c5169"
      unitRef="usd">45872000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yOC9mcmFnOjQwYjQ0ZDhlZDA5YzQwNTI4NmY5MzVmMTk0NTBkMDdjL3RhYmxlOjRjY2I2Mjk0MmFjZDQ4MTQ5YzhmOGFjN2FkOWQ3OTQ4L3RhYmxlcmFuZ2U6NGNjYjYyOTQyYWNkNDgxNDljOGY4YWM3YWQ5ZDc5NDhfMzctMS0xLTEtODE_83f345fd-974d-4265-917d-d768e37e2b6e"
      unitRef="usd">8836000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i0faaba5fcd6b485781cadacae8b2fd8e_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yOC9mcmFnOjQwYjQ0ZDhlZDA5YzQwNTI4NmY5MzVmMTk0NTBkMDdjL3RhYmxlOjRjY2I2Mjk0MmFjZDQ4MTQ5YzhmOGFjN2FkOWQ3OTQ4L3RhYmxlcmFuZ2U6NGNjYjYyOTQyYWNkNDgxNDljOGY4YWM3YWQ5ZDc5NDhfMzctMy0xLTEtODE_cee0b293-ceb0-4953-ae83-8f4438739191"
      unitRef="usd">23892000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yOC9mcmFnOjQwYjQ0ZDhlZDA5YzQwNTI4NmY5MzVmMTk0NTBkMDdjL3RhYmxlOjRjY2I2Mjk0MmFjZDQ4MTQ5YzhmOGFjN2FkOWQ3OTQ4L3RhYmxlcmFuZ2U6NGNjYjYyOTQyYWNkNDgxNDljOGY4YWM3YWQ5ZDc5NDhfMzgtMS0xLTEtODE_ea351bef-7b2b-4f7e-8962-8cc63230105b"
      unitRef="usd">3650000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i0faaba5fcd6b485781cadacae8b2fd8e_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yOC9mcmFnOjQwYjQ0ZDhlZDA5YzQwNTI4NmY5MzVmMTk0NTBkMDdjL3RhYmxlOjRjY2I2Mjk0MmFjZDQ4MTQ5YzhmOGFjN2FkOWQ3OTQ4L3RhYmxlcmFuZ2U6NGNjYjYyOTQyYWNkNDgxNDljOGY4YWM3YWQ5ZDc5NDhfMzgtMy0xLTEtODE_7a082a19-31b5-4d40-bf39-1d29d7673c74"
      unitRef="usd">9068000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
      contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yOC9mcmFnOjQwYjQ0ZDhlZDA5YzQwNTI4NmY5MzVmMTk0NTBkMDdjL3RhYmxlOjRjY2I2Mjk0MmFjZDQ4MTQ5YzhmOGFjN2FkOWQ3OTQ4L3RhYmxlcmFuZ2U6NGNjYjYyOTQyYWNkNDgxNDljOGY4YWM3YWQ5ZDc5NDhfMzktMS0xLTEtODE_c2e046fd-e753-4546-8a12-2c4253a7006d"
      unitRef="usd">1448000</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
      contextRef="i0faaba5fcd6b485781cadacae8b2fd8e_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8yOC9mcmFnOjQwYjQ0ZDhlZDA5YzQwNTI4NmY5MzVmMTk0NTBkMDdjL3RhYmxlOjRjY2I2Mjk0MmFjZDQ4MTQ5YzhmOGFjN2FkOWQ3OTQ4L3RhYmxlcmFuZ2U6NGNjYjYyOTQyYWNkNDgxNDljOGY4YWM3YWQ5ZDc5NDhfMzktMy0xLTEtODE_95911ec1-04f9-43b9-a735-4a894158a1e7"
      unitRef="usd">455000</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock
      contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8zNC9mcmFnOjI5NTZiNTc1OTVlOTQzYmFhMTIxNmY2ZTRkODcyN2I3L3RleHRyZWdpb246Mjk1NmI1NzU5NWU5NDNiYWExMjE2ZjZlNGQ4NzI3YjdfNTg1_6683abc3-2202-47b1-aaa1-36c7348c94cf">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Incyte Corporation (including its subsidiaries, &#x201c;Incyte,&#x201d; &#x201c;we,&#x201d; &#x201c;us,&#x201d; or &#x201c;our&#x201d;) is a biopharmaceutical company focused on developing and commercializing proprietary therapeutics. Our portfolio includes compounds in various stages, ranging from preclinical to late stage development, and commercialized products JAKAFI&#xae; (ruxolitinib), ICLUSIG&#xae; (ponatinib), PEMAZYRE&#xae; (pemigatinib), OPZELURA&#x2122; (ruxolitinib cream),&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;MINJUVI&#xae; (tafasitamab) and MONJUVI&#xae; (tafasitamab-cxix), which is co-commercialized. Our operations are treated as one operating segment.&lt;/span&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8zNC9mcmFnOjI5NTZiNTc1OTVlOTQzYmFhMTIxNmY2ZTRkODcyN2I3L3RleHRyZWdpb246Mjk1NmI1NzU5NWU5NDNiYWExMjE2ZjZlNGQ4NzI3YjdfNTY1_7a40737b-841d-41c5-acaa-a34d84c938d0"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8zNy9mcmFnOjA1Zjc0OGVlZDVjMzQwNDk4OGIzODA3OTYzMzFkZmQ5L3RleHRyZWdpb246MDVmNzQ4ZWVkNWMzNDA0OTg4YjM4MDc5NjMzMWRmZDlfMjU2OQ_b55798b5-c121-4918-807e-d74e794fb9ff">&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. The condensed consolidated balance sheet as of September&#160;30, 2022, the condensed consolidated statements of operations, comprehensive income (loss), and stockholders&#x2019; equity for the three and nine months ended September&#160;30, 2022 and 2021, and the condensed consolidated statements of cash flows for the nine months ended September&#160;30, 2022 and 2021, are unaudited, but include all adjustments, consisting only of normal recurring adjustments, which we consider necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented. The condensed consolidated balance sheet at December&#160;31, 2021 has been derived from our audited consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Although we believe that the disclosures in these financial statements are adequate to make the information presented not misleading, certain information and footnote information normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States (&#x201c;U.S. GAAP&#x201d;) have been condensed or omitted pursuant to the rules and regulations of the Securities and Exchange Commission.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Results for any interim period are not necessarily indicative of results for any future interim period or for the entire year. The accompanying financial statements should be read in conjunction with the financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Principles of Consolidation.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The condensed consolidated financial statements include the accounts of Incyte Corporation and our wholly owned subsidiaries. All inter-company accounts, transactions, and profits have been eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Use of Estimates.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;There were no new accounting pronouncements issued nor adopted since our filing of the Annual Report on Form 10-K for the year ended December&#160;31, 2021, which could have a significant effect on our condensed consolidated financial statements.</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8zNy9mcmFnOjA1Zjc0OGVlZDVjMzQwNDk4OGIzODA3OTYzMzFkZmQ5L3RleHRyZWdpb246MDVmNzQ4ZWVkNWMzNDA0OTg4YjM4MDc5NjMzMWRmZDlfMjU3MA_f8588a00-f0de-43bd-970b-a8c950deaaf9">&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. The condensed consolidated balance sheet as of September&#160;30, 2022, the condensed consolidated statements of operations, comprehensive income (loss), and stockholders&#x2019; equity for the three and nine months ended September&#160;30, 2022 and 2021, and the condensed consolidated statements of cash flows for the nine months ended September&#160;30, 2022 and 2021, are unaudited, but include all adjustments, consisting only of normal recurring adjustments, which we consider necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented. The condensed consolidated balance sheet at December&#160;31, 2021 has been derived from our audited consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Although we believe that the disclosures in these financial statements are adequate to make the information presented not misleading, certain information and footnote information normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States (&#x201c;U.S. GAAP&#x201d;) have been condensed or omitted pursuant to the rules and regulations of the Securities and Exchange Commission.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Results for any interim period are not necessarily indicative of results for any future interim period or for the entire year. The accompanying financial statements should be read in conjunction with the financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8zNy9mcmFnOjA1Zjc0OGVlZDVjMzQwNDk4OGIzODA3OTYzMzFkZmQ5L3RleHRyZWdpb246MDVmNzQ4ZWVkNWMzNDA0OTg4YjM4MDc5NjMzMWRmZDlfMjU3MQ_b3dc0b72-bce1-4549-b1e3-f1b2efd0b5c8">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Principles of Consolidation.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The condensed consolidated financial statements include the accounts of Incyte Corporation and our wholly owned subsidiaries. All inter-company accounts, transactions, and profits have been eliminated in consolidation.&lt;/span&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8zNy9mcmFnOjA1Zjc0OGVlZDVjMzQwNDk4OGIzODA3OTYzMzFkZmQ5L3RleHRyZWdpb246MDVmNzQ4ZWVkNWMzNDA0OTg4YjM4MDc5NjMzMWRmZDlfMjU3Mg_e018aab4-9043-4060-8cc5-f56057f17f8a">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Use of Estimates.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.&lt;/span&gt;</us-gaap:UseOfEstimates>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV8zNy9mcmFnOjA1Zjc0OGVlZDVjMzQwNDk4OGIzODA3OTYzMzFkZmQ5L3RleHRyZWdpb246MDVmNzQ4ZWVkNWMzNDA0OTg4YjM4MDc5NjMzMWRmZDlfMjU3Mw_bb1ff614-bffb-4070-8fd8-eef86ae3c5b6">Recent Accounting PronouncementsThere were no new accounting pronouncements issued nor adopted since our filing of the Annual Report on Form 10-K for the year ended December&#160;31, 2021, which could have a significant effect on our condensed consolidated financial statements.</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80MC9mcmFnOmQwZTdiYzBhNTk1MjRkYzQ4MzU1MDkwYTlkNzVjNmIzL3RleHRyZWdpb246ZDBlN2JjMGE1OTUyNGRjNDgzNTUwOTBhOWQ3NWM2YjNfMjky_278a8d41-ecaa-4f21-9aaf-a06038536056">&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues are recognized under guidance within ASC 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The following table presents our disaggregated revenue for the periods presented (in thousands):  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.354%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.085%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;JAKAFI revenues, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;619,595&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;547,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,761,732&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,542,138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ICLUSIG revenues, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,929&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78,222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82,356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;PEMAZYRE revenues, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;MINJUVI revenues, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,932&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,845&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;OPZELURA revenues, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total product revenues, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;713,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;594,013&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,982,682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,673,974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;JAKAVI product royalty revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85,808&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94,655&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;240,386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;242,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;OLUMIANT product royalty revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86,572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98,689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154,875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;TABRECTA product royalty revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total product royalty revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110,293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;183,974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;350,253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;404,440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Milestone and contract revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;823,303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;812,987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,467,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,123,414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For further information on our revenue-generating contracts,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;refer to Note 7.&lt;/span&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80MC9mcmFnOmQwZTdiYzBhNTk1MjRkYzQ4MzU1MDkwYTlkNzVjNmIzL3RleHRyZWdpb246ZDBlN2JjMGE1OTUyNGRjNDgzNTUwOTBhOWQ3NWM2YjNfMjkz_ca3ec8a9-ecab-407d-ae0a-a9967943bb54">&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues are recognized under guidance within ASC 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The following table presents our disaggregated revenue for the periods presented (in thousands):  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.354%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.085%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;JAKAFI revenues, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;619,595&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;547,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,761,732&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,542,138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ICLUSIG revenues, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,929&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78,222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82,356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;PEMAZYRE revenues, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;MINJUVI revenues, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,932&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,845&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;OPZELURA revenues, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total product revenues, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;713,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;594,013&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,982,682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,673,974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;JAKAVI product royalty revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85,808&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94,655&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;240,386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;242,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;OLUMIANT product royalty revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86,572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98,689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154,875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;TABRECTA product royalty revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total product royalty revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110,293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;183,974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;350,253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;404,440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Milestone and contract revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;823,303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;812,987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,467,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,123,414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2be3671bbcdc48d9a2d0dd78d0bf79a1_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80MC9mcmFnOmQwZTdiYzBhNTk1MjRkYzQ4MzU1MDkwYTlkNzVjNmIzL3RhYmxlOjY1MTM0MjU3ZGY4ZDRhYmM4MGZkY2RmNzRiYTFjZmM4L3RhYmxlcmFuZ2U6NjUxMzQyNTdkZjhkNGFiYzgwZmRjZGY3NGJhMWNmYzhfMi0xLTEtMS04MQ_c0785d73-870a-4da1-b4ed-23f0e6885082"
      unitRef="usd">619595000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5cd55b8f35884c0687d725055f17e72c_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80MC9mcmFnOmQwZTdiYzBhNTk1MjRkYzQ4MzU1MDkwYTlkNzVjNmIzL3RhYmxlOjY1MTM0MjU3ZGY4ZDRhYmM4MGZkY2RmNzRiYTFjZmM4L3RhYmxlcmFuZ2U6NjUxMzQyNTdkZjhkNGFiYzgwZmRjZGY3NGJhMWNmYzhfMi0zLTEtMS04MQ_115d02d1-0d64-4360-a80a-1d5a6d88ee1b"
      unitRef="usd">547373000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i710215f6e6e248c4a2a3ff81e0391758_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80MC9mcmFnOmQwZTdiYzBhNTk1MjRkYzQ4MzU1MDkwYTlkNzVjNmIzL3RhYmxlOjY1MTM0MjU3ZGY4ZDRhYmM4MGZkY2RmNzRiYTFjZmM4L3RhYmxlcmFuZ2U6NjUxMzQyNTdkZjhkNGFiYzgwZmRjZGY3NGJhMWNmYzhfMi01LTEtMS04MQ_ad6e8142-7577-41b5-ae59-6fd02ead229f"
      unitRef="usd">1761732000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id03654679dfd4153b83d389aa2a13454_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80MC9mcmFnOmQwZTdiYzBhNTk1MjRkYzQ4MzU1MDkwYTlkNzVjNmIzL3RhYmxlOjY1MTM0MjU3ZGY4ZDRhYmM4MGZkY2RmNzRiYTFjZmM4L3RhYmxlcmFuZ2U6NjUxMzQyNTdkZjhkNGFiYzgwZmRjZGY3NGJhMWNmYzhfMi03LTEtMS04MQ_d69bbeef-5d39-4d2e-b8f6-8f4d54394e22"
      unitRef="usd">1542138000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib254aa03c50f46e7b589f20d3926968e_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80MC9mcmFnOmQwZTdiYzBhNTk1MjRkYzQ4MzU1MDkwYTlkNzVjNmIzL3RhYmxlOjY1MTM0MjU3ZGY4ZDRhYmM4MGZkY2RmNzRiYTFjZmM4L3RhYmxlcmFuZ2U6NjUxMzQyNTdkZjhkNGFiYzgwZmRjZGY3NGJhMWNmYzhfMy0xLTEtMS04MQ_ada731f4-abeb-4a63-b0a6-d581d26ef123"
      unitRef="usd">25929000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8c101f258c8f40a7aac78b3cbb764428_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80MC9mcmFnOmQwZTdiYzBhNTk1MjRkYzQ4MzU1MDkwYTlkNzVjNmIzL3RhYmxlOjY1MTM0MjU3ZGY4ZDRhYmM4MGZkY2RmNzRiYTFjZmM4L3RhYmxlcmFuZ2U6NjUxMzQyNTdkZjhkNGFiYzgwZmRjZGY3NGJhMWNmYzhfMy0zLTEtMS04MQ_a8b91d12-a38e-4f7f-af27-f6ee875089e1"
      unitRef="usd">28522000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3326e3ff6d134bd48eeeeede0550ad3c_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80MC9mcmFnOmQwZTdiYzBhNTk1MjRkYzQ4MzU1MDkwYTlkNzVjNmIzL3RhYmxlOjY1MTM0MjU3ZGY4ZDRhYmM4MGZkY2RmNzRiYTFjZmM4L3RhYmxlcmFuZ2U6NjUxMzQyNTdkZjhkNGFiYzgwZmRjZGY3NGJhMWNmYzhfMy01LTEtMS04MQ_fff2c755-848a-43bc-a78e-bfdceb318948"
      unitRef="usd">78222000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifa8bc47eb24948d78509e0f3fc38353b_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80MC9mcmFnOmQwZTdiYzBhNTk1MjRkYzQ4MzU1MDkwYTlkNzVjNmIzL3RhYmxlOjY1MTM0MjU3ZGY4ZDRhYmM4MGZkY2RmNzRiYTFjZmM4L3RhYmxlcmFuZ2U6NjUxMzQyNTdkZjhkNGFiYzgwZmRjZGY3NGJhMWNmYzhfMy03LTEtMS04MQ_10be6d93-b1e0-4934-aa53-3f39095c0375"
      unitRef="usd">82356000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9d0a3322355e44a99c106fd274d30424_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80MC9mcmFnOmQwZTdiYzBhNTk1MjRkYzQ4MzU1MDkwYTlkNzVjNmIzL3RhYmxlOjY1MTM0MjU3ZGY4ZDRhYmM4MGZkY2RmNzRiYTFjZmM4L3RhYmxlcmFuZ2U6NjUxMzQyNTdkZjhkNGFiYzgwZmRjZGY3NGJhMWNmYzhfNC0xLTEtMS04MQ_ae3348f3-b6be-4645-95e7-72c3700495bb"
      unitRef="usd">23414000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5a43e9d7d97347f9b3479daaca253e61_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80MC9mcmFnOmQwZTdiYzBhNTk1MjRkYzQ4MzU1MDkwYTlkNzVjNmIzL3RhYmxlOjY1MTM0MjU3ZGY4ZDRhYmM4MGZkY2RmNzRiYTFjZmM4L3RhYmxlcmFuZ2U6NjUxMzQyNTdkZjhkNGFiYzgwZmRjZGY3NGJhMWNmYzhfNC0zLTEtMS04MQ_232eb6f3-f59c-4d65-93ee-f460b25a6f5e"
      unitRef="usd">17562000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1522e02430214c97807e76b9d4f39eac_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80MC9mcmFnOmQwZTdiYzBhNTk1MjRkYzQ4MzU1MDkwYTlkNzVjNmIzL3RhYmxlOjY1MTM0MjU3ZGY4ZDRhYmM4MGZkY2RmNzRiYTFjZmM4L3RhYmxlcmFuZ2U6NjUxMzQyNTdkZjhkNGFiYzgwZmRjZGY3NGJhMWNmYzhfNC01LTEtMS04MQ_f752114a-29bb-4e72-aed7-8f8edb7a7862"
      unitRef="usd">60429000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i56581712c0e948f182f555824226c56a_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80MC9mcmFnOmQwZTdiYzBhNTk1MjRkYzQ4MzU1MDkwYTlkNzVjNmIzL3RhYmxlOjY1MTM0MjU3ZGY4ZDRhYmM4MGZkY2RmNzRiYTFjZmM4L3RhYmxlcmFuZ2U6NjUxMzQyNTdkZjhkNGFiYzgwZmRjZGY3NGJhMWNmYzhfNC03LTEtMS04MQ_7905e3c8-d2ff-4ea7-9a73-b1e5db51fe3d"
      unitRef="usd">48924000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i97181295a2fc4bc38ac82fa3dbaf41dc_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80MC9mcmFnOmQwZTdiYzBhNTk1MjRkYzQ4MzU1MDkwYTlkNzVjNmIzL3RhYmxlOjY1MTM0MjU3ZGY4ZDRhYmM4MGZkY2RmNzRiYTFjZmM4L3RhYmxlcmFuZ2U6NjUxMzQyNTdkZjhkNGFiYzgwZmRjZGY3NGJhMWNmYzhfNS0xLTEtMS04MQ_e8516bab-80bf-4f8f-973b-c142a77d1754"
      unitRef="usd">5932000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id1964ea37b1844a981da5845b1efc66f_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80MC9mcmFnOmQwZTdiYzBhNTk1MjRkYzQ4MzU1MDkwYTlkNzVjNmIzL3RhYmxlOjY1MTM0MjU3ZGY4ZDRhYmM4MGZkY2RmNzRiYTFjZmM4L3RhYmxlcmFuZ2U6NjUxMzQyNTdkZjhkNGFiYzgwZmRjZGY3NGJhMWNmYzhfNS0zLTEtMS04MQ_efca5931-3d0a-4f7b-8298-d44823540264"
      unitRef="usd">556000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3e487722166b436b9b1a0d17da42afcb_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80MC9mcmFnOmQwZTdiYzBhNTk1MjRkYzQ4MzU1MDkwYTlkNzVjNmIzL3RhYmxlOjY1MTM0MjU3ZGY4ZDRhYmM4MGZkY2RmNzRiYTFjZmM4L3RhYmxlcmFuZ2U6NjUxMzQyNTdkZjhkNGFiYzgwZmRjZGY3NGJhMWNmYzhfNS01LTEtMS04MQ_ab7f961e-9594-4b14-868d-54b6ab94683f"
      unitRef="usd">14845000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie79dcd193dd74e2692c4841bc97d7582_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80MC9mcmFnOmQwZTdiYzBhNTk1MjRkYzQ4MzU1MDkwYTlkNzVjNmIzL3RhYmxlOjY1MTM0MjU3ZGY4ZDRhYmM4MGZkY2RmNzRiYTFjZmM4L3RhYmxlcmFuZ2U6NjUxMzQyNTdkZjhkNGFiYzgwZmRjZGY3NGJhMWNmYzhfNS03LTEtMS04MQ_9b4f0305-aaf6-4a5a-8a68-f89d5b135968"
      unitRef="usd">556000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5b0a477af03843e4a3226411276628ad_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80MC9mcmFnOmQwZTdiYzBhNTk1MjRkYzQ4MzU1MDkwYTlkNzVjNmIzL3RhYmxlOjY1MTM0MjU3ZGY4ZDRhYmM4MGZkY2RmNzRiYTFjZmM4L3RhYmxlcmFuZ2U6NjUxMzQyNTdkZjhkNGFiYzgwZmRjZGY3NGJhMWNmYzhfNi0xLTEtMS04MQ_28722702-1275-48f1-ae65-cf1007459651"
      unitRef="usd">38140000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibde9c5a1859245f58beebcd0ab2f8837_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80MC9mcmFnOmQwZTdiYzBhNTk1MjRkYzQ4MzU1MDkwYTlkNzVjNmIzL3RhYmxlOjY1MTM0MjU3ZGY4ZDRhYmM4MGZkY2RmNzRiYTFjZmM4L3RhYmxlcmFuZ2U6NjUxMzQyNTdkZjhkNGFiYzgwZmRjZGY3NGJhMWNmYzhfNi0zLTEtMS04MQ_bea67331-00da-48e8-9151-505968bf96d9"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2d64d29a0d744eada29116a65f7ee606_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80MC9mcmFnOmQwZTdiYzBhNTk1MjRkYzQ4MzU1MDkwYTlkNzVjNmIzL3RhYmxlOjY1MTM0MjU3ZGY4ZDRhYmM4MGZkY2RmNzRiYTFjZmM4L3RhYmxlcmFuZ2U6NjUxMzQyNTdkZjhkNGFiYzgwZmRjZGY3NGJhMWNmYzhfNi01LTEtMS04MQ_7b039a9e-8330-4954-9958-54289ad6fd15"
      unitRef="usd">67454000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i76074454312246a08eeeb082fdac82d4_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80MC9mcmFnOmQwZTdiYzBhNTk1MjRkYzQ4MzU1MDkwYTlkNzVjNmIzL3RhYmxlOjY1MTM0MjU3ZGY4ZDRhYmM4MGZkY2RmNzRiYTFjZmM4L3RhYmxlcmFuZ2U6NjUxMzQyNTdkZjhkNGFiYzgwZmRjZGY3NGJhMWNmYzhfNi03LTEtMS04MQ_d701b3c8-3609-45a2-aea8-c7ee6c901dd5"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i85b99c1e194944f7bd3b5fb62f5a2182_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80MC9mcmFnOmQwZTdiYzBhNTk1MjRkYzQ4MzU1MDkwYTlkNzVjNmIzL3RhYmxlOjY1MTM0MjU3ZGY4ZDRhYmM4MGZkY2RmNzRiYTFjZmM4L3RhYmxlcmFuZ2U6NjUxMzQyNTdkZjhkNGFiYzgwZmRjZGY3NGJhMWNmYzhfNy0xLTEtMS04MQ_67f5f101-d48f-4fb6-816d-a03d2f78e2cf"
      unitRef="usd">713010000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i48a86cbfb7934ea9845c79f994c08295_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80MC9mcmFnOmQwZTdiYzBhNTk1MjRkYzQ4MzU1MDkwYTlkNzVjNmIzL3RhYmxlOjY1MTM0MjU3ZGY4ZDRhYmM4MGZkY2RmNzRiYTFjZmM4L3RhYmxlcmFuZ2U6NjUxMzQyNTdkZjhkNGFiYzgwZmRjZGY3NGJhMWNmYzhfNy0zLTEtMS04MQ_f7af14e2-a486-4f57-bd12-76676804cda1"
      unitRef="usd">594013000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie260e1a53b734cf0a4f57af01f2e311d_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80MC9mcmFnOmQwZTdiYzBhNTk1MjRkYzQ4MzU1MDkwYTlkNzVjNmIzL3RhYmxlOjY1MTM0MjU3ZGY4ZDRhYmM4MGZkY2RmNzRiYTFjZmM4L3RhYmxlcmFuZ2U6NjUxMzQyNTdkZjhkNGFiYzgwZmRjZGY3NGJhMWNmYzhfNy01LTEtMS04MQ_62feda78-90e1-4db2-9884-14d46974256c"
      unitRef="usd">1982682000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6c3d6351306b42baba694287efd653dc_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80MC9mcmFnOmQwZTdiYzBhNTk1MjRkYzQ4MzU1MDkwYTlkNzVjNmIzL3RhYmxlOjY1MTM0MjU3ZGY4ZDRhYmM4MGZkY2RmNzRiYTFjZmM4L3RhYmxlcmFuZ2U6NjUxMzQyNTdkZjhkNGFiYzgwZmRjZGY3NGJhMWNmYzhfNy03LTEtMS04MQ_5df67022-5324-4a62-bacf-10ef06a2543e"
      unitRef="usd">1673974000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id7988d7d482845398e5665259694affc_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80MC9mcmFnOmQwZTdiYzBhNTk1MjRkYzQ4MzU1MDkwYTlkNzVjNmIzL3RhYmxlOjY1MTM0MjU3ZGY4ZDRhYmM4MGZkY2RmNzRiYTFjZmM4L3RhYmxlcmFuZ2U6NjUxMzQyNTdkZjhkNGFiYzgwZmRjZGY3NGJhMWNmYzhfOC0xLTEtMS04MQ_d0ca02a5-cacb-49f3-bc5f-11cbd7f9dd0d"
      unitRef="usd">85808000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2f384ac250ef439885835d9b5c193ad9_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80MC9mcmFnOmQwZTdiYzBhNTk1MjRkYzQ4MzU1MDkwYTlkNzVjNmIzL3RhYmxlOjY1MTM0MjU3ZGY4ZDRhYmM4MGZkY2RmNzRiYTFjZmM4L3RhYmxlcmFuZ2U6NjUxMzQyNTdkZjhkNGFiYzgwZmRjZGY3NGJhMWNmYzhfOC0zLTEtMS04MQ_6a2bf343-021a-41a7-afed-faa1cfa075c9"
      unitRef="usd">94655000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i45b0b732fe1e49f8a7de40384f586a9b_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80MC9mcmFnOmQwZTdiYzBhNTk1MjRkYzQ4MzU1MDkwYTlkNzVjNmIzL3RhYmxlOjY1MTM0MjU3ZGY4ZDRhYmM4MGZkY2RmNzRiYTFjZmM4L3RhYmxlcmFuZ2U6NjUxMzQyNTdkZjhkNGFiYzgwZmRjZGY3NGJhMWNmYzhfOC01LTEtMS04MQ_828570d4-c813-4220-81d4-1a38237fdffc"
      unitRef="usd">240386000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie3424cac904843c0b18c3c76707b6e36_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80MC9mcmFnOmQwZTdiYzBhNTk1MjRkYzQ4MzU1MDkwYTlkNzVjNmIzL3RhYmxlOjY1MTM0MjU3ZGY4ZDRhYmM4MGZkY2RmNzRiYTFjZmM4L3RhYmxlcmFuZ2U6NjUxMzQyNTdkZjhkNGFiYzgwZmRjZGY3NGJhMWNmYzhfOC03LTEtMS04MQ_612ac2fa-25b1-4516-ab5a-59844db06be3"
      unitRef="usd">242295000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0672ace4d6734ee8aaf270d6c484063d_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80MC9mcmFnOmQwZTdiYzBhNTk1MjRkYzQ4MzU1MDkwYTlkNzVjNmIzL3RhYmxlOjY1MTM0MjU3ZGY4ZDRhYmM4MGZkY2RmNzRiYTFjZmM4L3RhYmxlcmFuZ2U6NjUxMzQyNTdkZjhkNGFiYzgwZmRjZGY3NGJhMWNmYzhfOS0xLTEtMS04MQ_3f050481-17c0-4c10-bb2e-e2ad9a8f50e9"
      unitRef="usd">20371000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9a5b8b62e0a34310b286dc3fd7b2e45f_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80MC9mcmFnOmQwZTdiYzBhNTk1MjRkYzQ4MzU1MDkwYTlkNzVjNmIzL3RhYmxlOjY1MTM0MjU3ZGY4ZDRhYmM4MGZkY2RmNzRiYTFjZmM4L3RhYmxlcmFuZ2U6NjUxMzQyNTdkZjhkNGFiYzgwZmRjZGY3NGJhMWNmYzhfOS0zLTEtMS04MQ_33bdf58b-9101-43e5-a0b0-05b542774d06"
      unitRef="usd">86572000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iae8216b0f9fa43a69bc74413e49ef99b_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80MC9mcmFnOmQwZTdiYzBhNTk1MjRkYzQ4MzU1MDkwYTlkNzVjNmIzL3RhYmxlOjY1MTM0MjU3ZGY4ZDRhYmM4MGZkY2RmNzRiYTFjZmM4L3RhYmxlcmFuZ2U6NjUxMzQyNTdkZjhkNGFiYzgwZmRjZGY3NGJhMWNmYzhfOS01LTEtMS04MQ_4b6d5704-2bab-4e91-aaf1-73cfe8149ffb"
      unitRef="usd">98689000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4bf0f6ad20014e71a14b23e5dd30857a_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80MC9mcmFnOmQwZTdiYzBhNTk1MjRkYzQ4MzU1MDkwYTlkNzVjNmIzL3RhYmxlOjY1MTM0MjU3ZGY4ZDRhYmM4MGZkY2RmNzRiYTFjZmM4L3RhYmxlcmFuZ2U6NjUxMzQyNTdkZjhkNGFiYzgwZmRjZGY3NGJhMWNmYzhfOS03LTEtMS04MQ_553d13aa-a14a-40b8-9ea3-a29098731bf9"
      unitRef="usd">154875000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic85f6d136e8245968800b43ce0542fe8_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80MC9mcmFnOmQwZTdiYzBhNTk1MjRkYzQ4MzU1MDkwYTlkNzVjNmIzL3RhYmxlOjY1MTM0MjU3ZGY4ZDRhYmM4MGZkY2RmNzRiYTFjZmM4L3RhYmxlcmFuZ2U6NjUxMzQyNTdkZjhkNGFiYzgwZmRjZGY3NGJhMWNmYzhfMTAtMS0xLTEtODE_0caa7c9e-6ec4-4c57-b7c5-af0cbcb46131"
      unitRef="usd">4114000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i63601b24528b4ff788ffb07ad33130f8_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80MC9mcmFnOmQwZTdiYzBhNTk1MjRkYzQ4MzU1MDkwYTlkNzVjNmIzL3RhYmxlOjY1MTM0MjU3ZGY4ZDRhYmM4MGZkY2RmNzRiYTFjZmM4L3RhYmxlcmFuZ2U6NjUxMzQyNTdkZjhkNGFiYzgwZmRjZGY3NGJhMWNmYzhfMTAtMy0xLTEtODE_3f570741-289f-4190-8a39-b398d393995f"
      unitRef="usd">2747000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6088baa6c1d2446691681da562d452f9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80MC9mcmFnOmQwZTdiYzBhNTk1MjRkYzQ4MzU1MDkwYTlkNzVjNmIzL3RhYmxlOjY1MTM0MjU3ZGY4ZDRhYmM4MGZkY2RmNzRiYTFjZmM4L3RhYmxlcmFuZ2U6NjUxMzQyNTdkZjhkNGFiYzgwZmRjZGY3NGJhMWNmYzhfMTAtNS0xLTEtODE_f29f0613-c032-47fa-b77e-4fdc7c934783"
      unitRef="usd">11178000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibb19c48e81f541858b2a7dd6f03bfa27_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80MC9mcmFnOmQwZTdiYzBhNTk1MjRkYzQ4MzU1MDkwYTlkNzVjNmIzL3RhYmxlOjY1MTM0MjU3ZGY4ZDRhYmM4MGZkY2RmNzRiYTFjZmM4L3RhYmxlcmFuZ2U6NjUxMzQyNTdkZjhkNGFiYzgwZmRjZGY3NGJhMWNmYzhfMTAtNy0xLTEtODE_0966a079-414a-4db7-add1-2f73dd8aa087"
      unitRef="usd">7270000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i37c7d1d637bf4ae98b18884511c75dd9_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80MC9mcmFnOmQwZTdiYzBhNTk1MjRkYzQ4MzU1MDkwYTlkNzVjNmIzL3RhYmxlOjY1MTM0MjU3ZGY4ZDRhYmM4MGZkY2RmNzRiYTFjZmM4L3RhYmxlcmFuZ2U6NjUxMzQyNTdkZjhkNGFiYzgwZmRjZGY3NGJhMWNmYzhfMTEtMS0xLTEtODE_bc615c69-81ec-45f8-9cc0-03315cc0357d"
      unitRef="usd">110293000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5c507c58a3df413e914b6c8ae5dbf2a2_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80MC9mcmFnOmQwZTdiYzBhNTk1MjRkYzQ4MzU1MDkwYTlkNzVjNmIzL3RhYmxlOjY1MTM0MjU3ZGY4ZDRhYmM4MGZkY2RmNzRiYTFjZmM4L3RhYmxlcmFuZ2U6NjUxMzQyNTdkZjhkNGFiYzgwZmRjZGY3NGJhMWNmYzhfMTEtMy0xLTEtODE_4918a1a6-8613-4d07-bcd9-e08df5f239c4"
      unitRef="usd">183974000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia628ec6831414d4f8e0d2c927a011f4a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80MC9mcmFnOmQwZTdiYzBhNTk1MjRkYzQ4MzU1MDkwYTlkNzVjNmIzL3RhYmxlOjY1MTM0MjU3ZGY4ZDRhYmM4MGZkY2RmNzRiYTFjZmM4L3RhYmxlcmFuZ2U6NjUxMzQyNTdkZjhkNGFiYzgwZmRjZGY3NGJhMWNmYzhfMTEtNS0xLTEtODE_e1976381-2e3a-470d-b628-7c807ed5c988"
      unitRef="usd">350253000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3231b94f87f649139a15ad91d06d9fd2_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80MC9mcmFnOmQwZTdiYzBhNTk1MjRkYzQ4MzU1MDkwYTlkNzVjNmIzL3RhYmxlOjY1MTM0MjU3ZGY4ZDRhYmM4MGZkY2RmNzRiYTFjZmM4L3RhYmxlcmFuZ2U6NjUxMzQyNTdkZjhkNGFiYzgwZmRjZGY3NGJhMWNmYzhfMTEtNy0xLTEtODE_07e794d9-a0ff-4e38-888d-cc8c09a64c9f"
      unitRef="usd">404440000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i897a57efbfea4fbeaa81a87e5862e1a7_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80MC9mcmFnOmQwZTdiYzBhNTk1MjRkYzQ4MzU1MDkwYTlkNzVjNmIzL3RhYmxlOjY1MTM0MjU3ZGY4ZDRhYmM4MGZkY2RmNzRiYTFjZmM4L3RhYmxlcmFuZ2U6NjUxMzQyNTdkZjhkNGFiYzgwZmRjZGY3NGJhMWNmYzhfMTItMS0xLTEtODE_e0f9643e-a737-47bc-afa2-b1cc8f52fb90"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i46bcaf0cac964264acfc8967fb4fed3e_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80MC9mcmFnOmQwZTdiYzBhNTk1MjRkYzQ4MzU1MDkwYTlkNzVjNmIzL3RhYmxlOjY1MTM0MjU3ZGY4ZDRhYmM4MGZkY2RmNzRiYTFjZmM4L3RhYmxlcmFuZ2U6NjUxMzQyNTdkZjhkNGFiYzgwZmRjZGY3NGJhMWNmYzhfMTItMy0xLTEtODE_824482b2-8d4c-4abf-a9f1-63721809e716"
      unitRef="usd">35000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2dece6fa44fc4ba59c58b479ca510a5f_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80MC9mcmFnOmQwZTdiYzBhNTk1MjRkYzQ4MzU1MDkwYTlkNzVjNmIzL3RhYmxlOjY1MTM0MjU3ZGY4ZDRhYmM4MGZkY2RmNzRiYTFjZmM4L3RhYmxlcmFuZ2U6NjUxMzQyNTdkZjhkNGFiYzgwZmRjZGY3NGJhMWNmYzhfMTItNS0xLTEtODE_37463e04-8d38-40f2-bb8d-d237bb5d9638"
      unitRef="usd">135000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iae3f552bb26a4c00a17d299e8d3f716b_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80MC9mcmFnOmQwZTdiYzBhNTk1MjRkYzQ4MzU1MDkwYTlkNzVjNmIzL3RhYmxlOjY1MTM0MjU3ZGY4ZDRhYmM4MGZkY2RmNzRiYTFjZmM4L3RhYmxlcmFuZ2U6NjUxMzQyNTdkZjhkNGFiYzgwZmRjZGY3NGJhMWNmYzhfMTItNy0xLTEtODE_e214f7f2-6d03-4330-ba68-347b554f0b58"
      unitRef="usd">45000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id673d80f31e74643a241d2f62db94ca9_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80MC9mcmFnOmQwZTdiYzBhNTk1MjRkYzQ4MzU1MDkwYTlkNzVjNmIzL3RhYmxlOjY1MTM0MjU3ZGY4ZDRhYmM4MGZkY2RmNzRiYTFjZmM4L3RhYmxlcmFuZ2U6NjUxMzQyNTdkZjhkNGFiYzgwZmRjZGY3NGJhMWNmYzhfMTMtMS0xLTEtODE_0ef8afa1-01fe-471a-976f-ed0821ca4053"
      unitRef="usd">823303000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i313b15d35b7045babd1ba61f84a077dd_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80MC9mcmFnOmQwZTdiYzBhNTk1MjRkYzQ4MzU1MDkwYTlkNzVjNmIzL3RhYmxlOjY1MTM0MjU3ZGY4ZDRhYmM4MGZkY2RmNzRiYTFjZmM4L3RhYmxlcmFuZ2U6NjUxMzQyNTdkZjhkNGFiYzgwZmRjZGY3NGJhMWNmYzhfMTMtMy0xLTEtODE_b57145b8-b47a-4548-8840-1115e62b568f"
      unitRef="usd">812987000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80MC9mcmFnOmQwZTdiYzBhNTk1MjRkYzQ4MzU1MDkwYTlkNzVjNmIzL3RhYmxlOjY1MTM0MjU3ZGY4ZDRhYmM4MGZkY2RmNzRiYTFjZmM4L3RhYmxlcmFuZ2U6NjUxMzQyNTdkZjhkNGFiYzgwZmRjZGY3NGJhMWNmYzhfMTMtNS0xLTEtODE_2d078e77-eda9-4927-8495-64e571acee2c"
      unitRef="usd">2467935000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0faaba5fcd6b485781cadacae8b2fd8e_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80MC9mcmFnOmQwZTdiYzBhNTk1MjRkYzQ4MzU1MDkwYTlkNzVjNmIzL3RhYmxlOjY1MTM0MjU3ZGY4ZDRhYmM4MGZkY2RmNzRiYTFjZmM4L3RhYmxlcmFuZ2U6NjUxMzQyNTdkZjhkNGFiYzgwZmRjZGY3NGJhMWNmYzhfMTMtNy0xLTEtODE_037a3c9d-3043-49e2-9bb3-4d454eaee55b"
      unitRef="usd">2123414000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80My9mcmFnOmU5ZDJjOTllOGFlODQ4MDdiZDgxMTY0ZThhOWVkYWU3L3RleHRyZWdpb246ZTlkMmM5OWU4YWU4NDgwN2JkODExNjRlOGE5ZWRhZTdfNDAzOA_b2c9608a-42e9-449f-ad0b-11d973cccc1c">&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of our marketable security portfolio for the periods presented (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.142%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.084%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt securities (government)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;292,941&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,441)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;286,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt securities (government)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;291,871&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,119)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;290,752&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our available-for-sale debt securities generally have contractual maturity dates of between 12 to 18 months. Debt security assets were assessed for risk of expected credit losses. As of September&#160;30, 2022 and December&#160;31, 2021, the available-for-sale debt securities were held in U.S.-government backed securities and in Treasury bonds and were assessed on an individual security basis to have a de minimis risk of credit loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;FASB accounting guidance defines fair value as the price that would be received to sell an asset or paid to transfer a liability (&#x201c;the exit price&#x201d;) in an orderly transaction between market participants at the measurement date. The standard outlines a valuation framework and creates a fair value hierarchy in order to increase the consistency and comparability of fair value measurements and the related disclosures. In determining fair value we use quoted prices and observable inputs. Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of us. The fair value hierarchy is broken down into three levels based on the source of inputs as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 1&#x2014;Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 2&#x2014;Valuations based on observable inputs and quoted prices in active markets for similar assets and liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 3&#x2014;Valuations based on inputs that are unobservable and models that are significant to the overall fair value measurement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recurring Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our marketable securities consist of investments in U.S. government debt securities that are classified as available-for-sale. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At September&#160;30, 2022 and December&#160;31, 2021, our Level 2 U.S. government debt securities were valued using readily available pricing sources which utilize market observable inputs, including the current interest rate and other characteristics for similar types of investments. Our long term investments classified as Level 1 were valued using their respective closing stock prices on The Nasdaq Stock Market. We did not experience any transfers of financial instruments between the fair value hierarchy levels during the nine months ended September&#160;30, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following fair value hierarchy table presents information about each major category of our financial assets measured at fair value on a recurring basis (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.354%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.085%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurement at Reporting Date Using:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Quoted Prices in&lt;br/&gt;Active Markets for&lt;br/&gt;Identical Assets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Significant Other&lt;br/&gt;Observable&lt;br/&gt;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance as of &lt;br/&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,690,622&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,690,622&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt securities (government)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;286,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;286,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long term investments (Note 7)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;149,124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;149,124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,839,746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;286,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,126,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.354%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.085%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurement at Reporting Date Using:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Quoted Prices in&lt;br/&gt;Active Markets for&lt;br/&gt;Identical Assets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Significant Other&lt;br/&gt;Observable&lt;br/&gt;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Balance as of&lt;br/&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,057,440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,057,440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt securities (government)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;290,752&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;290,752&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long term investments (Note 7)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;221,266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;221,266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,278,706&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;290,752&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,569,458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following fair value hierarchy table presents information about each major category of our financial liabilities measured at fair value on a recurring basis as (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.354%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.085%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurement at Reporting Date Using:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Quoted Prices in&lt;br/&gt;Active Markets for&lt;br/&gt;Identical Liabilities&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Significant Other&lt;br/&gt;Observable&lt;br/&gt;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance as of&lt;br/&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisition-related contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;206,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;206,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;206,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;206,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.354%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.085%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurement at Reporting Date Using:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted Prices in&lt;br/&gt;Active Markets for&lt;br/&gt;Identical Liabilities&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant Other&lt;br/&gt;Observable&lt;br/&gt;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance as of&lt;br/&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisition-related contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;244,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;244,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;244,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;244,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a rollforward of our Level 3 liabilities (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.718%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.082%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at January 1, &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;244,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration earned during the period but not yet paid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25,802)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value of contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,198)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at September 30,&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;206,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the contingent consideration was determined on the date of acquisition, June&#160;1, 2016, using an income approach based on projected future net revenues of ICLUSIG in the European Union and other countries for the approved third line treatment over 18 years, and discounted to present value at a rate of 10%. The fair value of the contingent consideration is remeasured each reporting period, with changes in fair value recorded in the condensed consolidated statements of operations. The valuation inputs utilized to estimate the fair value of the contingent consideration as of September&#160;30, 2022 and December&#160;31, 2021 included a discount rate of 10% and updated projections of future net revenues of ICLUSIG in the European Union and other countries for the approved third line treatment. The gain on change in fair value of the contingent consideration during the three and nine months ended September&#160;30, 2022 was due primarily to the changes in foreign currency exchange rates included within the updated projections of future net revenues of ICLUSIG.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We generally make payments to Takeda Pharmaceutical Company Limited quarterly based on the royalties or any additional milestone payments earned in the previous quarter. At September&#160;30, 2022 and December&#160;31, 2021, contingent consideration earned but not yet paid was $25.8 million and $19.6 million, respectively, and was included in accrued and other current liabilities.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock
      contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80My9mcmFnOmU5ZDJjOTllOGFlODQ4MDdiZDgxMTY0ZThhOWVkYWU3L3RleHRyZWdpb246ZTlkMmM5OWU4YWU4NDgwN2JkODExNjRlOGE5ZWRhZTdfNDAzOQ_4ee8e918-50a7-4e77-a4e9-09857604ecc2">&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of our marketable security portfolio for the periods presented (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.142%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.084%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt securities (government)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;292,941&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,441)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;286,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt securities (government)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;291,871&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,119)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;290,752&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
      contextRef="ia7f2a4b8ea5a46449d5a5c254bc02074_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80My9mcmFnOmU5ZDJjOTllOGFlODQ4MDdiZDgxMTY0ZThhOWVkYWU3L3RhYmxlOjY1NmQzZjMzM2YxZDQzZGM5YzMzYzY5ZDU5NWJlYzE2L3RhYmxlcmFuZ2U6NjU2ZDNmMzMzZjFkNDNkYzljMzNjNjlkNTk1YmVjMTZfMi0xLTEtMS04MQ_1dc2fff6-af85-4e92-9b71-31e0c0982ddb"
      unitRef="usd">292941000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax
      contextRef="ia7f2a4b8ea5a46449d5a5c254bc02074_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80My9mcmFnOmU5ZDJjOTllOGFlODQ4MDdiZDgxMTY0ZThhOWVkYWU3L3RhYmxlOjY1NmQzZjMzM2YxZDQzZGM5YzMzYzY5ZDU5NWJlYzE2L3RhYmxlcmFuZ2U6NjU2ZDNmMzMzZjFkNDNkYzljMzNjNjlkNTk1YmVjMTZfMi0zLTEtMS04MQ_26ece443-e4b3-47e6-a8c1-25780b999021"
      unitRef="usd">-6441000</us-gaap:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="ia7f2a4b8ea5a46449d5a5c254bc02074_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80My9mcmFnOmU5ZDJjOTllOGFlODQ4MDdiZDgxMTY0ZThhOWVkYWU3L3RhYmxlOjY1NmQzZjMzM2YxZDQzZGM5YzMzYzY5ZDU5NWJlYzE2L3RhYmxlcmFuZ2U6NjU2ZDNmMzMzZjFkNDNkYzljMzNjNjlkNTk1YmVjMTZfMi01LTEtMS04MQ_04ac5140-8240-4613-8f5a-e1dc963369f5"
      unitRef="usd">286500000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
      contextRef="ia665e98c13fa47db9c644a1bccf8d1eb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80My9mcmFnOmU5ZDJjOTllOGFlODQ4MDdiZDgxMTY0ZThhOWVkYWU3L3RhYmxlOjY1NmQzZjMzM2YxZDQzZGM5YzMzYzY5ZDU5NWJlYzE2L3RhYmxlcmFuZ2U6NjU2ZDNmMzMzZjFkNDNkYzljMzNjNjlkNTk1YmVjMTZfNS0xLTEtMS04MQ_9ee85ee2-66e0-496d-a4f2-d11e767a395a"
      unitRef="usd">291871000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax
      contextRef="ia665e98c13fa47db9c644a1bccf8d1eb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80My9mcmFnOmU5ZDJjOTllOGFlODQ4MDdiZDgxMTY0ZThhOWVkYWU3L3RhYmxlOjY1NmQzZjMzM2YxZDQzZGM5YzMzYzY5ZDU5NWJlYzE2L3RhYmxlcmFuZ2U6NjU2ZDNmMzMzZjFkNDNkYzljMzNjNjlkNTk1YmVjMTZfNS0zLTEtMS04MQ_a1bd7c94-0b72-4848-9363-a199d225d94a"
      unitRef="usd">-1119000</us-gaap:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="ia665e98c13fa47db9c644a1bccf8d1eb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80My9mcmFnOmU5ZDJjOTllOGFlODQ4MDdiZDgxMTY0ZThhOWVkYWU3L3RhYmxlOjY1NmQzZjMzM2YxZDQzZGM5YzMzYzY5ZDU5NWJlYzE2L3RhYmxlcmFuZ2U6NjU2ZDNmMzMzZjFkNDNkYzljMzNjNjlkNTk1YmVjMTZfNS01LTEtMS04MQ_572a3cb8-5d8e-4a7c-a211-cdde67126351"
      unitRef="usd">290752000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtInstrumentTerm
      contextRef="i10d9e02673514259891fcd1d9b719b8c_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80My9mcmFnOmU5ZDJjOTllOGFlODQ4MDdiZDgxMTY0ZThhOWVkYWU3L3RleHRyZWdpb246ZTlkMmM5OWU4YWU4NDgwN2JkODExNjRlOGE5ZWRhZTdfMjQ5_e5312223-e3aa-4109-907d-cff2d34e65a8">P12M</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentTerm
      contextRef="ibfc4e1b1be0040ea91db0d41c92a5dfe_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80My9mcmFnOmU5ZDJjOTllOGFlODQ4MDdiZDgxMTY0ZThhOWVkYWU3L3RleHRyZWdpb246ZTlkMmM5OWU4YWU4NDgwN2JkODExNjRlOGE5ZWRhZTdfMjU2_e6319dd8-f104-4d12-9c76-0987b9c852d1">P18M</us-gaap:DebtInstrumentTerm>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock
      contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80My9mcmFnOmU5ZDJjOTllOGFlODQ4MDdiZDgxMTY0ZThhOWVkYWU3L3RleHRyZWdpb246ZTlkMmM5OWU4YWU4NDgwN2JkODExNjRlOGE5ZWRhZTdfNDA0MA_1d1cdd63-a77f-4948-9740-1b477657d22d">&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following fair value hierarchy table presents information about each major category of our financial assets measured at fair value on a recurring basis (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.354%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.085%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurement at Reporting Date Using:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Quoted Prices in&lt;br/&gt;Active Markets for&lt;br/&gt;Identical Assets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Significant Other&lt;br/&gt;Observable&lt;br/&gt;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance as of &lt;br/&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,690,622&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,690,622&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt securities (government)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;286,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;286,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long term investments (Note 7)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;149,124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;149,124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,839,746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;286,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,126,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.354%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.085%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurement at Reporting Date Using:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Quoted Prices in&lt;br/&gt;Active Markets for&lt;br/&gt;Identical Assets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Significant Other&lt;br/&gt;Observable&lt;br/&gt;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Balance as of&lt;br/&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,057,440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,057,440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt securities (government)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;290,752&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;290,752&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long term investments (Note 7)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;221,266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;221,266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,278,706&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;290,752&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,569,458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i449d405309c143ba85c051e549663c3a_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80My9mcmFnOmU5ZDJjOTllOGFlODQ4MDdiZDgxMTY0ZThhOWVkYWU3L3RhYmxlOjEwZGVkYjM0NjIyMDRjZGZiNzAyOWU0YmMxZTdkNzQ1L3RhYmxlcmFuZ2U6MTBkZWRiMzQ2MjIwNGNkZmI3MDI5ZTRiYzFlN2Q3NDVfMi0xLTEtMS04MQ_25b0ec5e-4ded-441e-8358-28af440c50cb"
      unitRef="usd">2690622000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i06079cbfdc734317994c136835d0952f_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80My9mcmFnOmU5ZDJjOTllOGFlODQ4MDdiZDgxMTY0ZThhOWVkYWU3L3RhYmxlOjEwZGVkYjM0NjIyMDRjZGZiNzAyOWU0YmMxZTdkNzQ1L3RhYmxlcmFuZ2U6MTBkZWRiMzQ2MjIwNGNkZmI3MDI5ZTRiYzFlN2Q3NDVfMi0zLTEtMS04MQ_6cf6028e-3a45-4264-88ea-512326b28692"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ie3ce7b9a2a1a476b998fe7aa7ef489e2_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80My9mcmFnOmU5ZDJjOTllOGFlODQ4MDdiZDgxMTY0ZThhOWVkYWU3L3RhYmxlOjEwZGVkYjM0NjIyMDRjZGZiNzAyOWU0YmMxZTdkNzQ1L3RhYmxlcmFuZ2U6MTBkZWRiMzQ2MjIwNGNkZmI3MDI5ZTRiYzFlN2Q3NDVfMi01LTEtMS04MQ_b9d7958b-14b6-44e2-8bd9-6414129a0244"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i281946f958c146b0926f5dd53313b031_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80My9mcmFnOmU5ZDJjOTllOGFlODQ4MDdiZDgxMTY0ZThhOWVkYWU3L3RhYmxlOjEwZGVkYjM0NjIyMDRjZGZiNzAyOWU0YmMxZTdkNzQ1L3RhYmxlcmFuZ2U6MTBkZWRiMzQ2MjIwNGNkZmI3MDI5ZTRiYzFlN2Q3NDVfMi03LTEtMS04MQ_ee2cfcf0-e422-4d64-aea0-93b2c8d8ec45"
      unitRef="usd">2690622000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
      contextRef="i449d405309c143ba85c051e549663c3a_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80My9mcmFnOmU5ZDJjOTllOGFlODQ4MDdiZDgxMTY0ZThhOWVkYWU3L3RhYmxlOjEwZGVkYjM0NjIyMDRjZGZiNzAyOWU0YmMxZTdkNzQ1L3RhYmxlcmFuZ2U6MTBkZWRiMzQ2MjIwNGNkZmI3MDI5ZTRiYzFlN2Q3NDVfMy0xLTEtMS04MQ_9a99c6f4-4a24-4934-8946-f66d95333f08"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
      contextRef="i06079cbfdc734317994c136835d0952f_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80My9mcmFnOmU5ZDJjOTllOGFlODQ4MDdiZDgxMTY0ZThhOWVkYWU3L3RhYmxlOjEwZGVkYjM0NjIyMDRjZGZiNzAyOWU0YmMxZTdkNzQ1L3RhYmxlcmFuZ2U6MTBkZWRiMzQ2MjIwNGNkZmI3MDI5ZTRiYzFlN2Q3NDVfMy0zLTEtMS04MQ_849edfe4-e2b9-4ee5-9258-8b722be65003"
      unitRef="usd">286500000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
      contextRef="ie3ce7b9a2a1a476b998fe7aa7ef489e2_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80My9mcmFnOmU5ZDJjOTllOGFlODQ4MDdiZDgxMTY0ZThhOWVkYWU3L3RhYmxlOjEwZGVkYjM0NjIyMDRjZGZiNzAyOWU0YmMxZTdkNzQ1L3RhYmxlcmFuZ2U6MTBkZWRiMzQ2MjIwNGNkZmI3MDI5ZTRiYzFlN2Q3NDVfMy01LTEtMS04MQ_c5dfae1c-f1be-4cfd-a69b-0803e988c77a"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
      contextRef="i281946f958c146b0926f5dd53313b031_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80My9mcmFnOmU5ZDJjOTllOGFlODQ4MDdiZDgxMTY0ZThhOWVkYWU3L3RhYmxlOjEwZGVkYjM0NjIyMDRjZGZiNzAyOWU0YmMxZTdkNzQ1L3RhYmxlcmFuZ2U6MTBkZWRiMzQ2MjIwNGNkZmI3MDI5ZTRiYzFlN2Q3NDVfMy03LTEtMS04MQ_aa8b846f-88e7-4f63-9521-2224331976ca"
      unitRef="usd">286500000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:LongTermInvestments
      contextRef="i449d405309c143ba85c051e549663c3a_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80My9mcmFnOmU5ZDJjOTllOGFlODQ4MDdiZDgxMTY0ZThhOWVkYWU3L3RhYmxlOjEwZGVkYjM0NjIyMDRjZGZiNzAyOWU0YmMxZTdkNzQ1L3RhYmxlcmFuZ2U6MTBkZWRiMzQ2MjIwNGNkZmI3MDI5ZTRiYzFlN2Q3NDVfNC0xLTEtMS04MQ_e54f8cd1-dbbb-489c-8ee5-3f6530669ba1"
      unitRef="usd">149124000</us-gaap:LongTermInvestments>
    <us-gaap:LongTermInvestments
      contextRef="i06079cbfdc734317994c136835d0952f_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80My9mcmFnOmU5ZDJjOTllOGFlODQ4MDdiZDgxMTY0ZThhOWVkYWU3L3RhYmxlOjEwZGVkYjM0NjIyMDRjZGZiNzAyOWU0YmMxZTdkNzQ1L3RhYmxlcmFuZ2U6MTBkZWRiMzQ2MjIwNGNkZmI3MDI5ZTRiYzFlN2Q3NDVfNC0zLTEtMS04MQ_908727e5-1129-45bf-8304-09e6b54f4c82"
      unitRef="usd">0</us-gaap:LongTermInvestments>
    <us-gaap:LongTermInvestments
      contextRef="ie3ce7b9a2a1a476b998fe7aa7ef489e2_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80My9mcmFnOmU5ZDJjOTllOGFlODQ4MDdiZDgxMTY0ZThhOWVkYWU3L3RhYmxlOjEwZGVkYjM0NjIyMDRjZGZiNzAyOWU0YmMxZTdkNzQ1L3RhYmxlcmFuZ2U6MTBkZWRiMzQ2MjIwNGNkZmI3MDI5ZTRiYzFlN2Q3NDVfNC01LTEtMS04MQ_512018c2-1626-4b62-828b-f2c1b381b3fe"
      unitRef="usd">0</us-gaap:LongTermInvestments>
    <us-gaap:LongTermInvestments
      contextRef="i281946f958c146b0926f5dd53313b031_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80My9mcmFnOmU5ZDJjOTllOGFlODQ4MDdiZDgxMTY0ZThhOWVkYWU3L3RhYmxlOjEwZGVkYjM0NjIyMDRjZGZiNzAyOWU0YmMxZTdkNzQ1L3RhYmxlcmFuZ2U6MTBkZWRiMzQ2MjIwNGNkZmI3MDI5ZTRiYzFlN2Q3NDVfNC03LTEtMS04MQ_21e6d3a4-fcbf-4e43-8147-5d6c14263337"
      unitRef="usd">149124000</us-gaap:LongTermInvestments>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i449d405309c143ba85c051e549663c3a_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80My9mcmFnOmU5ZDJjOTllOGFlODQ4MDdiZDgxMTY0ZThhOWVkYWU3L3RhYmxlOjEwZGVkYjM0NjIyMDRjZGZiNzAyOWU0YmMxZTdkNzQ1L3RhYmxlcmFuZ2U6MTBkZWRiMzQ2MjIwNGNkZmI3MDI5ZTRiYzFlN2Q3NDVfNS0xLTEtMS04MQ_f3c666c1-b707-4f62-9fbc-d2320155afa3"
      unitRef="usd">2839746000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i06079cbfdc734317994c136835d0952f_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80My9mcmFnOmU5ZDJjOTllOGFlODQ4MDdiZDgxMTY0ZThhOWVkYWU3L3RhYmxlOjEwZGVkYjM0NjIyMDRjZGZiNzAyOWU0YmMxZTdkNzQ1L3RhYmxlcmFuZ2U6MTBkZWRiMzQ2MjIwNGNkZmI3MDI5ZTRiYzFlN2Q3NDVfNS0zLTEtMS04MQ_40996344-8ae0-413c-aaa4-7b2c1065b85d"
      unitRef="usd">286500000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ie3ce7b9a2a1a476b998fe7aa7ef489e2_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80My9mcmFnOmU5ZDJjOTllOGFlODQ4MDdiZDgxMTY0ZThhOWVkYWU3L3RhYmxlOjEwZGVkYjM0NjIyMDRjZGZiNzAyOWU0YmMxZTdkNzQ1L3RhYmxlcmFuZ2U6MTBkZWRiMzQ2MjIwNGNkZmI3MDI5ZTRiYzFlN2Q3NDVfNS01LTEtMS04MQ_dcd2578d-9ff8-4654-a070-00a3bf65132d"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i281946f958c146b0926f5dd53313b031_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80My9mcmFnOmU5ZDJjOTllOGFlODQ4MDdiZDgxMTY0ZThhOWVkYWU3L3RhYmxlOjEwZGVkYjM0NjIyMDRjZGZiNzAyOWU0YmMxZTdkNzQ1L3RhYmxlcmFuZ2U6MTBkZWRiMzQ2MjIwNGNkZmI3MDI5ZTRiYzFlN2Q3NDVfNS03LTEtMS04MQ_80560ba6-7a76-4725-a80a-df5c613b48b7"
      unitRef="usd">3126246000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ia17493513b37495cac5bb47509ffe782_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80My9mcmFnOmU5ZDJjOTllOGFlODQ4MDdiZDgxMTY0ZThhOWVkYWU3L3RhYmxlOjYyM2IyMmI2MmQzYTRjYTc5OWFmZGQyNDQ0NWYyMDhjL3RhYmxlcmFuZ2U6NjIzYjIyYjYyZDNhNGNhNzk5YWZkZDI0NDQ1ZjIwOGNfMi0xLTEtMS04MQ_08155833-39fd-4f7d-88e6-ad61151c6b0a"
      unitRef="usd">2057440000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i2f88761cfe5c4e21a116380b0db0c026_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80My9mcmFnOmU5ZDJjOTllOGFlODQ4MDdiZDgxMTY0ZThhOWVkYWU3L3RhYmxlOjYyM2IyMmI2MmQzYTRjYTc5OWFmZGQyNDQ0NWYyMDhjL3RhYmxlcmFuZ2U6NjIzYjIyYjYyZDNhNGNhNzk5YWZkZDI0NDQ1ZjIwOGNfMi0zLTEtMS04MQ_0b745b67-2522-41fe-84c9-9d763e074786"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i4b1ac47dfe8c49068229b687c55c61c7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80My9mcmFnOmU5ZDJjOTllOGFlODQ4MDdiZDgxMTY0ZThhOWVkYWU3L3RhYmxlOjYyM2IyMmI2MmQzYTRjYTc5OWFmZGQyNDQ0NWYyMDhjL3RhYmxlcmFuZ2U6NjIzYjIyYjYyZDNhNGNhNzk5YWZkZDI0NDQ1ZjIwOGNfMi01LTEtMS04MQ_2320fa4d-4fbd-4e13-825e-55b0531b1c30"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i09bab9220bbf47b692107d83bc042e87_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80My9mcmFnOmU5ZDJjOTllOGFlODQ4MDdiZDgxMTY0ZThhOWVkYWU3L3RhYmxlOjYyM2IyMmI2MmQzYTRjYTc5OWFmZGQyNDQ0NWYyMDhjL3RhYmxlcmFuZ2U6NjIzYjIyYjYyZDNhNGNhNzk5YWZkZDI0NDQ1ZjIwOGNfMi03LTEtMS04MQ_916381f4-d651-4533-b626-2b7de4908be3"
      unitRef="usd">2057440000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
      contextRef="ia17493513b37495cac5bb47509ffe782_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80My9mcmFnOmU5ZDJjOTllOGFlODQ4MDdiZDgxMTY0ZThhOWVkYWU3L3RhYmxlOjYyM2IyMmI2MmQzYTRjYTc5OWFmZGQyNDQ0NWYyMDhjL3RhYmxlcmFuZ2U6NjIzYjIyYjYyZDNhNGNhNzk5YWZkZDI0NDQ1ZjIwOGNfMy0xLTEtMS04MQ_debc402d-2273-4b60-a26b-c4b565d33190"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
      contextRef="i2f88761cfe5c4e21a116380b0db0c026_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80My9mcmFnOmU5ZDJjOTllOGFlODQ4MDdiZDgxMTY0ZThhOWVkYWU3L3RhYmxlOjYyM2IyMmI2MmQzYTRjYTc5OWFmZGQyNDQ0NWYyMDhjL3RhYmxlcmFuZ2U6NjIzYjIyYjYyZDNhNGNhNzk5YWZkZDI0NDQ1ZjIwOGNfMy0zLTEtMS04MQ_197ba2aa-18eb-4d46-b746-588d2f79d0d3"
      unitRef="usd">290752000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
      contextRef="i4b1ac47dfe8c49068229b687c55c61c7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80My9mcmFnOmU5ZDJjOTllOGFlODQ4MDdiZDgxMTY0ZThhOWVkYWU3L3RhYmxlOjYyM2IyMmI2MmQzYTRjYTc5OWFmZGQyNDQ0NWYyMDhjL3RhYmxlcmFuZ2U6NjIzYjIyYjYyZDNhNGNhNzk5YWZkZDI0NDQ1ZjIwOGNfMy01LTEtMS04MQ_51a76c85-5101-443c-b97e-2bb1d8621bef"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
      contextRef="i09bab9220bbf47b692107d83bc042e87_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80My9mcmFnOmU5ZDJjOTllOGFlODQ4MDdiZDgxMTY0ZThhOWVkYWU3L3RhYmxlOjYyM2IyMmI2MmQzYTRjYTc5OWFmZGQyNDQ0NWYyMDhjL3RhYmxlcmFuZ2U6NjIzYjIyYjYyZDNhNGNhNzk5YWZkZDI0NDQ1ZjIwOGNfMy03LTEtMS04MQ_82aea52c-e87f-4a7b-a107-0250287d59d2"
      unitRef="usd">290752000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:LongTermInvestments
      contextRef="ia17493513b37495cac5bb47509ffe782_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80My9mcmFnOmU5ZDJjOTllOGFlODQ4MDdiZDgxMTY0ZThhOWVkYWU3L3RhYmxlOjYyM2IyMmI2MmQzYTRjYTc5OWFmZGQyNDQ0NWYyMDhjL3RhYmxlcmFuZ2U6NjIzYjIyYjYyZDNhNGNhNzk5YWZkZDI0NDQ1ZjIwOGNfNC0xLTEtMS04MQ_6bb88631-e5f1-428e-93aa-168106df4c44"
      unitRef="usd">221266000</us-gaap:LongTermInvestments>
    <us-gaap:LongTermInvestments
      contextRef="i2f88761cfe5c4e21a116380b0db0c026_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80My9mcmFnOmU5ZDJjOTllOGFlODQ4MDdiZDgxMTY0ZThhOWVkYWU3L3RhYmxlOjYyM2IyMmI2MmQzYTRjYTc5OWFmZGQyNDQ0NWYyMDhjL3RhYmxlcmFuZ2U6NjIzYjIyYjYyZDNhNGNhNzk5YWZkZDI0NDQ1ZjIwOGNfNC0zLTEtMS04MQ_d40a28aa-409c-42c4-9072-96a87120e81b"
      unitRef="usd">0</us-gaap:LongTermInvestments>
    <us-gaap:LongTermInvestments
      contextRef="i4b1ac47dfe8c49068229b687c55c61c7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80My9mcmFnOmU5ZDJjOTllOGFlODQ4MDdiZDgxMTY0ZThhOWVkYWU3L3RhYmxlOjYyM2IyMmI2MmQzYTRjYTc5OWFmZGQyNDQ0NWYyMDhjL3RhYmxlcmFuZ2U6NjIzYjIyYjYyZDNhNGNhNzk5YWZkZDI0NDQ1ZjIwOGNfNC01LTEtMS04MQ_39fc07f7-8a5b-4172-bae9-056611e3e15f"
      unitRef="usd">0</us-gaap:LongTermInvestments>
    <us-gaap:LongTermInvestments
      contextRef="i09bab9220bbf47b692107d83bc042e87_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80My9mcmFnOmU5ZDJjOTllOGFlODQ4MDdiZDgxMTY0ZThhOWVkYWU3L3RhYmxlOjYyM2IyMmI2MmQzYTRjYTc5OWFmZGQyNDQ0NWYyMDhjL3RhYmxlcmFuZ2U6NjIzYjIyYjYyZDNhNGNhNzk5YWZkZDI0NDQ1ZjIwOGNfNC03LTEtMS04MQ_d6badb4f-4c30-40b4-a67b-933a60e1915f"
      unitRef="usd">221266000</us-gaap:LongTermInvestments>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ia17493513b37495cac5bb47509ffe782_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80My9mcmFnOmU5ZDJjOTllOGFlODQ4MDdiZDgxMTY0ZThhOWVkYWU3L3RhYmxlOjYyM2IyMmI2MmQzYTRjYTc5OWFmZGQyNDQ0NWYyMDhjL3RhYmxlcmFuZ2U6NjIzYjIyYjYyZDNhNGNhNzk5YWZkZDI0NDQ1ZjIwOGNfNS0xLTEtMS04MQ_7bddcf18-0b21-471c-ac86-a4446072507e"
      unitRef="usd">2278706000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i2f88761cfe5c4e21a116380b0db0c026_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80My9mcmFnOmU5ZDJjOTllOGFlODQ4MDdiZDgxMTY0ZThhOWVkYWU3L3RhYmxlOjYyM2IyMmI2MmQzYTRjYTc5OWFmZGQyNDQ0NWYyMDhjL3RhYmxlcmFuZ2U6NjIzYjIyYjYyZDNhNGNhNzk5YWZkZDI0NDQ1ZjIwOGNfNS0zLTEtMS04MQ_ba628b0b-58ed-4da7-870b-58ddeaf61d63"
      unitRef="usd">290752000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i4b1ac47dfe8c49068229b687c55c61c7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80My9mcmFnOmU5ZDJjOTllOGFlODQ4MDdiZDgxMTY0ZThhOWVkYWU3L3RhYmxlOjYyM2IyMmI2MmQzYTRjYTc5OWFmZGQyNDQ0NWYyMDhjL3RhYmxlcmFuZ2U6NjIzYjIyYjYyZDNhNGNhNzk5YWZkZDI0NDQ1ZjIwOGNfNS01LTEtMS04MQ_d75f811e-331a-46c5-ada2-0237ba185c7c"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i09bab9220bbf47b692107d83bc042e87_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80My9mcmFnOmU5ZDJjOTllOGFlODQ4MDdiZDgxMTY0ZThhOWVkYWU3L3RhYmxlOjYyM2IyMmI2MmQzYTRjYTc5OWFmZGQyNDQ0NWYyMDhjL3RhYmxlcmFuZ2U6NjIzYjIyYjYyZDNhNGNhNzk5YWZkZDI0NDQ1ZjIwOGNfNS03LTEtMS04MQ_f044234a-2f25-4aa2-93f4-41e97dd0bed5"
      unitRef="usd">2569458000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock
      contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80My9mcmFnOmU5ZDJjOTllOGFlODQ4MDdiZDgxMTY0ZThhOWVkYWU3L3RleHRyZWdpb246ZTlkMmM5OWU4YWU4NDgwN2JkODExNjRlOGE5ZWRhZTdfNDA0MQ_d38a3e21-410a-4676-ac46-b46aa8f5ba9c">&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following fair value hierarchy table presents information about each major category of our financial liabilities measured at fair value on a recurring basis as (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.354%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.085%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurement at Reporting Date Using:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Quoted Prices in&lt;br/&gt;Active Markets for&lt;br/&gt;Identical Liabilities&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Significant Other&lt;br/&gt;Observable&lt;br/&gt;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance as of&lt;br/&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisition-related contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;206,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;206,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;206,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;206,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.354%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.085%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurement at Reporting Date Using:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted Prices in&lt;br/&gt;Active Markets for&lt;br/&gt;Identical Liabilities&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant Other&lt;br/&gt;Observable&lt;br/&gt;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance as of&lt;br/&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisition-related contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;244,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;244,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;244,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;244,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i449d405309c143ba85c051e549663c3a_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80My9mcmFnOmU5ZDJjOTllOGFlODQ4MDdiZDgxMTY0ZThhOWVkYWU3L3RhYmxlOjgwNGUwODJiMTFlYjQyZDdiM2E2YWY3MWNhMDRjODBjL3RhYmxlcmFuZ2U6ODA0ZTA4MmIxMWViNDJkN2IzYTZhZjcxY2EwNGM4MGNfMi0xLTEtMS04MQ_91f11a4e-a6be-444a-acab-cf54e28f4c4e"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i06079cbfdc734317994c136835d0952f_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80My9mcmFnOmU5ZDJjOTllOGFlODQ4MDdiZDgxMTY0ZThhOWVkYWU3L3RhYmxlOjgwNGUwODJiMTFlYjQyZDdiM2E2YWY3MWNhMDRjODBjL3RhYmxlcmFuZ2U6ODA0ZTA4MmIxMWViNDJkN2IzYTZhZjcxY2EwNGM4MGNfMi0zLTEtMS04MQ_fa0360ca-60d0-4842-97e1-a5a728c0fe7a"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ie3ce7b9a2a1a476b998fe7aa7ef489e2_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80My9mcmFnOmU5ZDJjOTllOGFlODQ4MDdiZDgxMTY0ZThhOWVkYWU3L3RhYmxlOjgwNGUwODJiMTFlYjQyZDdiM2E2YWY3MWNhMDRjODBjL3RhYmxlcmFuZ2U6ODA0ZTA4MmIxMWViNDJkN2IzYTZhZjcxY2EwNGM4MGNfMi01LTEtMS04MQ_eaa8915d-0a14-4dfe-a9ca-3562e512ac3b"
      unitRef="usd">206000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i281946f958c146b0926f5dd53313b031_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80My9mcmFnOmU5ZDJjOTllOGFlODQ4MDdiZDgxMTY0ZThhOWVkYWU3L3RhYmxlOjgwNGUwODJiMTFlYjQyZDdiM2E2YWY3MWNhMDRjODBjL3RhYmxlcmFuZ2U6ODA0ZTA4MmIxMWViNDJkN2IzYTZhZjcxY2EwNGM4MGNfMi03LTEtMS04MQ_9c15157a-ab49-4762-a669-f9572b798c1f"
      unitRef="usd">206000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="i449d405309c143ba85c051e549663c3a_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80My9mcmFnOmU5ZDJjOTllOGFlODQ4MDdiZDgxMTY0ZThhOWVkYWU3L3RhYmxlOjgwNGUwODJiMTFlYjQyZDdiM2E2YWY3MWNhMDRjODBjL3RhYmxlcmFuZ2U6ODA0ZTA4MmIxMWViNDJkN2IzYTZhZjcxY2EwNGM4MGNfMy0xLTEtMS04MQ_748fb4b0-03dd-4c9b-9d60-64e3ea200786"
      unitRef="usd">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="i06079cbfdc734317994c136835d0952f_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80My9mcmFnOmU5ZDJjOTllOGFlODQ4MDdiZDgxMTY0ZThhOWVkYWU3L3RhYmxlOjgwNGUwODJiMTFlYjQyZDdiM2E2YWY3MWNhMDRjODBjL3RhYmxlcmFuZ2U6ODA0ZTA4MmIxMWViNDJkN2IzYTZhZjcxY2EwNGM4MGNfMy0zLTEtMS04MQ_21bb04c1-ed0b-492a-b861-50b8faf8ea37"
      unitRef="usd">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="ie3ce7b9a2a1a476b998fe7aa7ef489e2_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80My9mcmFnOmU5ZDJjOTllOGFlODQ4MDdiZDgxMTY0ZThhOWVkYWU3L3RhYmxlOjgwNGUwODJiMTFlYjQyZDdiM2E2YWY3MWNhMDRjODBjL3RhYmxlcmFuZ2U6ODA0ZTA4MmIxMWViNDJkN2IzYTZhZjcxY2EwNGM4MGNfMy01LTEtMS04MQ_9f3bb8d8-357a-473d-a310-697c94bbff70"
      unitRef="usd">206000000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="i281946f958c146b0926f5dd53313b031_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80My9mcmFnOmU5ZDJjOTllOGFlODQ4MDdiZDgxMTY0ZThhOWVkYWU3L3RhYmxlOjgwNGUwODJiMTFlYjQyZDdiM2E2YWY3MWNhMDRjODBjL3RhYmxlcmFuZ2U6ODA0ZTA4MmIxMWViNDJkN2IzYTZhZjcxY2EwNGM4MGNfMy03LTEtMS04MQ_d03edb7b-fe9f-4e3a-b695-d61fe2dd8c0b"
      unitRef="usd">206000000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ia17493513b37495cac5bb47509ffe782_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80My9mcmFnOmU5ZDJjOTllOGFlODQ4MDdiZDgxMTY0ZThhOWVkYWU3L3RhYmxlOjFhMWE3NzQzZWE1YjRkNjk4NjJjZDBiNjQwMTc2ZTQzL3RhYmxlcmFuZ2U6MWExYTc3NDNlYTViNGQ2OTg2MmNkMGI2NDAxNzZlNDNfMi0xLTEtMS04MQ_836b2cf9-ff71-40a5-9b26-6a0747202ac4"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i2f88761cfe5c4e21a116380b0db0c026_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80My9mcmFnOmU5ZDJjOTllOGFlODQ4MDdiZDgxMTY0ZThhOWVkYWU3L3RhYmxlOjFhMWE3NzQzZWE1YjRkNjk4NjJjZDBiNjQwMTc2ZTQzL3RhYmxlcmFuZ2U6MWExYTc3NDNlYTViNGQ2OTg2MmNkMGI2NDAxNzZlNDNfMi0zLTEtMS04MQ_9fcbf294-3aa7-480a-9201-861a9b40ac41"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i4b1ac47dfe8c49068229b687c55c61c7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80My9mcmFnOmU5ZDJjOTllOGFlODQ4MDdiZDgxMTY0ZThhOWVkYWU3L3RhYmxlOjFhMWE3NzQzZWE1YjRkNjk4NjJjZDBiNjQwMTc2ZTQzL3RhYmxlcmFuZ2U6MWExYTc3NDNlYTViNGQ2OTg2MmNkMGI2NDAxNzZlNDNfMi01LTEtMS04MQ_621e4c0d-0bc5-4ae8-8658-6a5c78e473ce"
      unitRef="usd">244000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i09bab9220bbf47b692107d83bc042e87_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80My9mcmFnOmU5ZDJjOTllOGFlODQ4MDdiZDgxMTY0ZThhOWVkYWU3L3RhYmxlOjFhMWE3NzQzZWE1YjRkNjk4NjJjZDBiNjQwMTc2ZTQzL3RhYmxlcmFuZ2U6MWExYTc3NDNlYTViNGQ2OTg2MmNkMGI2NDAxNzZlNDNfMi03LTEtMS04MQ_657b9689-7ec6-4145-8709-b877f9904376"
      unitRef="usd">244000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="ia17493513b37495cac5bb47509ffe782_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80My9mcmFnOmU5ZDJjOTllOGFlODQ4MDdiZDgxMTY0ZThhOWVkYWU3L3RhYmxlOjFhMWE3NzQzZWE1YjRkNjk4NjJjZDBiNjQwMTc2ZTQzL3RhYmxlcmFuZ2U6MWExYTc3NDNlYTViNGQ2OTg2MmNkMGI2NDAxNzZlNDNfMy0xLTEtMS04MQ_4ee17f61-63ef-414a-a50a-66f902af0bfc"
      unitRef="usd">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="i2f88761cfe5c4e21a116380b0db0c026_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80My9mcmFnOmU5ZDJjOTllOGFlODQ4MDdiZDgxMTY0ZThhOWVkYWU3L3RhYmxlOjFhMWE3NzQzZWE1YjRkNjk4NjJjZDBiNjQwMTc2ZTQzL3RhYmxlcmFuZ2U6MWExYTc3NDNlYTViNGQ2OTg2MmNkMGI2NDAxNzZlNDNfMy0zLTEtMS04MQ_1b21931c-305d-49eb-8187-e8fd72fb69fc"
      unitRef="usd">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="i4b1ac47dfe8c49068229b687c55c61c7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80My9mcmFnOmU5ZDJjOTllOGFlODQ4MDdiZDgxMTY0ZThhOWVkYWU3L3RhYmxlOjFhMWE3NzQzZWE1YjRkNjk4NjJjZDBiNjQwMTc2ZTQzL3RhYmxlcmFuZ2U6MWExYTc3NDNlYTViNGQ2OTg2MmNkMGI2NDAxNzZlNDNfMy01LTEtMS04MQ_21dde53f-aefd-47f3-8363-647ee3782b04"
      unitRef="usd">244000000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="i09bab9220bbf47b692107d83bc042e87_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80My9mcmFnOmU5ZDJjOTllOGFlODQ4MDdiZDgxMTY0ZThhOWVkYWU3L3RhYmxlOjFhMWE3NzQzZWE1YjRkNjk4NjJjZDBiNjQwMTc2ZTQzL3RhYmxlcmFuZ2U6MWExYTc3NDNlYTViNGQ2OTg2MmNkMGI2NDAxNzZlNDNfMy03LTEtMS04MQ_1d58347a-6f11-4fb9-8c64-4b0ecdb160bd"
      unitRef="usd">244000000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80My9mcmFnOmU5ZDJjOTllOGFlODQ4MDdiZDgxMTY0ZThhOWVkYWU3L3RleHRyZWdpb246ZTlkMmM5OWU4YWU4NDgwN2JkODExNjRlOGE5ZWRhZTdfNDA0Mg_d89a0064-bf65-4cff-970c-292c870c0392">&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a rollforward of our Level 3 liabilities (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.718%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.082%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at January 1, &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;244,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration earned during the period but not yet paid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25,802)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value of contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,198)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at September 30,&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;206,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="ia7f1808eadf04e878f5967c1674de235_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80My9mcmFnOmU5ZDJjOTllOGFlODQ4MDdiZDgxMTY0ZThhOWVkYWU3L3RhYmxlOmMxODFjZGJkMDdlNjQ5MmRiODQ5ZTEwNTYyYWY0NTljL3RhYmxlcmFuZ2U6YzE4MWNkYmQwN2U2NDkyZGI4NDllMTA1NjJhZjQ1OWNfMS0xLTEtMS04MQ_84808e2d-1c54-41d9-b88d-a24645c06031"
      unitRef="usd">244000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <incy:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityConsiderationEarned
      contextRef="i7c9b57b7436547ed808aaf19bca65fb0_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80My9mcmFnOmU5ZDJjOTllOGFlODQ4MDdiZDgxMTY0ZThhOWVkYWU3L3RhYmxlOmMxODFjZGJkMDdlNjQ5MmRiODQ5ZTEwNTYyYWY0NTljL3RhYmxlcmFuZ2U6YzE4MWNkYmQwN2U2NDkyZGI4NDllMTA1NjJhZjQ1OWNfMi0xLTEtMS04MQ_86c88e8d-f573-48c3-917a-bd5a1f6a4840"
      unitRef="usd">25802000</incy:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityConsiderationEarned>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="i7c9b57b7436547ed808aaf19bca65fb0_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80My9mcmFnOmU5ZDJjOTllOGFlODQ4MDdiZDgxMTY0ZThhOWVkYWU3L3RhYmxlOmMxODFjZGJkMDdlNjQ5MmRiODQ5ZTEwNTYyYWY0NTljL3RhYmxlcmFuZ2U6YzE4MWNkYmQwN2U2NDkyZGI4NDllMTA1NjJhZjQ1OWNfMy0xLTEtMS04MQ_a847138f-32d2-4374-add0-5cf70d55ad21"
      unitRef="usd">-12198000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i46f205a751e14f70bdffe84975b9278e_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80My9mcmFnOmU5ZDJjOTllOGFlODQ4MDdiZDgxMTY0ZThhOWVkYWU3L3RhYmxlOmMxODFjZGJkMDdlNjQ5MmRiODQ5ZTEwNTYyYWY0NTljL3RhYmxlcmFuZ2U6YzE4MWNkYmQwN2U2NDkyZGI4NDllMTA1NjJhZjQ1OWNfNC0xLTEtMS04MQ_de20677c-b785-47d5-a6ee-a4f5c0c68678"
      unitRef="usd">206000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <incy:FairValueInputsCashFlowsEstimatedPeriod
      contextRef="i65e0cbcc9a1c4a45843cde84fd23371f_D20160601-20160601"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80My9mcmFnOmU5ZDJjOTllOGFlODQ4MDdiZDgxMTY0ZThhOWVkYWU3L3RleHRyZWdpb246ZTlkMmM5OWU4YWU4NDgwN2JkODExNjRlOGE5ZWRhZTdfMzAzNQ_c1b06d7b-bb14-4af6-a041-fd310318ebf2">P18Y</incy:FairValueInputsCashFlowsEstimatedPeriod>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="ide8e43b5e4774c2b80fc1d692ccd6c5f_I20160601"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80My9mcmFnOmU5ZDJjOTllOGFlODQ4MDdiZDgxMTY0ZThhOWVkYWU3L3RleHRyZWdpb246ZTlkMmM5OWU4YWU4NDgwN2JkODExNjRlOGE5ZWRhZTdfMzA4NA_811e20b1-56a7-443d-9ce7-41725b388ebb"
      unitRef="number">0.10</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="i4769291f7a5e4844bdea08699b901a87_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80My9mcmFnOmU5ZDJjOTllOGFlODQ4MDdiZDgxMTY0ZThhOWVkYWU3L3RleHRyZWdpb246ZTlkMmM5OWU4YWU4NDgwN2JkODExNjRlOGE5ZWRhZTdfMzM5OA_8d43167e-eea9-4c1f-8b73-8367cda1e942"
      unitRef="number">0.10</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="i9dff9f829b91403384e43e22034102b6_I20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80My9mcmFnOmU5ZDJjOTllOGFlODQ4MDdiZDgxMTY0ZThhOWVkYWU3L3RleHRyZWdpb246ZTlkMmM5OWU4YWU4NDgwN2JkODExNjRlOGE5ZWRhZTdfMzM5OA_e9c3e9c5-e6da-404b-a5fa-568359f19f2e"
      unitRef="number">0.10</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <incy:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityConsiderationEarned
      contextRef="i651332485f95471bbc1f9997619b54c7_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80My9mcmFnOmU5ZDJjOTllOGFlODQ4MDdiZDgxMTY0ZThhOWVkYWU3L3RleHRyZWdpb246ZTlkMmM5OWU4YWU4NDgwN2JkODExNjRlOGE5ZWRhZTdfMzk1Ng_aca704c0-0d60-49ea-b122-e4ea91fb9654"
      unitRef="usd">25800000</incy:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityConsiderationEarned>
    <incy:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityConsiderationEarned
      contextRef="i8495b4244f744fd78c9b5dadcfa77dc2_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80My9mcmFnOmU5ZDJjOTllOGFlODQ4MDdiZDgxMTY0ZThhOWVkYWU3L3RleHRyZWdpb246ZTlkMmM5OWU4YWU4NDgwN2JkODExNjRlOGE5ZWRhZTdfMzk2Mw_8bd19288-3dd4-425d-847c-6ae1b1f2a0e0"
      unitRef="usd">19600000</incy:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityConsiderationEarned>
    <us-gaap:ConcentrationRiskDisclosureTextBlock
      contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80Ni9mcmFnOjA1ZTZhN2Q0ODZjZjRhMDBiZDMzMzEyMDk5Y2NmNTI4L3RleHRyZWdpb246MDVlNmE3ZDQ4NmNmNGEwMGJkMzMzMTIwOTljY2Y1MjhfMjAzNg_a400fce3-ddd4-46b4-a62f-708bf299e3e9">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2009, we entered into a collaboration and license agreement with Novartis Pharmaceutical International Ltd. (&#x201c;Novartis&#x201d;). In December 2009, we entered into a license, development and commercialization agreement with Eli Lilly and Company (&#x201c;Lilly&#x201d;). In December 2018, we entered into a research collaboration and licensing agreement with Innovent Biologics, Inc. (&#x201c;Innovent&#x201d;). In July 2019, we entered into a collaboration and license agreement with Zai Lab (Shanghai) Co., Ltd., a subsidiary of Zai Lab Limited (collectively, &#x201c;Zai Lab&#x201d;). The above collaboration partners comprised, in aggregate, 19% and 36% of the accounts receivable balance as of September&#160;30, 2022 and December&#160;31, 2021, respectively. For further information relating to these collaboration and license agreements,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;refer to Note 7.&lt;/span&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2011, we began commercialization and distribution of JAKAFI, in April 2020, we began commercialization and distribution of PEMAZYRE, and in October 2021, we began commercialization and distribution of OPZELURA. Our product revenues are concentrated in a number of these customers. The concentration of credit risk related to our JAKAFI, PEMAZYRE and OPZELURA product revenues is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.354%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.085%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Percentage of Total Net&lt;br/&gt;Product Revenues for the&lt;br/&gt;Three Months Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Percentage of Total Net&lt;br/&gt;Product Revenues for the&lt;br/&gt;Nine Months Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer B&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer C&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer E&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are exposed to risks associated with extending credit to customers related to the sale of products. Customers A, B, C, D and E comprised, in aggregate, 36% and 31% of the accounts receivable balance as of September&#160;30, 2022 and December&#160;31, 2021, respectively. The concentration of credit risk relating to our other product revenues or accounts receivable is not significant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We assessed our collaborative and customer receivable assets as of September&#160;30, 2022 according to our accounting policy for applying reserves for expected credit losses, noting minimal history of uncollectible receivables and the continued perceived creditworthiness of our third party sales relationships, upon which the expected credit losses were considered de minimis. As of September&#160;30, 2022 and December&#160;31, 2021, we had no allowance for doubtful accounts.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskDisclosureTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i683a8a412ece4de6b78e4947fd25373a_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80Ni9mcmFnOjA1ZTZhN2Q0ODZjZjRhMDBiZDMzMzEyMDk5Y2NmNTI4L3RleHRyZWdpb246MDVlNmE3ZDQ4NmNmNGEwMGJkMzMzMTIwOTljY2Y1MjhfNjg2_ab3f8eef-5679-4433-b3ed-eeed22b0d064"
      unitRef="number">0.19</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i1ed3ff5544594900b92ac9213a97bb21_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80Ni9mcmFnOjA1ZTZhN2Q0ODZjZjRhMDBiZDMzMzEyMDk5Y2NmNTI4L3RleHRyZWdpb246MDVlNmE3ZDQ4NmNmNGEwMGJkMzMzMTIwOTljY2Y1MjhfNjk0_b568484f-1a68-4db7-b5cc-84d847f0c884"
      unitRef="number">0.36</us-gaap:ConcentrationRiskPercentage1>
    <incy:SchedulesOfConcentrationOfRiskByRiskFactorRelatedToCollaborativePartnersTableTextBlock
      contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80Ni9mcmFnOjA1ZTZhN2Q0ODZjZjRhMDBiZDMzMzEyMDk5Y2NmNTI4L3RleHRyZWdpb246MDVlNmE3ZDQ4NmNmNGEwMGJkMzMzMTIwOTljY2Y1MjhfMjAzNw_304b7207-db09-46c0-83ef-67e9e4b26033">&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2011, we began commercialization and distribution of JAKAFI, in April 2020, we began commercialization and distribution of PEMAZYRE, and in October 2021, we began commercialization and distribution of OPZELURA. Our product revenues are concentrated in a number of these customers. The concentration of credit risk related to our JAKAFI, PEMAZYRE and OPZELURA product revenues is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.354%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.085%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Percentage of Total Net&lt;br/&gt;Product Revenues for the&lt;br/&gt;Three Months Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Percentage of Total Net&lt;br/&gt;Product Revenues for the&lt;br/&gt;Nine Months Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer B&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer C&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer E&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</incy:SchedulesOfConcentrationOfRiskByRiskFactorRelatedToCollaborativePartnersTableTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i3dc5046f317541c88021a56d36951298_D20220701-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80Ni9mcmFnOjA1ZTZhN2Q0ODZjZjRhMDBiZDMzMzEyMDk5Y2NmNTI4L3RhYmxlOjMzMjQ5OGRmOTQxMTQxMjhiODkwNDNjMzkwMmM5ZThhL3RhYmxlcmFuZ2U6MzMyNDk4ZGY5NDExNDEyOGI4OTA0M2MzOTAyYzllOGFfMy0xLTEtMS04MQ_744e7657-980d-4177-9990-8e4e77e4568f"
      unitRef="number">0.19</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ib26d36095867409f925663486648772f_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80Ni9mcmFnOjA1ZTZhN2Q0ODZjZjRhMDBiZDMzMzEyMDk5Y2NmNTI4L3RhYmxlOjMzMjQ5OGRmOTQxMTQxMjhiODkwNDNjMzkwMmM5ZThhL3RhYmxlcmFuZ2U6MzMyNDk4ZGY5NDExNDEyOGI4OTA0M2MzOTAyYzllOGFfMy0zLTEtMS04MQ_2a3b88d7-a0a2-4954-b336-15951c1980a1"
      unitRef="number">0.19</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i162968d5dc8e4fd680e4dc463271dc4b_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80Ni9mcmFnOjA1ZTZhN2Q0ODZjZjRhMDBiZDMzMzEyMDk5Y2NmNTI4L3RhYmxlOjMzMjQ5OGRmOTQxMTQxMjhiODkwNDNjMzkwMmM5ZThhL3RhYmxlcmFuZ2U6MzMyNDk4ZGY5NDExNDEyOGI4OTA0M2MzOTAyYzllOGFfMy01LTEtMS04MQ_38fb9bc3-210e-4c84-9788-7bb29293b7b9"
      unitRef="number">0.19</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="iefe171c3e83a4f289b8aae022d0e081b_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80Ni9mcmFnOjA1ZTZhN2Q0ODZjZjRhMDBiZDMzMzEyMDk5Y2NmNTI4L3RhYmxlOjMzMjQ5OGRmOTQxMTQxMjhiODkwNDNjMzkwMmM5ZThhL3RhYmxlcmFuZ2U6MzMyNDk4ZGY5NDExNDEyOGI4OTA0M2MzOTAyYzllOGFfMy03LTEtMS04MQ_433fd3ca-59cf-4f97-a23b-17c5c40ee63e"
      unitRef="number">0.19</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ifb602509071647998b5e683e940d1fcf_D20220701-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80Ni9mcmFnOjA1ZTZhN2Q0ODZjZjRhMDBiZDMzMzEyMDk5Y2NmNTI4L3RhYmxlOjMzMjQ5OGRmOTQxMTQxMjhiODkwNDNjMzkwMmM5ZThhL3RhYmxlcmFuZ2U6MzMyNDk4ZGY5NDExNDEyOGI4OTA0M2MzOTAyYzllOGFfNC0xLTEtMS04MQ_c6427519-87f9-4d9d-b15f-98c3ab36b566"
      unitRef="number">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ia8a7e40409944fc78088cd4baed567ac_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80Ni9mcmFnOjA1ZTZhN2Q0ODZjZjRhMDBiZDMzMzEyMDk5Y2NmNTI4L3RhYmxlOjMzMjQ5OGRmOTQxMTQxMjhiODkwNDNjMzkwMmM5ZThhL3RhYmxlcmFuZ2U6MzMyNDk4ZGY5NDExNDEyOGI4OTA0M2MzOTAyYzllOGFfNC0zLTEtMS04MQ_292b6fb9-0f0a-4aa7-8a85-f4c14aa87396"
      unitRef="number">0.11</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ia8ee030161c64a7e9c95b4e2fb66c573_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80Ni9mcmFnOjA1ZTZhN2Q0ODZjZjRhMDBiZDMzMzEyMDk5Y2NmNTI4L3RhYmxlOjMzMjQ5OGRmOTQxMTQxMjhiODkwNDNjMzkwMmM5ZThhL3RhYmxlcmFuZ2U6MzMyNDk4ZGY5NDExNDEyOGI4OTA0M2MzOTAyYzllOGFfNC01LTEtMS04MQ_ea0c4661-dc0e-42db-b3cd-9931976994ea"
      unitRef="number">0.11</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i8d5936e96208421793937f792f73038d_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80Ni9mcmFnOjA1ZTZhN2Q0ODZjZjRhMDBiZDMzMzEyMDk5Y2NmNTI4L3RhYmxlOjMzMjQ5OGRmOTQxMTQxMjhiODkwNDNjMzkwMmM5ZThhL3RhYmxlcmFuZ2U6MzMyNDk4ZGY5NDExNDEyOGI4OTA0M2MzOTAyYzllOGFfNC03LTEtMS04MQ_4c06f2c0-0670-4af4-afc9-83eaddac834a"
      unitRef="number">0.12</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i4b1f09000aa74166ade05d1c0dcfedd2_D20220701-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80Ni9mcmFnOjA1ZTZhN2Q0ODZjZjRhMDBiZDMzMzEyMDk5Y2NmNTI4L3RhYmxlOjMzMjQ5OGRmOTQxMTQxMjhiODkwNDNjMzkwMmM5ZThhL3RhYmxlcmFuZ2U6MzMyNDk4ZGY5NDExNDEyOGI4OTA0M2MzOTAyYzllOGFfNS0xLTEtMS04MQ_f5dd05ba-53b3-48da-a700-822029565f42"
      unitRef="number">0.15</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i1df4e17ddac14778b89ab7f884e13730_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80Ni9mcmFnOjA1ZTZhN2Q0ODZjZjRhMDBiZDMzMzEyMDk5Y2NmNTI4L3RhYmxlOjMzMjQ5OGRmOTQxMTQxMjhiODkwNDNjMzkwMmM5ZThhL3RhYmxlcmFuZ2U6MzMyNDk4ZGY5NDExNDEyOGI4OTA0M2MzOTAyYzllOGFfNS0zLTEtMS04MQ_f917bdd1-a6b6-4402-86b0-24f0b752f084"
      unitRef="number">0.17</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="iab7d5e90e123422ea957f7b149d1df86_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80Ni9mcmFnOjA1ZTZhN2Q0ODZjZjRhMDBiZDMzMzEyMDk5Y2NmNTI4L3RhYmxlOjMzMjQ5OGRmOTQxMTQxMjhiODkwNDNjMzkwMmM5ZThhL3RhYmxlcmFuZ2U6MzMyNDk4ZGY5NDExNDEyOGI4OTA0M2MzOTAyYzllOGFfNS01LTEtMS04MQ_6788b9eb-6ef3-4acd-8ffd-4f7bb09cbe20"
      unitRef="number">0.18</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i0cc4497fd77b42f18587cdf09d459c05_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80Ni9mcmFnOjA1ZTZhN2Q0ODZjZjRhMDBiZDMzMzEyMDk5Y2NmNTI4L3RhYmxlOjMzMjQ5OGRmOTQxMTQxMjhiODkwNDNjMzkwMmM5ZThhL3RhYmxlcmFuZ2U6MzMyNDk4ZGY5NDExNDEyOGI4OTA0M2MzOTAyYzllOGFfNS03LTEtMS04MQ_b552c8c8-9e8a-4aba-84c5-b21e3c9692ba"
      unitRef="number">0.18</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i1fae7539f0da469083ea910f00e0898b_D20220701-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80Ni9mcmFnOjA1ZTZhN2Q0ODZjZjRhMDBiZDMzMzEyMDk5Y2NmNTI4L3RhYmxlOjMzMjQ5OGRmOTQxMTQxMjhiODkwNDNjMzkwMmM5ZThhL3RhYmxlcmFuZ2U6MzMyNDk4ZGY5NDExNDEyOGI4OTA0M2MzOTAyYzllOGFfNi0xLTEtMS04MQ_7ae78a42-ab12-44e0-8dc4-fb5390ae8d53"
      unitRef="number">0.05</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ia675debc1ef84ae2b8ec00b9932e707b_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80Ni9mcmFnOjA1ZTZhN2Q0ODZjZjRhMDBiZDMzMzEyMDk5Y2NmNTI4L3RhYmxlOjMzMjQ5OGRmOTQxMTQxMjhiODkwNDNjMzkwMmM5ZThhL3RhYmxlcmFuZ2U6MzMyNDk4ZGY5NDExNDEyOGI4OTA0M2MzOTAyYzllOGFfNi0zLTEtMS04MQ_a66ce566-3cf9-4c4b-83eb-33b1d9e59d21"
      unitRef="number">0.09</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="iaebef62b75f545d4bddd48699efd1ed1_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80Ni9mcmFnOjA1ZTZhN2Q0ODZjZjRhMDBiZDMzMzEyMDk5Y2NmNTI4L3RhYmxlOjMzMjQ5OGRmOTQxMTQxMjhiODkwNDNjMzkwMmM5ZThhL3RhYmxlcmFuZ2U6MzMyNDk4ZGY5NDExNDEyOGI4OTA0M2MzOTAyYzllOGFfNi01LTEtMS04MQ_139b690a-ed40-4a97-b826-a2d59b681552"
      unitRef="number">0.05</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ie150bdc7743d4425a27721647c883684_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80Ni9mcmFnOjA1ZTZhN2Q0ODZjZjRhMDBiZDMzMzEyMDk5Y2NmNTI4L3RhYmxlOjMzMjQ5OGRmOTQxMTQxMjhiODkwNDNjMzkwMmM5ZThhL3RhYmxlcmFuZ2U6MzMyNDk4ZGY5NDExNDEyOGI4OTA0M2MzOTAyYzllOGFfNi03LTEtMS04MQ_e8fc0e09-f184-44f6-a737-7bf866bd1827"
      unitRef="number">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i35e2fb28114f48528d3537b9bb4d377b_D20220701-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80Ni9mcmFnOjA1ZTZhN2Q0ODZjZjRhMDBiZDMzMzEyMDk5Y2NmNTI4L3RhYmxlOjMzMjQ5OGRmOTQxMTQxMjhiODkwNDNjMzkwMmM5ZThhL3RhYmxlcmFuZ2U6MzMyNDk4ZGY5NDExNDEyOGI4OTA0M2MzOTAyYzllOGFfNy0xLTEtMS04MQ_8b1f2bb9-9a82-412d-87c3-4601341036d7"
      unitRef="number">0.09</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i7fb6ed6fc01c49089fc6fbcbb460178a_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80Ni9mcmFnOjA1ZTZhN2Q0ODZjZjRhMDBiZDMzMzEyMDk5Y2NmNTI4L3RhYmxlOjMzMjQ5OGRmOTQxMTQxMjhiODkwNDNjMzkwMmM5ZThhL3RhYmxlcmFuZ2U6MzMyNDk4ZGY5NDExNDEyOGI4OTA0M2MzOTAyYzllOGFfNy0zLTEtMS04MQ_da6fee56-35d5-433e-8137-087206b2a132"
      unitRef="number">0.11</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i0324e502e8e841449b5689a5c7c6f0ff_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80Ni9mcmFnOjA1ZTZhN2Q0ODZjZjRhMDBiZDMzMzEyMDk5Y2NmNTI4L3RhYmxlOjMzMjQ5OGRmOTQxMTQxMjhiODkwNDNjMzkwMmM5ZThhL3RhYmxlcmFuZ2U6MzMyNDk4ZGY5NDExNDEyOGI4OTA0M2MzOTAyYzllOGFfNy01LTEtMS04MQ_f0cc92d5-36fa-4cf9-849a-1d8843bd83d6"
      unitRef="number">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i589bb0c60aaa4a43b9a3cb4f9adb92ce_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80Ni9mcmFnOjA1ZTZhN2Q0ODZjZjRhMDBiZDMzMzEyMDk5Y2NmNTI4L3RhYmxlOjMzMjQ5OGRmOTQxMTQxMjhiODkwNDNjMzkwMmM5ZThhL3RhYmxlcmFuZ2U6MzMyNDk4ZGY5NDExNDEyOGI4OTA0M2MzOTAyYzllOGFfNy03LTEtMS04MQ_721d37b8-88d5-45f3-9a21-5decaccdb217"
      unitRef="number">0.11</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="idb10cbad0c1345b9be3e38c62201ded7_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80Ni9mcmFnOjA1ZTZhN2Q0ODZjZjRhMDBiZDMzMzEyMDk5Y2NmNTI4L3RleHRyZWdpb246MDVlNmE3ZDQ4NmNmNGEwMGJkMzMzMTIwOTljY2Y1MjhfMjc0ODc3OTA3MTU3Mg_a8f83248-17a0-48d4-9b03-6745d530440f"
      unitRef="number">0.36</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ia6ac11b8a7e34e69a3ca81e7967cd4db_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80Ni9mcmFnOjA1ZTZhN2Q0ODZjZjRhMDBiZDMzMzEyMDk5Y2NmNTI4L3RleHRyZWdpb246MDVlNmE3ZDQ4NmNmNGEwMGJkMzMzMTIwOTljY2Y1MjhfMTQ0NQ_549a57a9-d4c5-43ee-8822-eb588b3e723d"
      unitRef="number">0.31</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="i3b4376f8fc614de98c9cf647198c504e_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80Ni9mcmFnOjA1ZTZhN2Q0ODZjZjRhMDBiZDMzMzEyMDk5Y2NmNTI4L3RleHRyZWdpb246MDVlNmE3ZDQ4NmNmNGEwMGJkMzMzMTIwOTljY2Y1MjhfMjAwMg_ad520e3d-f0d0-4a17-bc98-e3eeff7bc945"
      unitRef="usd">0</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="iab26fe441f0d4ab984456365a7f7cff0_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80Ni9mcmFnOjA1ZTZhN2Q0ODZjZjRhMDBiZDMzMzEyMDk5Y2NmNTI4L3RleHRyZWdpb246MDVlNmE3ZDQ4NmNmNGEwMGJkMzMzMTIwOTljY2Y1MjhfMjAwMg_da0774b3-7857-4ca1-91ac-d1ccb80af192"
      unitRef="usd">0</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80OS9mcmFnOjRlZjZkOWQ4ZTExMjQ1NjFiMWFmZGYwNDk0OWQ4OWYxL3RleHRyZWdpb246NGVmNmQ5ZDhlMTEyNDU2MWIxYWZkZjA0OTQ5ZDg5ZjFfMTU2OA_bf33dabc-e105-4e3e-8b64-46fdac16fb0c">&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our inventory balance consists of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.083%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work-in-process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,895&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,768&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventory&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101,133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories, stated at the lower of cost and net realizable value, consist of raw materials, work in process and finished goods. At September&#160;30, 2022, $45.9 million of inventory was classified as current on the condensed consolidated balance sheet as we expect this inventory to be consumed for commercial use within the next twelve months. At September&#160;30, 2022, $55.3 million of inventory was classified as non-current on the condensed consolidated balance sheet as we did not expect this inventory to be consumed for commercial use within the next twelve months. We obtain some inventory components from a limited number of suppliers due to technology, availability, price, quality or other considerations. The loss of a supplier, the deterioration of our relationship with a supplier, or any unilateral violation of the contractual terms under which we are supplied components by a supplier could adversely affect our total revenues and gross margins.&lt;/span&gt;&lt;/div&gt;We capitalize inventory after U.S. Food and Drug Administration (FDA) approval as the related costs are expected to be recoverable through the commercialization of the product. Costs incurred prior to FDA approval are recorded as research and development expense in our statements of operations. At September&#160;30, 2022, inventory with approximately $56.8 million of product costs incurred prior to FDA approval had not yet been sold. We expect to sell the pre-commercialization inventory over the next 28 months and, as a result, cost of product revenues will reflect a lower average per unit cost of materials.</us-gaap:InventoryDisclosureTextBlock>
    <incy:ScheduleOfInventoryTableTextBlock
      contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80OS9mcmFnOjRlZjZkOWQ4ZTExMjQ1NjFiMWFmZGYwNDk0OWQ4OWYxL3RleHRyZWdpb246NGVmNmQ5ZDhlMTEyNDU2MWIxYWZkZjA0OTQ5ZDg5ZjFfMTU2OQ_02f1df61-6d38-491e-bfcb-7b328fe39b44">&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our inventory balance consists of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.083%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work-in-process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,895&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,768&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventory&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101,133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</incy:ScheduleOfInventoryTableTextBlock>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="i3b4376f8fc614de98c9cf647198c504e_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80OS9mcmFnOjRlZjZkOWQ4ZTExMjQ1NjFiMWFmZGYwNDk0OWQ4OWYxL3RhYmxlOmEzMzJhN2ZlMjZhZjQwYjNiZmU0MDg2MjA4NDBjYmRiL3RhYmxlcmFuZ2U6YTMzMmE3ZmUyNmFmNDBiM2JmZTQwODYyMDg0MGNiZGJfMS0xLTEtMS04MQ_dcdebcbb-8548-4365-b354-d4c446000232"
      unitRef="usd">32289000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="iab26fe441f0d4ab984456365a7f7cff0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80OS9mcmFnOjRlZjZkOWQ4ZTExMjQ1NjFiMWFmZGYwNDk0OWQ4OWYxL3RhYmxlOmEzMzJhN2ZlMjZhZjQwYjNiZmU0MDg2MjA4NDBjYmRiL3RhYmxlcmFuZ2U6YTMzMmE3ZmUyNmFmNDBiM2JmZTQwODYyMDg0MGNiZGJfMS0zLTEtMS04MQ_7e12962a-d5cc-4076-ab17-08daf7829218"
      unitRef="usd">1275000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="i3b4376f8fc614de98c9cf647198c504e_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80OS9mcmFnOjRlZjZkOWQ4ZTExMjQ1NjFiMWFmZGYwNDk0OWQ4OWYxL3RhYmxlOmEzMzJhN2ZlMjZhZjQwYjNiZmU0MDg2MjA4NDBjYmRiL3RhYmxlcmFuZ2U6YTMzMmE3ZmUyNmFmNDBiM2JmZTQwODYyMDg0MGNiZGJfMi0xLTEtMS04MQ_8b51c554-984b-4fc6-8fd6-947a66b22771"
      unitRef="usd">35465000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="iab26fe441f0d4ab984456365a7f7cff0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80OS9mcmFnOjRlZjZkOWQ4ZTExMjQ1NjFiMWFmZGYwNDk0OWQ4OWYxL3RhYmxlOmEzMzJhN2ZlMjZhZjQwYjNiZmU0MDg2MjA4NDBjYmRiL3RhYmxlcmFuZ2U6YTMzMmE3ZmUyNmFmNDBiM2JmZTQwODYyMDg0MGNiZGJfMi0zLTEtMS04MQ_89cf84b6-b9e6-497e-ae66-27ca6022f9c9"
      unitRef="usd">39895000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="i3b4376f8fc614de98c9cf647198c504e_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80OS9mcmFnOjRlZjZkOWQ4ZTExMjQ1NjFiMWFmZGYwNDk0OWQ4OWYxL3RhYmxlOmEzMzJhN2ZlMjZhZjQwYjNiZmU0MDg2MjA4NDBjYmRiL3RhYmxlcmFuZ2U6YTMzMmE3ZmUyNmFmNDBiM2JmZTQwODYyMDg0MGNiZGJfMy0xLTEtMS04MQ_6da1d5d6-36b4-46fd-96d8-abf9be137b7f"
      unitRef="usd">33379000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="iab26fe441f0d4ab984456365a7f7cff0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80OS9mcmFnOjRlZjZkOWQ4ZTExMjQ1NjFiMWFmZGYwNDk0OWQ4OWYxL3RhYmxlOmEzMzJhN2ZlMjZhZjQwYjNiZmU0MDg2MjA4NDBjYmRiL3RhYmxlcmFuZ2U6YTMzMmE3ZmUyNmFmNDBiM2JmZTQwODYyMDg0MGNiZGJfMy0zLTEtMS04MQ_b4a2f260-96bd-426d-b6ee-368d5900fdb7"
      unitRef="usd">15768000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <incy:InventoryNetCurrentAndNoncurrent
      contextRef="i3b4376f8fc614de98c9cf647198c504e_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80OS9mcmFnOjRlZjZkOWQ4ZTExMjQ1NjFiMWFmZGYwNDk0OWQ4OWYxL3RhYmxlOmEzMzJhN2ZlMjZhZjQwYjNiZmU0MDg2MjA4NDBjYmRiL3RhYmxlcmFuZ2U6YTMzMmE3ZmUyNmFmNDBiM2JmZTQwODYyMDg0MGNiZGJfNC0xLTEtMS04MQ_706c2491-5909-41a5-809c-d8ba2dd74c03"
      unitRef="usd">101133000</incy:InventoryNetCurrentAndNoncurrent>
    <incy:InventoryNetCurrentAndNoncurrent
      contextRef="iab26fe441f0d4ab984456365a7f7cff0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80OS9mcmFnOjRlZjZkOWQ4ZTExMjQ1NjFiMWFmZGYwNDk0OWQ4OWYxL3RhYmxlOmEzMzJhN2ZlMjZhZjQwYjNiZmU0MDg2MjA4NDBjYmRiL3RhYmxlcmFuZ2U6YTMzMmE3ZmUyNmFmNDBiM2JmZTQwODYyMDg0MGNiZGJfNC0zLTEtMS04MQ_4556f752-9c40-45ac-8315-ca88352ce8cc"
      unitRef="usd">56938000</incy:InventoryNetCurrentAndNoncurrent>
    <us-gaap:InventoryNet
      contextRef="i3b4376f8fc614de98c9cf647198c504e_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80OS9mcmFnOjRlZjZkOWQ4ZTExMjQ1NjFiMWFmZGYwNDk0OWQ4OWYxL3RleHRyZWdpb246NGVmNmQ5ZDhlMTEyNDU2MWIxYWZkZjA0OTQ5ZDg5ZjFfMjI1_ebbecdb4-26c9-4d83-b94d-769efb8410c7"
      unitRef="usd">45900000</us-gaap:InventoryNet>
    <us-gaap:InventoryNoncurrent
      contextRef="i3b4376f8fc614de98c9cf647198c504e_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80OS9mcmFnOjRlZjZkOWQ4ZTExMjQ1NjFiMWFmZGYwNDk0OWQ4OWYxL3RleHRyZWdpb246NGVmNmQ5ZDhlMTEyNDU2MWIxYWZkZjA0OTQ5ZDg5ZjFfNDEx_66d16c9d-3ae8-400a-8ae6-983e418c0c47"
      unitRef="usd">55300000</us-gaap:InventoryNoncurrent>
    <incy:InventoryRecordedAsResearchAndDevelopmentExpense
      contextRef="i3b4376f8fc614de98c9cf647198c504e_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80OS9mcmFnOjRlZjZkOWQ4ZTExMjQ1NjFiMWFmZGYwNDk0OWQ4OWYxL3RleHRyZWdpb246NGVmNmQ5ZDhlMTEyNDU2MWIxYWZkZjA0OTQ5ZDg5ZjFfMTMyNA_40ce8814-d52e-4dcc-8334-d2fa13699701"
      unitRef="usd">56800000</incy:InventoryRecordedAsResearchAndDevelopmentExpense>
    <incy:PeriodOfDeviationFromAverageCostOfGoodsSold
      contextRef="i7ea3b32b349549ab8ef8819fd6f23c57_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80OS9mcmFnOjRlZjZkOWQ4ZTExMjQ1NjFiMWFmZGYwNDk0OWQ4OWYxL3RleHRyZWdpb246NGVmNmQ5ZDhlMTEyNDU2MWIxYWZkZjA0OTQ5ZDg5ZjFfMTQ2Ng_20a2c3ff-9391-484b-ae3d-724276f34d41">P28M</incy:PeriodOfDeviationFromAverageCostOfGoodsSold>
    <incy:LicenseAgreementsTextBlock
      contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMzg0ODI5MDgxODYzMg_fc868bab-f4b9-4ab1-bd06-38bca590a86a">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Novartis&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2009, we entered into a Collaboration and License Agreement with Novartis. Under the terms of the agreement, Novartis received exclusive development and commercialization rights outside of the United States to our JAK inhibitor ruxolitinib and certain back-up compounds for hematologic and oncology indications, including all hematological malignancies, solid tumors and myeloproliferative diseases. We retained exclusive development and commercialization rights to JAKAFI (ruxolitinib) in the United States and in certain other indications. Novartis also received worldwide exclusive development and commercialization rights to our MET inhibitor compound capmatinib and certain back-up compounds in all indications.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under this agreement, we were initially eligible to receive up to $174.0 million for the achievement of development milestones, up to $495.0 million for the achievement of regulatory milestones and up to $500.0 million for the achievement of sales milestones. In addition, under an amendment to this agreement, we were initially eligible to receive up to $75.0 million of additional potential development and regulatory milestones relating to graft-versus-host-disease (&#x201c;GVHD&#x201d;). We have recognized and received, in the aggregate, $157.0 million for the achievement of development milestones, $340.0 million for the achievement of regulatory milestones, and $200.0 million for the achievement of sales milestones through September&#160;30, 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2022, we recognized a $15.0 million regulatory milestone for the positive opinion issued by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) that recommends granting marketing authorization for capmatinib (TABRECTA) as a monotherapy for the treatment of adults with advanced non-small cell lung cancer. Additionally, in May 2022, we recognized a $45.0 million regulatory milestone as a result of the European Commission&#x2019;s approval of JAKAVI (ruxolitinib) as the first post-steroid treatment for acute and chronic GVHD.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We also are eligible to receive tiered, double-digit royalties ranging from the upper-teens to the mid-twenties on future JAKAVI net sales outside of the United States, and tiered, worldwide royalties on TABRECTA net sales that range from 12% to 14%. We are obligated to pay to Novartis tiered royalties in the low single-digits on future JAKAFI net sales within the United States contingent on certain conditions. During the three and nine months ended September&#160;30, 2022, such royalties on net sales within the United States totaled $30.3 million and $81.3 million, respectively, and were reflected in cost of product revenues on the condensed consolidated statements of operations. During the three and nine months ended September&#160;30, 2021, such royalties on net sales within the United States totaled $26.9 million and $70.6 million, respectively, and were reflected in cost of product revenues on the condensed consolidated statements of operations. At September&#160;30, 2022 and December&#160;31, 2021, $221.7 million and $148.1 million, respectively, of accrued royalties were included in accrued and other current liabilities on the condensed consolidated balance sheets. Each company is responsible for costs relating to the development and commercialization of ruxolitinib in its respective territories, with costs of collaborative studies shared equally. Novartis is also responsible for all costs relating to the development and commercialization of capmatinib.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We had no milestone and contract revenue under the Novartis agreement for the three months ended September&#160;30, 2022, and we had $60.0 million for the nine months ended September&#160;30, 2022. Product royalty revenue related to Novartis net sales of JAKAVI outside of the United States for the three and nine months ended September&#160;30, 2022 was $85.8 million and $240.4 million, respectively. Product royalty revenue related to Novartis net sales of JAKAVI outside of the United States for the three and nine months ended September&#160;30, 2021 was $94.7 million and $242.3 million, respectively. Product royalty revenue related to Novartis net sales of TABRECTA worldwide for the three and nine months ended September&#160;30, 2022 was $4.1 million and $11.2 million, respectively. Product royalty revenue related to Novartis net sales of TABRECTA worldwide for the three and nine months ended September&#160;30, 2021 was $2.7 million and $7.3 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Lilly &#x2013; Baricitinib&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2009, we entered into a License, Development and Commercialization Agreement with Lilly. Under the terms of the agreement, Lilly received exclusive worldwide development and commercialization rights to our JAK inhibitor baricitinib, and certain back-up compounds for inflammatory and autoimmune diseases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under this agreement, we were initially eligible to receive up to $150.0 million for the achievement of development milestones, up to $365.0 million for the achievement of regulatory milestones and up to $150.0 million for the achievement of sales milestones. We have recognized and received, in aggregate, $149.0 million for the achievement of development milestones, $335.0 million for the achievement of regulatory milestones and $50.0 million for the achievement of sales milestones through September&#160;30, 2022. We are also eligible to receive tiered, double-digit royalty payments on future global sales with rates ranging up to the mid-twenties if a product is successfully commercialized. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2020, we amended our agreement with Lilly to enable Lilly to develop and commercialize baricitinib for the treatment of COVID-19. As part of the amended agreement, in addition to the royalties described above, we will be entitled to receive additional royalty payments with rates in the low teens on global net sales of baricitinib for the treatment of COVID-19 that exceed a specified aggregate global net sales threshold.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2022, we recognized a $40.0 million regulatory milestone for the FDA approval of OLUMIANT as a first-in-disease systemic treatment for adults with severe alopecia areata. Additionally, in June 2022 we recognized a $20.0 million regulatory milestone for the European Commission&#x2019;s approval for OLUMIANT for the treatment of adults with severe alopecia areata, and a $10.0 million regulatory milestone for the Ministry of Health, Labour and Welfare of Japan&#x2019;s approval for OLUMIANT for the treatment of adults with severe alopecia areata in Japan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We had no milestone and contract revenue under the Lilly agreement for the three months ended September&#160;30, 2022, and we had $70.0 million for the nine months ended September&#160;30, 2022. Product royalty revenue related to Lilly net sales of OLUMIANT outside of the United States for the three and nine months ended September&#160;30, 2022 was $20.4 million and $98.7 million, respectively. Product royalty revenue related to Lilly net sales of OLUMIANT outside of the United States for the three and nine months ended September&#160;30, 2021 was $86.6 million and $154.9 million, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Lilly - Ruxolitinib&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2016, we entered into an amendment to the agreement with Lilly that amended the non-compete provision of the agreement to allow us to engage in the development and commercialization of ruxolitinib in the GVHD field. Lilly is eligible to receive up to $40.0 million in regulatory milestone payments relating to ruxolitinib in the GVHD field. In May 2019, the approval of JAKAFI in steroid-refractory acute GVHD triggered a $20.0 million milestone payment to Lilly. In March 2022, the positive recommendation from the European Medicines Agency for regulatory approval of ruxolitinib in the GVHD field triggered an additional $20.0 million milestone payment to Lilly, which was recorded as research and development expense in our condensed consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Agenus&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2015, we entered into a License, Development and Commercialization Agreement with Agenus Inc. and its wholly-owned subsidiary, 4-Antibody AG (now known as Agenus Switzerland Inc.), which we collectively refer to as Agenus. Under this agreement, which was amended in February 2017, the parties have agreed to collaborate on the discovery of novel immuno-therapeutics using Agenus&#x2019; antibody discovery platforms. Under the terms of the amended agreement, we received exclusive worldwide development and commercialization rights to four checkpoint modulators directed against GITR, OX40, LAG-3 and TIM-3 as well as two undisclosed targets. Targets may be designated profit-share programs, where all costs and profits are shared equally by us and Agenus, or royalty-bearing programs, where we are responsible for all costs associated with discovery, preclinical, clinical development and commercialization activities. There are currently no profit-share programs. For each royalty-bearing product other than GITR and one undisclosed target, Agenus will be eligible to receive tiered royalties on global net sales ranging from 6% to 12%. For GITR and one undisclosed target, Agenus will be eligible to receive 15% royalties on global net sales. The agreement may be terminated by us for convenience upon 12 months&#x2019; notice and may also be terminated under certain other circumstances, including material breach. On October 19, 2022 we notified Agenus that we were terminating the OX40 project.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2022, we have paid Agenus milestones totaling $30.0 million and Agenus is eligible to receive up to an additional $500.0 million in future contingent development, regulatory and commercialization milestones across all programs in the collaboration.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, in 2017 we purchased 10.0&#160;million shares of Agenus Inc.&#x2019;s common stock for an aggregate purchase price of $60.0 million in cash, or $6.00 per share. In 2020, we sold an aggregate of approximately 3.7&#160;million shares of Agenus Inc.&#x2019;s common stock resulting in gross proceeds of approximately $17.2 million. In 2021, we sold an aggregate of approximately 2.0&#160;million shares of Agenus Inc.&#x2019;s common stock resulting in gross proceeds of approximately $10.5 million. The fair market value of our long term investment in Agenus Inc. at September&#160;30, 2022 and December&#160;31, 2021 was $24.8 million and $38.9 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We intend to hold the investment in Agenus Inc. for the foreseeable future and therefore, are accounting for our shares held in Agenus Inc. at fair value whereby the investment is marked to market through earnings in each reporting period. Given our intent to hold the investment for the foreseeable future, we have classified the investment within long term investments on the accompanying condensed consolidated balance sheets. For the three and nine months ended September&#160;30, 2022, we recorded an unrealized gain of $1.3 million and an unrealized loss of $14.1 million, respectively, based on the change in fair value of Agenus Inc.&#x2019;s common stock during the respective periods. For the three and nine months ended September&#160;30, 2021, we recorded an unrealized loss of $2.8 million and an unrealized gain of $29.1 million, respectively, based on the change in fair value of Agenus Inc.&#x2019;s common stock during the respective periods. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Merus&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2016, we entered into a Collaboration and License Agreement with Merus N.V. (&#x201c;Merus&#x201d;). Under this agreement, the parties have agreed to collaborate with respect to the research, discovery and development of bispecific antibodies utilizing Merus&#x2019; technology platform. The collaboration encompasses up to ten independent programs. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2022, we decided to opt-out of the continued development of MCLA-145, a bispecific antibody targeting PD-L1 and CD137. We continue to collaborate with Merus and leverage the Merus platform to develop a pipeline of novel agents, as we continue to hold worldwide exclusive development and commercialization rights to up to ten additional programs. Of these ten additional programs, Merus retained the option, subject to certain conditions, to co-fund development of up to two such programs. If Merus exercises its co-funding option for a program, Merus would be responsible for funding 35% of the associated future global development costs and, for certain of such programs, would be responsible for reimbursing us for certain development costs incurred prior to the option exercise. Merus will also have the right to participate in a specified proportion of detailing activities in the United States for one of those co-developed programs. All costs related to the co-funded collaboration programs are subject to joint research and development plans and overseen by a joint development committee, but we will have final determination as to such plans in cases of dispute. We will be responsible for all research, development and commercialization costs relating to all other programs. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For each program as to which Merus does not have commercialization or development co-funding rights, Merus is eligible to receive up to $100.0 million in future contingent development and regulatory milestones, and up to $250.0 million in commercialization milestones as well as tiered royalties ranging from 6% to 10% of global net sales. For each program as to which Merus exercises its option to co-fund development, Merus is eligible to receive a 50% share of profits (or sustain 50% of any losses) in the United States and be eligible to receive tiered royalties ranging from 6% to 10% of net sales of products outside of the United States. If Merus opts to cease co-funding a program as to which it exercised its co-development option, then Merus will no longer receive a share of profits in the United States but will be eligible to receive the same milestones from the co-funding termination date and the same tiered royalties described above with respect to programs where Merus does not have a right to co-fund development and, depending on the stage at which Merus chose to cease co-funding development costs, Merus will be eligible to receive additional royalties ranging up to 4% of net sales in the United States. As of September&#160;30, 2022, we have paid Merus milestones totaling $3.0 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, in 2016 we entered into a Share Subscription Agreement with Merus, pursuant to which we purchased 3.2&#160;million common shares of Merus for an aggregate purchase price of $80.0 million in cash, or $25.00 per share. In January 2021, we purchased 350,000 common shares in Merus&#x2019; underwritten public offering of 4,848,485 common shares at the public offering price of $24.75 per share, or an aggregate purchase price of $8.7 million. The fair market value of our total long term investment in Merus at September&#160;30, 2022 and December&#160;31, 2021 was $71.1 million and $112.9 million, respectively. As of September&#160;30, 2022, we owned approximately 8% of the outstanding common shares of Merus.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have concluded that we have the ability to exercise significant influence, but not control, over Merus based primarily on our ownership interest, the level of intra-entity transactions between us and Merus related to development expenses, as well as other qualitative factors. We have elected the fair value option to account for our long term investment in Merus whereby the investment is marked to market through earnings in each reporting period. We believe the fair value option to be the most appropriate accounting method to account for securities in publicly held collaborators for which we have significant influence. For the three and nine months ended September&#160;30, 2022, we recorded an unrealized loss of $9.3 million and $41.8 million, respectively, based on the change in fair value of Merus&#x2019; common shares during the respective periods. For the three and nine months ended September&#160;30, 2021, we recorded an unrealized gain of $3.3 million and $13.3 million, respectively, based on the change in fair value of Merus&#x2019; common shares during the respective periods. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Calithera&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2017, we entered into a Collaboration and License Agreement with Calithera Biosciences, Inc. (&#x201c;Calithera&#x201d;). Under this agreement, we received an exclusive, worldwide license to develop and commercialize small molecule arginase inhibitors, including INCB01158. We had initially agreed to co-fund 70% of the global development costs for the development of the licensed products for hematology and oncology indications, but effective September 30, 2020 Calithera opted out of its co-funding obligation, and we became responsible for funding all of the development costs of INCB01158 and any other licensed products. In September 2022, we notified Calithera of our exercise of our right to terminate the Collaboration and License Agreement for convenience, effective in December 2022. As a result of the termination, rights to INCB01158 and the other licensed products will revert to Calithera.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, in 2017, we entered into a Stock Purchase Agreement with Calithera, pursuant to which we purchased 1.7&#160;million shares of Calithera common stock for an aggregate purchase price of $8.0 million in cash, or $4.65 per share. In June 2022, Calithera effected a one-for-twenty stock split of its outstanding common stock, adjusting our ownership to 86,021 shares of Calithera&#x2019;s common stock. The fair market value of our long term investment in Calithera at September&#160;30, 2022 and December&#160;31, 2021 was $0.3 million and $1.1 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We intend to hold the investment in Calithera for the foreseeable future and therefore, are accounting for our shares held in Calithera at fair value whereby the investment is marked to market through earnings in each reporting period. Given our intent to hold the investment for the foreseeable future, we have classified the investment within long term investments on the accompanying condensed consolidated balance sheets. For the three months ended September&#160;30, 2022 we recorded a nominal unrealized gain, and for the nine months ended September&#160;30, 2022 we recorded an unrealized loss of $0.9 million, based on the change in fair value of Calithera&#x2019;s common stock during the respective periods. For the three and nine months ended September&#160;30, 2021 we recorded an unrealized gain of $0.2 million and an unrealized loss of $4.6 million, respectively, based on the change in fair value of Calithera&#x2019;s common stock during the respective periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;MacroGenics&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2017, we entered into a Global Collaboration and License Agreement with MacroGenics, Inc. (&#x201c;MacroGenics&#x201d;). Under this agreement, we received exclusive development and commercialization rights worldwide to MacroGenics&#x2019; INCMGA0012 (formerly MGA012), an investigational monoclonal antibody that inhibits PD-1. Except as set forth in the succeeding sentence, we have sole authority over and bear all costs and expenses in connection with the development and commercialization of INCMGA0012 in all indications, whether as a monotherapy or as part of a combination regimen. MacroGenics has retained the right to develop and commercialize, at its cost and expense, its pipeline assets in combination with INCMGA0012. In addition, MacroGenics has the right to manufacture a portion of both companies&#x2019; global clinical and commercial supply needs of INCMGA0012.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2022, we amended our agreement with MacroGenics to reflect changes related to the payment of certain milestones and paid MacroGenics $30.0 million. As of September 30, 2022, we have paid MacroGenics developmental milestones totaling $100.0 million. After the amendment, MacroGenics will be eligible to receive up to an additional $335.0 million in future contingent development and regulatory milestones, and up to $330.0 million in sales milestones as well as tiered royalties ranging from 15% to 24% of global net sales.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development expenses for the three and nine months ended September&#160;30, 2022 also included $41.6 million and $69.9 million, respectively, of development costs incurred pursuant to the MacroGenics agreement. Research and development expenses for the three and nine months ended September&#160;30, 2021 also included $17.8 million and $49.0 million, respectively, of development costs incurred pursuant to the MacroGenics agreement. At September&#160;30, 2022 and December&#160;31, 2021, a total of $2.7 million and $0.7 million of such costs were included in accrued and other liabilities on the condensed consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Syros&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2018, we entered into a Target Discovery, Research Collaboration and Option Agreement with Syros Pharmaceuticals, Inc. (&#x201c;Syros&#x201d;). Under this agreement, Syros will use its proprietary gene control platform to identify novel therapeutic targets with a focus in myeloproliferative neoplasms and we have received options to obtain exclusive worldwide rights to intellectual property resulting from the collaboration for up to seven validated targets. We will have exclusive worldwide rights to develop and commercialize any therapies under the collaboration that modulate those validated targets. We have agreed to pay Syros up to $54.0 million in target selection and option exercise fees should we decide to exercise all of our options under the agreement. For products resulting from the collaboration against each of the seven selected and validated targets, we have agreed to pay up to $50.0 million in potential development and regulatory milestones and up to $65.0 million in potential sales milestones. Syros is also eligible to receive low single-digit royalties on net sales of products resulting from the collaboration.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, in 2018, we entered into a Stock Purchase Agreement with Syros, pursuant to which we purchased 0.8&#160;million shares of Syros common stock for an aggregate purchase price of $10.0 million in cash, or $12.61 per share. Subsequently in 2018, we entered into an Amended Stock Purchase Agreement with Syros, pursuant to which we purchased an additional 0.1&#160;million shares of Syros common stock for an aggregate purchase price of $1.4 million in cash, or $9.55 per share. In September 2022, Syros effected a one-for-ten stock split of its outstanding common stock, adjusting our ownership to 93,753 shares of Syros&#x2019;s common stock. The fair market value of our long term investment in Syros as of September&#160;30, 2022 and December&#160;31, 2021 was $0.6 million and $3.1 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We intend to hold the investment in Syros for the foreseeable future and therefore, are accounting for our shares held in Syros at fair value whereby the investment is marked to market through earnings in each reporting period. Given our intent to hold the investment for the foreseeable future, we have classified the investment within long term investments on the accompanying condensed consolidated balance sheets. For the three and nine months ended September&#160;30, 2022, we recorded an unrealized loss of $0.3 million and $2.5 million, respectively, based on the change in fair value of Syros&#x2019; common stock during the respective periods. For the three and nine months ended September&#160;30, 2021, we recorded an unrealized loss of $0.9 million and $6.0 million, respectively, based on the change in fair value of Syros&#x2019; common stock during the respective periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Innovent &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;I&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;n December 2018, we entered into a Research Collaboration and Licensing Agreement with Innovent. Under the terms of this agreement, Innovent received exclusive development and commercialization rights to our clinical-stage product candidates pemigatinib, itacitinib and parsaclisib in hematology and oncology in mainland China, Hong Kong, Macau and Taiwan. We are eligible to receive up to an additional $94.0 million in potential development and regulatory milestones.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize development and regulatory milestones upon confirmation of achievement of the event, as development and regulatory approvals are events not controllable by us but rather development activities of Innovent and decisions made by regulatory agencies. In March 2022, we recognized a $5.0 million milestone for approval of PEMAZYRE (pemigatinib) in China.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the event of commercialization of the licensed molecule, we are eligible to receive up to $202.5 million in potential sales milestones from Innovent. We will recognize sales milestones in the corresponding period of the product sale upon confirmation of net sales milestone threshold achievement by Innovent. We are also eligible to receive tiered royalties from the high-teens to the low-twenties on future sales of products resulting from the collaboration. We retain an option to assist in the promotion of the three product candidates in the Innovent territories.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Zai Lab&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2019, we entered into a Collaboration and License Agreement with Zai Lab. Under the terms of this agreement, Zai Lab received development and exclusive commercialization rights to INCMGA0012 in hematology and oncology in mainland China, Hong Kong, Macau and Taiwan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The agreement allows for Zai Lab to continue development of the licensed molecule and to submit the licensed molecule to authorities for regulatory approval within the agreement territory, upon which we are eligible for up to $22.5 million in potential development and regulatory milestones. We recognize development and regulatory milestones upon confirmation of achievement of the event, as development and regulatory approvals are events not controllable by us but rather development activities of Zai Lab and decisions made by regulatory agencies.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the event of commercialization of the licensed molecule, we are eligible to receive up to $37.5 million in potential sales milestones from Zai Lab. We will recognize sales milestones in the corresponding period of the product sale upon confirmation of net sales milestone threshold achievement by Zai Lab. We are also eligible to receive tiered royalties from the low to mid-twenties on future product sales resulting from the collaboration. We also retain an option to assist in the promotion of INCMGA0012 in Zai Lab&#x2019;s licensed territories.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;MorphoSys&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2020, we entered into a Collaboration and License Agreement with MorphoSys AG and MorphoSys US Inc., a wholly-owned subsidiary of MorphoSys AG (together with MorphoSys AG, &#x201c;MorphoSys&#x201d;), covering the worldwide development and commercialization of MOR208 (tafasitamab), an investigational Fc engineered monoclonal antibody directed against the target molecule CD19 that is currently in clinical development by MorphoSys. MorphoSys has exclusive worldwide development and commercialization rights to tafasitamab under a June 2010 collaboration and license agreement with Xencor, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the agreement, we received exclusive commercialization rights outside of the United States, and MorphoSys and we have co-commercialization rights in the United States, with respect to tafasitamab. MorphoSys is responsible for leading the commercialization strategy and booking all revenue from sales of tafasitamab in the United States, and we and MorphoSys are both responsible for commercialization efforts in the United States and will share equally the profits and losses from the co-commercialization efforts. We will lead the commercialization strategy outside of the United States, and will be responsible for commercialization efforts and book all revenue from sales of tafasitamab outside of the United States, subject to our royalty payment obligations set forth below. We and MorphoSys have agreed to co-develop tafasitamab and to share development costs associated with global and U.S.-specific clinical trials, with Incyte responsible for 55% of such costs and MorphoSys responsible for 45% of such costs. Each company is responsible for funding any independent development activities, and we are responsible for funding development activities specific to territories outside of the United States. All development costs related to the collaboration are subject to a joint development plan. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;MorphoSys is eligible to receive up to $737.5 million in future contingent development and regulatory milestones and up to $315.0 million in commercialization milestones as well as tiered royalties ranging from the mid-teens to mid-twenties of net sales outside of the United States. MorphoSys&#x2019; right to receive royalties in any particular country will expire upon the last to occur of (a) the expiration of patent rights in that particular country, (b) a specified period of time after the first post-marketing authorization sale of a licensed product comprising tafasitamab in that country, and (c) the expiration of any regulatory exclusivity for that licensed product in that country. As of September&#160;30, 2022, we have paid MorphoSys milestones totaling $2.5 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, under the terms of the agreement and pursuant to a related purchase agreement, we purchased American Depositary Shares (&#x201c;ADSs&#x201d;), each representing 0.25 of an ordinary share of MorphoSys AG, for an aggregate purchase price of $150.0 million or $41.33 per ADS (such ADSs to be purchased, the &#x201c;New ADSs&#x201d;). The fair market value of our long term investment in MorphoSys as of September&#160;30, 2022 and December&#160;31, 2021 was $18.3 million and $34.2 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We intend to hold the investment in MorphoSys for the foreseeable future and therefore, are accounting for our shares held in MorphoSys at fair value whereby the investment is marked to market through earnings in each reporting period. Given our intent to hold the investment for the foreseeable future, we have classified the investment within long term investments on the accompanying condensed consolidated balance sheets. For the three and nine months ended September&#160;30, 2022, we recorded an unrealized gain of $0.8 million and an unrealized loss of $15.9 million, respectively, based on the change in fair value of MorphoSys&#x2019; ordinary shares during the respective periods. For the three and nine months ended September&#160;30, 2021, we recorded an unrealized loss of $27.3 million and $60.2 million, respectively, based on the change in fair value of MorphoSys&#x2019; ordinary shares during the respective periods. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our 50% share of the United States loss for the commercialization of tafasitamab for the three and nine months ended September&#160;30, 2022 was $1.8 million and $9.1 million, respectively, and is recorded as collaboration loss sharing on the condensed consolidated statement of operations. Our 50% share of the United States loss for the commercialization of tafasitamab for the three and nine months ended September&#160;30, 2021 was $9.1 million and $29.5 million, respectively, and is recorded as collaboration loss sharing on the condensed consolidated statement of operations. Research and development expenses for the three and nine months ended September&#160;30, 2022, includes $21.9 million and $70.4 million, respectively, related to our 55% share of the co-development costs for tafasitamab. Research and development expenses for the three and nine months ended September&#160;30, 2021, includes $21.5 million and $55.8 million, respectively, related to our 55% share of the co-development costs for tafasitamab. At September&#160;30, 2022 and December&#160;31, 2021, $72.5 million and $21.5 million, respectively, was included in accrued and other liabilities on the condensed consolidated balance sheets for amounts due to MorphoSys under the agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Nimble&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2020, we entered into a Collaboration and License Agreement with Nimble Therapeutics, Inc. (&#x201c;Nimble&#x201d;). Under the terms of this agreement, Nimble will utilize their peptide synthesis, screening and optimization platform for discovery and validation of peptides against specified targets. Under the agreement, Nimble is eligible to receive up to $8.0 million in future contingent discovery milestones and up to $127.0 million in future contingent development and regulatory milestones. Additionally, in the event of successful commercialization, Nimble is eligible to receive up to $130.0 million in future contingent sales milestones and tiered royalties on net sales in the low single digits.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;InnoCare&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2021, we entered into a Collaboration and License Agreement with Sunny Investments Limited, a wholly-owned subsidiary of InnoCare Pharma Limited (&#x201c;InnoCare&#x201d;). InnoCare received development and exclusive commercialization rights to tafasitamab in hematology and oncology in mainland China, Hong Kong, Macau and Taiwan. In September 2021, we recognized an upfront payment under this agreement of $35.0 million upon our transfer of technology related to the licensed product candidate to InnoCare, which was recorded in milestone and contract revenues on the consolidated statement of operations for the year ended December 31, 2021. Under the terms of this agreement, we are eligible to receive up to an additional $82.5 million in potential development, regulatory and commercial milestones. We recognize development and regulatory milestones upon confirmation of achievement of the event, as development and regulatory approvals are events not controllable by us but rather development activities of InnoCare and decisions made by regulatory agencies. In the event of commercialization, we will recognize sales milestones in the corresponding period of the product sale upon confirmation of net sales milestone threshold achievement by InnoCare.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Syndax&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2021, we entered into a Collaboration and License Agreement with Syndax Pharmaceuticals, Inc. (&#x201c;Syndax&#x201d;), covering the worldwide development and commercialization of SNDX-6352 (&#x201c;axatilimab&#x201d;). Axatilimab, currently in clinical development by Syndax, is a monoclonal antibody that blocks the colony stimulating factor-1 (CSF-1) receptor. Syndax has exclusive worldwide development and commercialization rights to axatilimab under a June 2016 license agreement with UCB Biopharma Sprl. The agreement became effective in December 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the agreement, we received exclusive commercialization rights outside of the United States, and Syndax and we have co-commercialization rights in the United States, with respect to axatilimab. We will be responsible for leading the commercialization strategy and booking all revenue from sales of axatilimab globally, and Syndax will have the option to co-commercialization axatilimab with Incyte in the United States. Incyte and Syndax will share equally the profits and losses from the co-commercialization efforts in the United States. Sales of axatilimab outside the United States will be subject to our royalty payment obligations to Syndax, as set forth below. We and Syndax have agreed to co-develop axatilimab and to share development costs associated with global and U.S.-specific clinical trials, with Incyte responsible for 55% of such costs and Syndax responsible for 45% of such costs. Each company is responsible for funding any independent development activities. All development costs related to the collaboration are subject to a joint development plan. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2021, we paid Syndax an upfront, non-refundable payment of $117.0 million, which was recorded in research and development expense on the consolidated statement of operations for the year ended December 31, 2021. Syndax is eligible to receive up to $220.0 million in future contingent development and regulatory milestones and up to $230.0 million in sales milestones as well as tiered royalties ranging in the mid-teens on net sales in Europe and Japan and low double digit percentage on net sales in the rest of the world outside of the United States. Syndax&#x2019; right to receive royalties in any particular country will expire upon the last to occur of (a) the expiration of patent rights in that particular country, (b) a specified period of time after the first post-marketing authorization sale of a licensed product comprising axatilimab in that country, and (c) the expiration of any regulatory exclusivity for that licensed product in that country.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, under the terms of the agreement and pursuant to a related stock purchase agreement, we purchased approximately 1.4&#160;million shares of Syndax common stock for an aggregate purchase price of $35.0 million, or $24.62 per share. We completed the purchase of the shares on December 9, 2021 when the closing price on The Nasdaq Stock Market was $17.48 per share. Of the $35.0 million aggregate purchase price paid, $24.8 million was allocated to our stock purchase and was recorded within long term investments and $10.2 million, representing premium paid on the purchase, was allocated to research and development expense on the consolidated statement of operations for the year ended December 31, 2021. The fair market value of our long term investment in Syndax as of September&#160;30, 2022 and December&#160;31, 2021 was $34.2 million and $31.1 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We intend to hold the investment in Syndax for the foreseeable future and therefore, are accounting for our shares held in Syndax at fair value whereby the investment is marked to market through earnings in each reporting period. Given our intent to hold the investment for the foreseeable future, we have classified the investment within long term investments on the accompanying condensed consolidated balance sheets. For the three and nine months ended September&#160;30, 2022, we recorded an unrealized gain of $6.8 million and $3.1 million, respectively, based on the change in fair value of Syndax&#x2019;s common stock during the respective periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Maruho&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2022, we entered into a strategic alliance agreement with Maruho, Co., Ltd (&#x201c;Maruho&#x201d;) for the development, manufacturing and exclusive commercialization of ruxolitinib cream, for treatment of autoimmune and inflammatory dermatology indications in Japan. Maruho will receive the rights to develop, manufacture and exclusively commercialize ruxolitinib cream, and other potential future topical formulations of ruxolitinib, in autoimmune and inflammatory dermatologic diseases, including vitiligo and atopic dermatitis, in Japan. Under the terms of the agreement, we received an upfront payment from Maruho which was deferred and recorded in other liabilities on the condensed consolidated balance sheet and we are eligible to receive additional potential development, regulatory and commercial milestones and royalties on net sales of the licensed product in Japan.&lt;/span&gt;&lt;/div&gt;</incy:LicenseAgreementsTextBlock>
    <incy:LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived
      contextRef="i1be6071c11dc4f5baede897a7c3899d8_D20091101-20091130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfODI1_f44bb478-267e-46d5-b796-aef0c956d174"
      unitRef="usd">174000000</incy:LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived>
    <incy:LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived
      contextRef="i820b7b86437a49c2992e40c5dc8911be_D20091101-20091130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfODgy_a7ace47e-c7f2-4efc-9363-5d1f7f4f509b"
      unitRef="usd">495000000</incy:LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived>
    <incy:LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived
      contextRef="ic2d99eb0d2fc48a4a62cef1d76a3b8fa_D20091101-20091130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfOTQw_413d1127-5909-45a9-97a9-d25e82fd8f82"
      unitRef="usd">500000000</incy:LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived>
    <incy:LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived
      contextRef="i05006b85a9704e02902b03623fc8c5f7_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMTAzMA_25f486ca-0a6c-4e25-8067-b2d180345676"
      unitRef="usd">75000000</incy:LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived>
    <incy:LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone
      contextRef="ia6687beeb4034e3bbce66e159508b36e_D20091101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMTE5NA_8035000c-89ee-4eb5-9ac3-ae670b8b1769"
      unitRef="usd">157000000</incy:LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone>
    <incy:LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone
      contextRef="ieaa23329fa064e728b6bab53e01e305b_D20091101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMTI0NA_ca55c87c-b5f1-48d1-a4c1-6509a5a1fadd"
      unitRef="usd">340000000</incy:LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone>
    <incy:LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone
      contextRef="i50b34d5e81624a7b80626a7696d9e0d1_D20091101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMTI5Nw_c16a3517-fd15-46bc-9f6a-6876ad1cee18"
      unitRef="usd">200000000</incy:LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone>
    <incy:LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone
      contextRef="i7de6dcd9947241819b8f342b010b13b8_D20220401-20220430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMTM3Nw_8faa5a5e-84c1-4a12-898e-cde61bd21802"
      unitRef="usd">15000000</incy:LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone>
    <incy:LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone
      contextRef="i3447a97d263a4e71b726a6da1a319017_D20220501-20220531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMTczMg_1ad1b1f5-abcc-4181-9a80-508647ae13c9"
      unitRef="usd">45000000</incy:LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone>
    <incy:PercentageOfRoyaltyRatePayments
      contextRef="if75967c7131848209fa546f5389ff144_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMjEzMw_9fdce69e-f34b-4a3c-9285-2e65315c6223"
      unitRef="number">0.12</incy:PercentageOfRoyaltyRatePayments>
    <incy:PercentageOfRoyaltyRatePayments
      contextRef="i949fa939c8164aa79569420d1f965a48_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMjEzOQ_28ee6d1f-2183-4dfd-8bf6-80bbdf62074e"
      unitRef="number">0.14</incy:PercentageOfRoyaltyRatePayments>
    <us-gaap:IncreaseDecreaseInRoyaltiesPayable
      contextRef="i2abac4d4d9084b0cbd214384a0bdd136_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMjM5OQ_d8124bc7-696d-42ba-a5d5-f9120d0e6de9"
      unitRef="usd">30300000</us-gaap:IncreaseDecreaseInRoyaltiesPayable>
    <us-gaap:IncreaseDecreaseInRoyaltiesPayable
      contextRef="ifa4602ca397f4df8b24c50991489996f_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMjQwNg_c6b5b176-deeb-4d12-b3a1-20a84babb333"
      unitRef="usd">81300000</us-gaap:IncreaseDecreaseInRoyaltiesPayable>
    <us-gaap:IncreaseDecreaseInRoyaltiesPayable
      contextRef="i829cf684375a4486846e54a47708b378_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMjYxOQ_4338cd59-a7a4-4fc4-accd-95b37e288ca7"
      unitRef="usd">26900000</us-gaap:IncreaseDecreaseInRoyaltiesPayable>
    <us-gaap:IncreaseDecreaseInRoyaltiesPayable
      contextRef="i02be7adafa9342b0a09344a3239b2392_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMjYyNw_b0f81238-dc2d-4ad5-9310-84e0e0c307ba"
      unitRef="usd">70600000</us-gaap:IncreaseDecreaseInRoyaltiesPayable>
    <incy:RoyaltiesPayable
      contextRef="i6881c415becd47fa9f89334bb95c5996_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMjc2Mg_b6f1ecb0-1e68-4214-83d6-af6483937098"
      unitRef="usd">221700000</incy:RoyaltiesPayable>
    <incy:RoyaltiesPayable
      contextRef="ifbfff633ca0a4e9ea1abbaec86cf758b_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMjc2OQ_c2da91bf-7341-44f7-8473-0bf70e49634e"
      unitRef="usd">148100000</incy:RoyaltiesPayable>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic15fa27e6524408cb2ade84bf1015e8a_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMTY0OTI2NzU2MDE1Ng_6701459b-e25d-4e22-ab29-4ed5841548e4"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5aa252a5e50f412c987b6f82e79e1f2d_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMzI2OA_6f54ce1f-cef0-4f95-aafe-54600d4f0566"
      unitRef="usd">60000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:IncreaseDecreaseInRoyaltiesPayable
      contextRef="iab260328ac9041409b390a6d753ed302_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMTY0OTI2NzU2MjkzNA_195feef1-4413-4eeb-8436-01141ab6e9c3"
      unitRef="usd">85800000</us-gaap:IncreaseDecreaseInRoyaltiesPayable>
    <us-gaap:IncreaseDecreaseInRoyaltiesPayable
      contextRef="i51a40b9a674c444c9eabfee9d2524c4a_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMTY0OTI2NzU2Mjk0Mg_59315349-e32b-4bfa-8caf-58312a861b66"
      unitRef="usd">240400000</us-gaap:IncreaseDecreaseInRoyaltiesPayable>
    <us-gaap:IncreaseDecreaseInRoyaltiesPayable
      contextRef="ia6dcb750836e4de6b839dbd19f02184f_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMTY0OTI2NzU2Mjk1MA_705ccb3d-3961-4cad-b664-2b882f5b4c72"
      unitRef="usd">94700000</us-gaap:IncreaseDecreaseInRoyaltiesPayable>
    <us-gaap:IncreaseDecreaseInRoyaltiesPayable
      contextRef="ife40116eb76549f19cb03e7d7d84733b_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMTY0OTI2NzU2Mjk1NA_788de323-3808-4aa3-abc2-cc20a034f461"
      unitRef="usd">242300000</us-gaap:IncreaseDecreaseInRoyaltiesPayable>
    <us-gaap:IncreaseDecreaseInRoyaltiesPayable
      contextRef="iff64b50b378d484492f7f8d0962ecace_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMTY0OTI2NzU2Mjk2Ng_ca585b35-583d-469f-a51a-e15b222d5f57"
      unitRef="usd">4100000</us-gaap:IncreaseDecreaseInRoyaltiesPayable>
    <us-gaap:IncreaseDecreaseInRoyaltiesPayable
      contextRef="i2d83cfa285a94cdf9e3c412825e16ed7_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMTY0OTI2NzU2Mjk3MA_88fa8d63-0b4c-41d0-b966-cceaa150fc79"
      unitRef="usd">11200000</us-gaap:IncreaseDecreaseInRoyaltiesPayable>
    <us-gaap:IncreaseDecreaseInRoyaltiesPayable
      contextRef="i51a445bbbf1c4bb2b3b6e0b802471593_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMTY0OTI2NzU2Mjk3NA_22f0e6d4-bcb9-4808-92bf-bc2b5936e4e8"
      unitRef="usd">2700000</us-gaap:IncreaseDecreaseInRoyaltiesPayable>
    <us-gaap:IncreaseDecreaseInRoyaltiesPayable
      contextRef="i30a2ee091dab4a71840f5db6371badf9_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMTY0OTI2NzU2Mjk3OA_178e03dd-bed5-4f35-91ec-beb1dc97ea57"
      unitRef="usd">7300000</us-gaap:IncreaseDecreaseInRoyaltiesPayable>
    <incy:LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived
      contextRef="idadd52c621494f53a41ccc71303f0944_D20091201-20091231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfNDI1OQ_1b7243ff-9618-4b2a-9555-82a6be30d5de"
      unitRef="usd">150000000</incy:LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived>
    <incy:LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived
      contextRef="i5da7cd5ffebe4fc2b3889b38d5a3dd8f_D20091201-20091231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfNDMxNQ_b2fc3d72-5572-4551-a9d5-29a51c2a5068"
      unitRef="usd">365000000</incy:LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived>
    <incy:LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived
      contextRef="i1a1df5969f734568b13fa48eb0fff053_D20091201-20091231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfNDM3Mw_90085308-e8f1-4a76-b982-246598da733a"
      unitRef="usd">150000000</incy:LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived>
    <incy:LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone
      contextRef="i03d9a6dbc0bb43aaa8228030c1e90e5c_D20091201-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfNDQ2NA_9fd2ac0d-6587-47cd-bb7e-f466051ac9d4"
      unitRef="usd">149000000</incy:LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone>
    <incy:LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone
      contextRef="i4562ffe6c4de4f0c8852be62011ecaa1_D20091201-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfNDUxNA_84e9dc49-c52d-47a4-aede-6bf98020309e"
      unitRef="usd">335000000</incy:LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone>
    <incy:LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone
      contextRef="ib271257c3c244c8491614777e365abbd_D20091201-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfNDU2Ng_3f39f4fc-9aee-4913-b74a-bfd73ff299f9"
      unitRef="usd">50000000</incy:LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone>
    <incy:LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone
      contextRef="iaa7f2cb6de4b491abfc72a3a790e6c24_D20220601-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfNTI1Mg_c181d209-012c-48a5-b24d-de8333e3a6e5"
      unitRef="usd">40000000</incy:LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone>
    <incy:LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone
      contextRef="if3576f8af5d9438f8a88daefbfe6e46c_D20220601-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfNTQyNg_a715d0cc-93fc-40c4-afa0-d382ab574c2e"
      unitRef="usd">20000000</incy:LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone>
    <incy:LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone
      contextRef="id7fe066d0c744249bf7ad5af413886e0_D20220601-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfNTU2NQ_6248ba08-3745-4033-b61c-24b45eb1a67a"
      unitRef="usd">10000000</incy:LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if134f6ece59c4973a0b3eb0c742df2b4_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMTY0OTI2NzU2MDI1Mw_3d7b3767-f112-4617-8a69-01e7fdefe58b"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9c21ab11171944d088ad94775faa82d3_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfNTc5Ng_c8d93d48-1012-4479-ac85-fe4d61d0c480"
      unitRef="usd">70000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:IncreaseDecreaseInRoyaltiesPayable
      contextRef="i773d88ed6ec246e38116cf7dcfe2b613_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMTY0OTI2NzU2MzAwMg_3cd8a57d-9131-4454-9686-0a0915558323"
      unitRef="usd">20400000</us-gaap:IncreaseDecreaseInRoyaltiesPayable>
    <us-gaap:IncreaseDecreaseInRoyaltiesPayable
      contextRef="i67b271a11f4749eca413dadc55b898ff_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMTY0OTI2NzU2MzAwNg_8d8d2bcd-e901-4a91-b722-cc65f2583903"
      unitRef="usd">98700000</us-gaap:IncreaseDecreaseInRoyaltiesPayable>
    <us-gaap:IncreaseDecreaseInRoyaltiesPayable
      contextRef="i95f4766b35c44fb7bd203becd9f77ad2_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMTY0OTI2NzU2MzAxMA_5dd7b9ac-ab3b-4f5a-9ae0-ad318f08db54"
      unitRef="usd">86600000</us-gaap:IncreaseDecreaseInRoyaltiesPayable>
    <us-gaap:IncreaseDecreaseInRoyaltiesPayable
      contextRef="i332c91272a044c69bed32a22f727d46f_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMTY0OTI2NzU2MzAxNA_7ec7bb2e-9434-4bd3-a38b-a46a7b1c871b"
      unitRef="usd">154900000</us-gaap:IncreaseDecreaseInRoyaltiesPayable>
    <incy:LicenseAgreementAdditionalMilestonePayments
      contextRef="i6a0eb481719843cb8e92803e3eabf444_I20160630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfNjQwMQ_f9436196-f759-4e28-811c-9cc8373609ef"
      unitRef="usd">40000000</incy:LicenseAgreementAdditionalMilestonePayments>
    <incy:LicenseAgreementMilestonePaymentAmountPaid
      contextRef="ic8ef5df1d4014903a83c4bd9313a8063_D20190501-20190531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfNjU1NQ_4fad3e88-aa56-44c7-bf0a-b8243bb7f1c3"
      unitRef="usd">20000000</incy:LicenseAgreementMilestonePaymentAmountPaid>
    <incy:LicenseAgreementMilestonePaymentAmountPaid
      contextRef="i27b0ba8514fd434a9cc2954162a2955e_D20220301-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfNjczNw_678aff54-6e94-460e-b229-439a4bd99f3d"
      unitRef="usd">20000000</incy:LicenseAgreementMilestonePaymentAmountPaid>
    <incy:PercentageOfRoyaltyRatePayments
      contextRef="ie98f2f82461347b486999bb44539bcea_D20170201-20170228"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfODAyNA_8f52c278-858b-4865-9976-cdf41b518f59"
      unitRef="number">0.06</incy:PercentageOfRoyaltyRatePayments>
    <incy:PercentageOfRoyaltyRatePayments
      contextRef="i77e092a0d9e54838988930228ca59678_D20170201-20170228"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfODAzMA_d0c7b198-dcf8-4cfd-83df-15f8de47cc0a"
      unitRef="number">0.12</incy:PercentageOfRoyaltyRatePayments>
    <incy:PercentageOfRoyaltyRatePayments
      contextRef="i322b83e81195460e8c7931fafc090d9a_D20170201-20170228"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfODExMg_f93bb8db-379f-4c4b-b7e6-f7919d2aefdb"
      unitRef="number">0.15</incy:PercentageOfRoyaltyRatePayments>
    <incy:LicenseAgreementTerminationNoticePeriod
      contextRef="i5094eb7ec3484534bab11f2216427143_D20170201-20170228"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfODIwNQ_67973603-2436-4b9b-a695-f6378a4fdfcb">P12M</incy:LicenseAgreementTerminationNoticePeriod>
    <incy:LicenseAgreementMilestonePaymentAmountPaid
      contextRef="i0c8cef81f270473fadccddb9df52f115_D20150101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfODM1NQ_1e5c086c-908d-4794-be33-6bfed4d6721e"
      unitRef="usd">30000000</incy:LicenseAgreementMilestonePaymentAmountPaid>
    <incy:LicenseAgreementAdditionalMilestonePayments
      contextRef="id92745e544bc4129ab3571e6e1882924_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfODQxMg_5dc082e0-a4e4-4a6d-b7fb-fbd08e92083c"
      unitRef="usd">500000000</incy:LicenseAgreementAdditionalMilestonePayments>
    <incy:PurchaseOfCommonStockUnderStockPurchaseAgreementInShares
      contextRef="i6c3197a1985e4c74a433c4e949b9a513_D20170101-20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfODU2Nw_14196459-7f6b-47a3-bf6f-60e157cf7795"
      unitRef="shares">10000000</incy:PurchaseOfCommonStockUnderStockPurchaseAgreementInShares>
    <us-gaap:EquityMethodInvestmentAggregateCost
      contextRef="i5eaa2a7f03b24bb684bd8c6d31d0037c_I20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfODY0Mw_f3fd0edd-773e-4b6c-b6a5-ad825a92cd62"
      unitRef="usd">60000000</us-gaap:EquityMethodInvestmentAggregateCost>
    <us-gaap:SharePrice
      contextRef="i5eaa2a7f03b24bb684bd8c6d31d0037c_I20171231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfODY1OQ_82792910-4d89-4af0-84d8-a78d859ea6f9"
      unitRef="usdPerShare">6.00</us-gaap:SharePrice>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="iac9dda7781924f1c941a441ab2e2b22e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfODcxOA_ea32b2ad-82e3-4e1a-bd4a-b8cc3b8d23fc"
      unitRef="shares">3700000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="iac9dda7781924f1c941a441ab2e2b22e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfODgwNA_4faac56b-12d1-4962-884e-e7538ce83bae"
      unitRef="usd">17200000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i181b872577d8409197ea188e8c75e75e_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfODg1NA_0360cc81-9b74-4a3d-8b60-5be085e428de"
      unitRef="shares">2000000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i181b872577d8409197ea188e8c75e75e_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfODkzOQ_8e7821fd-a517-41af-be00-5e741071436e"
      unitRef="usd">10500000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:LongTermInvestments
      contextRef="i75f5d515a0904070a5f78ec1c95a20f5_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfOTAyNg_3a977b1d-a43b-417c-803b-12e5ec99447c"
      unitRef="usd">24800000</us-gaap:LongTermInvestments>
    <us-gaap:LongTermInvestments
      contextRef="ib46ef2e3f9964aa1ae70251f66606bb7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfOTAzMw_e8a51482-40c8-46ba-a0de-f11f024af68c"
      unitRef="usd">38900000</us-gaap:LongTermInvestments>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i0fde4e1ee3904f46bc27b6433525d662_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfOTYzMg_07e388d6-a7de-4c5f-a002-bdd616a53040"
      unitRef="usd">1300000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i6737e877e1fd425cadb82670cc929c9d_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfOTYzOQ_aca92aba-6b65-4197-8a44-1e73173866dd"
      unitRef="usd">-14100000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i595a69e029b4481b8df26f1ffe67629c_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfOTgxNA_7c2148ab-b050-4911-b313-92507546869a"
      unitRef="usd">-2800000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i9682bdfe1eb449eca0f0c2c52870768b_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfOTgyMg_8e818c06-cc4b-4bf6-bfc4-cce1a98d58ca"
      unitRef="usd">29100000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <incy:LicenseAgreementMaximumNumberOfIndependentPrograms
      contextRef="i9334ed3cba224fde929ed123a17c88d3_D20161201-20161231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMTAyNDc_4b413e53-2cb9-4a15-843c-d5d47c83fc86"
      unitRef="item">10</incy:LicenseAgreementMaximumNumberOfIndependentPrograms>
    <incy:LicenseAgreementNumberOfAdditionalPreclinicalDiscoveryPrograms
      contextRef="i9011187ffb7d41f38db3ce85ad7e7768_D20220101-20220131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMTA1OTY_29317eff-173e-4da0-856d-826a0230f636"
      unitRef="item">10</incy:LicenseAgreementNumberOfAdditionalPreclinicalDiscoveryPrograms>
    <incy:LicenseAgreementNumberOfAdditionalPreclinicalDiscoveryPrograms
      contextRef="i9011187ffb7d41f38db3ce85ad7e7768_D20220101-20220131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMTA2MzA_29317eff-173e-4da0-856d-826a0230f636"
      unitRef="item">10</incy:LicenseAgreementNumberOfAdditionalPreclinicalDiscoveryPrograms>
    <incy:NumberOfProgramsUnderWhichResultingProductsAreCoFundedForDevelopment
      contextRef="i9011187ffb7d41f38db3ce85ad7e7768_D20220101-20220131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMTA3NDQ_6812575c-ad80-4c01-ad22-4f98bf4b1554"
      unitRef="item">2</incy:NumberOfProgramsUnderWhichResultingProductsAreCoFundedForDevelopment>
    <incy:PercentageFundingOnCostOnPossibleElectionOfCodevelopmentOfCompounds
      contextRef="i9011187ffb7d41f38db3ce85ad7e7768_D20220101-20220131"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMTA4NTc_ca9d82b6-388a-4c42-beda-b7ab69ca32d4"
      unitRef="number">0.35</incy:PercentageFundingOnCostOnPossibleElectionOfCodevelopmentOfCompounds>
    <incy:LicenseAgreementAdditionalMilestonePayments
      contextRef="i3734c8248498448d986bbd533587971e_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMTE2OTM_3b6382ce-2c7b-426b-b377-e718b8721cc0"
      unitRef="usd">100000000</incy:LicenseAgreementAdditionalMilestonePayments>
    <incy:LicenseAgreementAdditionalMilestonePayments
      contextRef="id2a299f69c6442bebb13283c32eb5495_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMTE3NjY_ba5491bd-e36e-484a-b4fb-549032efa7ba"
      unitRef="usd">250000000</incy:LicenseAgreementAdditionalMilestonePayments>
    <incy:PercentageOfRoyaltyRatePayments
      contextRef="i68cb2d0ea17a41489814062745e1a6d8_D20161201-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMTE4NDI_02cad6e3-e2f7-453c-9372-41b7972ccbe0"
      unitRef="number">0.06</incy:PercentageOfRoyaltyRatePayments>
    <incy:PercentageOfRoyaltyRatePayments
      contextRef="ida045afcbce447a1922f7d64f607e199_D20161201-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMTE4NDg_57a6e4e4-45e5-4b17-a823-dc23a587d806"
      unitRef="number">0.10</incy:PercentageOfRoyaltyRatePayments>
    <incy:CollaborationAgreementProfitSharingPercentage
      contextRef="ic6746d80cb784b16bb25e182d074023d_D20161201-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMTE5ODM_963b4172-4fdf-40b5-8c6e-9ef381d71fc5"
      unitRef="number">0.50</incy:CollaborationAgreementProfitSharingPercentage>
    <incy:PercentageOfProfitsLosses
      contextRef="ic6746d80cb784b16bb25e182d074023d_D20161201-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMTIwMTY_326a4398-86b0-4950-a682-b18ac21210fe"
      unitRef="number">0.50</incy:PercentageOfProfitsLosses>
    <incy:PercentageOfRoyaltyRatePayments
      contextRef="i3fda94064174414ba40e5f53bd348807_D20161201-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMTIxMTI_87d01eea-1181-4e98-a826-9d3c3cbbd785"
      unitRef="number">0.06</incy:PercentageOfRoyaltyRatePayments>
    <incy:PercentageOfRoyaltyRatePayments
      contextRef="i7ab2a3895a964a1292f9330cada8a771_D20161201-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMTIxMTg_5d2c7eab-c4b4-419a-aaba-23b9322d847c"
      unitRef="number">0.10</incy:PercentageOfRoyaltyRatePayments>
    <incy:PercentageOfRoyaltyRatePayments
      contextRef="i8440f47d04e64df1b565b9e18146f65e_D20161201-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMTI3MjE_0e830723-e24a-4ecb-b7fe-880a78b52b30"
      unitRef="number">0.04</incy:PercentageOfRoyaltyRatePayments>
    <incy:LicenseAgreementMilestonePaymentAmountPaid
      contextRef="idad439e73b814d62ac3f923adfd04e2a_D20161201-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMTI4MDg_6ba2c56e-2577-4ea3-8d1f-e6dc5a7e9092"
      unitRef="usd">3000000</incy:LicenseAgreementMilestonePaymentAmountPaid>
    <incy:PurchaseOfCommonStockUnderStockPurchaseAgreementInShares
      contextRef="i1a445305a100467ca73640bc7fefa6b1_D20160101-20161231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMTI5MjE_5d16f035-c3ff-4ab9-8c8f-84fbfa512581"
      unitRef="shares">3200000</incy:PurchaseOfCommonStockUnderStockPurchaseAgreementInShares>
    <us-gaap:EquityMethodInvestmentAggregateCost
      contextRef="i68df7b52e15747f7ae8531c9b598597e_I20161231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMTI5ODM_0a877a22-1f40-4b09-a240-25f8036b4170"
      unitRef="usd">80000000</us-gaap:EquityMethodInvestmentAggregateCost>
    <us-gaap:SharePrice
      contextRef="i68df7b52e15747f7ae8531c9b598597e_I20161231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMTI5OTg_411acfad-b326-4131-aefb-040013157700"
      unitRef="usdPerShare">25.00</us-gaap:SharePrice>
    <incy:EquityMethodInvestmentSharesPurchased
      contextRef="i372a75620ad046e48dae561ae27ead65_D20210101-20210131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMTMwMzI_69724b78-7ebd-4e6b-a7ca-55be1f4ee3fb"
      unitRef="shares">350000</incy:EquityMethodInvestmentSharesPurchased>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i372a75620ad046e48dae561ae27ead65_D20210101-20210131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMTMwOTE_86beeed0-7680-42e0-8e6a-6977d3026f8e"
      unitRef="shares">4848485</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SharePrice
      contextRef="i4725ae58984b44c88c59c206c45fa1d2_I20210131"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMTMxNDA_3c92d28d-b407-4b6d-9358-7c20d835c8fe"
      unitRef="usdPerShare">24.75</us-gaap:SharePrice>
    <us-gaap:EquityMethodInvestmentQuotedMarketValue
      contextRef="i4725ae58984b44c88c59c206c45fa1d2_I20210131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMTMxODg_eca02933-3ef3-4880-8ba0-a6cafd56ed06"
      unitRef="usd">8700000</us-gaap:EquityMethodInvestmentQuotedMarketValue>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="idc8b97af450a4ea5ad6a270978aca78f_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMTMyNzQ_ed1d75de-3290-433d-b947-6717b92bc09c"
      unitRef="usd">71100000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i9eec6fea7a9943da8efef567ce22965f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMTMyODE_3e1677e9-3065-4024-b85e-dfa68d70325e"
      unitRef="usd">112900000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="idc8b97af450a4ea5ad6a270978aca78f_I20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMTMzMzI_9a6a5edd-40fe-484d-80aa-c62711079cf2"
      unitRef="number">0.08</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i223beeaf3ff34be8ac561d2f33d4ee03_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMTQwNjk_ba86cf9b-add7-4273-8a3a-73c871856d53"
      unitRef="usd">-9300000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i2c2d69aa47e742379d1cce352dedd9ae_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMTQwNzY_c635bc29-f6c8-4b20-adb4-1d7d9ca8fa9d"
      unitRef="usd">-41800000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i3700fa75a23a4f7eb6dcb20a8debd956_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMTQyNDU_59048e50-b21e-473f-b6f8-e350170d1ebe"
      unitRef="usd">3300000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i2665334fe7184425872feb9740fab18e_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMTQyNTI_02c0c7b5-07ae-446f-8042-5abc4d99f713"
      unitRef="usd">13300000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <incy:LicenseAgreementPercentageOfFutureGlobalDevelopmentCostsFunded
      contextRef="i4764998569344819b699915846b00247_D20170101-20170131"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMTY0OTI2NzU1Njk5OA_51e8c286-32d8-4399-987c-cb888f803030"
      unitRef="number">0.70</incy:LicenseAgreementPercentageOfFutureGlobalDevelopmentCostsFunded>
    <incy:PurchaseOfCommonStockUnderStockPurchaseAgreementInShares
      contextRef="i7d98c2063e874805b3cd156154e95b6a_D20170101-20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMTY0NTU_375aed82-cdd3-4824-ae56-3493d580425c"
      unitRef="shares">1700000</incy:PurchaseOfCommonStockUnderStockPurchaseAgreementInShares>
    <us-gaap:EquityMethodInvestmentAggregateCost
      contextRef="i040b9736a2b34584b9200ad4e2e9a3fa_I20170131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMTY1MjY_3174e569-17cb-4566-9c93-0ada39e0bc5e"
      unitRef="usd">8000000</us-gaap:EquityMethodInvestmentAggregateCost>
    <us-gaap:SharePrice
      contextRef="i040b9736a2b34584b9200ad4e2e9a3fa_I20170131"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMTY1NDE_33e9c95c-7666-45ed-b909-03cf60367c3f"
      unitRef="usdPerShare">4.65</us-gaap:SharePrice>
    <us-gaap:InvestmentOwnedBalanceShares
      contextRef="i3851ace877124ec6913ece53ee3910da_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMTY2NzA_e35f7c44-9239-4b50-9afb-a6e399fca7ab"
      unitRef="shares">86021</us-gaap:InvestmentOwnedBalanceShares>
    <us-gaap:LongTermInvestments
      contextRef="i976bcd6e91034b90afc59a80f582f14d_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMTY3ODk_e14c1b07-7d44-44fa-a12b-6299a611d55d"
      unitRef="usd">300000</us-gaap:LongTermInvestments>
    <us-gaap:LongTermInvestments
      contextRef="i14a2cf26acb6415995411f908d84bb40_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMTY3OTY_5150b1e4-45a5-45a0-aaf6-9dc4e4676b9d"
      unitRef="usd">1100000</us-gaap:LongTermInvestments>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i73a305e484884469b7b72fee3888f57d_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMTczOTE_8af2b665-9e84-46b0-88df-85eed7866226"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="ibf490fff4c3b444c824506cac379e2c3_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMTczOTg_5edaa1db-092b-4a95-abef-0e50009a035c"
      unitRef="usd">-900000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="ia0e5eed879114b4fb4f2900138c56b8c_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMTc1NzE_0425eb40-29b2-40db-9358-a048095fb61b"
      unitRef="usd">200000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="ibb93f3e466f7462fb5aade7477f8d7d9_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMTc1Nzg_56394181-84ae-4712-8582-81b8ce72b41b"
      unitRef="usd">-4600000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <incy:LicenseAgreementMilestonePaymentAmountPaid
      contextRef="ied65757537b34a7aa71eb6babf067549_D20220701-20220731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMTg5OTg_a5ac1b00-b673-4bd6-b918-22ada3827a91"
      unitRef="usd">30000000</incy:LicenseAgreementMilestonePaymentAmountPaid>
    <incy:LicenseAgreementMilestonePaymentAmountPaid
      contextRef="ibd823a98e80f479cb6963127d5b61c4f_D20171001-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMjE5OTAyMzM3NDQwOA_42850a07-4594-4baf-94ea-83c92f04a153"
      unitRef="usd">100000000</incy:LicenseAgreementMilestonePaymentAmountPaid>
    <incy:LicenseAgreementAdditionalMilestonePayments
      contextRef="ieca316d43e864d6c9e1338c719db09da_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMTkwOTc_4685e3d4-4992-4657-bc09-dce98484c860"
      unitRef="usd">335000000</incy:LicenseAgreementAdditionalMilestonePayments>
    <incy:LicenseAgreementAdditionalMilestonePayments
      contextRef="id5aed6962c28461aa5a91abb86e50e12_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMjE5OTAyMzM3NDQ3MQ_0adcc62f-887b-4284-97e9-ba592751918f"
      unitRef="usd">330000000</incy:LicenseAgreementAdditionalMilestonePayments>
    <incy:PercentageOfRoyaltyRatePayments
      contextRef="ic18f95fb157047e8b27cafc65fd5af9c_D20171001-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMjE5OTAyMzM3NDUzNg_2b373cb2-cd94-4a9c-b2b6-f802e42a76f5"
      unitRef="number">0.15</incy:PercentageOfRoyaltyRatePayments>
    <incy:PercentageOfRoyaltyRatePayments
      contextRef="ie6e53682249b48c2b89c302c106844f5_D20171001-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMjE5OTAyMzM3NDU0Mw_ccabf42c-de9f-4eac-94b5-d6092d12deb7"
      unitRef="number">0.24</incy:PercentageOfRoyaltyRatePayments>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="icf19c78006d9495182f71ef7c21fe380_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMTkyOTA_09340265-5a81-41b8-ad0b-20fe3c95baa4"
      unitRef="usd">41600000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i3985fee19ddf43a38f40f8f7a256fbdf_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMTkyOTc_027e7249-8bce-4f74-b451-405786bb0ef9"
      unitRef="usd">69900000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="icb1732c8fda74656b87657355bf486ce_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMTk0NTk_cffb66fa-473f-4b21-b75e-e81264d01a04"
      unitRef="usd">17800000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i73db6105ad88412f9de49662c370a570_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMTk0NjY_e6a10ab8-2f87-49f7-901a-1d53ae406d6d"
      unitRef="usd">49000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="ieaa2a400ed804a53b1afde32908c0c07_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMTk1Nzg_6a28f845-aa02-4eaf-b3e9-b2304a095968"
      unitRef="usd">2700000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="i2dbf58f06d2f47308c3bad5301982ece_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMTk1ODU_cee79967-8757-452b-9ac3-e6cd150a5d16"
      unitRef="usd">700000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <incy:NumberOfProgramTargets
      contextRef="i70fb3b0153d340f5aab70006b97df6d0_D20180101-20180131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMjAxMjQ_e7f44c25-deac-4476-978d-c37acfa4e49d"
      unitRef="item">7</incy:NumberOfProgramTargets>
    <incy:LicenseAgreementTargetSelectionAndOptionExerciseFeePayments
      contextRef="i152e5989713548879ee454b4d94dc97d_I20180131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMjAzMjY_ded90122-f7b8-47bd-8393-c9302d2e1b83"
      unitRef="usd">54000000</incy:LicenseAgreementTargetSelectionAndOptionExerciseFeePayments>
    <incy:NumberOfProgramTargets
      contextRef="i70fb3b0153d340f5aab70006b97df6d0_D20180101-20180131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMjA1MDk_e7f44c25-deac-4476-978d-c37acfa4e49d"
      unitRef="item">7</incy:NumberOfProgramTargets>
    <incy:LicenseAgreementAdditionalMilestonePayments
      contextRef="icafda92b12fb4c439f26f3cbf5162d94_I20180131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMjA1NzI_f202e2af-0858-443d-aad0-ed2a94d64f97"
      unitRef="usd">50000000</incy:LicenseAgreementAdditionalMilestonePayments>
    <incy:LicenseAgreementAdditionalMilestonePayments
      contextRef="i9b71fd409f444f9ab70ba536a99e012b_I20180131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMjA2MzY_76333360-00fe-4c9f-b100-4706aeff4733"
      unitRef="usd">65000000</incy:LicenseAgreementAdditionalMilestonePayments>
    <incy:PurchaseOfCommonStockUnderStockPurchaseAgreementInShares
      contextRef="i4802cd742cea475fa7d4e4c77f6ed61f_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMjA4OTk_681cca77-e42e-4204-afe4-4b38be697f36"
      unitRef="shares">800000</incy:PurchaseOfCommonStockUnderStockPurchaseAgreementInShares>
    <us-gaap:EquityMethodInvestmentAggregateCost
      contextRef="i8cf0a385b080416f8c84cece61770144_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMjA5NjY_f0d7f23a-1db3-4748-8ccb-d54cd46b4da3"
      unitRef="usd">10000000</us-gaap:EquityMethodInvestmentAggregateCost>
    <us-gaap:SharePrice
      contextRef="i8cf0a385b080416f8c84cece61770144_I20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMjA5ODI_48b9457f-c1af-4a3e-80d8-3023d9b0253a"
      unitRef="usdPerShare">12.61</us-gaap:SharePrice>
    <incy:PurchaseOfCommonStockUnderStockPurchaseAgreementInShares
      contextRef="i56216a9c32c046e293518645fa59581e_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMjExMjg_aedbab66-84d3-4f2e-bf34-22264e307d01"
      unitRef="shares">100000</incy:PurchaseOfCommonStockUnderStockPurchaseAgreementInShares>
    <us-gaap:EquityMethodInvestmentAggregateCost
      contextRef="i84229a0cf41042c4af314a95d0c76e40_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMjExOTY_e8bdc782-bc7e-4d3e-8b35-8e3d4d5784e7"
      unitRef="usd">1400000</us-gaap:EquityMethodInvestmentAggregateCost>
    <us-gaap:SharePrice
      contextRef="i84229a0cf41042c4af314a95d0c76e40_I20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMjEyMTI_a59b8406-e74c-4a97-90f2-9346e24c38e1"
      unitRef="usdPerShare">9.55</us-gaap:SharePrice>
    <us-gaap:InvestmentOwnedBalanceShares
      contextRef="icc792aa24edf4db4b607a35782e9f099_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMjE5OTAyMzM2MzAxNA_7179ada7-6160-425e-ad71-b36e0d056faa"
      unitRef="shares">93753</us-gaap:InvestmentOwnedBalanceShares>
    <us-gaap:LongTermInvestments
      contextRef="ia7d2cecabe5d473b9e10bcd188d283ba_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMjEzMDU_903a7518-6b01-4d6d-9cb6-aaa15fea7db5"
      unitRef="usd">600000</us-gaap:LongTermInvestments>
    <us-gaap:LongTermInvestments
      contextRef="i8210542f8d5e44b9852bd20e5f5e3854_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMjEzMTI_6b103f73-a8bb-4754-bf0b-a8f5bb609ead"
      unitRef="usd">3100000</us-gaap:LongTermInvestments>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="ic8f331242d08460fbf44354246d36f87_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMjE4OTM_2d7a6c88-cfb2-4b6f-b808-880484b2b904"
      unitRef="usd">-300000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i7c697b731e83449fa55119d8b2fbba64_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMjE5MDA_93c4fb6d-1f04-416b-865b-56e0f00b3992"
      unitRef="usd">-2500000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i6adb3d95448a44468d8489293e1ea749_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMjIwNjk_cb38310c-2f02-4b71-b82e-f2ab9273a59b"
      unitRef="usd">-900000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i09a141eea49e49258b3beebd24497e7e_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMjIwNzc_556a7eb2-50a3-4ae1-9b0b-79ab98c64af1"
      unitRef="usd">-6000000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <incy:LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived
      contextRef="ic09f0ce12baa4ba48de314895f364fc0_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMjI1ODc_19bae5a4-28f8-459e-ab91-d50ab2573035"
      unitRef="usd">94000000</incy:LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived>
    <incy:LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone
      contextRef="idf1c0108786a4620836caeb03784ce6c_D20220301-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMjI5MjY_f23c10a3-9799-4d20-a86d-274fc010346a"
      unitRef="usd">5000000</incy:LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone>
    <incy:LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived
      contextRef="ie995745d247a45d38430829bee3187e8_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMjMwODE_a3ea809a-63ca-465c-bf47-959852a0c50e"
      unitRef="usd">202500000</incy:LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived>
    <incy:LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived
      contextRef="i96f4281beb534126a1eef106e0789ece_D20190701-20190731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMjQwNTU_b4101689-40a4-43c1-9db4-1f9bd40204a6"
      unitRef="usd">22500000</incy:LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived>
    <incy:LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived
      contextRef="iebdcdab801a74c27a6126ac544405996_D20190701-20190731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMjQ0NjM_932fb58e-d01e-411c-a9f3-739b424bf198"
      unitRef="usd">37500000</incy:LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived>
    <incy:LicenseAgreementPercentageOfFutureGlobalDevelopmentCostsFunded
      contextRef="i900f0ac816ab4775ab2106619f594870_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMjY0Nzg_8e7202fa-9c53-484d-9b58-ad6c4e1f4f1c"
      unitRef="number">0.55</incy:LicenseAgreementPercentageOfFutureGlobalDevelopmentCostsFunded>
    <incy:LicenseAgreementPercentageOfFutureGlobalDevelopmentCostsFunded
      contextRef="i591cacee8aca4012a248fa2c96cea301_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMjY1MjU_6404916a-7cb5-4b93-a821-8aeecb61533f"
      unitRef="number">0.45</incy:LicenseAgreementPercentageOfFutureGlobalDevelopmentCostsFunded>
    <incy:LicenseAgreementAdditionalMilestonePayments
      contextRef="i6aecf3dce21d42e7851bf481a425bc46_I20200131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMjY4Njc_57b257d2-4f90-4e89-a2b2-3c2d794d66d0"
      unitRef="usd">737500000</incy:LicenseAgreementAdditionalMilestonePayments>
    <incy:LicenseAgreementAdditionalMilestonePayments
      contextRef="i8d1b83baba194bed8477bb9ea0de3df7_I20200131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMjY5Mzk_c4f8298e-158e-495d-9c0c-0c64d3616cb5"
      unitRef="usd">315000000</incy:LicenseAgreementAdditionalMilestonePayments>
    <incy:LicenseAgreementMilestonePaymentAmountPaid
      contextRef="ifecd0798049d402f9683bec43016bf55_D20200101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMjE5OTAyMzM3NTExMw_af743f64-9346-47af-8187-b18fa27440ce"
      unitRef="usd">2500000</incy:LicenseAgreementMilestonePaymentAmountPaid>
    <incy:SubsidiaryStockConversionRatio
      contextRef="i7acbcf60ab2042008f713a4d43e83de9_I20200131"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMjc2NTM_948c84b9-bc21-47a0-9d83-49fd8812923f"
      unitRef="number">0.25</incy:SubsidiaryStockConversionRatio>
    <us-gaap:EquityMethodInvestmentAggregateCost
      contextRef="i7acbcf60ab2042008f713a4d43e83de9_I20200131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMjc3Mjk_02e44de7-a619-42dd-92f2-5075a37d7f94"
      unitRef="usd">150000000</us-gaap:EquityMethodInvestmentAggregateCost>
    <us-gaap:SharePrice
      contextRef="i7acbcf60ab2042008f713a4d43e83de9_I20200131"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMjc3MzU_ebf8058d-d024-4573-a963-7dc1345f562f"
      unitRef="usdPerShare">41.33</us-gaap:SharePrice>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i2ed4e89797ba4aaf9b7ebc41ec200ef4_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMjc4NzQ_8ef6afce-bbbf-431b-b7a0-0d776a0ba8ea"
      unitRef="usd">18300000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="ia375a7c89bc74d8bbfbae792527a8710_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMjc4ODE_01f45f8b-5bc4-4102-a418-8e54d8b1b76f"
      unitRef="usd">34200000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i743d644eae334843b9ede7cb71b9c67d_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMjg0NzI_4ed8502c-773e-40f8-85f9-bab6f490a874"
      unitRef="usd">800000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i9415bb6d6cbd4c08a203ce650cc97142_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMjg0Nzk_296632a7-11b8-42f8-a09a-e1113e2e700e"
      unitRef="usd">-15900000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i5c84e3647ab24388b648b9a8ab264afa_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMjg2NTQ_3b834a63-cd0a-486b-9172-5ce1998e00dd"
      unitRef="usd">-27300000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="idaa0f5c512544ed5bb9ed44eff567a1b_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMjg2NjE_0f4cf5b3-1b71-445f-bf1e-363f22ae1845"
      unitRef="usd">-60200000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <incy:CollaborationAgreementProfitLossSharingRatio
      contextRef="ie043e97a1aa74373b87fb3609b47dd3c_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMjg3Nzk_117c7714-2562-48bf-ab42-287e0b60aefa"
      unitRef="number">0.50</incy:CollaborationAgreementProfitLossSharingRatio>
    <incy:CollaborationAgreementProfitLossSharingRatio
      contextRef="ie686f463b19c46aea6f673458c296cfa_D20220701-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMjg3Nzk_c9fb1329-6c2d-4e02-a83d-05f1954c6a14"
      unitRef="number">0.50</incy:CollaborationAgreementProfitLossSharingRatio>
    <incy:CollaborationLossSharingExpense
      contextRef="i49acad92f3dd479a8b0f38d89cfdd456_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMTY0OTI2NzU2MzAzNA_93f8e007-0ed9-47fe-8c6b-47214778c14c"
      unitRef="usd">1800000</incy:CollaborationLossSharingExpense>
    <incy:CollaborationLossSharingExpense
      contextRef="ibf40aaa491714d97a2353162af92483b_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMTY0OTI2NzU2MzAzOA_ff2682ae-5643-4fc8-a708-906f9303689e"
      unitRef="usd">9100000</incy:CollaborationLossSharingExpense>
    <incy:CollaborationAgreementProfitLossSharingRatio
      contextRef="ie043e97a1aa74373b87fb3609b47dd3c_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMTY0OTI2NzUzMTE2Mg_117c7714-2562-48bf-ab42-287e0b60aefa"
      unitRef="number">0.50</incy:CollaborationAgreementProfitLossSharingRatio>
    <incy:CollaborationAgreementProfitLossSharingRatio
      contextRef="ie686f463b19c46aea6f673458c296cfa_D20220701-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMTY0OTI2NzUzMTE2Mg_c9fb1329-6c2d-4e02-a83d-05f1954c6a14"
      unitRef="number">0.50</incy:CollaborationAgreementProfitLossSharingRatio>
    <incy:CollaborationLossSharingExpense
      contextRef="i52bb96abc5854205a71aecc9f552d0a1_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMTY0OTI2NzU2MzA0Mg_4da9328f-136b-4300-a87f-396ad0b44815"
      unitRef="usd">9100000</incy:CollaborationLossSharingExpense>
    <incy:CollaborationLossSharingExpense
      contextRef="i052ba28ba496497ba9474f71db32c295_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMTY0OTI2NzU2MzA0Ng_d1ad0eae-09ac-4875-99e5-de5cb874d7a6"
      unitRef="usd">29500000</incy:CollaborationLossSharingExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i8d57ef7a2a5e4baea3532431671ef13c_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMjkzMjA_7e381838-ead2-4377-ac3d-78fe76055a85"
      unitRef="usd">21900000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i339dc7a864644d6fa19c079e6c5c35f2_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMjkzMjc_bc0e5fd9-efd1-4bc8-9aa3-b382d79bb7fc"
      unitRef="usd">70400000</us-gaap:ResearchAndDevelopmentExpense>
    <incy:LicenseAgreementPercentageOfFutureGlobalDevelopmentCostsFunded
      contextRef="i900f0ac816ab4775ab2106619f594870_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMTY0OTI2NzUzMTE1NA_8e7202fa-9c53-484d-9b58-ad6c4e1f4f1c"
      unitRef="number">0.55</incy:LicenseAgreementPercentageOfFutureGlobalDevelopmentCostsFunded>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ib8a2da8278cb46e5a34861f79068cd18_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMjk0ODU_e9db3092-d5bb-464c-9191-be1a4a0d5c26"
      unitRef="usd">21500000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="iaffe85fc70e4417eb1de69b0992095b4_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMjk0OTI_fe9b0a46-0cd4-4767-91c4-2df7fb0b1d79"
      unitRef="usd">55800000</us-gaap:ResearchAndDevelopmentExpense>
    <incy:LicenseAgreementPercentageOfFutureGlobalDevelopmentCostsFunded
      contextRef="i900f0ac816ab4775ab2106619f594870_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMTY0OTI2NzUzMTE1OA_8e7202fa-9c53-484d-9b58-ad6c4e1f4f1c"
      unitRef="number">0.55</incy:LicenseAgreementPercentageOfFutureGlobalDevelopmentCostsFunded>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="i058a1a9cef2b4e36bcbc453963f518d2_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMjk1OTM_83eb6406-bdba-4b49-b92a-35650bf21556"
      unitRef="usd">72500000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="i8ea67dc6fe88438cbc0a45ad09002fec_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMjk2MDA_e78a98c8-b30b-4230-8b40-f8567f1e5fae"
      unitRef="usd">21500000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <incy:LicenseAgreementAdditionalMilestonePayments
      contextRef="i68d610f80f7e4dd1b7076852e33351b9_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMzAxMTE_4debf633-fd21-408d-9090-7218c64e69da"
      unitRef="usd">8000000</incy:LicenseAgreementAdditionalMilestonePayments>
    <incy:LicenseAgreementAdditionalMilestonePayments
      contextRef="if241609d783147a2a65ee7d8f3cfab8e_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMzAxNjY_47bd9251-d374-4b55-955d-29d4105bf083"
      unitRef="usd">127000000</incy:LicenseAgreementAdditionalMilestonePayments>
    <incy:LicenseAgreementAdditionalMilestonePayments
      contextRef="i0c67636b0e5c40e3bccf2287aa2dd24e_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMzAzMjU_f582fc9d-aaaa-4da4-83c8-6eecc4f02589"
      unitRef="usd">130000000</incy:LicenseAgreementAdditionalMilestonePayments>
    <incy:LicenseAgreementUpfrontPaymentReceived
      contextRef="i54911354715749fdbd74f62ce9dd1ad8_D20210901-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMzA4MTg_459bd0a0-4f34-45d9-81b4-7ec9ff50b28a"
      unitRef="usd">35000000</incy:LicenseAgreementUpfrontPaymentReceived>
    <incy:LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived
      contextRef="i7e81499535aa4d19aae8e5cfa7cac860_D20220930-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMzExMjY_af6fad5a-6ddc-4530-9d9a-22f0732d8e96"
      unitRef="usd">82500000</incy:LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived>
    <incy:LicenseAgreementPercentageOfFutureGlobalDevelopmentCostsFunded
      contextRef="ic4b6bf4c21e94e4e8eac1ce2ff2aca3c_D20210901-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMzMwNDM_fb0b58a2-968f-4f47-b96d-c9b639e85856"
      unitRef="number">0.55</incy:LicenseAgreementPercentageOfFutureGlobalDevelopmentCostsFunded>
    <incy:LicenseAgreementPercentageOfFutureGlobalDevelopmentCostsFunded
      contextRef="i2fc0a1b5bbc34643b361651b2d12a002_D20210901-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMzMwODc_a3bb9425-63e2-4d4b-8042-b9cbe7c9a5e7"
      unitRef="number">0.45</incy:LicenseAgreementPercentageOfFutureGlobalDevelopmentCostsFunded>
    <incy:LicenseAgreementUpfrontPaymentAmountPaid
      contextRef="ice2384877b1e441482f1b13c9a8dae52_D20211201-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMzMzMzg_4237e32e-0b68-4fd6-b4ae-d6b0402307b0"
      unitRef="usd">117000000</incy:LicenseAgreementUpfrontPaymentAmountPaid>
    <incy:LicenseAgreementAdditionalMilestonePayments
      contextRef="i381ad8904ad94b698038402e2dbae630_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMzM1MDA_b50845c5-8d6a-4d12-9fec-ec11eff2c413"
      unitRef="usd">220000000</incy:LicenseAgreementAdditionalMilestonePayments>
    <incy:LicenseAgreementAdditionalMilestonePayments
      contextRef="i9c8cc765b77d4e319490794de2d57720_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMzM1NzM_eb96498f-a658-47c3-bd61-a73692404c8c"
      unitRef="usd">230000000</incy:LicenseAgreementAdditionalMilestonePayments>
    <incy:PurchaseOfCommonStockUnderStockPurchaseAgreementInShares
      contextRef="ic75be732674a48cc932a3908c0f0125f_D20210901-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMzQzMDg_fc3c0ac1-59dd-4239-86ed-4833ba1481ac"
      unitRef="shares">1400000</incy:PurchaseOfCommonStockUnderStockPurchaseAgreementInShares>
    <us-gaap:EquityMethodInvestmentAggregateCost
      contextRef="iab65428e773d4e1f81be1d9a26ea6741_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMzQzNzY_e6663e3a-97d0-4bbd-b87a-d9f3d93c1553"
      unitRef="usd">35000000</us-gaap:EquityMethodInvestmentAggregateCost>
    <us-gaap:SharePrice
      contextRef="i8fa5c0ac0f304b3f986fce0cfbaa390d_I20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMzQzODM_ec278ac5-e8b8-4b8b-9fab-c1ec9d74b48a"
      unitRef="usdPerShare">24.62</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="i5ae4ff1b717c42c4b158977281cf10aa_I20211209"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMzQ0OTc_9b5c8fb6-f531-4d61-a0e3-b162bb75b238"
      unitRef="usdPerShare">17.48</us-gaap:SharePrice>
    <us-gaap:EquityMethodInvestmentAggregateCost
      contextRef="i5ae4ff1b717c42c4b158977281cf10aa_I20211209"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMTY0OTI2NzU2MzA4Mw_7f7047b9-8237-417e-a326-092eac9020ad"
      unitRef="usd">35000000</us-gaap:EquityMethodInvestmentAggregateCost>
    <us-gaap:LongTermInvestments
      contextRef="i5ae4ff1b717c42c4b158977281cf10aa_I20211209"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMzQ1NTI_c434401e-ffb6-49ce-9c51-64618209b24c"
      unitRef="usd">24800000</us-gaap:LongTermInvestments>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ib136551050f34038b1062509c10fd644_D20211209-20211209"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMzQ2NDE_f8a9e4ea-e422-4f02-91da-cf00b31ea9ae"
      unitRef="usd">10200000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:LongTermInvestments
      contextRef="i8a234f090f5e47568ec964b185b6ea18_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMzQ4ODU_f5d1a61a-5624-4210-967b-10bcab93fe3b"
      unitRef="usd">34200000</us-gaap:LongTermInvestments>
    <us-gaap:LongTermInvestments
      contextRef="i8f65aa20c7b04a3aa4af35f8d8783e0d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMzQ4OTI_ff958607-bc16-475d-86ca-0607c1b92cac"
      unitRef="usd">31100000</us-gaap:LongTermInvestments>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i0eb6eb6c67a046c99cb82fbf4c1e3ab3_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMzU0NjA_297cc7b9-cd5b-4c0b-befb-c1a0a719f6c6"
      unitRef="usd">6800000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i91c3988b9dd7488dbbd895a2cfde280d_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81Mi9mcmFnOmY2Mjg4MjM3ZmE1YTRmZTJhYzQ1MGQ5YWQ4M2Q4NWE5L3RleHRyZWdpb246ZjYyODgyMzdmYTVhNGZlMmFjNDUwZDlhZDgzZDg1YTlfMzU0ODk_8c642c54-0b62-4248-aa7e-e524fa61a919"
      unitRef="usd">3100000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81OC9mcmFnOjU3NjUyN2FlNjcwYTRkOTFhOTFlNGY3MmIxZjA0ZTI4L3RleHRyZWdpb246NTc2NTI3YWU2NzBhNGQ5MWE5MWU0ZjcyYjFmMDRlMjhfMTkxNg_d44e7b40-0da4-4fe3-8de7-eb03f075de5e">&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net consists of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.083%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Office equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115,507&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Computer equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88,239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,871&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Land&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Building and leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;432,748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;434,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;225,442&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;220,052&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;917,713&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;899,640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(201,980)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(175,720)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;715,733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;723,920&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2017, we acquired additional adjacent buildings to our global headquarters in Wilmington, Delaware and in 2019, began demolition of these buildings and construction of a new laboratory and office building totaling approximately 200,000 square feet. The certificate of occupancy was received in December 2021 and we capitalized approximately $158.2 million in building and office equipment that was previously included in construction in progress as of December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2018, we signed an agreement to rent a building in Morges, Switzerland for an initial term of 15 years plus one year of free rent, with multiple options to extend for an additional 20 years. The building serves as our new European headquarters and consists of approximately 100,000 square feet of office space. This building allowed for consolidation of our European operations that were located in Geneva and Lausanne, Switzerland. In June 2019, we obtained control of the Morges building to begin our construction activity, which was completed in 2020. At that time, we determined the lease to be a finance lease and recorded a lease liability of $31.1 million and a finance lease right-of-use asset of $29.1 million, net of a lease incentive from our landlord of $2.0 million. We have capitalized approximately $19.5 million in leasehold improvements as of September&#160;30, 2022 relating to Morges.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2018, we signed an agreement to purchase land located in Yverdon, Switzerland. The land was purchased, in cash, for approximately $4.8 million. Upon this parcel, we are constructing a large molecule production facility. Construction activity commenced in July 2018, and as of September&#160;30, 2022, we have capitalized approximately $190.5 million in costs for construction, ground preparation and architectural and engineering studies. Inspection from competent authorities was finalized in March 2022, and in June 2022 Swissmedic authorities granted the GMP drug manufacturing license for this facility.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81OC9mcmFnOjU3NjUyN2FlNjcwYTRkOTFhOTFlNGY3MmIxZjA0ZTI4L3RleHRyZWdpb246NTc2NTI3YWU2NzBhNGQ5MWE5MWU0ZjcyYjFmMDRlMjhfMTkxNw_012c23bd-a4e6-454f-916a-991cae0ab49e">&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net consists of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.083%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Office equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115,507&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Computer equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88,239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,871&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Land&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Building and leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;432,748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;434,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;225,442&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;220,052&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;917,713&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;899,640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(201,980)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(175,720)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;715,733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;723,920&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i6a62ea7776234ba0824931335a0d4825_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81OC9mcmFnOjU3NjUyN2FlNjcwYTRkOTFhOTFlNGY3MmIxZjA0ZTI4L3RhYmxlOjA5YjE0NDQwYTQ3MTQyNTliMTNkZWVlYjE3OTVlOTMyL3RhYmxlcmFuZ2U6MDliMTQ0NDBhNDcxNDI1OWIxM2RlZWViMTc5NWU5MzJfMS0xLTEtMS04MQ_69520d85-accc-4ad4-b499-cf32e927686f"
      unitRef="usd">22527000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i132cda3dcfdc4ce6853fafa85f1782e7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81OC9mcmFnOjU3NjUyN2FlNjcwYTRkOTFhOTFlNGY3MmIxZjA0ZTI4L3RhYmxlOjA5YjE0NDQwYTQ3MTQyNTliMTNkZWVlYjE3OTVlOTMyL3RhYmxlcmFuZ2U6MDliMTQ0NDBhNDcxNDI1OWIxM2RlZWViMTc5NWU5MzJfMS0zLTEtMS04MQ_78f7b62a-4774-493b-ba99-603f324db1ee"
      unitRef="usd">22554000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ie059b8e396a34f60beab49836d33d129_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81OC9mcmFnOjU3NjUyN2FlNjcwYTRkOTFhOTFlNGY3MmIxZjA0ZTI4L3RhYmxlOjA5YjE0NDQwYTQ3MTQyNTliMTNkZWVlYjE3OTVlOTMyL3RhYmxlcmFuZ2U6MDliMTQ0NDBhNDcxNDI1OWIxM2RlZWViMTc5NWU5MzJfMi0xLTEtMS04MQ_98572c18-afef-4cd9-b8d0-221aec7fc395"
      unitRef="usd">115507000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i2df7a55feb96443a96a33b7ff9a2e1a5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81OC9mcmFnOjU3NjUyN2FlNjcwYTRkOTFhOTFlNGY3MmIxZjA0ZTI4L3RhYmxlOjA5YjE0NDQwYTQ3MTQyNTliMTNkZWVlYjE3OTVlOTMyL3RhYmxlcmFuZ2U6MDliMTQ0NDBhNDcxNDI1OWIxM2RlZWViMTc5NWU5MzJfMi0zLTEtMS04MQ_7a8d141e-e46c-4053-802c-ba3186d9a84f"
      unitRef="usd">105040000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i8ffd71f442ea4f50bb5fe72e558fe509_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81OC9mcmFnOjU3NjUyN2FlNjcwYTRkOTFhOTFlNGY3MmIxZjA0ZTI4L3RhYmxlOjA5YjE0NDQwYTQ3MTQyNTliMTNkZWVlYjE3OTVlOTMyL3RhYmxlcmFuZ2U6MDliMTQ0NDBhNDcxNDI1OWIxM2RlZWViMTc5NWU5MzJfMy0xLTEtMS04MQ_af24db96-6545-4307-bafc-da6ef54feac4"
      unitRef="usd">88239000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i0b31e55bf720475390b524cce573a3d0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81OC9mcmFnOjU3NjUyN2FlNjcwYTRkOTFhOTFlNGY3MmIxZjA0ZTI4L3RhYmxlOjA5YjE0NDQwYTQ3MTQyNTliMTNkZWVlYjE3OTVlOTMyL3RhYmxlcmFuZ2U6MDliMTQ0NDBhNDcxNDI1OWIxM2RlZWViMTc5NWU5MzJfMy0zLTEtMS04MQ_b216feef-2ada-4f18-a5c0-06665e1d37dd"
      unitRef="usd">79871000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i706ab952dd37469eaeedc74245929deb_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81OC9mcmFnOjU3NjUyN2FlNjcwYTRkOTFhOTFlNGY3MmIxZjA0ZTI4L3RhYmxlOjA5YjE0NDQwYTQ3MTQyNTliMTNkZWVlYjE3OTVlOTMyL3RhYmxlcmFuZ2U6MDliMTQ0NDBhNDcxNDI1OWIxM2RlZWViMTc5NWU5MzJfNC0xLTEtMS04MQ_4be0ddd9-3110-4fd7-a209-f3638feed77e"
      unitRef="usd">10139000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i15460e5c3abd492e81486c9dd98ed0f9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81OC9mcmFnOjU3NjUyN2FlNjcwYTRkOTFhOTFlNGY3MmIxZjA0ZTI4L3RhYmxlOjA5YjE0NDQwYTQ3MTQyNTliMTNkZWVlYjE3OTVlOTMyL3RhYmxlcmFuZ2U6MDliMTQ0NDBhNDcxNDI1OWIxM2RlZWViMTc5NWU5MzJfNC0zLTEtMS04MQ_67d53221-d4e3-4f34-9757-3fd2d6b200b4"
      unitRef="usd">10494000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="if7d77528a6e8420e9064a4b8b5c0de47_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81OC9mcmFnOjU3NjUyN2FlNjcwYTRkOTFhOTFlNGY3MmIxZjA0ZTI4L3RhYmxlOjA5YjE0NDQwYTQ3MTQyNTliMTNkZWVlYjE3OTVlOTMyL3RhYmxlcmFuZ2U6MDliMTQ0NDBhNDcxNDI1OWIxM2RlZWViMTc5NWU5MzJfNS0xLTEtMS04MQ_22c80cbd-37c5-4bb9-9ffc-39cb9c677ded"
      unitRef="usd">432748000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ie3fdcc8f5ffb478da66863c12a1b6a68_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81OC9mcmFnOjU3NjUyN2FlNjcwYTRkOTFhOTFlNGY3MmIxZjA0ZTI4L3RhYmxlOjA5YjE0NDQwYTQ3MTQyNTliMTNkZWVlYjE3OTVlOTMyL3RhYmxlcmFuZ2U6MDliMTQ0NDBhNDcxNDI1OWIxM2RlZWViMTc5NWU5MzJfNS0zLTEtMS04MQ_17bf5350-049d-4c17-8c88-89b4b424a962"
      unitRef="usd">434321000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ia4b01aa79b8543cb89e4d2fe5b5782db_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81OC9mcmFnOjU3NjUyN2FlNjcwYTRkOTFhOTFlNGY3MmIxZjA0ZTI4L3RhYmxlOjA5YjE0NDQwYTQ3MTQyNTliMTNkZWVlYjE3OTVlOTMyL3RhYmxlcmFuZ2U6MDliMTQ0NDBhNDcxNDI1OWIxM2RlZWViMTc5NWU5MzJfNi0xLTEtMS04MQ_a3bc336f-ff3d-4c46-913a-c3237150b9bb"
      unitRef="usd">23111000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="id090587fece240a682b2eb53308bef79_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81OC9mcmFnOjU3NjUyN2FlNjcwYTRkOTFhOTFlNGY3MmIxZjA0ZTI4L3RhYmxlOjA5YjE0NDQwYTQ3MTQyNTliMTNkZWVlYjE3OTVlOTMyL3RhYmxlcmFuZ2U6MDliMTQ0NDBhNDcxNDI1OWIxM2RlZWViMTc5NWU5MzJfNi0zLTEtMS04MQ_7087a382-dda1-4c83-a486-f72f9d9f32fb"
      unitRef="usd">27308000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i51126f0e89df4b60bd2aacb656a90f1a_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81OC9mcmFnOjU3NjUyN2FlNjcwYTRkOTFhOTFlNGY3MmIxZjA0ZTI4L3RhYmxlOjA5YjE0NDQwYTQ3MTQyNTliMTNkZWVlYjE3OTVlOTMyL3RhYmxlcmFuZ2U6MDliMTQ0NDBhNDcxNDI1OWIxM2RlZWViMTc5NWU5MzJfNy0xLTEtMS04MQ_98a076fe-4bd6-4e37-937f-9d07c00fb263"
      unitRef="usd">225442000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i5fa10fd48d3a49168a51c3085f8e84c2_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81OC9mcmFnOjU3NjUyN2FlNjcwYTRkOTFhOTFlNGY3MmIxZjA0ZTI4L3RhYmxlOjA5YjE0NDQwYTQ3MTQyNTliMTNkZWVlYjE3OTVlOTMyL3RhYmxlcmFuZ2U6MDliMTQ0NDBhNDcxNDI1OWIxM2RlZWViMTc5NWU5MzJfNy0zLTEtMS04MQ_3bbccb1c-5c6d-4f78-8222-5698d13d2fa4"
      unitRef="usd">220052000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i3b4376f8fc614de98c9cf647198c504e_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81OC9mcmFnOjU3NjUyN2FlNjcwYTRkOTFhOTFlNGY3MmIxZjA0ZTI4L3RhYmxlOjA5YjE0NDQwYTQ3MTQyNTliMTNkZWVlYjE3OTVlOTMyL3RhYmxlcmFuZ2U6MDliMTQ0NDBhNDcxNDI1OWIxM2RlZWViMTc5NWU5MzJfOC0xLTEtMS04MQ_df536d46-f7c6-4434-afbb-3f90afb5233c"
      unitRef="usd">917713000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="iab26fe441f0d4ab984456365a7f7cff0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81OC9mcmFnOjU3NjUyN2FlNjcwYTRkOTFhOTFlNGY3MmIxZjA0ZTI4L3RhYmxlOjA5YjE0NDQwYTQ3MTQyNTliMTNkZWVlYjE3OTVlOTMyL3RhYmxlcmFuZ2U6MDliMTQ0NDBhNDcxNDI1OWIxM2RlZWViMTc5NWU5MzJfOC0zLTEtMS04MQ_17abe797-8def-4316-b441-03b0e003ceab"
      unitRef="usd">899640000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i3b4376f8fc614de98c9cf647198c504e_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81OC9mcmFnOjU3NjUyN2FlNjcwYTRkOTFhOTFlNGY3MmIxZjA0ZTI4L3RhYmxlOjA5YjE0NDQwYTQ3MTQyNTliMTNkZWVlYjE3OTVlOTMyL3RhYmxlcmFuZ2U6MDliMTQ0NDBhNDcxNDI1OWIxM2RlZWViMTc5NWU5MzJfOS0xLTEtMS04MQ_e2530b54-253c-43fb-8e1c-22c82e07973d"
      unitRef="usd">201980000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="iab26fe441f0d4ab984456365a7f7cff0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81OC9mcmFnOjU3NjUyN2FlNjcwYTRkOTFhOTFlNGY3MmIxZjA0ZTI4L3RhYmxlOjA5YjE0NDQwYTQ3MTQyNTliMTNkZWVlYjE3OTVlOTMyL3RhYmxlcmFuZ2U6MDliMTQ0NDBhNDcxNDI1OWIxM2RlZWViMTc5NWU5MzJfOS0zLTEtMS04MQ_f8bfc1d0-5e2b-4793-998c-5850017cd44f"
      unitRef="usd">175720000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i3b4376f8fc614de98c9cf647198c504e_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81OC9mcmFnOjU3NjUyN2FlNjcwYTRkOTFhOTFlNGY3MmIxZjA0ZTI4L3RhYmxlOjA5YjE0NDQwYTQ3MTQyNTliMTNkZWVlYjE3OTVlOTMyL3RhYmxlcmFuZ2U6MDliMTQ0NDBhNDcxNDI1OWIxM2RlZWViMTc5NWU5MzJfMTAtMS0xLTEtODE_3aafd813-5d68-4624-8b09-081364e4344c"
      unitRef="usd">715733000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="iab26fe441f0d4ab984456365a7f7cff0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81OC9mcmFnOjU3NjUyN2FlNjcwYTRkOTFhOTFlNGY3MmIxZjA0ZTI4L3RhYmxlOjA5YjE0NDQwYTQ3MTQyNTliMTNkZWVlYjE3OTVlOTMyL3RhYmxlcmFuZ2U6MDliMTQ0NDBhNDcxNDI1OWIxM2RlZWViMTc5NWU5MzJfMTAtMy0xLTEtODE_5f66a3d6-adfe-4c63-a21b-6ad97e73191a"
      unitRef="usd">723920000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="i1b500a53ba8b41b09f796fe4eaf76bef_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81OC9mcmFnOjU3NjUyN2FlNjcwYTRkOTFhOTFlNGY3MmIxZjA0ZTI4L3RleHRyZWdpb246NTc2NTI3YWU2NzBhNGQ5MWE5MWU0ZjcyYjFmMDRlMjhfMzUw_c271d9c6-d13e-41b4-8c22-aed1e2b3ee96"
      unitRef="sqft">200000</us-gaap:AreaOfRealEstateProperty>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i2370b8e265a34d1aa69e4cb0d71b393f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81OC9mcmFnOjU3NjUyN2FlNjcwYTRkOTFhOTFlNGY3MmIxZjA0ZTI4L3RleHRyZWdpb246NTc2NTI3YWU2NzBhNGQ5MWE5MWU0ZjcyYjFmMDRlMjhfNDQ3_daf95d58-cc57-4a55-97e4-a4c8ce92b4bb"
      unitRef="usd">158200000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:LesseeFinanceLeaseTermOfContract1
      contextRef="i3e022afff69a4662b44f01a7c0e13f2b_I20180228"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81OC9mcmFnOjU3NjUyN2FlNjcwYTRkOTFhOTFlNGY3MmIxZjA0ZTI4L3RleHRyZWdpb246NTc2NTI3YWU2NzBhNGQ5MWE5MWU0ZjcyYjFmMDRlMjhfNjQ1_750e04d7-ef84-4589-a84d-f8582908caef">P15Y</us-gaap:LesseeFinanceLeaseTermOfContract1>
    <us-gaap:LesseeFinanceLeaseExistenceOfOptionToExtend
      contextRef="i98615f967e4d480b8209d68fbee3cb04_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81OC9mcmFnOjU3NjUyN2FlNjcwYTRkOTFhOTFlNGY3MmIxZjA0ZTI4L3RleHRyZWdpb246NTc2NTI3YWU2NzBhNGQ5MWE5MWU0ZjcyYjFmMDRlMjhfNjUz_eee59fee-30e3-4141-9ee4-9b3be7b6fab6">true</us-gaap:LesseeFinanceLeaseExistenceOfOptionToExtend>
    <us-gaap:LesseeFinanceLeaseRenewalTerm1
      contextRef="i3e022afff69a4662b44f01a7c0e13f2b_I20180228"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81OC9mcmFnOjU3NjUyN2FlNjcwYTRkOTFhOTFlNGY3MmIxZjA0ZTI4L3RleHRyZWdpb246NTc2NTI3YWU2NzBhNGQ5MWE5MWU0ZjcyYjFmMDRlMjhfNzIw_b725e206-34d9-4061-b33a-1ba6d3ec244c">P20Y</us-gaap:LesseeFinanceLeaseRenewalTerm1>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="i5b1c37d431a944d2bedb8074e5a6d652_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81OC9mcmFnOjU3NjUyN2FlNjcwYTRkOTFhOTFlNGY3MmIxZjA0ZTI4L3RleHRyZWdpb246NTc2NTI3YWU2NzBhNGQ5MWE5MWU0ZjcyYjFmMDRlMjhfODA3_3dd474a9-4784-4eed-a01c-5737ecac5c94"
      unitRef="sqft">100000</us-gaap:AreaOfRealEstateProperty>
    <us-gaap:FinanceLeaseLiability
      contextRef="ia946998af0fa49ddb26d6ca660cd4f96_I20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81OC9mcmFnOjU3NjUyN2FlNjcwYTRkOTFhOTFlNGY3MmIxZjA0ZTI4L3RleHRyZWdpb246NTc2NTI3YWU2NzBhNGQ5MWE5MWU0ZjcyYjFmMDRlMjhfMTE2OA_c023e40c-8fbe-414f-907c-c47e7737fda4"
      unitRef="usd">31100000</us-gaap:FinanceLeaseLiability>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="ia946998af0fa49ddb26d6ca660cd4f96_I20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81OC9mcmFnOjU3NjUyN2FlNjcwYTRkOTFhOTFlNGY3MmIxZjA0ZTI4L3RleHRyZWdpb246NTc2NTI3YWU2NzBhNGQ5MWE5MWU0ZjcyYjFmMDRlMjhfMTIxMw_02da30ce-8abb-4599-b034-6009410fd936"
      unitRef="usd">29100000</us-gaap:FinanceLeaseRightOfUseAsset>
    <incy:FinanceLeaseLeaseIncentiveReceivable
      contextRef="ia946998af0fa49ddb26d6ca660cd4f96_I20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81OC9mcmFnOjU3NjUyN2FlNjcwYTRkOTFhOTFlNGY3MmIxZjA0ZTI4L3RleHRyZWdpb246NTc2NTI3YWU2NzBhNGQ5MWE5MWU0ZjcyYjFmMDRlMjhfMTI2Mw_4fbff588-1caa-4135-88a5-156ba518ea81"
      unitRef="usd">2000000</incy:FinanceLeaseLeaseIncentiveReceivable>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i5f74da13198248b88b7490d0362d5443_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81OC9mcmFnOjU3NjUyN2FlNjcwYTRkOTFhOTFlNGY3MmIxZjA0ZTI4L3RleHRyZWdpb246NTc2NTI3YWU2NzBhNGQ5MWE5MWU0ZjcyYjFmMDRlMjhfMTMwMQ_8937a92e-ea45-4440-8e65-ef192fc2f3ae"
      unitRef="usd">19500000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PaymentsToAcquireRealEstate
      contextRef="ied0dbe564f15462a80f773631b1b4a84_D20180701-20180731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81OC9mcmFnOjU3NjUyN2FlNjcwYTRkOTFhOTFlNGY3MmIxZjA0ZTI4L3RleHRyZWdpb246NTc2NTI3YWU2NzBhNGQ5MWE5MWU0ZjcyYjFmMDRlMjhfMTQ5MA_6240eaab-220f-48bc-9d81-08796bf8b7eb"
      unitRef="usd">4800000</us-gaap:PaymentsToAcquireRealEstate>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="if65cebf5f28640cc97c1750992f7d09c_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV81OC9mcmFnOjU3NjUyN2FlNjcwYTRkOTFhOTFlNGY3MmIxZjA0ZTI4L3RleHRyZWdpb246NTc2NTI3YWU2NzBhNGQ5MWE5MWU0ZjcyYjFmMDRlMjhfMTY2NA_d9050097-c6c7-43ce-bd6a-4d7925e30d65"
      unitRef="usd">190500000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock
      contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82MS9mcmFnOjc0YjUwYTRkZjA5YTQ0M2Q4ODE1ZTk1ZDk2YTlmZjRjL3RleHRyZWdpb246NzRiNTBhNGRmMDlhNDQzZDg4MTVlOTVkOTZhOWZmNGNfMTMy_8aeaea41-b5ec-46ba-af0d-11574888116e">&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued and other current liabilities consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.778%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.083%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Royalties&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1.97pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;248,455&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1.97pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;168,412&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Clinical related costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1.97pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;152,764&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1.97pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;109,486&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Sales allowances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1.97pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;186,112&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1.97pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;136,541&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sales and marketing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1.97pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;31,001&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1.97pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;35,750&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1.97pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;8,836&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1.97pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;27,098&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1.97pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;8,492&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1.97pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;10,554&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1.97pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;64,154&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1.97pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;45,754&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total accrued and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1.97pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;699,814&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1.97pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;533,595&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82MS9mcmFnOjc0YjUwYTRkZjA5YTQ0M2Q4ODE1ZTk1ZDk2YTlmZjRjL3RleHRyZWdpb246NzRiNTBhNGRmMDlhNDQzZDg4MTVlOTVkOTZhOWZmNGNfMTMz_6a0d7f94-e8c6-4b87-ad1c-ad49a7cd24da">&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued and other current liabilities consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.778%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.083%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Royalties&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1.97pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;248,455&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1.97pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;168,412&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Clinical related costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1.97pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;152,764&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1.97pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;109,486&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Sales allowances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1.97pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;186,112&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1.97pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;136,541&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sales and marketing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1.97pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;31,001&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1.97pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;35,750&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1.97pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;8,836&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1.97pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;27,098&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1.97pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;8,492&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1.97pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;10,554&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1.97pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;64,154&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1.97pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;45,754&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total accrued and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1.97pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;699,814&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1.97pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;533,595&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccruedRoyaltiesCurrent
      contextRef="i3b4376f8fc614de98c9cf647198c504e_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82MS9mcmFnOjc0YjUwYTRkZjA5YTQ0M2Q4ODE1ZTk1ZDk2YTlmZjRjL3RhYmxlOjZhZTQxMzg4MGEzYjQyNGZiYjY1OGM4OGViZDQ3YmNhL3RhYmxlcmFuZ2U6NmFlNDEzODgwYTNiNDI0ZmJiNjU4Yzg4ZWJkNDdiY2FfMS0xLTEtMS04MQ_ae0acdc3-370c-4ddb-9674-57ea43d4b69c"
      unitRef="usd">248455000</us-gaap:AccruedRoyaltiesCurrent>
    <us-gaap:AccruedRoyaltiesCurrent
      contextRef="iab26fe441f0d4ab984456365a7f7cff0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82MS9mcmFnOjc0YjUwYTRkZjA5YTQ0M2Q4ODE1ZTk1ZDk2YTlmZjRjL3RhYmxlOjZhZTQxMzg4MGEzYjQyNGZiYjY1OGM4OGViZDQ3YmNhL3RhYmxlcmFuZ2U6NmFlNDEzODgwYTNiNDI0ZmJiNjU4Yzg4ZWJkNDdiY2FfMS0zLTEtMS04MQ_1bf422bd-02a6-4e0d-9251-d105a63f1f34"
      unitRef="usd">168412000</us-gaap:AccruedRoyaltiesCurrent>
    <incy:AccruedClinicalRelatedCostsCurrent
      contextRef="i3b4376f8fc614de98c9cf647198c504e_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82MS9mcmFnOjc0YjUwYTRkZjA5YTQ0M2Q4ODE1ZTk1ZDk2YTlmZjRjL3RhYmxlOjZhZTQxMzg4MGEzYjQyNGZiYjY1OGM4OGViZDQ3YmNhL3RhYmxlcmFuZ2U6NmFlNDEzODgwYTNiNDI0ZmJiNjU4Yzg4ZWJkNDdiY2FfMi0xLTEtMS04MQ_02d50681-eb87-4a02-b20e-03689a7854b9"
      unitRef="usd">152764000</incy:AccruedClinicalRelatedCostsCurrent>
    <incy:AccruedClinicalRelatedCostsCurrent
      contextRef="iab26fe441f0d4ab984456365a7f7cff0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82MS9mcmFnOjc0YjUwYTRkZjA5YTQ0M2Q4ODE1ZTk1ZDk2YTlmZjRjL3RhYmxlOjZhZTQxMzg4MGEzYjQyNGZiYjY1OGM4OGViZDQ3YmNhL3RhYmxlcmFuZ2U6NmFlNDEzODgwYTNiNDI0ZmJiNjU4Yzg4ZWJkNDdiY2FfMi0zLTEtMS04MQ_944130c7-c23d-4ba2-8b96-b87fd14db4e1"
      unitRef="usd">109486000</incy:AccruedClinicalRelatedCostsCurrent>
    <us-gaap:ProvisionForLossOnContracts
      contextRef="i3b4376f8fc614de98c9cf647198c504e_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82MS9mcmFnOjc0YjUwYTRkZjA5YTQ0M2Q4ODE1ZTk1ZDk2YTlmZjRjL3RhYmxlOjZhZTQxMzg4MGEzYjQyNGZiYjY1OGM4OGViZDQ3YmNhL3RhYmxlcmFuZ2U6NmFlNDEzODgwYTNiNDI0ZmJiNjU4Yzg4ZWJkNDdiY2FfMy0xLTEtMS04MQ_ee5e4dfe-b64d-49a7-bf71-71eeed33702d"
      unitRef="usd">186112000</us-gaap:ProvisionForLossOnContracts>
    <us-gaap:ProvisionForLossOnContracts
      contextRef="iab26fe441f0d4ab984456365a7f7cff0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82MS9mcmFnOjc0YjUwYTRkZjA5YTQ0M2Q4ODE1ZTk1ZDk2YTlmZjRjL3RhYmxlOjZhZTQxMzg4MGEzYjQyNGZiYjY1OGM4OGViZDQ3YmNhL3RhYmxlcmFuZ2U6NmFlNDEzODgwYTNiNDI0ZmJiNjU4Yzg4ZWJkNDdiY2FfMy0zLTEtMS04MQ_5fbe2fa4-628e-4229-84a8-83255610c741"
      unitRef="usd">136541000</us-gaap:ProvisionForLossOnContracts>
    <us-gaap:AccruedMarketingCostsCurrent
      contextRef="i3b4376f8fc614de98c9cf647198c504e_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82MS9mcmFnOjc0YjUwYTRkZjA5YTQ0M2Q4ODE1ZTk1ZDk2YTlmZjRjL3RhYmxlOjZhZTQxMzg4MGEzYjQyNGZiYjY1OGM4OGViZDQ3YmNhL3RhYmxlcmFuZ2U6NmFlNDEzODgwYTNiNDI0ZmJiNjU4Yzg4ZWJkNDdiY2FfNC0xLTEtMS04MQ_8243f0f5-ecc2-43db-a04a-b5cb16fa651c"
      unitRef="usd">31001000</us-gaap:AccruedMarketingCostsCurrent>
    <us-gaap:AccruedMarketingCostsCurrent
      contextRef="iab26fe441f0d4ab984456365a7f7cff0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82MS9mcmFnOjc0YjUwYTRkZjA5YTQ0M2Q4ODE1ZTk1ZDk2YTlmZjRjL3RhYmxlOjZhZTQxMzg4MGEzYjQyNGZiYjY1OGM4OGViZDQ3YmNhL3RhYmxlcmFuZ2U6NmFlNDEzODgwYTNiNDI0ZmJiNjU4Yzg4ZWJkNDdiY2FfNC0zLTEtMS04MQ_415a6aef-15e1-4126-a5d0-5ac3858250df"
      unitRef="usd">35750000</us-gaap:AccruedMarketingCostsCurrent>
    <us-gaap:ConstructionPayableCurrent
      contextRef="i3b4376f8fc614de98c9cf647198c504e_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82MS9mcmFnOjc0YjUwYTRkZjA5YTQ0M2Q4ODE1ZTk1ZDk2YTlmZjRjL3RhYmxlOjZhZTQxMzg4MGEzYjQyNGZiYjY1OGM4OGViZDQ3YmNhL3RhYmxlcmFuZ2U6NmFlNDEzODgwYTNiNDI0ZmJiNjU4Yzg4ZWJkNDdiY2FfNS0xLTEtMS04MQ_b487cebe-a338-474a-a26f-b115759dea80"
      unitRef="usd">8836000</us-gaap:ConstructionPayableCurrent>
    <us-gaap:ConstructionPayableCurrent
      contextRef="iab26fe441f0d4ab984456365a7f7cff0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82MS9mcmFnOjc0YjUwYTRkZjA5YTQ0M2Q4ODE1ZTk1ZDk2YTlmZjRjL3RhYmxlOjZhZTQxMzg4MGEzYjQyNGZiYjY1OGM4OGViZDQ3YmNhL3RhYmxlcmFuZ2U6NmFlNDEzODgwYTNiNDI0ZmJiNjU4Yzg4ZWJkNDdiY2FfNS0zLTEtMS04MQ_b54001b6-b732-4f07-8437-65a0c0fadbb7"
      unitRef="usd">27098000</us-gaap:ConstructionPayableCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i3b4376f8fc614de98c9cf647198c504e_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82MS9mcmFnOjc0YjUwYTRkZjA5YTQ0M2Q4ODE1ZTk1ZDk2YTlmZjRjL3RhYmxlOjZhZTQxMzg4MGEzYjQyNGZiYjY1OGM4OGViZDQ3YmNhL3RhYmxlcmFuZ2U6NmFlNDEzODgwYTNiNDI0ZmJiNjU4Yzg4ZWJkNDdiY2FfNi0xLTEtMS04MQ_f48f57f4-2f68-404b-a5b9-65041e3e3aac"
      unitRef="usd">8492000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="iab26fe441f0d4ab984456365a7f7cff0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82MS9mcmFnOjc0YjUwYTRkZjA5YTQ0M2Q4ODE1ZTk1ZDk2YTlmZjRjL3RhYmxlOjZhZTQxMzg4MGEzYjQyNGZiYjY1OGM4OGViZDQ3YmNhL3RhYmxlcmFuZ2U6NmFlNDEzODgwYTNiNDI0ZmJiNjU4Yzg4ZWJkNDdiY2FfNi0zLTEtMS04MQ_6af6d329-2e66-42a9-a71c-4d94b2d9821c"
      unitRef="usd">10554000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i3b4376f8fc614de98c9cf647198c504e_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82MS9mcmFnOjc0YjUwYTRkZjA5YTQ0M2Q4ODE1ZTk1ZDk2YTlmZjRjL3RhYmxlOjZhZTQxMzg4MGEzYjQyNGZiYjY1OGM4OGViZDQ3YmNhL3RhYmxlcmFuZ2U6NmFlNDEzODgwYTNiNDI0ZmJiNjU4Yzg4ZWJkNDdiY2FfNy0xLTEtMS04MQ_eadb0bf6-13be-439d-9215-5eacb98cfb2e"
      unitRef="usd">64154000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="iab26fe441f0d4ab984456365a7f7cff0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82MS9mcmFnOjc0YjUwYTRkZjA5YTQ0M2Q4ODE1ZTk1ZDk2YTlmZjRjL3RhYmxlOjZhZTQxMzg4MGEzYjQyNGZiYjY1OGM4OGViZDQ3YmNhL3RhYmxlcmFuZ2U6NmFlNDEzODgwYTNiNDI0ZmJiNjU4Yzg4ZWJkNDdiY2FfNy0zLTEtMS04MQ_4a88afb6-6979-4af0-8193-a24f637444a5"
      unitRef="usd">45754000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i3b4376f8fc614de98c9cf647198c504e_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82MS9mcmFnOjc0YjUwYTRkZjA5YTQ0M2Q4ODE1ZTk1ZDk2YTlmZjRjL3RhYmxlOjZhZTQxMzg4MGEzYjQyNGZiYjY1OGM4OGViZDQ3YmNhL3RhYmxlcmFuZ2U6NmFlNDEzODgwYTNiNDI0ZmJiNjU4Yzg4ZWJkNDdiY2FfOC0xLTEtMS04MQ_5e504513-4f82-4378-8e28-e1fa6b016994"
      unitRef="usd">699814000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="iab26fe441f0d4ab984456365a7f7cff0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82MS9mcmFnOjc0YjUwYTRkZjA5YTQ0M2Q4ODE1ZTk1ZDk2YTlmZjRjL3RhYmxlOjZhZTQxMzg4MGEzYjQyNGZiYjY1OGM4OGViZDQ3YmNhL3RhYmxlcmFuZ2U6NmFlNDEzODgwYTNiNDI0ZmJiNjU4Yzg4ZWJkNDdiY2FfOC0zLTEtMS04MQ_7e7dd0c9-90a4-47ff-bc05-976ffc1b3f43"
      unitRef="usd">533595000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RleHRyZWdpb246ZmFlNDc5YmVlYzk3NGU3Njk4MDJlOTE5MjQ4MDEwYzRfNDkzMA_41f3d2a3-5e8b-493b-a94b-03e0c5e8b09a">&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recorded $45.4 million and $135.7 million of stock compensation expense on our condensed consolidated statements of operations for the three and nine months ended September&#160;30, 2022, respectively. We recorded $42.7 million and $134.8 million of stock compensation expense on our condensed consolidated statements of operations for the three and nine months ended September&#160;30, 2021, respectively. Stock compensation expense included within our condensed consolidated statements of operations included research and development expense of $25.8 million, $80.2 million, $26.3 million and $84.2 million for the three and nine months ended September&#160;30, 2022 and 2021, respectively. Stock compensation expense included within our condensed consolidated statements of operations also included selling, general and administrative expense of $18.9 million, $53.5 million, $15.9 million and $49.5 million for the three and nine months ended September&#160;30, 2022 and 2021, respectively. Stock compensation expense included within our condensed consolidated statements of operations also included cost of product revenues of $0.7 million, $2.0 million, $0.5 million and $1.1 million, respectively, for the three and nine months ended September&#160;30, 2022 and 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We utilized the Black-Scholes valuation model for estimating the fair value of the stock compensation granted, with the following weighted-average assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.998%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Employee Stock Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Employee Stock Purchase Plan&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Average risk-free interest rates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.03&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Average expected life (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.17&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.16&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.88&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.00&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.50&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.50&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.50&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.50&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average fair value (in dollars)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The risk-free interest rate is derived from the U.S. Federal Reserve rate in effect at the time of grant. The expected life calculation is based on the observed and expected time to the exercise of options by our employees based on historical exercise patterns for similar type options. Expected volatility is based on the historical volatility of our common stock over the period commensurate with the expected life of the options. A dividend yield of zero is assumed based on the fact that we have never paid cash dividends and have no present intention to pay cash dividends. Nonemployee awards are measured on the grant date by estimating the fair value of the equity instruments to be issued using the expected term, similar to our employee awards.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Option activity under our 2010 Stock Incentive Plan (the &#x201c;2010 Stock Plan&#x201d;) was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.083%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares Subject to&lt;br/&gt;Outstanding Options&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted Average&lt;br/&gt;Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,763,460&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88.39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,755,963&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(477,371)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66.69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options cancelled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(989,465)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,052,587&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87.41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our annual stock option grants generally have a 10-year term and vest over four years, with 25% vesting after one year and the remainder vesting in 36 equal monthly installments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted stock unit (&#x201c;RSU&#x201d;) and performance share (&#x201c;PSU&#x201d;) award activity under the 2010 Stock Plan was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.083%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares Subject to&lt;br/&gt;Outstanding Awards&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Grant Date Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,966,888&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84.91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs granted &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,473,892&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77.14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;PSUs granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154,685&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs released&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(845,095)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87.06&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;PSUs released&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(184,401)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs cancelled &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(337,265)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83.94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;PSUs cancelled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,720)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65.76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,226,984&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;RSUs and PSUs are granted to our employees at the share price on the date of grant. Each RSU represents the right to acquire one share of our common stock. Each RSU granted in connection with our annual equity awards will vest 25% annually over four years, while each RSU granted as outstanding merit awards or as part of retention award programs will vest in a single installment at the end of four years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We grant PSUs with performance and/or service-based milestones with graded and/or cliff vesting over &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RleHRyZWdpb246ZmFlNDc5YmVlYzk3NGU3Njk4MDJlOTE5MjQ4MDEwYzRfMjcyMw_f68315b0-93a7-445d-8854-3803f7e59595"&gt;three&lt;/span&gt; to four years. The shares of our common stock into which each PSU may convert is subject to a multiplier based on the level at which the financial, developmental and market performance conditions are achieved over the service period. Compensation expense for PSUs with financial and developmental performance conditions is recorded over the estimated service period for each milestone when the performance conditions are deemed probable of achievement. For PSUs containing performance conditions which were not deemed probable of achievement, no stock compensation expense is recorded. Compensation expense for PSUs with market performance conditions is calculated using a Monte Carlo simulation model as of the date of grant and recorded over the requisite service period. For the three and nine months ended September&#160;30, 2022 we recorded $3.2 million and $5.1 million, respectively, of stock compensation expense for PSUs on our condensed consolidated statements of operations. For the three and nine months ended September&#160;30, 2021 we recorded $1.7 million and $5.0 million of stock compensation expense for PSUs on our condensed consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our shares available for grant under the 2010 Stock Plan. Each RSU and PSU grant reduces the available share pool by 2 shares.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.718%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.082%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Shares Available&lt;br/&gt;for Grant&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1.97pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;10,113,298&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Options, RSUs and PSUs granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(7,013,475)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Options, RSUs and PSUs cancelled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1.97pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,680,482&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Balance at September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1.97pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4,780,305&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Based on our historical experience of employee turnover, we have assumed an annualized forfeiture rate of 5% for our options, RSUs and PSUs. Under the true-up provisions of the stock compensation guidance, we will record additional expense if the actual forfeiture rate is lower than we estimated, and will record a recovery of prior expense if the actual forfeiture is higher than we estimated.&lt;/span&gt;&lt;/div&gt;Total compensation cost of options granted but not yet vested, as of September&#160;30, 2022, was $51.2 million, which is expected to be recognized over the weighted average period of approximately 1.1 years. Total compensation cost of RSUs granted but not yet vested, as of September&#160;30, 2022, was $235.5 million, which is expected to be recognized over the weighted average period of approximately 2.0 years. Total compensation cost of PSUs granted but not yet vested, as of September&#160;30, 2022, was $19.6 million, which is expected to be recognized over the weighted average period of 2.2 years, should the underlying performance conditions be deemed probable of achievement.</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="id673d80f31e74643a241d2f62db94ca9_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RleHRyZWdpb246ZmFlNDc5YmVlYzk3NGU3Njk4MDJlOTE5MjQ4MDEwYzRfNDU_94dbb63b-d340-4620-b4b0-f499d20e1c18"
      unitRef="usd">45400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RleHRyZWdpb246ZmFlNDc5YmVlYzk3NGU3Njk4MDJlOTE5MjQ4MDEwYzRfNTI_77269058-c8d5-4d99-a677-835161cb99be"
      unitRef="usd">135700000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i313b15d35b7045babd1ba61f84a077dd_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RleHRyZWdpb246ZmFlNDc5YmVlYzk3NGU3Njk4MDJlOTE5MjQ4MDEwYzRfMTk0_a6724285-2381-4881-84a1-0552e445143e"
      unitRef="usd">42700000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i0faaba5fcd6b485781cadacae8b2fd8e_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RleHRyZWdpb246ZmFlNDc5YmVlYzk3NGU3Njk4MDJlOTE5MjQ4MDEwYzRfMjAy_b5698e30-e255-4780-a17b-e5a71d5c12aa"
      unitRef="usd">134800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i70b041b0d1e8409a9b019c7f878e45a2_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RleHRyZWdpb246ZmFlNDc5YmVlYzk3NGU3Njk4MDJlOTE5MjQ4MDEwYzRfNDcy_b70fcb63-e0bf-40c6-a067-28ad6f892f6d"
      unitRef="usd">25800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i49a1f92f5e85446da96c93ad448dbab8_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RleHRyZWdpb246ZmFlNDc5YmVlYzk3NGU3Njk4MDJlOTE5MjQ4MDEwYzRfNDc2_137831cf-9286-4fd9-98ed-4a0c7b054b38"
      unitRef="usd">80200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ia4fb38d378634c26b981ddc5c86f5524_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RleHRyZWdpb246ZmFlNDc5YmVlYzk3NGU3Njk4MDJlOTE5MjQ4MDEwYzRfNDgw_8e15fafb-4a4d-4822-9ef8-0029bb7cc9b1"
      unitRef="usd">26300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i383fc0ace0f847c4a6eb8bb43c13caff_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RleHRyZWdpb246ZmFlNDc5YmVlYzk3NGU3Njk4MDJlOTE5MjQ4MDEwYzRfNDg4_e6230a0c-dcb4-4864-88f9-a08698d59d0d"
      unitRef="usd">84200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i5835316ce7724afea3bdb29dcb3a2253_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RleHRyZWdpb246ZmFlNDc5YmVlYzk3NGU3Njk4MDJlOTE5MjQ4MDEwYzRfNjk2_ee7199e7-1fef-4d99-af7d-502bf0f5c0ff"
      unitRef="usd">18900000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ib017a2d350ba431d9ba79b402e1cfb7f_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RleHRyZWdpb246ZmFlNDc5YmVlYzk3NGU3Njk4MDJlOTE5MjQ4MDEwYzRfNzAw_aa451054-e2e4-4eac-963f-8eaa3f454c5c"
      unitRef="usd">53500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i89ed3c93c92745279b334fa5c4526831_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RleHRyZWdpb246ZmFlNDc5YmVlYzk3NGU3Njk4MDJlOTE5MjQ4MDEwYzRfNzA0_206fb634-f4b4-4f54-9f70-00ce959ff6dd"
      unitRef="usd">15900000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i7f29ae45641b4afcab178d487b406c8b_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RleHRyZWdpb246ZmFlNDc5YmVlYzk3NGU3Njk4MDJlOTE5MjQ4MDEwYzRfNzEx_91080fd0-0d35-4a60-b228-1d0ed5c347f6"
      unitRef="usd">49500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="icce988e289034a3fb382746bd6fb055e_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RleHRyZWdpb246ZmFlNDc5YmVlYzk3NGU3Njk4MDJlOTE5MjQ4MDEwYzRfOTAw_12769d50-e126-45a1-a95e-47d5453f57da"
      unitRef="usd">700000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="idcbe2a87e3f1451b8c00c0d575bc9286_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RleHRyZWdpb246ZmFlNDc5YmVlYzk3NGU3Njk4MDJlOTE5MjQ4MDEwYzRfOTA0_3fcff9bb-fb71-4f3b-b7cf-3a0f518cbbee"
      unitRef="usd">2000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i743fbd319cfc457b9da040d45ac71e11_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RleHRyZWdpb246ZmFlNDc5YmVlYzk3NGU3Njk4MDJlOTE5MjQ4MDEwYzRfOTA4_58ecc451-66a9-4f76-82fd-d382529ba12e"
      unitRef="usd">500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i29928027a77447828aad4cf785a73286_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RleHRyZWdpb246ZmFlNDc5YmVlYzk3NGU3Njk4MDJlOTE5MjQ4MDEwYzRfOTE1_857ec78a-2a61-472c-89af-c8009c00122c"
      unitRef="usd">1100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <incy:ScheduleOfShareBasedPaymentAwardStockOptionsAndEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock
      contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RleHRyZWdpb246ZmFlNDc5YmVlYzk3NGU3Njk4MDJlOTE5MjQ4MDEwYzRfNDkzMQ_ca94d15a-666f-42ca-8b65-529f7421e5a8">&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We utilized the Black-Scholes valuation model for estimating the fair value of the stock compensation granted, with the following weighted-average assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.998%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Employee Stock Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Employee Stock Purchase Plan&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Average risk-free interest rates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.03&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Average expected life (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.17&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.16&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.88&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.00&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.50&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.50&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.50&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.50&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average fair value (in dollars)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</incy:ScheduleOfShareBasedPaymentAwardStockOptionsAndEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="id3db81cbe7d44bf4b59daffdc638772b_D20220701-20220930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RhYmxlOjJjNWRmMDU2OTZiNDRhMmViMGNlOGIxM2NlMzJlZjdhL3RhYmxlcmFuZ2U6MmM1ZGYwNTY5NmI0NGEyZWIwY2U4YjEzY2UzMmVmN2FfNC0xLTEtMS04MQ_c8a715f1-b690-435c-8e54-fa201b5e0e9b"
      unitRef="number">0.0290</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i18064623ae8c40b0b87d8d75806827d8_D20210701-20210930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RhYmxlOjJjNWRmMDU2OTZiNDRhMmViMGNlOGIxM2NlMzJlZjdhL3RhYmxlcmFuZ2U6MmM1ZGYwNTY5NmI0NGEyZWIwY2U4YjEzY2UzMmVmN2FfNC0zLTEtMS04MQ_a2e44b72-acee-4595-84fe-3074963ca34e"
      unitRef="number">0.0076</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i88f8a540b3d94b20983f8902eae30ae2_D20220101-20220930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RhYmxlOjJjNWRmMDU2OTZiNDRhMmViMGNlOGIxM2NlMzJlZjdhL3RhYmxlcmFuZ2U6MmM1ZGYwNTY5NmI0NGEyZWIwY2U4YjEzY2UzMmVmN2FfNC01LTEtMS04MQ_059d373f-38cb-42e6-8ccd-680e415d7ddd"
      unitRef="number">0.0203</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="id7acb0824a524ce2b1a6d6eeb3f5b6b8_D20210101-20210930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RhYmxlOjJjNWRmMDU2OTZiNDRhMmViMGNlOGIxM2NlMzJlZjdhL3RhYmxlcmFuZ2U6MmM1ZGYwNTY5NmI0NGEyZWIwY2U4YjEzY2UzMmVmN2FfNC03LTEtMS04MQ_86652c2d-4222-42df-b3aa-b39c65995845"
      unitRef="number">0.0060</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="ia05518f1a01d4291b4add6208b75e939_D20220701-20220930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RhYmxlOjJjNWRmMDU2OTZiNDRhMmViMGNlOGIxM2NlMzJlZjdhL3RhYmxlcmFuZ2U6MmM1ZGYwNTY5NmI0NGEyZWIwY2U4YjEzY2UzMmVmN2FfNC05LTEtMS04MQ_3ed65a4f-9972-43be-8c3b-b9a4ae5be875"
      unitRef="number">0.0422</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="ie12951e0177049569a4eaac01ed75693_D20210701-20210930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RhYmxlOjJjNWRmMDU2OTZiNDRhMmViMGNlOGIxM2NlMzJlZjdhL3RhYmxlcmFuZ2U6MmM1ZGYwNTY5NmI0NGEyZWIwY2U4YjEzY2UzMmVmN2FfNC0xMS0xLTEtODE_7d23ca57-7c52-4286-b3af-ccc03f0c9b51"
      unitRef="number">0.0028</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="icaf56e010147488ebeb835f2e5b31900_D20220101-20220930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RhYmxlOjJjNWRmMDU2OTZiNDRhMmViMGNlOGIxM2NlMzJlZjdhL3RhYmxlcmFuZ2U6MmM1ZGYwNTY5NmI0NGEyZWIwY2U4YjEzY2UzMmVmN2FfNC0xMy0xLTEtODE_19e7a41a-c872-43e0-8d4e-790d29af52b2"
      unitRef="number">0.0344</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i6c730d6b5a3349088cf01b0df9f09e86_D20210101-20210930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RhYmxlOjJjNWRmMDU2OTZiNDRhMmViMGNlOGIxM2NlMzJlZjdhL3RhYmxlcmFuZ2U6MmM1ZGYwNTY5NmI0NGEyZWIwY2U4YjEzY2UzMmVmN2FfNC0xNS0xLTEtODE_6addcd47-8518-4c95-a2ba-df2b5e42b36b"
      unitRef="number">0.0022</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="id3db81cbe7d44bf4b59daffdc638772b_D20220701-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RhYmxlOjJjNWRmMDU2OTZiNDRhMmViMGNlOGIxM2NlMzJlZjdhL3RhYmxlcmFuZ2U6MmM1ZGYwNTY5NmI0NGEyZWIwY2U4YjEzY2UzMmVmN2FfNS0xLTEtMS04MQ_75098eff-10b0-4de5-8e3e-6c9d083c844a">P5Y2M1D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i18064623ae8c40b0b87d8d75806827d8_D20210701-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RhYmxlOjJjNWRmMDU2OTZiNDRhMmViMGNlOGIxM2NlMzJlZjdhL3RhYmxlcmFuZ2U6MmM1ZGYwNTY5NmI0NGEyZWIwY2U4YjEzY2UzMmVmN2FfNS0zLTEtMS04MQ_d371da05-30fb-4f42-b2af-1b4a34846c3b">P5Y1M28D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i88f8a540b3d94b20983f8902eae30ae2_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RhYmxlOjJjNWRmMDU2OTZiNDRhMmViMGNlOGIxM2NlMzJlZjdhL3RhYmxlcmFuZ2U6MmM1ZGYwNTY5NmI0NGEyZWIwY2U4YjEzY2UzMmVmN2FfNS01LTEtMS04MQ_ca0f57dc-ef5f-4de5-ba7d-a1536acb6225">P4Y10M17D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="id7acb0824a524ce2b1a6d6eeb3f5b6b8_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RhYmxlOjJjNWRmMDU2OTZiNDRhMmViMGNlOGIxM2NlMzJlZjdhL3RhYmxlcmFuZ2U6MmM1ZGYwNTY5NmI0NGEyZWIwY2U4YjEzY2UzMmVmN2FfNS03LTEtMS04MQ_5c607da5-3160-4022-a2e7-5f44855b7f13">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="ia05518f1a01d4291b4add6208b75e939_D20220701-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RhYmxlOjJjNWRmMDU2OTZiNDRhMmViMGNlOGIxM2NlMzJlZjdhL3RhYmxlcmFuZ2U6MmM1ZGYwNTY5NmI0NGEyZWIwY2U4YjEzY2UzMmVmN2FfNS05LTEtMS04MQ_98689577-db6d-48e0-8be3-7e66e4ba1ead">P0Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="ie12951e0177049569a4eaac01ed75693_D20210701-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RhYmxlOjJjNWRmMDU2OTZiNDRhMmViMGNlOGIxM2NlMzJlZjdhL3RhYmxlcmFuZ2U6MmM1ZGYwNTY5NmI0NGEyZWIwY2U4YjEzY2UzMmVmN2FfNS0xMS0xLTEtODE_0cf380b9-0cc9-4c1d-b993-b87a45fcdcb6">P0Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="icaf56e010147488ebeb835f2e5b31900_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RhYmxlOjJjNWRmMDU2OTZiNDRhMmViMGNlOGIxM2NlMzJlZjdhL3RhYmxlcmFuZ2U6MmM1ZGYwNTY5NmI0NGEyZWIwY2U4YjEzY2UzMmVmN2FfNS0xMy0xLTEtODE_d2084140-5820-49c3-82e1-254c049ffdfc">P0Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i6c730d6b5a3349088cf01b0df9f09e86_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RhYmxlOjJjNWRmMDU2OTZiNDRhMmViMGNlOGIxM2NlMzJlZjdhL3RhYmxlcmFuZ2U6MmM1ZGYwNTY5NmI0NGEyZWIwY2U4YjEzY2UzMmVmN2FfNS0xNS0xLTEtODE_05acc9dd-00aa-4b57-935b-5b7a5229dcdc">P0Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="id3db81cbe7d44bf4b59daffdc638772b_D20220701-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RhYmxlOjJjNWRmMDU2OTZiNDRhMmViMGNlOGIxM2NlMzJlZjdhL3RhYmxlcmFuZ2U6MmM1ZGYwNTY5NmI0NGEyZWIwY2U4YjEzY2UzMmVmN2FfNi0xLTEtMS04MQ_80ecb2dc-d8c0-4e6c-a1aa-0a72e0810e6f"
      unitRef="number">0.35</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i18064623ae8c40b0b87d8d75806827d8_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RhYmxlOjJjNWRmMDU2OTZiNDRhMmViMGNlOGIxM2NlMzJlZjdhL3RhYmxlcmFuZ2U6MmM1ZGYwNTY5NmI0NGEyZWIwY2U4YjEzY2UzMmVmN2FfNi0zLTEtMS04MQ_a4bb9ac7-09c3-4a6a-be6d-aed8ff9b4bba"
      unitRef="number">0.38</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i88f8a540b3d94b20983f8902eae30ae2_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RhYmxlOjJjNWRmMDU2OTZiNDRhMmViMGNlOGIxM2NlMzJlZjdhL3RhYmxlcmFuZ2U6MmM1ZGYwNTY5NmI0NGEyZWIwY2U4YjEzY2UzMmVmN2FfNi01LTEtMS04MQ_85176926-7dc9-4d16-8569-ce22f308cbdf"
      unitRef="number">0.36</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="id7acb0824a524ce2b1a6d6eeb3f5b6b8_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RhYmxlOjJjNWRmMDU2OTZiNDRhMmViMGNlOGIxM2NlMzJlZjdhL3RhYmxlcmFuZ2U6MmM1ZGYwNTY5NmI0NGEyZWIwY2U4YjEzY2UzMmVmN2FfNi03LTEtMS04MQ_dc43027c-8d4a-4bda-9246-9f9b7f6ec34b"
      unitRef="number">0.39</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="ia05518f1a01d4291b4add6208b75e939_D20220701-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RhYmxlOjJjNWRmMDU2OTZiNDRhMmViMGNlOGIxM2NlMzJlZjdhL3RhYmxlcmFuZ2U6MmM1ZGYwNTY5NmI0NGEyZWIwY2U4YjEzY2UzMmVmN2FfNi05LTEtMS04MQ_4160abcb-8ac4-4343-9ebc-8b09e837b918"
      unitRef="number">0.31</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="ie12951e0177049569a4eaac01ed75693_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RhYmxlOjJjNWRmMDU2OTZiNDRhMmViMGNlOGIxM2NlMzJlZjdhL3RhYmxlcmFuZ2U6MmM1ZGYwNTY5NmI0NGEyZWIwY2U4YjEzY2UzMmVmN2FfNi0xMS0xLTEtODE_7845db89-c37d-48b6-8167-979b3d96d380"
      unitRef="number">0.25</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="icaf56e010147488ebeb835f2e5b31900_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RhYmxlOjJjNWRmMDU2OTZiNDRhMmViMGNlOGIxM2NlMzJlZjdhL3RhYmxlcmFuZ2U6MmM1ZGYwNTY5NmI0NGEyZWIwY2U4YjEzY2UzMmVmN2FfNi0xMy0xLTEtODE_d4213e69-0ee2-4e16-9ffd-73b949ef7a5c"
      unitRef="number">0.27</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i6c730d6b5a3349088cf01b0df9f09e86_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RhYmxlOjJjNWRmMDU2OTZiNDRhMmViMGNlOGIxM2NlMzJlZjdhL3RhYmxlcmFuZ2U6MmM1ZGYwNTY5NmI0NGEyZWIwY2U4YjEzY2UzMmVmN2FfNi0xNS0xLTEtODE_2397b2b1-1b96-4acc-a9bb-043e3f4d6c50"
      unitRef="number">0.31</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="id3db81cbe7d44bf4b59daffdc638772b_D20220701-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RhYmxlOjJjNWRmMDU2OTZiNDRhMmViMGNlOGIxM2NlMzJlZjdhL3RhYmxlcmFuZ2U6MmM1ZGYwNTY5NmI0NGEyZWIwY2U4YjEzY2UzMmVmN2FfNy0xLTEtMS04MQ_9e5d8866-c443-4cb8-af97-c602e51e21dc"
      unitRef="usdPerShare">27.57</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i18064623ae8c40b0b87d8d75806827d8_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RhYmxlOjJjNWRmMDU2OTZiNDRhMmViMGNlOGIxM2NlMzJlZjdhL3RhYmxlcmFuZ2U6MmM1ZGYwNTY5NmI0NGEyZWIwY2U4YjEzY2UzMmVmN2FfNy0zLTEtMS04MQ_b778dfc3-dad3-44e1-94ef-6d57195b012c"
      unitRef="usdPerShare">28.84</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i88f8a540b3d94b20983f8902eae30ae2_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RhYmxlOjJjNWRmMDU2OTZiNDRhMmViMGNlOGIxM2NlMzJlZjdhL3RhYmxlcmFuZ2U6MmM1ZGYwNTY5NmI0NGEyZWIwY2U4YjEzY2UzMmVmN2FfNy01LTEtMS04MQ_29de48ec-44c0-42ef-883b-e0f9a01d04a0"
      unitRef="usdPerShare">25.96</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="id7acb0824a524ce2b1a6d6eeb3f5b6b8_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RhYmxlOjJjNWRmMDU2OTZiNDRhMmViMGNlOGIxM2NlMzJlZjdhL3RhYmxlcmFuZ2U6MmM1ZGYwNTY5NmI0NGEyZWIwY2U4YjEzY2UzMmVmN2FfNy03LTEtMS04MQ_576342e8-d943-4e06-850f-b75d4ad8e958"
      unitRef="usdPerShare">29.32</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ia05518f1a01d4291b4add6208b75e939_D20220701-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RhYmxlOjJjNWRmMDU2OTZiNDRhMmViMGNlOGIxM2NlMzJlZjdhL3RhYmxlcmFuZ2U6MmM1ZGYwNTY5NmI0NGEyZWIwY2U4YjEzY2UzMmVmN2FfNy05LTEtMS04MQ_935d9cea-15e0-4c3e-b61b-3d555b425ed0"
      unitRef="usdPerShare">16.46</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ie12951e0177049569a4eaac01ed75693_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RhYmxlOjJjNWRmMDU2OTZiNDRhMmViMGNlOGIxM2NlMzJlZjdhL3RhYmxlcmFuZ2U6MmM1ZGYwNTY5NmI0NGEyZWIwY2U4YjEzY2UzMmVmN2FfNy0xMS0xLTEtODE_f784f131-38ba-4c3f-a058-81ea2aa758e2"
      unitRef="usdPerShare">18.20</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="icaf56e010147488ebeb835f2e5b31900_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RhYmxlOjJjNWRmMDU2OTZiNDRhMmViMGNlOGIxM2NlMzJlZjdhL3RhYmxlcmFuZ2U6MmM1ZGYwNTY5NmI0NGEyZWIwY2U4YjEzY2UzMmVmN2FfNy0xMy0xLTEtODE_ad921593-cac4-4b02-a9d0-41b412c595a5"
      unitRef="usdPerShare">15.38</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i6c730d6b5a3349088cf01b0df9f09e86_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RhYmxlOjJjNWRmMDU2OTZiNDRhMmViMGNlOGIxM2NlMzJlZjdhL3RhYmxlcmFuZ2U6MmM1ZGYwNTY5NmI0NGEyZWIwY2U4YjEzY2UzMmVmN2FfNy0xNS0xLTEtODE_a7227e70-ed3f-45c2-b0b8-cfa4d6a4920b"
      unitRef="usdPerShare">18.82</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RleHRyZWdpb246ZmFlNDc5YmVlYzk3NGU3Njk4MDJlOTE5MjQ4MDEwYzRfMTU1Ng_32b7e63e-c92c-4c7c-9b6c-3b9f7134b0e2"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RleHRyZWdpb246ZmFlNDc5YmVlYzk3NGU3Njk4MDJlOTE5MjQ4MDEwYzRfNDkyNw_877736fa-406d-4e32-a891-ae27871cf2ed">&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Option activity under our 2010 Stock Incentive Plan (the &#x201c;2010 Stock Plan&#x201d;) was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.083%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares Subject to&lt;br/&gt;Outstanding Options&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted Average&lt;br/&gt;Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,763,460&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88.39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,755,963&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(477,371)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66.69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options cancelled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(989,465)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,052,587&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87.41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ica61680f037f4dedb0e7d3fa6de64097_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RhYmxlOjQ5NWIwY2MyNzUyYjRkNWU4ZWM5NGY0MWRmYTdkYzI2L3RhYmxlcmFuZ2U6NDk1YjBjYzI3NTJiNGQ1ZThlYzk0ZjQxZGZhN2RjMjZfMi0xLTEtMS04MQ_d4622f95-1301-41f6-b2d6-38d815dd0d8c"
      unitRef="shares">12763460</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="ica61680f037f4dedb0e7d3fa6de64097_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RhYmxlOjQ5NWIwY2MyNzUyYjRkNWU4ZWM5NGY0MWRmYTdkYzI2L3RhYmxlcmFuZ2U6NDk1YjBjYzI3NTJiNGQ1ZThlYzk0ZjQxZGZhN2RjMjZfMi0zLTEtMS04MQ_5fc55be3-d2bf-44a4-a310-3d8c055f1415"
      unitRef="usdPerShare">88.39</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="i88f8a540b3d94b20983f8902eae30ae2_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RhYmxlOjQ5NWIwY2MyNzUyYjRkNWU4ZWM5NGY0MWRmYTdkYzI2L3RhYmxlcmFuZ2U6NDk1YjBjYzI3NTJiNGQ1ZThlYzk0ZjQxZGZhN2RjMjZfMy0xLTEtMS04MQ_31d2022b-d9de-462b-bea4-e78baf09bdc2"
      unitRef="shares">1755963</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i88f8a540b3d94b20983f8902eae30ae2_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RhYmxlOjQ5NWIwY2MyNzUyYjRkNWU4ZWM5NGY0MWRmYTdkYzI2L3RhYmxlcmFuZ2U6NDk1YjBjYzI3NTJiNGQ1ZThlYzk0ZjQxZGZhN2RjMjZfMy0zLTEtMS04MQ_e2a73acf-e71e-43bb-bbff-9001916e9621"
      unitRef="usdPerShare">75.32</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i88f8a540b3d94b20983f8902eae30ae2_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RhYmxlOjQ5NWIwY2MyNzUyYjRkNWU4ZWM5NGY0MWRmYTdkYzI2L3RhYmxlcmFuZ2U6NDk1YjBjYzI3NTJiNGQ1ZThlYzk0ZjQxZGZhN2RjMjZfNC0xLTEtMS04MQ_c3d00e27-3fe5-470f-991d-caaf28ad3032"
      unitRef="shares">477371</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i88f8a540b3d94b20983f8902eae30ae2_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RhYmxlOjQ5NWIwY2MyNzUyYjRkNWU4ZWM5NGY0MWRmYTdkYzI2L3RhYmxlcmFuZ2U6NDk1YjBjYzI3NTJiNGQ1ZThlYzk0ZjQxZGZhN2RjMjZfNC0zLTEtMS04MQ_6e98de4a-d865-4659-b72c-ab0c02896af9"
      unitRef="usdPerShare">66.69</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="i88f8a540b3d94b20983f8902eae30ae2_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RhYmxlOjQ5NWIwY2MyNzUyYjRkNWU4ZWM5NGY0MWRmYTdkYzI2L3RhYmxlcmFuZ2U6NDk1YjBjYzI3NTJiNGQ1ZThlYzk0ZjQxZGZhN2RjMjZfNS0xLTEtMS04MQ_080417ef-f910-4bcf-81b3-89cffff963a4"
      unitRef="shares">989465</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="i88f8a540b3d94b20983f8902eae30ae2_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RhYmxlOjQ5NWIwY2MyNzUyYjRkNWU4ZWM5NGY0MWRmYTdkYzI2L3RhYmxlcmFuZ2U6NDk1YjBjYzI3NTJiNGQ1ZThlYzk0ZjQxZGZhN2RjMjZfNS0zLTEtMS04MQ_cb18677c-c7bd-457f-bf1d-42792a8c815f"
      unitRef="usdPerShare">88.60</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i63709951184741bbb03325606fc77885_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RhYmxlOjQ5NWIwY2MyNzUyYjRkNWU4ZWM5NGY0MWRmYTdkYzI2L3RhYmxlcmFuZ2U6NDk1YjBjYzI3NTJiNGQ1ZThlYzk0ZjQxZGZhN2RjMjZfNi0xLTEtMS04MQ_d35c603c-4bee-42a8-a47f-bda95e551fc2"
      unitRef="shares">13052587</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i63709951184741bbb03325606fc77885_I20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RhYmxlOjQ5NWIwY2MyNzUyYjRkNWU4ZWM5NGY0MWRmYTdkYzI2L3RhYmxlcmFuZ2U6NDk1YjBjYzI3NTJiNGQ1ZThlYzk0ZjQxZGZhN2RjMjZfNi0zLTEtMS04MQ_0d88809e-01e2-4527-8bab-7d3f3af05092"
      unitRef="usdPerShare">87.41</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="i88f8a540b3d94b20983f8902eae30ae2_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RleHRyZWdpb246ZmFlNDc5YmVlYzk3NGU3Njk4MDJlOTE5MjQ4MDEwYzRfMTk5Nw_9be6d543-df6d-49c2-bf0f-0b6cb5e1b6dc">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i88f8a540b3d94b20983f8902eae30ae2_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RleHRyZWdpb246ZmFlNDc5YmVlYzk3NGU3Njk4MDJlOTE5MjQ4MDEwYzRfMjAyNA_5acc6b02-5917-4088-933a-71fb9d991358">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i88f8a540b3d94b20983f8902eae30ae2_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RleHRyZWdpb246ZmFlNDc5YmVlYzk3NGU3Njk4MDJlOTE5MjQ4MDEwYzRfMjAzMw_c41627f0-fbf6-49a7-83e9-8ca8350517e2"
      unitRef="number">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i48621c6db4cc4ac9ad02fc57e325cfda_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RleHRyZWdpb246ZmFlNDc5YmVlYzk3NGU3Njk4MDJlOTE5MjQ4MDEwYzRfMjA1MA_b086a7cb-ca01-45a6-adcb-597c0b791951">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i04c8ff8acdef44f4b58b1deff299fcc5_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RleHRyZWdpb246ZmFlNDc5YmVlYzk3NGU3Njk4MDJlOTE5MjQ4MDEwYzRfMjA4Mg_318609a9-3b7a-4af8-9a09-8bbaf562b30e">P36M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <incy:ScheduleOfShareBasedCompensationOtherThanStockOptionsActivityTableTextBlock
      contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RleHRyZWdpb246ZmFlNDc5YmVlYzk3NGU3Njk4MDJlOTE5MjQ4MDEwYzRfMzg0ODI5MDcwMjIzOA_7af86c5e-890c-4552-abca-749cd47bb432">&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted stock unit (&#x201c;RSU&#x201d;) and performance share (&#x201c;PSU&#x201d;) award activity under the 2010 Stock Plan was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.083%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares Subject to&lt;br/&gt;Outstanding Awards&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Grant Date Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,966,888&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84.91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs granted &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,473,892&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77.14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;PSUs granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154,685&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs released&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(845,095)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87.06&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;PSUs released&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(184,401)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs cancelled &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(337,265)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83.94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;PSUs cancelled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,720)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65.76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,226,984&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</incy:ScheduleOfShareBasedCompensationOtherThanStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="iab26fe441f0d4ab984456365a7f7cff0_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RhYmxlOmRiMmY0YzhiNGUzOTRlOTg4NDMyMjRiZThmNGJhODI1L3RhYmxlcmFuZ2U6ZGIyZjRjOGI0ZTM5NGU5ODg0MzIyNGJlOGY0YmE4MjVfMi0xLTEtMS04MQ_24f2ab48-fef7-4665-af8e-cb16e00a048d"
      unitRef="shares">3966888</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue
      contextRef="iab26fe441f0d4ab984456365a7f7cff0_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RhYmxlOmRiMmY0YzhiNGUzOTRlOTg4NDMyMjRiZThmNGJhODI1L3RhYmxlcmFuZ2U6ZGIyZjRjOGI0ZTM5NGU5ODg0MzIyNGJlOGY0YmE4MjVfMi0zLTEtMS04MQ_be369b35-fa0f-4dc9-a3e4-dd4d93e3b570"
      unitRef="usdPerShare">84.91</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i6a259c2680304a099d7306f0be37ed62_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RhYmxlOmRiMmY0YzhiNGUzOTRlOTg4NDMyMjRiZThmNGJhODI1L3RhYmxlcmFuZ2U6ZGIyZjRjOGI0ZTM5NGU5ODg0MzIyNGJlOGY0YmE4MjVfMy0xLTEtMS04MQ_70188805-a0a1-4fe9-b6d9-10aca48d1f49"
      unitRef="shares">2473892</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue
      contextRef="i6a259c2680304a099d7306f0be37ed62_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RhYmxlOmRiMmY0YzhiNGUzOTRlOTg4NDMyMjRiZThmNGJhODI1L3RhYmxlcmFuZ2U6ZGIyZjRjOGI0ZTM5NGU5ODg0MzIyNGJlOGY0YmE4MjVfMy0zLTEtMS04MQ_af9a280d-67cc-4c5c-83b2-2bd91e47815b"
      unitRef="usdPerShare">77.14</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ie5ac7148ca1b4e0cac828a4f764cc338_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RhYmxlOmRiMmY0YzhiNGUzOTRlOTg4NDMyMjRiZThmNGJhODI1L3RhYmxlcmFuZ2U6ZGIyZjRjOGI0ZTM5NGU5ODg0MzIyNGJlOGY0YmE4MjVfNC0xLTEtMS01MTY1_bfafa54d-18f1-495f-ab32-fe04f75c96da"
      unitRef="shares">154685</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue
      contextRef="ie5ac7148ca1b4e0cac828a4f764cc338_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RhYmxlOmRiMmY0YzhiNGUzOTRlOTg4NDMyMjRiZThmNGJhODI1L3RhYmxlcmFuZ2U6ZGIyZjRjOGI0ZTM5NGU5ODg0MzIyNGJlOGY0YmE4MjVfNC0zLTEtMS01MTY1_ac85576b-9af7-4fec-8a79-7648c69c46d9"
      unitRef="usdPerShare">77.67</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue>
    <incy:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod
      contextRef="i6a259c2680304a099d7306f0be37ed62_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RhYmxlOmRiMmY0YzhiNGUzOTRlOTg4NDMyMjRiZThmNGJhODI1L3RhYmxlcmFuZ2U6ZGIyZjRjOGI0ZTM5NGU5ODg0MzIyNGJlOGY0YmE4MjVfNC0xLTEtMS04MQ_4959bd94-823b-47fe-ae4d-944c965538bd"
      unitRef="shares">845095</incy:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod>
    <incy:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedIntrinsicValue
      contextRef="i6a259c2680304a099d7306f0be37ed62_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RhYmxlOmRiMmY0YzhiNGUzOTRlOTg4NDMyMjRiZThmNGJhODI1L3RhYmxlcmFuZ2U6ZGIyZjRjOGI0ZTM5NGU5ODg0MzIyNGJlOGY0YmE4MjVfNC0zLTEtMS04MQ_00984ce6-9eed-437c-b31e-f0e34458695b"
      unitRef="usdPerShare">87.06</incy:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedIntrinsicValue>
    <incy:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod
      contextRef="ie5ac7148ca1b4e0cac828a4f764cc338_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RhYmxlOmRiMmY0YzhiNGUzOTRlOTg4NDMyMjRiZThmNGJhODI1L3RhYmxlcmFuZ2U6ZGIyZjRjOGI0ZTM5NGU5ODg0MzIyNGJlOGY0YmE4MjVfNS0xLTEtMS04MQ_a5a38164-ab12-4852-be57-448f728ce9f8"
      unitRef="shares">184401</incy:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod>
    <incy:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedIntrinsicValue
      contextRef="ie5ac7148ca1b4e0cac828a4f764cc338_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RhYmxlOmRiMmY0YzhiNGUzOTRlOTg4NDMyMjRiZThmNGJhODI1L3RhYmxlcmFuZ2U6ZGIyZjRjOGI0ZTM5NGU5ODg0MzIyNGJlOGY0YmE4MjVfNS0zLTEtMS04MQ_85777c7b-4b54-41a0-a712-2e863eed8ed7"
      unitRef="usdPerShare">69.25</incy:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i6a259c2680304a099d7306f0be37ed62_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RhYmxlOmRiMmY0YzhiNGUzOTRlOTg4NDMyMjRiZThmNGJhODI1L3RhYmxlcmFuZ2U6ZGIyZjRjOGI0ZTM5NGU5ODg0MzIyNGJlOGY0YmE4MjVfNi0xLTEtMS04MQ_905059fa-88cd-4b97-be82-40298e5edf65"
      unitRef="shares">337265</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue
      contextRef="i6a259c2680304a099d7306f0be37ed62_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RhYmxlOmRiMmY0YzhiNGUzOTRlOTg4NDMyMjRiZThmNGJhODI1L3RhYmxlcmFuZ2U6ZGIyZjRjOGI0ZTM5NGU5ODg0MzIyNGJlOGY0YmE4MjVfNi0zLTEtMS04MQ_2cce5492-49ae-485e-a809-7ceaa3ec9dee"
      unitRef="usdPerShare">83.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="ie5ac7148ca1b4e0cac828a4f764cc338_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RhYmxlOmRiMmY0YzhiNGUzOTRlOTg4NDMyMjRiZThmNGJhODI1L3RhYmxlcmFuZ2U6ZGIyZjRjOGI0ZTM5NGU5ODg0MzIyNGJlOGY0YmE4MjVfNy0xLTEtMS04MQ_39f700ef-fd33-4fdc-9c4d-4e2cc786412d"
      unitRef="shares">1720</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue
      contextRef="ie5ac7148ca1b4e0cac828a4f764cc338_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RhYmxlOmRiMmY0YzhiNGUzOTRlOTg4NDMyMjRiZThmNGJhODI1L3RhYmxlcmFuZ2U6ZGIyZjRjOGI0ZTM5NGU5ODg0MzIyNGJlOGY0YmE4MjVfNy0zLTEtMS04MQ_bdf7cbc7-de22-4f43-ade8-e8d7ca771e32"
      unitRef="usdPerShare">65.76</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="i3b4376f8fc614de98c9cf647198c504e_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RhYmxlOmRiMmY0YzhiNGUzOTRlOTg4NDMyMjRiZThmNGJhODI1L3RhYmxlcmFuZ2U6ZGIyZjRjOGI0ZTM5NGU5ODg0MzIyNGJlOGY0YmE4MjVfOC0xLTEtMS04MQ_f76df767-e157-4748-bb85-e929790822a0"
      unitRef="shares">5226984</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue
      contextRef="i3b4376f8fc614de98c9cf647198c504e_I20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RhYmxlOmRiMmY0YzhiNGUzOTRlOTg4NDMyMjRiZThmNGJhODI1L3RhYmxlcmFuZ2U6ZGIyZjRjOGI0ZTM5NGU5ODg0MzIyNGJlOGY0YmE4MjVfOC0zLTEtMS04MQ_aab0f7bf-0473-4ac8-b938-a83e08425aeb"
      unitRef="usdPerShare">81.29</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue>
    <incy:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesPerRestrictedStockUnits
      contextRef="i6a259c2680304a099d7306f0be37ed62_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RleHRyZWdpb246ZmFlNDc5YmVlYzk3NGU3Njk4MDJlOTE5MjQ4MDEwYzRfMjM1Nw_97d1ac4a-c111-4e56-8c26-edd057ea89cf"
      unitRef="shares">1</incy:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesPerRestrictedStockUnits>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i6a259c2680304a099d7306f0be37ed62_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RleHRyZWdpb246ZmFlNDc5YmVlYzk3NGU3Njk4MDJlOTE5MjQ4MDEwYzRfMjQ1OQ_9b5488de-10e0-4c1d-bec6-5f5f90777f6c"
      unitRef="number">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i6a259c2680304a099d7306f0be37ed62_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RleHRyZWdpb246ZmFlNDc5YmVlYzk3NGU3Njk4MDJlOTE5MjQ4MDEwYzRfMjQ3Ng_5d9645d6-f14a-4398-961b-85f5e7e4cbe9">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i6a259c2680304a099d7306f0be37ed62_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RleHRyZWdpb246ZmFlNDc5YmVlYzk3NGU3Njk4MDJlOTE5MjQ4MDEwYzRfMjYxOA_47ece34c-bb88-4791-af82-f9267a633ab7">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="id70f31d4f5454cf2a35efe177f68fc3a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RleHRyZWdpb246ZmFlNDc5YmVlYzk3NGU3Njk4MDJlOTE5MjQ4MDEwYzRfMjczMA_e551f03b-b006-4e6d-af3c-db0b56a0ae76">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ibf315c942d3a4e75bf4c724b522cbd2a_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RleHRyZWdpb246ZmFlNDc5YmVlYzk3NGU3Njk4MDJlOTE5MjQ4MDEwYzRfMzUzMg_d07ba07a-db8c-4e51-89fa-8fa1424409e7"
      unitRef="usd">3200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ie5ac7148ca1b4e0cac828a4f764cc338_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RleHRyZWdpb246ZmFlNDc5YmVlYzk3NGU3Njk4MDJlOTE5MjQ4MDEwYzRfMzUzOQ_2b6d3bc9-404f-41a2-be82-1495af266fb9"
      unitRef="usd">5100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i815d3de20f4a4db7baa12ac1511dc801_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RleHRyZWdpb246ZmFlNDc5YmVlYzk3NGU3Njk4MDJlOTE5MjQ4MDEwYzRfMzY5MQ_d906033e-61b0-4541-a4ea-8a4d57112813"
      unitRef="usd">1700000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ib0879ceff7714c68a441c12f87a02bb6_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RleHRyZWdpb246ZmFlNDc5YmVlYzk3NGU3Njk4MDJlOTE5MjQ4MDEwYzRfMzY5OA_97db18fe-5b19-4b94-ab00-a3bd927d3aa9"
      unitRef="usd">5000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock
      contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RleHRyZWdpb246ZmFlNDc5YmVlYzk3NGU3Njk4MDJlOTE5MjQ4MDEwYzRfNDkyOQ_3cae79b0-35fa-4bcd-916a-3ffd05ed6df3">&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our shares available for grant under the 2010 Stock Plan. Each RSU and PSU grant reduces the available share pool by 2 shares.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.718%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.082%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Shares Available&lt;br/&gt;for Grant&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1.97pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;10,113,298&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Options, RSUs and PSUs granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(7,013,475)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Options, RSUs and PSUs cancelled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1.97pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,680,482&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Balance at September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1.97pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4,780,305&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="iab26fe441f0d4ab984456365a7f7cff0_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RhYmxlOjYwZjdiNTJlMzBiMjQ2OWQ5NjA0NmJhZmRkYTRjZjhmL3RhYmxlcmFuZ2U6NjBmN2I1MmUzMGIyNDY5ZDk2MDQ2YmFmZGRhNGNmOGZfMS0xLTEtMS04MQ_13a4c123-7ad1-401e-9936-7d9754ee639d"
      unitRef="shares">10113298</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <incy:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGranted
      contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RhYmxlOjYwZjdiNTJlMzBiMjQ2OWQ5NjA0NmJhZmRkYTRjZjhmL3RhYmxlcmFuZ2U6NjBmN2I1MmUzMGIyNDY5ZDk2MDQ2YmFmZGRhNGNmOGZfMi0xLTEtMS04MQ_04b5f21d-8c7d-4aaa-9d8d-9f8c2f1b6e25"
      unitRef="shares">7013475</incy:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGranted>
    <incy:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCanceled
      contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RhYmxlOjYwZjdiNTJlMzBiMjQ2OWQ5NjA0NmJhZmRkYTRjZjhmL3RhYmxlcmFuZ2U6NjBmN2I1MmUzMGIyNDY5ZDk2MDQ2YmFmZGRhNGNmOGZfMy0xLTEtMS04MQ_4879474b-60f0-43a6-ba76-7a9eb6821836"
      unitRef="shares">1680482</incy:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCanceled>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i3b4376f8fc614de98c9cf647198c504e_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RhYmxlOjYwZjdiNTJlMzBiMjQ2OWQ5NjA0NmJhZmRkYTRjZjhmL3RhYmxlcmFuZ2U6NjBmN2I1MmUzMGIyNDY5ZDk2MDQ2YmFmZGRhNGNmOGZfNC0xLTEtMS04MQ_d4160612-3c50-44e7-a120-8d97855e52da"
      unitRef="shares">4780305</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <incy:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedAnnualizedForfeitureRate
      contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RleHRyZWdpb246ZmFlNDc5YmVlYzk3NGU3Njk4MDJlOTE5MjQ4MDEwYzRfNDA2Mg_3c4f98c9-2215-4640-a5f0-75317c218d49"
      unitRef="number">0.05</incy:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedAnnualizedForfeitureRate>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i63709951184741bbb03325606fc77885_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RleHRyZWdpb246ZmFlNDc5YmVlYzk3NGU3Njk4MDJlOTE5MjQ4MDEwYzRfNDQyOQ_1128a7c2-f6c0-4c7e-a7fa-0d05bf55b19b"
      unitRef="usd">51200000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i88f8a540b3d94b20983f8902eae30ae2_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RleHRyZWdpb246ZmFlNDc5YmVlYzk3NGU3Njk4MDJlOTE5MjQ4MDEwYzRfNDUxOA_bfcfd8df-9948-4647-83e4-101da884e53f">P1Y1M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i6afeedfad1cd4882a7d671b04f209a35_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RleHRyZWdpb246ZmFlNDc5YmVlYzk3NGU3Njk4MDJlOTE5MjQ4MDEwYzRfNDYwMg_f81d4a66-11d2-47a3-8d86-6cef342b131f"
      unitRef="usd">235500000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i6a259c2680304a099d7306f0be37ed62_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RleHRyZWdpb246ZmFlNDc5YmVlYzk3NGU3Njk4MDJlOTE5MjQ4MDEwYzRfNDY5MQ_ed9e8914-c170-42de-af87-427f3e235aa2">P2Y</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="if444048235584a2399361851f892f5df_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RleHRyZWdpb246ZmFlNDc5YmVlYzk3NGU3Njk4MDJlOTE5MjQ4MDEwYzRfNDc2OQ_19abb64c-a6d8-4f27-b39c-74ac8278c0d3"
      unitRef="usd">19600000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="ie5ac7148ca1b4e0cac828a4f764cc338_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82NC9mcmFnOmZhZTQ3OWJlZWM5NzRlNzY5ODAyZTkxOTI0ODAxMGM0L3RleHRyZWdpb246ZmFlNDc5YmVlYzk3NGU3Njk4MDJlOTE5MjQ4MDEwYzRfNDg0NA_76609b24-3170-4e51-aab3-1529dd2c8804">P2Y2M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82Ny9mcmFnOjk4ZDFkMDFmNDQ0YjRmMWRhYTAwMmY1YjM2YjRkNTlkL3RleHRyZWdpb246OThkMWQwMWY0NDRiNGYxZGFhMDAyZjViMzZiNGQ1OWRfMTg5Ng_ae4e25f7-775b-4761-9ba7-e8684ea58a2e">&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three and nine months ended September&#160;30, 2022, we recorded income tax expense of approximately $35.8 million and $136.3 million, respectively. For the three and nine months ended September&#160;30, 2021, we recorded income tax expense of approximately $27.7 million and $65.7 million, respectively. The tax expense for the three and nine months ended September&#160;30, 2022 increased as compared to that for the prior year periods due to the release of our valuation allowance against a majority of our U.S. research and development tax credit carryforwards and other deferred tax assets at December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the fourth quarter of 2021, we assessed the valuation allowance and considered positive evidence, including significant cumulative consolidated and U.S. income over the three years ended December&#160;31, 2021, consistent growth in product revenues, and expectations regarding future profitability. We also assessed negative evidence, including the potential impact of competition, clinical failures and patent expirations on our projections. After assessing both the positive evidence and negative evidence, we determined it was more likely than not that the majority of our U.S. deferred tax assets would be realized in the future and released the associated valuation allowance as of December&#160;31, 2021. This resulted in a benefit of $569.0 million. As of December&#160;31, 2021, we maintained a valuation allowance of $408.2 million against a portion of our remaining U.S. deferred tax assets as well as select state and foreign deferred tax assets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The balance of our unrecognized tax benefits (including penalties and interest) increased by approximately $11.2 million during the nine months ended September&#160;30, 2022, resulting in movements to other liabilities and deferred income tax asset on the condensed consolidated balance sheet. The overall increase is primarily driven by unrecognized tax benefits related to current year operations and research and development tax credits. We accrue interest and penalties related to unrecognized tax benefits as a component of its provision for income taxes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2022, the Inflation Reduction Act of 2022 (&#x201c;IRA&#x201d;) was enacted into law. The IRA includes a 15% corporate alternative minimum tax and a 1% excise tax on share repurchases. We do not expect the IRA to have a material impact on our consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="id673d80f31e74643a241d2f62db94ca9_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82Ny9mcmFnOjk4ZDFkMDFmNDQ0YjRmMWRhYTAwMmY1YjM2YjRkNTlkL3RleHRyZWdpb246OThkMWQwMWY0NDRiNGYxZGFhMDAyZjViMzZiNGQ1OWRfMTA0_1bf08831-f9e4-4b7d-a68d-0496219d7d9e"
      unitRef="usd">35800000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82Ny9mcmFnOjk4ZDFkMDFmNDQ0YjRmMWRhYTAwMmY1YjM2YjRkNTlkL3RleHRyZWdpb246OThkMWQwMWY0NDRiNGYxZGFhMDAyZjViMzZiNGQ1OWRfMTEx_804a46e3-fe1d-49e5-822f-cf6fc6b43dab"
      unitRef="usd">136300000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i313b15d35b7045babd1ba61f84a077dd_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82Ny9mcmFnOjk4ZDFkMDFmNDQ0YjRmMWRhYTAwMmY1YjM2YjRkNTlkL3RleHRyZWdpb246OThkMWQwMWY0NDRiNGYxZGFhMDAyZjViMzZiNGQ1OWRfMjA1_475dc974-66a8-4c78-bd83-8e4294fd0aa1"
      unitRef="usd">27700000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i0faaba5fcd6b485781cadacae8b2fd8e_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82Ny9mcmFnOjk4ZDFkMDFmNDQ0YjRmMWRhYTAwMmY1YjM2YjRkNTlkL3RleHRyZWdpb246OThkMWQwMWY0NDRiNGYxZGFhMDAyZjViMzZiNGQ1OWRfMjEy_5b1a998d-5ca6-4838-926f-e6fe7b74180f"
      unitRef="usd">65700000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability
      contextRef="i0efcc1efa4d94a789080eb3693e147ff_D20211001-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82Ny9mcmFnOjk4ZDFkMDFmNDQ0YjRmMWRhYTAwMmY1YjM2YjRkNTlkL3RleHRyZWdpb246OThkMWQwMWY0NDRiNGYxZGFhMDAyZjViMzZiNGQ1OWRfMTE5Nw_8cfcfba2-178c-4d30-a397-d1a184768d6c"
      unitRef="usd">-569000000</us-gaap:IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="iab26fe441f0d4ab984456365a7f7cff0_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82Ny9mcmFnOjk4ZDFkMDFmNDQ0YjRmMWRhYTAwMmY1YjM2YjRkNTlkL3RleHRyZWdpb246OThkMWQwMWY0NDRiNGYxZGFhMDAyZjViMzZiNGQ1OWRfMTI1MA_e07066ab-a2ad-43b3-9a6d-5a513c0d010a"
      unitRef="usd">408200000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:UnrecognizedTaxBenefitsPeriodIncreaseDecrease
      contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV82Ny9mcmFnOjk4ZDFkMDFmNDQ0YjRmMWRhYTAwMmY1YjM2YjRkNTlkL3RleHRyZWdpb246OThkMWQwMWY0NDRiNGYxZGFhMDAyZjViMzZiNGQ1OWRfMTQ3OA_b8133689-fd8a-402c-bb64-9c11610bed09"
      unitRef="usd">11200000</us-gaap:UnrecognizedTaxBenefitsPeriodIncreaseDecrease>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV83MC9mcmFnOjU3ZWMzMTQ0ODQwYjQwZjI5ZWIzODQzYTg4ZDgxYjFkL3RleHRyZWdpb246NTdlYzMxNDQ4NDBiNDBmMjllYjM4NDNhODhkODFiMWRfMjMy_6f595d0e-e8ae-4980-82dd-7499e97822cb">&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net income per share was calculated as follows for the periods indicated below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.354%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.085%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112,775&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;181,739&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;312,199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;384,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted average common shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;222,415&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;220,845&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;221,801&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;220,243&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic net income per share&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted net income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112,775&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;181,739&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;312,199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;384,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average common shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;222,415&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;220,845&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;221,801&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;220,243&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dilutive stock options and awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,760&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,403&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,825&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,870&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted average shares used to compute diluted net income per share &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;224,175&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;222,248&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;223,626&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;222,113&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Diluted net income per share&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The potential common shares that were excluded from the diluted net income per share computation are as follows:&lt;/span&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.354%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.085%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding stock options and awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,150,022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,841,440&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,979,096&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,917,824&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV83MC9mcmFnOjU3ZWMzMTQ0ODQwYjQwZjI5ZWIzODQzYTg4ZDgxYjFkL3RleHRyZWdpb246NTdlYzMxNDQ4NDBiNDBmMjllYjM4NDNhODhkODFiMWRfMjMw_f351d487-73f8-43d6-a091-4b36c9a5f268">&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net income per share was calculated as follows for the periods indicated below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.354%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.085%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112,775&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;181,739&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;312,199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;384,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted average common shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;222,415&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;220,845&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;221,801&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;220,243&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic net income per share&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted net income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112,775&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;181,739&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;312,199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;384,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average common shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;222,415&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;220,845&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;221,801&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;220,243&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dilutive stock options and awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,760&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,403&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,825&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,870&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted average shares used to compute diluted net income per share &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;224,175&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;222,248&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;223,626&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;222,113&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Diluted net income per share&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="id673d80f31e74643a241d2f62db94ca9_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV83MC9mcmFnOjU3ZWMzMTQ0ODQwYjQwZjI5ZWIzODQzYTg4ZDgxYjFkL3RhYmxlOmMwN2IyNDkzMWM1ZTRjMmQ5ODM3MjNmMGYwYzRiNzAxL3RhYmxlcmFuZ2U6YzA3YjI0OTMxYzVlNGMyZDk4MzcyM2YwZjBjNGI3MDFfMi0xLTEtMS04MQ_d875d86c-0f08-4319-9f87-d30d8491c6ff"
      unitRef="usd">112775000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i313b15d35b7045babd1ba61f84a077dd_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV83MC9mcmFnOjU3ZWMzMTQ0ODQwYjQwZjI5ZWIzODQzYTg4ZDgxYjFkL3RhYmxlOmMwN2IyNDkzMWM1ZTRjMmQ5ODM3MjNmMGYwYzRiNzAxL3RhYmxlcmFuZ2U6YzA3YjI0OTMxYzVlNGMyZDk4MzcyM2YwZjBjNGI3MDFfMi0zLTEtMS04MQ_155eec71-464c-4522-9363-ec73b2048488"
      unitRef="usd">181739000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV83MC9mcmFnOjU3ZWMzMTQ0ODQwYjQwZjI5ZWIzODQzYTg4ZDgxYjFkL3RhYmxlOmMwN2IyNDkzMWM1ZTRjMmQ5ODM3MjNmMGYwYzRiNzAxL3RhYmxlcmFuZ2U6YzA3YjI0OTMxYzVlNGMyZDk4MzcyM2YwZjBjNGI3MDFfMi01LTEtMS04MQ_81133bf9-e978-4185-984e-250ec059d283"
      unitRef="usd">312199000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i0faaba5fcd6b485781cadacae8b2fd8e_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV83MC9mcmFnOjU3ZWMzMTQ0ODQwYjQwZjI5ZWIzODQzYTg4ZDgxYjFkL3RhYmxlOmMwN2IyNDkzMWM1ZTRjMmQ5ODM3MjNmMGYwYzRiNzAxL3RhYmxlcmFuZ2U6YzA3YjI0OTMxYzVlNGMyZDk4MzcyM2YwZjBjNGI3MDFfMi03LTEtMS04MQ_234631f3-72e1-4ac5-9a4a-e38bd2cc5489"
      unitRef="usd">384730000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="id673d80f31e74643a241d2f62db94ca9_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV83MC9mcmFnOjU3ZWMzMTQ0ODQwYjQwZjI5ZWIzODQzYTg4ZDgxYjFkL3RhYmxlOmMwN2IyNDkzMWM1ZTRjMmQ5ODM3MjNmMGYwYzRiNzAxL3RhYmxlcmFuZ2U6YzA3YjI0OTMxYzVlNGMyZDk4MzcyM2YwZjBjNGI3MDFfNC0xLTEtMS04MQ_2123c9ba-e1ad-4467-a8be-4c8418130262"
      unitRef="shares">222415000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i313b15d35b7045babd1ba61f84a077dd_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV83MC9mcmFnOjU3ZWMzMTQ0ODQwYjQwZjI5ZWIzODQzYTg4ZDgxYjFkL3RhYmxlOmMwN2IyNDkzMWM1ZTRjMmQ5ODM3MjNmMGYwYzRiNzAxL3RhYmxlcmFuZ2U6YzA3YjI0OTMxYzVlNGMyZDk4MzcyM2YwZjBjNGI3MDFfNC0zLTEtMS04MQ_5bd6a5a2-dbf5-456a-b037-394f4d8317ae"
      unitRef="shares">220845000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV83MC9mcmFnOjU3ZWMzMTQ0ODQwYjQwZjI5ZWIzODQzYTg4ZDgxYjFkL3RhYmxlOmMwN2IyNDkzMWM1ZTRjMmQ5ODM3MjNmMGYwYzRiNzAxL3RhYmxlcmFuZ2U6YzA3YjI0OTMxYzVlNGMyZDk4MzcyM2YwZjBjNGI3MDFfNC01LTEtMS04MQ_7536cac3-495c-4a0c-8a85-1237d878f469"
      unitRef="shares">221801000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i0faaba5fcd6b485781cadacae8b2fd8e_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV83MC9mcmFnOjU3ZWMzMTQ0ODQwYjQwZjI5ZWIzODQzYTg4ZDgxYjFkL3RhYmxlOmMwN2IyNDkzMWM1ZTRjMmQ5ODM3MjNmMGYwYzRiNzAxL3RhYmxlcmFuZ2U6YzA3YjI0OTMxYzVlNGMyZDk4MzcyM2YwZjBjNGI3MDFfNC03LTEtMS04MQ_79bb4581-06dc-48d7-a705-5a61f23b1db1"
      unitRef="shares">220243000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="id673d80f31e74643a241d2f62db94ca9_D20220701-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV83MC9mcmFnOjU3ZWMzMTQ0ODQwYjQwZjI5ZWIzODQzYTg4ZDgxYjFkL3RhYmxlOmMwN2IyNDkzMWM1ZTRjMmQ5ODM3MjNmMGYwYzRiNzAxL3RhYmxlcmFuZ2U6YzA3YjI0OTMxYzVlNGMyZDk4MzcyM2YwZjBjNGI3MDFfNi0xLTEtMS04MQ_872a83aa-845e-41b2-be4d-6cedc43af54b"
      unitRef="usdPerShare">0.51</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i313b15d35b7045babd1ba61f84a077dd_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV83MC9mcmFnOjU3ZWMzMTQ0ODQwYjQwZjI5ZWIzODQzYTg4ZDgxYjFkL3RhYmxlOmMwN2IyNDkzMWM1ZTRjMmQ5ODM3MjNmMGYwYzRiNzAxL3RhYmxlcmFuZ2U6YzA3YjI0OTMxYzVlNGMyZDk4MzcyM2YwZjBjNGI3MDFfNi0zLTEtMS04MQ_7ec30160-6df5-4e47-b06d-91c64a4917a8"
      unitRef="usdPerShare">0.82</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV83MC9mcmFnOjU3ZWMzMTQ0ODQwYjQwZjI5ZWIzODQzYTg4ZDgxYjFkL3RhYmxlOmMwN2IyNDkzMWM1ZTRjMmQ5ODM3MjNmMGYwYzRiNzAxL3RhYmxlcmFuZ2U6YzA3YjI0OTMxYzVlNGMyZDk4MzcyM2YwZjBjNGI3MDFfNi01LTEtMS04MQ_eac17a46-037d-4f29-807e-953c19a42858"
      unitRef="usdPerShare">1.41</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i0faaba5fcd6b485781cadacae8b2fd8e_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV83MC9mcmFnOjU3ZWMzMTQ0ODQwYjQwZjI5ZWIzODQzYTg4ZDgxYjFkL3RhYmxlOmMwN2IyNDkzMWM1ZTRjMmQ5ODM3MjNmMGYwYzRiNzAxL3RhYmxlcmFuZ2U6YzA3YjI0OTMxYzVlNGMyZDk4MzcyM2YwZjBjNGI3MDFfNi03LTEtMS04MQ_7eda252c-dfda-48b6-83ec-24f875a9c9de"
      unitRef="usdPerShare">1.75</us-gaap:EarningsPerShareBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="id673d80f31e74643a241d2f62db94ca9_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV83MC9mcmFnOjU3ZWMzMTQ0ODQwYjQwZjI5ZWIzODQzYTg4ZDgxYjFkL3RhYmxlOmMwN2IyNDkzMWM1ZTRjMmQ5ODM3MjNmMGYwYzRiNzAxL3RhYmxlcmFuZ2U6YzA3YjI0OTMxYzVlNGMyZDk4MzcyM2YwZjBjNGI3MDFfOC0xLTEtMS04MQ_73eee42b-921c-4b8c-aa20-564825f2243b"
      unitRef="usd">112775000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i313b15d35b7045babd1ba61f84a077dd_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV83MC9mcmFnOjU3ZWMzMTQ0ODQwYjQwZjI5ZWIzODQzYTg4ZDgxYjFkL3RhYmxlOmMwN2IyNDkzMWM1ZTRjMmQ5ODM3MjNmMGYwYzRiNzAxL3RhYmxlcmFuZ2U6YzA3YjI0OTMxYzVlNGMyZDk4MzcyM2YwZjBjNGI3MDFfOC0zLTEtMS04MQ_92f78c9e-01b0-490e-86c7-60548558da96"
      unitRef="usd">181739000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV83MC9mcmFnOjU3ZWMzMTQ0ODQwYjQwZjI5ZWIzODQzYTg4ZDgxYjFkL3RhYmxlOmMwN2IyNDkzMWM1ZTRjMmQ5ODM3MjNmMGYwYzRiNzAxL3RhYmxlcmFuZ2U6YzA3YjI0OTMxYzVlNGMyZDk4MzcyM2YwZjBjNGI3MDFfOC01LTEtMS04MQ_3a675a31-f116-4d78-98b5-b486cf0f5c2e"
      unitRef="usd">312199000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i0faaba5fcd6b485781cadacae8b2fd8e_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV83MC9mcmFnOjU3ZWMzMTQ0ODQwYjQwZjI5ZWIzODQzYTg4ZDgxYjFkL3RhYmxlOmMwN2IyNDkzMWM1ZTRjMmQ5ODM3MjNmMGYwYzRiNzAxL3RhYmxlcmFuZ2U6YzA3YjI0OTMxYzVlNGMyZDk4MzcyM2YwZjBjNGI3MDFfOC03LTEtMS04MQ_e153ac2f-17b1-4630-9c03-54acfbd2a008"
      unitRef="usd">384730000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="id673d80f31e74643a241d2f62db94ca9_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV83MC9mcmFnOjU3ZWMzMTQ0ODQwYjQwZjI5ZWIzODQzYTg4ZDgxYjFkL3RhYmxlOmMwN2IyNDkzMWM1ZTRjMmQ5ODM3MjNmMGYwYzRiNzAxL3RhYmxlcmFuZ2U6YzA3YjI0OTMxYzVlNGMyZDk4MzcyM2YwZjBjNGI3MDFfMTAtMS0xLTEtODE_9e0c61af-9055-43fa-ba4d-d7c0529635db"
      unitRef="shares">222415000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i313b15d35b7045babd1ba61f84a077dd_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV83MC9mcmFnOjU3ZWMzMTQ0ODQwYjQwZjI5ZWIzODQzYTg4ZDgxYjFkL3RhYmxlOmMwN2IyNDkzMWM1ZTRjMmQ5ODM3MjNmMGYwYzRiNzAxL3RhYmxlcmFuZ2U6YzA3YjI0OTMxYzVlNGMyZDk4MzcyM2YwZjBjNGI3MDFfMTAtMy0xLTEtODE_5dad9b28-2a9a-4e52-a6e9-d47709d2f127"
      unitRef="shares">220845000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV83MC9mcmFnOjU3ZWMzMTQ0ODQwYjQwZjI5ZWIzODQzYTg4ZDgxYjFkL3RhYmxlOmMwN2IyNDkzMWM1ZTRjMmQ5ODM3MjNmMGYwYzRiNzAxL3RhYmxlcmFuZ2U6YzA3YjI0OTMxYzVlNGMyZDk4MzcyM2YwZjBjNGI3MDFfMTAtNS0xLTEtODE_ef623ab0-d91f-4cba-93a3-b10eb71edc00"
      unitRef="shares">221801000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i0faaba5fcd6b485781cadacae8b2fd8e_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV83MC9mcmFnOjU3ZWMzMTQ0ODQwYjQwZjI5ZWIzODQzYTg4ZDgxYjFkL3RhYmxlOmMwN2IyNDkzMWM1ZTRjMmQ5ODM3MjNmMGYwYzRiNzAxL3RhYmxlcmFuZ2U6YzA3YjI0OTMxYzVlNGMyZDk4MzcyM2YwZjBjNGI3MDFfMTAtNy0xLTEtODE_bbd6a8e8-68dd-4cba-abbc-2cc10d67a96d"
      unitRef="shares">220243000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="id673d80f31e74643a241d2f62db94ca9_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV83MC9mcmFnOjU3ZWMzMTQ0ODQwYjQwZjI5ZWIzODQzYTg4ZDgxYjFkL3RhYmxlOmMwN2IyNDkzMWM1ZTRjMmQ5ODM3MjNmMGYwYzRiNzAxL3RhYmxlcmFuZ2U6YzA3YjI0OTMxYzVlNGMyZDk4MzcyM2YwZjBjNGI3MDFfMTEtMS0xLTEtODE_09b090d4-284b-4833-851b-7d30282b15a9"
      unitRef="shares">1760000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i313b15d35b7045babd1ba61f84a077dd_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV83MC9mcmFnOjU3ZWMzMTQ0ODQwYjQwZjI5ZWIzODQzYTg4ZDgxYjFkL3RhYmxlOmMwN2IyNDkzMWM1ZTRjMmQ5ODM3MjNmMGYwYzRiNzAxL3RhYmxlcmFuZ2U6YzA3YjI0OTMxYzVlNGMyZDk4MzcyM2YwZjBjNGI3MDFfMTEtMy0xLTEtODE_8f01af22-a328-4ea6-b150-fbdc6093a3e6"
      unitRef="shares">1403000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV83MC9mcmFnOjU3ZWMzMTQ0ODQwYjQwZjI5ZWIzODQzYTg4ZDgxYjFkL3RhYmxlOmMwN2IyNDkzMWM1ZTRjMmQ5ODM3MjNmMGYwYzRiNzAxL3RhYmxlcmFuZ2U6YzA3YjI0OTMxYzVlNGMyZDk4MzcyM2YwZjBjNGI3MDFfMTEtNS0xLTEtODE_8dfe6654-fa3f-4e88-adcf-d524e76f9657"
      unitRef="shares">1825000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i0faaba5fcd6b485781cadacae8b2fd8e_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV83MC9mcmFnOjU3ZWMzMTQ0ODQwYjQwZjI5ZWIzODQzYTg4ZDgxYjFkL3RhYmxlOmMwN2IyNDkzMWM1ZTRjMmQ5ODM3MjNmMGYwYzRiNzAxL3RhYmxlcmFuZ2U6YzA3YjI0OTMxYzVlNGMyZDk4MzcyM2YwZjBjNGI3MDFfMTEtNy0xLTEtODE_aa051aa9-9bf5-4d8d-938f-5b4b26911960"
      unitRef="shares">1870000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="id673d80f31e74643a241d2f62db94ca9_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV83MC9mcmFnOjU3ZWMzMTQ0ODQwYjQwZjI5ZWIzODQzYTg4ZDgxYjFkL3RhYmxlOmMwN2IyNDkzMWM1ZTRjMmQ5ODM3MjNmMGYwYzRiNzAxL3RhYmxlcmFuZ2U6YzA3YjI0OTMxYzVlNGMyZDk4MzcyM2YwZjBjNGI3MDFfMTItMS0xLTEtODE_7403eb44-612f-4347-b500-3cd293f3f0b6"
      unitRef="shares">224175000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i313b15d35b7045babd1ba61f84a077dd_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV83MC9mcmFnOjU3ZWMzMTQ0ODQwYjQwZjI5ZWIzODQzYTg4ZDgxYjFkL3RhYmxlOmMwN2IyNDkzMWM1ZTRjMmQ5ODM3MjNmMGYwYzRiNzAxL3RhYmxlcmFuZ2U6YzA3YjI0OTMxYzVlNGMyZDk4MzcyM2YwZjBjNGI3MDFfMTItMy0xLTEtODE_470f850d-3005-4a13-8433-976876d22aef"
      unitRef="shares">222248000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV83MC9mcmFnOjU3ZWMzMTQ0ODQwYjQwZjI5ZWIzODQzYTg4ZDgxYjFkL3RhYmxlOmMwN2IyNDkzMWM1ZTRjMmQ5ODM3MjNmMGYwYzRiNzAxL3RhYmxlcmFuZ2U6YzA3YjI0OTMxYzVlNGMyZDk4MzcyM2YwZjBjNGI3MDFfMTItNS0xLTEtODE_0d6e88b3-1922-43b7-b004-c880b943dbaa"
      unitRef="shares">223626000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i0faaba5fcd6b485781cadacae8b2fd8e_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV83MC9mcmFnOjU3ZWMzMTQ0ODQwYjQwZjI5ZWIzODQzYTg4ZDgxYjFkL3RhYmxlOmMwN2IyNDkzMWM1ZTRjMmQ5ODM3MjNmMGYwYzRiNzAxL3RhYmxlcmFuZ2U6YzA3YjI0OTMxYzVlNGMyZDk4MzcyM2YwZjBjNGI3MDFfMTItNy0xLTEtODE_c38829b3-5e07-4d95-8ff9-f8950c0e4a07"
      unitRef="shares">222113000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareDiluted
      contextRef="id673d80f31e74643a241d2f62db94ca9_D20220701-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV83MC9mcmFnOjU3ZWMzMTQ0ODQwYjQwZjI5ZWIzODQzYTg4ZDgxYjFkL3RhYmxlOmMwN2IyNDkzMWM1ZTRjMmQ5ODM3MjNmMGYwYzRiNzAxL3RhYmxlcmFuZ2U6YzA3YjI0OTMxYzVlNGMyZDk4MzcyM2YwZjBjNGI3MDFfMTQtMS0xLTEtODE_5d4f5551-fd13-4b5b-a158-e78f52f17b96"
      unitRef="usdPerShare">0.50</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i313b15d35b7045babd1ba61f84a077dd_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV83MC9mcmFnOjU3ZWMzMTQ0ODQwYjQwZjI5ZWIzODQzYTg4ZDgxYjFkL3RhYmxlOmMwN2IyNDkzMWM1ZTRjMmQ5ODM3MjNmMGYwYzRiNzAxL3RhYmxlcmFuZ2U6YzA3YjI0OTMxYzVlNGMyZDk4MzcyM2YwZjBjNGI3MDFfMTQtMy0xLTEtODE_e4598fc6-e143-4244-baed-40bd2942c3b5"
      unitRef="usdPerShare">0.82</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV83MC9mcmFnOjU3ZWMzMTQ0ODQwYjQwZjI5ZWIzODQzYTg4ZDgxYjFkL3RhYmxlOmMwN2IyNDkzMWM1ZTRjMmQ5ODM3MjNmMGYwYzRiNzAxL3RhYmxlcmFuZ2U6YzA3YjI0OTMxYzVlNGMyZDk4MzcyM2YwZjBjNGI3MDFfMTQtNS0xLTEtODE_7e77e1ec-f234-4a9f-80be-50e1827aacbd"
      unitRef="usdPerShare">1.40</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i0faaba5fcd6b485781cadacae8b2fd8e_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV83MC9mcmFnOjU3ZWMzMTQ0ODQwYjQwZjI5ZWIzODQzYTg4ZDgxYjFkL3RhYmxlOmMwN2IyNDkzMWM1ZTRjMmQ5ODM3MjNmMGYwYzRiNzAxL3RhYmxlcmFuZ2U6YzA3YjI0OTMxYzVlNGMyZDk4MzcyM2YwZjBjNGI3MDFfMTQtNy0xLTEtODE_7246d545-6874-43bd-ac5d-250eb19dd4fb"
      unitRef="usdPerShare">1.73</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV83MC9mcmFnOjU3ZWMzMTQ0ODQwYjQwZjI5ZWIzODQzYTg4ZDgxYjFkL3RleHRyZWdpb246NTdlYzMxNDQ4NDBiNDBmMjllYjM4NDNhODhkODFiMWRfMjMx_16b66089-12e9-4614-93e4-275685129f84">The potential common shares that were excluded from the diluted net income per share computation are as follows:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.354%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.085%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding stock options and awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,150,022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,841,440&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,979,096&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,917,824&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i4265039234524ff8ba29f3a4b5d9b5b7_D20220701-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV83MC9mcmFnOjU3ZWMzMTQ0ODQwYjQwZjI5ZWIzODQzYTg4ZDgxYjFkL3RhYmxlOjViODcxNGQxOTNmZjQzMmQ4M2U4NmIzNzdiN2YwMzc1L3RhYmxlcmFuZ2U6NWI4NzE0ZDE5M2ZmNDMyZDgzZTg2YjM3N2I3ZjAzNzVfMi0xLTEtMS04MQ_8c1e39ce-8577-46df-8714-38ad85cca7aa"
      unitRef="shares">11150022</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i6fd8c5827aa44407ac99325c6ecd1dcd_D20210701-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV83MC9mcmFnOjU3ZWMzMTQ0ODQwYjQwZjI5ZWIzODQzYTg4ZDgxYjFkL3RhYmxlOjViODcxNGQxOTNmZjQzMmQ4M2U4NmIzNzdiN2YwMzc1L3RhYmxlcmFuZ2U6NWI4NzE0ZDE5M2ZmNDMyZDgzZTg2YjM3N2I3ZjAzNzVfMi0zLTEtMS04MQ_8b82bd14-bff2-4de7-8805-ad960ab89d6f"
      unitRef="shares">11841440</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i09060caa1e0a470da42482940ed7fad9_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV83MC9mcmFnOjU3ZWMzMTQ0ODQwYjQwZjI5ZWIzODQzYTg4ZDgxYjFkL3RhYmxlOjViODcxNGQxOTNmZjQzMmQ4M2U4NmIzNzdiN2YwMzc1L3RhYmxlcmFuZ2U6NWI4NzE0ZDE5M2ZmNDMyZDgzZTg2YjM3N2I3ZjAzNzVfMi01LTEtMS04MQ_5be23014-f18e-48a2-9edb-76bd4269a059"
      unitRef="shares">10979096</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i45da57132f0b4b1baefd68fba20589ad_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV83MC9mcmFnOjU3ZWMzMTQ0ODQwYjQwZjI5ZWIzODQzYTg4ZDgxYjFkL3RhYmxlOjViODcxNGQxOTNmZjQzMmQ4M2U4NmIzNzdiN2YwMzc1L3RhYmxlcmFuZ2U6NWI4NzE0ZDE5M2ZmNDMyZDgzZTg2YjM3N2I3ZjAzNzVfMi03LTEtMS04MQ_5122a78f-bfc3-42a0-aa16-636a51a4b7a0"
      unitRef="shares">9917824</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock
      contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV83My9mcmFnOjlkZDZlNTZmNWEzYzQwY2VhZDY2OWZjZDZjZmEzNDhiL3RleHRyZWdpb246OWRkNmU1NmY1YTNjNDBjZWFkNjY5ZmNkNmNmYTM0OGJfMTMxNg_ae5257c1-81a9-466e-800f-e5c954d4a039">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Defined Contribution Plans&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have a defined contribution plan qualified under Section 401(k) of the Internal Revenue Code covering all U.S. employees and defined contribution plans for other Incyte employees in Europe and Japan. Employees may contribute a portion of their compensation, which is then matched by us, subject to certain limitations. Defined contribution expense for the three and nine months ended September&#160;30, 2022 was $5.1 million and $14.7 million, respectively. Defined contribution expense for the three and nine months ended September&#160;30, 2021 was $4.4 million and $12.8 million, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Defined Benefit Pension Plans&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have defined benefit pension plans for our employees in Europe which provide benefits to employees upon retirement, death or disability. The assets of the pension plans are held in collective investment accounts represented by the cash surrender value of an insurance policy and are classified as Level 2 within the fair value hierarchy.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The net periodic benefit cost was as follows (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.354%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.085%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Service cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,008)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,114)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(45)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of prior service cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of actuarial losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;864&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net periodic benefit cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;The components of net periodic benefit cost other than the service cost component are included in &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV83My9mcmFnOjlkZDZlNTZmNWEzYzQwY2VhZDY2OWZjZDZjZmEzNDhiL3RleHRyZWdpb246OWRkNmU1NmY1YTNjNDBjZWFkNjY5ZmNkNmNmYTM0OGJfNjA0NzMxMzk1NDEzMQ_cd32c16f-4695-4a46-9bef-320c5c331b0a"&gt;other income (expense), net&lt;/span&gt; on the condensed consolidated statements of operations. We expect to contribute a total of $6.4 million to the pension plans in 2022 inclusive of the amounts contributed to the plan during the current period.</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="id673d80f31e74643a241d2f62db94ca9_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV83My9mcmFnOjlkZDZlNTZmNWEzYzQwY2VhZDY2OWZjZDZjZmEzNDhiL3RleHRyZWdpb246OWRkNmU1NmY1YTNjNDBjZWFkNjY5ZmNkNmNmYTM0OGJfNDQ3_590e7f5f-a6ff-4fe9-ac2a-b7e9904656ad"
      unitRef="usd">5100000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV83My9mcmFnOjlkZDZlNTZmNWEzYzQwY2VhZDY2OWZjZDZjZmEzNDhiL3RleHRyZWdpb246OWRkNmU1NmY1YTNjNDBjZWFkNjY5ZmNkNmNmYTM0OGJfNDU0_5330c57c-05f8-4ea5-a6fc-6adf72dec224"
      unitRef="usd">14700000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="i313b15d35b7045babd1ba61f84a077dd_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV83My9mcmFnOjlkZDZlNTZmNWEzYzQwY2VhZDY2OWZjZDZjZmEzNDhiL3RleHRyZWdpb246OWRkNmU1NmY1YTNjNDBjZWFkNjY5ZmNkNmNmYTM0OGJfNTMy_72450f3c-b8f0-4c33-b742-7aeef648cb96"
      unitRef="usd">4400000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="i0faaba5fcd6b485781cadacae8b2fd8e_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV83My9mcmFnOjlkZDZlNTZmNWEzYzQwY2VhZDY2OWZjZDZjZmEzNDhiL3RleHRyZWdpb246OWRkNmU1NmY1YTNjNDBjZWFkNjY5ZmNkNmNmYTM0OGJfNTM5_18bd2aea-25ef-419e-928a-767355e4c029"
      unitRef="usd">12800000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:ScheduleOfNetBenefitCostsTableTextBlock
      contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV83My9mcmFnOjlkZDZlNTZmNWEzYzQwY2VhZDY2OWZjZDZjZmEzNDhiL3RleHRyZWdpb246OWRkNmU1NmY1YTNjNDBjZWFkNjY5ZmNkNmNmYTM0OGJfMTMxNw_22ceaa82-9816-47b1-8303-66fa91fcbe44">&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The net periodic benefit cost was as follows (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.354%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.085%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Service cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,008)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,114)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(45)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of prior service cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of actuarial losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;864&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net periodic benefit cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfNetBenefitCostsTableTextBlock>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="id673d80f31e74643a241d2f62db94ca9_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV83My9mcmFnOjlkZDZlNTZmNWEzYzQwY2VhZDY2OWZjZDZjZmEzNDhiL3RhYmxlOmIzOTBjYWUzNzEwYzRiMGFhZWMxNTA0NGFkOTNlYzQ3L3RhYmxlcmFuZ2U6YjM5MGNhZTM3MTBjNGIwYWFlYzE1MDQ0YWQ5M2VjNDdfMi0xLTEtMS04MQ_e925c116-ddf7-43d3-b66a-49f226a78572"
      unitRef="usd">2376000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i313b15d35b7045babd1ba61f84a077dd_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV83My9mcmFnOjlkZDZlNTZmNWEzYzQwY2VhZDY2OWZjZDZjZmEzNDhiL3RhYmxlOmIzOTBjYWUzNzEwYzRiMGFhZWMxNTA0NGFkOTNlYzQ3L3RhYmxlcmFuZ2U6YjM5MGNhZTM3MTBjNGIwYWFlYzE1MDQ0YWQ5M2VjNDdfMi0zLTEtMS04MQ_8df81eae-35b6-479e-bfa5-9160676aebb1"
      unitRef="usd">1975000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV83My9mcmFnOjlkZDZlNTZmNWEzYzQwY2VhZDY2OWZjZDZjZmEzNDhiL3RhYmxlOmIzOTBjYWUzNzEwYzRiMGFhZWMxNTA0NGFkOTNlYzQ3L3RhYmxlcmFuZ2U6YjM5MGNhZTM3MTBjNGIwYWFlYzE1MDQ0YWQ5M2VjNDdfMi01LTEtMS04MQ_187add67-4d63-4381-b5ca-b0b0dd7056c3"
      unitRef="usd">7336000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i0faaba5fcd6b485781cadacae8b2fd8e_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV83My9mcmFnOjlkZDZlNTZmNWEzYzQwY2VhZDY2OWZjZDZjZmEzNDhiL3RhYmxlOmIzOTBjYWUzNzEwYzRiMGFhZWMxNTA0NGFkOTNlYzQ3L3RhYmxlcmFuZ2U6YjM5MGNhZTM3MTBjNGIwYWFlYzE1MDQ0YWQ5M2VjNDdfMi03LTEtMS04MQ_1a388701-72bd-4183-b313-b79ab09456aa"
      unitRef="usd">5927000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="id673d80f31e74643a241d2f62db94ca9_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV83My9mcmFnOjlkZDZlNTZmNWEzYzQwY2VhZDY2OWZjZDZjZmEzNDhiL3RhYmxlOmIzOTBjYWUzNzEwYzRiMGFhZWMxNTA0NGFkOTNlYzQ3L3RhYmxlcmFuZ2U6YjM5MGNhZTM3MTBjNGIwYWFlYzE1MDQ0YWQ5M2VjNDdfMy0xLTEtMS04MQ_552fd83d-c21a-4fe4-981c-1f2de8007b98"
      unitRef="usd">61000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i313b15d35b7045babd1ba61f84a077dd_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV83My9mcmFnOjlkZDZlNTZmNWEzYzQwY2VhZDY2OWZjZDZjZmEzNDhiL3RhYmxlOmIzOTBjYWUzNzEwYzRiMGFhZWMxNTA0NGFkOTNlYzQ3L3RhYmxlcmFuZ2U6YjM5MGNhZTM3MTBjNGIwYWFlYzE1MDQ0YWQ5M2VjNDdfMy0zLTEtMS04MQ_54c4b414-5448-4b6d-b6e3-b7c8ddf6aef0"
      unitRef="usd">23000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV83My9mcmFnOjlkZDZlNTZmNWEzYzQwY2VhZDY2OWZjZDZjZmEzNDhiL3RhYmxlOmIzOTBjYWUzNzEwYzRiMGFhZWMxNTA0NGFkOTNlYzQ3L3RhYmxlcmFuZ2U6YjM5MGNhZTM3MTBjNGIwYWFlYzE1MDQ0YWQ5M2VjNDdfMy01LTEtMS04MQ_aff3f740-01bf-42d9-9ddf-700a96f53702"
      unitRef="usd">187000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i0faaba5fcd6b485781cadacae8b2fd8e_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV83My9mcmFnOjlkZDZlNTZmNWEzYzQwY2VhZDY2OWZjZDZjZmEzNDhiL3RhYmxlOmIzOTBjYWUzNzEwYzRiMGFhZWMxNTA0NGFkOTNlYzQ3L3RhYmxlcmFuZ2U6YjM5MGNhZTM3MTBjNGIwYWFlYzE1MDQ0YWQ5M2VjNDdfMy03LTEtMS04MQ_f3688557-78c1-43e2-b3bf-4675fa7a3018"
      unitRef="usd">68000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="id673d80f31e74643a241d2f62db94ca9_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV83My9mcmFnOjlkZDZlNTZmNWEzYzQwY2VhZDY2OWZjZDZjZmEzNDhiL3RhYmxlOmIzOTBjYWUzNzEwYzRiMGFhZWMxNTA0NGFkOTNlYzQ3L3RhYmxlcmFuZ2U6YjM5MGNhZTM3MTBjNGIwYWFlYzE1MDQ0YWQ5M2VjNDdfNC0xLTEtMS04MQ_3cff4304-c613-4696-ab20-ae1a7f8388b2"
      unitRef="usd">1008000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="i313b15d35b7045babd1ba61f84a077dd_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV83My9mcmFnOjlkZDZlNTZmNWEzYzQwY2VhZDY2OWZjZDZjZmEzNDhiL3RhYmxlOmIzOTBjYWUzNzEwYzRiMGFhZWMxNTA0NGFkOTNlYzQ3L3RhYmxlcmFuZ2U6YjM5MGNhZTM3MTBjNGIwYWFlYzE1MDQ0YWQ5M2VjNDdfNC0zLTEtMS04MQ_ab94bb6c-49a4-4f76-8ab3-eaea602b19a0"
      unitRef="usd">15000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV83My9mcmFnOjlkZDZlNTZmNWEzYzQwY2VhZDY2OWZjZDZjZmEzNDhiL3RhYmxlOmIzOTBjYWUzNzEwYzRiMGFhZWMxNTA0NGFkOTNlYzQ3L3RhYmxlcmFuZ2U6YjM5MGNhZTM3MTBjNGIwYWFlYzE1MDQ0YWQ5M2VjNDdfNC01LTEtMS04MQ_5e8cdf0c-46fc-4496-a257-312dfda120de"
      unitRef="usd">3114000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="i0faaba5fcd6b485781cadacae8b2fd8e_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV83My9mcmFnOjlkZDZlNTZmNWEzYzQwY2VhZDY2OWZjZDZjZmEzNDhiL3RhYmxlOmIzOTBjYWUzNzEwYzRiMGFhZWMxNTA0NGFkOTNlYzQ3L3RhYmxlcmFuZ2U6YjM5MGNhZTM3MTBjNGIwYWFlYzE1MDQ0YWQ5M2VjNDdfNC03LTEtMS04MQ_db580ebb-047a-43e6-9015-f49534564c62"
      unitRef="usd">45000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="id673d80f31e74643a241d2f62db94ca9_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV83My9mcmFnOjlkZDZlNTZmNWEzYzQwY2VhZDY2OWZjZDZjZmEzNDhiL3RhYmxlOmIzOTBjYWUzNzEwYzRiMGFhZWMxNTA0NGFkOTNlYzQ3L3RhYmxlcmFuZ2U6YjM5MGNhZTM3MTBjNGIwYWFlYzE1MDQ0YWQ5M2VjNDdfNS0xLTEtMS04MQ_ea0dde9f-d187-4bd7-bb19-c92f1f8fb815"
      unitRef="usd">193000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="i313b15d35b7045babd1ba61f84a077dd_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV83My9mcmFnOjlkZDZlNTZmNWEzYzQwY2VhZDY2OWZjZDZjZmEzNDhiL3RhYmxlOmIzOTBjYWUzNzEwYzRiMGFhZWMxNTA0NGFkOTNlYzQ3L3RhYmxlcmFuZ2U6YjM5MGNhZTM3MTBjNGIwYWFlYzE1MDQ0YWQ5M2VjNDdfNS0zLTEtMS04MQ_51a84e99-b7dc-4f28-aafc-05216f458571"
      unitRef="usd">54000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV83My9mcmFnOjlkZDZlNTZmNWEzYzQwY2VhZDY2OWZjZDZjZmEzNDhiL3RhYmxlOmIzOTBjYWUzNzEwYzRiMGFhZWMxNTA0NGFkOTNlYzQ3L3RhYmxlcmFuZ2U6YjM5MGNhZTM3MTBjNGIwYWFlYzE1MDQ0YWQ5M2VjNDdfNS01LTEtMS04MQ_3a6a5f37-a597-44f0-84db-fdd75a6c2c8f"
      unitRef="usd">580000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="i0faaba5fcd6b485781cadacae8b2fd8e_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV83My9mcmFnOjlkZDZlNTZmNWEzYzQwY2VhZDY2OWZjZDZjZmEzNDhiL3RhYmxlOmIzOTBjYWUzNzEwYzRiMGFhZWMxNTA0NGFkOTNlYzQ3L3RhYmxlcmFuZ2U6YjM5MGNhZTM3MTBjNGIwYWFlYzE1MDQ0YWQ5M2VjNDdfNS03LTEtMS04MQ_132ba763-4de1-4785-aa75-c61306eb5ffe"
      unitRef="usd">162000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanActuarialGainLoss
      contextRef="id673d80f31e74643a241d2f62db94ca9_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV83My9mcmFnOjlkZDZlNTZmNWEzYzQwY2VhZDY2OWZjZDZjZmEzNDhiL3RhYmxlOmIzOTBjYWUzNzEwYzRiMGFhZWMxNTA0NGFkOTNlYzQ3L3RhYmxlcmFuZ2U6YjM5MGNhZTM3MTBjNGIwYWFlYzE1MDQ0YWQ5M2VjNDdfNi0xLTEtMS04MQ_c6403f34-4c69-41ab-8c64-2bcdc7e31662"
      unitRef="usd">-89000</us-gaap:DefinedBenefitPlanActuarialGainLoss>
    <us-gaap:DefinedBenefitPlanActuarialGainLoss
      contextRef="i313b15d35b7045babd1ba61f84a077dd_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV83My9mcmFnOjlkZDZlNTZmNWEzYzQwY2VhZDY2OWZjZDZjZmEzNDhiL3RhYmxlOmIzOTBjYWUzNzEwYzRiMGFhZWMxNTA0NGFkOTNlYzQ3L3RhYmxlcmFuZ2U6YjM5MGNhZTM3MTBjNGIwYWFlYzE1MDQ0YWQ5M2VjNDdfNi0zLTEtMS04MQ_2bdcfcae-e9e2-4739-b9e3-6a1b533b8cc1"
      unitRef="usd">-288000</us-gaap:DefinedBenefitPlanActuarialGainLoss>
    <us-gaap:DefinedBenefitPlanActuarialGainLoss
      contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV83My9mcmFnOjlkZDZlNTZmNWEzYzQwY2VhZDY2OWZjZDZjZmEzNDhiL3RhYmxlOmIzOTBjYWUzNzEwYzRiMGFhZWMxNTA0NGFkOTNlYzQ3L3RhYmxlcmFuZ2U6YjM5MGNhZTM3MTBjNGIwYWFlYzE1MDQ0YWQ5M2VjNDdfNi01LTEtMS04MQ_1f57476c-a902-4aaf-8df3-c494fd5656ae"
      unitRef="usd">-266000</us-gaap:DefinedBenefitPlanActuarialGainLoss>
    <us-gaap:DefinedBenefitPlanActuarialGainLoss
      contextRef="i0faaba5fcd6b485781cadacae8b2fd8e_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV83My9mcmFnOjlkZDZlNTZmNWEzYzQwY2VhZDY2OWZjZDZjZmEzNDhiL3RhYmxlOmIzOTBjYWUzNzEwYzRiMGFhZWMxNTA0NGFkOTNlYzQ3L3RhYmxlcmFuZ2U6YjM5MGNhZTM3MTBjNGIwYWFlYzE1MDQ0YWQ5M2VjNDdfNi03LTEtMS04MQ_e3f8b210-e745-4d3a-a50a-b34be67d5d55"
      unitRef="usd">-864000</us-gaap:DefinedBenefitPlanActuarialGainLoss>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="id673d80f31e74643a241d2f62db94ca9_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV83My9mcmFnOjlkZDZlNTZmNWEzYzQwY2VhZDY2OWZjZDZjZmEzNDhiL3RhYmxlOmIzOTBjYWUzNzEwYzRiMGFhZWMxNTA0NGFkOTNlYzQ3L3RhYmxlcmFuZ2U6YjM5MGNhZTM3MTBjNGIwYWFlYzE1MDQ0YWQ5M2VjNDdfNy0xLTEtMS04MQ_14189936-f6da-434b-94da-51e50d75bc8b"
      unitRef="usd">1711000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i313b15d35b7045babd1ba61f84a077dd_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV83My9mcmFnOjlkZDZlNTZmNWEzYzQwY2VhZDY2OWZjZDZjZmEzNDhiL3RhYmxlOmIzOTBjYWUzNzEwYzRiMGFhZWMxNTA0NGFkOTNlYzQ3L3RhYmxlcmFuZ2U6YjM5MGNhZTM3MTBjNGIwYWFlYzE1MDQ0YWQ5M2VjNDdfNy0zLTEtMS04MQ_f9df3853-e1c3-4c22-b432-d91a0154341f"
      unitRef="usd">2325000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV83My9mcmFnOjlkZDZlNTZmNWEzYzQwY2VhZDY2OWZjZDZjZmEzNDhiL3RhYmxlOmIzOTBjYWUzNzEwYzRiMGFhZWMxNTA0NGFkOTNlYzQ3L3RhYmxlcmFuZ2U6YjM5MGNhZTM3MTBjNGIwYWFlYzE1MDQ0YWQ5M2VjNDdfNy01LTEtMS04MQ_a49bec3f-9552-4a07-ba47-b2a3ee6e5383"
      unitRef="usd">5255000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i0faaba5fcd6b485781cadacae8b2fd8e_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV83My9mcmFnOjlkZDZlNTZmNWEzYzQwY2VhZDY2OWZjZDZjZmEzNDhiL3RhYmxlOmIzOTBjYWUzNzEwYzRiMGFhZWMxNTA0NGFkOTNlYzQ3L3RhYmxlcmFuZ2U6YjM5MGNhZTM3MTBjNGIwYWFlYzE1MDQ0YWQ5M2VjNDdfNy03LTEtMS04MQ_e0420025-e55e-42d1-80ea-44797309952a"
      unitRef="usd">6976000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsCurrentFiscalYear
      contextRef="i3b4376f8fc614de98c9cf647198c504e_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV83My9mcmFnOjlkZDZlNTZmNWEzYzQwY2VhZDY2OWZjZDZjZmEzNDhiL3RleHRyZWdpb246OWRkNmU1NmY1YTNjNDBjZWFkNjY5ZmNkNmNmYTM0OGJfMTIxMQ_a7873449-fc3f-403f-9315-f08a38725afe"
      unitRef="usd">6400000</us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsCurrentFiscalYear>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV83OS9mcmFnOmY0ZjhhYWQ5YmI0NDRmNGNhYjI5ZTc0ZDFiODIwNGU3L3RleHRyZWdpb246ZjRmOGFhZDliYjQ0NGY0Y2FiMjllNzRkMWI4MjA0ZTdfOTM4_09ec0565-9c0b-4e1d-9d33-7d6dacd8708a">&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have entered into the collaboration agreements described in Note 7, as well as various other collaboration agreements that are not individually, or in the aggregate, significant to our operating results or financial condition at this time. We may in the future seek to license additional rights relating to technologies or drug development candidates in connection with our drug discovery and development programs. Under these agreements, we may be required to pay upfront fees, milestone payments, and royalties on sales of future products.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the ordinary course of our business, we may become involved in lawsuits, proceedings, and other disputes, including commercial, intellectual property, regulatory, employment, and other matters. We record a reserve for these matters when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80NzAvZnJhZzoyMjQ4NGIyOWNjZGY0Y2VmYjgzNDg5Y2RlMjY5ZTQ3ZC90ZXh0cmVnaW9uOjIyNDg0YjI5Y2NkZjRjZWZiODM0ODljZGUyNjllNDdkXzM4NDgyOTA2OTgyMzU_2e7e7035-4c7e-467e-b40f-c9ad9cee1943">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Villaris&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2022, we announced that we entered into an agreement to acquire Villaris Therapeutics, Inc. ("Villaris"), a biopharmaceutical company focused on the development of novel antibody therapeutics for vitiligo. Under the terms of the agreement, Incyte will acquire Villaris and the exclusive global rights to develop and commercialize auremolimab (VM6), an anti-IL-15R&#x3b2; monoclonal antibody, for all uses, including in vitiligo and other autoimmune and inflammatory diseases. Upon effectiveness of the agreement, Incyte will make an upfront payment of $70.0 million, and Villaris shareholders will be eligible for up to $310.0 million upon achievement of certain development and regulatory milestones, as well as up to an additional $1.05 billion in commercial milestones on net sales of the product. The agreement is subject to clearance by the U.S. antitrust authorities under the Hart-Scott-Rodino Act and will become effective as soon as this condition has been met.&lt;/span&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
    <incy:LicenseAgreementUpfrontPaymentAmountPaid
      contextRef="i1c305a826fd9438ab670f7c9b7fa8ab4_D20221001-20221031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80NzAvZnJhZzoyMjQ4NGIyOWNjZGY0Y2VmYjgzNDg5Y2RlMjY5ZTQ3ZC90ZXh0cmVnaW9uOjIyNDg0YjI5Y2NkZjRjZWZiODM0ODljZGUyNjllNDdkXzE2NDkyNjc0NDIxOTU_e7ce6795-dedd-4bfa-9120-a2544fc6a101"
      unitRef="usd">70000000</incy:LicenseAgreementUpfrontPaymentAmountPaid>
    <incy:LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived
      contextRef="if0d0cff0ce394041bc79b1987d42f3cd_D20221001-20221031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80NzAvZnJhZzoyMjQ4NGIyOWNjZGY0Y2VmYjgzNDg5Y2RlMjY5ZTQ3ZC90ZXh0cmVnaW9uOjIyNDg0YjI5Y2NkZjRjZWZiODM0ODljZGUyNjllNDdkXzE2NDkyNjc0NDIyNTM_21093b74-9b49-428d-8e15-623b19b55030"
      unitRef="usd">310000000</incy:LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived>
    <incy:LicenseAgreementMilestoneOnNetSalesOfProduct
      contextRef="i2aa7c5f2196a496abe03ba33b71612a9_D20221001-20221031"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZmZiYTNlZTUzODRjODZiZWNkYjM4ZmYxMTdjYTlhL3NlYzplMmZmYmEzZWU1Mzg0Yzg2YmVjZGIzOGZmMTE3Y2E5YV80NzAvZnJhZzoyMjQ4NGIyOWNjZGY0Y2VmYjgzNDg5Y2RlMjY5ZTQ3ZC90ZXh0cmVnaW9uOjIyNDg0YjI5Y2NkZjRjZWZiODM0ODljZGUyNjllNDdkXzE2NDkyNjc0NDIzNTU_0e156dce-18b5-4c13-901a-eb9801d464cc"
      unitRef="usd">1050000000.00</incy:LicenseAgreementMilestoneOnNetSalesOfProduct>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>83
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M#%)6[J6K$I!HWY03,,?1YN 2@%$6,FT*1B8,.P%S?4_3;>+"P*4N@74'G>[
MJGLEC9[,@0_HD1>\DFN4TI]LI%]):U$ER@M"(0B,SA#/8YZCA<"$X=#Q'6U(
M(Q/FDY"JC6\0 1/F8DK= (Y V$4@M$;@W:_2E+]'65G72/K?]4XF/U=F:)ND
M%7I*L@-7$RA9_W5(ZU3-A(\5SQ(A9\I:.A89/)DFZK).-[QJI@H4L=#H_$>"
M@U!?WTT8";$6U@C@P@2'@18O$X:IXXV$"SN][W1^L*1D6?)0ME+;N"E'*0,!
MND;'[(6OS_TE@ HQTU<(".6X^IX&H$C(3N;34/>)W\:OV,/7QM8&JL9&'[R
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M(\I]\W+<0RE$F3>7.YYL>*4 \OMM68J7&_6 [@W.Q?\!4$L#!!0    ( ,.
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M=*"VV*%Y"X,,K:T]8,1Y%+'(/-X"#)44HA$S1S9D%U#&#W)^>K :F4_/6A%
M44L"4-%&J&@)*IK 0M-9;[(%] <I#*!0$H ,!M2<EZ=K XY!F6>=[M!U)OH<
M]0&TR730OZY"@+8I$7#WI_,4;E,D@.I28*'IA#6I%HI1*$"!8WO&B)F(<OOJ
M3$8KIPFJ4X&%IM/1Y$#H&>H%*'#@SLQ%?>CVW)D<U(J!5E<@L'SJW#3)!/J4
MH@$*:/681,S,$+B==*8!M7  %4V<CHA.1),DH%VK!TZ>/5!;O,-G#X"A??8
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M>Q,@T"GS>62.:\!.*;XX/A:K1GTSM_K^3AUC:] C.L8V!,)E&QW1,;8AK&,
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M].V;*E]MGN#],:^J?+%Y.9.I6G-K _7]?9Y7W][4#P7?/Y?^^K]02P,$%
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MC8LNFL3+JKSL2)851>$CDUAB%LTU7F2 *P!^7S(FWSIJ@OIJ-/H?4$L#!!0
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MTO=(N@FVCM\ "QOP11$O2^B0'"_ >QZSFQMVT'T43O\&4$L#!!0    ( ,.
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M.&%I L:7!J=/W2 #[7_AZ&]02P,$%     @ PX!A54N)Y7(!!   $PD  !D
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M:D'C-_!Z2>0.A@\P? >M_P902P,$%     @ PX!A51H.>WFJ'@  G84  !D
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M@]QTENT'\='/'M5'9T =6324>S07?6#YXVQ++LY+#^P )_'/Q4(YC>>G9?I
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M"AO3;HT( NE) B&&_TWQ5;TGJ\,DZ\Z+.FLIH" 8I'8CZ\SG:C_Y#1%"-L&
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MOX:ZI8YUV'ZSFX-5FC#GIO$YU8<MND@U&Y!K/E$,8FRQ2G:93-=V;GF<]!8
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M;O9T[*.@=J?;.X3*%W-3467>O&]]H$OX#-,>UW4<?DW'S29-JM,6YTUN /?
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ML'V&6-&\[[TZ%LKZNT=TWY3?KZ8_<;A4L4"E:OEO'*9-57)_]XVUS?7^@[Y
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MKM">5IN4[I?^5(M^LJ[5KG2Y\A/U-M<M92FU*#>]TC5W-'\**GX-D&/4E&V
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M"\NKX8TO0JG!&LFIFD&Y]A9O%>S\V94%OM;?"UF7XM5-JQITW">B)G\R\ C
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M,EE>@/<+8_SFA@-L#YAG_P-02P,$%     @ PX!A54-AH]SH @  8@8  !D
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M' O@?6EQ@'0/[*#_KIO]!U!+ P04    " ##@&%5/>V+K$H#   N"   &0
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M9P2]=68[]8A1NS!JH05JQ0R@=M8P]0BR,(Q1M&I;F5&^@Z;OV4L=Y32BMY!
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MR6:'*;Z109H#N#\76#R;B5%0O[JG?P-02P,$%     @ PX!A55*8Z,@X P
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MT7>>HTP2)^ H.#.>P., V8E,<SW+":@5Q,BE.+)]=XP;8<^-\,7<N%E](>S
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MS&8+G/,X9R.:TWB:^YG%TY0%G>?92PR'D+R!]&+$PC3E'M%%SL)$^#Y(U7D
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M@ZM!XH'NYEBG6%6WLV.I+$VB=EO2Z$?M#.C[2BF[4UR _9_)]"]02P,$%
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MU_0[U!M6MWYNM]K2%OAC3;\=,"Z [DNM[<%P"<8?6?874$L#!!0    ( ,.
M857BK<M8=P8  )DS   9    >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;+6;
M;7/:1A#'OXJ&9CK)3!IT#WIR,3.8N[2D<>+!=CK-.P7.AHF0J"3LY-M7$K+$
MG8XSX.T;&\3N3^RM=M'_[C1X3-+OV4*(W/JQBN+LO+?(\_59OY_-%F(59N^2
MM8B+3^Z2=!7FQ=OTOI^M4Q'.*Z=5U,>V[?97X3+N#0?5L:MT.$@V>;2,Q55J
M99O5*DQ_7H@H>3SOH=[3@>GR?I&7!_K#P3J\%]<BOUU?I<6[?D.9+U<BSI9)
M;*7B[KPW0F><>*5#9?%E*1ZSG==6&<JW)/E>OIG,SWMV^8U$)&9YB0B+?P]B
M+**H)!7?X]\:VFO.63KNOGZBOZ^"+X+Y%F9BG$1_+^?YXKSG]ZRYN LW43Y-
M'O\4=4!.R9LE45;]M1ZWMI3VK-DFRY-5[5Q\@]4RWOX/?]0#L>-0</0.N';
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MY6OL7(\$WI[*]YMP?6.X'T9_C=Y/=&$:_8Z]UB!A#!+&@6#2X ?-X <GEWH
M.?R0, 8)XT P:?B1W=Y?VR\L]AJP6W<N"IQ ^6$>:^P<ZA%/+7>-'?)<Y!&U
MWG6&#L6(^/J"1SNB AF#GHP_WEY/_M!&:_0\]JH#I3%0&H>BR3G ;0[PR95?
MNT(E 9+&0&D<BB8GH958R"@A#JE^TBE"[ 0X4(M?8^8[&*NUWS7S?*R:<8U9
M(2T<=T_=MY(&F37-%;\<??UGRK6!&EV/ON8@:0R4QJ%H<A):H86<TPL?5%V!
MTA@HC4/1Y"2T"@L9%<0AA>]V*UJ2V?48=\V0Y[B=PN^:N395VPC7F%$_P'ON
M\%&K:)!9TEQ./GVX_:*]R3=['GW)0=(8*(U#T>0<M#(+^:?7/:C4 J4Q4!J'
MHLE):.46,LJ)0^H^T*AV]=Y\K+/:^7VN1ZYKA*A/U1F]9UCR3'HK;+!9V'R^
M^LH_WDY'NAC-KL=>;J T!DKC4#0Y":W0PNCDFL>@2@N4QD!I'(HF)Z%56M@H
M(@ZH^1JP6X'$1U2=S].8*29,8^)ZU%'N&KB1)(?9:AELUC+-#'[R,XSRG^:
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M(>@:%"B-0]'DK.QL\WO!/C_8C7ZP._U@M_K]'SJ-M#J-O'2W7PV0;M519SE
M8X4]JN[UTU@AA#Q?;01=,P][>[0!:>40,<NARV4DLCR)A17&<VN6Q'D:[NS\
MTP8/NBX%2F.@- Y%DW/3ZC9R^M8_ BK40&D,E,:A:'(26J%&7KH!L ;L[L)5
M)PLU)L2Q;77"4&.&-'9<8T<ELVVL_9U'#58BO:^>\<B*(M_$^7;K>7.T>8YD
M5#T]H1R_0&=CI#G.T!G?/B72XK</K5R&Z?TRSJQ(W!6GLM]Y126EV^= MF_R
M9%T]Z/ MR?-D5;U<B' NTM*@^/PN2?*G-^4)FJ=QAO\!4$L#!!0    ( ,.
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M:&PU['"%W2!(8X#/%T+HW<0$:/O+V6]02P,$%     @ PX!A5<MD2436#
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MD^F1"*%)/2C-__"X-75XX#/I?_5,A3K#Q:K4CW94-XY%J7=-+[0WLSI@U_I
M/Y;;,8Y.CS9SH'OJ0FD>E.:C:$U5TEJ55*G*9_X>1.+]^H4%:2AE*#O]Q78N
MB./]^OR9_.L_ XT$R4*JE)%ML@BSN52M5+ (TI4\G_Z^=TI_)X_!SS#>QIVR
M53;A8MDB:2:49D%I-I3F0&DNE.9!:3Z*UBRIVAS4$>Z@#K4'H3032K.@-!M*
M<Z T%TKSH#0?16L61>T3ZFJCL.QGR"9XWWW)1HY[EENQ31E91?PEB$@B^Y/\
M(C,C5T%& K)AJ:PCT3EC4B;3]8-AA':C#YNCB =UFRZN"JB'"*794)H#I;E0
MF@>E^2A:LRIJ\U)7NY>G#2-UX,7= Y)F0FD6E&9#:0Z4YD)I'I3FHVC-0JB-
M4WV$&#-!;50HS832+"C-AM(<*,V%TCPHS4?1FD51^ZFZTJ2:/;$TY(M\TCWA
M0A8(6?*TF"<*DZ#X;KU\)RH+)]@73F?=J//HE,3%%VT[JP3JL4)I%I1F0VD.
ME.9":1Z4YJ-HS2JIO59=;;96,U"GIK*X6#-9-^L@.7M6ZS%,3DYF0=U:*,V$
MTBPHS8;2'"C-A=(\*,U'T9K553O!^A0Q,(.:OU":":594)H-I3E0F@NE>5":
MCZ(U[R*J+66JMI2QDUEELM9DEM;Z9O>#NDV75@649D%I-I3F0&DNE.9!:3Z*
MUJR*VN"F:H/[+QF(G785U:VYM,^!TDPHS8+2;"C-@=)<*,V#TGP4K5E=M5%/
M*6 @1J%6.Y1F0FD6E&9#:0Z4YD)I'I3FHVC-HJBM=JIT+=$#,:/35:3M@1C4
M:X?2+"C-AM(<*,V%TCPHS4?1FE51>^U4[;57 S&3O;*(;_+2^$R>V6H;!8*G
M[\60ZX''L:R%,/]*XFXV^3&492+D4*R[9T'ZK@]0F@FE65":#:4Y4)H+I7E0
MFH^B-6NH=N;I$#'<@KKT4)H)I5E0F@VE.5":"Z5Y4)J/HC6+HG;IJ?K^YJJ'
MV ^X2!PLBBMW>5U_EA.I3G!QP4 =?"C-@M)L*,V!TEPHS8/2_))V>%N"H6FG
M;N:@M35/U9;YE\4BS =-\@HC;A=%5A:$6+,SBP)Z3W1).[S#8J@U]KF4.]2*
M/S.K#<WJ0&DNE.9!:?['Q[>IY-H^IQ_<JYS?STDVVW2^#@Z%6MW;T:E8J D.
MI9E0F@6EV5": Z6Y4)H'I?DH6K-&:A.<(DQP"C7!H3032K.@-!M*<Z T%TKS
MH#0?16O^!&)M@AMJ$_QIWV7P)9GS..;)[K<!RM'/KE^I-JI*Y^#',$CG+*PZ
M[:5E!*694)H%I=E0F@.EN5":9QS?H:VWQID^*F.S.&HOW%![X97N-VG^Q=U6
MB73*'FIG0VDFE&9!:3:4YD!I+I3F&<>WSH^.K[!\5-*F\FN?VE#?4/XDS_W%
MZ;V4_I67%+^=O=FO[S[I0WUK*,V$TBPHS8;2'"C-A=*\DM90?UOY4#.Z?_";
M\C%+5\4S##)Y'M\F(D]RL+9Z3L*7XND K?4/^JVI=ZRW]%N[:[VCWWJ[IR/4
M:7</:W@,TE689"1B2]D$[68LN\!T]_R#W8+@F^*7[E^X$#PN7JY9((=C^0;R
M_27G8K^0)ZB>0C'[/U!+ P04    " ##@&%50+7YOP$-  !KKP  &0   'AL
M+W=O<FMS:&5E=',O<VAE970T-BYX;6RUW?USHD@>Q_%_A?*VKG)5.Z. FH=+
MK)H,S]SLIB:3O9\9;94:!1<PV;FZ/_Y 441)!Z_>J:W:,81^-<;^A@8^@=N7
M./F1SH7(E+^6BRB]Z\RS;'73[:;CN5@&Z<=X):+\.],X6099_F4RZZ:K1 23
M3:/EHJOU>L/N,@BCSNAVL^PA&=W&ZVP11N(A4=+U<ADD/^_%(GZYZZB=W8*O
MX6R>%0NZH]M5,!./(GM:/23Y5]V],@F7(DK#.%(2,;WK?%)O_(%6--BL\4<H
M7M*#UTKQ5K['\8_B"W=RU^D56R068IP51)#_\RP^B\6BD/+M^+-$._L^BX:'
MKW>ZM7GS^9OY'J3B<[SX=SC)YG>=JXXR$=-@O<B^QB^.*-_0H/#&\2+=_%]Y
M*=?M=93Q.LWB9=DXWX)E&&W_#?XJ?Q '#=3K5QIH90/MJ$'_M1[TLH%^U$"_
M>J5!OVS0/VJ@::\T&)0-!FT;#,L&P[8-+LL&EVT;7)4-KMK^E*[+!M=M>U![
MNT^NU[K)_L/>#KKM*-D,,2/(@M%M$K\H2;%^[A4O-N-TTSX?66%4E-1CEN3?
M#?-VV>A?X3BO#Z%\FB5"Y*62I<H'Y8M(UJER88@L"!?I/Y1?E*Z2SH-$I$H8
M*4]1F*6_Y@OSU]_F\3H-HDEZV\WRK2G,[KCL^7[;L_9*SZKR)8ZR>:J8T41,
M&MJ;\O;Z6^UM>?OKM]J[;VR_]A;@R8'+G@3HYI_C_L/4=A_FO285O2#ZJ.CJ
MKXK6TS0ES,2R8:L^MS=4Y>G14"Y^J8V [3\-L"&'#3'>P>IP#Q<;>: W#0,Y
M^RA6.=LKWW/)-C!6>T:5,#:S-0ZS->[_\R-O\UEZS-OT6V_?:V^S5@?Z_I>:
MOG'UUK_4FGX];8U^LU%,96[253 6=YU\KI**Y%ET1G__FSKL_;.IJ$C,(#&3
MQ"P2LTG,(3&7Q#P2\R&L5E;]?5GU9?KH*<HG[8OP/V*BS/+)NG*QB--\=I!/
MC!=Q-%,RD2SS.<&S2+-7:T[:P;DU1V(&B9E;;+C!BH.:Y]&'X;!WVWT^K*6&
ME;3+_N!H-;MAM4M-[6OUU9PF[4J_[M=7<\FWZ9&8#V&UD3W8C^R!=&1O)KQ-
MXU7:[-SQ2F(&B9DD9I&836(.B;DDYI&8#V&U2AKN*VD(3+V&9%F1F$%B)HE9
M)&:3F$-B+HEY).9#6*VL+O=E=2G=05E!F"C+(/DA,N4Y6*R%$D^5>)VTGWE)
M_7-+CL0,$C,O3Z9!EZK:.YYZD5W:K;ITR"Y=$O-:;;]_NI:J:M<'J]7&]=5^
M7%])Q_7O+Y%(TGFX4E8BR?<<63 3RD60*L%N0=-IA7LI>NY@)C&#Q,PMIJH'
M/_3>Q][5T6 FN[1;=>F07;HDYK7:?A_JLC;DK_=#_OJ]CZ*E'9P[_$G,(#'S
M^O20]EH_^5U^NI9^LI+=0/75JY-?TJ>KJ:>82[Y)C\1\"*N-:[5774KJO7T4
MK?Q7<1]^;[P<)&U][K!%-0/53%2S4,U&-0?57%3S4,VGM'IM'5RF58'CZA*A
M2HS4#%0S4<U"-1O5'%1S4<U#-9_2ZB6F526F27=?#R+97A!55DE>;<J%&VVN
M2:YVR_^1[]NDEZKOY3V<77];[>I@.J+U/UX.ZM,1 ^W41#4+U6Q4<U#-134/
MU7Q*JQ=6=35>E5Z5''V.E\O\\*;,'*S6R7@>I/GAST6X6UA4EJ2JT"OUI38X
M/& 8]'K'LWP#[=5$-0O5;%1S4,U%-0_5?$JKEU5U-5Z57X[_;;W\GN^:XNE!
M-F\=343RDH19)J*\TKXOPG&^PE0D831K7V_H5?I2.ZRW_E7QW\E^#+T$CVH6
MJMFHYJ":BVH>JOF45B^X*B2@RE,"?^PNO)3U%HS_7(=)8_3S7DZ=74.#DQ-3
M5Y>G>RPT$X!J%JK9J.:@FHMJ'JKYE%8OH"H;H$JOD;X>LY&W.[M:T$0 JIFH
M9J&:C6H.JKFHYJ&:3VGUJJJB >HE<6H0#0"@FH%J)JI9J&:CFH-J+JIYJ.93
M6KW$JI2"*H\I5(=:87Z M1+Y_Z),627Q+ F6Q26O5_[6YE[NGEUU:%2AU X/
MS-2C*:6)]FBAFHUJ#JJYJ.:AFD]I]5JJX@^J//]0U5(PF83%W]4&B[R4Q#A?
M,1SGKR=A.HZ?1?*S58%=OSF(/\LWZ.RR03,.J&:AFHUJ#JJYJ.:AFD]I];\!
MK6(8FCR&4178OGXVIP65;"Z4O,/U(BO.!N;?G*S'6:H45[S&\8=IL=)$F<:)
M,A'/8A&OBKFDI/3*S3@LO:,_2ODLW])S*P_53%2S4,U&-0?57%3S4,VGM'KE
M52$-37J%>O0I3>-Q&&1%&:VS=5Y7LT7\O=BE'134.$[SHOM5":?*YL82^<I9
M7!1@N5*+^&NY&4<I1WUP7'UH?@/53%2S4,U&-0?57%3S4,VGM'KU5?D-39[?
M^!(N1)K%D5!6P<]-J2V#B2CW?8OR)$FP.TG26%=H? /5#%0S4<U"-1O5'%1S
M4<TKM5IV^22(X%-]ULNJ2F]H\O3&+M7[])O[S324QV^?OIF/C=6#QC10S4 U
M$]4L5+-1S4$U%]4\5/,IK5YE59A#ZP,G\34TF8%J!JJ9J&:AFHUJ#JJYJ.:A
MFD]I]1*KXAN:/+[QD,33,-N$-S9IJ+</L] ,!ZH9J&:BFH5J-JHYJ.:BFE=J
M1X?U@^/IX'MD.+0JPZ'),QP/U=_I;L\P%C6U^1M&D397$9KM0#4#U4Q4LU#-
M1C4'U5Q4\TKMK2IZC\R&5F4V-/G]''8'55_"*%RNFT^OHX$-5#-0S40U"]5L
M5'-0S44U#]5\2JO75Q78T*Z(PRDTG8%J!JJ9J&:AFHUJ#JJYJ.:AFD]I]1*K
M<AR:/,?Q-?X9++*?NY/M:7$'B_I5KTCD1UO!0J1MCK70>UJ@FH%J)JI9J&:C
MFH-J+JIYI79\HYCA\33Q/:(<>A7ET-O=4:.<)N:O?HNC#T^-I]_EU+D5A&H&
MJIFH9J&:C6H.JKFHYJ&:3VGU0JN2&SIQ>PT=O;T&JAFH9J*:A6HVJCFHYJ*:
MAVH^I=5+K(IGZ/)X!CM?E'=V=BFB40U4,U'-0C4;U1Q4<U'-*[6WYHM4I_4:
M.WCN1;NLQI?@K]=.*\J%LPN'?>X%^^ +]LD7[*,OV&=?L ^_8)]^P3[^XCU2
M&GJ5TM")E(:.IC10S4 U$]4L5+-1S4$U%]4\5/,IK5YB54I#EZ<TX&DB&N%
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MH30/2O-1M*:,#RD<^D8.9Y<L0[5<\Q59[>0N963)GEC$MYFDR8(+*<A9($A
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M%=3W*\[E_B1S4.TUG?\+4$L#!!0    ( ,. 8569/\K%4 8  $,^   9
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MU._K.):'D3Q!]4&@^?\!4$L#!!0    ( ,. 8559&.=[6 ,  "@-   9
M>&PO=V]R:W-H965T<R]S:&5E=#4P+GAM;,57;6_;-A#^*P>U&%I@C63Y+<YL
M XZ3805F($B0#=TW1CI;1"E2)6D[*?;C=Z1DQ=X4(2D$[(M-4GP>WG-W/)VF
M>Z6_F@S1PF,NI)D%F;7%11B:),.<F3-5H*0G:Z5S9FFJ-Z$I-++4@W(1QE$T
M"G/&93"?^K4;/9^JK15<XHT&L\USII\N4:C]+.@%AX5;OLFL6PCGTX)M\ [M
M?7&C:1;6+"G/41JN)&A<SX)%[V+9\P"_XP^.>W,T!B?E0:FO;O(YG061LP@%
M)M91,/K;X1*%<$QDQ[>*-*C/=,#C\8']5R^>Q#PP@TLE_N2IS6;!>0 IKME6
MV%NU_PTK04/'ERAA_"_LR[WC20#)UEB55V"R(.>R_&>/E2.. ,33#(@K0/Q:
M0+\"]+W0TC(OZXI9-I]JM0?M=A.;&WC?>#2IX=*%\<YJ>LH)9^>_\X1B@K#8
M:$0*CS7P"3Y+J78TA@]7:!D7YN/QXB>XO[N"#^\_PGO@$E9<" J(F8:6['&L
M85*=?5F>';]P=@]62MK,P+5,,6W +]OQDQ9\2'ZHG1$?G'$9MQ*NF#Z#?N]G
MB*,X;K*G'7Z'!<&C)OB).?TZ-GW/-WB![PIW=,T*%Q5@,H5;W&P%LTH_.:<C
MY89$ W_#BCWR?)LW!:#U %<B+DS!$IP%5 ,,ZAT&\Y_>]4;1+TWJ.R([\<6@
M]L7 L_=?G:=-<@==RNV([$3NL)8[; W]?;'6J@H[SW-,.;-(][^*.A3LR:>%
M5?" 5$X3I&*8PI8N@@91^8H=?-7DJM;SW^JJDFSDR=R+8S>?#*;AKL$!H]H!
MHU8'O)3K-]>KQ5]?;J^;)+4ROE521V0GXL>U^'$'R3[N4FY'9"=RSVNYYZVQ
M7N1J2[E,6:PVDG^G/'9I7R<U]2I@,TKG).-4$7W>JS4P(%/HA4UDZ?/-:'+4
M^7^R<U@G9ZF^U;X?5#^IU4]:U2\5W6^=<";X=^9;F]<6]U;>MR9 1V0G+NA%
MSUU(U$'&5R0=*>Z*[53R4>/5^Y]+?+L!;W97R38YND;4YYP-_U7GPZ->E/)Z
MXUMT XF[XF5;6J_6GP$+W_R&S]O+;PAJQS9<&A"X)FAT-J;7C"[;\G)B5>$[
MVP=EJ4_VPXP^95"[#?1\K90]3-P!]<?1_!]02P,$%     @ PX!A59ESDJ"I
M @  K@<  !D   !X;"]W;W)K<VAE971S+W-H965T-3$N>&ULQ55M;],P$/XK
MIS"A38*F35\WVDCK"@*T2M.F@<0W-[FVUAP[V$[;\>LY.VDH6A<AQ,27Q&?[
MGGN>\_D\WBK]8-:(%G:9D&82K*W-+\+0)&O,F&FI'"6M+)7.F"53KT*3:V2I
M=\I$&+7;@S!C7 ;QV,_=Z'BL"BNXQ!L-IL@RIA^G*-1V$G2"_<0M7ZVMFPCC
M<<Y6>(?V/K_19(4U2LHSE(8K"1J7D^"R<S$=N?U^PQ>.6W,P!J=DH=2#,SZE
MDZ#M"*' Q#H$1K\-7J$0#HAH?*\P@SJD<SP<[]$_>.VD9<$,7BGQE:=V/0E&
M :2X9(6PMVK[$2L]?8>7*&'\%[;EWN%Y $EAK,HJ9V*0<5G^V:[*PX%#%#WC
M$%4.D>==!O(L9\RR>*S5%K3;36ANX*5Z;R+'I3N4.ZMIE9.?C:]Y0AE&N%QI
M1$JV-? 6OC$.UVP!IS.TC MS=C!W;5.RYFS'LR*#$^ 2YEP(RK 9AY88.=PP
MJ:)/R^C1,]$[,%?2K@V\ERFFO_N'I*26$^WE3*-&P,^%:$&W\P:B=N<<[N]F
M<'IRUH#;K=/4];B]9W!GN*'ZS5V"@,D4;G%5"&:5?G3JD8Y)XE']C;#NQEV8
MG"4X">A*&=0;#.+7KSJ#]KL&TKV:=,^C=__X;(\Q[+T PW[-L-^8UOM\J565
M4IYEF')FD<J\RBCD[-&GW"I8(/6 !.D*IU!0M6@0E3RVEW=,71G_W,=W#6H3
M1U&K/PXW1U@/:M:#1M97BJCJA#/!?S#?6YIKH!'M+S,\K+D._T$-#%^ X:AF
M./K/-3!Z4@/=X9,:" ]Z*)WNRK\4!A)52%NVTWJV?HPNRQ[\:WOYDLV97G%I
M0."27-NM(16A+E^'TK J]QUYH2SU=S]<TX.*VFV@]:52=F^X /43'?\$4$L#
M!!0    ( ,. 857;]3652@@  "U4   9    >&PO=V]R:W-H965T<R]S:&5E
M=#4R+GAM;+6<;6_;.!+'OPKA72Q:X+:VGOR030RDEBAU<3T437KWFK%I6Z@>
MO!*=-(O[\$O)BF5*#&MO__LFL969WU":D8::87C]E!=?RRWG@GQ+DZR\&6R%
MV%T-A^5RRU-6OLMW/)-_6>=%RH3\6FR&Y:[@;%4KI<G0'HW&PY3%V6!^71_[
M5,RO\[U(XHQ_*DBY3U-6/+_G2?YT,[ &+P<^QYNMJ X,Y]<[MN%W7'S9?2KD
MM^&1LHI3GI5QGI&"KV\&M]95Y'B50BWQWY@_E2>?274J#WG^M?KR874S&%4C
MX@E?B@K!Y*]'ON!)4I'D./YHH(.CS4KQ]/,+G=8G+T_F@95\D2?_BU=B>S.8
M#LB*K]D^$9_SIX@W)U0/<)DG9?V3/!UDQ^,!6>Y+D:>-LAQ!&F>'W^Q;<R%.
M%"1'KV W"G97P7U%P6D4G',MN(V">ZX%KU'PN@JOG?2X41B?:V'2*$S.59@V
M"M/:NP=WU+[TF6#SZR)_(D4E+6G5ASH@:FWIPCBK8O=.%/*OL=03\W_'2QF(
MG-QN"LYE3(J2_$H^YL5NF]\]E^2-SP6+D_*M//KESB=O?GY+?B9Q1NZW^;YD
MV:J\'@HYC HV7#8FWQ],VJ^8="0_$]N2!-F*KS3ZOEE_]CU]^AW[I@$,Y?4[
M7D3[Y2*^MXW$.[Y[1YS1OX@]LFW-@!;GJUNZZ_%CUH,?LTY_S'IH5O?Y4JI;
MKUJ/S.J_L^RH/C)XTCG>#D[-<\Z^'73Q?6"X>D:5;:[*'5ORFX%,)R4O'OE@
M_LM/UGCTFRXVD# ?"0N0,(J$A4A8!((I\>8>X\TUT>=?,CGA2.(_^8ILY$2#
MO$GR4CYL95)/\FQ#!"]2^;1]Y*5X-1@/!L:U@6JF\CC_=3R6]\+C:9!IA.R)
MZW7$?(W8Q+9<6Q4+=+2I,W-5,6H\]4M=CH1%()CB<N_H<L_H<CG+2MA#7K!Z
M[E;YFY1;5L391N?= \L[N=369#SK>+<O-+/<CI"O$1IY7L>S?2%[YD[&'<<:
M3_!2QR)A$0BF.'9\=.S8Z-C/DLB*Y9;(:9&</C_*]X)===<2_FU7)16=>\>]
MZ^U,W=%HTG&P1LQQ9V['>WY?S!I-7:_KOZ O-YMZCM>YS:GQ="]U,Q(6@6"*
MFR='-T^,;FXGQ[>ASJ5&[4LG!TB8CX0%2!A%PD(D+ +!E$B;'B-M"IB,3I'Q
MAH3Y2%B A%$D+$3"(A!,B;?9,=YFQB<;97%!4E9\Y8(\LF3/2;XF^;XX?RXZ
MZR>@J3/J3D:-H[@TR,XR&2!-TEEO^JLQ&?:E'-?N2D6@@2G^MD9M\6?T3[]^
M-!9.'3#M>5PC)-\_>M?,U\E9WJSG3IW<>-2[NM1\^I?>Z%!:A**IKC^I^UD_
M-(TQJU^:5Z T'TH+H#0*I8506H2BJ2%GMR%G ^8S#005>$B:#Z4%4!J%TD(H
M+4+1U,!KB[J6L8;WM][,&Z12"K%ZF6BA%?/ZB:TO-AFY_;S6%_.\7CJEYM.]
MV-70:BJ*IKJZK:=:YH+J[7)9[.5TIO)T+K9<3EYC]A GL8BY_G'3+V9.[)X#
M%V:S%S]'SC(:0(W2AN:9C8::L6DB.D*-3?5S6T2US%74T^D+^3_Y\I\/]X%/
M[NYO[X,[K9N19<8%E.9#:0&41J&T$$J+4#0U!-MRKS5&3&>0A<\%E.9#:0&4
M1J&T$$J+4#0U\-H"M&6N0'\J\G4L7E[6F^81J1M*V@@\T"SKY(D^>N=U$QRT
MU'R6S0!JDT)I(906H6AJQ+2%9,M8-S1F2_G]GJU9&0N6L@<B@VNU7XIZ G4G
M!R(?<MJ@@I:=H30?2@N@- JEA5!:A**I0=I6GZT9(I\B2[D+*,V'T@(HC4)I
M(906H6CJXKVV"FZ;J^"7K<AH8&KYO_>^J)&:6;VRP%E2@4;*GO7>R*CY+"_U
M,)06H6BJA]MBMWU^L5OF._^D!%3EN<]\LT^8R(MG\C%.>"GR3%\L,)NY].$#
MI?E06@"E42@MA-(B%$T-S;8H;B.*XC:T* ZE^5!: *51*"V$TB(430V\MBAN
MFXOBQR<=V;'G^E&8LA4G^VQ5%TT/4<E>HE(;E-!UT%":#Z4%4!IM:$H^[]=A
MH38C%$T-MK8L;YO+\G\G 4NYC^Q;G.Y3;? A:^,+*,V'T@(HC4)I(906H6AJ
MD+8]!=M#I&)H)P%*\Z&T $JC4%H(I44HFAIX;2?!-J\<OUVMXNK=DR4D[6;E
MLLG(8LO/S,K0A@.4YD-I 91&H;002HL:FM(O=B:G<P8U\MI6@GW^8G:9;Q=Y
MFO)B&5=K @_5D+/3,739.Y3F0VD!E$:AM!!*BU T-3;;IH6-6/YN0QL14)H/
MI050&H720B@M0M'4P&L;$;9Y'3PV'4/[%5":#Z4%4!J%TD(H+;(U:_NK)5*O
MI&.G[40XYDY$)QU_;XVVF79I;$%I/I060&D42@NAM A%4R.P[90X%B#I.M ^
M")3F0VD!E$:AM!!*BU T-?#:/HAC+'?/J<RKU3*F?$W6>[$ON+)0>YF7,O6^
M825A9"??4.2QM]K A/9)H#2_H7761'7_B3N &J506@BE12B:&G$G6[U\IP&B
M)ML/V?)9:-<ZF3D7!Q5VPQ?LCB_8+5^P>[Y@-WWY)_HA3ML/<5Q$FH7V.* T
M'TH+H#0*I8506H2BJ8'7]C@<\_]-@-(LM <"I?D-K;OTN)=FH<T-*"V$TB(4
M[1!QPY.]!E->;.I])TL9.?M,'/99.QX][FUY6^_HV#G^WKI:6)KCOG45'':N
M;/&'C30_LF(39R5)^%J:&KV;R!,K#GM3'KZ(?%?O=/B0"Y&G]<<M9RM>5 +R
M[^L\%R]?*@/''4+G?P%02P,$%     @ PX!A5:>/F*JJ @  Z@@  !D   !X
M;"]W;W)K<VAE971S+W-H965T-3,N>&ULO59K3]LP%/TK5H8FD 9YE#Y@;22@
M0INT3HB*[;.;W#86?F2VT\)^_:Z=-'13B28$?$E\;=]SS[G7K_%&Z7M3 %CR
M(+@TDZ"PMCP/0Y,5(*@Y425('%DJ+:A%4Z]"4VJ@N7<2/$RB:! *RF20CGW?
MC4['JK*<2;C1Q%1"4/UX"5QM)D$<;#MNV:JPKB-,QR5=P1SL77FCT0I;E)P)
MD(8I230L)\%%?'X91\[!S_C!8&-VVL1)62AU[XRO^22('"/@D%D'0?&WABO@
MW"$ACU\-:-#&=(Z[[2WZM1>/8A;4P)7B/UENBTDP"D@.2UIQ>ZLV7Z 1U'=X
MF>+&?\FFGCO$B%EEK!*-,]J"R?I/'YI$[#@DR3,.2>.0>-YU(,]R2BU-QUIM
MB':S$<TUO%3OC>28=%696XVC#/UL^HUEF&(@%RL-@-FVAAR3[TPL.)##*5C*
MN#EZZCHF,_K 1"7( 6&2S!CGF%LS#BUR<8AAUL2]K.,FS\2=0WE">M$GDD1)
M0N[F4W)X</0W3(A26CU)JR?QN*?/X%Y7MM) ,B4MDRO40W)F,K4&_8CIXX )
ME;"7;R>NVQSGIJ093 )<_0;T&H+TXX=X$'WN8-UK6?<\>N^_J["/8>\-&)ZV
M#$\[\WJ1Y\QM(\J?TDA*^E@OF4KFH(DM@/!&"=TJV2>D#C7PH=RQL4Y'XW"]
MAUV_9=?O9#>%-9XOI8M'J,S)+:PJ3JW"HL\ZB]X)^\*4#EK2@U<H^N -& Y;
MAL/W*WH=JK]3]#@9[B_[J.4WZN1WI80 G3'*V6_J#_GN:G>BO3"79RW7LU>H
M]MD;,(RCI[L@>K]Z-[%V=WG<B_XI>+AS<[E7P(SJ%9.&<%BB5W0RQ/6BZXNU
M-JPJ_66V4!:O1M\L\#$"VDW \:52=FNX^[%]WJ1_ %!+ P04    " ##@&%5
MEE][HK("  "Y"   &0   'AL+W=O<FMS:&5E=',O<VAE970U-"YX;6RM5FM/
MVS 4_2M6AB:01I,F?3#61H(R-*150E1LG]WDIK7P([.=%O[]KITTM%.I8.J7
MQ'9\CL^YOO;-:*WTDUD"6/(LN#3C8&EM>1F&)EN"H*:C2I#XI5!:4(M=O0A-
MJ8'F'B1X&$?1(!24R2 =^;%[G8Y493F3<*^)J82@^N4:N%J/@VZP&7A@BZ5U
M V$Z*ND"9F ?RWN-O;!ER9D :9B21$,Q#JZZEY.AF^\G_&*P-EMMXIS,E7IR
MG;M\'$1.$'#(K&.@^%K!!#AW1"CC3\,9M$LZX'9[PW[KO:.7.34P4?PWR^UR
M'%P$)(>"5MP^J/4/:/ST'5^FN/%/LF[F1@')*F.5:,"H0#!9O^ES$X<M0+?W
M!B!N /&_@/X;@*0!)-YHK<S;NJ&6IB.MUD2[V<CF&CXV'HUNF'2[.+,:OS+$
MV?0GRW!+@%PM- #NCC7DG-Q)J294 SF] 4L9-V?;@^?$TH(:9JF@<^P]SF[(
MZ<D9.2%,DBGC'+?'C$*+ZMP:8=8HF=1*XC>4=,E42;LTY+O,(=_%A^BJM19O
MK%W'!PEG4'9($GTA<13'^_2\']X]("=I(YUXON3=D=ZCZ;KFZ.WG<$?ZTI0T
M@W& 9]: 7D&0?O[4'43?]AD\$MF.W5YKMW>(/7TL"XW[24KZXLSBB<\ #VQ.
M*MQ>37@3#;J)QKY@'%SAH\&HR0:>S-UMJS3IC\+5'HO]UF+_H,4I?6:B$ON4
M'P1^5/F1R'8\#EJ/@R-D[>"8=H]$MF-WV-H=OBMKJ<P)$P)R1BW@O<L!;V()
M;39;1>;P7SE=K_]U*PTOXLYK(M8A."CRHR$(MZJ# +WP1=.03%72UH6B'6WK
M\I4O1^'K]+JH3ZE>,&D(AP*A46>(J:GK0EEWK"I]K9DKBY7+-Y?X;P':3<#O
MA5)VTW$+M'\KZ5]02P,$%     @ PX!A59KAM1/G!P  X4T  !D   !X;"]W
M;W)K<VAE971S+W-H965T-34N>&ULM9QK;Z-(%H;_2LD[6J6EZ9@JP)=L8BD=
M+A5I>Q0EG=G/M%VQ47/Q DXZJ_WQ6V ,+D-J\,R[7Q+ G.?%KM><\CG ]5N:
M_<@W0A3D9QPE^<UH4Q3;J_$X7VY$'.27Z58D\I67-(N#0JYFZW&^S42PJH+B
M:,P,8S*.@S 9+:ZK;0_9XCK=%5&8B(>,Y+LX#K+W+R)*WVY&='38\!BN-T6Y
M8;RXW@9K\22*Y^U#)M?&#645QB+)PS0AF7BY&=W2*VZR,J#:X_=0O.5'RZ1\
M*]_3]$>Y<K^Z&1GE$8E(+(L2$<A_K^).1%%)DL?Q[QHZ:C3+P./E ]VKWKQ\
M,]^#7-RET;_"5;&Y&<U&9"5>@EU4/*9O7-1OR"YYRS3*J[_DK=[7&)'E+B_2
MN Z61Q"'R?Y_\+/^((X"J/5! *L#V&F _4& 60>80Q6L.L :JF#7 ?90A4D=
M,!FJ,*T#ID,59G7 K!K=_7!48^D$1;"XSM(WDI5[2UJY4!FBBI9#&":E=Y^*
M3+X:RKAB\<]P*8THR.TZ$T)ZLLC)9_+TGJR"G^3"$4401ODGN>GYR2$7OWPB
MOY QR3=!)G(2)N0Y"8O\5[E1+G_;I+L\2%9RO=WA:QA%TJ+Y];B0!UM*CI?U
M@=WM#XQ]<&"4?$V38I,3-UF)54^\JX\W_RC>U\?/-?%C^2$WGS0[?-)?F!;H
MB.4E,>:_$F8PVO=Y# @WZ8?ACC[\26QEN/%AN#L\G/6$>W]-W?]KZOQ/JRLC
M:3;?&;/BF8._,SW']&7/L/H994JZRK?!4MR,9,[)1?8J1HN__XU.C'_T>0,)
M<Y P%PGSD# ?">,@F.(WJ_&;I:,OO"#,Y#D_^R&G,E&:K$DALEB>75]%7GQH
M/RWR7/OM89,*5LZ&7A>,43:97(]?CXV%U'2[FM2:4V:IFAY2TQ^FR4&:BAGL
MQ@RVU@R/DAADRPV1J59.TE[E['-;FJ#/ UK2N1Y PAPDS-W#[*-1,V>684Q/
MG&)W!M<TK;EEJ[OY71HU9I8]/3$[[^+F,]NT6;.;,KR39G@GVN%]3N0OD"C\
MCUB1M?SE02ZB-)<3,#G+'_S-UPJ<.^I(F(.$N9/..'V>3(R3,9]T!NDSFUKV
MR6Y^#VO*J,5.AKR/-C/G5O^03YLAGVJ'_+X9SG+&O)][]XVKEG+NN")A#A+F
M(F$>$N8C81P$4QPW:QPW TQ@9TB_(6$.$N8B81X2YB-A' 13_#9O_#;'3V"U
MR'/M-^].$2@U3M* @Y1T>R0M=BKI(27]09(<)*DX@1IMO<GX?T]P] KG6@-*
M<Z TMZ8=C^ADUO$05-/OT30[7Q6.TE1==%2UI%H7?3Q+T@>>;0XDS8'27"C-
M@])\*(VC:*K96&LV!I@NU1"4\9 T!TISH30/2O.A-(ZBJ<9KZ\Q46U9</&]?
MLE3^+-P&[]7/PUVR$AF):CL&!SOVNA%:?JYI2F&,3HW.! JJZD)I'I3F0VD<
M15-]UM:7J;[ 7/?[_DN<MIY8U1<?Q7H7!46:O9>=/#DG2Q.1R_V^!C_#>!?W
M&@]:>(;2'"C-A=(\*,V'TCB*IMJSK7A3&Y%_H=5N*,V!TEPHS8/2?"B-HVBJ
M\=I:/-47XV]7J["\PB:(2'PX_1V2<5YGXV(C!F9D:%T>2G.@-)=VR^F,&9W9
M@@=5]0>J<I2JZJFVV$_UU?XFU]ZE<2RR95@60X+J.J[!*1;:"8#2'"C-A=(\
M*,V'TCB*IKJR;0A01$> 0EL"4)H#I;E0F@>E^5 :1]%4X[6= :IO#6!3++1G
M *4Y4)I+NZ5^9O:E6&A_8: J1ZFJUUFV+0:F;S$T*;99>/[M_IOKD*=OM]_<
MIS[GZ(GG.@=*<Z T%TKSH#0?2N,HFNK"MD7!*""E,FB[ DISH#072O.@-!]*
MXRB::KRV7<&T5>F%)[-FF*Q)^D)>=L4N$\>7"9)EFLO$>A'D)"!;^?M#;OO4
M:TQH.P-*<VH:I4>)R+@\O9+/A8IZ4)H/I7$4375<VZ=@^CY%DV?OD^5[(08E
M7&A_ DISH#072O.@-!]*XRB:ZL*VB\$L1,*%]B>@- =*<Z$T#TKSH32.HJG&
M:_L33'])/BCA0OL74)I3TTX2KMU)N-#&!)3F0VD<15,=US8FF+XQ\52DRQ]D
MN\N6F^"X*%*EX&%7D^L5SK8;M!T!I;E0F@>E^5 :1]%45[:M#39%)&!H]P)*
M<Z T%TKSH#0?2N,HFFJ\MGO!M$7JQ</A1"@S\#*-XS0A>76&W->/]V?+9J?&
MGN1"GB'K>]7[4S*TWP&E.36-LN-KLBZMTXP,[6- :3Z4QE$TU8)M'X/I^QB-
MN[:9/ N>&K'77//.-76FW:FEW^EUSW8-M LQ["UX4%%_F"A'B:I/"&A[$*:^
M!_$@SSO5J:4VQ,5]4CU#8WO8WGO"J:&SX^_T]-*:G7A"KWVN)WI$F74Y.;GY
MT86*>L-$?:@H_T-1=;#;4K^IOQOA3]W?5#.5F^JMSLT==WKIL\<:6M*'TCPH
MS8?2.(JF&JPMZ9OZDOZC&'[3?XU2KM4V.G>!W>D5S_85] 8#*,V#TGPHC:-H
M>U^-CYX#%8ML73T3+)<SD5U2E")'6YOGCMU63]LZV7Y'KQS:L]VE5U[?=I]>
M\?W3QEK9_<//O@;9.DQR$HD7>0C&Y=0>D6S_/+']2I%NJZ=3?4^+(HVKQ8T(
MY+2]W$&^_I*FQ6&E%&B>ZK;X'U!+ P04    " ##@&%5ZV>*"%P$  #[&
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M(C+ (3/ T*E!K1%DLG9':&/M0P*!]@@RW:#G42)-U>/YU)_G94F6)O""/8?
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M3_"&<%V@SF\9D\\[>OV[_[]C^1U02P,$%     @ PX!A58]*93>L!P  \4P
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M9Z,_>4I<2)$UGLBLN+9JV<$&!2R_CKB;C-WAT/5.NW>'.GC<;#0>#WJ.V2Q
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M1%/>\TMY1\5C4;;2I)':TG"3AW$:$S+W;X;\8S.<I#$.>[,'9'%/%D^2+6&
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M_8B5J&.D?PM%3K4BI^X%;#72U_N5TZ5LPBAVTT,5.93&H#2.HIG;-[4B]Z<
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MTPW;-RT<N5$[[9BE4Z;8@RQ_=P[+"YQMBAZKXT;@C5P[ZOR=>C[HP+7)<@Z
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MLXL;07?Z0/B5"D$S?;DE."9,-9#OUY2*]QO50?6;POQ_4$L#!!0    ( ,.
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MAP#*&N#WM91F/[$!AE],_@M02P,$%     @ PX!A5?DVU9-3 P  %@X  !D
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MU1D\?YRKBQMP':#>3QF3FX86J*Z"P]]02P,$%     @ PX!A556K=_\3!
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MU6-"O3&R='WP41KLJFZ9XV0%R@K@]Y7$K#8;JZ"=U9+?4$L#!!0    ( ,.
M854^Q\<0) ,  ,D*   9    >&PO=V]R:W-H965T<R]S:&5E=#8W+GAM;*U6
M;6_:,!#^*U963:W4$0B!M@PBE9=ID]:M*NKV8=H'DQQ@S;$SVY3VW^_LA QH
MB-J-+R2V[WG.]]QQN?Y:JE]Z"6#(8\J%'GA+8[*>[^MX"2G5#9F!P).Y5"DU
MN%0+7V<*:.) *?>#9K/KIY0)+^J[O5L5]>7*<";@5A&]2E.JGH; Y7K@M;S-
MQAU;+(W=\*-^1A<P!7.?W2I<^25+PE(0FDE!%,P'WG6K-^E:>V?PC<%:;[T3
M&\E,RE]V\2D9>$U[(> 0&\M \?$ (^#<$N$U?A><7NG2 K??-^P?7.P8RXQJ
M&$G^G25F.? N/9+ G*ZXN9/KCU#$T[%\L>3:_9)U;MN]\DB\TD:F!1AOD#*1
M/^ECH<,6(+@\  @*0+ ':(4' .T"T-X'= X P@(0OM1#IP"XT/T\=B?<F!H:
M]95<$V6MD<V^./4=&O5BPM;)U"@\98@ST23-N'P"($,0,&>&W'(J-'E'OE"E
MJ$TB.1V#H8SK,]R]GX[)Z<D9.2%,D!O&.29;]WV#-[%\?EQX'>9>@P->V^1&
M"K/49"(22"KPXWK\50W>1P5*&8*-#,.@EG *68.TF^<D: 9!Q7U&+X>WJL+Y
M/^^3?_:^(T:[K(FVXVL?X+L#PQ1@,S";JM#DQ_5,&X5_ZY]5V<[YPFH^V^IZ
M.J,Q##SL91K4 WC1VS>M;O-]E=3')!L?DVQR)+*=I(1E4L(Z]FB,>1"0D!@+
M7['9RK59>,3OA8:JE.1L5X[-?BP>HDX#B^-A6^GG-F$CW+49/[=IA8V+7:-)
MA5'0N"R-=@+NE %W:@/^+&/J@I1S#%IC#<)CS%<)$PMBED"LP"P&/$LS*;!8
MJU2H=_$5>11V,J3 -E>(>79.!%21C6K)7EN8QR2;'(EL)T_=,D_=6A%'*Z5L
MJW@"JEQ!QF:O3#4QTE!>E9_NL\+I[E?@J-;]:V5_@</)D1SF:OI;W^84U,(-
M11KU60F3M^1RMYR[KMVXL;<_;/5&K8K],<YI^5CUESX?\FZH6C!4G\,<734;
M%U@F*A^<\H61F9L,9M+@G.%>ESAK@K(&>#Z7TFP6UD$YO49_ %!+ P04
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M+F[42O/R])+TZ07O]W\#4$L#!!0    ( ,. 857;=K!Q,0(  (DI   :
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MK?\X?GR6G6WZMWPV_EEQ\0)02P$"% ,4    " ##@&%5!T%-8H$   "Q
M$               @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    (
M ,. 855($9GT[@   "L"   1              "  :\   !D;V-0<F]P<R]C
M;W)E+GAM;%!+ 0(4 Q0    ( ,. 85697)PC$ 8  )PG   3
M  "  <P!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ PX!A543D
MBPG;!0  Y1X  !@              ("!#0@  'AL+W=O<FMS:&5E=',O<VAE
M970Q+GAM;%!+ 0(4 Q0    ( ,. 854Q]S%W=P<   ,@   8
M  " @1X.  !X;"]W;W)K<VAE971S+W-H965T,BYX;6Q02P$"% ,4    " ##
M@&%5DB 5(6P#  "4"P  &               @('+%0  >&PO=V]R:W-H965T
M<R]S:&5E=#,N>&UL4$L! A0#%     @ PX!A5:<6:%#D!P  S2D  !@
M         ("!;1D  'AL+W=O<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0
M   ( ,. 857+(T!2^@,  &T.   8              " @8<A  !X;"]W;W)K
M<VAE971S+W-H965T-2YX;6Q02P$"% ,4    " ##@&%5S=(Q.;T*  "C7@
M&               @(&W)0  >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L!
M A0#%     @ PX!A56;GBJ.I P  )@T  !@              ("!JC   'AL
M+W=O<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0    ( ,. 856U,9IMZ <
M .XA   8              " @8DT  !X;"]W;W)K<VAE971S+W-H965T."YX
M;6Q02P$"% ,4    " ##@&%5&H+\]ED#  !"!P  &               @(&G
M/   >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%     @ PX!A56&Z
M@%5]!0  ( X  !D              ("!-D   'AL+W=O<FMS:&5E=',O<VAE
M970Q,"YX;6Q02P$"% ,4    " ##@&%5\YU(&  $  "("   &0
M    @('J10  >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    (
M ,. 857)5X0Z=@D  +<;   9              " @2%*  !X;"]W;W)K<VAE
M971S+W-H965T,3(N>&UL4$L! A0#%     @ PX!A53.RQYR%!0  (PX  !D
M             ("!SE,  'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q02P$"
M% ,4    " ##@&%52XGE<@$$   3"0  &0              @(&*60  >&PO
M=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    ( ,. 854:#GMYJAX
M )V%   9              " @<)=  !X;"]W;W)K<VAE971S+W-H965T,34N
M>&UL4$L! A0#%     @ PX!A50)L66-9!@  ; X  !D              ("!
MHWP  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4    " ##@&%5
M0V&CW.@"  !B!@  &0              @($S@P  >&PO=V]R:W-H965T<R]S
M:&5E=#$W+GAM;%!+ 0(4 Q0    ( ,. 856-:;@NW @  .L7   9
M      " @5*&  !X;"]W;W)K<VAE971S+W-H965T,3@N>&UL4$L! A0#%
M  @ PX!A52:6)ERQ!0  XPT  !D              ("!98\  'AL+W=O<FMS
M:&5E=',O<VAE970Q.2YX;6Q02P$"% ,4    " ##@&%5/>V+K$H#   N"
M&0              @(%-E0  >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+
M 0(4 Q0    ( ,. 856M_1#$?00  "(*   9              " @<Z8  !X
M;"]W;W)K<VAE971S+W-H965T,C$N>&UL4$L! A0#%     @ PX!A55K6?EO2
M P  .@@  !D              ("!@IT  'AL+W=O<FMS:&5E=',O<VAE970R
M,BYX;6Q02P$"% ,4    " ##@&%50,KH=>X#  !I"   &0
M@(&+H0  >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4 Q0    ( ,.
M854C9RF6\@4  +,0   9              " @;"E  !X;"]W;W)K<VAE971S
M+W-H965T,C0N>&UL4$L! A0#%     @ PX!A53K_74/K P  <@@  !D
M         ("!V:L  'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q02P$"% ,4
M    " ##@&%58=CJ4\8$  "!#P  &0              @('[KP  >&PO=V]R
M:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    ( ,. 8552F.C(. ,  (P'
M   9              " @?BT  !X;"]W;W)K<VAE971S+W-H965T,C<N>&UL
M4$L! A0#%     @ PX!A552M9P*3 @  @04  !D              ("!9[@
M 'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"% ,4    " ##@&%5LF%R
M(C #  #%!@  &0              @($QNP  >&PO=V]R:W-H965T<R]S:&5E
M=#(Y+GAM;%!+ 0(4 Q0    ( ,. 85649'=M_0(  '<&   9
M  " @9B^  !X;"]W;W)K<VAE971S+W-H965T,S N>&UL4$L! A0#%     @
MPX!A51R0I6)P!0  8@X  !D              ("!S,$  'AL+W=O<FMS:&5E
M=',O<VAE970S,2YX;6Q02P$"% ,4    " ##@&%5BG75D(T#   Z"0  &0
M            @(%SQP  >&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4
M Q0    ( ,. 856N!S)QZ0(  %@&   9              " @3?+  !X;"]W
M;W)K<VAE971S+W-H965T,S,N>&UL4$L! A0#%     @ PX!A57$(--8Z @
MU 0  !D              ("!5\X  'AL+W=O<FMS:&5E=',O<VAE970S-"YX
M;6Q02P$"% ,4    " ##@&%5XJW+6'<&  "9,P  &0              @('(
MT   >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4 Q0    ( ,. 854V
M#OJ"5 ,  -8,   9              " @7;7  !X;"]W;W)K<VAE971S+W-H
M965T,S8N>&UL4$L! A0#%     @ PX!A55JL.E1Y!   _A<  !D
M     ("! =L  'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( ,. 857!K@%M1P,  &L*   9              "
M@0[P  !X;"]W;W)K<VAE971S+W-H965T-#(N>&UL4$L! A0#%     @ PX!A
M5<MD2436#   5;H  !D              ("!C/,  'AL+W=O<FMS:&5E=',O
M<VAE970T,RYX;6Q02P$"% ,4    " ##@&%5YYB"@C@+   ^IP  &0
M        @(&9  $ >&PO=V]R:W-H965T<R]S:&5E=#0T+GAM;%!+ 0(4 Q0
M   ( ,. 854HVNN. PD  )%B   9              " @0@, 0!X;"]W;W)K
M<VAE971S+W-H965T-#4N>&UL4$L! A0#%     @ PX!A54"U^;\!#0  :Z\
M !D              ("!0A4! 'AL+W=O<FMS:&5E=',O<VAE970T-BYX;6Q0
M2P$"% ,4    " ##@&%5L'Q^L7 &  !W.@  &0              @(%Z(@$
M>&PO=V]R:W-H965T<R]S:&5E=#0W+GAM;%!+ 0(4 Q0    ( ,. 8569/\K%
M4 8  $,^   9              " @2$I 0!X;"]W;W)K<VAE971S+W-H965T
M-#@N>&UL4$L! A0#%     @ PX!A5?T09"44"0  '&@  !D
M ("!J"\! 'AL+W=O<FMS:&5E=',O<VAE970T.2YX;6Q02P$"% ,4    " ##
M@&%561CG>U@#   H#0  &0              @('S. $ >&PO=V]R:W-H965T
M<R]S:&5E=#4P+GAM;%!+ 0(4 Q0    ( ,. 8569<Y*@J0(  *X'   9
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M970U-2YX;6Q02P$"% ,4    " ##@&%5ZV>*"%P$  #[&   &0
M    @('+50$ >&PO=V]R:W-H965T<R]S:&5E=#4V+GAM;%!+ 0(4 Q0    (
M ,. 856/2F4WK <  /%,   9              " @5Y: 0!X;"]W;W)K<VAE
M971S+W-H965T-3<N>&UL4$L! A0#%     @ PX!A50*)#S8@ P  LPD  !D
M             ("!06(! 'AL+W=O<FMS:&5E=',O<VAE970U."YX;6Q02P$"
M% ,4    " ##@&%5ZI7<87((   !3   &0              @(&890$ >&PO
M=V]R:W-H965T<R]S:&5E=#4Y+GAM;%!+ 0(4 Q0    ( ,. 856@BO$-7P0
M -L4   9              " @4%N 0!X;"]W;W)K<VAE971S+W-H965T-C N
M>&UL4$L! A0#%     @ PX!A508X51.F P  Z T  !D              ("!
MUW(! 'AL+W=O<FMS:&5E=',O<VAE970V,2YX;6Q02P$"% ,4    " ##@&%5
MV'=80HP$  !?&   &0              @(&T=@$ >&PO=V]R:W-H965T<R]S
M:&5E=#8R+GAM;%!+ 0(4 Q0    ( ,. 857A72$+B0(  &X&   9
M      " @7=[ 0!X;"]W;W)K<VAE971S+W-H965T-C,N>&UL4$L! A0#%
M  @ PX!A5?DVU9-3 P  %@X  !D              ("!-WX! 'AL+W=O<FMS
M:&5E=',O<VAE970V-"YX;6Q02P$"% ,4    " ##@&%55:MW_Q,$   =$0
M&0              @('!@0$ >&PO=V]R:W-H965T<R]S:&5E=#8U+GAM;%!+
M 0(4 Q0    ( ,. 857%MGF\ZP(  +<)   9              " @0N& 0!X
M;"]W;W)K<VAE971S+W-H965T-C8N>&UL4$L! A0#%     @ PX!A53['QQ D
M P  R0H  !D              ("!+8D! 'AL+W=O<FMS:&5E=',O<VAE970V
M-RYX;6Q02P$"% ,4    " ##@&%5#N!GV8T#  "'#   &0
M@(&(C $ >&PO=V]R:W-H965T<R]S:&5E=#8X+GAM;%!+ 0(4 Q0    ( ,.
M854EC,-^\ (  .4(   9              " @4R0 0!X;"]W;W)K<VAE971S
M+W-H965T-CDN>&UL4$L! A0#%     @ PX!A5;IW.\E; @  0@8  !D
M         ("!<Y,! 'AL+W=O<FMS:&5E=',O<VAE970W,"YX;6Q02P$"% ,4
M    " ##@&%5YKM9ED<#  #*%   #0              @ $%E@$ >&PO<W1Y
M;&5S+GAM;%!+ 0(4 Q0    ( ,. 8567BKL<P    !,"   +
M  "  7>9 0!?<F5L<R\N<F5L<U!+ 0(4 Q0    ( ,. 857%#@&$E04  &0N
M   /              "  6": 0!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4
M" ##@&%5VW:P<3$"  ")*0  &@              @ $BH $ >&PO7W)E;',O
M=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    " ##@&%5I,C#=_H!  "T*
M$P              @ &+H@$ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08
..3@!. %D5  "VI $    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>397</ContextCount>
  <ElementCount>287</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>109</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report instance="incy-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.incyte.com/role/DocumentandEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="incy-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.incyte.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="incy-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.incyte.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="incy-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.incyte.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="incy-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.incyte.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="incy-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.incyte.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="incy-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.incyte.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="incy-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.incyte.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="incy-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Disclosure - Organization and Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.incyte.com/role/OrganizationandBusiness</Role>
      <ShortName>Organization and Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="incy-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.incyte.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="incy-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - Revenues</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.incyte.com/role/Revenues</Role>
      <ShortName>Revenues</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="incy-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - Fair Value of Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.incyte.com/role/FairValueofFinancialInstruments</Role>
      <ShortName>Fair Value of Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="incy-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - Concentrations of Credit Risk and Current Expected Credit Losses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.incyte.com/role/ConcentrationsofCreditRiskandCurrentExpectedCreditLosses</Role>
      <ShortName>Concentrations of Credit Risk and Current Expected Credit Losses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="incy-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - Inventory</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.incyte.com/role/Inventory</Role>
      <ShortName>Inventory</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="incy-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - License Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.incyte.com/role/LicenseAgreements</Role>
      <ShortName>License Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="incy-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - Property and Equipment, net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.incyte.com/role/PropertyandEquipmentnet</Role>
      <ShortName>Property and Equipment, net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="incy-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - Accrued and Other Current Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.incyte.com/role/AccruedandOtherCurrentLiabilities</Role>
      <ShortName>Accrued and Other Current Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="incy-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - Stock Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.incyte.com/role/StockCompensation</Role>
      <ShortName>Stock Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="incy-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.incyte.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="incy-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0000020 - Disclosure - Net Income Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.incyte.com/role/NetIncomePerShare</Role>
      <ShortName>Net Income Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="incy-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0000021 - Disclosure - Employee Benefit Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.incyte.com/role/EmployeeBenefitPlans</Role>
      <ShortName>Employee Benefit Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="incy-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0000022 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.incyte.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="incy-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0000023 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.incyte.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="incy-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0000024 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.incyte.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.incyte.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="incy-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0000025 - Disclosure - Revenues (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.incyte.com/role/RevenuesTables</Role>
      <ShortName>Revenues (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.incyte.com/role/Revenues</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="incy-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>0000026 - Disclosure - Fair Value of Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.incyte.com/role/FairValueofFinancialInstrumentsTables</Role>
      <ShortName>Fair Value of Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.incyte.com/role/FairValueofFinancialInstruments</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="incy-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>0000027 - Disclosure - Concentrations of Credit Risk and Current Expected Credit Losses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.incyte.com/role/ConcentrationsofCreditRiskandCurrentExpectedCreditLossesTables</Role>
      <ShortName>Concentrations of Credit Risk and Current Expected Credit Losses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.incyte.com/role/ConcentrationsofCreditRiskandCurrentExpectedCreditLosses</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="incy-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>0000028 - Disclosure - Inventory (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.incyte.com/role/InventoryTables</Role>
      <ShortName>Inventory (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.incyte.com/role/Inventory</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="incy-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>0000029 - Disclosure - Property and Equipment, net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.incyte.com/role/PropertyandEquipmentnetTables</Role>
      <ShortName>Property and Equipment, net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.incyte.com/role/PropertyandEquipmentnet</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="incy-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>0000030 - Disclosure - Accrued and Other Current Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.incyte.com/role/AccruedandOtherCurrentLiabilitiesTables</Role>
      <ShortName>Accrued and Other Current Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.incyte.com/role/AccruedandOtherCurrentLiabilities</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="incy-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>0000031 - Disclosure - Stock compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.incyte.com/role/StockcompensationTables</Role>
      <ShortName>Stock compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="incy-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>0000032 - Disclosure - Net Income Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.incyte.com/role/NetIncomePerShareTables</Role>
      <ShortName>Net Income Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.incyte.com/role/NetIncomePerShare</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="incy-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>0000033 - Disclosure - Employee Benefit Plans (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.incyte.com/role/EmployeeBenefitPlansTables</Role>
      <ShortName>Employee Benefit Plans (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.incyte.com/role/EmployeeBenefitPlans</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="incy-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>0000034 - Disclosure - Organization and Business (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.incyte.com/role/OrganizationandBusinessDetails</Role>
      <ShortName>Organization and Business (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.incyte.com/role/OrganizationandBusiness</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="incy-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>0000035 - Disclosure - Revenues (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.incyte.com/role/RevenuesDetails</Role>
      <ShortName>Revenues (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.incyte.com/role/RevenuesTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="incy-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>0000036 - Disclosure - Fair Value of Financial Instruments - Marketable securities portfolio (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.incyte.com/role/FairValueofFinancialInstrumentsMarketablesecuritiesportfolioDetails</Role>
      <ShortName>Fair Value of Financial Instruments - Marketable securities portfolio (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="incy-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>0000037 - Disclosure - Fair Value of Financial Instruments - Assets measured on a recurring basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.incyte.com/role/FairValueofFinancialInstrumentsAssetsmeasuredonarecurringbasisDetails</Role>
      <ShortName>Fair Value of Financial Instruments - Assets measured on a recurring basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="incy-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>0000038 - Disclosure - Fair Value of Financial Instruments - Liabilities measured on a recurring basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.incyte.com/role/FairValueofFinancialInstrumentsLiabilitiesmeasuredonarecurringbasisDetails</Role>
      <ShortName>Fair Value of Financial Instruments - Liabilities measured on a recurring basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="incy-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>0000039 - Disclosure - Fair Value of Financial Instruments - Level 3 liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.incyte.com/role/FairValueofFinancialInstrumentsLevel3liabilitiesDetails</Role>
      <ShortName>Fair Value of Financial Instruments - Level 3 liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="incy-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>0000040 - Disclosure - Fair Value of Financial Instruments - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.incyte.com/role/FairValueofFinancialInstrumentsNarrativeDetails</Role>
      <ShortName>Fair Value of Financial Instruments - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="incy-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>0000041 - Disclosure - Concentrations of Credit Risk and Current Expected Credit Losses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.incyte.com/role/ConcentrationsofCreditRiskandCurrentExpectedCreditLossesDetails</Role>
      <ShortName>Concentrations of Credit Risk and Current Expected Credit Losses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.incyte.com/role/ConcentrationsofCreditRiskandCurrentExpectedCreditLossesTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="incy-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>0000042 - Disclosure - Inventory (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.incyte.com/role/InventoryDetails</Role>
      <ShortName>Inventory (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.incyte.com/role/InventoryTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="incy-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>0000043 - Disclosure - License Agreements - Novartis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.incyte.com/role/LicenseAgreementsNovartisDetails</Role>
      <ShortName>License Agreements - Novartis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="incy-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>0000044 - Disclosure - License Agreements - Lilly (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.incyte.com/role/LicenseAgreementsLillyDetails</Role>
      <ShortName>License Agreements - Lilly (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="incy-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>0000045 - Disclosure - License Agreements - Agenus (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.incyte.com/role/LicenseAgreementsAgenusDetails</Role>
      <ShortName>License Agreements - Agenus (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="incy-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>0000046 - Disclosure - License Agreements - Merus (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.incyte.com/role/LicenseAgreementsMerusDetails</Role>
      <ShortName>License Agreements - Merus (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="incy-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>0000047 - Disclosure - License Agreements - Calithera (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.incyte.com/role/LicenseAgreementsCalitheraDetails</Role>
      <ShortName>License Agreements - Calithera (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="incy-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>0000048 - Disclosure - License Agreements - MacroGenics (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.incyte.com/role/LicenseAgreementsMacroGenicsDetails</Role>
      <ShortName>License Agreements - MacroGenics (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="incy-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>0000049 - Disclosure - License Agreements - Syros (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.incyte.com/role/LicenseAgreementsSyrosDetails</Role>
      <ShortName>License Agreements - Syros (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="incy-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>0000050 - Disclosure - License Agreements - Innovent (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.incyte.com/role/LicenseAgreementsInnoventDetails</Role>
      <ShortName>License Agreements - Innovent (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="incy-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>0000051 - Disclosure - License Agreements - Zai Lab (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.incyte.com/role/LicenseAgreementsZaiLabDetails</Role>
      <ShortName>License Agreements - Zai Lab (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="incy-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>0000052 - Disclosure - License Agreements - MorphoSys (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.incyte.com/role/LicenseAgreementsMorphoSysDetails</Role>
      <ShortName>License Agreements - MorphoSys (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="incy-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>0000053 - Disclosure - License Agreements - Nimble (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.incyte.com/role/LicenseAgreementsNimbleDetails</Role>
      <ShortName>License Agreements - Nimble (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="incy-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>0000054 - Disclosure - License Agreements - InnoCare (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.incyte.com/role/LicenseAgreementsInnoCareDetails</Role>
      <ShortName>License Agreements - InnoCare (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="incy-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>0000055 - Disclosure - License Agreements - Syndax (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.incyte.com/role/LicenseAgreementsSyndaxDetails</Role>
      <ShortName>License Agreements - Syndax (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="incy-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>0000056 - Disclosure - Property and Equipment, net - Property and equipment, net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.incyte.com/role/PropertyandEquipmentnetPropertyandequipmentnetDetails</Role>
      <ShortName>Property and Equipment, net - Property and equipment, net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="incy-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>0000057 - Disclosure - Property and Equipment, net - Buildings and construction (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.incyte.com/role/PropertyandEquipmentnetBuildingsandconstructionDetails</Role>
      <ShortName>Property and Equipment, net - Buildings and construction (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="incy-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>0000058 - Disclosure - Accrued and Other Current Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.incyte.com/role/AccruedandOtherCurrentLiabilitiesDetails</Role>
      <ShortName>Accrued and Other Current Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.incyte.com/role/AccruedandOtherCurrentLiabilitiesTables</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="incy-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>0000059 - Disclosure - Stock Compensation - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.incyte.com/role/StockCompensationNarrativeDetails</Role>
      <ShortName>Stock Compensation - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="incy-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>0000060 - Disclosure - Stock Compensation - Valuation assumptions used for value of stock compensation granted (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.incyte.com/role/StockCompensationValuationassumptionsusedforvalueofstockcompensationgrantedDetails</Role>
      <ShortName>Stock Compensation - Valuation assumptions used for value of stock compensation granted (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="incy-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>0000061 - Disclosure - Stock Compensation - Option activity under the 2010 stock plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.incyte.com/role/StockCompensationOptionactivityunderthe2010stockplanDetails</Role>
      <ShortName>Stock Compensation - Option activity under the 2010 stock plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="incy-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>0000062 - Disclosure - Stock Compensation - RSU award and PSU activity under the 2010 stock plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.incyte.com/role/StockCompensationRSUawardandPSUactivityunderthe2010stockplanDetails</Role>
      <ShortName>Stock Compensation - RSU award and PSU activity under the 2010 stock plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="incy-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>0000063 - Disclosure - Stock Compensation - Shares available for grant (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.incyte.com/role/StockCompensationSharesavailableforgrantDetails</Role>
      <ShortName>Stock Compensation - Shares available for grant (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="incy-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>0000064 - Disclosure - Income taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.incyte.com/role/IncometaxesDetails</Role>
      <ShortName>Income taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="incy-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>0000065 - Disclosure - Net Income Per Share - Net income (loss) per share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.incyte.com/role/NetIncomePerShareNetincomelosspershareDetails</Role>
      <ShortName>Net Income Per Share - Net income (loss) per share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="incy-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>0000066 - Disclosure - Net Income Per Share - Antidilutive securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.incyte.com/role/NetIncomePerShareAntidilutivesecuritiesDetails</Role>
      <ShortName>Net Income Per Share - Antidilutive securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="incy-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>0000067 - Disclosure - Employee Benefit Plans - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.incyte.com/role/EmployeeBenefitPlansNarrativeDetails</Role>
      <ShortName>Employee Benefit Plans - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="incy-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>0000068 - Disclosure - Employee Benefit plans - Net periodic benefit cost (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.incyte.com/role/EmployeeBenefitplansNetperiodicbenefitcostDetails</Role>
      <ShortName>Employee Benefit plans - Net periodic benefit cost (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="incy-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>0000069 - Disclosure - Subsequent Events - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.incyte.com/role/SubsequentEventsNarrativeDetails</Role>
      <ShortName>Subsequent Events - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="incy-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9999.htm</HtmlFileName>
      <LongName>Uncategorized Items - incy-20220930.htm</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/role/uncategorizedFacts</Role>
      <ShortName>Uncategorized Items - incy-20220930.htm</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 4 fact(s) appearing in ix:hidden were eligible for transformation: dei:EntityFilerCategory, us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1, us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 -  incy-20220930.htm 4</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-Q" original="incy-20220930.htm">incy-20220930.htm</File>
    <File>exhibit101_amendment3toglo.htm</File>
    <File>incy-20220930.xsd</File>
    <File>incy-20220930_cal.xml</File>
    <File>incy-20220930_def.xml</File>
    <File>incy-20220930_lab.xml</File>
    <File>incy-20220930_pre.xml</File>
    <File>incy-9302022xex311.htm</File>
    <File>incy-9302022xex312.htm</File>
    <File>incy-9302022xex321.htm</File>
    <File>incy-9302022xex322.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="848">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="29">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>89
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "incy-20220930.htm": {
   "axisCustom": 1,
   "axisStandard": 28,
   "contextCount": 397,
   "dts": {
    "calculationLink": {
     "local": [
      "incy-20220930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "incy-20220930_def.xml"
     ]
    },
    "inline": {
     "local": [
      "incy-20220930.htm"
     ]
    },
    "labelLink": {
     "local": [
      "incy-20220930_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "incy-20220930_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "incy-20220930.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 518,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 4,
    "http://xbrl.sec.gov/dei/2022": 6,
    "total": 10
   },
   "keyCustom": 44,
   "keyStandard": 243,
   "memberCustom": 60,
   "memberStandard": 42,
   "nsprefix": "incy",
   "nsuri": "http://www.incyte.com/20220930",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20220930.htm",
      "contextRef": "i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Document and Entity Information",
     "role": "http://www.incyte.com/role/DocumentandEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20220930.htm",
      "contextRef": "i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "incy-20220930.htm",
      "contextRef": "i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000010 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://www.incyte.com/role/SummaryofSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "incy-20220930.htm",
      "contextRef": "i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "incy-20220930.htm",
      "contextRef": "i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000011 - Disclosure - Revenues",
     "role": "http://www.incyte.com/role/Revenues",
     "shortName": "Revenues",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "incy-20220930.htm",
      "contextRef": "i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "incy-20220930.htm",
      "contextRef": "i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000012 - Disclosure - Fair Value of Financial Instruments",
     "role": "http://www.incyte.com/role/FairValueofFinancialInstruments",
     "shortName": "Fair Value of Financial Instruments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "incy-20220930.htm",
      "contextRef": "i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20220930.htm",
      "contextRef": "i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000013 - Disclosure - Concentrations of Credit Risk and Current Expected Credit Losses",
     "role": "http://www.incyte.com/role/ConcentrationsofCreditRiskandCurrentExpectedCreditLosses",
     "shortName": "Concentrations of Credit Risk and Current Expected Credit Losses",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20220930.htm",
      "contextRef": "i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "incy-20220930.htm",
      "contextRef": "i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000014 - Disclosure - Inventory",
     "role": "http://www.incyte.com/role/Inventory",
     "shortName": "Inventory",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "incy-20220930.htm",
      "contextRef": "i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "incy-20220930.htm",
      "contextRef": "i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "incy:LicenseAgreementsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000015 - Disclosure - License Agreements",
     "role": "http://www.incyte.com/role/LicenseAgreements",
     "shortName": "License Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "incy-20220930.htm",
      "contextRef": "i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "incy:LicenseAgreementsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "incy-20220930.htm",
      "contextRef": "i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000016 - Disclosure - Property and Equipment, net",
     "role": "http://www.incyte.com/role/PropertyandEquipmentnet",
     "shortName": "Property and Equipment, net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "incy-20220930.htm",
      "contextRef": "i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "incy-20220930.htm",
      "contextRef": "i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000017 - Disclosure - Accrued and Other Current Liabilities",
     "role": "http://www.incyte.com/role/AccruedandOtherCurrentLiabilities",
     "shortName": "Accrued and Other Current Liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "incy-20220930.htm",
      "contextRef": "i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "incy-20220930.htm",
      "contextRef": "i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000018 - Disclosure - Stock Compensation",
     "role": "http://www.incyte.com/role/StockCompensation",
     "shortName": "Stock Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "incy-20220930.htm",
      "contextRef": "i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "incy-20220930.htm",
      "contextRef": "i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000019 - Disclosure - Income Taxes",
     "role": "http://www.incyte.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "incy-20220930.htm",
      "contextRef": "i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20220930.htm",
      "contextRef": "i3b4376f8fc614de98c9cf647198c504e_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS",
     "role": "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20220930.htm",
      "contextRef": "i3b4376f8fc614de98c9cf647198c504e_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "incy-20220930.htm",
      "contextRef": "i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000020 - Disclosure - Net Income Per Share",
     "role": "http://www.incyte.com/role/NetIncomePerShare",
     "shortName": "Net Income Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "incy-20220930.htm",
      "contextRef": "i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "incy-20220930.htm",
      "contextRef": "i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000021 - Disclosure - Employee Benefit Plans",
     "role": "http://www.incyte.com/role/EmployeeBenefitPlans",
     "shortName": "Employee Benefit Plans",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "incy-20220930.htm",
      "contextRef": "i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "incy-20220930.htm",
      "contextRef": "i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000022 - Disclosure - Commitments and Contingencies",
     "role": "http://www.incyte.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "incy-20220930.htm",
      "contextRef": "i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "incy-20220930.htm",
      "contextRef": "i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000023 - Disclosure - Subsequent Events",
     "role": "http://www.incyte.com/role/SubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "incy-20220930.htm",
      "contextRef": "i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "incy-20220930.htm",
      "contextRef": "i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000024 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.incyte.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "incy-20220930.htm",
      "contextRef": "i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "body",
       "html"
      ],
      "baseRef": "incy-20220930.htm",
      "contextRef": "i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000025 - Disclosure - Revenues (Tables)",
     "role": "http://www.incyte.com/role/RevenuesTables",
     "shortName": "Revenues (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "body",
       "html"
      ],
      "baseRef": "incy-20220930.htm",
      "contextRef": "i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "incy-20220930.htm",
      "contextRef": "i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000026 - Disclosure - Fair Value of Financial Instruments (Tables)",
     "role": "http://www.incyte.com/role/FairValueofFinancialInstrumentsTables",
     "shortName": "Fair Value of Financial Instruments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "incy-20220930.htm",
      "contextRef": "i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "incy-20220930.htm",
      "contextRef": "i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "incy:SchedulesOfConcentrationOfRiskByRiskFactorRelatedToCollaborativePartnersTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000027 - Disclosure - Concentrations of Credit Risk and Current Expected Credit Losses (Tables)",
     "role": "http://www.incyte.com/role/ConcentrationsofCreditRiskandCurrentExpectedCreditLossesTables",
     "shortName": "Concentrations of Credit Risk and Current Expected Credit Losses (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "incy-20220930.htm",
      "contextRef": "i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "incy:SchedulesOfConcentrationOfRiskByRiskFactorRelatedToCollaborativePartnersTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "incy-20220930.htm",
      "contextRef": "i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "incy:ScheduleOfInventoryTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000028 - Disclosure - Inventory (Tables)",
     "role": "http://www.incyte.com/role/InventoryTables",
     "shortName": "Inventory (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "incy-20220930.htm",
      "contextRef": "i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "incy:ScheduleOfInventoryTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "incy-20220930.htm",
      "contextRef": "i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000029 - Disclosure - Property and Equipment, net (Tables)",
     "role": "http://www.incyte.com/role/PropertyandEquipmentnetTables",
     "shortName": "Property and Equipment, net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "incy-20220930.htm",
      "contextRef": "i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20220930.htm",
      "contextRef": "i3b4376f8fc614de98c9cf647198c504e_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "role": "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20220930.htm",
      "contextRef": "i3b4376f8fc614de98c9cf647198c504e_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "baseRef": "incy-20220930.htm",
      "contextRef": "i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000030 - Disclosure - Accrued and Other Current Liabilities (Tables)",
     "role": "http://www.incyte.com/role/AccruedandOtherCurrentLiabilitiesTables",
     "shortName": "Accrued and Other Current Liabilities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "baseRef": "incy-20220930.htm",
      "contextRef": "i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "incy-20220930.htm",
      "contextRef": "i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "incy:ScheduleOfShareBasedPaymentAwardStockOptionsAndEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000031 - Disclosure - Stock compensation (Tables)",
     "role": "http://www.incyte.com/role/StockcompensationTables",
     "shortName": "Stock compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "incy-20220930.htm",
      "contextRef": "i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "incy:ScheduleOfShareBasedPaymentAwardStockOptionsAndEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "baseRef": "incy-20220930.htm",
      "contextRef": "i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000032 - Disclosure - Net Income Per Share (Tables)",
     "role": "http://www.incyte.com/role/NetIncomePerShareTables",
     "shortName": "Net Income Per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "baseRef": "incy-20220930.htm",
      "contextRef": "i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "incy-20220930.htm",
      "contextRef": "i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000033 - Disclosure - Employee Benefit Plans (Tables)",
     "role": "http://www.incyte.com/role/EmployeeBenefitPlansTables",
     "shortName": "Employee Benefit Plans (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "incy-20220930.htm",
      "contextRef": "i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20220930.htm",
      "contextRef": "i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000034 - Disclosure - Organization and Business (Details)",
     "role": "http://www.incyte.com/role/OrganizationandBusinessDetails",
     "shortName": "Organization and Business (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20220930.htm",
      "contextRef": "i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20220930.htm",
      "contextRef": "id673d80f31e74643a241d2f62db94ca9_D20220701-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000035 - Disclosure - Revenues (Details)",
     "role": "http://www.incyte.com/role/RevenuesDetails",
     "shortName": "Revenues (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "body",
       "html"
      ],
      "baseRef": "incy-20220930.htm",
      "contextRef": "ib254aa03c50f46e7b589f20d3926968e_D20220701-20220930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "incy-20220930.htm",
      "contextRef": "ia7f2a4b8ea5a46449d5a5c254bc02074_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000036 - Disclosure - Fair Value of Financial Instruments - Marketable securities portfolio (Details)",
     "role": "http://www.incyte.com/role/FairValueofFinancialInstrumentsMarketablesecuritiesportfolioDetails",
     "shortName": "Fair Value of Financial Instruments - Marketable securities portfolio (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "incy-20220930.htm",
      "contextRef": "ia7f2a4b8ea5a46449d5a5c254bc02074_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20220930.htm",
      "contextRef": "i3b4376f8fc614de98c9cf647198c504e_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermInvestments",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000037 - Disclosure - Fair Value of Financial Instruments - Assets measured on a recurring basis (Details)",
     "role": "http://www.incyte.com/role/FairValueofFinancialInstrumentsAssetsmeasuredonarecurringbasisDetails",
     "shortName": "Fair Value of Financial Instruments - Assets measured on a recurring basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "incy-20220930.htm",
      "contextRef": "i281946f958c146b0926f5dd53313b031_I20220930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "incy-20220930.htm",
      "contextRef": "i281946f958c146b0926f5dd53313b031_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000038 - Disclosure - Fair Value of Financial Instruments - Liabilities measured on a recurring basis (Details)",
     "role": "http://www.incyte.com/role/FairValueofFinancialInstrumentsLiabilitiesmeasuredonarecurringbasisDetails",
     "shortName": "Fair Value of Financial Instruments - Liabilities measured on a recurring basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "incy-20220930.htm",
      "contextRef": "i281946f958c146b0926f5dd53313b031_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "incy-20220930.htm",
      "contextRef": "ia7f1808eadf04e878f5967c1674de235_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000039 - Disclosure - Fair Value of Financial Instruments - Level 3 liabilities (Details)",
     "role": "http://www.incyte.com/role/FairValueofFinancialInstrumentsLevel3liabilitiesDetails",
     "shortName": "Fair Value of Financial Instruments - Level 3 liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "incy-20220930.htm",
      "contextRef": "ia7f1808eadf04e878f5967c1674de235_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20220930.htm",
      "contextRef": "id673d80f31e74643a241d2f62db94ca9_D20220701-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS",
     "role": "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20220930.htm",
      "contextRef": "id673d80f31e74643a241d2f62db94ca9_D20220701-20220930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:CostOfRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "incy-20220930.htm",
      "contextRef": "i651332485f95471bbc1f9997619b54c7_D20220101-20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "incy:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityConsiderationEarned",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000040 - Disclosure - Fair Value of Financial Instruments - Narrative (Details)",
     "role": "http://www.incyte.com/role/FairValueofFinancialInstrumentsNarrativeDetails",
     "shortName": "Fair Value of Financial Instruments - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "incy-20220930.htm",
      "contextRef": "i651332485f95471bbc1f9997619b54c7_D20220101-20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "incy:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityConsiderationEarned",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "incy-20220930.htm",
      "contextRef": "i3b4376f8fc614de98c9cf647198c504e_I20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000041 - Disclosure - Concentrations of Credit Risk and Current Expected Credit Losses (Details)",
     "role": "http://www.incyte.com/role/ConcentrationsofCreditRiskandCurrentExpectedCreditLossesDetails",
     "shortName": "Concentrations of Credit Risk and Current Expected Credit Losses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:AllowanceForDoubtfulAccountsReceivable",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "incy-20220930.htm",
      "contextRef": "iab26fe441f0d4ab984456365a7f7cff0_I20211231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "incy:ScheduleOfInventoryTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "incy-20220930.htm",
      "contextRef": "i3b4376f8fc614de98c9cf647198c504e_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000042 - Disclosure - Inventory (Details)",
     "role": "http://www.incyte.com/role/InventoryDetails",
     "shortName": "Inventory (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "incy:ScheduleOfInventoryTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "incy-20220930.htm",
      "contextRef": "i3b4376f8fc614de98c9cf647198c504e_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20220930.htm",
      "contextRef": "id673d80f31e74643a241d2f62db94ca9_D20220701-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000043 - Disclosure - License Agreements - Novartis (Details)",
     "role": "http://www.incyte.com/role/LicenseAgreementsNovartisDetails",
     "shortName": "License Agreements - Novartis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "incy:LicenseAgreementsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "incy-20220930.htm",
      "contextRef": "ifbfff633ca0a4e9ea1abbaec86cf758b_I20211231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "incy:RoyaltiesPayable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20220930.htm",
      "contextRef": "id673d80f31e74643a241d2f62db94ca9_D20220701-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000044 - Disclosure - License Agreements - Lilly (Details)",
     "role": "http://www.incyte.com/role/LicenseAgreementsLillyDetails",
     "shortName": "License Agreements - Lilly (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "incy-20220930.htm",
      "contextRef": "i03d9a6dbc0bb43aaa8228030c1e90e5c_D20091201-20220930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "incy:LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20220930.htm",
      "contextRef": "i3b4376f8fc614de98c9cf647198c504e_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermInvestments",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000045 - Disclosure - License Agreements - Agenus (Details)",
     "role": "http://www.incyte.com/role/LicenseAgreementsAgenusDetails",
     "shortName": "License Agreements - Agenus (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "incy-20220930.htm",
      "contextRef": "i181b872577d8409197ea188e8c75e75e_D20210101-20211231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20220930.htm",
      "contextRef": "id673d80f31e74643a241d2f62db94ca9_D20220701-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000046 - Disclosure - License Agreements - Merus (Details)",
     "role": "http://www.incyte.com/role/LicenseAgreementsMerusDetails",
     "shortName": "License Agreements - Merus (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "incy-20220930.htm",
      "contextRef": "i9eec6fea7a9943da8efef567ce22965f_I20211231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:InvestmentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20220930.htm",
      "contextRef": "i3b4376f8fc614de98c9cf647198c504e_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermInvestments",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000047 - Disclosure - License Agreements - Calithera (Details)",
     "role": "http://www.incyte.com/role/LicenseAgreementsCalitheraDetails",
     "shortName": "License Agreements - Calithera (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "incy-20220930.htm",
      "contextRef": "i14a2cf26acb6415995411f908d84bb40_I20211231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:LongTermInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20220930.htm",
      "contextRef": "id673d80f31e74643a241d2f62db94ca9_D20220701-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000048 - Disclosure - License Agreements - MacroGenics (Details)",
     "role": "http://www.incyte.com/role/LicenseAgreementsMacroGenicsDetails",
     "shortName": "License Agreements - MacroGenics (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "incy-20220930.htm",
      "contextRef": "icf19c78006d9495182f71ef7c21fe380_D20220701-20220930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20220930.htm",
      "contextRef": "i3b4376f8fc614de98c9cf647198c504e_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermInvestments",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000049 - Disclosure - License Agreements - Syros (Details)",
     "role": "http://www.incyte.com/role/LicenseAgreementsSyrosDetails",
     "shortName": "License Agreements - Syros (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "incy-20220930.htm",
      "contextRef": "i8210542f8d5e44b9852bd20e5f5e3854_I20211231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:LongTermInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20220930.htm",
      "contextRef": "id673d80f31e74643a241d2f62db94ca9_D20220701-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)",
     "role": "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20220930.htm",
      "contextRef": "id673d80f31e74643a241d2f62db94ca9_D20220701-20220930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "incy-20220930.htm",
      "contextRef": "ic09f0ce12baa4ba48de314895f364fc0_D20220101-20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "incy:LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000050 - Disclosure - License Agreements - Innovent (Details)",
     "role": "http://www.incyte.com/role/LicenseAgreementsInnoventDetails",
     "shortName": "License Agreements - Innovent (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "incy-20220930.htm",
      "contextRef": "ic09f0ce12baa4ba48de314895f364fc0_D20220101-20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "incy:LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "incy-20220930.htm",
      "contextRef": "i96f4281beb534126a1eef106e0789ece_D20190701-20190731",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "incy:LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000051 - Disclosure - License Agreements - Zai Lab (Details)",
     "role": "http://www.incyte.com/role/LicenseAgreementsZaiLabDetails",
     "shortName": "License Agreements - Zai Lab (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "incy-20220930.htm",
      "contextRef": "i96f4281beb534126a1eef106e0789ece_D20190701-20190731",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "incy:LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20220930.htm",
      "contextRef": "id673d80f31e74643a241d2f62db94ca9_D20220701-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000052 - Disclosure - License Agreements - MorphoSys (Details)",
     "role": "http://www.incyte.com/role/LicenseAgreementsMorphoSysDetails",
     "shortName": "License Agreements - MorphoSys (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "incy-20220930.htm",
      "contextRef": "ia375a7c89bc74d8bbfbae792527a8710_I20211231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:InvestmentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "incy-20220930.htm",
      "contextRef": "i68d610f80f7e4dd1b7076852e33351b9_I20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "incy:LicenseAgreementAdditionalMilestonePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000053 - Disclosure - License Agreements - Nimble (Details)",
     "role": "http://www.incyte.com/role/LicenseAgreementsNimbleDetails",
     "shortName": "License Agreements - Nimble (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "incy-20220930.htm",
      "contextRef": "i68d610f80f7e4dd1b7076852e33351b9_I20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "incy:LicenseAgreementAdditionalMilestonePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "incy-20220930.htm",
      "contextRef": "i54911354715749fdbd74f62ce9dd1ad8_D20210901-20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "incy:LicenseAgreementUpfrontPaymentReceived",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000054 - Disclosure - License Agreements - InnoCare (Details)",
     "role": "http://www.incyte.com/role/LicenseAgreementsInnoCareDetails",
     "shortName": "License Agreements - InnoCare (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "incy-20220930.htm",
      "contextRef": "i54911354715749fdbd74f62ce9dd1ad8_D20210901-20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "incy:LicenseAgreementUpfrontPaymentReceived",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20220930.htm",
      "contextRef": "iab26fe441f0d4ab984456365a7f7cff0_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermInvestments",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000055 - Disclosure - License Agreements - Syndax (Details)",
     "role": "http://www.incyte.com/role/LicenseAgreementsSyndaxDetails",
     "shortName": "License Agreements - Syndax (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "incy-20220930.htm",
      "contextRef": "i8f65aa20c7b04a3aa4af35f8d8783e0d_I20211231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:LongTermInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "incy-20220930.htm",
      "contextRef": "i3b4376f8fc614de98c9cf647198c504e_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000056 - Disclosure - Property and Equipment, net - Property and equipment, net (Details)",
     "role": "http://www.incyte.com/role/PropertyandEquipmentnetPropertyandequipmentnetDetails",
     "shortName": "Property and Equipment, net - Property and equipment, net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "incy-20220930.htm",
      "contextRef": "i3b4376f8fc614de98c9cf647198c504e_I20220930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "incy-20220930.htm",
      "contextRef": "i3b4376f8fc614de98c9cf647198c504e_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000057 - Disclosure - Property and Equipment, net - Buildings and construction (Details)",
     "role": "http://www.incyte.com/role/PropertyandEquipmentnetBuildingsandconstructionDetails",
     "shortName": "Property and Equipment, net - Buildings and construction (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "incy-20220930.htm",
      "contextRef": "i1b500a53ba8b41b09f796fe4eaf76bef_I20191231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:AreaOfRealEstateProperty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "sqft",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "baseRef": "incy-20220930.htm",
      "contextRef": "i3b4376f8fc614de98c9cf647198c504e_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccruedRoyaltiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000058 - Disclosure - Accrued and Other Current Liabilities (Details)",
     "role": "http://www.incyte.com/role/AccruedandOtherCurrentLiabilitiesDetails",
     "shortName": "Accrued and Other Current Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "baseRef": "incy-20220930.htm",
      "contextRef": "i3b4376f8fc614de98c9cf647198c504e_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccruedRoyaltiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "incy-20220930.htm",
      "contextRef": "id673d80f31e74643a241d2f62db94ca9_D20220701-20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000059 - Disclosure - Stock Compensation - Narrative (Details)",
     "role": "http://www.incyte.com/role/StockCompensationNarrativeDetails",
     "shortName": "Stock Compensation - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "incy-20220930.htm",
      "contextRef": "id673d80f31e74643a241d2f62db94ca9_D20220701-20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20220930.htm",
      "contextRef": "id7612db9fbac4f99a07f20a1f367748a_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY",
     "role": "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20220930.htm",
      "contextRef": "if318fa6e60cf4269ad7b22fe4b7d3bed_D20210101-20210331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "incy:ScheduleOfShareBasedPaymentAwardStockOptionsAndEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "incy-20220930.htm",
      "contextRef": "ia05518f1a01d4291b4add6208b75e939_D20220701-20220930",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000060 - Disclosure - Stock Compensation - Valuation assumptions used for value of stock compensation granted (Details)",
     "role": "http://www.incyte.com/role/StockCompensationValuationassumptionsusedforvalueofstockcompensationgrantedDetails",
     "shortName": "Stock Compensation - Valuation assumptions used for value of stock compensation granted (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "incy:ScheduleOfShareBasedPaymentAwardStockOptionsAndEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "incy-20220930.htm",
      "contextRef": "ia05518f1a01d4291b4add6208b75e939_D20220701-20220930",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "incy-20220930.htm",
      "contextRef": "ica61680f037f4dedb0e7d3fa6de64097_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000061 - Disclosure - Stock Compensation - Option activity under the 2010 stock plan (Details)",
     "role": "http://www.incyte.com/role/StockCompensationOptionactivityunderthe2010stockplanDetails",
     "shortName": "Stock Compensation - Option activity under the 2010 stock plan (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "incy-20220930.htm",
      "contextRef": "ica61680f037f4dedb0e7d3fa6de64097_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "incy:ScheduleOfShareBasedCompensationOtherThanStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "incy-20220930.htm",
      "contextRef": "iab26fe441f0d4ab984456365a7f7cff0_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000062 - Disclosure - Stock Compensation - RSU award and PSU activity under the 2010 stock plan (Details)",
     "role": "http://www.incyte.com/role/StockCompensationRSUawardandPSUactivityunderthe2010stockplanDetails",
     "shortName": "Stock Compensation - RSU award and PSU activity under the 2010 stock plan (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "incy:ScheduleOfShareBasedCompensationOtherThanStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "incy-20220930.htm",
      "contextRef": "iab26fe441f0d4ab984456365a7f7cff0_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "incy-20220930.htm",
      "contextRef": "iab26fe441f0d4ab984456365a7f7cff0_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000063 - Disclosure - Stock Compensation - Shares available for grant (Details)",
     "role": "http://www.incyte.com/role/StockCompensationSharesavailableforgrantDetails",
     "shortName": "Stock Compensation - Shares available for grant (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "incy-20220930.htm",
      "contextRef": "iab26fe441f0d4ab984456365a7f7cff0_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20220930.htm",
      "contextRef": "id673d80f31e74643a241d2f62db94ca9_D20220701-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000064 - Disclosure - Income taxes (Details)",
     "role": "http://www.incyte.com/role/IncometaxesDetails",
     "shortName": "Income taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "incy-20220930.htm",
      "contextRef": "i0efcc1efa4d94a789080eb3693e147ff_D20211001-20211231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "baseRef": "incy-20220930.htm",
      "contextRef": "id673d80f31e74643a241d2f62db94ca9_D20220701-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000065 - Disclosure - Net Income Per Share - Net income (loss) per share (Details)",
     "role": "http://www.incyte.com/role/NetIncomePerShareNetincomelosspershareDetails",
     "shortName": "Net Income Per Share - Net income (loss) per share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "baseRef": "incy-20220930.htm",
      "contextRef": "id673d80f31e74643a241d2f62db94ca9_D20220701-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20220930.htm",
      "contextRef": "i4265039234524ff8ba29f3a4b5d9b5b7_D20220701-20220930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000066 - Disclosure - Net Income Per Share - Antidilutive securities (Details)",
     "role": "http://www.incyte.com/role/NetIncomePerShareAntidilutivesecuritiesDetails",
     "shortName": "Net Income Per Share - Antidilutive securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20220930.htm",
      "contextRef": "i4265039234524ff8ba29f3a4b5d9b5b7_D20220701-20220930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "incy-20220930.htm",
      "contextRef": "id673d80f31e74643a241d2f62db94ca9_D20220701-20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanCostRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000067 - Disclosure - Employee Benefit Plans - Narrative (Details)",
     "role": "http://www.incyte.com/role/EmployeeBenefitPlansNarrativeDetails",
     "shortName": "Employee Benefit Plans - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "incy-20220930.htm",
      "contextRef": "id673d80f31e74643a241d2f62db94ca9_D20220701-20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanCostRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock",
       "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "incy-20220930.htm",
      "contextRef": "id673d80f31e74643a241d2f62db94ca9_D20220701-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanServiceCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000068 - Disclosure - Employee Benefit plans - Net periodic benefit cost (Details)",
     "role": "http://www.incyte.com/role/EmployeeBenefitplansNetperiodicbenefitcostDetails",
     "shortName": "Employee Benefit plans - Net periodic benefit cost (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock",
       "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "incy-20220930.htm",
      "contextRef": "id673d80f31e74643a241d2f62db94ca9_D20220701-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanServiceCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "incy-20220930.htm",
      "contextRef": "i1c305a826fd9438ab670f7c9b7fa8ab4_D20221001-20221031",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "incy:LicenseAgreementUpfrontPaymentAmountPaid",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000069 - Disclosure - Subsequent Events - Narrative (Details)",
     "role": "http://www.incyte.com/role/SubsequentEventsNarrativeDetails",
     "shortName": "Subsequent Events - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "incy-20220930.htm",
      "contextRef": "i1c305a826fd9438ab670f7c9b7fa8ab4_D20221001-20221031",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "incy:LicenseAgreementUpfrontPaymentAmountPaid",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20220930.htm",
      "contextRef": "id673d80f31e74643a241d2f62db94ca9_D20220701-20220930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical)",
     "role": "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20220930.htm",
      "contextRef": "id673d80f31e74643a241d2f62db94ca9_D20220701-20220930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20220930.htm",
      "contextRef": "i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000008 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "role": "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20220930.htm",
      "contextRef": "i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20220930.htm",
      "contextRef": "i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000009 - Disclosure - Organization and Business",
     "role": "http://www.incyte.com/role/OrganizationandBusiness",
     "shortName": "Organization and Business",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20220930.htm",
      "contextRef": "i30a5c2efaf9c4c5a854f2c98e8c91d08_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9999": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "incy-20220930.htm",
      "contextRef": "i7acbcf60ab2042008f713a4d43e83de9_I20200131",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentAggregateCost",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "",
     "isDefault": "false",
     "longName": "Uncategorized Items - incy-20220930.htm",
     "role": "http://xbrl.sec.gov/role/uncategorizedFacts",
     "shortName": "Uncategorized Items - incy-20220930.htm",
     "subGroupType": "",
     "uniqueAnchor": null
    }
   },
   "segmentCount": 109,
   "tag": {
    "country_JP": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "JAPAN",
        "terseLabel": "JAPAN"
       }
      }
     },
     "localname": "JP",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.incyte.com/role/LicenseAgreementsLillyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "UNITED STATES"
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.incyte.com/role/LicenseAgreementsCalitheraDetails",
      "http://www.incyte.com/role/LicenseAgreementsLillyDetails",
      "http://www.incyte.com/role/LicenseAgreementsMerusDetails",
      "http://www.incyte.com/role/LicenseAgreementsMorphoSysDetails",
      "http://www.incyte.com/role/LicenseAgreementsNovartisDetails",
      "http://www.incyte.com/role/LicenseAgreementsSyndaxDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.incyte.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.incyte.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.incyte.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.incyte.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.incyte.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.incyte.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r537"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.incyte.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r538"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.incyte.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.incyte.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.incyte.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.incyte.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.incyte.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.incyte.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.incyte.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.incyte.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.incyte.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]",
        "terseLabel": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.incyte.com/role/LicenseAgreementsMorphoSysDetails",
      "http://www.incyte.com/role/LicenseAgreementsSyndaxDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.incyte.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.incyte.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.incyte.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.incyte.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r546"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.incyte.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.incyte.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.incyte.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.incyte.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.incyte.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]",
        "terseLabel": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.incyte.com/role/LicenseAgreementsMorphoSysDetails",
      "http://www.incyte.com/role/LicenseAgreementsSyndaxDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.incyte.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r534"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.incyte.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r536"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.incyte.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.incyte.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "incy_AccruedAndOtherCurrentLiabilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing accrued and other current liabilities.",
        "label": "Accrued and other current liabilities",
        "terseLabel": "Accrued and other current liabilities"
       }
      }
     },
     "localname": "AccruedAndOtherCurrentLiabilityMember",
     "nsuri": "http://www.incyte.com/20220930",
     "presentation": [
      "http://www.incyte.com/role/FairValueofFinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "incy_AccruedClinicalRelatedCostsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.incyte.com/role/AccruedandOtherCurrentLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for clinical related costs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Clinical Related Costs Current",
        "terseLabel": "Clinical related costs"
       }
      }
     },
     "localname": "AccruedClinicalRelatedCostsCurrent",
     "nsuri": "http://www.incyte.com/20220930",
     "presentation": [
      "http://www.incyte.com/role/AccruedandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "incy_AchievementOfMilestoneAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information by different categories of achievement of milestones.",
        "label": "Achievement of Milestone [Axis]",
        "terseLabel": "Achievement of Milestone [Axis]"
       }
      }
     },
     "localname": "AchievementOfMilestoneAxis",
     "nsuri": "http://www.incyte.com/20220930",
     "presentation": [
      "http://www.incyte.com/role/LicenseAgreementsAgenusDetails",
      "http://www.incyte.com/role/LicenseAgreementsCalitheraDetails",
      "http://www.incyte.com/role/LicenseAgreementsInnoventDetails",
      "http://www.incyte.com/role/LicenseAgreementsLillyDetails",
      "http://www.incyte.com/role/LicenseAgreementsMacroGenicsDetails",
      "http://www.incyte.com/role/LicenseAgreementsMerusDetails",
      "http://www.incyte.com/role/LicenseAgreementsMorphoSysDetails",
      "http://www.incyte.com/role/LicenseAgreementsNimbleDetails",
      "http://www.incyte.com/role/LicenseAgreementsNovartisDetails",
      "http://www.incyte.com/role/LicenseAgreementsSyndaxDetails",
      "http://www.incyte.com/role/LicenseAgreementsSyrosDetails",
      "http://www.incyte.com/role/LicenseAgreementsZaiLabDetails",
      "http://www.incyte.com/role/SubsequentEventsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "incy_AchievementOfMilestoneDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Different categories of achievement of milestones.",
        "label": "Achievement of Milestone [Domain]",
        "terseLabel": "Achievement of Milestone [Domain]"
       }
      }
     },
     "localname": "AchievementOfMilestoneDomain",
     "nsuri": "http://www.incyte.com/20220930",
     "presentation": [
      "http://www.incyte.com/role/LicenseAgreementsAgenusDetails",
      "http://www.incyte.com/role/LicenseAgreementsCalitheraDetails",
      "http://www.incyte.com/role/LicenseAgreementsInnoventDetails",
      "http://www.incyte.com/role/LicenseAgreementsLillyDetails",
      "http://www.incyte.com/role/LicenseAgreementsMacroGenicsDetails",
      "http://www.incyte.com/role/LicenseAgreementsMerusDetails",
      "http://www.incyte.com/role/LicenseAgreementsMorphoSysDetails",
      "http://www.incyte.com/role/LicenseAgreementsNimbleDetails",
      "http://www.incyte.com/role/LicenseAgreementsNovartisDetails",
      "http://www.incyte.com/role/LicenseAgreementsSyndaxDetails",
      "http://www.incyte.com/role/LicenseAgreementsSyrosDetails",
      "http://www.incyte.com/role/LicenseAgreementsZaiLabDetails",
      "http://www.incyte.com/role/SubsequentEventsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "incy_AgenusMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents details pertaining to Agenus with whom we have entered into a License, Development and Commercialization Agreement.",
        "label": "Agenus",
        "terseLabel": "Agenus"
       }
      }
     },
     "localname": "AgenusMember",
     "nsuri": "http://www.incyte.com/20220930",
     "presentation": [
      "http://www.incyte.com/role/LicenseAgreementsAgenusDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "incy_AggregateConcentrationCustomersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to the aggregate list of concentration customers.",
        "label": "Customer A, B, C D, and E",
        "terseLabel": "Customer A, B, C, D and E"
       }
      }
     },
     "localname": "AggregateConcentrationCustomersMember",
     "nsuri": "http://www.incyte.com/20220930",
     "presentation": [
      "http://www.incyte.com/role/ConcentrationsofCreditRiskandCurrentExpectedCreditLossesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "incy_AmendedStockPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents amended stock purchase agreement.",
        "label": "Amended stock purchase agreement",
        "terseLabel": "Amended stock purchase agreement"
       }
      }
     },
     "localname": "AmendedStockPurchaseAgreementMember",
     "nsuri": "http://www.incyte.com/20220930",
     "presentation": [
      "http://www.incyte.com/role/LicenseAgreementsSyrosDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "incy_AmericanDepositarySharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents American Depositary Shares.",
        "label": "ADSs",
        "terseLabel": "ADSs"
       }
      }
     },
     "localname": "AmericanDepositarySharesMember",
     "nsuri": "http://www.incyte.com/20220930",
     "presentation": [
      "http://www.incyte.com/role/LicenseAgreementsMorphoSysDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "incy_AriadPharmaceuticalsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to ARIAD Pharmaceuticals.",
        "label": "ARIAD",
        "terseLabel": "ARIAD"
       }
      }
     },
     "localname": "AriadPharmaceuticalsMember",
     "nsuri": "http://www.incyte.com/20220930",
     "presentation": [
      "http://www.incyte.com/role/FairValueofFinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "incy_BuildingAndLeaseholdImprovementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information relating to building and leasehold improvements.",
        "label": "Building and leasehold improvements",
        "terseLabel": "Building and leasehold improvements"
       }
      }
     },
     "localname": "BuildingAndLeaseholdImprovementsMember",
     "nsuri": "http://www.incyte.com/20220930",
     "presentation": [
      "http://www.incyte.com/role/PropertyandEquipmentnetBuildingsandconstructionDetails",
      "http://www.incyte.com/role/PropertyandEquipmentnetPropertyandequipmentnetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "incy_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityConsiderationEarned": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in the value of a contingent consideration liability attributable to consideration earned by the acquiree in a business combination.",
        "label": "Business Combination, Contingent Consideration Arrangements, Change In Amount Of Contingent Consideration Liability, Consideration Earned",
        "negatedLabel": "Contingent consideration earned during the period but not yet paid"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityConsiderationEarned",
     "nsuri": "http://www.incyte.com/20220930",
     "presentation": [
      "http://www.incyte.com/role/FairValueofFinancialInstrumentsLevel3liabilitiesDetails",
      "http://www.incyte.com/role/FairValueofFinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "incy_CalitheraBiosciencesIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents details pertaining to our long-term investment in Calithera Biosciences, Inc with whom we have entered into a License and Commercialization Agreement.",
        "label": "Calithera",
        "terseLabel": "Calithera"
       }
      }
     },
     "localname": "CalitheraBiosciencesIncMember",
     "nsuri": "http://www.incyte.com/20220930",
     "presentation": [
      "http://www.incyte.com/role/LicenseAgreementsCalitheraDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "incy_CollaborationAgreementProfitLossSharingRatio": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ratio of sharing profit and losses under the collaboration agreement.",
        "label": "Collaboration Agreement Profit Loss Sharing Ratio",
        "terseLabel": "Profit (loss) sharing ratio"
       }
      }
     },
     "localname": "CollaborationAgreementProfitLossSharingRatio",
     "nsuri": "http://www.incyte.com/20220930",
     "presentation": [
      "http://www.incyte.com/role/LicenseAgreementsMorphoSysDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "incy_CollaborationAgreementProfitSharingPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the percentage of profits and losses shared under the collaboration agreement.",
        "label": "Collaboration Agreement Profit Sharing Percentage",
        "terseLabel": "Profit sharing (as a percent)"
       }
      }
     },
     "localname": "CollaborationAgreementProfitSharingPercentage",
     "nsuri": "http://www.incyte.com/20220930",
     "presentation": [
      "http://www.incyte.com/role/LicenseAgreementsMerusDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "incy_CollaborationAndLicenseAgreementWithZaiLabLtdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the collaboration and license agreement with Zai Lab Ltd.",
        "label": "Zai Lab Ltd",
        "terseLabel": "Zai Lab Ltd"
       }
      }
     },
     "localname": "CollaborationAndLicenseAgreementWithZaiLabLtdMember",
     "nsuri": "http://www.incyte.com/20220930",
     "presentation": [
      "http://www.incyte.com/role/LicenseAgreementsZaiLabDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "incy_CollaborationLossSharingExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 5.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The expense recognized during the reporting period for collaboration loss sharing.",
        "label": "Collaboration Loss Sharing Expense",
        "terseLabel": "Collaboration loss sharing"
       }
      }
     },
     "localname": "CollaborationLossSharingExpense",
     "nsuri": "http://www.incyte.com/20220930",
     "presentation": [
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.incyte.com/role/LicenseAgreementsMorphoSysDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "incy_CollaborationPartnersaBCAndDMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to both the Collaboration partners A, B, C and D.",
        "label": "Collaboration Partner A, B, C and D",
        "terseLabel": "Collaboration Partner A, B, C and D"
       }
      }
     },
     "localname": "CollaborationPartnersaBCAndDMember",
     "nsuri": "http://www.incyte.com/20220930",
     "presentation": [
      "http://www.incyte.com/role/ConcentrationsofCreditRiskandCurrentExpectedCreditLossesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "incy_CommercializationMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to certain commercialized events on the basis of which certain milestones are achieved.",
        "label": "Commercialization Milestones",
        "terseLabel": "Commercialization Milestones"
       }
      }
     },
     "localname": "CommercializationMilestonesMember",
     "nsuri": "http://www.incyte.com/20220930",
     "presentation": [
      "http://www.incyte.com/role/LicenseAgreementsInnoventDetails",
      "http://www.incyte.com/role/LicenseAgreementsLillyDetails",
      "http://www.incyte.com/role/LicenseAgreementsMacroGenicsDetails",
      "http://www.incyte.com/role/LicenseAgreementsMerusDetails",
      "http://www.incyte.com/role/LicenseAgreementsMorphoSysDetails",
      "http://www.incyte.com/role/LicenseAgreementsNimbleDetails",
      "http://www.incyte.com/role/LicenseAgreementsNovartisDetails",
      "http://www.incyte.com/role/LicenseAgreementsSyndaxDetails",
      "http://www.incyte.com/role/LicenseAgreementsSyrosDetails",
      "http://www.incyte.com/role/LicenseAgreementsZaiLabDetails",
      "http://www.incyte.com/role/SubsequentEventsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "incy_CorporateAndGovernmentDebtSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by government or corporate business, banks and other entities with a promise of repayment.",
        "label": "Debt securities (government)",
        "terseLabel": "Debt securities (government)"
       }
      }
     },
     "localname": "CorporateAndGovernmentDebtSecuritiesMember",
     "nsuri": "http://www.incyte.com/20220930",
     "presentation": [
      "http://www.incyte.com/role/FairValueofFinancialInstrumentsMarketablesecuritiesportfolioDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "incy_CustomerAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to the customer A.",
        "label": "Customer A [Member]",
        "terseLabel": "Customer A"
       }
      }
     },
     "localname": "CustomerAMember",
     "nsuri": "http://www.incyte.com/20220930",
     "presentation": [
      "http://www.incyte.com/role/ConcentrationsofCreditRiskandCurrentExpectedCreditLossesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "incy_CustomerBMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to the customer B.",
        "label": "Customer B [Member]",
        "terseLabel": "Customer B"
       }
      }
     },
     "localname": "CustomerBMember",
     "nsuri": "http://www.incyte.com/20220930",
     "presentation": [
      "http://www.incyte.com/role/ConcentrationsofCreditRiskandCurrentExpectedCreditLossesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "incy_CustomerCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to the customer C.",
        "label": "Customer C [Member]",
        "terseLabel": "Customer C"
       }
      }
     },
     "localname": "CustomerCMember",
     "nsuri": "http://www.incyte.com/20220930",
     "presentation": [
      "http://www.incyte.com/role/ConcentrationsofCreditRiskandCurrentExpectedCreditLossesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "incy_CustomerDMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to the customer D.",
        "label": "Customer D [Member]",
        "terseLabel": "Customer D"
       }
      }
     },
     "localname": "CustomerDMember",
     "nsuri": "http://www.incyte.com/20220930",
     "presentation": [
      "http://www.incyte.com/role/ConcentrationsofCreditRiskandCurrentExpectedCreditLossesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "incy_CustomerEMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to the customer E.",
        "label": "Customer E",
        "terseLabel": "Customer E"
       }
      }
     },
     "localname": "CustomerEMember",
     "nsuri": "http://www.incyte.com/20220930",
     "presentation": [
      "http://www.incyte.com/role/ConcentrationsofCreditRiskandCurrentExpectedCreditLossesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "incy_DevelopmentAndRegulatoryMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to certain development and regulatory events on the basis of which certain milestones are achieved.",
        "label": "Development and Regulatory Milestones",
        "terseLabel": "Development and Regulatory Milestones"
       }
      }
     },
     "localname": "DevelopmentAndRegulatoryMilestonesMember",
     "nsuri": "http://www.incyte.com/20220930",
     "presentation": [
      "http://www.incyte.com/role/LicenseAgreementsInnoventDetails",
      "http://www.incyte.com/role/LicenseAgreementsMacroGenicsDetails",
      "http://www.incyte.com/role/LicenseAgreementsMerusDetails",
      "http://www.incyte.com/role/LicenseAgreementsMorphoSysDetails",
      "http://www.incyte.com/role/LicenseAgreementsNimbleDetails",
      "http://www.incyte.com/role/LicenseAgreementsNovartisDetails",
      "http://www.incyte.com/role/LicenseAgreementsSyndaxDetails",
      "http://www.incyte.com/role/LicenseAgreementsSyrosDetails",
      "http://www.incyte.com/role/LicenseAgreementsZaiLabDetails",
      "http://www.incyte.com/role/SubsequentEventsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "incy_DevelopmentMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to certain development events on the basis of which certain milestones are achieved.",
        "label": "Development Milestones",
        "terseLabel": "Development Milestones"
       }
      }
     },
     "localname": "DevelopmentMilestonesMember",
     "nsuri": "http://www.incyte.com/20220930",
     "presentation": [
      "http://www.incyte.com/role/LicenseAgreementsLillyDetails",
      "http://www.incyte.com/role/LicenseAgreementsMacroGenicsDetails",
      "http://www.incyte.com/role/LicenseAgreementsNovartisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "incy_DevelopmentRegulatoryAndCommercializationMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents development regulatory and commercialization milestones.",
        "label": "Development, Regulatory and Commercialization Milestones",
        "terseLabel": "Development, Regulatory and Commercialization Milestones"
       }
      }
     },
     "localname": "DevelopmentRegulatoryAndCommercializationMilestonesMember",
     "nsuri": "http://www.incyte.com/20220930",
     "presentation": [
      "http://www.incyte.com/role/LicenseAgreementsAgenusDetails",
      "http://www.incyte.com/role/LicenseAgreementsCalitheraDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "incy_EliLillyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents details pertaining to Eli Lilly with whom we have entered into a License, Development and Commercialization Agreement.",
        "label": "Eli Lilly",
        "terseLabel": "Eli Lilly"
       }
      }
     },
     "localname": "EliLillyMember",
     "nsuri": "http://www.incyte.com/20220930",
     "presentation": [
      "http://www.incyte.com/role/LicenseAgreementsLillyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "incy_EquityMethodInvestmentSharesPurchased": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the aggregate shares purchased of investments accounted for under the equity method of accounting.",
        "label": "Equity Method Investment, Shares Purchased",
        "terseLabel": "Common shares purchased (in shares)"
       }
      }
     },
     "localname": "EquityMethodInvestmentSharesPurchased",
     "nsuri": "http://www.incyte.com/20220930",
     "presentation": [
      "http://www.incyte.com/role/LicenseAgreementsMerusDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "incy_FairValueInputsCashFlowsEstimatedPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of time used to measure cash flows to find the present value of an amount to be paid or received in the future as an input to measure fair value.",
        "label": "Fair Value Inputs Cash Flows Estimated Period",
        "terseLabel": "Projected cash flows period"
       }
      }
     },
     "localname": "FairValueInputsCashFlowsEstimatedPeriod",
     "nsuri": "http://www.incyte.com/20220930",
     "presentation": [
      "http://www.incyte.com/role/FairValueofFinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "incy_FinanceLeaseLeaseIncentiveReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of lease incentive receivable from landlord under finance leases.",
        "label": "Finance Lease, Lease Incentive Receivable",
        "terseLabel": "Finance lease, lease incentive receivable"
       }
      }
     },
     "localname": "FinanceLeaseLeaseIncentiveReceivable",
     "nsuri": "http://www.incyte.com/20220930",
     "presentation": [
      "http://www.incyte.com/role/PropertyandEquipmentnetBuildingsandconstructionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "incy_FutureContingentDiscoveryMilestoneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to future contingent discovery milestone.",
        "label": "Future contingent discovery milestones",
        "terseLabel": "Future contingent discovery milestones"
       }
      }
     },
     "localname": "FutureContingentDiscoveryMilestoneMember",
     "nsuri": "http://www.incyte.com/20220930",
     "presentation": [
      "http://www.incyte.com/role/LicenseAgreementsNimbleDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "incy_GvhdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to GVHD, an Graft-Versus-Host Disease field.",
        "label": "GVHD",
        "terseLabel": "GVHD"
       }
      }
     },
     "localname": "GvhdMember",
     "nsuri": "http://www.incyte.com/20220930",
     "presentation": [
      "http://www.incyte.com/role/LicenseAgreementsLillyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "incy_ICLUSIGMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to ICLUSIG, a kinase inhibitor.",
        "label": "ICLUSIG",
        "terseLabel": "ICLUSIG"
       }
      }
     },
     "localname": "ICLUSIGMember",
     "nsuri": "http://www.incyte.com/20220930",
     "presentation": [
      "http://www.incyte.com/role/RevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "incy_IncyteMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents member information pertaining to Incyte.",
        "label": "Incyte",
        "terseLabel": "Incyte"
       }
      }
     },
     "localname": "IncyteMember",
     "nsuri": "http://www.incyte.com/20220930",
     "presentation": [
      "http://www.incyte.com/role/LicenseAgreementsMorphoSysDetails",
      "http://www.incyte.com/role/LicenseAgreementsSyndaxDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "incy_InnocarePharmaLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to InnoCare Pharma Limited (\"InnoCare\").",
        "label": "InnoCare",
        "terseLabel": "InnoCare"
       }
      }
     },
     "localname": "InnocarePharmaLimitedMember",
     "nsuri": "http://www.incyte.com/20220930",
     "presentation": [
      "http://www.incyte.com/role/LicenseAgreementsInnoCareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "incy_InnoventBiologicsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents details pertaining to Innovent Biologics, Inc with whom we have entered into a research collaboration and licensing agreement.",
        "label": "Innovent",
        "terseLabel": "Innovent"
       }
      }
     },
     "localname": "InnoventBiologicsIncMember",
     "nsuri": "http://www.incyte.com/20220930",
     "presentation": [
      "http://www.incyte.com/role/LicenseAgreementsInnoventDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "incy_InventoryNetCurrentAndNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.incyte.com/role/InventoryDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the aggregate carrying amount of current and noncurrent portion, net of valuation reserves and allowances, as of the balance sheet date of inventories.",
        "label": "Inventory Net Current and Noncurrent",
        "totalLabel": "Total inventory"
       }
      }
     },
     "localname": "InventoryNetCurrentAndNoncurrent",
     "nsuri": "http://www.incyte.com/20220930",
     "presentation": [
      "http://www.incyte.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "incy_InventoryRecordedAsResearchAndDevelopmentExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the aggregate carrying amount of current and noncurrent portion, net of valuation reserves and allowances, as of the balance sheet date of inventories recorded as research and development expense.",
        "label": "Inventory, Recorded as Research and Development Expense",
        "terseLabel": "Inventory incurred prior to FDA approval"
       }
      }
     },
     "localname": "InventoryRecordedAsResearchAndDevelopmentExpense",
     "nsuri": "http://www.incyte.com/20220930",
     "presentation": [
      "http://www.incyte.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "incy_InvestmentInSyndaxPharmaceuticalsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents investment information pertaining to Syndax Pharmaceuticals Inc.",
        "label": "Investment in Syndax",
        "terseLabel": "Investment in Syndax"
       }
      }
     },
     "localname": "InvestmentInSyndaxPharmaceuticalsIncMember",
     "nsuri": "http://www.incyte.com/20220930",
     "presentation": [
      "http://www.incyte.com/role/LicenseAgreementsSyndaxDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "incy_JAKAFIMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to JAKAFI (ruxolitinib), an oral Janus associate kinase (JAK) inhibitor sold within the United State of America.",
        "label": "JAKAFI",
        "terseLabel": "JAKAFI",
        "verboseLabel": "JAKAFI"
       }
      }
     },
     "localname": "JAKAFIMember",
     "nsuri": "http://www.incyte.com/20220930",
     "presentation": [
      "http://www.incyte.com/role/LicenseAgreementsNovartisDetails",
      "http://www.incyte.com/role/RevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "incy_JakaviMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to JAKAVI (ruxolitinib), an oral Janus associate kinase (JAK) inhibitor sold outside the United State of America.",
        "label": "JAKAVI",
        "terseLabel": "JAKAVI"
       }
      }
     },
     "localname": "JakaviMember",
     "nsuri": "http://www.incyte.com/20220930",
     "presentation": [
      "http://www.incyte.com/role/LicenseAgreementsNovartisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "incy_JakaviRoyaltyRevenuesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to JAKAVI royalty revenues, an oral Janus associate kinase (JAK) inhibitor sold within the United State of America.",
        "label": "JAKAVI Royalty Revenues",
        "terseLabel": "JAKAVI Royalty Revenues"
       }
      }
     },
     "localname": "JakaviRoyaltyRevenuesMember",
     "nsuri": "http://www.incyte.com/20220930",
     "presentation": [
      "http://www.incyte.com/role/RevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "incy_LandLocatedWithinYParcSwitzerlandsLargestTechnologyParkInYverdonMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to land located with Y-PARC, Switzerland's largest technology park in Yverdon.",
        "label": "Land in Y-PARC, Switzerland's largest technology park, Yverdon",
        "terseLabel": "Land in Y-PARC, Switzerland's largest technology park, Yverdon"
       }
      }
     },
     "localname": "LandLocatedWithinYParcSwitzerlandsLargestTechnologyParkInYverdonMember",
     "nsuri": "http://www.incyte.com/20220930",
     "presentation": [
      "http://www.incyte.com/role/PropertyandEquipmentnetBuildingsandconstructionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "incy_LicenseAgreementAdditionalMilestonePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the additional milestone payments to be made under the license agreement.",
        "label": "License Agreement Additional Milestone Payments",
        "terseLabel": "Additional milestone payments under the license agreement"
       }
      }
     },
     "localname": "LicenseAgreementAdditionalMilestonePayments",
     "nsuri": "http://www.incyte.com/20220930",
     "presentation": [
      "http://www.incyte.com/role/LicenseAgreementsAgenusDetails",
      "http://www.incyte.com/role/LicenseAgreementsLillyDetails",
      "http://www.incyte.com/role/LicenseAgreementsMacroGenicsDetails",
      "http://www.incyte.com/role/LicenseAgreementsMerusDetails",
      "http://www.incyte.com/role/LicenseAgreementsMorphoSysDetails",
      "http://www.incyte.com/role/LicenseAgreementsNimbleDetails",
      "http://www.incyte.com/role/LicenseAgreementsSyndaxDetails",
      "http://www.incyte.com/role/LicenseAgreementsSyrosDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "incy_LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the earning recognized and the payment received for the achievement of a predefined milestone under the license agreement.",
        "label": "License Agreement, Amount Recognized and Received for Achievement of a Predefined Milestone",
        "terseLabel": "Amount recognized and received for the achievement of a predefined milestone"
       }
      }
     },
     "localname": "LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone",
     "nsuri": "http://www.incyte.com/20220930",
     "presentation": [
      "http://www.incyte.com/role/LicenseAgreementsInnoventDetails",
      "http://www.incyte.com/role/LicenseAgreementsLillyDetails",
      "http://www.incyte.com/role/LicenseAgreementsNovartisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "incy_LicenseAgreementMaximumNumberOfIndependentPrograms": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the maximum number of independent programs encompassed under the collaboration agreement.",
        "label": "License Agreement, Maximum Number Of Independent Programs",
        "terseLabel": "Number of independent programs"
       }
      }
     },
     "localname": "LicenseAgreementMaximumNumberOfIndependentPrograms",
     "nsuri": "http://www.incyte.com/20220930",
     "presentation": [
      "http://www.incyte.com/role/LicenseAgreementsMerusDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "incy_LicenseAgreementMilestoneOnNetSalesOfProduct": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement, Milestone on Net Sales of Product",
        "label": "License Agreement, Milestone on Net Sales of Product",
        "terseLabel": "Milestone payments for net sales of product"
       }
      }
     },
     "localname": "LicenseAgreementMilestoneOnNetSalesOfProduct",
     "nsuri": "http://www.incyte.com/20220930",
     "presentation": [
      "http://www.incyte.com/role/SubsequentEventsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "incy_LicenseAgreementMilestonePaymentAmountPaid": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount of the milestone payment made under the license agreement.",
        "label": "License Agreement Milestone Payment Amount Paid",
        "terseLabel": "Milestone payment made under license agreement"
       }
      }
     },
     "localname": "LicenseAgreementMilestonePaymentAmountPaid",
     "nsuri": "http://www.incyte.com/20220930",
     "presentation": [
      "http://www.incyte.com/role/LicenseAgreementsAgenusDetails",
      "http://www.incyte.com/role/LicenseAgreementsCalitheraDetails",
      "http://www.incyte.com/role/LicenseAgreementsLillyDetails",
      "http://www.incyte.com/role/LicenseAgreementsMacroGenicsDetails",
      "http://www.incyte.com/role/LicenseAgreementsMerusDetails",
      "http://www.incyte.com/role/LicenseAgreementsMorphoSysDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "incy_LicenseAgreementNumberOfAdditionalPreclinicalDiscoveryPrograms": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of additional preclinical discovery programs.",
        "label": "License Agreement, Number of Additional Preclinical Discovery Programs",
        "terseLabel": "Number of additional preclinical discovery programs"
       }
      }
     },
     "localname": "LicenseAgreementNumberOfAdditionalPreclinicalDiscoveryPrograms",
     "nsuri": "http://www.incyte.com/20220930",
     "presentation": [
      "http://www.incyte.com/role/LicenseAgreementsMerusDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "incy_LicenseAgreementPercentageOfFutureGlobalDevelopmentCostsFunded": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the percentage of future global development costs funded under the license agreement.",
        "label": "License Agreement Percentage of Future Global Development Costs Funded",
        "terseLabel": "Funding of future development costs (as a percent)"
       }
      }
     },
     "localname": "LicenseAgreementPercentageOfFutureGlobalDevelopmentCostsFunded",
     "nsuri": "http://www.incyte.com/20220930",
     "presentation": [
      "http://www.incyte.com/role/LicenseAgreementsCalitheraDetails",
      "http://www.incyte.com/role/LicenseAgreementsMorphoSysDetails",
      "http://www.incyte.com/role/LicenseAgreementsSyndaxDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "incy_LicenseAgreementTargetSelectionAndOptionExerciseFeePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the target selection and option exercise fee payments to be made under the license agreement.",
        "label": "License Agreement Target Selection and Option Exercise Fee Payments",
        "terseLabel": "Target selection and option exercise fee payment"
       }
      }
     },
     "localname": "LicenseAgreementTargetSelectionAndOptionExerciseFeePayments",
     "nsuri": "http://www.incyte.com/20220930",
     "presentation": [
      "http://www.incyte.com/role/LicenseAgreementsSyrosDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "incy_LicenseAgreementTerminationNoticePeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the notice period for the termination of license agreement.",
        "label": "License Agreement, Termination Notice, Period",
        "terseLabel": "Period of notice for termination of license agreement"
       }
      }
     },
     "localname": "LicenseAgreementTerminationNoticePeriod",
     "nsuri": "http://www.incyte.com/20220930",
     "presentation": [
      "http://www.incyte.com/role/LicenseAgreementsAgenusDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "incy_LicenseAgreementUpfrontPaymentAmountPaid": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount of the upfront payment made under the license agreement.",
        "label": "License Agreement Upfront Payment Amount Paid",
        "terseLabel": "Upfront payment under license agreement"
       }
      }
     },
     "localname": "LicenseAgreementUpfrontPaymentAmountPaid",
     "nsuri": "http://www.incyte.com/20220930",
     "presentation": [
      "http://www.incyte.com/role/LicenseAgreementsSyndaxDetails",
      "http://www.incyte.com/role/SubsequentEventsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "incy_LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the upfront and immediate milestone payment received under the license agreement.",
        "label": "License Agreement, Upfront Payment and Immediate Milestone Payment to be Received",
        "terseLabel": "Upfront and immediate milestone payment to be received under license agreement"
       }
      }
     },
     "localname": "LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived",
     "nsuri": "http://www.incyte.com/20220930",
     "presentation": [
      "http://www.incyte.com/role/LicenseAgreementsInnoCareDetails",
      "http://www.incyte.com/role/LicenseAgreementsInnoventDetails",
      "http://www.incyte.com/role/LicenseAgreementsLillyDetails",
      "http://www.incyte.com/role/LicenseAgreementsNovartisDetails",
      "http://www.incyte.com/role/LicenseAgreementsZaiLabDetails",
      "http://www.incyte.com/role/SubsequentEventsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "incy_LicenseAgreementUpfrontPaymentReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the upfront payment received under the license agreement.",
        "label": "License Agreement, Upfront Payment Received",
        "terseLabel": "Upfront payment received under license agreement"
       }
      }
     },
     "localname": "LicenseAgreementUpfrontPaymentReceived",
     "nsuri": "http://www.incyte.com/20220930",
     "presentation": [
      "http://www.incyte.com/role/LicenseAgreementsInnoCareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "incy_LicenseAgreementsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreements",
        "label": "License Agreements",
        "terseLabel": "License Agreements"
       }
      }
     },
     "localname": "LicenseAgreementsDisclosureAbstract",
     "nsuri": "http://www.incyte.com/20220930",
     "xbrltype": "stringItemType"
    },
    "incy_LicenseAgreementsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element may be used to describe all significant license agreements of the reporting entity.",
        "label": "License Agreements [Text Block]",
        "terseLabel": "License Agreements"
       }
      }
     },
     "localname": "LicenseAgreementsTextBlock",
     "nsuri": "http://www.incyte.com/20220930",
     "presentation": [
      "http://www.incyte.com/role/LicenseAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "incy_MINJUVIMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to MONJUVI/MINJUVI (tafasitamab-cxix).",
        "label": "MINJUVI",
        "terseLabel": "MINJUVI"
       }
      }
     },
     "localname": "MINJUVIMember",
     "nsuri": "http://www.incyte.com/20220930",
     "presentation": [
      "http://www.incyte.com/role/RevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "incy_MacrogenicsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents details pertaining to MacroGenics with whom we have entered into an exclusive global collaboration and license agreement.",
        "label": "MacroGenics",
        "terseLabel": "MacroGenics"
       }
      }
     },
     "localname": "MacrogenicsMember",
     "nsuri": "http://www.incyte.com/20220930",
     "presentation": [
      "http://www.incyte.com/role/LicenseAgreementsMacroGenicsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "incy_MerusNVMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Merus N. V.",
        "label": "Merus",
        "terseLabel": "Merus"
       }
      }
     },
     "localname": "MerusNVMember",
     "nsuri": "http://www.incyte.com/20220930",
     "presentation": [
      "http://www.incyte.com/role/LicenseAgreementsMerusDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "incy_MilestoneAndContractRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to milestone and contract revenues.",
        "label": "Milestone and contract revenues",
        "terseLabel": "Milestone and contract revenues"
       }
      }
     },
     "localname": "MilestoneAndContractRevenueMember",
     "nsuri": "http://www.incyte.com/20220930",
     "presentation": [
      "http://www.incyte.com/role/LicenseAgreementsNovartisDetails",
      "http://www.incyte.com/role/RevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "incy_MilestoneRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to milestone revenue.",
        "label": "Milestone revenues",
        "terseLabel": "Milestone and contract revenues"
       }
      }
     },
     "localname": "MilestoneRevenueMember",
     "nsuri": "http://www.incyte.com/20220930",
     "presentation": [
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "domainItemType"
    },
    "incy_MorphosysAgMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents member information pertaining to MorphoSys AG.",
        "label": "MorphoSys AG",
        "terseLabel": "MorphoSys AG"
       }
      }
     },
     "localname": "MorphosysAgMember",
     "nsuri": "http://www.incyte.com/20220930",
     "presentation": [
      "http://www.incyte.com/role/LicenseAgreementsMorphoSysDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "incy_NimbleMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Nimble.",
        "label": "Nimble",
        "terseLabel": "Nimble"
       }
      }
     },
     "localname": "NimbleMember",
     "nsuri": "http://www.incyte.com/20220930",
     "presentation": [
      "http://www.incyte.com/role/LicenseAgreementsNimbleDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "incy_NovartisMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents details pertaining to Novartis with whom we have entered into a Collaboration and License Agreement.",
        "label": "Novartis",
        "terseLabel": "Novartis"
       }
      }
     },
     "localname": "NovartisMember",
     "nsuri": "http://www.incyte.com/20220930",
     "presentation": [
      "http://www.incyte.com/role/LicenseAgreementsNovartisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "incy_NumberOfProgramTargets": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of program targets identified.",
        "label": "Number Of Program Targets",
        "terseLabel": "Number of program targets"
       }
      }
     },
     "localname": "NumberOfProgramTargets",
     "nsuri": "http://www.incyte.com/20220930",
     "presentation": [
      "http://www.incyte.com/role/LicenseAgreementsSyrosDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "incy_NumberOfProgramsUnderWhichResultingProductsAreCoFundedForDevelopment": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of programs in which the resulting products are co-funded for development.",
        "label": "Number of Programs Under Which The Resulting Products Are Co-Funded For Development",
        "terseLabel": "Number of programs under the resulting products are co-funded for development"
       }
      }
     },
     "localname": "NumberOfProgramsUnderWhichResultingProductsAreCoFundedForDevelopment",
     "nsuri": "http://www.incyte.com/20220930",
     "presentation": [
      "http://www.incyte.com/role/LicenseAgreementsMerusDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "incy_OfficeBuildingMorgesSwitzerlandMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information relating to the office building located in Morges, Switzerland.",
        "label": "Office Building in Morges, Switzerland",
        "terseLabel": "Office Building in Morges, Switzerland"
       }
      }
     },
     "localname": "OfficeBuildingMorgesSwitzerlandMember",
     "nsuri": "http://www.incyte.com/20220930",
     "presentation": [
      "http://www.incyte.com/role/PropertyandEquipmentnetBuildingsandconstructionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "incy_OfficeBuildingWilmingtonDelawareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information relating to the office building located in Wilmington, Delaware.",
        "label": "Office Building in Wilmington, Delaware",
        "terseLabel": "Office Building in Wilmington, Delaware"
       }
      }
     },
     "localname": "OfficeBuildingWilmingtonDelawareMember",
     "nsuri": "http://www.incyte.com/20220930",
     "presentation": [
      "http://www.incyte.com/role/PropertyandEquipmentnetBuildingsandconstructionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "incy_OlumiantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Baricitinib for the treatment of moderate-to-severe rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to, one or more disease-modifying antirheumatic drugs (DMARDs).",
        "label": "OLUMIANT",
        "terseLabel": "OLUMIANT"
       }
      }
     },
     "localname": "OlumiantMember",
     "nsuri": "http://www.incyte.com/20220930",
     "presentation": [
      "http://www.incyte.com/role/LicenseAgreementsLillyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "incy_OlumiantRoyaltyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to OLUMIANT royalty revenues, a treatment of adults with moderately-to-severely active rheumatoid arthritis.",
        "label": "OLUMIANT Royalty Revenues",
        "terseLabel": "OLUMIANT Royalty Revenues"
       }
      }
     },
     "localname": "OlumiantRoyaltyMember",
     "nsuri": "http://www.incyte.com/20220930",
     "presentation": [
      "http://www.incyte.com/role/LicenseAgreementsLillyDetails",
      "http://www.incyte.com/role/RevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "incy_OperatingLeaseRightOfUseAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual agreement that stipulates the lessee pay the lessor for use of an asset under operating lease.",
        "label": "Operating lease right-of-use assets",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetsMember",
     "nsuri": "http://www.incyte.com/20220930",
     "presentation": [
      "http://www.incyte.com/role/PropertyandEquipmentnetPropertyandequipmentnetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "incy_OpzeluraMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to OPZELURA (ruxolitinib) cream, a novel cream formulation of Incyte's selective JAK1/JAK2 inhibitor ruxolitinib.",
        "label": "OPZELURA",
        "terseLabel": "OPZELURA"
       }
      }
     },
     "localname": "OpzeluraMember",
     "nsuri": "http://www.incyte.com/20220930",
     "presentation": [
      "http://www.incyte.com/role/RevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "incy_PaymentOfContingentConsideration": {
     "auth_ref": [],
     "calculation": {
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow with regard to the contingent consideration during the period.",
        "label": "Payment of Contingent Consideration",
        "negatedLabel": "Payment of contingent consideration"
       }
      }
     },
     "localname": "PaymentOfContingentConsideration",
     "nsuri": "http://www.incyte.com/20220930",
     "presentation": [
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "incy_PemazyreMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to PEMAZYRE (pemigatinib), a selective fibroblast growth factor receptor (FGFR) inhibitor, for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with an FGFR2 fusion or other rearrangement as detected by an FDA-approved test.",
        "label": "PEMAZYRE",
        "terseLabel": "PEMAZYRE"
       }
      }
     },
     "localname": "PemazyreMember",
     "nsuri": "http://www.incyte.com/20220930",
     "presentation": [
      "http://www.incyte.com/role/LicenseAgreementsInnoventDetails",
      "http://www.incyte.com/role/RevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "incy_PercentageFundingOnCostOnPossibleElectionOfCodevelopmentOfCompounds": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the percentage of associated future global development costs from the initiation of a Phase IIb trial provided the entity elects to co-develop any compounds and/or indications.",
        "label": "Percentage Funding on Cost on Possible Election of Co-development of Compounds",
        "verboseLabel": "Associated future global development costs , if elected to co-develop (as a percent)"
       }
      }
     },
     "localname": "PercentageFundingOnCostOnPossibleElectionOfCodevelopmentOfCompounds",
     "nsuri": "http://www.incyte.com/20220930",
     "presentation": [
      "http://www.incyte.com/role/LicenseAgreementsMerusDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "incy_PercentageOfProfitsLosses": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the percentage of profits (losses).",
        "label": "Percentage of Profits (Losses)",
        "terseLabel": "Percentage of profit (losses)"
       }
      }
     },
     "localname": "PercentageOfProfitsLosses",
     "nsuri": "http://www.incyte.com/20220930",
     "presentation": [
      "http://www.incyte.com/role/LicenseAgreementsCalitheraDetails",
      "http://www.incyte.com/role/LicenseAgreementsMerusDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "incy_PercentageOfRoyaltyRatePayments": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents range of tiered, double-digit royalty payments on future global sales if product is successfully commercialized.",
        "label": "Percentage Of Royalty Rate Payments",
        "terseLabel": "Royalty payments on future global net sales (as a percent)"
       }
      }
     },
     "localname": "PercentageOfRoyaltyRatePayments",
     "nsuri": "http://www.incyte.com/20220930",
     "presentation": [
      "http://www.incyte.com/role/LicenseAgreementsAgenusDetails",
      "http://www.incyte.com/role/LicenseAgreementsMacroGenicsDetails",
      "http://www.incyte.com/role/LicenseAgreementsMerusDetails",
      "http://www.incyte.com/role/LicenseAgreementsNovartisDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "incy_PeriodOfDeviationFromAverageCostOfGoodsSold": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the length of time in which cost of goods sold will deviate from average due to unusual and/or infrequent conditions.",
        "label": "Period Of Deviation From Average, Cost Of Goods Sold",
        "terseLabel": "Period of lower average per unit cost of materials"
       }
      }
     },
     "localname": "PeriodOfDeviationFromAverageCostOfGoodsSold",
     "nsuri": "http://www.incyte.com/20220930",
     "presentation": [
      "http://www.incyte.com/role/InventoryDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "incy_PreSeptember2022StockSplitSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pre September 2022 -Stock Split Shares",
        "label": "Pre September 2022 -Stock Split Shares [Member]",
        "terseLabel": "Pre September 2022 -Stock Split Shares"
       }
      }
     },
     "localname": "PreSeptember2022StockSplitSharesMember",
     "nsuri": "http://www.incyte.com/20220930",
     "presentation": [
      "http://www.incyte.com/role/LicenseAgreementsSyrosDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "incy_ProductGroupOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the royalty-bearing product other than GITR, OX40 and one undisclosed target.",
        "label": "Royalty-bearing product other than GITR, OX40 and one undisclosed target",
        "terseLabel": "Royalty-bearing product other than GITR, OX40 and one undisclosed target"
       }
      }
     },
     "localname": "ProductGroupOneMember",
     "nsuri": "http://www.incyte.com/20220930",
     "presentation": [
      "http://www.incyte.com/role/LicenseAgreementsAgenusDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "incy_ProductGroupTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the royalty-bearing product GITR, OX40 and one undisclosed target.",
        "label": "Royalty-bearing product GITR, OX40 and one undisclosed target",
        "terseLabel": "Royalty-bearing product GITR, OX40 and one undisclosed target"
       }
      }
     },
     "localname": "ProductGroupTwoMember",
     "nsuri": "http://www.incyte.com/20220930",
     "presentation": [
      "http://www.incyte.com/role/LicenseAgreementsAgenusDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "incy_PurchaseOfCommonStockUnderStockPurchaseAgreementInShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the purchase of common stock under Stock Purchase Agreement.",
        "label": "Purchase of common stock under stock purchase agreement in shares",
        "terseLabel": "Purchase of common stock under Stock Purchase Agreement (in shares )"
       }
      }
     },
     "localname": "PurchaseOfCommonStockUnderStockPurchaseAgreementInShares",
     "nsuri": "http://www.incyte.com/20220930",
     "presentation": [
      "http://www.incyte.com/role/LicenseAgreementsAgenusDetails",
      "http://www.incyte.com/role/LicenseAgreementsCalitheraDetails",
      "http://www.incyte.com/role/LicenseAgreementsMerusDetails",
      "http://www.incyte.com/role/LicenseAgreementsSyndaxDetails",
      "http://www.incyte.com/role/LicenseAgreementsSyrosDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "incy_RegulatoryMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to certain regulatory events on the basis of which certain milestones are achieved.",
        "label": "Regulatory Milestones",
        "terseLabel": "Regulatory Milestones"
       }
      }
     },
     "localname": "RegulatoryMilestonesMember",
     "nsuri": "http://www.incyte.com/20220930",
     "presentation": [
      "http://www.incyte.com/role/LicenseAgreementsInnoventDetails",
      "http://www.incyte.com/role/LicenseAgreementsLillyDetails",
      "http://www.incyte.com/role/LicenseAgreementsNovartisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "incy_RoyaltiesPayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount of royalties payable.",
        "label": "Royalties Payable",
        "terseLabel": "Royalties payable"
       }
      }
     },
     "localname": "RoyaltiesPayable",
     "nsuri": "http://www.incyte.com/20220930",
     "presentation": [
      "http://www.incyte.com/role/LicenseAgreementsNovartisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "incy_ScheduleOfInventoryTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of carrying amount of inventories as of the balance sheet date.",
        "label": "Schedule of Inventory [Table Text Block]",
        "terseLabel": "Schedule of inventory"
       }
      }
     },
     "localname": "ScheduleOfInventoryTableTextBlock",
     "nsuri": "http://www.incyte.com/20220930",
     "presentation": [
      "http://www.incyte.com/role/InventoryTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "incy_ScheduleOfShareBasedCompensationOtherThanStockOptionsActivityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure represents the schedule of share based compensation other than stock options activity.",
        "label": "Schedule of RSU award and PSU activity under the 2010 Stock Plan",
        "terseLabel": "Schedule of RSU award and PSU activity under the 2010 Stock Plan"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationOtherThanStockOptionsActivityTableTextBlock",
     "nsuri": "http://www.incyte.com/20220930",
     "presentation": [
      "http://www.incyte.com/role/StockcompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "incy_ScheduleOfShareBasedPaymentAwardStockOptionsAndEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock options plan and employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share Based Payment Award, Stock Options and Employee Stock Purchase Plan Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of valuation assumptions used for valuation of fair value of stock compensation granted"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsAndEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",
     "nsuri": "http://www.incyte.com/20220930",
     "presentation": [
      "http://www.incyte.com/role/StockcompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "incy_SchedulesOfConcentrationOfRiskByRiskFactorRelatedToCollaborativePartnersTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark, related to the collaborative partners.",
        "label": "Schedules of Concentration of Risk by Risk Factor Related to Collaborative Partners [Table Text Block]",
        "terseLabel": "Schedule of concentration of credit risk related to collaborative partners"
       }
      }
     },
     "localname": "SchedulesOfConcentrationOfRiskByRiskFactorRelatedToCollaborativePartnersTableTextBlock",
     "nsuri": "http://www.incyte.com/20220930",
     "presentation": [
      "http://www.incyte.com/role/ConcentrationsofCreditRiskandCurrentExpectedCreditLossesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of shares of employee compensation programs, other than options, released during the period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Released In Period",
        "terseLabel": "Released (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod",
     "nsuri": "http://www.incyte.com/20220930",
     "presentation": [
      "http://www.incyte.com/role/StockCompensationRSUawardandPSUactivityunderthe2010stockplanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedIntrinsicValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share weighted average intrinsic value of equity-based compensation awards released. Excludes stock and unit options.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Released Intrinsic Value",
        "terseLabel": "Released (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedIntrinsicValue",
     "nsuri": "http://www.incyte.com/20220930",
     "presentation": [
      "http://www.incyte.com/role/StockCompensationRSUawardandPSUactivityunderthe2010stockplanDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedAnnualizedForfeitureRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the expected annualized forfeiture rate for options granted.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions Expected Annualized Forfeiture Rate",
        "terseLabel": "Assumed annualized forfeiture rate (as a percent)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedAnnualizedForfeitureRate",
     "nsuri": "http://www.incyte.com/20220930",
     "presentation": [
      "http://www.incyte.com/role/StockCompensationNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCanceled": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares canceled under an established share-based compensation plan.",
        "label": "Share Based Compensation Arrangement by Share Based Payment Award Number of Shares Canceled",
        "terseLabel": "Options, RSUs and PSUs cancelled (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCanceled",
     "nsuri": "http://www.incyte.com/20220930",
     "presentation": [
      "http://www.incyte.com/role/StockCompensationSharesavailableforgrantDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGranted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares granted under an established share-based compensation plan.",
        "label": "Share Based Compensation Arrangement by Share Based Payment Award Number of Shares Granted",
        "negatedTerseLabel": "Options, RSUs and PSUs granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGranted",
     "nsuri": "http://www.incyte.com/20220930",
     "presentation": [
      "http://www.incyte.com/role/StockCompensationSharesavailableforgrantDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesPerRestrictedStockUnits": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of shares awarded for each restricted share units.",
        "label": "Share Based Compensation Arrangement by Share Based Payment Award Number of Shares Per Restricted Stock Units",
        "terseLabel": "Number of shares awarded for each RSU (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesPerRestrictedStockUnits",
     "nsuri": "http://www.incyte.com/20220930",
     "presentation": [
      "http://www.incyte.com/role/StockCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "incy_StockIssuedDuringPeriodValueStockOptionsAndRestrictedStockUnitsExercisedAndEmployeeStockPurchasePlan": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value stock issued during the period as a result of the exercise of stock options and restricted stock units and the aggregate change in value for stock issued during the period as a result of employee stock purchase plan.",
        "label": "Stock Issued During Period Value Stock Options and Restricted Stock Units Exercised and Employee Stock Purchase Plan",
        "verboseLabel": "Issuance of shares of Common Stock upon exercise of stock options and settlement of employee restricted stock units and performance shares, net of shares withheld for taxes and shares of Common Stock under the ESPP"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsAndRestrictedStockUnitsExercisedAndEmployeeStockPurchasePlan",
     "nsuri": "http://www.incyte.com/20220930",
     "presentation": [
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "incy_StockPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents stock purchase agreement.",
        "label": "Stock purchase agreement",
        "terseLabel": "Stock purchase agreement"
       }
      }
     },
     "localname": "StockPurchaseAgreementMember",
     "nsuri": "http://www.incyte.com/20220930",
     "presentation": [
      "http://www.incyte.com/role/LicenseAgreementsAgenusDetails",
      "http://www.incyte.com/role/LicenseAgreementsCalitheraDetails",
      "http://www.incyte.com/role/LicenseAgreementsMerusDetails",
      "http://www.incyte.com/role/LicenseAgreementsSyndaxDetails",
      "http://www.incyte.com/role/LicenseAgreementsSyrosDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "incy_SubsidiaryStockConversionRatio": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of parent common shares issuable upon conversion for each share of subsidiary stock to be converted.",
        "label": "Subsidiary Stock, Conversion Ratio",
        "terseLabel": "Share conversion"
       }
      }
     },
     "localname": "SubsidiaryStockConversionRatio",
     "nsuri": "http://www.incyte.com/20220930",
     "presentation": [
      "http://www.incyte.com/role/LicenseAgreementsMorphoSysDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "incy_SyndaxPharmaceuticalsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents member information pertaining to Syndax Pharmaceuticals Inc.",
        "label": "Syndax",
        "terseLabel": "Syndax"
       }
      }
     },
     "localname": "SyndaxPharmaceuticalsIncMember",
     "nsuri": "http://www.incyte.com/20220930",
     "presentation": [
      "http://www.incyte.com/role/LicenseAgreementsSyndaxDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "incy_SyrosPharmaceuticalsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents details pertaining to Syros Pharmaceuticals, Inc with whom we have entered into a target discovery, research collaboration and option agreement.",
        "label": "Syros Pharmaceuticals, Inc.",
        "terseLabel": "Syros Pharmaceuticals, Inc."
       }
      }
     },
     "localname": "SyrosPharmaceuticalsIncMember",
     "nsuri": "http://www.incyte.com/20220930",
     "presentation": [
      "http://www.incyte.com/role/LicenseAgreementsSyrosDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "incy_TABRECTAPRODUCTANDSERVICESMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "TABRECTA PRODUCT AND SERVICES",
        "label": "TABRECTA PRODUCT AND SERVICES [Member]",
        "terseLabel": "TABRECTA PROD SERV"
       }
      }
     },
     "localname": "TABRECTAPRODUCTANDSERVICESMember",
     "nsuri": "http://www.incyte.com/20220930",
     "presentation": [
      "http://www.incyte.com/role/LicenseAgreementsNovartisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "incy_TabrectaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to TABRECTA, treatment of adult patients with metastatic NSCLC whose tumors have a mutation that leads to MET exon 14 skipping (METex14).",
        "label": "TABRECTA",
        "terseLabel": "TABRECTA"
       }
      }
     },
     "localname": "TabrectaMember",
     "nsuri": "http://www.incyte.com/20220930",
     "presentation": [
      "http://www.incyte.com/role/LicenseAgreementsNovartisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "incy_TabrectaRoyaltyRevenuesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to TABRECTA royalty revenues, treatment of adult patients with metastatic NSCLC whose tumors have a mutation that leads to MET exon 14 skipping (METex14).",
        "label": "TABRECTA Royalty Revenues",
        "terseLabel": "TABRECTA Royalty Revenues"
       }
      }
     },
     "localname": "TabrectaRoyaltyRevenuesMember",
     "nsuri": "http://www.incyte.com/20220930",
     "presentation": [
      "http://www.incyte.com/role/RevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "incy_TafasitamabMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to tafasitamab.",
        "label": "tafasitamab",
        "terseLabel": "tafasitamab"
       }
      }
     },
     "localname": "TafasitamabMember",
     "nsuri": "http://www.incyte.com/20220930",
     "presentation": [
      "http://www.incyte.com/role/LicenseAgreementsInnoCareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "incy_TafasitamabProductAndServiceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tafasitamab Product and Service",
        "label": "Tafasitamab Product and Service [Member]",
        "terseLabel": "Tafasitamab Product and Service"
       }
      }
     },
     "localname": "TafasitamabProductAndServiceMember",
     "nsuri": "http://www.incyte.com/20220930",
     "presentation": [
      "http://www.incyte.com/role/LicenseAgreementsMorphoSysDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "incy_VillarisMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Villaris",
        "label": "Villaris [Member]",
        "terseLabel": "Villaris"
       }
      }
     },
     "localname": "VillarisMember",
     "nsuri": "http://www.incyte.com/20220930",
     "presentation": [
      "http://www.incyte.com/role/SubsequentEventsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r37",
      "r39",
      "r86",
      "r87",
      "r225",
      "r232"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.incyte.com/role/LicenseAgreementsMorphoSysDetails",
      "http://www.incyte.com/role/LicenseAgreementsSyndaxDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Domain]",
        "terseLabel": "Investment, Name [Domain]"
       }
      }
     },
     "localname": "EquityMethodInvesteeNameDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.incyte.com/role/LicenseAgreementsAgenusDetails",
      "http://www.incyte.com/role/LicenseAgreementsCalitheraDetails",
      "http://www.incyte.com/role/LicenseAgreementsMerusDetails",
      "http://www.incyte.com/role/LicenseAgreementsMorphoSysDetails",
      "http://www.incyte.com/role/LicenseAgreementsSyndaxDetails",
      "http://www.incyte.com/role/LicenseAgreementsSyrosDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_EuropeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Europe [Member]",
        "terseLabel": "Europe"
       }
      }
     },
     "localname": "EuropeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.incyte.com/role/LicenseAgreementsLillyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r159",
      "r247",
      "r251",
      "r502"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.incyte.com/role/ConcentrationsofCreditRiskandCurrentExpectedCreditLossesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r208",
      "r209",
      "r210",
      "r211",
      "r224",
      "r231",
      "r293",
      "r295",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r470",
      "r499",
      "r503",
      "r531",
      "r532"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.incyte.com/role/FairValueofFinancialInstrumentsMarketablesecuritiesportfolioDetails",
      "http://www.incyte.com/role/InventoryDetails",
      "http://www.incyte.com/role/LicenseAgreementsAgenusDetails",
      "http://www.incyte.com/role/LicenseAgreementsCalitheraDetails",
      "http://www.incyte.com/role/LicenseAgreementsInnoCareDetails",
      "http://www.incyte.com/role/LicenseAgreementsInnoventDetails",
      "http://www.incyte.com/role/LicenseAgreementsLillyDetails",
      "http://www.incyte.com/role/LicenseAgreementsMacroGenicsDetails",
      "http://www.incyte.com/role/LicenseAgreementsMerusDetails",
      "http://www.incyte.com/role/LicenseAgreementsMorphoSysDetails",
      "http://www.incyte.com/role/LicenseAgreementsNimbleDetails",
      "http://www.incyte.com/role/LicenseAgreementsNovartisDetails",
      "http://www.incyte.com/role/LicenseAgreementsSyndaxDetails",
      "http://www.incyte.com/role/LicenseAgreementsSyrosDetails",
      "http://www.incyte.com/role/LicenseAgreementsZaiLabDetails",
      "http://www.incyte.com/role/StockCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r208",
      "r209",
      "r210",
      "r211",
      "r224",
      "r231",
      "r293",
      "r295",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r470",
      "r499",
      "r503",
      "r531",
      "r532"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.incyte.com/role/FairValueofFinancialInstrumentsMarketablesecuritiesportfolioDetails",
      "http://www.incyte.com/role/LicenseAgreementsAgenusDetails",
      "http://www.incyte.com/role/LicenseAgreementsMacroGenicsDetails",
      "http://www.incyte.com/role/LicenseAgreementsMerusDetails",
      "http://www.incyte.com/role/LicenseAgreementsNovartisDetails",
      "http://www.incyte.com/role/StockCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r159",
      "r247",
      "r251",
      "r502"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.incyte.com/role/ConcentrationsofCreditRiskandCurrentExpectedCreditLossesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r156",
      "r209",
      "r210",
      "r247",
      "r249",
      "r472",
      "r498",
      "r500"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.incyte.com/role/LicenseAgreementsAgenusDetails",
      "http://www.incyte.com/role/LicenseAgreementsInnoCareDetails",
      "http://www.incyte.com/role/LicenseAgreementsInnoventDetails",
      "http://www.incyte.com/role/LicenseAgreementsLillyDetails",
      "http://www.incyte.com/role/LicenseAgreementsMorphoSysDetails",
      "http://www.incyte.com/role/LicenseAgreementsNovartisDetails",
      "http://www.incyte.com/role/RevenuesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r156",
      "r209",
      "r210",
      "r247",
      "r249",
      "r472",
      "r498",
      "r500"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.incyte.com/role/LicenseAgreementsAgenusDetails",
      "http://www.incyte.com/role/LicenseAgreementsInnoCareDetails",
      "http://www.incyte.com/role/LicenseAgreementsInnoventDetails",
      "http://www.incyte.com/role/LicenseAgreementsLillyDetails",
      "http://www.incyte.com/role/LicenseAgreementsMorphoSysDetails",
      "http://www.incyte.com/role/LicenseAgreementsNovartisDetails",
      "http://www.incyte.com/role/RevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r203",
      "r208",
      "r209",
      "r210",
      "r211",
      "r224",
      "r231",
      "r261",
      "r293",
      "r295",
      "r328",
      "r329",
      "r330",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r470",
      "r499",
      "r503",
      "r531",
      "r532"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.incyte.com/role/FairValueofFinancialInstrumentsMarketablesecuritiesportfolioDetails",
      "http://www.incyte.com/role/InventoryDetails",
      "http://www.incyte.com/role/LicenseAgreementsAgenusDetails",
      "http://www.incyte.com/role/LicenseAgreementsCalitheraDetails",
      "http://www.incyte.com/role/LicenseAgreementsInnoCareDetails",
      "http://www.incyte.com/role/LicenseAgreementsInnoventDetails",
      "http://www.incyte.com/role/LicenseAgreementsLillyDetails",
      "http://www.incyte.com/role/LicenseAgreementsMacroGenicsDetails",
      "http://www.incyte.com/role/LicenseAgreementsMerusDetails",
      "http://www.incyte.com/role/LicenseAgreementsMorphoSysDetails",
      "http://www.incyte.com/role/LicenseAgreementsNimbleDetails",
      "http://www.incyte.com/role/LicenseAgreementsNovartisDetails",
      "http://www.incyte.com/role/LicenseAgreementsSyndaxDetails",
      "http://www.incyte.com/role/LicenseAgreementsSyrosDetails",
      "http://www.incyte.com/role/LicenseAgreementsZaiLabDetails",
      "http://www.incyte.com/role/StockCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r203",
      "r208",
      "r209",
      "r210",
      "r211",
      "r224",
      "r231",
      "r261",
      "r293",
      "r295",
      "r328",
      "r329",
      "r330",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r470",
      "r499",
      "r503",
      "r531",
      "r532"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.incyte.com/role/FairValueofFinancialInstrumentsMarketablesecuritiesportfolioDetails",
      "http://www.incyte.com/role/InventoryDetails",
      "http://www.incyte.com/role/LicenseAgreementsAgenusDetails",
      "http://www.incyte.com/role/LicenseAgreementsCalitheraDetails",
      "http://www.incyte.com/role/LicenseAgreementsInnoCareDetails",
      "http://www.incyte.com/role/LicenseAgreementsInnoventDetails",
      "http://www.incyte.com/role/LicenseAgreementsLillyDetails",
      "http://www.incyte.com/role/LicenseAgreementsMacroGenicsDetails",
      "http://www.incyte.com/role/LicenseAgreementsMerusDetails",
      "http://www.incyte.com/role/LicenseAgreementsMorphoSysDetails",
      "http://www.incyte.com/role/LicenseAgreementsNimbleDetails",
      "http://www.incyte.com/role/LicenseAgreementsNovartisDetails",
      "http://www.incyte.com/role/LicenseAgreementsSyndaxDetails",
      "http://www.incyte.com/role/LicenseAgreementsSyrosDetails",
      "http://www.incyte.com/role/LicenseAgreementsZaiLabDetails",
      "http://www.incyte.com/role/StockCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r38",
      "r39",
      "r86",
      "r87",
      "r225",
      "r232"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.incyte.com/role/LicenseAgreementsMorphoSysDetails",
      "http://www.incyte.com/role/LicenseAgreementsSyndaxDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "auth_ref": [
      "r173"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Axis]",
        "terseLabel": "Investment, Name [Axis]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.incyte.com/role/LicenseAgreementsAgenusDetails",
      "http://www.incyte.com/role/LicenseAgreementsCalitheraDetails",
      "http://www.incyte.com/role/LicenseAgreementsMerusDetails",
      "http://www.incyte.com/role/LicenseAgreementsMorphoSysDetails",
      "http://www.incyte.com/role/LicenseAgreementsSyndaxDetails",
      "http://www.incyte.com/role/LicenseAgreementsSyrosDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r157",
      "r158",
      "r247",
      "r250",
      "r501",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.incyte.com/role/LicenseAgreementsCalitheraDetails",
      "http://www.incyte.com/role/LicenseAgreementsLillyDetails",
      "http://www.incyte.com/role/LicenseAgreementsMerusDetails",
      "http://www.incyte.com/role/LicenseAgreementsMorphoSysDetails",
      "http://www.incyte.com/role/LicenseAgreementsNovartisDetails",
      "http://www.incyte.com/role/LicenseAgreementsSyndaxDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r157",
      "r158",
      "r247",
      "r250",
      "r501",
      "r513",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.incyte.com/role/LicenseAgreementsCalitheraDetails",
      "http://www.incyte.com/role/LicenseAgreementsLillyDetails",
      "http://www.incyte.com/role/LicenseAgreementsMerusDetails",
      "http://www.incyte.com/role/LicenseAgreementsMorphoSysDetails",
      "http://www.incyte.com/role/LicenseAgreementsNovartisDetails",
      "http://www.incyte.com/role/LicenseAgreementsSyndaxDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.",
        "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]",
        "terseLabel": "Accrued and Other Current Liabilities"
       }
      }
     },
     "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/AccruedandOtherCurrentLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r30",
      "r436"
     ],
     "calculation": {
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableMember": {
     "auth_ref": [
      "r517"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold.",
        "label": "Accounts Receivable [Member]",
        "terseLabel": "Accounts Receivable"
       }
      }
     },
     "localname": "AccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/ConcentrationsofCreditRiskandCurrentExpectedCreditLossesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsReceivableNet": {
     "auth_ref": [
      "r485",
      "r516"
     ],
     "calculation": {
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.",
        "label": "Accounts Receivable, after Allowance for Credit Loss",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesAndOtherLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.",
        "label": "Accrued Liabilities and Other Liabilities",
        "terseLabel": "Accrued and other liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesAndOtherLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/LicenseAgreementsMacroGenicsDetails",
      "http://www.incyte.com/role/LicenseAgreementsMorphoSysDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r32"
     ],
     "calculation": {
      "http://www.incyte.com/role/AccruedandOtherCurrentLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued and other current liabilities",
        "totalLabel": "Total accrued and other current liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/AccruedandOtherCurrentLiabilitiesDetails",
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities, Current [Abstract]",
        "terseLabel": "Accrued and Other Current Liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/AccruedandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccruedLiabilitiesMember": {
     "auth_ref": [
      "r32"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered.",
        "label": "Accrued Liabilities [Member]",
        "terseLabel": "Accrued Liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/LicenseAgreementsMacroGenicsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccruedMarketingCostsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.incyte.com/role/AccruedandOtherCurrentLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for the marketing, trade and selling of the entity's goods and services. Marketing costs would include expenditures for planning and executing the conception, pricing, promotion, and distribution of ideas, goods, and services; costs of public relations and corporate promotions; and obligations incurred and payable for sales discounts, rebates, price protection programs, etc. offered to customers and under government programs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Marketing Costs, Current",
        "terseLabel": "Sales and marketing"
       }
      }
     },
     "localname": "AccruedMarketingCostsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/AccruedandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedRoyaltiesCurrent": {
     "auth_ref": [
      "r7",
      "r32"
     ],
     "calculation": {
      "http://www.incyte.com/role/AccruedandOtherCurrentLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Royalties, Current",
        "terseLabel": "Royalties"
       }
      }
     },
     "localname": "AccruedRoyaltiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/AccruedandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r11",
      "r199"
     ],
     "calculation": {
      "http://www.incyte.com/role/PropertyandEquipmentnetPropertyandequipmentnetDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less accumulated depreciation and amortization"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/PropertyandEquipmentnetPropertyandequipmentnetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r19",
      "r43",
      "r44",
      "r45",
      "r487",
      "r508",
      "r509"
     ],
     "calculation": {
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r42",
      "r45",
      "r52",
      "r53",
      "r54",
      "r89",
      "r90",
      "r91",
      "r383",
      "r431",
      "r504",
      "r505"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r17"
     ],
     "calculation": {
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r89",
      "r90",
      "r91",
      "r338",
      "r339",
      "r340",
      "r393"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r298",
      "r341",
      "r342"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "verboseLabel": "Adjustments to reconcile net income to net cash provided by operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r332"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Stock compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/StockCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivable": {
     "auth_ref": [
      "r23",
      "r160",
      "r177",
      "r179",
      "r180"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable.",
        "label": "Accounts Receivable, Allowance for Credit Loss",
        "terseLabel": "Allowance for doubtful accounts"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/ConcentrationsofCreditRiskandCurrentExpectedCreditLossesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r118"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Potential common shares excluded from diluted net income (loss) per share computation ( in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/NetIncomePerShareAntidilutivesecuritiesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r118"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/NetIncomePerShareAntidilutivesecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r118"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/NetIncomePerShareAntidilutivesecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AreaOfRealEstateProperty": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area of a real estate property.",
        "label": "Area of Real Estate Property",
        "terseLabel": "Square footage"
       }
      }
     },
     "localname": "AreaOfRealEstateProperty",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/PropertyandEquipmentnetBuildingsandconstructionDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/LicenseAgreementsAgenusDetails",
      "http://www.incyte.com/role/LicenseAgreementsCalitheraDetails",
      "http://www.incyte.com/role/LicenseAgreementsInnoCareDetails",
      "http://www.incyte.com/role/LicenseAgreementsInnoventDetails",
      "http://www.incyte.com/role/LicenseAgreementsLillyDetails",
      "http://www.incyte.com/role/LicenseAgreementsMacroGenicsDetails",
      "http://www.incyte.com/role/LicenseAgreementsMerusDetails",
      "http://www.incyte.com/role/LicenseAgreementsMorphoSysDetails",
      "http://www.incyte.com/role/LicenseAgreementsNimbleDetails",
      "http://www.incyte.com/role/LicenseAgreementsNovartisDetails",
      "http://www.incyte.com/role/LicenseAgreementsSyndaxDetails",
      "http://www.incyte.com/role/LicenseAgreementsSyrosDetails",
      "http://www.incyte.com/role/LicenseAgreementsZaiLabDetails",
      "http://www.incyte.com/role/SubsequentEventsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r14",
      "r83",
      "r145",
      "r148",
      "r154",
      "r175",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r377",
      "r384",
      "r412",
      "r434",
      "r436",
      "r475",
      "r486"
     ],
     "calculation": {
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r5",
      "r28",
      "r83",
      "r175",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r377",
      "r384",
      "r412",
      "r434",
      "r436"
     ],
     "calculation": {
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r396"
     ],
     "calculation": {
      "http://www.incyte.com/role/FairValueofFinancialInstrumentsAssetsmeasuredonarecurringbasisDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/FairValueofFinancialInstrumentsAssetsmeasuredonarecurringbasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "auth_ref": [
      "r163",
      "r185"
     ],
     "calculation": {
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-Sale, Current",
        "terseLabel": "Marketable securities\u2014available-for-sale (amortized cost $292,941 and $291,871 as of September\u00a030, 2022 and December\u00a031, 2021, respectively; allowance for credit losses $0 as of September\u00a030, 2022 and December\u00a031, 2021)"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r302",
      "r303",
      "r304",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r322",
      "r323",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/StockCompensationNarrativeDetails",
      "http://www.incyte.com/role/StockCompensationOptionactivityunderthe2010stockplanDetails",
      "http://www.incyte.com/role/StockCompensationRSUawardandPSUactivityunderthe2010stockplanDetails",
      "http://www.incyte.com/role/StockCompensationValuationassumptionsusedforvalueofstockcompensationgrantedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/FairValueofFinancialInstrumentsNarrativeDetails",
      "http://www.incyte.com/role/LicenseAgreementsMacroGenicsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r389",
      "r390"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/FairValueofFinancialInstrumentsNarrativeDetails",
      "http://www.incyte.com/role/LicenseAgreementsMacroGenicsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r292",
      "r294",
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/FairValueofFinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r292",
      "r294",
      "r363",
      "r364",
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/FairValueofFinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": {
     "auth_ref": [
      "r72",
      "r370"
     ],
     "calculation": {
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 4.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.",
        "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability",
        "terseLabel": "(Gain) loss on change in fair value of acquisition-related contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "auth_ref": [
      "r366",
      "r367",
      "r369"
     ],
     "calculation": {
      "http://www.incyte.com/role/FairValueofFinancialInstrumentsLiabilitiesmeasuredonarecurringbasisDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FinancialLiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.",
        "label": "Business Combination, Contingent Consideration, Liability",
        "verboseLabel": "Acquisition-related contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/FairValueofFinancialInstrumentsLiabilitiesmeasuredonarecurringbasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent": {
     "auth_ref": [
      "r366",
      "r368"
     ],
     "calculation": {
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.",
        "label": "Business Combination, Contingent Consideration, Liability, Current",
        "terseLabel": "Acquisition-related contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput": {
     "auth_ref": [
      "r400"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of input used to measure contingent consideration liability from business combination.",
        "label": "Business Combination, Contingent Consideration, Liability, Measurement Input",
        "terseLabel": "Valuation input (as a percent)"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/FairValueofFinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": {
     "auth_ref": [
      "r366",
      "r368"
     ],
     "calculation": {
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.",
        "label": "Business Combination, Contingent Consideration, Liability, Noncurrent",
        "terseLabel": "Acquisition-related contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r77",
      "r78",
      "r79"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Unpaid purchases of property and equipment"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r3",
      "r8",
      "r75"
     ],
     "calculation": {
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.incyte.com/role/FairValueofFinancialInstrumentsAssetsmeasuredonarecurringbasisDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/FairValueofFinancialInstrumentsAssetsmeasuredonarecurringbasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r70",
      "r75",
      "r80"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents, restricted cash and investments at end of period",
        "periodStartLabel": "Cash, cash equivalents, restricted cash and investments at beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r70",
      "r413"
     ],
     "calculation": {
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase in cash, cash equivalents, restricted cash and investments"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r35",
      "r477",
      "r491"
     ],
     "calculation": {
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note 14)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r205",
      "r206",
      "r207",
      "r212",
      "r518"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r89",
      "r90",
      "r393"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in USD per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r16",
      "r234"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r16",
      "r436"
     ],
     "calculation": {
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "verboseLabel": "Common stock, $0.001 par value; 400,000,000 shares authorized; 222,454,839 and 221,084,433 shares issued and outstanding as of September\u00a030, 2022 and December\u00a031, 2021, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]",
        "terseLabel": "Retirement Benefits [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r48",
      "r50",
      "r51",
      "r58",
      "r480",
      "r493"
     ],
     "calculation": {
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive income"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computer Equipment [Member]",
        "terseLabel": "Computer Equipment"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/PropertyandEquipmentnetPropertyandequipmentnetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r132",
      "r133",
      "r159",
      "r409",
      "r410",
      "r517"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/ConcentrationsofCreditRiskandCurrentExpectedCreditLossesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r132",
      "r133",
      "r159",
      "r409",
      "r410",
      "r510",
      "r517"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/ConcentrationsofCreditRiskandCurrentExpectedCreditLossesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r132",
      "r133",
      "r159",
      "r409",
      "r410",
      "r510",
      "r517"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/ConcentrationsofCreditRiskandCurrentExpectedCreditLossesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskDisclosureTextBlock": {
     "auth_ref": [
      "r138"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.",
        "label": "Concentration Risk Disclosure [Text Block]",
        "terseLabel": "Concentrations of Credit Risk and Current Expected Credit Losses"
       }
      }
     },
     "localname": "ConcentrationRiskDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/ConcentrationsofCreditRiskandCurrentExpectedCreditLosses"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Concentration Risk [Line Items]",
        "terseLabel": "Concentration of risk"
       }
      }
     },
     "localname": "ConcentrationRiskLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/ConcentrationsofCreditRiskandCurrentExpectedCreditLossesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r132",
      "r133",
      "r159",
      "r409",
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Percentage of concentration risk"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/ConcentrationsofCreditRiskandCurrentExpectedCreditLossesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTable": {
     "auth_ref": [
      "r129",
      "r132",
      "r133",
      "r134",
      "r409",
      "r411",
      "r517"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Concentration Risk [Table]",
        "terseLabel": "Concentration Risk [Table]"
       }
      }
     },
     "localname": "ConcentrationRiskTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/ConcentrationsofCreditRiskandCurrentExpectedCreditLossesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r132",
      "r133",
      "r159",
      "r409",
      "r410",
      "r517"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/ConcentrationsofCreditRiskandCurrentExpectedCreditLossesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r82",
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Principles of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConstructionInProgressMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress [Member]",
        "terseLabel": "Construction in Progress"
       }
      }
     },
     "localname": "ConstructionInProgressMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/PropertyandEquipmentnetBuildingsandconstructionDetails",
      "http://www.incyte.com/role/PropertyandEquipmentnetPropertyandequipmentnetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConstructionPayableCurrent": {
     "auth_ref": [
      "r30"
     ],
     "calculation": {
      "http://www.incyte.com/role/AccruedandOtherCurrentLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for the acquisition of merchandise, materials, supplies and services pertaining to construction projects such as a housing development or factory expansion not classified as trade payables. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Construction Payable, Current",
        "terseLabel": "Construction in progress"
       }
      }
     },
     "localname": "ConstructionPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/AccruedandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConversionOfStockByUniqueDescriptionAxis": {
     "auth_ref": [
      "r77",
      "r78",
      "r79"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by description of stock conversions.",
        "label": "Stock Conversion Description [Axis]",
        "terseLabel": "Stock Conversion Description [Axis]"
       }
      }
     },
     "localname": "ConversionOfStockByUniqueDescriptionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/LicenseAgreementsSyrosDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConversionOfStockNameDomain": {
     "auth_ref": [
      "r77",
      "r78",
      "r79"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The unique name of a noncash or part noncash stock conversion.",
        "label": "Conversion of Stock, Name [Domain]",
        "terseLabel": "Conversion of Stock, Name [Domain]"
       }
      }
     },
     "localname": "ConversionOfStockNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/LicenseAgreementsSyrosDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfRevenue": {
     "auth_ref": [
      "r61",
      "r83",
      "r175",
      "r213",
      "r214",
      "r215",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r412"
     ],
     "calculation": {
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.",
        "label": "Cost of Revenue",
        "terseLabel": "Cost of product revenues (including definite-lived intangible amortization)"
       }
      }
     },
     "localname": "CostOfRevenue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing cost of sales.",
        "label": "Cost of Sales [Member]",
        "terseLabel": "Cost of Sales"
       }
      }
     },
     "localname": "CostOfSalesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/StockCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total costs and expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Costs and Expenses [Abstract]",
        "terseLabel": "Costs and expenses:"
       }
      }
     },
     "localname": "CostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditConcentrationRiskMember": {
     "auth_ref": [
      "r411"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that a specified receivable or amount at risk from a counterparty under a contractual arrangement is to a specified benchmark, such as total receivables, net revenues, pretax results. Risk is the materially adverse effects of loss attributable to (a) the failure to collect a significant receivable from a major customer or group of homogeneous accounts, or (b) a failure by a counterparty to perform under terms of a contractual arrangement.",
        "label": "Credit Concentration Risk [Member]",
        "terseLabel": "Credit Concentration Risk"
       }
      }
     },
     "localname": "CreditConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/ConcentrationsofCreditRiskandCurrentExpectedCreditLossesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r130",
      "r159"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer Concentration Risk"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/ConcentrationsofCreditRiskandCurrentExpectedCreditLossesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Debt Instrument, Term",
        "verboseLabel": "Contractual maturity dates"
       }
      }
     },
     "localname": "DebtInstrumentTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/FairValueofFinancialInstrumentsMarketablesecuritiesportfolioDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.incyte.com/role/FairValueofFinancialInstrumentsMarketablesecuritiesportfolioDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain (loss) in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain (Loss), before Tax",
        "terseLabel": "Net Unrealized Losses"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/FairValueofFinancialInstrumentsMarketablesecuritiesportfolioDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss": {
     "auth_ref": [
      "r165",
      "r185",
      "r188",
      "r189"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Allowance for Credit Loss",
        "terseLabel": "Marketable securities-allowance for credit losses"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAllowanceForCreditLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent": {
     "auth_ref": [
      "r164",
      "r185"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Current",
        "terseLabel": "Marketable securities-amortized cost"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAmortizedCostCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss": {
     "auth_ref": [
      "r185"
     ],
     "calculation": {
      "http://www.incyte.com/role/FairValueofFinancialInstrumentsAssetsmeasuredonarecurringbasisDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      },
      "http://www.incyte.com/role/FairValueofFinancialInstrumentsMarketablesecuritiesportfolioDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost excluding accrued interest, after allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Excluding Accrued Interest, after Allowance for Credit Loss",
        "terseLabel": "Amortized Cost",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/FairValueofFinancialInstrumentsAssetsmeasuredonarecurringbasisDetails",
      "http://www.incyte.com/role/FairValueofFinancialInstrumentsMarketablesecuritiesportfolioDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest": {
     "auth_ref": [
      "r185"
     ],
     "calculation": {
      "http://www.incyte.com/role/FairValueofFinancialInstrumentsMarketablesecuritiesportfolioDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount excluding accrued interest, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Excluding Accrued Interest",
        "terseLabel": "Estimated Fair Value"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleExcludingAccruedInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/FairValueofFinancialInstrumentsMarketablesecuritiesportfolioDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "auth_ref": [
      "r168"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale [Table Text Block]",
        "terseLabel": "Summary of marketable securities portfolio"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/FairValueofFinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "auth_ref": [
      "r345",
      "r346"
     ],
     "calculation": {
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 9.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.",
        "label": "Deferred Income Tax Assets, Net",
        "terseLabel": "Deferred income tax asset"
       }
      }
     },
     "localname": "DeferredIncomeTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r351"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "terseLabel": "Valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/IncometaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanActuarialGainLoss": {
     "auth_ref": [
      "r260"
     ],
     "calculation": {
      "http://www.incyte.com/role/EmployeeBenefitplansNetperiodicbenefitcostDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) from change in actuarial assumptions which (increases) decreases benefit obligation of defined benefit plan. Assumptions include, but are not limited to, interest, mortality, employee turnover, salary, and temporary deviation from substantive plan.",
        "label": "Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss)",
        "negatedLabel": "Amortization of actuarial losses"
       }
      }
     },
     "localname": "DefinedBenefitPlanActuarialGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/EmployeeBenefitplansNetperiodicbenefitcostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit": {
     "auth_ref": [
      "r257",
      "r274",
      "r285",
      "r287",
      "r288"
     ],
     "calculation": {
      "http://www.incyte.com/role/EmployeeBenefitplansNetperiodicbenefitcostDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of prior service cost (credit) recognized in net periodic benefit cost (credit) of defined benefit plan.",
        "label": "Defined Benefit Plan, Amortization of Prior Service Cost (Credit)",
        "verboseLabel": "Amortization of prior service cost"
       }
      }
     },
     "localname": "DefinedBenefitPlanAmortizationOfPriorServiceCostCredit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/EmployeeBenefitplansNetperiodicbenefitcostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsCurrentFiscalYear": {
     "auth_ref": [
      "r286",
      "r288"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of contributions received and expected to be received by defined benefit plan from employer in current fiscal year.",
        "label": "Defined Benefit Plan, Expected Future Employer Contributions, Current Fiscal Year",
        "terseLabel": "Current year expected contributions total"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedFutureEmployerContributionsCurrentFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/EmployeeBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets": {
     "auth_ref": [
      "r257",
      "r273",
      "r284",
      "r287",
      "r288"
     ],
     "calculation": {
      "http://www.incyte.com/role/EmployeeBenefitplansNetperiodicbenefitcostDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expected return (loss) recognized in net periodic benefit (cost) credit, calculated based on expected long-term rate of return and market-related value of plan assets of defined benefit plan.",
        "label": "Defined Benefit Plan, Expected Return (Loss) on Plan Assets",
        "negatedLabel": "Expected return on plan assets"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedReturnOnPlanAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/EmployeeBenefitplansNetperiodicbenefitcostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanInterestCost": {
     "auth_ref": [
      "r257",
      "r259",
      "r272",
      "r283",
      "r287",
      "r288"
     ],
     "calculation": {
      "http://www.incyte.com/role/EmployeeBenefitplansNetperiodicbenefitcostDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost recognized for passage of time related to defined benefit plan.",
        "label": "Defined Benefit Plan, Interest Cost",
        "verboseLabel": "Interest cost"
       }
      }
     },
     "localname": "DefinedBenefitPlanInterestCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/EmployeeBenefitplansNetperiodicbenefitcostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost": {
     "auth_ref": [
      "r270",
      "r281",
      "r287",
      "r288"
     ],
     "calculation": {
      "http://www.incyte.com/role/EmployeeBenefitplansNetperiodicbenefitcostDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of net periodic benefit cost (credit) for defined benefit plan.",
        "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit)",
        "totalLabel": "Net periodic benefit cost"
       }
      }
     },
     "localname": "DefinedBenefitPlanNetPeriodicBenefitCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/EmployeeBenefitplansNetperiodicbenefitcostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostCreditExcludingServiceCostStatementOfIncomeOrComprehensiveIncomeExtensibleList": {
     "auth_ref": [
      "r270",
      "r281"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of income or comprehensive income that includes components of net periodic benefit cost (credit), excluding service cost component, for defined benefit plan.",
        "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit) Excluding Service Cost, Statement of Income or Comprehensive Income [Extensible Enumeration]",
        "terseLabel": "Location of costs excluding the service component"
       }
      }
     },
     "localname": "DefinedBenefitPlanNetPeriodicBenefitCostCreditExcludingServiceCostStatementOfIncomeOrComprehensiveIncomeExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/EmployeeBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_DefinedBenefitPlanServiceCost": {
     "auth_ref": [
      "r258",
      "r271",
      "r282",
      "r287",
      "r288"
     ],
     "calculation": {
      "http://www.incyte.com/role/EmployeeBenefitplansNetperiodicbenefitcostDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.",
        "label": "Defined Benefit Plan, Service Cost",
        "verboseLabel": "Employer service cost"
       }
      }
     },
     "localname": "DefinedBenefitPlanServiceCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/EmployeeBenefitplansNetperiodicbenefitcostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanCostRecognized": {
     "auth_ref": [
      "r291"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost for defined contribution plan.",
        "label": "Defined Contribution Plan, Cost",
        "terseLabel": "Defined contribution expense"
       }
      }
     },
     "localname": "DefinedContributionPlanCostRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/EmployeeBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r73",
      "r143"
     ],
     "calculation": {
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Revenues"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/RevenuesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r247",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/RevenuesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r247"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "terseLabel": "Schedule of disaggregated revenue"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/RevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r301",
      "r302",
      "r333",
      "r334",
      "r336",
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "verboseLabel": "Stock Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/StockCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]",
        "verboseLabel": "Net income per share:"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r59",
      "r94",
      "r95",
      "r96",
      "r97",
      "r98",
      "r102",
      "r105",
      "r115",
      "r116",
      "r117",
      "r121",
      "r122",
      "r394",
      "r395",
      "r481",
      "r494"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Basic (in USD per share)",
        "verboseLabel": "Basic net income per share ( in USD per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.incyte.com/role/NetIncomePerShareNetincomelosspershareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic [Abstract]",
        "terseLabel": "Basic Net Income (Loss) Per Share"
       }
      }
     },
     "localname": "EarningsPerShareBasicAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/NetIncomePerShareNetincomelosspershareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]",
        "terseLabel": "Net income per share"
       }
      }
     },
     "localname": "EarningsPerShareBasicLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/NetIncomePerShareAntidilutivesecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r59",
      "r94",
      "r95",
      "r96",
      "r97",
      "r98",
      "r105",
      "r115",
      "r116",
      "r117",
      "r121",
      "r122",
      "r394",
      "r395",
      "r481",
      "r494"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Diluted (in USD per share)",
        "verboseLabel": "Diluted net income per share ( in USD per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.incyte.com/role/NetIncomePerShareNetincomelosspershareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDilutedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Diluted [Abstract]",
        "terseLabel": "Diluted Net Income (Loss) Per Share"
       }
      }
     },
     "localname": "EarningsPerShareDilutedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/NetIncomePerShareNetincomelosspershareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Diluted, Other Disclosure [Abstract]",
        "terseLabel": "Anti-dilutive securities"
       }
      }
     },
     "localname": "EarningsPerShareDilutedOtherDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/NetIncomePerShareAntidilutivesecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r118",
      "r119",
      "r120",
      "r123"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "verboseLabel": "Net Income Per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/NetIncomePerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r413"
     ],
     "calculation": {
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations",
        "terseLabel": "Effect of exchange rates on cash, cash equivalents, restricted cash and investments"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r32"
     ],
     "calculation": {
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Accrued compensation"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Additional Disclosure [Abstract]",
        "terseLabel": "Unrecognized compensation"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/StockCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r335"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation cost for nonvested option (in dollars)"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/StockCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Vesting period of recognition of the unrecognized compensation cost of nonvested awards"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/StockCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.",
        "label": "Employee Stock [Member]",
        "terseLabel": "Employee Stock"
       }
      }
     },
     "localname": "EmployeeStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/StockCompensationNarrativeDetails",
      "http://www.incyte.com/role/StockCompensationValuationassumptionsusedforvalueofstockcompensationgrantedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "terseLabel": "Share-based Payment Arrangement, Option"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/StockCompensationNarrativeDetails",
      "http://www.incyte.com/role/StockCompensationOptionactivityunderthe2010stockplanDetails",
      "http://www.incyte.com/role/StockCompensationValuationassumptionsusedforvalueofstockcompensationgrantedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services.",
        "label": "Equipment [Member]",
        "terseLabel": "Equipment"
       }
      }
     },
     "localname": "EquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/PropertyandEquipmentnetPropertyandequipmentnetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r52",
      "r53",
      "r54",
      "r89",
      "r90",
      "r91",
      "r93",
      "r99",
      "r101",
      "r124",
      "r176",
      "r234",
      "r235",
      "r338",
      "r339",
      "r340",
      "r354",
      "r355",
      "r393",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r431",
      "r504",
      "r505",
      "r506"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentAggregateCost": {
     "auth_ref": [
      "r29"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the aggregate cost of investments accounted for under the equity method of accounting.",
        "label": "Equity Method Investment, Aggregate Cost",
        "terseLabel": "Equity Method Investment, Aggregate Cost",
        "verboseLabel": "Purchase price of common stock"
       }
      }
     },
     "localname": "EquityMethodInvestmentAggregateCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/LicenseAgreementsAgenusDetails",
      "http://www.incyte.com/role/LicenseAgreementsCalitheraDetails",
      "http://www.incyte.com/role/LicenseAgreementsMerusDetails",
      "http://www.incyte.com/role/LicenseAgreementsMorphoSysDetails",
      "http://www.incyte.com/role/LicenseAgreementsSyndaxDetails",
      "http://www.incyte.com/role/LicenseAgreementsSyrosDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "auth_ref": [
      "r173"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.",
        "label": "Equity Method Investment, Ownership Percentage",
        "terseLabel": "Ownership percentage (as a percent)"
       }
      }
     },
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/LicenseAgreementsAgenusDetails",
      "http://www.incyte.com/role/LicenseAgreementsCalitheraDetails",
      "http://www.incyte.com/role/LicenseAgreementsMerusDetails",
      "http://www.incyte.com/role/LicenseAgreementsSyndaxDetails",
      "http://www.incyte.com/role/LicenseAgreementsSyrosDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EquityMethodInvestmentQuotedMarketValue": {
     "auth_ref": [
      "r174"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents the aggregate value of each identified investment accounted for under the equity method of accounting based on the quoted market price for those investments in common stock for which a quoted market price is available.",
        "label": "Equity Method Investment, Quoted Market Value",
        "terseLabel": "Value of shares acquired"
       }
      }
     },
     "localname": "EquityMethodInvestmentQuotedMarketValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/LicenseAgreementsMerusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss": {
     "auth_ref": [
      "r172",
      "r495"
     ],
     "calculation": {
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Unrealized Gain (Loss)",
        "negatedLabel": "Unrealized loss on long term investments",
        "terseLabel": "Unrealized loss on long term investments",
        "verboseLabel": "Unrealized gain (loss) on long term investments"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiUnrealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.incyte.com/role/LicenseAgreementsAgenusDetails",
      "http://www.incyte.com/role/LicenseAgreementsCalitheraDetails",
      "http://www.incyte.com/role/LicenseAgreementsMerusDetails",
      "http://www.incyte.com/role/LicenseAgreementsMorphoSysDetails",
      "http://www.incyte.com/role/LicenseAgreementsSyndaxDetails",
      "http://www.incyte.com/role/LicenseAgreementsSyrosDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EstimateOfFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r226",
      "r228",
      "r229",
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured as an estimate of fair value.",
        "label": "Estimate of Fair Value Measurement [Member]",
        "terseLabel": "Estimate of Fair Value Measurement"
       }
      }
     },
     "localname": "EstimateOfFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/FairValueofFinancialInstrumentsAssetsmeasuredonarecurringbasisDetails",
      "http://www.incyte.com/role/FairValueofFinancialInstrumentsLevel3liabilitiesDetails",
      "http://www.incyte.com/role/FairValueofFinancialInstrumentsLiabilitiesmeasuredonarecurringbasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair value of financial instruments"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/FairValueofFinancialInstrumentsAssetsmeasuredonarecurringbasisDetails",
      "http://www.incyte.com/role/FairValueofFinancialInstrumentsLevel3liabilitiesDetails",
      "http://www.incyte.com/role/FairValueofFinancialInstrumentsLiabilitiesmeasuredonarecurringbasisDetails",
      "http://www.incyte.com/role/FairValueofFinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r396",
      "r397",
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/FairValueofFinancialInstrumentsAssetsmeasuredonarecurringbasisDetails",
      "http://www.incyte.com/role/FairValueofFinancialInstrumentsLevel3liabilitiesDetails",
      "http://www.incyte.com/role/FairValueofFinancialInstrumentsLiabilitiesmeasuredonarecurringbasisDetails",
      "http://www.incyte.com/role/FairValueofFinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "auth_ref": [
      "r396",
      "r397"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of fair value of assets measured on recurring basis"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/FairValueofFinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r226",
      "r228",
      "r229",
      "r262",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r287",
      "r397",
      "r443",
      "r444",
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/FairValueofFinancialInstrumentsAssetsmeasuredonarecurringbasisDetails",
      "http://www.incyte.com/role/FairValueofFinancialInstrumentsLevel3liabilitiesDetails",
      "http://www.incyte.com/role/FairValueofFinancialInstrumentsLiabilitiesmeasuredonarecurringbasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByLiabilityClassAxis": {
     "auth_ref": [
      "r403",
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of liability.",
        "label": "Liability Class [Axis]",
        "terseLabel": "Liability Class [Axis]"
       }
      }
     },
     "localname": "FairValueByLiabilityClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/FairValueofFinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementBasisAxis": {
     "auth_ref": [
      "r226",
      "r228",
      "r229",
      "r396",
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement basis.",
        "label": "Measurement Basis [Axis]",
        "terseLabel": "Measurement Basis [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementBasisAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/FairValueofFinancialInstrumentsAssetsmeasuredonarecurringbasisDetails",
      "http://www.incyte.com/role/FairValueofFinancialInstrumentsLevel3liabilitiesDetails",
      "http://www.incyte.com/role/FairValueofFinancialInstrumentsLiabilitiesmeasuredonarecurringbasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r396",
      "r397",
      "r399",
      "r400",
      "r406"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/FairValueofFinancialInstrumentsAssetsmeasuredonarecurringbasisDetails",
      "http://www.incyte.com/role/FairValueofFinancialInstrumentsLiabilitiesmeasuredonarecurringbasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosureItemAmountsDomain": {
     "auth_ref": [
      "r226",
      "r228",
      "r229"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value.",
        "label": "Fair Value Measurement [Domain]",
        "terseLabel": "Fair Value Measurement [Domain]"
       }
      }
     },
     "localname": "FairValueDisclosureItemAmountsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/FairValueofFinancialInstrumentsAssetsmeasuredonarecurringbasisDetails",
      "http://www.incyte.com/role/FairValueofFinancialInstrumentsLevel3liabilitiesDetails",
      "http://www.incyte.com/role/FairValueofFinancialInstrumentsLiabilitiesmeasuredonarecurringbasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r403"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/FairValueofFinancialInstruments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r226",
      "r262",
      "r264",
      "r269",
      "r287",
      "r397",
      "r443"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Fair Value, Inputs, Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/FairValueofFinancialInstrumentsAssetsmeasuredonarecurringbasisDetails",
      "http://www.incyte.com/role/FairValueofFinancialInstrumentsLiabilitiesmeasuredonarecurringbasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r226",
      "r228",
      "r229",
      "r262",
      "r264",
      "r269",
      "r287",
      "r397",
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Fair Value, Inputs, Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/FairValueofFinancialInstrumentsAssetsmeasuredonarecurringbasisDetails",
      "http://www.incyte.com/role/FairValueofFinancialInstrumentsLiabilitiesmeasuredonarecurringbasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r226",
      "r228",
      "r229",
      "r262",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r287",
      "r397",
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Fair Value, Inputs, Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/FairValueofFinancialInstrumentsAssetsmeasuredonarecurringbasisDetails",
      "http://www.incyte.com/role/FairValueofFinancialInstrumentsLevel3liabilitiesDetails",
      "http://www.incyte.com/role/FairValueofFinancialInstrumentsLiabilitiesmeasuredonarecurringbasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock": {
     "auth_ref": [
      "r396",
      "r397"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of fair value of liabilities measured on recurring basis"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/FairValueofFinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": {
     "auth_ref": [
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents classes of liabilities measured and disclosed at fair value.",
        "label": "Fair Value by Liability Class [Domain]",
        "terseLabel": "Fair Value by Liability Class [Domain]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/FairValueofFinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "terseLabel": "Roll forward of Level 3 liabilities"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/FairValueofFinancialInstrumentsLevel3liabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r401",
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of roll forward of Level 3 liabilities"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/FairValueofFinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/FairValueofFinancialInstrumentsAssetsmeasuredonarecurringbasisDetails",
      "http://www.incyte.com/role/FairValueofFinancialInstrumentsLiabilitiesmeasuredonarecurringbasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": {
     "auth_ref": [
      "r402"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings",
        "terseLabel": "Change in fair value of contingent consideration"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/FairValueofFinancialInstrumentsLevel3liabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "auth_ref": [
      "r401"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "periodEndLabel": "Balance at the end of the period",
        "periodStartLabel": "Balance at the beginning of the period"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/FairValueofFinancialInstrumentsLevel3liabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r226",
      "r228",
      "r229",
      "r262",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r287",
      "r443",
      "r444",
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/FairValueofFinancialInstrumentsAssetsmeasuredonarecurringbasisDetails",
      "http://www.incyte.com/role/FairValueofFinancialInstrumentsLevel3liabilitiesDetails",
      "http://www.incyte.com/role/FairValueofFinancialInstrumentsLiabilitiesmeasuredonarecurringbasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r403",
      "r406"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair Value, Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/FairValueofFinancialInstrumentsAssetsmeasuredonarecurringbasisDetails",
      "http://www.incyte.com/role/FairValueofFinancialInstrumentsLiabilitiesmeasuredonarecurringbasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinanceLeaseLiability": {
     "auth_ref": [
      "r424",
      "r429"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease.",
        "label": "Finance Lease, Liability",
        "terseLabel": "Financing lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/PropertyandEquipmentnetBuildingsandconstructionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "auth_ref": [
      "r424"
     ],
     "calculation": {
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.",
        "label": "Finance Lease, Liability, Current",
        "terseLabel": "Finance lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r424"
     ],
     "calculation": {
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.",
        "label": "Finance Lease, Liability, Noncurrent",
        "verboseLabel": "Finance lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "auth_ref": [
      "r425",
      "r427"
     ],
     "calculation": {
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for principal payment on finance lease.",
        "label": "Finance Lease, Principal Payments",
        "negatedLabel": "Payment of finance lease liabilities"
       }
      }
     },
     "localname": "FinanceLeasePrincipalPayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAsset": {
     "auth_ref": [
      "r423"
     ],
     "calculation": {
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease.",
        "label": "Finance Lease, Right-of-Use Asset, after Accumulated Amortization",
        "terseLabel": "Finance lease right-of-use assets, net"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.incyte.com/role/PropertyandEquipmentnetBuildingsandconstructionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r166",
      "r167",
      "r169",
      "r170",
      "r171",
      "r178",
      "r181",
      "r182",
      "r183",
      "r184",
      "r186",
      "r187",
      "r190",
      "r191",
      "r227",
      "r233",
      "r392",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/FairValueofFinancialInstrumentsMarketablesecuritiesportfolioDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinancialLiabilitiesFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.incyte.com/role/FairValueofFinancialInstrumentsLiabilitiesmeasuredonarecurringbasisDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.",
        "label": "Financial Liabilities Fair Value Disclosure",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "FinancialLiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/FairValueofFinancialInstrumentsLiabilitiesmeasuredonarecurringbasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r12",
      "r194",
      "r195",
      "r196",
      "r197",
      "r436",
      "r474"
     ],
     "calculation": {
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 8.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IPOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First sale of stock by a private company to the public.",
        "label": "IPO [Member]",
        "terseLabel": "IPO"
       }
      }
     },
     "localname": "IPOMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/LicenseAgreementsMerusDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r56",
      "r145",
      "r147",
      "r150",
      "r153",
      "r155",
      "r473",
      "r478",
      "r483",
      "r496"
     ],
     "calculation": {
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Income before provision for income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r201",
      "r204"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/LicenseAgreementsCalitheraDetails",
      "http://www.incyte.com/role/StockCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r204"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/LicenseAgreementsCalitheraDetails",
      "http://www.incyte.com/role/StockCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r84",
      "r348",
      "r350",
      "r352",
      "r356",
      "r358",
      "r360",
      "r361",
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "verboseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r85",
      "r100",
      "r101",
      "r144",
      "r347",
      "r357",
      "r359",
      "r497"
     ],
     "calculation": {
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Provision for income taxes",
        "verboseLabel": "Income tax (benefit) expense"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.incyte.com/role/IncometaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability": {
     "auth_ref": [
      "r353"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income tax expense (benefit) from continuing operations attributable to an adjustment of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity.",
        "label": "Income Tax Expense (Benefit), Continuing Operations, Adjustment of Deferred Tax (Asset) Liability",
        "negatedLabel": "One-time benefit from associated valuation allowance"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/IncometaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "auth_ref": [
      "r76"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.",
        "label": "Income Taxes Paid, Net",
        "terseLabel": "Income taxes paid"
       }
      }
     },
     "localname": "IncomeTaxesPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued and other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDeferredIncomeTaxes": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.",
        "label": "Increase (Decrease) in Deferred Income Taxes",
        "negatedLabel": "Deferred income taxes"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventory"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInRoyaltiesPayable": {
     "auth_ref": [
      "r72"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the obligations due for compensation payments related to the use of copyrights, patents, trade names, licenses, technology. Royalty payments are also paid by the lease holders for oil, gas, and mineral extraction.",
        "label": "Increase (Decrease) in Royalties Payable",
        "terseLabel": "Royalties payable on net sales"
       }
      }
     },
     "localname": "IncreaseDecreaseInRoyaltiesPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/LicenseAgreementsLillyDetails",
      "http://www.incyte.com/role/LicenseAgreementsNovartisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "auth_ref": [
      "r106",
      "r107",
      "r108",
      "r117",
      "r300"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements",
        "verboseLabel": "Dilutive stock options and awards ( in shares)"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/NetIncomePerShareNetincomelosspershareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r55",
      "r142",
      "r421",
      "r422",
      "r482"
     ],
     "calculation": {
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryCurrentTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about inventory expected to be sold or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Current [Table]",
        "verboseLabel": "Inventory, Current [Table]"
       }
      }
     },
     "localname": "InventoryCurrentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/InventoryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Abstract]",
        "terseLabel": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r193"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/Inventory"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "auth_ref": [
      "r24",
      "r192"
     ],
     "calculation": {
      "http://www.incyte.com/role/InventoryDetails": {
       "order": 3.0,
       "parentTag": "incy_InventoryNetCurrentAndNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.",
        "label": "Inventory, Finished Goods, Net of Reserves",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r4",
      "r27",
      "r436"
     ],
     "calculation": {
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventory",
        "verboseLabel": "Inventories - current"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.incyte.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNoncurrent": {
     "auth_ref": [
      "r13"
     ],
     "calculation": {
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.",
        "label": "Inventory, Noncurrent",
        "terseLabel": "Inventory",
        "verboseLabel": "Inventories-noncurrent"
       }
      }
     },
     "localname": "InventoryNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.incyte.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryRawMaterialsNetOfReserves": {
     "auth_ref": [
      "r26",
      "r192"
     ],
     "calculation": {
      "http://www.incyte.com/role/InventoryDetails": {
       "order": 1.0,
       "parentTag": "incy_InventoryNetCurrentAndNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.",
        "label": "Inventory, Raw Materials, Net of Reserves",
        "terseLabel": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterialsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcessNetOfReserves": {
     "auth_ref": [
      "r25",
      "r192"
     ],
     "calculation": {
      "http://www.incyte.com/role/InventoryDetails": {
       "order": 2.0,
       "parentTag": "incy_InventoryNetCurrentAndNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.",
        "label": "Inventory, Work in Process, Net of Reserves",
        "terseLabel": "Work-in-process"
       }
      }
     },
     "localname": "InventoryWorkInProcessNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentOwnedBalanceShares": {
     "auth_ref": [
      "r511",
      "r512"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Balance held at close of period in number of shares.",
        "label": "Investment Owned, Balance, Shares",
        "terseLabel": "Ownership (in shares)"
       }
      }
     },
     "localname": "InvestmentOwnedBalanceShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/LicenseAgreementsCalitheraDetails",
      "http://www.incyte.com/role/LicenseAgreementsSyrosDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_InvestmentsFairValueDisclosure": {
     "auth_ref": [
      "r396"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.",
        "label": "Investments, Fair Value Disclosure",
        "terseLabel": "Fair market value of our long term investments"
       }
      }
     },
     "localname": "InvestmentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/LicenseAgreementsMerusDetails",
      "http://www.incyte.com/role/LicenseAgreementsMorphoSysDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LandMember": {
     "auth_ref": [
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Part of earth's surface not covered by water.",
        "label": "Land [Member]",
        "terseLabel": "Land"
       }
      }
     },
     "localname": "LandMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/PropertyandEquipmentnetPropertyandequipmentnetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LesseeFinanceLeaseExistenceOfOptionToExtend": {
     "auth_ref": [
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates (true false) whether lessee has option to extend finance lease.",
        "label": "Lessee, Finance Lease, Existence of Option to Extend [true false]",
        "terseLabel": "Options to extend"
       }
      }
     },
     "localname": "LesseeFinanceLeaseExistenceOfOptionToExtend",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/PropertyandEquipmentnetBuildingsandconstructionDetails"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_LesseeFinanceLeaseRenewalTerm1": {
     "auth_ref": [
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's finance lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Finance Lease, Renewal Term",
        "terseLabel": "Renewal term of agreement to rent"
       }
      }
     },
     "localname": "LesseeFinanceLeaseRenewalTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/PropertyandEquipmentnetBuildingsandconstructionDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeFinanceLeaseTermOfContract1": {
     "auth_ref": [
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Finance Lease, Term of Contract",
        "terseLabel": "Initial lease term"
       }
      }
     },
     "localname": "LesseeFinanceLeaseTermOfContract1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/PropertyandEquipmentnetBuildingsandconstructionDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r31",
      "r83",
      "r149",
      "r175",
      "r213",
      "r214",
      "r215",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r378",
      "r384",
      "r385",
      "r412",
      "r434",
      "r435"
     ],
     "calculation": {
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r22",
      "r83",
      "r175",
      "r412",
      "r436",
      "r476",
      "r489"
     ],
     "calculation": {
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r6",
      "r33",
      "r83",
      "r175",
      "r213",
      "r214",
      "r215",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r378",
      "r384",
      "r385",
      "r412",
      "r434",
      "r435",
      "r436"
     ],
     "calculation": {
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liability [Member]",
        "terseLabel": "Liability"
       }
      }
     },
     "localname": "LiabilityMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/FairValueofFinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermInvestments": {
     "auth_ref": [
      "r9"
     ],
     "calculation": {
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.incyte.com/role/FairValueofFinancialInstrumentsAssetsmeasuredonarecurringbasisDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).",
        "label": "Long-Term Investments",
        "terseLabel": "Long-Term Investments",
        "verboseLabel": "Fair market long term investments"
       }
      }
     },
     "localname": "LongTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.incyte.com/role/FairValueofFinancialInstrumentsAssetsmeasuredonarecurringbasisDetails",
      "http://www.incyte.com/role/LicenseAgreementsAgenusDetails",
      "http://www.incyte.com/role/LicenseAgreementsCalitheraDetails",
      "http://www.incyte.com/role/LicenseAgreementsSyndaxDetails",
      "http://www.incyte.com/role/LicenseAgreementsSyrosDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MeasurementInputDiscountRateMember": {
     "auth_ref": [
      "r398"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using interest rate to determine present value of future cash flows.",
        "label": "Measurement Input, Discount Rate [Member]",
        "terseLabel": "Measurement Input, Discount Rate"
       }
      }
     },
     "localname": "MeasurementInputDiscountRateMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/FairValueofFinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r398"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]",
        "terseLabel": "Measurement Input Type [Axis]"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/FairValueofFinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]",
        "terseLabel": "Measurement Input Type [Domain]"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/FairValueofFinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by (used in) financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r70",
      "r71",
      "r74"
     ],
     "calculation": {
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash provided by operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r1",
      "r46",
      "r49",
      "r54",
      "r57",
      "r74",
      "r83",
      "r92",
      "r94",
      "r95",
      "r96",
      "r97",
      "r100",
      "r101",
      "r113",
      "r145",
      "r147",
      "r150",
      "r153",
      "r155",
      "r175",
      "r213",
      "r214",
      "r215",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r395",
      "r412",
      "r479",
      "r492"
     ],
     "calculation": {
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "totalLabel": "Net income",
        "verboseLabel": "Net income"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS",
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "auth_ref": [
      "r94",
      "r95",
      "r96",
      "r97",
      "r102",
      "r103",
      "r114",
      "r117",
      "r145",
      "r147",
      "r150",
      "r153",
      "r155"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "terseLabel": "Basic net income"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/NetIncomePerShareNetincomelosspershareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": {
     "auth_ref": [
      "r104",
      "r109",
      "r110",
      "r111",
      "r112",
      "r114",
      "r117"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Diluted",
        "terseLabel": "Diluted net income (loss)"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/NetIncomePerShareNetincomelosspershareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonUsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Countries excluding the United States of America (US).",
        "label": "Non-US [Member]",
        "terseLabel": "Non-US"
       }
      }
     },
     "localname": "NonUsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/LicenseAgreementsLillyDetails",
      "http://www.incyte.com/role/LicenseAgreementsMerusDetails",
      "http://www.incyte.com/role/LicenseAgreementsNovartisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r139"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/OrganizationandBusinessDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OfficeEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine.",
        "label": "Office Equipment [Member]",
        "terseLabel": "Office Equipment"
       }
      }
     },
     "localname": "OfficeEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/PropertyandEquipmentnetPropertyandequipmentnetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r145",
      "r147",
      "r150",
      "r153",
      "r155"
     ],
     "calculation": {
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Income from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r424"
     ],
     "calculation": {
      "http://www.incyte.com/role/AccruedandOtherCurrentLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/AccruedandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r2",
      "r88",
      "r138",
      "r388"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]",
        "verboseLabel": "Organization and Business"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/OrganizationandBusiness"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r13"
     ],
     "calculation": {
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 10.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets, net"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r375",
      "r376",
      "r382"
     ],
     "calculation": {
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Foreign currency translation loss"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r47",
      "r50",
      "r375",
      "r376",
      "r382"
     ],
     "calculation": {
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Other comprehensive income (loss)",
        "totalLabel": "Other comprehensive loss"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS",
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]",
        "verboseLabel": "Other comprehensive loss:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax": {
     "auth_ref": [
      "r41",
      "r43"
     ],
     "calculation": {
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan.",
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax",
        "negatedLabel": "Defined benefit pension gain, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which reported facts about other comprehensive income have been included.",
        "label": "Other Comprehensive Income (Loss) [Member]",
        "terseLabel": "Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/LicenseAgreementsCalitheraDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r40",
      "r43"
     ],
     "calculation": {
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "terseLabel": "Unrealized loss on marketable securities, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherIntangibleAssetsNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 7.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated amortization of finite-lived and indefinite-lived intangible assets classified as other.",
        "label": "Other Intangible Assets, Net",
        "terseLabel": "Other intangible assets, net"
       }
      }
     },
     "localname": "OtherIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r32",
      "r436"
     ],
     "calculation": {
      "http://www.incyte.com/role/AccruedandOtherCurrentLiabilitiesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "terseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/AccruedandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
        "label": "Other Noncash Income (Expense)",
        "negatedLabel": "Other, net"
       }
      }
     },
     "localname": "OtherNoncashIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other income (expense), net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]",
        "terseLabel": "Payables and Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Payment, Tax Withholding, Share-Based Payment Arrangement",
        "negatedLabel": "Tax withholdings related to restricted and performance share vesting"
       }
      }
     },
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireLongtermInvestments": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, beyond the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the long-term.",
        "label": "Payments to Acquire Long-Term Investments",
        "negatedLabel": "Purchase of long term investments"
       }
      }
     },
     "localname": "PaymentsToAcquireLongtermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "auth_ref": [
      "r162"
     ],
     "calculation": {
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for purchase of marketable security.",
        "label": "Payments to Acquire Marketable Securities",
        "negatedLabel": "Purchases of marketable securities"
       }
      }
     },
     "localname": "PaymentsToAcquireMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireProductiveAssets": {
     "auth_ref": [
      "r65",
      "r371",
      "r372",
      "r373"
     ],
     "calculation": {
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.",
        "label": "Payments to Acquire Productive Assets",
        "negatedLabel": "Capital expenditures"
       }
      }
     },
     "localname": "PaymentsToAcquireProductiveAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireRealEstate": {
     "auth_ref": [
      "r65"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow from the acquisition of a piece of land, anything permanently fixed to it, including buildings, structures on it and so forth; includes real estate intended to generate income for the owner; excludes real estate acquired for use by the owner.",
        "label": "Payments to Acquire Real Estate",
        "terseLabel": "Purchase price"
       }
      }
     },
     "localname": "PaymentsToAcquireRealEstate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/PropertyandEquipmentnetBuildingsandconstructionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "auth_ref": [
      "r261",
      "r263",
      "r269",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r287",
      "r289",
      "r290",
      "r291",
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for retirement benefits.",
        "label": "Retirement Benefits [Text Block]",
        "terseLabel": "Employee Benefit Plans"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/EmployeeBenefitPlans"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PerformanceSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement awarded for meeting performance target.",
        "label": "Performance Shares [Member]",
        "terseLabel": "Performance Shares"
       }
      }
     },
     "localname": "PerformanceSharesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/StockCompensationNarrativeDetails",
      "http://www.incyte.com/role/StockCompensationRSUawardandPSUactivityunderthe2010stockplanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PortionAtFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r407"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured at fair value for financial reporting purposes.",
        "label": "Portion at Fair Value Measurement [Member]",
        "terseLabel": "Portion at Fair Value Measurement"
       }
      }
     },
     "localname": "PortionAtFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/FairValueofFinancialInstrumentsAssetsmeasuredonarecurringbasisDetails",
      "http://www.incyte.com/role/FairValueofFinancialInstrumentsLevel3liabilitiesDetails",
      "http://www.incyte.com/role/FairValueofFinancialInstrumentsLiabilitiesmeasuredonarecurringbasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r15",
      "r230"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in USD per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r15",
      "r230"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r15",
      "r436"
     ],
     "calculation": {
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "verboseLabel": "Preferred stock, $0.001 par value; 5,000,000 shares authorized; none issued or outstanding"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r28"
     ],
     "calculation": {
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.",
        "label": "Proceeds from Sale and Maturity of Marketable Securities",
        "terseLabel": "Sale and maturities of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfLongtermInvestments": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from sales of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, beyond the current operating cycle.",
        "label": "Proceeds from Sale of Long-Term Investments",
        "terseLabel": "Sale of long term investments"
       }
      }
     },
     "localname": "ProceedsFromSaleOfLongtermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockPlans": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from the stock plan during the period.",
        "label": "Proceeds from Stock Plans",
        "terseLabel": "Proceeds from issuance of common stock under stock plans"
       }
      }
     },
     "localname": "ProceedsFromStockPlans",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]",
        "terseLabel": "Product revenues, net"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.incyte.com/role/RevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r1",
      "r46",
      "r49",
      "r54",
      "r69",
      "r83",
      "r92",
      "r100",
      "r101",
      "r145",
      "r147",
      "r150",
      "r153",
      "r155",
      "r175",
      "r213",
      "r214",
      "r215",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r375",
      "r380",
      "r381",
      "r386",
      "r387",
      "r395",
      "r412",
      "r483"
     ],
     "calculation": {
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "verboseLabel": "Net income"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]",
        "terseLabel": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r200"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Long-Lived Tangible Asset [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/PropertyandEquipmentnetBuildingsandconstructionDetails",
      "http://www.incyte.com/role/PropertyandEquipmentnetPropertyandequipmentnetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r202",
      "r519",
      "r520",
      "r521"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "verboseLabel": "Property and Equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/PropertyandEquipmentnet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r10",
      "r198"
     ],
     "calculation": {
      "http://www.incyte.com/role/PropertyandEquipmentnetPropertyandequipmentnetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property and Equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/PropertyandEquipmentnetBuildingsandconstructionDetails",
      "http://www.incyte.com/role/PropertyandEquipmentnetPropertyandequipmentnetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/PropertyandEquipmentnetBuildingsandconstructionDetails",
      "http://www.incyte.com/role/PropertyandEquipmentnetPropertyandequipmentnetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r200",
      "r436",
      "r484",
      "r490"
     ],
     "calculation": {
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.incyte.com/role/PropertyandEquipmentnetPropertyandequipmentnetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.incyte.com/role/PropertyandEquipmentnetPropertyandequipmentnetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r200"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/PropertyandEquipmentnetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r198"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Long-Lived Tangible Asset [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/PropertyandEquipmentnetBuildingsandconstructionDetails",
      "http://www.incyte.com/role/PropertyandEquipmentnetPropertyandequipmentnetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProvisionForLossOnContracts": {
     "auth_ref": [
      "r237"
     ],
     "calculation": {
      "http://www.incyte.com/role/AccruedandOtherCurrentLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cumulative provision for contract losses not offset against related costs accumulated on the balance sheet.",
        "label": "Provision for Loss on Contracts",
        "terseLabel": "Sales allowances"
       }
      }
     },
     "localname": "ProvisionForLossOnContracts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/AccruedandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RealEstatePropertiesAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by ownership of the property.",
        "label": "Real Estate Property Ownership [Axis]",
        "terseLabel": "Real Estate Property Ownership [Axis]"
       }
      }
     },
     "localname": "RealEstatePropertiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/PropertyandEquipmentnetBuildingsandconstructionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RealEstatePropertiesDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents categories of ownership of real estate properties.",
        "label": "Real Estate Properties [Domain]",
        "terseLabel": "Real Estate Properties [Domain]"
       }
      }
     },
     "localname": "RealEstatePropertiesDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/PropertyandEquipmentnetBuildingsandconstructionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "License Agreements"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/LicenseAgreementsAgenusDetails",
      "http://www.incyte.com/role/LicenseAgreementsCalitheraDetails",
      "http://www.incyte.com/role/LicenseAgreementsInnoCareDetails",
      "http://www.incyte.com/role/LicenseAgreementsInnoventDetails",
      "http://www.incyte.com/role/LicenseAgreementsLillyDetails",
      "http://www.incyte.com/role/LicenseAgreementsMacroGenicsDetails",
      "http://www.incyte.com/role/LicenseAgreementsMerusDetails",
      "http://www.incyte.com/role/LicenseAgreementsMorphoSysDetails",
      "http://www.incyte.com/role/LicenseAgreementsNimbleDetails",
      "http://www.incyte.com/role/LicenseAgreementsNovartisDetails",
      "http://www.incyte.com/role/LicenseAgreementsSyndaxDetails",
      "http://www.incyte.com/role/LicenseAgreementsSyrosDetails",
      "http://www.incyte.com/role/LicenseAgreementsZaiLabDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r344",
      "r471",
      "r533"
     ],
     "calculation": {
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development",
        "verboseLabel": "Research and development expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.incyte.com/role/LicenseAgreementsMacroGenicsDetails",
      "http://www.incyte.com/role/LicenseAgreementsMorphoSysDetails",
      "http://www.incyte.com/role/LicenseAgreementsSyndaxDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and Development Expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/StockCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashAndInvestmentsNoncurrent": {
     "auth_ref": [
      "r514",
      "r515"
     ],
     "calculation": {
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The noncurrent cash, cash equivalents and investments that is restricted as to withdrawal or usage. Restrictions may include legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or entity statements of intention with regard to particular deposits classified as long-term; that is not expected to be released from such existing restrictions within one year of the balance sheet date or operating cycle, whichever is longer. Excludes compensating balance arrangements that are not agreements which legally restrict the use of cash amounts shown on the balance sheet. Includes noncurrent cash equivalents and investments that are similarly restricted as to withdrawal, usage or disposal.",
        "label": "Restricted Cash and Investments, Noncurrent",
        "terseLabel": "Restricted cash and investments"
       }
      }
     },
     "localname": "RestrictedCashAndInvestmentsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted Stock Units (RSUs)"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/StockCompensationNarrativeDetails",
      "http://www.incyte.com/role/StockCompensationRSUawardandPSUactivityunderthe2010stockplanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r18",
      "r235",
      "r436",
      "r488",
      "r507",
      "r509"
     ],
     "calculation": {
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 6.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r89",
      "r90",
      "r91",
      "r93",
      "r99",
      "r101",
      "r176",
      "r338",
      "r339",
      "r340",
      "r354",
      "r355",
      "r393",
      "r504",
      "r506"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]",
        "terseLabel": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r140",
      "r141",
      "r146",
      "r151",
      "r152",
      "r156",
      "r157",
      "r159",
      "r246",
      "r247",
      "r472"
     ],
     "calculation": {
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Total revenues",
        "verboseLabel": "Revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.incyte.com/role/LicenseAgreementsLillyDetails",
      "http://www.incyte.com/role/LicenseAgreementsNovartisDetails",
      "http://www.incyte.com/role/RevenuesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r248",
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Revenue from Contract with Customer [Text Block]",
        "terseLabel": "Revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/Revenues"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenues:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability": {
     "auth_ref": [
      "r428",
      "r430"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for finance lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Finance Lease Liability",
        "terseLabel": "Leased assets obtained in exchange for new finance lease liabilities"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r428",
      "r430"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Leased assets obtained in exchange for new operating lease liabilities"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RisksAndUncertaintiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risks and Uncertainties [Abstract]",
        "terseLabel": "Risks and Uncertainties [Abstract]"
       }
      }
     },
     "localname": "RisksAndUncertaintiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RoyaltyMember": {
     "auth_ref": [
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Money for usage-based right to asset.",
        "label": "Royalty [Member]",
        "terseLabel": "Product royalty revenues"
       }
      }
     },
     "localname": "RoyaltyMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.incyte.com/role/LicenseAgreementsNovartisDetails",
      "http://www.incyte.com/role/RevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Gross proceeds from sale of stock"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/LicenseAgreementsAgenusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/LicenseAgreementsMerusDetails",
      "http://www.incyte.com/role/StockCompensationNarrativeDetails",
      "http://www.incyte.com/role/StockCompensationValuationassumptionsusedforvalueofstockcompensationgrantedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Shares divested (in shares)",
        "verboseLabel": "Number of shares in underwritten public offering (in shares)"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/LicenseAgreementsAgenusDetails",
      "http://www.incyte.com/role/LicenseAgreementsMerusDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SalesRevenueProductLineMember": {
     "auth_ref": [
      "r131"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from specified product or service, when it serves as benchmark in concentration of risk calculation. Includes, but is not limited to, revenue from contract with customer and other sources.",
        "label": "Revenue, Product and Service Benchmark [Member]",
        "terseLabel": "Revenue, Product and Service Benchmark"
       }
      }
     },
     "localname": "SalesRevenueProductLineMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/ConcentrationsofCreditRiskandCurrentExpectedCreditLossesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of accrued and other current liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/AccruedandOtherCurrentLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r118"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/NetIncomePerShareAntidilutivesecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r118"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of antidilutive securities excluded from the computation of earnings per share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/NetIncomePerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-Sale [Line Items]",
        "terseLabel": "Summary of marketable security portfolio"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/FairValueofFinancialInstrumentsMarketablesecuritiesportfolioDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r117"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of calculation of net income (loss) per share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/NetIncomePerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNetBenefitCostsTableTextBlock": {
     "auth_ref": [
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net benefit costs for pension plans and/or other employee benefit plans including service cost, interest cost, expected return on plan assets, gain (loss), prior service cost or credit, transition asset or obligation, and gain (loss) recognized due to settlements or curtailments.",
        "label": "Schedule of Net Benefit Costs [Table Text Block]",
        "verboseLabel": "Schedule of net periodic benefit cost"
       }
      }
     },
     "localname": "ScheduleOfNetBenefitCostsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/EmployeeBenefitPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock": {
     "auth_ref": [
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the changes in outstanding nonvested shares.",
        "label": "Schedule of Nonvested Share Activity [Table Text Block]",
        "terseLabel": "Summary of shares available for grant"
       }
      }
     },
     "localname": "ScheduleOfNonvestedShareActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/StockcompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r200"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/PropertyandEquipmentnetBuildingsandconstructionDetails",
      "http://www.incyte.com/role/PropertyandEquipmentnetPropertyandequipmentnetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r432",
      "r433"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/LicenseAgreementsAgenusDetails",
      "http://www.incyte.com/role/LicenseAgreementsCalitheraDetails",
      "http://www.incyte.com/role/LicenseAgreementsInnoCareDetails",
      "http://www.incyte.com/role/LicenseAgreementsInnoventDetails",
      "http://www.incyte.com/role/LicenseAgreementsLillyDetails",
      "http://www.incyte.com/role/LicenseAgreementsMacroGenicsDetails",
      "http://www.incyte.com/role/LicenseAgreementsMerusDetails",
      "http://www.incyte.com/role/LicenseAgreementsMorphoSysDetails",
      "http://www.incyte.com/role/LicenseAgreementsNimbleDetails",
      "http://www.incyte.com/role/LicenseAgreementsNovartisDetails",
      "http://www.incyte.com/role/LicenseAgreementsSyndaxDetails",
      "http://www.incyte.com/role/LicenseAgreementsSyrosDetails",
      "http://www.incyte.com/role/LicenseAgreementsZaiLabDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r297",
      "r299",
      "r302",
      "r303",
      "r304",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r322",
      "r323",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/StockCompensationNarrativeDetails",
      "http://www.incyte.com/role/StockCompensationOptionactivityunderthe2010stockplanDetails",
      "http://www.incyte.com/role/StockCompensationRSUawardandPSUactivityunderthe2010stockplanDetails",
      "http://www.incyte.com/role/StockCompensationValuationassumptionsusedforvalueofstockcompensationgrantedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r305",
      "r321",
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Schedule of option activity under the 2010 Stock Plan"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/StockcompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in net income (trading) and investment in equity security with change in fair value recognized in net income (FV-NI).",
        "label": "Debt Securities, Trading, and Equity Securities, FV-NI [Table]",
        "verboseLabel": "Debt Securities, Trading, and Equity Securities, FV-NI [Table]"
       }
      }
     },
     "localname": "ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/FairValueofFinancialInstrumentsMarketablesecuritiesportfolioDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling, General and Administrative Expenses [Member]",
        "terseLabel": "Selling, General and Administrative Expenses"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/StockCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Additional General Disclosures [Abstract]",
        "terseLabel": "Available Shares for Grant"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/StockCompensationSharesavailableforgrantDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r302"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "terseLabel": "Vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/StockCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "terseLabel": "Cancelled (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/StockCompensationRSUawardandPSUactivityunderthe2010stockplanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue": {
     "auth_ref": [
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average intrinsic value of award forfeited under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Intrinsic Value, Amount Per Share",
        "terseLabel": "Cancelled (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/StockCompensationRSUawardandPSUactivityunderthe2010stockplanDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/StockCompensationRSUawardandPSUactivityunderthe2010stockplanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue": {
     "auth_ref": [
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average intrinsic value of award granted under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Intrinsic Value, Amount Per Share",
        "terseLabel": "Granted (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/StockCompensationRSUawardandPSUactivityunderthe2010stockplanDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue": {
     "auth_ref": [
      "r315",
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average intrinsic value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instrument Other than Option, Nonvested, Intrinsic Value",
        "terseLabel": "Share price of shares available (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/StockCompensationRSUawardandPSUactivityunderthe2010stockplanDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "RSU and PSU Activity Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/StockCompensationRSUawardandPSUactivityunderthe2010stockplanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology [Abstract]",
        "terseLabel": "Weighted-average fair value assumptions"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/StockCompensationValuationassumptionsusedforvalueofstockcompensationgrantedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r329"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Dividend yield (as a percent)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/StockCompensationNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Volatility (as a percent)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/StockCompensationValuationassumptionsusedforvalueofstockcompensationgrantedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Average risk-free interest rates (as a percent)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/StockCompensationValuationassumptionsusedforvalueofstockcompensationgrantedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Stock compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/StockCompensationNarrativeDetails",
      "http://www.incyte.com/role/StockCompensationOptionactivityunderthe2010stockplanDetails",
      "http://www.incyte.com/role/StockCompensationRSUawardandPSUactivityunderthe2010stockplanDetails",
      "http://www.incyte.com/role/StockCompensationValuationassumptionsusedforvalueofstockcompensationgrantedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": {
     "auth_ref": [
      "r306",
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number",
        "periodEndLabel": "Outstanding at the end of the period (in shares)",
        "periodStartLabel": "Outstanding at the beginning of the period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/StockCompensationRSUawardandPSUactivityunderthe2010stockplanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "periodEndLabel": "Ending Balance (in shares)",
        "periodStartLabel": "Beginning Balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/StockCompensationSharesavailableforgrantDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "negatedTerseLabel": "Options cancelled (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/StockCompensationOptionactivityunderthe2010stockplanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": {
     "auth_ref": [
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures",
        "terseLabel": "Options granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/StockCompensationOptionactivityunderthe2010stockplanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average fair value (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/StockCompensationValuationassumptionsusedforvalueofstockcompensationgrantedDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r306",
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Outstanding at the end of the period (in shares)",
        "periodStartLabel": "Outstanding at the beginning of the period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/StockCompensationOptionactivityunderthe2010stockplanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Option Activity Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/StockCompensationOptionactivityunderthe2010stockplanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r306",
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Exercise prices of options outstanding (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/StockCompensationOptionactivityunderthe2010stockplanDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "verboseLabel": "Stock Options Weighted Average Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/StockCompensationOptionactivityunderthe2010stockplanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r302",
      "r303",
      "r304",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r322",
      "r323",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/StockCompensationNarrativeDetails",
      "http://www.incyte.com/role/StockCompensationOptionactivityunderthe2010stockplanDetails",
      "http://www.incyte.com/role/StockCompensationRSUawardandPSUactivityunderthe2010stockplanDetails",
      "http://www.incyte.com/role/StockCompensationValuationassumptionsusedforvalueofstockcompensationgrantedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/StockCompensationOptionactivityunderthe2010stockplanDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Cancelled (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/StockCompensationOptionactivityunderthe2010stockplanDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/StockCompensationOptionactivityunderthe2010stockplanDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-Based Payment Arrangement, Tranche One [Member]",
        "terseLabel": "Share-based Payment Arrangement, Tranche One"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/StockCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-Based Payment Arrangement, Tranche Two [Member]",
        "terseLabel": "Share-based Payment Arrangement, Tranche Two"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheTwoMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/StockCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price",
        "terseLabel": "Per share price (In USD per share)"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/LicenseAgreementsAgenusDetails",
      "http://www.incyte.com/role/LicenseAgreementsCalitheraDetails",
      "http://www.incyte.com/role/LicenseAgreementsMerusDetails",
      "http://www.incyte.com/role/LicenseAgreementsMorphoSysDetails",
      "http://www.incyte.com/role/LicenseAgreementsSyndaxDetails",
      "http://www.incyte.com/role/LicenseAgreementsSyrosDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "auth_ref": [
      "r302"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of vesting of award under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage",
        "terseLabel": "Percentage of units vesting at the end of each calendar year (as a percent)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/StockCompensationNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value [Abstract]",
        "verboseLabel": "RSU and PSU Grant Price"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/StockCompensationRSUawardandPSUactivityunderthe2010stockplanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r303"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "terseLabel": "Stock option grant term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/StockCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r327"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Average expected life (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/StockCompensationValuationassumptionsusedforvalueofstockcompensationgrantedDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r81",
      "r88"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r36",
      "r52",
      "r53",
      "r54",
      "r89",
      "r90",
      "r91",
      "r93",
      "r99",
      "r101",
      "r124",
      "r176",
      "r234",
      "r235",
      "r338",
      "r339",
      "r340",
      "r354",
      "r355",
      "r393",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r431",
      "r504",
      "r505",
      "r506"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.incyte.com/role/InventoryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r89",
      "r90",
      "r91",
      "r124",
      "r472"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockCompensationPlanMember": {
     "auth_ref": [
      "r118"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement in which award of equity shares are granted. Arrangement includes, but is not limited to, grantor incurring liability for product and service based on price of its shares.",
        "label": "Share-Based Payment Arrangement [Member]",
        "terseLabel": "Share-Based Payment Arrangement"
       }
      }
     },
     "localname": "StockCompensationPlanMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/NetIncomePerShareAntidilutivesecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r15",
      "r16",
      "r234",
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Issuance of shares of Common Stock under the ESPP"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.",
        "label": "Stock Issued During Period, Shares, Issued for Services",
        "terseLabel": "Issuance of shares of Common Stock for services rendered"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesIssuedForServices",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r15",
      "r16",
      "r234",
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture",
        "terseLabel": "Issuance of shares of Common Stock upon exercise of stock options and settlement of employee restricted stock units and performance shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r15",
      "r16",
      "r234",
      "r235",
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "negatedTerseLabel": "Options exercised (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/StockCompensationOptionactivityunderthe2010stockplanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.",
        "label": "Stock Issued During Period, Value, Issued for Services",
        "terseLabel": "Issuance of shares of Common Stock for services rendered"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueIssuedForServices",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r15",
      "r16",
      "r235",
      "r322"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture",
        "terseLabel": "Issuance of shares of Common Stock upon exercise of stock options and settlement of employee restricted stock units, net of shares withheld for taxes"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r16",
      "r20",
      "r21",
      "r83",
      "r161",
      "r175",
      "r412",
      "r436"
     ],
     "calculation": {
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": {
     "auth_ref": [
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.",
        "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio",
        "terseLabel": "Effected stock split (as a percent)"
       }
      }
     },
     "localname": "StockholdersEquityNoteStockSplitConversionRatio1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/LicenseAgreementsCalitheraDetails",
      "http://www.incyte.com/role/LicenseAgreementsSyrosDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/SubsequentEventsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r420",
      "r438"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/SubsequentEventsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r420",
      "r438"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]",
        "terseLabel": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/SubsequentEventsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r420",
      "r438"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/SubsequentEventsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r420",
      "r438"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/SubsequentEventsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r437",
      "r439"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/LicenseAgreementsMerusDetails",
      "http://www.incyte.com/role/StockCompensationNarrativeDetails",
      "http://www.incyte.com/role/StockCompensationValuationassumptionsusedforvalueofstockcompensationgrantedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental Schedule of Cash Flow Information"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r166",
      "r167",
      "r169",
      "r170",
      "r171",
      "r227",
      "r233",
      "r392",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/FairValueofFinancialInstrumentsMarketablesecuritiesportfolioDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r374"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/LicenseAgreementsAgenusDetails",
      "http://www.incyte.com/role/LicenseAgreementsCalitheraDetails",
      "http://www.incyte.com/role/LicenseAgreementsInnoCareDetails",
      "http://www.incyte.com/role/LicenseAgreementsInnoventDetails",
      "http://www.incyte.com/role/LicenseAgreementsLillyDetails",
      "http://www.incyte.com/role/LicenseAgreementsMacroGenicsDetails",
      "http://www.incyte.com/role/LicenseAgreementsMerusDetails",
      "http://www.incyte.com/role/LicenseAgreementsMorphoSysDetails",
      "http://www.incyte.com/role/LicenseAgreementsNimbleDetails",
      "http://www.incyte.com/role/LicenseAgreementsNovartisDetails",
      "http://www.incyte.com/role/LicenseAgreementsSyndaxDetails",
      "http://www.incyte.com/role/LicenseAgreementsSyrosDetails",
      "http://www.incyte.com/role/LicenseAgreementsZaiLabDetails",
      "http://www.incyte.com/role/SubsequentEventsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease": {
     "auth_ref": [
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in unrecognized tax benefits attributable to uncertain tax positions taken in tax returns.",
        "label": "Unrecognized Tax Benefits, Period Increase (Decrease)",
        "terseLabel": "Increase in unrecognized tax benefits"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsPeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/IncometaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r125",
      "r126",
      "r127",
      "r128",
      "r135",
      "r136",
      "r137"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VestingAxis": {
     "auth_ref": [
      "r302",
      "r303",
      "r304",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r322",
      "r323",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Axis]",
        "terseLabel": "Vesting [Axis]"
       }
      }
     },
     "localname": "VestingAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/StockCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VestingDomain": {
     "auth_ref": [
      "r302",
      "r303",
      "r304",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r322",
      "r323",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Domain]",
        "terseLabel": "Vesting [Domain]"
       }
      }
     },
     "localname": "VestingDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/StockCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r104",
      "r117"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted average shares used to compute diluted net income per share ( in shares)",
        "verboseLabel": "Diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.incyte.com/role/NetIncomePerShareNetincomelosspershareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "verboseLabel": "Shares used in computing net income per share:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r102",
      "r117"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted average common shares outstanding (in shares)",
        "verboseLabel": "Basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.incyte.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.incyte.com/role/NetIncomePerShareNetincomelosspershareDetails"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 7
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1377-109256"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1707-109256"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1757-109256"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1500-109256"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(15))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org/topic&trid=2144383"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "https://asc.fasb.org/topic&trid=2134479"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26626-111562"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aaa)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org/topic&trid=2196928"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117546-209714"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(i)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "https://asc.fasb.org/topic&trid=2126998"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "https://asc.fasb.org/topic&trid=2155823"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 4.C)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "35",
   "Topic": "605",
   "URI": "https://asc.fasb.org/extlink&oid=126916656&loc=d3e57777-111642"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130558-203045"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130550-203045"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "https://asc.fasb.org/topic&trid=49130388"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123453770&loc=SL108413299-114919"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(l)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(o)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(p)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(q)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4587-114921"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.12)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "https://asc.fasb.org/topic&trid=2235017"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126962052&loc=d3e4991-113900"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966325&loc=d3e6819-128478"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "b",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966325&loc=d3e6819-128478"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(1)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e7008-128479"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=127000608&loc=d3e9135-128495"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126928898&loc=d3e9212-128498"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126928898&loc=d3e9215-128498"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569643-111683"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org/topic&trid=2197479"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594809&loc=d3e13220-108610"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(i-k)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "https://asc.fasb.org/topic&trid=2122774"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(5))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(d))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(c)",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=99383244&loc=d3e12121-115841"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=120413173&loc=SL6242262-115580"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=127002003&loc=SL6242269-115581"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=126942793&loc=d3e3073-115593"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=126942805&loc=d3e3115-115594"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=SL120174063-112916"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r534": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r535": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r536": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r537": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r538": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r539": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r540": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)"
  },
  "r541": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)"
  },
  "r542": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)"
  },
  "r543": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)"
  },
  "r544": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)"
  },
  "r545": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)"
  },
  "r546": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(12))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>90
<FILENAME>0000879169-22-000010-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000879169-22-000010-xbrl.zip
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MMARA(_RSN<FYH]%I M*./MW#+%&5WL7Q"#G+;L!$2Z[*,+N("%3:HT4$\A[
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MD*T"=&TQ\.K!]4D@$S03>TL15RF$4$2R49WF%>$M!'<38N U )USEA@8*GC
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MOKV_C7N\0ZDJM['Y@ C%1$PUN6!":#9)<F4 RGL3L%N+OE9U[6QH4:*&2UB
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M1:!MLD!7JX:61R"3F3BKWF%ND#CFOOA9T7,QX 1W!-IV-;0\*E%J%@T*U69
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MM.]MHUY.C:/4V(JQO;@?YE9BXZ)4CL8FI 'HY1V7-X_+:]'+QCN08)R@(%B
MS"%BIE"2<MJT(;3IVG%Y\[B\%KT<4.6$*=$0$1!XSN0+0\M4.;LB ]#+.RYO
M'I?7HI<K6U.8JBG60U"=+%X\EMAM<94ZI&H26[Z=]/-(?.O%BYF\4))\\ W?
M';F-9IHB%6NY)S5[D-B--*&5U(O25J@?;S/9Q"W:.VIO/+77LDL["7GVCCWD
M )D8I2':W#18=+Z$(5CMO]S!;9"VR+)$DZS:HUJ@A;ZE0GIO\50\YEP7V^I-
MMF> ]0>;!]AY!9O#D:JO_I&'[=<^MK\.QKN]ANST53_@W=N?75[GZKO]=6OZ
ML-V:S?I5^I=_[R<=3%\K1497;$B4:?:2O#P[=#FIY<YP8HS@$T$N+F<G8$K?
M9JPD9!D +Z^.')=C_"-Y<3*F^71VNCS"?^FT+*[F+&RJ:P50@^RH876S-47U
M>]AH1\L_I.6=Z9&JG][ =/1V(8AV[%P6.TTP)C(&RLF &)>-8^.C\ZU@"6VK
MU=?R9<*M2=UN$[JNZ#=B8A$&H]&O9RX2H]B0@T'V\4//OIDD7:/BW!SV_ D3
MM\R4$"+GO<N-3 1)#CDR<?!BK'@3>&O8L]VF9SWD"88]U"!HHP/2\,)$%RG%
M'&L6<Y8;MQ7DV6FL*^-0JA)KT2@ D@.+-JOL]Z ZRQJV&@.<:RRXX! ,E4-7
M88"ZG#M?'7LX>RRSUZ/R_B6?$,^DS&E[.-J)!Y?G*"PIUPP@:0Q07?2D3M)R
M4C,7*UGR-AM[$0>$"XZ&S5M@V%B.?D\_T^O1=C$T7)ZA83GK!"TM6C FZRT"
MJJ=M%""VX#&W9@$&&JF.)LN(5+] !J[>CV=0SF6?BXI!($HYQ RNUT;+,1#@
M0!FXG+F2'0-7P$!'3 4JU&P0V!2NSH)'(,.U6A\'D!'^1SRY]3^WOKV_##(^
MGNM-[E_J.YF^F-&KP]X=X^Q*BR7]V>G-IX^WA8JK3^AN!-&X0CZG!K4A.RC!
MY&P!<\YQ"$FP.RINAU5$ETN+"#ZI%P;41U$"$*34IX<3#F!OP8Z*6[(UP+$D
MJM1U8I_A(24; 'GG,^N?CSM/[:CXI5!Q]=G0$=$6L(&E5$A*R(;9>V#.H03U
MT)O?]'$]R%U)H\/&K;7H?2%#(%G($C-)P5A:"LB;WQIV[6 LKQUJL:&12Q*#
M S!8V%%O:\Y-S7(0I.%'4;].?$[JG6E/(R[S\YTFVQ6"KS[N"40N. H23 /K
M2L;$L:&3E,4V5X<?]WPQY%E#(@N[:+Q#*MF !9/99T.QIN"E>C.4BK'KEH<7
M-#J83IYNT>KTF@R:)3"<*28H %!4G' 3R57-G+XRE*ZF.TYNDYV,M7 *!GT\
MZ[2+/E>N-C?5@0A#Z7:WX^25Q=.KG]II L;:*)QB@-QL+FR\I)HJ0O)^*)V^
M=IR\,DZNH6-7B\ ]13%A!03H;30:5I.CDT+GU1L&K2>?W+K]Z-Z=)[=^>/3P
M[E/]]^#NXWN/?KQ_Y][C'4^'HS%=15\:N;[/!$IM67S1X!E=$+6H@ZC,L./I
M%Z [>RP$@9F;+<#LV',4PV@<)!NR'[[NW/%T&[2H-^1$3+:5&"AI2&1:J!Q]
MLDQJ7H>O17<\W09]6JG6X$IT%C*TX EL*3V%U_AF\EG.KK+87>Q]WL#UKR^V
M5,2]\>C!:#P^O5I>]ATY[O*[GI=4<R942J6&UH0%6E$_CYCUKQK(UXIM +P<
M!#F6-+K^PIZ-0=+2DJTMY)A;\A BLO6- (5-:\T$OZ/E1M'RKV^9'"0[C:^9
M8N5BF,$3$3J'QIMB>Z^U4#Y@YV8&\1N^"W_C7.X20VNU9T[];2Q0U>6:@A@<
M2U2V6"E$=@#LV3P+M-&.<8GD89>L"ZGXX@ *@B+:NY0F\3$0<]V19TO=US+7
ME"DU5SBJ^6$E$'$KR9&GI,XK*J_.YZ#C!8?BCD,;N9OZX?CD:$23^17/ UTB
M!7T)4]SQ\L,@+FG)T(<4&U(+-8-'?81821JK;Q:(90##X ^0ZV_?.YE-7ZTD
M77$WW@8\&&IJ8F*LIB0 !YE;HAJH@?6(4<P !L..HZOW"=__L%W#H%D/+4J1
MD ODY,FP%^Z#PM7F& :01K+*8; Q!G/UB1RY.%7.UMID,T UB*0R(J70^G10
M]0-(Y/@BF;*&HF?)5T2I:E8<1/%H;=_K5DL3Q]'Z =B42Z+W:'I*X_EG<V75
MO%S2&O@@S5A,?4:)K&V0($LA%7R5:@F!,>,@.KCMR+D:<JZAS%105L;(/A2
MQHFK,[[OXLXM:7CBAI^$MB/G<#//O"O9NN3( )286:IWY%Q++E6(;?B99SMR
M#C;=+)(1!NS!"8(OC)+["K7XOJ41 'J5!1LW<1;G2TJ;6,/\T'>O#^OR"?]K
M<0H;/YR+^9SB%"@MU&8K& O9>$)?@&OV5A\J=;N!M?F\$&]_L'DY0#O*71GE
MWK>Q-E^Z#._9H4O) G*)#1,&"ZV"!\JEN!S 1E4!.82++6?^(G3RF\?/W?K1
M=@V$'GOYRX=I?CD#03(VU]!!M!Z2RHZ8<V8&"#YSD47=!)O,64Y*?^!P$P?"
MU=2CO@SS;[V0R<E5L^_\K>]FTY-7#_^PN?;G6F2-QRZ9V')VJ,.ES+2*R1J/
MU2P!T&-&U*A+Z5:H5TS'@1)Q=?)W1\3E$-$[Q^@%K55!$(U@22I;&[5BLK)S
MJ!9Q)?71WZ?'DU^F2YD)T#M73\9*^WO_.AGUF8SYX;3>G[Q6O]]OQV]?%3F@
M(_FS(V.07 TF@W"2X@'58P/W5<WFG(W@D@4_ *XNS;0-$D!3L$A#Q2P92+Y1
M+:56SK4%UZP-"P##1B_A_.G="+^J]T5IOK4V[%H)L\(ZUE]J=@F":BG@7J0B
M$_N0K$2QB"X[V-S"N3M"?8)05U+/-Q9O<R*;,0B4! 3>%Y ,F3,%>^$^[+G[
MV-2=>JN2"$LAR./YM/S\P\FL'-*QW'HQD\4!5^_;+FF!]-"E;4_N+4LI->/9
M 7-$X(HE5F^K,3Z5Q3K&CE1#(M5[:P5I:86LJ>1:*26TZI::+1EZ_1I+[,2Q
M<V=SL>9" YDOG3"?.\UH+J]&S/+VA*-E3"ZD7F?09/4Z0BI$>G =))W/M_^Z
MX+[#^/,P_E/KULO".(46:K"!3#9@DJ'0$DK1 1W(F18V5W%N.+17HOT8HC0G
MON7<VP!:DF1<L"W&:")SVMQ>#L-!:WG-'DRK F)%O(ZM!I&+2QQ5K@<7:HQ#
M*;F^P;!M0CJO3X(IB6T57"A4&5U,II3LLFJD@:3S#@CC-91F5%\8LQB7&:!K
MHMI<;+:7E$A141Y(5NQ0,%Y+<FF.Z+@VM=:*<4_+-\T45X+#9%+$H938'A#&
MJ\_1[#W(I/K"Y#1FK:(66JJ*);*I()[M(+/QO)1'?[!Y,NHR\PK[,CLY/OCQ
MBF>GXJ4+:9P=^E>CE9/)Z!R^N1R]@^-(Z/AD)F<_N+]S\>F+-RZ>]X]_F@S&
M6HNI-4X5;/-8V1?!0#5)TA'_L>.V.S(LRRW;Y82N/GDHZ  AH_KEFE%#H!I4
M7NLM3E8V.W2]FJ7^/[T,<VM2KR(Q;ZW4O)+0N_8DT]QB+A' L3!;[] 7[X0#
MY V?*%DGV]:\N#<LFL7>$[(:44U"T!N:HP43%ZO"EF+%#S3*</BVNM3.35,_
MR\P.( .!6N$B 'T%N.]]JQ%:-$ELS@/EQNJR+;>8&R4F4/-@"B<$MJJ$>H,3
M5%.2P#A?!\*-#6C,O<4D\:U25G<"-H$Z%R8P$EKP7#T@FC00DER-<]FTY@Q;
MS,-$[,AC#M27L:S+KF7O3:%*2"G9@?)P>=G:.QZNA(<(8!JD:D BU&8YQ,!9
MW::%V.)9@L..ASMW?&5ZOH+/DCPKX6IT5'S+SE-MG9&.!D"_+QS!1<\V;P)9
M8R"F0LE',%Q2DT:1SQW912[N8%<4_E*FXN4,S.>O5ZV*7I=.QOVLY8Z/)H-J
M2QR<V) @M42"P=N2.60,.<E949$=JX;$J@\J=RPKT\@G1RE$9T@]1Q3H9;5#
MM"0N"=48/EZ]WN#%K,<G?#RJ(YJ=/J:.X((E'TK?^S\\W':6?,9B^9)6UR"Y
MH"3"C,"]\066D(LSL4!H9*L[2S7<,6G3F?1!9N,'Y/B<Q;""G!,U"(9 **B-
M(9=,3DBJ@;!M]F+80.!:WJ)2%BFQ"27*&7PE%-6G0?6J.)=C:%N?-KR:T;4L
M;^Z<9Q%JOC4/+#JFU)=7U[RO(&*&4K]XDW%;?^*P*Z[&3 1)$CB?<K6EB ^N
M2JV9Y,M)'-[$%*5E+;@D8YHJ<W*>H"7A6 NK2L<J7'.(7T[F\,J4\NI3AUV,
MP7MHTINA@PN87!.51Z#0L\6/M\GM0%YI.+2L'I(I0LX88O9]#T#F7G+-!H3(
MQCA('^VZW^2XZ-_-R=RA\6A^*#.Z/9H>EY%,BAS?GY0KGES[4SO=EQ7@IIJQ
M![1>, &:P+Y4JT(K@.3 D0901V'PLVP#H-O26AB#49_@-4YF#VHW.#MC2 6]
MDTR^T5EAA:':C1W+/HP&/[93GS.WB\%2Z7L,K0.-X[/UO5V6[]M*K:ET/M>R
M@97%=\3Y:[,^2RKGG5/D4J,H2[R:&T.MA$QH6D#7+-2MGZ1;$WQ+FK2S0*XT
M%ZEP!!MRKW1M6S98U7DPF*V?M%L'?,N;Q$N>O D""*A18<R<N,>%XA&QA50'
M,(GW;I5D4J9'\BX7Z,&T++9Q?+B4\K!#=6=Z]&HFA_T$K^7L8U^:*5__S"(W
MR*:U!L4SP&*+7#"Q4/$IBRM#:I2X8]Z@ICO)2!"IG0<6&)K^WV6C,0V6$!F'
M4"AAQ[Q!SL$R9]^\0(PM072- U&5!"DUK*GF <S![I@WR(EAJ3$D_<\G]D")
M*%GAR,3-Q!0@?ZSSTN;I]3^]:7S%&WBIS*8O9#(JFU5!*BUG8I K.D\9!?M>
MA*S17H[>NE0#1UN@G<U#6W-!H V<Z-D1Z-?I8G-Y L4E6:!"WL8*7C!"C26+
M]:JXDLV537XW0;B!+F_=E0DVI [&5=+S:FIA!%*WEZ,K#B%:HD#9$C-&"4:L
MV]PIZ74S;MVU,%9'M67UI+38<FAL0^^U(<@N%6HEAJ8D;&>U]S;<.ZZY'L:6
M.S\U.3ZB<Y 9L#C&7+QQQ9J( "T,E!\KK(FQW?PHS>:2T)A8,^1@T34-T%HJ
MSC;Q: 8T#;\1**YG2MMG#$U$%6UMX,EC ].P)7(A-JYM0%/:&X/BZJ>'"]OD
M7<%6*4'L,\(IAN1#X 88BPQH>G@S4%S+5&ORE:,U@2HB6-=R%<A18P'?NP<D
M,Z"IUHU!<0W3EKW-#Q@C%0U0\&RI5?$N&RRFF+2YDP87X-VF,4V*/#X4^9U)
M\ENES$ZD/A@1C\:C^6CK8JPEA?.N<@O85"*Y!LDK SQ3#=[8C$Z*;&ZFR8X+
M2T];,8T]&QM\]:JQ A$GA2QR3K7%NK#N%B^RHG&P^:JGL^GQ#X<T.Z(B)_->
MUF8%B<=X^<1C7%J>NPU.0L:<K ^ >IM%( "#QD.U**J+Q..-!'*]@?'**/)>
MUC N+6NX4*_UYU@%&D,!GWO+"E_4T-OH%/HO$?4A+0H,FWV94^^'8W(#@):[
M#V$5F9%R%F,=?XGLNSK4ET3\O[XVL2FT S2NU 2N"$$*C5*%WB,WM2@UVO:1
M>-E$1;ND!)PK(M+Z=G1<7/G.5'_PK+]V7M#E]NG3R>A?)W)7CLML].I7Y;_X
M,C_,Y+&\FB].UV.FQ4<>ZT7FC_7F7 6Q_[K@6]9.,RS-D,? 1D-[&QL6A*)A
M7+0I&0OGKG]'_HTA_^>:SV7%?B$ZJRZZ>%=Z%3&7?; 8>[VGD -:V9G/%3#H
MECZO4G=6=-U6%)S+9$H#:U10 #5O@7*HIJ0H9]NO=F-@\\; IAC34E)V1 ZD
M-J@,'$TB'Q(ZR<WDO+D3[,/GS^J)L\39> U:-'XIQ!(J)-_KD1LNU2)6AYXW
M/)US;<39%/C061/ -:Q! #AC<%S=HL^&J"B'S5U,&3!\RUO_*-B\MPY<-0C1
M-&X 7O&$6+V&4FD ^4)#PW']Z46IQ)PX>2OH ;+&.\':7)%=8Z8( T@O&CKH
MJ\]&BE39UQP D  @]KH*F#7H%2N4( \@&VG0H*\E><EDLF!%"+) =@&YEUI5
M!ZW#/DGZ@FKUK0WTU><Z%:,15Q'KF*@W/<,JOK?6#,U':,4,Q+SO%D7O3R;3
MU_K2[=%T/'TQ*MOJFFJS1>F("2-!= 9]+"1L?.HS^;&<$]9?$-9O7C!Q.5I=
M!9'ZV/AA-JTG9?YP]EAFKT?E_4O^($?T]G3VV3OE-Y>O_O)\]<N9*Y6<0X*@
M7C21_N,1O$&7U;-ZBTEP9V W?6/@EV)9<VS@T+)P\&!=)-6"S9HH)F&6LRT(
M-I^+_OY@\RSKNIFZ&5+@SG0\)I[.SE)])_6!6OG)>Y.]/XWFA\]I](#XP;Q>
M\?I4OG0D<W;H<FPNUU*)T5@-5HM+%#N=BX:S8$+.<<?D3;>Y7SR%LS'-4$$;
MB2&E0*P1=XPVMY !TQ#BLDMM IC.7AU.CT^/;[WX7%I5&=U\("]H?&_Q\S]P
MX.5T_D>B=I N.V1;J$AO@T-@K",'V,B5'(N0AD #8$FW;'=ZOUR9O=);=OIQ
MVX3E$62Y?!PD7R)):;X6<;:"DX3!]OVEEL %+A 7"W#FR\H]'I*RNU)ZOK=F
M:):6=HS5<E^99[(96"JJ,V/.0J:*KRWM&+>A"FQX5&M2JDD9#>0*QK4<E7A2
M0/U@Y!;.&KV:C7:&.UOT*5=IUN$J$Q4N+1H5W@:4-MB2]02+4G*^2MYLP[6$
M1;!;:GU&A29WY=7T>#3OK6*O**'U2JR!DPJ".>7$!$0M<Q*5.%:*HB8-MCY5
M;%4&?(G9?5[CW%0P<TE0D;DQ2<HNN$28[/9W=5@59$O<$@^^1@ A\1X0>D9F
ME50X6<XE#J*3PQ"P6W\:6 8;F&.-A2L4@^2,+Q*#*24G"VX@,PU# WH-4TH%
M07R$I,('/")'0,Z$^C0"-?IR4K]6!_1:TKTJD6FA!.N"&O :>E1>]5'KW<_)
M\I>3[K52H-=0SLIHS)(54B)UU\DSIL8^FLR0:O5E *9[Q4L)"UY=-)GX3J8O
M9O3JL&<!GEVN].GJV>G-IX^WR_1+Q-@@>K:Y0"2AV&+J#3F+R[&<F_[-%G-?
M(E%6+P8A4Z&:7?.U0E)QP*9YK)A+TQ?.6[=O-E'^(!/NB2J=/NEQ1'Q^U*U)
M/3]LLR;7=AS]-$>Y@2$BR%;#DZKNS_G@;734L@/T/ "OM^/HECO<X%1T1^(2
M,( S@9(ET8"ZA>"J(3N06&O'T=5P=#V[@I2DY)#5DD;HD^D9$K1D*WNGNC ,
M)$S<<71E'%U]A(LU).D5[RD(L 8NZNH=J+?O[0SLNPAWD_7H9JVXKJ>1@<^U
M),(($:#&1AJ&FI0EEE!\:$.88MXX%%>O:1C)54*7L#!$">0!HVTIFXB]4L<
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M=*T8LAR8BX<(GGVT48-35ZTC8]P 6/D'6[ROBI##'@R#)*M:2X^ *;'M\\:
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MPVRJOW=^^L.8%HN8G5F+!<W;IQWB,U0O#G[8VJC(NT,&$E)8[THE7U5TE-Y
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MVI_.7LCQXU]&\[<R&U]QR&]QS[@]ATN *6.TH>78*ZL!ZEA7650C-A;1T,3
M ))[-A6O]>?M!%8IE2IX2QDTQF2IC":!!(HUA@$4EMPT3*^FH6:&F#-2,TTE
M<*WL>@,_BM&4"CHVSV35#J:_J*J6%ZDDJ&2]S>@ &9$39%.-CZX& /^%CZ;-
M4V2;,KZEFLH2(K2^].&H%S)-/GK+EH%PX6-5"IVE4/<'FZNF_X!!?:WCP;3H
MV_6GT?QP-'GV \W*>QPZ?D"=5?,G4@XGT_'TQ:D>\//]R;/7,JO3R=4ZX2Z;
M+ID^?7;H4BISM!B*< O-881%']9B4^@ENENJ)I?--QM7/\&QO?R[$H.B,;GI
M\R_5"H+)E%G]7$D-$PH$<@/8DW$!Z/U)F1[)NQI,"_#T@ \Y]4B.17$\5.Z]
M5ZWEWIM7>K:KKB:VKLY]MJF!"(*J+&*E'$OV5 &P,C$.*"H; L"KC\P(&GNL
M/F'T4%SDC+;6$@K&WE4,!M1^8^,!7DMG#H^^5P0L8AI"*D!1&)G!%^L+M3:@
MSAQ# 'CU33L"+AI5%DG) 34ASQJXYUK8DW-A"/LB_Q3 CV4\UE#L.YG(C,8*
M\ZUZ-)J,5.OIP:_E'.DK",G6[XU5725RU0?#!-[6S#UYHU?7LZ5Q:MOFC3<&
MZM7[9<Q2O4JMDEV"X!1F[Z%7Z-$G$?T06GT.$.JU>.C47"8-ER+T69A6B&W"
M"IAT9,>"O&T>>F.@7KVO+D4RHCC,Q@/Y+KUU>$>NL;$)0;;-5]^9'L\?ML<T
MWDY_K!I+'&$2WRP$RUB,*::&%%CM-L9M\\<KA7/U/C>!CLCJ;2Y-W6SB7,F
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MJH0D@LD#*.RU3NUS)5MWHD\FJP>TJ ;3,K/QWH5H8BLI(0Z@(-Z&0+*\C#_
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M,5 -!I2"#9XASI-$QEN!@L6!1*5)(@!>2DF32EDC\#X"#T6)B[W[N-ABJBR
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M*948S#0*0AZF4?RUWKJ&(NM6$Z$Q&#8&WRGF%WN&CSW$]?>0B7^.R\JA\TM
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MI\/*JN!-H<O!K >,W[E[@@M^%X??F9I=R3@'%CU8A(E3Q)4B""Q_@0B/(L9
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MF%/<U+P [BX!-^^4 P5P]P:X<S7%DU9.RHB2\Q+QD!2RH& 0"S982J)6(6;
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MK:T %VE*,%]B%$QSKZ6+/CBF4R)$@=EI04NMG'UH_ULXT1$ '[EAM)^03?"
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M4BF4P PWA"!)J42Y"PU2'"QR.$J7A$BL=HEY"MX4UP15"W(6Y"S(^4N>.K/
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MA\W.;N-?Z6.=S?:'C?7?:O^L_SKNFV/?'0??;'3[C?'^X#C=SH^:C?#=A83
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MR8]KP>=K6Q/#M=;WV^?VJ;KP(5NGC:FA\^GZC7!>W)H%HOGL'ASW+D81%3)
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M3 MST)@\7)K _!69VX]R5/.?]'B#X_2PXT2S<GV"Y*OEN\;AX##=.K@T<]7
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MUX*QPFDG:<06C%&"'=4R>):" FK@XH'J1!0F7QB3S_H8&',AY_@@DQ5+SJ)
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M\6S&60[;C0WHD1+SZ#V]LFD_+6P? _]W#B*HJ)U.[R0+Q/:@LM5@= 3C/\T
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MK )KJP1KOSP(K@U@GO#JC@#G_>AHU,E*\-L^ -:%B?#6MKL9PGZ/ &%Q=<X
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MJ)_Y^Z!_$32]'Y'K1_L9V=P%XH7MG-C3P=J_YS/6VETTNX"7YW[C#%.ZMYS
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MA)9M]/L6/LV0.7AUD%]N=3>.8/V'V^E[T6ASG[ZNB:"@YL)0\U*2EO0:;.J
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M!3!07UH_[ O<>7C0[H<J+T4U[$<[K O8P3?]ZEL'N%)$[)WWQA+/+1>:,Q\
M[5*@C"F2LFX,DY6U;CQ^,>=K. >Y,9*]LH.#-YW>R> UD,-1+C7T5^T,FH,M
MV%3_(HSZI]'V5Q.H?OBDMGFV<=9Z]\D3AV50#CF7&X;:))'%G* 4&,&,Z.@2
M!:U37V;&*B_9H%$3!!C&-37DK>\!A<5!WO QO8/>9*O^A'QO%'T@/4"ONB3]
M8/,C9TY$KA3WU&F</ G24.^#]*+N'3.E@POI1Q>0WC@C)FMB.I=FB#X_*N&M
MC4^:$!!*CB A<W$*S@(R/L(KHJAP3 .9.*"2J]+H7^O5'0&P/:CRRH^C+JJ8
MP:M_7OAR[,]M5">@O%2^]DL,+CDF^KG",%BL4P"#NX,(&(PKC=5BJRX[-AC"
M/[6WL3ZC/YX\?C >;[[59#@UF%2C(1#&V9C XP10ZMO?869U);@+*V(,W6!*
MY%IPM&:D:86XR5>3,G$9S&LC'#AIRFH_R%)< ?L8DI0%KM*<NQ MUM(89S"Q
M-X6(%99:+$O!=<!2@3,B540Q6H.X)PEII^H@6N6#)=%P^@UCX=KM-6 ?F*0I
M;"?AF#'- 4 C6 B,$TR=O-Y>*-M[#]L;C6?P1Z H@T4<<X>L2!8 5#-A$C&)
MQFL1\RJ$UM P.A[CUD1_RU"5V?]AE;@Q..Y;N"W<QM_@%_XF",X<S@T/^C'6
M@^GFIQS!3PX&5>QFI+L))6OU&!YSW ?B[8.VG@&Y?N",,.CU00&'\8'I&D$S
MK.+7R5 S: XNX#1+D<D*_=#RKM\V9FN)S9./L)^Q"[O3@;4\LI]A:>WI6"["
MRN[ !\%6?QU84)E]'(W+& ,NP$A/JS_;1^V\:/\=V3Y8+'"#<S,CKVF_=VH[
M=:@;T%:^/EN)>6GA%C 3$*.][LSC)J>WDPT!+?)+NS<:3&^^7FT,?T!V-FZF
MQ,GS+I\-UR3VOW=PTDA!&*-<BV0$5\0Y@')CC)+$.,&]^IY/7ZS2B:E\=FC^
MF;3V/UEO%>8>(YS;R7(3+7*$4A0Y"&^2G)$B)[N(]:N>^4SJG2GJWH6N-#?"
M<<IY4O G*)W/CH(-/EFE@J<U79$I75T-3RITM=QT19LGG[0+Q%"M$0L!K&\J
M M)<>21M)(XD:G'$H"68=7DC735 ,@V.8UUZOG,Z-L@SA)U+.0!4ZWU_E.V'
M"\%?R\;A;$#R)6EV?:>@>I.^VZ:%R[4?$HKW+@.O1,O6,K#5 UM*K.>.,CF4
M=R(?<HL9,$';P^I]>_"Y7KM7DU5[_?5X[$.;7)!/2F<*O2Q&&[C?7(>YN>8)
M7B3V+$ON0JL]X<G##;*WLW?0HN\PW/]P[_#]07/S=^!)T+7/7I\V-S^+7=HZ
M:NUL\<L\V=S\I],Z>LWV@(_ABJ/6V]<GS>S.AU\V=[9.@,\/=^DN:1X>I.;A
MQEG&>E"4DH\,A9HGI>/(2IJ0PCH7Z#01]/JUB5H!3+61D8W3"%) BFBUYLX'
M;5W$ ;.D,8B-@*_D.CR&JK?5K5J@VM<GF!1CTZA.8E6'KM<H >J>K>KL =>;
M>BRZV0+PV7U2V7W0UFM/;NU\@3N!7M8>7-8-M_+]QO(E-[P8AO7JEYQ>3_%O
MTY_4;\EOOZ[#Q>=JVXTCFCR_ :(- *YW/.Z&TLWNG"-@C9RGUCZ;#'=^B*\[
M;5!1LUY;\^Y$:9V.IO[FIJ$0?=U0LF/3]OW!C:M4.]_G!['5[<*:P[O?V[#-
M^VT_:,!G_F)5IA?,#>6/$8P:AO%S>[1G80&LJW[Y.XOQ ]O^%59AO5'O"@B*
M:C!R(*W;.5 >P&YZ]52K_R4_YT*N3(8[N>IBM-DBA-%\B9?&=0Q[#7;%(.\3
M6&M@%S1J4;0/8]P'6ZMQ1]<5V,U66TXH[!(/4;I<$=)PE0(53#'['37[BI/C
M"@#^!<0$']C]2);'>_'0&-@ZW*>?K /@BC$A(97)WEZ&'(L!Q1@#I0Z 3?*L
ME=S@JKC;OI(86$I"<"X,-Q@[0ZTWE#!KE'.4?$?-+?MZRWW]C#\Y(377/"%B
MI48\.(6<\!Y4S@!:9\(>A-?:2W95U_S7U*T#BF0V!+*+WL=V'3< -O],HY,?
M,M%G%=CUZDVO7Z51OU93V]VQ\9#):-R(,ON.:H_/X#+@7 N$@_- G<=0+*N'
M>?CUXKX?$ZP@+%:MWJH+]?YR2]#+ZNKS:P-*+YD^I0WH8XSE =N ?E=?OR_S
MJ_;%_.T/8AAUXJ!VJ%Q(J^V4Y=7OI_GO-P"]O?[[<9.DG=ZK"ZC[$O^:J%;U
M&CQK:^WD$\/<*8H5"@Z#KB(]1CK73Y0JFL@=E9BQIY%I/F^^$5*;!@YTZ>YU
MIM X+&/8;[O1U)OQQ\;_VWBS56OA&Z"1=[+TQ7>^RU^OFQM[N^]?CSU-<*]M
M(-3QF.C=Q[3]U][K/S^\WUBOMD?]?/H21G[FK,7VZZ.D"8M,G%G56(^<Z"19
M#X"-ZL'#)H?W_K(;QX^]-/WLQIFV'0.YF!/SIVLRG54]R.F@KHXGY_</)OG^
M@R>9LE_Z_Y;!/HG^O^9R#\X) ZUN&\Y:"EQ8LQG9QL7&6W'<DO.O"5R]G\+5
MY%"__G*G/FUOC@_97^=#]D4TYRRK/+_*K1S)<.,B+YRFGT)?V6]EU91%^MXB
ME>;<MZA^4WH\WWKAR")8\(FN32&JA1#5L\B9GYBDU<;/9,/_7$[H"J4^7GLR
MQ((7F,O$B!*<>*V!D*R0@4DC"#53-YLJ)WX7!4OAN\-W8OOM^Z/MG7<P#OAS
M>-#>WOQ\TMILP;>?3W*$4HYBNE*P]*QYVMK\S/?>[HI6CEC:?'VZ_7:+;^]L
MX"9MGL&_I[MG=534Y<QUQ7E44BAD- XY)P1>&8.1CO"YBEQ(G:X]+UR^(DJ/
MP17_NHU8N6N_P (SMX491S.D8".T5!R;9*B0DG$M)==*T30Y@)[ #"DP\Y P
M,]O+@UJ6"[0I9+&EB!O!D6-,(B) 'G@"X&-)@9D",\L),T12(W40P8-83$%J
M''GP7#*J"/SK2OS2(\+,;&,+II,SSC,$6!\1]YHCH[1&.1K)4,.<<J; 3(&9
MY829F")1Q+.HF>6):N.TM1$ )>"(-7&7PND*S#PDS,QV>>",I<"\1<+XA'@R
MH-=0YA!17GB.8Y0L%IBY)<P\ATIDYRZEWY]9^=J[ 6!R$E.!#59$<F6,=B)*
MS:+A.)#D4_$:/18 7BISY26G2A"#M$H&\6 "<D0D9+1GUC'IP R_-D/^QRI<
MK3S&+:CU6 &+V<K_VJK(,<?&<)Z\TEAK'[BS,0BIK"^^GT<$BSG?CZ%.YDY8
M.&&+N+4*::L%2MP3>*<5,QDL2 &+ A;W!Q8Q8H:))""Z #>,SPGZ,7<1EEXH
M5CPXCP@6LQZ<:+'G4A(4?/;@T."08SX@8Q@Q2@+61UO HH#%?8*%#L(P&8VD
M6'-*E&&&J:0,38IAID/QPSPB6,SY83R6B>;2+E+A7 "3(YN\R5DD0*/6:\;M
M.$6L@,6SB]YY]<QZ6=RQFJ0C"1L8$:CCG$AI0\0B$(^#3S$$6EPMCX9Q\ZW.
MD@@!"V>18"XW[0D6684QRA4=J!%2I%QKDH@%^9I7'N,>X=3JR8,%"8E'HK)(
M)5PI[;2Q3B6MX5,&.E%QM3PB6,RZ6I(ARH5 D)5.(LXQ15HZC"A/V"E!$\Y5
M(H@J8%' XMY<+4X%$0V.A#).:;1&@/'D"#<!<$3+XFIY1+"8=;5(I;4ST2$9
M$V@6U@>D4PJ(PVXY;+R+%,^V#RA@4<!BT6"!O>?<J!24<IPFHH56/H!E$K@P
M'HOB:GE$L)AUM3@AJ-=>(Q-U/L0!@T1S+Y"C)#)OI*'.%K!XIE$MFR6JY5O6
M4[)1"682#I9+@[-WTA"<<([J,]H55\NC8=Q\?V0%^Z0MI\@Z0L%ZBACIX#E*
M#G8/VZB#8&LO?]K3\E2\R>7HZ1Z,)ZE$B,Z3F#2WD3H=?:ZK:1B-"BM7/"V/
MB!6SGA8KI8]"2L1\CH#SW.53)X<8<R28*$S=\?>G(X +5A2LN!$KHHM)4J=$
M$EP$[G+1\]P0+*9 8B#%T?*(6#'K:"',.-#[+(J!YV-JHY#35")+@X!O- ';
MJN@5!2ON,[6(".R"5XJSP#D5EBI%<Y"]UYI)S8N?Y1&Q8M;/$G7R8!<:E(CF
M8(/DGJZ**:1<TE*Z0#15);+^F8:TO"XA+=^J.2-R/"_5A/#$M: Z,,&4,\[Q
MP)0J?I;'P[CYFC,ZM\=RSB!C-46<T("T\@QQB4GN=LID4 NPG9Z**[F<.RT>
M*U1R,@8)LI9X;K VR<OD/$ %T*#2MOA9'A$K9OTLP<H4HY"(B2 09RPB34 ?
MPEI1+!VUA-%%Y ,4L"A@<>,A-:,\"DRCCIH3SDUNQF.L\ I  Z=4'"V/"!:S
MCI:$O3<4<(+)9!'/GEG-C44D:,V9"YJ%A:0E%[ H8'$36 @-!@?V$EMKN06J
M,Y9YQY.QP1GJ8_&T/")8S'I:%"5@%CJ-M,Z:A4@,[!%*D(#-L-X'1XDJFL4E
M3\N_Z[XFLWV&9]N1K61OGH^Q;E43OQ[W!N/F,KG93&X6,^CY=MUPIN[(":.-
MW;R%TYXT<.5Y]YK9WC2YV=[ CCM<3;K0#-:K5^>7;C2JWQO5JT:U67>L>;VH
M+IO!$>R=#=B#%2V<<9%%IKW,JDF(X7O-[)\7\OQ$[RH/]_<,D(4U=SZPYOXG
MJY,&%5$CHBS.*3H<&8<9DHJ#T<(PYSC=T)OQ[CTWK;2>$)>+7S >998N5I.H
MC%0^\'"Y2%CIN?ECN[SS#K?>?1*@/0IE#0HYUI&S"-:GIA1%)[1V+"K* NSL
M51GQH%TW;]<X:])^,W?.&O>1O](AJ]>_=KCM0=7M#:L!8'<[@6SJ#B^UFU]9
MV,^=WS/FYS7QLUWZQDVJIV[WF;7(/QD.OK=SL(C],+/>DU7-GQSW.FU_6O>=
ML<?'G=/\6>Y-W?\RZ483I_WI)QO8J?O3-_(6Y&N/VMW,R=5!&P8W;OX\ZOI)
MM^<\PHO!#NI9#,?$,6YX7AUGYH8)3F]_TNL/#V!M!O6$\ECA;3_4':!/:RDV
M$6U 58.#]C$,9'0,!'9RT/8'];VO'V]U$L?MWP;M4/>_#G$\]#:(PHT?ION3
M6!W8;R#F:! N'PHXSI1,.GE)>(A&>^.3Y(K *X%Y_+1UG2Q$XC),;N2V<9EK
MW_3ZF[V1&Z919V/"+._/EWRM&O>\A0=_';Y([:\QH+/8[YT#J7QN.'JX<9(E
M9! 41Q90PB%'0!"%G#<:@88"NK&"UUQ\P]"ZNJW649DBYP1NR*TSFG,AF116
M)>53PO6V7A%^95L7NZW!8J6X8TAIH1#WEB!#K$>!>.\TMHD8NO:RV[LB'J]\
M4-GI1M0@&"9;<2Z/+DF<?U_J##N60?46?+<!+3=K/R2X[EU.7=_.K.X +=>K
MK2Y(Z0SY\RMQ/ZUNI^QQ_M#-]L #LH_Z2].S=OOO*<F_[P"A?][^^([O[;S^
MVCQ\1UJ';]K-CV^.]M[NGK0V/^/\W?;'W:^72;[U]A\@]'=B;_.@ _<^;6U^
MH,V/6U]W/^Y]WCO<P-L[^;M]L7?X!C3"#W1[XY-+C 7K/(H$@T88\WF$DQQQ
MF7)VM$P.^[4+@;N1,4-)G<-W82>4YL0G8RDHD41K91*%#Z_TN'V _L7;Z7QO
MEZH5\:-LZ[M/F"82DB1(!J81-R0BE[Q#RC&J4V3&<?XT6A'G7KWMZ=:?FR*U
MIC88#J9FR[A-;E8X?VEWX9/>")X9!K\^R;ZYBJP#FY3NKIH]2'?7JY>N1"^T
M^3Z.N6'H+=O*/=4%F1II%=AGT_5X?MWBWMN3"DP#^#&8&/=6V?W:H[*E6XO_
MO;_Y+_=)R?T[)-B-JCD08'-*?ZTXW$[O)^ZD>:NU.SI"H3=$DWN>FZYL-16^
M\<DA/*-Y]@>8NWN=YN'>P=[ANY/=PU9[[^@#;F[N4S!3>6OS]\/=H_?MRR>'
MNSM@UF9S%^;7.GIS!->UF_2/H[V==R?;F[M@*N_CYENXU]L_4G.^)%?P.47/
M.03*-RB+3 KDF.#92<RY!$JC.2:)T0;5J] "8I&A  7P"N MQE57 .]Q 6\V
M"%-%0HVD%@7A/>)8R9PBGX,P@TU*4T.)7GM)&E0MJ@SAO>/=<ZC/\;'7_XS
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M(8CG8#B;*R\HRBG@ >.! Y51?5E43;2*C&J-#',V ]VH,VR,C<49PCL7AB=
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M'Q,&6\P(9&V*2.3>?8$G+*1<>REO%8QR:Y?G^O1<?"(Q3\_I=EK?9-:].W-
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MD>K7P_FNKV3=ZWCFE[K:GXY.P*LZ::*WUUOYG:@-G%-&*G#]C(=_A)6"6N[
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M0O'9U?UGCW'-TZ8?7H-;]V>_V]NNVU<SQ#WTV/W:+F.513J<C.(?DVECAQ&
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MR8)G0H.VH-Z3)D'Z3)(.5%(NJ GTV0MP&ZXY.-@4XA_?4"SS #'^5G;O+>]
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M<HQ91)R5@45/BZC9I<LWJ]FE/78![+"7?(_EW@>N1+;KWX^R?0-K/N-03/R
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MQNY+LO:H[?/9=\NYYL_%;MGJ#6/--&H;WO='Q2X9:ELP@?W:[Z-^<30TB0W
M#,_.T6W!86R%IS'99#SWPFK!$_5&1^T-"5C?X\0 !@1B-QS /I8]B_'XI@8#
M(%$,=.JES?; =WJ#43^.![\#(_H-MO:CGXL,M/G7!!D\WCW\4B#"7LXEVOF,
MF_0SW]I\3_9VCLC>YA&%>QSO'6X?SB'#^7:[M9,181L0H'/0VOQ\OK?YC3>+
M?*._ 6'V#K:^[AVW/K:R<7FVKVV$_W."G(@><7 R$'B  1$B%-=:$R+!%(@
MGB<P[\41RW,OZE_^( ;8ZK;2_'KNY&5^PPMVOB\M#BH9CF!&)>).*V0#\?"#
M&ZM\H."LS2W8B[31I]&F5Z"-'Z--YU(@)H<0,4RBNJF78\T9Q__5S@96+P>)
MP^#?[^[KML#C%DEE%\EO918;/';'G@SBN\DOOX;VX*1CS]ZUN\7@BR_].K[8
M."-.G,PEL16S6[[]ZVD[# ]RGF8#E[F:XY*0\9W';S>*MZZDY)7O*=J@C-WX
M-FZ0&]^[[;*$-)32C[KL[>]Q+!<_6-K ^GYS<$?9S9U%=?,?O28K.@>\8G\Y
M.<#ZKOV[$*L+,[\&%OY_7/^7]8R]-Q8*O_X)N<@J8^1B/LC,?+R%NO+MWIGM
MS)AL;ZO%.^'7E0P\I(+VG@G.#:,>GN/\,R;CY]32YUW^0A;'1OF+*!-XK 4X
M+A/8.]C;^?P#[L&;']^?[QY^/FM]A+$>[I*MCTV^]?'O]M[F9[9[W#JX6B;0
M.O[0:6V^A^?Y!O=LM5N;G_#>\1_MUN$7#N/E>U__.&IMAO8N_9":LZ7Q-F+K
M@V>(*0P&?P@.&:DX$@K< !:XDR9GBW!=YV(^%'"//>/!)>L5VE1HL\1:_@IM
MGAEM9@B'7.*4NH PM9D?% =DJ" H$"RL9(DDEC.,)* -F4_R?HA%]I(,K]_A
MI3R6\G"M2$P:W-)WX(:'O-3S5:;M6+9=4:0AC-5\,L_;Y33_GF>YTOA%:_QL
MDP%,@\!2$Q1S:(I;3)&C."+,I#96:<&=R7GFM*[D?'.U9_1)7Z>Z/'5CK-1E
M^>HRO4$:6#J&O4*>YIX<SE*D<W]R4)X4   =CR2GX)HZU_))&^1+#UD4FO$7
MR-F@S";.>6;WV3/O]]RO$QT62(?RO3V FWWH]?_;&PRVNI,BJY?!U?DRD&&6
M6C]&$7FNY'>2 S+ WHE<4@0I$F,,#-QW&@ 9M*R3NTSG17/+5<JU8+:,2KF6
MH%S3VZY(+F9.>R2IC@A<5(,TMQII1H60!#9DGK==)NN"SZ=COU:_=+R[=D/M
MV/:/8DY JYS29PAV-R>S6YG8SZ'KK5G">TTY2S@)%+VGB+/@D,7<(B>\(S)9
M*8C/%3EUC.]0]<HA77JDME*5YU:5Z6V1$V&EC0D1$0GBA$ID1296M9YEG@"!
M0P)5$74EY@M0WI(S2A_5[:VRFQ>YF4Y/_S@!M,*'1>/#[.&QXUKYZ"*RC&F4
M:\>1!;A'+J>+"A.BU7AM7=<UNR-657FDJ[SW5IJU%,V:WGF=@-4G3B*G&!BI
M"2MP2)E"L'C8XV2#<ZIHZHK-?%'1*_1'"]&_VJR]<TV5P9LVMA>UE5Y,]"S1
M0Z7TBU;ZV;/2Q'42*G%$4^:[QAP\4^$,*#WF)++(K/5Y.^7F40'>RC%]CLVQ
MTI6EZ<KT!BEMDH%1@VB4$G%J#;**Y Q&PQT-1M,<Q2&X+L0=:05OP37=NJE>
MIO)-E[.A7BDZK-!AT>APY; 4#&3LDD2$9=8E9G*>(1%(1.L!ZGUR-*ZM2UXG
M=Z%#Y9FN].9;Z=6SZ]5,0-AJ;1.XI=(H@[A-&&EB<F,!GB13G',KUM9Y#@@_
M;==]29OK3J:RSPTY[RY/O:FRZK:V"7BV<P)N*#&3[?^**Q\6.2VOL@YBP0?1
M%9(^'Y)>:;LN(JR/( SQI/,IM-)(1ZI1),E*AXDTF6L5?M8U66A>= 4Y%>2L
M@NE60<XR(&?:>%-1A8"]009;CKA*"3F/<Y,-F9(GCB7.UM8%8W5A[BCUO$>O
MI5MZ+XU%CV<VC)/>H&".?U<2"WZ/ER08_YQE*AGK)+[\BG6@>Z/AS5^9(QWX
M">HE8$Q3Y KE7$W]? !+%+]@B3KH7\+\MXA</]HC9!,\X3O;.;5G@[5?9BE-
MVETT/>M7)^S&:4GIV0SG$A%#YK@N",+>@2<<^_E3,":[,F.I'?0S[OWC[O51
MX H41#&]E!GX,E\9&/QV_;JU?S$T7P0W:G\->_X('NGX)'8'Q?PLD]3KDJ K
M]W*Y',-T6=)?![8??\ODFA<4EBM""M6:\/L=%YC/MK[^T=G[VA2M\^U.ZWQ7
M;&UNG,$^\6-KYQ.&WW\T/S;Q55*HO0+SO8![P/V/6.MCY@H\XLW-/SI;.^]%
M\_ S_/[^=/=\.[4VC\Z;&_NP/;- +4,B:H>X80Y9PQW"+&*?7\/&EAM[NPN[
M\$;>;1ELWR' ZB@I.05CE'K"M56!."T-UJ^#1NIKO.35?PAI99"*!8T3(U%Q
MR9FEG 2:) W.<-#_L22K&4F^M4%%9\P?>RF\T^+]_D?^]67PKOX$*?^R;WAP
M3H)@!\9Q[@Z,D>,.H\2-"11'XHG.L:C&O/LTPZS_$"%X%)Q50O!,0K#S:5\I
M"M"4>\;I(/+AGT%6*H4T$T02[XQQF0J;B8:Z60I@OQX46YR?FOI:+.>^UKMH
M !+RWV&J84G,[C3\4Q)GY]8EE]U*2K;0"/_E;DI9T+J 1;5C$*>#02UV,_[<
MR+?;CR4!ZO?8.2L(W!\%68PP1T1@PBG,A;,NY!Y )&ENL0)?H)!6,H$L4DGK
M<TIK<^<([X-L4DZU0)1I@KB&'[ 8!&$A*/C4@G &XLKI;=+Z4,S"R5IG1?)!
M.JZ%TL3;8+T%(X"FH.-8"D@E!<N0@L.-LWTG)&P9#*-(A<C-EC"R1#D4A54D
M"$^HM1FT;B,,7S70(E=!ZZ^;!W?1;C-WEVL_;J07UX"[QH+W.8\V1+AYKVST
M>3$5#^M[HK##N9MP(%%SL)*-P\1XE;32D0M+*SMOJ7:>!W51.'FP]%#$+B&.
MO4062X6HMD$F;< (#VOK5-RB+?4'B0 WEB2X+/A)@G,9K)'>,!LXUP%VT<K*
M6[((T'W"E&;$)V2HEHBG8! @:,A\,EXY++AC8.MK?$MGX(>)@.4)+AG@MI)Q
M3Z4SFH3@A=<RP5[-*]-IJ2+P[71?1R+ [W*PYIG_0%.*3$P:84R-<\I[XW(G
M)-E@"W3W-$L>6Q\QV,S*<RNCT\YQY@GS-J7*=%JN%/#]*"GXX-BCX!T'*9 <
M:9W Z<,:;*H@3,"P%VA^6XOP)WAFQ:=_@K4#XM2[O- @PH-TO]5KWV(W3AII
MV'#<[K8'PWYQBO)8ZT> X\R(]!$<:VY3M,P%1PW,-K.4"E99/\N4^,,CNA^C
M(L9$A4B*:1SA2"H@@:G+9>P>I]RH6S?,@K8^L'>5I8$)["QG)!AGE7$<TP@;
ML%.ILGZ6*0+G&Z?[UG)!P,@!?S'FOKS6(R-90CI:RQ(7'.R2?'![2Z^>AXF
M-C$P,'F]H8H+"LO/&$]6>/A#@B%663_+%0&\3[%,X )QE'C>]Q((@TD*@_7C
MHQ$F@0N4V9_$+2CP8.M')6HL^+R2YW9RR5M'E Y<*P #Z;6KK)^E2L'['_N&
M8(U3@&4'> 9#6&+D*-6(!!R#\(RK)-?6^:V-'U^\]9/)<?,'QIWO8"C?8W<4
M!P\U=3QHCLXY=P8S#C@*_AZ@G70!- T+$2M39XGBO;4#^QRA2IH@,(J9:80+
M2Y U(B*N@N""):&"75O'MP3''[;-@54;J=4JLD1@AW7: YSB()1P/@<:*DMG
MN1* ]\'=3@G<>02&)H%MCCD$KGU"S(*E2[1W+L;;VQT_3 (4![T/C!B?P+91
MS@2+.0X@>EZ12"I#9\D2P/>%CAZ6@B IK0$)4!)IF@(*@,Z"@B]"<N76K6TI
M'VKG4 /*CJFR2G&N--76!NZ3TL(J-H&!RLY9EA"\)_M:J.B5MHA:"3"@J$?:
MV(2\QM@ 2!-*<W%O8YZ?[1(&IBV4^D*LGL8RLMX* N[+EH=SB6T;I[8?"GMK
MZZ2PCG+?V^.33N\LQN+E/\=MIG-3W+]M9U2(W,9@,#HN/[]2+1-_2G;<YWUO
M#0]$6  9F1"GWB+MI$  ,$EQ2B(LV:O)=AL-VV6'W"S_OW6L/T(@7[U,[?E]
M(A^@""%V"BV),/[C<8OWW#[1MOO%Y^*DH>(UI\[C)KKUPLB_TG6Q'%X,R'X'
M@_X;*-^E++[*'HP %*#/"V]KJ!K&/.ZJRV_!6(VU&FLUUFJL>:SW:QO[U$ZL
ME-Q0PG=;9[15;TLZL>O&\;6QP;<(IJ>W,%T30[B6+>''< _<.'OF?I-WS_Y\
MJSZM'\:NTT[A.C5+C^E]]I@6(8EO<RY;V?FLIK(2R]6:R]O%<O%[]$N?M]E&
MZL^R+[_>*7JJ.+'7-E4Y%'@?[K$[G_9-31FIIJR2LI60LC<Y,94L58A52=D*
M3AEY2R3'Q4-OC ^8^NW!$4K9*VSG=8F#8:UOA[=P'=.[Y^%^<G$M#]I*L7V5
M1UHWY49T1]E2OYHEQ8+3Q+NH N<N<2=,L"D%+YE6BKH[\N3XU>R(ZY,B-OI]
MV_U6I/_]=G;]J?<'V^[G$^TX=9J]#6O] 9;ZTWBEMV&A+W(G$'V9Q]MCDK _
M#EM?MX^;FU_HULY>N[6Y?= \_KO=_-CJ;'W\]*-)6YWF.5SO,,R1A#6/FV3O
MX^YI:V=7M(X_X=;']V=[7S^=[M(O?/?P_3G\>P[7.F[-=\?SVBHB$D%.&HPX
M$Q[I*#@((L7$B8BC<3D#R\RG8)5I$S=1G#Y-L\C*\^@5FO7/9^6.KG#J-IPB
M&DLN*;-1>XX==EH%'92 ES6%7^_(Y:MP:N5Q:IK,T&:^#*<HLB#XB LCD.8I
M(H85-Y)YRWB1)ZCF.X]5.%7AU$_$*:V3M@(0BA6M2K#1+&F#:;2181OI'5GG
M%4ZM/$Z1*9S"8"TSQ1)BVCO$:91(>Q^0U#AR(H(*N7"+-O!\V7J%4Q5._4R_
M3UGOL*;<"LI]I(Y8&62,CB7AI--WI,57.+7R.,6FNZ)+*:BG 2"*4O@1$G+,
M6OAAO!3&",U%MJ=DY?=5.+52.&6Q$$0G8C$)G)I<JQR"I%@[):)A=Q&S5CBU
M\C@EIG"*Q2"%Y0D9HW+?#!?!GLIE@L9R&X6+6N4.1 TZ3P!3X52%4S\1IR*A
M1I"(B5*8&R%!8*.U'I,8%/S%JOC42\>I'X!112Q]:_/]O@J4>2L44EYD@TK+
M;% EY+W'+&%OG"#9H*+SK(454%5 ]1.!RMLD9,R.'5=<Z^BBTTPD"KLK(P;C
M*D#U\H'J[!*HB(G*<F*1UX5%%3'2@4>D# [4@"Q01]?668//\^A70%4!U4\$
M*ND5PT$Z81GC!FOM$\[,S<DD;.*=Q T54*T^4+6F+"H)\NP#5TB#OX^X-P)9
MZBP*B3H1.75,NL*BJER_.X'JP?E@J?C?B\P'RU1D/A.,==HIUO[5[M;.HNT/
M_OTHY+Y['E9OZ6^C*GE4=M<UL.GNADUW']A\/UZLG=@_)C,4.?#T_ET8]?/B
M5>AY-WK^-9/7I00V&D -$>PPXB$*I".+2'H3L&9><V[7UD6#J/E.CD]7D_MD
MWKYZ57M4@E*E:B]"U:93DP)3)%@L$,.9KCYQBARUH'F.6\8UEYZY0M5DI6K/
MI&J/RK&I5.U%J-IT=HW/O) J>!232.6NYJP*R!+!I/5.4EJ<!FE=J=IS&9"/
M21.I5.U%J-IT@HCP$JM@85<#5QIQ0$WPOJ-"(G&NA7 JD=P]O(%QI6K/I&J/
MRG2H5.U%J-ITCH/14ANA% I.YE9'.2+O(D,J2AFYLR3:4'#@5JKV7*KVJ,/Z
M2M5>A*K-'--CGYC&SB#LO4'<DX"<,0R!<VYY;IH*1F2E:\^J:X\Z;ZYT[87H
MVM1)<P!3A1..D= 43$CC&=(TPJH*[@%E4PK)5[KVK+KVJ"/32M=>AJY-'Y9B
M86%#"P%A;"WB3BADF' ('#5PU'-'OW ?77L+O!%_]SHV<Z0/SY["$/'JLRV>
MR -!GS7;8H(CEVM9Y5L\&$+:,R>&&D?O:/ H: ^[=90>60)8@JVB$6N"HTQK
MZVR^$<OCDBU>?$K%3\C]>O68\T1.APIS7@#FS+ Z<.>,]0KA[!QP*RUR409D
M8]"Y,1B\;0%S%I4R7V%.A3F+YF>H,.<%8,[T&;(61$E#)5(A1P #D4@+:9"/
ME":&M7<AVSF+XI&I,*?"G$5S+528\P(P9_HP/7C.,%4^5]KDZ$RPR% ND0$;
M1R49/>,.,&>^F7>%.17FK 9O0H4Y+P!SIK,*.""'==XA;3U'G'&&3'0 02Y'
M_IERAFC G/F>JA7F5)BS&AP(%>:\ ,R994'07 2GP9MB*J<R.7"NB%3(*)/]
M:QF8QFOKM HB5Z"SJGP&%>B\"-"9SC/AE+ H#<(Q4L0CR8Y5"D@Q9[B)25GA
M 714!3H5Z*PH-T$%.B\!=*83;B@SRE%'$'%&(FZ]1]8XAS!GD24>I!>X<J_>
M%@/!U^*/&) =4Q$D4,;:]ZR-!0]!Z'4ZUS$1/&0.KD7/E9N)__.D1UQMN;YQ
M8Q@-PI^Q7\#RJN92C7N*?X0/#@>?NC#<=B],Q'9,H%&\N0D;Q,56<K%3X&JC
MN'NC.)M)JS)1!*VE1)YSAKAW&MED%/(2@T="(B6A,$X;XLGVZ?6(^="M8I$Y
MUQ6PO7)@6YF$K0K8E@%LT[E;3BD=DF<HV # !FXW,CPF)(-0Q B'"<W IAOZ
MR42"%;!5P+9D8%N9K+ *V)8!;-,)8M2$R'7T@&DY$9X"IFG-'(HXF7QXCKDM
MSC :YLDY8A6P5<"V;%=T55+/*F!;!K#-4+HHR0#.-((M#2RVB'/F*T[(*1&X
M#3H:H0'83(,]F5&U K8*V)8,;"N3WU8!VS* ;89 AXE@?+2(B @6FV<1.4D<
M8D$(X3@5,8#%1F2#5Q9;!6PO#=A6)HFN K:E'!Y,Y],EI7DBC""FG<W(EA#L
M<QII$BVU5@D=*2";;M G]VFLD*U"MB4CV\IDZE7(MAQDFTK:L\%0(@Q#OBA/
M<)@B:P)8;V"X$^J%$58 LHG&TZN_*V2KD&W)R+8RZ8 5LBT%V:8S ZVB5$6%
M40Q@KG'A*<H'X\@GRX.TW%#L"IM-KU*8K<C/^V5H72?"OZ']?7V.* Q>G SE
MV/:_M;MEJR0Z"TV'H\&PG<[*E]K= )+XCLD"_I:LO#0K[\Y!K/7;@R.4^C'6
MVN/N7+4^B'NM/0"=Z[>_QU!+_=YQ;0B?_=+XJU'[$.%UVZEM1[CK]SC^=+<6
M4XI^6+/#XJ-#&&>MEVK?LOXT:OE.L[V'8*[]J%.H:KY7P9!7@]_SEWNNN'2H
MV6ZX_%IQR6&O^$3\$?N^/2ANT2O5N.;.:KU1OQ:/3SJ]LQBGKGG0'@Q[_;R\
MEU\\L4-X7/A:ZO5K@S;,KNW7AF<G<7*]1FV2&ES[?I$;/#?4J4M/?2J/"H;B
M>\?'O;RJ/7]4ZX&(%5\Y*7"F>!/ :E3,WVE[>#!^L.E)@NL4\S$9T48-Y*P-
M8A-J9^W8"?D##\O%9MB"TL5DD_'<"ZL%3]0;';4W)&"]$@4@F^.'+#.QIX@0
MWZ7VCQC0>>SW7GR&=B?^OVW S7#B*)=[QQ\ZK4TOX!YP_R/6^OB%M0Z/>'/S
MC\[6SGO1//P,O[\_W3W?3LV=+Z3U;9]1IZ)D$7E#/;B_RB/CI$?,F:0( ZLQ
MN[]YJN:0-$NQS=,.<C8CS0D^ +^ #I^":%O0[F[,8GMBVR"P=G!P(7^#0C?+
MC_1J)X ;L+ %A'0+*00]/;%G5[[3J+5ZW8E^UFP6 [A./]:.HP5%N!Q'@1JU
MD#4#M!HP"<1O""@^'N1%XO!8/^+_1H5N=@?#_BA+V"#?WV40&XS@JJ/!Y+N7
M8!+[Q_5+O>_-0,=X:(V+O:: _%NH1!^E55<4R1_$,.K$K72]2OV5061LL6S
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MOPUG@L*)D<"3X(+[1"T3,462=U-PZ%G5"N-G+OEY<V._Z'B(F4,.8PEVM@R
M,\RCX+ 3TF(;E;P59VH[$W]O<)W-#?L3B ALBK ?%ILBZ'+MV)YE,<G.=*T]
MJ TN6'IA6SL>=8;MDTX;5+/4Z+'_V(G?8R?O<.6U\DNIW04@:-M.'<QE>+=W
MDM<>[/;LJP+,'<7A#&# +4.[[$:?/00831N^%DH<*-S6$DKRET!:&K5I@:O%
M'_GWF"5H"I NQE#<='88-]R[G>M"?#Y%F+IU%E,0S,P:/C.(XG;%Q%T@&\Q
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MX_Y)K\CXA^6)_6[I&X GT#X>'9=BV<U&#?DG."*^/2A%-9/S%G1"_7@R I$
ML2N7/O0*/Z%TJ,HG@'O"&,H*FEK&V_ZT)W3!Y74IXY>,N)=<7M>4!%PM2+K?
M*;7":R_OD),VX'K#R4$G; RU(IMEF6>=[VT_6RJ#28^M%3GH9,U)?LOA%[;W
MM7D..P'>VOQ\NGOX^73O\)/8^PK?V?Q\OKOS#7:B;S]V#S_,[32MG0#W;?Z
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M1TP%?Q7\O4WX>VIM4@5_*P1_; K^*..2D<20HA%,0.L!_BRW*#+M O5><&T
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M5VUZJA3U*JWXIZ<55[)4R5*5HG[_3)2_8O][V\?"IGXDG\*;YEUYO<PJS]U
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MWE8M]$^_OL+I_51-[W>:7JL6I5_ G(1#T1OOU:T/QV>C/WZ_/*[F^WO-]T+
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MR($  4D2@?T3&3HH78]<B)D-62ZM0"<&'*3I2M%-)3K;&ZXKLR)5T5N8)IB
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MTQQ2!X]%&-M^5A"J'V%R2\!3"'&+H;%TKC-05'93"<W3VAW8X4&5/66]5KP
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M@M^"3_J)#[QUUB4:'I(XP^83.R!XEKH=-J]:O=8T"O4;10+['!D#:^#\6IB
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M1D%'?4UW=87)73EHC]^/)(\Q-H7S^)35X[6=&2.S[ R-M%)\H'MHJ>A"N]/
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MN'HUK-KH:$]U':%"GQ#!.E$X]Q!YHMD8VQW*Q5!G3TQ24!+"1\ZRVUD8"VS
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M98GO:B(IK!LD<\@%UK&+Y"2?D5&G328>7L[_H,+D\J.^AFZ%"@));V-O@P'
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M 'W9,]=2_%Z\O6NC4S/X\=C&^HN:J_*>>F_OH]DWNH7WL0ZWBT#"L(W@]/D
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M=XIV*U6U%A&CLL >S<^Y/%>B;CS E!R#)&+X##<XP[Y%GA=.@Y[3)FL[1=W
MAB<C-P.%S9D+NQYVPI)9Y5\+$+9;/ ]\ZP9O@E2HK4":>:I0]2%F<!W)&^W.
M?C46.&2IROOU][^^"^^SF,_ XSTY_>L._9+^<U>*)3KT (ZD8CQ^"YNKX-93
M31TUN.F.,VI75T,VB<B,P:%P-!^.I\ BIE&D73%SV\@LXYFF4O#IMXZ 72-
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MGGXE)(*O#]%[6.ANR&\,RJ;S1'-;ZG?$WIYYMP7<M&0096DRC.[A].6XV_4
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M&,+#%I]2D4>";IJ,+3;]#N+(($%PDI&NFM4<WPF<L3;T(J8!D*+J4[TM^M1
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M>^M"H33UK"T=WUHCX*/[+"MMI@-+H?OALHRW6QVKRO!*Q?D(;9LR08,"66X
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M[CFL_]"$U=:IX[S_E>IL5592W<8K \';[BS;%KMZCL+&']&R0!GM$3V[M?/
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ME]5HE.I%-N[3DB$NJFO^P<3=_LGGLY (!O(R13Z#4^TKF@"1@DN*O^2EP)^
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M)YBSL,=[5]UN'3JUZP%PNLK@>RVEJS5RS0?9LW^H+Z0YNO;T-++&/CLK%"T
M)G#?G:#* ,=?7K^9IOF7##'LX!&Q<?%2!,^#K0\=E&!'G[^,C6U6B>ZH9X7.
M6C$;LO<$H4,_"CW/<2_!/"\X] DF^4V>QAJO;U3U@-C 2S<JK6--6D1:BO#
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M2]9R;+5+*S< O(:*<I7BEY$[C+.2*".J[[N$$(@H?*71"<=TOZ+4(<J1 EQ
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MHC0=CF 3$(<R9!:'9@/E!9X^*F()',V0YDNRE)?H9.& DL&:U3WT0N$HJ )
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M8B)3@\DA<A/4=9W?N8YOFS6W6?-NFS5?@;6T6?,:!H(BR)%Z-@ASF!8!CS(
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M?1@T]<,#KY]1HE3Z-['AJ!RD0-80C6TD>CQ=;1+<)@B\#SR:V>#_F2$@.*<
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MIAAXW$HN%K3PH]4\KLT,\DZ#&TYC3(2"T^ONUP3*8S50/&Z(.%B<8R*O1OX
MK803A-V?.\@(0$\>;208>T0OX/XQX[+K8#LEIR@&:P ZK$*$?<VN/)R*/GS,
MB]%-?CG1$T!*_TD2A]\$U7KE GI\R?3!#!EOP03;0C?^[2/_.+=Q.DAG1VW*
M*7$_EH_?DAN,"KF/OBV#X7@?%IX:$&P&UA6F0\8DL0 T!%CCJ&<)(;W_(IE1
MK?)541 ^AQZ@I;^$LDK'*TN]?%&V#--JH82T#IT6T;SF^U;*@6&YEH[O%;F6
MG4P6E3"PEJ8-&^P$O^MK;7RIHL*0+A]@8ZJ\B7[W4LQ64)!L _;C,A"_&UR/
M]PD#VWB,PC@!.Y]DUH9<)X(2$:":4O"(\8PX[41BGA6!"W#@18"5 \55<TW9
MP:V[3EK_F" Q^G528L.>76GU0^PY=DD\Y4-K7PV='P)@H5P9H1+)O$]Z#1N
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MS?G0(\EI!H1#&/3FG)H;(_?A2,3RPRLJ>^RG[O-L)2 N&2Y!4NO(SS$MHL1
MU%'.69<ANB=63&Z;4C)* Q6._<3>YL0*!+KR<&^!:.PGXI8G8L[-7X+BMZ(C
MIH=8%WCS&?=L3^!^P3MQOX-N=>(DX&/4C:2_%Q5%E43R14<<4GQKAF,MJQ:
M=)*6SA7<]_-V=^9M4*D^1T,7H_/@C P?= CK<=+MI_4VIQ4(+Q A#; ?HR2H
MR7H/-33]HT:J158NS/BJ)>5879:SZ?:)_>-AV[[:8]ONP+/LL6W_@A9+^-3[
M>F$34L6KS]=.[5#-DK1X"D#7]=.AP^E7F4 NP$Q%L;53!0*O*D7P#4%MT=(A
ME:7]X?8Y?)9(1\\,KM2$S*E@I^XZFE&^)?9H$+V;M2J;TC18HK?T(D.R[CW=
M10JA]:(3->M!?#PS">Z7Q&TNB1EZTWRG.C4UE%W#K1AM*=A\TS<@<AH4N=!7
MOY^K.^N;:CZT7Y1-Q WN04WVEZ0-*"UC:U&33T33EBD8\Q%'!8TVV\J8.^NH
MVK2:B- _D=MN>FP"*C3L:ZK"E +]B2+#AA"J\X!PA>NY[WL2< B (:*HH=5Z
M;@HD^*LKZC*[,Z&BLILS%PL366<RAWAHZP@BOX+ WF>*>)\O"=+)F/2:.OJ)
M:TKEB6+&M\OK)WY837T>U#$'NF:=!+<CRHR@E'C%>!*%JUFWL*B]*IM%#VL"
MN8%R- 7N'>/""B'22DF[1\;/K28\_ [EG$2 Z9,!'^X25$0J]^$T?U]SLQRP
MUFMA_>!E."<_0=A5)OER [!I$!<D ,RLER_#&41%(79*ZKPKH,O$3%R78(=G
M]VP6UJLV;Q:$K%VMJOE2!27#!NN:>V(= 81BC&(UV:)%*EFHS%3=;$(%:+58
M0P=AP,+5X$\-&_OT]+3?DD+$'<PKSX2N:!>EJ3^OF0G,"SPQZ!A6-;U)8A_*
MMBO#?;KZG*0WYR!F6= _VA <3<L%Z%X3*'"*"Z;^_3G;WW):=F&3A._W$#.F
MW:IX;0/X9$ 7MTU@23R[#"7EB==GS>S"?1KP&\U!,0CT<W51E5H+@7_-*L8X
M&J2G)9OV%&]O&'5_9K&" ;;0-#E+BU&')@A:8E%-F7W*\*C/*,+\@(Y>D#8=
MAQAA!BT'] .5Z/[!?+\(UWM'^._E4A0BGI[\>';PZ,$1^ERE9;E:EN-RTA!9
MDVUWM'&D%$&3YFHA4EO4<Q!_-&31N:/)9K7NW&$8XNFHZ?6>.XGT<"RX/RN,
M!8V0Y^$.FR.X;.CHZBH,L8=%07**0:G),<8=WC-N[J='J0;:>L6\<=/8$KW\
M?3U>)3MRYHX:(%880^HD)@7KZGUZMH:]LFX1RNMC4/\W$;;C7:]M5KFQ8$/"
M]>Q5,Y>S<O$QT/D[?'RR -?@)DU5N:Y!  YMQJT5!.TT3!33BZT/8B(%YY#F
MF]<K5>9)CF'SN3+:&L_A=1].SM,%$Z7T1Z 7  P(4^63=,52-.^OG60:2I$*
M.AR]"1NHFY:Q&6>+1/5J ZYU<E[+=^C6#-:9=.4Z2!)MO]_6U5 H1RQ1OPA*
M.!PA:Y+CJ=OP?[M+@-)%[F87SGPHX!FH2"/3!*1;9AU9O-(3'0C&8/1%" WF
M\=]?#C$?C+Y@A(E^YW#T:N!*R0^3 YKB@H9"KZ@1R$UF&J:%@1P+BGX@.KNZ
MK"33Q<W 6 <E45-2B]'@/@P+!$EYFLI^G7XXCJMC_YH6AG=-20S?HL;$4-?2
MZ71PD3;9^7A!U""@=23=*ON::A\IRQ:H6!INM652I)4#CILH8#P$A6$X'L-S
M[K##Q61=Y ,DPJB]]74?3-*)4 ZR,<C?G#8IU@Q85</G, !\$G [$K["+<WB
MP75*02D;@?M=2!*+Z3CA-6C#(>B^$&1YZ5OFW92X":PKFR6 */2L'YBK-WA"
M,Y']($P#>!C7G3$-IZN9NC&I9V/N6S+*G@% #B?M@96-IX7X&F*JW%I.?L=,
M+\@[E2AUE@Q"TQN%/5!!,G=H;.5H;(-?7QH'&?@"\VV3>+EECX"&C&;M8U6:
M#5[K\161?V<JEI*&BAH?Z:O4XD/)OY;$?TA#Q=I>KL"\*F)\?,'T:AS!(&1A
M@5!@ABP.&5^[ND@_EMOFE3U14F+YESEB^\AS0<D]V>4OM)4.9UET2Z61R\5[
M^\Z!VTQ#@ZZ7D.J3ZJ*ML)*((3,]%&FO9_3T>?YL7^BYU=H?*#)=\H*HENA<
M9Q5ZAUAQ/ ;_O2Y5SIZ5,%WG^KH;HCG;@UHBJ.7K/:CE#CS+'M3R+VBM0"LK
MMDK":\DN(R<;_,N4A3%*-9)IJLKQ)><(]V?,K4*1$LY.A<7"/0S7HYYKUJFQ
M69M"F4X%YS(6W>#>*7R=N$;W4WF;4[DFRO:J(Z)946RLNV[-Q1D?<^QGY39G
M9=DTB*C6"Y>)CQD.):?-XZH)(_Z2>%#<M7"U_0S>X@RF9/(NM<:L'?<A1_6$
MB*$YX4S5+TIG]TJ^?9V&<.)OV/"',V%)3>E,Q15%(3!"A5*P@?@6>B@#^<G#
MT0O*&22D9$BO#,JR]BBE)F% VTTN,"":YZ(>0%$2M&A]M:VK5N?E^)T7F!FH
MV-%CR]GGRFYAG.K.%\LD%54/Y9<2MK(M>LLT9L'U77-/+$8O9F8S#DLNTEIF
M127BF(VF&Z6E@V4SJ\<;;U6BHHHF:_,2=\YUN1'.QBQ5IDER8B36.2N[E6,\
M*[?(",HW"H,4#6;6K3DN0KW2M/IPN=N$"#)J*-FT-!U6Q_Z:Z]@#&)?1\YJ+
MJ(MFC96!1XVO/.$SEI2"S/,Q_L_P+UHPBL8U@1FG)8/R\\LGQP6]Q=GSGU^<
M'K]\RS--4F@'DQ*H'4H,SRO3#!^4B9XW$R ;@KTY8(FN47M9K>?A->KP?.WJ
MDA99I\GB%0,3<4U]KR'E&7#&0Z%H4543+@B IFM.NO%0_P/0P0&4)TT7:4=4
M32ZL2Z+?#JONGZ8H+7)OX;OCMB'!#'N?$MK)88Y^6H>[,-1 MA_F\CQLO,X)
MY&$(=5JLC$\?/)Q?X(&2 1X<P'*"/0Q_5P=SMHG#B;0YJEY#XTKT1FQF:%64
MY N7D[# 2[\BJ,JSX.P-:9:LUG,0Q-#;AROP7@X_O*S/P09K^)K(2QM6-V,9
M1%2*$0+\PM@-E.8CS$W^RKRCI2809K1DF;VPTJL98W<6"Y$%P B0 D>TS8GQ
M"M_^J5RLJ6GNX8.'#V7S)#ODBOL')FUUI?,3+&WU#F4[5Y%RJ)^;B)]3[FG9
M,8(CV,D6 [:!;!P%,65K2NAHJ[A _>"?-.2FD"Y=%2NBNO32Z3S$!+41N0%Y
M@3*^ *O3,=OP>-UU4;:&9B:8RY)+*M!U)/$D>K9>J4N&Q_:0%XA4&\+I5[&6
MF&(QUP[6S6H#2F)W'[R0DV%\J@/R;*3^RJ6*%ERF?6P&R;\I@LJ*0+Q#MA4:
MA]0?E%6??CVOJI7C,O4],=O*^]%<,HE?Y261;&/EV*JXL8Z^HC*48O"4,!:K
MAY2#PJ_7@M1Q(+@A$%YXP# TTTK^?J,=-0_.'!5Z(0 89I\4V&>T4,>2ST$U
MX>0@;%7A^"1AP'!U>C;%?W%53LTV 8,6@":7LPV9.R"JN&9841*B) >%3ANW
M->RX!<RWOFP:8PCF :&)@0^ZZN)5JL5DV81KXVFH@T6SXWU#]JPZ;]V  YDU
M(62DMP0>=D?K[:?CES^_&0FFK7 ?/?0?L8.F^@Y4<LDG2@>V&%$VN6.W:[9>
M7,A(1YT]1L^%:YR^//G^T;='1P]X*A=CZ*&,;6H^>K##'_1ULE(]M95XWM59
MV'OCDLB85^4Y'?YZ%@%54OHB!-=!235%[T7V%!T0*V7EQ@I5,8\;H H'?+ ,
M7$@'+W1V= %^(FRAE,#]H?> KJNWH0F*6%E>ES3>*V(8QM@-^QOC]8KHY\*<
M'1 4;]T=7(9G.!"@!8 <6Y D$5%] [1(8DP1QLESTU.Q)U;$B<KAG^#.#5XH
MJKID!1G#W59,/4\\_++;A$(2W6FS%) #4&#A>!O#R.+W'4-TF-_]QMA#(PUU
MS/84$,J4TTB3>3293@D#X^\6U44IW9/*.WHO^%6?4IA:)VO$<>XKG2R<<_@L
MS\CHO U&_QU'YZ"3UC@OS"!M&M&\C('U>8GS8@%X1_J+]TV(0LENP<N=1E@L
MW1@;3WB>>*+ VSS@>S(!NOGXZCA&WYXW6!_]#=QNF*=@$(/_3O*5P3/_4JE&
MW?M$OR!&AM,P&%CW>)6F[8,X>QS?(A'!Q_P  S@U 9%LD$**]8+, 1[^2MD0
M#KCHY8!*FX""&*(/-=.H(V=2*%"F["!#9?2V?D2&'S)X20 F]GP-CJT>'L%=
MIQ"/53]-8 $/U8MX39057R(X 6B_&7DHHR?NJH6^\)[;F\Z8.Q5^6L]@<(^&
MH@Q]JIO'X-\_/V9(9FPI&#;.78C<YH3609 P+MMQO:#P0?V_!;M#=':3UV/(
M-WH<(.0F!-46SU[C,WT"-E)IP(W#N+0P._-4F'_=SX+ ]\(Z71(479 :<</2
M/=SV]G^"F%:,NY!MB"]/PY'ZB)\BO (T5>(FFJIS&@\?)=+2'8P2ITV[*R1D
M<*+>QD7*E(\RLU,O6-YQPG'M:L7[CJR8,.I/TK#-"^XNQBQ^VX<'4X?\.+QG
MQ3Z3\<9$J00Z=L,1,88"F7AX8>/R*2>FD)LQ^C<72:_IK-8R7!KSP:S5_)"]
M[%=2E]-05F"@EE%T9\..\^^/!P/Y9@\#N0//<NLPD+OKV)VM5YT*)&9-"]?2
MMCL &6<@4APXAV,79$_62P@SD8_(0N(N8\%5"FEQLX8'G_8=KFF0068;5>4"
M6FJ&!(SO&B)$KKWS*1=(>O<0BFG.UUTL_'K<UN=VUF@V!\&@RL&[\U<4P]]>
M5FD:AZM_5HN58D0?:UO8F'+NB759VWH<!5 ]4P?5SEB[G-3N47"#.(YH1/!_
MZC/+ XGBN6HN^H*(ZXA RT-",&X=HX=4>N!A<@[>I D#36Y*!:Z/.)3GFRUS
M"K)Y:?4611]!9[N?DELP-.MRF<VGN:]D ;7YYCZTG?W(S"MCE@W"5)MNEI31
M6 V!T>=QA9%$-G(SV.[D*2554IVCO.]/J &D5VKTOG97N"[+D-#&]WI<[T%$
M?;H0)Y(;,PIK89E5P;%C%ZA7+1U''9CJ0S5>XTLFX*W*3]-J@HX/AR\@GQ7Y
M1]>M815=KKC7#?0*-_B^JFY$3:D7J!(*3[R4B.4^EVY=*0_"X8B2[FUU*5U2
MO-XZ[0K!<_94/CA6K!:0Y?,E=_>D* Q68>=.8/MEZ5EG:Q$?-+&+O38,<%4A
M"R#5D..P3BF+-WH=#/RZ&KV:E:*8->585CLU+*_$.?^:KDBWX)1#^.ICW]]G
MJF:<*46TH$:?'[6F.3ZG@VYF.P09--)J1G&6];1P>PDWL#W9;E4?E'$A!-DS
M27X^X^(HYS_7%]2HQQ4UNNVI?B^\:B(-AA=]R&4 G02.0.W<M&'KN&]-7V5@
MS87A6507S:KFKOA:1;ZU58XR_0?XG( 3BXO@9?%Q$J<0#?Y0) NC3.%8.('"
MFJEC%=A&GZ;4VD+"F) ^\JK\@#NFDFT82,T\>L5KA%6Z^\*8T%E#P YV6?"D
MM@APO! ]/TJO(7Z%G\&]VU5\[\D(V*,'W\W+#_5\/:?[MGPI_.'H.[?%9N65
M"HJMRG<,!*%[ZJ3+H].$8ZW9;+_%+:]P ;@A+<VKY*";]>J@F1XLFS%Y:&%+
MDOO"HG=L5T/TR!-CPWY>+2K*N*/!BR^_;<W8PM!9#79IOHRM>]V</*WS.DS-
M6-H^DMGPN_QT,=ZL*EUR?"'M$033 ]P9'5LD',1FAF7[#9]4Z%2F\RF$Y ?*
M^0/;$,>9ANI5V:Y&3^1-@W7X1?,@E*SRC9 >TN,[6F)5%K&S+D-C:L#N-8%"
M-7^2$0K/M,1?RSEGO"A9Y?TJ?+O8<FF]&)_9:?V!9U[MN Q98KO-Z&A"'E+B
MRUDXSAE/)7E,H:J0C8N5ETD?EI"1;"\JS735CDLJK!-[Y4:!&LZ(=U7OL)$+
MAB]Q", X;AC$PFP^CD3F?Y^F)CY[V<@X=R.JN<@ASU//Y\IBHY@BPW[$-WR3
M3+&^GCA,9*XF]F&N(Z<;-/7=6^6UIWU$<['@LL6$[(R2LR!1M6&,M*==D)FW
M.?/@)Y>VW\X)8N7DJ?PB;VKGD9#&9H>!&B1\,-X&U74L$MGDI  C99G[XM?%
M["K;$W*^4#X$>,<\@-S1JRA'+AV8**E26^L@G8,4V%'H0AF9*0C885]2J;T>
M6X#,Z4H:8'90O$%+'H&*;K7TY?("1J)2(W*49!AR)SOD>#(G0<U5:T6@6:F4
M2?US1@Q)+V(M='5B28&#RYP/BTIP!C17BZN2B.U(5!1\RGT3Q3+2WBXE')4:
M^"IX+*H$[PI4=@<C;ZAR/>4$0YSR]Q7/>;.X:,"*(0Y2"/0OZ/E5HHL"\#HW
M&[P<6)U:?TB?H0#@?92B%P=(*!9GAJ964);K6=5)PA[N:T&.,R%:U28NR-LZ
MA\/#.+(V[ 2J0RVXTNX76J$6Q\UNH7&E<P.UUIV:.C;G*!Z+6]A;,5S"U=[L
M#@='O.Z!I=?UB(=MYCWP!;$M@$KFT>,'W^O'7YJ_ #)U+I2M:+MH0+M)R!0+
MH6:@]=?&XY=]$5 O]K=FPE:7I#!XJ>&*R"@ZCYBOJ \7AK!JH25,Y([A+825
ME:TZ;J#I#Y4IE=.9.Z:3?GQ6CH=C>J7[PWP; CQAAT4_@#<.BD3JT64WB\DG
M3%J>&?"SF*4)N,W=Y"W=&L$\-#,0B'%X%>MPESNR%E&VD^WKI%F*E1OFP!EZ
M&QQ%8@XL2G7CF5U4#\'\1,=^:>N+!JWX1J4;Q@)( MF6L2IW0V/&6;IX+DOE
M/7=%3C-?J&_Y((P=6^.:UH@XZ$Q@?[250!K@86BB\T33O%6 AJX7G9+04$*"
M:8&+],#?#J+PSKX@[%0LT6*W&0VZU\8FMR)S,,1">HZA'K>F,F#NO'#8"F&)
MS^" (U:&UTXD-U16XW,:\4]KVICB#IHS"S13ZM=%TFLY*-4XWHQ@V3NAXHEM
M\T&-9$;JP<IOD<88\0+ZU!*&6+JOU#A+OW 515-5.]:<M_N "'W+*?<NA/!D
M:;<KSOLEBUP.A&?KL25U%MZ.G:\GI,VWW0"%.:ZN:#DQ 5^L\:H3%"V>-WBZ
MF//: ["5!C/1Y@?_D]2[2L1P10%7"4-Z$KCQQ07Z'3,%Z_!G/EF& IA!KXN_
M'L94N,ANR#S\QRL1?[LO$=^!9]F7B,U6QEPR: N9TY*/&''FY)!)N/\=W-/J
M%\&PM>(X,M@$7*P13FX!K2] Y3&873@R0VK$"RB7-H01KY6/=9FQS0C&Q$>!
M,(8$6AKIVE&G][8[N<++P%\UTW$X.B8R+>J;V_K&0I7)R5JUX/YQ%4DZ6J[/
M9V$D)# G1THYW=IJN=;62$TH:2&>V:PHB&#': [<W[4TG;V<#'XN2M:&K;V7
MB1K"@J&F +<\7#Z8V$D2?0QS.V+%M!?E0C ,GK*.1UJB&VZ7]\E:2N&O.=*C
M!;\.?FS)W57^MB8H)2D"]?PB3^J.DF%,Y*!?!*Z!OS@GGENN7D1A#^?3('N*
ME:2U/?%=9C.W=/EX=S$M7)-_5&._4V*\<DQ!U<!?M.3./8E,@KQ>6%9* 7KB
MBVL$8\2UL2\NCX78O8T/<$(OJA/#I+8K )B%%YFK;(G#KNGJS%7W7@YB""+*
M+0;RL$J :'SF,4?ELJU,RV87=51S#O-+TW1@/4;:"+LUN' 722) UUA!J0;E
MH:1>,%I9N5Q9:>%^^/EY"(Z$PCVAK-40A)9'5K:U)VQROS'-!O& Z6@1E) Q
MP9K/#S_W^25.WXM-O'GV_AZ8,(EBJ.F%#AF-$L*>4HM 69)"-SS2@%8[[5=
M4 YE]4+,D-43V/%/S1('%F$$I"EEQ^0D$Y]TKPYE+'(P+-M0GPT8PII<6W(H
M8GPDO.P]9$L$UU[[5;-;5G(>AZ41_"+NF,>:;1'Q;V\@U)OY.A?P7^62(#U<
M=^W*N2'4EDO6H]#.$^["&=;F&.Q@C&U?\H+Q\</J#-X)0:M@/II-.>/N"QX
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M6%%P]S%FQ!ZZ8O6/BG9'V "7]5)I0F:S8.77W$T5E@,UCPF@.H:QGJ&RH?0
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MJ^LY.'0T4\Z)DP&C0B&Q0%B$$PZ0H4F>$C=F(NGW-!1KEG/W4-9M&?/X-L*
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M?7'2($OHX /'E%WG[_WM</0],;Z%4^!8LG8*@J";A0B9_R@$]@?CQE*.-+G
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MMZG3*IS[G= .N21&@M)2IS,7X>6:WF 4P]4WF!TY;3RNHQ^OJPUNTF:GPKZ
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MHZ(*0]QHPU[57179MB-C G(1BXO&T;=[7<+>]#!-4VHNVV1S :@K'$#TD+L
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ML@[N4$$+@Z(^A"YS_*=O5BVDUB%T\?-YK<XC_0"^@MQE*\M9;$I-VHA,2Z5
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M.\T'4@U0&F0[*Y["KW6T7O'/B* _AOJKEW;LBZJEAPS(QH[I2CGCF/WU1.F
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MJ1S8PNXH9B1NX $C<3]DAS1I0D5(GX<HEW2)+%P89)UV5LYP-FSX/<2<.6-
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MP%P7+LT<'>,3(D>;[O:+51EL/V&WO;<<Z'[;[!2]G*=%UEG6,RK%,O.Y]I4
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MVX9C-]%<N_6 1S?8Z:#VD0Z%@NIS9[.2!XTOG[[D?=@WX*RH2CZ#=95)X_M
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M<Z2R5MMRA4,9I00'4(F7DA/I63B.O@<$X(P*."=H\YHI$4W=0'I8[%'=D35
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M=V]OVO?MATYW]%NW.QZ9T6. HR6I)9@9B8J$,4MK3"<-ZL2H3@1[XBI5QP-
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M@^N6*Z /,JOO2JA+2Z"M]=7R)*R$F)=;?]Z%"1Z4JZ!ER;CSLD .DAYV<D'
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MNF7TM_Z\_B^&.?[C;_\/4$L#!!0    ( ,. 855W&0OBJHX  !=]!@ 5
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MF 20RZ*DL);S;1MU=^&_8?L=".$!+@(?G\BJ=^\D9%VK4A&P\DG6&F1PW"O
M: VB3-PT[U&XGJ3?KA$VP6Z ].@J];4;]@&G9R?)V))8B>"LKH%WI,"/+!]X
M]-(&H7-L3KYQ7XICMY0-=#X$4]#5W#],0[72&X8\ODCPO_R@YE/.9Q?95MDK
M#)+V]6""!,6R!*?)DD/M!,Z4*#YVRCY;RT7N(>C6BKFW9D'#X[7KE,?E3!^(
M%1<Y0"PFR504@)P;\BE%H+F0'KF3SGFN,S.M;6^%*#LK 1_>!B;ML1C ::)9
MCF<%I]>'6[4?\(.G#!_HD;.'/UI217>8RT"EY2WGL9N*]"8&,MDS=/?=8A,+
MWFJ:D[&Y-KK4%&=;YT%;1.0N22];\[_LOZ4^43"_]X;:!]36=Y?/)]//DRF%
MRS217R9?<#JNDMT.;Y8=*V+V19D,VM?+ YLH>$$4H'EVV03FG+EC>RNN2[J/
MN?W 8'? 3H9'I>%Y6[UG>A?&'R^2M*.,(<EHP/#*&%V+2IW+ 4K2*MJH4KR;
MG;=6JOK5@,?OAJVOWX;G!E="+*]S.XC1L![EQM#;KT!94_EWX=M <XT+36Z*
M(Z7QS@E'"Y.OA7;>0M"Q &+0RABI4)I# /"18I*V^/516&/<_D&:.CL_NS(D
MK;*6'$QAM*447@D 9:E];A+:I",++;JMW1ITN]D+:ZM]TD)GC;?(?X0_;@K"
M<D%6\RTJI:U2B8/SFKX-A7FAT/O0Z9KY*?!N#GJ X*VMLY5OWO;R2B[V_3,,
ML_,IYLDX3*N'4#F^8YB--F&C:#/PT+DEZ\S_3G:))\<XD%^D=,DJ:1]S]EIF
M'5$'SAU[*KNDHP@;'E4N9;@8C;R_5Z,01Z>7KOG%V&_&[Y9#TR^\GHRO)*EM
MP6\<#QO)K7)U<?(8Z#]:0G0V@X@N.)LDLN8-MYM.8&.2MS#[5#/+Z)]*6/,E
MG%8@KT3\:32KQ] DT4FT5I<D5.W!1KYT$ (B6@<B>2FBRH'[UO62G87;?K2Z
M.RN\1R8W"(+;3Q#9-/V%YY =S0^X+PB*1P6.?D+1.6U[2F9286M^F&-+A=H?
MH]XC6QG@8/K59/RQWD>_''_!RW8.)S*03RPH5D)>&XZ(HL [C2#)DRNT_YI4
M6G-K/B#&MVQSFZ(R0-K(A4X>6LMM8%PG5)5"COZ#PM>D;_+04]))*IXHM&IL
M+BN%^9:-I@U" ^2:M%#1Q2&J#P%=# 6*]VK1^PBB#@Q\%BH$9[C*^^@B;S4G
M97\,<C>X[TT>RW+V/WZ]G&M]ZL]3_.]SI'!Z<2HI%',Z" 3&626WR1R\T0:L
M]UES<@"B:KUT=A!K5Q<K.[*755;;"+<!G+8K$1\2\/+:L8N( Z6U=!!O1]DJ
MK:%=93J-<=F1"86DM)*J=KM*M1Z4:XC,.*A-AJRC3R2VC@-V9CI/I8_L@>7T
M@6-+%C.[6HLO#^IYT*BL(LE,3K76EYS,'!Q$)9--B?3C6G?KZ2+7#L."5H!V
M,)B-T!C@E.W&2W/UY?\<X90&^?3U%7[!TXL4+!ZS,HS4(!?]])B"@/0:><N=
M+R5$V;R=63?)_O2#&J,WP+'$@^_!?7F7V: =A-VB4[12T)V[1\T0[[)L-85K
M6SO?2J&#E&B4(RF+#I=5'H;68$>K>F1HM=#-ZQ1V;UO=_:?],*T^* UI4B_'
MG\_GLX4&^#)EPB@3$JW205=^N*(%K==!$>SD$;BBK%"#N=WWQ=D/UZD1D*M,
M9D,4AO2=;H@FEL2I-+5, M"*CI7G45N(GC002HZ\$I_K--@*<U^<;\U UD%A
M2RN(7(H6+4:;*!*M\JG*O!!9)$E9D27Q9'@>S*.^+\ZW9B#KH#"D9WSKR&(1
M'"SV6IJ><,$J\#I5&JC(:,:Y@ Y!H5:9#WBZ\[!(?\9;K? :X!+O;<US("SF
M5W(^<--X:?E=1!THS.HAYLZ#K,UAOLN!/S!&0VYCUP+6B\=G9Y/SZQ(J(8-*
M(BDPQ<J:L4UK-2.'S"5CLS.)>=>Z55(7N78=236WG^9@#-$YHY>-4P09B@#:
MSBF<#%J"EYR!S4)JEK)+%H]C_>GI%S7#=Z,%J#LX P18+V;ST5F8XYO20586
MG#.%2\@!R94KT8&30H+,P4=EN.:J-=U2'_EVP+<^%-!WNY$/A=(>5(G<<#)W
M4"K29_2AZT76UL1=2E(R*$UAE7;6*EK&O)%9LA)%+D;$\B0E:1\Y=I\2]^JZ
M96(JBI /D# [4'6[]TYPLGZ6E<Q.N]B:OVNO*D=^/)_1HV:SYY.S2+!6ZZS\
MQ#0.H4I?S4;TAH<+H[T0\NN)8]*QVATEEDRA6O09G-,&0LC>6>4X+1>-=;:&
MF(>>S]K',N^N_4.C.L2I[7)1N:&S!Q-R%4-C::<B1ZOVI34(P9I 6R+ZQ**T
M/#=/D^@FVK=L<$.@-V3(O/%Q%=.,!<83*<OKVFK75_(;!5$;'XL)TL76;NTW
MGDZ]D7GN!/=#2J?V23EOF0)+$R3MA@B^YN*54(JT-BI66K>G_R;2J7O9RQKI
MU'UPVU$N;!<1_TRGWA#:-9)BU\%E1R9$<2EF0;*%7"^,F7(0/.T"PK" .=CD
M<!NYL8>23CVTY?2!8U?IU(%E%G-R(%$%4!9)6L5(4.9*4BP9)@>[^#BX=.I>
M@*Z33MT'C=VE4ROGE$$9@,M8* 3FEO9IA>"*YP)MS-$,6%-VU.G4C?R@5NCM
M/)VZB[!_IE.W1'RCG-=UX-IY.K6I3<44UR#0)U#U/B?*J$':8()Q(?BRE2WP
M$-.IMV=:?5#:=CJUMD98PX!IB:!"D.!%[;E-^S>ZQ=50ZR2  TZG[@5DGW3J
M'BAL.9U:N<!=J;S)K"8\R%3 D1\)R;CBLB&/$@=SF XOG;JU@:R#PI;3J;/E
M6++FD'6H?5LH O 44("O3(3%FJ!L)Z+<;R.=NK6!K(/"#M*I.0682GD%S"1+
M"UR.$!-**!DI-& N\M#Z/OGHTZG;GSNOA]>.TZF[B/IG.G4#F#?(9EP'HUVE
M4WL=PZ(=JV>R)N2Q @$UA07DFTF'4<HPV#79H:53;V(_S<'8<3IUTAA59+0)
M\'HB[YT )W@$%,@">6Q>Z=9I9H>?3MT+WPT6H#[@[#J=FD)!YVLIG#9!@,JR
M5!?1 6?9EF!8<K9UZ=GQI%/W GJ3=.H^*.U#.O4B6#B]=C4'S)U>-=3@B=*=
MYG@G*SHA8X7%)$K.JLC@;' E9L-BL+02Z2>SHE<-NOLTME=7B56*,1,\#Q"Q
M)GZF+"":VG3+.RNUI%U:[2,SZ*M6*=!7PCPNPV+07\>3.,/IEQIC+0)M^GA"
MJ!/$BR3;<)IJ\W3Z\MWD]/3GR?3W,,TG%'E932L,L"AI.=#6@J-(?W'[B5(D
MD<Q@YZA#3>K0LUW[6/U*[W0O+&;(,]\;COT_1_-/]R8SNSV;V;L[VKY,+E\\
MZ\06;I/SM5>D232I@!",<5!J[3>MJ<*;3NU[-KR/VG@B.S3]_3"X#O==V[66
MUET]N]=//)M.:\NFQ6[__%/]\N7X(HIY4YXJN;CUTQ=A.L9\8B+J%$6N# @.
M%'(!GGL.A64NHH\IWO7O5S0)W=D4_GP[#LZ0MI0-TV5-6+$D_$)V4'M^O!S7
M-B&U/4B=)OW:["2@-B[X"(([69DZ(SC)/3"D4,LGG;4<K!)CZ,G]^2X=@E4-
MV?>AZ98JDY4V&086$ZT),7!2O>$0LV/"25L)F_;D5>GA@.VR#(PGRWEP&K1,
ML2;.)G UBM"*)XG)<-/\..X;+P-K$K=M%?<]+ -[-/.-Y2R"$9 3IZD)4:D@
MB@<MC"E1<)[;%]A^(TG0O:QFS23H'NCM/$&UB[!_)D&W1'RS).@UX-J]C:6@
M)6H-SIG*-4K>G/,4$;&LC%&Q1#/<C?W!)T%OS[1ZH+3E%,;BK48I:PD=N<HJ
MD%2>M "(EON GA;UP:Y'#B^%L1>0/5(8^Z P; '9P]2!B1OI=0'+,DV[> ;1
M)@_)6J4<M\6F 1MQ'&<*8R-O:6.\!C@=Z\4!UT'4/U,8&\"\"2'C&ACM+(41
MG2H400-+E5L[9 -1TS+-0E#19JXRVC]3&#>WG^9@[#B%46N3$@L)M$^UV[9#
MB#EX,-(D<A216=:ZFO (4AC[X+O! M0'G%VG,**VP8=B0>3:[$\F1R]5T>"1
M,RF*0V=:.]3'D\+8"^A-4AC[H+0'*8ROP[1>?W[!X5(7[PTQ=,KBXW.ZDZJH
M?#8F.EI20MV;:,W1QM$:8XV0-5Y_*E7QWF"[OV*Y/O3GS/B<E0<> UD]&@N!
M4(.H G?"RIS-8#[++E,4%SD$=\+BYV'VZ>?3R>^SY>N<W^)T-,DG5FA$Z6J/
M2F: 8NT",4B*ET@]+-,^Q) ]]0KT&?#0,P#[&-6MI(XA !E@4UZ#!/:&$[R8
MVXF7.27!,SBN+:AL-3C+:I>?E&-6*5O1NL"[@=C?HF7N"O7C2;VS-M?>P0&*
M$H5FK35Y/%&!3R[8Z(36=VO5_TR]V[W='Y#1#)EFM_%IJ^(HG%/TNB=.$W$Q
M0HP8(;"8<Y*IID#MH8MUP)DLFZSRN\%]7S)9EJ_[L_3?YZ/9!=3UN"Y*EH)U
M'@IR7R^)# 2I/5@I,*82,.;6J: K1#G\VY=>=K'"!]D$GP%..Q\2JWXY1;P\
MKNLBX$!W+4\*MYL;EB90=C"/S7'8B<%@YI["/ 4Y>0&*6W*210Q@7$K&19^M
M;[UK[LA0GKA)V8V=]%%_ZT#EV704\MM/87H6$I[/1RF<SI;7@<IHS";0BKE@
MOM!(7W%3N00Q<EN\B*E3)+%ZC.V[^HW1F+17Y;!Y']=AP&F873*<,)MMT G<
M@J^K& >QIJ?X8)@U0:!,@QU+/B30M^UUM,-JR$!M\[J:N]-;<GAWF.#0R;1#
M36[GV26;&M1P!>0-K6'(C)3!)EI['21I(V@7&"@9#-0V4A"R#HJTP$(>+#WS
ML,R]>R[,P5E['R,8P,IOG*0OG):HBY#,T;9EL#+VZ@B^]E2(T6:71<D)6^><
MWQ'AH M'6X \:8?0 &[EW1N7#_1W%PEG2%/*7$/$$$%IIR"JF("5I(6ISJYJ
M?=^V2I9OVYEL@M  A<$/R77Y?G21;" '<+54N_'<VJ#7P20V4/T ^] C$BI=
MC$=KP5 83@N>JG00*4**MO*K>!-EZT+E;1O%$_[-MFVBC\:W8 LUP:]><[X+
M\V6*GTHQ2><DY'K#KSAY=Z'6U'BKN<K,V\#*P#9Q7ZKM>RZM,'S"-#8$8(@$
MH7 :Q@G??T*<OZJ_O3RT1:FC4]Y!XI'D\A[!U>8G67KE>?0\A-8\$:MD^;:]
MD"8(W;<<-83E+ ^!.T@VU!7:2JEV='?6!+T.)K&!ZH>X-5LMH8Z\MIF7P&ST
MH# 9\%'6+A<UUUR;4GSKP'C;1O'4/=F6;:*/QIO?D*4T/<=,2^.;^2></J>E
MD3;#NZ$XK8%>&^Z 9T.+I)(>HJ@[8<B5(S[SQ.]L-JLNR[H,MX-[LT;@3 ;5
M[$KWHF$)Q_,)Z6$\O\B?FTW*<]I"1_-WH]EO89POY_#BC\^8YI@O/JOD7!NQ
M46\ZY,8E'DWG?*?DPVG.N6"YJ%14\<I9<E<-1JTY?:3P9-/!-]L';HU>!WUU
ME?J62$H6BX22"J.02W((%&4!#TH;%CS#T+I<?K4TF^YW]Y[\EMQ,^D'XB/Q$
M&<4%!@_"A%0;=!4(FF7P);N,B7DEW- SO2'/]I>_1E9P=\MKIO0!XJIGIZ>3
MW^N:__-D^M/D/,[+^2FMV(NZ4 H8<+0X^#[1UD=/ZSPDS6MP&1RX5 ENE64N
M6U-R\^Z*W20[&B,9 (@!_.5[D[^(&T54,B<A(<1Z]F"+@,@HC&0F8E(I.\,&
M7SFVFEV]K96BOWKW)>_YWE1^_/HCCM.GLS#][8*P*:24-7)(*M8^[F33$8NF
MF858$CIG;6ONOJ=DVM4!3@O8G[*D3=2_C87D2KKE<68'^08ZFWE*MMV<T+1%
M]$ES:0#'+LR&18E!UBORK#.MOI$B5,$""(5:L2Q+-JV;N.[&7)XXN]FMM?1!
M80 K>1].D9RF+S@^Q[?323Y/\[H_+VDI, G,7 ":1#,W0D&P60(I(XMD;<FA
M==["HP+M@0N[$7Z3H90_1+ASSZ->MELS-EA/]I\XD_7FPU8N0 1GG+'2!&:;
MKQNK9#DR>VBB\JUL)5^OKME9X=YHZ4&*2N<7!%Z4.VJ?0RY<>I5;WS8_(LYQ
MNZ5K*7V K/?[L[V^6^\BVK:<T5WG*S6#\,G8=S/];^7TXUK$6%#Q;!T89EFM
MD%;D3Z4 &+2VW!F/S1O#;]TT^ON<@UM&'[4/81'GL_GD#*?W1%PRDPED+)L"
MH2@#JJ9J>6<])!U]YI9YDKBU53PNTAYX%^O"=]<L&NI^ %?SXI)JE7"*=DGK
MZDQ3X*!$31#W%(UQ'E!I7DQJ7O[_J$!'9!;-]-YPO9A-YR?_"/]G,ET:[46E
M2HHH(K<<'#):%:5WX%SE2I0ERDQ.-P5)7:R 'G_# NB[:_0?'OD(7,H&*FV8
M\UZE>1W.\$VY)=.E/7<1JH__^ 3>*P79KL?8 J')4.IM_'(_)EQP4F !"G55
MO0^B%2<P U*5Z(V,E9SY\#!?X0IN$?+N6FV=*_9\<DH_FEPL8F_#=#ZF>88?
MGS\;YY\NMQD2)==L?/(X8@%E/&U@(7$0+G"ML_2BW.':6)$H]O18V]NY&R(R
M&4Z=#5VY"_$NI_GL4A;K+;KD!+!4#\Z51/!82=5\%M89<B1,[@;M[0<?/HX;
M**KY*WHIRX]+:@YI;1 V@$V*EIV8##B9.<4"@F>9/=>%]P+MQR,#;1U%-3R$
MNR7+\^5= :,H@-%>(86E (Z'#,[6]S\QSXL(+L=^;]KS(P-M'44U]'EOR;)<
MJM&F%*64M+=7/M98#WJT0^":&\:LP62[I4C?>?#1@+:.HAJ6Q=R2Y<6E+%Y1
M5"PU+=7:5/;GZ,$+4<#EP&51#*VPO4![<62@K:.H^Z#IS4H4/GZ<XL<PQUM!
M])6CO3S@8"2'R!&,19(00P+RKQ7H&++FO'B.3V:B=Q_NX %NK]3[L)OFU0DO
MQU](ULGTZP;E!O>>L7']P.-2W2D(L))QXUQ(,F?%/',B6R:L35J%8F(XN?>T
M#7-"Y@3RV:+R9)FI6<C1T:%(H)=7@&+)@5?:$,BEE""3],W;;=Z78M-CYBLU
MO0N__X,>/AV%T]EKG+\I[[#REN#L)%.8G8JW8"NYH4J<U^B;?(2H52I,.Y-:
ME\@^+=7V#YPWM("[Y\R-%3_ #<25A/^<3'][.7X[G22<W1'1D%N?*7JF^,S)
MR]8Y7GJP/G F%+G]KG7F=@>QCL<X&JE^@*O+*Q%_)N7./F'^93+)=T04QGN;
MA*; (JC:UA+!^23!!B,D:425U#I'NX-8QV,=C53?.A"_DH]$NBR]N^ ,2!??
MG'C.4LDI@4\JT<*6&#@1-'B9LJT'=59U"_*>&NE@H6ZOQP$(FF[*=\*3L4I'
M!9@N@M)(4O$,R261"^>NF,%V AK_8)'>6)D#<%Y<RW)M:R%PFVAK 5ZY6U24
M!4+E*788,W=1!B9:9QP\(,81P;R>:EN?"ER[H9CJ _.S6=U#:(!/]0*E]B6?
M?#Z[+)X>S_!$^V1TJJE7Q9*P%,R"9R0[*<0P9NIA?3?"[[XC'RSTP^MYY9G!
MFD9QT=3M32&Q+F@J?R;=//N"T_ 1GT]FY&<L/([WD]-\$M%S[:.&C#4-FUE#
M\0F+4 ICB,8EZ;J=LO<8]+!-82CMWK<"VVPCN'0_+M)M8I0JQ(PUB;]FWC-.
M7XD,TE"TFIUDPK8^^'A0D&U5ZPZU!:RMU%T7Z=;#U'>UH=@B.\,'8XWV'GQT
MEG3!(P3O.!26ZQ&=< 8[T5(_D:%R->"NDL\:X#;95'^-TXX60BSO)CJ(T3#)
M[,;0VT\K6U/Y=^';0',# ADL!?I%9XA,T]I4:MZ4H@6*6:T5.L=HUS@$ !_)
M$6N+7Q^%-4_J_6-T=GZV-*0LM<G*@!8BUBZZB^:*M>B!%[UHH&<ZG;0_F<][
M8]#M7L&MK?9)"YUM@_GKU2A5__W9QRE>M-Y\/?D2IO/1)M1>3SYSX[NW?E+?
MN8OCFOG$).=1666<=MGJS'*,)1D32SQY\NF;>:GO\'31BIH>^?7#-(QG(5W.
M_]);<T8@][J D=*#\B'4JF$'I9Z?H1,^V4YY\CT<UJ=DVB@^NZO/7S_36S:>
MOPU?SR[."%^>G6$>5?;=T2G.YI,Q7G[V8?(C7E328C[)IHB"0D,2AD),CZQ>
M2PO03'J>,J>UM3QEF@WEV7Y4U]1P;L5X.T"H=>+JW2E<M ZNQQ<?QZ-_+1@9
MEW+^/)D^2Y]&^&7QBV_*VRDNX,-\-;N3S&E1,#* E3Z#,LH"+0T!'&DV6J:\
ML-T22]K*=<Q&MT7$6B?@7E/<O2GO)E_#Z?QK)1._?$=F)]PJ%ARW@+[&WUI)
M",G4!)N2'**O*=U=3YT>&^B8S*.E3@<HH'\Y3E,,,_P)+_Y].;X0<H0S$G$1
M:S/OL^5*@>+15(O4%&O[ .3J&XFHE,BMN32?ENI(3&0@&%KG"]\3)D=% 8 -
M((,DB4J(X&SR8*U4EA?,T8=.*\&1XKJYU@:X8+SD]ZD'W\\G-6LRS?\YFG^Z
M2I?](YV>Y]IJH%+TSC!_"'^<)"&LTVB@1,W)]#C%_#1MVI.$CXEI[ESKMBYK
MB'DD5K,MH!I>9UZ=UJ=/F,]/ZR;WL&9F/WZ]]<GBA:CNC^6B (\N@(JJ@$LR
M YK,DA/D[=C6_6W7$G1;=QZ#6M7P$.WZAF0YTTI*\*8\FT[KN=?")U^PF9BD
MA0X*0DD2E-*.G&KEP,1@G(E.1]4Z+^Y!079UD[(%_">M<1@@A?*&.+.+Q*YP
M_9.;VK@\ZNPB[D T4CU%W0VU5 .0[Y+/;0&A/3"L8A+)YCPD(1,HX0KMV$*"
MQY"MUYRUYU+>"X-Z@I!J]_;4!YC61S#+,_IE92]FVM&YJL<_E?!59_".96!1
MF*"")(&ZY7W=?N[V_>5!,9BT46#KL]Q;9WU7)WP7YLPP<5<R"'+:0$E9LXEM
M!*X*#RG99*+LA.OJ,8[?S6BIY-;9^ ^+M61&["#8PRY%+RO8!7U04TR>QGD#
MA;9O1O:(@-JX+#0W$&U&4%I0=$ZB 1:F8\PH1>B6K[E]I%=LU[L!NH\>6P-\
M(UWX2JSE-H."R2RDA&1KB3D3J3+4U<Q$49N\*)^2[H3O(X-L;]-NC,-D "6V
MWJO?X<?ST_H+7^^)9;-+@02#R .YGEP8"%XQ<%R(F(TH:+O=>JT>XRB@;:3"
M]L1?9V?DO8S"Z>A?B\3O>](5XTT62H,-S)'O0=,F;[& M.1W2K*](CI2UCPU
MU%'@W%:AK1VO&PO,XN9]I4TZZ3)M1I7:JC)=U9NU8(.&8I-.CD6CK.F[9#\Z
MXE& /XAZ&U-Z7C:P>#-]C],OHW29LEJPY(((TC /RE*4X9PB!6AT445NHNO4
M'>")+,^'QC[^2*R)UH>Q@GK:<"G1[-+XNPC5,.=^I2#;S\#?'*/[@#=2<.,4
M[]7")=J3@N<>+#)6^V 7\)I%8(6%DE F=Y>@[A!0?R1M?TN@]]'K *?OE[E5
MRRQWI/EY'R!&487A%KPH%$HHKXU/&?$N=>3F:0LW!=AN?G\C4.YF(:RMT=;!
M&6U,4TSSL(P3"R\^Q<JM4<^&;4H0<KT:"%EQXRENE-UX06\_=P=)).MK>-)&
M/:V#K;^'W\*7T?)>3E1GDL( \@#%A2!1"P=(L8#+6BF*$3KA=/.I!XO2VJII
M'2']_=E_/OOYY=7]"$]1: $E\NJF2[(3Y244YR/G*F'(W2Z8;C[UD%>_S534
M^GVZ/E,=YV4JV&5VV!7+H;<L)=JY2Z*-O*3:=2/7S/'H35'9\]+M=.K)H0X>
MU;;*;/U:?GCVX[L7SS\\>_ONS4^_TK^O?WK_XMU_O7S^XOVE<+Q$$U1M>T(N
M6KW*E.!5MA2="<EM-+EPWVW;>V*D@P>ZJ2H;AZ771;2.AM*E<-H#4),0&2$4
MYB!Q-$6B\")W2JW=]PK^[1Y#K*??AMG6=PMNNXAQ?!7^O92_HD)\'<T-6.'/
M>>6]I95(ZEJ%(9. 6!TWH[VV2L4<?8N>,/M1X=\"OSX*:UWA3YJZKE97R:&T
M68!V2&N)\XDV$A& %A)'$9'*+G9BR7NJPO_FH+NK\.^E]DD+G36,]^]3#2AA
M6.TZ A18U;W:D/NMN:.85ODH<BR.M3BXWQ-ZAK7!6UMGC=^\*]JF7W#R<1H^
M?QJE<'K1O!ZU2RE2Y,PMDG/M/'CCR-?.CCDM"R>_K@&0*P7X-OR?-OIO6"&T
M$.JBKN.F2)<^?A>A&GI'*P79OJ_4"*C)4%INO2ZL%$X(89119-K6RMHW-)&8
MNE22MVA-P21B/#SH'_&RMHE\'^4V1#Q5#H3IUY-?WY^@2X47&K*(N)B3 <>"
M!IT<!?&AF"0?(ZJ;8?K+Q\F7'RZ?>('PY3?7 %^/M]VMNY'B)QMI;8 N!*\G
MXU^7F1S"DLC1!]#:D#.!% 5$XSEP&S29I>%.MN;QN3'\(>.YJ397OI!#,F>]
M&IV>;M*BYO$'MN?,6BWO'<(L):Q@LC:BKLQE%,PFHY2I 6U,/(L'"+-N/7I@
MMBQ/+IX*G#Q]5>^58F10"V# 9<FCT4K<2T+\)MBR;$;GT3'(LIY#6*LA>.-!
M<"5Y,DQ'WNU^ZFC9LOH8SA!L67T0VG.V+..M-!$Y2$DAMV)%0O2UT8,@#>=B
M;.K(;W3T;%G-C&Z+B V1=+0&48>03FG)/016'8"<>:UR$)"%,ZZ4'*UNW;+C
M.!A5UK&Y;0&U&V8N6W+2HK9H9MZ#JLT-8P@9A!%)8E)!=F.N/79FKDTLIS$,
MK9FY[JVG.2^T'4[O;MJS$Y7(SY5<@=4QU)B2%DOM%AGZBJ/G+.=N1<<]!CT2
M:QA4UZT;!=^5\ZYT%WONVS#*)S*:[-%2&&N+K3WM:GE\)E^.:<D2LT+J;CDE
MW<<\9HMHI.F]X>?2MAY[8("L1+V-P@*NL C">^>*(6/FV'B#.6Q^KDUVFN$A
MVF]^+JM%+-PGR-'3&R)#S6!V%G11W!045LO65(-'P,_5"_]._%Q]<-@#&J4N
MXO[)S[41R!OR*:V#T!X8EA8ED. &&/..Q%:TEFNCP<C$)/G\7BISC :U%C_7
M-NVI#S"M$_)?G(X6MP)+49+WUD4!7B1R\V4VY-7%NM]'$T7BUH1N_O/MY^X_
M/U<O#"9M%-@XS>S!NDA'$PB.HC4G:ETD,@LD!HFGI416G,^ETTM_]&7BZ_@=
M3;3>\*CM\?*#+D)]0V7BO3#J5#&\CH*W5B:NF<A6I0BL7O4K7A>F1 N3, E3
MS-IXW2+;>\_+Q-N#WD>OK3?O-Z?G9Z,PGB^S9)VTR88(*(*[Z/<=A X@E&?"
M!FUUZ':W?/NY^U(^U4O3DS9J:GW!NQ3E=@VN%4A3HATGR-K]$Y,"+Z,&5@1W
M+B!3+/8";B]K]S?&;WVEM7[Q?OGR*2^KT[.W7G@&)DM15Y1$ M6,1Y6L8T@?
M.M8)N^MG'CQ@:ZIG.YRE%VR.(7&162W%K-EO.D>(CBM *11W-B>?-^&O_#;<
MWY9*;GV/^#B]:@?!CI6OM@\FW?EJUU#H5OEJ.9KLC:3-(M4&OUIS\"9K\"5:
MG4-*H8@]17I=OMI!@.ZCQVWRU?*(V0;#:(?AM%49@^ B?2M8L"5P&[CK=FYU
M('RUO7#HRE?;1XE;Y*L5VCA>6T8R0TZ[TC&"]\8!>7F,G#V#672C1SH,*LNU
MH6VDPAWPU2KN>1:%II@KFR[6%J%(TBF;5,G<D^O8">"#XJM=&^>V"FU\_'A=
M<6^TQ9Q-J)6ZBY;J!J(D<;3/+#$C1 EWLK.^)3J0=8^;U]/O@'0@7<0X/CJ0
M7LI?02>QCN8&I -)*3-;BJT4RB2.R@J""1HP2Q99O1YCZ1  [$0'T@*_/@IK
M30=RBQTA,A_)3!BP6K:B*GN?URD!*BR^:#1"=FIH?!B,$KW4OI)1HH_.&M_3
MKBZ7=DGH9,GC=E[;2F(K*DF-!2&3E=8%&4NG]J'?!J/$NEMH&_UOC5&BBU#?
M&J-$+Z Z\0JLH^6M,4JH+#(WBD/20H *]?Q<Z@Q2ZF)R<=FE%DD<A\ HT1[Y
M/LH=AE%"2H;>>0>FKF$*.8(+/E%T;EA,H?[WL;*G0V64Z*7X^XP2?;36> =_
M<3Z=?+[R1WSA*,@8:=/AH)BD:=0V,13?6R\+A>&R!=W+S3$/&<&-]#? ^_?W
MMR?".8.6&3 EZ4I-%<%+IL#;%'-$@ZD\1E70[_W[^]M#1F]-K0U03GJ3@T2+
M++@E)U J6Y-U7>4@B1$HD..^6!+2M,YLWD-&EW7PW%2;*Z]MAV1T>?81Q^>S
MEI0NMY_8GM/E$8GOD+JP;$LFV# KK2SM<,+1%U$YGFHAEKQ/ZG+[V0.SNC"O
MHTA2@(W14=AL!,1<<W"TCMEFDAO;%_L/R.KREH)44F+X6&//B_2B=S3:5=EK
MRB%6$G7PT=$BYQDYGDPXT )-TL'3?T.GJXDG!MK#(M(^4-^ZGVBITZ$)5C[@
M]&PT7MRBO)[,Z4,2?C3))SQ&;ID5X%UMW8E!@S?DF=@02V")([?KU1&O&/"8
M\!]"QZTO)?L4.OM$GJAQY)]R,E=-8@8A7>5EX4';R(MW:YG"0964-[.&1IIN
MG2O8APN!^<RL884\WT"1IW.)EK(2:F=H\H*]LZ5C,M%A\TXT,XE6NFZ=0_CV
M?)H^A1EM8_7*?3)^/Y^DWWXE9VVZ^&KY\=4\7H[??PI3G)V8Z*)7P0,J1T(S
MQLFD4P'G/4L4'ZD@NR7BKRO!,5G+5E!H>$&^U,B+_SX?U63U^:=)?CG^0G:]
ML/6/).='4M7SR6Q^DHOFW+  &IT'E4NIY2BQ4J-*J5C*F76ZN>OA3G<0ZTBL
M9R@@AF SJ1;[=DKKXDF./DAC%?E"E5?%8":#3;5817D*!0O3Z3%ZX;4H2JY&
M/S+DUU3K?8#-Q@"'>KNY6+!>GU>-T#>+5>KE;':.9)8WYGY"PBFFA0'C,-9F
M>@J<(8O,M>Z\,%=8Z'2BW,<$>LAW;$8R%#3WS<@V-*/GD_%L1$]=Q%5+BLDW
MMX25)7E9*7N*R.1/*^5)(8&#3,)GSK7@O/7NTDO XS6DQN#<MR2WJ26]FHP_
MUL#\>D.<G>3LH^'D8:=8>P0J3\;MA 1NLXU!A9RQ];KS@!A'9A6;*OH^]GX8
MS_3-[V.<SCZ-/E^?WYU0C.64L!;J*72=.(-H<J1--)(7C5[FYH2<G84[,CL9
M!I0'SLTV[J5P(>E[3.?34:4-_?G+Z]&OXRG6?'3,OY F7TUF-?RB^#S0+AE4
M953)@D,@5PNL5,J)$$K.P\0V3TEVE(;3%(X'K&9CMJKU<OQ*MDJ'(H#G8$ Y
M'8!">@.T6B:3?1*I.;GT81,V;N3 # [1?A,VNDRR6@H*$V,%E"P,'.H,EDEG
MO<["Y=;LH$= V-@+_TZ$C7UPV ->O2[B_DG8N!'(&Q+LK8/0'AA6EL6IF"@P
MY(P</41ZLWRP$(H.GG.KW5T^G^,PJ+4(&[=I3WV :4YSL$CW659L:\8=C^3%
M!69)D$@B.86 2>LB?<[R[OW!*EJ#&T_=?[+&7OJ?M%!>ZSR4AZ^NE@15&- R
M94 +&VIKM@!.J=J0**=@8E:9=R.G>6R4(T:YF7*W0U&R6+XD&5V*7H#3!D&1
M25(\K\FI\B5HQ8SEH5NKIF,A)%K'K6RIY.V045VF[G81[$@)B7IATIFG9AV%
M;I60R&5CDRVZ)D'6^E/.(;)Z_^P7%"S6N(ZT<0=#2#0,T'WT." AT37W"NUL
M3Q-TY&(MFMH'/50*2E4\1&45%,V]1V60RVZK_=HB[!,32B\,5Y 9#0C -FBZ
M=;(L&%$@T5L"*@7R2APYI#E8EKF77-L[!O&-TG2OXQ8TT7K#Y,(G6#<["/4-
MT73WPJ@;8_,:"MX:37?VRFN6/=1BGXL^!([E5!.ALQ J>88-^?KWE::[/>A]
M]-K:3[B4ZI?IY/SSF_&R[K78+$TL$5!7@L;:BCV*FMXL+7-%1W2V6_?"!Q^_
M+QS"O?0^::JTUF<V-R7Z\/MD24/-DE129K"FD#L1:4,*V3K '#%K&:+ )^L1
M5S_^J&!<3VFM63:NW(Z',R[N_Q3Q=3B[6)=L0*<M0[!:\-H52%TR9&H=:YN\
M[&4+3KM-9/PVW+FMH=B8.6^57)>O61?)&OI^CTNS \*?K:$Z&122QDO6$Q*R
MJ**DQ1F0F7J/@0)<*!80=62Y%);%8_05^VPLCU$$[:&M]$%BT'M!:QPFXVE"
MM2V&$KQ>AF8'(H>L:</&;#J>+N[D7K"UJE=> ?;14^-CH&LN2A3"&&[(B<VU
M]BAX!9YC3>H,0HBLB\J=DFR/DRAW70]A/?TV9O6[R5O918SC(\KMI?P51*OK
M:&Y HMP0A$Y2<[#6I]H36T+4G@.*Y+Q1HJ2[A #["6 GHMP6^/516&NB7-+4
M->DK<\:E6.<A=&4,-9FB6%X@":>Q>).LZ93@^111[LU!=T>4VTOMDQ8Z:[Q%
MWF;LS2FC16$ ):]7-CI5WE\/-,<2F&2"W\V*.626X[7!6UMG*]^\(:F\_H'3
MMDQ>MQ[8GLAKM;QW>+R,Y 078X(Y5,$%YT5,02G.M O1/<#C=>O1 ]-X)=0&
M([W/WE$0I"H/DU/T9F<3<BS"A&!:9Y8.2N-UCV3FXBU8UO.^)& ^5W3&\[?3
MRIM'*O"Z.)V=K+.G5R/:VN#;^+K/:<6#3;ET"Y'ZC[V'!4A]#.)Q>I^VFA^:
M_VLIYS4%S=LI)OK3!:_B:)8F7W#Z]4ITPYW0HM33@BHZK9X06;V(*$H8]#R)
MV*U1YV9R'+,!#8A(ZR.7I:A+81:D-/_\-$J?WN&,8I'1^./5C<H4GT]^/J\;
MQ,^3Z8V\E1-FG2@N,5BTHUA,($09H##4B26GK>E&+]9"FF,RK*VCTSIC]+KD
MMXI&XKX95ZZ:-^.WD]EL%$_QQ2DNE%69D?*UT NBI,\3^AM::[U@DBP%4K"F
ME@-*"#(KB*E>W%EO6,==KH$PQV1<V\:F-;59+PJVJ K/M5-Z+AJ4U12*%*6
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M^!2EZL8%?"RD%NMXHBV5W#JOX-$2X"Z"'2FI12],.G,=K*/0K9):Q,R"4;J
ML['4NV<#CB4&L?)(%E]$#$]FOAX6J<4P0/?1XX"D%M>4"[2S/5V77]L/9E4\
MF.(5*)HY!&T$Z&PY1A:<+KH3^FN+L$\$"+TP7$%[,2  C7G)-F*?9=:;&)(
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MH6D?2U$"+XS;E%)1V(T0Z&!( X8!NH\>!R0-H$WLNFS]7HEZBDX4;1QH77M
MYRRKTU+KXT6RHE#X+KNQ '4=<9\H 7HAM((2H)UZ6V_I-X2\)Y>/-J,F.V?2
MD,7'DB$6<EA9R8$[*UP)LB_L.T9Z&$Q6H+Z10IO7Q#Y)1.&B#%'2 B=S]K3
M)0;!F01922FD=\D&W@GN@V+\6/OU;JO0(=+U+\N[K70.R?LTF0).P0JXH@5-
MEX6D95#"=>+>/\[BFG6\]/7UVYA XV:N>Q<QCJ^XII?R5Q1GK*.Y 8MKM"I)
M.*=!>$_QO; )HK:!O$X6G$TNIMRB1&,_BFM:X-='8:V+:TA3-PI%2@PZ% ,I
M90M*UU:!@CM@R1OM2\K*Y ;(W1IT=\4UO=0^::&SQO6GMZM\E&166!_ ,)H3
MA7H>@I2T:R<=7,":X=(I!^ P*J/6!F]MG0UP3W'5]@CQ=FZ^%9'QVL0U&,=H
M4]>6UA=$$)SE8*,+%ENW&UHER_%[0TW1&""AXR&YEG05'20;Z$9TM52[N?QL
M@UX'D]A ]5M:0BXEI!>!\TS!N?6R$BL(!">=!$.QNF0A^FA:5T!MVRB>N,#<
MMDWTT?@0U][WTM,NMSDA@[>EEGII3* P*'!H%7@*[3//EBG9B>ARH_3 7=UT
MML+KR5S -92]DQJG]U^GDZ;53;<>V+ZN:;6\=RJ:5(XZ*E48,E3"YZ **H75
M#1>I8+A?T73KT0/7,F7KG:W5!"SDVG]*\VH2#K)/Y'QZD8)NW;!KT%JFU^?5
MW-^4M]-*Z7/V(4P_XGQV\G_;^[;F-I)<S??]+]C-^^5E(]S7<(3'=MCMF3C[
MHL@+4F:,1/J0DJ=]?OTBJ:LID:HBLXH4I>X(M2RY64A\J 20"7PPM![!I(84
M0ZZ,>AF"=@%B5%X$>J^<[':M]OCG'V!%<1]@?SI_;:#!H?N1KF3ZC&>X7'0M
M=_Y6O_G][WIPO, _\%[/3&:L**. ^YI">>/ *\4A\B*9,$I(73HAOX,0QV0>
M8V'1^IZF5Y^5,9R[$B'K3(&8C1I\4>2!7531:,K%9;<;F^?=T];,1EKING7M
MS<T F0^E7CK-ILNI,E_(=\\?GR_S=GH]"SI8)U,2#JRNEUN)HJD88@8GDM9,
MY.)UMXO[;24X)FL9!84!FJ >YX1^<TIRGI*J?ITM+DZ24I8GPR%X[4 )9TA$
M8>B/G#F'21C;.L?I(-:16,]00 S1_E0M]N.<]D5R@@:=9@:X-+3A9:[J%(P,
M)5D*KR3E=[)UF\G=TX\,^2W5VI",\8Z\Y/X$\'R;WB\WJH0I1E<L9+2QSG*F
MD"?0.I6W+&95+*[&$PU8?];+<V1&T$SU ]"&O9M-3__"^?F=C)1)!9T%HSA'
MILKL$$.!R)0"RQ1#*;Q+JR7=.UO#(V(<F1'LJNB'V-MAXH-JH_/%U\FWN^;_
M$UL0C3<(S.<ZIM+5/G]I0 N+H4AM.T[7V#E*>$2X([.384!Y:#VNC?5\QG0Y
M7Y[C_O']_>3+=(ZU+ [SGZ3(=[,%I4^15LRC "9<JD0 I4ZY"E!;692@J$9Z
M,XCI/"794=I-4S@>&HW?.<RL"=/7V1E]VN)*XO>S"US^]/.WL\G%KS,R^7F]
MI?I4;QSX2>%&H2D,LJGN4>8$WBL!%$-IQK@4]+O6P6A/&8_,D :%Z)%#LYV)
M<K<K><A"NFBD!&X*UAF\U?<F!P9SD%EGG['UOO2\F1MVLJG!(3ILYH8BG&.5
MBUJH8&DE5@/E]@%,*=Z(G+,UK8EFCH"YH1?^G9@;^N!P  WV7<1]96[8">0=
M.^VW0>@ #"MIGZ,4$@H7^NK-\M&2W^;"VY(4_=,ZGSL(@]J*N6%,>^H#3.L+
MR&55Q\>O87X>$EY>U%E#]T?^!2^\X@IT\*0%Z7,]OB091=)*9..3Z#8\<>-C
M#I_1H1="LT'4V[IZX?%;K)M9&K3.S,G< _<D3K0((?D(+ O%3:(7877:\SK<
M-SSEF&%OI=SF7?[GRR*PC?+Q8)QGH@#*0*F=TQ&\EA:L#D$QQXOIV C<X6%'
M; .M53T.Q<?2^6GIE(BF@#%U7S*L7E!:"L2-+[$$&TH4W2S@2.A=MDE*6BIY
M5'J7+H(=*;U++TPZLWYLH]!1Z5TDLRS4 1/<.5<KX&A[2UF31[*%9\$U]]W<
M_;.A=QD&Z#YZW!N]BRQ.1FG)T_"ZES&A(/H8:6M31:)0^( BX(CH77HAM!6]
M2Q_UMH[IGR:IR,J3L6</,BI5I:M,&)&!79[G%Y$R'B'KQ]:HMU7H8*P?) ,&
M)2F/M'4L<.$(,0<+G-OL@T%C73,6@9<1O&VOWP%9/[J(<7RL'[V4OX8U8AO-
M#<CZX=%$SZ2C7<+4TYY@P!7:0W0.*ODD-4^=KB'W#6 GUH\6^/51V* C=5U
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MH;SF%__K6Y("HW^32B!E*'5<%\7IV2$PHS&$3+:,W0A CJ7I<IL HZ626X_
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MBE H=>)6F5 4SS$F1![J)( BA6;V80W*ZJ</7(7" I?!4]PDO*@SX2V#Z'@
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MQTYS/)XHXG[LV<?O)IMHO743#7Y;C=A61;QAI^\@9,L6FZZ"C=^ LSN&L[$
M:-VITUG8A,P(JQT(B1P420@^T?;H#*.7104K19,^GOU:R88NGST921^]CWRR
M@EQRD;6B):M"HG$-#GD$QY*2GGL15T_C#OQD94!D>IRG]%%KXQ#B\P5YQ;KD
M/W%V.@_?OE;1KF)7*9W3(D )M2#<:0]!TMJ+=USY' 17JL'KOU: EQ%,M-%_
MPZK(I5!7-XSW1;H)F3L(U3""6"O(^!%#(Z!F0VFY<9BP7C@FN556,\B&Y%(B
M)Q(NDQ?,+OEBI4JFTXW,84&_(0P8$_D^RFV(>*K^;O[CY,OGDQA"U%H;4,8$
M4"IP"$H8<,Z98I <.=M$E79S0'/]B5<(7__A#N"[YXWKZALI?K:3UD:<[A=3
M\4QF!28R!8HQ\DKH$PAGI$[!F-*Q6>I8IOMMXZ9;*KEA=?O3<W"Z"':DT_UZ
M8=)YZ-LV"AUUNE_.D:% !;)X#8J'0N8=&)3:&V\$YTJ( T5ZR^E^PP#=1X^M
M >X\>@QK$QU3%H(SE:E+&?#<:JBWOU)'3-P?[V2W7@AM-=FMCWI;N_2G!Y%%
MBBN2LXP"%(%0>3HK[9.&S QI);+B3>X$_K.:[+8UZFT5.@1YTM5N5DJ61F@0
MF2=0TBH(5FLH)EJ.IG@5.I5Z'R?5V;9G+-OIMV$SVBKS4!<QCH_JK)?RUU!E
M;:.Y :G.&"/?X+@#C56<5!)$[0TDKF7(I1B[.DWY, 'L1'76 K\^"AN4ZLR+
MP%+4"J+RD1)V5FH34 1$+T3D*5KLU/_[/*C.>JE]+=59'YVUOJ:X=1B/=P@^
M_"GB[94=16S.15IS8%%40GL#T?@,TI# 67K%3).;C!UD?!F.>#04&[8+5[G7
MR74=E7:1K*$[WRS-'FY&1D-U-B@DC?W-$Q*FHI3(]-*HDAEYTQ)(5ADAL9!]
M2CFC;C$4=A_&LNDNY0!MI0\2[>LK;U;^=OI4TX6VK#AG(>M40$6K*?QB#)AV
MR4MABO7=V!.[/W/<@*4E3+/A=3P&F>O'^8R<^<6/,,U5.\M3JRE>W/LQWOOQ
M#AROVSUH9^K7!NM;880-:)GS!!?CJ!QST2A?2A3&1N:#R2?;/7*WIL>;#_]X
M%I:GCK</?G?;L^Z+50ZE 4;1."CDI4[%H2A;I"1-#L(W9Z)Y6JI=FSW7/N'/
M>65CX%:S6%P"VK[IC4Z1@2N8(#F-D6GFPNJDT^'6O)1H_,ZNQI:QVM39$("&
M"=UM6UM*E^>7R^3B-_PVQS19'LW2]V>X5/LTOSF?S2^NCVS7+N9$J$PYJ!25
MUB-7 CE!*D()+CG%(E.*=H/&AM1*]J,SN;V .D"C^EK!WB/)1J^-U3R!SG5(
MCJ"H)#(2U9!HA062N#E+QB9YCLZ(FBF_85OBPR.3M5)>G9*$%!2E)!9*1DI7
ML#CPCI$^$J> -8LHO6AL)%UE&XNJ9V S&02*0^'G6;ND7WY4]H=E1IPSMX6Y
MNC/6<??,%W L(A@63 K.2+2M3:R#6/L_S&QI#EVWIBUA&=-U50%O;]*?%G$@
MPIX.XNV'I*<YM%U-9T=<]F1"G&NM9+ @@Z>=NY[%>!X3 <ZR5URGQ$9+68<V
MG2?H> [!<OK ,8#%?"AEDO!6L)O19"I@1&TA>5D[ID0$"MX<6.V9T85SGCHU
M(_>PD4<%.: (>5O(9JWU/4!&ORI.R%8RR4B2D&IP)R2$&!@D5*S>0EORM8WA
M/WK@=]'Q ._]K[/S;Y<7.%\52_%00_L(S-8[8FX$1*LT1*^ETI9;BZV9;]>(
M<GPFT$+G V3&[\+T9LA[/5B,0140(F=0NM0F6:> >TWK#EF;;LVC?>CU;Y]^
M?(!OJ=F&1!/+F[1?+B=G>3(]I16^P[# K[.S_/;\VWQV5:][4TKKT%EN9 %+
M]EBKC20XM!8,*D'_C5+S%?#7W%1V>][QP#V4DANV!R]%_$"K#Q<DXU+ 3Y/3
MKQ<?RI<%OEDL\%; 9+D/7-+:K2$!E?,DH,Y@8K),.*F-[G9?W>5I1V8#S14\
MP%257V?3Q<7\<EDE]K:>XY_.<7$KF\XFR(04?5:FA*)HE](F@\1"@:DPJN36
M-S*;Y#D>\VBN_;5E[L.7,=SL= OZ>;JWGO9U#$\]::A"AEXK7*EDT%D7$WU1
M(@E5@HG:FL24#<SI(+Q:5\GPU#,'+V7 F SS7E-<HFN$X@I0P,)!DB'&Z$01
MI?74V^%+&=[,,=0BV7#V^Z+R =P\\83"+IE9<"14<E"'2$#DDH&0RBOC>.:N
MT\SL7@35C\MR0+O<=M;PD).Z@=('..9XHJS"*!]EM@60DBY0CKZ+629(PG,N
M%2LVM#:)9UC7LHMA- 1@@".1=^2)$?^83,,TX3*"JT/1Z@C-Z<4\I M^(HOA
M9+GD[WT-WE%*" D%!%M)(Z6S[4>Z/"G4T1E)6QB&."]Y(.#O?T\6% 0D_% ^
M?*O*_VOV^S(J.#'6*I<#AT0['$7\GH+]9!+((BR%==(JUHF,;R>+62O>"["=
M-M T/)%9+^HGG.)_PEFU=GZ2A3 %A8 L5,T2#2,;%P$H:%8.69:Z6Z/;3H9S
M7Z(78"M; ]#PH.9&NOMRO9N$.#F;4 #%;9"EQ,I2E,AFBPX0'(_ BU<BF"*$
M:UTX\J@@1V<,NZM[@*.:GVSSY\.D$\FK"7H.*!2)EH4#CQ0PY<*""5F5;%L'
MJQO$.6I[V$7U#=D(EB>,/]EI_?)V6B=K3K[3YI5P\GU9)^4,BZ:4.D7(&$JS
MB@+/48.BY(MK'U)P*T''FB/<+D\[&NB'T6_#EM;;]8<?RQN%OV9O$BU]CG>9
M]HD((4G#,QCG R@>$9Q@%"E'KUE"J[5I?8"[09RCL8W6JG]H%3M/MNU<12ES
MC$(E#E'7*DK!R7H-9M#>^E"$U+:TON-]AO7-NUC)(% <2GWS@V.]"2ZN>$;0
MF!)RI@0JJ\JEJ2#X:&NYO\Y6BL(&&,K^N"P'7\G<"_@'T]D; ## \=EC<MT0
M,':0;*"JY?52[:=8N0UZ'4QB!]6/:QR^<.Z3T& X.4]EO *'08+Q25I& 6EA
MK7/:L8WBB3+DL6VBC\9;,R=<U;_>7';^:W)V3O^YJ-><9^$_87[#?*00=3%2
M0RI>+)N*(,08*<1F241GN-3=:I&Z/6_\0+45/+-A==N:(?-G$?]!"L3%Y_],
M+OX'YV=WQ7(I%>;12,BIUMP'[R!:3)1P&T8QM2 GJ;= ?\WCCA'\%IIM_>K7
M:LAW]:]@_M?DXNMD^E\?Z</OR;AX%ZK4%W]A^CJ=G<U.?]!?^/?;Z7]]QWF>
M3:^7H(N-)#>':L8US]+@F9(@7<G99X8*4R?C:"//<5C/'K 9X&:N2S^/*T8$
M%BM#K*7=CY)V"%86R)$KKPK*&%M?K!Q#[^4N&4MK6,:TG'MU?UU$?.V]W!':
M+3KHML%E3[V7B6)VHYVGK;D253$FP5G:*;DL*0BG'*I\+*;3H/=R:,OI T?K
M:*ACOX!$P4,H!A*K=/9)DT?W.8!/& LG!Y]$-\+XY]R4T0NG+9HR^BAY@+K$
MC47AI8XUIO )M"PU8L\&*,J+8+T4O&@F>6[?D/?<2O*W,9#FVE^[0S0LR?]\
M,4O_KGV$M,LNB9C>AWEM.?F..U3?/_VA.Q?:]Y1[E1U0)B_JI$VEK2I.>UT)
MK+ER"DT4QI\\_?$[7JY]#7/\A3:0?/\A;^@9TU.\<EIW?^7ZDO#-?\(\WUTH
MI1RU*@HA^7J6ER@^#[6HB+-@O#5).M^Z8&-WJ7<NOS\[NTHJ'Q?E][_KMWB2
MHDL\UP;8'%-]RP0$:3AD3CD&MTREYKQ<W20;?[<;V=(>E.ZW!VP A[FUDOX(
MD_D_P]EEK>2Y/%_6@R[JFE*EO9M\GV3:=3Y=7>9[G9U08'P])U/.440@+7A9
M8NW/CTFTYK@<?%$OSI@/RTP&2#F7TL>G%QA7%TB+F<ROB!QQ/IGE$Y%T5MEQ
M<#RH>KP3((CL0>N,(KO"LFT=9383_F7:]>BP#\')N*T>EU_^B8O::WVU%'Y2
MO$276(%H,_DD+AP$+27Y)/HWFB*C;\U9U%+^EVG%^P!_@&:.K=_(^VM9UADO
M:$6UXC2<X@DSKE@3& 1K:E8;',3(*\M]T3ZE@.A:=^0.LI"7:=I[-8?6U"%;
M*_3]947J0UG^MJ[F$ZUN/JF1U#)I_T*FL#AQ24O!M06IO 2ER1G1"RW EQ1M
M4@ZUZW;*.:R<+\:0#PWSALTUNRUM4V;P9CJ]K(-*,?\QFQ><7%S.<9DE%!6U
ML(J#2;6O.1B$F)RBY#DS)EQ2489AK7L;L5^-_3 LHF$+T8VB?S__=C;[@?@9
MY]\G"=>L_?1TCJ<D[6^312TP)]D7;^)BV8-]$G+T-F1665%K.0"+$'CTH&+.
M)'PTTC5GB-Q5Z!=CT/N!>8!.ITX+>#^[&CIU%3PM_II=A+/[O_]UMKAX/[OX
M+[SXA&EV.JVOXTE")E0R'# 84=5*B6\4O,Z.PH0^^@<L9^/8[S:+&=^N1S:L
M;<QZ<*L8X#AOL(5=9<GD@ZY_5/\>/XE6"9M+A")H5U&B>'#9>Y#%*H.N\"CE
M<WD''EWAZXMQ,/8SZ$"7)]WL8IV?O9XK$25FCU5\QD!E)R 86HUEWCKNL]78
M^OJQF?!CM4SN^T1E+V ?2L_EVVF:G>/G6O*][%*M_T-=]'(^@?7:%44;!N;J
MJ:*$X)."2+N(4R5FE5JW3VT09_]US*/:QVP8G :(+=:(=C.^I(-P Y4V;Q1L
M/T7-S6#L9AX[8#"ZH<@L%$_&@4S%52%5;?"PD'- KQ.K/!C/WT">*%W>CWWT
M4?T@';P+I _\^F::?\/O>#9;UF!>%P3=S+1(MG#,#IRKB[?<0(PE5YX^SESP
MQJX>XS=HY7U2K/'3@(9 /NCJ;8O"$,59>$:_.OT3IS@/9W5N:#XGC=?\IA9D
M7LMZRX<O3*!41P%/6,>%1@>QLJ$'$06S2GI,J77LW4? 8S*>X9 99$#-XH*B
MN7!V*Q"SR(4G@0JKX^2E9. H@8"::GIFD%G6OA)^18AC,H?=-#Q 1G\5A=\.
M7J.\4,E0QV%Y6IJ,&B*GQ#$I$@-#+>QH7?WPDP O.Y79'HM]U(FM5<3=,J:Y
M-I"\#^>W(QL[K&F@G&>(]>PG5=K!3/J6@XV%\5!UNJW7QGR*PGH!147:K*.S
M$# '8$Q[[FEI)K8.MI^/W3Z1P1VXV?:!=LA[J%JL<\6:?1T@<&\5RL@@)B9!
M42H!WGE+F8:BWZ20I&L=@JT5Y@"O\P?'>MV%STY #9 #/E;P]>GSEVOAHBDJ
MQ8)U=CRK0:N%:((&Q9+3*I=,&6K[8X+U KU:4D/ AF!6P'F9S<\K,>]52>'-
M3,64F9,4T*:8;>U>*. MA;O:8"R1=F^O6U?\KQ'EU8*:@#1$ZG 9%Y,\"?,?
M-=&EG*J:]Q6YA-/!&F,@2ZWJ%)$,7D3Z8ZA#EXV7+C=O\5LGS,O.-=M@-$1;
MQYTX]2WY4/XB=2Q"NG< TT7"H;+()Z7;3T[8",Y5(QD&BR&RO:<ES4AOB,\&
M7-*TT;J:<5C4P)E$EFSE:FM]:;\O:WDB$]N;L?2!8.@<ZX:<,81L?4+:.4T&
MI1(%[8PCA>_1EV(2_:XU1<0C8NPAEFF,UJ8L:0M5#Y ?7;=X+>W<&A5$HJ K
M6XPD@!3@,00*D+)3T<84;>LXY-[C7W;DL2T. PQ\NA;EVMZ["#-06/&3(/N)
M(+:&Y7%X=]#I #O_ST+%6OF8O(&2ZX@I7^=,H/-0G&#H4+."K7/8$0!^PND/
M@V\?58YWR+_<J&@OH_WNP_2F1 ,ID4ZL),BQ7MN:)""&P@"-+9&$C3JV+KWO
M(=[X$< .0'8[C]\9A?%8C.Z)^M=_9M>B9L<JL;,%X7)M"\CU+=%(,$=A<T11
MU$A\1(^)=]P&LQT*#7>8Q?SBY%.-AI8;ILB>2[-LE$9:;!U*Y#!'B%E(GI/V
MN=NY%7WJ/3.@/]V9P$\/?)D1XO8Z;]BK?BO$M?UU$:-/5-C%!-J_X4_'@3LH
M?Q6^'30WQ!M\0RO*3-:!493#-2=Q!(,@K0(*>6SD6@C-.]V [1O -7%>>_SZ
M**PQ;O\@39U?GM\8DO+:A<3K610M1B;:58PTX"(M)3F>1>QT _X$<C\]=#SW
MNI/:9RUTUC#.6@H2_KXGB"\Z1J8HX,O"7)WZN&(44 H2LV(60^ET[/H4>/<?
M^@S!VUIG>V% KN0;RV_"'0'')<4!93;_7GDY9F51_Y=T[W\YI<BA4CDVI$S>
M78KV',N--;-"RBRT$\HRXRN[MF$L>.8*Q5E2*$F9NWQ(RKR[/'MG<=;<>L:4
M@F 5O0U&2G#>6@@.;391%=V\VW+_+,Y-N7'>U%E4%U]G>3E$Z+;OW6DN>,D:
M6,W %1D2>0M*YESBC)6<50B#$) .NZP#K MI:^.#4NXV,)5#)Y_^-%G\^X\Y
MXEO:Y>:XN%BR0WGO"HODN,F_:G*Y*M0>0DT>&+UGV1G/6H^H&GQ1S^A-&,H4
MAWQ5=K:C0V*GWD2I]A?.S_E)8I*EQ"WX+".H6")]EST4R[@S+J?@6H^Y'VXU
MKZ]&,_[4MI9S2(S7FU;VS]D9?<S9Y.+'\K6/+K*8=()$:Z)T&RGO$RD"1N7I
M7Q1L&"[W89?U^I:,,MY@!UL:BE=[FR5>-4,L_JSIX^+M-=W]O[!2*F-^\QWG
MX127O_R-5GFKCY,26-)!:B#'J>K\U (Q" [T4V:0\'"N>3?ZN$M\?8V:O48C
MV-@ =4;MKM6X)8?)N0"3:G@I<FTO*AFD$X$;Z5B4S<]"7B!MVD[I^%[ /A3:
MM)^[/'FTT2 JD+G>0OA2R3T3 U.P2')G29368=&1\0GTLH&-? )]L'@N_=A=
MUO3*)]"+3Z"7F8S1F+T-QL_%?K-QQ:&R8-&GJ^8_+S4%)S$'9C+/],L7:[>]
M^ 0.SFS[0#LJGX RR3"5,R1?.::,*228TB QV> -A<1FL#$"1\HGT OKSGP"
M?8 :XLYE;9=8#B:[0M%Q">A!)9\A5KY%8;E"Z2,:WYR[^7B[>'>)\-I@-,29
M:X?VL@X2OG;Q;@/G%HV96V"QGRY>R2G]%BI"RH&VVIP$.&D\L%2T#8:;7%KS
MF#R[+MZ!C:4/!"-U\7(,(5ARE3S2LE5E8R0'[ $Y+\P4D73SZY?GTL7;"ZT.
M7;Q]5+TV*AFR-O$JAJHZ^#ZY^'$YI>=>?$7!.%M6NGVCT*UE$6*/Q[6O-MQV
MK2MEA9XYQKAP6GJE2M31:*.299E;R83*#\L*>SQX[_6#WME,:^.012R@2O80
M/'<@Z,5@3C,I1'.7\7SK!Z]O6#Y<7BPNPC37H:BSL[,_9O/ZRQ,,#ID($7)!
MVDU<DI7GV@*O!,5<*J=B:[J$859R@)EG6TMN?>76P" .J3#PX:JN)JB>E!RR
ME9&R;E(G9=W"0'2!LK.2C.?:!R,.II)CW2*>D7$WM*[A#'X+T]C'"72O2_,3
MH:-,,EE F6IC;93@M4Q@,N>!:V1*'7;=Q:N5[]<HAC@VJL'CV\7B$O-OEW-2
MTY585^2&]TY(%[__C?,TH26=>!:D,J% 1D<2%\O!>1\!27-9&6-E^P.!WE*^
MFNKPX!Y@*=S=!.J[-\QH%YU3 61!1_FXS> 5&M#!,K0BA]B> K/],EX-^@#,
M8XA*M>9!4T1/;RGSD*74%#05\BC%"L"<44C!M)6C7W'O%D_O5:LKM8XW6^7'
M^21AM>MR;=<VFQQ](,]=ZK&?$0("HYU3.Y.8"IQ)U7K8]OBK?$:[T,$E\4,8
MT@$F/1U7?))3SIJ;"#(G6J86M.\RRRCPQ6RM4L[(UE41(RWM&;TD(UGI?EZJ
M7B9V4 5L78KN?UZJ,-DK(1T$XS)%54*!*\Z#"8X"=Z9B;#_=>[SEO;Y1N[Y1
M>S*U@QJ3MI+L=ELM=V3XA2$!XB0HQ (>E89H1")8A Q^)!++@5;X^FX-_6X-
M9W#[.(%Y:K6/Y-@;UQM\E$I18%YLC+2=!-I86/(@BO#!VUBD/YR*[.W6^/J*
M#?V*#6ET!]V>F*2-6(R'8@(#Q8,$%Y&#M8Y;4GTTICE'Q ML3]SI"&$O8!]F
M>Z+!.@I+&2A,UL-6B1"L#R"X2X$+7VQN;:Y'UI[8RP8VMB?VP>*@LN,-?2%=
MUO3:GMBK/;&7F8S1Y[4-QL_%?K6J8R%4AFCK;'I5"UYLRF!4RMDS##F-?E=Y
M,';;JSWQX,RV#[2CMB=F;44M-8&B%-9>N@(A>@1C1/%<2F:;C^DX]O;$7EAW
M;D_L ]1>&@$^??X2JE(H<?Q(WX[5$+#%8]LW!NRZ]I4& 1ZU+5Y&;[E0S-1I
MQ-'(X&*JPVL%/FP0V$* O3<*H,\\)(Z@D=-[HLFLZ>TP4+MMA4NY./_:*' K
MP>__?4F(OITN*&];[DP?"-CY7U_#=7/(XOUL^AT7%YCOU]MPKP+9%>6JT0I0
MMHX#Y.A E^*-+\($>3 -!%NM\ !]1EO+;W9].KP!'5+#P?N;IJF'RWY0,\7J
M<#87+2#&Y>&E I\3K3'YF&/D-N;1KT\;K.L9O1HCV&:KUV@HPSJD8IXGX5@I
M8P]:T@)+HEV,%JM2813Q>D'I5E&<>?I-MZ$C!^%EGFW7PS-ZB88TL(95!S7N
M'W"1G_ ,Z_]TN\SB,)LZ02JGS&MQ!4(TVD-,PL8DHS:KHS<>)D@CR_SZ?CSR
M?ARRW1Q2W\:3*[V^V;VW5&E-L"9Z**P6[%N=P0=#7[Q*6;(@76@]3'C$Y;V^
M37OQ-KN9V2'UA?2)3K7CAK8*#0HY.555RR!06*AE1K&$;'W)A_(J;9WV;*G[
M^+2,L;>9O3D]G>-IN*@C3.:3Z6*2KKB_;RB^/5J>C24$<IT37KR&8)(%R3EG
MG.E8Q"![VSX6^XQVNH;G-@=O5L\J"[WU,#\O_$1';R(RBG^$HW"(L0#!:0&L
M-E0GYW(Q!\,IL>TB]_3^'+X!CW]<NH/U/:O7[>><?&75P5M;!]U"-IHB"DO?
MA20#.&%R*E'@O?GT!__.;5KIZXNW[Q>OF1T^QY.BG[<:83EE3QJTC;18Z2@>
M<4@[#S=%Y>2Y6JW_W>-YT>M+U/TE.GQS>H['2%<- C\MF97$% H%N?:'JI@2
M1.,*N)BM"D84;I_/S<7:9;Z^;OOV66TL\*";4; 2C&05P2%GH!*O!7 V0I B
M!A5R%*9YJ<D+;$;9Z0QB+V ?9C-*"DP432Z.L5R='7F\4%! R;J4)(3+S6EJ
MCZP9I9<-;&Q&Z8/%<RGF[[*FUV:47LTHO<QDC*K^;3!^+O9;0I'2!G(L)0B*
M2T($7YG:3&V"U(P59(/,'W\6=MNK&>7@S+8/M .8ZR>D,'E2)S$OR]B_$""+
M3Y^_7/<Y&.0)92P4L'L2SI'>0J%XV*(7)5GZN-*Z"6JC0 =X434XYK.A !N@
M0O@CSLML?AZF"9=*65R+Y5@1AB/%),984$(QB))Q"I:]LUQ'RWGK2Z UHKQ:
M4!.0UNY$#9N:WN/%VRG]"4G@I:!OIA>3/#F[O)A\QP6FRSD] !<[]"_U?,+.
MK4J[K&BE*ZFXQ%U"[V0]"10N<LT2<YS6)T4*^:3GLW9L:0SSZ61ZNKAY%IGR
M)-U+D[,3KMJ35I7*N&Y-(6D!DC&GBZ*\V;2NZ=\LT<XMG"N?_EO5*^;E0=-O
MDT5-I.OITNTYF(J925,"!1PZT1>.X(N2P#BG]3,57;(#*^ )$<??%QO:S(/&
MS0'A&<!KWG\S/]^^F;__G<XNZ87_@S17/<?EQ=7TH;*ZNC?GL\OIQ4GP,D:=
M+5C*]D&Q8"%H)D'YX,CQ%X?-BS&;"+Y_RVMJ'JMG*Z-C.T1.>WM,M>-RKLZJ
MI'5,!*<A%TVKD1(AUEI'"E"%#^2_E&Y>GM!T!6.=4 ^X1>X1TH,Y@MYMX;_\
M>/P#EL<,NG:-H]7 I:DERY2">2/*LF4F!1<#8NN$9\#E[/]X?'PC;;N/-S.6
M 7;WQR6[SZ'10;Z!3L^?DFU/)^&'8@R=C'1')/=A<2BSB'6HO+?+PC&/0"&.
M QVS3L4*B[KY?>!>+.VIL^OG:FA] !PB8%VE9*G'9]?'7$H&9:PQ)%JD=7,*
MF (66]MMC$'E2_+-.VW6BS-^]M,6N\?F7#50_"BD29=Q@?]]29'D[]_K,>S[
M,)^'JI5=&)&>^LS=Z8YZ2;TZ[#B;P+BE-SQZQ;GWPB<L&!D&)J./)T]^^H[O
MY<\??Y?*N,)%M,B DEE*:Y4EZXO: )F&-E&GH$KS@8QK9-FIZOC=))'EXYO3
M.2Z3E2_?Z 6<7MR<ZB^S^8]ADD]HITVR#M!TFM."HPC@LI:4NQ7.D\B*TOU.
MU<)=G[B'BX\68/]4A#N(=AL>Z'41<IK?GI]CGH0+_,?D#!<7LRE>_^ZOV2^T
M>26DURV?J")X\K1;JN YJ*Q)7:XH*#&[++F.JL06!M)1GA=@/D,@TS"V>70)
MMX)^F+['B\^!_O2A?)S/\F6Z.#&NB!Q9!H66@=+10U#,@4V8+#D!<KQL*Q/:
M]-1C-)1F6AYB",O/J[\ZZ3 F)!8" M>,9(K9UV;Y6(M3D1542;/FE?2/R#%:
M)6]+"VBFV$,YYZP5!!_*O8*#9?J7M34J&PV8R#$JQRGS(VU ENB,4<$HT=I$
M'A5D;V>+.\,[:ZWF(4Y:[I69D(-[/YN&NY_\1=\M*CWI;+JX([9]4MRACOKZ
MB;J?D[\&(*\>I8R T $85K$YURHB0"8JOXF1$$Q!BLA54-I*(6+K[>8@#.J)
M [[]VU,?8%I'L_^<G)V%^>1&%,U*L1H1DJJB9/+;3CL)7$4>>9+6K0YX6Q.O
M_ORY>SAB&Q*#61L%MDY[WZ2O$_R^7.&'<ALP7YES*$):'PFI%(&<* (%81)0
MHG'19:^LZH3K^F<\^RBBI0Y;M](_+M;U:7$7P1Z/&'J!O(_KOJ:8/(WS#@IM
MO3%O%# JKJ07'+*N$]L29^"U*:"Y+C;27N69.U"DUWCC_0#=1X^M ?Z-I#J;
M?;L^]_J$IY=G]:__N)7QQJ4(%,F1-,"Q9%"RT%Z6O89"#L6[PEADNA/879\X
MGK=NC-!L:/6V]MB_SL[/ZR3&<#;YG^5=W0/IG W(HY*0-$\4AT:*2YAB8$D3
MR7'$[+N=03_YJ*- O:U"A[@67XE6;IKB7*B7_3&#-77%62IP##T8'H0B.ZQ1
MZ,#'A?MNQ&Y]&M1"U4/0NCP4Z]KJNP@V5(OT.J'V<\;3!+JGS6$'O8^S-=ST
M55,F:ND?T*QR7$C:O4**":3P16@M DL#7\T/;1!/G-&,:P]]U#V\'=P<+&CN
MLQ&T]6FT=1*Z@UBR!:DS<N$QQZ'OD_;6O=D&J,WP;Z'EO@52US^N7RK-T__]
M7_\?4$L#!!0    ( ,. 855 4?GGS0 ! 'HT"@ 5    :6YC>2TR,#(R,#DS
M,%]L86(N>&ULU+UY<^0XDB_X__L4V)YG,UEF0A</\$#/\4QY]>9L5J4VC^XW
MKVPM#!<E3H5(-<E0IOK3+\ C#D4$"3! BMW5E@J%2+C[#Z3#X?#CW_[7C_LU
M>!1%F>;9O__!_:/S!R REO,TN_WW/WS[^A[&?_A?__$__L>__5\0_N_7GS^"
MMSG;W(NL F\*02K!P?>TN@-_Y:+\'21%?@_^FA>_IX\$PO^H;WJ3/SP5Z>U=
M!3S'\Y[_M?@3HI$?^D$,F8<)1,SU($U$!",/B]AA$0M]]^KV3QA1X7E!!)&@
M#*+0CR!V&(5.[/D>H=0+<5 /NDZSW_^D_J&D%$ *EY7UK__^A[NJ>OC3SS]_
M__[]CS]HL?YC7MS^[#F._W-W]1_:RW\<7?_=KZ]V,<8_UW_=7EJFIRZ4P[H_
M_^]?/GYA=^*>P#0K*Y(Q1:!,_U367W[,&:EJS ?Y F>O4+_![C*HOH(2/]_]
MXX^2_^$__@< #1Q%OA:?10+4SV^?/YPEB7]65_R<B5LULS>B2'/^I2)%]9%0
ML9;<UZ-53P_BW_]0IO</:]%]=U>(Y/2PZZ(X&%5QB167;JBX_*=SQ'Z^@'U+
M_%;'O%I@KA;W5UL\]F'ZJS5VOTK](*9G>(_,Q2PW#]2[C,_U[&Y)7<SZ]!S;
M>BSRBJQG>"QV9/987JLO/LI/+1DU4(\RK>FTJGN/5?&C$AD7C;8\&!JD_-__
M(#^MTHP]K3[G3V1=I:*\(4^$KL4J")'#W81"[E(,$?5C2 D7,*2A<'V$'1S2
M5;5]H%<B@]^^=+1K CVC_\% INK,NUF(,M\4;+>JW:]/+55RE5+K6OQS1NY%
M^4#:&R2+R@!HN/Z/+7_@H6'PWW[>R6&*W'I:/-9S07%S.12\-:9J2V Z2 [(
M3 B->)##23HEJ.X$(/?Y1MJ)N=(JSQZ?/YX%+6<'[*V5E907ST')63\HC<I1
MET!E=3K8=VJ%<OJFGX^F[;KHV" %&T"XO>)GEDL+[Z&"!\^?LH@U^*URC9EN
M$)'D_@#R@HM"6NLG6-\^<9L2WA+RL'J]*=-,E.4U^]LF+5/U"%S_2,M5Z,2N
MP[T0TMCW(/)8 C$5,>0D<:05'CM.%.LHL $Z2U-E'9M@CT_PF^+T_]-[DX=P
M[5=O%M&:6-&- 4K[[=6$86<ZE%*"&H.$E+06HAWB9_6"_RS65=E]4[_R]>L^
M1&66%U]3U$X%Z%X^3AE\R)C<MI?BK6A^?LB^5#G[_2Y?RS'*=Y)4]?0Y7Z_?
MY\5W4O"52U#@QIQ (8A4$I1[,$;(A4GDBYARY(D F2@)0_I+4QX=^^!5)\!/
M(,W O@S_ AHIS)2)Z;SH*9D)T9Y8^1@ #7Y3(H!6!HNZ:21ZEG26*?59==E(
M:)[KN+'#C--]-T6>I-7'O"Q7&*/8PTA %GL(HD @B%WFP<B/A/R:QG&4K!Y%
M07-=Q;8;W.0MVB<QW<OTJZCDR\/R>\V]R@G ]/3-.! F5B5*^@^U]."58NVG
M*_7K>J,\W. F+VJ[YKJJBI1N*F5O@RH'O\KW(,\JR=]:7?8ADZN+*"M[RN48
M*DMZ8V_@657"L4#/W_835YB]R/7NZ#U)B[^0]48JBX=-5;XAY=W[=?Z]?%=6
MZ?W.&[?RJ</C.$"0(->!B",&:<1#Z"01CB/L.E&@M;TQ(;HT<T4B_M^"J4,:
M)CD&B6(9/-2L&G@M=!'7\.M,@./$VD-Q#&J60<,S4$R#FFNP91O<3 6J@8=H
M G!G<APUC"E/D>14@$TI$95*^%[:!)M"[#^\\MLDS7CM7VJ=3>"QGAUY,\DZ
MGY.\C,H+2"H'+4 AF$@?Y9C2@E0W)IM*#4M*=4>JP-JGEJ@9K\>TY:4RG)A>
MYY7N6//YM RE.W!UF=X[SO![*Q)1%((W5L!7\N.Z+$552L-@A8,X<$(_@1ZG
M 43(DZN$GW H,/%0S*,X9D;[V_.DEK8V=)RVEB&HR _Y1DAFS6S$'FSU;$8[
MB$V\"FS!:@U)R29H^+P"O_9 9FP6#J-AR4SL(32KV3@L\',S4N,.,S7!1;IZ
MEU5RKWG-N7QJRIN\K,CZ_Z0/;W(N5IBQT'-%#$4<,8B$_(1]PB$*$Q91J9U=
MXNNHB'XR2U,/#:>@9?4*-,P"R2U0[.HIB0%D^Q6$/;PF5@YCH=)6#GI(G% ,
MI6!_O,T??Y8#-#I!?MBI@H%A9U$#>J)U*D#SZG%6POLT4S%:'Y4CZK,*6/N4
M?"M%K5Q6W&&!&WD^Q"*4.@ '!&***8Q(3"+/07XH7!,SH8?6TA1!RRI8U^[8
M.I(/Y@F4-GIC+L@'/C,U&OJ@UK,:+ $X]>:QQ:YF\PI\[L"3K#;FPQ4@B9Q$
M<,WD/FNSKK>2U_?*)_7W>LMES[#0 ,R29=%':5;30D/DY[:%SBWCM,MU(<BG
MY+,@:[FWD?-\4^0/HJB>5JZ@,9;_P9 Z/D34BR")PP0Z(G:0%WHAH<1$M9PC
MM#2]\N5O&Z)VVWE>D5M#Q_19,/64APV()M8<BD7ETE!,@H9+T+%I3RD, 6%)
M(YPE,ZLZ&!+VN2X8O'Z$\_K+4Y&7-W>DN)?3OJE21M:EW,?\(NZI*%8T8"Z/
MF -)2&.(7)JH4RD.XPA1QKS$050_I+"7U.*4@6(6/..V/J<Y[X,S15?#/6T-
MLXFUPQQP&3B>K<$V?YPB%Q5)U_6AB/R0J;.^*@?G\6VR7;[?Y??@NP!WY%$
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MLOXO08J5AT/7"Z7A&0>J(P>-*<0."6',<92PV U=:J9JK;"U-)7;,@B>)&]
MM (!MB\#J/**K TUKITYU-2\L\_,Q!JX%0BT$M6%V)3KMIV=1JJN?'L!#N2Z
M MV4-J(!)9M%16T5:UL*VPY3\RINJT >*7"[HU]89$C1SDK1<J-HIME&Q5PU
MQ^^J/#?_[TU3(?=3\K9MM2)OK,_A=P58$\*#F(0<<H=[$ 5!J'H6!Y Z(D1A
MC/W$%=U)G)Y2M\WBB".ZJ4_G,@&K]%X VBJ3>DM,RC)G:5WE2U7=;EO#KM?Y
M=U6E=&29(UO3K*?U7V3J9B^HU H'7K7B_70%=A*"G8A78">D<F]T8M:#O*HE
M_6F*6K]3S8+M,DZVV'N9VD^6P3U;,,HVG7'KQC7GJ2)&ULIW_2%[0QY2:8$V
M/8SJL\U5X!!$HXA!G/ (HH122!+N0DY)[(>1CQ+?J$;=,,FE&>X[CL&#9!FF
M&6 -TV;:6P-L/7UL%\*)->P>>HI;%0S1\GMUT"O+GJ+4A\>2ZM,@.*LRTP?@
MN7HRN--&F1=1W*=9K>U^S2OYQ[;PE!<'48BPBL'G"41<4(BI_#7D4>3[;AQY
M7+\FG2;1I2F=MNN8M"^RFLNFW]R.=_47FW$.Y^9B1)B#!83GCG*X GM,@X;K
M*_/B;+J@7E)QY7)P7Z@L6O,8MPW)ZJ=9U5P9>*(GJYW2#Z-9G90S8[U@391^
MZ?KKGPS<:\O3_*NHFI%3MC6"RVH5>'[DLR2"GN^'*JP-0XH0AH2[OFK1%=%(
MK&HWZ5A?\FG"1OI_2WZZMT=RV;XK*=LZ%)AD]%+O\!G<Q_I_+T?S13R\"MZ.
M[^V?%.?@U1NYSY*[_RD=N?V@3>:J/4/VA9VQ_6 ,NUL'[A]3FXG=";Y9BT^)
M:B>6R=E]^JI"&[Z*']7KM=JG22W$O,2+8!RXJO$7BB%Q$8,Q3G B/.1$KG[1
MP4%R2[--.X;5BIUV+)L4'AK$5\/JM(K:U.?\>X!MN06_U?P"Q3"H.=:,M=#$
MT*2"DTTL9S(O)8.;-2D W]7!E^@R4A1/RE^["ZGMGE 5!TC*+LB6DG7;Y5O(
MI8"3REKJIS:8_96?!D>9L?R3KD2'-:"T[QIG4M8%:7^5[)/RKG&KMC[558!<
M5UJ1&'H"<8C",($D<1)58B5P&,-"L,CL\.HLK06>0BE6ZZ[U9I;B>3CU3,/+
M()HI-[\NL]TR"=JSGU<MGQ8MOD$L+)EXY^G,:M,-BOO<B!N^89Q*^"S(^ETI
M5Q[1=F^3.K^MTT.(($E,'!B[3@!1$@<02RL.QL3#). 13P0V.<8X3VIIUIKB
M%#2L@AVO(VLG]2"LIR;LX#:QGA@+F;&B&$;#DJ;H(32KJA@6^+FNT+ACG+*0
M^\9&]WQ4K45=AS+".(4!=1.5>LXA1D) YKM23&DR1#0T\3L=C+Y$YU):<V?V
M]A]")D02T2!TH1>IS".48!AS$D'D!P*%V/?=D*X>14%S7:4Z&K1]*DN'34]/
MCH9B8M6H,.@,)\7:3^"Z:N+:ZLULE8,;4O0=11GKR)-(6%*+AV//J@E/BO5<
M^9V^:)R^VZN*\B%[V%2JX%J[=%/./<$X@5+MN1"))(;4\R.I"Y'P7$&9%R4F
MQM%Y4DLSCO9+Q=2L L7K2..H!V&]E]X.;A-K@+&0&;_XPVA8T@(]A&95"<,"
M/]</&G>,# S+JI2GZTV5/NYE]+W[P=8;+KA* 53)*IO&R?<I>4>*+,UNRQM1
MU,DJ33[TRO&)B(+8@P%A46-443?R(7<Y)8(EV'&84>R8#:Z6IH)N\DI.GRJB
MRIIPJ+9MF&C%:L*(:['E+]G6!@&OUO7Z*VWBYI:ZN5@K/'@%QE8&LC/U>@IO
M]@F=6#?NR[.7[ S>'<SEGDS*'=U)I0XDF\I"5VV5#8LQ<3:!MA4V9X6G>2/K
M;,)X%'QG=?"11=LVM!1_VTB%]$[Y[-5Z<OTCE=OC,$AB1@+HX1A+"Q'[$+L^
M@2Z)'=?Q$(^H5K6A 3I+T\T[-D'-9VWJ&!9:.X.HGH*T@-/49YNG( *_*2XM
MVH(#.-@J:G:&RKR5R_I%/2I/-G"YK7@MJ5Z**OU[JWQNBC0OFHK>0H5;-$$S
M*QS')!040YXX/D0X)I#0A$#'9\17Z0*A[YFYA,8QLCS?T3[7:M%_4'R#LF'<
M2F"7U@3I:9WI09]8*9T.^GH^![48H)5CON@O$RPGBP738N*%(\-,@!J.$S,:
M;9S6;)KF*BLMSZ0N;GT_KAO$B% /ABP0$'D1@CB2MA,+>.#P* DH)R:VTTDJ
M2[.<VE[H6RY'NM1.(ZJGQ2[&:6(E90Z1L?+IA<"2;CE-8U;5T2OF<\W0?_&8
M<-&Q/;9_K3O%?TJ:4K)R'_=9E%61JMH!=:[5MRRMRA6F M,$AU!NL3R(?.K#
MV)?651*$S/.\0*H/_4*OT_*Z-"74,*V6^M:G1I0HHDD_$83=@<]?OIG7T)YC
MUOM5W,+F<NHM9NW=U*S*#4Y4Y0:[!Z&1N7:U[:1N,E!!+?=R'@&3 -[%/ HO
ME%PV^*(7N\ENG.4;)9FUF-]9\.\/&)Z6A1FCC6?!\C!4>1Z2UERRK1GLQYSZ
M#"/HNRZ"R/%CB#%UH1]Y4>RA@&%F=+QVEM+2UO5IW+)&FPLK6+V,:];Z+F,0
MB^G<LR^QVQ@45\-%:^60_OGIOZHEJ<Z /I.J:^<4)\@+:11!@4)?JHB(0,*D
MGO"0%XG(]2G#1F'/PR27IBN.PE6N0,<T4%Q?%N)S G(]_6$7R(D5R1"&X+>&
MY0F#?\[C,U$0T F"+QH,=!Z H:"@GCM'!@?5/?M.M-M>B=@1+N8)='WLJK*!
M#%+F8AB().0BC%R'8I,HZK.4C+3,#!'57Q4-H_:>PV#J*1(K$$VL/QH>KX#B
M$M1L@AV?%H-<AJ"P%;ARELZ\P2A#XAX%F S>,'*'LJU/W;]]HL^W3_4_?Y%;
MIC2[K5N"JBT44]Z#6[%*A,L2$260B2" R(T32+$3P"24&H:+P/-CHZK2DW"Y
M-&MGQYERAM0^#O#8L Y(5?M*1%:7E:J](HRLY:^D:(I2OR(E("J>4 UAVD]P
MDF= <R_VTC,[A__SLJZ$C1NT%14TLM8%KEII+6X&IYP,6QO)27B<=Q,Z)<Q'
M&]A)B9DM.JI);7.$]XNH[G*NB@N4E1"_RA>H]> @$L9>%!/H>R*!B 8AQ(D@
M,$*ADP3(IQX+=!M ]Y-:FOIO.&PJVBDN1S2#'L"V7R/;16QBM6H.EE&O:#T<
M+F@?/4!@MH[2>H+N-YG6O&.LO_SA85UK);)^0\J[]^O\^X<LR8O[1FMUO8:0
M)TU(S&*H,G\A4G7NJ5(:- Y"@CSJ)Q29><^UZ"Y-9>RS#?8+%2D9@!("[$EA
MZF37FPI=E[MU@"=WP.]A>Q+/25H\&0)ES3NO1W5F7[T1%,>>>[/;+]@_]QT_
MEN?.']O.T^_S(A&IZC92?LB:8GA_%<K<$OSZ4132V.IZ4]\4*1,K'SO()PQ!
MACF#*(E\2+E'H0@%IX&($?%BXZWUC (L38>^4:7$UFNY[5*Q1-^^O-TEY8W9
M1L_Y*!CLL!<ZP0O8?)<#N^\6A"NP!X/*SVR N (=%*#% G1@@!H-RYOS%YA'
MF_OV.=F??TO_ I-S<K?_$GR,B+UMJ:O>B:J#RJW\+#^5*6^[J*Q$Y/@T81YT
M!"+*%T A(1S!B >$!7'@!(ZO5PM0BYZ6XIJU'F"GBE1QS"W/ZN..:8.0QT&\
M^]<3>QC.U-UZ!]Z.6?!F*O ,(CYM@CA7Q=8[ >K"B_FF2M0^Z'M:J<#,6^6:
MKO+Z<.+<(PKXIE">:W5-4Q;=5NBF+I"]P9>#@\P7/JDKST$ I/9-(TNMM6&2
M;7.K[/:+N*T7DE5,HH0RQ&&,5(%6Y+@P=K$G=32)O1B'M"[WK[\3.4MI:5N&
M741ZWK$*RI97P^IB9\'5L^VM0#:Q'MZAM>42?!E"R[S2V! 2MJJ.G:4S;P6R
M(7&/JI$-WC#&@A/WY.]/11<]AR(2.H)2Z,:J\6CH8D@#@2%*7.$Y?NA&OI97
M]L382U,!-^]^N?X___7YG8D%<0B6CK$U&H*I3:N+I3>QED:C,'\^2[KG'5;U
M3DF:U99/#CK(P*L'<9_>JE<PI3]= 2)7CK5@==&A)*5%3M>DK,!MD7^7!E9"
MF%1[TLY2.D%^>/7^S^\__R3)W*4TE5]<[9HQ%8)LVYH2OI%*K+'1)&^/:;XI
MUT_--8)?@4VF&&9-V4>E6]?RKX0_*E<8EZ\_N!<5475;4P;87:ZD3>55<MN7
MY?>D&9=D0#'C@613UCGY4L77);HED;W0!E("+JJF(S=]JN]Z>PW)PT.1/\JO
M*E%:ZQ-U^D'IM_T.;YG1TCO)ZZ%==_J2D6YJ582W-1-;7WBY/<)A 1-4(@-]
MCU&(>.)#XCDAC",?)ZX?)@09E9#L([8T1;[E]>#8K-0YVS$'6M-A:PF^J9VK
MXY$S]WUJ0&++3]E':EZ?HH;01_X_G7M&6'IO-F65WXOB;;=^!P13S\,PC#T$
M$:4QI"X*H.\(+V&"Q6[B:IMZSP9?FHKHV -O#>R=YX!IF'L7P##QJ[Y#8#A;
M1./9T;?]+H!D2<9?[1W;8FC+WCD#3J_!\_R>^2R>,]P>F#SGKC%36%RDJW=9
ME59/UYS+R2EKI?BIN)$FIR0C5B1R8I$D(0P]Q"!R?5_N4V,*(Y]%-(Y#ZH2>
MCO(:(K0T1=;P"EIFKT#-KC+<.X;U7NI!?/MUG4W4)M9[XP'3?I-UT3AAW<@=
MW!]O\\>?Y1"-82,_[.R9P8%G>?5UQ>O4@/;UX[9!V_R9.KFN_"@>Q=KMO%<Q
MCID?<1A[L0,1"0-(DC""5 B7Q[$;,ZK5%U*#UM(4PRZWZZK)$97/>LTO<,UV
M/WWXZFU^+*$VL6+H 6R"?%H-3"QM?OHHS;KWT1#Y^=9'YY:1I0'O'];YDQ!U
M69 N.9^XTHRHRZ-2#R+NAI!XR(=1XI 8T\C!0BM/H8?&TK1$QV)3<<FP%N )
M"/44PH7 3&TA'& RP;O?([ZM&H G*,Q; ?"\B$?U_WHN'>'5^)@RU;GP^K80
MM=/DEW0MY XD$Y]49^HO1/ZFJHWF?,,J]<9'Q&,(<B$"B.)(0!JJ@NIRCY4$
M.*!^K!5X:TQY:7I@RRMX:$(/ROH40G6W*!7C38GDFG4#+X'17&AX4Z9">&*%
MTK(-MGQ?@1W>>094#Z\O'<HWTZ)LX*B9"NV9O#A643?SXHQ!KM?%8S3@?/Z?
M,7(>.(=&#3!B4;AFK-@(_D;^/65D_5FLU:&IJC-=OMD4JC_>*A!8(!(PF# 2
MRJ5 &G\X5N4-(H\252S%9_J!#L/TEK8 =*R"HN&U+H%O4GQ3 V(-#6\7N(GU
M>LLLV&+7LEN7KB]!R[!=# WTMUTL9]+:;TA1/"D7^V-=EH;4VEGYVBE9JU &
M4-X)J;AY[;1+0$[7=>!%GBE?/5-B<7EYD6]N[^1/TEY),JX,FSHV0MDU[.33
M_D?P326+5+G\.E$!'*V3O\8*/*AR]4VC O7U.B4T73?MI%YQR:J*H$CEG^7J
M4E?OD&3:K^J*J.H88;T77,B>F&0F3< ZSVY%\9.M$P3]6>]=<32&F6^=T9?I
M8'4QN&UDX2V59+'M(!1Z44"2@,(H<F.(HC""F,8,Q@G!"0L=[CM&L;,'HR]M
MO6@*F.CT%M) 3L]K,!J/J9<!;2C,*VB=$ME6U:R#L>>ME'5*K*/J6"<OLM8^
MB54;4J1D_6>29G4?Z,@E@D9<0.$D/D3<$Y"P!$,2><AS0S]T_40O,\F JM9C
M/&M^TO.F/*1C&:CVEL(P&%X'>+VWWQ:8+]GPJ/OMT]9JN0);*8 2HVWB/6F[
MHW.P3=?;Z(CB2S<R.@>!1M>BL[>.3,41E0KJJL]"N:3TI$S0#]DVI/]:A1'7
M5N8J"442.]R1^]( 0^2JU$F!&42>(_PHXL3%B4DQ3WW21L;'#-4]E>NFSEQ[
M:'E78<@[TYIL&3?,W-&?"SV=-0W"$ZLN!6X=^GFS!^ZK>F>49C_M)?Q<#\-L
MGO)CC)BM'"!]PO,F!1D#<I0E9#[".%6V'?&C('+_T>Z/GSK/!8X\&GEQ B/*
M HC\)('41QPZH?*O>9Z/S9J/]Y-;VGYI]]JL%;O[[@,S)36 LIYBLH?=Q,IH
M!UO-Z178\GHUZ%\S5CYZJ%A2. /$9E4R>H(_5RR:=XW=L=%JUW3[^I&D:^6]
M>Y\7ZE3@J_K\5?RH7DLQ?E]A&D8^B4+H(<PA8@)#*EQ568(1%#,L"#8*W# A
MOC1%\V5S?T^*)[5UDS]_%TU"6+F5IO9C)ODZS4UW<@83HKNEFP;FR?=VM ([
MON46KN,<)GD!%>_@MYI[H-@'-?\6G4)C8+.VMS,@/?,FSQR4X]W>B#%&YNZU
MA1T_)==9E?)TO5'9HCOB[WZP]49::^^EH*KJSZ9J^^2^(X7*0%!U>^N:/S57
M*Y6=XY!(JCT/>Q!%S(4Q9@(Z L?4"SQ7"-\HV\\J>XM3D7M5-??EVWNI02<A
M4(\:V)-1W=1)6;<M;+H<-B^\:6*AW:= 3^N^W-Q.K)=?8EK-LQXG0=]6GJ1=
MYN;-K)P$V*-<S&FHC%M$ZI/,ZXR_^Z&JPHE=3K+C^2C"G@,]P7R(XB2 )&0$
MBL#S8I2X+(R,ZHF>([0TQ=[$7:C#?M%R^B<SA7P643W5:@.GB97D#J*.R4F2
MNX>0L*2PSI*95?4,"?M<B0Q>/U'98O,RD:N0^XSX 8&88 $1(C$D 8XAXSZA
M!-.Z'EA[,/G58H%B<U9'G*1^G<7OUP0GL8.2Q$;MS:><7TV3\86F:SD5A2\J
M*#QCO>#Q$S%72> 1'"ZKZN]XB(T+^UY RCR]_J-4BNLV3U<%9;D)#H7@' I7
M&9&1_$0]*BU))Z <(S?DH58%H1-C+\UNK-D#;6:X23C;*=SZ5>J%:$RL"DV
M,$J'/R/RJ SXYV/-EO1^1HC]//=SEUR8VO[Z:7>\LB9E63]H210Z#@TC*#RF
M:K4F".+0B:'':>(*$KM!0D8EMY^BMKA7MN,0U"R."D+MAU?/-+(&VM1OMAE>
MX_/9^W"PG=%^DM;+Y+3WB7TVJ[WW)@NYK]><I\I2(.MM8E5K1I2K$'N(^(F
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M;VS^CX+-DLUO1GM60W\4+,^M^W&#C$W)S<I\G?)ZM;Z1G]C3;MN<2(.=Q"*
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M$D8.@1R%4C6'V(-QC!Q(?(^XCA-2!P6K*J_(6L]<FY9=(_V^97I"9=7) Y1
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M5NEY<YBBV8;EM6$7G$9($JQT2:PM')1"S&,*6<1"Z7LQC:255GDU_MQ4R/D
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M*+I#$G/3:%L.!_I\=]A9.GH'(3*RUNG4;='L@8J_,7R[!\*[=NCN"+R-%_=
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M,QA.5&DP?'F8,M*NAN8^L[KJ+.XV95&JCT-9C0ME?*62I0E,9,HABGREC?S
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M0YMK-'3'-K+Z@)VBWN 0W!R&U%H0GSS@UAZ88^&X T89IN!N,T*S976YTQ0
MW;8IB4.EKWP<0>210)U($W4B364((RXCWQ-"'4^M/*&G2<U.<36E4)<[CO_-
M3E_UP&JFF]R -;(>ZC!YM:T?.T;7E_-H.-(N/80FU23G!7ZM-0S>&*8A/HNR
M[HFD"P%OBP_<KSM9 P_KI1JOJ!RF"XX]S#VN"RTG7-E  8*810F4A'@R]B6G
MQ*IYM27]N>F2NA72KG>(G1ZQ!=],N8P(Z<@:Y[!#UY9]W;*EFS/42-#<Q[C3
M10/!<Z2@;*E/JK4&0O-:E0T=YN)<R?K(6.>8+6B<"(Q$ GW,/*@SB" )&(9!
MY/DI%VF*B57'[1-TYJ:O]K,F]Q(=!V<D[N%J?C:[$*T)#F&[_,2:R5$3%(_A
MX#Y/<8_*6Z4K'A.U)VOQZ.,#JIW<9DRL"G']/1=5OL?OV5*HA; 2;;)'E:BD
MVW8O(@\GTB<Q#!%"$,4AA803!&F(?,0BY+/8*&+9DN[<M,664_#4)(8]$BZ:
MR@C+6BQ 6KDL2EI83$6_0AD1X-%/5S5\6Z[!#NUM&EZ3.J<X'P=<BU(@XX \
M496/K[J)35%YU'2@/*EQ7<OJ7X]]7[E^X.!+=U7HPQ[3WAH>%L--5Y[#7L:]
MRAL#7G?4:^AV&]46"\HY%56H8 H1CSQ($68P9ICS,(EP*-!%'89NYQHPN-_O
M1JV77'%[8;.@6\MH03=HC6XN'C0&&B?J[SP:8_4 NGV;:+_S I_M]W/XQ@#K
M\9[07+"2?%V_D&7Y\E4\B]5&;#LK1((D$?<A#3"%B#($L20$RC3EQ(]%A(B1
M-_T\J;FIB/OK]U\_WMQ?@X9;T+)K8;'T8VM@ 3I#;&0U,3Y8%A:=,]"F-^*R
ME5SGCTWE-9&7)*M".\LUV"*<-PCGC5A7H,P%J6,[=%8EWRQ+9?"5637@CZQ\
M (^B)+J<>,; YV\WMS?@Q\-:F7WEYG&=%^"!/"L3$#RVJ7CE RG!4A!>:+J_
M?[P'XJ?ZM8] \5?V]*3Y>:=^*W[ZZ!=7!J/1E/7:B/TC3&<6&DFR9PF:O3%
ML^L DY4"70W)]$O\6H>M"36(#EC[H.@LUU4W2]VZ1]FBBY!BG"3*'N0)5?9@
M@E*(E1D(4QD&. ZES[E17MH@ZG/3_UO^]0W(ILJX>LJS=:X7Q:\?K@%Y>LK7
MSV1IH>&L)\1@AQ@3YI$WC2WK.LZV9EX7H6O9;TK.;04 C01C FZQRXP)_!MY
M#[ZKPZANMPT8R?.7JB;@UJ' FGMR/2FK]:K]I^Y\4%74T%>%ZC%=I+#>1O3(
M^;.H0WW(<KG^H</;U'95UQG4!&D=\@:*!Z'>YIJR^DO6 *N#@O+.=Y%WOPO>
M^2Y$#;"KO6CHQ/9N3]:#3K=C#95W;Q,;/,C0O*2GK"3+:C#>5BBJM?3[3?EY
M7?Y=U([ ,"*I1]5&AI",(0K#"!(2<!AB$F+$, \C8>7B,"0\M]WLC]63X@H\
MJ?$>2"&J)?C4MOG1"TJ<[8Q^V408^D1&@'=L#TG-,NCR#%JF =V40+$-7L09
M=_> !!$[J)SE@AB2G3CMPPZ,PPP/R_>')G/H^(!ONK.37FJW>I)U^_FZ^!8/
M@B"E?@J]Q->Z*I"0R)1 0E/B>XR0F%A5 ^VE-C<%U83';+D%+;L#:YWU0VVF
MC9P!.+HA/1B[ >D=!I@XR^_HHS5Q@H>!V(<9'B8O#3C9__;\P%L'K? 3&O$8
MQ@SY2FG$(4Q3+X1(!+$( AP1;J0T7HT[-_7PV]_^XX/%P:\#D,$9>IC8(R_J
MX1);'&*'23XGOZB&2:?E@M]R(DOX-_4MJN7W'^NBU!DE0MFZ0&9BR5V=#@\1
MZSWW=1Z?[D1WR./>6>W(GX>9,[]F*WU^O]4HMX'<+TT8]P)[B8AEP&#L4P(1
M9A'$,=)QB6F"B!=)+["Z7.XC-C=MU?"JO>B%Z.9CV-DPO?B:F3"N4!M9V;6
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M'[=*&RQ2SEA"/ E]CG3YOE@HDRH*E)D5<!'C5+#07Y3KDBS-["ISTE;+=LO
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M"/,APT&E'QN;-DH"WF@)EEO%@/Y$/%UFPWX);FP\VO'MF<ZMWF!/<5!KODE
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MUVG/,>OQ6K=]PYU4>@<BWLF9_F%IMB>-$^3]O%I.D.0HEQF&'#-KGB+(HJR
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MCR$64:;M+H)A@I(BED51D-@IZ'XPB<?&J.MR(PLM*U1:6#V):FG!0HM;756
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MP")&QN13*2R0_FN,<H1C+!*%O.*00@HW-L9<NZY?K'@#E5$[-6A7F86]#\6
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MVJ.9+J4'0PZ9&S,-/! ]D]A:&["CS@W8*@3V--H>O;W>@!VMZK.U<*07$.-
M_!A"HD&I-""$AZP;LND.F]>'Z>JYI+/E^N1*9 )SGD"91\9"$P4L4!Q!20DO
M1!)E48&<-ZW[;8^-,!]^_O67^]M/CQZ[KP.P'':CW2'HF:JNU]YCS]D=A8'V
MFN_HHN3:Y)F5S$:*FY#RY4)2ZS,W42[/<SL+)5S.8:6W2J94YY-<Z3WIO!2
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MTH*8E'$-1DKB<K#$I<RRR?B7K*,@[K]Y*TC(]B%Q$$=[1L72@GH]',&[RXL
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MN.&\N#B#:#E+(,H(%<6(+#,4'%J@!(^5TDW8^JQJ7P#M0V??X;1^P7FXZ!J
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MX%Y;:F/M^] G">HY&;@Z?.IQOP4HQ7AY<3DJ<;)-X8[5PE3,,21+23"QM/<
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M&Y5!V92EJ]V2;R,Q_2JWXR/L0>^,*E)JTSY;-Z0X0*_=?T3%-AE=:JYM.QV
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M)-* A8A<&<_PS3<>&O+H[/&91_C(V>,_6OETD7IG%*Y=FS*XBJN /AW:(\H
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MC*G:/M(>9#9B,!P?5)/C2KB)I-OKG+Y;7'XTJ5-2T(8)$GFID*8:B#?:$Y/
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MBQFHY8H]&XY&C&.U$TZ?).A00^>.!,J;EIX*#Q+/+BZ(#R7T;#(G@:+C0G6
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MJJ%!I35)LVV:R4;'>X2D7(!BM<T*!9$=ED2PV!J:HG1(3FN0CHVI";E"$CF
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M 8*4,OB 295AQ?^+?<E'$61J#&I&QD9HJ@S$)"M4DRG7PH%HZ$V_^!)?\L<
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ML$/*KBBU_LBE*'2-0Y7%R6980>2M M;:Z)QLST-^$+BFSF#>E+'](>U9-+*
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M-F D%NY8%$8T3SIXAIYQKU+.LJN=KH<.,'4W^VOG5%YSPJ1(EL4,+FX2_F.
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M2?1>ZRR+1\@8&3^--?U<2'"$V#M SC_(GZPM:JM-6:."2.099(N1")8"/(9
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M/4#NY7XADINHA(J0<DAUAI( )XT'EHJVP7"32^O^>)?;I><@]1_>I><0772
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M>I49)/TYUWQFX7E9O-#BV=Y-\ QXNY DQ:TDZN'H%UITKN8$J/7OM*YPMDG
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M6A8#"G84_)Y[:E?QVP @:R;QX0NF=F_4+S&L\#__X_\!4$L#!!0    ( ,.
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M*5>E9RN*+J0IUHARBG&Q&VJ]13FQ!?N&V\WEG\<K=D3FM*'(C'7I7O9@F_S
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M9DB",I]I-0/*A#F_JP[:3<6/D!5*+P!;YU,=&)$_PB_B[47*A/9+Y;[HQ*/
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MI8H)8O%]]#%\?X3=11'>JY Y'N*5>:SR%]_/NV?]*>]^5#CY U!+ P04
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M,#(R,#DS,%]D968N>&UL4$L! A0#%     @ PX!A54!1^>?-  $ >C0* !4
M             ( !]^D# &EN8WDM,C R,C Y,S!?;&%B+GAM;%!+ 0(4 Q0
M   ( ,. 855?B,E.S[X  #FR"  5              "  ??J! !I;F-Y+3(P
M,C(P.3,P7W!R92YX;6Q02P$"% ,4    " ##@&%5OMG^=L<'   _)@  %@
M            @ 'YJ04 :6YC>2TY,S R,#(R>&5X,S$Q+FAT;5!+ 0(4 Q0
M   ( ,. 856T39JNR@<  'HF   6              "  ?2Q!0!I;F-Y+3DS
M,#(P,C)X97@S,3(N:'1M4$L! A0#%     @ PX!A59,H$W.5!   KQ   !8
M             ( !\KD% &EN8WDM.3,P,C R,GAE>#,R,2YH=&U02P$"% ,4
M    " ##@&%5E9<;]8T$  #$$   %@              @ &[O@4 :6YC>2TY
F,S R,#(R>&5X,S(R+FAT;5!+!08     "P + .8"  !\PP4    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
